Guidelines on TaT 1 (Non-muscle invasive)
Bladder Cancer M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle...
25 downloads
1266 Views
9MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Guidelines on TaT 1 (Non-muscle invasive)
Bladder Cancer M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou
© European Association of Urology 2009
TABLE OF CONTENTS
PAGE
1.
BACKGROUND
3
2.
EPIDEMIOLOGY
3
3. CLASSIFICATION 3.1 Tumour, Nodes, Metastases classification (TNM) 3.2 Histological grading of non-muscle invasive bladder tumours 3.2.1 WHO/ISUP grading 3.3 Controversial definition of non-muscle invasive (superficial) tumours 3.4 Inter- and intra-observer variability in staging and grading
3 3 4 4 4 4
4.
5
RISK FACTORS
5. DIAGNOSIS 5.1 Symptoms of TaT1 bladder tumours 5.2 Physical examination 5.3 Imaging 5.3.1 Intravenous urography and CT scan 5.3.2 Ultrasonography (US) 5.4 Urinary cytology 5.5 Urine molecular tests 5.6 Cystoscopy 5.7 Transurethral resection of TaT1 bladder tumours 5.8 Bladder and prostatic urethra biopsies 5.9 Fluorescence cystoscopy 5.10 Second resection 5.11 Pathological report 5.12 Recommendations for primary assessment of TaT1 bladder tumours
5 5 5 5 5 5 5 5 6 6 6 6 6 7 7
6.
7
PREDICTING RECURRENCE AND PROGRESSION IN TaT1 TUMOURS
7. ADJUVANT TREATMENT 7.1 Intravesical chemotherapy 7.1.1 One, immediate, post-operative intravesical instillation of chemotherapy 7.1.2 Additional adjuvant intravesical chemotherapy instillations 7.1.3 Optimizing intravesical chemotherapy 7.2 Intravesical BCG immunotherapy 7.2.1 Efficacy of bacillus Calmette-Guérin (BCG) 7.2.2 The optimal BCG schedule 7.2.3 The optimal dose of BCG 7.2.4 BCG toxicity 7.2.5 Indications for BCG 7.3 Treatment of failures of intravesical therapy 7.3.1 Failure of intravesical chemotherapy 7.3.2 Failure of intravesical BCG immunotherapy 7.4 Recommendations for intravesical therapy
9 9 9 9 10 10 10 10 10 11 11 11 11 11 11
8.
CYSTECTOMY FOR NON-MUSCLE INVASIVE BLADDER CANCER
12
9.
FOLLOW-UP OF PATIENTS WITH TaT1 BLADDER TUMOURS 9.1 Recommendations for follow-up cystoscopy
12 12
10.
REFERENCES
13
11.
ABBREVIATIONS USED IN THE TEXT
19
2
LIMITED TEXT UPDATE MARCH 2009
1. BACKGROUND The first European Association of Urology (EAU) Guidelines on Bladder Cancer were published in 2002 (1). It was later decided to develop separate guidelines for different categories of bladder tumours: • TaT1 papillary tumours (non-muscle invasive bladder cancer) • Upper urinary tract tumours • Carcinoma in situ (CIS) • Muscle invasive bladder tumours. Separate guidelines have been published in European Urology for CIS and upper urinary tract tumours (2-3). This overview represents the updated EAU guidelines on TaT1 (non-muscle invasive) bladder cancer.
2. EPIDEMIOLOGY Bladder carcinoma is the most common malignancy of the urinary tract. In Europe, the highest incidence (given as ASR = age-standardized rate) is reported from its Western (23.6 in males and 5.4 in females) and Southern parts (27.1 in males and 4.1 in females), followed by Northern Europe (16.9 in males and 4.9 in females). The lowest incidence can be observed in Eastern European countries (14.7 in males and 2.2 in females, respectively) (4). Approximately 75-85% of patients with bladder cancer present with disease confined to the mucosa (stage Ta, CIS) or submucosa (stage T1).
3. CLASSIFICATION 3.1 Tumour, Nodes, Metastases Classification (TNM) The 2002 TNM classification approved by the Union International Contre le Cancer (UICC) has been widely accepted (Table 1) (5). It differs from the previous versions in the definition of stage T2 and T3 tumours.
Table 1: 2002 TNM classification of urinary bladder cancer T - Primary tumour TX Primary tumour cannot be assessed T0 No evidence of primary tumour Ta Non-invasive papillary carcinoma Tis Carcinoma in situ: ‘flat tumour’ T1 Tumour invades subepithelial connective tissue T2 Tumour invades muscle T2a Tumour invades superficial muscle (inner half) T2b Tumour invades deep muscle (outer half) T3 Tumour invades perivesical tissue: T3a Microscopically T3b Macroscopically (extravesical mass) T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall T4a Tumour invades prostate, uterus or vagina T4b Tumour invades pelvic wall or abdominal wall N - Lymph nodes NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Metastasis in a single lymph node 2 cm or less in greatest dimension N2 Metastasis in a single lymph node more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, none more than 5 cm in greatest dimension N3 Metastasis in a lymph node more than 5 cm in greatest dimension
LIMITED TEXT UPDATE MARCH 2009
3
M - Distant metastasis MX Distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis
3.2
Histological grading of non-muscle invasive bladder tumours
In 1998, the new classification of non-invasive urothelial tumours was proposed by the World Health Organization (WHO) and the International Society of Urological Pathology (ISUP) (1998 WHO/ISUP classification) and published by the WHO in 2004 (6,7) (Table 2). Its major contribution is a detailed histological description of the various grades, employing specific cytological and architectural criteria. A website (www. pathology.jhu.edu/bladder) illustrating examples of various grades was developed to improve accuracy further in using the system.
Table 2: WHO grading in 1973 and in 2004 (6,7) 1973 WHO grading Urothelial papilloma Grade 1: well differentiated Grade 2: moderately differentiated Grade 3: poorly differentiated 2004 WHO grading Urothelial papilloma Papillary urothelial neoplasm of low malignant potential (PUNLMP) Low-grade papillary urothelial carcinoma High-grade papillary urothelial carcinoma
3.2.1 WHO/ISUP grading The 2004 WHO grading differentiates between papillary urothelial neoplasms of low malignant potential (PUNLMP) and low-grade and high-grade urothelial carcinomas. PUNLMP are defined as lesions that do not have cytological features of malignancy but show normal urothelial cells in a papillary configuration. Although they have a negligible risk for progression, they are not completely benign and still have a tendency to recur. The intermediate grade (grade 2), which was the subject of controversy in the 1973 WHO classification, has been eliminated. The use of the 2004 WHO classification is advocated, as this should result in a uniform diagnosis of tumours, which is better classified according to risk potential. However, until the 2004 WHO classification has been validated by more clinical trials, tumours should be graded using both the 1973 and the 2004 WHO classifications (8). The majority of clinical trials published so far on TaT1 bladder tumours have been performed using the 1973 WHO classification, and therefore the following guidelines are based on the 1973 WHO grade classification.
3.3
Controversial definition of non-muscle invasive (superficial) tumours
A papillary tumour confined to the mucosa is classified as stage Ta according to the TNM system. Tumours that have invaded the lamina propria are classified as stage T1. As Ta and T1 tumours can be removed by transurethral resection (TUR), they are grouped under the heading of non-muscle invasive (superficial) bladder cancer for therapeutic purposes. Also included under this heading are flat, high-grade tumours confined to the mucosa, classified as carcinoma in situ (CIS). However, molecular biology techniques and clinical experience have demonstrated the highly malignant, invasive potential of CIS and T1 lesions. Therefore, the terms nonmuscle invasive and superficial bladder cancer are a suboptimal description.
3.4
Inter- and intra-observer variability in staging and grading
Despite well-defined criteria for the diagnosis of urothelial carcinoma, there is significant variability among pathologists defining dysplasia and CIS. There is also important interobserver variability in classifying stage T1 versus Ta tumours and grading tumours (9,10). As a consequence, this working party strongly recommends that the urologist reviews histological findings with the pathologist.
4
LIMITED TEXT UPDATE MARCH 2009
4. RISK FACTORS Many of the aetiological factors for the development of bladder tumours are known and the urologist should be aware of the types of occupational exposures that may be related to urothelial carcinogens (11). Aromatic amines were the first to be recognized. At-risk groups include workers in the following industries: printing, iron and aluminium processing, industrial painting, gas and tar manufacturing (level of evidence: 3). Another prominent risk factor is cigarette smoking, which triples the risk of developing bladder cancer (12,13) (level of evidence: 3a). Smoking leads to higher mortality from bladder cancer during long-term followup, even though in a multivariate analysis the prognostic effect of smoking was weaker than that of other factors, such as stage, grade, size and multifocality of the tumour (14).
5. DIAGNOSIS 5.1
Symptoms of TaT1 bladder tumours
Haematuria is the most common finding in TaT1 bladder tumours. TaT1 tumours do not cause bladder pain and rarely present with bladder irritation, dysuria or urgency. In patients who do complain of these symptoms, CIS may be suspected.
5.2
Physical examination
Physical examination will not reveal TaT1 bladder tumours.
5.3
Imaging
5.3.1 Intravenous urography and CT scan Large tumours may be seen as filling defects in the bladder. Intravenous urography (IVU) is also used to detect filling defects in the calyces, renal pelvis and ureters, and hydronephrosis, which may indicate the presence of a ureteral tumour. The necessity to perform routine IVP once a bladder tumour has been detected is now questioned because of the low incidence of significant findings obtained with this method (15-17) (level of evidence: 3). The incidence of upper urinary tract tumours is low (1.8%), but increases to 7.5% in tumours located in the trigone (16). The risk of tumour recurrence in the upper urinary tract during follow-up increases in multiple and high-risk tumours (18). In many centres, computed tomography (CT) urography is used as an alternative to conventional IVU (19). Especially in invasive tumours of the upper tract, CT urography gives more information than IVU (level of evidence: 4). However, CT urography has the disadvantage of a much higher radiation exposure than IVU. 5.3.2 Ultrasonography (US) Ultrasonography (US) has been used with increasing frequency as the initial tool to assess the urinary tract. This is not only because it avoids the use of contrast agents, but also because sensitive transducers have improved imaging of the upper urinary tract and bladder. Transabdominal US permits characterization of renal masses, detection of hydronephrosis and visualization of intraluminal filling defects in the bladder. Combined with plain abdominal film, it can be as accurate as IVU in the diagnosis of the cause of haematuria (15,16) (level of evidence: 3).
5.4
Urinary cytology
Examination of a voided urine or bladder-washing specimen for exfoliated cancer cells has high sensitivity in high-grade tumours but low sensitivity in low-grade tumours (level of evidence: 3). It is thus useful when a highgrade malignancy or CIS is present; however, a negative result cannot exclude the presence of a low-grade cancer. Positive urinary cytology may indicate urothelial tumour anywhere in the urinary tract, from the calyx, through the ureters, into the bladder and proximal urethra. Cytological interpretation is user-dependent (20). The evaluation can be hampered by low cellular yield, urinary tract infections, stones or intravesical instillations. In experienced hands however the specificity exceeds 90% (21) (level of evidence: 2b). Cytology should be performed on fresh urine with adequate fixation. Morning urine is not suitable as cytolysis may be often present.
5.5
Urine molecular tests
Many studies have focused on evaluating urinary molecular markers. Several tests based on detection of soluble markers or cell-associated markers are available (21). Most of these tests have a better sensitivity
LIMITED TEXT UPDATE MARCH 2009
5
for detecting bladder cancer than urinary cytology, but specificity is lower (level of evidence: 2b). It remains unclear whether these tests offer additional information that is useful for decision-making, follow-up, treatment and prognosis of non-muscle invasive bladder tumours (21-24). Moreover, the additional costs of some of these tests should be considered.
5.6
Cystoscopy
The diagnosis of bladder cancer ultimately depends on cystoscopic examination of the bladder and histological evaluation of the resected tissue. In general, cystoscopy is initially performed in the office, using flexible instruments. If a bladder tumour has been visualized in earlier imaging studies, a diagnostic cystoscopy can be omitted since the patient will undergo TUR. A careful description of the finding is necessary. It should include the site, size, number and appearance (papillary or solid) of the tumours as well as a description of mucosal abnormalities. Use of a bladder diagram is recommended.
5.7
Transurethral resection of TaT1 bladder tumours
The goal of the TUR in TaT1 bladder tumours is to make the correct diagnosis and remove all visible lesions. The strategy of resection depends on the size of the lesion. Small tumours (less than 1 cm) can be resected en bloc, where the specimen contains the complete tumour plus a part of the underlying bladder wall. Some experts believe that a deep resection is not necessary in small apparently low grade lesions with a previous history of TaG1 tumour. Larger tumours should be resected separately in fractions, which include the exophytic part of the tumour, the underlying bladder wall with the detrusor muscle and the edges of the resection area. The specimens from different fractions must be referred to the pathologist in separate containers to enable him to make a correct diagnosis. Cauterization has to be avoided as much as possible during the resection to prevent tissue destruction. A complete and correct TUR is essential for the prognosis of the patient (25).
5.8
Bladder and prostatic urethra biopsies
Bladder tumours are often multifocal. Moreover TaT1 tumours can be accompanied by CIS or dysplasia. These lesions may present themselves as velvet-like, reddish areas indistinguishable from inflammation or may be not visible at all. The biopsies from normal-looking mucosa in patients with TaT1 tumours, so called random biopsies (R-biopsies) or selected site mucosal biopsies, are not routinely recommended. The likelihood of detecting CIS, especially in low-risk tumours, is extremely low (less than 2%) and the choice of adjuvant intravesical therapy is not influenced by the biopsy result (26) (level of evidence: 2a). Cold cup biopsies from normal-looking mucosa should be performed when cytology is positive or when exophytic tumour is of non-papillary appearance. When abnormal areas of urothelium are seen, it is advised to take ‘cold cup’ biopsies or biopsies with a resection loop. Material obtained by random or directed biopsies must be sent for pathological assessment in separate containers. The involvement of the prostatic urethra and ducts in male patients with TaT1 bladder tumours has been reported. Although the exact risk is not known, it seems to be higher if tumour is located on the trigone or bladder neck, in the presence of bladder CIS and in multiple tumours (27,28) (level of evidence: 3). In these cases and when cytology is positive, with no evidence of tumour in the bladder, or when abnormalities of prostatic urethra are visible, biopsies of the prostatic urethra are recommended. The biopsy is taken using resection loop from the precolicular area.
5.9
Fluorescence cystoscopy
As a standard procedure, cystoscopy and TUR are performed using white light. However, the use of white light may lead to missing lesions that are present but not visible. Fluorescence cystoscopy is performed using violet light after intravesical instillation of a photosensitizer, usually 5-aminolaevulinic acid (5-ALA) or hexaminolaevulinate (HAL). It has been confirmed that fluorescence-guided biopsy and resection are more sensitive than conventional procedures in detecting malignant tumour, particularly CIS (29-31) (level of evidence: 2a). However, false-positivity can be induced by inflammation and recent TUR or intravesical instillation. The benefit of fluorescence-guided TUR for recurrence-free survival was shown in several, small, randomized clinical trials (32-34), but its value remains to be proven in improving the outcome of patients for progression rates or survival. The additional costs of the equipment should be considered.
5.10
Second resection
The significant risk of residual tumour after the initial TUR of TaT1 lesions has been demonstrated (25,35) (level of evidence: 1). Persistent disease after resection of T1 tumours was observed in 33-53% of patients (35-41).
6
LIMITED TEXT UPDATE MARCH 2009
Moreover, the tumour may be understaged by the initial resection. The likelihood that a TaT1, high-grade tumour has been understaged and is therefore muscle invasive is 10% (36,37). As the treatment of a TaT1, high-grade tumour and a T2 tumour is completely different, correct staging is important. A second TUR should be considered when the initial resection was incomplete, e.g. when multiple and/or large tumours are present, or when the pathologist has reported that the specimen contained no muscle tissue. Furthermore, a second TUR should be performed when a high-grade, non-muscle invasive tumour or a T1 tumour has been detected at the initial TUR. It has been demonstrated that a second TUR can increase recurrence-free survival (39,40) (level of evidence: 2a). There is no consensus about the strategy and timing of a second TUR. Most authors recommend resection at 2-6 weeks after the initial TUR. The procedure should include a resection of the primary tumour site.
5.11
Pathological report
Pathological investigation of the specimen obtained by TUR and biopsies is an essential step in the diagnosis of bladder cancer. The pathological report should specify the grade of the lesion and the depth of tumour invasion into the bladder wall and should give information about whether the lamina propria and muscle are present in the specimen (42). Close cooperation between urologist and pathologist is recommended.
5.12 Recommendations for primary assessment of TaT1 bladder tumours • • • • • • • •
•
• •
Renal and bladder ultrasonography, IVU or CT in selected cases (tumours located in the trigone). (Grade of recommendation: B) Cystoscopy with description of the tumour (site, size, number and appearance) and mucosal abnormalities. A bladder diagram is recommended. (Grade of recommendation: C) Urine analysis Urine cytology TUR in one piece for small tumours (less than 1 cm), including a part from the underlying bladder wall. (Grade of recommendation: B) TUR in fractions (including muscle tissue) for larger tumours. (Grade of recommendation: B) Biopsies of abnormal-looking urothelium, biopsies from normal-looking mucosa when cytology is positive or when exophytic tumour is of non-papillary appearance. (Grade of recommendation: C) Biopsy of the prostatic urethra in the case of bladder neck tumour, when bladder CIS is present or suspected, in the case of positive cytology without evidence of tumour in the bladder or when abnormalities of prostatic urethra are visible. If it was not performed during the initial procedure it can be completed at the time of the second resection. The biopsy is taken using resection loop from the precolicular area (Grade of recommendation: C) If equipment is available, fluorescence-guided biopsy when bladder CIS is suspected (e.g. positive cytology, recurrent tumour with previous history of a high grade lesion) (Grade of recommendation: C) A second TUR at 2-6 weeks after the initial resection when it was incomplete or when a high-grade or T1 tumour was detected. (Grade of recommendation: B) The pathological report should specify the grade, the depth of tumour invasion and whether the lamina propria and muscle are present in the specimen. (Grade of recommendation: C)
6. PREDICTING RECURRENCE AND PROGRESSION IN TaT1 TUMOURS The classic way to categorize patients with TaT1 tumours is to divide them into risk groups based on prognostic factors derived from multivariate analyses. Using such a technique, it was proposed to divide patients into low-risk, intermediate-risk and high-risk groups (43). When using these risk groups, however, no difference is usually made between the risk of recurrence and progression. Although prognostic factors may indicate a high risk for recurrence, the risk of progression may still be low and other tumours may have a high risk of both recurrence and progression. In order to separately predict the short-term and long-term risks of both recurrence and progression in individual patients, the European Organization for Research and Treatment of Cancer (EORTC) developed a scoring system and risk tables (44). The basis for these tables is the EORTC database, which provided
LIMITED TEXT UPDATE MARCH 2009
7
individual patient data for 2,596 patients diagnosed with TaT1 tumours who were randomized in seven EORTC trials. Patients with CIS only were not included. Seventy eight percent received intravesical treatment, mostly chemotherapy. They did not however have a second TUR or receive maintenance BCG. The scoring system is based on the six most significant clinical and pathological factors: • number of tumours • tumour size • prior recurrence rate • T category • presence of concomitant CIS • tumour grade. Table 3 illustrates the weights applied to various factors for calculating the total scores for recurrence and progression. Table 4 shows the total scores stratified, as in the original article (44), into four categories reflecting various probabilities of recurrence and progression at 1 and 5 years. With combining two of the four categories distinctly in recurrence and progression, the EAU working group suggests to use, as shown in the rightmost column in table 4, a 3-tier system defining low, intermediate and high risk groups for recurrence and progression.
Table 3: Weighting used to calculate recurrence and progression scores Factor Number of tumours Single 2-7 > 8 Tumour diameter < 3 cm > 3 cm Prior recurrence rate Primary < 1 recurrence/year > 1 recurrence/year Category Ta T1 Concomitant CIS No Yes Grade (1973 WHO) G1 G2 G3 Total score CIS = carcinoma in situ
8
Recurrence
Progression
0 3 6
0 3 3
0 3
0 3
0 2 4
0 2 2
0 1
0 4
0 1
0 6
0 1 2 0-17
0 0 5 0-23
LIMITED TEXT UPDATE MARCH 2009
Table 4: Probability of recurrence and progression according to total score Recurrence score 0 1-4 5-9 10-17
Probability of recurrence at 1 year % (95% CI) 15 (10-19) 24 (21-26) 38 (35-41) 61 (55-67)
Probability of recurrence at 5 years % (95% CI) 31 (24-37) 46 (42-49) 62 (58-65) 78 (73-84)
Recurrence risk group
Progression score 0 2-6 7-13 14-23
Probability of progression at 1 year % (95% CI) 0.2 (0-0.7) 1 (0.4-1.6) 5 (4-7%) 17 (10-24)
Probability of progression Progression at 5 years risk group % (95% CI) 0.8 (0-1.7) Low risk 6 (5-8) Intermediate risk 17 (14-20) High risk 45 (35-55)
Low risk Intermediate risk High risk
Note: Electronic calculators for Tables 3 and 4 are available at http://www.eortc.be/tools/bladdercalculator/
7. ADJUVANT TREATMENT 7.1
Intravesical chemotherapy
7.1.1 One, immediate, post-operative intravesical instillation of chemotherapy Although a state-of-the-art TUR by itself could eradicate a TaT1 tumour completely, these tumours will recur in a high percentage of cases and progress to muscle invasive bladder cancer in a limited number of cases. The high variability in the 3-month recurrence rate indicates that TUR is incomplete or provokes recurrences in a considerable percentage of patients (25). It is therefore necessary to consider adjuvant therapy in all patients. In a meta-analysis of seven randomized trials (1,476 patients with a median follow-up of 3.4 years), one immediate instillation of chemotherapy after TUR decreased the percentage of patients with recurrence by 12% (from 48.4% to 36.7%) and the odds of recurrence by 39%. The benefit was confirmed in both single and multiple tumours (45) (level of evidence: 1a). The difference of 12% means that in every 100 patients, 12 TURs may be avoided with one postoperative instillation, i.e. that 8.5 patients must be treated to prevent one recurrence. Since the costs of a TUR, anaesthesia and hospitalization in most countries exceed the cost of 8.5 times one instillation, this procedure is considered to be cost-effective. The effect can be explained by the destruction of circulating tumour cells, immediately after TUR, or as an ablative effect (chemoresection) of residual tumour cells at the resection site. The timing of the instillation is crucial. In all studies, the instillation was administered within 24 hours. One study reported that if the first instillation was not given the same day as TUR, there was a twofold increase in the relative risk of recurrence (46) (level of evidence: 2a). There is no single drug that is superior with regards to efficacy. Mitomycin C, epirubicin and doxorubicin have all shown a beneficial effect (45) (level of evidence: 1b). One immediate post-operative instillation of chemotherapy should be given in all patients after TUR of presumably non-muscle invasive bladder cancer. Severe complications have been reported in patients in whom extravasation of the drug occurred (47). Thus, an immediate instillation should be omitted in case of overt or suspected intra- or extra-peritoneal perforation, which is most likely to appear in extensive TUR procedures. Clear instructions should be given to the nursing staff for controlling the free flow of the bladder catheter at the end of the instillation. 7.1.2 Additional adjuvant intravesical chemotherapy instillations The need for further adjuvant intravesical therapy depends on the patient’s prognosis. In patients with a low risk of tumour recurrence (see Table 4), a single immediate instillation reduces the risk of recurrence and may be considered to be the standard treatment in these patients (45) (level of evidence: 1a). No further treatment should be given in these patients prior to a subsequent recurrence. For other patients, however, it remains an incomplete treatment as the likelihood of recurrence and/or progression is considerable. The effect of the immediate instillation of chemotherapy occurs during the first and second year (48,49) (level of evidence: 1b). It has been calculated from the data of five randomized trials (49) that the
LIMITED TEXT UPDATE MARCH 2009
9
reduction of recurrence lasts for a period of approximately 500 days. The choice between further chemotherapy or immunotherapy largely depends on the risk that needs to be reduced: recurrence or progression. A meta-analysis of EORTC and Medical Research Council data, comparing intravesical chemotherapy to TUR alone, demonstrated that chemotherapy prevents recurrence but not progression (50) (level of evidence: 1a). The efficacy of intravesical chemotherapy in reducing the risk of tumour recurrence was confirmed by two other meta-analyses in primary (51) and recurrent tumours (52). It is still controversial how long and how frequently instillations of intravesical chemotherapy have to be given. From a systematic review of the literature of randomized clinical trials, which compared different schedules of intravesical chemotherapy instillations, one could only conclude that the ideal duration and intensity of the schedule remains undefined because of conflicting data (53). 7.1.3 Optimizing intravesical chemotherapy One randomized trial has demonstrated that adapting the urinary pH, decreasing the urinary excretion and buffering the intravesical solution reduced the recurrence rate (54) (level of evidence: 1b). Another randomized trial documented that concentration was more important than the duration of the treatment (55) (level of evidence: 1b). In view of these data, which need confirmation, it seems advisable to ask the patient not to drink the morning before instillation and to dissolve the drug in a buffered solution at optimal pH.
7.2
Intravesical BCG immunotherapy
7.2.1 Efficacy of Bacillus Calmette-Guérin (BCG) Several meta-analyses have addressed important questions concerning the efficacy of BCG in TaT1 bladder tumours. None of them however are based on individual patient data. Four meta-analyses confirmed that BCG after TUR is superior to TUR alone or TUR and chemotherapy in preventing recurrences of TaT1 tumours (56-59) (level of evidence: 1a). Two meta-analyses demonstrated that BCG therapy prevents, or at least delays, the risk of tumour progression (60,61) (level of evidence: 1a). A meta-analysis carried out by the EORTC evaluated data from 4,863 patients enrolled in 24 randomized trials. A total of 3,967 (81.6%) patients had only papillary tumours and 896 (18.4%) had primary or concomitant CIS. Five different BCG strains were used, and in 20 out of the 24 trials some form of BCG maintenance was used. In four trials only, a 6-week induction course was used. Based on a median follow-up of 2.5 years and a maximum of 15 years, 260 out of 2,658 patients (9.8%) on BCG progressed compared to 304 out of 2,205 (13.8%) in the control groups (TUR alone, TUR plus intravesical chemotherapy, or TUR plus another immunotherapy). This result is a reduction of 27% in the odds of progression with BCG treatment (p = 0.0001). The size of the reduction is similar in patients with TaT1 papillary tumours and in those with CIS (61). However, another two meta-analyses suggested a possible bias in favour of BCG by the inclusion of patients previously treated with intravesical chemotherapy in the studies (62,63). 7.2.2 The optimal BCG schedule For optimal efficacy, BCG must be given in a maintenance schedule (59-61) (level of evidence: 1a). In the EORTC meta-analysis, only patients receiving maintenance BCG benefited. In the four trials where no maintenance was given, no reduction in progression was observed. In the 20 trials in which some form of BCG maintenance was given, a reduction of 37% in the odds of progression was observed (p = 0.00004). The metaanalysis was unable to determine which BCG maintenance schedule was the most effective (61). In their metaanalyses, Böhle et al. concluded that at least 1 year of maintenance BCG was required to show the superiority of BCG over mitomycin C in preventing recurrence or progression (59,60). Although some modifications have been tried, induction BCG instillations are classically given according to the empirical 6-weekly induction schedule introduced by Morales 30 years ago. However, many different maintenance schedules have been used, ranging from a total of 10 instillations given in 18 weeks, to 30 instillations given over 3 years (64). The optimal number of induction instillations and the optimal frequency and duration of maintenance instillations remain unknown. Based on the extent of intravesical immune response, it is suggested that three, consecutive, weekly instillations give a maximum response (65). 7.2.3 The optimal dose of BCG To reduce BCG toxicity, a number of authors have proposed one-third and one-quarter dose instillations of BCG. Comparing one-third dose to full-dose BCG in 500 patients, the Spanish Oncology Group (CUETO) found no overall difference in efficacy. However, there was a suggestion that a full dose of BCG may be more effective in multifocal disease (66,67) (level of evidence: 1b). Although fewer patients reported toxicity with the reduced dose, the incidence of severe systemic toxicity was similar in the standard- and reduced-dose groups. The same Spanish group showed in a prospective randomized trial that one-third of the standard dose of BCG
10
LIMITED TEXT UPDATE MARCH 2009
may be the minimum effective dose in intermediate-risk tumours. A further reduction to one-sixth dose resulted in a decrease in efficacy for preventing recurrence with no decrease in toxicity (68). 7.2.4 BCG toxicity Assuming that maintenance therapy is necessary for optimal efficacy, the issue of BCG toxicity becomes more relevant. Due to the more pronounced side-effects of BCG compared to intravesical chemotherapy, reluctance still exists about BCG use. Deaths due to BCG sepsis and the high frequency of BCG-induced cystitis have compromised the use of BCG. However, with increased experience in applying BCG, the side-effects now appear to be less prominent. Serious side-effects are encountered in less than 5% of patients and can be effectively treated in virtually all cases (69) (level of evidence: 1b). Major complications can appear after systemic absorption of the drug. Thus, BCG should not be administered during the first 2 weeks after TUR, in patients with haematuria and after traumatic catheterization. 7.2.5 Indications for BCG Although BCG is a very effective treatment, consensus exists that not all patients with non-muscle invasive bladder cancer should be treated with BCG due to the risk of toxicity. Ultimately, the choice of treatment will depend upon the patient’s risk of recurrence and progression. The use of BCG will not alter the natural course of the disease in tumours at low risk of recurrence and progression (see Table 4) and may be considered to be over-treatment for this category. In patients with tumours at high risk of progression, for whom a cystectomy is not carried out, after an immediate instillation of chemotherapy, BCG including a maintenance schedule is indicated. Although patients at intermediate-risk of progression were included in the meta-analyses (59,60), a separate confirmation of the superiority of BCG in these patients is not available. BCG can be offered in this group if chemotherapy is badly tolerated or if the patient continues to have recurrences in spite of repeated chemotherapy instillations. BCG should then be given for at least 1 year.
7.3
Treatment of failures of intravesical therapy
7.3.1 Failure of intravesical chemotherapy Patients with non-muscle invasive recurrences after intravesical chemotherapy can profit from BCG instillations (62). 7.3.2 Failure of intravesical BCG immunotherapy Treatment with BCG is considered to have failed in following situations: a. Whenever muscle invasive tumour is detected during follow-up. b. If high-grade, non-muscle invasive tumour is present at both 3 and 6 months (70). In patients with tumour present at 3 months, an additional BCG course provokes complete response in more than 50% of cases, both in patients with papillary tumours and CIS (70,71). c. Any worsening of the disease under BCG treatment, such as a higher number of recurrences, higher T or higher grade, or appearance of CIS, in spite of an initial response (level of evidence: 3). Patients with a later recurrence after completion of BCG therapy can be treated according to the risk classification (Tables 3 and 4). Changing from BCG to intravesical chemotherapy or device-assisted chemotherapy instillations can yield responses in selected cases with non-muscle invasive BCG failure. However, experience is limited and these strategies are considered experimental. Because of the high risk of development of muscle invasive tumour in these patients (70,72) (level of evidence: 3), immediate cystectomy is strongly advocated upon BCG failure.
7.4
Recommendations for adjuvant therapy
• •
The type of intravesical therapy is based on the risk groups as shown in Table 4 In patients at low risk of tumour recurrence and progression, one immediate instillation of chemotherapy is strongly recommended as the complete adjuvant treatment. (Grade of recommendation: A) In patients at an intermediate or high risk of recurrence and an intermediate risk of progression, one immediate instillation of chemotherapy should be followed by further instillations of chemotherapy or a minimum of 1 year of BCG. (Grade of recommendation: A) If chemotherapy is given, it is advised to use the drug at its optimal pH and to maintain the concentration of the drug during instillation by reducing fluid intake. The optimal schedule and the duration of the chemotherapy instillations remain unclear, but it should probably be given for 6 to 12 months. (Grade of recommendation: B) In patients at high risk of tumour progression, after an immediate instillation of chemotherapy, intravesical BCG for at least 1 year is indicated. (Grade of recommendation: A)
•
•
•
LIMITED TEXT UPDATE MARCH 2009
11
• •
Immediate radical cystectomy may be offered to patients at highest risk of tumour progression. In patients with BCG failure, cystectomy is recommended. (Grade of recommendation: C) The absolute risks of recurrence and of progression do not always indicate the risk at which a certain therapy is optimal. The choice of therapy may be considered differently according to what risk is acceptable for the individual patient and the urologist.
8. CYSTECTOMY FOR NON-MUSCLE INVASIVE BLADDER CANCER Many experts consider it is reasonable to propose immediate cystectomy to those patients with non-muscle invasive tumour who are at high risk of progression. According to the risk tables of the EORTC (see Tables 3 and 4) these are: • multiple recurrent high-grade tumours • high-grade T1 tumours • high-grade tumours with concomitant CIS. Cystectomy is advocated in patients with non-muscle invasive BCG failure as mentioned above. Delaying cystectomy in these patients may lead to decreased disease-specific survival (73).
9. FOLLOW-UP OF PATIENTS WITH TaT1 BLADDER TUMOURS Because of the risk of recurrence and progression, patients with TaT1 bladder tumours need be followed; however, the frequency and duration of cystoscopies should reflect the individual patient’s degree of risk. Using risk tables (see Tables 3 and 4), we are able to predict the short-term and long-term risks of both recurrence and progression in individual patients and can adapt the follow-up schedule accordingly (44): a. The prompt detection of muscle invasive and high-grade non-muscle invasive recurrences is critical since a delay in diagnosis and therapy threatens a patient’s life. b. Tumour recurrence in the low-risk group is nearly always low stage and low grade. Small, non-invasive (Ta), low-grade papillary recurrences do not present an immediate danger to the patient and their early detection is not essential for successful therapy (74-81) (level of evidence: 2b). c. The result of the first cystoscopy after TUR at 3 months is a very important prognostic factor for recurrence and for progression (44,72,82,83) (level of evidence: 1a). The first cystoscopy should thus always be performed 3 months after TUR in all patients with TaT1 bladder tumour. Randomized studies investigating the possibility of safely reducing follow-up cystoscopies are lacking. The following recommendations are therefore based only on retrospective experience.
9.1
Recommendations for follow-up cystoscopy
•
Patients with tumours at low risk of recurrence and progression should have a cystoscopy at 3 months. If negative, the following cystoscopy is advised at 9 months and consequently yearly for 5 years. (Grade of recommendation: C) Patients with tumours at high risk of progression should have a cystoscopy and urinary cytology at 3 months. If negative, the following cystoscopies and cytologies should be repeated every 3 months for a period of 2 years, every 4 months in the third year, every 6 months thereafter until 5 years, and yearly thereafter. A yearly exploration of the upper tract is recommended. (Grade of recommendation: C) Patients with intermediate-risk of progression (about one-third of all patients) should have an in-between follow-up scheme using cystoscopy and cytology, adapted according to personal and subjective factors. (Grade of recommendation: C)
•
•
12
LIMITED TEXT UPDATE MARCH 2009
10. REFERENCES 1.
2.
3.
4. 5. 6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C; European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002;41(2):105-12. http://www.ncbi.nlm.nih.gov/pubmed/12074395 Oosterlinck W, Solsona E, van der Meijden APM, Sylvester R, Boehle A, Rintala E, Lobel B; European Association of Urology. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol 2004;46(2):147-54. http://www.ncbi.nlm.nih.gov/pubmed/15245806 van der Meijden APM, Sylvester R, Oosterlinck W, Solsona E, Boehle A, Lobel B, Rintala E; for the EAU Working Party on Non Muscle Invasive Bladder Cancer. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005;48(3):363-71. http://www.ncbi.nlm.nih.gov/pubmed/15994003 Ferlay J, Bray F, Pisani P, Parkin DM. Globcan 2002, Cancer Incidence, Mortality and Prevalence Worldwide, IARC CancerBase No. 5, version 2.0. Lyon: IARCC Press, 2004. Sobin DH, Wittekind Ch, eds. TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss, 2002. pp. 199-202. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22(12):1435-48. http://www.ncbi.nlm.nih.gov/pubmed/9850170 Sauter G, Algaba F, Amin M, Busch C, Cheville J, Gasser T, Grignon DJ, Hofstadter F, Lopez-Beltran A, Epstein JI. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein Jl, Sesterhenn I, eds. WHO classification of classification of tumors of the urinary system and male genital organs. Lyon: IARCC Press, 2004, pp. 29-34. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46(2):170-6. http://www.ncbi.nlm.nih.gov/pubmed/15245809 Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 WHO/ISUP classification of urothelial neoplasms: practical choices for patient care. J Urol 2002;168(3):968-72. http://www.ncbi.nlm.nih.gov/pubmed/12187201 Bol MG, Baak J, Buhr-Wildhagen S, Kruse AJ, Kjellevold K, Janssen EA, Mestad O, Ogreid P.Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003;169(4):1291-4. http://www.ncbi.nlm.nih.gov/pubmed/12629345 McCahy PJ, Harris CA, Neal E. The accuracy of recording of occupational history in patients with bladder cancer. Br J Urol 1997;79(1):91-3. http://www.ncbi.nlm.nih.gov/pubmed/9043504 Zeegers MP, Tan FE, Dorant E, van den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000;89(3):630-9. http://www.ncbi.nlm.nih.gov/pubmed/10931463 Bjerregaard BK, Raaschou-Nielsen O, Sørensen M, Frederiksen K, Christensen J, Tjønneland A, Overvad K, Chapelon FC, Nagel G, Chang-Claude J, Bergmann MM, Boeing H, Trichopoulos D, Trichopoulou A, Oikonomou E, Berrino F, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, Buenode-Mesquita HB, Kiemeney L, Gram IT, Braaten T, Lund E, Gonzalez CA, Berglund G, Allen N, Roddam A, Bingham S, Riboli E. Tobacco smoke and bladder cancer–in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2006;119(10):2412-6. http://www.ncbi.nlm.nih.gov/pubmed/16894557 Aveyard P, Adab P, Cheng KK, Wallace D, Hey K, Murphy ME. Does smoking status influence the prognosis of bladder cancer ? A systematic review. BJU Int 2002;90(3):228-39. http://www.ncbi.nlm.nih.gov/pubmed/12133057 Goessl C, Knispel HH, Millar K, Klan R. Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol 1997;157(2):480-1 http://www.ncbi.nlm.nih.gov/pubmed/8996338 Palou J, Rodriguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A, Villavicencio H. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumors. J Urol 2005;174(3):859-61. http://www.ncbi.nlm.nih.gov/pubmed/16093970
LIMITED TEXT UPDATE MARCH 2009
13
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
14
Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. Long-term follow-up of a bladder carcinoma cohort: routine followup urography is not necessary. J Urol 1998;160(1):45-8. http://www.ncbi.nlm.nih.gov/pubmed/9628602 Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Huguet-Pérez J, Vicente-Rodríguez J. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol 2000;164(4):1183-7. http://www.ncbi.nlm.nih.gov/pubmed/10992362 Nolte-Ernsting C, Cowan N. Understanding multislice CT urography techniques: many roads lead to Rome. Eur Radiol 2006;16(12):1670-86. http://www.ncbi.nlm.nih.gov/pubmed/16953373 Raitanen M-P, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, Tammela TL; FinnBladder Group. Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41(3):284-9. http://www.ncbi.nlm.nih.gov/pubmed/12180229 Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 2005;66(6 Suppl 1):35-63. http://www.ncbi.nlm.nih.gov/pubmed/16399415 Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt P, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003;169(6):1975-82. http://www.ncbi.nlm.nih.gov/pubmed/12771702 Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analysis. Urology 2003;61(1):109-18. http://www.ncbi.nlm.nih.gov/pubmed/12559279 Van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47(6):736-48. http://www.ncbi.nlm.nih.gov/pubmed/15925067 Brausi M, Collette L, Kurth K, van der Meijden A, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester R; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41(5):523-31. http://www.ncbi.nlm.nih.gov/pubmed/12074794 van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta,T1 bladder tumors: a report of the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999;35(4):267-71. http://www.ncbi.nlm.nih.gov/pubmed/10419345 Matzkin H, Soloway MS, Hardeman S. Transitional cell carcinoma of the prostate. J Urol 1991;146(5):1207–12. http://www.ncbi.nlm.nih.gov/pubmed/1942262 Mungan MU, Canda AE, Tuzel E, Yorukoglu K, Kirkali Z. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol 2005;48(5):760-3. http://www.ncbi.nlm.nih.gov/pubmed/16005563 Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M; Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171(1):135-8. http://www.ncbi.nlm.nih.gov/pubmed/14665861 Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, Johansson E, Gartner T, Lange N, van den Bergh H, Leisinger HJ. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for photodiagnosis of superficial bladder cancer –a multicenter study. J Urol 2003;170(1):226-9. http://www.ncbi.nlm.nih.gov/pubmed/12796694 Hungerhuber E, Stepp H, Kriegmair M, Stief Ch, Hofstetter A, Hartmann A, Knuechel R, Karl A, Tritschler S, Zaak D. Seven years´ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007;69(2):260-4. http://www.ncbi.nlm.nih.gov/pubmed/17320660
LIMITED TEXT UPDATE MARCH 2009
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
Daniltschenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, Loening SA, Schnorr D. Longterm benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005;174(6):2129-33. http://www.ncbi.nlm.nih.gov/pubmed/16280742 Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid -induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005;96(6):798-802. http://www.ncbi.nlm.nih.gov/pubmed/16153204 Denziger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, Filbeck T. Clinically relevant risk of reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid –induced fluorescence diagnosis: 8-years results of prospective randomized study. Urology 2007;69(4):675-9. http://www.ncbi.nlm.nih.gov/pubmed/17445650 Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003;43(3):241-5. http://www.ncbi.nlm.nih.gov/pubmed/12600426 Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004;45(5):539-46. http://www.ncbi.nlm.nih.gov/pubmed/15082193 Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165(3):808-10. http://www.ncbi.nlm.nih.gov/pubmed/11176474 Schips L, Augustin H, Zigeuner RE, Gallé G, Habermann H, Trummer H, Pummer K, Hubmer G. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59(2):220-3. http://www.ncbi.nlm.nih.gov/pubmed/11834389 Grimm M-O, Steinhoff Ch, Simon X, Spiegelhalder P, Ackermann R, Vögeli, TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170(2 Pt 1):433-7. http://www.ncbi.nlm.nih.gov/pubmed/12853793 Divrik RT, Yildirim Ü, Zorlu F, Özen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175(5):1641-4. http://www.ncbi.nlm.nih.gov/pubmed/16600720 Jahnson S, Wiklund F, Duchek M, Mestad O, Rintala E, Hellsten S, Malmström PU. Results of secondlook resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol 2005;39(3):206-10. http://www.ncbi.nlm.nih.gov/pubmed/16127800 Lopez-Beltran A, Bassi P, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol 2004;45(3):257-66. http://www.ncbi.nlm.nih.gov/pubmed/15036668 Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164(3 Pt 1):680-4. http://www.ncbi.nlm.nih.gov/pubmed/10954628 Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes A, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466-77. http://www.ncbi.nlm.nih.gov/pubmed/16442208 Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1):2186-90. http://www.ncbi.nlm.nih.gov/pubmed/15126782 Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P, Korhonen H, Liukkonen T; FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002;42(2):167-74. http://www.ncbi.nlm.nih.gov/pubmed/12160589
LIMITED TEXT UPDATE MARCH 2009
15
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
16
Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol 2004;46(3):336-8. http://www.ncbi.nlm.nih.gov/pubmed/15306104 Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999;161(4):1120-3. http://www.ncbi.nlm.nih.gov/pubmed/10081851 Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999;86(9):1818-26. http://www.ncbi.nlm.nih.gov/pubmed/10547556 Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parkmar MK, Bijnens L. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Part on Superficial Bladder Cancer. J Urol 1996;156(6):1934-41. http://www.ncbi.nlm.nih.gov/pubmed/8911360 Huncharek M, Geschwind J-F, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000;53(7):676-80. http://www.ncbi.nlm.nih.gov/pubmed/10941943 Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001;21(1B):765-70. http://www.ncbi.nlm.nih.gov/pubmed/11299841 Sylvester RJ, Oosterlinck W and Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non muscle invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008;53(4):709-19. http://www.ncbi.nlm.nih.gov/pubmed/18207317 Au JL, Baladament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ; International Mitomycin C Consortium. International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93(8):597-604. http://www.ncbi.nlm.nih.gov/pubmed/11309436 Kuroda M, Niijima T, Kotake T, Akaza H, Hinotsu S; 6th Trial of the Japanese Urological Cancer Research Group. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer –The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 2004;45(5):600-5. http://www.ncbi.nlm.nih.gov/pubmed/15082202 Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, Mason MD. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88(3):209-16. http://www.ncbi.nlm.nih.gov/pubmed/11488731 Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67(6):1216-23. http://www.ncbi.nlm.nih.gov/pubmed/16765182 Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a metaanalysis of randomized trials. BJU Int 2004;93(4):485-90. http://www.ncbi.nlm.nih.gov/pubmed/15008714 Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):90-5. http://www.ncbi.nlm.nih.gov/pubmed/12478111 Böhle A, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63(4):682-7. http://www.ncbi.nlm.nih.gov/pubmed/15072879
LIMITED TEXT UPDATE MARCH 2009
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168(5):1964-70. http://www.ncbi.nlm.nih.gov/pubmed/12394686 Huncharek, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder. Am J Clin Oncol. 2003;26(4):402- 7. http://www.ncbi.nlm.nih.gov/pubmed/12902895 Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 2004;27(5):522-8. http://www.ncbi.nlm.nih.gov/pubmed/15596924 Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarasody MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163(4):1124-9. http://www.ncbi.nlm.nih.gov/pubmed/10737480 Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decok M, Pirson M, Jurion F, Palfliet K, Denis O, Simon J, Schulmann CC. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000;37(4):470-7. http://www.ncbi.nlm.nih.gov/pubmed/10765079 Martinez-Pineiro JA, Flores N, Isorna S, Solsona E, Sebastian JL, Pertusa C, Rioja LA, MartinezPineiro L, Vela R, Camacho JE, Nogueira JL, Pereira I, Resel L, Muntanola P, Galvis F, Chesa N, de Torres JA, Carballido J, Bernuy C, Arribas S, Madero R; for CUETO (Club Urológico Español De Tratamiento Oncológico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89(7):671-80. http://www.ncbi.nlm.nih.gov/pubmed/11966623 Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Gomez JM, Martin MG, Molina JR, Collado AG, Flores N, Isorna S, Pertusa C, Rabadan M, Astobieta A, Camacho JE, Arribas S, Madero R; Club Urológico Español De Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174(4 Pt 1):1242-7. http://www.ncbi.nlm.nih.gov/pubmed/16145378 Ojea A, Nogueira JL, Solsona E, Flores N, Fernández Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R; CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: lowdose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C. Eur Urol 2007;52(5):1398-1406. http://www.ncbi.nlm.nih.gov/pubmed/17485161 van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta, T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44(4):429-34. http://www.ncbi.nlm.nih.gov/pubmed/14499676 Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003;169(5):1706-8. http://www.ncbi.nlm.nih.gov/pubmed/12686813 Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH. High grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005:66 (6 Suppl 1):90-107. http://www.ncbi.nlm.nih.gov/pubmed/16399418 Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000;164(3 Pt 1):685-9. http://www.ncbi.nlm.nih.gov/pubmed/10953125 Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007;177(4):1283-6. http://www.ncbi.nlm.nih.gov/pubmed/17382713
LIMITED TEXT UPDATE MARCH 2009
17
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
18
Oge O, Erdem E, Atsu N, Ahin A, Ozen H. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. Eur Urol 2000;37(3):271-4. http://www.ncbi.nlm.nih.gov/pubmed/10720851 Holmäng S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001;165(4);1124-8. http://www.ncbi.nlm.nih.gov/pubmed/11257652 Fujii Y, Kawakami S, Koga F, Nemoto T, Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 2003;92(6):559-62. http://www.ncbi.nlm.nih.gov/pubmed/14511033 Leblanc B, Duclos AJ, Bénard F, Côté J, Valiquette L, Paquin JM, Mauffette F, Faucher R, Perreault JP.Long-term follow-up of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 1999;162(6);1946-50. http://www.ncbi.nlm.nih.gov/pubmed/10569544 Zieger K, Wolf H, Olsen PR, Hojgaard K. Long-term follow-up of non-invasive bladder tumours (stage Ta): recurrence and progression. BJU Int 2000;85(7):824-8. http://www.ncbi.nlm.nih.gov/pubmed/10792160 Borhan A, Reeder JE, O’Connell MJ, Wright KO, Wheeless LL, di Sant’ Agnese PA, McNally ML, Messing EM. Grade progression and regression in recurrent urothelial cancer. J Urol 2003;169(6):2106-9. http://www.ncbi.nlm.nih.gov/pubmed/12771728 Soloway M, Bruck DS, Kim SS. Expectant management of small recurrent, non-invasive papillary bladder tumours. J Urol 2003;170(2 Pt 1):438-41. http://www.ncbi.nlm.nih.gov/pubmed/12853794 Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 2006;49(2):303-7. http://www.ncbi.nlm.nih.gov/pubmed/16413659 Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002;167(4):1634-7. http://www.ncbi.nlm.nih.gov/pubmed/11912378 Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 2005;173(4):1008-11. http://www.ncbi.nlm.nih.gov/pubmed/15758711
LIMITED TEXT UPDATE MARCH 2009
11. ABBREVIATIONS USED IN THE TEXT
This list is not comprehensive for the most common abbreviations.
5-ALA ASR BCG CIS CT CUETO EAU EORTC HAL ISUP IVU PUNLMP TNM TUR UICC US WHO
5-aminolaevulinic acid age-standardized rate bacillus Calmette-Guérin carcinoma in situ computed tomography Club Urológico Español de Tratamiento Oncológico (Spanish Oncology Group) European Association of Urology European Organization for Research and Treatment of Cancer hexaminolaevulinic acid International Society of Urological Pathology intravenous urography papillary urothelial neoplasms of low malignant potential tumour, node, metastasis transurethral resection Union International Contre le Cancer ultrasonography World Health Organization
Conflict of interest All members of the Non-Muscle Invasive Bladder Cancer guidelines writing panel have provided disclosure statements of all relationships which they have and which may be perceived as a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
LIMITED TEXT UPDATE MARCH 2009
19
20
LIMITED TEXT UPDATE MARCH 2009
Guidelines on
Bladder Cancer Muscle-invasive and Metastatic A. Stenzl, N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes
© European Association of Urology 2009
TABLE OF CONTENTS
PAGE
1
INTRODUCTION
5
2
EPIDEMIOLOGY AND RISK FACTORS 2.1 Epidemiology 2.2 Risk factors for bladder cancer 2.3 Conclusions 2.4 Recommendation 2.5 References
5 5 6 7 7 7
3 CLASSIFICATION 3.1 Tumour, Nodes, Metastases Classification (TNM) 3.2 Histological grading of non-muscle-invasive bladder tumours 3.2.1 WHO/ISUP grading 3.3 References 3.4 Pathology 3.4.1 Urologist handling of the specimens 3.4.2 Pathologist handling of the specimens 3.4.3 Pathology of muscle-invasive bladder cancer 3.4.4 Guidelines on assessment of tumour specimens 3.5 References
8 8 9 9 9 9 9 10 10 10 10
4 DIAGNOSIS AND STAGING 4.1 Diagnosis 4.1.1 Symptoms 4.1.2 Physical examination 4.1.3 Imaging 4.1.3.1 Intravenous urography and CT scan 4.1.3.2 Ultrasonography 4.1.4 Urinary cytology and urinary markers 4.1.5 Cystoscopy 4.1.6 Transurethral resection of invasive bladder tumours 4.1.7 Bladder and prostatic urethral biopsy 4.1.8 Fluorescence cystoscopy 4.1.9 Second resection 4.1.10 Concomitant prostate cancer 4.1.11 Recommendations for primary assessment of presumably invasive bladder tumours 4.1.12 References 4.2 Imaging for staging in verified bladder tumours 4.2.1 Local staging of invasive bladder cancer 4.2.1.1 MR imaging for local staging of invasive bladder cancer 4.2.1.2 CT for local staging of invasive bladder cancer 4.2.2 Imaging of nodal involvement 4.2.3 Extravesical urothelial carcinoma 4.2.4 Distant metastases other than lymph nodes 4.2.5 Conclusions 4.2.6 Recommendations for staging 4.3 References
11 11 11 11 11 11 11 11 12 12 12 12 12 13 13 13 14 15 15 15 15 15 15 15 16 16
5
17 17 18 18 18
2
TREATMENT FAILURE OF NON-MUSCLE INVASIVE BLADDER TUMOURS 5.1 High-risk non-muscle-invasive urothelial carcinoma 5.2 Carcinoma in situ 5.3 Recommendations 5.4 References
UPDATE MARCH 2008
6
NEOADJUVANT CHEMOTHERAPY 6.1 Conclusions 6.2 Recommendations 6.3 References
20 21 21 21
7 RADICAL SURGERY AND URINARY DIVERSION 7.1 Removal of the tumour bearing bladder 7.1.1 Background 7.1.2 Timing and delay of cystectomy 7.1.3 Indications 7.1.4 Technique and extent 7.1.5 Laparoscopic cystectomy 7.2 Urinary diversion after radical cystectomy 7.2.1 Ureterocutaneostomy 7.2.2 Ileal conduit 7.2.3 Continent cutaneous urinary diversion 7.2.4 Ureterocolonic diversion 7.2.5 Orthotopic neobladders 7.3 Morbidity and mortality 7.4 Survival 7.5 Conclusions 7.6 Recommendations 7.6.1 Recommendations for radical surgery 7.6.2 Recommendations for urinary diversion 7.7 References
23 23 23 24 24 24 25 25 25 25 25 26 26 26 26 26 27 27 27 27
8
NON-RESECTABLE TUMOURS 8.1 Palliative cystectomy for muscle-invasive bladder carcinoma 8.2 Conclusions 8.3 Recommendations 8.4 References
31 31 31 32 32
NEOADJUVANT BLADDER CANCER 9 neoadjuvantRADIOTHERAPY radioactivityINinMUSCLE-INVASIVE muscle-invasive bladder cancer 9.1 Pre-operative radiotherapy 9.1.1 Retrospective studies 9.1.2 Randomized studies 9.2 Conclusions 9.3 Recommendation s 9.4 References
32 32 32 32 33 33 33
10 BLADDER-SPARING TREATMENTS 10.1 Transurethral resection of bladder tumour (TURBT) 10.1.1 Conclusion and recommendation 10.1.2 References 10.2 External beam radiotherapy 10.2.1 Conclusions 10.2.2 Recommendation 10.2.3 References 10.3 Chemotherapy 10.3.1 Conclusion 10.3.2 Recommendation 10.3.3 References 10.4 Multimodality treatment 10.4.1 Conclusions 10.4.2 Recommendations 10.4.3 References
34 34 35 35 35 35 35 35 36 36 36 37 37 37 38 38
UPDATE MARCH 2008
3
11
ADJUVANT CHEMOTHERAPY 11.1 Conclusion 11.2 Recommendation 11.3 References
38 39 39 39
12
METASTATIC DISEASE 12.1 Prognostic factors and treatment decisions 12.2 Single-agent chemotherapy 12.3 Standard first-line chemotherapy for ‘fit’ patients 12.4 Carboplatin-containing chemotherapy in ‘fit’ patients 12.5 Non-platinum combination chemotherapy 12.6 Chemotherapy in patients ‘unfit”’ for cisplatin 12.7 Second-line treatment 12.8 Low-volume disease and post-chemotherapy surgery 12.9 Conclusions 12.10 Recommendations 12.11 References
40 40 40 41 41 41 41 41 42 42 42 42
13.
QUALITY OF LIFE 13.1 Conclusions 13.2 Recommendations 13.3 References
47 48 48 48
14
FOLLOW-UP 14.1 Conclusions and recommendations according to condition 14.2 General recommendations for follow-up 14.3 References
50 50 51 51
15
ABBREVIATIONS USED IN THE TEXT
53
4
UPDATE MARCH 2008
1. INTRODUCTION The EAU guideline group for muscle-invasive and metastatic bladder cancer (MiM-BC) have prepared this guideline to help urologists assess the evidence-based management of muscle-invasive and metastatic bladder cancer and to incorporate the guideline recommendations into their clinical practice. Publications concerning muscle-invasive and metastatic bladder cancer are mostly based on retrospective analysis, including some larger multicentre studies and well-designed controlled studies. Only a few randomized studies are available, so that it is difficult to obtain high-level evidence-based data. The recommendations provided in the current guidelines are based on a systemic literature search using Medline, the Cochrane Central Register of Systematic Reviews, and reference lists in publications and review articles. There is clearly a need for continuous re-evaluation of the information presented in the current guideline by an expert panel. It has to be emphasized that the current guideline contains information for the treatment of an individual patient according to a standardized approach. The information should be considered as providing recommendations without legal implications. The level of evidence and grade of recommendation provided in this guideline follow the listings in Table 1. The aim of grading the recommendations is to provide transparency between the underlying evidence and the recommendation given. Table 1: Levels of evidence and grade of guideline recommendations as used by EAU (1) Level Type of evidence 1a Evidence obtained from meta-analysis of randomized trials 1b Evidence obtained from at least one randomized trial 2a Evidence obtained from one well-designed controlled study without randomization 2b Evidence obtained from at least one other type of well-designed quasi-experimental study 3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports 4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities Grade Nature of recommendations A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomized trial B Based on well-conducted clinical studies, but without randomized clinical trials C Made despite the absence of directly applicable clinical studies of good quality
1.1
Reference
1.
Modified from Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [access date February 2009].
2. EPIDEMIOLOGY AND RISK FACTORS 2.1
Epidemiology
In 2006, in Europe, an estimated 104,400 incident cases of bladder cancer were diagnosed, of which 82,800 were diagnosed in men and 21,600 in women. This represents 6.6% of the total cancers in men and 2.1% in women, with an estimated male-to-female ratio of 3.8:1. In men, bladder cancer was the fourth most common cancer. Bladder cancer resulted in 4.1% of total deaths for cancer in men and 1.8% of total deaths in women (1). At the initial diagnosis of bladder cancer, 70% of cases are diagnosed as non-muscle-invasive disease and 30% as muscle-invasive disease. Among patients treated with radical cystectomy because of muscle-invasive disease, 57% had muscle invasion at presentation, while 43% had been initially diagnosed with non-muscle-invasive disease that progressed despite organ-preserving treatment (2). Approximately onethird of patients diagnosed with muscle-invasive bladder cancer have undetected metastasis at the time of treatment of the primary tumour (3), while 25% of patients submitted to radical cystectomy present with lymph node involvement at the time of surgery.
UPDATE MARCH 2008
5
2.2
Risk factors for bladder cancer
Tobacco smoking. Tobacco smoking is the most well-established risk factor for bladder cancer, causing about 50-65% of male cases and 20-30% of female cases. A casual relationship has been established between an exposure to tobacco and cancer in studies in which chance, bias and confounding can be ruled out with reasonable confidence (4). The alleged carcinogenic constituents of tobacco smoke include arylamines, particularly the potent carcinogen 4-aminobiphenyl, polycyclic aromatic hydrocarbons (PAHs), N-nitroso compounds, heterocyclic amines and various epoxides. The incidence of bladder cancer is directly related to the duration of smoking and number of cigarettes smoked per day (5). There is also a higher risk of bladder cancer in those who start smoking at a young age and for those exposed to environmental tobacco smoke during childhood (6). An immediate decrease in the risk of bladder cancer has been observed in those who quit smoking. This reduction was about 40% within 1 to 4 years of quitting smoking and reached 60% after 25 years of cessation (5). The promotion of cessation of smoking would result in the incidence of bladder cancer decreasing equally in men and women. Occupational exposure to chemicals. Occupational exposure is the second most important risk factor for bladder cancer. Work-related cases account for 20-25% of all bladder cancer cases in several series. The substances involved in chemical exposure have been benzene derivatives and arylamines (2-naphthylamine, 4-ABP, 4,4’-methylenedianiline and o-toluidine). Professions in which this exposure occurs include those that use dyes, rubbers, textiles, paints, leathers and chemicals (7). Because of strict regulations, these chemicals have contributed minimally to the current incidence of bladder cancer in Western countries. In fact, a trend towards a decrease in bladder cancer due to occupational exposure has been reported in a pooled analysis of 11 case-control studies on bladder cancer conducted in European countries between 1976 and 1996 (8). An example of occupational exposure is aromatic amines, which are established carcinogens for urothelium and which can be inactivated by a metabolic acetylation pathway. It has been postulated that patients with slow acetylation capability were more susceptible to bladder cancer than rapid acetylators. NAT1 and NAT-2 are N-acetyltransferase genes located on the short arm of human chromosome 8 and involved in amine inactivation. The presence of an NAT2 slow acetylation genotype has been related to a higher risk of bladder cancer (9). Other risk factors include phenacetin, which was included in 1987 among proven human carcinogens by the International Agency for Research on Cancer (IARC). Some studies have suggested that the risk of bladder cancer due to phenacetin is dose-dependent; however, the data is controversial concerning its metabolite acetaminophen (10). External beam radiation therapy. Increased rates of secondary bladder malignancies have been reported after external beam radiation therapy (EBRT) for gynaecological malignancies with relative risks of 2 to 4 (11). In patients treated for prostate cancer, the incidence of bladder cancer was significantly lower in patients treated with radical prostatectomy than in patients who underwent EBRT (12). Dietary factors. Several dietary factors had been related to bladder cancer, but the results of different studies have been controversial. Currently, there is limited evidence of a causal relationship between bladder cancer and dietary factors. A meta-analysis of 38 articles reporting data on diet and bladder cancer supported the hypothesis that vegetable and fruit intake reduced the risk of bladder cancer (13). Chronic urinary tract infection. Muscle-invasive bladder cancer, particularly invasive squamous cell carcinoma, is directly related to the presence of chronic urinary tract infection. Bladder schistosomiasis has been considered a definitive cause of urinary bladder cancer with an associated five-fold risk. Schistosomiasis is the second most common parasitic infection after malaria, with about 600 million people exposed to infection in Africa, Asia, South America and the Caribbean (14). In the same way as cyclophosphamide, an alkylating agent used for treatment of lymphoproliferative diseases and other non-neoplastic diseases, it has been correlated with posterior development of muscle-invasive bladder cancer with a period of latency of 6-13 years. Acrolein is a metabolite of cyclophosphamide and is responsible for an increase in the incidence of bladder cancer, which is independent of the occurrence of haemorrhagic cystitis related to the same treatment (15, 16). Gender. Finally, differences in bladder cancer incidence by gender have been studied. In a retrospective study of patients submitted to radical cystectomy, it was demonstrated that women are more likely to be diagnosed with primary muscle-invasive disease than men (85% vs 51%) (2). It has been proposed that women are more likely to be older than men when diagnosed with a direct effect on their survival. In addition, delayed diagnosis is more likely in women after haematuria is observed because the differential diagnosis in women includes diseases more prevalent than bladder cancer (17). Differences in the gender prevalence of bladder cancer may also be due to other factors than tobacco and chemical exposure. In a large prospective cohort study, post-menopausal status was associated with
6
UPDATE MARCH 2008
an increase in bladder cancer risk even after adjusting for smoking status. Thus, the differences in oestrogen and androgen levels between men and women could be responsible for some of the difference in gender prevalence of bladder cancer (18).
2.3
Conclusions
• •
The incidence of muscle invasive disease has not changed for a period of 5 years. Active and passive tobacco smoking continues to be the major risk factor while exposure-related incidence is decreasing (Level of evidence: 2a). The estimated male to female ratio was 3.8:1, with women more likely to be diagnosed with primary muscle invasive disease than men. Currently, treatment decisions cannot be based on molecular markers.
• •
2.4
Recommendation
•
The most important primary prevention for muscle-invasive bladder cancer is to eliminate active and passive smoking (Grade of recommendation: B).
2.5
References
1.
Ferlay J, Autier P, Boniol M. Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581-92. http://www.ncbi.nlm.nih.gov/pubmed/17287242 Vaidya A, Soloway MS, Hawke C, Tiguert R, Civantos F. De novo muscle invasive bladder cancer: is there a change in trend?. J Urol 2001;165(1):47-50. http://www.ncbi.nlm.nih.gov/pubmed/11125361 Prout GR Jr, Griffin PP, Shipley WU. Bladder carcinoma as a systemic disease. Cancer 1979;43(6):2532-9. http://www.ncbi.nlm.nih.gov/pubmed/455239 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004;83:1-1438. http://www.ncbi.nlm.nih.gov/pubmed/15285078 Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, Lopez-Abente G, Tzonou A, ChangClaude J, Bolm-Audorff U, Jöckel KH, Donato F, Serra C, Wahrendorf J, Hours M, T’Mannetje A, Kogevinas M, Boffetta P. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 casecontrol studies. Int J Cancer 2000;86(2):289-94. http://www.ncbi.nlm.nih.gov/pubmed/10738259 Bjerregaard BK, Raaschou-Nielsen O, Sørensen M, Frederiksen K, Christensen J, Tjønneland A, Overvad K, Chapelon FC, Nagel G, Chang-Claude J, Bergmann MM, Boeing H, Trichopoulos D, Trichopoulou A, Oikonomou E, Berrino F, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, Buenode-Mesquita HB, Kiemeney L, Gram IT, Braaten T, Lund E, Gonzalez CA, Berglund G, Allen N, Roddam A, Bingham S, Riboli E. Tobacco smoke and bladder cancer–in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2006;119(10):2412-6. http://www.ncbi.nlm.nih.gov/pubmed/16894557 Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002;10(6):311-22. http://www.ncbi.nlm.nih.gov/pubmed/15285078 Kogevinas M, T’Mannetje A, Cordier S, Ranft U, González CA, Vineis P, Chang-Claude J, Lynge E, Wahrendorf J, Tzonou A, Jöckel KH, Serra C, Porru S, Hours M, Greiser E, Boffetta P. Occupation and bladder cancer among men in Western Europe. Cancer Causes and Control 2003;14(10):907-14. http://www.ncbi.nlm.nih.gov/pubmed/14750529 García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366(9486):649-59. http://www.ncbi.nlm.nih.gov/pubmed/16112301 Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK.Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000;82(7):1364-9. http://www.ncbi.nlm.nih.gov/pubmed/10755416 Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 2006;174(1):107-10. http://www.ncbi.nlm.nih.gov/pubmed/15947588
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
UPDATE MARCH 2008
7
12.
13.
14.
15.
16.
17.
18.
Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll PR, Kane CJ; Cancer of the Prostate Strategic Urologic Research Endeavor Investigators. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2007;177(3):883-7. http://www.ncbi.nlm.nih.gov/pubmed/17296367 Steinmaus CM, Nuñez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000;151(7):693-702. http://www.ncbi.nlm.nih.gov/pubmed/10752797 [No authors listed.] Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June, 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241. http://www.ncbi.nlm.nih.gov/pubmed/7715068 Kaldor JM, Day NE, Kittelmann B, Pettersson F, Langmark F, Pedersen D, Prior P, Neal F, Karjalainen S, Bell J et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a casecontrol study. Int J Cancer 1995;63(1):1-6. http://www.ncbi.nlm.nih.gov/pubmed/7558434 Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J et al. Bladder and kidney cancer following cyclophosphamide therapy for nonHodgkin’s lymphoma. J Natl Cancer Inst 1995;87(7):524-30. http://www.ncbi.nlm.nih.gov/pubmed/7707439 Cárdenas-Turanzas M, Cooksley C, Pettaway CA, Sabichi A, Grossman HB, Elting L. Comparative outcomes of bladder cancer. Obstet Gynecol 2006;108(1):169-75. http://www.ncbi.nlm.nih.gov/pubmed/16816072 McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 2006;163(3):236-44. http://www.ncbi.nlm.nih.gov/pubmed/16319290
3. CLASSIFICATION 3.1
Tumour, Nodes, Metastases Classification (TNM)
The 2002 TNM classification approved by the Union International Contre le Cancer (UICC) has been widely accepted (Table 2) (1). It differs from the previous versions in the definition of stage T2 and T3 tumours.
Table 2: 2002 TNM classification of urinary bladder cancer T - Primary tumour TX Primary tumour cannot be assessed T0 No evidence of primary tumour Ta Non-invasive papillary carcinoma Tis Carcinoma in situ: ‘flat tumour’ T1 Tumour invades subepithelial connective tissue T2 Tumour invades muscle T2a Tumour invades superficial muscle (inner half) T2b Tumour invades deep muscle (outer half) T3 Tumour invades perivesical tissue T3a Microscopically T3b Macroscopically (extravesical mass) T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall T4a Tumour invades prostate, uterus or vagina T4b Tumour invades pelvic wall or abdominal wall N - Lymph nodes NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Metastasis in a single lymph node 2 cm or less in greatest dimension N2 Metastasis in a single lymph node more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, none more than 5 cm in greatest dimension N3 Metastasis in a lymph node more than 5 cm in greatest dimension
8
UPDATE MARCH 2008
M - Distant metastasis MX Distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis
3.2
Histological grading of non-muscle-invasive bladder tumours
In 1998, the new classification of non-invasive urothelial tumours was proposed by the World Health Organization (WHO) and the International Society of Urological Pathology (ISUP) (1998 WHO/ISUP classification). It was published by the WHO in 2004 (2, 3) (Table 3). Its major contribution is a detailed histological description of the various grades using specific cytological and architectural criteria. A website (www.pathology.jhu.edu/bladder) illustrating examples of various grades was developed to improve accuracy further in using the system. Table 3: WHO grading in 1973 and in 2004 (2, 3) 1973 WHO grading • Urothelial papilloma • Grade 1: well differentiated • Grade 2: moderately differentiated • Grade 3: poorly differentiated 2004 WHO grading • Urothelial papilloma • Papillary urothelial neoplasm of low malignant potential (PUNLMP) • Low-grade papillary urothelial carcinoma • High-grade papillary urothelial carcinoma 3.2.1 WHO/ISUP grading The 2004 WHO grading differentiates between papillary urothelial neoplasms of low malignant potential (PUNLMP) and low-grade and high-grade urothelial carcinomas. The PUNLMP are defined as lesions that do not have cytological features of malignancy but show normal urothelial cells in a papillary configuration. Although they have a negligible risk for progression, they are not completely benign and still have a tendency to recur. The intermediate grade (grade 2), which was controversial in the 1973 WHO classification, has been eliminated. The use of the 2004 WHO classification is advocated, as this should result in a uniform diagnosis of tumours, which will be better classified according to risk potential. However, until the 2004 WHO classification has been validated by more clinical trials, tumours should be graded using both the 1973 and the 2004 WHO classifications (4). Most clinical trials published so far on bladder tumours have been performed using the 1973 WHO classification and this edition of the guidelines therefore uses the 1973 WHO grade classification.
3.3
References
1.
Sobin DH, Wittekind Ch, eds. In: TNM Classification of Malignant Tumours. 6th edn. New York: WileyLiss, 2002; pp. 199-202. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22(12):1435-48. http://www.ncbi.nlm.nih.gov/pubmed/9850170 Sauter G, Algaba F, Amin M, Busch C, Cheville J, Gasser T, Grignon DJ, Hofstadter F, Lopez-Beltran A, Epstein JI. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein Jl, Sesterhenn I, eds. WHO classification of classification of tumors of the urinary system and male genital organs. Lyon: IARCC Press, 2004, pp. 29-34. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46(2):170-6. http://www.ncbi.nlm.nih.gov/pubmed/15245809
2.
3.
4.
3.4
Pathology
3.4.1 Urologist handling of the specimens In transurethral resection (TUR) specimens, the superficial and deep areas of the tumour must be sent to pathology separately. If random biopsies of the flat mucosa have been done, each biopsy of the flat mucosa must also be sent separately.
UPDATE MARCH 2008
9
In radical cystectomy, bladder fixation must be performed as soon as possible. The pathologist must open the specimen from the urethra to the bladder dome and fix the specimen in formalin. In some circumstances, this procedure can also be performed by the urologist. In a female cystectomy specimen, the length of the urethral segment removed en bloc with the specimen should be checked preferably by the urological surgeon (1). 3.4.2 Pathologist handling of the specimens Handling of specimens should follow the general rules as published by a collaborative group of pathologists and urologists (2). It must be stressed that it can be very difficult to certify the presence of a neoplastic lesion using gross examination of the cystectomy specimen after TUR or chemotherapy, and it is therefore necessary to include the entire retracted or ulcerated area. Of the margins, it is mandatory to study the urethra, ureter, the prostate in men, and radial margins (3). In urethra-sparing cystectomy, the level of urethral dissection, the completeness of the prostate specifically at the apex (in men), and the inclusion of the entire bladder neck and the amount of adjacent urethra (in women) should be documented. 3.4.3 Pathology of muscle-invasive bladder cancer At this stage, there are no cases of papillary urothelial neoplasms of low malignant potential and low-grade carcinoma. All cases are high-grade urothelial carcinomas (grade II or grade III in WHO 1973). For this reason, no more prognostic information can be provided by grading muscle-invasive bladder cancer (4). However, some morphological subtypes can be most important for prognosis and treatment decisions, as in: • Small-cell carcinomas • Urothelial carcinomas with squamous and/or glandular partial differentiation • Spindle cell carcinomas • Some urothelial carcinomas with trophoblastic differentiation. For staging, TNM 2002 is recommended. The pattern of muscular invasion can provide some prognostic information. Most cases show nodular or cordonal growth, but about 44% of cases show an infiltrative pattern. According to some authors (4), the median survival time of a patient with an infiltrative pattern is lower than with other pattern types (p = 0.06). Blood vessel invasion and lymph node infiltration have an independent prognostic significance (5). It seems that the pN category is closely associated with the number of lymph nodes studied by the pathologist. For this reason, some authors have observed that more than nine lymph nodes have to be investigated to reflect pN0 appropriately (6). New prognostic markers are under study (7). Currently, insufficient evidence exists to recommend the standard use of p53 as a prognostic marker in high-risk muscle-invasive disease, since it will not yield sufficient data upon which to base treatment in an individual patient. 3.4.4 GUIDELINES ON ASSESSMENT OF TUMOUR SPECIMENS Mandatory evaluations • Depth of invasion (categories pT2 vs pT3a, pT3b or pT4) • Margins with special attention paid to the radial margin • Histological subtype, if it has clinical implications • Extensive lymph node representation (more that eight) Optional evaluations • Bladder wall blood vessel invasion • Pattern of muscle invasion
3.5
REFERENCES
1. 2.
Stenzl A. Current Concepts for Urinary Diversion in Women. Eur Urol(EAU Update Series 1);2003:91-9. Lopez-Beltran A, Bassi PF, Pavone-Macaluso M, Montironi R, European Society of Uropathology; Uropathology Working Group. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group. Vichows Arch 2004;445(2):103-10. http://www.ncbi.nlm.nih.gov/pubmed/15185074 Herr HW. Pathologic evaluation of radical cystectomy specimens. Cancer 2002;95(3):668-9. http://www.ncbi.nlm.nih.gov/pubmed/12209761
3.
10
UPDATE MARCH 2008
4.
5.
6. 7.
Jimenez RE, Gheiler E, Oskanian P, Tiguert R, Sakr W, Wood DP Jr, Pontes JE, Grignon DJ. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progressionfree survival. Am J Surg Pathol 2000;24(7):980-7. http://www.ncbi.nlm.nih.gov/pubmed/10895820 Leissner J, Koeppen C, Wolf HK. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 2003;169:955-60. http://www.ncbi.nlm.nih.gov/pubmed/12576821 Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008;18(1):1-8. http://www.ncbi.nlm.nih.gov/pubmed/18090481 Tiguert R, Lessard A, So A, Fradet Y. Prognostic markers in muscle invasive bladder cancer. World J Urol 2002;20:190-5. http://www.ncbi.nlm.nih.gov/pubmed/12196903
4. DIAGNOSIS AND STAGING 4.1
Diagnosis
4.1.1 Symptoms Painless haematuria is a common finding. In addition, there is a group of patients who complain of urgency, dysuria, increased frequency and pelvic pain. Pelvic pain and all the symptoms related to urinary tract obstruction are found in more advanced tumours. 4.1.2 Physical examination Physical examination should include rectal and vaginal bimanual palpation. A palpable pelvic mass can be found in patients with locally advanced tumours. In addition, bimanual examination should be carried out before and after TUR to assess whether there is a palpable mass or the tumour fixed to the pelvic wall (1,2). 4.1.3 Imaging 4.1.3.1 Intravenous urography and CT scan Large tumours may be seen as filling defects in the bladder. Intravenous urography (IVU) is also used to detect filling defects in the calices, renal pelvis and ureters, and hydronephrosis, which may indicate the presence of a ureteral tumour. The necessity to perform routine intravenous pyelography once a bladder tumour has been detected is now questioned because of the low incidence of significant findings obtained with this method (3-5) (Level of evidence: 3). The incidence of upper urinary tract tumours is low (1.8%), but increases to 7.5% in tumours located in the trigone (4). In many centres, computed tomography (CT) urography is used as an alternative to conventional IVU (6). CT tomography gives more information than IVU, especially in invasive tumours of the upper tract (Level of evidence: 2a). 4.1.3.2 Ultrasonography Ultrasonography (US) is increasingly used as the initial tool to assess the urinary tract. This is not only because it avoids the use of contrast agents, but also because sensitive transducers have improved imaging of the upper urinary tract and bladder. Transabdominal US permits characterization of renal masses, detection of hydronephrosis and visualization of intraluminal filling defects in the bladder. Combined with plain abdominal film, it can be as accurate as IVU in diagnosing the cause of haematuria (1, 2) (Level of evidence: 3). 4.1.4 Urinary cytology and urinary markers Examination of a voided urine or bladder-washing specimen for exfoliated cancer cells has high sensitivity in high-grade tumours (Level of evidence: 3). It is therefore useful when a high-grade malignancy or carcinoma in situ (CIS) is present. Positive urinary cytology may indicate urothelial tumour anywhere in the urinary tract from the calix, through the ureters, into the bladder and proximal urethra. Cytological interpretation is user-dependent (7). The evaluation can be hampered by low cellular yield, urinary tract infections, stones or intravesical instillations. In experienced hands, however, specificity exceeds 90% (8) (Level of evidence: 2b). Cytology should be performed on fresh urine with adequate fixation. Morning urine is not suitable as cytolysis may be often present. There is no urinary marker registered specifically for the diagnosis of invasive bladder cancer. However, since most invasive tumours are high-grade, the positive predictive value of markers may be higher.
UPDATE MARCH 2008
11
4.1.5 Cystoscopy The diagnosis of bladder cancer ultimately depends on cystoscopic examination of the bladder and histological evaluation of the resected tissue. In general, cystoscopy is initially performed in the office, using flexible instruments. If a bladder tumour has been visualized in earlier imaging studies, such as 3D ultrasonography, multidetector row CT or MRI a diagnostic cystoscopy can be omitted since the patient will undergo TUR for a histological diagnosis. A careful description of the finding is necessary. It should include the site, size, number and appearance (papillary or solid) of the tumours as well as a description of mucosal abnormalities. Use of a bladder diagram is recommended. 4.1.6 Transurethral resection of invasive bladder tumours The goal of TUR is to make the correct diagnosis, which means including bladder muscle in the resection biopsies. The strategy of resection depends from the size of the lesion. Small tumours (less than 1 cm) can be resected en bloc, where the specimen contains the complete tumour plus a part of the underlying bladder wall including bladder muscle. Larger tumours have to be resected separately in fractions, which include the exophytic part of the tumour, the underlying bladder wall with the detrusor muscle and the edges of the resection area. The specimens from different fractions must be referred to the pathologist in separate containers to enable him to make a correct diagnosis. Cauterization has to be avoided as much as possible during the resection to prevent tissue destruction. 4.1.7 Bladder and prostatic urethral biopsy Bladder tumours are often multifocal. Moreover tumours can be accompanied by CIS or dysplasia. These lesions may present themselves as velvet-like, reddish areas, indistinguishable from inflammation or may be not visible at all. The biopsies from normal-looking mucosa in patients with bladder tumours, so called random biopsies (R-biopsies) or selected site mucosal biopsies, are only recommended if fluorescent areas are seen with photodynamic diagnosis (PDD). Cold cup biopsies from normal-looking mucosa should be performed when cytology is positive, when exophytic tumour is of non-papillary appearance, or when fluorescent areas are seen with PDD. When abnormal areas of urothelium are seen, it is advised to take ‘cold cup’ biopsies or biopsies with a resection loop. Material obtained by random or directed biopsies must be sent for pathological assessment in separate containers. The involvement of the prostatic urethra and ducts in male patients with bladder tumours has been reported. Although the exact risk is not known, it seems to be higher if tumour is located on the trigone or bladder neck, in the presence of bladder CIS and in multiple tumours (9, 10) (Level of evidence: 3). In these cases and when cytology is positive or when abnormalities of prostatic urethra are visible, biopsies of the prostatic urethra are recommended. The biopsy is taken using resection loop from the precolicular area. Special care must be taken with tumours at the bladder neck and trigone in female patients where urethral preservation in subsequent orthotopic neobladder is planned. Tumour bladder neck biopsies are advisable but not mandatory, provided frozen section at the urethral margin is taken at the time of surgery (Level of evidence 4). 4.1.8 Fluorescence cystoscopy As a standard procedure, cystoscopy and TUR are performed using white light. However, the use of white light may lead to missing lesions that are present but not visible. Fluorescence cystoscopy is performed using filtered blue light after intravesical instillation of a photosensitizer, usually (5-ALA) or hexaminolaevulinate (HAL). It has been confirmed that fluorescenceguided biopsy and resection are more sensitive than conventional procedures in detecting malignant tumour, particularly CIS (11-13) (Level of evidence: 2a). However, false-positive results can be induced by inflammation, a recent TUR, or intravesical instillation therapy. 4.1.9 Second resection There is a significant risk of residual tumour after the initial TUR (14, 15) (Level of evidence: 1). Persistent disease was observed in 33-53% of patients (15-21). Moreover, the tumour may be understaged by the initial resection. There is a 10% probability that tumours initially staged as being of a lower stage are in fact muscleinvasive (16, 17). Correct staging is extremely important since it will directly affect the treatment modality. A second TUR should always be performed when the initial resection has been incomplete, e.g. when multiple and/or large tumours are present, or when the pathologist has reported that the specimen contained no muscle tissue. Furthermore, a second TUR should be performed when a high-grade, non-muscle-invasive tumour or a T1 tumour has been detected at the initial TUR. There is no consensus about the strategy and
12
UPDATE MARCH 2008
timing of a second TUR. Most authors recommend resection at 2-6 weeks after the initial TUR. The procedure should include a resection of the primary tumour site. 4.1.10 Concomitant prostate cancer Ruling out progressive prostate cancer should be considered since 25-46% of patients submitted to cystectomy for bladder cancer (22) appear to have prostate cancer on final pathology. Unless the entire prostate is to be removed during cystectomy, any type of prostate cancer should be excluded. 4.1.11 Recommendations for primary assessment of presumably invasive bladder tumours • Renal and bladder ultrasonography, IVU or CT prior to TUR (Grade of recommendation: B). • Cystoscopy with description of the tumour (site, size, number and appearance) and mucosal abnormalities. A bladder diagram is recommended (Grade of recommendation: C). • TUR in one piece for small tumours (less than 1 cm), including a part from the underlying bladder muscle wall (Grade of recommendation: B). • TUR in fractions (including muscle tissue) for larger tumours (Grade of recommendation: B). • Biopsies of abnormal-looking urothelium, biopsies from normal-looking mucosa when cytology is positive or when exophytic tumour is of non-papillary appearance or in case of fluorescence if PDD is used (Grade of recommendation: C). • Biopsy of the prostatic urethra in the case of bladder neck tumour, when bladder CIS is present or suspected or when abnormalities of prostatic urethra are visible (Grade of recommendation: C). • Careful inspection with histological evaluation of the bladder neck and urethral margin, either prior to or at the time of cystoscopy in women undergoing a subsequent orthotopic neobladder (Grade of recommendation: C). • A second TUR at 2-6 weeks after the initial resection when it was incomplete or when a high-grade or T1 tumour was detected (Grade of recommendation: B). • The pathological report should specify the grade, the depth of tumour invasion and whether the lamina propria and muscle are present in the specimen (Grade of recommendation: C). 4.1.12 References 1. Fossa SD, Ous S, Berner A. Clinical significance of the ‘palpable mass’ in patients with muscle infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. Br J Urol 1991;67(1):54-60. http://www.ncbi.nlm.nih.gov/pubmed/1993277 2. Wijkstrom H, Norming U, Lagerkvist M, Nilsson B, Naslund I, Wiklund P. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. Br J Urol 1998;81(5):686-91. http://www.ncbi.nlm.nih.gov/pubmed/9634042 3. Goessl C, Knispel HH, Millar K, Klan R. Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol 1997;157(2):480-1. http://www.ncbi.nlm.nih.gov/pubmed/8996338 4. Palou J, Rodriguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A, Villavicencio H. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumors. J Urol 2005;174(3):859-61. http://www.ncbi.nlm.nih.gov/pubmed/16093970 5. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. Long-term follow-up of a bladder carcinoma cohort: routine followup urography is not necessary. J Urol 1998;160(1):45-8. http://www.ncbi.nlm.nih.gov/pubmed/9628602 6. Nolte-Ernsting C, Cowan N. Understanding multislice CT urography techniques: many roads lead to Rome. Eur Radiol 2006;16(12):1670-86. http://www.ncbi.nlm.nih.gov/pubmed/16953373 7. Raitanen M-P, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, Tammela TL; FinnBladder Group. Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41(3):284-9. http://www.ncbi.nlm.nih.gov/pubmed/12180229 8. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 2005;66 (6 Suppl 1):35-63. http://www.ncbi.nlm.nih.gov/pubmed/16399415
UPDATE MARCH 2008
13
9.
10.
11.
12.
13.
14.
15.
16.
16.
18.
19.
20.
21.
22.
4 .2
Matzkin H, Soloway MS, Hardeman S. Transitional cell carcinoma of the prostate. J Urol 1991;146(5):1207-12. http://www.ncbi.nlm.nih.gov/pubmed/1942262 Mungan MU, Canda AE, Tuzel E, Yorukoglu K, Kirkali Z. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol 2005;48(5):760-3. http://www.ncbi.nlm.nih.gov/pubmed/16005563 Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M; Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171(1):135-8. http://www.ncbi.nlm.nih.gov/pubmed/14665861 Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, Johansson E, Gartner T, Lange N, van den Bergh H, Leisinger HJ. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for photodiagnosis of superficial bladder cancer –a multicenter study. J Urol 2003;170(1):226-9. http://www.ncbi.nlm.nih.gov/pubmed/12796694 Hungerhuber E, Stepp H, Kriegmair M, Stief Ch, Hofstetter A, Hartmann A, Knuechel R, Karl A, Tritschler S, Zaak D. Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007;69(2):260-4. http://www.ncbi.nlm.nih.gov/pubmed/17320660 Brausi M, Collette L, Kurth K, van der Meijden A, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester R; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41(5):523-31. http://www.ncbi.nlm.nih.gov/pubmed/12074794 Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003;43(3):241-5. http://www.ncbi.nlm.nih.gov/pubmed/12600426 Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004;45(5):539-46. http://www.ncbi.nlm.nih.gov/pubmed/15082193 Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165(3):808-10. http://www.ncbi.nlm.nih.gov/pubmed/11176474 Schips L, Augustin H, Zigeuner RE, Gallé G, Habermann H, Trummer H, Pummer K, Hubmer G. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59(2):220-3. http://www.ncbi.nlm.nih.gov/pubmed/11834389 Grimm MO, Steinhoff Ch, Simon X, Spiegelhalder P, Ackermann R, Vögeli, TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170(2 Pt 1):433-7. http://www.ncbi.nlm.nih.gov/pubmed/12853793 Divrik RT, Yildirim Ü, Zorlu F, Özen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175(5):1641-4. http://www.ncbi.nlm.nih.gov/pubmed/16600720 Jahnson S, Wiklund F, Duchek M, Mestad O, Rintala E, Hellsten S, Malmström PU. Results of secondlook resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol 2005;39(3):206-10. http://www.ncbi.nlm.nih.gov/pubmed/16127800 Damiano R, Di Lorenzo G, Cantiello F, De Sio M, Perdona S, D’Armiento M, Autorino R. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol 2007;52(3):648-57. http://www.ncbi.nlm.nih.gov/pubmed/17600614
Imaging for staging in verified bladder tumours
Imaging is indicated only if there is a clinical consequence. The treatment and prognosis for invasive bladder cancer is determined by tumour stage and grade (1). Tumour staging must be accurate for selecting the correct treatment In clinical practice. The use of CT scan and magnetic resonance imaging (MRI) has largely replaced other imaging modalities for staging of invasive bladder cancer. The purpose of imaging for staging invasive bladder cancer is to:
14
UPDATE MARCH 2008
• Assess the extent of local tumour invasion • Detect tumour spread to lymph nodes • Detect tumour spread to other distant organs, (liver, lung, bones, peritoneum, pleura, kidney, adrenal gland and others). 4.2.1 Local staging of invasive bladder cancer Both CT and MRI may be used for assessment of local invasion (2) but they are unable to detect microscopic invasion of perivesical fat (T3a) (3). The aim of CT and MRI is therefore to detect T3b disease or higher. 4.2.1.1 MRI for local staging of invasive bladder cancer MRI has superior soft tissue contrast resolution compared with CT, but poorer spatial resolution. In studies performed before the availability of multidetector-row CT (MDCT), MRI was reported to be more accurate for local assessment. The accuracy of MRI for primary tumour staging varies from 73% to 96% (mean 85%). These values were 10-33% (mean 19%) higher than those obtained with CT (4). Fast dynamic contrast-enhanced MRI helps to differentiate bladder tumour from surrounding tissues because enhancement of the tumour occurs earlier than the normal bladder wall due to neovascularization (5, 6). Fast dynamic MRI with images acquired at one image per second helps to distinguish tumour from postbiopsy reaction (5). 4.2.1.2 CT for local staging of invasive bladder cancer The advantages of CT include shorter acquisition time, wider coverage in a single breath hold, and lower susceptibility to various patient factors. CT scan is unable to differentiate between stages Ta to T3a, but it is useful clinically for detecting invasion into the perivesical fat (T3b) and adjacent organs. The accuracy of CT in determining extravesical tumour extension varies from 55% to 92% (7) and increases with more advanced disease (8). A study by Kim et al. to determine the accuracy of MDCT for detection and staging of bladder cancer showed that CT had lower sensitivity (89%) and higher specificity (95%) compared to MRI for diagnosis of perivesical invasion, while the cancer detection rate and overall accuracy for perivesical invasion were similar (9). These findings are explained by better visualization of perivesical fat invasion on MRI, but because only mild inflammation around bladder cancers mimics perivesical invasion, this results in overstaging with MRI. 4.2.2 Imaging of nodal involvement The assessment of nodal status based simply on size is limited by the inability of both CT and MRI to identify metastases in normal sized or minimally enlarged nodes. Sensitivities for detection of lymph node metastases are low, ranging from 48% to 87%. Specificities are also lowas nodal enlargement may be due to benign pathology. Overall, the results of CT and MRI for detection of lymph node metastases in a variety of primary pelvic tumours are similar (10-14). Pelvic nodes greater than 8 mm and abdominal nodes greater than 10 mm in maximum short axis diameter (MSAD) should be regarded as enlarged on CT and MRI (15, 17). 4.2.3 Extravesical urothelial carcinoma MDCT urography is the technique of choice for diagnosing upper urinary tract urothelial cancer (18, 19). MDCT urography should be incorporated into the CT staging protocol to rule out extravesical carcinoma. 4.2.4 Distant metastases other than lymph nodes Prior to any treatment aimed at cure, it is essential to evaluate the presence of distant metastases. MDCT and MRI are the diagnostic tools of choice to detect metastases to lung and liver. Metastases to bones or brain at presentation of invasive bladder cancer are rare. Bone scan and additional brain imaging are therefore not routinely indicated unless the patient has specific symptoms or signs to suggest bone or brain metastases (20, 21). MRI is more sensitive and specific for diagnosing bone metastases than bone scintigraphy (22, 23) (Level of evidence: 2b). 4.2.5 Conclusions • Diagnosis of invasive bladder cancer is made by cystoscopy and biopsy. • Imaging is used for formal staging only if it will make a difference to the selection of treatment options. • In all T1 tumours considered for conservative treatment, a second TUR is recommended before deciding on definite treatment (Grade of recommendation: B). • MRI is still the preferred modality if the patient is considered for radical treatment. MDCT due to its higher specificity may be equivalvent to MRI regarding local staging.
UPDATE MARCH 2008
15
•
CT is recommended if there is suspicion of locally advanced or metastatic disease precluding radical treatment (Level of evidence: 2b-3).
4.2.6 Recommendations for staging • For optimal local staging, either MRI with fast dynamic contrast-enhancement or MDCT with contrast enhancement are recommended for patients considered suitable for radical treatment (Grade of Recommendation: B). • For patients with confirmed muscle-invasive bladder cancer, MDCT of the chest, abdomen and pelvis is the optimal form of staging, including MDCT urography for complete examination of the upper urinary tracts. If MDCT is not available, lesser alternatives are excretory urography and a chest X-ray (Grade of Recommendation: B).
4.3
References
1.
Jewett HJ. Proceedings: Cancer of the bladder. Cancer 1973;32(5):1072-4. http://www.ncbi.nlm.nih.gov/pubmed/4757902 Husband JE, Olliff JF, Williams MP, Heron CW, Cherryman GR. Bladder cancer: staging with CT and MR imaging. Radiology 1989;173(2):435-40. http://www.ncbi.nlm.nih.gov/pubmed/2798874 Paik ML, Scolieri MJ, Brown Sl, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 2000;163(6):1693-6. http://www.ncbi.nlm.nih.gov/pubmed/10799162 Barentsz JO, Jager GJ, Witjes JA, Ruijs JH. Primary staging of urinary bladder carcinoma: the role of MR imaging and a comparison with CT. Eur Radiol 1996;6(2):129-33. http://www.ncbi.nlm.nih.gov/pubmed/8797968 Barentsz JO, Jager GJ, van Vierzen PB, Witjes JA, Strijk SP, Peters H, Karssemeijer N, Ruijs SH. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology 1996;201(1):185-93. http://www.ncbi.nlm.nih.gov/pubmed/8816542 Mallampati GK, Siegelman ES. MR imaging of the bladder. Magn Reson Imaging Clin N Am 2004;12(3):545-55. http://www.ncbi.nlm.nih.gov/pubmed/15271370 Kundra V, Silverman PM. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol 2003 180(4):1045-54. http://www.ncbi.nlm.nih.gov/pubmed/12646453 Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadoliniumenhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994;193(1):239-45. http://www.ncbi.nlm.nih.gov/pubmed/8090898 Kim JK, Park S-Y, Ahn HJ, Kim CS, Cho KS. Bladder cancer: analysis of multidetector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 2004;231(3):725-31. http://www.ncbi.nlm.nih.gov/pubmed/15118111 Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared- rapid gradient-echo sequence. AJR Am J Roentgenol 1996;167(6):1503-7. http://www.ncbi.nlm.nih.gov/pubmed/8956585 Yang WT, Lam WW, Yu MY, Cheung TH, Metreweli C. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol 2000;175(3):759-66. http://www.ncbi.nlm.nih.gov/pubmed/10954463 Kim SH, Kim SC, Choi BI, Han MC. Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. Radiology 1994;190(3):807-11. http://www.ncbi.nlm.nih.gov/pubmed/8115631 Kim SH, Choi BI, Lee HP, Kang SB, Choi YM, Han MC, Kim CW. Uterine cervical carcinoma: comparison of CT and MR findings. Radiology 1990;175(1):45-51. http://www.ncbi.nlm.nih.gov/pubmed/2315503
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
16
UPDATE MARCH 2008
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Oyen RH, Van Poppel HP, Ameye FE, Van de Voorde WA, Baert AL, Baert LV. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 1994;190(2):315-22. http://www.ncbi.nlm.nih.gov/pubmed/8284375 Barentsz JO, Engelbrecht MR, Witjes JA, de la Rosette JJ, van der Graaf M. MR imaging of the male pelvis. Eur Radiol 1999;9(9):1722-36. http://www.ncbi.nlm.nih.gov/pubmed/10602944 Vinnicombe SJ, Norman AR, Nicolson V, Husband JE. Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography [published erratum appears in Radiology 1995 Sep;196(3):800]. Radiology 1995;194(2):349-55. http://www.ncbi.nlm.nih.gov/pubmed/7824709 Dorfman RE, Alpern MB, Gross BH, Sandler MA. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 1991;180(2):319-22. http://www.ncbi.nlm.nih.gov/pubmed/2068292 Cowan NC, Turney BW, Taylor NJ, McCarthy CL, Crew JP. Multidetector computed tomography urography (MDCTU) for diagnosing upper urinary tract tumour. BJU Int 2007;99(6):1363-70. http://www.ncbi.nlm.nih.gov/pubmed/17428251 Van Der Molen AJ, Cowan NC, Mueller-Lisse UG, Nolte-Ernsting CC, Takahashi S, Cohan RH; CT Urography Working Group of the European Society of Urogenital Radiology (ESUR). CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol 2008;18(1):4-17. http://www.ncbi.nlm.nih.gov/pubmed/17973110 Braendengen M, Winderen M, Fosså SD. Clinical significance of routine pre-cytectomy bone scans in patients with muscle-invasive bladder cancer. Br J Urol 1996;77(1):36-40. http://www.ncbi.nlm.nih.gov/pubmed/8653315 Brismar J, Gustafson T. Bone scintigraphy in staging bladder carcinoma. Acta Radiol 1988;29(2):2512. http://www.ncbi.nlm.nih.gov/pubmed/2965914 Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, Ruehm SG, Barkhausen J. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004;233(1):139-48. http://www.ncbi.nlm.nih.gov/pubmed/15317952 Schmidt GP, Schoenberg SO, Reiser MF, Baur-Melnyk A. Whole-body MR imaging of bone marrow. Eur J Radiol 2005;55(1):33-40. http://www.ncbi.nlm.nih.gov/pubmed/15950099
5. TREATMENT FAILURE OF NON-MUSCLE INVASIVE BLADDER TUMOURS 5.1
High-risk non-muscle-invasive urothelial carcinoma
The recurrence and progression rate of non-muscle-invasive bladder cancer is strongly associated with tumour grade and invasion into the lamina propria. The progression to T2 tumours varies from 6% to 25% in Ta and from 27% to 48% in T1 tumours of all grades. Inter- and intra-observer varying abilities in grading as well as staging and completeness of TUR are key variables confounding the results of present long-term studies of TUR, with or without intravesical therapy. The understaging error in TaT1 tumours of 35% to 62% presented in large cystectomy series is due to the presence of recurrent tumours of largely unknown pre-cystectomy therapy and the lack of a second TUR (1-3) (Level of evidence: 3). The latter identifies 24% to 49% T2 tumours diagnosed initially as non-muscleinvasive tumours (4, 5) (Level of evidence: 3). However, in spite of these disadvantages, recent meta-analyses have shown that intravesical therapy with Bacillus Calmette-Guerin (BCG) maintenance therapy prevents recurrence (6) and progression (7) - but not significantly overall- or disease specific survival - compared to no therapy, intravesical chemotherapy or a BCG induction course only (7, 8) (Level of evidence: 1). Especially in patients with small tumours (< 3 cm) and without associated CIS, the progression rate is low (20% within 5 years), with approximately 90% of patients keeping their intact bladder during follow-up of up to 10 years (9) (Level of evidence: 2). The EAU guidelines therefore recommend a complete TUR and intravesical therapy in patients with high-grade TaT1-tumours (10) (Grade of recommendation: C). Initial cystectomy can be considered based on tumour multiplicity, size, concomitant in situ cancer and
UPDATE MARCH 2008
17
urothelial tumour of the prostatic urethra (10) (Grade of recommendation: C). Although the percentage of patients with primary TaT1 tumours and the indication for cystectomy in TaT1 tumours is not specified in large cystectomy series, the 10-year recurrence-free survival is approximately 80% and similar to TUR and BCG maintenance therapy (1, 3, 11, 12) (Level of evidence: 3). In case of recurrent Ta/T1, mostly associated with carcinoma in situ, the understaging at time of cystectomy is 34%, but the 10-year survival is not significantly different for patients with pT1 and pT2 tumours (13) (Level of evidence: 3). This is in contrast to an earlier report indicating a significant worse outcome for patients with previous TUR(s) (14) (Level of evidence: 3). Undoubtedly, patients with muscle-invasive recurrence are best treated with radical cystectomy. However, the outcome in terms of presence of lymph node metastases and cancer-free survival may be inferior to patients with the same tumour stage, but who receive radical cystectomy at first presentation (15) (Level of evidence: 3). There is uncertainty about the treatment of patients who develop tumour recurrence in spite of BCG therapy because of different BCG therapy schedules and the absence of a uniform definition of BCG failure. It has been indicated that the recurrence (persistence) of tumour at 9 months in spite of BCG therapy is associated with a 30% chance of invasive tumours and death due to metastatic disease (16) (Level of evidence: 3). Solsona et al. demonstrated that 80% of patients who had persistent disease at 3 months progressed to muscle invasive disease (17) (Level of evidence: 3). In addition, adequate tissue sampling from the prostatic urethra is an essential factor in considering the outcome of conservative treatment, since urethral tumours are associated with a significant decrease in tumour-free survival (18) (Level of evidence: 3). However, with careful selection and surveillance a durable complete response can be achieved also in patients diagnosed with superficial bladder transitional cell carcinoma involving the prostatic urethra (19). Based on these findings, cystectomy should be performed in appropriate patients at least at 9 months, because additional BCG therapy yields a response rate of only 27% to 51% and of unknown duration (20, 21) (Grade of recommendation: C). Salvage chemotherapy is associated with minor responses and should not be offered (22, 23) (Level of evidence: 3). Patients with superficial disease recurring within 2 years of initial TUR plus BCG therapy have a better outcome than patients who already have muscle-invasive disease indicating that cystectomy should be performed at first recurrence, even in case of superficial disease (Level of evidence: 3; Grade of recommendation: C) (15).
5.2
Carcinoma in situ
Primary CIS confined to the bladder is treated with intravesical BCG, yielding a complete response rate of 83-93% (24, 25) (Level of evidence: 2). CIS associated with Ta/T1 is treated according to the overt tumour. Approximately 50% of patients develop recurrent disease with muscle invasion or extravesical tumour (24, 26) (Level of evidence: 2). Between 11% and 21% die of the disease within 5-7 years after an initial complete response (24, 27) (Level of evidence: 2). Non-responders or incomplete responders have a significant risk of tumour progression of 33% to 67% (17, 28) (Level of evidence: 2). Cystectomy should be performed in patients with an incomplete response at 9 months, tumour recurrence within the bladder, or extravesical recurrence (Grade of recommendation: B).
5.3
Recommendations
•
In all T1 tumours at high risk of progression (such as high grade, multifocality, CIS present, and tumour size, as outlined in the non-muscle-invasive bladder cancer EAU guideline), immediate radical cystectomy is an option (Grade of recommendation: B). In all T1 patients failing intravesical therapy, cystectomy is an option. A delay in cystectomy increases the risk of progression and cancer-specific death (Grade of recommendation: B).
•
5.4
References
1.
Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006;176(2):486-92. http://www.ncbi.nlm.nih.gov/pubmed/16813874 Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE. Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21(4):690-6. http://www.ncbi.nlm.nih.gov/pubmed/12586807 Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19(3):666-75. http://www.ncbi.nlm.nih.gov/pubmed/11157016
2.
3.
18
UPDATE MARCH 2008
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165(3):808-10. http://www.ncbi.nlm.nih.gov/pubmed/11176474 Herr WH. The value of second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162(1):74-6. http://www.ncbi.nlm.nih.gov/pubmed/10379743 Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2003;(3):CD003231. http://www.ncbi.nlm.nih.gov/pubmed/12917955 Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168(5):1964-70. http://www.ncbi.nlm.nih.gov/pubmed/12394686 Böhle A, Bock PR. Intravesical BCG versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumour progression. Urology 2004;63(4):682-6. http://www.ncbi.nlm.nih.gov/pubmed/15072879 Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. Eur Urol 2004;45(6):730-5. http://www.ncbi.nlm.nih.gov/pubmed/15149744 Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C; European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002;41(2):105-12. http://www.ncbi.nlm.nih.gov/pubmed/12074395 Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. Urology 2002;59(2):227-31. http://www.ncbi.nlm.nih.gov/pubmed/11834391 Margel D, Tal R, Golan S, Kedar D, Engelstein D, Baniel J. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. Urology 2007;69(1):78-82. http://www.ncbi.nlm.nih.gov/pubmed/17270621 Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, Groshen S, Lieskovsky G, Boyd SD, Skinner DG. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995;76(5):833-9. http://www.ncbi.nlm.nih.gov/pubmed/8625187 Stöckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R. Radical cystectomy often too late?. Eur Urol 1987;13(6):361-7. http://www.ncbi.nlm.nih.gov/pubmed/3428318 Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 2001;166(4):1296-9. http://www.ncbi.nlm.nih.gov/pubmed/11547061 Merz VW, Marth D, Kraft R, Ackermann DK, Zingg EJ, Studer U.E. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol 1995;75(2):180-4. http://www.ncbi.nlm.nih.gov/pubmed/7850322 Solsona E, Iborra I, Rubio J, Casanova J, Almenar S. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int 2004;94(9):1258-62. http://www.ncbi.nlm.nih.gov/pubmed/15610101 Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005;48(1):53-9. http://www.ncbi.nlm.nih.gov/pubmed/15967252 Taylor JH, Davis J, Schellhammer P. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. Clin Genitourin Cancer 2007;5(6):386-9. http://www.ncbi.nlm.nih.gov/pubmed/17956711
UPDATE MARCH 2008
19
20.
21.
22.
23.
24.
25.
26.
27.
28.
Brake M, Loertzer H, Horsch R, Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000;163(6):1697-701. http://www.ncbi.nlm.nih.gov/pubmed/10799163 Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, Lauretti S, Sternberg CN. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: longterm results. J Urol 1995;154(6):2054-8. http://www.ncbi.nlm.nih.gov/pubmed/7500457 Malmström PU, Wijkström H, Lundholm C, Wester K, Busch C, Norlén BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999;161(4):1124-7. http://www.ncbi.nlm.nih.gov/pubmed/10081852 Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163(3):761-7. http://www.ncbi.nlm.nih.gov/pubmed/10687972 Jakse G, Hall R, Bono A, Höltl W, Carpentier P, Spaander JP, van der Meijden AP, Sylvester R. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 2001;40(2):144-50 http://www.ncbi.nlm.nih.gov/pubmed/11528191 Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 2000;163(1):68-71. http://www.ncbi.nlm.nih.gov/pubmed/10604316 Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163(4):1124-9. http://www.ncbi.nlm.nih.gov/pubmed/10737480 de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P; European Organization for the Research and Treatment of Cancer-Genito-Urinary Group. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--GenitoUrinary Group Phase III Trial (30906). J Urol 2005;173(2):405-9. http://www.ncbi.nlm.nih.gov/pubmed/15643181 Hudson MA, Herr WH. Carcinoma in situ of the bladder. J Urol 1995;53(3 Pt 1):564-72. http://www.ncbi.nlm.nih.gov/pubmed/7861485
6. NEOADJUVANT CHEMOTHERAPY The standard treatment for patients with muscle-invasive bladder cancer is radical cystectomy. However, this ‘gold standard’ only provides 5-year survival in about 50% of patients (1-5). In order to improve these unsatisfactory results, the use of peri-operative chemotherapy has been explored since the 1980s. There are many advantages of neoadjuvant chemotherapy, i.e. administering chemotherapy to patients with operable urothelial carcinoma of the urinary bladder before the planned definitive surgery (or radiation). These advantages include: • Chemotherapy is delivered at the earliest time point, when the burden of micrometastatic disease is expected to be low • In vivo chemosensitivity is tested • The tolerability of chemotherapy is expected to be better before than after cystectomy. The disadvantages of neoadjuvant chemotherapy include: • For clinical staging with CT or MRI, over- and under-staging is likely to happen with a staging accuracy of only 70% (6, 7). Overtreatment is the possible negative consequence • Delayed cystectomy might compromise the outcome in patients not sensitive to chemotherapy (8, 9) • Side effects of chemotherapy might affect outcome of surgery and type of urinary diversion.
20
UPDATE MARCH 2008
Several randomized phase III trials investigated the question of whether or not neoadjuvant chemotherapy improved survival, with conflicting results (10-27). Most patients were < 70 years old, had a performance status (PS) of 0-1 and a creatinine clearance of > 50-60 mL/minute, due to the kind of chemotherapy (single-agent cisplatin or cisplatin combination chemotherapy) scheduled. Differences in trial design were mainly the type of chemotherapy (i.e. single-agent cisplatin or combination chemotherapy) and the number of cycles planned. From the statistical point of view, the studies differed in size, patient characteristics (e.g. clinical T-stages included), and the kind of definitive treatment allowed (cystectomy or radiotherapy or both). Because of the lack of clarity, even though a considerable number of randomized trials had been performed, three meta-analyses were undertaken to answer the very important question of whether or not neoadjuvant chemotherapy prolongs survival (28-30). The first meta-analysis, published in 2003 (28), included 10 randomized trials (except for results of the INT 0080-study [20]) and showed a 13% reduction in the risk of death, equivalent to 5% absolute benefit at 5 years (increased overall survival from 45% to 50%). The second meta-analysis, published in 2004 (29), included 11 of 16 randomized trials with overall survival data of 2605 patients. A statistically significant decrease in the risk of death (10%) was seen, corresponding to an absolute improvement in overall survival of 5% (from 50% to 55%). In the most recent meta-analysis, published in 2005 (30), with updated independent patient data (IPD) of 11 randomized trials (3,005 patients), a statistically significant survival benefit in favour of neoadjuvant chemotherapy was also seen. The results of this analysis confirmed the previously published data and showed 5% absolute improvement in survival at 5 years. The Nordic combined trial showed an absolute benefit of 8% in survival at 5 years and in the subgroup clinical T3, 11%, translating into 9 patients needed to treat (26). Of note, only cisplatin combination chemotherapy with at least one additional chemotherapeutic agent resulted in a meaningful benefit (28, 30); the regimens tested were MVA(E)C, CMV, CM, cisplatin/adriamycin, cisplatin/5fluorouracil (5-FU), and CarboMV. To date, it is unknown if more modern chemotherapy regimen are as effective. The presence of micrometastases is postulated to be lower in smaller tumours (T2) compared to more extensive tumours (T3b-T4b). T4 stage tumours are prone to a higher degree of clinical understaging because macrometastic nodal deposits are detected more often in post-cystectomy specimens of these extensive tumours (31). Further data is in support of neoadjuvant chemotherapy in the subgroup of T2b-T3b tumours (former classification T3), which has been shown to provide a modest but substantial improvement in long-term survival and significant downstaging.
6.1
Conclusions
•
Neoadjuvant cisplatin-containing combination chemotherapy improves overall survival by 5-7% at 5 years (Level of evidence: 1a), irrespective of the type of definitive treatment used. Neoadjuvant chemotherapy has its limitations regarding patient selection, current development of surgical technique, and current chemotherapy combinations.
•
6.2
Recommendations
•
Neoadjuvant cisplatin-containing combination chemotherapy should be considered in muscleinvasive bladder cancer, irrespective of definitive treatment (Grade of recommendation: A). Neoadjuvant chemotherapy is not recommended in patients with PS > 2 and impaired renal function (Grade of recommendation: B).
•
6.3
References
1.
Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;24(3):296-304. http://www.ncbi.nlm.nih.gov/pubmed/16518661 Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19(3):666-75. http://www.ncbi.nlm.nih.gov/pubmed/11157016 Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, Reuter V. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165(4):1111-6. http://www.ncbi.nlm.nih.gov/pubmed/11257649 Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, Pagano F. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999;161(5):1494-7. http://www.ncbi.nlm.nih.gov/pubmed/10210380
2.
3.
4.
UPDATE MARCH 2008
21
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
22
Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997;158(2):393-9. http://www.ncbi.nlm.nih.gov/pubmed/9224310 Sternberg CN, Pansadoro V, Calabro F, Schnetzer S, Giannarelli D, Emiliozzi P, De Paula F, Scarpone P, De Carli P, Pizzo M, Platania A, Amini M. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003;97(7):1644-52. http://www.ncbi.nlm.nih.gov/pubmed/12655521 Herr HW, Scher HI. Surgery of invasive bladder cancer: is pathologic staging necessary? Semin Oncol 1990;17(5):590-7. http://www.ncbi.nlm.nih.gov/pubmed/2218571 Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003;169(1):110-5; discussion 115. http://www.ncbi.nlm.nih.gov/pubmed/12478115 Stein JP. Contemporary concepts of radical cystectomy and the treatment of bladder cancer. J Urol 2003;169(1):116-7. http://www.ncbi.nlm.nih.gov/pubmed/12478116 Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N, Dunn J, Boulas J, Latief T. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991;67(6):608-15. http://www.ncbi.nlm.nih.gov/pubmed/2070206 Font A, Saladie JM, Carles J, Pinsach L, Barnardas A, et al. Improved survival with induction chemotherapy in bladder cancer: preliminary results of a randomized trial. Ann Oncol 1994;5:71, abstr 355. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, Flores N, Roncero CR, Portillo JA, Escudero A, Jimenez Cruz F, Isorna S. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995;153(3 Pt 2):964-73. http://www.ncbi.nlm.nih.gov/pubmed/7853584 Rintala E, Hannisdahl E, Fossa SD, Hellsten S, Sander S. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand J Urol Nephrol 1993;27(3):355-62. http://www.ncbi.nlm.nih.gov/pubmed/8290916 Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996;155(6):1903-6. http://www.ncbi.nlm.nih.gov/pubmed/8618283 [No authors listed] Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999;354(9178):533-40. http://www.ncbi.nlm.nih.gov/pubmed/10470696 Hall R. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (m) and vinblastin (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 2002;21:178A, abstr 710. Bassi P PG, Cosciani S, Lembo A, Anselmo G, Sperandio P, et al . Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: The G.U.O.N.E. multicenter phase III trial. Eur Urol 1998 (Suppl);33:142, abstr 567. Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer–Nordic cystectomy trial 2. Scand J Urol Nephrol 2002;36(6):419-25. http://www.ncbi.nlm.nih.gov/pubmed/12623505 Sengelov L, von der Maase H, Lundbeck F, Barlebo H, Colstrup H, Engelholm SA, Krarup T, Madsen EL, Meyhoff HH, Mommsen S, Nielsen OS, Pedersen D, Steven K, Sørensen B. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol 2002;41(5):447-56. http://www.ncbi.nlm.nih.gov/pubmed/12442921 Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349(9): 859-66. http://www.ncbi.nlm.nih.gov/pubmed/12944571
UPDATE MARCH 2008
21. 22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
Italian Bladder Cancer Study Group (GISTV). Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. J Chemother 1996;8(suppl 4):345-6. Orsatti M, Curotto A, Canobbio L, Guarneri D, Scarpati D, Venturini M, Franzone P, Giudici S, Martorana G, Boccardo F, et al. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 1995;33(1):173-8. http://www.ncbi.nlm.nih.gov/pubmed/7642415 Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16(11):3576-83. http://www.ncbi.nlm.nih.gov/pubmed/9817278 Marcuello E TJ, Villavicencio H, Algaba F, Maroto P, Huidobro G, et al. A phase III trial of neoadjuvant chemotherapy (NCT) in patients (PTS) with invasive bladder cancer (IBC). Preliminary results: NCT improves pathological complete response rate. Eur J Cancer 1995;31A:S241, abstr 1155. Cannobio L CA, Boccardo F, Venturini M, Orsatti M, Vitale V, et al. A randomized study between neoadjuvant chemoradiotherapy (CT-RT) before radical cystectomy and cystectomy alone in bladder cancer. A 6 year follow-up. Proc Am Soc Clin Oncol 1995;14:245, abstr 654. Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004;45(3):297-303. http://www.ncbi.nlm.nih.gov/pubmed/15036674 Abol-Enein H E-MM, El Baz M, Ghoneim MA. Neo-adjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomized study. Br J Urol 1997;79(Suppl 4):174. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361(9373):1927-34. http://www.ncbi.nlm.nih.gov/pubmed/12801735 Winquist E, Kirchner TS, Segal R, Chin J, Lukka H; Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171(2 Pt 1):561-9. http://www.ncbi.nlm.nih.gov/pubmed/14713760 Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48(2):202-205; discussion 205-6. http://www.ncbi.nlm.nih.gov/pubmed/15939524 Sherif A HL, Rintala E, Mestad O, Nilsson J, Nilsson S, Malmstrom PU, Wijkström H; Nordic Urothelial Cancer Group. Downstaging and pathoanatomical outcome following neoadjuvant cisplatinum based combination chemotherapy for muscle invasive bladder carcinoma: An analysis of selected patients from two combined randomised prospective Nordic trials. Urology 2006;68(Suppl 1):137, MP-1307.
7. Radical surgery and urinary diversion 7.1
Removal of the tumour bearing bladder
7.1.1 Background Radical cystectomy is the standard treatment for localized muscle invasive bladder cancer in most countries of the Western Hemisphere (1, 2). New interest in quality-of-life issues has increased the trend toward bladder preservation treatment modalities, like radio- and/or chemotherapy (see Chapters 9 and 10). Performance status and age influence the choice of primary therapy, as well as type of urinary diversion with cystectomy being reserved for younger patients without concomitant disease and better performance status. The value of assessing overall health before recommending and proceeding with surgery was emphasized in a recent multivariate analysis, which demonstrated an association between co-morbid disease and adverse pathological and survival outcome following radical cystectomy (3). There is still controversy about age, radical cystectomy and the type of urinary diversion. Cystectomy is associated with the greatest risk reduction in disease-related and non-disease related death in patients older
UPDATE MARCH 2008
23
than 80 years (3). The largest retrospective single-institution study on cystectomy to date demonstrated that patients above 80 years did have an increased postoperative morbidity but not an increased mortality. Some patients even successfully underwent a neobladder procedure in this group, but the majority of patients were treated with an ileal conduit diversion (4). 7.1.2 Timing and delay of cystectomy In a retrospective series of 153 patients with a clear indication for radical surgery of locally advanced bladder cancer, a delay of treatment beyond 90 days of primary diagnosis caused a significant increase in extravesical disease (81 vs. 52%) (5). The delay of cystectomy not only affects the outcome but also the type of urinary diversion. In organconfined urothelial cancer of the bladder the average time from the primary diagnosis to cystectomy was 12.2 months in neobladder and 19.1 months in ileal conduit patients. It was even more striking for those patients who had an organ confined invasive cancer diagnosed; in neobladder patients the average time to surgery was 3.1 and in ileal conduit patients 15.1 months (6). Similar results have been observed in a series of 247 patients where superior recurrence-free survival and overall survival was significantly better in those treated within the 90 day period compared to others who were treated after a longer period (7). 7.1.3 Indications Traditionally radical cystectomy is recommended for patients with muscle-invasive bladder cancer T2-T4a, N0-Nx, M0 (1). Other indications include high-risk and recurrent superficial tumours, BCG-resistant Tis, T1G3 (see chapter 5), as well as extensive papillary disease that cannot be controlled with TUR and intravesical therapy alone. Salvage cystectomy is indicated for non-responders to conservative therapy, recurrences after bladder sparing treatments, non-urothelial carcinomas (these tumours respond poorly to chemo- and radiotherapy) and as a purely palliative intervention for e.g. fistula formation, pain or recurrent macrohematuria (see section 8.1: palliative cystectomy). 7.1.4 Technique and extent Radical cystectomy includes the removal of the bladder and adjacent organs, that is prostate and seminal vesicles in men, and uterus and adnexa in women (8). The inclusion of the entire prostate in male patients, and the extent of urethrectomy and vaginal resection in female patients, however, has recently been questioned (9, 10). Various techniques of partial prostate- sparing cystoprostatectomy in male patients with localized tumours have been proposed and results of series with a longer follow-up have been published (11, 12). A randomized study comparing patients with and without remnant portions of the prostate is lacking and will be difficult to perform. Autopsy studies as well as studies looking at the unsuspected incidence of prostate cancer in cystoprostatectomy specimens suggest that in approximately 23-54% of patients a prostate cancer is found in the cystoprostatectomy specimen. Up to twenty-nine percent of these cancers may be clinically significant, locally recurrent or even metastatic in patients with prostatic tissue preserving radical cystectomy (13-15). Furthermore urothelial cancer in the prostate was detected in 32 and 33% (69/240 cases and 77/235 cases, resp.) of patients undergoing radical cystoprostatectomy (14, 16). In another study 50/121 of the cystoprostatectomy specimens (41%) removed for urothelial cancer had unsuspected prostate cancer. Twenty-four of these 50 tumours (48%) were clinically significant. In the same study 58/121 patients (48%) had urothelial carcinoma in the prostate of which 19 (33%) had apical involvement (17). Overall in the above mentioned series only 26 to 33% of the patients undergoing cystoprostatectomy for bladder cancer had neither prostate cancer nor prostatic urothelial cancer in the specimen. Radical cystectomy also includes the dissection of regional lymph nodes. There is a substantial amount of literature about the extent of lymphadenectomy. Yet, data regarding its clinical significance are controversial. In retrospective studies extended lymphadenectomy (removal of the obturator, internal, external, common iliac and presacral nodes as well as nodes at the aortic bifurcation) has been reported to improve survival in patients with muscle invasive bladder cancer. The curative value of lymph node dissection, however, is still unknown and a standardized lymph node dissection has yet to be defined (18-20). There are several localization studies with regards to lymphadenectomy (21, 22) which demonstrated both retrospectively and prospectively that lymph nodes in bladder cancer patients are not found outside the pelvis if the pelvic lymph nodes are free of tumour. Furthermore progression free survival as well as overall survival might be correlated with the amount of lymph nodes removed during surgery. Removal of more than 15 lymph nodes has been postulated to be both sufficient for the evaluation of the lymph node status as well as beneficial for overall survival in retrospective studies (19, 22, 23). Interindividual differences in the number of pelvic and retroperitoneal lymph nodes and difficulties in processing of the removed tissue by pathologists
24
UPDATE MARCH 2008
were not taken into account in these studies (18). A distal ureteral segment (length not specified) should be resected and in case of CIS a frozen section for evaluation of the surgical margins should be performed (8, 24). Urethrectomy is recommended if there are positive margins at the level of urethral dissection, positive margins anywhere on the bladder specimen (in both sexes), if the primary tumour is located at the bladder neck or in the urethra (in women), or if tumour extensively infiltrates the prostate (1, 25, 26). 7.1.5 Laparoscopic cystectomy Laparoscopic cystectomy has been shown to be feasible both in male and female patients (27, 28). The cystectomy itself and the subsequent urinary diversion can be done hand-assisted, robot-assisted or unaided (29). With the currently available technology and when using intestinal segments for the urinary diversion, to date a majority of authors favour an extracorporeal approach (28). There are no data confirming or declining benefits of laparoscopic cystectomy for the patients’ quality of life, tumour specific and overall survival.
7.2
Urinary Diversion after radical cystectomy
From an anatomical standpoint three alternatives are presently used after cystectomy: • abdominal diversion such as ureterocutaneostomy, ileal or colonic conduit, and various forms of a cutaneous continent pouch • urethral diversion which includes various forms of gastrointestinal pouches attached to the urethra as a continent, orthotopic urinary diversion (neobladder, orthotopic bladder substitution • rectosigmoid diversions, such as uretero(ileo-)rectostomy. Different types of segments of the intestinal tract have been used for reconstruction of the urinary tract, including stomach, ileum, colon, and the appendix (30). Although several studies have compared certain aspects of health-related quality of life, like sexual function, urinary continence and body image in patient cohorts with different types of urinary diversion, more work is necessary in this field with regards to preoperative tumour stage and functional situation, socioeconomic status, time interval to primary surgery etc. Patients undergoing continent urinary diversion have to be both motivated to learn and manually skilful to deal with their diversion. Debilitating neurological and psychiatric illnesses, limited life expectancy, and impaired liver or renal function as well as TCC of the urethral margin or other surgical margins are contraindications to more complex forms of urinary diversion. Relative contraindications specific for an orthotopic neobladder are high-dose preoperative radiation therapy, complex urethral stricture disease and severe urethral sphincter related incontinence (31-33). 7.2.1 Ureterocutaneostomy Ureteral diversion to the abdominal wall is the simplest form of cutaneous diversion. It is considered as a safe procedure and therefore preferred in older or otherwise compromised patients in need of a supravesical diversion (34, 35). Others have demonstrated, however, that in carefully selected elderly patients all other forms of wet and dry urinary diversions including orthotopic bladder substitutions are possible (4). Technically either one ureter to which the other shorter one is attached end-to-side is connected to the skin (transuretero-ureterocutaneostomy) or both ureters are directly anastomosed to the skin. Due to the smaller diameter of the ureters stoma stenosis seems to be more frequent than with intestinal stomas (34). 7.2.2 Ileal conduit The ileal conduit is still an established option with well-known/predictable results. However, up to 48% of the patients develop early complications including urinary tract infections, pyelonephritis, uretero-ileal leakage and stenosis (36). Stomal complications in up to 24% and functional and/or morphological changes of the upper urinary tract in up to 30% are the main complications in long-term follow-up studies (37-39). An increase in complications was seen with increasing follow-up in the Berne series of 131 patients followed for a minimum of 5 years (median follow-up 98 months) (37): the rate of complications increased from 45% at 5 years to 94% in those surviving longer than 15 years. In the latter group 50% and 38% of the patients had upper urinary tract changes and urolithiasis, respectively. 7.2.3 Continent cutaneous urinary diversion A low-pressure detubularized ileal reservoir can be used as a continent cutaneous urinary diversion for selfcatheterization; gastric, ileocecal and sigma pouches have also been described (40-42). Different anti-reflux techniques can be used [8e]. Most patients have a well functioning reservoir with daytime and night time continence approaching 93% (43). A stomal stenosis in 23.5% of patients with appendix stoma and 15% with an efferent intussuscepted ileal nipple was observed in a study reviewing retrospectively the results of
UPDATE MARCH 2008
25
more than 800 patients. Stone formation in the pouch occurred in 10% of patients (43-45). In a small series of previously irradiated female patients incontinence and stomal stenosis was 18% (8/44 patients) (46). 7.2.4 Ureterocolonic diversion The oldest and most common form was primarily a refluxive and later an antirefluxive connection of ureters into the intact rectosigmoideum (uretero[recto]sigmoidostomy) (47, 48). Most of the indications for this procedure have become obsolete due to a high incidence of upper urinary tract infections and a long term risk of developing colon cancer (49, 50). Bowel frequency and urge incontinence were additional side effects of this type of urinary diversion. A possibility to circumvent the above mentioned problems is to interpose a segment of ileum between ureters and rectum or sigmoid in order to augment capacity and to avoid a direct interaction between urothelium, colonic mucosa, together with faeces and urine (51). 7.2.5 Orthotopic neobladder An orthotopic bladder substitution to the urethra is now commonly used both in men and women. Contemporary reports document the safety and long-term reliability of this procedure. In several large centres this has become the diversion of choice for a majority of patients undergoing cystectomy (33, 52). The gastrointestinal segment most frequently used for bladder substitution is the terminal ileum whereas there is less experience with ascending colon, including coecum, and the sigmoid (1). The emptying of the reservoir anastomosed to the urethra requires abdominal straining, intestinal peristalsis and sphincter relaxation. Early and late morbidity in up to 22 % of the patients is reported (53, 54). Long-term complications include diurnal and nocturnal incontinence (8-10 and 20 to 30%, resp.), ureterointestinal stenosis (3-18%), urinary retention (4-12%) both in males and female patients, metabolic disorders and vitamin B12 deficiency in series with 1,054 and more than 1,300 patients (33, 55). In a recent study, which compared cancer control and patterns of disease recurrence in neobladder and conduit patients, no cancer specific survival difference could be identified between the two groups when adjusting for pathological stage (56). Urethral recurrence in neobladder patients seems rare (1.5-7% both for male and female patients) (33, 57). These results indicate that the choice of a neobladder both in male and female patients does not compromise the oncological outcome of cystectomy. The advantage in the quality of life compared to a non-continent diversion remains a matter of debate (58-60. Various forms of upper tract reflux protection including a simple isoperistaltic tunnel, an ileal intussusception, a tapered ileal prolongation implanted subserosally, and a direct (sub)mucosal or subserosal ureteral implantation, have been described (45, 53, 54). According to the reported long term results the upper urinary tract is protected sufficiently by either method.
7.3
Morbidity and mortality
In a recent comprehensive study regarding long-term results in 1,054 patients, perioperative mortality was 3%, and early complications, defined as any complication within 3 months of surgery, were reported in 28% (52, 55). Late morbidity is usually due to the type of urinary diversion (see above). Early morbidity associated with radical cystectomy for non-muscle invasive disease (at high risk for disease progression) is similar and not less than that associated with muscle invasive tumours (61).
7.4
Survival
The outcome according to a multiinstitutional database of 888 consecutive patients undergoing cystectomy and lymphadenectomy for bladder cancer revealed a mean recurrence-free and bladder cancer specific survival of 58% and 66%, resp. at 5 years (62). The recurrence-free and overall survival in a large single centre study of 1,054 male and female patients was 68% and 66% at 5 years and 60% and 43%, at 10 years, respectively (2). In node positive patients, 10-year disease-specific and overall survival rates in another study have been reported to be 27.7% and 20.9% respectively (63). In this cohort, 10-year disease-specific and overall survival rates were 72.9% vs. 49.1% for organ confined (defined as < pT3a), and 33.3% vs. 22.8% for non-organ confined disease (63). In another study, 5-year recurrence-free survival was 76% in patients with pT1 tumours, 74% for pT2, 52% in pT3, and 36% in pT4 tumours (64). Tumour stage and nodal involvement are the only independent predictors of survival (65).
7.5
Conclusions
• •
Cystectomy is the preferred curative treatment for localised bladder neoplasm (Level of evidence: 3) Radical cystectomy includes removal of regional lymph nodes, the extent of which has not been sufficiently defined (Level of evidence: 3) Radical cystectomy in both sexes must not include the removal of the entire urethra in all cases, which may then serve as outlet for an orthotopic bladder substitution (Level of evidence: 3)
•
26
UPDATE MARCH 2008
• •
Terminal ileum and colon are the intestinal segments of choice for urinary diversion (Level of evidence: 3) The type of urinary diversion does not affect oncological outcome (Level of evidence: 3)
7.6
Recommendations
7.6.1 Recommendations for radical cystectomy • Radical cystectomy in T2-T4a, N0-NX, M0, and high risk non-muscle invasive BC as outlined above (Grade of recommendation: B) • No preoperative radiotherapy (Grade of recommendation: A) • Lymph node dissection should be an integral part of cystectomy, extent not established (Grade of recommendation: B) • Preservation of the urethra is reasonable if margins are negative. If no bladder substitution is attached the urethra must be checked regularly (Grade of recommendation: B) • Laparoscopic and robot assisted laparoscopic cystectomy may be an option. Current data, however, have not sufficiently proven its advantages or disadvantages (Grade of recommendation: C). 7.6.2 Recommendations for urinary diversion • Treatment is recommended at centers experienced in major types of diversion techniques and postoperative care (Grade of recommendation: B) • Before cystectomy, the patient should be counselled adequately regarding all possible alternatives, and the final decision should be based on a consensus between patient and surgeon (Grade of recommendation: B). • An orthotopic bladder substitute should be offered to male and female patients lacking any contraindications and who have no tumour in the urethra and at the level of urethral dissection (Grade of recommendation: B)
7.7
References
1.
Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W, Mills RD, Montie JD, Sagalowsky AI, Stein JP, Stenzl A, Studer UE, Volkmer BG. Urinary diversion. Urology 2007;69(1 Suppl):17-49. http://www.ncbi.nlm.nih.gov/pubmed/17280907 Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19(3):666-75. http://www.ncbi.nlm.nih.gov/pubmed/11157016 Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol 2003;169(1):105-9. http://www.ncbi.nlm.nih.gov/pubmed/12478114 Figueroa AJ, Stein JP, Dickinson M, Skinner EC, Thangathurai D, Mikhail MS, Boyd SD, Lieskovsky G, Skinner DG. Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer 1998;83(1):141-7. http://www.ncbi.nlm.nih.gov/pubmed/9655304 Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 2003;170(4 Pt 1):1085-7. http://www.ncbi.nlm.nih.gov/pubmed/14501697 Hautmann RE, Paiss T. Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy?. J Urol 1998;159(6):1845-50. http://www.ncbi.nlm.nih.gov/pubmed/9598473 Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003;169(1):110-5; discussion 115. http://www.ncbi.nlm.nih.gov/pubmed/12478115 Stenzl A, Nagele U, Kuczyk M, Sievert K, Anastasiadis A, Seibold J, Corvin S. Cystectomy – Technical Considerations in Male and Female Patients. EAU Update Series 2005;3:138-46. Vallancien G, Abou El Fettouh H, Cathelineau X, Baumert H, Fromont G, Guillonneau B. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 2002;168(6): 2413-7. http://www.ncbi.nlm.nih.gov/pubmed/12441929 Muto G, Bardari F, D’Urso L, Giona C. Seminal sparing cystectomy and ileocapsuloplasty: long-term followup results. J Urol 2004;172(1):76-80. http://www.ncbi.nlm.nih.gov/pubmed/15201741
2.
3.
4.
5.
6.
7.
8. 9.
10.
UPDATE MARCH 2008
27
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28
Botto H, Sebe P, Molinie V, Herve JM, Yonneau L, Lebret T. Prostatic capsule- and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients. BJU Int 2004;94(7):1021-5. http://www.ncbi.nlm.nih.gov/pubmed/15541120 Colombo R, Bertini R, Salonia A, Da Pozzo LF, Montorsi F, Brausi M, Roscigno M, Rigatti P. Nerve and seminal sparing radical cystectomy with orthotopic urinary diversion for select patients with superficial bladder cancer: an innovative surgical approach. J Urol 2001;165(1):51-5; discussion 55. http://www.ncbi.nlm.nih.gov/pubmed/11125362 Abdelhady M, Abusamra A, Pautler SW, Chin JL, Izawa JI. Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens. BJU Int 2007;99(2):326-9. http://www.ncbi.nlm.nih.gov/pubmed/17026595 Pettus JA, Al-Ahmadie H, Barocas DA, Koppie TM, Herr H, Donat SM, Dalbagni G, Reuter VE, Olgac S, Bochner BH. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol 2008;53(2):370-5. http://www.ncbi.nlm.nih.gov/pubmed/17689003 Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr. Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol 2007;25(6):460-4. http://www.ncbi.nlm.nih.gov/pubmed/18047952 Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol 2006;37(6):726-34. http://www.ncbi.nlm.nih.gov/pubmed/16733214 Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr., Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol 2004;171(2 Pt 1):646-51. http://www.ncbi.nlm.nih.gov/pubmed/14713778 Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002;167(3): 1295-8. http://www.ncbi.nlm.nih.gov/pubmed/11832716 Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000;85(7):817-23. http://www.ncbi.nlm.nih.gov/pubmed/10792159 Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 1998;160(6 Pt 1):2015-9; discussion 2020. http://www.ncbi.nlm.nih.gov/pubmed/9817313 Ghoneim MA, Abol-Enein H. Lymphadenectomy with cystectomy: is it necessary and what is its extent? Eur Urol 2004;46(4):457-61. http://www.ncbi.nlm.nih.gov/pubmed/15363560 Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 2005;23(10):2358-65. http://www.ncbi.nlm.nih.gov/pubmed/15800327 Studer UE, Collette L. Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy. Eur Urol 2006;50(5):887-9; discussion 889-92. http://www.ncbi.nlm.nih.gov/pubmed/16956714 Stenzl A, Bartsch G, Rogatsch H. The remnant urothelium after reconstructive bladder surgery. Eur Urol 2002;41(2):124-31. http://www.ncbi.nlm.nih.gov/pubmed/12074398 Stenzl A, Colleselli K, Bartsch G. Update of urethra-sparing approaches in cystectomy in women. World J Urol 1997;15(2):134-8. http://www.ncbi.nlm.nih.gov/pubmed/9144904 Nagele U, Kuczyk M, Anastasiadis AG, Sievert KD, Seibold J, Stenzl A. Radical cystectomy and orthotopic bladder replacement in females. Eur Urol 2006;50(2):249-57. http://www.ncbi.nlm.nih.gov/pubmed/16806663 Vallancien G, Cathelineau X, Barret E, Rozet F. [Laparoscopy in the treatment of urologic cancers]. Bull Cancer 2007;94(12):1072-4. http://www.ncbi.nlm.nih.gov/pubmed/18156115
UPDATE MARCH 2008
28.
29.
30. 31.
32.
33.
34.
35.
36.
37.
38.
39.
40. 41.
42.
43.
44.
Haber GP, Campbell SC, Colombo JR, Jr, Fergany AF, Aron M, Kaouk J, Gill IS. Perioperative outcomes with laparoscopic radical cystectomy: “pure laparoscopic” and “open-assisted laparoscopic” approaches. Urology 2007;70(5):910-5. http://www.ncbi.nlm.nih.gov/pubmed/18068447 Cathelineau X, Jaffe J. Laparoscopic radical cystectomy with urinary diversion: what is the optimal technique? Curr Opin Urol 2007;17(2):93-7. http://www.ncbi.nlm.nih.gov/pubmed/17285017 Stenzl A. Bladder substitution. Curr Opin Urol 1999;9(3):241-5. http://www.ncbi.nlm.nih.gov/pubmed/10726098 Tanrikut C, McDougal WS. Acid-base and electrolyte disorders after urinary diversion. World J Urol 2004;22(3):168-71. http://www.ncbi.nlm.nih.gov/pubmed/15290206 Farnham SB, Cookson MS. Surgical complications of urinary diversion. World J Urol 2004;22(3): 157-67. http://www.ncbi.nlm.nih.gov/pubmed/15316737 Hautmann RE, Volkmer BG, Schumacher MC, Gschwend JE, Studer UE. Long-term results of standard procedures in urology: the ileal neobladder. World J Urol 2006;24(3):305-14. http://www.ncbi.nlm.nih.gov/pubmed/16830152 Deliveliotis C, Papatsoris A, Chrisofos M, Dellis A, Liakouras C, Skolarikos A. Urinary diversion in highrisk elderly patients: modified cutaneous ureterostomy or ileal conduit?. Urology 2005;66(2): 299-304. http://www.ncbi.nlm.nih.gov/pubmed/16040096 Kilciler M, Bedir S, Erdemir F, Zeybek N, Erten K, Ozgok Y. Comparison of ileal conduit and transureteroureterostomy with ureterocutaneostomy urinary diversion. Urol Int 2006;77(3):245-50. http://www.ncbi.nlm.nih.gov/pubmed/17033213 Nieuwenhuijzen JA, de Vries RR, Bex A, van der Poel HG, Meinhardt W, Antonini N, Horenblas S. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol, 2008;53(4):834-44. http://www.ncbi.nlm.nih.gov/pubmed/17904276 Madersbacher S, Schmidt J, Eberle JM, Thoeny HC, Burkhard F, Hochreiter W, Studer UE. Long-term outcome of ileal conduit diversion. J Urol 2003;169(3):985-90. http://www.ncbi.nlm.nih.gov/pubmed/12576827 Wood DN, Allen SE, Hussain M, Greenwell TJ, Shah P.J. Stomal complications of ileal conduits are significantly higher when formed in women with intractable urinary incontinence. J Urol 2004;172(6 Pt 1):2300-3. http://www.ncbi.nlm.nih.gov/pubmed/15538253 Neal DE. Complications of ileal conduit diversion in adults with cancer followed up for at least five years. Br Med J (Clin Res Ed) 1985;290(6483):1695-7. http://www.ncbi.nlm.nih.gov/pubmed/3924218 Benson MC, Olsson CA. Continent urinary diversion. Urol Clin North Am 1999;26(1):125-47, ix. http://www.ncbi.nlm.nih.gov/pubmed/10086055 Gerharz EW, Kohl UN, Melekos MD, Bonfig R, Weingartner K, Riedmiller H. Ten years’ experience with the submucosally embedded in situ appendix in continent cutaneous diversion. Eur Urol 2001;40(6):625-31. http://www.ncbi.nlm.nih.gov/pubmed/11805408 Jonsson O, Olofsson G, Lindholm E, Tornqvist H. Long-time experience with the Kock ileal reservoir for continent urinary diversion. Eur Urol 2001;40(6):632-40. http://www.ncbi.nlm.nih.gov/pubmed/11805409 Wiesner C, Bonfig R, Stein R, Gerharz EW, Pahernik S, Riedmiller H, Thuroff J.W. Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs. World J Urol 2006;24(3):315-8. http://www.ncbi.nlm.nih.gov/pubmed/16676186 Wiesner C, Stein R, Pahernik S, Hahn K, Melchior SW, Thuroff JW. Long-term followup of the intussuscepted ileal nipple and the in situ, submucosally embedded appendix as continence mechanisms of continent urinary diversion with the cutaneous ileocecal pouch (Mainz pouch I). J Urol 2006;176(1):155-9; discussion 159-60. http://www.ncbi.nlm.nih.gov/pubmed/16753391
UPDATE MARCH 2008
29
45.
46.
47.
48. 49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
30
Thoeny HC, Sonnenschein MJ, Madersbacher S, Vock P, Studer U.E. Is ileal orthotopic bladder substitution with an afferent tubular segment detrimental to the upper urinary tract in the long term? J Urol 2002;168(5):2030-4; discussion 2034. http://www.ncbi.nlm.nih.gov/pubmed/12394702 Leissner J, Black P, Fisch M, Hockel M, Hohenfellner R. Colon pouch (Mainz pouch III) for continent urinary diversion after pelvic irradiation. Urology 2000;56(5):798-802. http://www.ncbi.nlm.nih.gov/pubmed/11068305 Simon J. Ectopia Vesicae (Absence of the anterior walls of the Bladder and the pubic abdominal parietes) Operation for directing the orifices of the ureteres into the rectum, temporary success. JAMA 1911;56:398. Coffey R. Physiologic implantation of the severed ureter or common bile duct into the intestine. JAMA 1911;56:397. Azimuddin K, Khubchandani IT, Stasik JJ, Rosen L, Riether RD. Neoplasia after ureterosigmoidostomy. Dis Colon Rectum 1999;42(12):1632-8. http://www.ncbi.nlm.nih.gov/pubmed/10613486 Gerharz EW, Turner WH, Kalble T, Woodhouse CR. Metabolic and functional consequences of urinary reconstruction with bowel. BJU Int 2003;91(2):143-9. http://www.ncbi.nlm.nih.gov/pubmed/12519116 Kalble T, Busse K, Amelung F, Waldherr R, Berger MR, Edler L, Riedmiller H. Tumor induction and prophylaxis following different forms of intestinal urinary diversion in a rat model. Urol Res 1995;23(6):365-70. http://www.ncbi.nlm.nih.gov/pubmed/8788273 Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;24(3):296-304. http://www.ncbi.nlm.nih.gov/pubmed/16518661 Stein J., Dunn MD, Quek ML, Miranda G, Skinner DG. The orthotopic T pouch ileal neobladder: experience with 209 patients. J Urol 2004;172(2):584-7. http://www.ncbi.nlm.nih.gov/pubmed/15247737 Abol-Enein H, Ghoneim M.A. Functional results of orthotopic ileal neobladder with serous-lined extramural ureteral reimplantation: experience with 450 patients. J Urol 2001;165(5):1427-32. http://www.ncbi.nlm.nih.gov/pubmed/11342891 Stein JP, Skinner DG. Results with radical cystectomy for treating bladder cancer: a ‘reference standard’ for high-grade, invasive bladder cancer. BJU Int 2003;92(1):12-7. http://www.ncbi.nlm.nih.gov/pubmed/12823375 Yossepowitch O, Dalbagni G, Golijanin D, Donat SM, Bochner BH, Herr HW, Fair WR, Russo P. Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol 2003;169(1):177-81. http://www.ncbi.nlm.nih.gov/pubmed/12478130 Stein JP, Clark P, Miranda G, Cai J, Groshen S, Skinner D.G. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 2005;173(4):1163-8. http://www.ncbi.nlm.nih.gov/pubmed/15758728 Gerharz EW, Mansson A, Hunt S, Skinner EC, Mansson W. Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol 2005;174(5):1729-36. http://www.ncbi.nlm.nih.gov/pubmed/16217273 Hobisch A, Tosun K, Kinzl J, Kemmler G, Bartsch G, Holtl L, Stenzl A. Life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. Semin Urol Oncol 2001;19(1):18-23. http://www.ncbi.nlm.nih.gov/pubmed/11246729 Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol 2005;173(4):1318-22. http://www.ncbi.nlm.nih.gov/pubmed/15758789 Cookson MS, Chang SS, Wells N, Parekh DJ, Smith JA Jr. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol 2003;169(1):101-4. http://www.ncbi.nlm.nih.gov/pubmed/12478113 Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner S.P. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176(6 Pt 1):2414-22; discussion 2422. http://www.ncbi.nlm.nih.gov/pubmed/17085118
UPDATE MARCH 2008
63.
64.
65.
Gschwend JE, Dahm P, Fair W.R. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol 2002;41(4):440-8. http://www.ncbi.nlm.nih.gov/pubmed/12074817 Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE. Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21(4):690-6. http://www.ncbi.nlm.nih.gov/pubmed/12586807 Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, Pagano F. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999;161(5):1494-7. http://www.ncbi.nlm.nih.gov/pubmed/10210380
8. NON-RESECTABLE TUMOURS 8.1
Palliative cystectomy for muscle-invasive bladder carcinoma
For patients with inoperable locally advanced tumours (T4b, invading the pelvic or abdominal wall), radical cystectomy usually is not a therapeutic option (1). Treatment of these patients remains a clinical challenge. These patients are candidates for palliative treatments, such as palliative radiotherapy. Inoperable locally advanced tumours may be accompanied by several debilitating symptoms, including bleeding, pain, dysuria and urinary obstruction. There are several treatment options for patients with these symptoms. In advanced bladder cancer cases complicated by bleeding, cystectomy with urinary diversion is the most invasive treatment. It carries the greatest morbidity and should be considered only if there are no other options (1). In patients with locally advanced pelvic cancer and urinary bladder involvement, palliative radical cystectomy with urinary diversion using intestinal segments is usually performed for the relief of symptoms such as pain, recurrent bleeding, urgency and fistula formation (2). Zebic et al.(3) retrospectively analysed patients aged > 75 years, who had received radical cystectomies with either curative or palliative intent. The indications for palliative cystectomy were advanced pelvic malignancy with severe irritating voiding symptoms, severe pain and recurrent macrohaematuria requiring blood transfusions (3). Zebic et al. concluded that elderly people have a greater risk of perioperative morbidity and mortality, especially those with very advanced pelvic malignancies, who have undergone palliative cystectomy (3). Advanced muscle-invasive bladder cancer can be associated with ureteral obstruction. In invasive tumours, the mechanism of ureteral obstruction is probably caused by a combination of mechanical blockage by the tumour and invasion of ureteral orifices by tumour cells interfering with ureteral peristalsis. Bilateral ureteral obstruction, or unilateral obstruction to a solitary functioning kidney, can result in uraemia. Treatment of such patients is still a dilemma. El-Tabey et al.(4) retrospectively reviewed the records of patients who presented with bladder cancer and obstructive uraemia. Patients with inoperable locally advanced bladder tumours (23 patients, 37.7%) were treated with permanent nephrostomy tubes to relieve obstruction; radical cystectomy was not an option. In 10 patients (26.3%), who underwent surgery, palliative cystectomy without lymphadenectomy was carried out for advanced nodal involvement in four patients and locally advanced disease infiltrating the pelvic wall in six patients. In all patients, local pelvic recurrence was reported within the first year of follow-up (4). In one study post-operative outcome of primary radical cystectomy in 20 T4 bladder cancer patients (of which seven cases were T4b) was reported. The authors concluded that primary cystectomy for the treatment of T4 bladder cancer was technically feasible and had a very tolerable therapy-related morbidity and mortality (5).
8.2
Conclusions
• • •
Primary radical cystectomy in T4b bladder cancer is not a curative option. If there are symptoms, radical cystectomy may be a therapeutic/palliative option. Intestinal or non-intestinal forms of urinary diversion can be used with or without palliative cystectomy.
UPDATE MARCH 2008
31
8.3
Recommendations
•
For patients with inoperable locally advanced tumours (T4b), primary radical cystectomy is not a curative option (Grade of recommendation: B). The indication for performing a palliative cystectomy is symptom relief. Morbidity of surgery and quality of life should be weighed against other options (Level of evidence: 3; Grade of recommendation: B/C).
• •
8.4
References
1.
Ok JH, Meyers FJ, Evans CP. Medical and surgical palliative care of patients with urological malignancies. J Urol 2005;174(4 Pt 1):1177-82. http://www.ncbi.nlm.nih.gov/pubmed/16145365 Ubrig B, Lazica M, Waldner M, Roth S. Extraperitoneal bilateral cutaneous ureterostomy with midline stoma for palliation of pelvic cancer. Urology 2004;63(5):973-5. http://www.ncbi.nlm.nih.gov/pubmed/15134993 Zebic N, Weinknecht S, Kroepfl D. Radical cystectomy in patients aged > or = 75 years: an updated review of patients treated with curative and palliative intent. BJU Int 2005;95(9):1211-4. http://www.ncbi.nlm.nih.gov/pubmed/15892803 El-Tabey NA, Osman Y, Mosbah A, Mohsen T, Abol-Enein H. Bladder cancer with obstructive uremia: oncologic outcome after definitive surgical management. Urology 2005;66(3):531-5. http://www.ncbi.nlm.nih.gov/pubmed/16140072 Nagele U, Anastasiadis AG, Merseburger AS, Corvin S, Hennenlotter J, Adam M, Sievert KD, Stenzl A, Kuczyk MA. The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World J Urol 2007;25(4):401-5. http://www.ncbi.nlm.nih.gov/pubmed/17525849
2.
3.
4.
5.
9. NEO-ADJUVANT RADIOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER 9.1
Pre-operative radiotherapy
9.1.1 Retrospective studies Several retrospective studies have looked at the effect of pre-operative radiotherapy in patients with bladder cancer. The largest retrospective series was from the MD Anderson Cancer Center in the USA (n = 526). It showed that 50 Gy pre-operative radiotherapy resulted in down-staging in 73% of cT3 patients versus 29% of patients who did not receive pre-operative radiotherapy (1, 2). Local control was also improved from 72% to 91% in pT3b patients (n = 91), but not in pT2 or pT3a patients. The improvement in survival in this retrospective series was from 40% to 52%. The results of a non-randomized study comparing 40 Gy, 5-20 Gy and no radiotherapy showed that only 40 Gy pre-operative radiotherapy improved the percentage of local recurrence from 27% to 11% and survival from 21% to 63% (3). Overall, nearly all the retrospective studies investigating the effect of pre-operative radiotherapy with doses of 40-50 Gy, followed after 4-6 weeks by cystectomy, showed (1-9): • down-staging of the tumour stage (40-65% of patients) • lower risk of local recurrence (10-42%) • improved survival (11-12%). Some studies found that the improvement in local control was highest for T3b tumours (2-4). Other studies found that achievement of a pathological complete remission (pCR) is a prognostic factor for survival (3-5). One retrospective study (5) found no significant increase in toxicity due to pre-operative radiotherapy (10% versus 3%). 9.1.2 Randomized studies There are five randomized studies investigating pre-operative radiotherapy. The largest randomized trial (234 evaluable patients), using pre-operative radiotherapy 45 Gy/1.8-2.2 Gy in muscle-invasive tumours, showed a significant increase in pCR (9% to 34%) in favour of pre-operative radiotherapy and no significant increase in 5-year survival of 33% to 45% (10). In patients who were not given adjuvant chemotherapy, survival was significantly better in those who received pre-operative radiotherapy (25–52%). pCR was a prognostic factor for better survival. A major drawback of this study is that almost 50% of patients did not receive the planned treatment and were excluded form the analysis. The Southwest Oncology Group (SWOG) trial (n = 124), which
32
UPDATE MARCH 2008
used a pre-operative dose of 5 x 4 Gy, did not show a survival advantage (11). A study from Egypt, dealing with patients with bladder cancer caused by bilharzia (predominantly squamous cell carcinoma, n = 92) also showed a significant survival advantage for > T3 tumours, but a marginal and non-significant difference for the whole group (12). A small, randomized study of 44 patients (13) also showed a significant increase in pCR (18–55%) and a small increase in 5-year survival (61–72%, not significant), but the disadvantages of this study were a small patient population and differing radiotherapy schedules (32-54 Gy). Finally, in another small, three-armed study (n = 72), patients were randomized between surgery, surgery with pre-operative radiotherapy (45 Gy in 4-5 weeks) and radiotherapy alone (50-60 Gy in 4-6 weeks) (14). Pre-operative radiotherapy resulted in 24% of patients achieving pCR. There were no significant differences in survival or toxicity between the three arms. There was no reported increase in toxicity due to pre-operative radiotherapy in any of the abovementioned studies. The effect on the local recurrence rate was not specifically documented in any of the studies. Three of the randomized studies looked at down-staging and found an increase in pCR following preoperative radiotherapy from 9% to 34% (10), 0% to 24% (14) and from 18% to 55% (13). Local recurrences were not reported (10, 14) nor were they similar (13). All six randomized studies looked at survival. The largest study found a significant survival advantage from 25% to 52% in those patients who did not receive adjuvant chemotherapy (10). The Egyptian study found a survival advantage only for T3 patients or higher (12). No study found a significant survival advantage for the whole group. A meta-analysis of the randomized trials on the value of pre-operative radiotherapy showed an odds ratio for the difference in 5-year survival of 0.71 (CI: 0.48-1.06). However, the meta-analysis was potentially biased by the many patients in the largest trial, who did not receive the planned treatment. When the results of the largest trial were excluded, the odds ratio became 0.95 (CI: 0.57-1.55), indicating that improved survival with pre-operative radiotherapy had not been proven (15, 16).
9.2
Conclusions
•
It is not proven that pre-operative radiotherapy for operable muscle-invasive bladder cancer increases survival (Level of evidence: 2). It is shown that pre-operative radiotherapy for operable muscle-invasive bladder cancer, using a dose of 45-50 Gy in fractions of 1.8-2 Gy results in down-staging after 4-6 weeks (Level of evidence: 2). Pre-operative radiotherapy with a dose of 45-50 Gy/1.8-2 Gy does not seem to significantly increase toxicity after surgery (Level of evidence: 3). There are suggestions in older literature that pre-operative radiotherapy will result in a decrease in local recurrence of muscle-invasive bladder cancer (Level of evidence: 3).
•
• •
9.3
Recommendations
• •
Pre-operative radiotherapy is not recommended to improve survival (Grade of recommendation: B). Pre-operative radiotherapy for operable muscle-invasive bladder cancer results in tumour downstaging after 4-6 weeks (Grade of recommendation: A-C).
9.4
References
1.
Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer 1994;74(10):2819-27. http://www.ncbi.nlm.nih.gov/pubmed/7954243 Cole CJ, Pollack A, Zagars GK, Dinney CP, Swanson DA, von-Eschenbach AC. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 1995;32(2):331-40. http://www.ncbi.nlm.nih.gov/pubmed/7751174 Spera JA, Whittington R, Littman P, Solin LJ, Wein AJ. A comparison of preoperative radiotherapy regimens for bladder carcinoma. The University of Pennsylvania experience. Cancer 1988;61(2):25562. http://www.ncbi.nlm.nih.gov/pubmed/3334959 Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 1997;37(1):41-9. http://www.ncbi.nlm.nih.gov/pubmed/9054875
2.
3.
4.
UPDATE MARCH 2008
33
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Chougule P, Aygun C, Salazar O, Young JJ Jr, Prempree T, Amin P. Radiation therapy for transitional cell bladder carcinoma. A ten-year experience. Urology 1988;32(2):91-5. http://www.ncbi.nlm.nih.gov/pubmed/3135646 Batata MA, Chu FC, Hilaris BS, Whitmore WF, Kim YS, Lee MZ. Bladder cancer in men and women treated by radiation therapy and/or radical cystectomy. Urology 1981;18(1);15-20. http://www.ncbi.nlm.nih.gov/pubmed/6789529 Fossa SD, Ous S, Berner A. Clinical significance of the “palpable mass” in patients with muscleinfiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. Br J Urol 1991;67(1):54-60. http://www.ncbi.nlm.nih.gov/pubmed/1993277 Gilloz A, Heritier P. Comparative study of actuarial survival rates in P3 P4 (N+ Mo) transitional cell carcinoma of bladder managed by total cystectomy alone or associated with preoperative radiotherapy and pelvic lymphadenectomy. Prog Clin Biol Res 1984;162B:15-9. http://www.ncbi.nlm.nih.gov/pubmed/6504893 Smith JA, Batata M, Grabstald H, Sogani PC, Herr H, Whitmore WF Jr. Preoperative irradiation and cystectomy for bladder cancer. Cancer 1982;49:869-973. http://www.ncbi.nlm.nih.gov/pubmed/6800628 Slack NH, Bross ID, Prout GR. Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol 1977;9:393-405. http://www.ncbi.nlm.nih.gov/pubmed/330958 Smith JA, Crawford ED Paradelo JC et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol 1997;157:805-7; discussion 807-8. http://www.ncbi.nlm.nih.gov/pubmed/9072571 Ghoneim MA, Ashamallah AK, Awaad HK, Whitmore WF Jr. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol 1985;134(2):266-8. http://www.ncbi.nlm.nih.gov/pubmed/3894693 Anderstrom C, Johanson S, Nilsson S, Unsgaard B, Wahlqvist L. A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. Eur Urol 1983;9(3):142-7. http://www.ncbi.nlm.nih.gov/pubmed/6861819 Blackard CE, Byar DP. Results of a clinical trial of surgery and radiation in stages II and III carcinoma of the bladder. J Urol 1972;108(6):875-8. http://www.ncbi.nlm.nih.gov/pubmed/5082739 Huncharek M, Muscat J, Geschwind JF. Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res 1998;18(3b):1931-4. http://www.ncbi.nlm.nih.gov/pubmed/9677446 Widmark A, Flodgren P, Damber JE, Hellsten S, Cavallin-Stahl E. A systematic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol 2003;42(5-6):567-81. http://www.ncbi.nlm.nih.gov/pubmed/14596515
10. BLADDER-SPARING TREATMENTS 10.1
Transurethral resection of bladder tumour
When patients, with an initially invasive bladder cancer, presenting with pT0 or pT1 status at second resection are selected for transurethral resection of bladder tumour (TURBT) alone, about half of them will have to undergo radical cystectomy for recurrent muscle-invasive cancer, with a disease-specific death rate ranging up to 47% within this group (1, 2). A disease-free status at restaging TUR appears to be crucial in making the decision not to perform radical cystectomy (3, 4). It is only possible to consider TUR alone as a therapeutic option if tumour growth is limited to the superficial muscle layer and if restaging biopsies are negative for residual tumour (5). TUR alone should only be considered as a therapeutic option, when the patient is unfit for cystectomy or a multimodality bladder-preserving approach or refuses open surgery (6).
34
UPDATE MARCH 2008
10.1.1 Conclusion and recommendation • TUR alone is not a curative treatment option in most patients (Level of evidence: 2a; Grade of recommendation: B). 10.1.2 References 1. Barnes RW, Dick AL, Hadley HL, Johnston OL. Survival following transurethral resection of bladder carcinoma. Cancer Res 1977;37(8 Pt 2):2895-7. http://www.ncbi.nlm.nih.gov/pubmed/872119 2. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001;19(1):89-93. http://www.ncbi.nlm.nih.gov/pubmed/11134199 3. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Calabuig C. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term follow-up of a prospective study. J Urol 1998;159:95-98; discussion 98-99. http://www.ncbi.nlm.nih.gov/pubmed/9400445 4. Holmang S, Hedelin H, Anderstrom C, Johansson SL. Long-term follow-up of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol 1997;158(2):38992. http://www.ncbi.nlm.nih.gov/pubmed/9224309 5. Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987;138(5):1162-3. http://www.ncbi.nlm.nih.gov/pubmed/3669160 6. Whitmore WF Jr, Batata MA, Ghoneim MA, Grabstald H, Unal A. Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol 1977:118(1 Pt 2):184-7. http://www.ncbi.nlm.nih.gov/pubmed/875217
10.2
External beam radiotherapy
The target field usually comprises the bladder only, with a safety margin of 1.5-2 cm to allow for unavoidable organ movements (1-4). Any beneficial effect with larger pelvic fields has not been demonstrated. The target dose for curative radiotherapy for bladder cancer is 60-66 Gy, with a subsequent boost using external radiotherapy or interstitial brachytherapy. The daily dose is usually 1.8-2 Gy, and the course of radiotherapy should not extend beyond 6-7 weeks to minimize the repopulation of cancer cells. The use of modern standard radiotherapy techniques results in major, related, late morbidity of the urinary bladder or bowel in less than 5% of tumour free-patients (5-9). Besides the response to radiotherapy, important prognostic factors for outcome include tumour size, hydronephrosis and the completeness of the initial TURBT. Overall 5-year survival rates in patients with muscle-invasive bladder cancer range between 30% and 60%, with a cancer-specific survival rate of 20% and 50%, with or without a complete response following radiotherapy, respectively (10-14). Based on available trials, a Cochrane analysis has demonstrated that radical cystectomy has an overall survival benefit compared to radiotherapy (15). 10.2.1 Conclusions • External beam radiotherapy alone should only be considered as a therapeutic option when the patient is unfit for cystectomy or a multimodality bladder-preserving approach (Level of evidence: 3). • Radiotherapy can also be used to stop bleeding from the tumour when local control cannot be achieved by transurethral manipulation because of extensive local tumour growth (Level of evidence: 3). 10.2.2 Recommendation • There is evidence that radiotherapy alone is less effective than curative therapy (surgery or trimodality treatment) (Grade or recommendation: B). 10.2.3 References 1. Gospodarowicz MK, Blandy JP. Radiation therapy for organ-conservation for invasive bladder carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. Lippincott: Williams and Wilkins, 2000; pp. 487-496. 2. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986;7(4): 299-310. http://www.ncbi.nlm.nih.gov/pubmed/3101140
UPDATE MARCH 2008
35
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
10.3
Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, Herman JG, Garrett PG, Chua T, Duncan W et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142(6):1448-53; discussion 1453-4. http://www.ncbi.nlm.nih.gov/pubmed/2585617 Gospodarowicz MK, Quilty PM, Scalliet P, Tsujii H, Fossa SD, Horenblas S, Isaka S, Prout R, Shipley WU, Wijnmaalen AJ et al. The place of radiation therapy as definitive treatment of bladder cancer. Int J Urol 1995;2(Suppl 2):41-8. http://www.ncbi.nlm.nih.gov/pubmed/7553304 Shipley WU, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. Int J Radiat Oncol Biol Phys 1997;39(4):937-43. http://www.ncbi.nlm.nih.gov/pubmed/9369144 Maciejewski B, Majewski S. Dose fractionation and tumor repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991;21(3):163-70. http://www.ncbi.nlm.nih.gov/pubmed/1924851 De Neve W, Lybeert MLM, Goor C, Crommelin NA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995;36(3):183-8. http://www.ncbi.nlm.nih.gov/pubmed/8532904 Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, Rodel C, Schoenberg M, Shipley W. Radiotherapy for bladder cancer. Urology 2007;69(1 Suppl):80-92. http://www.ncbi.nlm.nih.gov/pubmed/17280910 Whitmore WF Jr, Batata MA, Ghoneim MA, Grabstald H, Unal A. Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol 1977;118(1 Pt 2):184-7. http://www.ncbi.nlm.nih.gov/pubmed/875217 Pollack A, Zagars GZ. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 1996;14(2):86-95. http://www.ncbi.nlm.nih.gov/pubmed/8734736 De Neve W, Lybeert ML, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995;36(3):183-8. http://www.ncbi.nlm.nih.gov/pubmed/8532904 Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995;31(2):247-54. http://www.ncbi.nlm.nih.gov/pubmed/7836076 Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326(24):1593-8. http://www.ncbi.nlm.nih.gov/pubmed/1584260 Naslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year followup of a randomized clinical trial. Acta Oncol 1994;33(4):397-402. http://www.ncbi.nlm.nih.gov/pubmed/8018372 Shelley MD, Barber J, Wilt T, Mason MD. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002;(1):CD002079. http://www.ncbi.nlm.nih.gov/pubmed/11869621
Chemotherapy
Chemotherapy alone rarely produces durable complete responses. A clinical complete response rate of up to 56% as reported in some series must be weighed against a staging error of > 60% (1-2). In the case of an initially incomplete TUR, a pathological complete response rate of 8-26% can be expected following an additional cisplatin-based systemic therapy (3-5). The use of cisplatin-based chemotherapy as the primary therapy for locally advanced (T3/T4) tumours has resulted in complete and partial local responses in 11% and 34% of cases, respectively (6-7). 10.3.1 Conclusion With cisplatin-based chemotherapy as primary therapy for locally advanced tumours in highly selected patients, complete and partial local responses have been reported (Level of evidence: 2b). 10.3.2 Recommendation Chemotherapy alone is not recommended as primary therapy for localized bladder cancer (Grade of recommendation: A).
36
UPDATE MARCH 2008
10.3.3 References 1. Scher HI, Yagoda A, Herr HW, Sternberg CN, Bosl G, Morse MJ, Sogani PC, Watson RC, Dershaw DD, Reuter V et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 1988;139(3):470-4. http://www.ncbi.nlm.nih.gov/pubmed/3343728 2. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998;16(4):1298-301. http://www.ncbi.nlm.nih.gov/pubmed/9552029 3. Scattoni V, Da Pozzo L, Nava L, Broglia L, Galli L, Torelli T, Campo B, Maffezzini M, Rigatti P. Five-year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer. Eur Urol 1995;28(2):102-7. http://www.ncbi.nlm.nih.gov/pubmed/8529731 4. Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990;144(3):662-5. http://www.ncbi.nlm.nih.gov/pubmed/2388322 5. Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. J Urol 1996;155(6):1897-902. http://www.ncbi.nlm.nih.gov/pubmed/8618282 6. Roberts JT, Fossa SD, Richards B, Kaye SB, White EF, Robinson MC, Uscinska B, Parmar MK. Results of Medical Research Council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder. Br J Urol 1991;68(2):162-8. http://www.ncbi.nlm.nih.gov/pubmed/1884143 7. Martinez-Piñeiro JA, Gonzalez Martin M, Arocena F, Flores N, Roncero CR, Portillo JA, Escudero A, Jimenez Cruz F, Isorna S. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995;153(3 Pt 2):964-73. http://www.ncbi.nlm.nih.gov/pubmed/7853584
10.4
Multimodality treatment
Recent organ-preservation strategies combine TURBT, chemotherapy and radiation (1-5). The rationale for performing TURBT and radiation is to achieve local tumour control. Application of systemic chemotherapy, most commonly as methrotrexate, cisplatin and vinblastine (MCV), aims at the eradication of micrometastasis. Many protocols use cisplatin and/or 5-FU and, recently, gemcitabine with radiation because of their established role as radiosensitizers. Cisplatin-based chemotherapy in combination with radiotherapy, following TURBT, results in a complete response rate of 60-80%. It is recommended that early cystectomy is performed in individuals who do not achieve a complete response following combination therapy. This will allow about 40-45% of patients to survive with an intact bladder at 4-5 years (5). A comparable long-term survival rate of 50-60% at 5 years’ follow-up is reported by both multimodality bladder-preserving trials and cystectomy series. However, both therapeutic approaches have never been directly compared and patients in multimodality series are highly selected (5-7). A bladder-preserving multimodality strategy requires very close multidisciplinary co-operation and a high level of patient compliance. Even if a patient has shown a complete response to a multimodality bladder-preserving strategy, the bladder remains a potential source of recurrence. About half of patients can be expected to survive with their native bladder intact. A T0 status at repeat TUR after the initial transurethral resection of the primary tumor, followed by chemotherapy in combination with radiotherapy, was identified as a prognostically important variable. However, even the latter patients are at a life-long risk of developing intravesical tumor recurrences with the need for meticulous surveillance and multiple invasive procedures. It has been postulated that a delay in radical cystectomy due to an initial bladder-preserving approach increases the risk of lymph node metastases to a lymph-node positive rate of 26% when cystectomy becomes necessary due to treatment failure. 10.4.1 Conclusions • There are comparable long-term survival rates in cases of multimodality treatment success (Level of evidence: 3). • Delay in surgical therapy can compromise survival rates. (Level of evidence: 2b].
UPDATE MARCH 2008
37
10.4.2 Recommendations • TUR alone is not a curative treatment option in most patients (grade of recommendation: B). • Radiotherapy alone is less effective than surgery (grade of recommendation: B). • Chemotherapy alone is not recommended as primary therapy for localized bladder cancer (grade of recommendation: B). • Multimodality treatment is an alternative in selected, well-informed and compliant patients where cystectomy is not considered for clinical or personal reasons (Grade of recommendation: B). 10.4.3 References 1. Shipley WU, Kaufman DS, Zietman AL, Griffin PP, Heney NM, Althausen AF. Selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur J Cancer 1995:31A(Suppl 5):S239. 2. Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur Urol 1998;33 Suppl 4:324. http://www.ncbi.nlm.nih.gov/pubmed/9615208 3. Housset M, Dufour E, Maulard-Durtux C. Concomitant 5-fluouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol 1997;16:1139A (abstr). http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_search_results_vi ew&selectedConfs=17,31,30,29,28&SearchFilter1=Title&SearchTerm1=cisplatin&SearchFilter2=Author &SearchTerm2=&SearchFilter3=Author&SearchTerm3=Housset 4. Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, Dunst J, Sauer R, Rodel C. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 24(15):2318-24. http://www.ncbi.nlm.nih.gov/pubmed/16710030 5. Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20(14):3061-71. http://www.ncbi.nlm.nih.gov/pubmed/12118019 6. Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF, Heney NM, Shipley WU. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001;58(3):380-5. http://www.ncbi.nlm.nih.gov/pubmed/11549485 7. Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, Althausen AF, Zietman AL. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60(1):62-7; discussion 67-8. http://www.ncbi.nlm.nih.gov/pubmed/12100923
11. ADJUVANT CHEMOTHERAPY Adjuvant chemotherapy for patients after radical cystectomy with pT3/4 and/or lymph node positive (N+) disease without clinically detectable metastases (M0) is under debate (1, 2). The benefits of chemotherapy in the adjuvant setting include: • Chemotherapy is administered after accurate pathological staging • Overtreatment in patients at low risk for micrometastases is avoided • No delay in definitive surgical treatment, especially in patients not sensitive to chemotherapy. The drawbacks of adjuvant chemotherapy are: • Assessment of in-vivo chemosensitivity of the tumour is not possible • Delay or intolerability of chemotherapy, due to post-operative morbidity. There is not enough evidence in favour of the routine use of adjuvant chemotherapy (2, 8). To date, there have been only five published randomized trials of adjuvant chemotherapy (3-7) and one meta-analysis (8), with updated individual patient data from six trials and a total of only 491 patients for survival analysis. Furthermore, all these trials are sub-optimal with serious deficiencies, such as low sample size (underpowered), use of substandard chemotherapy, early stopping of patient entry and flaws in design
38
UPDATE MARCH 2008
and statistical analysis, including irrelevant endpoints or a lack of recommendations concerning salvage chemotherapy for relapse or metastases (2). The data are not convincing enough to give an unequivocal recommendation for the use of adjuvant chemotherapy. From the evidence so far available, it is unclear whether immediate adjuvant chemotherapy or chemotherapy at the time of relapse is superior or if the two approaches are equivalent with respect to the end-point overall survival. In recent trial updates, cisplatin-based combination chemotherapy was able to produce long-term disease-free survival, even in metastatic disease, albeit mainly in patients with lymph node metastases only and in good PS (9-11). Patients with extravesical and/or node positive disease following cystectomy should be enrolled in clinical trials whenever possible. In non-protocol-eligible patients, adjuvant cisplatin-based chemotherapy is an option provided the patient is well informed about the scarce data available. Published trials of randomized adjuvant chemotherapy have used 3-4 cycles of CMV (cisplatin, methotrexate, vinblastine), CISCA (cisplatin, cyclophosphamide, and adriamycine), MVA(E)C (methotrexate, vinblastine, adriamycine or epirubicine, and cisplatin) and CM (cisplatin, methotrexate) (12). There is no evidence that more modern or carboplatin-containing chemotherapy combinations are as effective. Patients ineligible for cisplatin should not receive adjuvant chemotherapy.
11.1 Conclusion •
Adjuvant chemotherapy is under debate. Neither randomized trials nor a meta-analysis have provided sufficient data to support the routine use of adjuvant chemotherapy (Level of evidence: 1a).
11.2 Recommendation •
Adjuvant chemotherapy is advised within clinical trials, but not for routine use because it has not been studied sufficiently (Grade of recommendation: A).
11.3
References
1.
Cohen SM, Goel A, Phillips J, Ennis RD, Grossbard ML. The role of perioperative chemotherapy in the treatment of urothelial cancer. Oncologist 2006;11(6):630-40. http://www.ncbi.nlm.nih.gov/pubmed/16794242 Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 2000;11(7):851-6. http://www.ncbi.nlm.nih.gov/pubmed/10997813 Bono A, Benvenuti C, Gibba A, Guazzeri S, Cosciani-Cunico S, Anselmo G. Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol Ital 1997;11(1):5-8. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155(2):495-9; discussion 499-500. http://www.ncbi.nlm.nih.gov/pubmed/8558644 Stockle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thuroff JW, Huber C, Hohenfellner R. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995;153(1):47-52. http://www.ncbi.nlm.nih.gov/pubmed/7966789 Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, Markwalder R, Senn E, Sonntag RW. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994;152(1):81-4. http://www.ncbi.nlm.nih.gov/pubmed/8201695 Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Krailo M, Groshen S. Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer. Semin Urol 1990;8(4):279-84. http://www.ncbi.nlm.nih.gov/pubmed/2284533 Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48(2):189-199; discussion 99-201. http://www.ncbi.nlm.nih.gov/pubmed/15939530
2.
3.
4.
5.
6.
7.
8.
UPDATE MARCH 2008
39
9.
10.
11.
12.
von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602-8. http://www.ncbi.nlm.nih.gov/pubmed/16034041 Sternberg CN. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. Semin Oncol 2007;34(2):122-8. http://www.ncbi.nlm.nih.gov/pubmed/17382795 Stadler WM, Hayden A, von der Maase H, Roychowdhur D, Dogliotti L, Seymour L, Kaufmann D, Moore M. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002;7(4):153-7. http://www.ncbi.nlm.nih.gov/pubmed/12474531 Lehmann J, Retz M, Wiemers C, Beck J, Thuroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kalbe T, Sternberg D, Wellek S, Stockle M; AUO-AB 05/95. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005;23(22):4963-74. http://www.ncbi.nlm.nih.gov/pubmed/15939920
12. METASTATIC DISEASE Approximately 30% of patients with urothelial cancer present with muscle-invasive disease; about half will relapse after radical cystectomy depending on the pathological stage of the primary tumour and the nodal status. Local recurrence accounts for about 30% of relapses, whereas distant metastases are more common. About 10-15% of patients are already metastatic at diagnosis (1). Before the development of effective chemotherapy, patients with metastatic urothelial cancer rarely exceeded the median survival of 3-6 months (2).
12.1
Prognostic factors and treatment decisions
Bladder cancer is a chemosensitive tumour. Response rates differ with respect to patient-related factors and pre-treatment disease. Prognostic factors for response and survival have been established. In a multivariate analysis, Karnofsky PS of 80% or less and the presence of visceral metastases were independently prognostic of poor survival after treatment with MVAC (methotrexate, vinblastine, adriamycine and cisplatin). These so-called ‘Bajorin’ prognostic factors (3) have also been validated for newer combination chemotherapies (4, 5) and are crucial for assessing phase II study results and stratifying phase III trials (6, 7). Additional data on the prognostic value of elevated alkaline phosphatase and the number of disease sites (> or < three) were generated prospectively (8). A retrospective analysis showed that, in elderly patients, an ECOG (Eastern Cooperative Oncology Group) PS 2-3 and a haemoglobin level of <10 mg/dl were independent predictors of poor survival (9). Age itself has no impact on response or toxic events (9). Besides these prognostic factors, treatment decisions should also be based on a patient’s renal function to decide whether a patient is ‘fit’ enough to receive a cisplatin-containing combination regimen (creatinine clearance > 60 mL/min, PS, co-morbidity) (10-14). So far, there is no generally accepted definition for ‘fit’ or ‘unfit’ patients (15).
12.2
Single-agent chemotherapy
Varying response rates of single-agent first-line chemotherapy have been reported with only 12% for cisplatin compared to MVAC (7), 12% for carboplatin (10), 42% for paclitaxel (16), 31% for docetaxel (17), 29% for methotrexate, 19% for adriamycin, 15% for epirubicin, 13% for mitomycin C, 35% for 5-FU, 14% for vinblastine, 29% for ifosfamide and 8% for cyclophosphamide (18, 19). The most robust single-agent data is a response rate of about 25% for gemcitabine for first- and second-line use in several, larger-sized, phase II trials (20-27). Responses with single agents are usually short-lived and complete responses are rare. Of note, no long-term disease-free survival has been reported with single-agent chemotherapy. The median survival in such patients is only about 6-9 months. Patients with PS WHO 3-4, with or without additional negative prognostic factors, are not expected to benefit from combination chemotherapy. The most appropriate approach for this patient group is best supportive care or, at most, single-agent chemotherapy.
40
UPDATE MARCH 2008
12.3
Standard first-line chemotherapy for ‘fit’ patients
Cisplatin-containing combination chemotherapy has been the standard of care since the late 1980s. MVAC has been superior to cisplatin monotherapy and CISCA (cisplatin, cyclophosphamide and adriamycine) (7, 28) and, more recently, to cisplatin/docetaxel (29). MVAC and gemcitabine/cisplatin (GC) have prolonged survival up to 14.8 and 13.8 months, respectively (30-32). Neither of the two combinations was proven to be superior over the other, but equivalence was not tested, with response rates of 46% and 49% for MVAC and GC, respectively. The long-term survival results confirmed the anticipated equivalence of the two regimens (8). The major difference between the above-mentioned combinations was toxicity, with GC being less toxic (32). MVAC is better tolerated with the use of GCSF (29, 33). High-dose intensity MVAC (HD-MVAC) with GCSF is less toxic and more efficacious than standard MVAC in terms of dose density, complete response and 2-year survival rate. However, there is no significant difference in median survival between the two regimens (34, 35). Further intensification of treatment using new triplets, dose-dense schedules or adding targeted therapies is still being investigated. These approaches should be reserved for clinical trials and are not considered suitable for routine use.
12.4
Carboplatin-containing chemotherapy in ‘fit’ patients
Carboplatin-containing chemotherapy is not proven to be equivalent to cisplatin combinations. However, it is probably inferior and therefore should not be considered interchangeable or standard. The only randomized phase III study of carboplatin-containing chemotherapy had a disappointing response rate of only 28.2% in the investigational arm (paclitaxel/carboplatin) compared to MVAC and had to be closed down early because of a low accrual rate. There is therefore no evidence that this doublet might have adequate efficacy for first-line use (36). Various carboplatin versus cisplatin combination chemotherapies in randomized phase II trials have produced lower complete response rates and a shorter overall survival for the carboplatin arms (37-39).
12.5
Non-platinum combination chemotherapy
Gemcitabine and paclitaxel combinations in different schedules have been studied as both first- and secondline treatments. Apart from severe pulmonary toxicity with a weekly schedule of both drugs, this combination has been well tolerated and produced response rates between 38% and 60% in both lines. Because there has not been a randomized comparison. Because there has not been a randomized comparison to standard cisplatin chemotherapy, non-platinum combination-chemotherapy is not recommended for first-line use in patients who are fit enough (27, 40-45).
12.6
Chemotherapy in patients ‘unfit’ for cisplatin
Up to 50% of patients are unfit for cisplatin-containing chemotherapy, either due to a poor PS and/or impaired renal function, or due to co-morbidity that forbids high-volume hydration (46, 47). In such cases, carboplatin combination or single-agent chemotherapy is reasonable (10, 11). Non-platinum combinations, as front-line chemotherapy in patients with two adverse prognostic factors (GFR < 50-60 mL/min and PS > 2) should be reserved for investigational use because they have not been tested in purely ‘unfit’ patients and might be too toxic. Trials with clearly defined ‘unfit’ patients or patients with multiple adverse prognostic factors are rare. However, the first randomized phase II/III trial in this setting is currently being conducted by the EORTC. It compares carboplatin/vinblastin/methotrexate and carboplatin/gemcitabine in patients unfit for cisplatin (www.eortc.be).
12.7
Second-line treatment
Second-line chemotherapy data are highly variable and prognostic factors are unclear in this setting. Suggested prognostic factors include the choice of front-line chemotherapy (adjuvant/neoadjuvant), prior chemosensitivity, PS and the ‘Bajorin’-prognostic factors. There is not yet enough data to define a chemotherapy standard in this setting. Re-exposition 12 months or more after response to a prior chemotherapeutic regimen is a reasonable strategy. Second-line response rates of paclitaxel (weekly), docetaxel, oxaliplatin, topotecan, lapatinib, gefitinib and bortezomib range between 0% and 13% in small phase II trials (48-55). Gemcitabine has been studied with excellent response rates also for second-line use (20, 24-27). However, most patients already receive this drug as part of their front-line treatment. Vinflunine, a new third-generation vinca-alcaloid, has shown objective response rates of 18% and disease control in 67% (56). Publication of a phase III trial of vinflunine randomized against best supportive care is awaited. In a phase II trial, pemetrexed 500 mg/m2, given every 3 weeks, showed a promising response rate of 28% and manageable toxicity with the addition of vitamin B12 and folinic acid supplementation and
UPDATE MARCH 2008
41
dexamethasone prophylaxis (57). The excellent response rate could not be confirmed by a second, smallersized trial; however, this may have been due to patient selection (58). Ifosfamide had a response rate of 20% but is prone to considerable toxicity (59). Paclitaxel/gemcitabine showed response rates of 38-60%, depending on pre-treatment response and indication of prior chemotherapy. Unfortunately, no randomized trial has been conducted to assess the true value of this second-line combination (2, 41, 45).
12.8
Low-volume disease and post-chemotherapy surgery
With cisplatin-containing combination chemotherapy, patients with lymph node metastases only, good PS and an adequate renal function may achieve excellent response rates, including a high degree of complete responses, with up to 20% of patients achieving long-term disease-free survival (8, 35, 60, 61). Stage migration may play a role in this positive prognostic development. A retrospective study of post-chemotherapy surgery after a partial or complete response indicated that post-chemotherapy surgery may contribute to long-term disease-free survival in selected patients (62-64).
12.9 Conclusions • •
•
• • •
• • •
Urothelial carcinoma is a chemosensitive tumour. Performance status and the presence or absence of visceral metastases are independent prognostic factors for survival. These factors are at least as important as the type of chemotherapy administered (Level of evidence: 3). Cisplatin-containing combination chemotherapy is able to achieve a median survival of up to 14 months, with long-term disease-free survival reported in about 15% of patients with nodal disease and good PS (Level of evidence: 1b). Single-agent chemotherapy provides low response rates of usually short duration (Level of evidence: 2a). Carboplatin-combination chemotherapy is less effective than cisplatin-based chemotherapy in terms of CR and survival (Level of evidence: 2a). Non-platinum combination chemotherapy has produced substantial responses in first- and secondline use, but has not been tested against standard chemotherapy in fit patients or in a purely unfit patient group (Level of evidence: 2a). To date, there is no defined standard chemotherapy for ‘unfit’ patients with advanced or metastatic urothelial cancer (Level of evidence: 2b). Small-sized phase II trials provide evidence of moderate response rates for single agents or nonplatinum combinations at second-line use (Level of evidence: 2a). Post-chemotherapy surgery after a partial or complete response may contribute to long-term disease-free survival (Level of evidence: 3).
12.10 Recommendations • • • • •
Prognostic factors guide treatment selection (Grade of recommendation: B). First-line treatment for fit patients: use cisplatin-containing combination chemotherapy with GC, MVAC, preferably with GCSF, or HD-MVAC with GCSF (Grade of recommendation: A). Carboplatin and non-platinum combination chemotherapy as first-line treatment in patients fit for cisplatin is not recommended (Grade of recommendation: B). First-line treatment in patients unfit for cisplatin: use carboplatin combination chemotherapy or single agents (Grade of recommendation: C). Second-line treatment: consider single agents or paclitaxel/gemcitabine if the patient has a good PS (Grade of recommendation: C).
12.11 References 1.
2.
3.
42
Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005;174(1):14-20. http://www.ncbi.nlm.nih.gov/pubmed/15947569 Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 2003;46(Suppl):S105-S115. http://www.ncbi.nlm.nih.gov/pubmed/12850531 Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17(10):3173-81. http://www.ncbi.nlm.nih.gov/pubmed/10506615
UPDATE MARCH 2008
4.
5.
6.
7.
8.
9.
10.
11.
12. 13.
14.
15.
16.
17.
18. 19.
Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Diaz-Rubio E, Cortes-Funes H, Baselga J; Spanish Oncology Genitourinary Group. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002;95(4):751-7. http://www.ncbi.nlm.nih.gov/pubmed/12209718 Sengelov L, Kamby C, von der Maase H. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 2001;39(6):634-42. http://www.ncbi.nlm.nih.gov/pubmed/11464051 Bajorin D. The phase III candidate: can we improve the science of selection? J Clin Oncol 2004;22(2):211-3. http://www.ncbi.nlm.nih.gov/pubmed/14665614 Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, StuartHarris R, Sarosdy MF, Lowe BA et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10(7):1066-73. http://www.ncbi.nlm.nih.gov/pubmed/1607913 von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602-8. http://www.ncbi.nlm.nih.gov/pubmed/16034041 Bamias A, Efstathiou E, Moulopoulos LA, Gika D, Hamilos G, Zorzou MP, Kakoyiannis C, Kastritis E, Bozas G, Papadimitriou C, Dimopoulos MA. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 2005;16(2):307-13. http://www.ncbi.nlm.nih.gov/pubmed/15668289 Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, De Torres J, Morote J, Lopez M, Sole LA. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992;70(7):1974-9. http://www.ncbi.nlm.nih.gov/pubmed/1525774 Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer. Eur J Cancer 2001;37(17):2212-5. http://www.ncbi.nlm.nih.gov/pubmed/11677109 Yagoda A. Chemotherapy of metastatic bladder cancer. Cancer 1980;45(7 Suppl):1879-88. http://www.ncbi.nlm.nih.gov/pubmed/7189443 Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 2006;24(19):3095-100. http://www.ncbi.nlm.nih.gov/pubmed/16809735 Carles J, Nogue M, Domenech M, Perez C, Saigi E, Villadiego K, Guasch I, Ibeas R. Carboplatingemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000;59(1):24-7. http://www.ncbi.nlm.nih.gov/pubmed/10895062 Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007;69(1 Suppl):62-79. http://www.ncbi.nlm.nih.gov/pubmed/17280909 Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12(11):2264-70. http://www.ncbi.nlm.nih.gov/pubmed/7525883 de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J, Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 1998;78(10):1342-5. http://www.ncbi.nlm.nih.gov/pubmed/9823976 Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987;60(3 Suppl):574-85. http://www.ncbi.nlm.nih.gov/pubmed/3297286 Roth BJ, Bajorin DF. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 1995;153(3 Pt 2):894-900. http://www.ncbi.nlm.nih.gov/pubmed/7853569
UPDATE MARCH 2008
43
20.
21.
22.
23. 24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
44
von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003;3(1):11-9. http://www.ncbi.nlm.nih.gov/pubmed/12597345 Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15(12):3441-5. http://www.ncbi.nlm.nih.gov/pubmed/9396395 Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15(11):3394-8. http://www.ncbi.nlm.nih.gov/pubmed/9363871 Marenco D, Castagneto B, Zai S. Gemcitabine monochemotherapy in the elderly patient with advanced bladder cancer. Proc Am Soc Clin Oncol 2002;21:150b (abstr 2414). Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994;5(2):182-4. http://www.ncbi.nlm.nih.gov/pubmed/8186164 Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M, De Lena M. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998;34(8): 1208-12. http://www.ncbi.nlm.nih.gov/pubmed/9849481 Gebbia V, Testa A, Borsellino N et al. Single agent 2’,2’-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 1999;150(1):11-5. http://www.ncbi.nlm.nih.gov/pubmed/10367539 Albers P, Siener R, Hartlein M, Fallahi M, Haeutle D, Perabo FG, Steiner G, Blatter J, Muller SC; German TCC Study Group of the German Association of Urologic Oncology. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma – prognostic factors for response and improvement of quality of life. Onkologie 2002;25(1):47-52. http://www.ncbi.nlm.nih.gov/pubmed/11893883 Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8(6):1050-5. http://www.ncbi.nlm.nih.gov/pubmed/2189954 Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA; Hellenic Cooperative Oncology Group. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004;22(2):220-8. http://www.ncbi.nlm.nih.gov/pubmed/14665607 Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989;64(12): 2448-58. http://www.ncbi.nlm.nih.gov/pubmed/2819654 Sternberg CN, Yagoda A, Scher HI et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988;139(3):461-9. http://www.ncbi.nlm.nih.gov/pubmed/3343727 von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068-77. http://www.ncbi.nlm.nih.gov/pubmed/11001674 Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318(22):1414-22. http://www.ncbi.nlm.nih.gov/pubmed/2452983
UPDATE MARCH 2008
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L; European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19(10):2638-46. http://www.ncbi.nlm.nih.gov/pubmed/11352955 Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Collette L; EORTC GenitoUrinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42(1):50-4. http://www.ncbi.nlm.nih.gov/pubmed/16330205 Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004;100(8):1639-45. http://www.ncbi.nlm.nih.gov/pubmed/15073851 Petrioli R, Frediani B, Manganelli A, Barbanti G, De Capua B, De Lauretis A, Salvestrini F, Mondillo S, Francini G. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996;77(2):344-51. http://www.ncbi.nlm.nih.gov/pubmed/8625244 Carteni G, Dogliotti L, Crucitta E, Martoni A, Siena S, Onat H, Bertetto O, Bono A, Amadori D, Marini L. Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). Proc Am Soc Clin Oncol 2003;22: abstr 1543. http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=23&abstractI D=102093 Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Sole LA, Baselga J. Carboplatinbased versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997;80(10):1966-72. http://www.ncbi.nlm.nih.gov/pubmed/9366300 Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92(12):2993-8. http://www.ncbi.nlm.nih.gov/pubmed/11753976 Meluch AA, Greco FA, Burris HA 3rd, O’Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19(12):3018-24. http://www.ncbi.nlm.nih.gov/pubmed/11408496 Parameswaran R, Fisch MJ, Ansari RH, Fox EP, Sweeney CJ, Einhorn LH. A Hoosier Oncology Group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc Am Soc Clin Oncol 2001;200:abstr 798. http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_ view&confID=10&abstractID=798 Guardino AE, Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies. Proc Am Soc Clin Oncol 2002;21: abstr 2413. http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?abstractID= 2413&confID=16&index=y&vmview=abst_detail_view Fechner GH, Siener R, Reimann M et al. Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma. J Urol 2002;167(Suppl 4):abstr 284.
UPDATE MARCH 2008
45
45.
46.
47. 48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
46
Kaufman DS, Carducci MA, Kuzel T, Todd MB, Raghavan D, Oh WK, Smith MR, Nicol SJ, Stadler WW. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): a completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc Am Soc Clin Oncol 2002;21: abstr 767. http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_ view&confID=16&abstractID=767 Nogue-Aliguer M, Carles J, Arrivi A, Juan O, Alonso L, Font A, Mellado B, Garrido P, Saenz A; Spanish Cooperative Group. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003;97(9):2180-6. http://www.ncbi.nlm.nih.gov/pubmed/12712469 Balducci L. Evidence-based management of cancer in the elderly. Cancer Control 2000;7(4):368-76. http://www.ncbi.nlm.nih.gov/pubmed/10895132 Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20(4):937-40. http://www.ncbi.nlm.nih.gov/pubmed/11844814 Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997;75(4):606-7. http://www.ncbi.nlm.nih.gov/pubmed/9052419 McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15(5):1853-7. http://www.ncbi.nlm.nih.gov/pubmed/9164195 Moore M, Winquist E, Vokes E, Hirte H, Hoving K, Stadler W. Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional cell carcinoma of the urothelial tract (TCC) who have received prior chemotherapy. Proc Am Soc Clin Oncol 2003;22: abstr 1638. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&c onfID=23&abstractID=100319 Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ Sr. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs 1998;16(2):191-5. http://www.ncbi.nlm.nih.gov/pubmed/9848585 Petrylak D, Faulkner J, Van Veldhuizen P, Mansukhani M, Crawford E. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: a Southwest Oncology Group Trial. Proc Am Soc Clin Oncol 2003;22: abstr 1619. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&c onfID=23&abstractID=104215 Sridhar S, Stadler W, Le L, Hedley D, Pond G, Wright J, Vokes E, Thomas S, Moore M. Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, Vol 23, No 16S Part I of II (June 1 Suppl), 2005:4677. http://prostateca.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view &confID=34&abstractID=33648 Wulfing C, Machiels J, Richiels D, Grimm M, Treiber U, de Groot M, Beuzeboc P, Farrel J, Stone NL, Leopold L, El-Hariry I. A single arm, multicenter, open-label, ph II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, Vol 23, No 16S, Part I of II (June 1 Suppl) 2005:4594. http://prostateca.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnex toid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abst ractID=31739 Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B, James N. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinumcontaining regimen. Br J Cancer 2006;94(10):1395-401. http://www.ncbi.nlm.nih.gov/pubmed/16622447 Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, NicolSJ, Kaufman DS. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24(21):3451-7. http://www.ncbi.nlm.nih.gov/pubmed/16849761
UPDATE MARCH 2008
58.
59.
60.
61.
62.
63.
64.
Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007;25(3):265-70. http://www.ncbi.nlm.nih.gov/pubmed/17146733 Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, Loehrer PJ Sr. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997;15(2):589-93. http://www.ncbi.nlm.nih.gov/pubmed/9053481 Stadler WM. Gemcitabine doublets in advanced urothelial cancer. Semin Oncol 2002;29(1 Suppl 3):15-9. http://www.ncbi.nlm.nih.gov/pubmed/11894003 Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19(9):2527-33. http://www.ncbi.nlm.nih.gov/pubmed/11331332 Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165(3):811-4. http://www.ncbi.nlm.nih.gov/pubmed/1117647 Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 2003;169(6):2113-7. http://www.ncbi.nlm.nih.gov/pubmed/12771730 Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004;171(1):145-8. http://www.ncbi.nlm.nih.gov/pubmed/14665863
13. QUALITY OF LIFE The evaluation of health-related quality of life (HRQL) considers physical, emotional and social functioning. Several questionnaires, e.g. FACT (Functional Assessment of Cancer Therapy)-G (1), EORTC QLQ-C30 (1) and SF (Short Form)-36 (3, 4), have been validated for assessing HRQL in patients with bladder cancer. A psychometrical test such as the FACT-BL should be used for recording bladder cancer morbidity. Recently, new intensive interviewing techniques add valuable information to our knowledge of HRQL, which greatly depends on patients’ individual preferences in life (5). Unfortunately, most retrospective studies do not evaluate the association between HRQL and bladder cancer-specific issues after cystectomy, such as incontinence or potency. Furthermore, important co-variables, such as a patient’s age, mental status, coping ability and gender, have only rarely been considered (6). It remains difficult to predict the impact of post-therapeutic symptoms because of individual differences in symptom tolerance. There is controversy about which type of urinary diversion is best for a patient’s quality of life (7). Some studies have not demonstrated any difference (8, 9). As a result of improvement in surgical techniques and orthotopic bladder substitution, some more recent studies are in favour of the continent bladder substitutes (10-17). In one study (17), a statistically significant difference in HRQL in favour of neobladders was observed. Notably, HRQL parameters have been shown to represent an independent prognostic parameter for overall survival (18). Patients with a continent bladder-substitute generally score more favourably than those with an incontinent diversion, as judged by body image, social activity and physical function (11, 16). In non-curative or metastatic bladder cancer, HRQL is reduced because of associated micturition problems, bleeding, pain and therefore disturbance of social and sexual life (19). Relief of bladder-related symptoms can be obtained by palliative surgery (20), radiotherapy (21) and/or chemotherapy (22), though there is limited literature describing HRQL in palliatively treated bladder cancer patients (23). Alternative definitive treatments of muscle-invasive bladder cancer, e.g. trimodality bladder-sparing procedures, have shown similar survival times compared to cystectomy. However, the impact on HRQL has been controversial (24-29).
UPDATE MARCH 2008
47
13.1 Conclusions • •
There is no randomized prospective HRQL study evaluating different forms of definitive treatment for invasive bladder cancer. The overall HRQL after cystectomy remains good in most patients, whichever type of urinary diversion is used. Some data suggests that continent diversions produce a better HRQL (Level of evidence: 2b).
13.2 Recommendations • •
HRQL in patients with muscle-invasive bladder cancer should be assessed using validated questionnaires (Grade of recommendation: A). Continent urinary diversions should be offered for reasons of HRQL, whenever a patient’s age, personality, coping ability and tumour variables are suitable (Grade of recommendation: C).
13.3
References
1.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570-9. http://www.ncbi.nlm.nih.gov/pubmed/8445433 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-76. http://www.ncbi.nlm.nih.gov/pubmed/8433390 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473-83. http://www.ncbi.nlm.nih.gov/pubmed/1593914 Ware JE Jr, Keller SD, Gandek B, Brazier JE, Sullivan M. Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment. Int J Technol Assess Health Care 1995;11(3):525-51. http://www.ncbi.nlm.nih.gov/pubmed/7591553 Ramirez A, Perrotte P, Valiquette L, Benard F, McCormack M, Saad F, Fournier C, Shariat S, Karakiewicz PI. Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients. Can J Urol 2005;12(1):2537-42. http://www.ncbi.nlm.nih.gov/pubmed/15777491 Mansson A, Caruso A, Capovilla E, Colleen S, Bassi P, Pagano F, Mansson W. Quality of life after radical cystectomy and orthotopic bladder substitution: a comparison between Italian and Swedish men. BJU Int 2000;85(1):26-31. http://www.ncbi.nlm.nih.gov/pubmed/10619940 World Health Organization (WHO) Consensus Conference on Bladder Cancer, Hautmann RE, AbolEnein H, Hafez K, Haro I, Mansson W, Mills RD, Montie JD, Sagalowsky AI, Stein JP, Stenzl A, Studer UE, Volkmer BG. Urinary diversion. Urology 2007;69(1 Suppl):17-49. http://www.ncbi.nlm.nih.gov/pubmed/17280907 Mansson A, Davidsson T, Hunt S, Mansson W. The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference?. BJU Int 2002;90(4):386-90. http://www.ncbi.nlm.nih.gov/pubmed/12175394 Wright JL, Porter MP. Quality-of-life assessment in patients with bladder cancer. Nat Clin Pract Urol 2007;4(3):147-54. http://www.ncbi.nlm.nih.gov/pubmed/17347659 van der Veen JH, van Andel G, Kurth KH. Quality-of-life assessment in bladder cancer. World J Urol 1999;17(4):219-24. http://www.ncbi.nlm.nih.gov/pubmed/10460404 Dutta SC, Chang SC, Coffey CS, Smith JA Jr, Jack G, Cookson MS. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. J Urol 2002;168(1):164-7. http://www.ncbi.nlm.nih.gov/pubmed/12050514 Okada Y, Oishi K, Shichiri Y, Kakehi Y, Hamaguchi A, Tomoyoshi T, Yoshida O. Quality of life survey of urinary diversion patients: comparison of continent urinary diversion versus ileal conduit. Int J Urol 1997;4(1):26-31. http://www.ncbi.nlm.nih.gov/pubmed/9179663
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
48
UPDATE MARCH 2008
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Gerharz EW, Weingartner K, Dopatka T, Kohl UN, Basler HD, Riedmiller HN. Quality of life after cystectomy and urinary diversion: results of a retrospective interdisciplinary study. J Urol 1997;158(3 Pt 1):778-85. http://www.ncbi.nlm.nih.gov/pubmed/9258080 Hart S, Skinner EC, Meyerowitz BE, Boyd S, Lieskovsky G, Skinner DG. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. J Urol 1999;162(1):77-81. http://www.ncbi.nlm.nih.gov/pubmed/10379744 Hara I, Miyake H, Hara S, Gotoh A, Nakamura I, Okada H, Arakawa S, Kamidono S. Health-related quality of life after radical cystectomy for bladder cancer: a comparison of ileal conduit and orthotopic bladder replacement. BJU Int 2002;89(1):10-13. http://www.ncbi.nlm.nih.gov/pubmed/11849152 Hardt J, Filipas D, Hohenfellner R, Egle UT. Quality of life in patients with bladder carcinoma after cystectomy: first results of a prospective study. Qual Life Res 2000;9(1):1-12. http://www.ncbi.nlm.nih.gov/pubmed/10981202 Hobisch A, Tosun K, Kinzl J, Kemmler G, Bartsch G, Holtl L, Stenzl A. Life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. Semin Urol Oncol 2001;19(1):18-23. http://www.ncbi.nlm.nih.gov/pubmed/11246729 Roychowdhury DF, Hayden A, Liepa AM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 2003;21(4):673-8. http://www.ncbi.nlm.nih.gov/pubmed/12586805 Fossa SD, Aaronson N, Calais da Silva F, Denis L, Newling D, Hosbach G, Kaalhus O. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. Eur Urol 1989;16(5):335-9. http://www.ncbi.nlm.nih.gov/pubmed/2476317 Nagele U, Anastasiadis AG, Merseburger AS, Corvin S, Hennenlotter J, Adam M, Sievert KD, Stenzl A, Kuczyk MA. The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World J Urol 2007;25(4):401-5. http://www.ncbi.nlm.nih.gov/pubmed/17525849 Fokdal L, Hoyer M, von der Maase H. Radical radiotherapy for urinary bladder cancer: treatment outcomes. Expert Rev Anticancer Ther 2006;6(2):269-79. http://www.ncbi.nlm.nih.gov/pubmed/17525849 Rodel C, Weiss C and Sauer R. Organ preservation by combined modality treatment in bladder cancer: the European perspective. Semin Radiat Oncol 2005;15(1):28-35. http://www.ncbi.nlm.nih.gov/pubmed/15662604 Mommsen S, Jakobsen A, Sell A. Quality of life in patients with advanced bladder cancer. A randomized study comparing cystectomy and irradiation–the Danish Bladder Cancer Study Group (DAVECA protocol 8201). Scand J Urol Nephrol Suppl 1989;125:115-20. http://www.ncbi.nlm.nih.gov/pubmed/2699072 Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061-71. http://www.ncbi.nlm.nih.gov/pubmed/12118019 Merseburger AS, Kuczyk MA. The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery. Curr Opin Urol 2007;17(5):358-62. http://www.ncbi.nlm.nih.gov/pubmed/17762631 Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, Rodel C, Schoenberg M, Shipley W. Radiotherapy for bladder cancer. Urology 2007;69(1 Suppl):80-92. http://www.ncbi.nlm.nih.gov/pubmed/17280910 Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006;24(35):5536-44. http://www.ncbi.nlm.nih.gov/pubmed/17158539 Zietman AL, Shipley WU, Kaufman DS. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy. Ann Med 2000;32(1):34-42. http://www.ncbi.nlm.nih.gov/pubmed/10711576 Lodde M, Palermo S, Comploj E, Signorello D, Mian C, Lusuardi L, Longhi E, Zanon P, Mian M, Pycha A. Four years experience in bladder preserving management for muscle invasive bladder cancer. Eur Urol 2005;47(6):773-8; discussion 778-9. http://www.ncbi.nlm.nih.gov/pubmed/15925072
UPDATE MARCH 2008
49
14. FOLLOW-UP An appropriate schedule for disease monitoring should be based on: • natural timing of recurrence • probability of disease recurrence • functional deterioration at particular sites • possibilities of treatment of a recurrence (1). Contemporary cystectomy series demonstrate a 5-15% chance of pelvic recurrence. Most recurrences manifest during the first 24 months, with many occurring within 6-18 months after surgery. However, there have been late recurrences up to 5 years after cystectomy. Variables associated with the development of a pelvic recurrence include the pathological stage (of the primary tumour) and lymph node status. Patients have a poor prognosis after pelvic recurrence; the median survival ranges from 4-8 months following diagnosis, despite treatment. Definitive therapy can sometimes provide a prolonged survival, but provides significant palliation of symptoms in most cases. Treatment is systemic chemotherapy, local surgery or radiotherapy. Distant recurrences are seen in up to 50% of patients treated with cystectomy. Most recurrences occur in the first 24 months, although progression has been observed after more than 10 years. Again, pathological stage of the primary tumour and nodal status are risk factors. The most likely sites for distant recurrences are the lungs, liver and bones (2). Upper urinary tract recurrence is rarely seen (2-7%), but when it develops, it usually does so within 22-40 months after cystectomy (1-4). Surveillance regimens often fail to detect tumours before symptoms develop. However, radical nephroureterectomy can provide prolonged survival (3). The incidence of secondary urethral tumour is 5-17% and is particularly likely to occur at 1-3 years after surgery. Prophylactic urethrectomy at the time of cystectomy is no longer justified in most patients. In men, the most important risk factor for the development of urethral recurrence is prostatic stromal invasion (21-64%) (5-7). In women, the risk factor is disease at the bladder neck (8). Multiple studies demonstrate that the risk of urethral recurrence after orthotopic diversion (0.9-4%) (5, 9-11) is significantly less than after nonorthotopic diversion (6.4-11.1%) (5,10). There is little data and agreement about the follow-up of the urethra. Some authors recommend routine surveillance urethral wash cytology and UCS (9), while others question the need for routine urethral surveillance (9, 12-14). Urethral washes and urine cytology do not appear to have any effect on survival (12, 15, 16). Treatment is influenced by the local stage and grade of a urethral occurrence: • In CIS in the urethra, BCG instillations have shown success rates of 83% (11). • In invasive disease, urethrectomy should be performed if the urethra is the only site of disease. • In distant disease, systemic chemotherapy is indicated (2).
14.1
Conclusions and recommendations according to condition
Condition Conclusion or recommendation Level of evidence or grade of recommendation Secondary Staging and treatment should be done as for primary 3 urethral tumour urethral tumour For non-invasive tumour, local organ conservative C treatment is advised In isolated invasive disease, a urethrectomy should B be performed Urethral washes and cytology are not recommended A for follow-up Pelvic recurrence The prognosis is poor 2b Treatment should be individualized depending on the local extent and symptoms Radiotherapy, chemotherapy and possibly surgery are C options for treatment, either alone or in combination Upper urinary tract Specific upper urinary tract imaging is only indicated in B recurrence case of clinical symptoms; radical nephroureterectomy can provide prolonged survival
50
UPDATE MARCH 2008
14.2
General recommendations for follow-up
This advice for follow-up is entirely based on expert opinion. General remarks are that follow up should be dependent on the stage of the initial tumour after cystectomy. This means that the higher the initial tumour stage, the larger the chance for subsequent tumour recurrence. A higher follow-up frequency will therefore result in identifying more recurrences. Non-oncological follow-up, for example monitoring of kidney function, seems indicated life long. After 5 years of follow-up, oncological surveillance may be stopped to be continued by functional surveillance. At every visit, the following should be performed: • History • Physical examination • Bone scan only when indicated.
14.3
References
1.
Malkowicz SB, van Poppel H, Mickisch G, Pansadoro V, Thuroff J, Soloway MS, Chang S, Benson M, Fukui I. Muscle-invasive urothelial carcinoma of the bladder. Urology 2007;69(1 Suppl):3-16. http://www.ncbi.nlm.nih.gov/pubmed/17280906 Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 2003;30(4):777-89. http://www.ncbi.nlm.nih.gov/pubmed/14680314 Sanderson KM, Cai J, Miranda G, Skinner DG, Stein JP. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol 2007;177:2088-94. http://www.ncbi.nlm.nih.gov/pubmed/17509294 Stenzl A, Bartsch G, Rogatsch H. The remnant urothelium after reconstructive bladder surgery. Eur Urol 2002;41(2):124-31. http://www.ncbi.nlm.nih.gov/pubmed/12074398 Freeman JA, Tarter TA, Esrig D, Stein JP, Elmajian DA, Chen SC, Groshen S, Lieskovsky G, Skinner DG. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 1996;156(5):1615-9. http://www.ncbi.nlm.nih.gov/pubmed/8863551 Hardeman SW, Soloway MS. Urethral recurrence following radical cystectomy. J Urol 1990;144(3):666-9. http://www.ncbi.nlm.nih.gov/pubmed/2388323 Levinson AK, Johnson DE, Wishnow KI. Indications for urethrectomy in an era of continent urinary diversion. J Urol 1990;144(1):73-5. http://www.ncbi.nlm.nih.gov/pubmed/2359182 Stenzl A, Draxl H, Posch B, Colleselli K, Falk M, Bartsch G. The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract? J Urol 1995;153(3 Pt 2):950-5. http://www.ncbi.nlm.nih.gov/pubmed/7853581 Huguet J, Palou J, Serrallach M, Sole Balcells FJ, Salvador J, Villavicencio H. Management of urethral recurrence in patients with Studer ileal neobladder. Eur Urol 2003;43(5):495-8. http://www.ncbi.nlm.nih.gov/pubmed/12705993 Nieder AM, Sved PD, Gomez P, Kim SS, Manoharan M, Soloway MS. Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology 2004;64(5):950-4. http://www.ncbi.nlm.nih.gov/pubmed/15533484 Varol C, Thalmann GN, Burkhard FC, Studer UE. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol 2004;172(3):937-42. http://www.ncbi.nlm.nih.gov/pubmed/15311003 Lin DW, Herr HW, Dalbagni G. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. J Urol 2003;169(3):961-3. http://www.ncbi.nlm.nih.gov/pubmed/12576822 Sherwood JB, Sagalowsky AI. The diagnosis and treatment of urethral recurrence after radical cystectomy. Urol Oncol 2006;24(4):356-61. http://www.ncbi.nlm.nih.gov/pubmed/16818191 Slaton JW, Swanson DA, Grossman HB, Dinney CP. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 1999;162(3 Pt 1):710-4. http://www.ncbi.nlm.nih.gov/pubmed/10458349
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
UPDATE MARCH 2008
51
15.
16.
52
Erckert M, Stenzl A, Falk M, Bartsch G. Incidence of urethral tumor involvement in 910 men with bladder cancer. World J Urol 1996;14(1):3-8. http://www.ncbi.nlm.nih.gov/pubmed/8646239 Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol 2004;172(4 Pt 1):1342-7. http://www.ncbi.nlm.nih.gov/pubmed/15371837
UPDATE MARCH 2008
15. ABBREVIATIONS USED IN THE TEXT
This list is not comprehensive for the most common abbreviations
ARCO ARCON ASCO 5-ALA BC BCG CI CIS CISCA CM CMV CT EAU EBRT ECOG EORTC FACT 5-FU GC GFR GCSF HAL HD-MVAC HRQL IARC IPD ISUP IVU MCV MDCT MiM-BC MRC MR(I) MVAC MVA(E)C NAT OS PAHs PCR PET PS PUNLMP R-biopsies SF-36 SWOG TCC TNM TUR TURBT UICC UC US UUT WHO
accelerated radiotherapy with carbogen accelerated radiotherapy with carbogen nicotinamide American Society of Clinical Oncology 5-aminolaevulinic acid bladder cancer Bacille Calmette-Guérin confidence interval carcinoma in situ cisplatin, cyclophosphamide plus adriamycin cisplatin, methotrexate cisplatin, methotrexate plus vinblastine computed tomography European Association of Urology external beam radiation therapy Eastern Cooperative Oncology Group European Organization for Research and Treatment of Cancer Functional Assessment of Cancer Therapy 5-Fluorouracil gemcitabine plus cisplatin glomerular filtration rate granulocyte colony stimulating factor hexaminolaevulinate high-dose methotrexate, vinblastine, adriamycin plus cisplatin health-related quality of life International Agency for Research on Cancer independent patient data International Society of Urological Pathology Intravenous urography methrotrexate, cisplatin and vinblastine multidetector-row CT Muscle-invasive and metastatic bladder cancer Medical Research Council (UK) magnetic resonance (imaging) methotrexate, vinblastine, adriamycin plus cisplatin methotrexate, vinblastine, adriamycine or epirubicine, and cisplatin N-acetyltransferase overall survival polycyclic aromatic hydrocarbons pathological complete remission positron emission tomography performance status papillary urothelial neoplasms of low malignant potential random biopsies Short Form-36 Southwest Oncology Group transitional cell carcinoma Tumour, Node, Metastases transurethral resection transurethral resection of bladder tumour Union International Contre le Cancer urethrocystoscopy ultrasonography upper urinary tract World Health Organization
UPDATE MARCH 2008
53
Conflict of interest All members of the Muscle-Invasive and Metastatic Bladder Cancer guidelines writing panel have provided disclosure statements of all relationships which they have and which may be perceived as a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
54
UPDATE MARCH 2008
Guidelines on
Prostate Cancer A. Heidenreich (chairman), M. Bolla, S. Joniau, T.H. van der Kwast, V. Matveev, M.D. Mason, N. Mottet, H-P. Schmid, T. Wiegel, F. Zattoni
© European Association of Urology 2009
TABLE OF CONTENTS
page
1
BACKGROUND 1.1 Reference
7 7
2.
BACKGROUND 2.1 References
8 8
3.
CLASSIFICATION 3.1 Gleason score 3.2 References
8 9 9
4.
RISK FACTORS 4.1 References
9 10
5.
SCREENING AND EARLY DETECTION 5.1 References
10 11
6. DIAGNOSIS 6.1 Digital rectal examination (DRE) 6.2 Prostate specific antigen (PSA) 6.2.1 Free/total PSA ratio (f/t PSA) 6.2.2 PSA velocity (PSAV), PSA doubling time (PSADT) 6.2.3 PCA3 marker 6.3 Transrectal ultrasonography (TRUS) 6.4 Prostate biopsy 6.4.1 Baseline biopsy 6.4.2 Repeat biopsy 6.4.3 Saturation biopsy 6.4.4 Sampling sites and number of cores 6.4.5 Diagnostic transurethral resection of the prostate (TURP) 6.4.6 Seminal vesicle biopsy 6.4.7 Transition zone biopsy 6.4.8 Antibiotics 6.4.9 Local anaesthesia 6.4.10 Fine-needle aspiration biopsy 6.4.11 Complications 6.5 Pathology of prostate needle biopsies 6.5.1 Grossing and processing 6.5.2 Microscopy and reporting 6.6 Pathohistology of radical prostatectomy (RP) specimens 6.6.1 Processing of the RP specimen 6.6.2 RP specimen report 6.6.2.1 Gleason score 6.6.2.2 Interpreting the Gleason score 6.6.2.3 Definition of extraprostatic extension 6.6.3 Prostate cancer volume 6.6.4 Surginal margin status 6.6.5 Other factors 6.7 References
13 13 13 13 14 14 14 14 14 14 14 14 15 15 15 15 15 15 15 15 15 16 17 17 17 18 18 18 19 19 19 19
7.
24 24 26 27 28 28
2
STAGING 7.1 T-staging 7.2 N-staging 7.3 M-staging 7.4 Guidelines for the staging of prostate cancer (PCa) 7.5 References
Update march 2009
8. TREATMENT: DEFERRED TREATMENT (WATCHFUL WAITING [WW] / ACTIVE MONITORING 8.1 Introduction 8.1.1 Definition 8.2 Deferred treatment of localised PCa (stage T1-T2, Nx-N0, M0) 8.2.1 Watchful waiting (WW) 8.2.2 Active surveillance 8.3 Deferred treatment for locally advanced PCa (stage T3-T4, Nx-N0, M0) 8.4 Deferred treatment for metastatic PCa (stage M1) 8.5 Summary of deferred treatment 8.5.1 Indications 8.5.2 Options 8.6 References
33 33 33 34 34 36 37 38 38 38 38 39
9. TREATMENT: RADICAL PROSTATECTOMY 9.1 Introduction 9.2 Low-risk localised PCa: cT1-T2a AND Gleason score 2-6 and PSA < 10 9.2.1 Stage T1a-T1b PCa 9.2.2 Stage T1c and T2a PCa 9.3 Intermediate-risk localised PCa: cT2b-T2c OR Gleason score = 7 or PSA 10-20 9.3.1 Oncological results of RP in low- and intermediate risk PCa 9.4 High-risk localised PCa: cT3a OR Gleason score 8-10 or PSA > 20 9.4.1 Locally-advanced PCa: cT3a 9.4.2 High-grade PCa: Gleason score 8-10 9.4.3 PCa with PSA > 20 9.5 Very high-risk localised PCa: cT3b-T4 N0 or any T, N1 9.5.1 cT3b-T4 N0 9.5.2 Any T, N1 9.5.2.1 Indication and extent of extended pelvic lymph node dissection (eLND) 9.5.2.2 Therapeutic role of eLND 9.5.2.3 Morbidity 9.5.2.4 Summary of eLND 9.6 Summary of RP in high-risk localised disease 9.7 Neoadjuvant hormonal therapy and RP 9.7.1 Summary of neoadjuvant and adjuvant hormonal treatment and RP 9.8 Complications and functional outcome 9.9 Summary of indications for nerve-sparing surgery 9.10 Guidelines and recommendations for RP 9.11 References
42 42 43 43 43 43 44 44 44 45 45 46 46 46 46 47 47 47 47 47 48 48 48 49 49
10. TREATMENT: DEFINITIVE RADIATION THERAPY 10.1 Introduction 10.2 Technical aspects: three dimensional conformal radiotherapy and intensity modulated external beam radiotherapy 10.3 Localised prostate cancer T1-2c N0, M0 10.3.1 T1a-T2a, N0, M0 and Gleason score ≤ 6 and PSA < 10 ng/mL (low-risk group) 10.3.2 T2b or PSA 10-20 ng/mL, or Gleason score 7 (intermediate-risk group) 10.3.3 T2c or Gleason score > 7 or PSA > 20 ng/mL (high-risk group) 10.3.4 Prophylactic irradiation of pelvic lymph nodes in high-risk localised prostate cancer 10.4 Innovative techniques 10.4.1 Intensity modulated radiotherapy 10.4.2 Proton beam and carbon ion beam therapy 10.5 Transperineal brachytherapy 10.6 Late toxicity 10.7 Immediate post-operative external irradiation for pathological tumour stage T3 N0 M0 10.8 Locally advanced prostate cancer: T3-4 N0, M0 10.8.1 Neoadjuvant and concomitant hormonal therapy 10.8.2 Concomitant and long-term adjuvant hormonal therapy 10.8.3 Long-term adjuvant hormonal therapy 10.8.4 Neoadjuvant, concomitant and long-term adjuvant hormonal therapy
56 56
Update march 2009
56 56 56 57 57 57 58 58 58 59 60 61 62 62 62 63 63
3
10.9 10.10 10.11
10.8.5 Short-term or long-term adjuvant hormonal treatment 10.8.6 Dose escalation with hormonal therapy Very high-risk prostate cancer: c or pN1 M0 Summary of definitive radiation therapy References
63 63 63 64 64
11. EXPERIMENTAL LOCAL TREATMENT OF PROSTATE CANCER 11.1 Background 11.2 Cryosurgery of the prostate (CSAP) 11.2.1 Indication for CSAP 11.2.2 Results of modern cryosurgery for PCa 11.2.3 Complications of CSAP for primary treatment of PCa 11.2.4 Summary of CSAP 11.3 High-intensity focused ultrasound (HIFU) of the prostate 11.3.1 Results of HIFU in PCa 11.3.2 Complications of HIFU 11.4 Radiofrequency interstitial tumour ablation (RITA) 11.5 Summary of experimental therapeutic options to treat clinically localized PCa 11.6 References
70 70 70 71 71 71 72 72 72 73 73 73 73
12. HORMONAL THERAPY 12.1 Introduction 12.2 Basics of hormonal control of the prostate 12.3 Different types of hormonal therapy 12.3.1 Testosterone-lowering therapy (castration) 12.3.1.1 Bilateral orchiectomy 12.3.1.2 Oestrogens 12.3.1.3 LHRH agonists 12.3.1.4 LHRH antagonists 12.3.2 Anti-androgens 12.3.2.1 Steroidal anti-androgens Cyproterone acetate (CPA) Megestrol acetate and medroxyprogesterone acetate 12.3.2.2 Non-steroidal anti-androgens Nilutamide Flutamide Bicalutamide 12.3.3 Combination therapies 12.3.3.1 Complete androgen blockade 12.3.3.2 Minimal androgen blockade (or peripheral androgen blockade) 12.3.3.3 Intermittent vs continuous androgen deprivation therapy 12.3.3.4 Immediate vs deferred ADT 12.4 Indications for hormonal therapy 12.5 Contraindications for various therapies 12.6 Outcome 12.7 Side-effects, QoL and cost of hormonal therapy 12.7.1 Side-effects 12.7.2 Quality of Life (QoL) 12.7.3 Cost-effectiveness of hormonal therapy options 12.8 Summary of hormonal therapy 12.9 References
74 74 75 75 75 75 75 76 77 78 78 78 78 78 79 79 79 81 81 81 81 83 84 84 85 85 85 86 87 87 88
13.
98
SUMMARY OF GUIDELINES ON PRIMARY TREATMENT OF PCa
14 FOLLOW-UP: AFTER PRIMARY TREATMENT WITH CURATIVE INTENT 14.1 Definition 14.2 Why follow-up? 14.3 How to follow-up? 14.3.1 PSA monitoring 14.3.2 Definition of PSA progression
4
99 99 99 99 99 99
Update march 2009
14.4 14.5 14.6
14.3.3 PSA monitoring after radical prostatectomy 14.3.4 PSA monitoring after radiation therapy 14.3.5 Digital rectal examination (DRE) 14.3.6 Transrectal ultrasonography (TRUS) and biopsy 14.3.7 Bone scintigraphy 14.3.8 Computed tomography (CT) and magnetic resonance imaging (MRI) When to follow-up? Guidelines for follow-up after treatment with curative intent References
100 100 100 100 100 100 101 101 101
15. FOLLOW-UP AFTER HORMONAL TREATMENT 15.1 Introduction 15.2 Purpose of follow-up 15.3 Methods of follow-up 15.3.1 Prostate-specific antigen monitoring 15.3.2 Creatinine, haemoglobin and liver function monitoring 15.3.3 Bone scan, ultrasound and chest X-ray 15.4 When to follow-up 15.4.1 Stage M0 patients 15.4.2 Stage M1 patients 15.4.3 Hormone-refractory patients 15.5 Guidelines for follow-up after hormonal treatment 15.6 References
103 103 103 103 103 103 104 104 104 104 104 104 105
16. TREATMENT OF BIOCHEMICAL FAILURE AFTER TRATMENT WITH CURATIVE INTENT 16.1 Background 16.2 Definitions 16.2.1 Definition of treatment failure 16.2.2 Definition of recurrence 16.3 Local or systemic relapse 16.3.1 Definition of local and systemic failure 16.4 Evaluation of PSA progression 16.5 Diagnostic procedures in patients with PSA relapse 16.6 Treatment of PSA-only recurrences 16.6.1 Radiation therapy for PSA-only recurrence after radical prostatectomy (RP) 16.6.2 Hormonal therapy 16.6.3 Observation 16.6.4 Management of PSA relapse after radical prostatectomy 16.7 Management of PSA failures after radiation therapy 16.7.1 Salvage cryosurgical ablation of the prostate (CSAP) for radiation failures 16.7.2 Salvage brachytherapy for radiation failures 16.7.3 Observation 16.7.4 Management of PSA-relapse after radiation therapy 16.8 Guidelines for second-line therapy after treatment with curative intent 16.9 References
106 106 106 106 106 106 107 108 109 109 109 110 111 111 111 112 112 112 113 113 113
17. HORMONE REFACTORY PROSTATE CANCER (HRPC) 17.1 Background 17.2 Definition of HRPC 17.3 Assessing treatment outcome in androgen-independent PCa 17.3.1 PSA level as marker of response 17.3.2 Other parameters 17.3.3 Trial end-points 17.4 Recommendations for assessing therapeutic response 17.5 Androgen deprivation in androgen-independent PCa 17.6 Secondary hormonal therapy 17.7 Anti-androgen withdrawal syndrome 17.8 Treatment alternatives after initial hormonal therapy 17.8.1 Bicalutamide 17.8.2 Switching to an alternative anti-androgen therapy
119 119 119 120 120 120 120 121 121 121 121 122 122 122
Update march 2009
5
17.8.3 Anti-androgen withdrawal accompanied by simultaneous ketoconazole 17.8.4 Oestogens 17.9 Non-hormonal therapy (cytotoxic agents) 17.9.1 Timing of chemotherapy in metastatic HRPC Taxanes in combination therapy Mitroxantrone combined with corticosteroids Alternative combination treatment approaches Estramustine in combination therapies Oral cyclophosphamide Suramin Salvage chemotherapy 17.10 Palliative therapeutic options 17.10.1 Painful bone metastases 17.10.2 Common complications due to bone mestatases 17.10.3 Bisphosphonates 17.11 Summary of treatment after hormonal therapy 17.12 Guidelines and recommendations for cytotoxic therapy in HRPC 17.13 Guidelines for palliative management of HRPC 17.14 Recommendations for palliative management of HRPC 17.15 References
122 122 123 123 123 124 124 124 124 124 124 125 125 125 125 126 126 126 126 126
18.
137
6
ABBREVIATIONS USED IN THE TEXT
Update march 2009
1. BACKGROUND The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have prepared this guidelines document to assist medical professionals assess the evidence-based management of prostate cancer. The multidisciplinary panel of experts include urologists, radiation oncologists, a medical oncologist and a pathologist. The recommendations provided in the current guidelines are based on a systemic literature search using Medline, the Cochrane Central Register of Controlled Trials, and reference lists in publications and review articles. Where possible a level of evidence (LE) and/or grade of recommendation (GR) have been assigned (1). Recommendations are graded in order to provide transparency between the underlying evidence and the recommendation given (Tables 1 and 2). Prior to publication external review has taken place. It has to be emphasised that the current guidelines contain information for the treatment of an individual patient according to a standardised general approach. Publication history information: The Prostate Cancer Guidelines were first published in 2001, with partial updates in 2003 and 2007, followed by the current full text update. But for one section (Chapter 14), all topics have been revised. Additionally, a quick reference guide is available. All texts can be viewed and downloaded for personal use at the society website: http://www.uroweb.org/professional-resources/guidelines/. Table 1: Level of evidence Level Type of evidence 1a Evidence obtained from meta-analysis of randomised trials 1b Evidence obtained from at least one randomised trial 2a Evidence obtained from one well-designed controlled study without randomisation 2b Evidence obtained from at least one other type of well-designed quasi-experimental study 3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports 4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities Modified from Sackett et al. (1). Table 2: Grade of recommendation Grade Nature of recommendations A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial B Based on well-conducted clinical studies, but without randomised clinical trials C Made despite the absence of directly applicable clinical studies of good quality Modified from Sackett et al. (1).
1.1
REFERENCE
1.
Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [accessed February 2009].
Update march 2009
7
2. BACKGROUND Cancer of the prostate (PCa) is now recognized as one of the most important medical problems facing the male population. In Europe, PCa is the most common solid neoplasm, with an incidence rate of 214 cases per 1000 men, outnumbering lung and colorectal cancer (1). Furthermore, PCa is currently the second most common cause of cancer death in men (2). In addition, since 1985, there has been a slight increase in most countries in the number of deaths from PCa, even in countries or regions where PCa is not common (3). Prostate cancer affects elderly men more often than young men. It is therefore a bigger health concern in developed countries with their greater proportion of elderly men. Thus, about 15% of male cancers are PCa in developed countries compared to 4% of male cancers in undeveloped countries (4). It is worth mentioning that there are large regional differences in incidence rates of PCa. For example, in Sweden, where there is a long life expectancy and mortality from smoking-related diseases is relatively modest, PCa is the most common malignancy in males, accounting for 37% of all new cases of cancer in 2004 (5).
2.1
REFERENCES
1.
Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16(3):481-8. http://www.ncbi.nlm.nih.gov/pubmed/15718248 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96. http://www.ncbi.nlm.nih.gov/pubmed/18287387 Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002;90(2):162-73. http://www.ncbi.nlm.nih.gov/pubmed/12081758 Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001;37(Suppl 8):S4-66. http://www.ncbi.nlm.nih.gov/pubmed/11602373 Cancer incidence in Sweden 2004. The National Board of Health and Welfare: Stockholm, 2005. http://www.socialstyrelsen.se/NR/rdonlyres/A23BCC9E-23B5-4747AAA923BB9CDF4B75/4753/20054291.pdf
2.
3.
4.
5.
3. CLASSIFICATION The 2002 TNM (Tumour Node Metastasis) classification for PCa is shown in Table 3 (1). The new TNM system is due to be published early in 2009, but was not yet available for citation. Table 3: Tumour Node Metastasis (TNM) classification of PCa*. T - Primary tumour TX Primary tumour cannot be assessed T0 No evidence of primary tumour T1 Clinically inapparent tumour not palpable or visible by imaging T1a Tumour incidental histological finding in 5% or less of tissue resected T1b Tumour incidental histological finding in more than 5% of tissue resected T1c Tumour identified by needle biopsy (e.g. because of elevated prostate-specific antigen [PSA] level) T2 Tumour confined within the prostate1 T2a Tumour involves one half of one lobe or less T2b Tumour involves more than half of one lobe, but not both lobes T2c Tumour involves both lobes T3 Tumour extends through the prostatic capsule2 T3a Extracapsular extension (unilateral or bilateral) T3b Tumour invades seminal vesicle(s) T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, external sphincter, rectum, levator muscles, or pelvic wall N - Regional lymph nodes3 NX Regional lymph nodes cannot be assessed
8
Update march 2009
N0 No regional lymph node metastasis N1 Regional lymph node metastasis M - Distant metastasis4 MX Distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis M1a Non-regional lymph node(s) M1b Bone(s) M1c Other site(s) 1
umour found in one or both lobes by needle biopsy, but not palpable or visible by imaging, is classified as T1c. T Invasion into the prostatic apex, or into (but not beyond) the prostate capsule, is not classified as T3, but as T2. 3 Metastasis no larger than 0.2 cm can be designated pN1mi. 4 When more than one site of metastasis is present, the most advanced category should be used. 2
*At the time of the publication of this document the updated TNM system was not yet available for citation.
3.1 Gleason score The Gleason score is the most commonly used system for grading adenocarcinoma of the prostate (2). The Gleason score can only be assessed using biopsy material (core biopsy or operative specimens). Cytological preparations cannot be used. The Gleason score is the sum of the two most common patterns (grades 1-5) of tumour growth found. The Gleason score ranges between 2 and 10, with 2 being the least aggressive and 10 the most aggressive. In needle biopsy, it is recommended that the worst grade always should be included, even if it is present in < 5% of biopsy material (3).
3.2
REFERENCES
1.
Sobin LH and Wittekind Ch (eds). TNM Classification of Malignant Tumours. 6th edn. Wiley-Liss: New York, 2002. http://www.wiley.com/WileyCDA/WileyTitle/productCd-0471222887.html Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111(1):58-64. http://www.ncbi.nlm.nih.gov/pubmed/4813554 Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol 2005 (Suppl);216:20-33. http://www.ncbi.nlm.nih.gov/pubmed/16019757
2.
3.
4. RISK FACTORS The factors that determine the risk of developing clinical PCa are not well known, although a few have been identified. There are three well-established risk factors for PCa: increasing age, ethnical origin and heredity. If one first-line relative has PCa, the risk is at least doubled. If two or more first-line relatives are affected, the risk increases 5- to 11-fold (1, 2). A small subpopulation of individuals with PCa (about 9%) has true hereditary PCa. This is defined as three or more affected relatives or at least two relatives who have developed earlyonset disease, i.e. before age 55 (3). Patients with hereditary PCa usually have an onset 6-7 years prior to spontaneous cases, but do not differ in other ways (4). The frequency of autopsy-detected cancers is roughly the same in different parts of the world (5). This finding is in sharp contrast to the incidence of clinical PCa, which differs widely between different geographical areas, being high in the USA and Northern Europe and low in Southeast Asia (6). However, if Japanese men move from Japan to Hawaii, their risk of PCa increases; if they move to California their risk increases even more, approaching that of American men (7) (level of evidence: 2). These findings indicate that exogenous factors affect the risk of progression from so-called latent PCa to clinical PCa. Factors such as food consumption, pattern of sexual behaviour, alcohol consumption, exposure to ultraviolet radiation and occupational exposure have all been discussed as being of aetiological importance (8). Prostate cancer is an ideal candidate for exogenous preventive measures, such as dietary and pharmacological prevention, due to some specific features: high prevalence, long latency, endocrine dependency, availability of serum markers (PSA) and histological precursor lesions (PIN). Dietary/nutritional
Update march 2009
9
factors that may influence disease development include total energy intake (as reflected by body mass index), dietary fat, cooked meat, micronutrients and vitamins (carotenoids, retinoids, vitamins C, D, and E), fruit and vegetable intake, minerals (calcium, selenium), and phyto-oestrogens (isoflavonoids, flavonoids, lignans). Since most studies reported to date are case-control analyses, there remain more questions than evidence-based data available to answer them. Several ongoing large randomised trials are trying to clarify the role of such risk factors and the potential for successful prostate cancer prevention (9). In summary, hereditary factors are important in determining the risk of developing clinical PCa, while exogenous factors may have an important impact on this risk. The key question is whether there is enough evidence to recommend lifestyle changes (lowered intake of animal fat and increased intake of fruit, cereals and vegetables) in order to decrease the risk (10). There is some evidence to support such a recommendation and this information can be given to male relatives of PCa patients who ask about the impact of diet (level of evidence: 2-3).
4.1
REFERENCES
1.
Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17(4):337-47. http://www.ncbi.nlm.nih.gov/pubmed/2251225 Gronberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996;77(1):138-43. http://www.ncbi.nlm.nih.gov/pubmed/8630920 Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89(8):3367-71. http://www.ncbi.nlm.nih.gov/pubmed/1565627 Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002;168(3):906-13. http://www.ncbi.nlm.nih.gov/pubmed/12187189 Breslow N, Chan CW, Dhom G, Drury RAB, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977;20(5):680-8. http://www.ncbi.nlm.nih.gov/pubmed/924691 Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002;90(2):162-73. http://www.ncbi.nlm.nih.gov/pubmed/12081758 Zaridze DG, Boyle P, Smans M. International trends in prostatic cancer. Int J Cancer 1984;33(2): 223-30. http://www.ncbi.nlm.nih.gov/pubmed/6693200 Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004;4(7):519-27. http://www.ncbi.nlm.nih.gov/pubmed/15229477 Schmid H-P, Engeler DS, Pummer K, Schmitz-Dräger B J. Prevention of prostate cancer: more questions than data. Cancer Prevention. Recent Results Cancer Res 2007;174:101-7. http://www.ncbi.nlm.nih.gov/pubmed/17302190 Schulman CC, Zlotta AR, Denis L, Schroder FH, Sakr WA. Prevention of prostate cancer. Scand J Urol Nephrol 2000;205(Suppl):50-61. http://www.ncbi.nlm.nih.gov/pubmed/11144904
2.
3.
4. 5.
6.
7.
8.
9.
10.
5. SCREENING AND EARLY DETECTION Population or mass screening is defined as the examination of asymptomatic men (at risk). It usually takes place as part of a trial or study and is initiated by the screener. In contrast, early detection or opportunistic screening comprises individual case findings, which are initiated by the person being screened (patient) and/or his physician. The primary endpoint of both types of screening has two aspects: 1. Reduction in mortality from PCa. The goal is not to detect more and more carcinomas, nor is survival the endpoint because survival is strongly influenced by lead-time from diagnosis. 2. The quality of life is important as expressed by quality-of-life adjusted gain in life years (QUALYs). Prostate cancer mortality trends range widely from country to country in the industrialised world (1). Decreased mortality rates due to PCa have occurred in the USA, Austria, UK and France, while in Sweden, 10
Update march 2009
the 5-year survival rate has increased from 1960 to 1988, probably due to increased diagnostic activity and greater detection of non-lethal tumours (2). However, this trend was not confirmed in a similar study from the Netherlands (3). The reduced mortality seen recently in the USA is often attributed to the widely adopted aggressive screening policy, but there is still no absolute proof prostate-specific antigen (PSA) screening reduces mortality due to PCa (4) (level of evidence: 2). A non-randomised screening project in Tyrol (Austria) may support the hypothesis that screening can be effective in reducing mortality from PCa. An early detection programme and free treatment have been used to explain the 33% decrease in the PCa mortality rate seen in Tyrol compared to the rest of Austria (5) (level of evidence: 2b). In addition, a Canadian study has claimed lower mortality rates in men randomised to active PCa screening (6), though these results have been challenged (7). Positive findings attributed to screening have also been contradicted by a comparative study between the US city of Seattle area (highly screened population) and the US state of Connecticut (seldom screened population) (8). The study found no difference in the reduction in the rate of PCa mortality (level of evidence: 2b), even allowing for the very great diversity in PSA testing and treatment. Prospective, preferably population-based, randomised trials are needed to properly evaluate the efficacy of PCa screening. Two large trials are underway, the PLCO (Prostate, Lung, Colorectal and Ovary) trial in the USA and the ERSPC (European Randomized Screening for Prostate Cancer) in Europe (9, 10). The main endpoint of these trials is difference in PCa mortality, with first results due in 2009 (level of evidence: 1b). Thus, there is currently no evidence for introducing widespread, population-based, screening programmes for early PCa detection in all men in a given population (4) (level of evidence: 2). A less controversial programme, which is also recommended by most guidelines, is using PSA with digital rectal examination (DRE) as an aid to early diagnosis (11) (see Section 6.1) (level of evidence: 3). Nevertheless, a few conclusions about screening intervals can be deduced from the ERSPC study (12): • A screening interval of 2 or 4 years had no impact on outcome in a cohort of 17,505 men aged 55-74 years • The rate of interval cancer, especially aggressive interval cancer, was low in this study (0.43% vs 0.74%) • Although the 2-year screening interval had a higher detection rate for PCa than the 4-year interval (13.14% vs 8.42%), it did not lead to lower incidences of interval PCa (0.11%) and aggressive interval PCa (0.12%) • A screening interval of 8 years might be enough in men with initial PSA levels ≤ 1 ng/ml (13) • A total of 1703 men had a PSA level ≤ 1 ng/ml when they first presented for screening. A total of 1327 men (79.3%) attended the second screening visit during which 13 men (0.98%) had PSA levels ≥ 3.0 ng/mL and three cancers were detected (0.23%) • A total of 1017 men (76.8%) attended the third screening visit during which 34 men (3.3%) had a PSA level ≥ 3.0 ng/mL and five cancers were detected (0.49%) • The 2344 subsequent PSA determinations during an 8-year period following the initial screening visit resulted in the detection of eight cancers (0.47%) • Thus, PSA screening every 8 years for men with PSA levels ≤ 1.0 ng/mL would mean fewer screening visits (with less cost and stress), with a minimal risk of missing aggressive cancer at a curable stage. The decision to undergo early PSA testing should be a shared decision between the patient and his physician (14, 15). PSA testing and digital rectal examination should be offered from the age of 45 years to men with a life expectancy of at least 10 years. The most recent research suggests further PSA testing is unnecessary in men ≥ 75 years and a PSA level ≤ 3 ng/mL at their first screening visit. This is because these men have a very low risk of dying from PCa (16).
5.1
REFERENCES
1.
Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the ‘PSA-ERA’. Int J Cancer 2001;92(6):893-8. http://www.ncbi.nlm.nih.gov/pubmed/11351313 2. Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO. Trends in prostate cancer survival in Sweden, 1960 through 1988, evidence of increasing diagnosis of non-lethal tumours. J Natl Cancer Inst 1996;88(17):1216-21. http://www.ncbi.nlm.nih.gov/pubmed/8780631
Update march 2009
11
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
12
Post PN, Kil PJ, Coebergh JW. Trends in survival of prostate cancer in southeastern Netherlands 1971-1989. Int J Cancer 1999;81(4):551-4. http://www.ncbi.nlm.nih.gov/pubmed/10225443 Ilic D, O’Connor D, Green S, Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 2007;18(3):279-85. http://www.ncbi.nlm.nih.gov/pubmed/17206534 Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schönitzer D, Severi G, Robertson C, Boyle P; Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58(3):417-24. http://www.ncbi.nlm.nih.gov/pubmed/11549491 Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, Lévesque J, Belanger A. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38(2):83-91. http://www.ncbi.nlm.nih.gov/pubmed/9973093 Boer R, Schroeder FH. Quebec randomized controlled trial on prostate cancer screening shows no evidence of mortality reduction. Prostate 1999;40(2):130-4. http://www.ncbi.nlm.nih.gov/pubmed/10386474 Lu-Yao G, Albertsen PC, Stamford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002;325(7367):740. http://www.ncbi.nlm.nih.gov/pubmed/12364300 De Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrolment in the European Randomized Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002;98(2):268-73. http://www.ncbi.nlm.nih.gov/pubmed/11857418 Schröder FH, Bangma CH, Roobol MJ. Is it necessary to detect all prostate cancers in men with serum PSA levels < 3 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 2008;53(5):901-8. http://www.ncbi.nlm.nih.gov/pubmed/18262712 Schmid H-P, Riesen W, Prikler L. Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 2004;50(1):71-8. http://www.ncbi.nlm.nih.gov/pubmed/15094160 Roobol MJ, Grenabo A, Schröder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst 2007;99(17):1296-303. http://www.ncbi.nlm.nih.gov/pubmed/17728218 Roobol MJ, Roobol DW, Schröder FH. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 2005;65(2):343-6. http://www.ncbi.nlm.nih.gov/pubmed/15708050 Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow D, Eyre HJ; American Cancer Society. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002;52(1):8-22. http://www.ncbi.nlm.nih.gov/pubmed/11814067 Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:27-41. http://www.ncbi.nlm.nih.gov/pubmed/19147867 Carter HB, Kettermann AE, Ferrucci L, Landis P, Trock BJ, Metter EJ. Prostate specific antigen testing among the elderly: when to stop. J Urol 2008;179 (Suppl):600, abstract 1751.
Update march 2009
6. DIAGNOSIS* The main diagnostic tools used to look for evidence of PCa include DRE, serum concentration of PSA and transrectal ultrasonography (TRUS). Diagnosis depends on the presence of adenocarcinoma in operative specimens, prostate biopsy cores or aspiration needle cytology. Histopathological examination also allows grading of the tumour.
6.1
Digital rectal examination (DRE)
Most prostate cancers are located in the peripheral zone of the prostate and may be detected by DRE when the volume is about 0.2 mL or larger. A suspect DRE is an absolute indication for prostate biopsy. In about 18% of all patients, PCa is detected by a suspect DRE alone, irrespective of the PSA level (1) (level of evidence: 2a). A suspect DRE in patients with a PSA level of up to 2 ng/mL has a positive predictive value of 5-30% (2) (level of evidence: 2a).
6.2 Prostate-specific antigen (PSA) The measurement of PSA level has revolutionised the diagnosis of PCa (3). Prostate-specific antigen (PSA) is a kallikrein-like serine protease produced almost exclusively by the epithelial cells of the prostate. For practical purposes, it is organ-specific but not cancer-specific. Thus, serum levels may be elevated in the presence of benign prostatic hypertrophy (BPH), prostatitis and other non-malignant conditions. The level of PSA as an independent variable is a better predictor of cancer than suspicious findings on DRE or TRUS (4). There are many different commercial test kits for measuring PSA, but no commonly agreed international standard exists (5). The level of PSA is a continuous parameter: the higher the value, the more likely is the existence of PCa (Table 4). This means there is no universally accepted cut-off or upper limit. The finding that many men may harbour PCa, despite low levels of serum PSA, has been underscored by recent results from a US prevention study (6) (level of evidence: 2a). Table 4 gives the rate of PCa in relation to serum PSA for 2950 men in the placebo-arm and with normal PSA values. Table 4: Risk of PCa in relation to low PSA values PSA level (ng/mL) • 0-0.5 • 0.6-1 • 1.1-2 • 2.1-3 • 3.1-4
Risk of PCa 6.6% 10.1% 17.0% 23.9% 26.9%
PSA = prostate-specific antigen. These findings highlight an important issue about lowering the PSA-level threshold, which is how to avoid detecting insignificant cancers with a natural history unlikely to be life threatening (7). As yet, there is no long-term data to help determine the optimal PSA threshold value for detecting non-palpable, but clinically significant, PCa (level of evidence: 3). Several modifications of serum PSA value have been described, which may improve the specificity of PSA in the early detection of PCa. They include: PSA density, PSA density of the transition zone, age-specific reference ranges and PSA molecular forms. However, these derivatives and certain PSA isoforms (cPSA, proPSA, BPSA, iPSA) have limited usefulness in the routine clinical setting and have therefore not been considered for inclusion in these guidelines. 6.2.1 Free/total PSA ratio (f/t PSA) The free/total PSA ratio (f/t PSA) is the concept most extensively investigated and most widely used in clinical practice to discriminate BPH from PCa, and has been used to stratify the risk of PCa for men with total PSA levels between 4 and 10 ng/mL and with a negative DRE. In a prospective multicentre trial, PCa was found on biopsy in 56% of men with a f/t PSA < 0.10, but in only 8% of men with f/t PSA > 0.25 (8) (level of evidence: 2a). Nevertheless, the concept must be used with caution as several pre-analytical and clinical factors may influence the f/t PSA. For example, free PSA is unstable at both 4°C and at room temperature. In addition, * Acknowledgment: Section 6.4 is partly based on the Guidelines of the AUO Study Group Urologic Oncology of the Austrian Society of Urologists and Andrologists (W. Höltl, W. Loidl, M. Rauchenwald, M. Müller, M. Klimpfinger, A. Schratter-Sehn, C. Brössner). Update march 2009
13
assay characteristics may vary and concomitant BPH in large prostates may result in a ‘dilution effect’ (9). Furthermore, f/t PSA is clinically useless in total serum PSA values > 10 ng/mL and in follow-up of patients with known PCa. 6.2.2 PSA velocity (PSAV), PSA doubling time (PSADT) There are two methods of measuring PSA over time. These are: • PSA velocity (PSAV), defined as an absolute annual increase in serum PSA (ng/mLyear) (10) (level of evidence: 1b). • PSA doubling time (PSADT), which measures the exponential increase of serum PSA over time reflecting a relative change (11). These two concepts may have a prognostic role in patients with treated PCa (12). However, they have limited use in the diagnosis of PCa because of several unresolved issues, including background noise (total volume of prostate, BPH), the interval between PSA determinations, and acceleration/deceleration of PSAV and PSADT over time. Prospective studies have not shown these measurements can provide additional information compared to PSA alone (13, 14). 6.2.3 PCA3 marker In contrast to the serum markers discussed above, PCA3 is measured in urine sediment obtained after prostatic massage (15). Determination of this PCa-specific gene is experimental. In the near future, several molecular diagnostic tests may move out of the laboratory into the clinical setting (16). So far, none of the above biomarkers can be used to counsel an individual patient on the need to perform a prostate biopsy to rule out PCa.
6.3
Transrectal ultrasonography (TRUS)
The classic picture of a hypoechoic area in the peripheral zone of the prostate will not always be seen (17). Gray-scale TRUS does not detect areas of PCa with adequate reliability. Replacing systematic biopsies by targeted biopsies of suspect areas is therefore unproductive. However, additional biopsies of suspect areas may be useful.
6.4 Prostate biopsy 6.4.1 Baseline biopsy The need for prostate biopsies should be determined on the basis of the PSA level and/or a suspicious DRE. The patient’s biological age, potential co-morbidities (ASA Index and Charlson Comorbidity Index) and the therapeutic consequences should also be considered. The first elevated PSA level should not prompt an immediate biopsy. The PSA level should be verified after a few weeks by the same assay under standardised conditions (i.e. no ejaculation and no manipulations, such as catheterisation, cystoscopy or TUR, and no urinary tract infections) in the same diagnostic laboratory, using the same methods (18, 19) (level of evidence: 2a). The ultrasound-guided perineal approach is a useful alternative in special situations, e.g. after rectal amputation. Its detection rates are comparable to those of the transrectal approach (20) (level of evidence: 1b). 6.4.2 Repeat biopsy Indications are rising and/or persistent PSA, suspicious DRE and atypical small acinar proliferation (ASAP). The optimal timing is uncertain and depends on the histological outcome of the baseline ASAP biopsy and the index of a persistent suspicion of PCa (high or dramatically rising PSA, suspect DRE, family history). The later the repeat biopsy is done, the higher the detection rate (21). High-grade prostatic intraepithelial neoplasia (PIN) is no longer considered an indication for re-biopsy (22) (level of evidence: 2a). A repeat biopsy should therefore be prompted by other clinical features, like DRE findings and PSA level. If PIN is extensive (i.e. in several biopsies) this could be a reason for early re-biopsy. 6.4.3 Saturation biopsy The incidence of PCa detected by saturation repeat biopsy is between 30% and 43% and depends on the number of cores sampled during earlier biopsies (23) (level of evidence: 2a). In special situations, saturation biopsy may be performed with the transperineal technique. This will detect an additional 38% of PCa. The high rate of urinary retention (10%) is a drawback (3D- stereotactic biopsy) (24) (level of evidence: 2b). 6.4.4 Sampling sites and number of cores On baseline biopsies, the sample sites should be as far posterior and lateral in the peripheral gland as possible. 14
Update march 2009
Additional cores should be obtained from suspect areas by DRE/TRUS. These should be chosen on an individual basis. Sextant biopsy is no longer considered adequate. At a glandular volume of 30-40 mL, at least eight cores should be sampled. More than 12 cores are not significantly more conclusive (25) (level of evidence: 1a). The British Prostate Testing for Cancer and Treatment Study has recommended 10-core biopsies (26) (level of evidence: 2a). 6.4.5 Diagnostic transurethral resection of the prostate (TURP) The use of diagnostic TURP instead of repeat biopsies is of minor importance. Its detection rate is no better than 8% and makes it a poor tool for cancer detection (27) (level of evidence: 2a). 6.4.6 Seminal vesicle biopsy Indications for seminal vesicle biopsies are not well defined. At PSA levels > 15-20 ng/mL, a biopsy is only useful if the outcome will have a decisive impact on treatment, i.e. if the biopsy result rules out radical removal for tumour involvement or radiotherapy with intent to cure. At PSA levels > 15-20 ng/L, the odds of tumour involvement are 20-25% (28) (level of evidence: 2a). 6.4.7 Transition zone biopsy Transition zone (TZ) sampling during baseline biopsies provides a very low detection rate and TZ sampling should therefore be confined to repeat biopsies (29) (level of evidence: 1b). 6.4.8 Antibiotics Oral or intravenous antibiotics are state-of-the-art treatment. Optimal dosing and treatment time vary. Quinolones are the drugs of choice, with ciprofloxacin superior to ofloxacin (30) (level of evidence: 1b). 6.4.9 Local anaesthesia Ultrasound-guided peri-prostatic block is state-of-the-art (31) (level of evidence: 1b). It does not make any difference whether the depot is apical or basal. Intrarectal instillation of a local anaesthetic is clearly inferior to peri-prostatic infiltration (32) (level of evidence: 1b). 6.4.10 Fine-needle aspiration biopsy Fine-needle aspiration biopsy is not as effective as TRUS-guided transrectal core biopsy because of the lack of uropathologists experienced in cytology. In addition, TRUS-guided transrectal core biopsies provide more information on the extent of the tumour. 6.4.11 Complications Complication rates are low (Table 5) (33). Minor complications include macrohaematuria and haematospermia. Severe post-procedural infections have been reported in < 1% of cases. The recent increase in the number of biopsy cores performed has not increased the rate of severe complications requiring treatment. Low-dose aspirin is no longer an absolute contraindication (34) (level of evidence: 1b). Table 5: Percentage given per biopsy session, irrespective of the number of cores* Complications • Haematospermia • Bleeding from urethra, urinary bladder (> 1 day) • Fever • Urosepsis • Rectal bleeding • Urine retention • Prostatitis • Epididymitis
% of biopsies 37.4 14.5 0.8 0.3 2.2 0.2 1.0 0.7
* Adapted from Consensus Guidelines NCCN, Version 1.2007 (33).
6.5 Pathology of prostate needle biopsies 6.5.1 Grossing and processing Prostate core biopsies taken from different sites are usually sent to the pathology laboratory in separate vials and should be processed in separate cassettes. Before processing, record the number of cores per vial and
Update march 2009
15
length of each core. There is a significant correlation between the length of prostate biopsy tissue on the histological slide and the detection rate of PCa (35). To achieve optimal flattening and alignment of individual cores, embed a maximum of three cores per cassette and use sponges or paper to keep the cores stretched and flat (36, 37). To optimise the detection of small lesions, blocks should be cut in three levels (38). It may be of help if intervening tissue sections are routinely mounted in case additional immunostaining is needed. 6.5.2 Microscopy and reporting Diagnosis of prostate cancer is based on histological examination. However, immunostaining may also be helpful (39, 40). Ancillary staining techniques (e.g. basal cell staining) and additional (deeper) sections should be considered if a suspect glandular lesion is identified (38, 40). For suspicious lesions in biopsies, diagnostic uncertainty may often be resolved by intradepartmental consultation and a second opinion from an external institution (39). Use concise clear terminology to report prostate biopsies (37) (Table 6) and avoid terms such as ’atypia‘, ’atypical glands‘ or ‘possibly malignant‘. Table 6: Diagnostic terms used to report prostate biopsy findings* • Benign/negative for malignancy. If appropriate, include a description (e.g. atrophy). Chronic inflammation may be added (optional) • Active inflammation, negative for malignancy • Atypical adenomatous hyperplasia/adenosis, no evidence of malignancy • Granulomatous inflammation, negative for malignancy • High-grade PIN, negative for adenocarcinoma • High-grade PIN with atypical glands suspicious for adenocarcinoma • Focus of atypical glands/lesion suspicious for adenocarcinoma • Adenocarcinoma *From Van der Kwast, 2003 (36). PIN = prostatic intra-epithelial neoplasia. For each biopsy site, report the proportion of biopsies positive for carcinoma and the Gleason score, using the system adopted in 2005 (41). According to current international convention, the (modified) Gleason score of cancers detected in a prostate biopsy consists of the Gleason grade of the dominant (most extensive) carcinoma component plus the highest grade, irrespective of its extent (no 5% rule). When the carcinoma largely consists of grade 4/5 carcinoma, identification of a small portion (< 5% of the carcinoma) of Gleason grade 2 or 3 glands should be ignored. A diagnosis of Gleason score 4 or lower should not be given on prostate biopsies (41). The presence of high-grade PIN and extraprostatic extension should be reported. In addition to a report of the carcinoma features for each biopsy site, provide an overall Gleason score based on findings in the individual biopsies. The presence of perineural invasion is usually reported, even though there is conflicting evidence about its usefulness as a prognosticator of unfavourable disease (42, 43). The proportion (%) or length (mm) of tumour involvement per biopsy site correlates with tumour volume, extraprostatic extension and prognosis after prostatectomy (43-45) and should therefore be recorded. The length of carcinoma (mm) and the percentage of carcinoma involvement of the biopsy have equal prognostic impact (46). The extent of a single, small focus of adenocarcinoma, which is located in only one of the biopsies, should be clearly stated (e.g. < 1 mm or < 1%), as this might be an indication for further diagnostic work-up before selecting therapy. In some studies, a finding of < 3 mm carcinoma in one biopsy with a Gleason score 5–6 has often been associated with insignificant cancer and with an increased risk of vanishing cancer (4749). A prostate biopsy that does not contain glandular prostate tissue could be reported as inadequate for diagnostics, except on staging biopsies. A recent study evaluated the concordance of pattern and change of prognostic groups for the conventional and the modified Gleason grading (50). The evaluation was based on 172 prostatic needle biopsies of patients who subsequently underwent RP. Four prognostic Gleason grading groups were considered, divided into scores of 2–4, 5–6, 7 and 8–10. To check the discriminative power of the modified Gleason grading, the time of biochemical progression-free outcome, according to prognostic groups, was compared between standard and revised grading. The greatest impact of the International Society of Urological Pathology consensus recommendations for Gleason grading was seen on the secondary pattern, which had the lowest percentage of concordance and was reflected in a change toward higher Gleason prognostic groups. Of 172 patients in whom the Gleason prognostic group was changed (to higher grades) based solely on the consensus criteria, 46 (26.7%) had a higher pre-operative PSA level, more extensive tumours and positive surgical
16
Update march 2009
margins, and a higher pathological stage. In this series, the revised Gleason grading identified more patients in the aggressive prognostic group Gleason score 8–10, who had a significantly shorter time to biochemical progression-free outcome after radical prostatectomy (log rank p = 0.011). These findings have shown that the recommendations of the International Society of Urological Pathology are a valuable refinement of the standard Gleason grading system.
6.6 Pathohistology of radical prostatectomy (RP) specimens 6.6.1 Processing of the RP specimen The histopathological examination of RP specimens aims to provide information about the actual pathological stage, grade and surgical margin status of the prostate cancer. The weight and dimensions of the specimen are recorded before embedding it for histological processing. It is generally recommended that RP specimens are totally embedded to enable the best assessment of location, multifocality and heterogeneity of the cancer. However, for cost-efficiency purposes, partial embedding using a standard method may also be considered, particularly for large-sized prostates (> 60 g). The most acceptable method includes the complete embedding of the posterior (dorsal) part of the prostate in addition to a single mid-anterior left and right section. Compared to total embedding, this method of partial embedding permitted detection of 98% of prostate cancers with a Gleason score ≥ 7 and accurate staging in 96% of cases (51). Upon receipt in the histopathology lab, the entire RP specimen is inked in order to appreciate the surgical margin status. The specimen is fixed in buffered formalin, preferably prior to incision of the sample, as incision causes distortion of the tissue. Generally, appropriate fixation is achieved by immersing the RP specimen in fixative for a few days. Fixation can be enhanced by injecting formalin using 21-gauge syringes, which provides a more homogeneous fixation and sectioning after 24 hours (52). After fixation, the apex is removed and cut with (para)sagittal or radial sections; the shave method is not recommended (53). Separate sagittal sectioning of the bladder neck is optional. The remainder of the RP specimen is generally cut in transverse sections at 3-4 mm steps, perpendicularly to the posterior surface. The resulting tissue slices can be embedded and processed either as whole-mounts or after quadrant sectioning. Whole-mount processing provides better topographic visualisation of the carcinoma and a faster histopathological examination. However, it is a more time-consuming and more expensive technique requiring specialised equipment and personnel. Although whole-mount sectioning may be necessary for research, its advantages do not outweigh its disadvantages for routine sectioning. Recommendations • Total embedding of a prostatectomy specimen is preferred, either by conventional (quadrant sectioning) or by whole-mount sectioning • The entire surface of RP specimens should be inked before cutting in order to evaluate the surgical margin status • The apex should be separately examined using the cone method with sagittal or radial sectioning.
6.6.2 RP specimen report The pathology report provides essential information on the prognostic characteristics relevant for making clinical decisions. The report includes: • typing (> 95% of PCa represent conventional (acinic) adenocarcinomas) • grading according to the Gleason score • (sub)staging and surgical margin status of the tumour • if appropriate, location and extent of extraprostatic extension, sidedness of extraprostatic extension or seminal vesicle invasion, location and extent of positive surgical margins • additional information may be provided on multifocality, diameter of the dominant tumour and the zonal location (transition zone, peripheral zone, anterior horn) of the dominant tumour. Given the complex information to be provided on each RP specimen, the use of synoptic-(like) or checklist reporting is recommended (see table 7). Synoptic reporting of surgical specimens results in more transparent and complete pathology reporting (54).
Update march 2009
17
Table 7: Example checklist - reporting of prostatectomy specimens Histologic type Type of carcinoma (e.g. conventional acinar, ductal, etc.) Histologic grade Primary (predominant) grade Secondary grade Tertiary grade (if applicable) Total / global Gleason score Approximate percentage of Gleason grade 4 or 5 (optional) Tumour quantitation (optional) Percentage of prostatic gland involved Tumour size of dominant nodule (if identified), greatest dimension in mm Pathologic staging (pTNM) Presence of extraprostatic extension (focal or extensive) If present: specify site(s) Presence of seminal vesicle invasion If applicable: Regional lymph nodes: - Location - Number of lymph nodes retrieved - Number of lymph nodes involved Surgical margins Presence of carcinoma at margin If present: specify site(s) and extra- or intraprostatic Other If identified: presence of angioinvasion Location (site, zone) of dominant tumour (optional) Perineural invasion (optional) If present: specify extra-or intra-prostatic 6.6.2.1. Gleason score Grading of conventional prostatic adenocarcinomas using the (modified) Gleason score system (41) is the single strongest prognostic factor for clinical behaviour and treatment response. The Gleason score is therefore one of the parameters incorporated in nomograms that predict the risk of recurrence after prostatectomy (55). 6.6.2.2. Interpreting the Gleason score The Gleason score is the sum of the most dominant and second most dominant (in terms of volume) Gleason grade. If only one grade is present, the primary grade is doubled. If a grade comprises ≤ 5% of the cancer volume, this grade is not incorporated in the Gleason score (5% rule). Both the primary and the secondary grade should be reported in addition to the Gleason score (e.g. Gleason score 7 [4 + 3]). A global Gleason score is given when there are multiple tumours, but a separate tumour focus with a higher Gleason score should also be mentioned. A tertiary Gleason grade 4 or 5, particularly if exceeding 5% of the prostate cancer volume, is an unfavourable prognosticator for biochemical recurrence. The presence of the tertiary grade and its approximate proportion of the cancer volume should also be reported (56), in addition to the Gleason score. 6.6.2.3 Definition of extraprostatic extension The TNM staging system of the International Union Against Cancer (UICC) is recommended for pathological staging of carcinomas of the prostate (53, 57). It measures the anatomical extension of the cancer, which may (e.g. pT3 substaging) or may not (e.g. pT2 substaging) be prognostic. Extraprostatic extension is the recommended term for the presence of tumour beyond the confines of the prostate. Extraprostatic extension is defined as carcinoma admixed with periprostatic adipose tissue, or bulging out beyond the contour of the prostate gland, e.g at the neurovascular bundle or the anterior prostate. It is useful to report not only the location, but also the extent of extraprostatic extension because the extension is related to the risk of recurrence (58, 59). There are no well-established and internationally accepted definitions of the terms ‘focal’ and ‘non-focal’ or ‘extensive extraprostatic extension’. Some authors describe focal as ‘a few glands‘ (60) or extension less than 1 high power field (59), while others measure the depth of extent in mm (61). Currently, it is considered clinically useful to measure the extent of extraprostatic extension (e.g. less or more than 1 high power field or 1 mm). At the site of the apex, there is no agreed definition on how to determine extraprostatic extension. Here,
18
Update march 2009
tumour admixed with skeletal muscle does not constitute extraprostatic extension, and it should be noted that at the apex, a diagnosis of stage pT4 is not rendered. In the bladder neck, microscopic invasion of small fibres of smooth muscle is not equated to bladder wall invasion (62). Some consider tumour invasion of large bundles of smooth muscle to be gross invasion (63), as determined by the urologist, or a positive bladder neck margin to be equivalent to pT4 (64). 6.6.3 Prostate cancer volume The prognostic value of determining the volume of PCa in RP specimens is controversial with several conflicting studies either demonstrating or refuting its independent prognostic impact (59, 65-68). Nevertheless, a prostate cancer volume cut-off of 0.5 mL continues to be an important parameter to distinguish insignificant from clinically relevant cancers (65). Furthermore, continued improvement in radio-imaging of the prostate glands has allowed more accurate measurements of cancer volume before surgery. For these reasons, it may be recommended that, if present, the greatest dimension of the dominant tumour nodule should be provided in millimeters. 6.6.4 Surgical margin status Surgical margin status is an independent risk factor for biochemical recurrence. It is usually possible to provide clear information about the surgical margin status: positive if tumour cells are in touch with the ink on the surface of the specimen, and negative if not. The margin is negative if tumour cells are very close to the inked surface of the margin (66) or when they are at the surface of the tissue lacking any ink. If the tissue has severe crush artifacts (usually at the apex), it may not be possible to assign a surgical margin status (69). Surgical margin status is independent of the pathological stage and a positive margin is not evidence of extraprostatic extension (70). There is insufficient evidence to prove a relationship between the extent of positive margin and the risk of recurrence (59). However, it is recommended that some indication is given of the (multi)-focality and extent of margin positivity (e.g. linear extent in millimeters, or number of blocks with positive margin involvement). 6.6.5 Other factors According to the College of American Pathologists consensus statement (71), additional potential biomarkers, such as perineural invasion, neuroendocrine differentiation, microvessel density, nuclear roundness, chromatin texture, other karyometric factors, proliferation markers, prostate-specific antigen derivatives, and other factors (oncogenes, tumor suppressor genes, apoptosis genes, etc) have not been sufficiently studied to demonstrate their additional prognostic value and clinical usefulness outside the standard patient care setting (category III).
6.7
REFERENCES
1.
Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993:42(4):365-74. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/7692657 Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol 1999;161:835-9. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/10022696 Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-16. http://www.ncbi.nlm.nih.gov/pubmed/2442609 Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151(5):1283-90. http://www.ncbi.nlm.nih.gov/pubmed/7512659 Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L. Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 1996;7:3-16. http://www.ncbi.nlm.nih.gov/pubmed/8950358
2.
3.
4.
5.
Update march 2009
19
6.
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004:350(22):2239-46. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/15163773 7. Stamey TA, Freiha FS, McNeal J, Redwine EA, Whittemore AS, Schmid H-P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(3 Suppl):933-8. http://www.ncbi.nlm.nih.gov/pubmed/7679045 8. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998:279(19):1542-7. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/9605898 9. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997;79(1):104-9. http://www.ncbi.nlm.nih.gov/pubmed/8988733 10. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992:267(16):2215-20. (level of evidence: 1b) http://www.ncbi.nlm.nih.gov/pubmed/1372942 11. Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71(6):2031-40. http://www.ncbi.nlm.nih.gov/pubmed/7680277 12. Arlen PM, Bianco F, Dahut WL, D’Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O; Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008;179(6):2181-5; discussion 2185-6. http://www.ncbi.nlm.nih.gov/pubmed/18423743 13. Heidenreich A. Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA doubling time, and PSA velocity. Eur Urol 2008;54(5):976-7. http://www.ncbi.nlm.nih.gov/pubmed/18640768 14. Ramirez ML, Nelson EC, Devere White RW, Lara PN Jr, Evans CP. Current applications for prostatespecific antigen doubling time. Eur Urol 2008;64(2):291-302 http://www.ncbi.nlm.nih.gov/pubmed/18439749 15. Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA: DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15; discussion 15-6. http://www.ncbi.nlm.nih.gov/pubmed/12814669 16. Shappell SB. Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol 2008;10(1):4469. http://www.ncbi.nlm.nih.gov/pubmed/18470278 17. Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ, McLeary RD. Transrectal ultrasound in the diagnosis and staging of prostate cancer. Radiology 1989;170(3 Pt 1):609-15. http://www.ncbi.nlm.nih.gov/pubmed/2644656 18. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, Lanza E, Latkany L, Begg CB; Polyp Prevention Trial Study Group. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003:289(20):2695-700. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/12771116 19. Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006:52(1):59-64. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/16391327 20. Emiliozzi P, Corsetti A, Tassi B, Federico G, Martini M, Pansadoro V. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology 2003:61(5):961-6. (level of evidence: 1b) http://www.ncbi.nlm.nih.gov/pubmed/12736016
20
Update march 2009
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006:175(3 Pt 1):820-834. http://www.ncbi.nlm.nih.gov/pubmed/16469560 Moore CK, Karikehalli S, Nazeer T, Fisher HA, Kaufman RP, Jr., Mian BM. Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. J Urol 2005:173(1):70-2. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/15592031 Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI . High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006:50(3):498-505. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/16631303 Moran BJ, Braccioforte MH, Conterato DJ. Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol 2006:176(4 Pt 1):1376-81. (level of evidence: 2b) http://www.ncbi.nlm.nih.gov/pubmed/16952636 Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006:175(5):160512. (level of evidence: 1a) http://www.ncbi.nlm.nih.gov/pubmed/16600713 Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, Jewell D, Powell P, Gillatt D, Dedman D, Mills N, Smith M, Noble S, Lane A; ProtecT Study Group. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003:7(14):1-88. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/12709289 Zigeuner R, Schips L, Lipsky K, Auprich M, Salfellner M, Rehak P, Pummer K, Hubmer G. Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology 2003:62(5):883-7. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/14624913 Linzer DG, Stock RG, Stone NN, Ratnow R, Ianuzzi C, Unger P. Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. Urology 1996:48(5):757-61. (level of evidence: 2a) http://www.ncbi.nlm.nih.gov/pubmed/8911521 Pelzer AE, Bektic J, Berger AP, Halpern EJ, Koppelstatter F, Klauser A, Rehder P, Horninger W, Bartsch G, Frauscher F. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the Tyrol screening project. Eur Urol 2005:48(6):916-21. (level of evidence: 1b) http://www.ncbi.nlm.nih.gov/pubmed/16126324 Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000:85(6):682-5. (level of evidence: 1b) http://www.ncbi.nlm.nih.gov/pubmed/10759665 von Knobloch R, Weber J, Varga Z, Feiber H, Heidenreich A, Hofmann R. Bilateral fine-needle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy: a prospective randomised trial. Eur Urol 2002;41(5):508-14; discussion 514. (level of evidence: 1b) http://www.ncbi.nlm.nih.gov/pubmed/12074792 Adamakis I, Mitropoulos D, Haritopoulos K, Alamanis C, Stravodimos K, Giannopoulos A. Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine-prilocain cream. World J Urol 2004:22(4):281-4. (level of evidence: 1b) http://www.ncbi.nlm.nih.gov/pubmed/14689224 NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection V.2.2007. Page: PROSD-A, 3. http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, Barbone F, Selli C. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urol 2007;70(3):501-5. (level of evidence: 1b) http://www.ncbi.nlm.nih.gov/pubmed/17688919 Iczkowski KA, Casella G, Seppala RJ, Jones GL, Mishler BA, Qian J, Bostwick DG. Needle core length in sextant biopsy influences prostate cancer detection rate. Urology 2002;59(5):698-703. http://www.ncbi.nlm.nih.gov/pubmed/11992843
Update march 2009
21
36.
Van der Kwast TH, Lopes C, Santonja C, Pihl CG, Neetens I, Martikainen P, Di Lollo S, Bubendorf L, Hoedemaeker RF; Members of the pathology committee of the European Randomised Study of Screening for Prostate Cancer. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 2003;56(5):336-40. http://www.ncbi.nlm.nih.gov/pubmed/12719451 37. Rogatsch H, Moser P, Volgger H, Horninger W, Bartsch G, Mikuz G, Mairinger T. Diagnostic effect of an improved preembedding method of prostate needle biopsy specimens. Hum Pathol 2000;31(9):1102-7. http://www.ncbi.nlm.nih.gov/pubmed/11014578 38. Reyes AO, Humphrey PA. Diagnostic effect of complete histologic sampling of prostate needle biopsy specimens. Am J Clin Pathol 1998;109(4):416-22. http://www.ncbi.nlm.nih.gov/pubmed/9535395 39. Novis DA, Zarbo RJ, Valenstein PA. Diagnostic uncertainty expressed in prostate needle biopsies. A College of American Pathologists Q-probes Study of 15,753 prostate needle biopsies in 332 institutions. Arch Pathol Lab Med 1999;123(8):687-92. http://www.ncbi.nlm.nih.gov/pubmed/10420224 40. Iczkowski KA. Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med 2006;130(6):835-43. http://www.ncbi.nlm.nih.gov/pubmed/16740037 41. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP grading committee. The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42. http://www.ncbi.nlm.nih.gov/pubmed/16096414 42. De la Taille A, Katz A, Bagiella E, Olsson CA, O’Toole KM, Rubin MA. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999;54(6):1039-43. http://www.ncbi.nlm.nih.gov/pubmed/10604705 43. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, Blute ML, Zincke H. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001;91(11):2196-204. http://www.ncbi.nlm.nih.gov/pubmed/11391602 44. Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 2002;167(5):2032-5. http://www.ncbi.nlm.nih.gov/pubmed/11956432 45. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Aronson WJ; Search Database Study Group. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol 2004;171(6 Pt 1):2215-20. http://www.ncbi.nlm.nih.gov/pubmed/15126788 46. Brimo F, Vollmer RT, Corcos J, Kotar K, Bégin LR, Humphrey PA, Bismar TA. Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 2008;53(2):177-83. http://www.ncbi.nlm.nih.gov/pubmed/18752501 47. Herkommer K, Kuefer R, Gschwend JE, Hautmann RE, Volkmer BG. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol 2004;45(1):36-41. http://www.ncbi.nlm.nih.gov/pubmed/14667513 48. Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schröder FH, van der Kwast TH. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 2005;103(4):708-16. http://www.ncbi.nlm.nih.gov/pubmed/15648082 49. Trpkov K, Gao Y, Hay R, Yimaz A. No residual cancer on radical prostatectomy after positive 10-core biopsy: incidence, biopsy findings, and DNA specimen identity analysis. Arch Pathol Lab Med 2006;130(6):811-6. http://www.ncbi.nlm.nih.gov/pubmed/16740032 50. Billis A, Guimaraes MS, Freitas LL, Meirelles L, Magna LA, Ferreira U. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol 2008;180(2):548-52; discussion 552-3.
22
Update march 2009
51.
Sehdev AE, Pan CC, Epstein JI. Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. Hum Pathol 2001;32(5):494-9. http://www.ncbi.nlm.nih.gov/pubmed/11381367 52. Ruijter ET, Miller GJ, Aalders TW, van de Kaa CA, Schalken JA, Debruyne FM, Boon ME. Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. J Pathol 1997;183(3):369-75. http://www.ncbi.nlm.nih.gov/pubmed/9422995 53. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP grading committee. The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29(9):1228-42. http://www.ncbi.nlm.nih.gov/pubmed/16096414 54. Chan NG, Duggal A, Weir MM, Driman DK. Pathological reporting of colorectal cancer specimens: a retrospective survey in an academic Canadian pathology department. Can J Surg 2008;51(4):284-8. http://www.ncbi.nlm.nih.gov/pubmed/18815652 55. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of the prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58(6):843-8. http://www.ncbi.nlm.nih.gov/pubmed/11744442 56. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncology 2007;8(5):411-9. http://www.ncbi.nlm.nih.gov/pubmed/17466898 57. Ohori M, Kattan M, Scardino PT, Wheeler TM. Radical prostatectomy for carcinoma of the prostate. Mod Pathol 2004;17(3):349-59. http://www.ncbi.nlm.nih.gov/pubmed/14765206 58. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, Ohori M, Scardino PT. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 1998;29(8):856-62. http://www.ncbi.nlm.nih.gov/pubmed/9712429 59. Marks M, Koch, Lopez-Beltran A, Montironi R, Juliar B, Cheng L. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Human Pathology 2007;38(8):1207-11. http://www.ncbi.nlm.nih.gov/pubmed/17490720 60. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993;150(1): 135-41. http://www.ncbi.nlm.nih.gov/pubmed/7685422 61. Sung MT, Lin H, Koch MO, Davidson DD, Cheng L. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol 2007;31(2):311-8. http://www.ncbi.nlm.nih.gov/pubmed/17255778 62. Aydin H, Tsuzuki T, Hernandez D, Walsh PC, Partin AW, Epstein JI. Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology 2004;64(3):551-5. http://www.ncbi.nlm.nih.gov/pubmed/15351591 63. Hoedemaeker RF, Vis AN, Van Der Kwast TH. Staging prostate cancer. Microsc Res Tech 2000;51(5):423-9. http://www.ncbi.nlm.nih.gov/pubmed/11074612 64. Srigley JR, Amin MB, Epstein JI, Grignon DJ, Humphrey PA, Renshaw AA, Wheeler TM; Members of the Cancer Committee, College of American Pathologists. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med 2006;130(7):936-46. http://www.ncbi.nlm.nih.gov/pubmed/16831046 65. Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000;163(4):1155-60. http://www.ncbi.nlm.nih.gov/pubmed/10737486
Update march 2009
23
66.
67.
68.
69.
70.
71.
Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005;216:34-63. http://www.ncbi.nlm.nih.gov/pubmed/16019758 Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004;172(2):508-11. http://www.ncbi.nlm.nih.gov/pubmed/15247716 Van Oort IM, Witjes JA, Kok DE, Kiemeney LA, Hulsbergen-vandeKaa CA. Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer. World J Urol 2008;26(3):237-41. http://www.ncbi.nlm.nih.gov/pubmed/18265988 Evans AJ, Henry PC, Van der Kwast TH, Tkachuk DC, Watson K, Lockwood GA, Fleshner NE, Cheung C, Belanger EC, Amin MB, Boccon-Gibod L, Bostwick DG, Egevad L, Epstein JI, Grignon DJ, Jones EC, Montironi R, Moussa M, Sweet JM, Trpkov K, Wheeler TM, Srigley JR. Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol 2008;32(10):1503-12. http://www.ncbi.nlm.nih.gov/pubmed/18708939 Chuang AY, Epstein JI. Positive surgical margins in areas of capsular incision in otherwise organconfined disease at radical prostatectomy: histologic features and pitfalls. Am J Surg Pathol 2008;32(8):1201-6. http://www.ncbi.nlm.nih.gov/pubmed/18580493 Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124(7):995-1000. http://www.ncbi.nlm.nih.gov/pubmed/10888774
7. STAGING The primary extension assessment of prostate cancer (PCa) is usually made by digital rectal examination (DRE), prostate-specific antigen (PSA) measurement and bone scan, supplemented with computed tomography (CT) or magnetic resonance imaging (MRI) and chest X-ray in specific situations.
7.1
T-staging
The first level is the assessment of local tumour stage, where the distinction between intracapsular (T1-T2) and extracapsular (T3-T4) disease has the most profound impact on treatment decisions. DRE often underestimates the tumour extension; a positive correlation between DRE and pathological tumour stage was found in fewer than 50% of cases (1). However, more extensive examinations for adequate T-staging are only recommended in selected cases when more precise staging directly affects the treatment decision, i.e. when curative treatment is an option. Serum PSA levels increase with advancing stage. Nevertheless, when PSA level is measured in an individual patient, it appears to have a limited ability to predict the final pathological stage accurately. Due to the production of PSA by benign and malignant prostatic tissue, there is no direct relationship between serum PSA concentration and the clinical and pathological tumour stage (2-4). A combination of serum PSA level, Gleason score on prostate biopsy and clinical T-stage, however, has been proven to be more useful in predicting the final pathological stage than the individual parameters per se (5). The ability of the molecular forms of PSA to predict T-stage is still controversial. Percentage-free serum PSA did not appear to be able to predict organ-confined disease in the overall population: it could significantly predict favourable pathology in a subset of patients where DRE is normal and total PSA ranges from 4.1-10.0 ng/mL (6). Total PSA and PSA complexed to antichymotrypsin (PSA-ACT) may be superior to their density derivatives in the prediction of post-surgical pathological stage, but it does not seem to justify the substitution of PSA-ACT data in the Partin’s nomogram (7). Large multicentre studies are needed before any form of PSA can be used as a single modality for staging.
24
Update march 2009
The most commonly used method for viewing the prostate is transrectal ultrasound (TRUS). However, only 60% of tumours are visible with TRUS, and the remainder are not recognised due to their echogenicity. A combination of DRE and TRUS can detect T3a PCa more accurately than either method alone (8). TRUS is not able to determine tumour extension with sufficient accuracy to be recommended for routine use in staging. About 60% of pT3 tumours will not be detected pre-operatively by TRUS (9) (level of evidence: 3). Three-dimensional ultrasound (3D-US) is a non-invasive method of reproducing whole volume images of solid structures with a suggested staging accuracy of 91% (10). Several adjuncts to 3D greyscale TRUS have been investigated. A greater sensitivity for cancer detection has been achieved with the addition of power colour Doppler and contrast agents: the presence or absence of vessels crossing the capsule to determine an extracapsular extension was considered a significant predictive sign (11, 12). Unfortunately, recognition of these findings is largely operator-dependent. Thus, differentiation between T2 and T3 tumours should not be based on TRUS alone (13, 14). Furthermore, in a large multi-institutional study, TRUS was no more accurate at predicting organ-confined disease than was DRE (15). These findings were supported by another large study, which showed that there was no meaningful superiority of TRUS over DRE (16). Seminal vesicle invasion is predictive of local relapse and distant failure. Seminal vesicle biopsies may be used to increase the accuracy of pre-operative staging (17). This is not recommended as a first-line examination, but should be reserved for patients with a substantial risk of seminal vesicle invasion in whom a positive seminal vesicle biopsy would modify treatment decisions. Patients with a clinical stage greater than T2a and a serum PSA level of more than 10 ng/mL could be candidates for seminal vesicle biopsies (18, 19). Patients with any of the basal biopsies positive for cancer are more likely to have positive seminal vesicle biopsies (20). The biopsy Gleason score, serum PSA level and clinical stage are known to be independent predictors of adverse pathological features after radical prostatectomy (RP). Of the prostate needle biopsy parameters examined, the percentage of tissue with cancer was the strongest predictor for positive surgical margins, seminal vesicle invasion and non-organ-confined disease (21). An increased number of biopsies involved with tumour independently predicts extracapsular extension, margin involvement and lymph node invasion (22). In a multivariate analysis, the best risk predictors of extracapsular extension on one side were the overall average of positive biopsy cores being 15% or greater, and the average from three ipsilateral biopsies being 15% or greater. When used in combination, these two factors yielded a model with a positive predictive value of 37%, and a negative predictive value of 95%. The high negative predictive value of the side-specific model identifies patients who are good candidates for nerve-sparing surgery (23). Furthermore, it may be useful to correlate the bioptic Gleason score with the final pathological stage: about 70% of patients have localised disease when the biopsy Gleason score is ≤ 6 (24). Both CT and MRI are now of a high technical standard, but neither modality is sufficiently reliable to make their use mandatory in the assessment of local tumour invasion (25-27). Endorectal MRI (e-MRI) may allow for more accurate local staging by complementing the existing clinical variables by improvements in spatial characterisation of the prostatic zonal anatomy and molecular changes (28). Image quality and localisation improves significantly with e-MRI compared with external coil MRI (29). When compared with DRE and TRUS prostate biopsy findings, e-MRI contributes significant incremental value for local PCa staging (30), particularly in the pre-operative identification of extracapsular extension (ECE) and seminal vesicle invasion (SVI) when interpreted by dedicated genitourinary radiologists (31, 32, 33). E-MRI could impact on the decision to preserve or resect the neurovascular bundle (NVB) at the time of radical surgery (34). Similarly, e-MRI could be accurate in evaluating the presence of SVI (35). Features associated with the identification of SVI include low signal intensity within the seminal vesicle, and lack of preservation of normal seminal vesicle architecture. Combining these features with the presence both of tumour at the base of the prostate and ECE is highly predictive for the presence of SVI (35, 36). When assessed for the ability to predict organ-confined PCa, the contribution of e-MRI to staging nomograms was significant in all risk categories, but the greatest benefit was seen in the intermediate and high risk groups (37). The combination of dynamic contrast-enhanced MR imaging and T2-weighted MR imaging yields improved assessment of ECE and better results for PCa staging compared with either technique independently (38) (level of evidence: 3). Update march 2009
25
MR spectroscopic imaging (MRSI) allows for the assessment of tumour metabolism by displaying the relative concentrations of citrate, choline, creatinine and polyamines. Differences in the concentrations of these chemical metabolites between normal and malignant prostate tissues allow for better tumour localisation within the peripheral zone, increasing the accuracy of ECE detection among less-experienced readers, and decreasing interobserver variability (39). Furthermore, correlations have been demonstrated between the metabolic signal pattern and a pathological Gleason score, suggesting the potential for a non-invasive assessment of PCa aggressiveness (40). Despite the proposed accuracy and benefit of e-MRI and MRSI in PCa characterisation and localisation, e-MRI has several limitations that hamper its widespread application in PCa staging, e.g. difficulties in interpreting signal changes related to post-biopsy haemorrhage and inflammatory changes of the prostate, and the unquantifiable but significant inter- and intra-observer variability seen between both non-dedicated and dedicated radiologists that may lead to under- or overestimation of tumour presence and the local extent of disease (level of evidence: 3). The overall accuracy of 11C-choline positron emission tomography (PET) in defining local tumour stage (pT2 and pT3a-4) has been reported to be around 70%. PET tends to understage PCa, and has a limited value for making treatment decisions in patients with clinically localised PCa, especially if a nerve-sparing procedure is being considered (41) (level of evidence: 2b).
7.2
N-staging
N-staging should be performed only when the findings will directly influence a treatment decision. This is usually the case in patients for whom potentially curative treatments are planned. High PSA values, stages T2b-T3 disease, poor tumour differentiation and peri-neural tumour invasion have been associated with a higher risk of the presence of nodal metastases (5, 42, 43). The measurement of PSA level alone is unhelpful in predicting the presence of lymph node metastases for an individual patient. The nomograms could be used to define a group of patients with a low risk of nodal metastasis (< 10%, see reference number 44). In such cases, patients with a serum PSA level of less than 20 ng/mL, stage T2a or less, and a Gleason score of 6 or less may be spared N-staging procedures before potentially curative treatment (5). The extent of the Gleason 4 pattern in sextant biopsies has also been used to define the risk of N1 disease. If any core had a predominant Gleason 4 pattern, or > three cores any Gleason 4 pattern, the risk of nodal metastases was found to be 20-45%. For the remaining patients, the risk was 2.5%, supporting the idea that nodal staging is unnecessary in selected patients (45). In the current published literature, the results indicate that CT and MRI perform similarly in the detection of pelvic lymph node metastases, although CT seems to be slightly superior (46) (level of evidence: 2a). In either case, the decision about whether nodal involvement is present rests solely on whether there is enlargement of the investigated lymph nodes. The centimetre threshold used to decide whether a lymph node is pathologically involved varies between 0.5 cm and 2 cm. A threshold of 1 cm in the short axis for the oval nodes, and 0.8 cm for the round nodes, has been recommended as the criteria for the diagnosis of lymph node metastases (47). A fine-needle aspiration biopsy (FNAB) might provide a decisive answer in cases of positive imaging results. However, the lymph node can be difficult to reach because of the anatomical position. In addition, FNAB is not a highly sensitive staging procedure, and a false-negative rate of 40% has been reported (47). High-resolution MRI with lymphotrophic ultra-small super-paramagnetic iron oxide particles (USPIO) was more recently suggested in the detection of small and otherwise occult lymph node metastases in patients with PCa (48, 49). These iron nanoparticles are taken up by circulating macrophages, which travel to normal nodal tissue. The presence of the nanoparticles causes normal nodal tissue to turn black, and because malignant nodal tissue is unable to take up the agent, metastases will have a signal intensity higher than normal nodes, even in those that do not meet the standard size criteria for metastasis (50). In asymptomatic patients with newly diagnosed PCa and a serum PSA level of less than 20 ng/mL, the likelihood of positive findings on CT or MRI is approximately 1% (37). CT scanning may therefore be warranted in patients with a very high risk of harbouring lymph node metastases, as the specificity of a positive scan is high (93-96%). Patients with nodal metastases on CT can thus be spared operative lymphadenectomy (51). Radio-immunoscintigraphy and PET have been investigated in order to improve the diagnosis of metastatic disease to the lymph nodes. Both methods are still under investigation, and further evaluation is needed before they can be recommended for routine use in clinical practice, especially as negative results should
26
Update march 2009
be interpreted with caution (52). The results obtained using 18F-choline PET/CT scans for initial N-staging were discouraging, especially in terms of inability to detect small metastases/micrometastases (< 5 mm) (53). Furthermore, 11C-choline PET/CT has quite a low sensitivity for the detection of lymph node metastases, but performed better than clinical nomograms, with equal sensitivity and better specificity (54). The gold standard for N-staging is operative lymphadenectomy, either by open or laparoscopic techniques. It is worth pointing out that recent studies with more extensive lymphadenectomy have shown that the obturator fossa is not always the primary site for metastatic deposits in the lymph nodes, and pelvic lymph node dissection that is limited to the obturator fossa will therefore miss about 50% of lymph node metastases (55, 56). When deciding on pelvic lymph node dissection, extended lymphadenectomy should be considered, despite its disadvantages: it requires surgical experience; it is time-consuming; and it often leads to more complications than the limited procedures. Furthermore, it may fail to identify lymph node metastases, however present, even outside the region of extended dissection (57). The primary removal of the so-called sentinel lymph node (SLN), defined as the first lymph node that receives lymphatic drainage from PCa, has the main aim of reducing the eventual morbidity associated with an extended pelvic node dissection, while preserving maximal sensitivity for diagnosis of metastatic disease (58) (level of evidence: 3) (see section 9.5.2.1 ‘Treatment: radical prostatectomy, indication and extent of LND’).
7.3
M-staging
The axial skeleton is involved in 85% of patients who die from PCa (59). The presence and extent of bone metastases accurately reflect the prognosis for an individual patient. Elevated skeletal alkaline phosphatase levels may indicate the presence of bony metastasis in 70% of affected patients (60). Furthermore, the measurement of skeletal alkaline phosphatase and PSA at the same time increases clinical effectiveness to approximately 98% (61). In a prospective study, multiple regression analysis showed the extent of bone disease to be the only variable influencing the serum levels of skeletal alkaline phosphatase and PSA. However, in contrast to serum PSA, skeletal alkaline phosphatase demonstrated a statistical correlation with the extent of bone disease (62). Early detection of bone metastases will alert the clinician to the possible complications inherent in skeletal destruction. Bone scintigraphy remains the most sensitive method of assessing bone metastases, being superior to clinical evaluation, bone radiographs, serum alkaline phosphatase measurement and prostatic acid phosphatase (PAP) determination (63, 64). Technetium diphosphonates are the optimum radiopharmaceuticals currently available because of their extremely high bone-to-soft tissue ratio (65). A semi-quantitative grading system based on the extent of disease observed on the bone scan was found to correlate with survival (66). Increased 18F-fluoride uptake in malignant bone lesions reflects the increase in regional blood flow and bone turnover that characterise these lesions. Studies have shown that 18F-fluoride PET/CT is a highly sensitive and specific imaging modality for detection of bone metastases (67, 68). However, no definitive results have been obtained and therefore no final recommendations can be made (69). Besides bone, PCa may metastasise to any organ, but most commonly it affects distant lymph nodes, lung, liver, brain and skin. Clinical examination, chest X-ray, ultrasound, CT and MRI scans are appropriate methods of investigation, but only if symptoms suggest the possibility of soft-tissue metastasis. The need for reliable serum markers to improve the pre-treatment staging of patients with PCa has long been recognised. At present, PSA is the marker of choice. A pre-treatment serum PSA level greater than 100 ng/ mL has been found to be the single most important indicator of metastatic disease, with a positive predictive value of 100% (70). Furthermore, it has helped to reduce the number of patients with newly diagnosed PCa who require a bone scan. Patients with a low serum PSA concentration have only rarely been found to harbour detectable skeletal metastases. The correlation between serum PSA and bone scintigraphy in patients with newly diagnosed untreated PCa has been further investigated (71-75). Results suggest that a staging bone scan may be superfluous if the serum PSA concentration is less than 20 ng/mL in asymptomatic patients with well or moderately differentiated tumours. In contrast, in patients with poorly differentiated tumours and locally advanced disease, a staging bone scan should be obtained irrespective of the serum PSA value (76, 77).
Update march 2009
27
7.4 Guidelines for the staging of PCa
1.
An abnormal DRE result or elevated serum PSA measurement could indicate PCa. The exact cut-off level of what is considered to be a normal PSA value has not been determined, but values of approximately < 2-3 ng/mL are often used for younger men. 2. The diagnosis of PCa depends on histopathological (or cytological) confirmation. • Biopsy and further staging investigations are only indicated if they affect the management of the patient. 3. TRUS-guided systemic biopsy is the recommended method in most cases of suspected PCa. A minimum of 10 systemic, laterally directed, cores are recommended, with perhaps more cores in larger: • transition zone biopsies are not recommended in the first set of biopsies due to low detection rates • one set of repeat biopsies is warranted in cases with persistent indication (abnormal DRE, elevated PSA or histopathological findings suggestive of malignancy at the initial biopsy) for prostate biopsy • overall recommendations for further (three or more) sets of biopsies cannot be made; the decision must be made based on an individual patient. 4. Transrectal peri-prostatic injection with a local anaesthetic can be offered to patients as effective analgesia when undergoing prostate biopsies. 5. Local staging (T-staging) of PCa is based on findings from DRE and possibly MRI. Further information is provided by the number and sites of positive prostate biopsies, the tumour grade and the level of serum PSA. Despite its high specificity in the evaluation of ECE and SVI, TRUS is limited by poor contrast resolution, resulting in low sensitivity and tendency to understage PCa. Even with the advent of colour and power Doppler to assist in identifying tumour vascularity, the accuracy of TRUS in local staging remains inadequate. In comparison with DRE, TRUS, and CT, MRI demonstrates higher accuracy for the assessment of uni- or bilobar disease (T2), ECE and SVI (T3), as well as the invasion of adjacent structures (T4). However, the literature shows a wide range in the accuracy of T-staging by MRI, from 50-92%. The addition of dynamic contrast-enhanced MRI (DCE-MRI) can be helpful in equivocal cases. The addition of MRSI to MRI also increases accuracy and decreases interobserver variability in the evaluation of ECE. 6. Lymph node status (N-staging) is only important when potentially curative treatment is planned. Patients with stage T2 or less, PSA < 20 ng/mL and a Gleason score ≤ 6 have a lower than 10% likelihood of having node metastases and can be spared nodal evaluation. Given the significant limitations of pre-operative imaging in the detection of small metastases (< 5 mm), pelvic lymph node dissection remains the only reliable staging method in clinically localised. Currently, it seems that only methods of histological detection of lymph node metastases with high sensitivity, such as sentinel lymph node dissection or extended pelvic lymph node dissection, are suitable for lymph node staging in PCa. 7. Skeletal metastasis (M-staging) is best assessed by bone scan. This may not be indicated in asymptomatic patients if the serum PSA level is less than 20 ng/mL in the presence of well or moderately differentiated tumours. In equivocal cases, 18F-fluorodeoxyglucose-PET or PET/CT could be of value, especially to differentiate active metastases and healing bones. GR = grade of recommendation
7.5
GR C
B C B
C B
C A C
C
B
C
B
C
REFERENCES
1.
Spigelman SS, McNeal JE, Freiha FS, Stamey TA. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations. J Urol 1986;136(6):1228-30. http://www.ncbi.nlm.nih.gov/pubmed/3773095 2. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate-specific antigen in patients with prostate cancer. J Urol 1989;142(4):1011-7. http://www.ncbi.nlm.nih.gov/pubmed/2477559
28
Update march 2009
3.
Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141(4):873-9. http://www.ncbi.nlm.nih.gov/pubmed/2467013 4. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate specific antigen in the staging of localized prostate cancer: influence of tumour differentiation, tumour volume and benign hyperplasia. J Urol 1990;143(4):747-52. http://www.ncbi.nlm.nih.gov/pubmed/1690309 5. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of the prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58(6):843-8. http://www.ncbi.nlm.nih.gov/pubmed/11744442 6. Morote J, Encabo G, de Torres IM. Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer. Eur Urol 2000 Aug;38(2):225-9. http://www.ncbi.nlm.nih.gov/pubmed/10895016 7. Custovic Z, Kraus O, Tomaskovic I, Tarle M. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy. Anticancer Res 2007;27(4C):2817-21. http://www.ncbi.nlm.nih.gov/pubmed/17695453 8. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Detection of clinical unilateral T3a prostate cancer – by digital rectal examination or transrectal ultrasonography? BJU Int 2006;98(5):982-5. http://www.ncbi.nlm.nih.gov/pubmed/16945120 9. Enlund A, Pedersen K, Boeryd B, Varenhorst E. Transrectal ultrasonography compared to histopathological assessment for local staging of prostatic carcinoma. Acta Radiol 1990;31(6):597600. http://www.ncbi.nlm.nih.gov/pubmed/2278785 10. Mitterberger M, Pinggera GM, Pallwein L, Gradl J, Frauscher F, Bartsch G, Strasser H, Akkad T, Horninger W The value of three-dimensional transrectal ultrasonography in staging prostate cancer. BJU Int 2007;100(1):47-50. http://www.ncbi.nlm.nih.gov/pubmed/17433033 11. Sauvain JL, Palascak P, Bourscheid D, Chabi C, Atassi A, Bremon JM, Palascak R. Value of power Doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer. Eur Urol 2003;44(1):21-30; discussion 30-1. http://www.ncbi.nlm.nih.gov/pubmed/12814671 12. Zalesky M, Urban M, Smerhovský Z, Zachoval R, Lukes M, Heracek J. Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer. Int J Urol 2008;15(1):68-75; discussion 75. http://www3.interscience.wiley.com/journal/119407751 13. Oyen RH. Imaging modalities in diagnosis and staging of carcinoma of the prostate. In: Brady LW, Heilmann HP, Petrovich Z, Baert L, Brady LW, Skinner DG (eds). Carcinoma of the Prostate. Innovations & Management, 1996, Springer Verlag, Berlin, pp. 65-96. 14. Rorvik J, Halvorsen OJ, Servoll E, Haukaas S. Transrectal ultrasonography to assess local extent of prostatic cancer before radical prostatectomy. Br J Urol 1994;73(1):65-9. http://www.ncbi.nlm.nih.gov/pubmed/8298901 15. Smith JA Jr, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective multi-institutional trial. J Urol 1997;157(3):902-6. http://www.ncbi.nlm.nih.gov/pubmed/9072596 16. Liebross RH, Pollack A, Lankford SP, Zagars GK, von Eshenbach AC, Geara FB. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome. Cancer 1999;85(7):1577-85. http://www.ncbi.nlm.nih.gov/pubmed/10193949 17. Saliken JC, Gray RR, Donnelly BJ, Owen R, White LJ, Ali-Ridha N, So B, Ting PT. Extraprostatic biopsy improves the staging of localized prostate cancer. Can Assoc Radiol J 2000;51(2):114-20. http://www.ncbi.nlm.nih.gov/pubmed/10786920 18. Stone NN, Stock RG, Unger P. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol 1995;154(4):1392-6. http://www.ncbi.nlm.nih.gov/pubmed/7658545 19. Allepuz Losa CA, Sans Velez JI, Gil Sanz MJ, Mas LP, Rioja Sanz LA. Seminal vesicle biopsy in prostate cancer staging. J Urol 1995;154(4):1407-11. http://www.ncbi.nlm.nih.gov/pubmed/7544842
Update march 2009
29
20.
Guillonneau B, Debras B, Veillon B, Bougaran J, Chambon E, Vallancien G. Indications for preoperative seminal vesicle biopsies in staging of clinically localized prostatic cancer. Eur Urol 1997;32(2):160-5. http://www.ncbi.nlm.nih.gov/pubmed/9286646 21. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002;167(2 PT 1):516-20. http://www.ncbi.nlm.nih.gov/pubmed/11792909 22. Quinn DI, Henshall SM, Brenner PC, Kooner R, Golovsky D, O’Neill GF, Turner JJ, Delprado W, Grygiel JJ, Sutherland RL, Stricker PD. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer 2003;97(8):1884-93. http://www.ncbi.nlm.nih.gov/pubmed/12673714 23. Elliott SP, Shinohara K, Logan SL, Carroll PR. Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer. J Urol 2002;168(1):105-9. http://www.ncbi.nlm.nih.gov/pubmed/12050501 24. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC Jr, Leidich R, Lo R, Palmer K, Shinohara K, Spaulding JT. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathological diagnosis in prostate cancer. Urology 1995;46(2):205-12. http://www.ncbi.nlm.nih.gov/pubmed/7542823 25. Lee N, Newhouse JH, Olsson CA, Benson MC, Petrylak DP, Schiff P, Bagiella E, Malyszko B, Ennis RD. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999;54(3):490-4. http://www.ncbi.nlm.nih.gov/pubmed/10475360 26. May F, Treumann T, Dettmar P, Hartnung R, Breul J. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int 2001;87(1):66-9. http://www.ncbi.nlm.nih.gov/pubmed/11121995 27. Jager GJ, Severens JL, Thornbury JR, de la Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: should MR imaging be used? A decision analytic approach. Radiology 2000;215(2):445-51. http://www.ncbi.nlm.nih.gov/pubmed/10796923 28. Masterson TA, Touijer K. The role of endorectal coil MRI in preoperative staging and decision-making for the treatment of clinically localized prostate cancer. MAGMA 2008;21(6):371-7. http://www.springerlink.com/content/x762r7un2ml1117k/ 29. Heijmink SW, Fütterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ, Hulsbergen-Van de Kaa CA, Knipscheer BC, Kiemeney LA, Witjes JA, Barentsz JO. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T – comparison of image quality, localization, and staging performance. Radiology 2007;244(1):184-95. http://radiology.rsnajnls.org/cgi/content/full/244/1/184 30. Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen HN, Kattan MW. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005;174(6): 2158-63. http://www.ncbi.nlm.nih.gov/pubmed/16280755 31. Sala E, Akin O, Moskowitz CS, Eisenberg HF, Kuroiwa K, Ishill NM, Rajashanker B, Scardino PT, Hricak H. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006;238(3):929-37. http://radiology.rsnajnls.org/cgi/content/full/238/3/929 32. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MRI imaging. Radiology 2004;232(1):140-6. http://radiology.rsnajnls.org/cgi/content/full/232/1/140 33. Wang L, Mullerad M, Chen HN, Eberhardt Sc, Kattan MW, Scardino PT. Prostate cancer: incremental value of endorectal MRI findings for prediction of extracapsular extension. Radiology 2004;232(1): 133-9. http://radiology.rsnajnls.org/cgi/content/full/232/1/133 34. Hricak H, Wang L, Wei DC, Coakley FV, Akin O, Reuter VE. The role of preoperative endorectal MRI in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004;100(12):2655-63. http://www.ncbi.nlm.nih.gov/pubmed/15197809
30
Update march 2009
35.
Sala E, Akin O, Moskowitz CS, Eisemberg HF, Kuroiwa K, Ishill NM. Endorectal MRI in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006;238(3):929-37. http://radiology.rsnajnls.org/cgi/content/full/238/3/929 36. Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisemberg HF. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MRI to the Kattan Nomogram. Radiology 2007;242(1):182-8. http://radiology.rsnajnls.org/cgi/content/full/242/1/182 37. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ confined prostate cancer: incremental value of MRI and MRI sprectroscopic imaging to staging nomograms. Radiology 2006;238(2):597-603. http://radiology.rsnajnls.org/cgi/content/full/238/2/597 38. Fuchsjager M, Shukla-Dave A, Akin O, Barentsz, Hricak H. Prostate cancer imaging. Acta Radiol 2008;49:107-20. http://www.informaworld.com/smpp/1906288645-11741620/content~db=all?content=10.1080/02841 850701545821 39. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging – clinicopathologic study. Radiology 1999;213(2):473-80. http://radiology.rsnajnls.org/cgi/content/full/213/2/473 40. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S. Correlation of proton MR spectroscopic imaging with Gleason score based on step section pathologic analysis after radical prostatectomy. Radiology 2005;234(3):804-14. http://radiology.rsnajnls.org/cgi/content/full/234/3/804 41. Rinnab L, Blumstein NM, Mottaghy FM, Hautmann RE, Küfer R, Hohl K, Reske SN. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007;99(6):1421-6. http://www.ncbi.nlm.nih.gov/pubmed/17355373 42. Stone NN, Stock RG, Parikh D, Yeghiayan P, Unger P. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate. J Urol 1998;160(5):1722-6. http://www.ncbi.nlm.nih.gov/pubmed/9783940 43. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys 1996;34(1):33-9. http://www.ncbi.nlm.nih.gov/pubmed/12118563 44. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170(5):1798-803. 45. Haese A, Epstein JI, Huland H, Partin AW. Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer 2002;95(5):1016-21. http://www.ncbi.nlm.nih.gov/pubmed/12209685 46. Hoivels AM, Heesakkers RAM, Adang EM., Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clinical Radiology 2008;63:387-95. http://linkinghub.elsevier.com/retrieve/pii/S0009-9260(07)00334-0 47. GJ Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJH. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR-imaging with a three-dimensional T1-weighted magnetizationprepared-rapid gradient-echo sequence. Am J Roentgenol 1996;167(6):1503-7. http://www.ncbi.nlm.nih.gov/pubmed/8956585 48. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348(25):2491-9. http://www.ncbi.nlm.nih.gov/pubmed/12815134
Update march 2009
31
49. Heesakkers RA, Fütterer JJ, Hövels AM, van den Bosch HC, Scheenen TW, Hoogeveen YL, Barentsz JO. Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR imaging at 1.5 and 3.0 T: early experience. Radiology 2006;239(2):481-7. http://www.ncbi.nlm.nih.gov/pubmed/16641354 50. Bellin MF, Roy C, Kinkel K, Thoumas D, Zaim S, Vanel D, Tuchmann C, Richard F, Jacqmin D, Delcourt A, Challier E, Lebret T, Cluzel P. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles – initial clinical experience. Radiology 1998;207(3):799-808. http://www.ncbi.nlm.nih.gov/pubmed/9609907 51. Wolf JS Jr, Cher M, Dall’era M, Presti JC Jr, Hricak H, Carroll PR. The use and accuracy of crosssectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995;153(3Pt2):993-9. http://www.ncbi.nlm.nih.gov/pubmed/7853590 52. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002;41(5):425-9. http://www.ncbi.nlm.nih.gov/pubmed/12442917 53. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, Cservenyàk T, Hany TF. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35(2):253-63. http://www.ncbi.nlm.nih.gov/pubmed/17926036 54. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, Franceschelli A, Sanguedolce F, Bertaccini A, Farsad M, Giovacchini G, Fanti S, Grigioni WF, Fazio F, Montorsi F, Rigatti P, Martorana G. (11)C-choline positron emission tomography/computerized tomography for preoperative lymphnode staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008;54(2):392-401. http://www.ncbi.nlm.nih.gov/pubmed/18456393 55. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167(4):1681-6. http://www.ncbi.nlm.nih.gov/pubmed/11912387 56. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168(2):514-18, discussion 518. http://www.ncbi.nlm.nih.gov/pubmed/12131300 57. Weckermann D, Dorn R, Holl G, Wagner T, Harzmann R. Limitations of radioguided surgery in highrisk prostate cancer. Eur Urol 2007;51(6):1549-56. http://www.ncbi.nlm.nih.gov/pubmed/16996201 58. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol 2007;177(3): 916-20. http://www.ncbi.nlm.nih.gov/pubmed/17296375 59. Whitmore WF Jr. Natural history and staging of prostate cancer. Urol Clin North Am 1984;11(2): 205-20. http://www.ncbi.nlm.nih.gov/pubmed/6375067 60. Wolff JM, Ittel TH, Borchers H, Boekels O, Jakse G. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase. Anticancer Res 1999;19(4A):2653-5. http://www.ncbi.nlm.nih.gov/pubmed/10470213 61. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996;155(4):1348-51. http://www.ncbi.nlm.nih.gov/pubmed/8632571 62. Lorente JA, Valenzuela H, Morote J, Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 1999;26(6):625-32. http://www.ncbi.nlm.nih.gov/pubmed/10369948 63. McGregor B, Tulloch AG, Quinlan MF, Lovegrove F. The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 1978;50(3):178-81. http://www.ncbi.nlm.nih.gov/pubmed/753456 64. O’Donoghue EP, Constable AR, Sherwood T, Stevenson JJ, Chisholm GD. Bone scanning and plasma phosphatases in carcinoma of the prostate. Br J Urol 1978;50(3):172-7. http://www.ncbi.nlm.nih.gov/pubmed/753455
32
Update march 2009
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
Buell U, Kleinhans E, Zorn-Bopp E, Reuschel W, Muenzing W, Moser EA, Seiderer M. A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication. J Nucl Med 1982;23(3):214-17. http://www.ncbi.nlm.nih.gov/pubmed/6460854 Soloway MS, Hardemann SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M. Stratification of patients with metastatic prostate cancer based on the extent of disease on initial bone scan. Cancer 1988;61(1):195-202. http://www.ncbi.nlm.nih.gov/pubmed/3334948 Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, singleand multifield-of-view SPECT, 18F-fluoride PET/CT. J Nucl Med 2006;47(2):287-97. http://www.ncbi.nlm.nih.gov/pubmed/16455635 Beheshti M, Vali R, Langsteger W. [18F]Fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging 2007;34(8):1316-7. http://www.ncbi.nlm.nih.gov/pubmed/17476505 Bouchelouche K, Oehr P. Recent developments in urologic oncology: positron emission tomography molecular imaging. Curr Opin Oncol 2008;20(3):321-6. http://www.ncbi.nlm.nih.gov/pubmed/18391633 Rana A, Karamanis K, Lucas MG, Chisholm GD. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol 1992;69(3):277-81. http://www.ncbi.nlm.nih.gov/pubmed/1373666 Chybowski FM, Keller JJ, Bergstrahl EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other parameters. J Urol 1991;145(2):313-8. http://www.ncbi.nlm.nih.gov/pubmed/1703240 Kemp PM, Maguire GA, Bird NJ. Which patients with prostatic carcinoma require a staging bone scan? Br J Urol 1997;79(4):611-4. http://www.ncbi.nlm.nih.gov/pubmed/9126094 Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, Bagiella E, Singh A, Ennis RD. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000;48(5):1443-6. http://www.ncbi.nlm.nih.gov/pubmed/11121646 O’Donoghue JM, Rogers E, Grimes H, McCarthy P, Corcoran M, Bredin H, Given HF. A reappraisal of serial isotope bone scans in prostate cancer. Br J Radiol 1993;66(788):672-6. http://www.ncbi.nlm.nih.gov/pubmed/7536607 Wolff JM, Bares R, Jung PK, Buell U, Jakse G. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int 1996;56(3):169-73. http://www.ncbi.nlm.nih.gov/pubmed/8860738 Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998;33(4):376-81. http://www.ncbi.nlm.nih.gov/pubmed/9612680 Bruwer G, Heyns CF, Allen FJ. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol 1999;35(3):223-7. http://www.ncbi.nlm.nih.gov/pubmed/10072624
8. TREATMENT: DEFERRED TREATMENT (WATCHFUL WAITING/ACTIVE MONITORING) 8.1
Introduction
8.1.1 Definition There is a great difference between the incidence of and mortality from prostate cancer (PCa): in the USA in 2007, there were 218,900 new cases with only 27,050 deaths (1).
Update march 2009
33
Several autoptic studies of people dying from different causes have shown that while 60-70% of older men have histological PCa (2, 3), a large proportion of these tumours will not progress. PCa is diagnosed in only 15-20% of men during their lifetime, with a 3% lifetime risk of death (4). The incidence of small, localised, well-differentiated PCa is increasing, mainly as a result of prostate-specific antigen (PSA) screening and ‘multi-core’ schemes of prostate biopsy. These data suggest that a lot of the men with localised PCa would not, in fact, benefit from a definitive treatment. With the aim of reducing the risk of overtreatment in this subgroup of patients, two conservative management strategies have been proposed: • Watchful waiting (WW) Also known as ‘deferred treatment’ or ‘symptom-guided treatment’, this term was coined in the pre-PSA screening era (before 1990) and referred to the conservative management of PCa until the development of local or systemic progression, at which point the patient would be treated palliatively (transurethral resection of the prostate [TURP] or other procedures for urinary tract obstruction, and hormonal therapy or radiotherapy for the palliation of metastatic lesions). • Active surveillance (AS) Also known as ‘active monitoring’, this is the new term for the conservative management of PCa. Introduced in the past decade, it includes an active decision not to treat the patient immediately; to follow him with close surveillance and treat at pre-defined thresholds that classify progression (short PSA doubling time and deteriorating histopathological factors on repeat biopsy). In these cases, the treatment options are intended to be curative.
8.2
Deferred treatment of localised PCa (stage T1-T2, Nx-N0, M0)
8.2.1 Watchful waiting (WW) The rationale behind WW is the observation that PCa often progresses slowly, and is diagnosed in older men in whom there is a high incidence of co-morbidity and related high competitive mortality (5). WW can be considered as an option for treating patients with localised PCa in whom life expectancy is limited, or older patients with less aggressive cancers. There have been several attempts to summarise the key papers dealing with deferred treatment in patients with presumed localised PCa (6-10). Most of them present the same results as they analyse roughly the same series, but with a somewhat different methodology. The outcome studies on WW usually include patients whose PSA readings are not always available, and in whom the lesions are predominantly palpable, which would currently be defined as intermediate-risk tumours as described by D’Amico et al. (11). These studies include patients with a follow-up of up to 25 years, having as endpoints overall survival (OS) and disease-specific survival (DSS). Several WW series show a very consistent DSS ratio at 10 years, ranging from 82-87% (6, 12-17). In three studies with data beyond 15 years, the DSS was 80%, 79% and 58%, respectively (14, 16, 17). Two of them reported a 20-year DSS of 57% and 32%, respectively (14, 16). Chodak and co-workers reported a pooled analysis of the original data from 828 patients treated by WW (6). The paper is based on patients from six non-randomised studies (10, 18-23). The results describe cancerspecific survival (CSS) and metastasis-free survival after five and 10 years of follow-up (6) (level of evidence: 2b). Tumour grade is clearly significant, with very low survival rates for grade 3 tumours. Although the 10-year CSS rate is equally good (87%) for grade 1 and 2 tumours, the latter have a significantly higher progression rate, with 42% of these patients developing metastases (Table 8). Table 8: O utcome of deferred treatment in localised PCa in relation to tumour grade (6): percentage of patients (95% confidence interval) surviving at five and 10 years. Grade Disease-specific survival Grade 1 Grade 2 Grade 3 Metastasis-free survival Grade 1 Grade 2 Grade 3
34
5 years (%)
10 years (%)
98 (96-99) 97 (93-98) 67 (51-79)
87 (81-91) 87 (80-92) 34 (19-50)
93 (90-95) 84 (79-89) 51 (36-64)
81 (75-86) 58 (49-66) 26 (13-41)
Update march 2009
The importance of tumour grade on survival after conservative management of PCa was also underlined in a large register study utilising the Surveillance, Epidemiology and End Results (SEER) database of the National Cancer Institute in the USA (12) (level of evidence: 3). Patients with grade 1, 2 and 3 tumours had 10-year CSS rates of 92%, 76% and 43%, respectively, correlating with the data from the pooled analysis. The paper by Chodak and co-workers also specifically described the outcome for stage T1a patients (6), with cancer-specific 10-year survival rates of 96% and 94%, respectively, for grade 1 and 2 tumours. The metastasis-free survival rate was 92% for patients with grade 1 tumours, but 78% for those with grade 2 tumours, indicating a higher risk of progression in individuals with moderately differentiated tumours. This difference in progression rate correlates with other studies on stage T1a disease (24, 25). In order to stage patients accurately and not overlook the presence of more extensive and/or more poorly differentiated tumours, repeat examinations with PSA measurement, transrectal ultrasound (TRUS) and needle biopsy of the prostate remnant have been advocated, especially in younger males with a long life expectancy (26). The impact of grade on the risk of tumour progression and ultimately death from PCa is also described in a paper by Albertsen and co-workers (27). They re-evaluated all biopsy specimens using the more widely accepted Gleason score, and showed that the risk of PCa death was very high in Gleason 7-10 tumours, intermediate in Gleason 6 tumours, but low in Gleason 2-5 cancers (Table 9) (28, 29) (level of evidence: 3). This paper also showed that Gleason 6-10 tumours carry a continuously increasing risk of ending the patient’s life for up to 15 years of follow-up after conservative management. The CSS curves for this group of patients have been published in a recent discussion article on different methods of assessing outcome in treatment for localised PCa (28). Table 9: The 15-year risk of dying from PCa in relation to Gleason score at diagnosis in patients with localised disease aged 55-74 years (27, 28). Gleason score Risk of cancer death* (%) Cancer-specific mortality† (%) 2-4 4-7 8 5 6-11 14 6 18-30 44 7 42-70 76 8-10 60-87 93 * The figures on the risk of cancer death differ for different age groups and represent the true risk in the studied population (taking actual competing mortality from other causes into consideration). † The cancer-specific mortality compensates for differences in competing mortality and indicates the outcome if the patient actually lived for 15 years. Three randomised clinical trials have reported long-term follow-up of patients randomised to WW or radical prostatectomy (RP): the first was in the pre-PSA screening era (29); the second was at the beginning of PSA screening (30); and the third was a recent study, the results from which are not yet mature (1). The Veterans Administration Cooperative Urological Research Group between 1967 and 1975, randomised 142 patients affected by clinical localised PCa. The study was underpowered to detected treatment differences (31). Between 1989 and 1999, the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) randomised 695 patients with clinical stage T1-T2 to WW (348) or RP (347) (Table 10) (30). This study began after PSA screening was introduced into clinical practice, but only 5% of men were diagnosed by screening. After a median followup of 10.8 years, this study showed a significant decrease in cancer-specific mortality, overall mortality, metastatic risk progression and local progression in patients treated with RP vs WW (level of evidence: 1b).
Update march 2009
35
Table 10: O utcome of Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) at 10 years of follow-up (median of 8.2 years) (30). Disease-specific mortality Overall mortality Metastatic progression Local progression
RP (n 347) % (n) 9.6 (30) 27 (83) 15.2 (50) 19.2 (64)
WW (n 348) % (n) 14.9 (50) 32 (106) 35.4 (79) 44.3 (149)
Relative risk (95% CI) 0.56 (0.36-0.88) 0.74 (0.56-0.86) 0.60 (0.42-0.44) 0.33 (0.25-0.44)
p value 0.01 0.04 0.004 < 0.001
The results of three more years of follow-up were published recently. At 12 years’ follow-up, the group of patients treated with RP presented a favourably significant difference of 5.4% in PCa-specific mortality and 6.7% in non-metastatic progression (Table 11) (32) (level of evidence: 1b). Table 11: Outcome of Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) at 12 years of follow-up (median of 10.8 years) (32). Disease-specific mortality Metastatic progression
RP (n 347) % (n) 12.5 (43) 19.3
WW (n 348) % (n) 17.9 (68) 26
Relative risk (95% CI) 0.65 (0.2-11.1) 0.65 (0.47-0.88)
p value 0.03 0.006
The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT) (1) is an ongoing controlled multicentre randomised clinical trial comparing RP with WW in patients with clinical stage T1-T2 disease. Between 1994 and 2002, 731 patients with a median age of 67 years were enrolled. The median PSA was 7.8 ng/mL (mean 10.2 ng/mL). Three-quarters of the men had clinical stage T1c disease. Using previously developed tumour risk categorisations incorporating PSA levels, Gleason histological grade and tumour stage, approximately 43% had low-risk, 36% had medium-risk and 20% had high-risk PCa. Follow-up is planned for 15 years, and the primary endpoint is the overall mortality. PIVOT enrolees are more representative of men being diagnosed and treated in contemporary clinical practice than were those enrolled in SPCG-4. In summary: • Clinical stage T1c currently represents 40-50% of new cases of PCa (33). The incidence of small, localised, well-differentiated PCa is increasing, mainly as a result of PSA screening and ‘multi-core’ schemes of prostate biopsy. • The SPCG-4 study demonstrated significant advantages for RP over WW, but only 5% of those studied were PSA-screened patients. • During the past 20 years, there has apparently been a shift towards higher Gleason scoring levels (34), even in cases evaluating microscopic foci of PCa. Some tumours previously given a Gleason score of 6 (3 + 3), might be scored as 7 (3 + 4) or more today. • The lead time in PSA screening is about 10 years (35, 36). It is therefore possible that the cancer mortality from untreated, non-screen-detected PCa in patients with contemporary Gleason scores of 6 might be as low as 10% at 20-year follow-up (37). It would seem that many small, localised, well-differentiated PCas will not progress, and radical therapy may lead to substantial overtreatment with consequent problems in terms of quality of life and socio-economic costs. 8.2.2 Active surveillance AS was conceived with the aim of reducing the ratio of overtreatment in patients with clinically confined lowrisk PCa, without giving up radical treatment, as happened with the WW strategy. Only data from non-mature randomised clinical trials of AS with follow-up < 10 years are currently available. A multicentre clinical trial of AS versus immediate treatment was opened in the USA in 2006. Its results are expected in 2025. Choo, Klotz and co-workers were the first to report on a prospective AS protocol (38, 39). They enrolled 331 patients with clinical stage T1c or T2a, PSA ≤ 10 ng/mL and a Gleason score ≤ 6 (PSA ≤ 15 and Gleason score ≤ 7 [3 + 4] in patients above the age of 70 years). At a median follow-up of eight years, the overall survival was
36
Update march 2009
85%, DSS and metastasis-free survival were 99%. The median value of the PSA doubling time was 7 years; in 42% of patients it was > 10 years, and in 22% < 3 years. Thirty-three per cent of the patients subsequently underwent a radical treatment: 20% for a PSA doubling time < 3 years; 5% for Gleason score progression on repeat biopsies; and 10% because of patient preference. Soloway et al., evaluating 175 patients with a median follow-up of four years, reported no PCa deaths or metastatic disease and a ratio of only 8% having delayed treatment (40). Carter et al., looking at 407 patients with a median follow-up of 3.4 years, reported no PCa deaths (41). All these studies confirm that, in well selected patients with low-risk disease, there is a very low rate of progression and cancer-specific death, and only a few patients require delayed radical intervention. However, another five to seven more years of follow-up will be necessary in order to obtain definitive results. Different series have identified several eligibility criteria for enrollers: • clinically confined PCa (T1-T2) • Gleason score ≤ 7 • PSA < 15-20 ng/mL (5). Moreover, different criteria were applied to define cancer progression (5), although all groups used: • a PSA doubling time with a cut off ranging between ≤ 2 and ≤ 4years • Gleason score progression to ≥ 7 at re-biopsy, at intervals ranging from one to four years. These indicators are poorly validated and, currently, it is impossible to make evidence-based recommendations on when to intervene in patients with a long life expectancy. Data that include PSA and PSA changes over time are relatively sparse in the literature. In a recent review article, it was pointed out that patients with a PSA of < 3 ng/mL had no mortality from PCa within the first 10 years, and that PSA changes over time were relatively unreliable in determining the risk for tumour progression (42). The data above indicate a high risk of tumour progression after conservative treatment for some patients with apparently localised PCa. This has been supported by the results of other studies in which patients with a life expectancy exceeding 10 years have been shown to have a higher mortality rate from PCa when left without curative treatment (43-45). Long-term follow-up of the Johansson series shows the same outcome: there is a higher risk of dying from PCa in patients surviving more than 15 years with well and moderately differentiated tumours at diagnosis (46) (level of evidence: 3). For patients who choose deferred treatment, the risk of delaying hormone therapy until disease progression has occurred appears to be modest, although shorter CSS times have been reported after deferred therapy compared with immediate hormone therapy in presumed localised PCa (not utilising PSA for staging) after 15 years of follow-up (47). In contradiction of Lundgren et al. (47), the report of the Casodex Early Prostate Cancer Trialists’ Group programme showed higher mortality in a group of men with localised PCa treated with bicalutamide 150 mg than in those who received placebo (48). In summary, it seems that hormonal therapy should be withheld until there is definitive proof of disease activity (progression), but it is open to speculation whether there might be some benefit in delivering it before the patient develops metastatic disease (see below).
8.3
Deferred treatment for locally advanced PCa (stage T3-T4, Nx-N0, M0)
The literature reporting on deferred treatment for locally advanced PCa is sparse. There are no randomised studies that compare more aggressive treatments, such as radiotherapy or surgery, with or without hormones. Most patients whose disease progresses after deferred treatment of locally advanced PCa will be candidates for hormone therapy. There are reports from non-randomised studies showing that hormone treatment may safely be delayed until metastatic progression occurs, as no survival advantage was noted between patients treated with immediate orchiectomy compared with delayed treatment (49, 50). In a recent prospective randomised clinical phase III trial (EORTC 30981), 985 patients with T0-4 N0-2 M0 prostate cancer were randomly assigned to immediate androgen-deprivation therapy (ADT) or received ADT
Update march 2009
37
only on symptomatic disease progression or occurrence of serious complications (51, 52). After a median follow-up of 7.8 years, the overall survival hazard ratio was 1.25 (95% CI, 1.05-1.48; non-inferiority p > 0.1) favouring immediate treatment, seemingly due to fewer deaths of non-prostatic cancer causes (p = 0.06). The time from randomisation to progression of hormone refractory disease did not differ significantly, nor did prostate cancer-specific survival. The median time to the start of deferred treatment after study entry was seven years. In this group, 126 patients (25.6%) died without ever needing treatment (44% of the deaths in this arm). The conclusion drawn from this study is that immediate ADT resulted in a modest but statistically significant increase in overall survival but no significant difference in prostate cancer mortality or symptomfree survival. Furthermore, the authors identified significant risk factors associated with a significantly worse outcome: in both arms, patients with a baseline PSA > 50 ng/mL were at a > 3.5-fold higher risk of dying of PCa than patients with a baseline PSA ≤ to 8 ng/mL. If the baseline PSA was between 8 ng/mL and 50 ng/ mL, the risk of PCa death was approximately 7.5-fold higher in patients with a PSA doubling time < 12 months than in patients with a PSA doubling time > 12 months. The time to PSA relapse after response to immediate ADT correlated significantly with baseline PSA, suggesting that baseline PSA may also reflect disease aggressiveness. However, when early and delayed treatments were compared in a large randomised trial carried out by the Medical Research Council (MRC), a survival benefit for immediate hormone therapy was demonstrated (53), comparable with the results of the Lundgren et al. study mentioned above (47) (level of evidence: 1b). Also, a comparison of bicalutamide, 150 mg/day, with placebo showed that progression-free survival was better with early treatment in patients with locally advanced PCa (48) (level of evidence: 1b). Fifty selected asymptomatic patients (mean age 71 years) with highly or moderately differentiated stage T3 M0 PCa were followed up for 169 months (54). The five- and 10-year CSS rates were 90% and 74%, respectively, and the likelihood of being without treatment at five and 10 years was 40% and 30%, respectively. The authors concluded that WW might be a treatment option for selected patients with non-poorly differentiated T3 tumours and a life expectancy of less than 10 years (level of evidence: 3).
8.4
Deferred treatment for metastatic PCa (stage M1)
There are only very sparse data on this subject. The only candidates for such treatment should be asymptomatic patients with a strong wish to avoid treatment-related side-effects (level of evidence: 4). As the median survival time is about two years, the time without any treatment (before symptoms occur) is very short in most cases. The MRC trial highlighted the risk of developing symptoms (pathological fractures, spinal cord compression), and even death from PCa, without receiving the possible benefit from hormone treatment (53, 55) (level of evidence:1b). If a deferred treatment policy is chosen for a patient with advanced PCa, close follow-up must be possible.
8.5 Summary of deferred treatment 8.5.1 Indications In presumed localised PCa (Nx-N0, M0): • Stage T1a: well and moderately differentiated tumours. In younger patients with a life expectancy of > 10 years, re-evaluation with PSA, TRUS and biopsies of the prostatic remnant is recommended (level of evidence: 2a). • Stage T1b-T2b: well and moderately differentiated tumours. In asymptomatic patients with a life expectancy of < 10 years (level of evidence: 2a). 8.5.2 Options In presumed localised PCa (Nx-N0, M0): • stage T1b-T2b patients who are well informed and have well differentiated (or Gleason 2-4) PCa and a life expectancy of 10-15 years • all patients not willing to accept side-effects of active treatment • well informed, asymptomatic patients with high PSA levels for whom cure is unlikely (level of evidence: 3). In locally advanced disease (stage T3-T4): • asymptomatic patients with well or moderately differentiated cancer, PCa and a short life expectancy (level of evidence: 3) • PSA < 50 ng/mL and PSA doubling time > 12 months (level of evidence: 1).
38
Update march 2009
In metastatic disease (M1): • a very rare patient without any symptoms and the possibility of close follow-up (level of evidence: 4).
8.6
REFERENCES
1.
Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 2009;30(1):81-7. http://www.ncbi.nlm.nih.gov/pubmed/18783735 Rullis I, Schaeffer JA, Lilien OM. Incidence of prostatic carcinoma in the elderly. Urology 1975;6(3):295-7. http://www.ncbi.nlm.nih.gov/pubmed/1172317 Sakr, WA, Grignon, DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8(3):439-43. http://www.ncbi.nlm.nih.gov/pubmed/7803731 Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106-30. http://caonline.amcancersoc.org/cgi/content/full/56/2/106 Adolfsson J .Watchful waiting and active surveillance: the current position. BJU Int 2008;102(1):10-4. http://www.ncbi.nlm.nih.gov/pubmed/18422774 Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330(4):242-8. http://www.ncbi.nlm.nih.gov/pubmed/8272085 Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, Miller HC, Oesterling JE, Resnick MI, Smalley SR, Wasson JH. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 1995;154(6):2144-8. http://www.ncbi.nlm.nih.gov/pubmed/7500479 Thompson IM. Observation alone in the management of localized prostate cancer: the natural history of untreated disease. Urology 1994;43(2Suppl.):41-6. http://www.ncbi.nlm.nih.gov/pubmed/8272085 Schellhammer PF. Contemporary expectant therapy series: a viewpoint. Urology Symposium 1994;44(6A):47-52. Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localized prostate cancer. Cancer 1993;72(2):310-22. http://4www.ncbi.nlm.nih.gov/pubmed/8319164 D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-74. http://jama.ama-assn.org/cgi/content/full/280/11/969 Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349(9056):906-10. http://www.ncbi.nlm.nih.gov/pubmed/9093251 Sandblom G, Dufmats M, Varenhorst E. Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 2000;56(3):442-7. http://www.ncbi.nlm.nih.gov/pubmed/10962312 Johansson JE, Adami HO, Andersson SO, Bergström R, Krusemo UB, Kraaz W. Natural history of localized prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989;1(8642):799-803. http://www.ncbi.nlm.nih.gov/pubmed/2564901 Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE; for the Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352(19):1977-84. http://content.nejm.org/cgi/content/full/352/19/1977
2.
3.
4.
5. 6.
7.
8.
9. 10.
11.
12.
13.
14.
15.
Update march 2009
39
16.
Adolfsson J, Tribukait B, Levitt S. The 20-yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Eur Urol 2007 Oct;52(4):1028-35. http://www.ncbi.nlm.nih.gov/pubmed/17467883 17. Jonsson E, Sigbjarnarson HP, Tomasson J, Benediktsdottir KR, Tryggvadottir L, Hrafnkelsson J, Olafsdottir EJ, Tulinius H, Jonasson JG. Adenocarcinoma of the prostate in Iceland: a populationbased study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Scand J Urol Nephrol 2006;40(4):265-71. http://www.ncbi.nlm.nih.gov/pubmed/16916765 18. Moskovitz B, Nitecki A, Richter Levin D. Cancer of the prostate: is there a need for aggressive treatment? Urol Int 1987;42(1):49-52. http://www.ncbi.nlm.nih.gov/pubmed/3590404 19. Goodman CM, Busuttil A, Chisholm GD. Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate. Br J Urol 1988;62(6):576-80. http://www.ncbi.nlm.nih.gov/pubmed/3219513 20. Jones GW. Prospective, conservative management of localized prostate cancer. Cancer 1992;70(1Suppl.):307-10. http://www.ncbi.nlm.nih.gov/pubmed/1600492 21. Whitmore WF Jr, Warner JA, Thompson IM Jr. Expectant management of localized prostatic cancer. Cancer 1991;67(4):1091-6. http://www.ncbi.nlm.nih.gov/pubmed/1991257 22. Adolfsson J, Carstensen J, Löwhagen T. Deferred treatment in clinically localised prostatic carcinoma. Br J Urol 1992;69(2):183-7. http://www.ncbi.nlm.nih.gov/pubmed/1537031 23. Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267(16):2191-6. http://www.ncbi.nlm.nih.gov/pubmed/1556796 24. Lowe BA. Management of stage T1a Prostate cancer. Semin Urol Oncol 1996;14(3):178-82. http://www.ncbi.nlm.nih.gov/pubmed/8865481 25. Loughlin KR, Renshaw AA, Kumar S. Expectant management of stage A-1 (T1a) prostate cancer utilizing serum PSA levels: a preliminary report. J Surg Oncol 1999;70(1):49-53. http://www.ncbi.nlm.nih.gov/pubmed/9989421 26. Griebling TL, Williams RD. Staging of incidentally detected prostate cancer: role of repeat resection, prostate-specific antigen, needle biopsy, and imaging. Semin Urol Oncol 1996;14(3):156-64. http://www.ncbi.nlm.nih.gov/pubmed/8865478 27. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280(11): 975-80. http://www.ncbi.nlm.nih.gov/pubmed/9749479 28. Albertsen P, Hanley JA, Murphy-Setzko M. Statistical considerations when assessing outcomes following treatment for prostate cancer. J Urol 1999;162(2):439-44. http://www.ncbi.nlm.nih.gov/pubmed/10411053 29. Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K; Scandinavian Prostatic Cancer Group. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004 Nov;172(5Pt1):1871-6. http://www.ncbi.nlm.nih.gov/pubmed/15540741 30. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ; Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347(11):781-9. http://www.ncbi.nlm.nih.gov/pubmed/12226148 31. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 1995;172:65-72. http://www.ncbi.nlm.nih.gov/pubmed/8578259
40
Update march 2009
32.
Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE; Scandinavian prostate cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100(16):1144-54. http://jnci.oxfordjournals.org/cgi/content/full/100/16/1144 33. Klotz L. Active surveillance for prostate cancer: trials and tribulations. World J Urol 2008;26(5):437-42. http://www.ncbi.nlm.nih.gov/pubmed/18813934 34. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, Fine J. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005;97(17):1248-53. http://www.ncbi.nlm.nih.gov/pubmed/16145045 35. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for prostate cancer. J Natl Cancer Inst 2003;95(12):868-78. http://www.ncbi.nlm.nih.gov/pubmed/12813170 36. Törnblom M, Eriksson H, Franzén S, Gustafsson O, Lilja H, Norming U, Hugosson J. Lead time associated with screening for prostate cancer. Int J Cancer 2004;108(1):122-9. http://www.ncbi.nlm.nih.gov/pubmed/14618626 37. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why? Nat Clin Pract Oncol 2007;4(12):692-8. http://www.nature.com/ncponc/journal/v4/n12/full/ncponc0966.html 38. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167(4):1664-9. http://www.ncbi.nlm.nih.gov/pubmed/11912384 39. Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, Fleshner N, Bunting P, Kapusta L, Hruby G. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001;50(3):615-20. http://www.ncbi.nlm.nih.gov/pubmed/11395227 40. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008;101(2):165-9. http://www.ncbi.nlm.nih.gov/pubmed/17850361 41. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178(6):2359-64. http://www.ncbi.nlm.nih.gov/pubmed/17936806 42. Schmid HP, Adolfsson J, Aus G. Active monitoring (deferred treatment or watchful waiting) in the treatment of prostate cancer. A review. Eur Urol 2001;40(5):488-94. http://www.ncbi.nlm.nih.gov/pubmed/11752854 43. Aus G, Hugosson J, Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995;154(2 PT 1):460-5. http://www.ncbi.nlm.nih.gov/pubmed/7541864 44. Hugosson J, Aus G, Bergdahl C, Bergdahl S. Prostate cancer mortality in patients surviving more than 10 years after diagnosis. J Urol 1995;154(6):2115-17. http://www.ncbi.nlm.nih.gov/pubmed/7500471 45. Brasso K, Friis S, Juel K, Jorgensen T, Iversen P. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based study. J Urol 1999;161(2):524-8. http://www.ncbi.nlm.nih.gov/pubmed/9915440 46. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA 2004;291(22):2713-19. http://www.ncbi.nlm.nih.gov/pubmed/15187052 47. Lundgren R, Nordle O, Josefsson K. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicentre study with 15 years of followup. The South Sweden Prostate Cancer Study Group. J Urol 1995;153(5):1580-6. http://www.ncbi.nlm.nih.gov/pubmed/7714978 48. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at
Update march 2009
41
49.
50.
51.
52.
53.
54.
55.
median followup of 5.4 years. J Urol 2004;172(5Pt1):1865-70. http://www.ncbi.nlm.nih.gov/pubmed/15540740 Rana A, Chisholm GD, Khan M, Rashwan HM, Elton RA. Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate. Br J Urol 1994;74(5):637-41. http://www.ncbi.nlm.nih.gov/pubmed/7827816 Parker MC, Cook A, Riddle PR, Fryatt I, O’Sullivan J, Shearer RJ. Is delayed treatment justified in carcinoma of the prostate? Br J Urol 1985;57(6):724-8. http://www.ncbi.nlm.nih.gov/pubmed/4084734 Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24(12):1868-76. http://www.ncbi.nlm.nih.gov/pubmed/16622261 Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knönagel H, Loidl W, Isorna S, Sundaram SK, Debois M; EORTC Genitourinary Group. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53(5):941-9. http://www.ncbi.nlm.nih.gov/pubmed/18191322 The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79(2):235-46. [No authors listed.] http://www.ncbi.nlm.nih.gov/pubmed/9052476 Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of locally advanced non-metastatic prostate cancer: a long-term followup. J Urol 1999;161(2):505-8. http://www.ncbi.nlm.nih.gov/pubmed/9915436 Walsh PC. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol 1997;158(4):1623-4. http://www.ncbi.nlm.nih.gov/pubmed/9302187
9. TREATMENT: RADICAL PROSTATECTOMY 9.1
Introduction
The surgical treatment of prostate cancer (PCa) consists of radical prostatectomy (RP), which is the removal of the entire prostate gland between the urethra and the bladder, with resection of both seminal vesicles. In men with localised PCa and a life expectancy of 10 years or more, the goal of an RP by any approach must be eradication of the disease (1). There is no age threshold for RP. A patient should not be denied this procedure on the grounds of age alone (2). In fact, increasing co-morbidity with age greatly increases the risk of dying from non-PCa related causes (3, 4). Life expectancy estimation is paramount in the counselling of a patient for surgery. Radical prostatectomy was first applied at the beginning of the 20th century by Young (5) using a perineal approach, while Memmelaar and Millin were the first to perform retropubic RP (6). In 1982, Walsh and Donker described the anatomy of the dorsal venous complex and the neurovascular bundles. This resulted in a significant reduction of blood loss and improved continence and potency rates (7). Currently, radical prostatectomy is the only treatment for localised PCa that has shown a cancer-specific survival benefit when compared with conservative management in a prospective, randomised trial (8). Surgical expertise has decreased the complication rates and improved cancer cure (9-12). The retropubic approach is more commonly performed, as it enables simultaneous pelvic lymph node assessment to be carried out, which is an advantage over the perineal approach. It has been suggested that perineal radical prostatectomy might result in positive surgical margins more often than the retropubic approach (13), but this has not been confirmed (14). In the past 5-10 years, several European centres have acquired considerable experience with laparoscopic radical prostatectomy (15-18). More recently, the robotic-assisted laparoscopic RP has been developed. It is
42
Update march 2009
likely that laparoscopic, robot-assisted and perineal prostatectomies have lower morbidity than the retropubic operation, but randomised studies are as yet unavailable. Functional and short-term oncological outcomes of laparoscopic and robot-assisted RP seem comparable with the open technique in high-volume centres. However, long-term oncological outcomes are still unavailable (19).
9.2
Low-risk, localised PCa: cT1-T2a and Gleason score 2-6 and PSA < 10
9.2.1 Stage T1a-T1b PCa Stage T1a PCa is defined as an incidental histological finding of cancer in 5% or less of resected prostatic tissue (transurethral resection of the prostate [TURP] or open adenomectomy). Stage T1b PCa is defined as > 5% cancer. A recent Swedish register-based study in 23,288 men with incidental PCa detected at TURP or open adenoma enucleation showed a 10-year PCa mortality of 26.6%. No details on prostate-specific antigen (PSA) or Gleason score were provided. Neither were details available on the numbers of cases with cT1a or cT1b PCa (20). Although the risk of disease progression of untreated T1a PCa after five years is only 5%, these cancers can progress in about 50% of cases after 10-13 years (21). Thus, in younger patients with a life-expectancy of 15 years or more, the chance of disease progression is real. An RP may also be offered when the Gleason score is > 6. In contrast, most patients with T1b tumours are expected to show disease progression after five years, and aggressive treatment is often warranted (21). Patients with T1b lesions are offered RP when they have a life expectancy of 10 years or more. It is consequently very important to distinguish between T1a and T1b tumours. Systematic prostate biopsies of the remnant prostate may be useful to detect concomitant peripheral zone cancer, or to ascertain a more correct tumour grade. RP may be very difficult after a thorough TURP, when almost no residual prostate is left behind (22). 9.2.2 Stage T1c and T2a PCa Clinically unapparent tumour identified by needle biopsy because of an elevated PSA (cT1c) has become the most prevalent PCa. In an individual patient, it is difficult to differentiate between clinically insignificant and life-threatening PCa. Most reports, however, stress that cT1c tumours are mostly significant and should not be left untreated since up to 30% of cT1c tumours are locally advanced disease at final histopathology (23). The proportion of insignificant tumours varies between 11% and 16% (24, 25). Increasing the number of biopsies might carry the risk of detecting a higher number of insignificant cancers. However, a recent study has shown that increasing the number of biopsies to 12 did not increase the number of insignificant tumours (26). The major problem is how to recognise those tumours that do not need RP. The biopsy findings and the free PSA ratio are helpful in predicting insignificant disease (27). Partin tables may be very helpful in better selecting patients requiring surgical treatment because of their ability to provide an estimation of the final pathological stage (28). Other authors have suggested the incorporation of biopsy information, such as the number of cores or the percentage of cores invaded (29). When only one or a few cores are invaded and the percentage of invasion in one core is limited, the chance of finding an insignificant PCa is more likely, certainly when the lesion is of low Gleason grade (30). It might be reasonable to follow up some patients whose tumours are most likely to be insignificant. In general, however, RP should be advocated for patients with T1c tumours, bearing in mind that significant tumours will be found in most of these individuals. T2a patients with a 10-year life expectancy should be offered RP since 35-55% of them will have disease progression after five years if not treated. If watchful waiting (WW) is proposed for low-grade T2 cancer, it should be remembered that pre-operative assessment of tumour grade by needle biopsy is often unreliable (31). As a rule of thumb, an extended pelvic lymph node dissection (eLND) is not necessary in low-risk, localised PCa, as the risk for positive lymph nodes does not exceed 7% (32). A limited lymph node dissection should no longer be performed, as this will miss at least half of the nodes involved.
9.3
Intermediate-risk, localised PCa: cT2b-T2c or Gleason score = 7 or PSA 10-20
RP is one of the recommended standard treatments for patients with intermediate-risk PCa and a life
Update march 2009
43
expectancy of more than 10 years (33). The prognosis is excellent when the tumour is confined to the prostate based on pathological examination (34, 35). A policy of WW has been proposed for some patients with intermediate-risk localised tumours (36). However, when the tumour is palpable or visible on imaging and clinically still confined to the prostate, disease progression can be expected in most long-term survivors. The median time to progression of untreated T2 disease is reported to be 6-10 years. T2b cancer still confined to the prostate but involving more than half of a lobe or both lobes will progress in more than 70% of patients within five years (37). These data have been confirmed by a large randomised trial comparing RP and WW that included mostly T2 PCa patients showing a significant reduction in disease-specific mortality in favour of RP (8). Total surgical removal is an excellent option, and, if performed by an experienced surgeon, the patient’s subsequent quality of life should be satisfactory. Lower rates of positive surgical margins for high-volume surgeons suggest that experience and careful attention to surgical details, adjusted for the characteristics of the cancer being treated, can decrease positive surgical margin rates and improve cancer control with RP (38). As a rule of thumb, an eLND should be performed if the estimated risk for positive lymph nodes exceeds 7% (32). In all other cases, an eLND can be omitted, accepting a low risk of missing positive nodes. A limited lymph node dissection should no longer be performed, as this will miss at least half of the nodes involved. 9.3.1 Oncological results of RP in low-and intermediate risk PCa The results achieved in a number of studies involving RP are shown in Table 12. Table 12: Oncological results of RP in organ-confined disease Reference (no.) Han et al. (2001) (39) Catalona and Smith (1994) (40)
2404 925
Mean follow-up (months) 75* 28
Hull et al. (2002) (41)
1000
53
–
75
601
34
69
47
3170
60
70
52
Trapasso et al. (1994) (42) Zincke et al. (1994) (43) * = 15-year, 66%.
9.4
No. of patients
5-year PSA-free survival (%) 84 78
10-year PSA-free survival (%) 74 65
High-risk localised PCa: cT3a or Gleason score 8-10 or PSA > 20
The widespread use of PSA testing has led to a significant migration of stage and grade of PCa, with > 90% of men in the current era diagnosed with clinically localised disease (44). Despite the trends towards lower risk PCa, 20-35% of patients with newly diagnosed PCa are still classified as high risk, based on either PSA > 20 ng/mL, Gleason score > 8, or an advanced clinical stage (45). There is no consensus regarding the optimal treatment of men with high-risk PCa. 9.4.1 Locally advanced PCa: cT3a T3a cancer is defined as cancer that has perforated the prostate capsule. In the past, locally advanced PCa was seen in about 40% of all clinically diagnosed tumours. This figure is lower today, although its management remains controversial. Surgical treatment of clinical stage T3 PCa has traditionally been discouraged (46), mainly because patients have an increased risk of positive surgical margins and lymph node metastases and/or distant relapse (47, 48). Several randomised studies on radiotherapy with androgen-deprivation therapy (ADT) vs radiotherapy alone showed a clear advantage for the combination treatment. However, no trial has ever shown this approach to be superior to RP (49). Another problem is ‘contamination’ by the additional use of either adjuvant radiotherapy or immediate or delayed hormonal treatment in most of the series reporting the treatment of clinical T3 PCa. In recent years, there has been renewed interest in surgery for locally advanced PCa, and several retrospective case-series have been published. Although still controversial, it is increasingly evident that surgery has a place in treating locally advanced disease (50-55). Overstaging of cT3 PCa is relatively frequent and occurs in 13-27% of cases. These pT2 patients and patients with specimen-confined pT3 disease have similarly good biochemical and clinical PFS (54, 55). In about 33.5-
44
Update march 2009
66% of patients, positive section margins will be present, and 7.9-49% will have positive lymph nodes (56). Thus, 56-78% of patients primarily treated by surgery eventually require adjuvant or salvage radiotherapy or hormonal therapy (54, 55). Nevertheless, excellent 5-, 10- and 15-year overall survival (OS) and cancer-specific survival (CSS) rates have been published (Table 2). These rates surpass radiotherapy-alone series and are no different from radiotherapy combined with adjuvant hormonal therapy series (49). The problem remains the selection of patients before surgery that have neither lymph node involvement nor seminal vesicle invasion. Nomograms, including PSA level, stage and Gleason score, can be useful in predicting the pathological stage of disease (28, 56). In addition, nodal imaging with computed tomography (CT), and seminal vesicle imaging with magnetic resonance imaging (MRI), or directed specific puncture biopsies of the nodes or seminal vesicles can be helpful in recognising those patients unlikely to benefit from a surgical approach (57). RP for clinical T3 cancer requires sufficient surgical expertise to keep the level of morbidity acceptable. Increased overall surgical experience must contribute to a decreased operative morbidity and to better functional results after RP for clinical T3 cancer (54, 58). Table 13: Overall and cancer-specific survival rates for prostate cancer Survival no. of Median and/ OS (%) CSS (%) BPFS (%) CPFS (%) rate patients or mean 5 y 10 y 15 y 5 y 10 y 15 y 5 y 10 y 15 y 5 y 10 y 15 y survival rate Yamada 57 Median, 5.4 y 91.2 - - 45.5 - 81.4 et al. (77.6 at 7.5 y) (PSA > 0.4) (1994) (50) Gerber 242 Mean, 39 m - 85 57 - - 72 32 et al. Median, 26 m (meta free) (1997) (51) Van den 83 Median, 52 m 75 60 - 85 72 - 29 59 31 Ouden (PSA > 0.1) et al. (1998) (52) Isorna 83 Mean, 68.7 m 97.6 94.8 - 100 - 59.8 - Martinez (cT3a only) (PSA > 0.3) de la Riva et al. (2004) (53) Ward 841 Median, 10.3 y 90 76 53 95 90 79 58 43 38 85 73 67 et al. (PSA > 0.4) (2005) (54) Hsu et al. 200 Mean, 70.6 m 95.9 77 - 98.7 91.6 - 59.5 51.1 - 95.9 85.4 (2007) (55) (cT3a only) (PSA > 0.2) BPFS = biochemical progression-free survival; CSS = cancer-specific survival; CPFS = clinical progression-free survival; OS = overall survival; PSA = prostate-specific antigen. 9.4.2 High-grade PCa: Gleason score 8-10 Although most poorly differentiated tumours extend outside the prostate, the incidence of organconfined disease is between 26% and 31%. Patients with high-grade tumours confined to the prostate at histopathological examination still have a good prognosis after RP. Furthermore, one third of patients with a biopsy Gleason score ≥ 8 may in fact have a specimen Gleason score ≤ 7 with better prognostic characteristics. PSA value and the % of positive prostate biopsies may be helpful in selecting men with highgrade prostate cancer most likely to benefit from RP (59). 9.4.3 PCa with PSA > 20 Yossepowitch et al. reported the results of RP as a monotherapy in men with PSA > 20 ng/mL in a cohort with mostly clinically organ-confined tumours, and found a PSA failure rate of 44% and 53% at five and 10 years, respectively (60). D’Amico et al. found that men with PSA levels > 20 ng/mL had a 50% risk of PSA failure at five years after RP (61). Tiguert and co-workers presented the outcome for an identical cohort of patients who had a disease-free survival of 65% at five years after RP (62). More recently, Inman and co-workers described
Update march 2009
45
the long-term outcomes of RP with multimodal adjuvant therapy in men with PSA ≥ 50. Systemic progressionfree survival rates at 10 years were 83% and 74% for PSA 50-99 and ≥ 100, respectively, while overall CSS was 87%. These results argue for aggressive management with RP as initial step (63). As a rule of thumb, an eLND should be performed in all high-risk cases, as the estimated risk for positive lymph nodes will be in the range 15-40% (32). A limited lymph node dissection should no longer be performed, as this will miss at least half of the nodes involved.
9.5
Very high-risk localised prostate cancer: cT3b-T4 N0 or any T, N1
9.5.1 cT3b-T4 N0 Men with very high-risk PCa generally have a significant risk of disease progression and cancer-related death if left untreated. Very high-risk patients present two specific challenges. There is a need for local control as well as a need to treat any microscopic metastases likely to be present but undetectable until disease progression. The optimal treatment approach will therefore often necessitate multiple modalities. The exact combinations, timing and intensity of treatment continue to be strongly debated. Management decisions should be made after all treatments have been discussed by a multidisciplinary team (including urologists, oncologists, radiologists and pathologists), and after the balance of benefits and side-effects of each therapy modality has been considered by the patient with regard to his own individual circumstances. Provided that the tumour is not fixed to the pelvic wall, or that there is no invasion of the urethral sphincter, RP may be considered a reasonable first step in a selection of patients with low tumour volume. 9.5.2 Any T, N1 The indication for RP in all previously described stages assumes the absence of nodal involvement. Lymph node-positive (N+) disease will mostly be followed by systemic disease progression, and all patients with significant N+ disease will ultimately fail treatment. Nevertheless, the combination of RP and simultaneous hormonal treatment has been shown to achieve a 10-year CSS rate of 80% (64). However, it is questionable whether or not these results could also have been obtained with hormonal treatment alone. Most urologists are reluctant to perform RP for clinical N+ disease, or will cancel surgery if a frozen section shows lymph node invasion. It should also be noted that the definitive pathological examination after RP can show microscopic lymph node invasion. The incidence of tumour progression is lower in patients with fewer positive lymph nodes and in those with microscopic invasion only (65, 66). Clinical N+ patients usually have significant nodal involvement and will be treated with hormonal manipulation only. In patients who prove to be pN+ after RP, adjuvant hormonal treatment can be advocated, but the benefits should be judged against the side-effects of long-term hormonal therapy. PSA follow-up and hormonal treatment in the case of an increase in PSA level is therefore an acceptable option in selected cases. The most accurate staging method for the assessment of lymph node involvement is eLND. This includes removal of al node-bearing tissue from the area bounded by the external iliac vein anteriorly, the lateral pelvic side wall, the bladder wall medially, the floor of the pelvis posteriorly, Cooper’s ligament distally, and the internal iliac artery proximally. During recent years, there has been increasing interest in eLND, but controversy regarding indication and extent of ELND, its therapeutic role and morbidity remain. 9.5.2.1 Indication and extent of extrended pelvic lymph node dissectiori (eLND) Although it is generally accepted that eLND provides important information for prognosis (number of nodes involved, tumour volume, capsular perforation) that cannot be matched by any other current procedures, consensus has not been reached as to when eLND is indicated and to what extent it should be performed. When making such decisions, many physicians rely on nomograms based on pre-operative biochemical markers and biopsies (28). According to these nomograms, patients with a PSA value < 10 ng/mL and a biopsy Gleason score < 7 have a low risk of lymph node metastasis and, therefore, eLND might not be beneficial. However, the fact that most of these nomograms are based on a limited eLND (obturator fossa and external iliac vein) probably results in underestimation of the incidence of patients with positive nodes (32). Lymphography studies have shown that the prostate drains not only to the obturator and external iliac but also to the internal iliac and pre-sacral lymph nodes. Performing an eLND results in removal of all lymph nodes in these particular anatomical regions, producing a higher yield of removed lymph nodes (mean of 20 nodes) compared with limited LND (mean of 8-10 nodes). In patients with a PSA value < 10 and a Gleason score ≥ 7, an incidence of 25% nodal involvement was reported (67). Different reports mention that 19-35% of positive lymph nodes are found exclusively outside the area of the traditionally limited LND (68, 69).
46
Update march 2009
9.5.2.2 Therapeutic role of eLND Besides being a staging procedure, (extended) pelvic lymph node dissection might be curative, or at least beneficial, in a subset of patients with limited lymph node metastases (70-72). For an eLND to be representative, a mean of 20 lymph nodes should be removed (73). In some series, the number of nodes removed during lymphadenectomy correlated significantly with time to progression (74). At present, however, lymph node metastases are considered to be a sign of systemic disease. Whenever lymph node metastases are found, prognosis worsens and systemic therapy is advised. 9.5.2.3 Morbidity An eLND remains a surgical procedure, which adds morbidity to the treatment of PCa. When comparing limited vs extended LND, threefold higher complication rates were reported by some authors (75). Complications consist of lymphocoeles, lymphoedema, deep venous thrombosis and pulmonary embolism. Other authors, however, reported more acceptable complication rates (76, 77). 9.5.2.4 • • •
Summary of eLND eLND can play a role in the treatment of PCa for a subset of patients. The number of lymph nodes removed correlates with the time to progression. Concomitant morbidity has to be balanced against the therapeutic effects, and a decision will have to be made based on individual cases.
9.6
Summary of RP in high-risk localised disease
•
P is a reasonable treatment option in selected patients with cT3a PCa, Gleason score 8-10 or PSA > R 20. If RP is performed, an extended pelvic lymphadenectomy must be performed, as lymph node involvement is frequent. The patient must be informed about the likelihood of a multimodal approach. In case of adverse tumour characteristics (positive section margin, extracapsular extension, seminal vesicle invasion), adjuvant RT may be reasonably used after recuperation from surgery.
• •
Recently, Thompson and colleagues reported the results of a trial enrolling 431 men with pT3N0M0 PCa treated with RP. Patients were randomised to receive 60-64 Gy adjuvant RT or observation. Metastasis-free survival and OS were significantly better with radiotherapy (78). In cases of positive lymph nodes at final histopathology, adjuvant ADT may be considered. Messing et al. examined the role of immediate ADT vs observation in patients with positive lymph nodes found at initial surgery. At a median follow-up of 11.9 years, those receiving immediate ADT had a significant improvement in OS over those managed with observation (79).
9.7
Neoadjuvant hormonal therapy and RP
Generally, neoadjuvant or up-front therapy is defined as therapy given prior to definitive local curative treatment (e.g. surgery or radiation therapy). As PCa is an androgen-dependent tumour, neoadjuvant hormonal therapy (NHT) is an appealing concept. Attempts to decrease the size of the prostate before RP were first reported by Vallett as early as 1944 (80). In a recent Cochrane review and meta-analysis, the role of neoadjuvant and adjuvant hormonal therapy and prostatectomy were studied (81). Patients had predominantly localised T1 and T2 disease, low- and intermediate-grade, with Gleason scores < 7, and PSA < 20 ng/mL in most patients. The Cochrane review made the following observations: • Neoadjuvant hormonal therapy before RP does not provide a significant OS advantage over prostatectomy alone (pooled odds ratio [OR] 1.11; 95% confidence interval [CI] 0.67-1.85). • Neoadjuvant hormonal therapy before RP does not provide a significant advantage in disease-free survival over prostatectomy alone (pooled OR 1.24; 95% CI 0.97-1.57). • Neoadjuvant hormonal therapy before RP does substantially improve local pathological variables such as organ-confined rates, pathological down-staging, positive surgical margins and rate of lymph node involvement. • Adjuvant hormonal therapy following RP: the pooled data for five-year OS showed an OR of 1.50 and 95% CI 0.79-2.84. This was not statistically significant, although there was a trend favouring adjuvant hormonal therapy. Similarly, there was no survival advantage at 10 years. • Adjuvant hormonal therapy following RP: the pooled data for disease-free survival gave an overall OR of 3.73 and 95% CI 2.3-6.03. The overall effect estimate was highly statistically significant (p < 0.00001) in favour of the hormonal arm. • It is noteworthy that the Early Prostate Cancer Trialists’ Group (EPC) trial was not included in the
Update march 2009
47
•
9.7.1 • • •
• •
9.8
Cochrane review. The third update from this large randomised trial of bicalutamide, 150 mg once daily, in addition to standard care in localised and locally advanced, non-metastatic PCa was published in November 2005 (82). Median follow-up was 7.2 years. There was a significant improvement in objective progression-free survival (PFS) in the RP group. This improvement was only statistically significant in the locally advanced disease group (HR 0.75; 95% CI 0.61-0.91). There was no significant improvement in OS in the RP group, both the localised and locally advanced disease groups. In the WW group, there was an OS trend in favour of WW alone in the localised disease group (HR 1.16; 95% CI 0.99-1.37). Summary of neoadjuvant and adjuvant hormonal treatment and RP Neoadjuvant hormonal therapy before RP does not provide a significant OS advantage over prostatectomy alone. Neoadjuvant hormonal therapy before RP does not provide a significant advantage in disease-free survival over prostatectomy alone. Neoadjuvant hormonal therapy before RP does substantially improve local pathological variables such as organ-confined rates, pathological down-staging, positive surgical margins and rate of lymph node involvement. Adjuvant hormonal therapy following RP shows no survival advantage at 10 years. Adjuvant hormonal therapy following RP: the overall effect estimate was highly statistically significant (p < 0.00001) in favour of the hormonal arm.
Complications and functional outcome
The post-operative complications of RP are listed in Table 14. The mortality rate is 0-1.5% (75); urinary fistulas are seen in 1.2-4% of patients (83); and urinary incontinence persists after one year in 7.7% (84). In men undergoing prostatectomy, the rates of post-operative and late urinary complications are significantly reduced if the procedure is performed in a high-volume hospital and by a surgeon who performs a large number of such procedures (85-87). Erectile dysfunction used to occur in nearly all patients, but nerve-sparing techniques can be applied in early-stage disease (88). Patients who benefit from nerve-sparing RP may have a higher chance of local disease recurrence and should therefore be selected carefully. Table 14: Complications of RP Complication • Peri-operative death • Major bleeding • Rectal injury • Deep venous thrombosis • Pulmonary embolism • Lymphocoele • Urine leak, fistula • Slight stress incontinence • Severe stress incontinence • Impotence • Bladder neck obstruction • Ureteral obstruction • Urethral stricture
Incidence (%) 0.0-2.1 1.0-11.5 0.0-5.4 0.0-8.3 0.8-7.7 1.0-3.0 0.3-15.4 4.0-50.0 0.0-15.4 29.0-100.0 0.5-14.6 0.0-0.7 2.0-9.0
9.9 Summary of indications for nerve-sparing surgery* Reference name Pre-operative selection criteria Stage > T2 PSA > 10 Biopsy Gleason score 7 Biopsy Gleason score 8-10 Partin tables Side with > 50% tumour in biopsy Side with peri-neural invasion
48
Sofer (89) Walsh (90) + +
+
Alsikafi (91) Graefen (92) +
+
Bianco (93) +
+ +
+ + +/-
+ + +
Update march 2009
Intra-operative selection criteria Side of palpable tumour + Side of positive biopsy Induration of lateral pelvic fascia + Adherent to neurovascular bundles + Positive section margins 24% 5% 11% *Clinical criteria used by different authors when NOT to perform a nerve-sparing RP.
+ + + 5%
15.9%
erve-sparing RP can be performed safely in most men undergoing RP (94, 95). In the past decade, a dramatic N shift towards lower-stage tumours has become evident. More importantly, men are younger at the time of diagnosis and more interested in preserving sexual function. Nevertheless, clear contraindications are those patients in whom there is a high risk of extracapsular disease, such as any cT3 PCa, cT2c, any Gleason score > 7 on biopsy, or more than one biopsy > 6 at the ipsilateral side. Partin tables will help guide decision-making (28). If any doubt remains regarding residual tumour, the surgeon should remove the neurovascular bundle. Alternatively, the use of intra-operative frozen-section analysis can help guide these decisions. The patient must be informed before surgery about the risks of nerve-sparing surgery, the potency rates of the surgeon, and the possibility that, to ensure adequate cancer control, the nerves may be sacrificed despite any pre-operative optimism favouring the potential for their salvage. The early administration of intracavernous injection therapy could improve the definitive potency rates (96, 97) and the significance of sural nerve transplant needs further multicentre study (98). Finally, the early use of PDE-5 inhibitors in penile rehabilitation remains controversial. A recent study showed no benefit of daily early administration of vardenafil versus on-demand vardenafil in the postoperative period (99).
9.10 Guidelines and recommendations for RP LE Indications • In patients with low and intermediate risk localised PCa (cT1b-T2 and Gleason score 2-7 and PSA < 20) and a life expectancy > 10 years. Optional • Patients with stage T1a disease and a life expectancy > 15 years or Gleason score 7. • Selected patients with low-volume high-risk localised PCa (cT3a or Gleason score 8-10 or PSA > 20). • Highly selected patients with very high-risk localised PCa (cT3b-T4 N0 or any T N1) in the context of multimodality treatment. Recommendations • Short-term (three months) neoadjuvant therapy with gonadotrophin releasing-hormone analogues is not recommended in the treatment of stage T1-T2 disease. • Nerve-sparing surgery may be attempted in pre-operatively potent patients with low risk for extracapsular disease (T1c, Gleason score < 7 and PSA < 10 ng/mL or see Partin tables/ nomograms). • Unilateral nerve-sparing procedures are an option in stage T2a disease
1b
3 3 3
1a 3
4
LE = level of evidence
9.11
REFERENCES
1. Huland H. Treatment of localized disease: treatment of clinically localized prostate cancer (T1/T2). In: Murphy G, Denis L, Chatelain C, Griffiths K, Khoury S, Cockett AT (eds). Proceedings of the First International Consultation on Prostate Cancer, 1997, Scientific Communication International, Jersey, Channel Islands, pp. 227-257. 2. Corral DA, Bahnson RR. Survival of men with clinically localized prostate cancer detected in the eighth decade of life. J Urol 1994;151(5):1326-29. http://www.ncbi.nlm.nih.gov/pubmed/8158780 3. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280(11): 975-80. http://www.ncbi.nlm.nih.gov/pubmed/9749479
Update march 2009
49
4.
5. 6. 7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
50
Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004;171(4):1513-19. http://www.ncbi.nlm.nih.gov/pubmed/15017210 Young H. Radical perineal prostatectomy. Johns Hopkins Hosp Bull 1905;16:315-21. Memmelaar J, Millin T. Total prostatovesiculectomy; retropubic approach. J Urol 1949;62(3):340-8. http://www.ncbi.nlm.nih.gov/pubmed/18148289 Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982;128(3):492-7. http://www.ncbi.nlm.nih.gov/pubmed/7120554 Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S,Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE; Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100(16):1144-54. http://www.ncbi.nlm.nih.gov/pubmed/18695132 Potosky AL, Warren JL. Radical prostatectomy: does higher volume lead to better quality? J Natl Cancer Inst 1999;91(22):1906-7. http://www.ncbi.nlm.nih.gov/pubmed/10564667 Lepor H, Nieder AM, Ferrandino MN. Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J Urol 2001;166(5):1729-33. http://www.ncbi.nlm.nih.gov/pubmed/11586211 Augustin H, Hammerer P, Graefen M, Palisaar J, Noldus J, Fernandez S, Huland H. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol 2003;43(2):113-18. http://www.ncbi.nlm.nih.gov/pubmed/12565767 Maffezzini M, Seveso M, Taverna G, Giusti G, Benetti A, Graziotti P. Evaluation of complications and results in a contemporary series of 300 consecutive radical retropubic prostatectomies with the anatomic approach at a single institution. Urology 2003;61(5):982-6. http://www.ncbi.nlm.nih.gov/pubmed/12736020 Boccon-Gibod L, Ravery V, Vortos D, Toublanc M, Delmas V, Boccon-Gibod L. Radical prostatectomy for prostate cancer: the perineal approach increases the risk of surgically induced positive margins and capsular incisions. J Urol 1998;160(4):1383-5. http://www.ncbi.nlm.nih.gov/pubmed/9751359 Weldon VE, Tavel FR, Neuwirth H, Cohen R. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 1995;153(5):1565-9. http://www.ncbi.nlm.nih.gov/pubmed/7536268 Lein M, Stibane I, Mansour R, Hege C, Roigas J, Wille A, Jung K, Kristiansen G, Schnorr D, Loening SA, Deger S. Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies – experience at the Charité Hospital Berlin, Campus Mitte. Eur Urol 2006;50(6):1278-82; discussion 1283-4. http://www.ncbi.nlm.nih.gov/pubmed/16846677 Goeman L, Salomon L, De La Taille A, Vordos D, Hoznek A, Yiou R, Abbou CC. Long-term functional and oncological results after retroperitoneal laparoscopic prostatectomy according to prospective evaluation of 550 patients. World J Urol 2006;24(3):281-8. http://www.ncbi.nlm.nih.gov/pubmed/16508788 Rassweiler J, Stolzenburg J, Sulser T, Deger S, Zumbé J, Hofmockel G, John H, Janetschek G, Fehr JL, Hatzinger M, Probst M, Rothenberger KH, Poulakis V, Truss M, Popken G, Westphal J, Alles U, Fornara P. Laparoscopic radical prostatectomy– the experience of the German Laparoscopic Working Group. Eur Urol 2006;49(1):113-9. http://www.ncbi.nlm.nih.gov/pubmed/16337330 Rozet F, Galiano M, Cathelineau X, Barret E, Cathala N, Vallancien G. Extraperitoneal laparoscopic radical prostatectomy: a prospective evaluation of 600 cases. J Urol 2005;174(3):908-11. http://www.ncbi.nlm.nih.gov/pubmed/16093985 Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J, Van Poppel H. Retropubic, Laparoscopic, and Robot-Assisted Radical Prostatectomy: A Systematic Review and Cumulative Analysis of Comparative Studies. Eur Urol 2009; 25 Jan. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19185977
Update march 2009
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33. 34.
35.
36.
Andrèn O, Garmo H, Mucci L, Andersson SO, Johansson JE, Fall K. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 2009;100(1):170-3. http://www.ncbi.nlm.nih.gov/pubmed/19088721 Lowe BA, Listrom MB. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988;140(6):1340-4. http://www.ncbi.nlm.nih.gov/pubmed/3193495 Van Poppel H, Ameye F, Oyen R, Van de Voorde W, Baert L. Radical prostatectomy for localized prostate cancer. Eur J Surg Oncol 1992;18(5):456-62. http://www.ncbi.nlm.nih.gov/pubmed/1426296 Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens – a different view. J Urol 1997;157(1):244-50. http://www.ncbi.nlm.nih.gov/pubmed/8976263 Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumours. Urol Clin North Am 1993;20(4):687-93. http://www.ncbi.nlm.nih.gov/pubmed/7505977 Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumours found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 1994;152(5 Pt 2):1721-9. http://www.ncbi.nlm.nih.gov/pubmed/7523719 Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 2004;171(3): 1089-92. http://www.ncbi.nlm.nih.gov/pubmed/14767277 Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160(6 Pt 2): 2407-11. http://www.ncbi.nlm.nih.gov/pubmed/9817393 Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58(6):843-8. http://www.ncbi.nlm.nih.gov/pubmed/11744442 D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, Tomaszewski JE, Wein A. Combination of preoperative PSA level, biopsy Gleason score, percentage of positive biopsies and MRI T-stage to predict early failure in men with clinically localized prostate cancer. Urology 2000;55(4):572-7. http://www.ncbi.nlm.nih.gov/pubmed/10736506 Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 2000;24(4):477-8. http://www.ncbi.nlm.nih.gov/pubmed/10757394 Epstein JI, Steinberg GD. The significance of low grade prostate cancer on needle biopsy. A radical prostatectomy study of tumour grade, volume, and stage of the biopsied and multifocal tumour. Cancer 1990;66(9):1927-32. http://www.ncbi.nlm.nih.gov:/pubmed/1699655 Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, Rigatti P, Montorsi F, Karakiewicz PI. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006;98(4): 788-93. http://www.ncbi.nlm.nih.gov/pubmed/16796698 Schroder FH, Van den Ouden D, Davidson P. The role of surgery in the cure of prostatic carcinoma. Eur Urol Update Series 1992;1:18-23. Gibbons RP. Total prostatectomy for clinically localized prostatic cancer: long-term surgical results and current morbidity. NCI Monogr 1988;(7):123-6. http://www.ncbi.nlm.nih.gov/pubmed/3173498 Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24(2):395-406. http://www.ncbi.nlm.nih.gov/pubmed/9126237 Johansson JE, Andersson SO. Deferred treatment in localized prostatic cancer. Acta Oncol 1991;30(2):221-3. http://www.ncbi.nlm.nih.gov/pubmed/2029410
Update march 2009
51
37.
Graversen PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 1990;36(6):493-8. http://www.ncbi.nlm.nih.gov/pubmed/2247914 38. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, Gonen M, Reuter V, Scardino PT. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003;170(6 Pt 1):2292-5. http://www.ncbi.nlm.nih.gov/pubmed/14634399 39. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancerspecific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3):555-65. http://www.ncbi.nlm.nih.gov/pubmed/11590814 40. Catalona WJ, Smith DJ. 5-year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152 (5 Pt 2):1837-42. http://www.ncbi.nlm.nih.gov/pubmed/7523731 41. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167(2 Pt 1):528-34. http://www.ncbi.nlm.nih.gov/pubmed/11792912 42. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152(5 Pt 2):1821-5. http://www.ncbi.nlm.nih.gov/pubmed/7523728 43. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152(5Pt2):1850-7. http://www.ncbi.nlm.nih.gov/pubmed/7523733 44. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007 Jun;69(6):1095-101. http://www.ncbi.nlm.nih.gov/pubmed/17572194 45. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR; CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170(6 Pt 2): S21-S25; discussion S26-27. http://www.ncbi.nlm.nih.gov/pubmed/14610406 46. Hodgson D, Warde P, Gospodarowicz M. The management of locally advanced prostate cancer. Urol Oncol 1998;4:3-12. 47. Fallon B, Williams RD. Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am 1990;17(4):853-66. http://www.ncbi.nlm.nih.gov/pubmed/2219582 48. Boccon-Gibod L, Bertaccini A, Bono AV, Dev Sarmah B, Höltl W, Mottet N, Tunn U, Zamboglou N. Management of locally advanced prostate cancer: a European Consensus. Int J Clin Pract 2003;57(3):187-94. http://www.ncbi.nlm.nih.gov/pubmed/12723722 49. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002:360(9327):103-6. http://www.ncbi.nlm.nih.gov/pubmed/12126818 50. Yamada AH, Lieskovsky G, Petrovich Z, Chen SC, Groshen S, Skinner DG. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 1994;17(4):277-85. http://www.ncbi.nlm.nih.gov/pubmed/8048388 51. Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Ohori M, Theiss M, Schellhammer PF. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997;32(4):385-90. http://www.ncbi.nlm.nih.gov/pubmed/9412793
52
Update march 2009
52.
van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998;160(4):1392-7. http://www.ncbi.nlm.nih.gov/pubmed/9751362 53. Isorna Martinez de la Riva S, Belón López-Tomasety J, Marrero Dominguez R, Alvarez Cruz E, Santamaria Blanco P. [Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up]. Arch Esp Urol 2004;57(7):679-92. [article in Spanish] http://www.ncbi.nlm.nih.gov/pubmed/15536949 54. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95(6):751-6. http://www.ncbi.nlm.nih.gov/pubmed/15794776 55. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007;51(1):121-8; discussion 128-9. http://www.ncbi.nlm.nih.gov/pubmed/16797831 56. Joniau S, Hsu CY, Lerut E, Van Baelen A, Haustermans K, Roskams T, Oyen R, Van Poppel H. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007;51(2):388-96. http://www.ncbi.nlm.nih.gov/pubmed/16901622 57. Van Poppel H, Ameye F, Oyen R, Van de Voorde W, Baert L. Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol 1994;151(5):1310-14. http://www.ncbi.nlm.nih.gov/pubmed/8158777 58. Van Poppel H, Vekemans K, Da Pozzo L, Bono A, Kliment J, Montironi R, Debois M, Collette L. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 2006;42(8):1062-7. http://www.ncbi.nlm.nih.gov/pubmed/16624554 59. Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008;53(2):253-9. http://www.ncbi.nlm.nih.gov/pubmed/17949893 60. Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007;178(2):493-9;discussion 499. http://www.ncbi.nlm.nih.gov/pubmed/17561152 61. D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17(1):168-72. http://www.ncbi.nlm.nih.gov/pubmed/10458230 62. Tiguert LL, Harrel F, Fradet Y. Disease outcome of patients with a PSA > 20 treated by radical prostatectomy: analysis of 177 patients. J Urol 2006;175:311A. 63. Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC. Longterm outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or = 50 ng/mL. Cancer 2008;113(7):1544-51. http://www.ncbi.nlm.nih.gov/pubmed/18680171 64. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161(4):1223-7; discussion 1277-8. http://www.ncbi.nlm.nih.gov/pubmed/10081874 65. Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML. Specific survival in patients with node positive prostate cancer. a new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2008. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/18838212 66. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008;54(2):344-52. http://www.ncbi.nlm.nih.gov/pubmed/18511183
Update march 2009
53
67.
Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/mL undergoing radical prostatectomy for prostate cancer? Eur Urol 2006;50(2):272-9. http://www.ncbi.nlm.nih.gov/pubmed/16632187 68. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167(4):1681-6. http://www.ncbi.nlm.nih.gov/pubmed/11912387 69. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169(3): 849-54. http://www.ncbi.nlm.nih.gov/pubmed/12576797 70. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7. http://www.ncbi.nlm.nih.gov/pubmed/10235151 71. Aus G, Nordenskjöld K, Robinson D, Rosell J, Varenhorst E. Prognostic factors and survival in nodepositive (N1) prostate cancer – a prospective study based on data from a Swedish population-based cohort. Eur Urol 2003;43(6):627-31. http://www.ncbi.nlm.nih.gov/pubmed/12767363 72. Cheng L, Zincke H, Blute ML, Bergstrahl EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001;91(1):66-73. http://www.ncbi.nlm.nih.gov/pubmed/11148561 73. Weingärtner K, Ramaswamy A, Bittinger A, Gerharz EW, Vöge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J Urol 1996;156(6):1969-71. http://www.ncbi.nlm.nih.gov/pubmed/8911367 74. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168(2):514-8;discussion 518. http://www.ncbi.nlm.nih.gov/pubmed/12131300 75. Briganti A, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF, Roscigno M, Zanni G, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006;50(5): 1006-13. http://www.ncbi.nlm.nih.gov/pubmed/16959399 76. Heidenreich A et al. Extended pelvic lymphadenectomy in men undergoing radical retropubic prostatectomy (RRP) – an update on > 300 cases. J Urol 2004;171:a312. 77. Burkhard FC, Schumacher M, Studer UE. The role of lymphadenectomy in prostate cancer. Nat Clin Pract Urol 2005;2(7):336-42. http://www.ncbi.nlm.nih.gov/pubmed/16474786 78. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19167731 79. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di’SantAgnese PA, Trump D; Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472-9. http://www.ncbi.nlm.nih.gov/pubmed/16750497 80. Vallett BS. Radical perineal prostatectomy subsequent to bilateral orchiectomy. Delaware Med J 1944;16:19-20. 81. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;(4):CD006019. http://www.ncbi.nlm.nih.gov/pubmed/17054269 82. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97(2):247-54. http://www.ncbi.nlm.nih.gov/pubmed/16430622
54
Update march 2009
83. Hautmann RE, Sauter TW, Wenderoth UK. Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. Urology 1994;43(2 Suppl.):47-51. http://www.ncbi.nlm.nih.gov/pubmed/8116133 84. Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994;152(5 Pt 2):1817-9. http://www.ncbi.nlm.nih.gov/pubmed/7523727 85. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346(15):1138-44. http://www.ncbi.nlm.nih.gov/pubmed/11948274 86. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcome Study. J Natl Cancer Inst 2000;92(19):1582-92. http://www.ncbi.nlm.nih.gov/pubmed/11018094 87. Van Poppel H, Collette L, Kirkali Z, Brausi M, Hoekstra W, Newling DW, Decoster M, EORTC GU Group. Quality control of radical prostatectomy: a feasibility study. Eur J Cancer 2001;37(7):884-91. http://www.ncbi.nlm.nih.gov/pubmed/11313177 88. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152(5Pt2):1831-6. http://www.ncbi.nlm.nih.gov/pubmed/7523730 89. Sofer M, Savoie M, Kim SS, Civantos F, Soloway MS. Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion. J Urol 2003;169(1):153-6. http://www.ncbi.nlm.nih.gov/pubmed/12478125 90. Walsh RM, Thompson IM. Prostate cancer screening and disease management: how screening may have an unintended effect on survival and mortality-the camel’s nose effect. J Urol 2007;177(4): 1303-6. http://www.ncbi.nlm.nih.gov/pubmed/17382719 91. Alsikafi NF, Brendler CB. Surgical modifications of radical retropubic prostatectomy to decrease incidence of positive surgical margins. J Urol 1998;159(4):1281-5. http://www.ncbi.nlm.nih.gov/pubmed/9507853 92. Graefen M. Is the open retropubic radical prostatectomy dead? Eur Urol 2007 Nov;52(5):1281-3. http://www.ncbi.nlm.nih.gov/pubmed/17764828 93. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (‘trifecta’). Urology 2005; 66(5 Suppl.):83-94. http://www.ncbi.nlm.nih.gov/pubmed/16194712 94. Gontero P, Kirby RS. Nerve-sparing radical retropubic prostatectomy: techniques and clinical considerations. Prostate Cancer Prostatic Dis 2005;8(2):133-9. http://www.ncbi.nlm.nih.gov/pubmed/15711608 95. Sokoloff MH, Brendler CB. Indications and contraindications for nerve-sparing radical prostatectomy. Urol Clin North Am 2001;28(3):535-43. http://www.ncbi.nlm.nih.gov/pubmed/11590812 96. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, Rigatti P, Pizzini G, Miani A. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997;158(4):1408-10. http://www.ncbi.nlm.nih.gov/pubmed/9302132 97. Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res 2006;18(5):446-51. http://www.ncbi.nlm.nih.gov/pubmed/16482200 98. Secin FP, Koppie TM, Scardino PT, Eastham JA, Patel M, Bianco FJ, Tal R, Mulhall J, Disa JJ, Cordeiro PG, Rabbani F. Bilateral cavernous nerve interposition grafting during radical retropubic prostatectomy: Memorial Sloan-Kettering Cancer Center experience. J Urol 2007;177(2):664-8. http://www.ncbi.nlm.nih.gov/pubmed/17222654 99. Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, Stief C. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008 Oct;54(4):924-31. http://www.ncbi.nlm.nih.gov/pubmed/18640769
Update march 2009
55
10. TREATMENT: DEFINITIVE RADIATION THERAPY 10.1
Introduction
There are no randomised studies comparing radical prostatectomy with either external beam therapy or brachytherapy for localised prostate cancer, but the National Institutes of Health (NIH) consensus set up in 1988 (1) remains available: external irradiation offers the same long-term survival results as surgery; moreover, external irradiation provides a quality of life at least as good as that provided by surgery (2). Three-dimensional conformal radiotherapy (3D-CRT) is the gold standard and, at the beginning of the third millennium, intensity modulated radiotherapy (IMRT), an optimised form of 3D-CRT, is gradually gaining ground in centres of excellence. In addition to external irradiation, there has been continued and growing interest in transperineal low dose or high dose brachytherapy. In localised and locally advanced prostate cancer, several randomised phase III trials conducted by radiation therapy scientific societies, such as the Radiation Therapy Oncology Group (RTOG) and European Organisation for Research and Treatment of Cancer (EORTC), have established the indications for the combination of external irradiation and androgen deprivation treatment (ADT). Whatever the technique, the choice of treatment after the appropriate assessment of tumour extension must be based on a multidisciplinary approach taking account of: • the 2002 tumour node metastasis (TNM) classification • the Gleason score defined on a sufficient number of core biopsies (at least 12) • the baseline prostate-specific antigen (PSA) • the age of the patient • his co-morbidity, life expectancy and quality of life • d’Amico’s prognostic factor classification. Obtaining a patient’s consent is essential after giving full information regarding diagnosis, the therapeutic modalities and morbidity. Additional information on the various aspects of radiotherapy in the treatment of prostate cancer is available in a newly published extensive overview (3).
10.2
Technical aspects: three dimensional conformal radiotherapy and intensity modulated external beam radiotherapy
Anatomical data acquired by scanning the patient in a treatment position, are transferred to the 3D treatment planning system where the clinical target volume is visualised, following which a (surrounding) safety margin is added. At the time of irradiation, a multileaf collimator automatically and, in the case of IMRT, continuously, adapts to the contours of the target volume seen by each beam. Real-time verification of the irradiation field by means of portal imaging allows for comparison of the treated and simulated fields, and correction of deviations where displacement is more than 5 mm. Three-dimensional CRT improves local control through dose escalation without increasing the risk of morbidity. The use of IMRT is possible with linear accelerators equipped with the latest multileaf collimators and specific software. Movement of the leaves during the course of the irradiation allows for a more complex distribution of the dose to be delivered within the treatment field, and provides concave isodose curves, which are particularly useful as a means to spare the rectum. Whatever the techniques and their sophistication, quality assurance plays a major role in the management of radiotherapy, mandating the involvement of physicians, physicists, dosimetrists, radiographers, radiologists and computer scientists.
10.3
Localised prostate cancer T1-2c N0, M0
10.3.1 T1a-T2a, N0, M0 and Gleason score ≤ 6 and PSA < 10 ng/mL (low-risk group) Retrospective, non-randomised studies have shown that biochemical disease-free survival is significantly higher with a radiation dose ≥ 72 Gy compared with < 72 Gy (p = 0.04) (4). Two randomised trials focusing on clinical stages T1-3 N0 M0 paved the way for dose escalation: • The MD Anderson study compared 78 Gy with 70 Gy conventional radiotherapy: it included 305 stage T1-3 patients with a pre-treatment PSA level of more than 10 ng/mL and, with a median follow-up of
56
Update march 2009
•
8.7 years, showed a significant increase in freedom from biochemical and/or clinical failure for low-risk patients (p = 0.04) (5). The PROG 95-09 evaluated 393 T1b-T2b patients, of whom 75% had a Gleason score ≤ 6 and a PSA < 15 ng/mL. Patients were randomised to receive an initial boost to the prostate alone, using conformal protons of either 19.8 Gy or 28.8 Gy, and then 50.4 Gy to a larger volume. With a median follow-up of 5.5 years, there was a significant increase in five-year freedom from biochemical failure (p < 0.001) in favour of low-risk patients, who were given a higher dose (79.2 Gy), compared with those receiving a conventional dose (70.2 Gy) (6).
In daily practice, a minimum dose of 74 Gy is recommended. 10.3.2 T2b or PSA 10-20 ng/mL, or Gleason score 7 (intermediate-risk group) Many non-randomised studies have shown dose escalation to have a significant impact on five-year survival without biochemical relapse for patients classified as cT1c-T3, with a dose ranging from 76-81 Gy (4, 7, 8). A Dutch randomised phase III trial comparing 68 Gy with 78 Gy showed a significant increase in five-year freedom from clinical or biochemical failure for patients in an intermediate-risk group (9). The phase III trial of the French Federation of Cancer Centres compared 70 Gy with 80 Gy in 306 patients with a pelvic lymph node involvement risk of < 10% (Partin) or pN0, with no hormonal therapy allowed before, during or after radiotherapy. With a median follow-up of 59 months, high dose should provide a better five-year biological outcome in intermediate-risk patients, especially if the initial PSA > 15ng/mL (10). Patients who are reluctant to accept short-term hormonal treatment (11) can receive definitive radiotherapy alone provided that a dose escalation up to 78-80 Gy is proposed. 10.3.3 T2c or Gleason score > 7 or PSA > 20 ng/mL (high-risk group) External irradiation with dose escalation is mandatory since it improves the five-year biochemical disease-free survival, as shown in several phase III randomised trials. • The Dutch study comparing 68 Gy with 78 Gy showed a 10% increase in the five-year freedom from clinical or biochemical failure (p = 0.02) (9). • The MRC study comparing 64 Gy with 74 Gy, with neoadjuvant hormonal therapy, has shown an 11% difference in five-year biochemical disease-free survival (12). • The PROG 95-09 study, with a significant increase in five-year freedom from biochemical failure (p < 0.02) in favour of high-risk patients given a higher dose (79.2 Gy) vs those receiving a conventional dose (70.2 Gy) (9). • The MD Anderson study showed a significant increase in freedom from biochemical and/or clinical failure for high-risk patients (p = 0.004) (5). • The EORTC trial 22991, comparing 3D-CRT +/- IMRT with a choice of three levels of dose (70 Gy, 74 Gy and 78 Gy), with or without six months of neoadjuvant and concomitant hormonal therapy, was closed in April 2008 after recruiting 800 patients, and its results are awaited (13). In daily practice, a combination of external irradiation with short-term androgen deprivation is recommended, based on the results of a phase III randomised trial. This trial, which included 206 patients with a PSA of at least 10 ng/mL (maximum 40 ng/mL), a Gleason score of at least 7 (range 5-10), or radiographic evidence of extra-prostatic disease, compared 3D-CRT alone or in combination with six months of ADT. After a median follow-up of 7.6 years, intermediate- or high-risk patients without moderate or severe co-morbidity randomised to receive 3D-CRT plus ADT had a 13% improvement in overall survival rate (p < 0.001) (11). 10.3.4 Prophylactic irradiation of pelvic lymph nodes in high-risk localised prostate cancer Invasion of the pelvic lymph nodes is a poor prognostic factor and mandates systemic medical treatment because radiotherapy alone is insufficient (14). Prophylactic whole pelvis irradiation has been abandoned since randomised trials failed to show that patients benefited from prophylactic irradiation of the pelvic lymph nodes in high-risk cases (46-50 Gy). Such studies include the RTOG study with 484 T1b-T2 patients (15), the Standford study with only 91 patients (16), and the GETUG-01 trial, which included 444 T1b-T3 N0 pNx M0 patients (17). In order better to select patients who might benefit from pelvic lymph node irradiation, and to supplement the use of Partin’s tables (18) and/or the Roach formula (19), pelvic lymphadenectomy might be required, particularly for young patients, because its results will enable radiation oncologists to tailor both the planning target volume and the duration of ADT: specifically, no pelvic irradiation for pN0 patients, but pelvic irradiation for pN1 patients with long term ADT.
Update march 2009
57
10.4
Innovative techniques
10.4.1 Intensity modulated radiotherapy IMRT enables radiation oncologists to increase radiation doses homogeneously up to as much as 86 Gy within the target volume, while respecting the tolerance doses in organs at risk. Certainly, for dose escalation beyond 80 Gy, using conventional 2 Gy fraction sizes, or for dose escalation using hypofractionated radiotherapy, in which there has been renewed interest, IMRT is the only safe means of treatment delivery, although both treatment scenarios should be performed only within the confines of a properly designed clinical trial. The Memorial Sloan-Kettering Cancer Center has the largest experience with this technique, and its results have now been updated, reporting on disease control and toxicity in two cohorts of patients. In the first, 561 patients with organ-confined disease were treated with a dose of 81 Gy. The eight-year actuarial PSA relapse-free survival rates for patients in favourable, intermediate and unfavourable risk groups were 85%, 76% and 72%, respectively, according to the then-current American Society for Radiation Oncology (ASTRO) definition (20). In the second cohort, 478 patients with organ-confined disease were treated with a dose of 86.4 Gy. The fiveyear actuarial PSA relapse-free survival according to the nadir plus 2 ng/mL definition was 98%, 85% and 70% for the low-, intermediate-, and high-risk groups, respectively (21). To date, no randomised trials have been published comparing dose escalation using IMRT and 3D-CRT. However, several such trials are ongoing (UK NCRI, MD Anderson, Fox Chase, and Ottawa Health Research Institute), although one (Ottawa) is studying helical tomotherapy (see below), and two (NCRI and MD Anderson) are studying hypofractionated, doseescalated radiotherapy. With dose escalation using IMRT, organ movement becomes a critical issue, in terms of both tumour control and treatment toxicity, and evolving techniques will combine IMRT with some form of image-guided radiotherapy (IGRT), in which organ movement can be visualised and corrected for in real time, although the optimum means of achieving this is still unclear (22). Another evolving technique for the delivery of IMRT is tomotherapy, which uses a linear accelerator mounted on a ring gantry that rotates as the patient is delivered through the centre of the ring, analogous to spiral computed tomography (CT) scanning. Preliminary data suggest that this technique is feasible in prostate cancer treatment (23). 10.4.2 Proton beam and carbon ion beam therapy In theory, proton beams are an attractive alternative to photon beam radiotherapy for prostate cancer because they deposit almost all their radiation dose at the end of the particle’s path in tissue (the Bragg peak), in contrast to photons, which deposit radiation along their path. Additionally, there is a very sharp fall-off for proton beams beyond their deposition depth, meaning that critical normal tissues beyond this depth could be effectively spared, in contrast to photon beams, which will continue to deposit energy up to and including an exit dose as they leave the body. In practice, however, this has the disadvantage that dose distributions from protons are highly sensitive to changes in internal anatomy, such as might occur with bladder or rectal filling, and prostate proton therapy is usually delivered with lateral beams. It is also possible that high linear energy transfer (LET) radiation therapy using protons or carbon ions offers inherent biological advantages over photons, having more capacity for DNA damage dose-for-dose. Only one randomised trial has incorporated proton therapy in one arm: the Loma Linda/Massachusetts General Hospital trial discussed above compared standard-dose conformal radiotherapy with dose-escalated radiotherapy using protons for the boost dose (6). This trial cannot, however, be used as evidence for the superiority of proton therapy per se, as its use here could be viewed merely as a sophisticated method for dose escalation. In order to compare the efficacy of protons versus photons, a randomised trial using equivalent doses, comparing proton beam therapy with IMRT, would be needed, and such a study is under consideration by the RTOG. Two recent planning studies comparing conformal proton therapy with IMRT have yielded conflicting results, one suggesting that the two are equivalent in terms of rectal dose sparing, but IMRT is actually superior in terms of bladder sparing (24), and the other suggesting a clearer advantage to protons (25). Further studies are clearly needed, and in the interim, proton therapy must be regarded as a promising but experimental alternative to photon beam therapy. Theoretically, proton therapy might be associated with a lower risk of secondary
58
Update march 2009
cancers compared with IMRT, because of the lower integral dose of radiation, but there are no data in patients treated for prostate cancer to support this. Carbon ions offer similar theoretical advantages as protons as an alternative to photon beam therapy. In a phase II study, 175 patients with T1-3, N0-1, M0 prostate cancer were treated with carbon ions in a dose equivalent to 66 Gy in 20 fractions over five weeks (26). Treatment appeared to be well tolerated, with no RTOG grade 3 or 4 bowel or genitourinary toxicity, and an overall four-year biochemical disease-free rate of 88% (25). As with protons, a randomised trial comparing carbon ions with IMRT and using equivalent doses is required.
10.5
Transperineal brachytherapy
Transperineal brachytherapy is a safe and effective technique that generally requires fewer than two days of hospitalisation. There is consensus on the following eligibility criteria: • stage cT1b- T2a N0, M0, • a Gleason score ≤ 6 assessed on a sufficient number of random biopsies • an initial PSA level of≤ 10 ng/mL • ≤ 50% of biopsy cores involved with cancer • a prostate volume of < 50 cm3 • a good International Prostatic Symptom Score (IPSS) (27). Patients with low-risk prostate cancer are the most suitable candidates for low-dose rate (LDR) brachytherapy. Further guidelines on technical aspects of brachytherapy have been published recently, and are strongly recommended (28). In 1983, Holm et al. described the transperineal method with endorectal sonography in which the patient is positioned in a dorsal decubitus gynaecological position (29). Implantation is undertaken under general anaesthesia or spinal block, and involves a learning curve for the whole team: the surgeon for the delineation of the prostate and the placement of the needles, the physicist for real-time dosimetry, and the radiation oncologist for source loading. The sonography probe introduced into the rectum is fixed in a stable position. No randomised trials have been performed comparing brachytherapy with other curative treatment modalities, and outcomes are based on unrandomised case series. Results of permanent implants have been reported from different institutions, with a median follow-up ranging between 36 and 120 months (30). Recurrence-free survival after five and 10 years was reported to range from 71-93% and from 65-85%, respectively (31-38). A significant correlation has been shown between the implanted dose and recurrence rates (39). Patients receiving a D90 of > 140 Gy demonstrated a significantly higher biochemical control rate (PSA < 1.0 ng/mL) at four years than patients receiving less than 140 Gy (92% vs 68%). There is no benefit from adding neoadjuvant or adjuvant androgen deprivation to LDR brachytherapy (30). Some patients experience significant urinary complications following implantation, such as urinary retention (1.5-22%), post-implant transurethral resection of the prostate (TURP) (up to 8.7%), and incontinence (0-19%). A small randomised trial has suggested that prophylactic tamsulosin does not reduce the rates of acute urinary retention, but may improve urinary morbidity (40). This observation could usefully be further studied in a larger number of patients. Chronic urinary morbidity can occur in up to 20% of patients, depending on the severity of symptoms prior to brachytherapy. Previous TURP for benign prostatic hyperplasia increases the risk of postimplant incontinence and urinary morbidity. Brachytherapy-induced rectal morbidity with grade II/III proctitis occurs in 5-21% of patients. Erectile dysfunction develops in about 40% of patients after three to five years. In a recent retrospective analysis of 5621 men who had undergone LDR brachytherapy (41), urinary, bowel and erectile morbidity rates were 33.8%, 21% and 16.7%, respectively, with invasive procedure rates of 10.3%, 0.8% and 4%, respectively. In cases of permanent implants, iodine-125 in granular form is the radio-element of reference, while palladium-103 may be used for less differentiated tumours with a high doubling time. The dose delivered to the planning target volume is 160 Gy for iodine-125, and 120 Gy for palladium-103. A Gleason score of 7 remains a ‘grey area’, but patients with a Gleason score of 4 + 3 show no difference in outcome (42). A small randomised trial has suggested that, as one might expect, the use of stranded rather than loose seeds is associated with better seed retention and less seed migration, and this should be the standard choice (43).
Update march 2009
59
In cases of intermediate or high-risk localised prostate cancer, its combination with supplemental external irradiation (44) or neoadjuvant hormonal treatment (45) may be considered. The optimum dose of supplemental external beam radiation therapy (EBRT) is unclear. A randomised trial comparing 44 Gy with 20 Gy of EBRT plus palladium-103 brachytherapy closed early, showing no difference in biochemical outcomes (46). Non-permanent transperineal interstitial prostate brachytherapy using a high-dose rate iridium-192 stepping source and a remote afterloading technique can be applied with a total dose of 12-20 Gy in two to four fractions combined with fractionated external radiotherapy of 45 Gy (47). Higher doses of supplemental EBRT than this may best be delivered with IMRT, and a report from Memorial Sloan-Kettering indicates that such an approach is safe and feasible (48). Recent data suggest an equivalent outcome in terms of biochemical disease-free survival compared with high-dose EBRT (HD EBRT) (49). In a retrospective analysis of modern series (50, 51), biochemical diseasefree survival rates of 85.8%, 80.3% and 67.8% in men with low-, intermediate- and high-risk prostate cancer, respectively, are reported after a mean follow-up of 9.43 years. Quality-of-life changes are similar between HD EBRT and high-dose rate (HDR) brachytherapy in terms of diarrhoea and insomnia (52). However, the frequency of erectile dysfunction is significantly increased with HDR brachytherapy (86% vs 34%). A single randomised trial of EBRT versus EBRT plus HDR brachytherapy has been reported (53). A total of 220 patients with organ-confined prostate cancer were randomised to EBRT alone with a dose of 55 Gy in 20 fractions, or EBRT with a dose of 35.75 Gy in 13 fractions, followed by HDR brachytherapy with a dose of 17 Gy in two fractions over 24 hours. A significant improvement in biochemical relapse-free survival was seen in favour of the combined brachytherapy schedule (p = 0.03). There were no differences in the rates of late toxicity. Patients randomised to brachytherapy had significantly better quality of life as measured by their Functional Assessment of Cancer Therapy-prostate (FACT-P) score at 12 weeks (53). There is still a need to compare dose escalated EBRT plus hormone therapy, with the same plus a brachytherapy boost, in intermediate- and high-risk patients. For T1-2 N0 M0 disease, the five-year biochemical failure rates are similar for permanent seed implantation, high-dose (> 72 Gy) external radiation, combination seed/external irradiation, and radical prostatectomy. These were the results from a study that included 2991 patients diagnosed with T1-2 consecutive localised prostate cancer treated between 1990 and 1998 at the Cleveland Clinic Foundation and Memorial Sloan-Kettering Cancer Center with a minimum of one-year follow-up (49).
10.6
Late toxicity
Patients must be informed about the potential late genitourinary or gastrointestinal toxicity that may occur, as well as the impact of irradiation on erectile function. Late toxicity was analysed using a dose of 70 Gy in the prospective EORTC randomised trial 22863 (1987-1995) (54), in which 90% of patients were diagnosed as stage T3-4. A total of 377 patients (91%) out of 415 enrolled were evaluable for long-term toxicity, graded according to a modified RTOG scale. Eighty-six (22.8%) patients had grade ≥ 2 urinary or intestinal complications or leg oedema, of which 72 had grade 2 (moderate) toxicity, 10 had grade 3 (severe) toxicity, and four died due to grade 4 (fatal) toxicity. Although four (1%) late treatment-related deaths occurred, longterm toxicity was limited, with fewer than 5% grade 3 or 4 late complications being reported (Table 15). These data can be used as a baseline for comparison with irradiation techniques currently in use, such as 3D-CRT or IMRT. Table 15: Incidence of late toxicity by RTOG grade (from EORTC trial 22863) Toxicity
Grade 2
Grade 3
Grade 4
Cystitis Haematuria Urinary stricture Urinary incontinence Overall GU toxicity Proctitis
No. 18 18 18 18 47 31
No. 2 0 5 2 9 0
No. 0 0 4 0 4† 0
60
% 4.7 4.7 4.7 4.7 12.4 8.2
% 0.5 0 1.3 0.5 2.3
% 0 0 1 0 1† 0
Any significant toxicity (> grade 2) No. % 20 5.3 18 4.7 27 7.1 20 5.3 60 15.9 31 8.2
Update march 2009
Chronic diarrhoea Small bowel obstruction Overall GI toxicity Leg oedema Overall toxicity*
14 1 36 6 72
3.7 0.2 9.5 1.5 19.0
0 1 1 0 10
0.2 0.2 0 2.7
0 0 0 0 4
0 0 0 0 1
14 2 37 6 86
3.7 0.5 9.8 1.5 22.8
GU = genitourinary; GI = gastrointestinal. * Overall toxicity included genitourinary and gastrointestinal toxicity and leg oedema. As most patients had more than one type of toxicity, the overall toxicity does not result from simple addition. † Two of the grade 4 patients were irradiated with cobalt-60. Note: there was no other significant (≥ grade 2) toxicity among patients irradiated with cobalt-60 (n = 15) except for two patients with grade 4 genitourinary toxicity (stated above) and only one patient with grade 2 gastrointestinal toxicity. Radiotherapy affects erectile function to a lesser degree than surgery according to retrospective surveys of patients (2). A recent meta-analysis has shown that the one-year rate of probability for maintaining erectile function was 0.76 after brachytherapy, 0.60 after brachytherapy plus external irradiation, 0.55 after external irradiation, 0.34 after nerve-sparing radical prostatectomy, and 0.25 after standard radical prostatectomy. When studies with more than two years of follow-up were selected (i.e. excluding brachytherapy), the rates became 0.60, 0.52, 0.25, and 0.25, respectively, with a greater spread between the radiation techniques and surgical approaches (55). Recent studies have demonstrated a significantly increased risk of developing secondary malignancies of the rectum and bladder following EBRT (56, 57). In a retrospective evaluation of 30,552 and 55,263 men who had undergone either EBRT or radical prostatectomy, the risk of being diagnosed with rectal cancer increased 1.7fold in comparison with the surgery group (56). Another analysis (57) showed that the relative risk of developing bladder cancer increased by 2.34-fold compared with a healthy control population. Corresponding data on late toxicity has also been reported by the Memorial Sloan-Kettering Cancer Center group, from its experience in 1571 patients with T1-T3 disease treated with either 3D-CRT or IMRT in doses of between 66 Gy and 81 Gy, with a median follow-up of 10 years (58). Both acute GI and GU toxicity appeared to predict for corresponding late toxicity. The overall rates of NCIC-CTC grade 2 or more GI toxicity was 5% with IMRT, compared with 13% with 3D-CRT. The incidence of grade 2 or more late GU toxicity was 20% in patients treated with 81 Gy, compared with 12% in patients treated with lower doses. The overall incidence of grade 3 GI toxicity was 1%, and grade 3 GU toxicity was 3%. These data suggest that IMRT can successfully protect against late GI toxicity, but, interestingly, with dose escalation, GU toxicity may take over as the dominant morbidity (58).
10.7
Immediate post-operative external irradiation for pathological tumour stage T3 N0, M0
Extracapsular invasion (pT3) is associated with a risk of local recurrence, which can be as high as 30% (59). In a multifactorial analysis, the predictors of biochemical relapse are: • PSA level (p = 0.005) • Gleason score of the surgical specimen (p = 0.002) • positive surgical margins (p < 0.001) (60). Three prospective randomised trials have assessed the role of immediate post-operative radiotherapy. The EORTC study 22911, with a target sample size of 1005 patients, compared immediate post-operative radiotherapy (60 Gy) with radiotherapy delayed until local recurrence (70 Gy) in patients classified as pT3 pN0 after retropubic radical prostatectomy. Immediate post-operative radiotherapy proved to be well tolerated, with a risk of grade 3-4 urinary toxicity of less than 3.5% (61), without significant differences regarding the rate of incontinence and/or stricture of anastomosis (62). The study concludes that immediate post-operative radiotherapy after surgery significantly improves five-year clinical or biological survival: 72.2% vs 51.8% (p < 0.0001) (63). However, the EORTC study has not yet demonstrated improved metastasis-free and cancer-specific survival in this cohort of patients. The most suitable candidates for immediate radiation therapy might be those with multifocal positive surgical margins and a Gleason score > 7. The conclusions of the ARO trial 96-02 – based on a cohort of 385 patients – echoed those of EORTC since after a median follow-up of 54 months, biochemical progression-free survival was significantly improved in the radiotherapy group: 72% vs 54% (p = 0.0015) (64).
Update march 2009
61
In the same way, the SWOG 8794 trial randomised 425 pT3 patients, and the updated results (65), with a median follow-up of 11.5 years, show that adjuvant radiation significantly improved metastasis-free survival, with a 15-year metastasis-free survival of 46% vs 38% (p = 0.036) and a 15-year overall survival of 47% vs 37% (p = 0.053). Thus, for patients classified as T1-2 N0 (or T3 N0 with selected prognostic factors), pT3 pN0 with a high risk of local failure after radical prostatectomy due to capsular rupture, positive margins and/or invasion of the seminal vesicles, who present with a PSA level of < 0.1 ng/mL one month after surgery, two options can be offered within the frame of an informed consent: • either an immediate radiotherapy to the surgical bed (66) upon recovery of urinary function • or clinical and biological monitoring followed by salvage radiotherapy when the PSA exceeds 0.5 ng/ mL (67); 1.0 ng/mL seems to be a breakpoint above which the likelihood of local control is significantly reduced (68). A retrospective analysis based on 635 patients undergoing prostatectomy from 1982-2004, followed up through to December 2007, who experienced biochemical and/or local recurrence and received no salvage treatment (397) or salvage radiotherapy alone (160) within two years of biochemical recurrence has shown that salvage radiotherapy was associated with a threefold increase in prostate cancer-specific survival relative to those who received no salvage treatment (p < 0.001) (69). These two approaches, together with the efficacy of neo-adjuvant hormone therapy, are currently being compared in the UK MRC RADICALS randomised trial, and the role of short-term hormone therapy in combination with radiotherapy in the EORTC 22043 randomised trial.
10.8
Locally advanced prostate cancer: T3-4 N0, M0
The incidence of locally advanced prostate cancer has declined as a result of individual or mass screening. Pelvic lymph node irradiation is optional for N0 patients, but the results of radiotherapy alone are very poor (70). Because of the hormonal dependence of prostate cancer (71), ADT has been combined with external irradiation with the aim of: • reducing the risk of distant metastases by potentially sterilising micrometastases already present at the moment of diagnosis • decreasing the risk of non-sterilisation and/or local recurrence as a source of secondary metastases (72) through the effect of radiation-induced apoptosis (73, 74). Numerous randomised trials have confirmed the value of long-term administration. 10.8.1 Neoadjuvant and concomitant hormonal therapy The RTOG study 86-10 included 471 patients with bulky (5 x 5 cm) tumours T2-4N0-X M0. ADT was administered two months before irradiation and during irradiation, or in the case of relapse in the control arm. Thirty-two per cent of patients were diagnosed as T2, 70% as T3-4, and 91% as N0. The hormone treatment consisted of oral eulexine, 250 mg three times daily, and goserelin acetate (Zoladex), 3.6 mg every four weeks by subcutaneous injection. The pelvic target volume received 45 Gy, and the prostatic target volume received 20-25 Gy. The 10-year overall survival estimates – 43% vs 34% – favoured ADT and irradiation, but the difference was not significant (p = 0.12). There was a significant improvement in the 10-year disease-specific mortality (23% vs 36%; p = 0.01), disease-free survival (11% vs 3%; p < 0.0001), and biochemical failure (65% vs 80%; p < 0.0001), with the addition of ADT having no statistical impact on the risk of fatal cardiac events (75). 10.8.2 Concomitant and long-term adjuvant hormonal therapy The EORTC study 22863 recruited 415 patients diagnosed with T1-2 grade 3 WHO (World Health Organization), T3-4, N0 M0 and any histological grade, and compared radiotherapy plus adjuvant ADT, with radiotherapy alone. ADT was allowed in cases of relapse. A total of 82% of patients was diagnosed as T3, 10% as T4, and 89% as N0. The hormone treatment consisted of oral cyproterone acetate (CPA), 50 mg three times daily for one month, beginning one week before the start of radiotherapy, and goserelin acetate (Zoladex), 3.6 mg subcutaneously every four weeks for three years, starting on the first day of radiotherapy. The pelvic target volume received was 50 Gy, and the prostatic target volume was 20 Gy. With a median follow-up of 66 months, combination therapy compared with radiotherapy alone yielded significantly better survival (78% vs 62%, p = 0.001) (76). At a median follow-up of 9.1 years, the 10-year overall survival remained significantly higher – 58.1% vs 39.8%
62
Update march 2009
(p < 0.0001) – as did clinical progression-free survival – 47.7% vs 22.7% (p < 0.0001). The 10-year cumulative incidence of prostate cancer mortality was 11. 1% vs 31% (p < 0.0001), and the 10-year cumulative incidence of cardiovascular mortality was 11.1% vs 8.2% (p = 0.75) (77). 10.8.3 Long-term adjuvant hormonal therapy The RTOG study 85-31 recruited 977 patients diagnosed with T3-4 N0-1 M0, or pT3 after radical prostatectomy. ADT was begun in the last week of irradiation and continued up to relapse (group I) or was started at recurrence (group II). A total of 15% of patients in group I and 29% in group II had undergone radical prostatectomy, while 14% of patients in group I and 26% in group II were pN1. Goserelin acetate, 3.6 mg subcutaneously, was administered every four weeks. The pelvis received 45 Gy and the prostatic bed received 20-25 Gy. Patients diagnosed with stage pT3 received 60-65 Gy. With a median follow-up time of 7.6 years for all patients, the 10-year overall survival was significantly greater for the adjuvant arm, at 49% vs 39% (p = 0.002) (78). National Cancer Institute (NCI) of Canada /Medical Research Council intergroup PR3/PR07 study, including patients diagnosed with stage cT3-4 N0 M0, compared complete androgen blockade (CAB) (goserelin acetate 3.6 mg subcutaneously every four weeks and flutamide 750 mg/ day) alone and in combination with radiation 65-69 Gy (79, 80). The results are awaited. The SPCG-7/SFUO-3 randomised study (81) compared endocrine treatment alone, three months of CAB followed by continuous endocrine treatment using flutamide (439 patients) with the same treatment combined with radiotherapy (436 patients). After a median follow-up of 7.6 years, the 10-year cumulative incidence for prostate cancer-specific mortality was respectively 23.9% and 11.9% (difference 12%; 95% CI; 4.9-19.1%), and the 10-year cumulative incidence for overall mortality was 39.4% in the endocrine treatment alone group, and 29.6% in the endocrine plus radiotherapy group (difference 9.8%; 0.8-18%). 10.8.4 Neoadjuvant, concomitant and long-term adjuvant hormonal therapy The RTOG 92-02 trial closed in 1995 after accruing 1554 patients. Statistically significant improvements were observed in actuarial biochemical freedom from disease (bNED) control, distant metastatic failure, local control, and disease-free survival in patients receiving long-term ADT (LDAT) (before, during, and two years after radiotherapy), compared with short-term androgen deprivation (STAD) (two months before and during radiotherapy). With a median follow-up of 5.8 years, the LTAD treatment arm showed significant improvement over the STAD arm in all efficacy end-points except five-year overall survival, which was 80% vs 78.5% (p = 0.73), respectively. In a subset of patients that was not part of the original study design, with Gleason score 8-10 tumours, the LTAD arm showed significantly better overall survival after five years than the STAD arm, with 81% vs 70.7% (p = 0.04) (82). 10.8.5 Short-term or long-term adjuvant hormonal treatment Further to EORTC trial 22863, EORTC equivalence trial 22961 was set up to test whether similar survival could be achieved in patients who underwent irradiation (to 70 Gy) and six months of combined ADT without further ADT, i.e. STADT arm, compared with patients with 2.5 years of further treatment with luteinising hormonereleasing hormone analogue (LHRHa), i.e. LTADT arm. Eligible patients had T1c-2b N1-2 or pN1-2, or T2c-4 N0-2 (UICC 1992) M0 prostate cancer with PSA < 150 ng/mL. Non-inferior survival was defined as a mortality hazard ratio (HR) = 1.35 for SADT vs LADT. A total of 970 patients were randomised. With a 5.2-year median follow-up, the five-year overall survival rate was 85.3% on LADT, and 80.6% on SADT (HR = 1.43; 96.4% CI; 1.04-1.98), and failed to prove non-inferiority (83). 10.8.6 Dose escalation with hormonal therapy For bulky locally advanced prostate cancer, there might be a role for dose escalation as suggested by the excellent results of a retrospective series by the Memorial Sloan-Kettering Cancer Center devoted to 296 patients: 130 cT3a N0-X M0 and 166 cT3bN0-X M0. The prescribed doses to the prostate gland ranged from 66 Gy to 86.4 Gy; 95 patients received IMRT with dose escalation beyond 81 Gy. ADT was given for three months prior to radiotherapy to 189 patients (64%), and was continued during the course of radiotherapy for patients with high-grade disease. With a median follow-up of eight years, the five- and 10-year overall survival and cause-specific survival were respectively 91% and 65%, 95% and 83% (84).
10.9
Very high-risk prostate cancer: c or pN1, M0
Patients with a pelvic lymph node involvement lower than the iliac regional nodes, younger than 80 years old with WHO performance status 0-1 and no severe co-morbidity may be candidates for external beam irradiation plus immediate long-term hormonal manipulation. The RTOG 85-31 randomised phase III trial has shown, with
Update march 2009
63
a median follow-up of 6.5 years, that 95 patients out of the 173 pN1 patients who received pelvic radiotherapy with immediate hormonal therapy had better five and nine-year progression-free survival (PSA < 1.5 ng/mL), with 54% and 10% respectively versus 33% and 4% with radiation alone and hormonal manipulation instituted at the time of relapse (p < 0.0001). Multivariate analysis revealed this combination as having a statistically significant impact on overall survival, disease-specific failure, metastatic failure and biochemical control (85).
10.10 Summary of definitive radiation therapy
•
•
•
•
•
In localised prostate cancer T1c-T2c N0 M0, 3D-CRT with or without IMRT is recommended even for young patients who refuse surgical intervention. There is fairly strong evidence that low-, intermediate- and high-risk patients benefit from dose escalation For patients in the high-risk group, short-term ADT prior to and during radiotherapy results in increased overall survival. Transperineal interstitial brachytherapy with permanent implants is an option for patients with cT1T2a, Gleason score < 7 (or 3 + 4), PSA ≤ 10 ng/mL, prostate volume ≤ 50 mL, without a previous TURP and with a good IPSS. Immediate post-operative external irradiation after radical prostatectomy for patients with pathological tumour stage T3 N0 M0 improves biochemical and clinical disease-free survival. An alternative option is to give radiation at the time of biochemical failure, but before PSA rises above 1ng/mL. In locally advanced prostate cancer T3-4 N0 M0, overall survival is improved by concomitant and adjuvant hormonal therapy for a total duration of three years, with external irradiation for patients with a WHO 0-1 performance status. For a subset of patients with T2c-T3 N0-x and a Gleason score of 2- 6, short-term ADT before and during radiotherapy may favourably influence overall survival. In very high-risk prostate cancer, c-pN1 M0 with no severe co-morbidity, pelvic external irradiation and immediate long-term adjuvant hormonal treatment improve overall survival, disease-specific failure, metastatic failure and biochemical control.
LE 2
2a 2b
1 3 1
1b 2b
LE = level of evidence
10.11 REFERENCES 1.
2.
3.
4.
5.
6.
64
Consensus statement: the management of clinically localized prostate cancer. National Institutes of Health Consensus Development Panel (no authors listed). NCI Monogr 1988;(7):3-6. http://www.ncbi.nlm.nih.gov/pubmed/3050539 Fowler FJ, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance epidemiology and end results areas. J Clin Oncol 1996;14(8):2258-65. http://www.ncbi.nlm.nih.gov/pubmed/8708715 Nilsson S, Norlen BJ, Widmarks A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004;43(4):316-81. http://www.ncbi.nlm.nih.gov/pubmed/15303499 Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 2005;61(2):415-9. http://www.ncbi.nlm.nih.gov/pubmed/15667961 Kuban DA, Tucker SL, Dong L, Starkshall G, Huang EH, Cheung MR, Lee AK, and Pollack A. Long term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(1):67-74. http://www.ncbi.nlm.nih.gov/pubmed/17765406 Zietman AL, DeSilvio M, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. A randomized controlled trial JAMA 2005;294(10):1233-9. http://www.ncbi.nlm.nih.gov/pubmed/16160131
Update march 2009
7.
8.
9.
10.
11.
12.
13.
14.
15.
16. 17.
18.
19.
20.
Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Mohan R, Mageras GS, Ling CC, Fuks Z. The biological basis and clinical application of three dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994;21(5):580-97. http://www.ncbi.nlm.nih.gov/pubmed/7939749 Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41(3);491-500. http://www.ncbi.nlm.nih.gov/pubmed/9635694 Peeters ST, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, Bonfrer JMG, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24(13):1990-6. http://www.ncbi.nlm.nih.gov/pubmed/16648499 Beckendorf V, Guerif S, Le Prise E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 2004;60(4):1056-65. http://www.ncbi.nlm.nih.gov/pubmed/15519775 D’Amico A, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer; a randomized controlled trial. JAMA 2008;299(3):289-95. http://www.ncbi.nlm.nih.gov/pubmed/18212313 Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK; RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomized controlled trial. Lancet Oncol 2007;8(6):475-87. http://www.ncbi.nlm.nih.gov/pubmed/17482880 Bolla M. Three dimensional conformal radiotherapy alone vs three dimensional conformal therapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A phase III randomized study. EORTC protocol 22991, EORTC Data Centre, Brussels, 1999. http://pfsearch.ukcrn.org.uk/StudyDetail.aspx?TopicID=1&StudyID=871 Leibel SA, Fuks Z, Zelefsky MJ, Whitmore WF Jr. The effects of local and regional treatments on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994;28(1):7-16. http://www.ncbi.nlm.nih.gov/pubmed/8270461 Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, Perez CA. Elective irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77 06. Int J Radiation Oncology Biol Phys 1988;15(6):1307-16. http://www.ncbi.nlm.nih.gov/pubmed/3058656 Spaas PG, Bagshaw MA, Cox RS. The value of extended field irradiation in surgically staged carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1988;15:133 (abstract 36). Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, Wagner JP, Hay MH, Beckendorf V, Suchaud JP, Pabot du Chatelard JM, Bernier V, Voirin N, Perol D, Carrie C. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007;25(34):5366-73. http://www.ncbi.nlm.nih.gov/pubmed/18048817 Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445-51. http://www.ncbi.nlm.nih.gov/pubmed/9145716 Roach M, Marquez C, Yuo H, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1993;28(1):33-7. http://www.ncbi.nlm.nih.gov/pubmed/7505775 Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176(4 PT 1):1415-9. http://www.ncbi.nlm.nih.gov/pubmed/16952647
Update march 2009
65
21.
Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H. Ultrahigh dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008;71(2):330-7. http://www.ncbi.nlm.nih.gov/pubmed/18164858 22. Ling CC, Yorke E, Fuks Z. From IMRT to IGRT: frontierland or neverland? Radiother Oncol 2006;78(2):119-22. http://www.ncbi.nlm.nih.gov/pubmed/16413622 23. Keiler L, Dobbins D, Kulasekere R, Einstein D. Tomotherapy for prostate adenocarcinoma: a report on acute toxicity. Radiother Oncol 2007;84(2):171-6. http://www.ncbi.nlm.nih.gov/pubmed/17692975 24. Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, Bortfeld TR, Zietman AL, Delaney TF, Shipley WU. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys 69(2):444-53. http://www.ncbi.nlm.nih.gov/pubmed/17513063 25. Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, McKenzie C, Lawlor P, Henderson R, Li Z, Lin L, Olivier K, Keole S. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(3):744-51. http://www.ncbi.nlm.nih.gov/pubmed/17904306 26. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe JE, Kanai T, Morita S, Wakatsuki M, Shimazaki J, Tsujii H; Working Group for Genitourinary Tumors. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol 2006;81(1):57-64. http://www.ncbi.nlm.nih.gov/pubmed/16971008 27. Ash D, Flynn A, Batterman J, de Reijke T, Lavagnini P, Blank L; ESTRA/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57(3):315-21. http://www.ncbi.nlm.nih.gov/pubmed/11104892 28. Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, Venselaar J, Hoskin P; GEC ESTRO PROBATE Group. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007;83(1):3-10. http://www.ncbi.nlm.nih.gov/pubmed/17321620 29. Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I. Transperineal seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130(2):283-6. http://www.ncbi.nlm.nih.gov/pubmed/6876274 30. Machtens S, Baumann R, Hagemann J, Warszawski A, Meyer A, Karstens JH, Jonas U. Long-term results of interstitial brachytherapy (LDR-brachytherapy) in the treatment of patients with prostate cancer. World J Urol 2006;24(3):289-95. http://www.ncbi.nlm.nih.gov/pubmed/16645877 31. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Biol Phys 2001;51(1):31-40. http://www.ncbi.nlm.nih.gov/pubmed/11516848 32. Potters L, Klein EA, Kattan MW, Reddy CA, Ciezki JP, Reuther AM, Kupelian PA. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 2004;71(1):29-33. http://www.ncbi.nlm.nih.gov/pubmed/15066293 33. Sylvester JE, Blasko JC, Grimm R, Meier R, Spiegel JF, Malmgrem JA. Fifteen year follow-up of the first cohort of localized prostate cancer patients treated with brachytherapy. J Clin Oncol 2004;22(14S):4567. http://meeting.jco.org/cgi/content/abstract/22/14_suppl/4567 34. Potters L, Morgenstern C, Calugaru E, Fearn R, Jassal A, Presser J, Mullen E. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173(5):1562-6. http://www.ncbi.nlm.nih.gov/pubmed/15821486 35. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol 2005;173(3):803-7. http://www.ncbi.nlm.nih.gov/pubmed/15711273
66
Update march 2009
36.
37.
38.
39.
40.
41.
42.
43.
44. 45.
46.
47.
48.
49.
Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67(2):327-33. http://www.ncbi.nlm.nih.gov/pubmed/17084558 Lawton CA, DeSilvio M, Lee WR, Gomelia L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys 2007;67(1):39-47. http://www.ncbi.nlm.nih.gov/pubmed/17084551 Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008;179(5Suppl.):S20-S24. http://www.ncbi.nlm.nih.gov/pubmed/18405743 Stock RG, Stone NN. Importance of post-implant dosimetry in permanent brachytherapy. Eur Urol 2002;41(4):434-9. http://www.ncbi.nlm.nih.gov/pubmed/12074816 Elshaikh MA, Ulchaker JC, Reddy CA, Angermeier KW, Klein EA, Chehade N, Altman A, Ciezki JP. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys 62(1):164-9. http://www.ncbi.nlm.nih.gov/pubmed/15850917 Chen AB, D’Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006;24(33):5298-304. http://www.ncbi.nlm.nih.gov/pubmed/17114664 Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Biochemical outcome for hormone naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 2002;60(1):98-103. http://www.ncbi.nlm.nih.gov/pubmed/12100932 Reed DR, Wallner KE, Merrick GS, Arthurs S, Mueller A, Cavanagh W, Butler WB, Ford E, Sutlief SG. A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy 2007;6(2):129-34. http://www.ncbi.nlm.nih.gov/pubmed/17434106 Potters L, Cha C, Ashley R, Barbaris H, Leibel S. Is pelvic radiation necessary in patients undergoing prostate brachytherapy? Int J Radiat Oncol Biol Phys 1998;42:300 (abstract 2146). Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to highrisk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52(2):444-52. http://www.ncbi.nlm.nih.gov/pubmed/11872291 Wallner K, Merrick G, True L, Sherertz T, Sutlief S, Cavanagh W, Butler W. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. Radiother Oncol 2005;75(3):307-10. http://www.ncbi.nlm.nih.gov/pubmed/16086912 Galalae RM, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, Bertermann H, Buschbeck B, Kohr P, Kimmig B. Long term outcome after elective irradiation on the pelvic lymphatics and local dose escalation using high dose rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002;52(1):81-90. http://www.ncbi.nlm.nih.gov/pubmed/11777625 Zelefsky MJ, Nedelka MA, Arican ZL, Yamada Y, Cohen GN, Shippy AM, Park JJ, Zaider M. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy. Brachytherapy 2008;7(1):1-6. http://www.ncbi.nlm.nih.gov/pubmed/18299108 Kupelian PA, Potters L, Ciezki JP, Reddy CA, Reuther AM, Klein EA. Radical prostatectomy, external beam radiotherapy < 72 Gy, external radiotherapy > or = 72 Gy, permanent seed implantation or combined seeds/external beam radiotherapy for stage T1-2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58(1):25-33. http://www.ncbi.nlm.nih.gov/pubmed/14697417
Update march 2009
67
50.
Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF 3rd, Skoglund S, Galbreath RW, Merrick G. 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007;67(1):57-64. http://www.ncbi.nlm.nih.gov/pubmed/17084544 51. Phan TP, Syed AM, Puthawala A, Sharma A, Khan F. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 2007;177(1):123-7. http://www.ncbi.nlm.nih.gov/pubmed/17162020 52. Vordermark D, Wulf J, Markert K, Baier K, Kolbi O, Bekcmann G, Bratengeier K, Noe M, Schon G, Flentje M. 3-D conformal treatment of prostate cancer to 74 Gy vs high dose rate brachytherapy boost: a cross-sectional quality of life survery. Acta Oncol 2006;45(6):708-16. http://www.ncbi.nlm.nih.gov/pubmed/16938814 53. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007;84(2):114-20. http://www.ncbi.nlm.nih.gov/pubmed/17531335 54. Ataman F, Zurlo A, Artignan X, van Tienhoven G, Blank LE, Warde P, Dubois JB, Jeanneret W, Keuppens F, Bernier J, Kuten A, Collette L, Pierart M, Bolla M. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer 2004;40(11): 1674-81. http://www.ncbi.nlm.nih.gov/pubmed/15251156 55. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54(4):1063-8. http://www.ncbi.nlm.nih.gov/pubmed/12419432 56. Baxter NN, Trepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 2005;128(4):819-24. http://www.ncbi.nlm.nih.gov/pubmed/15825064 57. Liauw SL, Sylvester JE, Morris CG, Blasko JC, Grimm PD. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys 2006;66(3):669-73. http://www.ncbi.nlm.nih.gov/pubmed/16887293 58. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70(4):1124-9. http://www.ncbi.nlm.nih.gov/pubmed/18313526 59. Hanks GE. External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monogr 1988;(7):75-84. http://www.ncbi.nlm.nih.gov/pubmed/3050542 60. Kupelian PA, Katcher J, Levin HS, Klein EA. Staging T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997;37(5):1043-52. http://www.ncbi.nlm.nih.gov/pubmed/9169811 61. Bolla M, van Poppel H, Van Cangh PJ et al. Acute and late toxicity of post operative external irradiation in pT3N0 prostate cancer patients treated within EORTC trial 22911. Int J Rad Oncol Biol Phys 2002;54(Suppl.2):S62(abstract 103). 62. van Cangh PJ, Richard F, Lorge F, Castille Y, Moxhon A, Opsomer R, De Visscher L, Wese FX, Scaillet P. Adjuvant therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol 1998;159(1):164-6. http://www.ncbi.nlm.nih.gov/pubmed/9400462 63. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005;366(9485):572-8. http://www.ncbi.nlm.nih.gov/pubmed/16099293 64. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et al. Post-operative adjuvant radiotherapy in patients with pT3 prostate cancer after radical prostatectomy with postoperative undetectable PSA – a randomized controlled trial. J Clin Oncol 2008;(in press).
68
Update march 2009
65.
Swanson GP, Thompson IM, Tangen C, ParadeloJ, Cany-Hagino E, Crawford ED, Miller G, Lucia MS, Forman J, Chin J. Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. Int J Rad Oncol Biol Phys 2008;72:S31. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T7X-4T85W5M-2R&_user=10&_ coverDate=09%2F01%2F2008&_rdoc=78&_fmt=high&_orig=browse&_srch=doc-info(%23toc%23507 0%232008%23999279998.8998%23696337%23FLA%23display%23Volume)&_cdi=5070&_sort=d&_ docanchor=&_ct=1614&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1978c19de ba133909fb143c830f625f3 66. Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh A, Scrase C, Van Poppel H, Bolla M. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radition Oncology Group. Radioth Oncol 2007;84(2):121-7. http://www.ncbi.nlm.nih.gov/pubmed/17706307 67. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17(4):1155. 68. Wilder RB, Hsiang JY, Ji M, Earle JD, de Vere White R. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy. Am J Clin Oncol 2000;23(2):176-80. http://www.ncbi.nlm.nih.gov/pubmed/10776980 69. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancerspecific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760-9. http://www.ncbi.nlm.nih.gov/pubmed/18560003 70. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Standford University. NCI Monogr 1988;(7):47-60. http://www.ncbi.nlm.nih.gov/pubmed/3173503 71. Huggins C, Hodges CV. Studies on prostate cancer I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 2002;168(1):9-12. http://www.ncbi.nlm.nih.gov/pubmed/12050481 72. Leibel SA, Fuks Z, Zelefsky MJ, Whitmore WF Jr. The effects of local and regional treatments on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994;28(1):7-16. http://www.ncbi.nlm.nih.gov/pubmed/8270461 73. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumour system. Int J Radiat Oncol Biol Phys 1997;38(5):1067-70. http://www.ncbi.nlm.nih.gov/pubmed/9276373 74. Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NHA, Zagars GK, Meistrich M, Pollack A. Supraadditive apoptotic response of R3327-G rat prostate tumours to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997;38(5):1071-7. http://www.ncbi.nlm.nih.gov/pubmed/9276374 75. Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich M. Short-term neodajuvant androgen deprivation therapy and external-beam radiotherapy for localy advanced prostate cancer: long term results of RTOG 8610. J Clin Oncol 2008;26(4):585-91. http://www.ncbi.nlm.nih.gov/pubmed/18172188 76. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360(9327):103-6. http://www.ncbi.nlm.nih.gov/pubmed/12126818 77. Bolla M, Collette L, Van Tienhoven G, Warde W, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Piérart M. Ten year resulst of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy; a phase III EORTC study. Int J Radiat Oncol Biol Phys 2008;72(1 Suppl 1):S30-S31. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T7X-4T85W5M-2P&_user=10&_ coverDate=09%2F01%2F2008&_rdoc=77&_fmt=high&_orig=browse&_srch=doc-info(%23toc%23507 0%232008%23999279998.8998%23696337%23FLA%23display%23Volume)&_cdi=5070&_sort=d&_ docanchor=&_ct=1614&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=4210c0390 817dc3768d6bd16561e7d68 Update march 2009
69
78.
Pilepich MV, Winter K, Lawton C, Krisch RE, Wolkov H, Movsas B, Hug E, Asbell S, Grignon D. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Society Clin Oncol 2003;22:(abstr.1530). http://pediatricca.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnex toid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=23&abst ractID=101094 79. Warde P, Intergroup (NCIC CTG, CUOG, ECOG, CALGB, SWOG). Phase III randomized trial comparing total androgen blockade versus total androgen blockade plus pelvic irradiation in clinical stage T3-4, N0, M0 adenocarcinoma of the prostate. National Cancer Institute of Canada, Clinical Trials Group, 1995. https://www.swogstat.org/ROS/ROSBooks/Spring%202002/Intergroup/NCIC/PR3-2001.pdf 80. Mason M, Warde P, Sydes M, Cowan R, James N, Kirkbride P, Langley R, Latham J, Moynihan C, Anderson J, Millet J, Nutall J, Moffat L, Parulekar W, Parmar M; The National Cancer Institute of Canada Clinical Trials Group PR3/; Medical Research Council PR07 Trial Management Group. Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study. Clin Oncol (R Coll Radiol) 2005;17(4):217-8. http://www.ncbi.nlm.nih.gov/pubmed/15997913 81. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JÅ, Tasdemir I, Hoyer M, Wiklund F, Fosså SD for the Scandinavian Prostate Cancer Group Study, the Swedish Association for Urological Oncology. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 2008;373(9660):301-8. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61815-2/abstract 82. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group. RTOG 92-02: Phase III trial of long term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. J Clin Oncol 2003;21(21):3972-8. http://www.ncbi.nlm.nih.gov/pubmed/14581419 83. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Van der Meijden AP, Poortmans PM, Gez E, Kil P, Piérart M, Collette L. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT: Results of the randomized EORTC Phase III trial 22961. J Clin Oncol 2007;25:238s(abstr.5014). 84. Zelefsky MJ, Yamada Y, Kollmeier MA, Shippy AM, Nedelka MA. Long term outcome following threedimensional conformal/intensity modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008;53(6):1172-9. http://www.ncbi.nlm.nih.gov/pubmed/18222596 85. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on a national prospective randomized trial, RTOG 85-31. J Clin Oncol 2005;23(4):800-7. http://www.ncbi.nlm.nih.gov/pubmed/15681524
11. EXPERIMENTAL LOCAL TREATMENT OF PROSTATE CANCER 11.1
Background
Besides radical prostatectomy, external beam radiation and/or brachytherapy, cryosurgical ablation of the prostate (CSAP) and high-intensity focused ultrasound (HIFU) have emerged as alternative therapeutic options in patients with clinically localised prostate cancer (PCa) (1-4). Whereas HIFU is still considered to be an experimental treatment, CSAP has been recognised as a true therapeutic alternative as recommended by the guidelines of the American Urological Association. Both techniques have been developed as minimally invasive procedures that potentially have the same therapeutic efficacy as the established surgical and non-surgical options associated with reduced therapy-associated morbidity.
11.2
Cryosurgery of the prostate (CSAP)
Cryosurgery uses freezing techniques to induce cell death by:
70
Update march 2009
• • • •
dehydration resulting in protein denaturation direct rupture of cellular membranes by ice crystals vascular stasis and microthrombi, resulting in stagnation of the microcirculation with consecutive ischaemia apoptosis (1-4).
Freezing of the prostate is ensured by the placement of 12-15 17 G cryoneedles under transrectal ultrasound (TRUS) guidance, placement of thermosensors at the level of the external sphincter and the bladder neck, and insertion of a urethral warmer. Two freeze-thaw cycles are used under TRUS guidance, resulting in a temperature of -40 °C in the mid-gland and at the neurovascular bundle. 11.2.1 Indication for CSAP Patients who are ideal candidates for CSAP are those who have organ-confined PCa and those identified to have minimal extension beyond the prostate (1-3). The prostate should be ≤ 40 mL in size. Prostate glands that are > 40mL should be hormonally downsized in order to prevent technical difficulties in placing cryoprobes under the pubic arch. Prostate-specific antigen (PSA) serum levels should be < 20 ng/mL, and the biopsy Gleason score should be < 7. Since there are no, or only very few, data on the long-term outcome in terms of cancer control at 10 and 15 years, patients with a life expectancy > 10 years must be informed accordingly. 11.2.2 Results of modern cryosurgery for PCa When comparing treatment modalities, it is important to bear in mind that in modern radical prostatectomy series of patients with clinically organ-confined PCa, the risk of dying from PCa 10 years after surgery is as low as 2.4% (5). Therapeutic results have improved over time with enhanced techniques in terms of gas-driven probes and transperineal probe placement as used in third-generation cryosurgery (6-11). Objective assessment of PSA outcome is not easily performed because some institutions use PSA values < 0.1 ng/mL as an indicator of therapeutic success, whereas others use the American Society of Therapeutic Radiology and Oncology (ASTRO) criteria with three consecutive PSA increases. With regard to second-generation CSAP, if a PSA nadir < 0.5 ng/mL is used, biochemical-free survival at five years is 60% and 36% for low-risk and high-risk patients, respectively (6, 7). The seven-year biochemical-free survival, however, is 92% if ASTRO criteria are used. Long et al. (6) retrospectively analysed the multicentre pooled CSAP results of 975 patients who were stratified into three risk groups. Using PSA thresholds of 1.0 ng/mL and < 0.5 ng/mL at a mean follow-up of 24 months, the five-year actuarial biochemical progression-free rate was 76% and 60%, respectively, for the low-risk group, 71% and 45%, respectively, for the intermediate-risk group, and 61% and 36%, respectively, for the high-risk group. However, in a recent meta-analysis of 566 publications related to cryosurgery, it was demonstrated that no controlled trial was available for analysis, no survival data were presented, and no validated biochemical surrogate end-points were available (12). Cryosurgery showed a progression-free survival of 36-92% (projected one- to seven-year data), depending on risk groups and the definition of failure. Negative biopsies were seen in 72-87%, but no biopsy data were available for the currently used thirdgeneration cryotherapy machines. With regard to third-generation cryosurgery, clinical follow-up is short, with only 110/175 (63%) patients having a PSA follow-up at 12 months (6-11). Of these, 80 (73%) patients remain with a PSA nadir < 0.4 ng/mL, and 42/65 (76%) low-risk patients remain free from biochemical progression using the 0.4 ng/mL cut-off. A longer follow-up was reported by Bahn et al. (9) analysing the therapeutic results of 590 patients undergoing CSAP for clinically localised and locally advanced PCa. Using a PSA cut-off level of < 0.5 ng/mL, the sevenyear biochemical-free survival for low-, medium- and high-risk groups was 61%, 68% and 61%, respectively. Nerve-sparing cryosurgery, as reported recently (13), must still be considered to be an experimental therapeutic option. Nerve-sparing surgery was performed in nine patients with unilateral PCa confirmed on repeated biopsies, with CSAP being carried out on the side of the positive biopsy, whereas the negative biopsy side was spared from freezing. 11.2.3 Complications of CSAP for primary treatment of PCa Erectile dysfunction occurs in about 80% of patients and remains a consistent complication of the CSAP procedure, independent of the generation of the system used. The complication rates described with the third
Update march 2009
71
generation of cryosurgery include tissue sloughing in about 3%, incontinence in 4.4%, pelvic pain in 1.4% and urinary retention in about 2% (6-11). The development of fistula is usually rare, with < 0.2% in modern series. About 5% of all patients require transurethral resection of the prostate (TURP) for subvesical obstruction. Quality of life and sexuality following CSAP have been investigated in a clinical phase II trial recruiting 75 men (14). Quality-of-life analysis by the prostate-specific FACT-P questionnaire revealed that most subscales had returned to pre-treatment levels by 12 months after CSAP. Furthermore, no significant changes could be determined when comparing the 36-month with the 12-month data. With regard to sexuality, 37% of the men were able to have intercourse at three years after CSAP. 11.2.4 Summary of CSAP • Patients with low-risk PCa (PSA < 10 ng/mL, ≤ T2a, Gleason score ≤ 6) or intermediate-risk PCa (PSA > 10 ng/mL, or Gleason score ≥ 7, or stage ≥ 2b) represent potential candidates for CSAP. • Prostate size should be < 40 mL at the time of therapy. • Long-term results are lacking, and five-year biochemical progression-free rates are inferior to those achieved by radical prostatectomy in low-risk patients. Patients must be informed accordingly.
11.3
High-intensity focused ultrasound (HIFU)
HIFU consists of focused ultrasound waves emitted from a transducer to cause tissue damage by mechanical and thermal effects as well as by cavitation (15). The goal of HIFU is to heat malignant tissues above 65 °C in order to destroy them by coagulative necrosis. HIFU is performed under general or spinal anesthesia, with the patient in the lateral (Ablatherm®) or supine (Sonablate® 500) position; the procedure is time-consuming, with about 10 g prostate tissue being treated in one hour. In a recent review, 150 papers related to HIFU were identified and evaluated with regard to various oncological and functional outcome parameters (12). No controlled trial was available for analysis, and no survival data were presented. No validated biochemical, surrogate end-point was available for HIFU therapy. 11.3.1 Results of HIFU in PCa As with CSAP, it appears to be difficult to interpret oncological outcome in patients undergoing HIFU since various PSA thresholds are defined and no international consensus exists on objective response criteria. The results of HIFU are limited, with outcome data from fewer than 1000 PCa cases having been published in the literature. According to the recent review paper mentioned above (12), HIFU showed progression-free survival (based on PSA +/- biopsy data) of 63-87% (projected three- to five-year data), but median follow-up in the studies ranged from 12-24 months only. In one of the largest single-centre studies, 227 patients with clinically organ confined PCa were treated with HIFU and their outcome data were analysed after a mean follow-up of 27 months (range = 12-121 months) (16). The projected five-year biochemical disease-free survival was 66%, and or only 57% if patients had exhibited a pre-therapeutic PSA value of 4-10 ng/mL. Incontinence and bladder neck stricture decreased over time from 28% and 31% to 9% and 6%, respectively. In one of the studies (17), a significant decrease in pre-treatment PSA serum levels from 12 ng/mL to 2.4 ng/mL was observed. However, 50% of the 14 patients demonstrated positive prostate biopsies during follow-up. In another study (18), a complete response rate defined by PSA < 4 ng/mL and six negative biopsies was achieved in 56% of the patients. Summarising the efficacy results of a European multicentre study comprising the data of 559 patients with mainly low- and intermediate-risk PCa, Thüroff et al. (18) reported on a negative biopsy rate of 87.2% in 288 men with a follow-up of at least six months. A PSA nadir after six months follow-up could be determined in 212 patients, and it was as high as 1.8 ng/mL. However, it could be demonstrated that the PSA nadir might be reached at 12-18 months following the initial procedure. Blana et al. reported on 146 patients undergoing HIFU with a mean follow-up of 22.5 months (19). The mean PSA level at initiation of therapy was 7.6 ng/mL; the PSA nadir achieved after three months was 0.07 ng/mL. However, after 22 months the median PSA level was 0.15 ng/mL. Of the 137 men available for analysis, 93.4% demonstrated a negative control biopsy. The PSA nadir appears to be strongly associated with treatment failure (20) (p < 0.001). Patients with a PSA nadir of 0.0-0.2 ng/mL have a treatment failure rate of only 11%, compared with 46% in patients with a PSA nadir of 0.21-1.00 ng/mL, and 48% with a PSA nadir of >1.0 ng/mL. Recently, the group updated its results, with a total of 163 men treated for clinically organ-confined PCa. Within
72
Update march 2009
the 4.8 +/- 1.2 years of follow-up, the actuarial disease-free survival rate at five years was 66%, with salvage treatment initiated for 12% of the patients (21). 11.3.2 Complications of HIFU Urinary retention appears to be one of the most common side-effects of HIFU, developing in almost all patients, with the mean interval of catheterisation via a suprapubic tube varying between 12 and 35 days (1517). Grade I and II urinary stress incontinence occurs in about 12% of patients. Subsequent TURP or bladder neck incision to treat subvesical obstruction is common, and is sometimes even performed at the time of HIFU. Post-operative impotence will occur in approximately 55-70% of patients.
11.4
Radio-frequency interstitial tumour ablation (RITA)
Radio-frequency interstitial tumour ablation (RITA) is a recently developed minimally invasive therapeutic option delivering radio-frequency energy via a needle electrode placed inside the prostate and resulting in coagulative necrosis by heating the tissue up to 100 °C. Clinical application so far has been limited to two small studies demonstrating the feasibility and safety of the procedure (22, 23). However, there are reliable data with regard to oncological control of PCa.
11.5
Summary of experimental therapeutic options to treat clinically localised PCa
Recommendation GR • CSAP has evolved from an investigational therapy to a possible alternative treatment for PCa in C patients who are unfit for surgery or with a life expectancy < 10 years • All other minimally invasive treatment options – such as HIFU, RITA, microwave and electro- C surgery – are still experimental or investigational. For all of these procedures, a longer follow-up is mandatory to assess their true role in the management of PCa GR = grade of recommendation
11.6
REFERENCES
1.
Fahmy WE, Bissada NK. Cyrosurgery for prostate cancer. Arch Androl 2003;49(5):397-407. http://www.ncbi.nlm.nih.gov/pubmed/12893518 2. Rees J, Patel B, Macdonagh R, Persad R. Cryosurgery for prostate cancer. BJU Int 2004;93(6):710-4. http://www.ncbi.nlm.nih.gov/pubmed/15049977 3. Han KR, Belldegrun AS. Third–generation cryosurgery for primary and recurrent prostate cancer. BJU Int 2004;93(1):14-8. http://www.ncbi.nlm.nih.gov/pubmed/14678360 4. Beerlage HP, Thüroff S, Madersbacher S, Zlotta AR, Aus G, de Reijke TM, de la Rosette JJMCH. Current status of minimally invasive treatment options for localized prostate carcinoma. Eur Urol 2000;37(1):2-13. http://www.ncbi.nlm.nih.gov/pubmed/10671777 5. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167(2 Pt 1):528-34. http://www.ncbi.nlm.nih.gov/pubmed/11792912 6. Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr. Five-year retrospective, multiinstitutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001;57(3):518-23. http://www.ncbi.nlm.nih.gov/pubmed/11248631 7. Donelly BJ, Saliken JC, Ernst DS, Ali-Ridha N, Brasher PMA, Robinson JW, Rewcastle JC. Prospective trial of cryosurgical ablation of the prostate: five year results. Urology 2002;60(4):645-9. http://www.ncbi.nlm.nih.gov/pubmed/12385926 8. Han K, Cohen J, Miller R, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldegrun AS. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicentre experience. J Urol 2003;170(4 Pt 1):1126-30. http://www.ncbi.nlm.nih.gov/pubmed/14501706 9. Bahn DK, Lee F, Baldalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002;60(2 Suppl 1): 3-11. http://www.ncbi.nlm.nih.gov/pubmed/12206842
Update march 2009
73
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Koppie TM, Shinohara K, Grossfeld GD, Presti JC Jr, Carroll PR. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. J Urol 1999;162(2):427-32. http://www.ncbi.nlm.nih.gov/pubmed/10411051 De La Taille A, Benson MC, Bagiella E, Burchardt M, Shabsigh A, Olsson CA, Katz AE. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int 2000;85(3):281-6. http://www.ncbi.nlm.nih.gov/pubmed/10671882 Aus G. Current status of HIFU and cryotherapy in prostate cancer – a review. Eur Urol 2006;50(5): 927-34. http://www.ncbi.nlm.nih.gov/pubmed/16971038 Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal ‘nerve-sparing’ cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 2002;60(1):109-14. http://www.ncbi.nlm.nih.gov/pubmed/12100934 Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 2002;60(2 Suppl 1):12-8. http://www.ncbi.nlm.nih.gov/pubmed/12206843 Madersbacher S, Marberger M. High-energy shockwaves and extracorporeal high-intensity focused ultrasound. J Endourol 2003;17(8):667-72. http://www.ncbi.nlm.nih.gov/pubmed/14622487 Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51(2):381-7. http://www.ncbi.nlm.nih.gov/pubmed/16857310 Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 1999;161(1):156-62. http://www.ncbi.nlm.nih.gov/pubmed/10037389 Thüroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, Desgrandschamps F, de la Rosette JJMCH, Gelet A. High-intensity focused ultrasound and localized prostate cancer: efficacy from the European multicentric study. J Endourol 2003;17(8):673-7. http://www.ncbi.nlm.nih.gov/pubmed/14622488 Blana A, Walter B, Rogenhofer S, Wieland W. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004;63(2)297-300. http://www.ncbi.nlm.nih.gov/pubmed/14972475 Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006;98(3):537-9. http://www.ncbi.nlm.nih.gov/pubmed/16925749 Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, Walter B. Eight years’ experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008;72(6):1329-33. http://www.ncbi.nlm.nih.gov/pubmed/18829078 Zlotta AR, Djavan B, Matis C, Noel JC, Peny MO, Silverman DE, Marberger M, Schulman CC. Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol 1998;81(2):265-75. http://www.ncbi.nlm.nih.gov/pubmed/9488071 Djavan B, Zlotta AR, Susani M, Heinz G, Shariat S, Silverman DE, Schulman CC, Marberger M. Transperineal radiofrequency interstitial tumour ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. Urology 1997;50(6):986-92. http://www.ncbi.nlm.nih.gov/pubmed/9426739
12. HORMONAL THERAPY 12.1
Introduction
In 1941, Huggins and Hodges assessed the favourable effect of surgical castration and oestrogen administration on the progression of metastatic prostate cancer (PCa), demonstrating for the first time the responsiveness of PCa to androgen deprivation (1, 2). Since their pivotal studies, androgen-suppressing strategies have become the mainstay of the management of
74
Update march 2009
advanced PCa. Recently, however, there has been an evolution towards the use increasing use of hormonal treatment in younger men with earlier (i.e. non-metastatic) stages of disease or recurrent disease after definitive treatment, either as the primary single-agent therapy or as a part of a multimodality approach (3). Even if hormonal treatment effectively palliates the symptoms of advanced disease, there is no conclusive evidence at present that it can extend life.
12.2
Basics of hormonal control of the prostate
Prostate cells are physiologically dependent on androgens to stimulate growth, function and proliferation. Testosterone, although not tumorigenic, is essential for the growth and perpetuation of tumour cells (4). The testes are the source of most of the androgens, with only 5-10% (androstenedione, dihydroepiandrosterone and dihydroepiandrosterone sulphate) being derived from adrenal biosynthesis. Testosterone secretion is regulated by the hypothalamic-pituitary-gonadal axis. The hypothalamic luteinising hormone-releasing hormone (LHRH) stimulates the anterior pituitary gland to release luteinising hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates the Leydig cells of the testes to secrete testosterone. Within the prostate cells, testosterone is converted by the enzyme 5-∝-reductase into 5-∝-dihydrotestosterone (DHT), which is an androgenic stimulant approximately 10 times more powerful than the parent molecule (5). Circulating testosterone is peripherally aromatised and converted into oestrogens, which, together with circulating androgens, exert a negative feedback control on hypothalamic LH secretion. If prostate cells are deprived of androgenic stimulation, they undergo apoptosis (programmed cell death). Any treatment ultimately resulting in the suppression of androgen activity is referred to as androgen deprivation therapy (ADT).
12.3
Different types of hormonal therapy
Androgen deprivation can be achieved either by suppressing the secretion of testicular androgens by means of surgical or medical castration, or by inhibiting the action of the circulating androgens at the level of their receptor in prostate cells using competing compounds known as anti-androgens. Alternatively, these two modalities can be combined to achieve what is commonly known as complete (or maximal or total) androgen blockade (CAB). 12.3.1 Testosterone-lowering therapy (castration) 12.3.1.1 Bilateral orchiectomy Surgical castration is still considered the ‘gold standard’ for ADT against which all other treatments are rated. By removing the testicular source of androgens, a hypogonadal status with a considerable decline of testosterone concentrations is induced, although a very low level of testosterone (known as the ‘castration level’) persists. The standard castrate level is below 50 ng/dL. It was defined more than 40 years ago, when testosterone level testing was limited. Current methods, using chemiluminescence technology, have shown a mean value after surgical castration of 15 ng/dL (6). This observation has led to a revisiting of the current definition of castration, with some authors suggesting the use of a level below 20 ng/dL. Bilateral orchiectomy, either total or by means of a subcapsular technique (i.e. with preservation of tunica albuginea and epididymis), is a simple and virtually complication-free surgical procedure that can easily be performed under local anaesthesia (7). It is the quickest way to achieve a castration level, which is usually obtained in less than 12 hours. The main drawback of orchiectomy is that it may have a negative psychological effect: some men consider it to be an unacceptable assault on their manhood. In addition, it is irreversible and does not allow for intermittent treatment. The use of bilateral orchiectomy has declined recently, which can be attributed to the effects of stage migration towards earlier disease, and the introduction of equally effective pharmacological modalities of castration (8). 12.3.1.2 Oestrogens There are several mechanisms of action: • down-regulation of LHRH secretion • androgen inactivation
Update march 2009
75
• •
direct suppression of Leydig cell function direct cytotoxicity to the prostate epithelium (in vitro evidence only) (9).
The most commonly used oestrogen is diethylstilboestrol (DES). Early studies by the Veterans Administration Co-operative Urological Research Group (VACURG) (10) tested oral DES at a dosage of 5 mg/day. However, the treatment was associated with high cardiovascular morbidity and mortality due to first-pass hepatic metabolism and the formation of thrombogenic metabolites. Accordingly, subsequent studies (11) tested lower oral dosages, namely 3 mg and 1 mg. Both regimens provided a therapeutic efficacy comparable to that of bilateral orchiectomy, but the former was still associated with high cardiotoxicity. Although a 1 mg dose was associated with substantially fewer adverse cardiovascular events than the 5 mg dosage, the side-effects were still significantly greater than with castration. Because of these concerns, and the advent of LHRH agonists and anti-androgens, the use of DES had fallen out of favour until recently. There are three main reasons for the renewed interest in oestrogens. • First, as a response to the number of deleterious side-effects and high cost of long-term ADT with the widespread use of LHRH agonists: oestrogens suppress testosterone levels and do not seem to lead to bone loss and cognitive decline (12) (level of evidence: 3). • Second, in phase II trials with patients diagnosed with hormone-refractory prostate cancer (HRPC), oestrogenic compounds (DES, DES-diphosphate) have been shown to induce prostate-specific antigen (PSA) response rates as high as 86%. • Third, a new oestrogen receptor-β (ER-β), possibly involved in prostate tumorigenesis, has been discovered (9). Two different strategies have been used to try to neutralise the cardiotoxicity that is the main drawback of oestrogen therapy. These strategies use the parenteral route of administration, which avoids first-pass hepatic metabolism, plus the addition of cardiovascular protecting agents. The final analysis of the Scandinavian Prostatic Cancer Group Study 5, a prospective randomised trial of more than 900 men with metastatic PCa that compared a parenteral oestrogen (polyoestradiol phosphate) with CAB (orchiectomy or LHRH agonist plus flutamide), showed neither a significant difference in disease-specific and overall survival between the treatment arms, nor a significant increase in cardiovascular mortality in the oestrogen arm, although the occurrence of non-fatal adverse cardiovascular events was significantly higher in this group (increase in ischaemic heart and heart decompensation events) (13, for update see 14). On the other hand, three recent, though small, phase II trials of patients with advanced PCa or HRPC evaluated the combination of DES (1 mg/day or 3 mg/day), with either low dose (1 mg/day) warfarin sodium or low dose (75-100 mg/day) aspirin for the prevention of cardiovascular toxicity, and found a persistent rate of thromboembolic complications (15-17). In conclusion, DES is one of the classic forms of hormonal therapy. Although its efficacy was demonstrated many years ago and recently reconfirmed in a meta-analysis as comparable to that of bilateral orchiectomy (18) (level of evidence: 1a), the significant cardiovascular side-effects, even at lower dosages, remain a concern. Further data are needed before oestrogens will be readmitted into clinical practice as a standard first-line treatment option. 12.3.1.3 LHRH agonists Long-acting LHRH agonists (buserelin, goserelin, leuprorelin and triptorelin) have been used in advanced PCa for more than 15 years and are currently the predominant forms of ADT (3, 19). They are synthetic analogues of LHRH, generally delivered as depot injections on a one-, two-, three-, or six-monthly basis, that interfere with the hypothalamic-pituitary-gonadal axis. They initially stimulate pituitary LHRH receptors, inducing a transient rise in LH and FSH release, and consequently elevate testosterone production (known as ‘testosterone surge’ or ‘flare up’ phenomenon), which begins within approximately two or three days of the first injection and lasts through approximately the first week of therapy (20). Chronic exposure to LHRH agonists eventually results in down-regulation of LHRH-receptors, with subsequent suppression of pituitary LH and FSH secretion and testosterone production. The level of testosterone decreases to castration levels usually within two to four weeks (21, 22). However, approximately 10% of patients treated with LHRH agonists fail to achieve castration levels (23), or up to 15% if the threshold is defined as 20 ng/dL.
76
Update march 2009
In a recent meta-analysis evaluating single-therapy ADT for advanced PCa, LHRH agonists were shown to have comparable efficacy to orchiectomy and DES (18) (level of evidence: 1a). This observation questions the clinical impact of changing the castrate testosterone level definition from 50 ng/dL to 20 ng/dL. In addition, although only based on an indirect comparison, all seemed equally effective whatever their formulation (18) (level of evidence: 3). Today, LHRH agonists have become the ‘standard of care’ in hormonal therapy because they avoid the physical and psychological discomfort associated with orchiectomy, and lack the potential cardiotoxicity associated with DES. However, the main concerns associated with the administration of LHRH agonists are the potentially detrimental effects associated with the ‘flare phenomenon’ in advanced disease, namely increased bone pain, acute bladder outlet obstruction, obstructive renal failure, spinal cord compression, and fatal cardiovascular events due to hypercoagulation status. A recent review (24) addressing these issues concluded that clinical flare needs to be distinguished from the more common biochemical flare (i.e. increasing levels of PSA), and even from asymptomatic radiographic evidence of progression, and that patients at risk for clinical flare are overwhelmingly those with high volume, symptomatic, bony disease, accounting for only 4-10% of M1 patients. Concomitant therapy with an anti-androgens definitely decreases the incidence of clinical relapse, but it does not completely remove the possibility of its occurrence. Based on pharmacokinetic considerations, it is recommended that administration of anti-androgens should be started on the same day as the depot injection, and treatment should be continued for a two-week period. However, for patients with impending spinal cord compression, alternative strategies for immediately ablating testosterone levels must be considered, such as bilateral orchiectomy or LHRH-antagonists. Apart from those patients, the clinical impact of the flare up observation is unknown. Finally, some mini-flares have also been observed with the long-term use of analogues, with an unknown clinical impact. 12.3.1.4 LHRH antagonists In contrast to the agonists, LHRH antagonists bind immediately and competitively to LHRH receptors in the pituitary gland. The effect is a rapid decrease in LH, FSH and testosterone levels without any flare. This seemingly more desirable mechanism of action has made LHRH antagonists very attractive since their introduction, but practical shortcomings have limited clinical studies. Indeed, many of these compounds have been associated with serious and life-threatening histamine-mediated side-effects and, until recently, no depot formulation was available. Two recently published phase III randomised multicentre trials comparing the LHRH antagonist abarelix with the LHRH agonist leuprorelin acetate (25) and with CAB (26) in patients with metastatic or recurrent PCa showed no difference in achieving and maintaining castration levels of testosterone and in reducing serum PSA. The biochemical ‘flare up’ phenomenon was not reported in the abarelix arms, and the overall incidence of severe adverse events (including allergic reactions) was similar across all treatment groups. Data on survival end-points and long-term safety are not yet available. Abarelix has recently been licensed for clinical use by the US Food and Drug Administration, but its use is restricted to those patients with metastatic and symptomatic PCa for whom no other treatment option is available (27). Recently, another antagonist, called degarelix, has been presented with preliminary promising results. In a phase II dose-finding study of 187 men, most patients had a testosterone level below 0.5 ng/mL at day 3, with a sustained effect at one year and no testosterone surge. The median testosterone value at one year for the 78.6% of patients with a level below 0.5 ng/mL was 0.12 ng/mL. No patient reported any systemic allergic reaction (28). Overall, even if this new family appears appealing, its real advantages over LHRH agonists are far from being proven. So far its use is limited by a monthly formulation, compared with three-month and six-month depot formulations. The clinical advantage of the suppression of the initial flare up is only clinically relevant in a minority of metastatic patients, and finally antagonists must confirm their efficacy in the long-term, most available trials being limited to a one-year follow-up period.
Update march 2009
77
12.3.2 Anti-androgens Anti-androgens compete with testosterone and DHT for binding sites on their receptors in the prostate cell nucleus, thus promoting apoptosis and inhibiting PCa growth (29). These orally administered compounds are classified according to their chemical structure as steroidal (e.g. cyproterone acetate [CPA], megestrol acetate and medroxyprogesterone acetate) and non-steroidal or pure (e.g. nilutamide, flutamide and bicalutamide). Both classes compete with androgens at the receptor level, but while this is the sole action of non-steroidal anti-androgens, steroidal anti-androgens additionally have progestational properties with central inhibition of the pituitary gland. As a consequence, non-steroidal anti-androgens do not lower testosterone levels, which remain normal or, conversely, slightly elevated. 12.3.2.1 Steroidal anti-androgens These compounds are synthetic derivatives of hydroxyprogesterone. In addition to peripherally blocking androgen receptors, they have progestational properties and inhibit gonadotrophin (LH and FSH) release and suppress adrenal activity. At high doses, megestrol acetate is cytotoxic. Since steroidal anti-androgens lower testosterone levels, the main pharmacological side-effects are loss of libido and erectile dysfunction; gynaecomastia is quite rare. The non-pharmacological side-effects are cardiovascular toxicity (4-40% for CPA) and hepatotoxicity. Cyproterone acetate (CPA) CPA was the first anti-androgen to be licensed. It is the most widely used drug, but the less studied one, leaving most questions unanswered (such as the optimal dose), or unclear (e.g. comparison with standard forms of castration – surgical or with an agonist). There is only one randomised trial (30) comparing CPA with standard hormonal therapy (i.e. medical castration). Patients in arm A (no contraindications to DES) were randomly assigned to CPA, goserelin or DES, while patients in arm B (contraindications to DES) were assigned to CPA or goserelin. In arm A, treatment with CPA was associated with significantly poorer median overall survival (OS) than goserelin only; adjusting for baseline characteristics did not account for this difference. Two other studies on CPA monotherapy have been performed, but one did not report survival data (31), and the other used a non-standard treatment combination (DES and medroxyprogesterone acetate [32]). It is therefore difficult to draw any definite conclusions from these data about the relative efficacy of CPA and castration. As no dose-finding studies of CPA monotherapy have been conducted, the most effective dose is still unknown. Although CPA has a relatively long half-life (30-40 hours), it is usually administered in two or three fractionated doses of 100 mg each (33). The only comparative study on anti-androgens as monotherapy was recently published by the European Organisation for Research and Treatment of Cancer (EORTC). The final analysis of Protocol 30892 (a randomised trial of 310 patients comparing CPA with flutamide in metastatic PCa), showed no difference in cancer-specific survival (CSS) and OS at a median follow-up of 8.6 years, although the study was underpowered (34) (level of evidence: 1b). Megestrol acetate and medroxyprogesterone acetate Very limited information is available on these two compounds. Early studies with megestrol acetate demonstrated a symptomatic and partially beneficial clinical response, both in previously untreated metastatic PCa (35-37) and, to a lesser extent, in HRPC (38). No apparent dose response correlation was shown to exist in a recent trial (39). The overall poor efficacy precluded megestrol acetate and medroxyprogesterone acetate from being recommended as a primary or second-line hormonal therapy option. The only prospective randomised trial evaluating medroxyprogesterone acetate as primary therapy in advanced (M0-1) PCa is the EORTC 30761 study mentioned above (31), in which 236 patients were assigned to receive CPA, DES or medroxyprogesterone acetate. While no difference in CSS and OS was evident between CPA and DES, treatment with medroxyprogesterone acetate had a less favourable course with a shorter survival time and time to progression than either of the other two drugs tested. 12.3.2.2 Non-steroidal anti-androgens Non-steroidal anti-androgens have been promoted in monotherapy for quality of life (QoL) and compliance benefits over castration: since they do not suppress testosterone secretion, it is claimed that libido, overall physical performance and bone mineral density are preserved (40).
78
Update march 2009
Although no direct comparisons have been undertaken in a monotherapy setting, the three available drugs do not appear to differ in the severity of pharmacological side-effects, namely gynaecomastia, breast pain and hot flashes. However, there are differences in the non-pharmacological side-effects, with bicalutamide showing a more favourable safety and tolerability profile than nilutamide and flutamide (41). They all share a common liver toxicity, and liver enzymes must be checked on a regular basis when they are used. Nilutamide There are no comparative trials on nilutamide monotherapy with castration or with other anti-androgens (42). Only one non-comparative study has been carried out, including 26 patients with M1 PCa who received nilutamide 100 mg three times daily. The results showed that as few as 38.5% of patients experienced an objective response; the median progression-free survival (PFS) time was nine months and the median OS was 23 months (43). One large randomised controlled trial of 457 patients with M1, which compared orchiectomy plus nilutamide, 300 mg/day, with orchiectomy plus placebo, showed a significant benefit in CSS and OS for the combined therapy (44). Recently, nilutamide has been tested as a second-line hormonal therapy in HRPC with encouraging results (45, 46). Non-pharmacological side-effects are visual disturbances (i.e. delayed adaptation to darkness), alcohol intolerance, nausea, hepatotoxicity, and interstitial pneumonitis. The latter, even if exceptional, is potentially life-threatening and is specific to this drug. Nilutamide is not licensed for monotherapy. Flutamide Flutamide was the first non-steroidal anti-androgen available for clinical use, and has been studied as monotherapy for more than 20 years, but no dose-finding studies against a currently accepted end-point (e.g. PSA response) have been published. Flutamide is a pro-drug, and the half-life of the active metabolite is five to six hours, so it must be administered three times per day in order to maintain therapeutic serum levels. The recommended daily dosage is 750 mg (33). Early phase II trials demonstrated flutamide to be effective in the treatment of advanced PCa, albeit that the reported response rates cannot be correlated with currently recommended end-points. The main advantage shown in these studies was the preservation of sexual function, which was maintained in up to 80% of patients with no pre-treatment erectile dysfunction (47-50). This rate has not been confirmed in the above mentioned EORTC trial 30892 (34), in which as few as 20% of men treated with flutamide maintained sexual activity for up to seven years. Although several phase III studies have been conducted, the results are often difficult to evaluate because of several drawbacks, such as the use of non-standard combinations, short-term follow-up and underpowering. Of these studies, only two phase III randomised trials comparing flutamide monotherapy with standard therapy (orchiectomy [51] and CAB [52]) for advanced PCa have reported survival data; both showed no significant difference in OS for flutamide or castration for patients with a PSA < 100 ng/mL (52). At higher PSA, flutamide was inferior. Both trials were underpowered, however. Results are eagerly awaited from an ongoing Swedish study in which 700 patients with M1 PCa have been randomised to flutamide 250 mg three times daily or CAB (40). The non-pharmacological side-effects are diarrhoea and hepatotoxicity (occasionally fatal). Bicalutamide Early reports with bicalutamide monotherapy related only to the 50 mg dosage, which was that licensed for use in CAB. An overall analysis of these studies showed that, although bicalutamide 50 mg/day had clinical benefits, it was inferior to castration in terms of OS (median difference 97 days) (53). Subsequent dose-ranging studies established that bicalutamide 150 mg once daily achieved a PSA response similar to that seen with castration while maintaining a good tolerability profile (54). Accordingly, the 150 mg dosage was chosen for further evaluation as both primary and adjuvant monotherapy. As primary monotherapy, bicalutamide 150 mg/day has been compared with medical or surgical castration in two large prospective randomised trials with identical study designs, including a total of 1435 patients with locally advanced M0 or M1 PCa (55). A pooled analysis showed: • In M1 patients, an improvement in OS with castration, although the difference in median survival between the groups was only six weeks (55); a further post hoc analysis showed a survival benefit only for patients with higher PSA levels (> 400 ng/mL) at study entry (56).
Update march 2009
79
•
In M0 patients (N = 480), no significant difference was noted in OS (57) based on the Kaplan Meier test, with median survival being 63.5 months in the bicalutamide arm compared with 69.9 months in the castration one.
In two smaller randomised trials, high-dose bicalutamide was compared with CAB. In the first trial (251 patients with predominantly M1 stage), no difference in OS was apparent (58). In the second trial (220 patients with M0 and M1 stage), there was no difference in OS for well or moderately well differentiated tumours (59) (level of evidence: 1b), but both studies were underpowered, and the first one has not yet been fully published. As for the adjuvant setting, the ongoing Early Prostate Cancer Programme (EPCP), a study comprising three different clinical trials of similar design and including 8113 patients worldwide, was designated to evaluate the efficacy and tolerability of high-dose (150 mg/day) bicalutamide vs placebo given in addition to standard primary care (i.e. radical prostatectomy, radiotherapy and watchful waiting) in localised (T1-2, N0-X) or locally advanced (T3-4, any N, or any T N+) PCa. The first combined analysis of the programme showed that, after a median follow-up of three years, adjuvant bicalutamide provided a reduction of 42% in the risk of objective disease progression compared with standard care alone (60). After a median follow-up of 5.4 years, the positive effects of bicalutamide were obvious in patients with locally advanced disease (stage M0), but patients with localised disease given bicalutamide appeared to have a reduced survival compared with those given placebo (61). However, results obtained after a median follow-up of 7.4 years showed there was no benefit to PFS from the addition of bicalutamide to standard care in localised PCa, and identified a trend (hazard ratio [HR] 1.16, 95% CI 0.99-1.37, p = 0.07) towards decreased survival in patients otherwise undergoing watchful waiting (WW). However, in locally advanced disease, bicalutamide significantly improved PFS, irrespective of standard care. The same overall results were observed in the most recent arm 24 analysis (62). Bicalutamide significantly improved OS in patients receiving radiotherapy (HR 0.65, 95% CI 0.44-0.95, p = 0.03), which was driven by a lower risk of PCa-related deaths. Bicalutamide produced a trend towards improved OS in patients with locally advanced disease otherwise undergoing WW (HR 0.81, 95% CI 0.66-1.01, p = 0.06). No survival difference was evident in the prostatectomy subgroup (61). Even though the EPCP is a combination of three trials and among the largest ever conducted in prostate cancer patients, clear conclusions are difficult to present as many problems are apparent with these protocols (63). For example, three trials were grouped for analysis, but they are different in terms of patients (80% prostatectomy in trial 23 compared with 13% in trial 25). The treatment duration was two years in trial 23, but prolonged until progression in trials 24 and 25. The OS benefit claimed with radiotherapy is mainly driven by a respiratory or cardiovascular improvement, and not by a CSS benefit, which is different from other trials with LHRH agonists (64). Furthermore, the trials are underpowered for locally advanced patients, compared with oriented trials such as the Bolla (65) or Pilepich (66) trials. Finally, direct protocol analysis reveals quite different results, such as those from the EPCP 23 (80% prostatectomy, 19% radiotherapy) (67). At a median 7.7 years of follow-up, no PFS benefit was observed (HR 1.00; CI 0.84, 1.19, p = 0.991). Likewise, OS did not differ. Even after stratifying for disease stage, no PFS benefit was apparent. No QoL benefit has been demonstrated, as is claimed, as the EPCP trial did not use a QoL questionnaire. The only QoL data come from a specific questionnaire and a limited population. The observed benefit was only significant for physical capacity and sexual interest (not function!). For all other items considered (emotional well-being, vitality, social function, pain, activity limitation and bed disability), there was no difference compared with castration (68). The breast problems related to bicalutamide must also be discussed, as they might lead to a 16.4% treatment cessation (69). The clear trend (even if not statistically significant) suggesting a decreased OS in localised disease treated with WW is a clear argument against its use in such situations (61). The mechanisms remain unclear. Many questions are still debatable with this drug, such as the practical management after progression under bicalutamide, as no data are available. In conclusion, high-dose bicalutamide has emerged as an alternative to castration for patients with locally advanced (M0) if PFS is the target, and in highly selected, well-informed cases of M1 PCa with a low PSA, but should be avoided in patients with localised PCa. The QoL benefit over castration that was expected is, however, far from being proven. The survival benefit observed with an adjuvant use after radiotherapy in locally
80
Update march 2009
advanced situations must be considered with caution, as these three trials are far from having the power of any trial conducted with LHRH agonists. Non-pharmacological side-effects are mainly gynaecomastia (70%) and breast pain (68%). These might be prevented by anti-oestrogens (70, 71), prophylactic radiotherapy (72), or treatment with surgical mastectomy or radiotherapy (73). 12.3.3 Combination therapies 12.3.3.1 Complete androgen blockade Although serum testosterone levels are reduced by up to 95% by castration, the intraprostatic androgen stimulus is sustained by the conversion of circulating androgens of adrenal origin into DHT within the prostate cells. The action of these adrenal androgens is blocked by the addition of an anti-androgen to either surgical or pharmacological castration, a concept known as complete (or maximal or total) androgen blockade (CAB). A plethora of studies evaluating CAB over monotherapy have been carried out with contrasting results. From the most recent systematic reviews and meta-analyses it appears that at a follow-up of five years, CAB provides a small survival advantage (less than 5%) when compared with monotherapy (74-78, level of evidence: 1a), although some of the largest trials included are methodologically flawed (79). It remains debatable whether this small advantage, if any, can be meaningful when applied to everyday clinical practice. The benefit seems to be limited to patients taking non-steroidal anti-androgens and to appear only after five years of follow-up. Gastrointestinal, ophthalmological, and haematological side-effects are worse with combined androgen blockade. LHRH analogues and non-steroidal anti-androgens have the highest estimated quality-adjusted survival, but have an incremental cost of more than US$1 million per quality-adjusted live-year over orchiectomy alone. 12.3.3.2 Minimal androgen blockade (or peripheral androgen blockade) This derives from the combination of finasteride and a non-steroidal anti-androgen. The rationale behind the combination is that finasteride reduces intraprostatic levels of DHT by inhibiting 5-∝-reductase, while antiandrogen competes with the binding of the residual DHT to its receptor. The result is that testosterone levels are maintained within normal ranges to ensure acceptable sexual function and a reasonable QoL. In several phase II trials (80-84), the association of finasteride and flutamide, either in a concomitant or sequential regimen, has been evaluated in terms of PSA response rate in patients with advanced or biochemically recurrent PCa. Notwithstanding the small sample and short follow-up, nearly all patients experienced a substantial decline in PSA (by up to 96% compared with the level at entry). An update of one of these studies, at a long-term follow-up, reported on stronger end-points, such as castration-free survival (median: 37 months), androgen-independent PCa-free survival (median: 48.6 months) and OS rate (65% at five years). It was concluded that combination therapy can induce an overall period of hormone responsive disease exceeding four years (85). In all these trials, sexual function was reported to be preserved in between 55% and 86% of the men studied. The preliminary data make this treatment option most attractive in the management of patients for whom QoL is the primary issue. However, while awaiting the results of follow-up and larger controlled trials, this treatment is still regarded as investigational. 12.3.3.3 Intermittent vs continuous androgen deprivation therapy For reasons that as yet remain unclear, long-term CAB, which stimulates prostate cell apoptosis, fails to eliminate the entire malignant cell population, so that after a variable period (averaging 24 months) the tumour inevitably relapses, being characterised by an androgen-independent state of growth. Experimental data indicate that androgen-independent progression may begin early after the administration of hormonal therapy, coinciding with the cessation of androgen-induced differentiation of stem cells (86). It is therefore theoretically possible that if androgen deprivation is stopped prior to the progression of androgen-independent cells, any subsequent tumour growth would then be solely sustained by the proliferation of androgen-dependent stem cells, which should be susceptible once again to androgen withdrawal. In this way, cyclical ADT would delay the emergence of the androgen-independent clone. Thus, intermittent ADT may result in two other benefits: namely the preservation of QoL in the off-therapy periods and the reduction of cost. Several phase II trials have demonstrated the feasibility of intermittent androgen blockade (IAB) in metastatic
Update march 2009
81
or biochemically recurrent disease, with PSA response rates and symptom improvement similar to that of CAB, but phase III prospective, randomised controlled trials are still underway, and data on survival endpoints and QoL are not mature (87). Preliminary results of clinical phase III trials have demonstrated not significantly different efficacy for intermittent vs continuous ADT in men with PSA progression following radical prostatectomy and in advanced metastatic PCa (88-90). The South West Oncology Group (SWOG) trial 9346 randomised 1134 men with stage D2 PCa to intermittent and continuous ADT after seven months’ induction ADT with PSA reduction < 4 ng/mL. No significant differences with regard to survival in a very preliminary analysis were identified between treatment groups (88). A PSA reduction to < 0.2 ng/mL, < 4 ng/mL and > 4 ng/mL was identified as a significant prognostic factor with regard to survival, achieving 13 months, 44 months and 75 months, respectively. In some other trials, 75 patients were considered for IAD if they had achieved PSA serum levels < 4 ng/mL or at least 90% reduction of pre-treatment levels after 9 months of ADT (89). Patients went on when PSA values rose > 20 ng/mL at which the 9-month cycle of ADT was repeated. 86% of the men are alive at a median of 134 months, with a median survival of 95 months from the initial ADT cycle. A 100% and 70% survival at 5 years was calculated for those presenting with locally advanced disease and metastases at initial presentation, respectively. A prospective randomised multicentre trial including 68 patients with a mean follow-up of 31 months have been reported (90). In the intermittent androgen deprivation (IAD) group, the median cycle length was 9.5 months and the median percentage of time off therapy was 59.5%. The median three-year progression rate was significantly lower in the IAD group (7%) than in the CAD group (38.9%), suggesting that IAD maintains the androgen-dependent state of advanced PCa at least as long as does CAD. Another trial came to the same conclusions, but, once again this presented-only German study was underpowered and had too short a followup (91). The most recent and convincing data were presented during the 2007 American Society of Clinical Oncology (ASCO) meeting (92). In a prospective trial including 478 patients with M1 (40%) or N+ (N1 to 3) disease, 335 were randomised after six months of maximal androgen blockade if the PSA was below 4 ng/mL or if a decrease of more than 90% was observed. The mean initial PSA was 158 ng/mL in the intermittent arm, and 139 ng/mL in the continuous arm, respectively. In the intermittent arm, the treatment was resumed if the PSA was above 10 ng/mL and stopped when it went below 4 ng/mL. The main question was PFS. After a median follow up of 50.5 months, no significant difference was observed in the median PFS (16.6 months in the intermittent arm compared with 11.5 months in the continuous arm [p = 0.17], neither in the entire population nor in the N+ or M1 populations. In the IAD arm, 88% of patients were off treatment for more than 50% of the time, and normalised their testosterone in a mean of 70 days after stopping treatment. Recently a published randomised trial suggested a different IAD regimen, with fixed six-month periods of treatment (CAB) and surveillance (93). The PSA was not used to direct the treatment in this heterogeneous population (N = 129). After a mean of 44.8 months of follow up, no difference was observed in either OS, CSS or PFS. The QoL was also no different between the two groups, except that painkillers were required more often in the IAD arm, and the ability to get and maintain an erection was better in the IAD arm. IAD has not been shown to be associated with prolonged hormone-sensitive status. This treatment modality is well accepted by patients and increases their QoL during the periods without treatment, although still to a questionable level (94-96), and testosterone levels recover in most studies (97, 98), leading to an intermittent castration (not just an intermittent treatment delivery). Other benefits, such as a reduction in impact on the bones (99) or sexual activity (96), are also suspected. It must be acknowledged that, so far, IAD raises more questions than it has precise answers for, especially with regard to defining the best candidates, (100, 101). In addition, the threshold at which the ADT must be stopped or resumed are empirical (100). Nevertheless, several points are clear (102): • IAD is based on intermittent castration, and therefore only drugs leading to castration should be considered. • It is unclear if an LHRH agonist may be used alone, as the published experiences are based on CAB. • The initial (induction) cycle must last between six and nine months, otherwise testosterone recovery is unlikely. • The treatment is stopped only if patients have fulfilled all the following criteria: - well informed and compliant patient - no clinical progression
82
Update march 2009
•
•
• •
- a clear PSA response, empirically defined as a PSA below 4 ng/mL in metastatic patients, or 0.5 ng/mL in relapsing patients. A strict follow-up must then be applied, with clinical examination every three to six months (the more advanced the disease, the closer the follow-up), with PSA measurements at the same time and always performed in the same laboratory. The treatment is resumed when the patient reaches either a clinical progression, or a PSA value above a predetermined empirically fixed threshold (usually 4 ng/mL in non-metastatic situations, or 10-15 ng/mL in metastatic patients). The same treatment is used for at least three to six months. The next cycles are based on the same rules until the first sign of hormone refractory status.
In conclusion, IAD is currently widely offered to patients with PCa in various clinical settings, and its status should no longer be regarded as investigational (level of evidence: 2). 12.3.3.4 Immediate vs deferred ADT The most appropriate time to introduce hormonal therapy in patients with advanced PCa is still controversial, particularly whether ADT for locally advanced and asymptomatic metastatic disease delivered immediately at diagnosis favourably influences survival and QoL compared with ADT deferred while signs and symptoms of clinical progression remain a matter of debate. This point was partially discussed in section 8.3. The dispute derives from the lack of properly conducted, randomised, controlled trials, with many being methodologically flawed because of small size and underpowering, and the heterogeneity of patient enrolment with advanced PCa (i.e. locally advanced, nodal and metastatic stages of disease), as well as variability in the hormone treatments administered and of follow-up schedules and modalities used. Bearing these limitations in mind, evidence on immediate vs deferred ADT is provided by three systematic reviews of the literature (one of which is a meta-analysis). A report by the Agency for Health Care Policy and Research indicated that a possible survival advantage for early ADT existed in single studies where hormone treatment was the primary therapy, while the combined analysis showed no significant benefit. Furthermore, androgen suppression was shown to be the most cost-effective if initiated after patients had experienced symptoms from metastatic disease (74, 103). The Cochrane Library review extracted four good quality randomised controlled trials (namely VACURG I and II studies [10, 11], the MRC trial (104) and the Eastern Cooperative Oncology Group [ECOG] 7887 study [105]), which were all conducted in the pre-PSA era and included patients with advanced PCa who received early vs deferred ADT as primary therapy or adjuvant to radical prostatectomy, but not to radiotherapy. According to the analysis, early androgen suppression significantly reduces disease progression and complication rates due to the progression itself, but does not improve CSS, and provides a relatively small benefit in OS, with an absolute risk reduction of 5.5%, which does not become evident until after 10 years (106). Since 2002, the level 1 evidence suggesting immediate ADT in every pN+ patient after a prostatectomy has been questioned for several reasons. Some were discussed earlier (see section 9.7) such as the impact of a micronodal metastasis in a single node (107), which is far from being equivalent to a massive nodal involvement, as present in the Messing trial. Recently, the analysis of 719 patients from the SEER (Surveillance, Epidemiology and End Results, part of the US National Cancer Institute) database questioned the real impact of immediate ADT in pN+ patients after a radical prostatectomy (108). In the PSA era, the EORTC 30891 (109) gave the same results, namely a small benefit in OS, but no CSS benefit. Furthermore, only young patients with a high PSA might clearly benefit. Based on a systematic review of the literature, the recently published ASCO guidelines on initial hormonal treatment for androgen-sensitive metastatic, recurrent or progressive PCa concluded that no recommendation on when to start hormonal therapy in advanced asymptomatic PCa can be made until data from studies using modern diagnostic and biochemical tests and standardised follow-up schedules become available (110). Based on the meta-analysis, published treatment was most cost-effective when started after the onset of symptoms. Based on exploratory analysis, treatment with anti-androgen monotherapy does not lead to a survival benefit in men with localised PCa managed with non-definitive therapy, and the impact is still questionable after external beam therapy. This was explored in detail in section 12.3.2.2 with regard to the EPCP trials.
Update march 2009
83
For asymptomatic patients with locally or regionally advanced PCa who undergo radiotherapy, there is good evidence from several randomised controlled trials that concomitant and/or adjuvant hormonal therapy provides longer time-to-disease progression and/or longer OS than radiotherapy alone followed by androgen suppression at progression (111-114) (level of evidence: 1b).
12.4
Indications for hormonal therapy
Table 16 lists the indications for hormonal therapy. Table 16: Indications for hormonal therapy Hormonal therapy Indications for castration M1 symptomatic
M1 asymptomatic
N+
Locally advanced M0 Locally advanced symptomatic Locally advanced treated with radiotherapy
Locally advanced asymptomatic unfit for local definitive treatment Anti-androgens Short-term administration
Non-steroidal anti-androgen monotherapy
Benefits
LE
• To palliate symptoms and to reduce the risk for potentially catastrophic sequelae of advanced disease (spinal cord compression, pathological fractures, ureteral obstruction, extraskeletal metastasis) • Even without controlled randomised trail, this is the standard of care and must be applied and considered as level 1 evidence • Immediate castration to defer progression to a symptomatic stage and prevent serious disease progression-related complications (104) • An active clinical surveillance protocol might be an acceptable option in clearly informed patients if survival is the main objective • Immediate castration to prolong PFS and even OS (105) • Might be questioned in single micrometastasis after extended lymph node dissection and radical prostatectomy (115) • Immediate castration to improve cancer-free survival • (116) • High risk d’Amico: combined and prolonged ADT • Intermediate risk d’Amico: • if low dose (< 75 Gy) radiotherapy: six months of ADT • if high dose (> 75 Gy) radiotherapy: ADT questionable • Limited OS improvement not related to a CSS benefit (109)
1
1
1b
3
1b 3
1b 4 1 1b 2 1
• To reduce the risk of the ‘flare up’ phenomenon in patients 1b with advanced metastatic disease who are to receive an LHRH agonist (117, 118) 2 • Primary monotherapy as an alternative to castration in patients with locally advanced PCa (T3-4, any N, or any T N+) (57) (level of evidence: 2) • No place in localised disease as single treatment modality • Combined with radiotherapy: no clear recommendation is possible at the present time • Combined with radical prostatectomy: no place so far in an adjuvant setting
LE = level of evidence
12.5
Contraindications for various therapies (Table 17)
Table 17 lists the contraindications for various therapies. Table 17: Contraindications for various therapies Therapy Bilateral orchiectomy
84
Contraindications • Psychological reluctance to undergo surgical castration
Update march 2009
Oestrogens LHRH agonists alone Anti-androgens
12.6
• Known cardiovascular disease • Patients with metastatic disease at high risk for clinical ‘flare up’ phenomenon • Localised PCa as primary therapy • Known hepatic dysfunction
Outcome
Outcome depends on the stage and grade of disease at diagnosis. In M1 cases, the median OS ranges between 28 and 53 months (74); only 7% of patients with metastatic cancer treated with hormonal therapy are reported to live 10 years or more (119). Survival is likely to depend on the PSA level at diagnosis, the Gleason score, the volume of metastatic disease, and the presence of bony symptoms. In locally advanced M0 patients, the median OS is frequently reported to exceed 10 years (75).
12.7
Side-effects, QoL and cost of hormonal therapy
Many patients with PCa for whom long-term ADT is indicated are still young and physically and sexually active, so QoL is an issue of paramount importance when considering the various hormonal treatment options. In view of this, in selected patients, monotherapy with a non-steroidal anti-androgen (e.g. bicalutamide) is gaining increasing popularity because of its ability to maintain normal (or even higher) serum testosterone levels and its good tolerability profile. 12.7.1 Side-effects The many deleterious side-effects of long-term ADT have been well known for years. Some of these can have a detrimental effect on QoL, especially in young men, while others may contribute to an increased risk of serious health concerns associated with age. Loss of libido and erectile dysfunction are well known side-effects. The management of erectile dysfunction is not specific. Hot flashes are probably the most common side-effect of ADT. They appear three months after starting the treatment, persist in the long term in most patients, and have a significant impact on the QoL (120). Treatment modalities include hormonal therapy and antidepressants. Oestrogen receptor modulators or lowdose oestrogen therapies (0.5-1 mg/day), such as diethylstilboestrol, reduce their frequency and severity, but both are associated with a risk of cardiovascular complications (121). Soya phytoestrogens have shown efficacy for hot flushes in breast cancer patients (122), but have not yet been evaluated in men. Progesterone-based treatments, such as megestrol acetate, medroxyprogesterone acetate and CPA, have also demonstrated efficacy, with 80% of patients having shown improvement with CPA (123) or chlormadinone (124). Antidepressants may also have some efficacy. For example, venlafaxine (a non-specific selective noradrenaline and serotonin reuptake inhibitor) has shown efficacy in breast cancer patients, while the selective serotonin reuptake inhibitor sertraline appears to be effective in men with PCa (125). Other products have also been tested, including clonidine and veralipride, and even acupuncture (126). With a placebo effect influencing up to 30% of patients (127), few treatments are approved for the control of hot flashes in men with PCa. There is a lack of large, prospective randomised controlled trials in this area. More recently, other systemic side-effects have been described and must be paid increased attention. These include: bone problems, obesity and sarcopenia, lipid alterations and insulin resistance, metabolic syndrome, diabetes, and cardiovascular disease (128). ADT increases the non-metastatic fracture risk as a result of increased bone turn-over and decreased bone mineral density (BMD) in a time-dependent manner. This leads to an increased risk of fracture of up to 45% relative risk in the long term (129). This is a significant side-effect, as hip fractures in men are associated with a significant risk of death (130). Increased exercise and calcium supplementation are protective. Recently, bisphosphonates such as pamidronate, alendronate or zoledronic acid have been shown to increase the BMD in hip and spine by up to 7% in one year. The optimal regimen for zoledronic acid is still unclear. It is recommended once every four weeks in one study (131), while a yearly injection gave similar results in another (132). The optimal regimen is a very important question because of the risk of jaw necrosis, which might be dose and time-related (133).
Update march 2009
85
Before starting long term ADT, patients should be encouraged to adopt lifestyle changes (e.g. increase physical activity, stop smoking, decrease alcohol consumption and normalise their body mass index). A precise evaluation of the BMD should be performed by dual X-ray absorptiometry before starting long term ADT. An initial low BMD (T-score above 2.5 or above 1 in conjunction with other risk factors) indicates a high risk of subsequent non-metastatic fracture, suggesting the early use of preventive bisphosphonate therapy. Obesity and sarcopenia are common and often occur early on during the first year of ADT. An increase in body fat mass by up to 10%, and a decrease in lean tissue mass by up to 3% are expected (134). Both are linked to an increased risk of fracture. Lipid alterations are also frequent, and occur as early as the first three months of treatment (135). ADT also decreases insulin sensitivity and increases fasting plasma insulin levels (135), a marker of insulin resistance. Once again, exercise must be recommended as a protective tool. Metabolic syndrome is an association of independent cardiovascular disease risk factors often associated with insulin resistance. These include: • waist circumference > 102 cm • serum triglyceride > 1.7 mmol/L • blood pressure > 130/80 mmHg • HDL cholesterol < 1 mmol/L • glycaemia > 6.1 mmol/L. Its prevalence is higher during ADT compared with untreated men (136). ADT has been associated with an increased risk of diabetes mellitus, cardiovascular disease, and myocardial infarction in one study (137), and with a 20% increased risk of new cardiovascular disease after one year of treatment in another (138). Recently the analysis of the RTOG 92-02 data confirmed this increased cardiovascular risk (139) with no relationship with the duration of the ADT. These observations have, however, been up for discussion recently, as no increased cardiovascular mortality was demonstrated in RTOG 8610 (140), EORTC 30891 (109) or EORTC 22863 (64). In summary, if even six or fewer months of ADT might be associated with increased cardiovascular morbidity, the data on cardiovascular mortality are so far inconsistent. Again, prevention is associated with non-specific measures such as loss of weight, increased exercise, better nutrition and the cessation of smoking. 12.7.2 Quality of Life (QoL) Data on QoL during hormone treatment are scant because of a lack of solid evidence. The only large, prospective, randomised study is a double-blind placebo-controlled trial including 739 patients with M1 PCa, which compared orchiectomy plus flutamide vs orchiectomy plus placebo. The QoL was assessed in the first six months of treatment. Combined therapy resulted in lower QoL, with statistically significant differences in two QoL parameters, namely more frequent diarrhoea and worse emotional functioning, than castration alone (141). A prospective, non-randomised, observational study including 144 patients with locally advanced PCa or PSA failure after definitive local treatment showed that patients who received immediate ADT (by means of bilateral orchiectomy, LHRH agonist or CAB) reported a lower overall QoL (increased fatigue, emotional distress, and decreased physical functioning) than patients in the deferred hormone treatment arm (142) (level of evidence: 2a). A retrospective, non-randomised study including 431 patients with stage PCa who received orchiectomy or LHRH agonists as their primary therapy within 12 months of initial diagnosis, assessed healthrelated quality of life (HRQoL) outcomes at 12-months follow-up. Men receiving LHRH agonists reported more worry and physical discomfort and poorer overall health, and were less likely to believe themselves free of cancer than were orchiectomised patients. The stage at diagnosis had no significant independent effect on health outcome. However, the study was insufficiently powered (143) (level of evidence: 2b). A recent, small, randomised, controlled trial evaluated the HRQoL of patients with non-localised PCa allocated to leuprorelin, goserelin, CPA or no treatment at one-year follow-up. Both sexual and cognitive function significantly declined in men on all forms of androgen suppression, while emotional distress significantly increased in those assigned to CPA and no treatment (144) (level of evidence: 1b).
86
Update march 2009
IAD might be associated with an improved overall QoL based on the normal testosterone levels during the off treatment periods. So far the results are inconclusive, showing either no or a marginal QoL benefit. As for LHRH agonists, QoL was evaluated in the previously mentioned studies of bicalutamide monotherapy by means of a specific questionnaire covering 10 domains (sexual interest, sexual function, physical capacity, emotional well-being, vitality, social function, activity limitation, pain, bed disability and overall health). Separate analyses of data for M0 and M1 patients were performed at 12-month follow-up, and in both patient categories bicalutamide showed a significant advantage over castration in the domains of physical capacity and sexual interest (not sexual function) (57) (level of evidence: 1b). A further post hoc analysis, including only patients with sexual interest at study entry, found that significantly more patients receiving bicalutamide 150 mg/day maintained their interest in sex and felt that they were still sexually attractive than did those randomised to castration (145, 146). Data on QoL are also available from the early report of the study of Boccardo et al. (147), and support the findings of the two larger combined trials in that more men in the bicalutamide group than in the castration group reported a preserved libido and erectile function. Furthermore, a recent, small, prospective, randomised trial, including 103 patients with localised or locally advanced PCa who received bicalutamide 150 mg/day or medical castration, evaluated the changes in BMD after 96 weeks of treatment and showed it to be maintained with bicalutamide therapy (148) (level of evidence: 1b). The most common side-effects during non-steroidal anti-androgen monotherapy are gynaecomastia and breast pain, which are caused by an imbalance in the androgen:oestrogen ratio within the breast tissue. In the bicalutamide studies, these events were reported by up to 66% and 73% of patients, respectively, and might lead to a 16.4% treatment cessation. 12.7.3 Cost-effectiveness of hormonal therapy options A recent formal meta-analysis and literature review evaluated the cost-effectiveness of various long-term androgen suppression options in advanced PCa (e.g. bilateral orchiectomy, DES, LHRH-agonist, non-steroidal anti-androgen monotherapy, CAB with non-steroidal anti-androgens). For the analysis, a sophisticated statistical model was generated, assuming the base case at entry to be a 65-year-old man with a clinically evident, local recurrence of PCa and no distant metastases, followed for a 20-year time horizon. The study concluded that, for men who can accept it, bilateral orchiectomy is the most cost-effective form of ADT providing a higher quality-adjusted survival, while CAB is the least economically attractive option, yielding small health benefits for a high relative cost. Furthermore, the greatest QoL gains and least costs may be obtained by starting ADT when symptoms from distant metastases have occurred (103) (level of evidence: 1a). Finally, once ADT is started, if a clear response is obtained (see section 11.3.3. above), then IAD might be a useful way to lower treatment costs.
12.8
• • • •
•
•
Summary of hormonal therapy
In advanced PCa, ADT delays progression, prevents potentially catastrophic complications, and palliates symptoms effectively, but it does not prolong survival. In advanced PCa, all forms of castration as monotherapy (e.g. orchiectomy, LHRH and DES) have equivalent therapeutic efficacy. Non-steroidal anti-androgen monotherapy (e.g. bicalutamide) is an alternative to castration in patients with locally advanced disease. In metastatic PCa, the addition of a non-steroidal anti-androgen to castration (CAB) results in a small advantage in OS over castration alone, but is associated with increased adverse events, reduced QoL, and high costs. Intermittent ADT should no longer be regarded as experimental, even though long-term data from prospective randomised clinical trials are still awaited. ‘Minimal’ ADT should, however, continue to be seen as experimental In advanced PCa, immediate ADT (given at diagnosis) significantly reduces disease progression as well as the complication rate due to progression itself compared with deferred ADT (delivered at symptomatic progression).
Update march 2009
LE 1b 1b 2 1a
2
1b
87
•
However, the survival benefit is at best marginal and not related to an increased CSS. Bilateral orchiectomy might be the most cost-effective form of ADT, especially if initiated after the occurrence of symptoms from metastatic disease.
1b 3
LE = level of evidence
12.9
REFERENCES
1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. J Urol 2002;167(2P 2):948-51, discussion 952. http://www.ncbi.nlm.nih.gov/pubmed/11905923 2. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-23. 3. McLeod DG. Hormonal therapy: historical perspective to future directions. Urology 2003;61 (2 Suppl 1):3-7. http://www.ncbi.nlm.nih.gov/pubmed/12667881 4. Walsh PC. Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975;2(1):125-40. http://www.ncbi.nlm.nih.gov/pubmed/48206 5. Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW, McConnell JD. Expression and regulation of steroid 5-a-reductase 2 in prostate disease. J Urol 1994;152(2 Pt 1):433-7. http://www.ncbi.nlm.nih.gov/pubmed/7516976 6. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6):1021-4. http://www.ncbi.nlm.nih.gov/pubmed/11113751 7. Desmond AD, Arnold AJ, Hastie KJ. Subcapsular orchiectomy under local anaesthesia. Technique, results and implications. Br J Urol 1988;61(2):143-5. http://www.ncbi.nlm.nih.gov/pubmed/3349279 8. Melton LJ 3rd, Alothman KI, Achenbach SJ, O’Fallon WM, Zincke H. Decline in bilateral orchiectomy for prostate cancer in Olmsted county, Minnesota, 1956-2000. Mayo Clinic Proc 2001;76(12): 1199-203. http://www.ncbi.nlm.nih.gov/pubmed/11761500 9. Oh WK. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 2002;1(2):81-9. http://www.ncbi.nlm.nih.gov/pubmed/15046698 10. Byar DP. Proceedings: the Veterans Administration Co-operative Urological Research Group studies of cancer of the prostate. Cancer 1973;32(5):1126-30. http://www.ncbi.nlm.nih.gov/pubmed/4585929 11. Jordan WP Jr, Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 1977;70(12):1411-3. http://www.ncbi.nlm.nih.gov/pubmed/15046698 12. Scherr DS, Pitts WR Jr. The non-steroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003;170(5):1703-8. http://www.ncbi.nlm.nih.gov/pubmed/14532759 13. Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E; Scandinavian Prostatic Cancer Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer – Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002;36(6):405-13. http://www.ncbi.nlm.nih.gov/pubmed/12623503 14. Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42(3):220-9. http://www.ncbi.nlm.nih.gov/pubmed/18432528 15. Klotz L, McNeill I, Fleshner N. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999;161(1):169-72. http://www.ncbi.nlm.nih.gov/pubmed/10037391
88
Update march 2009
16.
17.
18.
19.
20.
21.
22.
23.
24. 25.
26.
27. 28.
29.
30.
31.
Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int 2000;85(9):1069-73. http://www.ncbi.nlm.nih.gov/pubmed/10848697 Rosenbaum E, Wygoda M, Gips M, Hubert A, Tochner Z, Gabizon A. Diethylstilbestrol is an active agent in prostate cancer patients after failure to complete androgen blockade. Proc ASCO 2000. J Clin Oncol 2000;349:1372A. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_ view&confID=2&abstractID=201964 Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77. http://www.ncbi.nlm.nih.gov/pubmed/10744594 Oefelein MG, Resnick MI. Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 2003;62(2):207-13. http://www.ncbi.nlm.nih.gov/pubmed/12893320 Agarwal DK, Costello AJ, Peters J, Sikaris K, Crowe H. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hypertrophy. BJU Int 2000;85(6):690-5. http://www.ncbi.nlm.nih.gov/pubmed/10759667 Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumourigenesis. Peptides 1999;20(10):1247-62. http://www.ncbi.nlm.nih.gov/pubmed/10573298 Limonta P, Montagnani MM, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10(4):709-20. http://www.ncbi.nlm.nih.gov/pubmed/11281820 Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000;164(3 Pt 1):726-9. http://www.ncbi.nlm.nih.gov/pubmed/10953134 Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58(2 Suppl 1):5-9. http://www.ncbi.nlm.nih.gov/pubmed/11502435 McLeod DG, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB. A phase 3, multicentre, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):756-61. http://www.ncbi.nlm.nih.gov/pubmed/11711355 Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB. A phase 3, multicentre, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167(4):1670-4. http://www.ncbi.nlm.nih.gov/pubmed/11912385 FDA/CDER. FDA approves new drug for advanced prostate cancer. November 25, 2003. http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01268.html Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008 Oct;54(4):805-13. http://www.ncbi.nlm.nih.gov/pubmed/18538469 Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003;91(5):455-61. http://www.ncbi.nlm.nih.gov/pubmed/12603397 Moffat LE. Comparison of Zoladex, diethylstilboestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990;18(Suppl 3):26-7. http://www.ncbi.nlm.nih.gov/pubmed/2151272 Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O’Boyle PJ. A prospective, randomized study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996;29(1):47-54. http://www.ncbi.nlm.nih.gov/pubmed/8821690
Update march 2009
89
32.
33.
34.
35.
36.
37.
38.
39.
40. 41.
42.
43.
44.
45.
46.
47.
48.
90
Pavone Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research and Treatment of Cancer Urological Group. J Urol 1986;136(3):624-31. http://www.ncbi.nlm.nih.gov/pubmed/2942707 Mahler C, Verhelst J, Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet 1998;34(5):405-17. http://www.ncbi.nlm.nih.gov/pubmed/9592622 Schroder FH, Whelan P, de Reijke TM, Kurth KH, Pavone Macaluso M, Mattelaer J, van Velthoven F, Debois M, Collette L. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the ‘European Organization for Research and Treatment of Cancer’ (EORTC) Protocol 30892. Eur Urol 2004;45(4):457-64. http://www.ncbi.nlm.nih.gov/pubmed/15041109 Johnson DE, Kaesler KE, Ayala AG. Megestrol acetate for treatment of advanced carcinoma of the prostate. J Surg Oncol 1975;7(1):9-15. http://www.ncbi.nlm.nih.gov/pubmed/1177459 Geller J, Albert J, Yen SSC. Treatment of advanced cancer of the prostate with megestrol acetate. Urology 1978;12(5):537-41. http://www.ncbi.nlm.nih.gov/pubmed/153029 Bonomi P, Pessis D, Bunting N, Block M, Anderson K, Wolter J, Rossof A, Slayton R, Harris J. Megestrol acetate use as primary hormonal therapy in stage D prostatic cancer. Semin Oncol 1985;12(1 Suppl 1):36-9. http://www.ncbi.nlm.nih.gov/pubmed/3975650 Patel SR, Kvols LK, Hahn RG, Windshitl H, Levitt R, Therneau T. A phase II randomized trial of megestrol acetate or dexamethasone in treatment of hormonally refractory advanced carcinoma of the prostate. Cancer 1990;66(4):655-8. http://www.ncbi.nlm.nih.gov/pubmed/2201425 Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, Vogelzang NJ. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. Cancer and Leukemia Group B Study 9181. Cancer 2000;88(4):825-34. http://www.ncbi.nlm.nih.gov/pubmed/10679652 Iversen P. Antiandrogen monotherapy: indications and results. Urology 2002;60 (3 Suppl.1):64-71. http://www.ncbi.nlm.nih.gov/pubmed/10679652 McLeod DG. Tolerability of non-steroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997;2(1):18-27. http://www.ncbi.nlm.nih.gov/pubmed/10388026 Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997;31(12):66-75. http://www.ncbi.nlm.nih.gov/pubmed/8997470 Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Martorana G, Giuliani L. Monotherapy with nilutamide, a pure non-steroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991;146(2):377-81. http://www.ncbi.nlm.nih.gov/pubmed/8997470 Dijkman GA, Janknegt RA, de Reijke TM, Debruyne FMJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997;158(1):160-3. http://www.ncbi.nlm.nih.gov/pubmed/9186345 Desai A, Stadler WM, Vogelzang N. Nilutamide: possible utility as a second-line hormonal agent. Urology 2001;58(6)1016-20. http://www.ncbi.nlm.nih.gov/pubmed/11744479 Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003;169(5):1742-44. http://www.ncbi.nlm.nih.gov/pubmed/12686822 Narayana AS, Loening SA, Culp DA. Flutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol 1981;53(2):152-3. http://www.ncbi.nlm.nih.gov/pubmed/7237048 Sogani, Vagaiwala MR, Whitmore WF Jr. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 1984;54(4):744-50. http://www.ncbi.nlm.nih.gov/pubmed/6378356
Update march 2009
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
Lundgren R. Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 1987;59(2): 156-8. http://www.ncbi.nlm.nih.gov/pubmed/3828712 Delaere KP, Van Thillo EL. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 1991;18(5 Suppl 6):13-8. http://www.ncbi.nlm.nih.gov/pubmed/1948117 Pavone Macaluso M. Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicentre, randomized study. SIU 23rd Congress 1994:354A. http://www.siu-urology.org/ Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997;32(4):391-5. http://www.ncbi.nlm.nih.gov/pubmed/9412794 Tyrrell CJ, Denis L, Newling DWW, Soloway M, Channer K, Cockshott ID. Casodex 10-200 mg daily, used as monotherapy for patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. Eur Urol 1998;33(1):39-53. http://www.ncbi.nlm.nih.gov/pubmed/9471040 Kolvenbag GJ, Nash A. Bicalutamide dosages used in the treatment of prostate cancer. Prostate 1999;39(1):47-53. http://www.ncbi.nlm.nih.gov/pubmed/10221266 Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. A randomized comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33(5):447-56. http://www.ncbi.nlm.nih.gov/pubmed/9643663 Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prost Cancer Prost Dis 1999;4(4):196-203. http://www.ncbi.nlm.nih.gov/pubmed/12497018 Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TLJ, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 2000;164(5):1579-82. http://www.ncbi.nlm.nih.gov/pubmed/11025708 Fourcade RO, Chatelain C, Poterre M et al. An open multicentre randomized study to compare the effect and safety of ‘Casodex’ (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur Urol 1998;33(Suppl 1):88,349A. Boccardo F, Barichello M, Battaglia M, Carmignani G, Comeri G, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Cortellini P, Rigatti P, Usai E, Rubagotti A. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002;42(5):481-90. http://www.ncbi.nlm.nih.gov/pubmed/12429158 Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer programme at median followup of 5.4 years. J Urol 2004;172(5 Pt 1):1865-70. http://www.ncbi.nlm.nih.gov/pubmed/15540740 McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006 Feb;97(2):247-54. http://www.ncbi.nlm.nih.gov/pubmed/16430622 Wirth M, Tyrrell C, Delaere K, Sánchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns CF, Navani S, Armstrong J. Bicalutamide (Casodex) 150 mg plus standard care in early nonmetastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years’ follow-up. Prostate Cancer Prostatic Dis 2007;10(1):87-93. http://www.ncbi.nlm.nih.gov/pubmed/17102802 Sternberg CN. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. BJU Int 2006 Mar;97(3):435-8. http://www.ncbi.nlm.nih.gov/pubmed/16469001
Update march 2009
91
64.
65.
66.
67.
68. 69.
70.
71.
72.
73.
74.
75.
76.
77.
92
Bolla L, Collette G, Van Tienhoven P, Warde JB, Dubois RO, Mirimanoff G, Storme J, Bernier, Kuten A, Piérart M. Ten Year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study. Proceedings of the American Society for Therapeutic Radiology and Oncology 50th Annual Meeting. Int Journal Radiat Oncol Biol Phys 2008;72(1 Suppl 1):S30-S31(abstr. 65). Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366(9485):572-8. http://www.ncbi.nlm.nih.gov/pubmed/16099293 Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285-90. http://www.ncbi.nlm.nih.gov/pubmed/15817329 McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7year median followup. J Urol 2006;176(1):75-80. http://www.ncbi.nlm.nih.gov/pubmed/16753373 Iversen P. Orchidectomy and oestrogen therapy revisited. Eur Urol 1998;34(Suppl 3):7-11. http://www.ncbi.nlm.nih.gov/pubmed/9854189 See WA, Tyrrell CJ; CASODEX Early Prostate Cancer Trialists’ Group. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 2006;132(Suppl 1):S7-S16. http://www.ncbi.nlm.nih.gov/pubmed/16896884 Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23(4):808-15. http://www.ncbi.nlm.nih.gov/pubmed/15681525 Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebocontrolled, dose-response study. Eur Urol 2007;52(1):106-14. http://www.ncbi.nlm.nih.gov/pubmed/17270340 Dicker AP. The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol 2003;4(1):30-6. http://www.ncbi.nlm.nih.gov/pubmed/12517537 Van Poppel H, Tyrrell CJ, Haustermans K, Cangh PV, Keuppens F, Colombeau P, Morris T, Garside L. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol 2005;47(5):587-92. http://www.ncbi.nlm.nih.gov/pubmed/15826748 Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/Technology Assessment No. 4. AHCPR Publication No. 99-E0012, May 1999, Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville, MD. http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.5028 Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000;355(9214):1491-8. [No authors listed.] http://www.ncbi.nlm.nih.gov/pubmed/10801170 Schmitt B, Bennett CL, Seidenfeld J, Samson DJ, Wilt TJ. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000;2:D001526. http://www.ncbi.nlm.nih.gov/pubmed/10796804 Schmitt B, Wilt TJ, Schellhammer PF, De Masi V, Sartor O, Crawford ED, Bennett CL. Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001;57(4):727-32. http://www.ncbi.nlm.nih.gov/pubmed/11306391
Update march 2009
78.
Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002;95(2):361-76. http://www.ncbi.nlm.nih.gov/pubmed/12124837 79. Collette L, Studer UE, Schroder FH, Denis LJ, Sylvester RJ. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. Prostate 2001;48(1):29-39. http://www.ncbi.nlm.nih.gov/pubmed/11391684 80. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side-effects. J Urol 1995;154(5):1645-6. http://www.ncbi.nlm.nih.gov/pubmed/7563310 81. Fleshner NE, Fair WR. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol 1996;78(6):907-10. http://www.ncbi.nlm.nih.gov/pubmed/9014718 82. Ornstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996;48(6):901-5. http://www.ncbi.nlm.nih.gov/pubmed/8973674 83. Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, Kaufman D, Kantoff P. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997;49(6):913-20. http://www.ncbi.nlm.nih.gov/pubmed/9187700 84. Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, Altwein J, Schroder F. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 1999;40(2):105-14. http://www.ncbi.nlm.nih.gov/pubmed/10386471 85. Oh WK, Manola J, Bittman L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 2003;62(1):99-104. http://www.ncbi.nlm.nih.gov/pubmed/12837431 86. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50(8):2275-82. http://www.ncbi.nlm.nih.gov/pubmed/2317815 87. Pether M, Goldenberg SL. Intermittent androgen suppression. BJU Int 2004;93(3):258-61. http://www.ncbi.nlm.nih.gov/pubmed/14764118 88. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D; Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT0162). J Clin Oncol 2006;24(24):3984-90. http://www.ncbi.nlm.nih.gov/pubmed/16921051 89. Lane TM, Ansell W, Farrugia D, Wilson P, Williams G, Chinegwundoh F, Philp T, Hines J, Oliver RT. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004;73(2):117-22. http://www.ncbi.nlm.nih.gov/pubmed/15331894 90. de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, Bouffioux C, Coppens L, Bonnet P, Andrianne R, Wlatregny D. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1(3):163-71. http://www.ncbi.nlm.nih.gov/pubmed/15046691 91. Tunn UW, Canepa G, Hillger H, Fuchs W. Intermittent androgen deprivation in patients with PSArelapse after radical prostatectomy – final results of a European randomized prospective phase-III clinical trial, AUO study AP 06/95, EC 507. American Urological Association 2007, abstr 600. http://www.auanet.org/content/press/press_releases/article.cfm?articleNo=18 92. Miller K, Steiner U, Lingnau A, Keilholz U, Witzsch U, Haider A, Wachter U, Rüssel C, Altwein J. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007;Part 1;25(18S):(abstr 5015). http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_ view&confID=47&abstractID=33936
Update march 2009
93
93.
Irani J, Celhay O, Hubert J, Bladou F, Ragni E, Trape G, Doré B; Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 2008 Aug;54(2):382-91. http://www.ncbi.nlm.nih.gov/pubmed/18339475 94. Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M; Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 2004 Aug;64(2):341-5. http://www.ncbi.nlm.nih.gov/pubmed/15302491 95. Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H, Corica T, Korbel E, Weinstein S, McCaul K. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006;42(8):1083-92. http://www.ncbi.nlm.nih.gov/pubmed/16632343 96. Calais da Silva FE, Calais da Silva FM, Gonçalves F, Santos A, Kliment J, Whelan P, Oliver RT, Antoniou N, Pastidis S, Robertson C, Queimadelos M. Evaluation of quality-of-life side effects and duration of therapy in a phase III study of intermittent monotherapy versus continuous combined androgen deprivation. ASCO Annual Meeting Proceedings J Clin Oncol 2008;26(15S):(abstr 5064). http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/5064?maxtoshow=&HITS=20&hits=20 &RESULTFORMAT=&fulltext=Calais+da+Silva&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT 97. Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? Urol Int 2005;75(3): 204-8. http://www.ncbi.nlm.nih.gov/pubmed/16215305 98. Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005;173(5):1567-71. http://www.ncbi.nlm.nih.gov/pubmed/15821487 99. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004;64(6):1182-6. http://www.ncbi.nlm.nih.gov/pubmed/15596194 100. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, Oliver T. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 2007;99(5):1056-65. http://www.ncbi.nlm.nih.gov/pubmed/17346277 101. Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL; FinnProstate Group. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol. 2008;180(3):915-9; discussion 919-20. http://www.ncbi.nlm.nih.gov/pubmed/18635219 102. Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 2007;100(4):738-43. http://www.ncbi.nlm.nih.gov/pubmed/17662079 103. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92(21):1731-9. http://www.ncbi.nlm.nih.gov/pubmed/11058616 104. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79(2):235-46. http://www.ncbi.nlm.nih.gov/pubmed/905247 105. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8. http://www.ncbi.nlm.nih.gov/pubmed/10588962 106. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002;(1):CD003506. http://www.ncbi.nlm.nih.gov/pubmed/11869665 107. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol. 2008;54(2):344-52. http://www.ncbi.nlm.nih.gov/pubmed/18511183
94
Update march 2009
108.
Wong Y, Freedland S, Hudes G, Mitra N, Montagnet C, Armstrong K. Androgen deprivation therapy (ADT) for node postive prostate cancer. ASCO Annual Meeting 2007;Part 1;25(18S):(abstr 5061). http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_ view&confID=47&abstractID=34790 109. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24(12):1868-76. http://www.ncbi.nlm.nih.gov/pubmed/16622261 110. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI: American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22(14):2927-41. http://www.ncbi.nlm.nih.gov/pubmed/15184404 111. Granfors T, Modig H, Damber J, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for non-metastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998;159(6):2030-4. http://www.ncbi.nlm.nih.gov/pubmed/9598512 112. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937-46. http://www.ncbi.nlm.nih.gov/pubmed/11240234 113. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Torecilla JL, Pfeffer JR, Cutajar CL, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360(9327):103-6. http://www.ncbi.nlm.nih.gov/pubmed/12126818 114. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-102. J Clin Oncol 2003;21(21):3972-8. http://www.ncbi.nlm.nih.gov/pubmed/14581419 115. Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001;166(6):2208-15. http://www.ncbi.nlm.nih.gov/pubmed/11696737 116. Boccon-Gibod L, Bertaccini A, Bono AV, Dev Sarmah B, Holtl W, Mottet N. Management of locally advanced prostate cancer. A European consensus. Int J Clin Pract 2003;57(3):187-94. http://www.ncbi.nlm.nih.gov/pubmed/12723722 117. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989;321(7):413-8. http://www.ncbi.nlm.nih.gov/pubmed/2503723 118. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl J Med 1989;321(7):419-24. http://www.ncbi.nlm.nih.gov/pubmed/2503724 119. Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2003;2(1):41-5. http://www.ncbi.nlm.nih.gov/pubmed/15046683 120. Kruus LK, Palmer S, Malkowicz S, Vaughn DJ, Coyne JC; University of Pennsylvania Cancer Center, Philadelphia, PA. The influence of fatigue and hot flashes on the quality of life in prostate cancer patients. ASCO Annual Meeting, 12-15 May 2001, San Francisco, USA, p. 1594. http://pediatricca.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/ 121. Steiner MS, Raghow S. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J Urol. 2003;21(1):31-6. http://www.ncbi.nlm.nih.gov/pubmed/12756492
Update march 2009
95
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133. 134.
135.
136.
137.
96
Smith MR. Complementary and alternative therapies for advanced prostate cancer. Hematol Oncol Clin North Am 2001;15(3):559-71. http://www.ncbi.nlm.nih.gov/pubmed/11525297 Eaton AC, McGuire N. Cyproterone acetate in treatment of post-orchidectomy hot flushes. Doubleblind cross-over trial. Lancet 1983;2(8363):1336-7. http://www.ncbi.nlm.nih.gov/pubmed/6139671 Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H. Hot Flashes During Androgen Deprivation Therapy With Luteinizing Hormone-Releasing Hormone Agonist Combined With Steroidal or Nonsteroidal Antiandrogen for Prostate Cancer. Urology 2008;25 Nov. http://www.ncbi.nlm.nih.gov/pubmed/19038426 Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999;162(1):98-102. http://www.ncbi.nlm.nih.gov/pubmed/10379749 Frisk J, Spetz AC, Hjertberg H, Petersson B, Hammar M. Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer – a prospective multicenter study with long-term follow-up. Eur Urol 2008; 14 Feb. http://www.ncbi.nlm.nih.gov/pubmed/18294761 Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19(23):4280-90. http://www.ncbi.nlm.nih.gov/pubmed/11731510 Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009;55(1):62-75. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6X10-4TNTK9R-5&_user=10&_ coverDate=01%2F31%2F2009&_alid=866162259&_rdoc=1&_fmt=high&_orig=search&_cdi=7228&_ sort=d&_docanchor=&view=c&_ct=1&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md 5=44563d9c6fe5dfacfa191328aab299e8 Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175(1):136-9; discussion 139. http://www.ncbi.nlm.nih.gov/pubmed/16406890 Cree M, Soskolne CL, Belseck E, Hornig J, McElhaney JE, Brant R, Suarez-Almazor M. Mortality and institutionalization following hip fracture. J Am Geriatr Soc 2000;48(3):283-8. http://www.ncbi.nlm.nih.gov/pubmed/10733054 Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008-12. http://www.ncbi.nlm.nih.gov/pubmed/12771706 Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25(9):1038-42. http://www.ncbi.nlm.nih.gov/pubmed/17369566 Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7(6):508-14. http://www.ncbi.nlm.nih.gov/pubmed/16750501 Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004;63(4):742-5. http://www.ncbi.nlm.nih.gov/pubmed/15072892 Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91(4):1305-8. http://www.ncbi.nlm.nih.gov/pubmed/16434464 Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24(24):3979-83. http://www.ncbi.nlm.nih.gov/pubmed/16921050 Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-56. http://www.ncbi.nlm.nih.gov/pubmed/16983113
Update march 2009
138.
Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; and the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110(7):1493-500. http://www.ncbi.nlm.nih.gov/pubmed/17657815 139. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008;54(4):816-23. http://www.ncbi.nlm.nih.gov/pubmed/18243498 140. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26(4): 585-91. http://www.ncbi.nlm.nih.gov/pubmed/18172188 141. Scherr D, Pitts WR Jr, Vaughan ED Jr. Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002;167(4 Pt 1):535-8. http://www.ncbi.nlm.nih.gov/pubmed/11792913 142. Moinpour CM, Savage MJ, Troxel A, Lovato LC, Einsenberger M, Veith RW, Higgins B, Skeel R, Yee M, Blumenstein BA, Crawford ED, Meyskens FL Jr. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998;90(20):1537-44. http://www.ncbi.nlm.nih.gov/pubmed/9790546 143. Herr HW, O’Sullivan M. Quality of life of asymptomatic men with non-metastatic prostate cancer on androgen deprivation therapy. J Urol 2000;163(6):1743-6. http://www.ncbi.nlm.nih.gov/pubmed/10799173 144. Potoski AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley W, Stephenson RA, Hoffman RM. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19(17):3750-7. http://www.ncbi.nlm.nih.gov/pubmed/11533098 145. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB, Gardiner RA. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 2004;93(7):975-9. http://www.ncbi.nlm.nih.gov/pubmed/15142146 146. Iversen P, Melezinek I, Schmidt A. Non-steroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int 2001;87(1):47-56. http://www.ncbi.nlm.nih.gov/pubmed/1112199 147. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Conti G, Cruciani G, Dammino S, Delliponti U, Ditonno P, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Spano G, for the Italian Prostate Cancer Project. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17(7):2027-38. http://www.ncbi.nlm.nih.gov/pubmed/10561254 148. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004;171(6 Pt 1):2272-6. http://www.ncbi.nlm.nih.gov/pubmed/15126801
Update march 2009
97
13. SUMMARY OF GUIDELINES ON PRIMARY TREATMENT OF PCa Stage T1a
Treatment Watchful waiting
Radical prostatectomy Radiotherapy
T1b-T2b
Hormonal Combination Watchful waiting
Radical prostatectomy Radiotherapy
Hormonal
Combination
T3-T4
Watchful waiting
Radical prostatectomy Radiotherapy
Hormonal Combination
N+, M0
Watchful waiting
M+
Radical prostatectomy Radiotherapy Hormonal Combination Watchful waiting
Radical prostatectomy Radiotherapy Hormonal
98
Comment Standard treatment for well-, and moderately, differentiated tumours and < 10-year life expectancy. In patients with > 10-year life expectancy, re-staging with TURP and biopsy is advised Optional in young patients with a long life expectancy, especially for poorly differentiated tumours Optional in younger patients with a long life expectancy, especially for poorly differentiated tumours. Higher complication risks after TURP, especially with interstitial radiation Not an option Not an option Asymptomatic patients with well-, and moderately, differentiated tumours and a life expectancy < 10 years. Patients who do not accept treatment-related complications Standard treatment for patients with life expectancy > 10 years who accept treatment-related complications Patients with a life expectancy > 10 years who accept treatment-related complications. Patients with contraindications for surgery. Unfit patients with 5-10 years of life expectancy and poorly differentiated tumours (combination therapy is recommended; see below) Symptomatic patients, who need palliation of symptoms, unfit for curative treatment Anti-androgens are associated with a poorer outcome compared to ‘watchful waiting’ and are not recommended For high-risk patients, neoadjuvant hormonal treatment (NHT) and concomitant hormonal therapy + radiotherapy results in increased overall survival. Option in asymptomatic patients with T3, well-differentiated and moderately differentiated tumours, and a life expectancy < 10 years Optional for selected patients with T3a and a life expectancy > 10 years T3 with > 5-10 years of life expectancy. Dose escalation > 70 Gy seems to be of benefit. A combination with hormonal therapy should be recommended (see below) Symptomatic patients, extensive T3-T4, high PSA level (> 25-50 ng/mL), PSA-DT < 1 year. Patient-driven, unfit patients Overall survival is improved by concomitant and adjuvant hormonal therapy (3 years) combined with external irradiation NHT + radical prostatectomy: no indication Asymptomatic patients. Patient driven (PSA < 20-50 ng/mL), PSA DT > 12 months. Requires very close follow-up No standard option No standard option Standard therapy in N > N1 No standard option. Patient-driven No standard option. May have worse survival/more complications than with immediate hormonal therapy. Requires very close follow-up Not an option Not an option (given for cure) Standard therapy. Mandatory in symptomatic patients
GR B
B B
A C B
A B
C A A
C
C A
A A B B C C A B B
C C A
Update march 2009
Combination
Must be otherwise systematically discussed Not an option
C
GR = grade of recommendation; TURP = transrectal urethral resection of prostate; NHT = neoadjuvant hormonal therapy; PSA = prostate-specific antigen; PSA-DT = prostate-specific doubling time.
14. FOLLOW-UP: AFTER TREATMENT WITH CURATIVE INTENT 14.1
Definition
Curative treatment is defined as radical prostatectomy or radiotherapy, either by external beam radiation or an interstitial technique, or any combination of these. Alternative treatment options that are not fully established, such f.i. HIFU, do not have a well-defined, validated PSA-cut-point to define biochemical failure but do generally follow the outlines given below.
14.2
Why follow-up?
The first question to be answered is: ‘If failure after curative treatment is so common, are follow-up efforts worthwhile?’ The answer to this question is definitely ‘Yes’. Recurrences will occur in a substantial number of patients who received treatment with intent to cure at various time points after the primary therapy. The second question to be answered is: ‘What is the reason for follow-up?’ Reasons may vary depending on the treatment given, patient age, comorbidity and the patient’s own wishes. In general, patients who receive curative therapy may be followed-up for any of the following reasons: • good responsible patient care • possibility of second-line treatment with curative intent • possibility of early hormonal therapy after failure • as part of a study protocol. Section 16 discusses treatment options after failure of primary therapy.
14.3
How to follow-up?
The procedures indicated at follow-up visits vary depending on the clinical situation. The examinations discussed below are routinely used for the detection of PCa progression or residual disease. The PSA level, and eventually DRE, are the only tests that need to be carried out routinely. A disease-specific history should be mandatory at every follow-up visit and should include psychological aspects, signs of disease progression and treatment-related complications. The examinations used for the evaluation of treatment-related complications must be individualized and are beyond the scope of these guidelines. The examinations used most often for cancer-related follow-up after curative surgery or radiation treatment are discussed below. 14.3.1 PSA monitoring The measurement of PSA level is a cornerstone in the follow-up after curative treatment. There is a difference in what can be expected after radical prostatectomy and radiotherapy, but PSA recurrence nearly always precedes clinical recurrence after either treatment, in some cases by many years (1-5). It is recommended that the finding of a single, elevated, serum PSA level should be re-confirmed before second-line therapy is started solely based on the PSA elevation. 14.3.2 Definition of PSA progression The level of PSA at which to define treatment failure differs between radical prostatectomy cases and radiation treated cases. Following radical retropubic prostatectomy, two consecutive values of 0.2 ng/mL or greater appear to represent an international consensus defining recurrent cancer (6, 7). Other authors have argued for an even higher cut-off of 0.4 ng/mL to better define patients with a high risk for clinical progression (5). It has been shown that patients with a PSA level between 0.1 ng/mL and 0.2 ng/mL after radical prostatectomy had neither clinical nor biochemical disease progression (8). Therefore, the use of an ultra-sensitive PSA assay is not justified for routine follow-up after radical prostatectomy (4). If ongoing randomized trials show that early adjuvant treatment after radical prostatectomy (given before PSA reaches > 0.2 ng/mL) improves survival, this issue should be reconsidered. Following radiation therapy, until recently, the definition of biochemical relapse was three consecutive increases according to the recommendation of ASTRO from 1996 (9). At the 2006 RTOG-ASTRO Consensus
Update march 2009
99
conference a new definition of radiation failure was established with as the main aim to establish a better correlation between the definition and clinical outcome. The new definition of radiation failure is a rise of 2 ng/mL above the post-treatment PSA-nadir (lowest value) (10). This definition is applicable for patients treated with or without hormonal therapy. After HIFU or cryotherapy, a variety of definitions for PSA-relapse have been used (11). Most of these are based on a cut-off of around 1 ng/mL, eventually combined with a negative post-treatment biopsy. As yet, none of these end-points have been validated against clinical progression or survival and therefore it is not possible to give firm recommendations on the definition of biochemical failure. 14.3.3 PSA monitoring after radical prostatectomy PSA is expected to be undetectable within 3 weeks after a successful radical prostatectomy (12). A persistently elevated PSA level means that PSA-producing tissue remains in the body. In patients treated with radical prostatectomy, this is generally thought to be residual cancer due to either micrometastases that were not detected or undetectable beforehand, or residual disease in the pelvis possibly due to positive surgical margins. A rapidly increasing PSA level (high PSA velocity, short PSA doubling time) indicates distant metastases, while a later and slowly increasing concentration of PSA is most likely to indicate local disease recurrence. The time to PSA recurrence and tumour differentiation are also important predictive factors distinguishing between local and systemic recurrence (13, 14). Both local treatment failure and distant metastases have been shown to occur with undetectable PSA levels. This is very rare and occurs almost only in patients with unfavourable pathology (undifferentiated tumours) (15, 16). This means that, in patients with a relatively favourable pathology (< pT3, pN0, Gleason score < 8), PSA measurement, together with the disease-specific history, could stand as the single test in follow-up after radical prostatectomy. 14.3.4 PSA monitoring after radiation therapy The PSA level falls slowly after radiotherapy compared with radical prostatectomy. The optimal cut-off value for a favourable PSA nadir after radiotherapy is somewhat controversial. Achieving a PSA nadir of less than 0.5 ng/mL seems to be associated with a favourable outcome (17). The interval before reaching the nadir PSA may be very long and can sometimes take up to 3 years or more. A PSA rising more than 2 ng/mL above the nadir PSA is the current definition of biochemical failure after radiotherapy (10). Also, after radiotherapy, the PSA doubling time has been shown to correlate to the site of recurrence; patients with local recurrence had a doubling time of 13 months compared to 3 months for those with distant failure (18). 14.3.5 Digital rectal examination (DRE) DRE is performed to assess whether or not there is any sign of local disease recurrence. It is very difficult to interpret the findings of DRE after curative therapy, especially after radiotherapy. A newly detected nodule should raise the suspicion of local disease recurrence. As mentioned previously, a local disease recurrence after curative treatment is possible without a concomitant rise in PSA level (15, 16). However, this has only been proven in patients with unfavourable pathology, i.e. those with undifferentiated tumours. Thus, PSA measurement and DRE comprise the most useful combination of tests as first-line examination in follow-up after radiotherapy or radical prostatectomy, but PSA measurement may well be the only test in cases with favourable pathology (19). 14.3.6 Transrectal ultrasonography (TRUS) and biopsy TRUS and biopsy have no place in the routine follow-up of asymptomatic patients and nowadays only rarely after biochemical failure. TRUS cannot stand alone as a diagnostic tool, but must usually be combined with biopsy to establish the presence of local disease recurrence. The purpose of the investigation is to confirm a histological diagnosis of local disease recurrence. It is only warranted if the finding of a local recurrence affects the treatment decision (see Section 16 for a more detailed discussion). 14.3.7 Bone scintigraphy The purpose of bone scintigraphy is to detect skeletal metastases. It is not recommended for the routine follow-up of asymptomatic patients, but may be indicated in individuals with elevated PSA levels for whom the findings will affect the treatment decision. It is also indicated in patients with symptoms arising from the skeleton, since metastatic disease may occur even if PSA is undetectable (15, 16). 14.3.8 Computed tomography (CT) or magnetic resonance imaging (MRI) CT or MRI have no place in the routine follow-up of asymptomatic patients. They may be used selectively in the evaluation after biochemical failure before treatment decisions are made (see Section 16).
100
Update march 2009
14.4
When to follow-up?
Most patients who fail treatment for PCa do so early, even if failure only becomes clinically obvious after years. The patient should therefore be followed-up more closely during the first years after treatment when the risk of failure is highest. PSA measurement, disease-specific history and DRE are recommended at the following intervals: 3, 6 and 12 months postoperatively, every 6 months thereafter until 3 years, and then annually. The purpose of the first clinic visit is mainly to detect treatment-related complications and to assist patients in coping with the new situation. Tumour or patient characteristics may allow alterations to this schedule. For example, patients with poorly differentiated and locally advanced tumours or with positive margins may be followed-up more closely than those with a well-differentiated, intracapsular or specimenconfined tumour. Obviously, advanced age or associated comorbidity may make further follow-up in asymptomatic patients superfluous.
14.5 Guidlines for follow-up after treatment with curative intent
• In asymptomatic patients, a disease-specific history and a serum PSA measurement supplemented by DRE are the recommended tests for routine follow-up. These should be performed at 3, 6 and 12 months after treatment, then every 6 months until 3 years, and then annually. • After radical prostatectomy, a serum PSA level of more than 0.2 ng/mL can be associated with residual or recurrent disease. • After radiation therapy, a rising PSA level over 2 ng/mL above the nadir PSA, rather than a specific threshold value, is the most reliable sign of persistent or recurrent disease. • Both a palpable nodule and a rising serum PSA level can be signs of local disease recurrence. • Detection of local recurrence by TRUS and biopsy is only recommended if it will affect the treatment plan. In most cases TRUS and biopsy are not necessary before second-line therapy. • Metastasis may be detected by pelvic CT/MRI or bone scan. In asymptomatic patients, these examinations may be omitted if the serum PSA level is less than 30 ng/mL but data on this topic are sparse. • Routine bone scans and other imaging studies are not recommended in asymptomatic patients. If a patient has bone pain, a bone scan should be considered irrespective of the serum PSA level.
GR B
B B B B C
B
GR = grade of recommendation
14.6
REFERENCES
1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancerspecific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3)555-65. http://www.ncbi.nlm.nih.gov/pubmed/11590814 2. Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 2002;168(2):536-41. http://www.ncbi.nlm.nih.gov/pubmed/12131304. 3. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 2005;173(3):797-802. http://www.ncbi.nlm.nih.gov/pubmed/15711272. 4. Taylor JA III, Koff SG, Dauser DA, McLeod DG. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int 2006;98(3):540-3. http://www.ncbi.nlm.nih.gov/pubmed/16925750.
Update march 2009
101
5.
Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco Jr FJ, Lilja H, Scardino PT. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24(24):3973-8. http://www.ncbi.nlm.nih.gov/pubmed/16921049 6. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, Teillac P, Tunn UW. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58(4):382-90. http://www.ncbi.nlm.nih.gov/pubmed/15161124 7. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163(6):1632-42. http://www.ncbi.nlm.nih.gov/pubmed/10799151 8. Schild SE, Wong WW, Novicki DE, Ferrigni RG, Swanson SK. Detection of residual prostate cancer after radical prostatectomy with the Abbott Imx PSA assay. Urology 1996;47(6):878-81. http://www.ncbi.nlm.nih.gov/pubmed/8677580 9. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37(5):1035-41. http://www.ncbi.nlm.nih.gov/pubmed/9169810 10. Roach III M, Hanks G, Thames jr H, Schelhammer P, Shipley WU, Sokol GE, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-74. http://www.ncbi.nlm.nih.gov/pubmed/16798415 11. Aus G. Current status of HIFU and cryotherapy in prostate cancer – a review. Eur Urol 2006;50(5): 927-34. http://www.ncbi.nlm.nih.gov/pubmed/16971038 12. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141(5):1076-83. http://www.ncbi.nlm.nih.gov/pubmed/2468795 13. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43(5):649-59. http://www.ncbi.nlm.nih.gov/pubmed/7513108 14. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152(5 Pt 2):1821-5. http://www.ncbi.nlm.nih.gov/pubmed/7523728 15. Oefelein MG, Smith N, Carter M, Dalton D, Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol 1995;154(6):2128-31. http://www.ncbi.nlm.nih.gov/pubmed/7500474 16. Leibman BD, Dilliouglugil O, Wheeler TM, Scardino PT. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 1995;76(12):2530-4. http://www.ncbi.nlm.nih.gov/pubmed/8625081 17. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failure after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006;64(4):1140-50. http://www.ncbi.nlm.nih.gov/pubmed/16198506 18. Hancock SL, Cox RS, Bagshaw MA. Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J Urol 1995;154(4):1412-17. http://www.ncbi.nlm.nih.gov/pubmed/7544843 19. Chaplin BM, Wildhagen MF, Schroder FH, Kirkels WJ, Bangma CH. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up. Eur Urol 2005;48(6):906-10. http://www.ncbi.nlm.nih.gov/pubmed/16126322
102
Update march 2009
15. Follow-up after hormonal treatment 15.1
Introduction
A large proportion of patients treated with hormonal therapy have either metastatic or locally advanced tumours at diagnosis. This will affect the scheme of follow-up because biochemical failure is often associated with rapid symptomatic progression.
15.2 Purpose of follow-up The main objectives of following-up these patients are: • to monitor the response to treatment • to ensure compliance with treatment • to detect potential complications of endocrine therapy • to guide the modalities of palliative symptomatic treatment at the time of hormonal escape. However, the usefulness of complementary investigations at various stages of the disease must be clarified in order to avoid unnecessary examinations and excessive economic cost to the community. On the other hand, strict recommendations for follow-up procedures are only useful if effective therapeutic strategies can be offered to patients in cases of disease progression. To date, the issue of early vs late initiation of non-hormonal treatment in hormone-refractory prostate cancer (HRPC) has still not been resolved, so follow-up should be performed on an individual basis. Based on current knowledge, it is not possible to formulate strict guidelines for follow-up procedures following hormonal therapy.
15.3
Methods of follow-up
15.3.1 Prostate-specific antigen monitoring Prostate-specific antigen (PSA) is a good marker for following the course of metastatic prostate cancer (PCa). The prognostic value of PSA (the prediction of the duration of response to endocrine treatment), based on either the initial pre-treatment value or the PSA decrease during the first three to six months, has been used to monitor prostate cancer over the past few decades (1, 2). The initial PSA level can reflect the extent of metastatic disease, although some poorly differentiated tumours do not secrete PSA. The prognostic value of the pre-treatment PSA value is variably assessed in the literature and should not be used solely to predict the duration of response to treatment (3). Treatment response may be assessed utilising the change in serum PSA level as a surrogate end-point for survival in patients with newly diagnosed metastatic PCa after hormonal treatment has been initiated. Patients with the lowest absolute value of serum PSA (< 0.2 ng/mL) also had the best survival compared with those obtaining a value of 0.2-4.0 ng/mL or > 4.0 ng/mL (4). Similar results have been seen in other studies of locally advanced and metastatic PCa (5, 6). The PSA response has been shown to be equally important for patients treated with hormonal therapy because of a rising PSA after treatments with curative intent (radical prostatectomy, radiation therapy). Patients with the best response also had the best survival (7, 8). Despite its usefulness in determining treatment response in individual patients, the role of PSA as a surrogate end-point in clinical trials is more controversial (9). After the initial phase of response to endocrine treatment, patients should be regularly monitored in order to detect and treat any complications of endocrine escape, as clinical disease progression occurs after a median interval of about 12-18 months of treatment in patients with stage M1 disease. It is well established that regular PSA control in asymptomatic patients allows the earlier detection of biochemical escape, as the rise in PSA level usually precedes the onset of clinical symptoms by several months. However, it must be stressed that the PSA level is not a reliable marker of escape and cannot stand alone as a follow-up test. Clinical disease progression (usually bone pain) with normal PSA levels has been reported to occur. 15.3.2 Creatinine, haemoglobin and liver function monitoring Creatinine monitoring has some value because it can detect upper urinary tract obstruction in cases of advanced cancer that might need to be relieved by, for example, percutaneous nephrostomy or double J-stent. Haemoglobin and liver function tests could suggest disease progression and/or toxicity of hormonal treatment, which can lead to interruption of hormonal treatment (i.e. liver toxicity from non-steroidal anti-androgens). The fact that haemoglobin levels will decrease by about 20% with androgen deprivation must be taken into consideration (10).
Update march 2009
103
Alkaline phosphatase and its bone-specific isoenzymes may be used to monitor patients with stage M1b disease. These markers have the advantage of not being directly influenced by hormonal therapy compared with PSA. It should be remembered that increases in serum concentrations of alkaline phosphatase might also be due to osteoporosis induced by androgen deprivation (11). In this scenario, the determination of bonespecific alkaline phosphatase might be helpful. 15.3.3 Bone scan, ultrasound and chest X-ray In routine practice, asymptomatic patients with a normal PSA level should not have a bone scan at regular intervals as disease progression is more reliably detected by PSA monitoring, which also has a lower cost (1214). Moreover, the interpretation of bone scans is sometimes difficult, and the appearance of a new site of uptake or deterioration of pre-existing lesions in an asymptomatic patient does not modify the therapeutic approach. In cases where there is a clinical or laboratory suspicion of disease progression, a chest X-ray or renal and hepatic ultrasound may be indicated. Imaging modalities must also be guided by symptoms. However, these examinations are not recommended for routine use in asymptomatic patients. In hormone-refractory disease, follow-up examinations should be individualised with the aim of maintaining the patient’s quality of life. During long term androgen deprivation therapy (ADT), regular measurement of bone mineral density (BMD) might be recommended (level of evidence: 3) based on the initial T-score (15): every two years if the initial T-score < 1.0, or yearly if the T-score is between 1.0 and 2.5 in the absence of associated risk factors. Otherwise an active treatment should have started at the initiation of ADT.
15.4
When to follow-up
After initiation of hormonal treatment, it is recommended that patients be followed-up at three and six months. These guidelines must be individualised, and each patient should be told to contact his physician in the event of troublesome symptoms. 15.4.1 Stage M0 patients If there is a good treatment response, i.e. symptomatic improvement, good psychological coping, good treatment compliance and a serum PSA level of less than 4 ng/mL, follow-up visits are scheduled every six months. 15.4.2 Stage M1 patients If there is a good treatment response, i.e. good symptomatic improvement, good psychological coping, good treatment compliance and a serum PSA level of less than 4 ng/mL, follow-up is scheduled every three to six months. Patients should be advised of clinical symptoms that could suggest spinal cord compression and told to consult a physician immediately should they occur. 15.4.3 Hormone-refractory patients Patients whose disease progresses, or who do not respond according to the criteria mentioned above, warrant an individualised follow-up scheme.
15.5 Guidelines for follow-up after hormonal treatment Recommendation • Patients should be evaluated at three and six months after the initiation of treatment. As a minimum, tests should include serum PSA measurement, digital rectal examination (DRE), and careful evaluation of symptoms in order to assess the treatment response and the side-effects of the treatments given • Follow-up should be tailored for the individual patient, according to symptoms, prognostic factors and the treatment given • In patients with stage M0 disease with a good treatment response, follow-up is scheduled every six months, and should include as a minimum a disease-specific history, DRE and serum PSA determination
104
GR B
C C
Update march 2009
C • In patients with stage M1 disease with a good treatment response, follow-up is scheduled for every three to six months. • As a minimum, this should include a disease-specific history, DRE and serum PSA determination, and is frequently supplemented with haemoglobin, serum creatinine and alkaline phosphatase measurements • Patients (especially if M1b status) should be advised on the clinical signs that could suggest spinal cord compression • When disease progression occurs, or if the patient does not respond to the treatment given, the C follow-up needs to be individualised • Routine imaging of stable patients is not recommended B GR = grade of recommendation
15.6
REFERENCES
1.
Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987;138(5):1181-4. http://www.ncbi.nlm.nih.gov/pubmed/2444720 2. Mecz Y, Barak M, Lurie A. Prognostic importance of the rate of decrease in prostatic specific antigen (PSA) levels after treatment of patients with carcinoma of prostate. J Tumour Marker Oncol 1989;4:323-8. 3. Petros JA, Andriole GL. Serum PSA after antiandrogen therapy. Urol Clin North Am 1993;20(4):749-56. http://www.ncbi.nlm.nih.gov/pubmed/7505983 4. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford DE, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984-90. http://www.ncbi.nlm.nih.gov/pubmed/16921051 5. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002;168(3):995-1000. http://www.ncbi.nlm.nih.gov/pubmed/12187207 6. Collette L, de Reijke TM, Schröder FH; EORTC Genito-Urinary Group. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2003;44(2):182-9. http://www.ncbi.nlm.nih.gov/pubmed/12875936 7. D’Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen M. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 2004;96(7):509-15. http://www.ncbi.nlm.nih.gov/pubmed/15069112 8. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D’Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005;23(27):6556-60. http://www.ncbi.nlm.nih.gov/pubmed/16170163 9. Collette L, BurzyKowski T, Carroll KJ, Newling D, Morris T and Schroder FH. Is prostate antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005;23(25):6139-48. http://www.ncbi.nlm.nih.gov/pubmed/16135480 10. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79(6):933-41. http://www.ncbi.nlm.nih.gov/pubmed/9202563 11. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001;58(2 Suppl 1):101-7. http://www.ncbi.nlm.nih.gov/pubmed/11502461 12. Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 1992;70(3):295-8. http://www.ncbi.nlm.nih.gov/pubmed/1384920 13. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145(5):907-23. http://www.ncbi.nlm.nih.gov/pubmed/1707989
Update march 2009
105
14.
Sissons GR, Clements MA, Peeling WB, Penney MD. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer? Br J Radiol 1992;65(778):861-4. http://www.ncbi.nlm.nih.gov/pubmed/1384917 15. Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 2003;21(5):392-8. http://www.ncbi.nlm.nih.gov/pubmed/14670551
16. TREATMENT OF BIOCHEMICAL FAILURE AFTER TREATMENT WITH CURATIVE INTENT 16.1
Background
Primary curative procedures such as radical prostatectomy and radiotherapy are well established therapeutic options in the management of localised prostate cancer (PCa). Technical advances in surgery and radiation therapy have improved therapeutic efficacy and decreased treatment-associated morbidity and toxicity, respectively. However, despite these improvements, there is still a significant risk of cancer recurrence after therapy, with between 27% and 53% of all patients undergoing radiation therapy or radical prostatectomy developing local or distant recurrences within 10 years of initial therapy, and 16-35% of patients receiving second-line treatment within five years of initial therapy (1-5, 6).
16.2
Definitions
16.2.1 Definition of treatment failure In previous years, treatment failure was defined as recurrence on digital rectal examination (DRE) or the development of metastatic disease. Currently, treatment failure is defined as a rising prostate-specific antigen (PSA) level based on a study of Pound et al. (7), which demonstrated that no patient followed for more than five years developed any recurrence without a concomitant rise in PSA. The level of PSA that defines treatment failure differs between radical prostatectomy cases and those treated with radiotherapy. Following radical retropubic prostatectomy, two consecutive values of PSA > 0.2 ng/mL appear to represent an international consensus defining recurrent cancer (6, 8). However, the most appropriate definition of biochemical progression after radical prostatectomy is still uncertain. In a retrospective analysis of 2782 men who had undergone radical prostatectomy for clinically localised PCa, Amling et al. (9) determined the best PSA cut-off point to be used to define biochemical recurrence. The authors demonstrated that once PSA recurrence was detected, a subsequent increase in PSA was noted in 49%, 62% and 72% of patients who had PSA levels of 0.2 ng/mL, 0.3 ng/mL and 0.4 ng/mL, respectively. These data indicate that only half the patients with a PSA of 0.2 ng/mL will progress further, and that they can therefore initially be managed by surveillance. Similar data have been presented by Stephenson et al. (10), who identified a PSA value ≥ 0.4 ng/mL as the best cut-off to explain the development of distant metastasis among 10 candidate definitions based on retrospective review of 75 patients who developed distant metastases after radical prostatectomy. Therefore, a cut-off of 0.4 ng/mL is appropriate for the definition of progression with clinical relevance necessitating salvage treatment. Following radiotherapy, a reasonable definition of biochemical relapse is three consecutive increases, according to the recommendation of the American Society for Therapeutic Radiology and Oncology (ASTRO) Consensus Panel (11). The new definition indicates a relapse if the PSA increase is ≥ 2 ng/mL higher than the PSA nadir value, independent of the serum concentration of the nadir (12). 16.2.2 Definition of recurrence Following radical prostatectomy, PSA values > 0.4 ng/mL represent recurrent cancer. Following radiotherapy, a PSA value of 2 ng/mL above the nadir after radiotherapy represents recurrent cancer.
16.3
Local or systemic relapse
With regard to further management once PSA relapse has been diagnosed, it is of major importance to determine whether the recurrence has developed at local or distant sites. About 50% of patients who underwent radical retropubic prostatectomy will have local disease, and the remainder will have either distant
106
Update march 2009
disease alone, or distant and local disease (11). Important parameters to help differentiate between local or distant relapse (Table 18) include: • the timing of the PSA increase after surgery • PSA velocity • PSA doubling time (PSADT) • the pathohistological stage • the Gleason score of the prostatectomy specimen. PSA elevations developing within the first two years following surgery are associated with distant recurrences (12). It has been shown that a median PSADT of 4.3 months is associated with distant relapse, whereas a median PSADT of 11.7 months predicts local failure (13). According to a recent study (14), PSA velocity of < 0.75 ng/mL/y was observed in 94% of patients with local recurrence, whereas 56% of patients with distant metastases demonstrated a PSA velocity of > 0.75 ng/mL/y. Table 18: Important clinical and pathohistological parameters predicting local and systemic relapse following radical prostatectomy Parameter • Interval to PSA relapse ≤ 1 year 1-2 years > 2 years > 3 years • PSA doubling time • Gleason score 2-4 5-6 7 8-10 • Pathological stage Organ confined (≤ pT2b) pT3a, R0 pT3a, R1 pT3b pTxpN1
Local recurrence
Systemic recurrence
7% 10% 61% 74% 11.7 months
93% 90% 39% 26% 4.3 months
0% 55% 39% 11%
0% 45% 61% 89%
40% 54% 48% 16% 7%
60% 46% 52% 84% 93%
With radiotherapy, any continuously rising PSA following a nadir after radiation is an indicator for local recurrence, systemic metastatic spread or a combination of both (11, 14-16). However, due to the well known PSA bounce phenomenon, biochemical recurrence is defined by three consecutive PSA rises above the nadir level according to ASTRO guidelines. After radiotherapy, a late and slowly rising PSA is a sign of local failure only. Local recurrence is defined by: • a prostatic biopsy demonstrating malignant cells 18 months or longer after initial radiotherapy • plus an associated rise in PSA • plus no evidence of metastatic spread documented by computed tomography (CT) or magnetic resonance imaging (MRI) and bone scintigraphy. 16.3.1 Definition of local and systemic failure • Local failure following radical prostatectomy is predicted with an 80% probability by PSA increase > three years after radical prostatectomy, a PSADT ≥ 11 months, a Gleason score ≤ 6, and stage ≤ pT3a pN0, pTx R1. • Systemic failure following radical prostatectomy is predicted with > 80% accuracy by a PSA increase < one year after radical prostatectomy, a PSADT of four to six months, a Gleason score of 8-10, and stage pT3b, pTxpN1. • Local failure after radiotherapy is documented by a positive prostatic biopsy and negative imaging studies.
Update march 2009
107
•
rostatic biopsy after radiotherapy is necessary only if local procedures such as salvage P prostatectomy are indicated in an individual patient.
16.4
Evaluation of PSA progression
In recent years, most patients with PSA progression following initial therapy with curative intent underwent physical and sonographic examinations, radiographic studies or biopsies of the prostatic fossa and the vesicourethral anastomosis to confirm the recurrence identified by serological studies. For patients with asymptomatic PSA-only progression, the yield is very low, and Lange et al. (14) have shown that biochemical failure precedes clinical disease by 6-48 months. In general, DRE is not useful in men with undetectable or very low PSA levels. In a recent study by Öbek et al. (17), it was shown that only 4/72 patients (5.5%) with a PSA recurrence following radical prostatectomy had an abnormal DRE. Traditionally, bone scans and abdominal CT scans have been used to evaluate PSA elevations following primary treatment. Both imaging studies, however, are characterised by a low sensitivity and specificity and might be safely omitted in the routine work-up of relapsing patients. Recently, Cher et al. (18) studied 144 bone scans in 93 patients with PSA recurrence after radical retropubic prostatectomy, of which 122 patients had undergone radical prostatectomy without any hormone treatment, whereas 22 patients had received either neoadjuvant or adjuvant androgen-deprivation therapy (ADT). Only 4.1% and 27% of the bone scintigrams were positive for metastatic disease; the lowest PSA associated with positive findings was 46 ng/mL in the absence of adjuvant ADT, whereas the lowest PSA value was 15.47 ng/mL in patients who had received hormonal therapy. The probability of a positive bone scan remains ≤ 5% until serum PSA reaches at least 40 ng/mL. Similar data have been achieved by other groups that have demonstrated that patients with a true positive bone scan had an average PSA level of > 60 ng/mL and a PSA velocity of 22 ng/mL/y (19, 20). On logistic regression analysis, PSA and PSA velocity predicted the findings on bone scan, and PSA velocity predicted the CT scan result. The probability of a positive bone scan and a positive CT scan was 9.4% and 14%, respectively, among the 132 patients with biochemical recurrence. However, there might be a slight difference between patients after radical retropubic prostatectomy compared with patients after radiation therapy, as demonstrated by Johnstone et al. (21) in whose study 5% and 30%, respectively, of the bone scans, were positive. In summary, bone scintigraphy and CT scans are of no additional diagnostic value unless the PSA serum levels are higher than 20 ng/mL or the PSA velocity is more than 20 ng/mL/y. Endorectal coil imaging has been described as a useful technique to detect local recurrences after radical prostatectomy (22). In a series of 48 patients, local recurrence was correctly identified in 81%, with the mean PSA at time of diagnosis being 2 ng/mL. Positron emission tomography (PET) has been successfully applied in many human cancers for early identification of local or systemic recurrences. In PCa, there are few, but promising, published data on the clinical efficacy of PET in detecting local recurrences after radical prostatectomy (23, 24). However, it must be borne in mind that the uptake of 11C-choline is not specific for PCa and might also be due to inflammatory intraprostatic lesions. In a series of 31 patients with biochemical progression after radical prostatectomy, (11C)acetate-PET demonstrated a high sensitivity and specificity for the detection of local recurrences if the PSA serum level was > 1 ng/mL (23). In another recent series of 43 patients with newly diagnosed prostate cancer, there was a significant correlation between the 11C-choline uptake and the intraprostatic location of PCa as analysed in radical prostatectomy specimens (25). Similar results have been reported for the detection of locally recurrent PCa after radiation therapy (26). However, sensitivity with regard to extraprostatic extension was significantly lower for 11C-PET when compared with MRI. The most recent series to evaluate the role of 11C-choline PET/CT in patients with biochemical recurrence after radical prostatectomy identified a significant PSA relationship: the sensitivity to identify the localisation of metastases was 20-36% at PSA levels ≤ 1 ng/mL, and increased to 63-83% in men with PSA levels ≥ 3 ng/mL (27-30). The role of choline PET/CT to detect local or systemic recurrences in men with PSA relapse following radiotherapy is unclear and based on very few studies (31). Thus no final recommendations can be made. Its sensitivity and specificity with regard to the detection of lymph node metastases is less reliable, and the routine use of 11C-PET cannot therefore be recommended, especially not for PSA values < 1 ng/mL. 108
Update march 2009
Immunoscintigraphy using a radiolabelled monoclonal antibody based on prostate-specific membrane antigen for messenger RNA (PSMA), called 111-indium capromab pendetide, might represent an innovative diagnostic approach, with an overall accuracy of up to 81% to detect the site of relapse in PSA-only recurrences following radical retropubic prostatectomy (23, 24, 32, 33). Independent of the PSA serum concentration, a capromab pendetide scan shows a diagnostic yield of 60-80%, and may help to stratify therapy according to the location of positive sites. A recent study (33) investigating 255 patients with PSA-only recurrence < 4.0 ng/mL after radical prostatectomy, showed capromab pendetide uptake in 72% throughout the range of post-operative PSA serum levels (0.1-4.0 ng/mL). Approximately 31%, 42% and 25% of patients exhibited local uptake, locoregional uptake and distant uptake, respectively, enabling therapy to be targeted according to the differentiation of local versus systemic relapse. It has been common practice to perform transrectal ultrasound- (TRUS) guided biopsies of the prostatic fossa, the anastomosis or the prostate gland to exclude local recurrence after radical retropubic prostatectomy or radiotherapy. However, according to available studies, routine biopsy of the vesicourethral anastomosis appears not to be justified based on a verification rate of only 54% (34-38). Only in the presence of a palpable lesion or a hypoechoic lesion on TRUS can the diagnostic yield of the biopsy be improved to approximately 80%. Furthermore, there is a strong correlation between the positive biopsy rate and PSA serum concentrations (34-38); 28% and 70% of the biopsies were positive if the PSA level was, respectively, below 0.5 ng/mL or greater than 2.0 ng/mL. It is common sense, nowadays, that routine anastomotic biopsy is not indicated, and the use of PSA and PSADT is sufficient for clinical practice. In addition, PSA-free survival in biopsy-proven recurrences does not differ significantly compared with PSA-only recurrences. With regard to PSA relapses following radiation therapy, routine prostate biopsy should no longer be performed for the evaluation of PSA-only recurrences, according to an ASTRO consensus recommendation (15). However, prostate biopsy documenting local recurrence represents the main cornerstone in the decision-making process for salvage radical prostatectomy in patients with rising PSA levels following a nadir after radiation therapy (3941). It is a general recommendation to wait about 18 months and three months following radiation therapy or seeds, and cryotherapy or high-intensity focused ultrasound (HIFU), respectively.
16.5
Diagnostic procedures in patients with PSA relapse
•
ollowing radical prostatectomy, CT scans of the pelvis and abdomen are of low sensitivity and F specificity in patients with PSA levels < 20 ng/mL or a PSA velocity of < 20 ng/mL/y Endorectal MRI or PET scans may help to detect local recurrences if PSA is > 1-2.0 ng/mL, but is not yet routine clinical practice If available, a capromab pendetide scan shows a diagnostic yield of 60-80% independent of the PSA serum level Following radiation therapy, local recurrence is documented by a positive biopsy > 18 months after the procedure.
• • •
16.6
Treatment of PSA-only recurrences
The timing and mode of treatment of PSA-only recurrence after radical prostatectomy or radiation therapy remains controversial. After radical retropubic prostatectomy observation, radiation therapy to the prostatic bed, (complete) androgen blockade, intermittent androgen deprivation (IAD), a combination of anti-androgens with 5-α-reductase inhibitors, and even early chemohormonal approaches are therapeutic options. The same therapeutic options may be applied for PSA recurrences following radiation therapy. In addition, salvage prostatectomy, cryotherapy and brachytherapy might be indicated in carefully selected patients. 16.6.1 Radiation therapy for PSA-only recurrence after radical prostatectomy Considering the numerous studies on the use of radiation therapy for PSA-only recurrence following radical retropubic prostatectomy, there is a growing body of parameters predicting outcome that might be helpful to differentiate between observation, radiation and hormonal therapy. As confirmed by various studies, the pre-radiation PSA level appears to be of critical importance for obtaining optimal treatment results (42-50). Applying a pre-radiation cut-off of < 2.5 ng/mL, Wu et al. (42) and Schild et al. (43) reported disease-free survival rates of 53% and 76%, compared with 8% and 26%, respectively, for patients with PSA serum levels > 2.5 ng/mL. Forman et al. (44) demonstrated a disease-free survival rate of 83% compared with 33% in patients with a PSA-only recurrence of less than 2.0 ng/mL and greater than 2.0 ng/mL, respectively. Nudell et al. (45) even reported progression-free survival rates of 58% and 21% in patients having undergone radiation of the prostate bed if PSA serum levels were below 1.0 ng/mL or greater than 1.0 ng/mL, respectively. Based on
Update march 2009
109
these data, ASTRO has published a consensus paper recommending a dose of at least 64 Gy when the PSA level is < 1.5 ng/mL after radical retropubic prostatectomy (15). These data of early salvage radiation therapy are corroborated by recent papers (51-53) demonstrating a significant difference with regard to the five-year biochemical-free and overall survival rates in patients being treated for PSA recurrence only or for palpable locally recurrent cancer. The analysis of patterns of treatment failure in SWOG 8974, a prospective randomised clinical trial to address whether high-risk post-prostatectomy patients benefited from immediate radiation therapy to the prostate fossa, identified a 77% freedom from PSA failure in a subgroup of patients with post-operative PSA levels ≤ 0.2 ng/mL (52). In men with PSA levels of > 0.2 ng/mL and ≤ 1.0 ng/mL, the five-year PSA recurrence-free survival was 34%, and 0% in patients post-operative PSA serum levels > 1.0 ng/mL. These data indicated that adjuvant radiation therapy is effective even in high-risk patients, and that the therapeutic benefit is most evident in the presence of minimal PSA serum levels. In another study, Stephenson et al. (53) evaluated prognostic models to predict the outcome of salvage radiation therapy on a cohort of 1603 men with PSA progression after radical prostatectomy who were operated on in 17 North American tertiary referral centres. The authors identified a significant relationship between PSA serum concentration at the time of radiation therapy and therapeutic outcome: the six-year biochemical-free survival was 48% in men with PSA < 0.5 ng/mL, whereas it was only 40%, 28% and 18% in men with PSA levels of 0.51-1 ng/mL, 1.01-1.5 ng/mL and > 1.5 ng/mL, respectively. Egewa et al. (49) reported five-year biochemical-free and overall survival rates of 69% and 96%, compared with 45% and 78%, respectively, in the group with palpable disease. However, there is still a lack of data from prospective randomised trials, and all of the studies being performed lack long-term follow-up, so the impact on survival is unknown. 16.6.2 Hormonal therapy In patients with a high pre-radical prostatectomy PSA > 20 ng/mL, a Gleason grade > 7, an extensive positive surgical margin and extensive extraprostatic tumour growth (pT3b, pTxpN1), immediate hormonal therapy might be indicated (46-50). The impact of early ADT on long-term survival is still unknown, however. In a retrospective observational multicentre study including 1352 patients with PSA recurrence following radical prostatectomy (51), early ADT resulted in a significant reduction of the development of clinical metastases compared with delayed ADT. There was, however, no significant effect on long-term survival. These recommendations are corroborated by a study (54) demonstrating that none of the patients with a Gleason score of 8, pT3b or pTxpN1 PCa remained disease-free following radiation therapy for PSA-only recurrence after radical prostatectomy. It is difficult to make recommendations for the optimal therapeutic management for PSA-only recurrences following radical prostatectomy or radiation therapy because of the lack of prospective randomised trials. There are only very few studies analysing the clinical utility of early androgen deprivation in locally advanced (M0) and metastatic PCA (54, 55). It is believed that for the M0 category of patients with pTxN1 disease who have undergone radical prostatectomy reflecting PSA-only recurrences, hormonal therapy would appear to be beneficial for some with a high probability of occult systemic metastases. There is some evidence that combined androgen blockade (CAB) has a pronounced survival benefit in patients with minimal metastatic disease, so patients with PSA-only recurrences might have a similarly improved survival with combined androgen deprivation (56, 57). Considering the speculative benefits, the sideeffects of traditional hormonal therapy – such as hot flushes, loss of libido, impotence, decreased muscle mass and osteoporosis – must not be underestimated. The use of anti-androgens alone might overcome these side-effects as demonstrated in recent studies. Although gynaecomastia and breast tenderness were the most predominant side-effects for the treatment of organ-confined and locally advanced PCa, the incidence of hot flushes, loss of libido and impotence was significantly lower than expected for luteinising hormone-releasing hormone (LHRH) agonists and CAB (58). Furthermore, the risk of objective progression of the disease was significantly reduced in patients receiving bicalutamide 150mg (59). Anti-androgens may represent a viable alternative to other modes of androgen deprivation for the management of PSA-only recurrences, especially in young and otherwise healthy men. Non-traditional ways of using hormonal therapy for PSA-only recurrence include IAD and oral therapies combining anti-androgens with 5-α-reductase inhibitors (60-67). In the setting of PSA-only recurrences, however, no prospective randomised trials and no clinical studies with sufficient data on long-term efficacy
110
Update march 2009
are available to justify a routine clinical application of IAD, despite its potential benefits. Summarising the series in which PSA-only recurrences were treated by IAD (60-64), PSA threshold levels at study-entry varied significantly, as did the PSA level at discontinuation of hormonal therapy. Only the study of 150 patients by Tunn (64) had a sufficiently appropriate study design to allow the drawing of important clinical conclusions. Patients were started on IAD for nine months when the postprostatectomy PSA serum level was greater than 3.0 ng/mL, and all patients reached a nadir of less than 0.5 ng/mL. IAD was restarted when PSA increased to more than 3.0 ng/mL. After a mean follow-up of 48 months, and a mean duration of hormonal therapy of 26.6 months, none of the patients had progressed to hormonerefractory disease. In some studies, finasteride and flutamide have been combined to manage PSA-only recurrences since both agents work additively by blocking the intraprostatic conversion of testosterone to dihydrotestosterone (DHT), and blocking the intracytoplasmic DHT receptor (65-67). In the latest report (66), including 73 patients, the application of finasteride (10 mg/day) and low-dose flutamide (250 mg/day) resulted in a mean PSA nadir of 1.35 ng/mL within six months. However, only 62% of the patients studied reached a PSA nadir of < 0.2 ng/mL. After a mean follow-up of 15 months, none of the patients had progressed to traditional hormonal therapy. However, longer follow-up of a larger patient cohort is needed, and randomised phase III trials using modern anti-androgens with fewer gastrointestinal and hepatic side-effects are mandatory. 16.6.3 Observation Observation until the development of clinically evident metastatic disease might represent a viable option for patients with a Gleason score ≤ 7, PSA recurrence longer than two years after surgery, and a PSADT longer than 10 months. In these patients, the median actuarial time for the development of metastasis will be eight years, and the median time from metastasis to death will be another five years. 16.6.4 Management of PSA relapse after radical prostatectomy Recommendations GR • Local recurrences are best treated by salvage radiation therapy with 64-66 Gy at a PSA serum B level ≤ 1.5 ng/mL • Expectant management is an option for patients with presumed local recurrence who are too B unfit or unwilling to undergo radiation therapy • PSA recurrence indicative of systemic relapse is best treated by early ADT resulting in decreased B frequency of clinical metastases • LHRH analogues/orchiectomy or bicalutamide 150 mg/day can both be used when there is A indication for hormonal therapy GR = grade of recommendation
16.7
Management of PSA failures after radiation therapy
In a recent review of the data of the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) comprising 2336 patients with PCa, Grossfeld et al. (68) demonstrated that 92% of patients initially irradiated received ADT for secondary treatment of PSA progression. In the absence of salvage procedures, the mean time interval from biochemical to clinical progression is approximately three years. Therapeutic options in these patients are ADT or local procedures, such as salvage radical prostatectomy, cryotherapy and interstitial radiation therapy (69-74). Salvage radical retropubic prostatectomy has not, however, gained widespread acceptance because of its associated morbidity, namely incontinence, local recurrences and rectal injuries. However, in well selected patients, the procedure might result in long-term disease-free survival. One has to consider that most series reporting on salvage radical prostatectomy include patients who were treated in the pre-PSA era without modern radiotherapeutic techniques, and local recurrences were usually detected at a late stage. Complications associated with the procedure were therefore quite high, with up to 65% of patients suffering from treatment-related morbidities. Up to 60% of patients in whom salvage radical prostatectomy was planned, had to undergo anterior or total exenteration for locally extensive disease associated with a high rate of local recurrences and a mean time to progression of only 1.3 years (46, 49, 52, 53). Recent reports analysing patients who were operated on during the past decade, have described far more optimistic outcomes after salvage radical prostatectomy. In the series examined by Gheiler et al. (73), 40 patients with a mean PSA of 14 ng/mL underwent salvage radical prostatectomy. When stratified by PSA less than or greater than 10 ng/mL, the three-year disease-specific survival was 68% and 26%, respectively.
Update march 2009
111
In the series reported by Garzotto and Wajsman (74), 24 patients underwent radical cystoprostatectomy or radical prostatectomy with neoadjuvant ADT. Neoadjuvant ADT was associated with a lower rate of positive surgical margins (21%) compared with patients in whom androgen deprivation failed and who exhibited a positive surgical margin rate of 80%. The authors demonstrated that disease-specific survival correlated strongly with the surgical margin status. At a mean follow-up of five years, the disease-specific survival rate was 95% and 44% for those with negative and positive surgical margins, respectively. Vaidya and Soloway (75) demonstrated a low complications rate, good post-operative continence and only one biochemical recurrence 36 months after salvage radical prostatectomy. Similar data have been achieved by Stephenson et al. (76), who reported on 100 consecutive patients undergoing radical salvage prostatectomy associated with a very low rate of peri-operative complications. The five-year progression-free rates have improved, and the results are similar to those of standard radical prostatectomy in cases of similar pathological stages. The 10-year cancer-specific and overall survival rates are in the ranges 70-75% and 60-66%, respectively, in contemporary series. In most contemporary series, organ-confined disease, negative surgical margins and the absence of seminal vesicle and/or lymph node metastases are favourable prognosticators associated with a better disease-free survival of approximately 70-80%, compared with 40-60% in patients with locally advanced PCa (77). In general, salvage radical retropubic prostatectomy should be considered only in patients with a low co-morbidity, a life expectancy of at least 10 years, an organ-confined PCa < T2, Gleason grade < 7, and presurgical PSA < 10 ng/mL. In all other patients, accurate pre-surgical staging is not easily defined after radiation therapy, increasing the risk not only for the necessity of anterior and total extirpation procedures, but also for associated complications and decreased long-term disease-specific survival. 16.7.1 Salvage cryosurgical ablation of the prostate (CSAP) for radiation failures Salvage cryosurgery has been proposed as an alternative to salvage prostatectomy as it has the potential advantage of less morbidity but equal efficacy. Only very few studies are available, and the results are not very promising. Pisters et al. (78) reported on 150 patients who had undergone CSAP for PSA recurrences following radiotherapy (n = 110) or other extensive pre-treatment (n = 40). After a mean follow-up of 13.5 months, 58% of patients exhibited biochemical failure, and only 31% demonstrated undetectable PSA serum levels. The complications associated with salvage CSAP were significant, and occurred in virtually all patients, with the main complications being urinary incontinence (73%), obstructive symptoms (67%), impotence (72%) and severe perineal pain (8%). After a one-year follow-up, incontinence resolved in the majority of patients, with persistent significant incontinence in 22% of patients (53%). According to a recent study by Cespedes et al. (79), the risk for urinary incontinence and impotence at least 12 months after CSAP are as high as 28% and 90%, respectively. In addition, 8-40% of patients complained about persistent rectal pain, and an additional 4% of men had undergone surgical procedures for the management of treatment-associated complications. With regard to oncological outcome, recent studies demonstrated that a durable PSA-response can be achieved in about 50% of patients with a pre-cryosurgery PSA of < 10 ng/mL (80). 16.7.2 Salvage brachytherapy for radiation failures The experience with salvage brachytherapy for radiation failures is very limited and there is only one study that includes a representative number of patients and a mean follow-up of 64 months (81-84). Grado et al. (83) treated 49 patients with transperineal TRUS-guided brachytherapy and reported three- and five-year disease-free survival rates of 48% and 43%, respectively. Beyer (84) reported a five-year biochemical freedom from relapse in 34-53% of patients, with local cancer control achieved in 98% of patients. However, the complication rate was quite severe, with 27% of the patients becoming incontinent, 14% needing palliative transurethral resection of the prostate (TURP) due to acute urinary retention, another 4% suffering from rectal ulcers, and 2% requiring permanent colostomy. 16.7.3 Observation Patients with signs of local recurrence only (low-risk patients with late recurrence and a slow PSA rise) who are not opting for second-line curative options are best managed by observation alone. A retrospective cohort analysis of hormonal therapy versus watchful waiting in 248 men with PSA failure after radiotherapy showed no advantage for hormonal therapy in the subgroup of men with a PSADT of > 12 months after radiotherapy. The five-year metastasis-free survival rate was 88% with hormonal therapy vs 92% with watchful waiting (p = 0.74) (85).
112
Update march 2009
16.7.4 Management of PSA relapse after radiation therapy Recommendation GR • Local recurrences may be treated by salvage radical prostatectomy in carefully selected patients C • CSAP and interstitial brachytherapy are alternative procedures in patients not suitable for surgery C • ADT is an option in patients with presumed systemic relapse B GR = grade of recommendation
16.8 Guidelines for second-line therapy after treatment with curative intent Recommendation GR • Presumed local failure Patients with presumed local failure only may be candidates for salvage B after radical radiotherapy radiotherapy. This should be given with at least 66 Gy and preferably prostatectomy before PSA has risen above 1.0 ng/mL. Other patients are best offered a period of watchful waiting (active monitoring), with possible hormonal therapy later on • Presumed local failure Selected patients may be candidates for salvage radical prostatectomy C after radiotherapy although patients should be informed about the comparatively high risk of complications. Other patients are best offered a period of watchful waiting (active monitoring), with possible hormonal therapy later on • Presumed distant failure There is some evidence that early hormonal therapy may be of benefit B in +/– local failure, delaying progression, and possibly achieving a survival benefit in comparison with delayed therapy. The results are not without controversy. Local therapy is not recommended except for palliative reasons GR = grade of recommendation
16.9
REFERENCES
1.
Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, Carroll PR. Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database. J Urol 1998;1609(4):1398-404. http://www.ncbi.nlm.nih.gov/pubmed/9751363 Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996;88(3-4):166-73. http://www.ncbi.nlm.nih.gov/pubmed/8632490 Fowler FJ Jr, Barry MJ, Lu-Yao GL, Roman A, Wasson JH, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993;42(6):622-9. http://www.ncbi.nlm.nih.gov/pubmed/8256394 Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemen JQ, Epstein JI, Walsh PC. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43(5):649-59. http://www.ncbi.nlm.nih.gov/pubmed/7513108 Bott SRJ. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004;7(3):211–6. http://www.ncbi.nlm.nih.gov/pubmed/15278094 Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery – what we have learned and where we are going. J Urol 1999;162(2):293-306. http://www.ncbi.nlm.nih.gov/pubmed/10411025 Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7. http://www.ncbi.nlm.nih.gov/pubmed/10235151 Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163(6):1632-42. http://www.ncbi.nlm.nih.gov/pubmed/10799151 Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 65(4):1146-51. http://www.ncbi.nlm.nih.gov/pubmed/11257657
2.
3.
4.
5.
6.
7.
8. 9.
Update march 2009
113
10.
Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, Lilja H, Scardino PT. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24(24): 3973 –78 http://www.ncbi.nlm.nih.gov/pubmed/16921049 11. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37(5):1035-41. http://www.ncbi.nlm.nih.gov/pubmed/9169810 12. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Biol Phys 65:965–74. http://www.mdconsult.com/das/citation/body/120674870-2/jorg=journal&source=MI&sp=16362265&s id=0/N/16362265/1.html 13. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152(5 Pt 2):1821-5. http://www.ncbi.nlm.nih.gov/pubmed/7523728 14. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141(4):873-9. http://www.ncbi.nlm.nih.gov/pubmed/2467013 15. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17(4):1155–63. http://www.ncbi.nlm.nih.gov/pubmed/10561174 16. Taylor JM, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 2001;50(5):1212-9. http://www.ncbi.nlm.nih.gov/pubmed/11483331 17. Öbek C, Neulander E, Sadek S, Soloway MS. Is there a role for digital rectal examination in the follow up of patients after radical prostatectomy. J Urol 1999;162(3 Pt 1):762-4. http://www.ncbi.nlm.nih.gov/pubmed/10458361 18. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, Banerjee M, Pontes JE, Wood DP Jr. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160(4):1387-91. http://www.ncbi.nlm.nih.gov/pubmed/9751361 19. Kane CJ, Amling CL, Johnstone PAS, Pak N, Lance RS, Thrasher B, Foley JP, Riffenburgh RH, Moul JW. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003;61(3):607–11. http://www.ncbi.nlm.nih.gov/pubmed/12639656 20. Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 2004;94(3):299–302. http://www.ncbi.nlm.nih.gov/pubmed/15291855 21. Johnstone PAS, Tarman GJ, Riffenburgh R. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol Oncol 1997;3108-14. 22. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004;231(2):279–385. http://www.ncbi.nlm.nih.gov/pubmed/15064390 23. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002;29(10):1380–4. http://www.ncbi.nlm.nih.gov/pubmed/12271422 24. Heinisch M, Dirisamer A, Loidl W, Stiober F, Gruy B, Haim S, Langsteger W (2006) Positron emission tomography/computed tomography with F-18-flourocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8:43-8. 25. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, Bertaccini A, Manferrari F, Castellucci P, Fanti S, Canini R, Grigioni WF, D’Errico Grigioni A. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176(3):954-60; discussion 960. http://www.ncbi.nlm.nih.gov/pubmed/16890665
114
Update march 2009
26.
Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007;99(6):1415-20. http://www.ncbi.nlm.nih.gov/pubmed/17428249 27. Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE, Wittbrodt M, Egghart G, Moeller P, Blumstein N, Reske S, Kuefer R. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 2008;81(2):191-7 http://www.ncbi.nlm.nih.gov/pubmed/18758218 28. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, Schuster T, Geinitz H, Treiber U, Schwaiger M. The detection rate of [11C]Choline-PET/CT depends on the serum PSAvalue in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008 Jan;35(1):18-23 http://www.ncbi.nlm.nih.gov/pubmed/17891394 29. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, Cservenyàk T, Hany TF. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008 Feb;35(2):253-63. http://www.ncbi.nlm.nih.gov/pubmed/17926036 30. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, Mancini M. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008 Sep;113(6):895-904. http://www.ncbi.nlm.nih.gov/pubmed/18414809 31. Heidenreich A, Semrau R, Thüer D, Pfister D. Radical salvage prostatectomy: Treatment of local recurrence of prostate cancer after radiotherapy. Urologe A 2008 Nov;47(11):1441-6. http://www.ncbi.nlm.nih.gov/pubmed/18806991 32. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD, Maguire R, Rogers B, Olsen JO, Badalament RA. Multicentre radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998;83(4):739–47. http://www.ncbi.nlm.nih.gov/pubmed/9708939 33. Levesque PE, Nieh PT, Zinman LN, Seldin DW, Libertino JA. Radiolabelled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998;51(6):978-84. http://www.ncbi.nlm.nih.gov/pubmed/9609636 34. Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, Maguire RT. 111Indium capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstScint Study Group. J Urol 1998;159(6):2041-6;discussion 2046-7. http://www.ncbi.nlm.nih.gov/pubmed/9598514 35. Raj GV, Partin AW, Polascik TJ. Clinical utility of Indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002;94(4):987-96. http://www.ncbi.nlm.nih.gov/pubmed/11920467 36. Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carroll P, Narayan P. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 1995;149(5):1024-8. http://www.ncbi.nlm.nih.gov/pubmed/7683341 37. Fowler JE Jr, Brooks J, Pandey P, Seaver LE. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995;153(3 Pt 2):1011-4. http://www.ncbi.nlm.nih.gov/pubmed/7531783 38. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996;47(2):225-31. http://www.ncbi.nlm.nih.gov/pubmed/8607239 39. Vaidya A, Soloway MS. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited. J Urol 2000;164(6):1998-2001. http://www.ncbi.nlm.nih.gov/pubmed/11061900 40. Shekarriz B, Upadhyay J, Pontes JE. Salvage radical prostatectomy. Urol Clin North Am 2001;28(3):545-53. http://www.ncbi.nlm.nih.gov/pubmed/11590813
Update march 2009
115
41.
Eastham JA, DiBlasio CJ, Scardino PT. Salvage radical prostatectomy for recurrence of prostate cancer radiation therapy. Curr Urol Rep 2003;4(3):211-5. http://www.ncbi.nlm.nih.gov/pubmed/12756084 42. Wu JJ, King SC, Montana GS, McKinstry CA, Anscher MS. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995;32(2):317-23. http://www.ncbi.nlm.nih.gov/pubmed/7538500 43. Schild SE, Buskirk SJ, Wong WW, Halyard MY, Swanson SK, Novicki DE, Ferrigni RG. The use of radiotherapy or patients with isolated elevation of prostate specific antigen following radical prostatectomy. J Urol 1996;156(5):1725-9. http://www.ncbi.nlm.nih.gov/pubmed/8863580 44. Forman JD, Meetze K, Pontes E, Wood DP Jr, Shamsa F, Rana T, Porter AT. Therapeutic irradiation for patients with an elevated postprostatectomy prostate specific antigen level. J Urol 1997;158(4):1436-9; discussion 1439-40. http://www.ncbi.nlm.nih.gov/pubmed/9302138 45. Nudell DM, Grossfeld GD, Weinberg VK, Roach M 3rd, Carroll PR. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999;54(6):1049-57. http://www.ncbi.nlm.nih.gov/pubmed/10604707 46. Carroll P. Rising PSA after a radical treatment. Eur Urol 2001;40(Suppl 2):9-16. http://www.ncbi.nlm.nih.gov/pubmed/11684859 47. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998;159(1):173-7;discussion 177-8. http://www.ncbi.nlm.nih.gov/pubmed/9400465 48. Haab F, Meulemans A, Boccon-Gibbod L, Dauge MC, Delmas V, Hennequin C, Benbunan D, BocconGibbod L. Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology 1995;45(6):1022-7. http://www.ncbi.nlm.nih.gov/pubmed/7539559 49. Egewa S, Matsumoto K, Suyama K, Soh S, Kuwao S, Iwamura M. Limited suppression of prostate specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy. Urology 1999;53(1):148-55. http://www.ncbi.nlm.nih.gov/pubmed/9886604 50. Vicini FA, Ziaja EL, Kestin LL, Brabbins DS, Stromberg JS, Gonzalez JA, Martinez AA. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999;54(1):111-17. http://www.ncbi.nlm.nih.gov/pubmed/10414736 51. MacDonald OK, Schild SE, Vora S, Andrews PE, Ferrigni RG, Novicki V, Swanson SK, Wong WW. Salvage radiotherapy for men with isolated rising PSA or local palpable recurrence after radical prostatectomy: do outcomes differ? Urology 2004;64(4):760-4. http://www.ncbi.nlm.nih.gov/pubmed/15491716 52. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. Predominant treatrment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007;25(16):222– 9. http://www.ncbi.nlm.nih.gov/pubmed/17538167 53. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25(15):2035–41 http://www.ncbi.nlm.nih.gov/pubmed/17513807 54. The MRC Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the MRC trial. Br J Urol 1997;79(2):235-46. http://www.ncbi.nlm.nih.gov/pubmed/9052476 55. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl J Med 1999;341(24):1781-8. http://www.ncbi.nlm.nih.gov/pubmed/10588962 56. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med 1989;321(7):419-24. http://www.ncbi.nlm.nih.gov/pubmed/2503724
116
Update march 2009
57.
Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D, Bono A, Sylvester R. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and EORTC Data Cancer. Eur Urol 1998;33(2):144-51. http://www.ncbi.nlm.nih.gov/pubmed/9519355 58. Wirth M, Tyrrell C, Wallace M, Delaere KP, Sanchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T, Stone A. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001;58(2):146-51. http://www.ncbi.nlm.nih.gov/pubmed/11489683 59. Wirth M. Delaying/reducing the risk of clinical tumour progression after primary curative procedures. Eur Urol 2001;40(Suppl 2):17-23. http://www.ncbi.nlm.nih.gov/pubmed/11684860 60. Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years’ follow-up. Mol Urol 1999;3(3):287-92. http://www.ncbi.nlm.nih.gov/pubmed/10851335 61. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996;48(5):800-4. http://www.ncbi.nlm.nih.gov/pubmed/8911533 62. Tunn UW. Intermittent endocrine therapy of prostate cancer. Eur Urol 1996;30(Suppl 1):22-5, discussion 38-9. http://www.ncbi.nlm.nih.gov/pubmed/8977986 63. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998;51(1):137-44. http://www.ncbi.nlm.nih.gov/pubmed/9457309 64. Tunn U, Eckhart O, Kienle E, Hillger H. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy - first results of a randomized prospective phase III clinical trial (AUO study AP06/95). Eur Urol (Suppl) 2003;1:24, no.86. 65. Ziada AM, Crawford ED. Advanced prostate cancer. Prostate Cancer Prostatic Dis 1999;2(S1):21-6. http://www.ncbi.nlm.nih.gov/pubmed/12496853 66 Harding P, Moul JW, McLeod DG. Combination flutamide and finasteride in PSA-only recurrence after prior local prostate cancer therapy. J Urol 1998;159(Suppl):130 (abstr). 67. Lisle T, Makenzie S, Ziada AM, Harding P, Rosenblum M, Stenner J, Moul JW, Crawford ED. Androgen deprivation therapy using finasteride and low-dose flutamide to treat PSA failure following therapy for clinically localized adenocarcinoma of the prostate. J Urol 1999;161(Suppl):299 (abstr). 68. Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS, Carroll PR. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 2002;168(2):530-5. http://www.ncbi.nlm.nih.gov/pubmed/12131303 69. Ahlering TE, Lieskovsky G, Skinner DG. Salvage surgery plus androgen deprivation for radioresistant prostatic carcinoma. J Urol 1992;147(3 Pt 2):900-2. http://www.ncbi.nlm.nih.gov/pubmed/1538492 70. Zincke H. Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcomes. J Urol 1992;147(3 Pt 2):894-9. http://www.ncbi.nlm.nih.gov/pubmed/1538491 71. Lerner SE, Blute ML, Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995;154(3):1103-9. http://www.ncbi.nlm.nih.gov/pubmed/7543608 72. Rogers E, Ohori M, Kassabian S, Wheeler TM, Scardino PT. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995;153(1):104-10. http://www.ncbi.nlm.nih.gov/pubmed/7526002 73. Gheiler EL, Tefilli MV, Tiguert R, Grignon D, Cher ML, Sakr W, Pontes JE, Wood DP Jr. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998;51(5):789-95. http://www.ncbi.nlm.nih.gov/pubmed/9610593 74. Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: result of a 5-year follow-up. J Urol 1998;159(3):950-4;discussion 954-5. http://www.ncbi.nlm.nih.gov/pubmed/9474190 75. Vaidya A, Soloway MS. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited. J Urol 2000;164(6):1998-2001. http://www.ncbi.nlm.nih.gov/pubmed/11061900
Update march 2009
117
76.
Stephenson AJ, Scardino PT, Bianco FJ, DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004;172(6 Pt 1):2239–43. http://www.ncbi.nlm.nih.gov/pubmed/15538239 77. Heidenreich A, Ohlmann C, Ozgür E, Engelmann U. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy] Urologe A 2006;45(4):474-81. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/16465521 78. Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CPM, Pettaway CA, Babaian RJ. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 1997;157(3):921-5. http://www.ncbi.nlm.nih.gov/pubmed/9072600 79. Cespedes RD, Pisters LL, von Eschenbach AC, McGuire EJ. Long-term follow-up of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. J Urol 1997;157(1):237-40. http://www.ncbi.nlm.nih.gov/pubmed/8976261 80. Clarke HS Jr, Eskridge MR, El-Zawahry AM, Keane TE. Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm. Can J Urol 2007 Dec;14 Suppl 1:24-7 http://www.ncbi.nlm.nih.gov/pubmed/18163941 81. Wallner KE, Nori D, Morse MJ, Sogani PC, Whitmore WF, Fuks Z. 125iodine reimplantation for locally progressive prostatic carcinoma. J Urol 1990;144(3):704-6. http://www.ncbi.nlm.nih.gov/pubmed/2388332 82. Parker CC, Dearnaley DP. The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol 1998;49(2):103-10. http://www.ncbi.nlm.nih.gov/pubmed/10052875 83. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swandon GP, Larson TR, Wilkes MM, Navickis RJ. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1):2-10. http://www.ncbi.nlm.nih.gov/pubmed/9886580 84. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999;54(5):880-3. http://www.ncbi.nlm.nih.gov/pubmed/10565751 85. Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 2003;97(4):1127-33. http://www.ncbi.nlm.nih.gov/pubmed/12569615
118
Update march 2009
17. Hormone refractory prostate cancer (HRPC) 17.1
Background
Cancer of the prostate is a heterogeneous disease and our knowledge of the mechanisms involved in androgen independence remains incomplete (1-5). It is known that androgen ablation provides a selective advantage to androgen-independent cells that grow and eventually comprise most of the tumour. An alteration in normal androgen signalling is thought to be central in the pathogenesis of androgen-independent PCa (6). Androgen independence is thought to be mediated through two main, overlapping, mechanisms, which are androgen-receptor (AR)-independent and AR-dependent. Androgen-receptor-independent mechanisms may be associated with the deregulation of apoptosis through the deregulation of oncogenes. High levels of bcl-2 expression are seen with greater frequency as PCa progress and the regulation of microtubule integrity may be a mechanism through which bcl-2 induces its anti-apoptotic effect (7-9). Indeed, most active chemotherapeutics in hormone-resistant prostate cancer (HRPC) work by inhibiting microtubule formation. The tumour suppressor gene p53 is more frequently mutated in androgen-independent PCa. Over-expression of bcl-2 and p53 in prostatectomy specimens has been shown to predict an aggressive clinical course (10-12). Clinical trials are underway to target the bcl-2 pathway (13) as the MDM2 oncogene (14). The PTEN (phosphatase and tensin homolog) suppressor gene may also be involved (15). However, direct AR-dependent mechanisms comprise the main pathway. Ligand-independent AR activation has been suspected, such as tyrosine kinase activated pathway (IGF-1, KGF, EGF). Epidermal growth factor (EGF) is a potent mitogen of prostate stromal and epithelial cells. It is produced in high levels locally and acts as a paracrine stimulator. In AR-independent tumours, autocrine stimulation may become more important, which could allow unregulated growth (16). Androgen receptor amplification is observed in one-third of HRPC tissues (17) and may lead to AR hypersensitivity. Androgen receptor mutations may lead to a functional change in AR function (3-5) (18). Because AR mutations are found in only a subpopulation of tumour cells, they are unlikely to be responsible for the entire spectrum of the AR-independent state (19). The AR mutations might be related to the selective pressure of anti-androgens (20). The recent discovery of gene fusion between the androgen-driven TMPRSS2 and the EGR-ETS oncogene family (21) raises the question of oncogene regulation through androgen regulation pathways. The mechanism of gene fusion is based on the association of an androgen-responsive element from an androgene-regulated gene with genes that are usually not androgen-regulated leading to their androgen regulation. Their implication in HRPC is currently only theoretical. Even in castrated patients, metastatic tissues have repeatedly shown high levels of androgens, suggesting a high level of intracrine synthesis (22, 23). It is possible that a high intraprostatic cholesterol level can activate specific androgen pathways (1).
17.2
Definition of HRPC
Hormone-refractory prostate cancer is a very heterogeneous disease. It includes different patient cohorts with significantly different median survival times (Table 19). Table 19: Estimated natural mean survival of patients with HRPC presenting with different clinical scenarios Patient characteristics Asymptomatic PSA ↑ • No metastases • Minimal metastases • Extensive metastases Symptomatic PSA ↑ • Minimal metastases • Extensive metastases
Estimated mean survival 24-27 months 16-18 months 9-12 months 14-16 months 9-12 months
The precise definition of recurrent or relapsed CaP remains controversial and several groups have recently published practical recommendations for defining HRPC (23, 24, 25, 26). Various different terms have been used to describe prostate cancers that relapse after initial hormonal ablation therapy, including HRPC, androgen-independent cancers and hormone-independent cancers (1). Androgen-independent, but hormone-sensitive PCa, must be differentiated from true HRPC. Although the former responds to secondary hormonal manipulations, such as anti-androgen withdrawal, oestrogens and
Update march 2009
119
corticosteroids, true HRPC is resistant to all hormonal measures, including ketoconazole and, in the future, abiraterone (see below) (27, 28). Table 20 lists the key defining factors of HRPC. Table 20: Definition of HRPC • Serum castration levels of testosterone (testosterone < 50 ng/dL, or < 1.7 nmol/L) • Three consecutive rises of PSA, 1 week apart, resulting in two 50% increases over the nadir, with a PSA > 2 ng/mL • Anti-androgen withdrawal for at least 4 weeks* • PSA progression, despite secondary hormonal manipulations* • Progression of osseous lesions: progression or appearance of two or more lesions on bone scan or soft tissue lesions using the RECIST criteria** and with nodes ≥ 2 cm in diameter * Either anti-androgen withdrawal or one secondary hormonal manipulation should have been done in order to fulfil the criteria for HRPC. ** From Therasse et al., 2000 (29).
17.3
Assessing treatment outcome in androgen-independent PCa
In general, the therapeutic outcome should be assessed using the guidelines for the evaluation of treatment response in solid tumours, recently published by the RECIST group (Response Evaluation Criteria In Solid Tumours) (29). However, 80-90% of patients do not have bi-dimensionally measurable disease. Patients with primarily soft tissue cancers often have a different prognosis to those with only osseous metastases. Osteoblastic bone metastases remain difficult to quantify accurately. Magnetic resonance imaging (MRI) might be an interesting tool for axial metastases (30). Because the cause of death in PCa patients is often unreliable, a more valid end-point may be an overall survival rate rather than a disease-specific one (31). 17.3.1 PSA level as marker of response Many contemporary studies use PSA as a marker of response, even though there is no consensus about the magnitude and duration of decline in PSA level. Prostate-specific antigen is being used as a rapid screening tool to test new agents for activity. However, conflicting evidence is emerging regarding the role of PSA as a marker for response. In addition, wide fluctuations have been seen in PSA values due to a transient effect of drugs on PSA production. The effects of drugs on PSA expression need to be considered when interpreting PSA response data, which must be viewed together with other clinical data (32-39). Nevertheless, it has been reproducibly shown that ≥ 50% PSA decline in pre-treatment PSA following therapy is associated with a significant survival advantage (40, 41). Kelly et al. (40) reported a statistically significant survival advantage in 110 patients with ≥ 50% PSA decline (> 25 months) compared to those who did not (8.6 months), while Smith et al. (41) showed that a PSA decline ≥ 50% for at least 8 weeks resulted in a longer mean survival time of 91 weeks versus only 38 weeks in patients with a smaller PSA reduction. An improved PSA response was also associated with prolonged survival in the TAX 327 study with a median survival of 33 months when the PSA was normalised (< 4 ng/mL) versus 15.8 months for abnormal PSA levels. However, it was clear in this trial that a PSA response was not a surrogate marker because the same PSA response rate was found in both docetaxel arms (45%), while improved survival was only apparent with the 3 weeks’ docetaxel regimen. 17.3.2 Other parameters The evaluation of molecular markers is just beginning. It includes a possible correlation between the positive findings of reverse transcriptase-polymerase chain reaction (RT-PCR) and poor survival (42); however, these data have to be corroborated in other trials before clinical recommendations can be made. In patients with symptomatic osseous lesions, pain reduction or complete pain relief may be used as parameters to assess palliative therapeutic response (43). 17.3.3 Trial end-points An increasing number of investigators advocate subjective end-points. However, investigators should currently apply the following: • use clearly defined end-points in trials, sufficiently powered to answer the hypothesis • report each response parameter individually, rather than as a complete or partial response • use PSA response, only with other clinical parameters of response • consider QoL end-points independently in symptomatic patients. However, in everyday practice, the evaluation of treatment response must be based on symptom improvement, prolonged survival, or other pre-defined targets.
120
Update march 2009
17.4
Recommendations for assessing therapeutic response
Recommendations • PSA decline ≥ 50% maintained for 8 weeks is associated with a significantly better outcome compared to a PSA decline < 50% • In non-osseous metastases from HRPC, assessment should adhere to the RECIST criteria • In patients with advanced symptomatic metastatic HRPC, therapeutic response can be assessed best by improvement of symptoms LE = level of evidence
17.5
LE 1a 1b 1b
Androgen deprivation in androgen-independent PCa
The existence of androgen-independent PCa demonstrates that disease progression occurs despite castration. The castration levels of testosterone must therefore be documented and a serum testosterone level < 50 ng/mL (1.7 nmol/L) should be documented at initial relapse on hormonal therapy (24, 44). The overall effect of continued testicular androgen suppression in HRPC is minimal. The recommendation to continue androgen deprivation with LHRH analogues, despite PSA progression, is based on the data of Manni et al. (45), which demonstrated significantly lower survival rates in patients without continuous androgen blockade. Two recent trials have challenged these data by showing only a marginal survival benefit for patients remaining on LHRH analogues during second- and third-line therapies (46, 47). However, in the absence of prospective data, the modest potential benefits outweigh the minimal risk of treatment and androgen suppression should be continued indefinitely in these patients. 17.6 Secondary hormonal therapy For the patient with progressive disease after androgen deprivation, there are many therapeutic options. They include anti-androgen withdrawal, addition of anti-androgens, anti-androgen replacement, oestrogenic compounds, adrenolytic agents and novel approaches (48). Figure 1 summarises the treatment modalities and expected responses. Figure 1: Flowsheet of the potential therapeutic options after PSA progression following initial hormonal therapy Mean Duration Metastic prostate cancer PSA ⇓ > 50% of Response LHRH-analogues
100%
Addition of antiandrogens
60-80%
Subcapsular orchiectomy
Addition of antiandrogens
CAB
36 months
Anti-androgen withdrawn
4-6 months
25-40%
Substitution of anti-androgen
4-6 months
30-40%
Anti-androgen withdrawal
5-6 months
40-60%
Secondary hormonal manipulation such as adrenal testosterone inhibitors, low-dose DES, steroids
4-8 months
50-70%
Non-hormonal therapy such as chemotherapy
10-12 months
LHRH = luteinising hormone releasing hormone; CAB = complete androgen blockade; DES = diethylstilboesterol.
17.7
Anti-androgen withdrawal syndrome
In 1993, Kelly and Scher (49) reported clinical and PSA responses in men who discontinued flutamide therapy upon development of progressive disease. The anti-androgen withdrawal syndrome was a critical discovery in Update march 2009
121
terms of understanding the biology of androgen independence, interpreting clinical trials, and treating patients (50-53). Approximately one-third of patients respond to anti-androgen withdrawal, as indicated by a ≥ 50% PSA decrease, for a median duration of approximately 4 months (Table 21). Anti-androgen withdrawal responses have also been reported with bicalutamide and megestrol acetate (54-60). Recently, in the SWOG 9426 trial, the results were reported of a subgroup of 210 patients, with a tumour stage of M0 or M1, who showed PSA progression despite CAB. A PSA response was observed in 21%, even though there was no radiographic response. Median progression-free survival was 3 months, with 19% (all MO) having 12 months’ or greater progression-free survival. Factors associated with increased progression-free and overall survival were a longer period of non-steroidal use, lower PSA at baseline and M0-stage. These results were obtained with patients on CAB following androgen withdrawal treatment. No data were available on the withdrawal effect following second-line anti-androgen treatment. In conclusion, androgen withdrawal should be systematically considered as a first-line modality in relapsing patients, even if its efficacy is limited (level of evidence: 2). Table 21: Frequency and duration of PSA response following anti-androgen withdrawal Anti-androgen Flutamide Flutamide Flutamide Flutamide Bicalutamide Combined results
17.8
No. of patients 57 82 39 21 17 210
> 50% decrease in PSA No. of patients (%) 16 (28%) 12 (15%) 11 (28%) 7 (33%) 5 (29%) 44 (21%)
Duration (months) 4.0 3.5 3.7 3.7 5.0 3 (median)
Treatment alternatives after initial hormonal therapy
Except in patients with non-castration testosterone levels, it is difficult to predict which subset of patients is most likely to respond to secondary hormonal strategies (61). 17.8.1 Bicalutamide Bicalutamide is a non-steroidal anti-androgen with a dose response, with higher doses producing a greater reduction in PSA level (62). Addition of an anti-androgen, such as bicalutamide or flutamide, to gonadal suppression at the time of PSA failure appears to result in declining PSA in only a few patients (63-65). 17.8.2 Switching to an alternative anti-androgen therapy There has been recent interest in another simple modality: the alternative anti-androgen therapy (66). After CAB in 232 progressing patients (76% being M1b), a withdrawal effect was observed in 31 men (15.1%). A secondline hormonal treatment was performed by giving an alternative non-steroidal drug (i.e. initial flutamide was replaced by bicalutamide and vice versa). An overall > 50% decline in PSA was observed in 83 men (35.8%), irrespective of any previous withdrawal effect, and lasting more than 6 months. The higher the PSA at the start of second-line therapy, the shorter the efficacy. 17.8.3 Anti-androgen withdrawal accompanied by simultaneous ketoconazole The adrenal glands secrete approximately 10% of circulating androgen in humans. Some tumour cells in androgen-independent states must retain androgen sensitivity, as a clinical response is induced by a further decrease in circulating androgen levels following bilateral adrenalectomy or administration of drugs inhibiting adrenal steroidogenesis. Aminoglutethimide, ketoconazole and corticosteroids act mainly via this mechanism (67-71) to produce a PSA response in about 25% of patients for about 4 months. However, the simultaneous addition of ketoconazole to anti-androgen withdrawal, produced a significantly increased PSA response (32% vs 11%) and a longer time to PSA progression (8.6 vs 5.9 months) compared to anti-androgen withdrawal alone (71). 17.8.4 Oestrogens Prostate cancer usually expresses oestrogen receptors, which are upregulated after androgen ablation in animal models. In-vitro oestrogens can activate mutant androgen receptors isolated from androgenindependent PCa, while high-dose oestrogens have achieved objective salvage responses. This may be due to the mitotic arrest of direct cytotoxic effects on the cells, perhaps through an apoptotic mechanism (72, 73). Recently, DES (74-76) achieved a positive PSA response between 24% and 80%, with an overall estimated survival of 63% at 2 years. However, even at low doses of DES, about one-third (31%) of patients developed
122
Update march 2009
deep venous thrombosis and 7% experienced myocardial infarction. A very promising drug, the CYP17 inhibitor abiraterone acetate, has achieved more 50% PSA decrease in clinical trials in patients with HRPC (77), including patients previously treated with ketokonazole (78) or even by docetaxel (79). A large phase III trial is underway, enrolling 1158 men, with overall survival as the primary objective. This new compound raises questions about HRPC definition status, as a clear response is apparent even in highly pretreated patients initially considered to be hormone-refractory.
17.9
Non-hormonal therapy (cytotoxic agents)
Several proven chemotherapeutic options are available for metastatic disease in HRPC (Table 22). A significant improvement in median survival of about 2 months occurred with docetaxel-based chemotherapy compared to mitoxantrone + prednisone therapy (80, 81). In the SWOG 99-16 trial, pain relief was similar in both groups, though side-effects occurred significantly more often with docetaxel than with mitoxantrone. Table 22: PSA response rates, mean survival, time to progression, and pain reduction in the large prospective randomised phase III trials of chemotherapy in patients with HRPC Study n PSA decrease Decrease in Survival TTP > 50% pain Tax 327 Mitoxantrone 32% 22% 16.5 months __ Docetaxel, 75 mg/m2 45%1 35%3 18.9 months1 __ Docetaxel, 30 mg/m2 48%1 31% 17.4 months __ SWOG 99-16 Mitoxantrone 336 50%1 __ 17.5 months2 6.3 months1 Docetaxel/EMP 338 27% __ 15.6 months 3.2 months CALGB 9182 Hydrocortisone 123 38%4 __ 12.3 months 2.3 months Mitoxantrone/HC 119 22% __ 12.6 months 3.7 months4 Tannock et al. Prednisone 81 22% 12% __ 43 weeks1 2 Mitoxantrone/Pred 80 33% 29% __ 18 weeks TTP = median time to progression; EMP = estramustine; HC = hydrocortisone; Pred = prednisone. 1p < 0.000; 2p = 0.001; 3p = 0.01; 4p < 0.03. 17.9.1 Timing of chemotherapy in metastatic HRPC The timing of chemotherapy varies in metastatic HRPC. In symptomatic patients, immediate use is advisable, every 3 weeks if possible as this schedule is associated with a survival improvement. However, a weekly regimen will result in the same symptom improvement. It must be considered in patients unable to receive the optimal regimen (level of evidence: 1b), as it is more effective than the best supportive care (82). In asymptomatic patients, timing is not so clear and must be discussed individually. Several poor prognostic factors have been described, such as PSA level > 114 ng/mL, a PSA doubling time (PSA–DT) < 55 days, or the presence of visceral metastases (83). A C-reactive protein (CRP) level below 8 mg/L (HR, 2.96) has also been suggested as predicting better survival (84). if (84).Age Ageby byitself itselfisisnot not aa contraindication to docetaxel (85). Currently, the only indication for chemotherapy in HRPC non-metastatic patients is inside clinical trials and patients should be advised to participate. Taxanes in combination therapy In an effort to improve treatment results further, several phase I and phase II trials are underway combining taxanes with anti-bcl-2, calcitriol (trial stopped due to unexpected toxicity), exisulid, and thalidomide, resulting in PSA responses of about 60% (86-89). In a randomised phase II trial of docetaxel + thalidomide (86), 75 men with chemotherapy-naïve HRPC were randomised to receive either docetaxel at 30 mg/m2 for 5 of every 6 weeks or docetaxel at the same dose and schedule plus thalidomide at 200 mg orally each day. A PSA decline of ≥ 50% was higher in the combination-treated group (53%) compared to the docetaxel-alone treated group (37%) (not statistically significant). Median progression-free survival and overall survival with combination treatment were 5.9 months and 68%, respectively, at 18 months versus 3.7 months and 43% in the docetaxelalone group (not statistically significant). However, there were considerable side-effects, with thromboembolic events occurring in 28% of the combination arm compared to no such events in the docetaxel arm. A recent phase III trial in HRPC patients confirmed the potential interest of thalidomide compared to placebo in nonmetastatic patients with a progression-free survival of 15 months versus 9.6 months (p = 0.0002) (90).
Update march 2009
123
Mitoxantrone combined with corticosteroids Mitoxantrone combined with corticosteroids (37, 91) has been extensively studied primarily in patients with symptomatic osseous lesions due to HRPC. In the CALGB 9182 study (91), 244 patients with symptomatic metastatic HRPC were randomised to receive either mitoxantrone + hydrocortisone, 12 mg/m2 every 3 weeks, or hydrocortisone alone. No differences were observed with regard to survival, PSA response, and median time to progression. However, the QoL was significantly improved in the combination arm. In another trial (37), 161 men with painful osseous metastases due to HRPC were randomised to receive mitoxantrone + prednisone versus prednisone alone. There was a significant benefit in pain reduction in the combination group (29%) versus prednisone alone (12%, p = 0.01). Furthermore, the duration of palliation was longer in patients who received mitoxantrone (43 vs 18 weeks, p < 0.0001). There were no significant differences with regard to PSA response and median survival time. However, again, QoL was improved significantly due to pain reduction. Alternative combination treatment approaches Encouraging results have been seen with alternative treatments evaluated in prospective clinical phase II trials, including pegylated doxorubicin, vinorelbine, a combination of paclitaxel, carboplatin and estramustine, a combination of vinblastine, doxorubicin and radionuclides, and a combination of docetaxel and mitoxantrone (92-98). The lack of representative randomised phase III trials and unknown long-term efficacy are major problems associated with all these studies. Estramustine in combination therapies The synergy observed for estramustine combined with other drugs that target microtubule action has generated promising results in prospective clinical trials (99). Estramustine + vinblastine has been the most studied estramustine combination. Although different doses of estramustine and vinblastine have been used in prospective randomised trials, significant PSA and measurable responses have been reported in three separate studies. Although time to progression and frequency of ≥ 50% PSA decrease was significantly higher in the combination arm, median survival did not differ significantly between the estramustine and the estramustine + vinblastine arms (100). A recent meta-analysis on estramustine (101) concluded that the addition of estramustine to chemotherapy increased the time to PSA progression and overall survival. However, there was a significant increased risk of thromboembolic events, up to 7% (102), requiring systematic prevention with coumadin. Oral cyclophosphamide Intravenous cyclophosphamide has been tested in many trials. However, there is currently interest in on oral cyclophosphamide, which seems to be less toxic than intravenous cyclophosphamide and may have greater activity (103, 104). A study of the oral cyclophosphamide + oral etoposide in 20 patients was similarly encouraging (105, 106). Cisplatin and carboplatin have activity against PCa as single agents and a welldocumented synergy with etoposide or paclitaxel in vitro in the treatment of other malignancies, such as lung and ovarian cancer. As estramustine is also synergistic with these drugs, combinations of three agents are now being tested. A combination of estramustine, etoposide and cisplatin (or carboplatin) has significant activity against poorly differentiated HRPC. A combination of estramustine, etoposide and paclitaxel has produced high response rates (107). Suramin Suramin activity against HRPC is likely to be mediated through the inhibition of binding of growth factors (e.g. transforming growth factor beta) to their receptors. Recent results have renewed interest in suramin’s initial promise in the treatment of HRPC (108-110). Salvage chemotherapy Since all patients who receive docetaxel-based chemotherapy for HRPC will progress within 6 to 8 months, there have been many clinical trials investigating the role of salvage chemotherapy. The results suggest the most appropriate approaches are intermittent docetaxel chemotherapy (111, 112), molecular-targeted therapy 113, 114) and second-line satraplatin (115). Second-line intermittent docetaxel has been used by several groups in clearly responding patients to first-line docetaxel (111, 112, 116 ). In general, a PSA response can be achieved in about 60% of patients with a median time to progression of about 6 months, while treatment-associated toxicity is minimal and similar to that of first-line docetaxel. Another, recently identified approach is molecular-targeted therapy (111-117, 118), though more research is needed in larger groups of patients. Platinum-based chemotherapeutic regimes have been investigated in patients with HRPC. Although
124
Update march 2009
the platinum complex, satraplatin, has shown activity against HRPC and some promise in clinical trials (39, 41), it was rejected for HRPC by the FDA in 2008. Many new drugs, such as gefitinib, bevasusimab (phase III trial CALB 90401), oblimersen (phase III trial EORTC 30021), and also a vaccine, G-Vax (119), are being tested in phase III trials. Patients should be advised to participate.
17.10 Palliative therapeutic options 17.10.1 Painful bone metastases Most patients with HRPC have painful bone metastases. External beam radiotherapy is highly effective (120), even as single fraction (121). The two radioisotopes, strontium-89 and samarium-153, can partially or completely decrease bone pain in up to 70% of patients, but should not be given too late when the pain is intractable. Early use can give rise to myelosuppression making subsequent chemotherapy more difficult (106, 122), even though a recent phase I trial has demonstrated manageable haematological toxicity with repeated administration of docetaxel and samarium-153 (123). The use of samarium-153 as consolidation therapy, following a clear docetaxel response, may also help with initially painful bone metastases (124). Palliative treatment with another radioisotope emitter, radium-233 has shown very promising phase II results in patients with painful bone metastases in terms of palliation and overall survival, and only a mild haematological toxicity (125). 17.10.2 Common complications due to bone metastases Common complications due to skeletal metastases include bone pain, vertebral collapse or deformity pathological fractures and spinal cord compression. Osteoporosis may also cause fractures and should be prevented (see above). Cementation is an effective treatment of painful fracture, clearly improving both pain and QoL (126). However, it is still important to offer standard palliative surgery, which can be very effective at managing osteoblastic metastases (127, 128). Impending spinal cord compression is an emergency. It must be recognised early and patients educated to recognise the warning signs. Once suspected, high-dose corticosteroids must be given and an MRI performed as soon as possible. A systematic neurosurgery consultation should be planned to discuss a possible decompression (129). Otherwise, external beam radiotherapy is the treatment of choice. 17.10.3 Bisphosphonates Recently, bisphosphonates have been used to inhibit osteoclast-mediated bone resorption and osteoclast precursors in HRPC to provide effective treatment of skeletal complications and to reduce pain or provide total pain relief. In the largest single phase III trial (130), 643 patients who had HRPC with bone metastases were randomised to receive zoledronic acid, 8 mg or 4 mg every 3 weeks for 15 consecutive months, or placebo. At 15 and 24 months of follow-up, patients treated with only 4 mg of zoledronic acid had fewer skeletalrelated events compared to the placebo group (44% vs 33%, p = 0.021) and fewer pathological fractures (13.1% vs 22.1%, p = 0.015). Furthermore, the time to first skeletal-related event was longer in the zoledronate group, so improving QoL. Patients were initially randomised to 4 or 8 mg of zoledronic acid, but the 8 mg dosage was later modified to 4 mg because of toxicity. Currently, bisphosphonates could be proposed to patients with HRPC bone metastases to prevent skeletal complications, even if the best dosing interval is unclear, but at present is every 3 weeks or less. The toxicity, e.g. jaw necrosis, of these drugs, especially aminobisphosphonate, must always be kept in mind (131). Patients should have a dental examination before starting a bisphosphonate. The risk of jaw necrosis is increased by a history of trauma, dental surgery or dental infection, as well as intravenous long-term bisphosphonate administration (132). Pain due to osseous metastases is one of the most debilitating complications of HRPC. Bisphosphonates have been highly effective with a response rate of 70-80% in small, open trials, which, associated with a low frequency of side-effects, makes bisphosphonates an ideal medication for palliative therapy of advanced HRPC (43, 133). Bisphosphonates should be considered early in the management of symptomatic HRPC. Critical issues of palliation must be addressed when considering additional systemic treatment, including management of pain, constipation, anorexia, nausea, fatigue and depression, which often occur (i.e. palliative external beam radiation, cortisone, analgesics and antiemetics). Hormone-refractory PCa is usually a debilitating disease, often affecting the elderly male. A multidisciplinary approach is required with input from medical oncologists, radiation oncologists, urologists, nurses, psychologists and social workers (134).
Update march 2009
125
17.11 Summary of treatment after hormonal therapy Recommendations GR • It is recommended to stop anti-androgen therapy once PSA progression is documented B • Four to six weeks after discontinuation of flutamide or bicalutamide, an eventual anti-androgen B withdrawal effect is apparent • No clear-cut recommendation can be made for the most effective drug for secondary hormonal C manipulations because data from randomised trials are scarce GR = grade of recommendation
17.12 Guidelines and recommendations for cytotoxic therapy in HRPC Guidelines and recommendations GR • Cytotoxic therapy should only be used to treat non-metastatic HRPC in clinical trials • In patients with a PSA rise only, two consecutive increases of PSA serum levels above a previous B reference level should be documented • Prior to treatment, PSA serum levels should be > 5 2 ng/mL to assure correct interpretation of B therapeutic efficacy • Potential benefits of cytotoxic therapy and expected side-effects should be discussed with each C individual patient • In patients with metastatic HRPCA, and who are candidates for cytotoxic therapy, docetaxel at A 75 mg/m2 every 3 weeks has shown a significant survival benefit • In patients with symptomatic osseous metastases due to HRPCA, either docetaxel or A mitoxantrone with prednisone or hydrocortisone are viable therapeutic options • Second-line docetaxel should be considered in previously responding patients to docetaxel B Otherwise, treatment is tailored to the individual patient GR = grade of recommendation
17.13 Guidelines for palliative management of HRPC Recommendations • Patients with symptomatic and extensive osseous metastases cannot benefit from medical treatment with regard to prolongation of life • Management of these patients has to be directed at improvement of QoL and mainly pain reduction • Effective medical management with the highest efficacy and a low frequency of side-effects is the major goal of therapy
17.14 Recommendations for palliative management of HRPC Recommendations GR • Bisphosphonates may be offered to patients with skeletal masses (mainly zoledronic acid has A been studied) to prevent osseous complications. However, the benefits must be balanced against the toxicity of these agents, in particular jaw necrosis must be avoided • Palliative treatments such as radionuclides, external beam radiotherapy, adequate use of B analgesics should be considered early in the management of painful osseous metastases • Spine surgery or decompressive radiotherapy might be an emergency A GR = grade of recommendation
17.15 REFERENCES 1.
Isaacs JT, Coffey DS. Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981;41(12 Pt 1):5070-5. http://www.ncbi.nlm.nih.gov/pubmed/7307008 2. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-18. http://www.ncbi.nlm.nih.gov/pubmed/6831420 3. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332(21):1393-8. http://www.ncbi.nlm.nih.gov/pubmed/7723794 4. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, Vihko P. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocr
126
Update march 2009
Metab 1995;80(12):3494-500. http://www.ncbi.nlm.nih.gov/pubmed/8530589 5. Visakorpi T, Hyytinen E, Kovisto P, Tanner M, Palmberg C, Keinanen R, Tammela T, Isola J, Kalloniemi OP. Amplification of the androgen receptor gene is common in recurrent prostate cancer from patients treated with androgen withdrawal. J Urol 1995;153:379A (abstr 603). 6. Schröder FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008;53(6):1129-37. http://www.ncbi.nlm.nih.gov/pubmed/18262723 7. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997;57(2):229-33. http://www.ncbi.nlm.nih.gov/pubmed/9000560 8. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85(20):1657-69. http://www.ncbi.nlm.nih.gov/pubmed/7692074 9. Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997;3(8):1389-97. http://www.ncbi.nlm.nih.gov/pubmed/9815823 10. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996;156(4):1511-6. http://www.ncbi.nlm.nih.gov/pubmed/8808919 11. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997;158(1):131-7. http://www.ncbi.nlm.nih.gov/pubmed/9186339 12. MacGrogan D, Bookstein R. Tumour suppressor genes in prostate cancer. Semin Cancer Biol 1997;8(1):11-9. http://www.ncbi.nlm.nih.gov/pubmed/9299577 13. Chi KN. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J Urol 2005;23(1):33-7. http://www.ncbi.nlm.nih.gov/pubmed/15723221 14. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003;100(20):11636-41. http://www.ncbi.nlm.nih.gov/pubmed/13130078 15. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H, van der Kwast TH, Trapman J. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006;208(5):699-707. http://www.ncbi.nlm.nih.gov/pubmed/16402365 16. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumour grade in human prostate cancer tissues. Clin Cancer Res 1996;2(8):1255-61. http://www.ncbi.nlm.nih.gov/pubmed/9816295 17. Koivisto PA, Schleutker J, Helin H, Ehren-van Eekelen C, Kallioniemi OP, Trapman J. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Clin Cancer Res 1999;5(11):3578-82. http://www.ncbi.nlm.nih.gov/pubmed/10589774 18. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999;20(1):22-45. http://www.ncbi.nlm.nih.gov/pubmed/10047972 19. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs TJ. Expression of bcl-2 and the progression of human and rodent prostate cancers. Clin Cancer Res 1996;2(2):389-98. http://www.ncbi.nlm.nih.gov/pubmed/9816182
Update march 2009
127
20.
Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B Study 9663. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. Clin Oncol 2003;21(14):2673-8. http://www.ncbi.nlm.nih.gov/pubmed/12860943 21. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-8. http://www.ncbi.nlm.nih.gov/pubmed/16254181 22. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66(5):2815-25. http://www.ncbi.nlm.nih.gov/pubmed/16510604 23. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7): 1148-59. http://www.ncbi.nlm.nih.gov/pubmed/18309951 24. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160(4):1220-9. http://www.ncbi.nlm.nih.gov/pubmed/9751323 25. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461-67. http://www.ncbi.nlm.nih.gov/pubmed/10550143 26. Heidenreich A, von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 2001;39(2):121-30. http://www.ncbi.nlm.nih.gov/pubmed/11223670 27. Waselenko JK, Dawson NA. Management of progressive metastatic prostate cancer. Oncology (Huntingt) 1997;11(10):1551-60; discussion 1560-3, 1567-8. http://www.ncbi.nlm.nih.gov/pubmed/9348559 28. Logothetis CJ, Hoosein NM, Hsieh JT. The clinical and biological study of androgen independent prostate cancer (AI PCa). Semin Oncol 1994;21(5):620-9. http://www.ncbi.nlm.nih.gov/pubmed/7524155 29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16. http://www.ncbi.nlm.nih.gov/pubmed/10655437 30. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005;65(2):178-87. http://www.ncbi.nlm.nih.gov/pubmed/15948151 31. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 1996;88(22):1623-34. http://www.ncbi.nlm.nih.gov/pubmed/8931606 32. Dawson NA, McLeod DG. The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. Eur J Cancer 1997;33(4):560-5. http://www.ncbi.nlm.nih.gov/pubmed/9274435 33. Kelly WK, Scher HI, Mazurmdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11(4):607-15. http://www.ncbi.nlm.nih.gov/pubmed/7683043
128
Update march 2009
34.
Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 1994;12(4):683-8. http://www.ncbi.nlm.nih.gov/pubmed/7512126 35. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994;12(10):2005-12. http://www.ncbi.nlm.nih.gov/pubmed/7523606 36. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K, Comis R. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10(11):1754-61. http://www.ncbi.nlm.nih.gov/pubmed/1383436 37. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996;14(6):1756-64. http://www.ncbi.nlm.nih.gov/pubmed/8656243 38. George DJ, Kantoff PW. Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 1999;26(2):303-10, viii. http://www.ncbi.nlm.nih.gov/pubmed/10361553 39. Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L, Eisenberger M. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 1990;8(11):1830-8. http://www.ncbi.nlm.nih.gov/pubmed/1700078 40. Kelly WK, Scher HI, Mazurmdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11(4):607-15. http://www.ncbi.nlm.nih.gov/pubmed/7683043 41. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16(5):1835-43. http://www.ncbi.nlm.nih.gov/pubmed/9586898 42. Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K, Kantoff PW. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 1997;50(1):100-5. http://www.ncbi.nlm.nih.gov/pubmed/9218026 43. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonates for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001;165(1):136-40. http://www.ncbi.nlm.nih.gov/pubmed/1112538 44. Klugo RC, Farah RN, Cerny JC. Bilateral orchiectomy for carcinoma of the prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy. Urology 1981;17(1):49-50. http://www.ncbi.nlm.nih.gov/pubmed/7456197 45. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, WhiteHersey D, Gordon R, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988;6(9):1456-66. http://www.ncbi.nlm.nih.gov/pubmed/3047336 46. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993;11(11):2167-72. http://www.ncbi.nlm.nih.gov/pubmed/8229130 47. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994;12(9):1868-75. http://www.ncbi.nlm.nih.gov/pubmed/8083710 48. Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent disease. Urology 2003;62(Suppl 1):87-94. http://www.ncbi.nlm.nih.gov/pubmed/14747046
Update march 2009
129
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62. 63. 64
65.
66.
130
Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal syndrome. J Urol 1993;149(3):607-9. http://www.ncbi.nlm.nih.gov/pubmed/7679759 Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11(8):1566-72. http://www.ncbi.nlm.nih.gov/pubmed/7687666 Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994;43(3):408-10. http://www.ncbi.nlm.nih.gov/pubmed/7510915 Dawson NA, McLeod DG. Dramatic prostate specific antigen decline in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995;153(6):1946-7. http://www.ncbi.nlm.nih.gov/pubmed/7538601 Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997;15(1):382-8. http://www.ncbi.nlm.nih.gov/pubmed/8996165 Blackledge GRP, Lowery K. Role of prostate-specific antigen as a predictor of outcome in prostate cancer. Prostate Suppl 1994;5:34-8. http://www.ncbi.nlm.nih.gov/pubmed/7513530 Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997;15(8):2928-38. http://www.ncbi.nlm.nih.gov/pubmed/9256137 Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998;159(1):149-53. http://www.ncbi.nlm.nih.gov/pubmed/9400459 Kucuk O, Blumenstein B, Moinpour C, et al. Phase II trial of Casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulations: a Southwest Oncology Group study (SWOG 9235). Proc Am Soc Clin Oncol (ASCO) 1996;15:245 (abstr). Osborn JL, Smith DC, Trump DL. Megestrol acetate in the treatment of hormone refractory prostate cancer. Am J Clin Oncol 1997;20(3):308-10. http://www.ncbi.nlm.nih.gov/pubmed/9167760 Gebbia V, Testa A, Gebbia N. Prospective randomized trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 1996;73(12):1576-80. http://www.ncbi.nlm.nih.gov/pubmed/8664133 Dawson NA, Conaway M, Halabi S, Winter EP, Small EJ, Lake D, Vogelzang NJ. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukaemia group B study 9181. Cancer 2000;88(4):825-34. http://www.ncbi.nlm.nih.gov/pubmed/10679652 Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997;15(1):382-8. http://www.ncbi.nlm.nih.gov/pubmed/8996165 McLeod DG. Antiandrogenic drugs. Cancer 1993;71(3 Suppl):1046-9. http://www.ncbi.nlm.nih.gov/pubmed/8428326 Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995;23:43-62. http://www.ncbi.nlm.nih.gov/pubmed/7621473 Dawson NA. Treatment of progressive metastatic prostate cancer (published erratum of serious dosage error appears in Oncology (Huntingt) 1993 Jun;7(6):2). Oncology 1993;7(5):17-24, 27; discussion 27-9. http://www.ncbi.nlm.nih.gov/pubmed/8512779 Fowler JE Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal deferred flutamide treatment. J Urol 1995;154(2 Pt 1):448-53. http://www.ncbi.nlm.nih.gov/pubmed/7541862 Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180(3):921-7. http://www.ncbi.nlm.nih.gov/pubmed/18635218
Update march 2009
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of ‘hormone refractory’ prostate cancer. J Natl Cancer Inst 1994;86(3):222-7. http://www.ncbi.nlm.nih.gov/pubmed/7506794 Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150(3):908-13. http://www.ncbi.nlm.nih.gov/pubmed/7688437 Rochlitz CF, Damon LE, Russi MB, Geddes A, Cadman EC. Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 1988;21(4):319-22. http://www.ncbi.nlm.nih.gov/pubmed/3370740 Mahler C, Verhelst J, Denis L. Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 1993;71(3 Suppl):1068-73. http://www.ncbi.nlm.nih.gov/pubmed/8428329 Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang N. Antiandrogen withdrawal alone or in combination with ketokonazole in androgenindependent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22(6):1025-33. http://www.ncbi.nlm.nih.gov/pubmed/15020604 Ferro MA, Gillatt D, Symes MO, Smith PJ. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology 1989;34(3):134-8. http://www.ncbi.nlm.nih.gov/pubmed/2476882 Robertson CN, Roberson KM, Padilla GM, O’Brien ET, Cook JM, Kim CS, Fine RL. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996;88(13):908-17. http://www.ncbi.nlm.nih.gov/pubmed/8656443 Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylbestrol as a second line hormonal agent in advanced prostate cancer. Urology 1998;52(2):25760. http://www.ncbi.nlm.nih.gov/pubmed/9697791 Klotz L, McNeill I, Fleshner N. A phase 1-2 trial of diethylbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999;161(1):169-72. http://www.ncbi.nlm.nih.gov/pubmed/10037391 Oh WK, Kanthoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicentre, randomized phase II trial of the herbal supplement PC-SPES and diethylbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004;22(18):3705-12. http://www.ncbi.nlm.nih.gov/pubmed/15289492 Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-71. http://www.ncbi.nlm.nih.gov/pubmed/18645193 Ryan, M. Smith MR, Rosenberg JE, Lin AM, Taplin M, Kantoff PW, Huey V, Kim J, Small EJ. Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). Abstract. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008;26(15S): #5018. http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/5018 Danila DC, Rathkopf DE, Morris MJ, Slovin SF, Schwartz LH, Farmer K, Anand A, Haqq C, Fleisher M, Scher HI. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. Abstract. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008;26(15S): #5019. http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/5019 Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin M, Burch PA, Berry D, Mounpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004;351(15):1513-20. http://www.ncbi.nlm.nih.gov/pubmed/15470214
Update march 2009
131
81.
82.
83.
84.
85.
86.
87.
88.
89.
86.
87.
88.
89.
90.
91.
132
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Ourdard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger M, and TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004;351(15):1502-12. http://www.ncbi.nlm.nih.gov/pubmed/15470213 Fosså SD, Jacobsen AB, Ginman C, Jacobsen IN, Overn S, Iversen JR, Urnes T, Dahl AA, Veenstra M, Sandstad B. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol 2007;52(6):1691-8. http://www.ncbi.nlm.nih.gov/pubmed/17306441 Eisenberger M, Garrett-Mayer ES, Ou Yang Y, de Wit R, Tannock I, Armstrong AJ. multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC). Abstract. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18S): #5058. http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/5058 Graff J, Lalani AS, Lee S, Curd JG, Henner WD, Ryan CW, Venner PM, Ruether JD, Chi KN, Beer TM, ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial. Abstract. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18S): #5074. http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/5074 Bompas E, Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, Flechon A, Joly F, Ferrero J, Fizazi K. Docetaxel-based chemotherapy in elderly patients (> 75 years) with castration resistant prostate cancer (CRPC): A French National study of 175 patients. Abstract. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008;26(15S): #5145. http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/5145 Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Lineham WM, Figg WD. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2532-9. http://www.ncbi.nlm.nih.gov/pubmed/15226321 Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001;28(4 Suppl 15):67-70. http://www.ncbi.nlm.nih.gov/pubmed/11685732 Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001;28(4 Suppl 15):49-55. http://www.ncbi.nlm.nih.gov/pubmed/11685729 Ryan CW, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. Semin Oncol 2001;28(4 Suppl 15):56-61. http://www.ncbi.nlm.nih.gov/pubmed/11685730 Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Lineham WM, Figg WD. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2532-9. http://www.ncbi.nlm.nih.gov/pubmed/1522632 Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001;28(4 Suppl 15):67-70. http://www.ncbi.nlm.nih.gov/pubmed/11685732 Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001;28(4 Suppl 15):49-55. http://www.ncbi.nlm.nih.gov/pubmed/11685729 Ryan CW, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. Semin Oncol 2001;28(4 Suppl 15):56-61. http://www.ncbi.nlm.nih.gov/pubmed/11685730 Figg W, Aragon-Ching JB, Steinberg, Gulley JL, Arlen PM, Sartor O, Petrylak DP, Higano CS, Hussain MH, Dahut WL. Randomized phase III trial of thalidomide (Th) or placebo (P) for non-metastatic PSA recurrent prostate cancer (PCa) treated with intermittent therapy. Abstract. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008;26(15S): #5016. http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/5016/ Kanthoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisine with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 1999;17(8):2506-13. http://www.ncbi.nlm.nih.gov/pubmed/10561316
Update march 2009
92.
93.
94.
95.
96.
97.
98.
99. 100.
101.
102.
103.
104.
Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19(9):2509-16. http://www.ncbi.nlm.nih.gov/pubmed/11331330 Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ. Phase II trial of paclitaxel, estramustine, etoposide and carboplatin in the treatment of patients with hormone-refractory prostate cancer. Cancer 2003;98(2):269-76. http://www.ncbi.nlm.nih.gov/pubmed/12872344 Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Antitumour activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995;76(3):453-62. http://www.ncbi.nlm.nih.gov/pubmed/8625127 Kelly WK, Curley T, Liebretz C, Dnistrian A, Schwartz M, Scher Hl. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995;13(9):2208-13. http://www.ncbi.nlm.nih.gov/pubmed/7545218 Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing shedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukaemia group B 9480. J Clin Oncol 2002;20(16):3369-75. http://www.ncbi.nlm.nih.gov/pubmed/12177096 Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L; Genitourinary Tract Group of the EORTC. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68(1):2-9. http://www.ncbi.nlm.nih.gov/pubmed/15741753 Oudard S, Caty A, Humblet Y, Beauduin M, Suc E, Piccart M, Rolland F, Fumoleau P, Bugat R, Houyau P, Monnier A, Sun X, Montcuquet P, Breza J, Novak J, Gil T, Chopin D. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 2001;12(6):847-52. http://www.ncbi.nlm.nih.gov/pubmed/11484963 Ohlmann C, Ozgur E, Engelmann U, Heidenreich A. Molecular triggered therapy in hormone refractory prostate cancer. Eur Urol Suppl 2006;5(2):93, abstract 281. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2004;91(8):1425-7. http://www.ncbi.nlm.nih.gov/pubmed/15467765 Fizazi K,Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S; Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists’ Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007;8(11):994-1000. http://www.ncbi.nlm.nih.gov/pubmed/17942366 Lubiniecki GM, Berlin JA, Weinstein RB, Konkle BA, Vaughn DJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics of the University of Pennsylvania, Philadelphia, PA; Presbyterian Hospital of the University of Pennsylvania, Philadelphia, PA. Risk of thromboembolic events (TE) with estramustine-based chemotherapy in hormone-refractory prostate cancer (HRPC): results of a meta-analysis. Abstract. Proc Am Soc Clin Oncol 2003;22: #1581. http://pediatricca.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnex toid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=23&inde x=y&abstractID=102825 Ohlmann C, Ozgur E, Wille S, Engelmann U, Heidenreich A. Second-line chemotherapy with docetaxel for prostate-specific antigen relapse in men with hormone refractory prostate cancer previously treated with docetaxel based chemotherapy. Eur Urol Suppl 2006;5(2):93, abstract 289. Lara PN Jr, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 2004;3(3):165-73. http://www.ncbi.nlm.nih.gov/pubmed/15636683
Update march 2009
133
105.
106.
107.
108.
109.
110.
111. 112.
113.
114.
115.
116.
117.
118.
134
Sternberg CN, Hetherington J, Paluchowska B, Slee PHTJ., Collette L, Debois M, Zurlo A. Randomized phase III trial of a new oral platinum, satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2003;22, abstract 1586. http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=7 6f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=23&index=y&a bstractID=100833 Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, Crook J, Gulenchyn KY, Hong KE, Wesolowski C, Yardlye J. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25(5):805-13. http://www.ncbi.nlm.nih.gov/pubmed/8478230 Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ. Phase II trial of paclitaxel, estramustine, etoposide and carboplatin in the treatment of patients with hormone-refractory prostate cancer. Cancer 2003;98(2):269-76. http://www.ncbi.nlm.nih.gov/pubmed/12872344 Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Antitumour activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995;76(3):453-62. http://www.ncbi.nlm.nih.gov/pubmed/8625127 Kelly WK, Curley T, Liebretz C, Dnistrian A, Schwartz M, Scher Hl. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995;13(9):2208-13. http://www.ncbi.nlm.nih.gov/pubmed/7545218 Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing shedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukaemia group B 9480. J Clin Oncol 2002;20(16):3369-75. http://www.ncbi.nlm.nih.gov/pubmed/12177096 Ohlmann C, Ozgur E, Engelmann U, Heidenreich A. Molecular triggered therapy in hormone refractory prostate cancer. Eur Urol Suppl 2006;5(2):93, abstr 281. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2004;91(8):1425-7. http://www.ncbi.nlm.nih.gov/pubmed/15467765 Ohlmann C, Ozgur E, Wille S, Engelmann U, Heidenreich A. Second-line chemotherapy with docetaxel for prostate-specific antigen relapse in men with hormone refractory prostate cancer previously treated with docetaxel based chemotherapy. Eur Urol Suppl 2006;5(2):93, abstract 289. Lara PN Jr, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 2004;3(3):165-73. http://www.ncbi.nlm.nih.gov/pubmed/15636683 Sternberg CN, Hetherington J, Paluchowska B, Slee PHTJ, Collette L, Debois M, Zurlo A. Randomized phase III trial of a new oral platinum, satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol: 2003;22, abstract 1586. http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=7 6f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=23&index=y&a bstractID=100833 Ansari J, Hussain SA, Zarkar A, Bliss J, Tanguay JD, Glaholm J. Docetaxel re-treatment for metastatic hormone refractory prostate cancer. Abstract. J Clin Oncol 2008;26(15S): #16016. http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/16066 Lara PN Jr, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 2004;3(3):165-73. http://www.ncbi.nlm.nih.gov/pubmed/15636683 Periman PO, Sonpavde G, Bernold DM, Weckstein DJ, Williams AW, Zhan F, Boehm KA, Asma L, Hutson TE. Sunitinib malate for metastatic castration resistant prostate cancer following docetaxelbased chemotherapy. Abstract. J Clin Oncol 2008;26(15S): #5157. http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/5157
Update march 2009
119.
Small EJ, Schellhamme PF, Higano CS, Neumanaitis J, Valone F, Hershberg R. Results of a placebocontrolled phase III trial of immunotherapy with APC8015for patients with hormone refractory prostate Cancer (HRPC). Abstract. J Clin Oncol 2005;23(16S): #4500. http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/4500 120. Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA. Evidence-based standards for cancer pain management. J Clin Oncol 2008;26(23):3879-85. http://www.ncbi.nlm.nih.gov/pubmed/18688056 121. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. Natl Cancer Inst 2005;97(11):798-804. http://www.ncbi.nlm.nih.gov/pubmed/15928300 122. Heidenreich A, Sommer F, Ohlmann CH, Schrader AJ, Olbert P, Goecke J, Engelmann UH. Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone refractory prostate carcinoma. Cancer 2004;101(5):948-56. http://www.ncbi.nlm.nih.gov/pubmed/15329902 123. Morris MJ, Pandit-Taskar N, Stephenson RD, Hong C, Slovin SF, Solit D, Rathkopf DE, Carrasquillo JA, Larson SM, Scher HI. Phase I study of docetaxel (Tax) and 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC). ). Abstract. J Clin Oncol 2008;26(15S): #5001. http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/5001 124. Laplanche A, Beuzeboc P, Lumbroso J, Massard C, Plantade A, Escudier B, Di Palma M, Bouzy J, Haddad V, Fizazi K. A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC). Abstract. J Clin Oncol 2007;25(18S): #5122. http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/5122 125. Nilsson S, Franzén L, Tyrrell C, Blom R , Tennvall JT, Lennernäs B, Johannessen DC, Sokal M, Parker C, Bruland ØS. Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): Results from a randomized, placebo-controlled, phase II study. Abstract. J Clin Oncol 2007;25(18S): #5071. http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/5071 126. Dutka J, Sosin P. Time of survival and quality of life of the patients operatively treated due to pathological fractures due to bone metastases. Ortop Traumatol Rehabil 2003;5(3):276-83. http://www.ncbi.nlm.nih.gov/pubmed/18034018 127. Frankel BM, Jones T, Wang C. Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation. Neurosurgery 2007;61(3):531-7; discussion 537-8. http://www.ncbi.nlm.nih.gov/pubmed/17881965 128. Marco RA, Sheth DS, Boland PJ, Wunder JS, Siegel JA, Healey JH. Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am 2000;82(5):642-51. http://www.ncbi.nlm.nih.gov/pubmed/10819275 129. George R, Jeba J, Ramkumar G, Chacko AG, Leng M, Tharyan P. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 2008:8;(4):CD006716. http://www.ncbi.nlm.nih.gov/pubmed/18843728 130. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goad JA, Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68. http://www.ncbi.nlm.nih.gov/pubmed/12359855 131. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19(3):420-32. http://www.ncbi.nlm.nih.gov/pubmed/17906299 132. Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS. Pathophysiology, risk factors and management of bisphosphonateassociated osteonecrosis of the jaw: Is there a diverse relationship of amino- and nonaminobisphosphonates? Crit Rev Oncol Hematol 2007;64(3):198-207. http://www.ncbi.nlm.nih.gov/pubmed/17855108
Update march 2009
135
133. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5(3):231-5. http://www.ncbi.nlm.nih.gov/pubmed/12496987 134. Esper PS, Pienta KJ. Supportive care in the patient with hormone refractory prostate cancer. Semin Urol Oncol 1997;15(1):56-64. http://www.ncbi.nlm.nih.gov/pubmed/9050140
136
Update march 2009
18. ABBREVIATIONS USED IN THE TEXT This list is not comprehensive for the most common abbreviations 3D-US ADT AS ASCO ASTRO AUA BMD bNED CAB CaP CPA CRT CSAP CSS CT DES DRE DHT DSS EBRT ECE ECOG eLND ELND e-MRI EORTC EPC EPCP ER-β ESRPC FACT-P FNAB FSH GI GR GU HD EBRT HDR HIFU HR HRPC HRQoL IAD IGRT IMRT IPSS LDAT LDR LE LET LH LHRH LHRHa LND MRC MRI MRSI
three-dimensional ultrasound androgen-deprivation therapy active surveillance American Society of Clinical Oncology American Society for Therapeutic Radiology and Oncology American Urological Association bone mineral density actuarial biochemical freedom from disease complete (or maximal or total) androgen blockade cancer of the prostate cyproterone acetate conformal radiotherapy cryosurgical ablation of the prostate cancer-specific survival computed tomography diethylstilboestrol digital rectal anticipation dihydrostestosterone disease-specific survival electron beam radiation therapy extracapsular extension Eastern Cooperative Oncology Group extended lymph node dissection elective lymph node dissection endorectal MRI European Organisation for Research and Treatment of Cancer Early Prostate Cancer Trialists’ Group Early Prostate Cancer Programme oestrogen receptor-β European Randomized Screening for Prostate Cancer Functional Assessment of Cancer Therapy-prostate fine-needle aspiration biopsy follicle-stimulating hormone gastrointestinal grade of recommendation genitourinary high-dose EBRT high-dose rate high-intensity focused ultrasound hazard ratio hormone-refractory prostate cancer health-related quality of life intermittent androgen deprivation image-guided radiotherapy intensity modulated radiotherapy International Prostatic Symptom Score long-term ADT low-dose rate (LDR) level of evidence linear energy transfer luteinising hormone luteinising hormone-releasing hormone luteinising hormone-releasing hormone analogue lymph node dissection Medical Research Council magnetic resonance imaging magnetic resonance spectroscopy imaging
Update march 2009
137
NHT neoadjvant hormonal therapy NIH National Institutes of Health NVB neurovascular bundle OR odds ratio OS overall survival PAP prostate acid phosphatase PCa prostate cancer PET positron emission tomography PFS progression-free survival PIN prostatic intraepithelial neoplasia PIVOT Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 PLCO Prostate, Lung, Colorectal and Ovary PSA prostate-specific antigen PSA-ACT PSA complexed to antichymotrypsin PSADT PSA doubling time PSAV PSA velocity PSMA prostate-specific membrane antigen for messenger RNA QoL quality of life QUALYs quality of life adjusted gain in life RITA radio-frequency interstitial tumour ablation RP radical prostatectomy RTOG Radiation Therapy Oncology Group SEER Surveillance, Epidemiology, and End Results SLN sentinel lymph node SPCG-4 Scandinavian Prostate Cancer Group Study Number 4 STAD short-term androgen deprivation SVI seminal vesicle invasion SWOG South West Oncology Group TNM Tumour Node Metastasis TZ transition zone TRUS transrectal ultrasound TURP transurethral resection of the prostate UICC Union Against Cancer USPIO ultra-small super-paramagnetic iron oxide particles VACURG Veterans Administration Co-operative Urological Research Group WHO World Health Organization WW watchful waiting
Aknowledgement The Prostate Cancer guidelines panel gratefully acknowledge the assistance of the following experts in the review process: Prof.Dr. L. Egevad, Prof.Dr. R. Montironi and Prof.Dr. H. Van Poppel. Conflict of interest All members of the Prostate Cancer Guidelines writing panel have provided disclosure statements on all relationships that they have and that might be perceived to be a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
138
Update march 2009
Guidelines on
Renal Cell Carcinoma B. Ljungberg, D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu
© European Association of Urology 2009
TABLE OF CONTENTS
page
1
INTRODUCTION 1.1 Reference
4 4
2.
EPIDEMIOLOGY AND AETIOLOGY 2.1 Conclusion 2.2 References
4 5 5
3. DIAGNOSIS AND STAGING 3.1 Symptoms 3.1.1 Physical examination 3.1.2 Laboratory findings 3.2 Radiological investigations 3.3 Conclusion 3.4 References
6 6 6 6 6 6 7
4. CLASSIFICATION AND PROGNOSTIC FACTORS 4.1 Classification 4.2 Prognostic factors 4.2.1 Anatomical factors 4.2.2 Histological factors 4.2.3 Clinical factors 4.2.4 Molecular factors 4.2.5 Prognostic systems and nomograms 4.3 Conclusion 4.4 References
8 8 9 9 9 10 10 10 10 10
5. TREATMENT OF LOCALISED DISEASE 5.1 Surgery 5.1.1 Embolisation 5.1.1.1 Conclusion 5.1.2 Nephron-sparing surgery 5.1.2.1 Conclusion 5.1.3 Laparoscopic nephrectomy 5.1.3.1 Conclusion 5.1.4 Partial laparoscopic nephrectomy 5.1.4.1 Conclusion 5.2 Alternative treatments to surgery 5.2.1 Conclusion 5.3 Adjuvant therapy 5.3.1 Conclusion 5.4 Surgical treatment of metastatic RCC (tumour nephrectomy) 5.4.1 Conclusion 5.5 Resection of metastases 5.5.1 Conclusion 5.6 Radiotherapy for metastases in RCC 5.6.1 Conclusion 5.7 References
13 13 13 13 14 14 14 14 15 15 15 15 15 16 16 16 16 16 16 16 17
6. SYSTEMIC THERAPY FOR METASTATIC RCC 6.1 Chemotherapy 6.1.1 Conclusion 6.2 Immunotherapy 6.2.1 Interferon-alpha monotherapy and combined with bevacizumab 6.2.1.1 Conclusion 6.2.2 Interleukin-2 6.2.2.1 Conclusion 6.3 Angiogenesis inhibitor drugs 6.3.1 Sorafenib 6.3.2 Sunitinib
20 20 20 21 21 21 21 21 21 21 21
2
Update march 2009
6.3.3 Bevacizumab monotherapy and combined with interferon-alpha 6.3.4 Mammalian target of rapamycin (mTOR) inhibitors 6.3.4.1 Temsirolimus 6.3.4.2 Everolimus 6.3.5 Conclusion 6.4 References
22 22 22 22 22 23
7.
SURVEILLANCE FOLLOWING RADICAL SURGERY FOR RCC 7.1 Introduction 7.2 Which investigations for which patient, and when? 7.3 Imaging modalities 7.4 Conclusion 7.5 References
24 24 25 25 26 26
8.
Summary of major amendments of the 2009 RCC guidelines update
27
9. ABBREVIATIONS USED IN THE TEXT
Update march 2009
28
3
1. INTRODUCTION The EAU Guideline Group for renal cell carcinoma (RCC) have prepared these guidelines to help urologists assess the evidence-based management of RCC and to help them incorporate the guidelines recommendations into their clinical practice. Publications concerning RCC are mostly retrospective analyses, which include some larger multicentre studies and well-designed controlled studies. As only a few randomised controlled trials are available, there is a lack of data with a strong evidence base. The recommendations provided in the current guideline are based on a systemic literature search using Medline, the Cochrane Central Register of Controlled Trials, and reference lists in publications and review articles. Where possible a level of evidence (LE) and/or grade of recommendation (GR) have been assigned (1). Recommendations are graded in order to provide transparency between the underlying evidence and the recommendation given (Tables 1 and 2). There is clearly a need for continuous re-evaluation at regular intervals by the RCC Guideline Group of the information provided in these guidelines. It has to be emphasised that the current guidelines contain information for the treatment of an individual patient according to a standardised general approach. The information should be considered as providing recommendations without legal implications. A summary of major amendments of the 2009 RCC guidelines update can be found on page 27 of this document. Publication history information: The Renal Cell Cancer Guidelines were first published in 2000. A partial update was achieved in 2001, followed by a full text update in 2007. The current 2009 version presents a partial update. Additionally, a quick reference guide is available. All texts can be viewed and downloaded for personal use at the society website: http://www.uroweb.org/professional-resources/guidelines/.
Table 1: Level of evidence Level Type of evidence 1a Evidence obtained from meta-analysis of randomised trials 1b Evidence obtained from at least one randomised trial 2a Evidence obtained from one well-designed controlled study without randomisation 2b Evidence obtained from at least one other type of well-designed quasi-experimental study 3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports 4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities Modified from Sackett et al. (1). Table 2: Grade of recommendation Grade Nature of recommendations A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial B Based on well-conducted clinical studies, but without randomised clinical trials C Made despite the absence of directly applicable clinical studies of good quality Modified from Sackett et al. (1).
1.2
REFERENCE
1.
Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [accessed February 2009].
2. EPIDEMIOLOGY AND AETIOLOGY Renal cell carcinoma represents 2-3% of all cancers (1), with the highest incidence occurring in Western countries. There is a worldwide and European annual increase in incidence of approximately 2%, though in Denmark and Sweden a continuing decrease has been observed during the last 20 years (2). In 1998, about
4
Update march 2009
30,000 patients were diagnosed with kidney cancer within the EU and approximately 15,000 died of the disease (3). Renal cell carcinoma is the most common solid lesion within the kidney. It comprises different RCC types with specific histopathological and genetic characteristics (4). There is a 1.5:1 predominance of men over women, with peak incidence occurring between 60 and 70 years of age. Aetiological factors include lifestyle factors, such as smoking, obesity and antihypertensive therapy (2, 5, 6). The most effective prophylaxis is to avoid cigarette smoking. Due to the increased detection of tumours by imaging techniques, such as ultrasound (US) and computerised tomography (CT), the number of incidentally diagnosed RCCs has increased. These tumours are more often smaller and of lower stage (7-9). However, despite the increased incidental detection rate, after the early 1990s mortality from RCC has stabilized showing a tendency towards decline (10).
2.1
Conclusion
A number of aetiological factors have been identified including smoking, obesity and antihypertensive drugs. Cigarette smoking is a definite risk factor for RCC (level of evidence: 2a). The roles of obesity and prolonged intake of antihypertensive medication as risk factors for RCC remain to be definitively clarified (level of evidence: 2a). Recommendation GR •T he most important primary prevention for RCC is to eliminate cigarette smoking and to avoid B obesity GR = grade of recommendation
2.2
REFERENCES
1.
European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.3, 730 entity dictionary (2001), Lyon, 2001. Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg 2004;93(2):88-96. http://www.ncbi.nlm.nih.gov/pubmed/15285559 EUCAN. http://www-dep.iarc.fr/eucan/eucan.htm Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B. The Heidelberg classification of renal cell tumours. J Pathol 1997;183(2):131-3. http://www.ncbi.nlm.nih.gov/pubmed/9390023 Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer - a quantitative review. Br J Cancer 2001;85(7):984-90. http://www.ncbi.nlm.nih.gov/pubmed/11592770 Pischon T, Lahmann PH, Boeing H, Tjonneland A, Halkjaer J, Overvad K, Klipstein-Grobusch K, Linseisen J, Becker N, Trichopoulou A, Benetou V, Trichopoulos D, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Monninkhof E, Peeters PH, Bueno-de-Mesquita HB, Buchner FL, Ljungberg B, Hallmans G, Berglund G, Gonzalez CA, Dorronsoro M, Gurrea AB, Navarro C, Martinez C, Quiros JR, Roddam A, Allen N, Bingham S, Khaw KT, Kaaks R, Norat T, Slimani N, Riboli E. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006;118(3):728-38. http://www.ncbi.nlm.nih.gov/pubmed/16094628 Patard JJ, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Prognostic significance of the mode of detection in renal tumours. BJU Int. 2002;90(4):358-63. http://www.ncbi.nlm.nih.gov/pubmed/12175389 Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol 2004;172(3):863-6. http://www.ncbi.nlm.nih.gov/pubmed/15310984 Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2001;163(2):426-30. http://www.ncbi.nlm.nih.gov/pubmed/10647646 Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P, La Vecchia C. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008;101(8):949-58 http://www.ncbi.nlm.nih.gov/pubmed/18241251
2. 3. 4.
5.
6.
7.
8.
9.
10.
Update march 2009
5
3. DIAGNOSIS AND STAGING 3.1
Symptoms
Many renal masses remain asymptomatic and non-palpable until late in the natural course of the disease (1) (level of evidence: 4). Today, more than 50% of RCCs are detected incidentally using non-invasive imaging to evaluate a variety of non-specific symptom complexes (1) (level of evidence: 4). The classic triad of flank pain, gross haematuria and palpable abdominal mass is now rare (6-10%) (2, 3) (level of evidence: 3). Paraneoplastic syndromes are found in around 30% of patients with symptomatic RCC, the most common of these being: hypertension, cachexia, weight loss, pyrexia, neuromyopathy, amyloidosis, elevated erythrocyte sedimentation rate, anaemia, abnormal liver function, hypercalcaemia, polycythaemia, etc. (1) (level of evidence: 4). A minority (25-30%) of patients are diagnosed as a result of symptoms due to metastatic disease, such as bone pain or persistent cough (1) (level of evidence: 4). 3.1.1 Physical examination Physical examination has a limited role in diagnosing RCC. However, it is valuable in some cases such as: • palpable abdominal mass • palpable cervical lymphadenopathy • non-reducing varicocele • bilateral lower extremity oedema, which suggests venous involvement. These findings should initiate radiological examinations. 3.1.2 Laboratory findings The most commonly assessed laboratory parameters are serum creatinine, haemoglobin, erythrocyte sedimentation rate, alkaline phosphatase and serum calcium (1, 4) (level of evidence: 4). The glomerular filtration rate (GFR) and separate bilateral renal function should be estimated when (5, 6) (level of evidence: 4): • renal function is of relevant clinical concern, as in patients with a solitary kidney tumour or bilateral tumours • renal function is compromised, as indicated by an increased concentration of serum creatinine, and in patients at risk for future renal impairment from intercurrent disorders such as diabetes, chronic pyelonephritis, renovascular, stone or renal polycystic disease.
3.2
Radiological investigations
Most renal tumours are diagnosed by abdominal ultrasound (US) and CT performed for various reasons (level of evidence: 4). Detection of a solid renal mass with US should be further investigated with a high-quality CT scan using contrast medium. This will confirm a diagnosis of RCC and provides information on the function and morphology of the contralateral kidney (5) (level of evidence: 3). • Abdominal CT assesses primary tumour extension with extrarenal spread and provides information on venous involvement, enlargement of locoregional lymph nodes, and condition of adrenal glands and the liver (level of evidence: 3). • Chest CT is the most accurate investigation for chest staging (6-13) (level of evidence: 3). However, at the very least, routine chest radiography, as a less accurate alternative to chest CT imaging, must be done for metastatic evaluation (level of evidence: 3). Magnetic resonance imaging (MRI) can be reserved primarily for patients with locally advanced malignancy, possible venous involvement, renal insufficiency or allergy to intravenous contrast (14-18) (level of evidence: 3). It is also an option for the evaluation of inferior vena cava tumour thrombus extension and unclassified renal masses (level of evidence: 3). Evaluation of the tumour thrombus can also be performed with Doppler US (19) (level of evidence: 3). In patients with any sign of impaired renal function, a renal scan and total renal function evaluation should be considered in order to optimise the treatment decision, e.g. the need to preserve renal function (6) (level of evidence: 2a). There is consensus that most bone and brain metastases are symptomatic at the time of diagnosis so that a routine bone scan or brain CT are not generally indicated (20, 21). However, if indicated by clinical or laboratory signs and symptoms, other diagnostic procedures may be applied, such as a bone scan, brain CT or MRI (level of evidence: 3). Renal arteriography, inferior venacavography or fine-needle biopsy (22-24) have only a limited role in the work-up of selected patients with RCC (level of evidence: 3).
3.3
Conclusion
In Europe, a large number of patients with RCC are still diagnosed due to clinical symptoms, such as palpable
6
Update march 2009
mass and haematuria, paraneoplastic and metastatic symptoms (level of evidence: 3). However, the number of incidentally detected RCCs is significantly increasing. Accurate staging of RCC with abdominal and chest CT or MRI is obligatory (level of evidence: 3). Chest CT is the most sensitive approach for chest staging. There is no role for routine bone scan or CT of the brain in the standard clinical work-up of asymptomatic patients. There is only a limited indication for fine-needle biopsy (level of evidence: 3). Recommendations GR • In a patient with one or more laboratory or physical findings, the possible presence of RCC A should be suspected • A plain chest X-ray can be sufficient for assessment of the lung in low-risk patients, but chest CT A is most sensitive • Abdominal CT and MRI are recommended for the work-up of patients with RCC and are the most A appropriate imaging modalities for TNM classification prior to surgery • In high-risk patients for bone metastases (raised alkaline phosphatase or bone pain), further A evaluation using an imaging approach should be done • Evaluation of renal function is recommended A GR = grade of recommendation
3.4
REFERENCES
1.
Novick AC, Campbell SC. Renal tumours. In: Walsh PC, Retik, AB, Vaughan ED, Wein AJ, eds. Campbell’s Urology. Philadelphia: WB Saunders, 2002, pp. 2672-2731. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol 2002;7(4):135-40. http://www.ncbi.nlm.nih.gov/pubmed/12474528 Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 2003;44(2):226-32. http://www.ncbi.nlm.nih.gov/pubmed/12875943 Sufrin G, Chasan S, Golio A, Murphy GP. Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol 1989;7(3):158-71. http://www.ncbi.nlm.nih.gov/pubmed/2690260 Song C, Bang JK, Park HK, Ahn H. Factors influencing renal function reduction after partial nephrectomy. J Urol 2009;181(1):48-53; discussion 53-4. http://www.ncbi.nlm.nih.gov/pubmed/19012914 Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001;66(1):6-18. http://www.ncbi.nlm.nih.gov/pubmed/11435813 Bechtold RE, Zagoria RJ. Imaging approach to staging of renal cell carcinoma. Urol Clin North Am 1997;24(3):507-22. http://www.ncbi.nlm.nih.gov/pubmed/9275976 Heidenreich A, Ravery V; European Society of Oncological Urology. Preoperative imaging in renal cell cancer. World J Urol 2004;22(5):307-15. http://www.ncbi.nlm.nih.gov/pubmed/15290202 Sheth S, Scatarige JC, Horton KM, Corl FM, Fishman EK. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. Radiographics 2001;21 Spec No:S237-54. http://www.ncbi.nlm.nih.gov/pubmed/11598260 Miles KA, London NJ, Lavelle JM, Messios N, Smart JG. CT staging of renal carcinoma: a prospective comparison of three dynamic computed tomography techniques. Eur J Radiol 1991;13(1):37-42. http://www.ncbi.nlm.nih.gov/pubmed/1889427 Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol 1993;150(4):1112-4. http://www.ncbi.nlm.nih.gov/pubmed/8371366 Doda SS, Mathur RK, Buxi TS. Role of computed tomography in staging of renal cell carcinoma. Comput Radiol 1986;10(4):183-8. http://www.ncbi.nlm.nih.gov/pubmed/3791984 Fritzsche PJ, Millar C. Multimodality approach to staging renal cell carcinoma. Urol Radiol 1992;14(1):3-7. http://www.ncbi.nlm.nih.gov/pubmed/1615571
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Update march 2009
7
14.
McClennan BL, Deyoe LA. The imaging evaluation of renal cell carcinoma: diagnosis and staging. Radiol Clin North Am 1994;32(1):55-69. http://www.ncbi.nlm.nih.gov/pubmed/8284361 15. Tammela TL, Leinonen AS, Kontturi MJ. Comparison of excretory urography, angiography, ultrasound and computed tomography for T category staging of renal cell carcinoma. Scand J Urol Nephrol 1991;25(4):283-6. http://www.ncbi.nlm.nih.gov/pubmed/1780704 16. Hricak H, Demas BE, Williams RD, McNamara MT, Hedgcock MW, Amparo EG, Tanagho EA. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 1985;154(3):709-15. http://www.ncbi.nlm.nih.gov/pubmed/3969475 17. Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging 1991;32(2):69-118. http://www.ncbi.nlm.nih.gov/pubmed/1863349 18. Krestin GP, Gross-Fengels W, Marincek B. [The importance of magnetic resonance tomography in the diagnosis and staging of renal cell carcinoma.] Radiologe 1992;32(3):121-6. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/1565792 19. Nishimura K, Hida S, Okada K, Yoshida O, Nishimuara K. Staging and differential diagnosis of renal cell carcinoma: a comparison of magnetic resonance imaging (MRI) and computed tomography (CT). Hinyokika Kiyo 1988;34(8):1323-31. http://www.ncbi.nlm.nih.gov/pubmed/3195400 20. Kabala JE, Gillatt DA, Persad RA, Penry JB, Gingell JC, Chadwick D. Magnetic resonance imaging in the staging of renal cell carcinoma. Br J Radiol 1991;64(764):683-9. http://www.ncbi.nlm.nih.gov/pubmed/1884119 21. Gupta NP, Ansari MS, Khaitan A, Sivaramakrishna MS, Hemal AK, Dogra PN, Seth A. Impact of imaging and thrombus level in management of renal cell carcinoma extending to veins. Urol Int 2004;72(2):129-34. http://www.ncbi.nlm.nih.gov/pubmed/14963353 22. Hendriksson C, Haraldsson G, Aldenborg F, Lindberg S, Pettersson S. Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. Scand J Urol Nephrol 1992;26(4):363-6. http://www.ncbi.nlm.nih.gov/pubmed/1292074 23. Marshall ME, Pearson T, Simpson W, Butler K, McRoberts W. Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. Urology 1990;36(4):300-2. http://www.ncbi.nlm.nih.gov/pubmed/2219605 24. Seaman E, Goluboff ET, Ross S, Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urol 1996;48(5):692-5. http://www.ncbi.nlm.nih.gov/pubmed/8911510 25. Brierly RD, Thomas PJ, Harrison NW, Fletcher MS, Nawrocki JD, Ashton-Key M. Evaluation of fine needle aspiration cytology for renal masses. BJU Int 2000;85(1):14-8. http://www.ncbi.nlm.nih.gov/pubmed/10619937 26. Dechet CB, Zincke H, Sebo TJ, King BF, LeRoy AJ, Farrow GM, Blute ML. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 2003;169(1):71-4. http://www.ncbi.nlm.nih.gov/pubmed/12478106
4. CLASSIFICATION AND PROGNOSTIC FACTORS 4.1
Classification
The 2002 TNM stage classification system is generally recommended for clinical and scientific use (1). It is unclear whether the current TNM classification is optimal for the prediction of survival in patients with RCC and it may require re-classification. The pT1 substratification, introduced in 2002 (1), has been validated by several studies (2-4) (level of evidence: 3). However, refinements are needed for pT3 tumours. Firstly, it has not been established whether renal sinus fat invasion only carries the same prognosis as does perinephric fat invasion (5, 6). Secondly, many studies have suggested that adrenal invasion is a very poor prognostic factor and that RCCs with this feature should be classified as T4 tumours (7, 8). Furthermore, it is still not clear whether the stratification of RCCs with venous invasion in T3b and T3c
8
Update march 2009
is accurate. More research is needed to investigate the independent prognostic value of vena caval invasion compared to renal vein invasion (9). More recently, the accuracy of the N1-N2 subclassification has been questioned (10). For adequate M-staging of patients with RCC, accurate pre-operative imaging (currently, chest and abdominal CT) should be performed (11, 12).
4.2 Prognostic factors Factors influencing prognosis can be classified into: anatomical, histological, clinical and molecular (13). 4.2.1 Anatomical factors Anatomical factors include tumour size, venous invasion, renal capsule invasion, adrenal involvement, and lymph node and distant metastasis. These factors are commonly gathered together in the universally used 2002 TNM staging classification system (Table 3). Table 3: The 2002 TNM staging classification system T - Primary tumour TX Primary tumour cannot be assessed T0 No evidence of primary tumour T1 Tumour < 7 cm in greatest dimension, limited to the kidney T1a Tumour < 4 cm in greatest dimension, limited to the kidney T1b Tumour > 4 cm but < 7 cm in greatest dimension T2 Tumour > 7 cm in greatest dimension, limited to the kidney T3 Tumour extends into major veins or directly invades adrenal gland or perinephric tissues but not beyond Gerota’s fascia T3a Tumour directly invades adrenal gland or perinephric tissues1 but not beyond Gerota’s fascia T3b Tumour grossly extends into renal vein(s)2 or its segmental branches, or the vena cava below the diaphragm T3c Tumour grossly extends into vena cava or its wall above diaphragm T4 Tumour directly invades beyond Gerota’s fascia N- Regional lymph nodes NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Metastasis in a single regional lymph node N2 Metastasis in more than 1 regional lymph node pN0 lymphadenectomy specimen ordinarily includes 8 or more lymph nodes. If the lymph nodes are negative, but the number ordinarily examined is not met, classify as pN0. M-
Distant metastasis MX Distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis
TNM stage grouping Stage I T1 N0 M0 Stage II T2 N0 M0 Stage III T3 N0 M0 T1, T2, T3 N1 M0 Stage IV T4 N0, N1 M0 Any T N2 M0 Any T Any N M1 1 Includes renal sinus (prepelvic fat). 2 Includes segmental (muscle-containing branches). A help desk for specific questions about TNM classification is available at http://www.uicc.org/tnm. 4.2.2 Histological factors Histological factors include Fuhrman grade, histological subtype, sarcomatoid features, microvascular invasion, tumour necrosis and collecting system invasion. Fuhrman nuclear grade is the most widely accepted histological grading system in RCC (14). Although affected by intra- and inter-observer discrepancies, it is an
Update march 2009
9
independent prognostic factor (15) (level of evidence: 3). According to the World Health Organization (WHO) classification (16), three major histological subtypes of RCC exist (level of evidence: 4): • conventional (clear cell) (80-90%) • papillary (10-15%) • chromophobe (4-5%). Many studies have shown a trend towards a better prognosis for patients with chromophobe, papillary and conventional (clear cell) RCCs, respectively (17, 18). However, the prognostic information provided by the RCC subtype is lost when stratified to tumour stage (18). Among papillary RCCs, two subgroups with different outcomes have been identified (19): • Type I are low-grade tumours with a chromophilic cytoplasm and a favourable prognosis. • Type II are mostly high-grade tumours with an eosinophilic cytoplasm and a great propensity for developing metastases (level of evidence: 3). The RCC type subclassification has been confirmed at the molecular level by cytogenetic and genetic analyses (20-22). 4.2.3 Clinical factors Clinical factors include patient performance status, localised symptoms, cachexia, anaemia and platelet count (23-27) (level of evidence: 3). 4.2.4 Molecular factors Numerous molecular markers being investigated include: carbonic anhydrase IX (CaIX), vascular endothelial growth factor (VEGF), hypoxia inducible factor (HIF), Ki67 (proliferation), p53, PTEN (phosphatase and tensin homolog) (cell cycle), E-cadherin, and CD44 (cell adhesion) (21, 22) (level of evidence: 3). As yet, these markers are not in widespread use. Recently, gene expression profiling has identified 259 genes, which predict survival independent of clinical prognostic factors in conventional RCCs, indicating that genetic information will improve prognostication (28). 4.2.5 Prognostic systems and nomograms Post-operative prognostic systems and nomograms that combine independent prognostic factors have been developed and externally validated (29-35). These systems may be more accurate than TNM stage or Fuhrman grade alone for predicting survival (level of evidence: 3). A substantial advantage of nomograms is their ability to measure predictive accuracy (PA), which enables objective evaluation of all new predictive parameters. Recently, new pre-operative nomograms with excellent PA have been designed (36, 37).
4.3
Conclusion
In patients with RCC, TNM stage, nuclear grade according to Fuhrman and RCC subtype (WHO, 2004; 16), should be performed because they contribute important prognostic information (level of evidence: 2). There are currently no prognostic integrated systems or molecular markers recommended for routine clinical use. Prognostic systems or nomograms can be useful for the stratified inclusion of patients into clinical trials (level of evidence: 2). Recommendations GR •T he current TNM classification system is recommended since it has consequences for prognosis B and therapy •T he Fuhrman grading system and classification of RCC subtype should be used B •T he use of integrated prognostic systems or nomograms is not routinely recommended, although B these systems can provide a rationale for enrolling patients into clinical trials •N o molecular prognostic marker is currently recommended for routine clinical use B GR = grade of recommendation
4.4
REFERENCES
1.
Sobin LH, Wittekind CH, eds. International Union Against Cancer (UICC). TNM classification of malignant tumours. 6th edn. New York: Wiley-Liss, 2002, pp. 193-195. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005;173(6):1889-92. http://www.ncbi.nlm.nih.gov/pubmed/15879769
2.
10
Update march 2009
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Salama ME, Guru K, Stricker H, Peterson E, Peabody J, Menon M, Amin MB, De Peralta-Venturina M. pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors. J Urol 2005;173(5):1492-5. http://www.ncbi.nlm.nih.gov/pubmed/15821466 Ficarra V, Schips L, Guille F, Li G, De La Taille A, Prayer Galetti T, Cindolo N, Novara G, Zigeuner RE, Bratti E, Tostain J, Altieri V, Abbou CC, Artibani W, Patard JJ. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 2005;104(5):968-74. http://www.ncbi.nlm.nih.gov/pubmed/16007683 Bonsib SM. The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. Am J Surg Pathol 2004;28(12):1594-600. http://www.ncbi.nlm.nih.gov/pubmed/15577678 Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol 2005;174(4 Pt 1):1218-21. http://www.ncbi.nlm.nih.gov/pubmed/16145373 Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukouyama H, Figlin RA, Belldegrun AS. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 2003;169(3):899-903; discussion 903-4. http://www.ncbi.nlm.nih.gov/pubmed/12576809 Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, Zincke H, Blute ML. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol 2005;173(3):918-21. http://www.ncbi.nlm.nih.gov/pubmed/15711327 Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 2005;104(1):53-60. http://www.ncbi.nlm.nih.gov/pubmed/15895375 Terrone C, Cracco F, Porpiglia F, Bollito E, Scoffone C, Poggio M, Berutti A, Ragni F, Cossu M, Scarpa RM, Rosetti SR. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006;49(2):324-31. http://www.ncbi.nlm.nih.gov/pubmed/16386352 Heidenreich A, Ravery V; European Society of Oncological Urology. Preoperative imaging in renal cell cancer. World J Urol 2004;22(5):307-15. http://www.ncbi.nlm.nih.gov/pubmed/15290202 Sheth S, Scatarige JC, Horton KM, Corl FM, Fishman EK. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. Radiographics 2001;21 Spec No:S237-S254. http://www.ncbi.nlm.nih.gov/pubmed/11598260 Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005;173(6):1853-62. http://www.ncbi.nlm.nih.gov/pubmed/15879764 Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655-63. http://www.ncbi.nlm.nih.gov/pubmed/7180965 Lang H, Lindner V, de Fromont M, Molinie V, Letourneux H, Meyer N, Martin M, Jacqmin D. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with > 15-year follow-up. Cancer 2005;103(3):625-9. http://www.ncbi.nlm.nih.gov/pubmed/15611969 Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds). In: Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyons: IARC Press, 2004, p. 7. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histological subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27(5):612-24. http://www.ncbi.nlm.nih.gov/pubmed/12717246 Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De LaTaille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histological subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23(12):2763-71. http://www.ncbi.nlm.nih.gov/pubmed/15837991
Update march 2009
11
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
12
Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001;32(6):590-5. http://www.ncbi.nlm.nih.gov/pubmed/11431713 Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L. Genetic basis of cancer of the kidney: diseasespecific approaches to therapy. Clin Cancer Res 2004;10(18 Pt 2):6282S-9S. http://www.ncbi.nlm.nih.gov/pubmed/15448018 Furge KA, Lucas KA, Takahashi M, Sugimura J, Kort EJ, Kanayama HO, Kagawa S, Hoekstra P, Curry J, Yang XJ, Teh BT. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 2004;64(12):4117-21. http://www.ncbi.nlm.nih.gov/pubmed/15205321 Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. A molecular classification of papillary renal cell carcinoma. Cancer Res 2005;65(13):5628-37. http://www.ncbi.nlm.nih.gov/pubmed/15994935 Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003;170(5):1742-6. http://www.ncbi.nlm.nih.gov/pubmed/14532767 Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. J Urol 2004;171(5):1810-3. http://www.ncbi.nlm.nih.gov/pubmed/15076282 Patard JJ, Leray E, Cindolo L, Ficarra V, Rodriguez A, De La Taille A, Tostain J, Artibani W, Abbou CC, Guille F, Chopin DK, Lobel B. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 2004;172(3):858-62. http://www.ncbi.nlm.nih.gov/pubmed/15310983 Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guille F, Patard JJ. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006;175(3 Pt 1):859-63. http://www.ncbi.nlm.nih.gov/pubmed/16469566 Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 2003;44(2):226-32. http://www.ncbi.nlm.nih.gov/pubmed/12875943 Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 2006;3(1):e13. http://www.ncbi.nlm.nih.gov/pubmed/16318415 Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166(1):63-7. http://www.ncbi.nlm.nih.gov/pubmed/11435824 Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19(6):1649-57. http://www.ncbi.nlm.nih.gov/pubmed/11250993 Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168(6):2395-400. http://www.ncbi.nlm.nih.gov/pubmed/12441925 Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97(7):1663-71. http://www.ncbi.nlm.nih.gov/pubmed/12655523 Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004;22(16):3316-22. http://www.ncbi.nlm.nih.gov/pubmed/15310775
Update march 2009
34.
35.
36.
37.
Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007;25(11):1316-22. http://www.ncbi.nlm.nih.gov/pubmed/17416852 Zigeuner R, Hutterer G, Chromecki T, Imamovic A, Kampel-Kettner K, Rehak P, Langner C, Pummer K. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 2008; Nov 28. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19062157 Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L, de La Taille A, Tostain J, Mulders PF, Bensalah K, Artibani W, Salomon L, Zigeuner R, Valeri A, Descotes JL, Rambeaud JJ, Mejean A, Montorsi F, Bertini R, Patard JJ. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2008; Jul 25. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/18715700 Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P and Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 2008;179(6):2146-51; discussion 2151. http://www.ncbi.nlm.nih.gov/pubmed/18423735
5. TREATMENT OF LOCALIsED DISEASE 5.1
Surgery
Until recently, radical nephrectomy that included the removal of the tumour-bearing kidney was the gold standard for curative therapy for localised RCC and it still offers a reasonable chance of curing the disease (1). There is no evidence to favour a specific surgical approach. The evidence also indicates that a routine adrenalectomy is not necessary during the surgical treatment of RCC, provided tumour staging is negative according to pre-operative imaging (CT, MRI). There are two exceptions to this general rule, which are: • a large upper pole tumour, which is associated with a risk of direct invasion of the adrenal gland • a tumour of > 7 cm maximum diameter, which is associated with a higher risk of intra-adrenal metastatic spread. Radical lymph node dissection does not improve survival in patients without clinically detectable lymph nodes and distant metastases (2) (level of evidence: 1a). In patients with palpable or CT-detected enlarged lymph nodes, lymph node dissection should still be performed to obtain adequate stage information. 5.1.1 Embolisation Indications for tumour embolisation include: • patients with gross haematuria who are not fit for surgical intervention • prior to surgical resection of large paravertebral metastases. There is no benefit in performing tumour embolisation before routine radical nephrectomy (level of evidence: 3) (3-9). 5.1.1.1 Conclusion Radical nephrectomy according to Robson is no longer the gold standard treatment for smaller renal tumours (level of evidence: 2b). Adrenalectomy is not recommended provided the adrenal is normal on pre-operative CT scan (level of evidence: 3). About half of adrenal metastases develop from larger upper pole tumours (level of evidence: 3). Extended lymphadenectomy does not improve survival in patients without clinically detectable lymph nodes and distant metastases and should be restricted to staging purposes in palpable and CT-detected enlarged lymph nodes (2) (level of evidence: 1b). Renal cell carcinomas with tumour thrombi have a higher stage and grade (level of evidence: 2b). Distant or lymph node metastases are twice as common (level of evidence: 3). This increased biological aggressiveness determines the clinical prognosis more than the presence or the cranial extension of intracaval thrombosis (level of evidence: 3) (10-23). Recommendations GR •S urgical therapy is the only curative therapeutic approach for the treatment of RCC. Routine A extended lymph node dissection in patients without detectable lymph nodes does not improve survival and can be restricted to staging purposes Update march 2009
13
•A drenalectomy, together with nephrectomy, except in the case of large upper pole tumours where direct invasion of the adrenal gland is likely, can be spared in most patients . •E mbolisation as a palliative approach can be beneficial in patients unfit for surgery with massive haematuria or profound local pain GR = grade of recommendation
B C
5.1.2 Nephron-sparing surgery Standard indications for nephron-sparing surgery are divided into the following categories: • absolute (anatomical or functional solitary kidney) • relative (functioning opposite kidney that is affected by a condition that might impair renal function in future) • elective (localised unilateral RCC with a healthy contralateral kidney). Relative indications also include patients with hereditary forms of RCC, who are at high risk of developing a tumour in the contralateral kidney in the future. 5.1.2.1 Conclusion Nephron-sparing surgery for RCC, when performed in patients with a solitary tumour < 4 cm maximum diameter, provides recurrence-free and long-term survival rates similar to those observed after a radical surgical procedure (level of evidence: 2b) (24-26). Nephron-sparing surgery carried out for absolute rather than elective indications has an increased complication rate and higher risk of developing locally recurrent disease, probably due to the larger tumour size (level of evidence: 3) (27, 28). There is some evidence that radical nephrectomy compared to nephron-sparing surgery carries an increased risk of impaired renal function, resulting in chronic renal insufficiency and proteinuria (level of evidence: 3) (29-31). In a few series, even patients with larger tumours (up to 7 cm), who have undergone nephron-sparing surgery, have shown oncological outcomes equivalent to those of radical surgery. If the tumour is completely resected, the thickness of the surgical margin does not impact on the likelihood of local recurrence (level of evidence: 3). Recommendations GR •N ephron-sparing surgery is an established curative approach for the treatment of RCC B •N ephron-sparing surgery for tumours > 4-7 cm maximum diameter can be performed in centres B with expertise in selected patients •A minimal tumour-free surgical margin following partial resection of RCC appears appropriate to B avoid the increased risk of local recurrence • If tumours of larger size are treated with nephron-sparing surgery, follow-up should be intensified B due to an increased risk of intrarenal recurrence GR = grade of recommendation 5.1.3 Laparoscopic nephrectomy Since its introduction, laparoscopic nephrectomy for RCC has become an established surgical procedure worldwide. Whether done retro- or trans-peritoneally, the laparoscopic approach must duplicate established open surgical oncological principles, which are: • early control of the renal vessels before tumour manipulation • wide specimen mobilisation external to Gerota’s fascia • avoidance of specimen traumatisation or rupture • intact specimen extraction. In the hands of experienced laparoscopic urological surgeons, and adhering to these principles of open radical nephrectomy, laparoscopic radical nephrectomy may now be considered a standard of care for patients with T1-2 RCCs. Intermediate outcome data indicate equivalent cancer-free survival rates when compared with open radical nephrectomy. 5.1.3.1 Conclusion Laparoscopy for radical nephrectomy has a lower morbidity when compared with open surgery (level of evidence: 3). Tumour control rates appear equivalent for T1-2 and possible T3a tumours in experienced hands (level of evidence: 3).
14
Update march 2009
Recommendation GR • Laparoscopic tumour nephrectomy should be performed in centres with laparoscopic expertise B • Laparoscopic tumour nephrectomy is likely to become a widely distributed treatment option. B It can be promoted in specialised centres treating kidney tumours GR = grade of recommendation 5.1.4 Partial laparoscopic nephrectomy In experienced hands, laparoscopic partial nephrectomy is an alternative to open nephron-sparing surgery for selected patients (32-35). The optimal indication for laparoscopic nephron-sparing surgery is a relatively small and peripheral renal tumour. It has been suggested that the oncological outcome following laparoscopic partial nephrectomy duplicates that of open nephron-sparing surgery (36, 37). However, currently, there are no larger studies able to reveal reliable long-term equivalence. Suggested disadvantages of the laparoscopic approach are the longer warm ischaemia time and increased intra-operative and post-operative complications compared with open surgery (38-40). 5.1.4.1 Conclusion Partial nephrectomy by laparoscopic surgery is technically feasible (level of evidence: 2b). Recommendations GR • Open partial nephrectomy currently remains the standard of care C • Laparoscopic partial nephrectomy should be limited to experienced centres C GR = grade of recommendation
5.2
Alternative treatments to surgery
Suggested alternatives to the surgical treatment of RCC have included image-guided percutaneous and minimally invasive techniques, e.g. percutaneous radiofrequency (RF) ablation (41, 42), cryoablation (43), microwave ablation, laser ablation and high-intensity focused ultrasound ablation (HIFU) (level of evidence: 2b) (44). Possible advantages of these and other techniques include reduced morbidity, outpatient therapy, and the ability to treat high-risk surgical candidates (level of evidence: 2b). Indications for minimally invasive techniques, including RF ablation, are small, incidentally found, renal cortical lesions in elderly patients, patients with genetic predisposition to multiple tumours, or patients with a solitary kidney, or bilateral tumours (level of evidence: 2b). Contraindications to the above-mentioned procedures include a poor life expectancy of < 1 year, multiple metastases, or difficulty for successful treatment due to size or location of tumour. In general, tumours > 5 cm or tumours in the hilum, the proximal ureter or central collecting system are not typically recommended for RF ablation (45). Absolute contraindications include irreversible coagulopathies or severe medical instability, such as sepsis. Although, even in high-risk patients, the reported complication rates are low, greater multicentre experience is needed to define the oncological success and complications of these procedures as an alternative to open or laparoscopic surgery. 5.2.1 Conclusion The formerly mentioned, minimally invasive approaches currently have the status of experimental treatment options for kidney cancer. Their efficacy should be further evaluated within clinical trials. Their disadvantage is a lack of adequate histopathological evaluation. However, their advantage is decreased invasiveness, enabling treatment of less well patients with a poor performance status and unfit for conventional surgery (level of evidence: 3). Recommendation GR •C urrently, patients not suitable for open or laparoscopic surgery due to a poor performance status B with smaller peripheral tumours should be considered for non-surgical alternative techniques • These techniques include image-guided percutaneous and minimally invasive techniques, e.g. B percutaneous radiofrequency ablation, cryoablation, microwave ablation, laser ablation and high-intensity focused ultrasound ablation GR = grade of recommendation
5.3
Adjuvant therapy
There is evidence that adjuvant tumour vaccination might improve the duration of the progression-free survival of selected subgroups of patients undergoing nephrectomy for T3 renal carcinomas. However, further confirmation is needed regarding the impact on overall survival (level of evidence: 1b) (46-50). Prognostic
Update march 2009
15
algorithms might identify patients likely to benefit most from adjuvant vaccination therapy. 5.3.1 Conclusion Adjuvant therapy with cytokines does not improve survival after nephrectomy (level of evidence: 1b). Recommendation GR • Outside controlled clinical trials, there is no indication for adjuvant therapy following surgery A GR = grade of recommendation
5.4
Surgical treatment of metastatic RCC (tumour nephrectomy)
Tumour nephrectomy is curative only if surgery can excise all tumour deposits. For most patients with metastatic disease, tumour nephrectomy is palliative and other systemic treatments are necessary. A meta-analysis of two randomised studies comparing nephrectomy + immunotherapy versus immunotherapy only showed that long-term survival increased in patients subjected to tumour nephrectomy (51). Nephrectomy in patients with metastatic disease is indicated for patients who are both suitable for surgery and have a good performance status (52). 5.4.1 Conclusion Tumour nephrectomy in combination with interferon-alpha (IFN-alpha) improves the survival of patients with metastatic RCC (mRCC) and a good performance status (level of evidence: 1b). Recommendation GR •T umour nephrectomy is recommended for metastatic RCC patients with a good performance status A when combined with IFN-alpha GR = grade of recommendation
5.5
Resection of metastases
Complete removal of metastatic lesions contributes to an improvement of clinical prognosis. Immunotherapy, where there has been complete resection of metastatic lesions or isolated local recurrences, does not contribute to an improvement in clinical prognosis (level of evidence: 2b) (52-56). 5.5.1 Conclusion Metastasectomy in patients with RCC has a definite role in improving the clinical prognosis (level of evidence: 3). Recommendations GR • In patients with synchronous metastatic spread, metastasectomy should be performed when B disease is resectable and the patient has a good performance status •T he clinical prognosis is worse in patients who have surgery for metachranous metastases B •M etastasectomy should be performed in patients with residual and resectable metastatic lesions B previously responding to immunotherapy and/or a limited (solitary lesion) number of metachranous metastases in order to improve the patient’s prognosis GR = grade of recommendation
5.6
Radiotherapy for metastases in RCC
Radiotherapy can be used for selected symptomatic patients with non-resectable brain or osseous lesions who do not respond to other conservative treatment approaches (57, 58). 5.6.1 Conclusion Radiotherapy of metastases from RCC can induce significant relief from symptoms, e.g. reduction of pain from a single bony deposit (level of evidence: 2b). Recommendation GR • In individual cases, radiotherapy for brain metastases (whole brain irradiation or stereotactic B approach) and osseous lesions can induce relief from symptoms due to mRCC (59, 60) GR = grade of recommendation
16
Update march 2009
5.7
REFERENCES
1.
Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101(3):297-301. http://www.ncbi.nlm.nih.gov/pubmed/5765875 Blom JH, van Poppel H, Maréchal JM, Jacqmin D, Schröder FH, de Prijck L,Sylvester R; for the EORTC Genitourinary Tract Cancer Group Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881. Eur Urol 2008 Oct 1. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/18848382 Bakal CW, Cynamon J, Lakritz PS, Sprayregen S. Value of preoperative renal artery embolization in reducing blood transfusion requirements during nephrectomy for renal cell carcinoma. J Vasc Interv Radiol 1993;4(6):727-31. http://www.ncbi.nlm.nih.gov/pubmed/8280991 Hemingway AP, Allison DJ. Complications of embolization: analysis of 410 procedures. Radiology 1988;166(3):669-72. http://www.ncbi.nlm.nih.gov/pubmed/3340761 Hom D, Eiley D, Lumerman JH, Siegel DN, Goldfischer ER, Smith AD. Complete renal embolization as an alternative to nephrectomy. J Urol 1999;161(1):24-7. http://www.ncbi.nlm.nih.gov/pubmed/10037359 Lanigan D, Jurriaans E, Hammonds JC, Wells IP, Choa RG. The current status of embolization in renal cell carcinoma - a survey of local and national practice. Clin Radiol 1992;46(3):176-8. http://www.ncbi.nlm.nih.gov/pubmed/1395422 Munro NP, Woodhams S, Nawrocki JD, Fletcher MS, Thomas PJ. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int 2003;92(3):240-4. http://www.ncbi.nlm.nih.gov/pubmed/12887475 Onishi T, Oishi Y, Suzuki Y, Asano K. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis. BJU Int 2001;87(4):312-5. http://www.ncbi.nlm.nih.gov/pubmed/11251521 Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol 2000;23(1): 6-12. http://www.ncbi.nlm.nih.gov/pubmed/10683065 O’Brien WM, Lynch JH. Adrenal metastases by renal cell carcinoma. Incidence at nephrectomy. Urology 1987;29(6):605-7. http://www.ncbi.nlm.nih.gov/pubmed/3576885 Angervall L, Wahlqvist L. Follow-up and prognosis of renal carcinoma in a series operated by perifascial nephrectomy combined with adrenalectomy and retroperitoneal lymphadenectomy. Eur Urol 1978;4(1):13-7. http://www.ncbi.nlm.nih.gov/pubmed/627219 Kozak W, Holtl W, Pummer K, Maier U, Jeschke K, Bucher A. Adrenalectomy-still a must in radical renal surgery? Br J Urol 1996;77(1):27-31. http://www.ncbi.nlm.nih.gov/pubmed/8653312 Kuczyk M, Munch T, Machtens S, Bokemeyer C, Wefer A, Hartmann J, Kollmannsberger C, Kondo M, Jonas U. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int 2002;89(6):517-22. http://www.ncbi.nlm.nih.gov/pubmed/11942955 Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 2005;48(2):252-7. http://www.ncbi.nlm.nih.gov/pubmed/15936136 Sandock DS, Seftel AD, Resnick MI. Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Urology 1997;49(1):28-31. http://www.ncbi.nlm.nih.gov/pubmed/9000180 Li GR, Soulie M, Escourrou G, Plante P, Pontonnier F. Micrometastatic adrenal invasion by renal carcinoma in patients undergoing nephrectomy. Br J Urol 1996;78(6):826-8. http://www.ncbi.nlm.nih.gov/pubmed/9014703 Leibovitch I, Raviv G, Mor Y, Nativ O, Goldwasser B. Reconsidering the necessity of ipsilateral adrenalectomy during radical nephrectomy for renal cell carcinoma. Urology 1995;46(3):316-20. http://www.ncbi.nlm.nih.gov/pubmed/7660505
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Update march 2009
17
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
18
von Knobloch R, Seseke F, Riedmiller H, Grone HJ, Walthers EM, Kalble T. Radical nephrectomy for renal cell carcinoma: is adrenalectomy necessary? Eur Urol 1999;36(4):303-8. http://www.ncbi.nlm.nih.gov/pubmed/10473989 Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol 2003;169(3):909-16. http://www.ncbi.nlm.nih.gov/pubmed/12576811 Bissada NK, Yakout HH, Babanouri A, Elsalamony T, Fahmy W, Gunham M, Hull GW, Chaudhary UB. Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology 2003;61(1):89-92. http://www.ncbi.nlm.nih.gov/pubmed/12559273 Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. Eur Urol 1997;31(1): 40-8. http://www.ncbi.nlm.nih.gov/pubmed/9032533 Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol 1996;155(2):448-50. http://www.ncbi.nlm.nih.gov/pubmed/8558632 Skinner DG, Pritchett TR, Lieskovsky G, Boyd SD, Stiles QR. Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg 1989;210(3):387-92; discussion 392-4. http://www.ncbi.nlm.nih.gov/pubmed/2774709 Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol 2000;163(3):730-736. J Urol 2000;163(3):730-6. http://www.ncbi.nlm.nih.gov/pubmed/10687966 Uzzo RG, Novick AC. Nephron-sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001;166(1):6-18. http://www.ncbi.nlm.nih.gov/pubmed/11435813 Delakas D, Karyotis I, Daskalopoulos G, Terhorst B, Lymberopoulos S, Cranidis A. Nephron-sparing surgery for localized renal cell carcinoma with a normal contralateral kidney: a European three-center experience. Urology 2002;60(6):998-1002. http://www.ncbi.nlm.nih.gov/pubmed/12475657 Kural AR, Demirkesen O, Onal B, Obek C, Tunc B, Onder AU, Yalcin V, Solok V. Outcome of nephronsparing surgery: elective versus imperative indications. Urol Int 2003;71(2):190-6. http://www.ncbi.nlm.nih.gov/pubmed/12890959 Hafez KS, Fergany AF, Novick AC. Nephron-sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999 Dec;162(6):1930-3. http://www.ncbi.nlm.nih.gov/pubmed/10569540 McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, Reuter VE, Russo P. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 2002;60(6):1003-9. http://www.ncbi.nlm.nih.gov/pubmed/12475658 Lundstam S, Jonsson O, Lyrdal D, Peeker R, Pettersson S. Nephron-sparing surgery for renal cell carcinoma-long-term results. Scand J Urol Nephrol 2003;37(4):299-304. http://www.ncbi.nlm.nih.gov/pubmed/12944187 Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75(12):1236-42. http://www.ncbi.nlm.nih.gov/pubmed/11126830 Desai MM, Strzempkowski B, Matin SF, Steinberg AP, Ng C, Meraney AM, Kaouk JH, Gill IS. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. J Urol 2005;173(1):38-41. http://www.ncbi.nlm.nih.gov/pubmed/15592021 Ono Y, Hattori R, Gotoh M, Yoshino Y, Yoshikawa Y, Kamihira O. Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already? Curr Opin Urol 2005;15(2):75-8. http://www.ncbi.nlm.nih.gov/pubmed/15725928 Link RE, Bhayani SB, Allaf ME, Varkarakis I, Inagaki T, Rogers C, Su LM, Jarrett TW, Kavoussi LR. Exploring the learning curve, pathological outcomes and perioperative morbidity of laparoscopic partial nephrectomy performed for renal mass. J Urol 2005;173(5):1690-4. http://www.ncbi.nlm.nih.gov/pubmed/15821559
Update march 2009
35. 36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
Novick AC. Laparoscopic and partial nephrectomy. Clin Cancer Res 2004;10(18 Pt 2):6322S-7S. http://www.ncbi.nlm.nih.gov/pubmed/15448025 Porpiglia F, Fiori C, Terrone C, Bollito E, Fontana D, Scarpa RM. Assessment of surgical margins in renal cell carcinoma after nephron sparing: a comparative study: laparoscopy vs open surgery. J Urol 2005;173(4):1098-101. http://www.ncbi.nlm.nih.gov/pubmed/15758709 Matin SF, Gill IS, Worley S, Novick AC. Outcome of laparoscopic radical and open partial nephrectomy for the sporadic 4 cm or less renal tumor with a normal contralateral kidney. J Urol 2002;168(4 Pt 1):1356-9; discussion 1359-60. http://www.ncbi.nlm.nih.gov/pubmed/12352392 Rassweiler J, Tsivian A, Kumar AV, Lymberakis C, Schulze M, Seeman O, Frede T. Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol 2003;169(6):2072-5. http://www.ncbi.nlm.nih.gov/pubmed/12771722 Makhoul B, De La Taille A, Vordos D, Salomon L, Sebe P, Audet JF, Ruiz L, Hoznek A, Antiphon P, Cicco A, Yiou R, Chopin D, Abbou CC. Laparoscopic radical nephrectomy for T1 renal cancer: the gold standard? A comparison of laparoscopic vs open nephrectomy. BJU Int 2004;93(1):67-70. http://www.ncbi.nlm.nih.gov/pubmed/14678371 Wille AH, Roigas J, Deger S, Tullmann M, Turk I, Loening SA. Laparoscopic radical nephrectomy: techniques, results and oncological outcome in 125 consecutive cases. Eur Urol 2004;45(4):483-8; discussion 488-9. http://www.ncbi.nlm.nih.gov/pubmed/15041113 Lui KW, Gervais DA, Mueller PR. Radiofrequency ablation: an alternative treatment method of renal cell carcinoma. Chang Gung Med J 2004;27(8):618-23. http://www.ncbi.nlm.nih.gov/pubmed/15553610 Lewin JS, Nour SG, Connell CF, Sulman A, Duerk JL, Resnick MI, Haaga JR. Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology 2004;232(3):835-45. http://www.ncbi.nlm.nih.gov/pubmed/15333798 Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, Kaouk JH, Desai MM, Novick AC. Renal cryoablation: outcome at 3 years. J Urol 2005;173(6):1903-7. http://www.ncbi.nlm.nih.gov/pubmed/15879772 Lin CH, Moinzadeh A, Ramani AP, Gill IS. Histopathologic confirmation of complete cancer-cell kill in excised specimens after renal cryotherapy. Urology 2004;64(3):590. http://www.ncbi.nlm.nih.gov/pubmed/15351611 Hines-Peralta A, Goldberg SN. Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res 2004;10(18 Pt 2):6328S-6334S. http://www.ncbi.nlm.nih.gov/pubmed/15448026 Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarossa M, Sacco C, Talamini R. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. Cancer 1996;77(12):2560-6. http://www.ncbi.nlm.nih.gov/pubmed/8640706 Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999;17(8):2521-9. http://www.ncbi.nlm.nih.gov/pubmed/10561318 Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21(16):3133-40. http://www.ncbi.nlm.nih.gov/pubmed/12810695 Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Woltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M; German Cooperative Renal Carcinoma ChemoImmunotherapy Trials Group (DGCIN). Adjuvant treatment with interleukin-2- and interferonalpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005;92(5):843-6. http://www.ncbi.nlm.nih.gov/pubmed/15756254
Update march 2009
19
50. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594-9. http://www.ncbi.nlm.nih.gov/pubmed/14987883 51. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171(3): 1071-6. http://www.ncbi.nlm.nih.gov/pubmed/14767273 52. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000;34(4):246-51. http://www.ncbi.nlm.nih.gov/pubmed/11095082 53. Pongracz N, Zimmerman R, Kotz R. Orthopaedic management of bony metastases of renal cancer. Semin Surg Oncol 1988;4(2):139-42. http://www.ncbi.nlm.nih.gov/pubmed/3393777 54. Tongaonkar HB, Kulkarni JN, Kamat MR. Solitary metastases from renal cell carcinoma: a review. J Surg Oncol 1992;49(1):45-8. http://www.ncbi.nlm.nih.gov/pubmed/1548881 55. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol 1999;35(3):197-203. http://www.ncbi.nlm.nih.gov/pubmed/10072620 56. Jackson RJ, Loh SC, Gokaslan ZL. Metastatic renal cell carcinoma of the spine: surgical treatment and results. J Neurosurg 2001;94(1 Suppl):18-24. http://www.ncbi.nlm.nih.gov/pubmed/11147860 57. Fossa SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol 1982;8(6): 340-2. http://www.ncbi.nlm.nih.gov/pubmed/6183119 58. Gez E, Libes M, Bar-Deroma R, Rubinov R, Stein M, Kuten A. Postoperative irradiation in localized renal cell carcinoma: the Rambam Medical Center experience. Tumori 2002;88(6):500-2. http://www.ncbi.nlm.nih.gov/pubmed/12597146 59. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryj J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363(9422):1665-72. http://www.ncbi.nlm.nih.gov/pubmed/15158627 60. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16(6):2261-6. http://www.ncbi.nlm.nih.gov/pubmed/9626229
6. SYSTEMIC THERAPY FOR METASTATIC RCC 6.1
Chemotherapy
Since RCCs develop from the proximal tubules, they have high levels of expression of the multiple-drug resistance protein P-glycoprotein and are therefore resistant to most chemotherapies. Chemotherapy seems to be effective only if 5-fluorouracil (5FU) is combined with immunotherapeutic agents (1). 6.1.1 Conclusion Only 5FU in combination with immunotherapy seems to be effective in patients with mRCC (level of evidence: 3). Recommendation GR • Chemotherapy as monotherapy should not be considered effective in patients with mRCC B GR = grade of recommendation
20
Update march 2009
6.2
Immunotherapy
6.2.1 Interferon-alpha monotherapy and combined with bevacizumab In randomised studies, IFN-alpha has proven superiority for survival over hormonal therapy in patients with mRCC (2). Interferon-alpha provided a response rate of 6-15%, together with a 25% decrease in the risk for tumour progression, and a modest survival benefit of 3-5 months when compared with placebo-equivalent (3, 4). Recently, bevacizumab + IFN-alpha demonstrated increased response rates and progression-free survival in first-line therapy compared to IFN-alpha monotherapy (5, 6). All recent randomised studies comparing antiangiogenic drugs in a first-line setting to IFN-alpha monotherapy have demonstrated a superiority for either sunitinib, bevacizumab + IFN-alpha or temsirolumus (5-8). 6.2.1.1 Conclusion Interferon-alpha monotherapy is no longer recommended as first-line therapy for mRCC (level of evidence: 1b). 6.2.2 Interleukin-2 Interleukin-2 (IL-2) has been used to treat mRCC since 1985 with response rates ranging from 7-27% (8-10). The optimal IL-2 regimen is not clear, but long-term (> 10 years) complete responders have been achieved with high-dose bolus IL-2 (11). The toxicity of IL-2 is substantially higher than that of IFN-alpha. It seems that only clear cell type RCC responds to immunotherapy. Interleukin-2 has not been validated in controlled randomised studies compared with best supportive care (4). 6.2.2.1 Conclusion Interleukin-2 has more side-effects than INF-alpha. High-dose IL-2 gives durable complete responders in a limited number of patients. Interleukin-2 remains the only cytokine suitable for monotherapy in selected patients with a good prognosis profile. Recommendations GR •M onotherapy with IFN-alpha can no longer be recommended as a first-line treatment for mRCC. A •B evacizumab + IFN-alpha is recommended as first-line therapy in low- and intermediate-risk B patients. Only selected patients with mRCC, revealing a good risk profile, and clear cell subtype histology, show clinical benefit from immunotherapy with IL-2. • Cytokine combinations, with or without additional chemotherapy, do not improve overall survival A compared with monotherapy GR = grade of recommendation
6.3
Angiogenesis inhibitor drugs
Recent advances in molecular biology have led to the development of several novel agents for the treatment of mRCC (Table 4). In sporadic clear cell RCC, HIF accumulation due to von Hippel Landau (VHL) inactivation, results in overexpression of VEGF and PDGF (platelet-derived growth factor), both of which promote neo-angiogenesis (12-14). This process substantially contributes to the development and progression of RCC. At present, four targeting drugs have been approved both in the USA and in Europe for the treatment of mRCC: • sorafenib (Nexavar®) • sunitinib (Sutent®) • bevacizumab (Avastin®) combined with IFN-alpha • temsirolimus (Torisel®). Several other new agents targeting angiogenesis are under investigation, as well as combinations of these new agents with each other or with cytokines. 6.3.1 Sorafenib Sorafenib is an oral multikinase inhibitor with activity against Raf-1 serine/threonine kinase, B-Raf, vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT-3) and c-KIT. A phase III trial comparing sorafenib and placebo after failure of a prior systemic immunotherapy reported a 3-month improvement in progression-free survival in favour of sorafenib (15). Survival seems to improve in patients crossed over from placebo to sorafenib treatment (16). 6.3.2 Sunitinib Sunitinib is an oxindol tyrosine kinase (TK) inhibitor. It selectively inhibits PDGFR, VEGFR, KIT and FLT-3 and has anti-tumour and anti-angiogenic activity. Phase II trials with sunitinib as second-line monotherapy in patients with mRCC demonstrated a partial response rate in 34-40% of patients and stable disease > 3 months in 27-29% of patients (17).
Update march 2009
21
In a recent phase III trial of first-line monotherapy that compared treatment with sunitinib to IFN-alpha, sunitinib achieved a longer progression-free survival than with IFN-alpha (11 vs 5 months, p < 0.000001). Results suggested monotherapy with IFN-alpha was inferior compared to sunitinib in low- and intermediaterisk patients with mRCC (18). Overall survival was 26.4 and 21.8 months in the sunitinib and IFN-alpha arms, respectively (p = 0.05) (18). In patients crossed over from IFN-alpha to sunitinib (n = 25), median survival times were 26.4 versus 20.0 months for sunitinib and IFN-alpha, respectively (p = 0.03). In patients who did not receive any post-study treatment, the median overall survival reached 28.1 months in the sunitinib group versus 14.1 months in the IFN-alpha group (p = 0.003). 6.3.3 Bevacizumab monotherapy and combined with interferon-alpha Bevacizumab is a humanised monoclonal antibody that binds isoforms of VEGF-A. Bevacizumab, 10 mg/kg every 2 weeks, in patients refractory to immunotherapy showed an increase in overall response (10%) and in progression-free survival versus placebo (19). A recent double-blind phase III trial (n = 649) in mRCC compared bevacizumab + IFN-alpha to IFN-alpha monotherapy (5).The median overall response was 31% in the bevacizumab + IFN-alpha group versus 13% in the IFN-alpha only group (p < 0.0001). Median progression-free survival increased significantly from 5.4 months with IFN-alpha to 10.2 months for bevacizumab + IFN-alpha (p < 0.0001), but only in low-risk and intermediate-risk patients. No benefit was seen in high-risk patients. No mature data are yet available on overall survival. 6.3.4 Mammalian target of rapamycin (mTOR) inhibitors 6.3.4.1 Temsirolimus Temsirolimus is a specific inhibitor of mammalian target of rapamycin (mTOR) (20). Patients with high-risk mRCC were randomised to receive first-line treatment with temsirolimus or IFN-alpha monotherapy or in combination. In the temsirolimus group, overall survival was 10.9 months versus 7.3 months in the IFN- group (p < 0.0069). However, overall survival in the temsirolimus + IFN-alpha group was not significantly improved (7). 6.3.4.2 Everolimus Everolimus is an oral mTOR inhibitor. A recent phase III study compared everolimus plus best supportive care (BSC) versus placebo plus BSC in patients who had failed previous anti-VEGF-R treatment. Median progression-free survival was 4 months with everolimus versus 1.9 months with placebo (p < 0.001) (12, 21). Table 4: Updated recommendations for first- and second-line systemic therapy in mRCC Treatment • 1st-line therapy
• 2nd-line therapy
Risk or prior treatment Low- or intermediate-risk High risk Prior cytokine Prior VEGFR Prior mTOR(-)
Recommended agent Sunitinib Bevacizumab + IFN-alpha Temsirolimus Sorafenib Everolimus Clinical trials
6.3.5 Conclusion Tyrosine kinase inhibitors (TKIs) increase progression-free survival and or overall survival as both first- and second-line treatment of mRCC (level of evidence: 1b). Sorafenib has proven efficacy as second-line treatment after failure of cytokine therapy (level of evidence: 1b). Sunitinib is more effective than IFN-alpha in treatmentnaïve, low- and intermediate-risk tumours (level of evidence: 1b). The association between bevacizumab and IFN-alpha is more effective than IFN-alpha in treatment-naïve, low- and intermediate-risk tumours (level of evidence: 1b). Temsirolimus monotherapy in high-risk mRCC patients is more effective than IFN-alpha or temsirolimus + IFN-alpha (level of evidence: 1b). Everolimus prolongs progression-free survival in patients who have failed treatment with TKIs. The role of the new drugs is still under development and combination studies are ongoing. To date, no data are available indicating the new agents have a curative effect. These agents appear to promise to stabilise mRCC for a prolonged period of time. However, their promise has to be balanced against their toxicity profile and the patient’s quality of life (level of evidence: 4).
22
Update march 2009
Recommendations GR • Sunitinib is recommended as first-line therapy in low- and intermediate-risk patients A • Bevacizumab + IFN-alpha is recommended as first-line therapy in low- and intermediate-risk patients A • Sorafenib is recommended as a second-line treatment for mRCC after cytokine failure A • Temsirolimus is recommended as first-line treatment in high-risk patients A • Everolimus can be recommended as second-line treatment after failure of tyrosine kinase inhibitors A GR = grade of recommendation
6.4
REFERENCES
1.
Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM, Vogelzang NJ. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003;170(4 Pt 1):1141-5. http://www.ncbi.nlm.nih.gov/pubmed/14501711 Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353(9146):14-7. http://www.ncbi.nlm.nih.gov/pubmed/10023944 Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96. http://www.ncbi.nlm.nih.gov/pubmed/11773181 Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;(1):CD001425. http://www.ncbi.nlm.nih.gov/pubmed/15674877 Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-11. http://www.ncbi.nlm.nih.gov/pubmed/18156031 Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24. http://www.ncbi.nlm.nih.gov/pubmed/17215529 Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22:2271-81. http://www.ncbi.nlm.nih.gov/pubmed/17538086 Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang A E, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;21(85):622-32. http://www.ncbi.nlm.nih.gov/pubmed/8468720 Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688-96. http://www.ncbi.nlm.nih.gov/pubmed/7884429 McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith, JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23(1):133-41. http://www.ncbi.nlm.nih.gov/pubmed/15625368 Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21(16):3127-32. http://www.ncbi.nlm.nih.gov/pubmed/12915604 Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12(24):7215-20. http://www.ncbi.nlm.nih.gov/pubmed/17189392
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Update march 2009
23
13.
14.
15.
16.
17.
18.
19.
20.
21.
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34. http://www.ncbi.nlm.nih.gov/pubmed/12890841 Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006;49(4):633-43. http://www.ncbi.nlm.nih.gov/pubmed/16481093 Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34. http://www.ncbi.nlm.nih.gov/pubmed/17215530 Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 2009;69(1):64-72. http://www.ncbi.nlm.nih.gov/pubmed/18774306 Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24. http://www.ncbi.nlm.nih.gov/pubmed/16330672 Figlin RA, Hutson TE, Tomczac P, Michaelson MD, Bukowski RM, Négrier S, Huang X, Kim ST, Chen I, Motzer RJ, et al. Overall survival with sunitinib versus interferon alfa as first-line treatment in metastatic renal-cell carcinoma. ASCO Annual Meeting Proceedings 2008. J Clin Oncol 2008;26(Suppl.):Abstr 5024. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_ view&confID=55&abstractID=32895 Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34. http://www.ncbi.nlm.nih.gov/pubmed/12890841 Larkin JM, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2006; 60(3):216-26. http://www.ncbi.nlm.nih.gov/pubmed/16860997 Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008;372(9637):449-56. http://www.ncbi.nlm.nih.gov/pubmed/18653228
7. SURVEILLANCE FOLLOWING RADICAL SURGERY FOR RCC 7.1
Introduction
Surveillance after radical surgery allows the urologist to monitor or identify: • post-operative complications • renal function • local recurrence • recurrence in the contralateral kidney • development of metastases. The method and timing of investigation has been the subject of many publications. There is no consensus on surveillance after radical surgery of the kidney. Post-operative complications and renal function are readily assessed by history, physical examination and measurement of serum creatinine. Repeated long-term monitoring of creatinine levels is indicated if there is impaired renal function before surgery or a post-operative significant increase in the serum creatinine level (1). Local recurrence is rare (1.8%), but early diagnosis is useful since the most effective treatment is
24
Update march 2009
cytoreductive surgery (2, 3). Recurrence in the contralateral kidney is also rare (1.2%) and is related to positive margins, multifocality and grade (4). The reason for surveillance is to identify metastases early. This is because a greater extension of tumour growth can reduce the possibility of surgical resection, which is considered the standard therapy in cases of resectable and, preferably solitary, metastatic lesions. In addition, within clinical trials, an early diagnosis of tumour recurrence might enhance the efficacy of a systemic treatment if the tumour burden is low.
7.2
Which investigations for which patients, and when?
Repeated intensive radiological surveillance for all patients is unnecessary because, for example, the outcome after surgery for small, well-differentiated tumours is almost always excellent. It is therefore reasonable to modify follow-up, taking into account the risk of developing recurrence or metastases. No randomised evidence exists, but there are large studies with long follow-up from which some conclusions can be drawn (level of evidence: 4). Prognostic factors can be classified into: anatomical (tumour size and stage, venous invasion, adrenal involvement, lymph node status), histological (grade, sarcoma, necrosis and collecting system invasion), clinical (performance status, anaemia, platelet count, cachexia) and molecular (5, 6). Although many molecular markers, using immunotherapy, vaccine, gene and angiogenesis techniques, are being investigated, none are yet in widespread use. Detailed information on molecular markers can be found in Section 4.2 Prognostic factors.
7.3
Imaging modalities
Where there is a low likelihood of relapse, chest X-ray and US are appropriate. Where the risk is intermediate or high, the investigation of choice is CT of chest and abdomen, though the significant morbidity of radiation dose with repeated CT scans should be taken into account (7). Dependent on the availability of new effective treatments, more strict follow-up schedules may be required. A problematic issue is the optimal duration of follow-up. It can be argued that follow-up by imaging is not cost effective after 5 years (8). Late metastases are more frequently solitary and justify more aggressive therapy with curative intent. Also, patients with small tumours in the contralateral kidney (2-3%) can be treated with nephron-sparing surgery. Furthermore, for tumours < 4 cm, there seems to be no difference in recurrence between partial and radical nephrectomy (9). Using many of these variables, several groups have designed scoring systems and algorithms to stratify patients into low-, intermediate- and high-risk groups for developing tumour recurrence or metastases. The frequency and type of investigation are different for each group (10-13). Examples of these scoring systems are shown in Tables 5 and 6. Table 5: S coring algorithm to predict metastases after nephrectomy in patients with clear cell RCC according to the Mayo Scoring System (13). Feature Primary tumour/T-stage T1a pT1b pT2 pT3-pT4 Tumour size < 10cm > 10cm Regional lymph node status pNx/pN0 pN1-pN2 Nuclear grade Grade 1-2 Grade 3 Grade 4 Tumour necrosis No necrosis Necrosis
Score 0 2 3 4 0 1 0 2 0 1 3 0 1
Risk groups can be stratified according to the Mayo Scoring System (13) into low-risk, 0-2, intermediate-risk,
Update march 2009
25
3-5, and high-risk, > 6. The use of scoring systems, such as the Mayo System, helps the urologist to select the use of imaging and to appropriately target those patients most in need of intensive surveillance. Table 6: A ccumulated risk of metastases (%) after nephrectomy in patients with clear cell RCC as defined in risk groups according to the Mayo Scoring System (13). Risk group • Low • Intermediate • High
7.4
Year 1 0.5 9.6 42.3
Year 3 2.1 20.2 62.9
Year 5 2.9 26.2 68.8
Year 10 7.5 35.7 76.4
Conclusion
In cases with a very low risk for tumour recurrence or systemic tumour progression, CT scans can be omitted as routine follow-up examinations. In these patients, a CT scan is only justified in cases of possible tumourassociated symptoms. In the intermediate-risk group, an intensified follow-up that includes CT scans at regular time intervals should be performed according to a risk-stratified nomogram. In high-risk patients, the follow-up examinations should include routine CT scans (level of evidence: 4). Recommendation GR •T he intensity of the follow-up programme for an individual patient should be adapted according to C the risk of tumour recurrence or systemic tumour progression, as determined by a risk nomogram developed for risk stratification GR = grade of recommendation
7.5
REFERENCES
1.
Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75(12):1236-42. http://www.ncbi.nlm.nih.gov/pubmed/11126830 Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal fossa recurrence after nephrectomy. J Urol 2000;164(2):322-5. http://www.ncbi.nlm.nih.gov/pubmed/10893575 Sandhu SS, Symes A, A’Hern R, Sohaib SA, Eisen T, Gore M, Christmas TJ. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int 2005;95(4):522-5. http://www.ncbi.nlm.nih.gov/pubmed/15705072 Bani-Hani AH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J Urol 2005;173(2):391-4. http://www.ncbi.nlm.nih.gov/pubmed/15643178 Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005;173(6):1853-62. http://www.ncbi.nlm.nih.gov/pubmed/15879764 Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histological subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23(12):2763-71. http://www.ncbi.nlm.nih.gov/pubmed/15837991 Ionising Radiation (Medical Exposures) Regulations 2000. National Radiation Protection Board 2000 www.hpa.org.uk http://www.hpa.org.uk/radiation/understand/radiation_topics/medical/diagnostic_radiology/national_ reference_doses.html http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733806727?p=11589346 078298 Montie J. Follow-up after partial or total nephrectomy for renal cell carcinoma. Urol Clin North Am 1994;21(4):725-7. http://www.ncbi.nlm.nih.gov/pubmed/7974900
2.
3.
4.
5.
6.
7.
8.
26
UPDATE MARCH 2009
9.
10.
11.
12.
13.
Patard JJ , Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004;171(6 Pt 1):2181-5; quiz 2435. http://www.ncbi.nlm.nih.gov/pubmed/15126781 Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999;84(4):40511. http://www.ncbi.nlm.nih.gov/pubmed/10468753 Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166(1):63-7. http://www.ncbi.nlm.nih.gov/pubmed/11435824 Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognosticated nomogram and risk group stratification system. J Urol 2005;174(2):466-72; discussion 472; quiz 801. http://www.ncbi.nlm.nih.gov/pubmed/16006866 Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97(7):1663-71. http://www.ncbi.nlm.nih.gov/pubmed/126555238.
The current document provides a limited update, with a summary of the amendments provided below.
8.
Summary of major amendments of the 2009 RCC guidelines update
Prognosis • Prognostic nomograms have been validated and one advantage of nomograms is their ability to measure predictive accuracy. Treatment • Interferon-alpha (IFN-alpha) is not recommended in a first-line setting as monotherapy in the treatment of metastatic RCC (mRCC) • Bevacizumab + IFN-alpha is recommended as first-line therapy in low- and intermediate-risk patients • Everolimus can be recommended as second-line therapy after tyrosine kinase inhibitor (TKI) failure
UPDATE MARCH 2009
27
9. ABBREVIATIONS USED IN THE TEXT
This list is not comprehensive for the most common abbreviations
5FU BSC CT FLT-3 HIF HIFU IFN-alpha IL-2 mRCC MRI mTOR PA PDGF PDGFR RCC RF TNM US VEGF VEGFR VHL WHO
5-fluorouracil best supportive care computerised tomography FMS-like tyrosine kinase 3 hypoxia inducible factor high-intensity focused ultrasound interferon-alpha interleukin-2 metastatic renal cell carcinoma magnetic resonance imaging mammalian target of rapamycin predictive accuracy platelet-derived growth factor platelet-derived growth factor receptor renal cell carcinoma radiofrequency Tumour Node Metastasis abdominal ultrasound vascular endothelial growth factor vascular endothelial growth factor receptor von Hippel-Lindau World Health Organization
Conflict of interest All members of the Renal Cell Cancer Guidelines writing panel have provided disclosure statements on all relationships that they have and that might be perceived to be a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
28
Update march 2009
Guidelines on
Penile Cancer G. Pizzocaro (Chairman), F. Algaba, S. Horenblas, E. Solsona, S. Tana, H. Van Der Poel, N. Watkin
© European Association of Urology 2009
TABLE OF CONTENTS
PAGE
1.
Introduction
4
2.
METHODOLOGY 2.1 References
4 4
3. DEFINITION OF PENILE CANCER
5
4.
EPIDEMIOLOGY 4.1 References
5 6
5. RISK FACTORS AND PREVENTION 5.1 References
6 7
6. TNM CLASSIFICATION AND PATHOLOGY 6.1 TNM classification 6.1.1 References 6.2 Pathology 6.2.1 Penile biopsy 6.2.2.1 Pathological categories 6.2.2.2 Histology and metastatic risk 6.2.3 References
8 8 9 9 10 10 10 10
7. DIAGNOSIS AND STAGING 7.1 Primary lesion 7.2 Regional lymph nodes 7.2.1 Lymphatic drainage of the penis 7.2.2 Non-palpable nodes 7.2.3 Risk factors 7.2.4 Palpable nodes 7.3 Distant metastases 7.4 Guidelines for the diagnosis of penile cancer 7.5 References
11 11 11 11 12 12 12 12 13 13
8. TREATMENT 8.1 Primary tumour 8.1.1 Category Tis and Ta 8.1.2 Category T1G1 8.1.3 Category T1G2-3 8.1.4 Category T2 (of the glans) 8.1.5 Category T2 (of the corpora) and T3 8.1.6 Category T4 8.1.7 Local disease recurrence 8.1.8 Technical aspects 8.1.8.1 Conservative surgery 8.1.8.2 Radical amputation 8.1.9 Radiotherapy 8.1.9.1 Recommendations for radiotherapy 8.1.10 Guidelines for treatment strategies for primary tumour 8.2 Treatment of regional lymph nodes 8.2.1 Management of patients with non-palpable inguinal nodes 8.2.1.1 Surveillance 8.2.1.2 Prognostic factors 8.2.1.3 Sentinel node biopsy (SNB) 8.2.2 Management of patients with palpable inguinal nodes 8.2.2.1 Inguinal LAD 8.2.2.2 Modified inguinal LAD 8.2.2.3 The role of pelvic LAD 8.2.2.4 Video-endoscopic inguinal and pelvic LAD
16 16 16 16 16 17 17 17 17 17 17 17 17 18 18 19 19 19 19 19 19 20 20 20 20
2
Update march 2009
8.2.3 Adjuvant chemotherapy 8.2.4 Management of patients with fixed or relapsed inguinal nodes 8.2.5 The role of radiotherapy 8.2.6 Guidelines for treatment strategies for nodal metastases 8.3 References
20 21 21 22 22
9.
27 27 27 27 27 28 28
FOLLOW-UP 9.1 How to follow-up 9.2 When to follow-up 9.3 Primary tumour 9.4 Regional recurrences 9.5 Guidelines for follow-up in penile cancer 9.6 References
10. QUALITY OF LIFE 10.1 Sexuality and fertility after penile cancer 10.1.1 Sexual activity and quality of life after penile cancer laser treatment 10.1.2 Sexual function after partial penectomy for penile cancer 10.2 Sexual mutilation, relapse and death 10.3 References
29 29 29 29 29 30
11.
31
ABBREVIATIONS USED IN THE TEXT
Update march 2009
3
1. INTRODUCTION The European Association of Urology (EAU) Guidelines Group on Penile Cancer has prepared this guidelines document to assist medical professionals in the management of penile cancer. The guidelines aim to provide detailed, up-to-date information, based on recent developments in our understanding and management of penile squamous cell carcinoma (SCC). However, it must be emphasised that these guidelines provide a standardised general approach to treating a patient and that the Guidelines provide guidance and recommendations without legal authority or implications. Publication history information: The Penile Cancer Guidelines were first published in 2001 and updated in 2004, followed by this full text update in 2009.
2. METHODOLOGY To update the last published guidelines in 2004, a meticulous PubMed literature search between October 2003 and October 2008 was carried out by all members of the Penile Cancer Consensus Group according to their field of interest (1). A total of 980 abstracts published on SCC of the penis were identified. Only one evidence-based peer-reviewed document was published during the period 2004 to 2008. This was the physician data query (PDQ) on ‘Penile Cancer Treatment’ (Health Professional Version) published by the National Cancer Institute , National Institutes of Health (Bethseda, USA) (2). No randomised controlled trials or Cochrane reviews were published. References used in the text have been assessed according to their level of scientific evidence (Table 1) and guideline recommendations have been graded (Table 2) according to the Oxford Centre for Evidence-based Medicine Levels of Evidence (3). The aim of grading recommendations is to provide transparency between the underlying evidence and the recommendation given. Publication history: The EAU Penile Cancer Guidelines were first published in 2000. Partial updates were achieved in 2001 and 2004, followed by the current version which presents a full text update. Additionally, a quick reference guide is available. All texts can be viewed and downloaded for personal use at the society website: http://www.uroweb.org/professional-resources/guidelines/. Table 1: Level of evidence Level Type of evidence 1a Evidence obtained from meta-analysis of randomised trials 1b Evidence obtained from at least one randomised trial 2a Evidence obtained from one well-designed controlled study without randomisation 2b Evidence obtained from at least one other type of well-designed quasi-experimental study 3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports 4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities Table 2: Grade of recommendation Grade Nature of recommendations A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial B Based on well-conducted clinical studies, but without randomised clinical trials C Made despite the absence of directly applicable clinical studies of good quality *modified from Sackett et al. (3)
2.1
REFERENCES
1.
Solsona E, Algaba F, Horenblas S, Pizzocaro G, Windahl T. EAU guidelines on penile cancer. Eur Urol 2004;46(1):1-8. http://www.ncbi.nlm.nih.gov/pubmed/15183542
4
Update march 2009
2. National Cancer Institute. Penile Cancer Treatment (PDQ). Health Professional Version. US National Institutes of Health, 2008, pp. 1-13. http://www.cancer.gov/cancertopics/pdq/treatment/penile/healthprofessional/allpages 3. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [Access date February 2009]
3. DEFINITION OF PENILE CANCER Penile cancer is a relatively rare SCC. It usually originates in the epithelium of the inner prepuce and glans. It shares a similar pathology and natural history with SCC of the oropharynx, female genitalia (cervix, vagina and vulva) and anus. Phimosis, poor hygiene and smoking are the major risk factors for penile cancer. Typing has been done of the human papillomaviruses (HPV) responsible for the sexual transmission of genital warts, condyloma acuminata SCC of the penis. An improved understanding of the natural history of the disease, earlier diagnosis, better technology, research group collaboration and centralisation of patients in centres of excellence has improved the cure rate for penile cancer from 50% in the 1990s to 80% in 2008.
4. EPIDEMIOLOGY In Western countries, primary malignant penile cancer is uncommon, with an incidence of less than 1.00 per 100,000 males in Europe and the United States of America (USA) (1, 2). There are, however, important geographical variations, with several European regions (Figure 1) reporting an incidence greater than 1.00 per 100,000 males (3). Incidence is also affected by race and ethnicity in North America (1), with the highest incidence of penile cancer found in white Hispanics (1.01 per 100,000), followed by Alaskan, Native/American Indians (0.77 per 100,000), Blacks (0.62 per 100,000) and White non-Hispanics (0.51 per 100,000). In contrast, in the non-Western world, the incidence rate of penile cancer is much higher and can represent 10-20% of malignant disease in men ranging from an age-adjusted incidence of 0.7 to 3 per 100,000 people in India to 8.3 per 1000,000 men in Brazil and even higher in Uganda, where it is the most commonly diagnosed cancer. Important risk factors include social and cultural habits, hygienic and religious practices (4). Penile carcinoma is rare in communities that practise circumcision in newborns or before puberty (Jews, Muslims and the Ibos of Nigeria). Early circumcision reduces the risk of penile cancer by 3 to 5 times. Adult circumcision does not protect against penile cancer. In the USA, the overall age-adjusted incidence rate decreased considerably between 1973 and 2002 from 0.84 per 100,000 in 1973-1982 to 0.69 per 100,000 in 1983-1992 and further to 0.58 per 100,000 in 19932002 (1). In European countries, the incidence during the 1980s and 1990s was stable or increased slightly (2). The incidence rate continuously increases with age (2); however, the disease has been reported in younger men and in children.
Update march 2009
5
Figure 1: Annual incidence rate (world standardised) by European region/country* Penis: ASR (World) (per 100,000) (All ages) Spain, Albacete Malta Switzerland, Neuchatel France, Haut-Rhin Italy, Ragusa Province UK, Scotland Denmark Austria, Tyrol Norway Spain, Asturias France, Bas-Rhin *UK, England Estonia Slovakia *Switzerland, Ticino The Netherlands *Belgium Flanders (excl. Limburg) Italy, Torino Poland, Warsaw city Germany, Saarland *Portugal, Vila Nova de Gaia Slovenia Italy, Sassari 0
0.5
1.0
1.5
2.0
*From Parkin et al. (2003) (3).
4.1
REFERENCES
1.
Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, Giuliano AR. Incidence trends in primary penile cancer. Urol Oncol 2007;25(5):361-7. http://www.ncbi.nlm.nih.gov/pubmed/17826651 ENCR (European Network of Cancer Registries). Eurocim version 4.0. European incidence database V2.2 (1999). Lyon, France: IARC, 2001. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds). Cancer Incidence in Five Continents. Vol. VIII. IARC Scientific Publications. No. 155. Lyon, France: IARC, 2002. http://www.iarc.fr/en/Publications/PDFs-online/Cancer-Epidemiology/IARC-Scientific-PublicationNo.-155 Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol 2004;5(4):240-7. http://www.ncbi.nlm.nih.gov/pubmed/15050955
2. 3.
4.
5. RISK FACTORS AND PREVENTION Risk factors for penile cancer were identified by the Karolinska Institute from a Medline search of published literature from 1966-2000 (1). Strong risk factors (OR > 10) identified by case-control studies included (level of evidence: 2a): • phimosis • chronic inflammatory conditions, e.g. balanoposthitis, lichen sclerosus and atrophicus (balanitis xerotica obliterans) • treatment with sporalene and ultraviolet A photochemotherapy. Sexual history (multiple partners, early age of first intercourse) and a self-reported history of condylomata were associated with a 3- to 5-fold increased risk of penile cancer. Smoking is also a risk factor. Cervical cancer in the wife was not consistently associated with penile cancer in the husband.
6
Update march 2009
In many case series, HPV DNA was identified in 70-100% intraepithelial neoplasia and in 40-50% of cases with invasive penile cancer. These results were confirmed by a population-based case control study (2). Among men not circumcised in childhood, phimosis was strongly associated with the development of invasive penile cancer (OR = 11.4; 95% CI 5.0-25.9), while cigarette smoking was associated with a 4.5-fold increased risk (95% CI 2.0-10.1). Human papillomavirus DNA was detected in 80% of tumour specimens; 69% were positive for HPV-16 (level of evidence: 2a). Smegma as a carcinogen has been clearly excluded (3). The risk of cancer among patients with condyloma acuminata increased for vulva, vagina, penis and anus (4) (level of evidence: 2b). Human papillomavirus-16 and -18 have a causal role in 70% of cancers of the cervix, vagina and anus and about 30-40% of cancers of the vulva, penis and oropharynx. Other cofactors are very likely to be necessary for progression from HPV infection to cancer (5). In June 2006, the US Food and Drug Administration (FDA) licensed the first vaccine to prevent cervical cancer and other HPV-associated diseases in women (6). The vaccine protects against infection with HPV-6, HPV-11, HPV-16 and HPV-18, which together are responsible for 70% of cervical cancers and 90% of genital warts. Human papillomavirus is highly transmissible, with a peak incidence soon after the onset of sexual activity. The recommended age for vaccination in females is 11-12 years (7), with catch-up vaccination recommended in females aged 13-26 years. However, vaccination is not a substitute for routine cervical cancer screening and vaccinated females should continue to have cervical cancer screening. Vaccination against HPV has also been recommended in males (8). Although a study found that mid-adult (25 years or older) women have a high level of acceptance for HPV vaccination (9), only 33% of males wanted the HPV vaccine, 27% did not and 40% were undecided (10). Interestingly, the presence of high-risk HPV DNA in penile cancer does not compromise prognosis. An early study (11) found no difference between HPV DNA-negative and HPV DNA-positive patients in lymph node metastases and 10-year survival rate. In a more recent study (12), disease-specific 5-year survival in the high-risk HPV-negative group was 78% versus 93% in the high-risk HPV-positive group (log rank test p = 0.03). This suggests the presence of high-risk HPV confers a survival advantage in patients with penile cancer. The virus plays an important role in oncogenesis through interaction with oncogenes and tumour suppressor genes (P53 and Rb-gene) (13).
5.1
REFERENCES
1. Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000;(205):189-93. http://www.ncbi.nlm.nih.gov/pubmed/11144896 2. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK, Krieger JN. Penile cancer: importance of circumcision, human papillomavirus and smoking in situ and invasive disease. Int J Cancer 2005;116(4):606-16. http://www.ncbi.nlm.nih.gov/pubmed/15825185 3. Van Howe RS, Hodges FM. The carcinogenicity of smegma: debunking a myth. Eur Acad Dermatol Venereol 2006;20(9):1046-54. http://www.ncbi.nlm.nih.gov/pubmed/16987256 4. Nordenvall C, Chang ET, Adami HO, Ye W. Cancer risk among patients with condylomata acuminata. Int J Cancer 2006;119(4):888-93. http://www.ncbi.nlm.nih.gov/pubmed/16557590 5. Munoz N, Castelisague X, de Gonzalez AB, Gissmann L. HPV in the etiology of human cancer. Vaccine 2006;24(Suppl 3):S3/1-10. http://www.ncbi.nlm.nih.gov/pubmed/16949995 6. Huang CM. Human papillomavirus and vaccination. Mayo Clin Proc 2008;83(6):701-6. http://www.ncbi.nlm.nih.gov/pubmed/18533087 7. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2):1-24. http://www.ncbi.nlm.nih.gov/pubmed/17380109 8. Giuliano AR. Human papillomavirus vaccination in males. Gynecol Oncol 2007;107(2 Suppl 1):S24S26. http://www.ncbi.nlm.nih.gov/pubmed/17938015
Update march 2009
7
9.
10.
11.
12.
13.
Ferris DG, Waller JL, Owen A and Smith J. Midadult women’s attitudes about receiving the prophylactic human papillomavirus vaccine. J Low Genit Tract Dis 2007;11(3):166-72. http://www.ncbi.nlm.nih.gov/pubmed/17596762 Ferris DG, Waller JL, Miller J, Patel P, Jackson L, Price GA, Wilson C. Men’s attitudes toward receiving the human papillomavirus vaccine. J Low Genit Tract Dis 2008;12(4):276-81. http://www.ncbi.nlm.nih.gov/pubmed/18820541 Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001;15;91(12):5-21. http://www.ncbi.nlm.nih.gov/pubmed/11413520 Lont AP, Kroon BK, Horenblas S, Gallee MP, Berkhof J, Meijer CJ, Snijders PJ. Presence of high risk human papilllomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer 2006;119(5):1078-81. http://www.ncbi.nlm.nih.gov/pubmed/16570278 Kayes O, Ahmed HU, Arya M, Minhas S. Molecular and genetic pathways in penile cancer. Lancet Oncol 2007;8(5):420-9. http://www.ncbi.nlm.nih.gov/pubmed/17466899
6. TNM CLASSIFICATION AND PATHOLOGY 6.1
TNM classification
The 2002 UICC Tumour Node Metastasis (TNM) classification (1) for penile cancer is shown in Table 3. Table 3: 2002 TNM (Tumour, Node, Metastasis) classification of penile cancer T - Primary tumour TX Primary tumour cannot be assessed T0 No evidence of primary tumour Tis Carcinoma in situ Ta Non-invasive verrucous carcinoma T1 Tumour invades subepithelial connective tissue T2 Tumour invades corpus spongiosum or cavernosum T3 Tumour invades urethra or prostate T4 Tumour invades other adjacent structures N - Regional lymph nodes NX Regional lymph nodes cannot be assessed N0 No evidence of lymph node metastasis N1 Metastasis in a single inguinal lymph node N2 Metastasis in multiple or bilateral superficial lymph nodes N3 Metastasis in deep inguinal or pelvic lymph nodes, unilateral or bilateral M - Distant metastases MX Distant metastases cannot be assessed M0 No evidence of distant metastases M1 Distant metastases This classification is in need of an update, particularly the definition of T2 category, as the prognosis of patients with tumour invasion of the corpus spongiosum is much better than invasion of the corpus cavernosum (2, 3). Rees et al. (2) reported on 72 patients with T2 tumours. Both local recurrence (35% vs 17%) and mortality (30% vs 21%) rates were higher in patients with tunical or cavernosal involvement after a mean follow-up of 3 years (level of evidence: 2b). The authors proposed defining T2a patients by spongiosum-only invasion and T2b patients by involvement of tunica or corpus cavernosum. However, a deeper analysis resulted in severe criticism and a new proposal for classification (3). A retrospective analysis of the records of 513 patients treated between 1956 and 2006 confirmed the above-mentioned difference between tumour invasion of corpus spongiosum and cavernosum. It also confirmed that there were no differences in long-term survival between T2 and T3, and no
8
Update march 2009
significant differences between N1 and N2 in the 1987-2002 TNM classification (level of evidence: 2a). A new TNM classification was therefore proposed for T2, T3, T4 and N1, N2, N3 (Table 4) (3). In the new proposed classification, retroperitoneal node metastases are considered to be distant metastases as for the neck, lung and other visceral organs. The new classification is much more appropriate than the present TNM categories, but it needs to be confirmed by UICC. Table 4: Proposed modification to 1987-2002 TNM classification* T - Primary tumour TX, T0, Tis, Ta and T1 Unchanged T2 Tumour invades corpus spongiosum T3 Tumour invades corpus cavernosum T4 Tumour invades adjacent structures (e.g. urethra, prostate) N - Regional lymph nodes Nx and N0 Unchanged N1 Unilateral inguinal metastases, mobile N2 Bilateral inguinal metastases N3 Fixed inguinal metastases or metastases in pelvic lymph nodes *From Leiitje et al. (2008) (3). 6.1.1 References 1. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. Philadelphia, PA: Wiley-Liss, 2002. 2. Rees RW, Freeman A, Borley N, Ralf DJ, Minhas S. PT2 penile squamous cell carcinomas: cavernosus vs. spongiosus invasion. Eur Urol Suppl 2008;7(3):111 (abstr 163). 3. Leijte JA, Gallee M, Antonini N, Horenblas S. Evaluation of current TNM classification of penile carcinoma. J Urol 2008;180(3):933-8; discussion 938. http://www.ncbi.nlm.nih.gov/pubmed/18635216
6.2
Pathology
Squamous cell carcinoma accounts for more than 95% of cases of malignant disease of the penis. Malignant melanomas and basal cell carcinoma are much less common. It is not known how often SCC is preceded by premalignant lesions (1). Although SCC is the most common penile neoplasia, different types and varying growth patterns have been identified (2-4) (Tables 5 and 6). Table 5: Premalignant lesions Lesions sporadically associated with SCC of the penis • Cutaneous horn of the penis • Bowenoid papulosis of the penis • Balanitis xerotica obliterans (lichen sclerosus et atrophicus) Lesions at high risk of developing SCC of the penis (up to one-third transform to invasive SCC) • Penile intraepithelial neoplasia (carcinoma in situ): erythroplasia of Queyrat and Bowen’s disease LE = level of evidence; SCC = squamous cell carcinoma. Table 6: Penile SCC Types of SCC • Classic • Basaloid • Verrucous and its varieties (2): - Warty (condylomatous) carcinoma - Verrucous carcinoma - Papillary carcinoma - Hybrid verrucous carcinoma - Mixed carcinomas (warty basaloid, adenobasaloid carcinoma) • Sarcomatoid • Adenosquamous
Update march 2009
9
Growth patterns of SCC • Superficial spread • Nodular or vertical-phase growth • Verrucous Differentiation grading systems for SCC • Broders’ system (5) • Maiche’s system score (6) SCC = squamous cell carcinoma. 6.2.1 Penile biopsy There is no need for biopsy if: • There is no doubt about the diagnosis and/or • Treatment of the lymph nodes is postponed after treatment of the primary tumour and/ or after histological examinations of the sentinel node(s). There is a need for histological confirmation if: • There is doubt about the exact nature of the lesion (metastasis, melanoma, etc) • Treatment of the lymph nodes is based on pre-operative histological information (risk-adapted strategy). In these cases an adequate biopsy is advised. When performing a biopsy, it is important to consider the findings from a study of biopsy size. The study of biopsies with an average size of 1.1 cm found there was: • difficulty in evaluating the extent of depth in 91% of biopsies • discordance between the grade at biopsy and the final specimen in 30% of cases • failure to detect cancer in 3.5% (1) • Thus, although a punch biopsy may be sufficient for superficial lesions, an excisional biopsy is preferred. 6.2.2.1 Pathological categories Traditionally, squamous cell carcinomas were considered as superficial or invasive. However, Cubilla et al. (2) has divided penile carcinoma into four categories: • superficial spreading • vertical growth • verrucous • multicentric. Different types of growth have different prognoses (3) and different ways of dissemination. The limits of surgical partial resections must therefore be set according to the growth pattern at the time of evaluation of the frozen sections (4). If the margins are studied following these criteria (including urethral and periurethral tissue), only 3-4 mm of tumourfree tissue is sufficient to consider the surgical margins to be negative (7). Basaloid SSC is a cellular subtype that is better recognised than before. It is highly aggressive. (8) 6.2.2.2 Histology and metastatic risk Histological subtypes carry different risks of developing metastatic lymph nodes: • condylomatous: 18.2% • SCC: 56.7% • sarcomatoid carcinoma: 89% (9). Similarly, invasion pattern (10) and vascular invasion (10, 11) are correlated with lymph node metastases, with 23.1% of positive lymph nodes associated with a nodular pattern and 64.6% with an infiltrative pattern. 6.2.3 1.
References Velazquez EF, Barreto JE, Rodriguez I, Piris A, Cubilla AL. Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int J Surg Pathol 2004;12(2):139-46. http://www.ncbi.nlm.nih.gov/pubmed/15173919 2. Cubilla AL, Barreto J, Caballero C, Ayala G, Riveros M. Pathologic features of epidermoid carcinoma of the penis. A prospective study of 66 cases. Am J Surg Pathol 1993;17(8):753-63. http://www.ncbi.nlm.nih.gov/pubmed/8338190
10
Update march 2009
3.
Villavicencio H, Rubio-Briones J, Regalado R, Chéchile G, Algaba F, Palou J. Grade, local stage and growth pattern as prognostic factors in carcinoma of the penis. Eur Urol 1997;32(4):442-7. http://www.ncbi.nlm.nih.gov/pubmed/9412803 4. Velazquez EF, Soskin A, Bock A, Codas R, Barreto JE, Cubilla AL. Positive resection margins in partial penectomies: sites of involvement and proposal of local routes of spread of penile squamous cell carcinoma. Am J Surg Pathol 2004;28(3):384-9. http://www.ncbi.nlm.nih.gov/pubmed/15104302 5. Broders AC. Squamous cell epithelioma of the skin: A study of 256 cases. Ann Surg 1921;73(2):141160. http://www.ncbi.nlm.nih.gov/pubmed/17864409 6. Maiche AG, Pyrhönen S, Karkinen M. Histological grading of squamous cell carcinoma of the penis: a new score system. Br J Urol 1991;67(5):522-526. http://www.ncbi.nlm.nih.gov/pubmed/1710163 7. Minhas S, Kayes O, Hegarty P, Kumar P, Freeman A, Ralph D. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 2005;96(7):1040-3. http://www.ncbi.nlm.nih.gov/pubmed/16225525 8. Cubilla AL, Reuter V, Velazquez E, Piris A, Saito S, Young RH. Histologic classification of penile carcinoma and its relation to outcome in 61 patients with primary resection. Int J Surg Pathol 2001;9(2):111-20. http://www.ncbi.nlm.nih.gov/pubmed/11484498 9. Bezerra AL, Lopes A, Landman G, Alencar GN, Torloni H, Villa LL. Clinicopathologic features and human papillomavirus DNA prevalence of warty and squamous cell carcinoma of the penis. Am J Surg Pathol 2001;25(5):673-8. http://www.ncbi.nlm.nih.gov/pubmed/11342782 10. Guimarães GC, Lopes A, Campos RS, Zequi Sde C, Leal ML, Carvalho AL, da Cunha IW, Soares FA. Front pattern of invasion in squamous cell carcinoma of the penis: new prognostic factor for predicting risk of lymph node metastases. Urology 2006;68(1):148-53. http://www.ncbi.nlm.nih.gov/pubmed/16844455 11. Busby JE, Pettaway CA. What’s new in the management of penile cancer? Curr Opin Urol 2005;15(5):350-7. http://www.ncbi.nlm.nih.gov/pubmed/16093861
7. DIAGNOSIS AND STAGING The primary tumour and regional lymph nodes must be staged correctly to enable the most appropriate treatment.
7.1
Primary lesion
Physical examination of a patient with penile cancer includes: • diameter of the penile lesion(s) or suspicious areas • location of lesion(s) on the penis • number of lesions • morphology of lesion(s): papillary, nodular, ulcerous or flat • relationship of lesion(s) to other structures, e.g. submucosa, tunica albuginea, urethra, • corpus spongiosum and corpus cavernosum • colour and boundaries of lesion(s) • penis length. Accurate histological diagnosis and staging of both the primary tumour and regional nodes are necessary in making treatment decisions (1). In a small series, physical examination alone was more reliable than imaging with ultrasound and/or MRI to judge infiltration into the corpora (2). Artificial erection with prostaglandin E1 (alprostadil) in combination with magnetic resonance imaging (MRI) was helpful in identifying the depth of tumour invasion of the corpora cavernosa and whether or not conservative surgery should be used (3, 4).
7.2
Regional lymph nodes
7.2.1 Lymphatic drainage of the penis Primary lymphatic drainage of penile cancer occurs to the inguinal nodes. A recent imaging study (5) has
Update march 2009
11
shown that all sentinel nodes are located in the superior and central inguinal zones with most found in the medial superior zone. No lymphatic drainage was observed from the penis to the inferior two regions of the groin and no direct drainage to the pelvic nodes was visualised. These findings confirm earlier studies (6-8). 7.2.2 Non-palpable nodes A careful inguinal physical examination is necessary. In the absence of palpable abnormalities, an inguinal ultrasound (7.5 mHz) may reveal abnormal nodes and can be used as a guide for fine-needle aspiration biopsy (9, 10). A sentinel node biopsy (SNB) (8) is not recommended because of a high rate of false-negative results (25%, range 9-50%) (11). However, recent reports suggest that dynamic SNB (using isosulphan blue and/ or technetium-99m (99mTc)-colloid sulphur) improved survival compared to a ‘wait-and-see’ policy (level of evidence: 3) and reduced toxicity compared to inguinal lymphadenectomy (LAD) (12, 13). A prospective study found dynamic SNB had 100% specificity and 78-80% sensitivity (14-18) (level of evidence: 2a). As analysis of dynamic SNB is operator-dependent (19) and relies on experience, the procedure is only available in a few centres. Because iliac lymph node metastases do not occur in the absence of inguinal metastases (19), an abdominal computed tomography (CT) scan is not necessary in patients with no inguinal node metastases. A conventional CT or MRI scan cannot detect micrometatases (20). Large studies are required to confirm promising results reported with nanoparticle-enhanced MRI and positron emission tomography (PET) or CT imaging (21, 22). 7.2.3 Risk factors The presence of lymph node metastases may be predicted from tumour characteristics other than T and G categories. Risk factors identified from retrospective studies include pathological subtype, perineural invasion, lymphovascular invasion, tumour depth or thickness, anatomical site, size and growth pattern, front of invasion, positive margins and urethral invasion (23). Several large series have identified lymphovascular invasion alone (24), lymphovascular invasion plus absent koilocytosis (25), lymphovascular invasion plus palpable inguinal nodes (26), high histological grade plus perineural invasion (27). The most important adverse pathological prognostic factors appear to be perineural invasion, vascular invasion and high histological grade (23). Nomograms can be used to evaluate the predictive power of clinical and pathological indicators (23, 26). 7.2.4 Palpable nodes Palpable nodes should be described as follows: • node consistency • node location(s) • diameter of node(s) or mass(es) • unilateral or bilateral localisation • number of nodes identified in each inguinal area • mobile or fixed nodes or masses • relationship (e.g. infiltration, perforation, etc) to other structures, such as the skin or Cooper ligament • oedema on leg and/or scrotum. Lymph node metastases in palpable nodes can be diagnosed using a percutaneous needle aspiration biopsy (cytology and/or histology punction). At the time of diagnosis of penile cancer, as many as 50% of palpable inguinal nodes will be reactive rather than due to lymph node metastasis. In contrast, during follow-up, nearly 100% of enlarged nodes are metastatic (28-30) (level of evidence: 2a). Thus, after allowing time for inflammatory reactions to subside, regional nodes should be evaluated within a few weeks after treatment of the primary tumour. Histological diagnosis can be done using fine-needle aspiration biopsy, tissue core biopsy or open biopsy, according to the preference of the pathologist (31, 32) (level of evidence: 2b). In the case of a negative biopsy and clinically suspicious nodes, a repeat biopsy or excisional biopsy should be performed. Imaging techniques (CT, MRI) are widely used, but are only useful for staging in patients with proven lymph node metastases. So far no imaging modality can identify microspcopic invasion. Imaging using PET (33) and the use of molecular biology are under investigation (34, 35).
7.3
Distant metastases
An assessment of distant metastases should be performed in patients with proven positive inguinal nodes (36) (level of evidence: 2b). Pelvic or abdominal CT scan should be used to identify pelvic (and retroperitoneal) adenopathies in patients with inguinal metastases. While this is not a very reliable diagnostic method, the detection of pelvic masses has a considerable impact on therapy and prognosis (39). Routine blood determination and chest X-rays are usually performed, despite the fact that lung metastasis
12
Update march 2009
is exceptionally rare. The value of SCC antigen determination as a staging tool is unclear and therefore not recommended for routine use (34). Biological studies are investigational (37). A diagnostic schedule is summarised in Table 7. Table 7: Diagnostic schedule for penile cancer Lesion level Primary tumour
Regional disease
• Non-palpable nodes • Palpable node
Distant metastases
Procedures Mandatory Advisable Physical examination Cytology or histology Physical examination Dynamic sentinel Ultrasound node biopsy* Ultra-sound (FNAC)* Cytology or histology Pelvic CT, if positive Abdominal CT inguinal nodes (chest X-rays)
Optional MRI Ultrasound
Bone scan in symptomatic patients
FNAC=fine needle aspiration biopsy;MRI = magnetic resonance imaging; PGE1 = prostaglandin E1; CT = computed tomography. *Dual techmique: isosulphan blue with technetium-99m (99mTc) colloid sulphur (8, 19). Regional lymph nodes are the regional disease.
7.4
Guidelines for the diagnosis of penile cancer
Primary tumour • Physical examination is mandatory, recording morphological and physical characteristics of the lesion • Cytological or histological diagnosis is mandatory Regional lymph node disease • Physical examination is mandatory • If nodes are non-palpable, ultrasound-guided FNAB • If FNAB is tumour-negative, dynamic SNB is indicated • If nodes are palpable, it is mandatory to record nodal morphological and physical and physical characteristics and to perform FNAB for histological diagnosis
GR B B
B B B B
Distant metastasis (beside inguinal nodes) • A pelvic CT scan is indicated if metastatic inguinal nodes are present B • An abdominal CT scan and chest X-ray are advisable if pelvic CT scan is positive B • A bone scan is advisable in M1 symptomatic patients C • Biological laboratory determinations for penile cancer are investigational None GR = grade of recommendation, MRI = magnetic resonance imaging; PGE1 = prostaglandin E1; FNAB = fine-needle aspiration biopsy; DSNB = sentinel node biopsy; CT = computed tomography.
7.5
REFERENCES
1.
Solsona E, Iborra I, Rubio J, Casanova JL, Ricós JV, Calabuig C. Prospective validation of the association of local tumor stage grade as a predictive factor for occult lymph node micrometastasis in patients with penile carcinoma and clinically negative inguinal lymph nodes. J Urol 2001;165(5): 1506-9. http://www.ncbi.nlm.nih.gov/pubmed/11342906 Horenblas S. The accuracy of ultrasound in squamous cell carcinoma. In: The Management of Penile Squamous Cell Carcinoma. A Retrospective and Prospective Study. Thesis. Amsterdam Zoetermeer: BV Export drukkerij, 1993, pp. 71-83. Kayes O, Minhas S, Allen C, Harc C, Freeman A, Ralph D. The role of magnetic resonance imaging in the local staging of penile cancer. Eur Urol 2007;51(5):1313-8. http://www.ncbi.nlm.nih.gov/pubmed/17113213
2.
3.
Update march 2009
13
4.
Lont AP, Besnard AP, Gallee MP, van Tinteren H, Horenblas S. A comparison of physical examination and imaging in determining the extent of primary penile carcinoma. BJU Int 2003;91(6):493-5. http://www.ncbi.nlm.nih.gov/pubmed/12656901 5. Leijte JA, Valdés Olmos RA, Nieweg OE, Horenblas S. Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT-CT: implications for the extent of inguinal lymph node dissection. Eur Urol 2008;54(4):885-90. http://www.ncbi.nlm.nih.gov/pubmed/18502024 6. Daseler EH, Anson BJ, Reimann AF. Radical excision of the inguinal and iliac lymph glands: a study based upon 450 anatomical dissections and upon supportive clinical observations. Surg Gynecol Obstet 1948;87(6):679-94. http://www.ncbi.nlm.nih.gov/pubmed/18120502 7. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39(2):456-66. http://www.ncbi.nlm.nih.gov/pubmed/837331 8. Catalona WJ. Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results. J Urol 1988;140(4):306-10. http://www.ncbi.nlm.nih.gov/pubmed/3418818 9. Saisorn I, Lawrentschut N, Leewansangtong S, Bolton DM. Fine-needle aspiration cytology predicts inguinal lymph node metastases without antibiotic pretreatment in penile carcinoma. BJU Int 2006;97(6):1125-8. http://www.ncbi.nlm.nih.gov/pubmed/16686716 10. Kroon BK, Horenblas S, Deurloo EE, Nieweg OE, Teertstra HJ. Ultrasonography-guided fineneedle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int 2005;95(4):517-21. http://www.ncbi.nlm.nih.gov/pubmed/15705071 11. Pettaway CA, Pisters LL, Dinney CPN, Jularbal F, Swanson DA, von Eschenbach AC, Ayala A. Sentinel lymph node dissection for penile carcinoma: the MD Anderson Cancer Center Experience. J Urol 1995;154(6):1999-2003. http://www.ncbi.nlm.nih.gov/pubmed/7500444 12. Horenblas S. Surgical management of carcinoma of the penis and scrotum. In: Petrovich Z, Baert L, Brady LW (eds). Medical Radiology. Diagnostic Imaging and Radiation Oncology. Carcinoma of the Kidney and Testis, and Rare Urologic Malignancies. Berlin: Springer-Verlag, 1999, pp. 341-54. 13. Pettaway CA, Jularbal FA, Babaian RJ, Dinney CPN, Pisters LL. Intraoperative lymphatic mapping to detect inguinal metastases in penile carcinoma: results of a pilot study. J Urol 1999;161:159 (abstr 612). 14. Akduman B, Fleshner NE, Ehrlich L, Klotz L. Early experience in intermediate-risk penile cancer with sentinel node identification using the gamma probe. Urology 2001;58(1):65-8. http://www.ncbi.nlm.nih.gov/pubmed/11445481 15. Perdonà S, Gallo L, Claudio L, Marra L, Gentile M, Gallo A. [Role of crural inguinal lymphadenectomy and dynamic sentinel lymph node biopsy in lymph node staging in squamous-cell carcinoma of the penis. Our experience.] Tumori 2003;89(4 Suppl):276-9. [article in Italian] http://www.ncbi.nlm.nih.gov/pubmed/12903620 16. Tanis PJ, Lont AP, Meinhardt W, Olmos RA, Nieweg OE, Horenblas S. Dynamic sentinel node biopsy for penile cancer: reliability of a staging technique. J Urol 2002;168(1):76-80. http://www.ncbi.nlm.nih.gov/pubmed/12050496 17. Wawroschek F, Vogt H, Bachter D, Weckermann D, Hamm M, Harzmann R. First experience with gamma probe guided sentinel lymph node surgery in penile cancer. Urol Res 2000;28(4):246-9. http://www.ncbi.nlm.nih.gov/pubmed/11011963 18. Lont AP, Horenblas S, Tanis PJ, Gallee MP, Van Tinteren H, Nieweg OE. Management of clinically node negative penile carcinoma: improved survival after the introduction of dynamic sentinel node biopsy. J Urol 2003;170(3):783-6. http://www.ncbi.nlm.nih.gov/pubmed/12913697 19. Leijte JA, Kroon BK, Valdés Olmos RA, Nieweg OE, Horenblas S. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol 2007;52(1):170-7. 20. Mueller-Lisse UG, Scher B, Scherr MK, Seitz M. Functional imaging in penile cancer: PET/computed tomography, MRI, and sentinel lymph node biopsy. Curr Opin Urol 2008;18(1):105-10. http://www.ncbi.nlm.nih.gov/pubmed/18090498 21. Tabatabaei S, Harisinghani M, McDougal WS. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol 2005;174:923-7; discussion 927. http://www.ncbi.nlm.nih.gov/pubmed/16093989
14
Update march 2009
22.
Scher B, Seitz M, Albinger W, Reiser M, Schlenker B, Stief C, Mueller-Lisse U, Dresel S. Value of PET and PET/CT in the diagnostics of prostate and penile cancer. Recent Results Cancer Res 2008;170:159-79. http://www.ncbi.nlm.nih.gov/pubmed/18019625 23. Cubilla AL. The role of pathologic prognostic factors in squamous cell carcinoma of the penis. World J Urol 2008 Sep 3. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/18766352 24. Lopes A, Hidalgo GS, Kowalski LP, Torloni H, Rossi BM, Fonseca FP. Prognostic factors in carcinoma of the penis: multivariate analysis of 145 patients treated with amputation and lymphadenectomy J Urol 1996;156(5):1637-42. http://www.ncbi.nlm.nih.gov/pubmed/8863559 25. Ornellas AA, Nóbrega BL, Wei Kin Chin E, Wisnescky A, da Silva PC, de Santos Schwindt AB. Prognostic factors in invasive squamous cell carcinoma of the penis: analysis of 196 patients treated at the Brazilian National Cancer Institute. J Urol 2008;180(4):1354-9. http://www.ncbi.nlm.nih.gov/pubmed/18707720 26. Ficarra V, Zattoni F, Artibani W, Cunico SC, Fandella A, Martignoni G, Novara G, Galetti TP, Zattoni F; GUONE Penile Cancer Project Members. Nomogram predictive of pathological inguinal lymph nodes involvement in patients with squamous cell carcinoma of the penis. J Urol 2006;175(6):1700-5. http://www.ncbi.nlm.nih.gov/pubmed/16697813 27. Velazquez EF, Ayala G, Liu H, Chaux A, Zanotti M, Torres J, Cho SI, Barreto JE, Soares F, Cubilla AL. Histologic grade and perineural invasion are more important than tumor thickness as predictor of nodal metastasis in penile squamous cell carcinoma invading 5 to 10 mm. Am J Surg Pathol 2008;32(7):974-9. http://www.ncbi.nlm.nih.gov/pubmed/18460979 28. Horenblas S, Van Tinteren H, Delamarre JFM, Moonen LM, Lustig V, van Waardenburg EW. Squamous cell carcinoma of the penis. III. Treatment of regional lymph nodes. J Urol 1993;149(3): 492-7. http://www.ncbi.nlm.nih.gov/pubmed/8437253 29. Ornellas AA, Seixas AL, Marota A, Wisnescky A, Campos F, de Moraes JR. Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 1994;151(5):1244-9. http://www.ncbi.nlm.nih.gov/pubmed/7512656 30. Pizzocaro G, Piva L, Nicolai N. Treatment of lymphatic metastasis of squamous cell carcinoma of the penis: experience at the National Tumor Institute of Milan. Arch Ital Urol Androl 1996;68(3):169-72. http://www.ncbi.nlm.nih.gov/pubmed/8767505 31. Senthil Kumar MP, Ananthakrishnan N, Prema V. Predicting regional node metastasis in carcinoma of the penis: a comparison between fine-needle aspiration cytology, sentinel lymph node biopsy and medial inguinal lymph node biopsy. Br J Urol 1998;81(3):453-7. http://www.ncbi.nlm.nih.gov/pubmed/9523669 32. Skoog L, Collins BT, Tani E, Ramos RR. Fine-needle aspiration cytology of penile tumors. Acta Cytol 1998;42(2):1336-40. http://www.ncbi.nlm.nih.gov/pubmed/9568135 33. Ravizzini GC, Wagner M, Borges-Neto S. Positron emission tomography detection of metastatic penile squamous cell carcinoma. J Urol 2001;165(5):1633-4. http://www.ncbi.nlm.nih.gov/pubmed/11342941 34. Laniado ME, Lowdell C, Mitchell H, Christsmas TJ. Squamous cell carcinoma antigen: a role in the early identification of nodal metastases in men with squamous cell carcinoma of the penis. BJU Int 2003;92(3):248-5. http://www.ncbi.nlm.nih.gov/pubmed/12887477 35. Lopez A, Bezena AL, Pinto CA, Serrano SV, de Mello CA, Villa LL. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. J Urol 2002;168:81-6. http://www.ncbi.nlm.nih.gov/pubmed/12050497 36. Zhu Y, Zhang SL, Ye DW, Yao XD, Jiang ZX, Zhou XY Predicting pelvic lymph node metastases in penile cancer patients: a comparison of computed tomography, Cloquet’s node, and disease burden of inguinal lymph nodes. Onkologie. 2008;31:37-41. 37. Kayes O, Ahmed HU, Arya M, Minhas S. Molecular and genetic pathways in penile cancer. Lancet Oncol 2007;8(5):420-9. http://www.ncbi.nlm.nih.gov/pubmed/17466899
Update march 2009
15
38.
Lont AP, Kroon BK, Gallee MP, van Tinteren H, Moonen LM, Horenblas S. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007;177(3):947-52; discussion 952. http://www.ncbi.nlm.nih.gov/pubmed/17296384
8. TREATMENT The primary tumour and regional lymph nodes are usually treated separately. It is important to avoid both overtreatment, which may lead to side-effects, and undertreatment, which may impair survival.
8.1
Primary tumour
8.1.1 Category Tis and Ta Tis and Ta are superficial lesions that can be treated with several conservative techniques: • topical 5-fluorouracil for Tis (1) • imiquimod 5% cream, an immune response modifier with good cosmetic and functional results on flat lesions (2) • laser therapy with carbon dioxide (CO2) or neodymium:yttrium-aluminum-garnet (Nd:YAG) lasers (3, 4) • photodynamic therapy (5) • Mohs’ micrographic surgery for Ta lesions (6, 7). However, conservative treatment may not be suitable in cases of multifocal lesions, which are responsible for 15% of recurrences. Total treatment of the glans surface combined with concomitant circumcision is strongly recommended (4) to avoid multiple recurrences (grade of recommendation: A). Cure with secondary healing was obtained in 94% of 106 Tis patients treated with peniscopically controlled CO2 laser excision. However, five patients had multiple recurrences and two required penile amputation (7). A recent paper on photodynamic therapy reported seven responses in 10 treated patients, but only four patients were recurrence-free after a mean follow-up of 35 months (5). Non-invasive verrucous carcinoma (Ta) needs a correct pre-operative diagnosis to avoid unnecessary extensive surgery (6). Furthermore, a recent report on Mohs’ micrographic surgery demonstrated a significant local recurrence rate for Tis and verrucous carcinoma as well as invasive SCC (7). In conclusion, the best results are achieved with laser surgery (level of evidence: 2b; grade of recommendation: B). 8.1.2 Category T1G1 For lesions limited (level of evidence: 2a) to the foreskin and sulcus, wide local excision with circumcision may provide adequate treatment. Pathological assessment of the surgical margin is mandatory; a margin of 3-4 mm is sufficient (8). For T1 tumours of the glans, peniscopically controlled CO2 laser excision alone cured 86% of 78 patients with histologically superficial infiltration (≤ 1 mm) of lamina propria (4). Another 40 patients had deeper infiltration (> 1 mm) with exophytic warty-like or plaque tumours. These patients received neo-adjuvant vinblastine, bleomycin and methotrexate (VBM) chemotherapy, with cure achieved in 33 (82%) patients. Of 18 (15%) relapsed patients, only eight (7%) needed penile amputation or radiotherapy (level of evidence: 2b). An alternative treatment of glans resurfacing (9) has shown promising results for preinvasive lesions (level of evidence: 2a). 8.1.3 Category T1G2-3 For patients who can guarantee they will attend for regular follow-up, a penis-preserving strategy is strongly recommended using wide local laser excision plus reconstructive surgery (10, 11) or glansectomy (12-14) (level of evidence: 2a). Treatment choice is influenced by tumour size and position on the glans and the side-effects of treatment. Meticulous follow-up is essential to enable immediate treatment of any local disease recurrence. There is no difference in the local recurrence rate (15% or more) between external radiation therapy, interstitial brachytherapy (BRT) laser therapy and wide local excision. Glansectomy has the lowest recurrence rate of 2% (13). Pathological assessment of surgical margins is essential when using these procedures to reduce the rate of local recurrence (12, 13, 15) (level of evidence: 2b). Generally, early diagnosis of local recurrence does not have a negative impact on survival (16) (level of evidence: 3).
16
Update march 2009
8.1.4 Category T2 (of the glans) A conservative strategy of total glansectomy, with or without resurfacing of the corporeal heads, is recommended (5, 14) (level of evidence: 2a). Partial glansectomy is an alternative in very carefully selected patients with tumours that include less than half of the glans and in whom close follow-up is possible (17) (level of evidence: 2b). Consider partial amputation in patients unfit for more conservative reconstructive surgery (13). 8.1.5 Category T2 (of the corpora) and T3 For tumours involving the tips of the corpora, partial amputation is standard treatment (18, 19) (level of evidence : 2a) . Reconstructive surgery with negative margins at frozen section analysis is an alternative in carefully selected patients (level of evidence: 2b). For large tumours involving more than the distal corpora, partial or radical amputation is standard (level of evidence: 2a). Traditionally, partial amputation has required removal of 2-cm tumour-free margins. This is almost certainly more than is necessary. However, it is essential to achieve tumour-free margins with pathological confirmation. A surgical margin of 5-10 mm is safe (15, 20, 21) (level of evidence: 2b). 8.1.6 Category T4 Deeply infiltrating tumours involving adjacent structures are often associated with disseminated disease at presentation and a short life expectancy. Palliative care may be most appropriate. In selected cases, downstaging with chemotherapy may be considered prior to total penectomy. Alternatives include surgery with adjuvant external beam irradiation (level of evidence: 3). 8.1.7 Local disease recurrence For local recurrence after conservative therapy, a second conservative procedure is strongly advised if there is no corpora cavernosa invasion (22) (level of evidence: 2b). However, if there is a large or deep infiltrating recurrence, partial or total amputation is strongly recommended. The incidence of local recurrence increases with penis preservation, but can be treated in most cases. Local recurrence after penile amputation has a poor prognosis (23). Combined chemotherapy and radiotherapy as for advanced head and neck cancer has not yet been tried. 8.1.8 Technical aspects of surgery 8.1.8.1 Conservative surgery The most important factors in the choice of conservative management are simplicity, morbidity of the procedure and the surgeon’s experience. Small areas of ablated/excised epithelium can heal without grafting. For a larger area, a skin graft provides a better cosmetic result in a shorter time (level of evidence: 3). 8.1.8.2 Partial/total amputation Stenosis of the neo-meatus or perineal urethrostomy is seen in approximately 7-10% and can be prevented by a spatulated repair. Orchidectomy should not be performed routinely (level of evidence: 3). 8.1.9 Radiotherapy External beam irradiation (ERT), brachytherapy (BRT) or both techniques together can be used. The ERT treatment is delivered with high-energy photons (4-6 MV) and uses CT scanning to define the target volume and to optimise dosage distribution. Different types of BRT can be used including external isotope mould, lowdose rate BRT, pulse-dose rate BRT or high-dose rate BRT. Primary tumour radiotherapy is an alternative organ-preserving approach with excellent results in selected patients with T1-2 lesions less than 4 cm in diameter (level of evidence: 2a). There have been no prospective studies or randomised trials to evaluate the different modalities of radiation treatment. A local control rate of about 60% has been reported using ERT, while BRT has achieved better control rates ranging from 70% to 90% (24-28). However, it is difficult to compare results using ERT and BRT because patients with large volume lesions (> 4 cm) are excluded from BRT. In addition, the different dosages used in different retrospective studies, even within the same institution, make it very difficult to compare results and side-effects. Local failure rates after radiotherapy were higher than after adequate partial penectomy, but salvage surgery can restore local control (28, 29). The high doses of radiation needed to achieve local control can cause iatrogenic complications. Urethral stenosis (20-35%), glans necrosis (10-20%) and late fibrosis are the most serious types of tissue damage and can result in a non-functioning penis.
Update march 2009
17
The penile preservation rate after radiotherapy is approximately 80%. The local control rate after BRT was recently reported as 90%, with an actuarial penile preservation rate of 87% at 5 years (29). Because of postradiation changes (necrosis, scars, ulcers), it may be difficult to differentiate radiation sequelae from persistent or recurrent tumour and very close follow-up is recommended. 8.1.9.1 Recommendations for radiation therapy Radiotherapy should be considered in two groups of patients with two different aims: • Organ-preserving treatment: in men with T1-2 glans or coronal sulcus lesions (< 4 cm), who are compliant for close follow-up. Both ERT combined with a BRT boost, or BRT alone, may be used to deliver the prescribed dose (> 60 Gy). • Palliative radiotherapy: in men with advanced or metastatic disease requiring palliative local treatment, the treatment of choice is ERT (40-50 Gy). 8.1.10 Guidelines for treatment strategies in primary tumour Primary tumour Category: Tis and Ta
LE 2a
GR B
2a
B
• Multifocal lesions and HPV-16 infection
Conservative therapy: CO2 or Nd:YAG lasers surgery are recommended Total glans resurfacing and circumcision are strongly recommended to prevent multiple recurrences
Category T1G1
T1G1 tumours are suitable for conservative surgery
2a
B
For glans lesions, CO2 laser surgery or resurfacing are appropriate For lesions of foreskin and sulcus, wide local excision with circumcision are appropriate with assessment of surgical margins Deeper infiltration may need adjuvant chemotherapy Penile-preserving treatment with wide local laser excision for complying patients with follow-up, or glansectomy are indicated Assessment of surgical margins reduces rate of local recurrence In these cases early diagnosis of local recurrence does not have an adverse impact on survival Total glansectomy, with or without resurfacing of corporeal heads Partial glansectomy is an alternative in very carefully selected patients with tumours less than half the glans and suitable for follow-up Consider partial amputation in patients unfit for follow-up Moderate partial amputation for tumours involving only tips of the corpora Partial or total amputation for larger tumours involving more than the distal corpora Traditionally, partial amputation has required removal of 2-cm tumour-free margins. A surgical margin of 5-10 mm is safe with pathological confirmation Deeply infiltrating tumours involving adjacent structures are often associated with disseminated disease at presentation . For patients in poor conditions with short life expectancy, palliative radiotherapy may be most appropriate Some patients may be suitable for down-staging with chemotherapy prior to surgery. Alternatives include adjuvant external beam irradiation if surgery is not possible. Local recurrence is more likely with penis preservation but it is usually treatable
2a
B
2a
B
2a 2a
B B
2b 2b
B C
2a
B
2b
B
2b 2a
B B
2a
B
2b
B
2a
C
2a
B
2a
B
2a
B
2a
B
Category T1G2-3
Category T2 (of glans)
Category T2 (of the corpora) and T3
Category T4
Local disease recurrence after conservative therapy
Second conservative procedure is strongly advised in absence of corpora cavernosa invasion Partial or total amputation is strongly recommended for large or deep infiltrating recurrence
18
Update march 2009
Main uses of radiotherapy
8.2
Local recurrence after penile amputation has a poor prognosis Organ-preserving treatment in selected patients with T1-2 glans or coronal sulcus lesions < 4 cm Palliative in advanced or metastatic disease not responsive to chemotherapy
2a 2b
B B
2b
B
Treatment of regional lymph nodes
Lymphadenectomy is the necessary surgical procedure for patients with inguinal lymph node metastases. Bilateral LAD is often followed by prolonged lymph leakage, which can result in leg and scrotal lymphoedema. Other surgical complications include skin flap necrosis, wound infection and haemorrhage from exposed femoral vessels. The procedure requires careful skin flap management, meticulous lymph node dissection, prophylactic antibiotics, compressive stoking and early ambulation. These complications occur in 30-70% of patients. Lymphadenectomy should therefore preferably only be performed in a therapeutic setting, where removal of lymph node metastases is indisputable. 8.2.1 Management of patients with non-palpable inguinal nodes 8.2.1.1 Surveillance In the past, patients with low-stage tumours and clinically unaffected inguinal nodes have often undergone surveillance strategies. The 2004 EAU guidelines ‘strongly’ recommended surveillance only in patients with superficial and well-differentiated tumours: Tis, TaG1-2, T1G1 and T1G2 with superficial growth and no vascular invasion (30). This approach was criticised following a study that found 82% of 100 consecutive patients had undergone unnecessary prophylactic LAD (31). 8.2.1.2 Prognostic factors For a long time, urologists have been oriented to look at pathological risk factors for metastases and pT3-T4 and all G3 patients were unequivocal candidates for bilateral LAD. In an old series (32), nodal metastases were found in 100% of pT3-T4, in 82% of pT2 and 23% of pT1. In particular, 16.5% of metastases were found in pT1G1 and 60% in pT1G2-3. No metastases were found in Ta or Tis. In a very recent series (33), lymph node metastases were found in 12% of pT1G2, a category that has therefore been defined as ‘intermediate risk’. A high histological grade and perineural invasion (21) or depth of invasion (34) are significant predictors of lymph node metastases. A nomogram (34) has identified palpable groin lymph nodes and vascular and/or lymphatic invasion as the most important predictors of lymph node metastases. A new nomogram with a larger international series of patients is ongoing (level of evidence: 2b). 8.2.1.3 Sentinel node biopsy (SNB) Catalona’s SNB (35) was a failure, but dynamic SNB appears very promising (36-39). The concept behind dynamic SNB assumes there is a stepwise and orderly progression of the primary node (the so-called sentinel node) to secondary lymph nodes. There may be more than one sentinel node. To identify the sentinel node(s), 99mTc-nanocolloid is injected around the penile tumour intradermally the day before surgery. The sentinel lymph node(s) are detected intra-operatively with a gamma X-ray detection probe and patent blue dye staining before being dissected and removed. If there is a positive histology, either on frozen section or definitive histology, a formal complete inguinal LAD is performed. The technique has been extensively studied in a few specialised centres. The Netherlands Cancer Institute group initially reported a high rate of false-negative cases (36). However, following modification of the technique, they reported a markedly reduced false-negative rate of 4.8% (39). However, the technique has been criticised for its steep learning curve and the need for the surgeon to perform a minimal number of 20 procedures per year (40) (level of evidence: 2a). 8.2.2 Management of patients with palpable inguinal nodes In patients with penile cancer, moderately enlarged palpable inguinal nodes, which are not fixed, may or may not signify metastatic disease. The rate of false-positive nodes has been reported as high as 50% (41), but recently much lower figures of 30% have been reported (42). Ultrasound with fine-needle aspiration biopsy provides an excellent, rapid and easy way to detect metastatic involvement. Of course this is only reliable in tumour-positive patients. In suspected cases with tumour-negative findings, fine-needle aspiration biopsy should be repeated. Dynamic SNB is not reliable in this group of patients and should not be used (43, 44). Thus, in all tumour-positive patients, early LAD should be performed (45, 46); bilateral LAD is the standard
Update march 2009
19
procedure. In contralateral non-palpable lymph nodes, surgical staging is recommended either by dynamic SNB or lymph node dissection (level of evidence: 2a). 8.2.2.1 Inguinal LAD Significant morbidity has been described including wound infection, skin necrosis, wound dehiscence, lymphoedema and lymphocele (47, 48). Optimal skin handling and careful dissection of skin flaps are two of the most important factors in preventing complications. Skin rotation flaps and myocutaneous flaps should be used for primary wound closure in advanced cases (49) (level of evidence: 2b). 8.2.2.2 Modified inguinal LAD This procedure is associated with less morbidity than standard LAD (50, 51). The rate of early complications was 6.8% (vs 41.4%) and the rate of late complications was 3.4% (vs 43.1%) for patients with modified LAD (51). However, reducing the field of dissection increased the possibility of falsenegative cases (level of evidence: 2b). The high false-negative rate described by Lopes et al. (52) should be considered in the light of recent findings concerning lymphatic drainage to the lateral superior Daseler’s zone, which was not dissected in this approach (53, 54). Current knowledge of lymphatic drainage at the penis suggests that a contemporary modified LAD should dissect the central and both superior Daseler’s zones of the inguinal region (grade of recommendation: B). 8.2.2.3 The role of pelvic LAD There is no direct lymphatic drainage from penile cancer to the pelvic lymph nodes (54, 55). Thus, if there is no involvement of inguinal nodes, pelvic LAD is not warranted. In contrast, if the Cloquet node or other two inguinal nodes are involved on one side, a contemporary pelvic lymph node dissection must be performed through an upward muscle-splitting incision. Pathological predictors for the potential involvement of pelvic nodes in patients with involved inguinal nodes are the number of positive inguinal lymph nodes and extracapsular extent of metastatic disease (56) (level of evidence: 2a). Pelvic LAD may be necessary as a secondary procedure. If bilateral dissection is indicated, it can be performed though a midline suprapubic extraperitoneal incision. The rate of positive pelvic nodes was 23% in cases with no more than two positive inguinal nodes and 56% for more than two positive inguinal nodes or if there is extracapsular extent in at least one inguinal node (57-59). If very aggressive histological subtypes of penile cancer (i.e. basaloid) are present, or there is strong expression of p53, pelvic lymph node dissection should be considered if any inguinal node is involved (60) (grade of recommendation: B). 8.2.2.4 Video-endoscopic inguinal and pelvic LAD This recently described technique is derived from laparoscopic surgery and has been evaluated only in small pilot studies (61, 62). It seems to carry a lower risk of skin complications, but a higher risk of lymphocele formation compared to an open approach; the reported overall complication rate was 23% (63). The reliability of this technique has not yet been assessed (level of evidence: 4). Laparoscopic pelvic node dissection for bilateral pelvic lymph node removal, following positive bilateral inguinal LAD, is a rational approach, but only if the dissection can be performed with similar accuracy as open surgery. 8.2.3 Adjuvant chemotherapy Adjuvant chemotherapy after resection of nodal metastases has been reported in a few series. There has been only one study group who reported consistent results with adjuvant post-operative chemotherapy in N+ patients (64, 65). Twenty-five consecutive patients with resected lymph node metastases from SCC of the penis received 12 weekly courses of adjuvant VBM (vincristine, bleomycin, methotrexate) chemotherapy between 1979 and 1990. All patients underwent ilioinguinal lymph node dissection and received adjuvant chemotherapy. Only four (16%) patients relapsed, and the other 21 had a long-term disease-free survival of 84%. These results compared favourably with a previous series of 31 patients, who underwent ilioinguinal lymph node dissection, alone or with adjuvant radiotherapy, between 1960 and 1978. The 5-year disease-free survival was only 37%. Among these 31 patients, only the involvement of a single, intranodal inguinal node metastasis was associated with good prognosis. In contrast, in the series of 25 patients treated with adjuvant chemotherapy (VBM), only bilateral and/or pelvic node involvement were significantly associated with poor prognosis, with 4 of 8 patients dying of penile cancer (level of evidence: 2a).
20
Update march 2009
Since 1991, pN2-N3 patients have been treated with three courses of adjuvant cisplatin and 5-fluorouracil (PF) with only two relapses (6.7%) in the first 30 treated patients (65) (level of evidence: 2a). 8.2.4 Management of patients with fixed or relapsed inguinal nodes Fourteen patients were treated with locally advanced or metastatic penile cancer with cisplatin, methotrexate and bleomycin (BMP) chemotherapy on days 2 to 5 (66). Toxicity was severe. Only three of the eight partial responders underwent surgery, while another two entered complete remission. In a confirmatory study by the Southwest Oncology Group (SWOG) (67), only six of 40 evaluable patients completed chemotherapy. Five complete and eight partial remissions were achieved, but at the cost of 11% treatment-related mortality and 17% life-threatening toxicity. Another study (68) of BMP chemotherapy in 13 patients reported one death from treatment-related toxicity and no complete remissions (level of evidence: 2a). A review was performed of 20 patients who had received neo-adjuvant chemotherapy, including BMP, for unresectable lymph node metastases during the period 1972 to 2005 (69). Twelve of 19 evaluable patients showed an objective tumour response. Five different chemotherapeutic regimens were used. Nine responders underwent subsequent surgery, of whom eight became long-term survivors without evidence of recurrent disease. Chemotherapy-related toxicity was fatal in three out of 10 patients treated with BMP (level of evidence: 2b). At the MD Anderson Cancer Center (Houston, TX, USA) (70), 10 patients were treated with surgical consolidation following a stable, partial, or complete response to four to five courses of the following chemotherapeutic regimens: paclitaxel, ifosfamide and cisplatin (ITP) in five patients, paclitaxel and carboplatin (PC) in two patients, and BMP in three patients. Three of the five patients treated with ITP had a pathologically documented complete remission and two of them are long-term survivors. The two patients treated with PC became disease-free with post-chemotherapy surgery. All three patients treated with BMP suffered severe toxicity and died of the disease. Systematic use of post-chemotherapy surgery in responsive patients was of main importance in the latter two studies (69, 70) (level of evidence: 2a). In addition, a preliminary report (71) on taxol combined with PF (TPF) chemotherapy in six consecutive patients with unresectable or relapsed inguinopelvic lymph node metastases from SCC of the penis suggests that TPF could have improved activity compared to PF alone in this clinical situation (65), as has been demonstrated in SCC of the head and neck in three randomised trials (72-74). In conclusion, adjuvant chemotherapy is strongly recommended in pN2-3 patients, and neo-adjuvant chemotherapy with taxanes seems to be active in unresectable or recurrent lymph node metastases (level of evidence: 2a, grade of recommendation: B). 8.2.5 The role of radiotherapy Prophylactic radiotherapy in clinical N0 patients is not recommended for the following reasons: • radiotherapy fails to prevent the development of metastatic lymph nodes (75) • complications of radiotherapy (76) • follow-up is more difficult due to fibrotic changes. Pre-operative radiotherapy in patients with fixed nodes can make the nodes operable, but it is not known whether node fixation is an inflammatory reaction or malignant growth (75, 76). Adjuvant radiotherapy may improve loco-regional control in patients with extensive metastases and/or extranodal spread. However, severe side-effects include oedema and pain (75).
Update march 2009
21
8.2.6 Guidelines for treatment strategies for nodal metastases Regional lymph nodes No palpable inguinal nodes
Palpable inguinal nodes
Pelvic nodes
Adjuvant chemotherapy
Patients with fixed or relapsed inguinal nodes
Radiotherapy
Management of regional lymph nodes is fundamental in the treatment of penile cancer Tis, Ta G1, T1G1: surveillance > T1G2: DSNB (NB: Inguinal LAD if histology is positive.) If DSNB not available: risk factors / nomogram decision-making Ultrasound-guided FNAB (NB: DSNB is unsuitable for palpable nodes) Negative biopsy: surveillance (repeat biopsy) Positive biopsy: inguinal LAD on positive side (NB: Modified LAD must include the central zone and both superior Daseler’s zones.) Pelvic LAD if there are: extranodal metastases; Cloquet node involved; > 2 inguinal node metastases Unilateral pelvic LAD if unilateral lymph node metastases with prolonged inguinal incision Bilateral pelvic LAD if bilateral inguinal metastases In patients with > 1 intranodal metastasis (pN2 pN3) after radical LAD, survival is improved by adjuvant chemotherapy (2 or 3 courses of cisplatin, fluorouracil (PF) chemotherapy) Neo-adjuvant chemotherapy is strongly recommended in patients with unresectable or recurrent lymph node metastases. Taxanes seems to improve the efficacy of standard PF chemotherapy Curative radiotherapy may be used for primary tumours of the glans penis and sulcus < 4 cm or for palliation Prophylactic radiotherapy in clinical N0 patients is not indicated
LE
GR
2a
B
2a
B
3 2a
C B
2a
B
2b
B
2a 2b
B B
2a
B
2a
B
2a
B
LE = level of evidence; GR = grade of recommendation; LAD = lymphadenectomy; FNAB = fine-needle aspiration biopsy; DSNB = sentinel node biopsy.
8.3
REFERENCES
1.
Goette DK, Carson TE. Erythroplasia of Queyrat: treatment with topical 5-fluorouracil. Cancer 1976;38(4):1498-502. http://www.ncbi.nlm.nih.gov/pubmed/991073 2. Taliaferro SJ, Cohen GF. Bowen’s disease of the penis treated with topical imiquimod 5% cream. J Drugs Dermatol 2008;7(5):483-5. http://www.ncbi.nlm.nih.gov/pubmed/18505144 3. van Bezooijen BP, Horenblas S, Meinhardt W, Newling DW. Laser therapy for carcinoma in situ of the penis. J Urol 2001;166(5):1670-1. http://www.ncbi.nlm.nih.gov/pubmed/11586199 4. Bandieramonte G, Colecchia M, Mariani L, Lo Vullo S, Pizzocaro G, Piva L, Nicolai N, Salvioni R, Lezzi V, Stefanon B, De Palo G. Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol 2008;54(4):875-84. http://www.ncbi.nlm.nih.gov/pubmed/18243513 5. Paoli J, Ternesten Bratel A, Löwhagen GB, Stenquist B, Forslund O, Wennberg AM. Penile intraepithelial neoplasia: results of photodynamic therapy. Acta Derm Venereol 2006;86(5):418-21. http://www.ncbi.nlm.nih.gov/pubmed/16955186 6. Hatzichristou DG, Apostolidis A, Tzortzis V, Hatzimouratidis K, Ioannides E, Yannakoyorgos K. Glansectomy: an alternative surgical treatment for Buschke-Löwenstein tumors of the penis. Urology 2001;57(5):966-9. http://www.ncbi.nlm.nih.gov/pubmed/11337304 7. Shindel AW, Mann MW, Lev RY, Sengelmann R, Petersen J, Hruza GJ, Brandes SB. Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol 2007;178(5):1980-5. http://www.ncbi.nlm.nih.gov/pubmed/17869306
22
Update march 2009
8.
Penile Cancer Treatment (PDQ®) Health Professional Version. National Cancer Institute, US National Institutes of Health, 2008, pp. 6-7. http://www.cancer.gov/cancertopics/pdq/treatment/penile/healthprofessional/allpages/print 9. Hadway P, Corbishley CM, Watkin NA. Total glans resurfacing for premalignant lesions of the penis: initial outcome data. BJU Int 2006;98(3):532-6. http://www.ncbi.nlm.nih.gov/pubmed/16925748 10. Frimberger D, Hungerhuber E, Zaak D, Waidelich R, Hofstetter A, Schneede P. Penile carcinoma. Is Nd:YAG laser therapy radical enough?. J Urol 2002;168(6):2418-21. http://www.ncbi.nlm.nih.gov/pubmed/12441930 11. Windalh T, Andersson SO. Combined laser treatment for penile carcinoma: results after long-term follow up. J Urol 2003;169(6):2118-21. http://www.ncbi.nlm.nih.gov/pubmed/12771731 12. Bissada NK, Yakout HH, Fahmy WE, Gayed MS, Touijer AK, Greene GF, Hanash KA. Multiinstitutional long-term experience with conservative surgery for invasive penile carcinoma. J Urol 2003;169(2): 500-2. http://www.ncbi.nlm.nih.gov/pubmed/12544296 13. Smith Y, Hadway P, Biedrzycki, Perry MJA, Corbishley C, Watkin NA. Reconstructive surgery forinvasive squamous cell carcinoma of the glans penis. Eur Urol 2007;52(4):1179-85. http://www.ncbi.nlm.nih.gov/pubmed/17349734 14. Davis JW, Schellhammer PF, Schlossberg SM. Conservative surgical therapy for penile and urethralcarcinoma. Urology 1999;53(2):386-92. http://www.ncbi.nlm.nih.gov/pubmed/9933060 15. Algaba F, Arce Y, López-Beltán A, Montironi R, Mikuz G, Bono AV. Intraoperative frozen section diagnosis in Urological Oncology. Eur Urol 2005;47(2):129-36. http://www.ncbi.nlm.nih.gov/pubmed/15661406 16. Gotsadze D, Matveev, B, Zak, B, Mamaladze V. Is conservative organ-sparing treatment of penile carcinoma justified? Eur Urol 2000;38(3):306-12. http://www.ncbi.nlm.nih.gov/pubmed/10940705 17. Minhas S, Kayes O, Hegarty P, Kumar P, Freeman A, Ralph D. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 2005;96(7):1040-3. http://www.ncbi.nlm.nih.gov/pubmed/16225525 18. Ornellas AA, Seixas ALC, Marota A, Wisnescky A, Campos F, de Moraes JR. Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 1994;151(5):1244-9. http://www.ncbi.nlm.nih.gov/pubmed/7512656 19. Lont AP, Gallee MP, Meinhardt W, van Tinteren H, Horenblas S. Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol 2006;176(2):575-80;discussion 580. http://www.ncbi.nlm.nih.gov/pubmed/16813892 20. Velázquez EF, Soskin A, Bock A, Codas R, Barreto JE, Cubilla AL. Positive resection margins in partial penectomies. Sites of involvement and proposal of local routes of spread of penile squamous cell carcinoma. Am J Surg Pathol 2004;28(3):384-9. http://www.ncbi.nlm.nih.gov/pubmed/15104302 21. Horenblas S, Van Tinteren H, Delemarre JFM, Boon TA, Moonen LMF, Lustig V. Squamous cell carcinoma of the penis. II. Treatment of the primary tumor. J Urol 1992;147(6):1533-8. http://www.ncbi.nlm.nih.gov/pubmed/1593683 22. Koch MO, Smith JA Jr. Local recurrence of squamous cell carcinoma of the penis. Urol Clin North Am 1994;21(4):739-43. http://www.ncbi.nlm.nih.gov/pubmed/7974902 23. Gotsadze D, Matveev B, Zak B, Mamaladze V. Is conservative organ-sparing treatment of penile carcinoma justified? Eur Urol 2000;38(3):306-12. http://www.ncbi.nlm.nih.gov/pubmed/10940705 24. Sarin R, Norman AR, Steel GG. Treatment results and prognostic factors in 101 men treated for squamous carcinoma of the penis. Int J Radiat Oncol Biol Phys 1997;38(4):713-22. http://www.ncbi.nlm.nih.gov/pubmed/9240637 25. Kiltie AE, Elwell C, Close A, Ash DV. Iridium-192 implantation for node-negative carcinoma of the penis: The Cookridge Hospital Experience. Clin Oncol (R Coll Radiol) 2000;12(1):25-31. http://www.ncbi.nlm.nih.gov/pubmed/10749016
Update march 2009
23
26.
Azrif M, Logue GP, Swindell R, Cowan RA, Wylie JP, Livsey JE. External-beam radiotherapy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol) 2006;18(4):320-5. http://www.ncbi.nlm.nih.gov/pubmed/16703750 27. Rozan R, Albuisson E, Giraud B, Donnarieix D, Delannes M, Pigneux J, Hoffstetter S, Gerbaulet A, Chinet-Charrot P, Goupil A, et al. Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol 1995;36(2):83-93. http://www.ncbi.nlm.nih.gov/pubmed/7501816 28. Zouhair A, Coucke PA, Jeanneret W, Douglas P, Do HP, Jichilinski P, Mirimanoff RO, Ozsahin M. Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis? Eur J Cancer 2001;37(2):198-203. http://www.ncbi.nlm.nih.gov/pubmed/11166146 29. Crook JM, Grimard L, Esche B, Pond G. Penile brachytherapy: results for 60 patients. Brachytherapy 2007;6:82. 30. Solsona E, Algaba F, Horenblas S, Pizzocaro G, Windahl T. EAU Guidelines on Penile Cancer. Eur Urol 2004;46(1):1-8. http://www.ncbi.nlm.nih.gov/pubmed/15183542 31. Hegarty PK, Kayes O, Freeman A, Christopher N, Ralph DJ, Minhas S. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int 2006;98(3):526-31. http://www.ncbi.nlm.nih.gov/pubmed/16925747 32. Pizzocaro G, Piva L, Nicolai N. [Treatment of lymphatic metastases for squamous cell carcinoma of the penis: experience at the National Tumor Institute of Milan.] Arch Ital Urol Androl 1996:68(3):169-72. [article in Italian] http://www.ncbi.nlm.nih.gov/pubmed/8767505 33. Hughes B, Leijte J, Shabbir M, et al. Lymphnode metastassis in intermediate risk penile squamous cell cancer. A multicentre experience. Eur Urol Suppl 2008;7(3):110 (abstract 160). 34. Ficarra V, Zattoni F, Artibani W. Cunico SC, Fandella A, Martignoni G, Novara G, Galetti TP, Zattoni F; GUONE Penile Cancer Project Members. Nomogram predictive of pathological inguinal lymph nodes involvement in patients with squamous cell carcinoma of the penis. J Urol 2006;175(6):1700-5. http://www.ncbi.nlm.nih.gov/pubmed/16697813 35. Catalona WJ. Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous vein: technique and preliminary results. J Urol 1988;140(2):306-10. http://www.ncbi.nlm.nih.gov/pubmed/3398125 36. Horenblas S, Jansen L, Meinhardt W, Hoefnagel CA, de Jong D, Nieweg OE. Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol 2000;163(1):100-4. http://www.ncbi.nlm.nih.gov/pubmed/10604324 37. Perdonà S, Autorino R, Gallo L, Di Lorenzo G, Cascini GL, Lastoria F, Marra L, De Sio M, Damiano R, Gallo A. Role of dynamic sentinel node biopsy in penile cancer: our experience. J Surg Oncol 2006;93(3):181-5. http://www.ncbi.nlm.nih.gov/pubmed/16482606 38. Kroon BK, Horenblas S, Estourgie SH, Lont AP, Valdes Olmos RA, Nieweg OE. How to avoid falsenegative dynamic sentinel node procedures in penile carcinoma. J Urol 2004;171(6 Pt 1):2191-4. http://www.ncbi.nlm.nih.gov/pubmed/15126783 39. Leijte JAP, Kroon BK, Valdes Olmos RD, Nieweg OE, Horenblas S. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol 2007;52(1):170-7. http://www.ncbi.nlm.nih.gov/pubmed/17316967 40. Ficarra V, Galfano A. Should the dynamic sentinel node biopsy (DSNB) be considered the gold standard in the evaluation of lymph node status in patients with penile carcinoma?. Eur Urol 2007;52(1):17-19; discussion 20-1. Epub 2007. http://www.ncbi.nlm.nih.gov/pubmed/17376585 41. Persky L, deKernion J. Carcinoma of the penis. CA Cancer J Clin 1986;36(5):258-73. http://www.ncbi.nlm.nih.gov/pubmed/3093013 42. Velasquez EF, Ayala C, Liu H, Chaux A, Zanotti M, Torres J, Cho SI, Barreto JE, Soares F, Cubilla AL. Histologic grade and perineal invasion are more important than tumor thickness as predictor of nodal metastases in penile squamous cell carcinoma invading 5 to 10 mm. Am J Surg Pathol 2008;32(7):974-9. http://www.ncbi.nlm.nih.gov/pubmed/18460979
24
Update march 2009
43.
Horenblas S. Lymphadenectomy for squamous cell carcinoma of the penis. Part 1: diagnosis of lymph node metastasis. BJU Int 2001;88:467-72. http://www.ncbi.nlm.nih.gov/pubmed/11589659 44. Preis E, Jakse G. [The significance of inguinal lymphadenectomy in carcinoma of the penis.] Urologe A 2006;45(Suppl 04):176-80. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/16933120 45. Kroon BK, Horenblas S, Estourgie SH, Lont AP, Valdes Olmos RA, Nieweg OE. How to avoid falsenegative dynamic sentinel node procedures in penile carcinoma. J Urol 2004;171(6 Pt 1):2191-4. http://www.ncbi.nlm.nih.gov/pubmed/15126783 46. Hungerhuber E, Schlenker B, Frimberger D, Linke R, Karl A, Stief CG, Schneede P. Lymphoscintigraphy in penile cancer: limited value of sentinel node biopsy in patients with clinically suspicious lymph nodes. World J Urol 2006;24(3):319-24. http://www.ncbi.nlm.nih.gov/pubmed/16688459 47. Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005;173(3):816-9 http://www.ncbi.nlm.nih.gov/pubmed/15711276 48. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds). Campbell-Walsh Urology. 9th edn. Philadelphia, PA: Saunders Elsevier, 2007. 49. Horenblas S. Lymphadenectomy for squamous cell carcinoma of the penis. Part 2: the role and technique of lymph node dissection. BJU Int 2001;88(5):473-83. http://www.ncbi.nlm.nih.gov/pubmed/11589660 50. Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the MD Anderson Cancer Center Experience. J Urol 2002;167(4):1638-42. http://www.ncbi.nlm.nih.gov/pubmed/11912379 51. Bouchot O, Rigaud J, Maillet F, Hetet JF, Karam G. Morbidity of inguinal lymphadenectomy for invasive penile carcinoma. Eur Urol 2004;45(6):761-5; discussion 765-6. http://www.ncbi.nlm.nih.gov/pubmed/15149749 52. Lopes A, Rossi BM, Fonseca FP, Morini S. Unreliability of modified inguinal lymphadenectomy for clinical staging of penile carcinoma. Cancer 1996;77(10):2099-102. http://www.ncbi.nlm.nih.gov/pubmed/8640676 53. Daseler EH, Anson BJ, Reimann AF. Radical excision of inguinal and iliac lymph glands: a study based upon 450 anatomical dissections and upon supportive clinical observations. Surg Gynecol Obstet 1948;87(6):679-94. http://www.ncbi.nlm.nih.gov/pubmed/18120502 54. Leijte JAP, Valdés Olmos RA, Nieweg OE, Horenblas S. Anatomical mapping of lymphatic drainage in penile cancer with SPECT-TC: implications for the extent of inguinal lymph node dissection. Eur Urol 2008;54(4):885-90. http://www.ncbi.nlm.nih.gov/pubmed/18502024 55. Cabanas RM. An approach for treatment of penile carcinoma. Cancer 1977;39(2):456-66. http://www.ncbi.nlm.nih.gov/pubmed/837331 56. Lont AP, Kroon BK, Gallee MP, van Tinteren H, Moonen LM, Horenblas S. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007;177(3):947-52; discussion 952. http://www.ncbi.nlm.nih.gov/pubmed/17296384 57. Ornellas AA, Seixas AL, Marota A, Wisnescky A, Campos F, de Moraes JR. Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 1994;151(5):1244-9. http://www.ncbi.nlm.nih.gov/pubmed/7512656 58. Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol 2003;170(2 Pt 1):359-65. http://www.ncbi.nlm.nih.gov/pubmed/12853775 59. Lopes A, Bezerra AL, Serrano SV, Hidalgo GS. Iliac nodal metastases from carcinoma of the penis treated surgically. BJU Int 2000;86(6):690-3. http://www.ncbi.nlm.nih.gov/pubmed/11069378 60. Zhu Y, Zhang SL, Ye DW, Yao XD, Jiang ZX, Zhou XY. Predicting pelvic lymph node metastases in penile cancer patients: a comparison of computed tomography, Cloquet’s node, and disease burden of inguinal lymph nodes. Onkologie 2008;31(1-2):37-41. http://www.ncbi.nlm.nih.gov/pubmed/18268397
Update march 2009
25
61. Tobias-Machado M, Tavares A, Ornellas AA, Molina WR Jr, Juliano RV, Wroclawski ER. Video endoscopic inguinal lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma. J Urol 2007;177(3):953-7;discussion 958. http://www.ncbi.nlm.nih.gov/pubmed/17296386 62. Tobias-Machado M, Tavares A, Silva MN, Molina Jr WR, Forseto PH, Juliano RV, Wroclawski ER. Can video endoscopic inguinal lymphadenectomy achieve a lower morbidity than open lymph node dissection in penile cancer patients?. J Endourol 2008;22(8):1687-91. http://www.ncbi.nlm.nih.gov/pubmed/18657031 63. Sotelo R, Sanchez-Salas R, Carmona O, Garcia A, Mariano M, Neiva G, Trujillo G, Novoa J, Cornejo F, Finelli A. Endoscopic lymphadenectomy for penile carcinoma. J Endourol 2007;21(4):364-7;discussion 367. http://www.ncbi.nlm.nih.gov/pubmed/17451323 64. Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 1988;27(6b):823-4. http://www.ncbi.nlm.nih.gov/pubmed/2466471 65. Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol 1997;32(1):5-15. http://www.ncbi.nlm.nih.gov/pubmed/9266225 66. Dexeus F, Logothetis C, Sella A, Amato R, Kilbourn R, Fitz K, Striegel A. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 1991;146(5):1284-7. http://www.ncbi.nlm.nih.gov/pubmed/1719241 67. Haas G, Blumenstein B, Gagliano R, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999;161(6):1823-5. http://www.ncbi.nlm.nih.gov/pubmed/10332445 68. Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int 2006;98(6):1225-7. http://www.ncbi.nlm.nih.gov/pubmed/17125480 69. Lijte JA, Kerst JM, Bais E, Antonini N, Horenblas S. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol 2007;52(2):488-94. http://www.ncbi.nlm.nih.gov/pubmed/17316964 70. Barmejo C, Busby JK, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007;177(4):1335-8. http://www.ncbi.nlm.nih.gov/pubmed/17382727 71. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2008 Jul 14. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/18649992 72. Hitt R, López-Pousa A, Martínez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23(34):8636-45. http://jco.ascopubs.org/cgi/content/full/23/34/8636 73. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-15. http://content.nejm.org/cgi/content/abstract/357/17/1705 74. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-704. http://content.nejm.org/cgi/content/abstract/357/17/1695 75. Kulkarni JN, Kamat MR. Prophylactic bilateral groin node dissection versus prophylactic radiotherapy and surveillance in patients with N0 and N1-2A carcinoma of the penis. Eur Urol 1994;26(2):123-8. http://www.ncbi.nlm.nih.gov/pubmed/7957466 76. Ravi R, Chaturvedi HK, Sastry DV. Role of radiation therapy in the treatment of carcinoma of the penis. Br J Urol 1994;74(5):646-51. http://www.ncbi.nlm.nih.gov/pubmed/7530129
26
Update march 2009
9. FOLLOW-UP Follow-up in penile carcinoma is important for several reasons: • It enables early detection of recurrence, which is important because most local and/or loco-regional recurrences are potentially curable • It is the only way to assess treatment and anticipate early and late complications • It is also important for patient (and physician) education. A rational follow-up scheme requires an understanding of the patterns of recurrence. Preferably, follow-up should be introduced within the framework of a randomised study. Based on a retrospective study, a follow-up schedule for penis cancer has been published (1).
9.1
How to follow-up
The aim of follow-up is to detect local and/or regional recurrences because they may be cured. In contrast, metastases at distant sites are always fatal (2). Risk stratification for recurrence is also helpful. Traditional follow-up methods have been inspection and physical evaluation. Modern ultrasound imaging is a useful adjunct, with promising results from new imaging modalities, such as PET scan and laser-directed MRI (3).
9.2
When to follow-up
The follow-up interval and strategies for patients with penile cancer are directed by the initial treatment of the primary lesion and regional lymph nodes. In the above-mentioned multicentre study (1), during the first 2 years of follow-up, the following occurred: • 74.3% of all recurrences • 66.4% of local recurrences • 86.1% of regional recurrences • 100% of distant recurrences. Of all recurrences, 92.2% occurred within the first 5 years (1). All recurrences after 5 years were local recurrences or new primaries. Thus, an intensive programme of follow-up during the first 2 years is rational with less intensive follow-up needed thereafter. In well-educated and motivated patients, follow-up can stop after 5 years, although they must continue to carry out regular self-examination.
9.3
Primary tumour
Local recurrence has been reported in up to 30% of patients treated with penile-preserving surgery, during the first 2 years following treatment. Local recurrence is more likely with all types of local therapy, i.e. local resection, laser therapy, BRT, Mohs’ procedure, and associated therapies (1, 4). However, in contrast to regional recurrences, local recurrences do not impact on survival (1, 4). Local recurrences are easily detected by the patient, his partner or doctor. Patient education is an important part of follow-up and the patient should be urged to visit a specialist if any changes are seen. Despite the fact that late local recurrences are well documented, it is reasonable to stop follow-up after 5 years, provided the patient will report local changes immediately (5). This is possible because life-threatening regional and distant metastases no longer occur, while recurrences that are local only are not life-threatening. The emphasis should be placed on patient self-examination. In patients who are unlikely to self-examine, long-term follow-up may be necessary. Following penile-preserving treatment, a follow-up visit every 3 months is advised in the first 2 years. We then advise a follow-up visit every half year, provided that the patient and partner have been well instructed to examine the penis regularly and to return if any abnormality is observed. It is important to stress that the patient must continue to carry out regular self-examination even after 5 years’ follow-up. After amputation, a less frequent time interval of every 6 months is advised. The risk of local recurrence is not more than 5% (1, 4).
9.4
Regional recurrences
Stringent follow-up is advised for the 2 years following surgery. This is because most regional recurrences occur within 2 years, whether a ‘wait-and-see’ policy has been followed or the patient has undergone SNB or inguinal LAD. Previous follow-up recommendations have relied heavily on physical examination of the inguinal regions. However, experience with ‘wait and see’ and dynamic SNB have shown that, despite intensive followup, regional recurrences have shown up unexpectedly (6). Ultrasound and immediate fine-needle aspiration
Update march 2009
27
have been encouraging in finding occult metastases (6, 7) and it seems reasonable to add ultrasound to a physical examination. Patients managed with a ‘wait-and-see’ policy have a higher risk of recurrence (9%) than patients staged surgically (2.3%), whether staging has been performed by LAD or dynamic SNB. This finding only applies to patients without histopathological evidence of lymph node metastases. Patients treated surgically because of lymph node metastases have an increased risk of recurrence (19%) (1). Based on these findings, a change in the follow-up scheme is proposed. For patients in a ‘wait-and-see’ programme and patients given LAD for proven lymph node metastases, follow-up should be every 3 months and should include ultrasound investigation of the groin. This intensive follow-up programme should be for 2 years, which is the period when recurrence is most likely. Imaging using CT has been replaced by ultrasound scanning with immediate fine-needle aspiration biopsy, although CT scans are still used in patients with a regional recurrence. So far, other imaging modalities have not proven reliable at detecting pelvic and retroperitoneal recurrences. Bone scan and other tests are only recommended in symptomatic patients. The role of PET scan is unclear and therefore not advised as a routine procedure.
9.5
Guidelines for follow-up in penile cancer
Table 8 provides a follow-up schedule for penile cancer with grades of recommendation. Table 8: Follow-up schedule for penile cancer Interval of follow-up
Examinations and Investigations
Years 1 and 2 Years 3, 4 and 5 Recommendations for follow-up of primary tumour Penile-preserving 3 months 6 months treatment Amputation
6 months
1 year
Maximum length of follow-up
Regular physician or 5 years self-examination Regular physician or 5 years self-examination
GR
C C
Recommendations for follow-up of the inguinal lymph nodes ‘Wait-and-see’
3 months
6 months
pN0
6 months
1 year
pN+
3 months
6 months
Regular physician or self-examination Ultrasound with FNAB Regular physician or self-examination Ultrasound with FNAB Regular physician or self-examination Ultrasound with FNAB
5 years
C
5 years
C
5 years
C
GR = grade of recommendation; FNAB = fine-needle aspiration biopsy.
9.6
REFERENCES
1.
Leijte JAP, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008;54(1):161-8. http://www.ncbi.nlm.nih.gov/pubmed/18440124 Horenblas S, van Tinteren H, Delamarre JFM, Moonen LM, Lustig V, van Waardenburg EW. Squamous cell carcinoma of the penis. III. Treatment of regional lymph nodes. J Urol 1993;149(3):492-7. http://www.ncbi.nlm.nih.gov/pubmed/8437253. Lont AP, Gallee MP, Meinhardt W, van Tinteren H, Horenblas S. Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol 2006;176(2):575-80;discussion 580. http://www.ncbi.nlm.nih.gov/pubmed/16813892
2.
3.
28
Update march 2009
4.
5.
6.
7.
Horenblas S, Newling DW. Local recurrence tumour after penis-conserving therapy. A plea for longterm follow-up. Br J Urol 1993;72(6):976-9. http://www.ncbi.nlm.nih.gov/pubmed/8306171 Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005;173(3): 816-9. http://www.ncbi.nlm.nih.gov/pubmed/15711276 Kroon BK, Horenblas S, Deurloo EE, Nieweg OE, Teertstra HJ. Ultrasonography-guided fineneedle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int 2005;95(4):517-21. http://www.ncbi.nlm.nih.gov/pubmed/15705071 Krishna RP, Sistla SC, Smile R, Krishnan R. Sonography: An underutilized diagnostic tool in the assessment of metastatic groin nodes. Clin Ultrasound 2008;36(4):212-7. http://www.ncbi.nlm.nih.gov/pubmed/17960822
10. QUALITY OF LIFE .
10.1
Sexuality and fertility after cancer
As more people achieve long-term survival after cancer, sexual dysfunction and infertility are increasingly recognised as negative consequences affecting quality of life (1). 10.1.1 Sexual activity and quality of life after penile cancer laser treatment A retrospective, face-to-face, structured interview study was carried out on Swedish patients treated with laser for localised penile carcinoma during 1986 to 2000 (2). Sixty-seven patients were treated, with 58 of them (mean age 63 years) still alive in 2006. Forty-six (79%) agreed to participate in the interview. Nearly all patients could recall their first symptom, with 37% reporting that they delayed seeking treatment for more than 6 months. Patients had a greater lifetime number of sexual partners and a greater lifetime prevalence of sexually transmitted infections than the comparable general Swedish population. Following laser treatment, there was a marked decrease in some sexual practices, such as manual stimulation or caressing and fellatio. Patient satisfaction with life overall was similar to that of the general population. In conclusion, some patients delayed seeking treatment for a considerable period despite awareness of the first local symptoms. Men with laser-treated localised penile carcinoma resumed their sexual activities to a large extent. Except for satisfaction with somatic health, a similar (or higher) proportion of patients were satisfied with life overall and with other domains of life including sexual life. 10.1.2 Sexual function after partial penectomy for penile cancer To compare sexual function and satisfaction before and after partial penectomy, 18 Brazilian patients were given a personal interview and answered the International Index of Erectile Function (IIEF) questionnaire to determine erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction with sexual life (3). The median patient age was 52 years. The medium penile length after partial penectomy was 4 cm in the flaccid state, with 55.6% of patients reporting erectile function that allowed sexual intercourse. The main reason given for not resuming sexual intercourse in 50% of sexually abstinent patients was feeling shame because of a small penis and the absence of the glans penis. Surgical complications also compromised resumption of sexual activity after amputation in 33.3% of these patients. However, 66.7% sustained the same frequency and level of sexual desire prior to surgery and 72.2% continued to have ejaculation and orgasm every time they had sexual stimulation or intercourse. Nevertheless, only 33.3% maintained their pre-operative sexual intercourse frequency and were satisfied with their sexual relationships with their partners and their overall sex life. In conclusion, the pre-operative and post-operative scores were statistically worse for all domains of sexual function after partial penectomy.
10.2
Sexual mutilation, relapse and death
Today, nearly 80% of penile cancer patients can be cured. Experience in management of this rare tumour is helpful (4). Referral to centers with experience is recommended. Psychological support is very important for these patients. Penile-sparing surgery obviously allows a better quality of life than penile amputation and must be considered whenever feasible
Update march 2009
29
10.3
REFERENCES
1.
Schover LR. Sexuality and fertility after cancer. Hematology Am Soc Hematol Educ Program 2005;523-7. http://www.ncbi.nlm.nih.gov/pubmed/16304430 2. Skeppner E, Windahl T, Andersson S, Fugl-Meyers KS. Treatment-seeking, aspects of sexual activity and life satisfaction in men with laser-treated penile carcinoma. Eur Urol 2008;54(3):631-9. http://www.ncbi.nlm.nih.gov/pubmed/18788122 3. Romero FR, Romero KR, Mattos MA, Garcia CR, Fernandes Rde C, Perez MD. Sexual function after partial penectomy for penile cancer. Urology 2005;66(6):1292-5. http://www.ncbi.nlm.nih.gov/pubmed/16360459 4. Leijte JA, Gallee M, Antonini N, Horenblas S. Evaluation of current TNM classification of penile carcinoma. J Urol 2008;180(3):933-8. http://www.ncbi.nlm.nih.gov/pubmed/18635216
30
Update march 2009
11. ABBREVIATIONS USED IN THE TEXT This list is not comprehensive for the most common abbreviations.
BMP cisplatin, methotrexate and bleomycin BRT brachytherapy CT computed tomography DSNB dynamic sentinel node biopsy EAU European Association of Urology ERT external beam irradiation FDA [US] Food and Drug Administration FNAB fine-needle aspiration biopsy HDR high-dose rate (brachytherapy) HPV human papillomavirus IIEF International Index of Erectile Function questionnaire ITP paclitaxel, ifosfamide and cisplatin LAD lymphadenectomy LDR low-dose rate (brachytherapy) MRI magnetic resonance imaging NCI National Cancer Institute Nd-YAG neodynium:yttrium-aluminum-garnet PC paclitaxel and carboplatin PDQ physician data query PDR pulse-dose rate (brachytherapy) PET positron emission tomography PF cisplatin and fluorouracil PGE1 prostaglandin E1 (alprostadil) SCC squamous cell carcinoma SNB sentinel node biopsy SWOG Southwest Oncology Group 99mTC technetium 99m TNM tumour, node, metastasis TPF taxanes combined with PF (cisplatin and fluorouracil) VBM vinblastine, bleomycin, methotrexate
Conflict of interest All members of the Penile Cancer Guidelines writing panel have provided disclosure statements on all relationships that they have and that might be perceived to be a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
Update march 2009
31
32
Update march 2009
Guidelines on
Testicular Cancer P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna
© European Association of Urology 2009
TABLE OF CONTENTS
page
1
BACKGROUND 1.1 Methods
4 4
2
PATHOLOGICAL CLASSIFICATION
5
3
DIAGNOSIS 3.1 Clinical examination 3.2 Imaging of the testis 3.3 Serum tumour markers at diagnosis 3.4 Inguinal exploration and orchidectomy 3.5 Organ-sparing surgery 3.6 Pathological examination of the testis 3.7 Diagnosis and treatment of carcinoma in situ (Tin) 3.8 Screening
5 5 5 6 6 6 6 7 7
4
STAGING 4.1 Diagnostic tools 4.2 Serum tumour markers: post-orchidectomy half-life kinetics 4.3 Retroperitoneal, mediastinal and supraclavicular lymph nodes and viscera 4.4 Staging and prognostic classifications 4.5 Prognostic risk factors
7 7 8 8 9 11
5
IMPACT ON FERTILITY AND FERTILITY-ASSOCIATED ISSUES
11
6
GUIDELINES ON DIAGNOSIS AND STAGING OF TESTICULAR CANCER
12
7 TREATMENT: STAGE I GERM CELL TUMOURS 7.1 Stage I seminoma 7.1.1 Surveillance 7.1.2 Adjuvant chemotherapy 7.1.3 Adjuvant radiotherapy 7.1.4 Retroperitoneal lymph node dissection (RPLND) 7.1.5 Risk-adapted treatment 7.2 Guidelines for the treatment of seminoma stage I 7.3 NSGCT stage I 7.3.1 Surveillance 7.3.2 Primary chemotherapy 7.3.3 Risk-adapted treatment 7.3.4 Retroperitoneal lymph node dissection 7.4 CS1S with (persistently) elevated serum tumour markers 7.5 Guidelines for the treatment of NSGCT stage I
12 12 12 12 12 13 13 13 13 13 14 14 14 15 15
8 TREATMENT: METASTATIC GERM CELL TUMOURS 8.1 Low-volume metastatic disease (stage IIA/B) 8.1.1 Stage IIA/B seminoma 8.1.2 Stage IIA/B non-seminoma 8.2 Advanced metastatic disease 8.2.1 Primary chemotherapy 8.3 Restaging and further treatment 8.3.1 Restaging 8.3.2 Residual tumour resection 8.3.3 Consolidation chemotherapy after secondary surgery 8.4 Systemic salvage treatment for relapse or refractory disease 8.4.1 Seminoma 8.4.2 Non-seminoma 8.4.3 Late relapse (≥ 2 years after end of first-line treatment) 8.5 Salvage surgery 8.6 Treatment of brain metastases
17 17 17 17 18 18 19 19 19 19 20 20 20 21 21 21
2
Limited update march 2009
8.7
Guidelines for the treatment of metastatic germ cell tumours
21
9 FOLLOW-UP AFTER CURATIVE THERAPY 9.1 General considerations 9.2 Follow-up: stage I non-seminoma 9.2.1 Follow-up investigations during surveillance 9.2.2 Follow-up after nerve-sparing RPLND 9.2.3 Follow-up after adjuvant chemotherapy 9.3 Follow-up: stage I seminoma 9.3.1 Follow-up after radiotherapy 9.3.2 Follow-up during surveillance 9.3.3 Follow-up after adjuvant chemotherapy 9.4 Follow-up: stage II and advanced (metastatic) disease
22 22 22 22 23 23 23 24 24 24 24
10 TESTICULAR STROMAL TUMOURS 10.1 Background 10.2 Methods 10.3 Classification 10.4 Leydig cell tumours 10.4.1 Epidemiology 10.4.2 Pathology of Leydig cell tumours 10.4.3 Diagnosis 10.4.4 Treatment 10.4.5 Follow-up 10.5 Sertoli cell tumour 10.5.1 Epidemiology 10.5.2 Pathology of Sertoli cell tumours 10.5.2.1 Classification 10.5.3 Diagnosis 10.5.4 Treatment 10.5.5 Follow-up 10.6 Granulosa cell tumour 10.7 Thecoma/fibroma group of tumours 10.8 Other sex cord/gonadal stromal tumours 10.9 Tumours containing germ cell and sex cord/gonadal stromal (gonadoblastoma) 10.10 Miscellaneous tumours of the testis 10.10.1 Tumours of ovarian epithelial types 10.10.2 Tumours of the collecting ducts and rete testis 10.10.3 Tumours (benign and malignant) of non-specific stroma
25 25 25 25 26 26 26 26 26 27 27 27 27 27 27 28 28 28 28 28 28 28 28 28 29
11.
REFERENCES 11.1 Germ cell tumours 11.2 Non-germ cell tumours
29 29 48
12.
ABBREVIATIONS USED IN THE TEXT
50
Limited update march 2009
3
1. Background Testicular cancer represents between 1% and 1.5% of male neoplasms and 5% of urological tumours in general, with 3-6 new cases occurring per 100,000 males/per year in Western society (1, 2). An increase in the incidence of testicular cancer was detected during the 1970s and 1980s, particularly in Northern European countries, and there is a clear trend towards an increased testicular cancer incidence in the last 30 years in the majority of the industrialised countries in North America, Europe and Oceania, although surprising differences in incidence rates are seen between neighbouring countries (3). Data from the Surveillance Epidemiology and End Results Program during the years 1973 to 1998 show a continuing increased risk among Caucasian men in the USA only for seminoma (4). Only 1-2% of cases are bilateral at diagnosis. The histological type varies, although there is a clear predominance (90-95%) of germ cell tumours (1). Peak incidence is in the third decade of life for nonseminoma, and in the fourth decade for pure seminoma. Familial clustering has been observed, particularly among siblings (5). Genetic changes have been described in patients with testicular cancer. A specific genetic marker (an isochromosome of the short arm of chromosome 12 – i(12p) – has been described in all histological types of germ cell tumours (5). Intratubular germ cell neoplasia (testicular intraepithelial neoplasia, Tin) shows the same chromosomal changes, and alterations in the p53 locus have been found in 66% of cases of testicular Tin (6). A deregulation in the pluripotent programme of fetal germ cells (identified by specific markers such as M2A, C-KIT and OCT4/NANOG) is probably responsible for the development of Tin and germ cell neoplasia. There is overlap in the development to seminoma and embryonal carcinoma as shown by genome-wide expression analysis and detection of alpha-fetoprotein (AFP) mRNA in some atypical seminoma (7, 8). Epidemiological risk factors for the development of testicular tumours are: a history of cryptorchidism or undescended testis, Klinefelter’s syndrome, familial history of testicular tumours among first-grade relatives (father/brothers), the presence of a contralateral tumour or Tin, and infertility (9-14). Tallness was associated with a risk of germ cell cancer, although further confirmation is needed (15). Testicular tumours show excellent cure rates. The main factors contributing to this are: careful staging at the time of diagnosis; adequate early treatment based on chemotherapeutic combinations, with or without radiotherapy and surgery; and very strict follow-up and salvage therapies. In the past decade, a decrease in the mean time delay to diagnosis and treatment has been observed (16). In the treatment of testicular cancer, the choice of centre where this treatment is going to be administered is of utmost importance. Although early stages can be successfully treated in a non-reference centre, the relapse rate is higher (17). In poor prognosis non-seminomatous germ cell tumours, it has been shown that overall survival within a clinical trial depended on the number of patients treated at the participating centre (worse < 5 patients enrolled) (18).
1.1
Methods
These guidelines represent implementation of previously published texts: the latest EAU guidelines were formally published as a review paper in 2005 (19) and as an EAU guideline, which was distributed among EAU members, in March 2006. As in 2006, this edition contains a separate chapter on testicular stromal tumours. A multidisciplinary team of urologists, medical oncologists, radiotherapists and a pathologist were involved in producing this text, which is based on a non-structured review of the literature through to October 2007 in the case of both the germ cell tumour and non-germ cell parts. Also, data from meta-analysis studies, Cochrane evidence, and the recommendations of the European Germ Cell Cancer Collaborative Group Meeting in Amsterdam in November 2006, as well as other available guidelines, have been included (20-27). Whenever possible, references have been labelled according to the principles of evidence-based medicine (EBM) (28). The nature of the recommendations in these guidelines is labelled according to the level of evidence (28).
4
Limited update march 2009
2. PATHOLOGICAL CLASSIFICATION The recommended pathological classification (modified from the 2004 version of the World Health Organization [WHO] guidance) is shown below (29). 1. Germ cell tumours • Intratubular germ cell neoplasia • Seminoma (including cases with syncytiotrophoblastic cells) • Spermatocytic seminoma (mention if there is sarcomatous component) • Embryonal carcinoma • Yolk sac tumour • Choriocarcinoma • Teratoma (mature, immature, with malignant component) • Tumours with more than one histological type (specify percentage of individual components). 2. Sex cord/gonadal stromal tumours • Leydig cell tumour • Malignant Leydig cell tumour • Sertoli cell tumour - lipid-rich variant - sclerosing - large cell calcifying • Malignant Sertoli cell tumour • Granulosa cell tumour - adult type - juvenile type • Thecoma/fibroma group of tumours • Other sex cord/gonadal stromal tumours - incompletely differentiated - mixed • Tumours containing germ cell and sex cord/gonadal stromal (gonadoblastoma). 3. Miscellaneous non-specific stromal tumours • Ovarian epithelial tumours • Tumours of the collecting ducts and rete testis • Tumours (benign and malignant) of non-specific stroma
3. DIAGNOSIS 3.1
Clinical examination
Testicular cancer generally affects young men in the third or fourth decade of life. It normally appears as a painless, unilateral mass in the scrotum or the casual finding of an intrascrotal mass (30). In approximately 20% of cases, the first symptom is scrotal pain, and up to 27% of patients with testicular cancer may have local pain (1). Occasionally, trauma to the scrotum may reveal the presence of a testicular mass. Gynaecomastia appears in 7% of cases and is more common in non-seminomatous tumours. Back and flank pain are present in about 11% of cases (16). Reduction in testis size can precede a testicular tumour (31). In about 10% of cases, a testicular tumour can mimic an orchioepididymitis, with consequent delay of the correct diagnosis (1, 2). Ultrasound must be performed in any doubtful case. Physical examination reveals the features of the mass and must always be carried out in conjunction with a general examination in order to find possible (supraclavicular) distant metastases, a palpable abdominal mass or gynaecomastia. A correct diagnosis must be established in all patients with an intrascrotal mass (32).
3.2
Imaging of the testis
Currently, diagnostic ultrasound serves to confirm the presence of a testicular mass and to explore the
Limited update march 2009
5
contralateral testis. Its sensitivity in detecting a testicular tumour is almost 100%, and it has an important role in determining whether a mass is intra- or extratesticular (33). Ultrasound is an inexpensive test, but it is unnecessary when the presence of a testicular tumour is clinically evident (34). Ultrasound of the testis has to be performed in young men without a palpable testicular mass who have retroperitoneal or visceral masses or elevated serum human chorionic gonadotrophin (hCG) or AFP (35-38). Ultrasound is recommended in the follow-up of the contralateral testis in the follow-up of patients at risk (39). Magnetic resonance imaging (MRI) offers higher sensitivity and specificity than ultrasound for diagnosing tumours (40-42) and may be able to differentiate seminomatous from non-seminomatous tumours. MRI of the scrotum offers a sensitivity of 100% and a specificity of 95-100% (43), but its high cost does not justify its use for diagnosis.
3.3
Serum tumour markers at diagnosis
Serum tumour markers are prognostic factors and contribute to diagnosis and staging (44). The following markers should be determined: • AFP (produced by yolk sac cells) • hCG (expression of trophoblasts). Lactate dehydrogenase (LDH) (marker of tissue destruction) is recommended for patients with metastatic disease. Globally, there is an increase in these markers in 51% of cases of testicular cancer (16, 30). Alphafetoprotein increases in 50-70% of patients with non-seminomatous germ cell tumour (NSGCT), and a rise in hCG is seen in 40-60% of patients with NSGCT. About 90% of non-seminomatous tumours present with a rise in one or two of the markers. Up to 30% of seminomas can present or develop an elevated hCG level during the course of the disease (45, 46). LDH is a less specific marker, and its concentration is proportional to tumour volume. Its level may be elevated in 80% of patients with advanced testicular cancer (45). It should be noted that negative marker levels do not exclude the diagnosis of a germ cell tumour. Other markers studied include placental alkaline phosphatase (PLAP), which may be of value in monitoring patients with pure seminoma. Cytogenetic and molecular markers are available in specific centres, but at present only contribute to research studies. Measurement of serum AFP, hCG and LDH (in advanced tumours) is mandatory, while that of PLAP is optional.
3.4
Inguinal exploration and orchidectomy
Every patient with a suspected testicular mass must undergo inguinal exploration with exteriorisation of the testis within its tunics. Immediate orchidectomy with division of the spermatic cord at the internal inguinal ring must be performed if a tumour is found. If the diagnosis is not clear, a testicular biopsy is taken for frozen section histological examination. In cases of disseminated disease and life-threatening metastases, it is current practice to start with up-front chemotherapy, and orchidectomy may be delayed until clinical stabilisation has occurred.
3.5
Organ-sparing surgery
Although organ-sparing surgery is not indicated in the presence of non-tumoural contralateral testis, it can be attempted in special cases with all the necessary precautions. In synchronous bilateral testicular tumours, metachronous contralateral tumours, or in a tumour in a solitary testis with normal pre-operative testosterone levels, organ preserving surgery can be performed when the tumour volume is less than 30% of the testicular volume and surgical rules are respected. In those cases, the rate of associated Tin is high (at least up to 82%), and all patients must be treated with adjuvant radiotherapy (20 Gy) at some point (47). Infertility will result after radiotherapy and the risk of long-term Leydig cell insufficiency after radiotherapy of a solitary testis is increased (48). Radiation treatment may be delayed in fertile patients who wish to father children. The option must be carefully discussed with the patient and surgery performed in a centre with experience (49, 50).
3.6 Pathological examination of the testis Mandatory pathological requirements: • Macroscopic features: side, testis size, maximum tumour size and macroscopic features of epididymis, spermatic cord and tunica vaginalis.
6
Limited update march 2009
•
• • •
ampling: a 1 cm2 section for every centimetre of maximum tumour diameter, including normal S macroscopic parenchyma (if present), albuginea and epididymis, with selection of suspected areas. At least one proximal and one distal section of spermatic cord plus any suspected area. Microscopic features and diagnosis: histological type (specify individual components and estimate amount as percentage) according to WHO 2004 (29): - presence or absence of peri-tumoural venous and/or lymphatic invasion - presence or absence of albuginea, tunica vaginalis, rete testis, epididymis or spermatic cord invasion - presence or absence of intratubular germ cell neoplasia (Tin) in non-tumour parenchyma intratubular germ cell neoplasia pT category according to Tumour Node Metastasis (TNM) 2002 Immunohistochemical studies: in seminoma and mixed germ cell tumour, AFP and hCG.
Advisable immunohistochemical markers, in cases of doubt, are: • in seminoma: cytokeratins (CAM 5.2), PLAP, c-kit • in intratubular germ cell neoplasia: PLAP, c-kit • other advisable markers: chromogranine A (Cg A), Ki-1 (MIB-1).
3.7 Diagnosis and treatment of carcinoma in situ (Tin) Contralateral biopsy has been advocated to rule out the presence of Tin (51). Although this is routine policy in some countries, the low incidence of Tin and contralateral metachronous testicular tumours (up to 9% and approximately 2.5%, respectively) (52, 53), the morbidity of Tin treatment, and the fact that most of these metachronous tumours are at a low stage at presentation make it controversial to recommend a systematic contralateral biopsy in all patients (54-56). It is still difficult to reach a consensus on whether the existence of contralateral Tin must be identified in all cases. However, biopsy of the contralateral testis should be offered to high-risk patients for contralateral Tin with a testicular volume of less than 12 mL, a history of cryptorchidism, or poor spermatogenesis (Johnson Score 1-3). A contralateral biopsy is not necessary for patients older than 40 years (57-62). A double biopsy is preferred to increase sensitivity. Once Tin is diagnosed, local radiotherapy (20 Gy in single fractions of 2 Gy) is the treatment of choice. Because this may produce infertility, the patient must be carefully counselled before treatment commences (54, 63). In addition to infertility, Leydig cell function and testosterone production may be impaired long-term following radiotherapy for Tin (49). Radiation treatment may be delayed in fertile patients who wish to father children (59).
3.8
Screening
Although there are no surveys proving the advantages of screening programmes, it has been demonstrated that stage and prognosis are directly related to early diagnosis. In the presence of clinical risk factors, selfphysical examination by the affected individual is advisable.
4. STAGING To determine the presence of metastatic or occult disease, the half-life kinetics of serum tumour markers must be assessed, the nodal pathway must be screened, and the presence of visceral metastases ruled out. Consequently, it is mandatory to assess: • the post-orchidectomy half-life kinetics of serum tumour markers • the status of retroperitoneal and supraclavicular lymph nodes, and the liver • the presence or absence of mediastinal nodal involvement and lung metastases • the status of brain and bone, if any suspicious symptoms are present.
4.1 Diagnostic tools The currently available tests include: • serial blood sampling • chest X-ray • abdominopelvic and thoracic computed tomography (CT) scan • abdominal and retroperitoneal ultrasound • MRI
Limited update march 2009
7
• •
positron emission tomography (PET) scan other specific examinations, depending on clinical suspicion.
4.2
Serum tumour markers: post-orchidectomy half-life kinetics
The mean serum half-life of AFP and hCG is 5-7 days and 2-3 days, respectively (45). Tumour markers have to be re-evaluated after orchidectomy to determine half-life kinetics. Marker decline in patients with clinical stage I disease should be assessed until normalisation has occurred. Post-orchidectomy markers are important to classify the patient according to the International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification. The persistence of elevated serum tumour markers after orchidectomy might indicate the presence of metastatic disease (macro- or microscopically), while the normalisation of marker levels after orchidectomy does not rule out the presence of tumour metastases. During chemotherapy, the markers should decline; persistence has an adverse prognostic value.
4.3 Retroperitoneal, mediastinal and supraclavicular lymph nodes and viscera Retroperitoneal and mediastinal lymph nodes are best assessed by means of a CT scan. The supraclavicular nodes are best assessed by physical examination. Abdominopelvic CT scanning offers a sensitivity of 70-80% in determining the state of the retroperitoneal nodes. Its accuracy depends on the size of the nodes; sensitivity and the negative predictive value increase using a 3 mm threshold to define metastatic nodes in the landing zones (62). Those figures decrease slightly in stages I and II (63, 64), with a rate of understaging of 25-30% (65). New generations of CT scans do not seem to improve the sensitivity. Magnetic resonance imaging produces similar results to CT scanning in the detection of retroperitoneal nodal enlargement (66). Again, the main objections to its routine use are its high cost and limited access to it. Nevertheless, MRI can be helpful when abdominopelvic CT or ultrasound are inconclusive (66), when CT scan is contraindicated because of allergy to contrast media, or when the physician or the patient are concerned about radiation dose. MRI is an optional test, and there are currently no indications for its systematic use in the staging of testicular cancer. Chest X-ray is the routine thorax examination. An anteroposterior and lateral chest X-ray could be considered as the only thoracic examination in seminoma when retroperitoneal and pelvic CT scans are negative (67). A chest CT scan is the most sensitive way to evaluate the thorax and mediastinal nodes. This exploration has to be recommended in patients with NSGCT because up to 10% of cases can present with small subpleural nodes that are not visible radiologically (1). The CT scan has high sensitivity but low specificity (66). A chest CT is mandatory in all patients with NSGCT, and in those patients with seminoma and a positive abdominopelvic CT scan (67). There is not enough evidence to support the use of the fluorodeoxyglucose-PET (FDG-PET) scan in the staging of testis cancer. It is recommended in the follow-up of patients with seminoma with any residual mass at least 4 weeks after chemotherapy in order to decide on watchful waiting or active treatment (68-71). Other examinations, such as brain or spinal CT, bone scan or liver ultrasound, should be performed if there is suspicion of metastases to these organs. A CT or MRI scan of the skull is advisable in patients with NSGCT and widespread lung metastases. Table I shows the recommended test at staging. Table 1: Recommended tests for staging at diagnosis Test Recommendation grade B Recommendation grade C Serum tumour markers Alpha-fetoprotein hCG LDH (for advanced tumours) Abdominopelvic CT scan All patients Slim adolescent Chest X-ray Seminoma* Chest CT scan NSGCT Testis ultrasound Clinical suspicion and normal scrotum at palpation MRI When abdominal CT is inconclusive All cases PET scan† Follow-up residual masses in seminoma Other If clinical suspicion
8
Limited update march 2009
Recommended further investigations Fertility investigations Total testosterone, LH, FSH, semen analysis, (should be offered) sperm banking hCG = human chorionic gonadotrophin; LDH = lactate dehydrogenase; CT = computed tomography; NSGCT = non-seminomatous germ cell tumour; MRI = magnetic resonance imaging; PET = positron emission tomography; LH = luteinising hormone; FSH = follicle-stimulating hormone. *If negative, abdominopelvic CT scan. †There is currently no indication for PET scan at diagnosis.
4.4
Staging and prognostic classifications
The staging system recommended in these guidelines is the 2002 TNM of the International Union Against Cancer (UICC) (Table 2) (72). This includes: • determination of the anatomical extent of disease • assessment of serum tumour markers, including nadir values of hCG, AFP and LDH after orchidectomy (S category) • clear definition of regional nodes • some N-category modifications related to node size. Table 2: TNM classification for testicular cancer (UICC, 2002, 6th edn [72]) pT Primary tumour1 pTX Primary tumour cannot be assessed (see note 1) pT0 No evidence of primary tumour (e.g. histological scar in testis) pTis Intratubular germ cell neoplasia (carcinoma in situ) pT1 Tumour limited to testis and epididymis without vascular/lymphatic invasion: tumour may invade tunica albuginea but not tunica vaginalis pT2 Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour extending through tunica albuginea with involvement of tunica vaginalis pT3 Tumour invades spermatic cord with or without vascular/lymphatic invasion pT4 Tumour invades scrotum with or without vascular/lymphatic invasion N Regional lymph nodes clinical NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Metastasis with a lymph node mass 2 cm or less in greatest dimension or multiple lymph nodes, none more than 2 cm in greatest dimension N2 Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, any one mass more than 2 cm but not more than 5 cm in greatest dimension N3 Metastasis with a lymph node mass more than 5 cm in greatest dimension pN Pathological pNX Regional lymph nodes cannot be assessed pN0 No regional lymph node metastasis pN1 Metastasis with a lymph node mass 2 cm or less in greatest dimension and 5 or fewer positive nodes, none more than 2 cm in greatest dimension pN2 Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence or extranodal extension of tumour pN3 Metastasis with a lymph node mass more than 5 cm in greatest dimension M Distant metastasis MX Distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis M1a Non-regional lymph node(s) or lung M1b Other sites S Serum tumour markers Sx Serum marker studies not available or not performed S0 Serum marker study levels within normal limits
Limited update march 2009
9
S1 S2 S3
LDH (U/l) < 1.5 x N and 1.5-10 x N or > 10 x N or
hCG (mIU/ml) < 5,000 and 5,000-50,000 or > 50,000 or
AFP (ng/ml) < 1,000 1,000-10,000 > 10,000
N indicates the upper limit of normal for the LDH assay. LDH, lactate dehydrogenase; hCG = human chorionic gonadotrophin; AFP = alpha-fetoprotein. 1Except for pTis and pT4, where radical orchidectomy is not always necessary for classification purposes, the extent of the primary tumour is classified after radical orchidectomy; see pT. In other circumstances, TX is used if no radical orchidectomy has been performed. According to the 2002 TNM classification, stage I testicular cancer includes the following substages: Stage IA Stage IB Stage IS
pT1 pT2, pT3 or pT4 Any patient/TX
N0 N0 N0
M0 M0 M0
S0 S0 S1-3
Stage IA patients have primary tumours limited to the testis and epididymis, with no evidence of microscopic vascular or lymphatic invasion by tumour cells on microscopy, no sign of metastases on clinical examination or imaging, and post-orchidectomy serum tumour marker levels within normal limits. Marker decline in patients with clinical stage I disease should be assessed until normalisation. Stage IB patients have a more locally invasive primary tumour, but no sign of metastatic disease. Stage IS patients have persistently elevated (and usually increasing) serum tumour marker levels after orchidectomy, which is evidence of subclinical metastatic disease (or possibly a second germ cell tumour in the remaining testis). If serum tumour marker levels are declining according to the expected half-life decay after orchidectomy, the patient is usually followed up until normalisation. In large population-based patient series, 75-80% of seminoma patients, and about 55% of patients with NSGCT cancer have stage I disease at diagnosis (73, 74). True stage IS (persistently elevated or increasing serum marker levels after orchidectomy) is found in about 5% of non-seminoma patients. If a staging retroperitoneal lymph node dissection (RPLND) was to be performed in stage IS patients, nearly all patients would be found to have pathological stage II disease (pN+) (1, 2, 5, 73). In 1997, the IGCCCG defined a prognostic factor-based staging system for metastatic testis tumour based on identification of some clinical independent adverse factors. This staging system has been incorporated into the TNM Classification and uses histology, location of the primary tumour, location of metastases and prechemotherapy marker levels in serum as prognostic factors to categorise patients into ‘good’, ‘intermediate’ or ‘poor’ prognosis (Table 3) (75). Table 3: Prognostic-based staging system for metastatic germ cell cancer (International Germ Cell Cancer Collaborative Group). Good-prognosis group Non-seminoma (56% of cases) 5-year PFS 89% 5-year survival 92% Seminoma (90% of cases) 5-year PFS 82% 5-year survival 86% Intermediate prognosis group Non-seminoma (28% of cases) 5 years PFS 75% 5-year survival 80%
10
All of the following criteria: • Testis/retroperitoneal primary • No non-pulmonary visceral metastases • AFP < 1,000 ng/mL • hCG < 5,000 IU/L (1,000 ng/mL) • LDH < 1.5 x ULN All of the following criteria: • Any primary site • No non-pulmonary visceral metastases • Normal AFP • Any hCG • Any LDH All of the following criteria: • Testis/retroperitoneal primary • No non-pulmonary visceral metastases • AFP > 1,000 and < 10,000 ng/mL or
Limited update march 2009
• hCG > 5,000 and < 50,000 IU/L or • LDH > 1.5 and < 10 x ULN Seminoma (10% of cases) Any of the following criteria: 5-year PFS 67% • Any primary site 5-year survival 72% • Non-pulmonary visceral metastases • Normal AFP • Any hCG • Any LDH Poor prognosis group Non-seminoma (16% of cases) Any of the following criteria: 5-year PFS 41% • Mediastinal primary 5-year survival 48% • Non-pulmonary visceral metastases • AFP > 10,000 ng/mL or • hCG > 50,000 IU/L (10,000 ng/mL) or • LDH > 10 x ULN Seminoma No patients classified as poor prognosis PFS = progression-free survival; AFP = alpha-fetoprotein; hCG = human chorionic gonadotrophin; LDH = lactate dehydrogenase.
4.5 Prognostic risk factors For seminoma stage I, tumour size (> 4 cm) and invasion of the rete testis have been identified as the most important predictors for relapse in multivariate analysis (20). For non-seminoma stage I, vascular invasion of the primary tumour in blood or lymphatic vessels is the most important predictor of occult metastatic disease. The proliferation rate, as well as the percentage of embryonal carcinoma, are additional predictors that improve upon the positive and negative predictive value of vascular invasion (76, 77). The significant prognostic pathological risk factors for stage I and clinical risk factors for metastatic disease are listed in Table 4. Table 4: Prognostic factors for occult metastatic disease in testicular cancer For seminoma Pathological (for stage I) Histopathological type • Tumour size (> 4 cm) • Invasion of the rete testis Clinical (for metastatic disease) • Primary location • Elevation of tumour marker levels • Presence of non-pulmonary visceral metastasis
For non-seminoma • Vascular/lymphatic in or peri-tumoural invasion • Proliferation rate > 70% • Percentage of embryonal carcinoma > 50%
5. IMPACT ON FERTILITY AND FERTILITY- ASSOCIATED ISSUES Sperm abnormalities are frequently found in patients with testis tumours. Furthermore, chemotherapy and radiation treatment can also impair fertility. In patients in the reproductive age group, pre-treatment fertility assessment (testosterone, luteinising hormone [LH] and FSH levels) should be performed, and semen analysis and cryopreservation should be offered. If cryopreservation is desired, it should be performed before or after orchidectomy, but in any case prior to chemotherapy treatment (48, 78-84). In cases of bilateral orchidectomy or low testosterone levels after treatment of Tin, life-long testosterone supplementation is necessary (85). For more detailed information, the reader is referred to the EAU Male Infertility Guidelines.
Limited update march 2009
11
6. GUIDELINES ON DIAGNOSIS AND STAGING OF TESTICULAR CANCER 1. 2.
3.
4.
Testicular ultrasound is mandatory (grade of recommendation: B). Orchidectomy and pathological examination of the testis are necessary to confirm the diagnosis and to define the local extension (pT category) (grade of recommendation: B). In a life-threatening situation due to extensive metastasis, chemotherapy must be started before orchidectomy. Serum determination of tumour markers (AFP, hCG, and LDH in metastatic disease) must be performed before and after orchidectomy for staging and prognostic reasons (grade of recommendation: B). The state of the retroperitoneal, mediastinal and supraclavicular nodes and viscera must be assessed in testicular cancer. In seminoma, a chest CT scan is not necessary if the abdominal nodes are negative (grade of recommendation: B).
7. TREATMENT: STAGE I GERM CELL TUMOURS 7.1
Stage I seminoma
After modern staging procedures, about 15-20% of stage I seminoma patients have subclinical metastatic disease, usually in the retroperitoneum, and will relapse after orchidectomy alone (86). 7.1.1 Surveillance Several prospective non-randomised studies of surveillance have been conducted during the past decade, the largest study coming from Canada with > 1500 patients (87). Previous meta-analysis from four studies showed an actuarial 5 years’ relapse-free rate of 82.3%. The Princess Margaret Hospital series (n = 1559) showed an overall relapse rate in unselected patients of 16.8%. The actuarial relapse rate is in the order of 15-20% at 5 years, and most of the relapses are first detected in infra-diaphragmatic lymph nodes (86, 88-90). Chemotherapy with dosing according to IGCCCG classification is a possible treatment for seminoma relapse under surveillance. However, 70% of patients with relapse are suitable for treatment with radiotherapy alone because of small volume disease at the time of recurrence. Only about 20% of these patients relapse again after salvage radiotherapy and then need salvage chemotherapy. The overall cancer-specific survival rate reported with surveillance performed by experienced centres is 97-100% for seminoma stage I (89, 90). The main drawback of surveillance is the need for more intensive follow-up, especially with repeated imaging examinations of the retroperitoneal lymph nodes, for at least 5 years after orchidectomy. This compares with the very low risk of subdiaphragmatic relapse after adjuvant radiotherapy. There is a small but clinically significant risk of relapse more than 5 years after orchidectomy for stage I seminoma which supports the need for long term surveillance (88). Cost analyses of surveillance compared with radiotherapy indicate that it is more expensive (91), but estimates vary, mainly depending on the follow-up schedules (92, 93). 7.1.2 Adjuvant chemotherapy A joint trial by the Medical Research Council (MRC) and the European Organisation for Research and Treatment of Cancer (EORTC) (MRC TE 19 trial), which compared one cycle of carboplatin (area under curve [AUC] 7) with adjuvant radiotherapy, did not show a significant difference with regard to recurrence rate, time to recurrence and survival after a median follow-up of 4 years (94). Therefore, adjuvant carboplatin therapy is an alternative to radiotherapy or surveillance in stage I seminoma (89, 90, 94). Two courses of adjuvant carboplatin seem to further reduce the relapse rate to the order of 1-3% (95, 96), but further experience and long-term observations are needed. 7.1.3 Adjuvant radiotherapy Seminoma cells are extremely radiosensitive. Adjuvant radiotherapy to a para-aortic (PA) field or to a hockeystick field (para-aortic and ipsilateral iliac nodes), with moderate doses (total 20-24 Gy), will reduce the relapse rate to only 1-3% (97-100). After modern radiotherapy, nearly all relapses will first occur outside the irradiated
12
Limited update march 2009
field (supradiaphragmatic lymph nodes or in the lungs) (97, 100). Based on the results of a large randomised MRC trial, Fossa et al. (97, 98) recommended radiotherapy to a PA field as standard treatment for patients with testicular seminoma stage I, T1-T3 and with undisturbed lymphatic drainage. Acute toxicity was reduced and the sperm count within the first 18 months was significantly higher after PA irradiation than after irradiation of the traditional dog-leg field. On the other hand, the relapse rate in the iliac lymph nodes was about 2% (all of them on the right side) after PA and 0% after dog-leg irradiation. Another possible site of failure is in the left renal hilum. PA irradiation should be tailored according to the site of the primary tumour. Adjuvant irradiation of supradiaphragmatic lymph nodes is not indicated in seminoma stage I. With regard to the irradiation dose, the MRC recently finished a large randomised trial of 20 Gy versus 30 Gy PA radiation in stage I seminoma that showed equivalence for both doses in terms of recurrence rates (98). The rate of severe radiation-induced long-term toxicity is less than 2%. Moderate chronic gastrointestinal (GI) sideeffects are seen in about 5% of patients, and moderate acute GI toxicity in about 60% (97). The main concern surrounding adjuvant radiotherapy is the potentially increased risk of radiation-induced secondary non-germcell malignancies (101-104). A scrotal shield can be of benefit during adjuvant radiotherapy in order to prevent scattered radiation toxicity in the contralateral testis (104). It is currently difficult to evaluate the long-term risks after adjuvant radiotherapy for stage I seminoma because former treatment procedures included larger fields, higher doses of radiotherapy and/or the use of alkylating chemotherapy. 7.1.4 Retroperitoneal lymph node dissection (RPLND) In a prospective, non-randomised study comparing radiotherapy and RPLND in stage I seminoma, there was a trend towards a higher incidence of retroperitoneal relapses (9.5%) after RPLND as primary treatment. Therefore this policy should not be recommended in stage I seminoma (105). 7.1.5 Risk-adapted treatment Using tumour size > 4 cm and rete testis invasion, patients with seminoma stage I may be subdivided into a low-and high-risk group of occult metastatic disease. Patients with and without both risk factors have a risk of occult disease of 32% and 12%, respectively. These risk factors were introduced by a meta-analysis of retrospective trials (20). A prospective trial based on these risk factors (no risk factors: surveillance; both risk factors: two courses of carboplatin AUC 7) showed the feasibility of a risk-adapted approach. Early data with limited follow-up indicate that patients without either risk factor have a 6.0% risk of relapse at 5 years. Patients at high risk treated with carboplatin experienced a 3.3% relapse rate (106).
7.2 Guidelines for the treatment of seminoma stage I 1. Surveillance (if facilities available and patient compliant) (grade of recommendation: B). 2. Carboplatin-based chemotherapy (one course at AUC 7) can be recommended as an alternative to radiotherapy and surveillance (grade of recommendation: A). 3. Adjuvant radiotherapy to a PA or hockey-stick field, to a total dose of 20 Gy (grade of recommendation: A).
7.3
NSGCT stage I
Up to 30% of NSGCT patients with clinical stage I (CS1) disease have subclinical metastases and will relapse if surveillance alone is applied after orchidectomy. 7.3.1 Surveillance Improvements in clinical staging and follow-up methods, and the availability of effective salvage treatment with cisplatin-based chemotherapy and post-chemotherapy surgery, have led to studies of only close surveillance after orchidectomy in CS1 NSGCT patients. The largest reports of the surveillance strategy indicate a cumulative relapse rate of about 30%, with 80% of relapses occurring during the first 12 months of follow-up, 12% during the second year and 6% during the third year, decreasing to 1% during the fourth and fifth years, and occasionally even later (107-110). About 35% of relapsing patients have normal levels of serum tumour markers at relapse. About 60% of relapses are in the retroperitoneum. Despite very close follow-up, 11% of relapsing patients presented with large-volume recurrent disease. The somewhat lower relapse rates reported from surveillance studies compared with some series of patients staged by RPLND (111) can be explained by the fact that some patients (presumably at risk) are excluded once surveillance is advised. Based on the overall cancer-specific survival data, surveillance within an experienced surveillance programme may be offered to patients with non-risk stratified clinical stage I non-seminoma as long as they are compliant and informed about the expected recurrence rate as well as the salvage treatment (112).
Limited update march 2009
13
7.3.2 Primary chemotherapy Several studies involving two courses of chemotherapy with cisplatin, etoposide and bleomycin (PEB) as primary treatment for high-risk patients (having about 50% risk of relapse) have been reported (113-118). In these series, involving more than 200 patients, some with a median follow-up of nearly 8 years (113), a relapse rate of only 2.7% was reported, with very little long-term toxicity. Two cycles of cisplatin-based adjuvant chemotherapy do not seem to adversely affect fertility or sexual activity (119). It is important to be aware of the slow-growing retroperitoneal teratomas after primary chemotherapy and of the risk of late chemoresistant cancer relapse (120). The need for repeated and long-term follow-up with imaging of the retroperitoneum after primary chemotherapy is not yet clear. The results of cost analyses comparing surveillance, RPLND and primary chemotherapy show different results among the reported studies, possibly because of differences in intensity and costs related to follow-up procedures (121). With a low frequency of follow-up CTs (such as has been proven effective for the surveillance strategy in non-seminoma CS1), the costs of follow-up can be considerably reduced (122). 7.3.3 Risk-adapted treatment Risk-adapted treatment is currently based on the risk factor vascular invasion. Stratifying patients with CS1 NSGCT according to their presumed risk of relapse is a rational option, as several studies have reported similar survival rates and a final cure rate close to 100% with all available treatment options using the risk-stratifying approach (113-118, 123-125). Risk-adapted treatment is therefore an equally effective alternative treatment of choice in CS1 NSGCT. Patients with vascular invasion are recommended to undergo adjuvant chemotherapy with two cycles of PEB, and patients without vascular invasion are recommended to undergo surveillance. Only if patients or doctors are not willing to accept the consequent risk-adapted treatment, or if there are circumstances that militate against the risk-adapted treatment option, should the remaining treatments be considered. Thus, the decision about treatment should be based on a thorough discussion with the patients, taking into account the described advantages and disadvantages, as well as the individual situation of the patient and/or the treatment centre. The Swedish-Norwegian Testicular Cancer Project (SWENOTECA) recently showed that in a large population-based study with a risk-adapted approach within a management programme and a median follow-up of 4.7 years, the relapse rate was 3.2% for patients with vascular invasion treated with only one adjuvant PEB (126). 7.3.4 Retroperitoneal lymph node dissection If RPLND is performed, about 30% of patients are found to have retroperitoneal lymph node metastases, which corresponds to pathological stage II (PS2) disease (105, 127, 128). If no retroperitoneal metastases are found at RPLND (PS1), approximately 10% of the PS1 patients relapse at distant sites (77, 111, 129-131). The main predictor of relapse in CS1 NSGCT managed by surveillance, for having PS2 disease and for relapse in PS1 after RPLND, is histopathological evidence of vascular invasion by tumour cells in, or near, the primary tumour in the testis (77, 107, 111, 131, 132). The presence of vascular invasion seems to be a very robust parameter, and is clinically usable even without centralised review by an expert panel (123, 131). Vascular invasion was the most predictive of stage in a multifactorial analysis. The absence of vascular invasion has a negative predictive value of 77%, thus allowing for surveillance in low-risk compliant patients (77). Patients without vascular invasion constitute about 50-70% of the CS1 population, and these patients have only a 15-20% risk of relapse on surveillance, compared with a 50% relapse rate in patients with vascular invasion. The risk of relapse for PS1 patients is less than 10% for those without vascular invasion and about 30% for those with vascular invasion (123, 131, 133, 134). If CS1 patients with PS2 are followed up only after RPLND, about 30% relapse, mainly at sites outside the abdomen and pelvis. The risk of relapse depends upon the amount of retroperitoneal disease resected (135137). If two (or more) courses of cisplatin-based chemotherapy are given adjuvant to RPLND in PS2 cases, the relapse rate is reduced to less than 2%, including teratoma relapse (111, 132, 138). The risk of retroperitoneal relapse after a properly performed nerve-sparing RPLND is very low (less than 2%), as is the risk of ejaculatory disturbance or other significant side-effects (132, 135, 136). The follow-up after RPLND is much simpler and less costly than that carried out during post-orchidectomy surveillance because of the reduced need for abdominal CT scans (132). A laparoscopic RPLND may become
14
Limited update march 2009
a good alternative to an open staging RPLND, but cannot currently be recommended as a standard diagnostic tool (139-142). In a randomised comparison of RPLND with one course of PEB chemotherapy, adjuvant chemotherapy significantly increased the 2-year recurrence-free survival to 99.41% (confidence interval [CI] 95.87%, 99.92%) as opposed to surgery, which had a 2-year recurrence-free survival of 92.37% (CI 87.21%, 95.50%). The difference was 7.04%, CI 2.52%, 11.56%. The hazard ratio to experience a tumour recurrence with surgery as opposed to chemotherapy was 7.937, CI 1.808, 34.48. Therefore, one course of adjuvant PEB is superior to RPLND with regard to recurrence rates in patients unstratified for risk factors (143). In the SWENOTECA data mentioned in section 7.3.3 it was also found that one adjuvant PEB reduced the number of recurrences for 90% for patients, whether vascular invasion was present or not (126).
7.4
CS1S with (persistently) elevated serum tumour markers
Serum tumour markers should be followed closely until levels fall into the reference values according to the expected half-life values for AFP and hCG. If the marker level increases after orchidectomy, the patient has residual disease. If RPLND is performed, up to 87% of these patients have pathologically documented nodes in the retroperitoneum (144). An ultrasound examination of the contralateral testicle must be performed, if this was not done initially. The treatment of true CS1S patients is still controversial. They may be treated with three courses of primary PEB chemotherapy and with follow-up as for CS1B patients (high risk, see below) after primary chemotherapy (145), or by RPLND (121). The presence of vascular invasion may strengthen the indication for primary chemotherapy as most CS1S with vascular invasion will need chemotherapy sooner or later anyway.
7.5 Guidelines for the treatment of NSGCT stage I CS1 risk-adapted treatments based on vascular invasion or surveillance are recommended treatment options (grade of recommendation: B) (Table 5). Table 5: Risk-adapted treatments for CS1 based on vascular invasion or surveillance GR CS1A (pT1, no vascular invasion): low risk 1. If the patient is willing and able to comply with a surveillance policy, long-term (at least B 5 years) close follow-up should be recommended. 2. Adjuvant chemotherapy or nerve-sparing RPLND in low-risk patients remain options for A those not willing to undergo surveillance. If RPLND reveals PN+ (nodal involvement) disease, chemotherapy with two courses of PEB should be considered. CS1B (pT2-pT4): high risk 1. Primary chemotherapy with two courses of PEB should be recommended. B 2. Surveillance or nerve-sparing RPLND in high-risk patients remain options for those not A willing to undergo adjuvant chemotherapy. If pathological stage II is revealed at RPLND, further chemotherapy should be considered. GR = grade of recommendation.
Limited update march 2009
15
Figure 1 provides a treatment algorithm for patients with NSGCT stage I. Figure 1: T reatment algorithm after orchidectomy according to individual risk factors in patients with non-seminoma NSGCT CS1 (22) Non-seminoma CS I
Low risk no vascular invasion
Standard option
Option if conditions against surveillance
High risk Vascular invasion present
Option if conditions against surveillance and chemotherapy
Option if conditions against chemotherapy
Standard option
OR
Surveillance
Adjuvant chemotherapy 2 cycles PEB
Nerve-sparing (NS) RPLND
Adjuvant chemotherapy 2 cycles PEB
NS RPLND
Surveillance
Relapse
Treatment according to the IGCCCCG classification (3-4 cycles PEB [or VIP] followed by resection in case of residual tumour) PEB = cisplatin, etoposide, bleomycin; CS = clinical stage; IGCCCG = International Germ Cell Cancer Collaborative Group; RLNPD = retroperitoneal lymph node dissection; VIP = etoposide, cisplatin, ifosfamide
16
Limited update march 2009
8. TREATMENT: METASTATIC GERM CELL TUMOURS The treatment of metastatic germ cell tumours depends on: • the histology of the primary tumour • prognostic groups as defined by the IGCCCG based on 5202 non-seminoma and 660 seminoma cases (Table 3) (146).
8.1
Low-volume metastatic disease (stage IIA/B)
8.1.1 Stage IIA/B seminoma So far, the standard treatment for stage IIA/B seminoma has been radiotherapy. The radiation dose delivered in stage IIA and IIB is approximately 30 Gy and 36 Gy, respectively. The standard radiation field compared with stage I will be extended from the PA region to the ipsilateral iliac field (the hockey-stick field). In stage IIB, the lateral borders should include the metastatic lymph nodes with a safety margin of 1.0-1.5 cm. This technique yields a relapse-free survival after 6 years for stage IIA and IIB of 95% and 89%, respectively. Overall survival is almost 100% (61, 89). In stage IIB chemotherapy (4 x etoposide and cisplatin [EP] or 3 x PEB in good prognosis) is an alternative to radiotherapy. Although more toxic in the short term, it appears that 4 x EP or 3 x PEB achieve a similar level of disease control (147). Single-agent carboplatin is not an alternative to standard PEB chemotherapy (148). 8.1.2 Stage IIA/B non-seminoma There is a general consensus that treatment should start with initial chemotherapy in all advanced cases of NSGCT except for stage II NSGCT disease without elevated tumour markers, which alternatively can be treated with primary RPLND or surveillance (149, 150). If surveillance is chosen, one follow-up after 6 weeks is indicated to document whether the lesion is growing, remaining stable or shrinking. A shrinking lesion is likely to be of non-malignant origin and should be observed further. A stable or growing lesion indicates either teratoma or an undifferentiated malignant tumour. If the lesion is growing without a corresponding increase in the tumour markers AFP or beta-hCG, RPLND should be performed by an experienced surgeon because of suspected teratoma. Patients with a growing lesion and a concomitant increase in the tumour markers AFP or beta-hCG should not undergo surgery; they require chemotherapy with PEB according to the treatment algorithm for patients with metastatic disease and IGCCCG recommendations (151-153) (Figure 2). There is no proven role for PET scans in this situation. Patients not willing to undergo primary chemotherapy have the option of primary nerve-sparing RPLND with adjuvant chemotherapy (two cycles of PEB) in case of metastatic disease (pII A/B). Primary chemotherapy and primary RPLND are comparable options in terms of outcome but side-effects and toxicity are different, allowing for involvement of the patient in selecting the treatment of choice (154). The cure rate with either approach will be close to 98% (138, 155-160).
Limited update march 2009
17
Figure 2: Treatment options in patients with non-seminoma clinical stage IIA (23) IIA Marker +
CS IIA, marker – either
Chemotherapy PEB X 3
Residual tumour
Follow-up after 6 weeks
NS-RPLND
PS I
PS IIA/B
either
Resection
or
Follow-up Independent of vascular invasion
Follow-up
PD
or
2 cycles PEB
+
marker
3 cycles PEB +/resection of residual tumour
NC
Regression
-
NS-RPLND or chemotherapy
NS-RPLND
Further follow-up
PEB = cisplatin, etoposide, bleomycin; NS = nerve-sparing; RPLND = retroperitoneal lymph node dissection; PS = pathological stage; PD = progressive disease; NC = no change.
8.2
Advanced metastatic disease
8.2.1 Primary chemotherapy The primary treatment of choice for advanced disease is three or four cycles of PEB combination chemotherapy (Table 6), depending on the IGCCCG risk classification (see Table 3). This regimen has proven superiority to cisplatin, vinblastine and bleomycin (PVB) in patients with advanced disease (161-163). Data support a 3-day regimen of administering combination chemotherapy to be equally effective as a 5-day regimen, but associated with increased toxicity (164). Table 6: PEB regimen (interval 21 days). Drug Dosage Duration of cycles Cisplatin 20 mg/m2 Days 1-5* Etoposide 100 mg/m2 Days 1-5 Bleomycin 30 mg (bolus) Days 1, 8, 15 *Plus hydration. PEB = cisplatin, etoposide, bleomycin For patients with a ‘good prognosis’, according to the IGCCCG Classification (146), standard treatment consists of three cycles of PEB or, in cases where bleomycin is contraindicated, four cycles of EP (146,163167). Therapy should be given without reduction of the doses at 21-day intervals; delaying the following chemotherapy cycle is justified only in cases of fever with granulocytopenia < 1000/mm3 or thrombocytopenia < 100,000/IU. There is no indication for prophylactic application of haematopoietic growth factors such as, for example, granulocyte colony-stimulating factor (G-CSF). However, if infectious complications have occurred during chemotherapy, prophylactic administration of G-CSF is recommended for the following cycles (165, 168). The ‘intermediate prognosis’ group in the IGCCCG has been defined as patients with a 5- year survival rate of about 80%. The available data support four cycles of PEB as standard treatment (146, 169). Due to the generally less favourable prognosis of patients in this group compared with those with a ‘good prognosis’, they may be treated in prospective trials such as, for example, the EORTC Genitourinary Tract Cancer Cooperative Group trial with PEB vs PEB + paclitaxel (169).
18
Limited update march 2009
For patients with a ‘poor prognosis’, standard treatment consists of four cycles of PEB. Four cycles of cisplatin, etoposide and ifosfamide (PEI) have the same effect, but are more toxic (170, 171). The 5-year progression-free survival is between 45% and 50%. A randomised study has shown no advantage in high-dose chemotherapy for the overall group of ‘poor prognosis’ patients. However, patients with a slow marker decline may represent a prognostically inferior subgroup (172). Since a matched-pair analysis resulted in a better survival rate (173175), poor prognosis patients should still be treated in ongoing prospective randomised trials, investigating the value of high-dose chemotherapy. Patients meeting ‘poor-prognosis’ criteria should therefore be transferred to a reference centre. There are no general recommendations for treatment modifications for patients with a poor general condition (Karnofsky < 50%), extended liver infiltration (> 50%), or extended pulmonary infiltration.
8.3 Restaging and further treatment 8.3.1 Restaging Restaging is performed by imaging investigations and re-evaluation of tumour markers. At marker decline and stable or regressive tumour manifestation, chemotherapy will be completed (three or four cycles, depending on the initial stage) (146, 176, 177). In the case of marker decline but growing metastases, resection of the tumour is obligatory after termination of induction therapy, other than in an emergency, according to local tumour growth (178). Only with documented marker growth after two courses of chemotherapy is an early crossover of therapy indicated. These patients are usually candidates for new drugs trials (173, 179). Patients with a low-level marker plateau post-treatment should be observed to see whether complete normalisation occurs. Salvage chemotherapy is indicated for documented marker rise only (180, 181). 8.3.2 Residual tumour resection A residual mass of seminoma should not be resected, irrespective of the size, but controlled by imaging investigations and tumour markers (182-188). FDG-PET has a high prognostic value in patients with residual masses after treatment of seminoma. In patients with residuals of > 3 cm, FDG-PET should be performed in order to gain more information on the viability of these residuals. In patients with residuals of < 3 cm, the use of FDG-PET is optional (189). On progression, salvage therapy is indicated (chemotherapy, salvage surgery, radiotherapy) (190-194). In the case of non-seminoma and complete remission after chemotherapy (no tumour visible), residual tumour resection is not indicated (195-200). In the case of any visible residual mass and marker normalisation, surgical resection is indicated. In patients with lesions < 1 cm, there still is an increased risk of residual cancer or teratoma (201). In persistent retroperitoneal disease, all areas of primary metastatic sites must be completely resected within 4-6 weeks of completion of chemotherapy. If technically feasible, a nerve-sparing procedure should be performed (195, 202-209). Overall, following PEB induction chemotherapy, only 10% of residual masses contain viable cancer, 50% contain mature teratoma, and 40% contain necrotic-fibrotic tissue. As yet, no imaging investigations, including PET or a prognosis model, are able to predict histological differentiation of the non-seminomatous residual tumour. Thus, residual tumour resection is mandatory (196-198, 208-218). The extent of surgery should be based on the risk of relapse of an individual patient and quality of life issues (203). If possible, all the masses should be resected, because a complete resection, in the setting of viable malignant cells, is more critical than recourse to post-operative chemotherapy (219). The histology may diverge in different organ sites (211). Resection of contralateral pulmonary lesions is not mandatory in case pathologic examination of the lesions from the first lung shows complete necrosis (220). 8.3.3 Consolidation chemotherapy after secondary surgery After resection of necrosis or mature teratoma, no further treatment is required. In the case of incomplete resection of vital carcinoma or immature teratoma, two adjuvant cycles of conventionally dosed cisplatinbased chemotherapy may be given in certain subgroups (e.g. ‘poor prognosis’ patients) (219, 221) (caution: cumulative doses of bleomycin). After complete resection of vital tumour < 10% of the total volume, adjuvant chemotherapy is not beneficial for preventing further relapse. The prognosis will definitely deteriorate if vital carcinoma is found in resection specimens after second- and third-line chemotherapy. In this latter situation, post-operative chemotherapy is not indicated and is unable to improve the prognosis (207, 212).
Limited update march 2009
19
8.4
Systemic salvage treatment for relapse or refractory disease
8.4.1 Seminoma Cisplatin-based combination salvage chemotherapy will result in long-term remissions for about 50% of the patients who relapse after first-line chemotherapy (222). The regimens of choice are four cycles of PEI/ VIP (etoposide, ifosfamide, cisplatin), four cycles of TIP (paclitaxel, ifosfamide, cisplatin) or four cycles of VeIP (vinblastine, ifosfamide, cisplatin). At present, it is impossible to determine whether conventionally dosed cisplatin-based combination chemotherapy is sufficient as first-salvage treatment or whether early intensification of first-salvage treatment with high-dose chemotherapy should be attempted (223). It is therefore of the utmost importance that these rare patients are treated within clinical trials and at experienced centres. 8.4.2 Non-seminoma Standard salvage treatment after first-line chemotherapy consists of either four cycles of PEI/VIP, four courses of TIP, or four cycles of VeIP, respectively (Table 7). Table 7: Standard PEI/VIP, TIP and VeIP chemotherapy (interval 21 days) Chemotherapy agents Dosage Duration of cycles PEI/VIP Cisplatin* 20 mg/m2 Days 1-5 Etoposide 75-100 mg/m2 Days 1-5 Ifosfamide† 1.2 g/m2 Days 1-5 TIP Paclitaxel Ifosfamide† Cisplatin*
250 mg/m2 1.5 g/ m2 25 mg/m2
24 hour continuous infusion day 1 Days 2-5 Days 2-5
VeIP Vinblastin 0.11 mg/kg Days 1 + 2 Ifosfamide† 1.2 g/m2 Days 1-5 Cisplatin* 20 mg/m2 Days 1-5 PEI/VIP = cisplatin, etoposide, ifosfamide; TIP = paclitaxel, ifosfamide, cisplatin; VelP = vinblastine, ifosfamide, cisplatin. *Plus hydration. †Plus mesna protection. Conventionally dosed salvage chemotherapy may achieve long-term remissions in 15-40% of patients, depending on individual risk factors (181, 224). Prognostic indicators of response to salvage therapy are (181, 224-226): • the location and histology of the primary tumour • the response to first-line treatment • the duration of remissions • the level of AFP and hCG at relapse. Salvage therapy with VeIP is probably not superior to other conventionally dosed cisplatin-based combination regimens (220-222). The use of conventionally dosed combination regimens with more than three agents will increase toxicity without improving the treatment outcome (227). Depending on the presence of adverse prognostic factors, the results of salvage therapy after first-line cisplatin based treatment are unsatisfactory (181, 228). Although some phase II trials indicate a 10% improvement in survival with early intensification of first-salvage treatment using high-dose chemotherapy, others fail to demonstrate such improvement (229-233). High dose chemotherapy offered no advantage as first salvage treatment according to the results of the randomised IT 94 trial in good prognosis patients (234). Patients with good prognostic features should therefore be offered conventional-dose first salvage treatment. Several phase II trials, as well as one retrospectively matched pair-analysis, have shown an improvement in survival in poor-prognosis patients with early intensification of first-salvage treatment using high-dose chemotherapy (225, 235-237) (EBM: 2B).
20
Limited update march 2009
Recently, paclitaxel and gemcitabine have proved to be active in the treatment of refractory germ cell tumours; both drugs are synergistic with cisplatin (238-240). However, all of these patients should be entered into ongoing multicentre studies to define the optimal approach to salvage treatment, and should be referred to centres experienced in caring for relapse and/or refractory patients (223). 8.4.3 Late relapse (≥ 2 years after end of first-line treatment) Late relapse is defined as any patient relapsing more than 2 years following chemotherapy for metastatic disease. If technically feasible, all patients with late relapse should undergo immediate radical surgery of all lesions, irrespective of the level of their tumour markers to resect completely all undifferentiated germ-cell tumour, mature teratoma or secondary non-germ cell cancer (120, 241). If the lesions are not completely resectable, biopsies should be obtained for histological assessment, and salvage chemotherapy should be initiated according to the histological results. If the patient responds to salvage chemotherapy, secondary surgery should be conducted whenever possible. In the case of unresectable, but localised, refractory disease, radiotherapy can be considered. To avoid excess mortality, late relapses should be treated only at centres experienced in managing such patients (242).
8.5
Salvage surgery
Residual tumours after salvage chemotherapy should be resected within 4-6 weeks after marker normalisation or when a marker plateau is reached. In the case of marker progression after salvage treatment and a lack of other chemotherapeutic options, resection of residual tumours (‘desperation surgery’) should be considered if complete resection of all tumour seems feasible (about 25% long-term survival may be achieved) (181, 205, 213, 216, 243-252).
8.6
Treatment of brain metastases
Brain metastases occur in the frame of a systemic relapse and rarely as an isolated relapse. The long-term survival of patients presenting with brain metastases at initial diagnosis is poor (30-40%), but even poorer is the development of a brain metastasis as a recurrent disease (the 5-year survival-rate is 2-5%) (253, 254). Chemotherapy is the initial treatment in this case, and some data support the use of consolidation radiotherapy, even in the case of a total response after chemotherapy (255). Surgery can be considered in the case of a persistent solitary metastasis, depending on the systemic state, the histology of the primary tumour and the location of the metastasis.
8.7 Guidelines for the treatment of metastatic germ cell tumours GR 1. L ow volume NSGCT stage IIA/B with elevated markers should be treated like ‘good or intermediate prognosis’ advanced NSGCT, with three or four cycles of PEB. Stage IIA/B without marker elevation can be treated by RPLND or close surveillance. 2. In metastatic NSGCT (> stage IIC) with a good prognosis, three courses of PEB is the primary A treatment of choice 3. In metastatic NSGCT with an intermediate or poor prognosis, the primary treatment of choice is A four courses of standard PEB 4. S urgical resection of residual masses after chemotherapy in NSGCT is indicated in the case of B visible residual masses and when serum levels of tumour markers are normal or normalising 5. S eminoma CSII A/B can initially be treated with radiotherapy. When necessary, chemotherapy can A be used as a salvage treatment with the same schedule as for the corresponding prognostic groups of NSGCT 6. In stage CS IIB, chemotherapy (4 x EP or 3 x PEB, in good prognosis) is an alternative to B radiotherapy. Although more toxic in the short term, it appears that 4 x EP or 3 x PEB achieve a similar level of disease control. 7. S eminoma stage IIC and higher should be treated with primary chemotherapy according to the A same principles used for NSGCT GR = grade of recommendation
Limited update march 2009
21
9. FOLLOW-UP AFTER CURATIVE THERAPY 9.1 General considerations The selection of the test to be performed in follow-up should adhere to the following principles (256). • The interval between examination and duration of testing should be consistent with the time of maximal risk of recurrence and the natural history of the tumour. • The tests should be directed at the most likely sites of recurrence and should have a high predictive value, both positive and negative. • Therapy should be available that will result in cure of the recurrence, significant prolongation of life or palliation of symptoms. The initiation of earlier therapy should improve the outcome compared with therapy given when the patient becomes symptomatic from the tumour recurrence. • The increased risk of second malignancy, both in the primary site and in other tissues that may have been exposed to the same carcinogens, or in which there is epidemiological evidence of increased risk, should also guide the ordering tests. Malignant and non-malignant complications of therapy must also be considered. Such testing should also be performed with a frequency and duration consistent with the nature of the risk, and include only tests with high positive- and negative-predictive values. The following considerations apply in a general manner for the selection of an appropriate schedule and testing in the follow-up of all stages of testis tumour. • Most recurrences after curative therapy will occur in the first 2 years; surveillance should therefore be most frequent and intensive during this time. • Late relapses can occur beyond 5 years, and therefore yearly follow-up for life may be advocated. • After RPLND, relapse in the retroperitoneum is rare, the most likely site of recurrence being the chest. • The value of chest X-ray has been recently questioned in the follow-up of patients with disseminated disease after complete remission (257, 258). • CT of the chest has a higher predictive value than chest X-ray (258). • The results of therapy are dependent on the bulk of disease; thus an intensive strategy to detect asymptomatic disease may be justifiable. • After chemotherapy or radiotherapy, there is a long-term risk of the development of secondary malignancies.
9.2
Follow-up: stage I non-seminoma
Approximately 5% of patients with CS1 NSGCT present with elevated levels of tumour markers after orchidectomy, and up to 25-30% relapse during the first 2 years (5, 113, 131, 134, 155, 259-262). The follow-up schedule will differ depending on which of the three possible treatment strategies was chosen: • surveillance • nerve-sparing RPLND • adjuvant chemotherapy. 9.2.1 Follow-up investigations during surveillance The results of a surveillance policy depend upon a careful pre-operative staging procedure and follow-up management. In a ‘wait and see’ policy, relapses will occur in 30% of cases. Of these relapses, 80% will occur in the first 12 months after orchidectomy, and approximately 12% during the second year. The median time to relapse is 6 months (range 1-62 months), but relapses after 3-5 years, and even later, can still occur, with an annual rate of 4% (108, 109). Relapse occurs mainly in the retroperitoneum: approximately 20% of patients have evident metastases in the retroperitoneum, and 10% in the mediastinum and lungs (263). Sometimes the only indication is an elevated level of tumour markers. A randomised trial of two versus five CT scans has been published by the MRC recommending the reduction of imaging during surveillance in this stage to one CT scan at 3 months after orchidectomy, and another at 12 months. The trial, with a cohort of 414 patients, was powered to exclude a 3% probability of detecting a patient during surveillance only, with a relapse presenting already-metastatic disease with ‘intermediate’ or ‘poor’ prognosis features. Relapses were detected in 15% with two CTs, and 20% with five CTs; 1.6% of these patients had ‘intermediate’ or ‘poor’ prognosis features. Only 10% of patients had high-risk features (vascular invasion). In summary, this first randomised trial yielded level 1 evidence for a minimum follow-up in patients with CS1 non-seminoma (122). The recommended follow-up schedule (Table 8) includes the minimum requirements for imaging, and adds recommendations for other surveillance tests.
22
Limited update march 2009
Table 8: Recommended minimum follow-up schedule in a surveillance policy: stage I non-seminoma Procedure Year 1 Physical examination 4 times Tumour markers 4 times Chest X-ray Twice Abdominopelvic CT scan Twice (at 3 and 12 months) CT= computed tomography scan.
2 3-5 4 times Twice per year 4 times Twice per year Twice
6-10 Once per year Once per year
During the initial post-treatment phase, follow-up consists of regular clinical examinations, the monitoring of serum tumour markers, and imaging investigations. The frequency and type of the examinations depend on the estimated risk of relapse, the chosen treatment strategy, and the time that has elapsed since completion of therapy, and should be modified according to these risks. However, only limited information about the optimal follow-up strategy exists, and currently recommendations can only be given for seminoma (264). For low-risk stage I non-seminoma, two abdominopelvic CT scans during the first year seem sufficient to detect relapses at an early stage (122). The significance of additional CT scans remains uncertain. No studies are available that address the optimal monitoring of such patients by serum tumour markers (AFP, beta-hCG). 9.2.2 Follow-up after nerve-sparing RPLND Retroperitoneal relapse after a properly performed nerve-sparing RPLND is rare. RPLND should eliminate the retroperitoneal nodes as a site of relapse and thus the need for repeated abdominal CT scans. The US Testicular Cancer Intergroup study data show retroperitoneal relapse in 7/264 patients with pathological stage I disease (and 20 pulmonary relapses); four of these seven had no marker elevation (265). In the Indiana series, only one relapse in 559 cases was reported (266). If a relapse occurs, it is generally in the chest, neck or at the margins of the surgical field. Pulmonary relapses occur in 10-12% of patients, and more than 90% of those relapses occur within 2 years of RPLND (74, 267). However, the low rate of retroperitoneal relapse after RPLND can only be achieved by surgery in specialised centres, as shown by the high in-field relapse rate (7/13 relapses) in the German randomised trial of RPLND versus one course of PEB (143). The recommended minimum follow-up schedule is shown in Table 9. Table 9: Recommended minimum follow-up schedule after retroperitoneal lymphadenectomy or adjuvant chemotherapy: stage I non-seminoma Procedure Year 1 Physical examination 4 times Tumour markers 4 times Chest X-ray Twice Abdominopelvic CT scan Once CT = computed tomography scan.
2 3-5 4 times Twice/year 4 times Twice/year Twice Once
6-10 Once/year Once/year
9.2.3 Follow-up after adjuvant chemotherapy Prospective reports with long-term follow-up after adjuvant chemotherapy have shown a low relapse rate (113, 114, 259, 260) of about 3%. In a randomised trial with one course of PEB versus RPLND, the relapse rate with adjuvant chemotherapy was 1% (2/174 patients, one with marker relapse, one with mature teratoma in the retroperitoneum) (143). The need for repeated and long-term assessment of the retroperitoneum is still not clear. Owing to the risk of developing a late, slow-growing teratoma in the retroperitoneum after adjuvant chemotherapy, an abdominal CT should still be performed (see Table 9).
9.3
Follow-up: stage I seminoma
The majority of patients with seminoma (70-80%) present with clinical stage I disease at diagnosis (89). In - 20% of cases, there is nodal radiological involvement at the level of the retroperitoneum, and only 5% of 15¬-20% patients present with distant metastasis (89). The relapse rate varies between 1% and 20%, depending on the post-orchidectomy therapy chosen. Only up to 30% of seminomas present with elevation of hCG at diagnosis or in the course of the disease.
Limited update march 2009
23
Consequently, in most cases, measurement of blood markers will not be a reliable test for follow-up (268). The treatment options post-orchidectomy in stage I seminoma are retroperitoneal radiotherapy, surveillance and adjuvant chemotherapy. Due to extreme radio- and chemosensitivity, high cure rates of almost 100% are reached with each of the approaches, even in cases of relapse. The costs of the different therapies vary, as do the expected side-effects (91, 269, 270). 9.3.1 Follow-up after radiotherapy Low doses of radiotherapy (20-24 Gy) limited to the retroperitoneal or the hockey-stick field achieve an overall survival rate of approximately 99% at 5-10 years (97-99, 271, 272). The rate of relapse is 1-2% and the most common time of presentation is within 18 months of treatment (97, 100, 270, 273, 274), although late relapses have also been described (275). The site of relapse is mainly at the supradiaphragmatic lymph nodes, mediastinum, lungs or bones. In a small proportion of cases, the tumour will relapse in the inguinal or external iliac nodes (89). The side-effects of radiotherapy include impaired spermatogenesis, GI symptoms (peptic ulceration), and induction of second malignancies (270, 276, 277). Up to 50% of patients can develop moderate toxicity grade I-II (268). The schedule of follow-up is described in Table 10. Table 10: Recommended minimum follow-up schedule for post-orchidectomy surveillance, radiotherapy or chemotherapy: stage I seminoma Procedure Year 1 2 3-4 Physical 3 times 3 times Twice/year examination Tumour markers 3 times 3 times Twice/year Chest X-ray Twice/year Twice/year Once/year Abdominopelvic CT scan Twice/year Twice/year Once/year CT = computed tomography scan.
5-10 Once/year Once/year Once/year Once/year
9.3.2 Follow-up during surveillance The actuarial risk of relapse at 5 years ranges between 6% (low risk) and 20% (106, 278-282). There is no increased risk of death. The median time to relapse ranges from 12-18 months, but up to 29% of relapses can develop later than this (87, 283). The sites of relapse are the PA lymph nodes in up to 82% of cases; the pelvic lymph nodes, inguinal nodes and lungs can also be affected (87, 284-288). Due to the high and often late rate of relapse, close and active follow-up is mandatory for at least 5 years (289) (see Table 10). 9.3.3 Follow-up after adjuvant chemotherapy One or two courses of carboplatin-based chemotherapy is an effective alternative treatment in stage I seminoma. The relapse rate is 1.9-4.5%. In general, this treatment is well tolerated, with only mild, acute and intermediate-term toxicity (289, 290). Long-term data on late relapses and survival are missing (see Table 10).
9.4
Follow-up: stage II and advanced (metastatic) disease
The more advanced the nodal stage of the disease, the higher the likelihood of recurrence (138). In general, the primary tumour bulk governs the outcome for patients with NSGCT (291). In stage II NSGCT, regardless of the treatment policy adopted, excellent survival rates of 97% are reached provided that relapse is identified as soon as possible (149, 150, 156). In advanced metastatic germ cell tumours, the extent of the disease is correlated with the response to therapy and with survival. The combination of cisplatin-based chemotherapy and surgery (aggressive multimodality) achieves cure rates of between 65% and 85%, depending on the initial extent of disease (292, 293). Complete response rates to chemotherapy are in the order of 50-60% (292); another 20-30% of patients could be rendered disease-free with post-chemotherapy surgery (294). The main reasons for failure of therapy in advanced NSGCT are (291, 295, 296): • the presence of bulky disease not responding completely to chemotherapy • unresectable residual teratoma after chemotherapy • the presence or development of chemoresistant non-germ elements, which account for 8.2% of cases.
24
Limited update march 2009
Table 11 gives the recommended minimum follow-up schedule in advanced NSGCT and seminoma. Table 11: Recommended minimum follow-up schedule in advanced NSGCT and seminoma Procedure Year 1 2 3-5 Thereafter Physical examination 4 times 4 times Twice per year Once per year Tumour markers 4 times 4 times Twice per year Once per year Chest X-ray 4 times 4 times Twice per year Once per year Abdominopelvic CT scan*† Twice Twice Once per year Once per year Chest CT scan†‡ As indicated As indicated As indicated As indicated Brain CT scan§ As indicated As indicated As indicated As indicated CT = computed tomography scan. *Abdominal CT scanning must be performed at least annually if teratoma is found in the retroperitoneum. †If the post-chemotherapy evaluation in a seminoma patient shows any mass > 3 cm, the appropriate CT scan should be repeated 2 and 4 months later to ensure that the mass is continuing to regress. If available, FDG-PET scanning can be performed. ‡A chest CT scan is indicated if abnormality is detected on chest X-ray and after pulmonary resection. §In patients with headaches, focal neurological findings, or any central nervous system symptoms.
10. TESTICULAR STROMAL TUMOURS 10.1
Background
Testicular stromal tumours are rare and account for only 2-4% of adult testicular tumours. However, only Leydig cell and Sertoli cell tumours are of clinical relevance. As no general recommendations have been published to date, the Testicular Cancer Working Group of the European Association of Urology (EAU) has decided to include these tumours in the EAU Germ Cell Tumour Guidelines. Recommendations for diagnosis and treatment are given only for Leydig and Sertoli cell tumours.
10.2
Methods
A Medline search for Leydig cell tumours (synonym: interstitial cell tumour) and Sertoli cell tumours (synonym: androblastoma) was performed. Approximately 850 papers were found. After excluding pure laboratory work without clinical data, female and paediatric tumours and animal cases, 371 papers and abstracts were reviewed. Double publications and papers with unclear histology or missing data on clinical course were excluded. The majority of the remaining 285 publications are case reports, with only a few papers reporting series of more than 10 cases, most of them published in the pathology literature. The true incidence of stromal tumours therefore remains uncertain, and the proportion of metastatic tumours can only be given approximately. Nevertheless, the symptoms for pre-operative suspicion of testicular stromal tumours and the characteristics of tumours at high risk for metastases are sufficiently well established (EBM: IIA and IIB) to enable recommendations to be made regarding diagnosis and surgical approach. However, no recommendations for appropriate follow-up can be given due to the absence of follow-up data in most reported cases, and the fatal outcome of metastatic tumours, irrespective of the therapy chosen. The individual publications have been rated according to EBM categories (see above). The literature research for clinical data on Leydig cell tumours resulted in 193 publications dealing with more than 480 tumours in adults, including three publications (1-3) reporting larger series on a total of 90 patients. Follow-up data of more than 2 years are available for about 80 patients. The literature research for clinical data on Sertoli cell tumours resulted in 93 publications dealing with more than 260 tumours in adults, including three publications (from the same group) (4-6) reporting on a total of 80 patients. Follow-up data of more than 2 years are available in fewer than 40 patients.
10.3
Classification
The non-germ cell tumours of the testicle include the sex cord/gonadal stromal tumours and the miscellaneous non-specific stromal tumours. The different histological subtypes of testicular tumours are defined according to the WHO classification 2004 (adapted) (7).
Limited update march 2009
25
10.4
Leydig cell tumours
10.4.1 Epidemiology Leydig cell tumours constitute about 1-3% of adult testicular tumours (2, 8) and 3% of testicular tumours in infants and children (8). The tumour is most common in the third to sixth decade in adults, with a similar incidence observed in every decade. Another peak incidence is seen in children aged between 3 and 9 years. Only 3% of Leydig cell tumours are bilateral (2). Occasionally, they occur in patients with Klinefelter’s syndrome (8). 10.4.2 Pathology of Leydig cell tumours Leydig cell tumours are the most common type of sex cord/gonadal stromal tumours. Histopathologically, they are well outlined and usually up to 5 cm in diameter. They are also solid, coloured yellow to tan, with haemorrhage and/or necrosis present in 30% of cases. Microscopically, the cells are polygonal, with eosinophilic cytoplasm with occasional Reinke crystals, regular nucleus, solid arrangement and capillary stroma. The cells express vimentin, inhibin, protein S-100, steroid hormones, calretinin and cytokeratin (focally) (7). About 10% of Leydig cell tumours are malignant tumours, which present with the following parameters: • large size (> 5 cm) • cytological atypia • increased mitotic activity (> 3 per 10 high-power field [HPF]) • increased MIB-1 expression (18.6% vs 1.2% in benign) • necrosis • vascular invasion (9) • infiltrative margins • extension beyond the testicular parenchyma • DNA aneuploidy (1,10). 10.4.3 Diagnosis Patients either present with a painless enlarged testis or the tumour is an incidental ultrasound finding. In up to 80% of cases, hormonal disorders with high oestrogen and oestradiol levels and low testosterone, increased levels of LH and FSH are reported (11, 12), while negative results are always obtained for the testicular germ cell tumour-markers AFP, hCG, LDH and PLAP. Approximately 30% of patients present with gynaecomastia (13, 14). Only 3% of tumours are bilateral (2). Leydig cell tumours must be distinguished from the multinodular tumour-like and often bilaterally occurring lesions of the androgenital syndrome (15). Diagnostic work-up must include markers, hormones (at least testosterone, LH and FSH; if not conclusive, additionally oestrogen, oestradiol, progesterone and cortisol), ultrasound of both testes, and CT scan of chest and abdomen. On ultrasound, it may be possible to observe well-defined, small, hypoechoic lesions with hypervascularisation, but the appearance is variable and is indistinguishable from germ cell tumours (16, 17). The proportion of metastatic tumours in all published case reports is only 10%. Within three larger series with longer follow-up, 18 metastatic tumours were found in a total of 83 cases (21.7%) (1-3). Histopathological signs of malignancy have been depicted above (see 4.2) (1, 10). In addition, patients of older age have a greater risk of harbouring a tumour of malignant potential. 10.4.4 Treatment Asymptomatic testicular tumours of small volume are often misinterpreted as germ cell tumours, and inguinal orchidectomy is performed. It is highly recommended to perform an organ-sparing procedure in every small intraparenchymal lesion in order to obtain the histological diagnosis. Especially in patients with symptoms of gynaecomastia or hormonal disorders, a non germ-cell tumour should be considered and immediate orchidectomy avoided (18). In cases of germ cell tumour in either frozen section or paraffin histology, orchidectomy is recommended as long as a contralateral normal testicle is present. In stromal tumours with histological signs of malignancy, especially in patients of older age, orchidectomy and retroperitoneal lymphadenectomy is recommended to prevent metastases (19). Without histological signs of malignancy, an individualised surveillance strategy after orchidectomy is recommended (CT follow-up may be most appropriate since specific tumour markers are not available). Tumours that have metastasised to lymph nodes, lung, liver or bone respond poorly to chemotherapy or radiation and survival is poor (19).
26
Limited update march 2009
10.4.5 Follow-up Recommendations for appropriate follow-up cannot be given because of the lack of follow-up data in most reported cases and the lethal outcome of metastatic tumours, irrespective of the therapy chosen.
10.5
Sertoli cell tumour
10.5.1 Epidemiology Sertoli cell tumours account for fewer than 1% of testicular tumours, and the mean age at diagnosis is around 45 years, with rare cases under 20 years of age (4, 20). On rare occasions, these tumours may develop in patients with androgen insensitivity syndrome and Peutz-Jeghers syndrome. 10.5.2 Pathology of Sertoli cell tumours The tumour is well circumscribed, yellow, tan or white, with an average diameter of 3.5 cm (4). Microscopically, the cells are eosinophilic to pale with vacuolated cytoplasm. The nuclei are regular with grooves and there may be inclusions. The arrangement of the cells is tubular or solid; a cord-like or retiform pattern is possible. The stroma is fine and capillary, but in some cases a sclerosing aspect predominates. The cells express vimentin, cytokeratins, inhibin (40%) and protein S-100 (30%) (4). The rate of malignant tumours ranges between 10% and 22%, and fewer than 50 cases have been reported (21-23). Signs of a malignant Sertoli tumour are: • large size (> 5 cm) • pleomorphic nuclei with nucleoli • increased mitotic activity (> 5 per 10 HPF) • necrosis • vascular invasion. 10.5.2.1 Classification Three subtypes have been described (20): • the classic Sertoli cell tumour (4) • the large cell calcifying form with characteristic calcifications (5, 24) • the rare sclerosing form (6, 25). 10.5.3 Diagnosis Patients present either with an enlarged testis or the tumour is an incidental ultrasound finding (26). Most classic Sertoli tumours are unilateral and unifocal. Hormonal disorders are infrequent, although gynaecomastia is sometimes seen (4). The testicular tumour-markers AFP, hCG, LDH and PLAP are always negative. Diagnostic work-up must include tumour markers, hormones (at least testosterone, LH and FSH; if not conclusive, additionally oestrogen, oestradiol, progesterone and cortisol), ultrasound of both testes and CT scan of chest and abdomen. Sertoli cell tumours are generally hypoechoic on ultrasound, but they can be of variant appearance and therefore cannot be safely distinguished from germ cell tumours (20). Only the large cell calcifying form has a characteristic image with brightly echogenic foci due to calcification (27, 28). The large cell calcifying form is diagnosed in younger men and is associated with genetic syndromes (Carney’s complex [29] and Peutz-Jeghers syndrome [30]) or, in about 40% of cases, endocrine disorders. A total of 44% of cases are bilateral, either synchronous or metachronous, and 28% show multifocality (24). The characteristics of metastatic tumours have been depicted above (24, 25). However, among patients whose tumours have been histopathologically classified as ‘malignant’ using these or similar characteristics (i.e. 18.8% of tumours in all reported cases), only 7% showed metastatic disease during follow-up. In the largest series with the longest follow-up, 7.5% of patients had been classified as ‘malignant’ at primary diagnosis and 11.7% showed metastatic disease long-term (4). In general, affected patients are of higher age, tumours are nearly always palpable, and show more than one sign of malignancy (4). Up to 20% of the large cell sclerosing form are malignant. There are some hints that discrimination between an early and late onset type may define a different risk for metastatic disease (5.5% compared with 23%) (20). Metastases in the infrequent sclerosing subtype are rare.
Limited update march 2009
27
10.5.4 Treatment Testicular tumours of small volume, otherwise asymptomatic, are often misinterpreted as germ cell tumours and inguinal orchidectomy is performed. It is highly recommended to proceed with an organ-sparing approach in small intraparenchymal testicular lesions until final histology is available. Especially in patients with symptoms of gynaecomastia or hormonal disorders or typical imaging on ultrasound (calcifications, small circumscribed tumours), organ-sparing surgery should be considered. Secondary orchidectomy can be performed if final pathology reveals a non-stromal (e.g. germ cell) tumour. Organ-sparing surgical approaches are justified as long as the remaining testicular parenchyma is sufficient for endocrine (and in stromal tumours also exocrine) function. In tumours with histological signs of malignancy, especially in patients of older age, orchidectomy and retroperitoneal lymphadenectomy are recommended to prevent metastases (19). Without signs of malignancy, an individualised surveillance strategy after orchidectomy is recommended (CT scans may be most appropriate since specific tumour-markers are not available). Tumours metastasising to lymph nodes, lung or bone respond poorly to chemotherapy or radiation, and survival is poor. 10.5.5 Follow-up Recommendations for appropriate follow-up cannot be given because of the lack of follow-up data in most reported cases and the lethal outcome of metastatic tumours, irrespective of the therapy chosen.
10.6 Granulosa cell tumour This is a rare tumour, with two variants: juvenile and adult. • The juvenile type is benign. It is the most frequent congenital testicle tumour and represents 6.6% of all prepubertal testicular neoplasms. The cystic appearance is characteristic of this tumour type (31). • With the adult type, the average age at presentation is 44 years. The typical morphology is of a homogeneous, yellow-grey tumour, with elongated cells with grooves in microfollicular and Call-Exner body arrangements. Malignant tumours represent around 20% of cases. They are usually > 7 cm diameter. Vascular invasion and necrosis are features suggestive of malignant biology (32).
10.7
Thecoma/fibroma group of tumours
These tumours are very rare and benign (7).
10.8
Other sex cord/gonadal stromal tumours
Sex cord/gonadal stromal tumours may be incompletely differentiated or mixed forms. There is limited experience with incompletely differentiated sex cord/gonadal stromal tumours and no cases of reported metastasis (7). In mixed tumour forms, all the histological components should be reported. However, the clinical behaviour is most likely to reflect the predominant pattern or the most aggressive component of the tumour (33)
10.9
Tumours containing germ cell and sex cord/gonadal stromal (gonadoblastoma)
If the arrangement of the germ cells are in a nested pattern and the rest of the tumour is composed of sex cord/gonadal stroma, the term gonadoblastoma is used. It is most frequent in gonadal dysgenesis with ambiguous genitalia. Bilateral tumours are present in 40% of cases. The prognosis is correlated with the invasive growth of the germinal component (34). In the case of a diffuse arrangement of the different components, there are some doubts about the neoplastic nature of the germinal cells and some authors consider them to be entrapped rather than neoplastic (35).
10.10 Miscellaneous tumours of the testis 10.10.1 Tumours of ovarian epithelial types These tumours resemble the epithelial tumours of the ovary. A cystic appearance with occasional mucinous material can be observed. Microscopically, the aspect is identical to their ovarian counterparts, and their evolution is similar to that of the different epithelial ovarian subtypes. Some Brenner types can be malignant (7). 10.10.2 Tumours of the collecting ducts and rete testis These tumours are very rare. Benign (adenoma) and malignant (adenocarcinoma) have been reported, with malignant tumours showing local growth with a mortality rate of 56% (18).
28
Limited update march 2009
10.10.3 Tumours (benign and malignant) of non-specific stroma These are very uncommon and have a similar criteria, prognosis and treatment as do the soft tissue sarcomas.
11 REFERENCES 11.1 Germ cell tumours 1. 2.
3.
4.
5. 6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Richie JP. Neoplasms of the testis, in Walsh PC et al. (eds). Campbell’s Urology. 7th ed. Philadelphia: Saunders, 1997: pp. 2411-2452. Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980;112(2):232-46. http://www.ncbi.nlm.nih.gov/pubmed/6106385 Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170(1):5-11. http://www.ncbi.nlm.nih.gov/pubmed/12796635 McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumours in the United States. Cancer 2003;97(1):63-70. http://www.ncbi.nlm.nih.gov/pubmed/12491506 Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337(4):242-53. http://www.ncbi.nlm.nih.gov/pubmed/9227931 Kuczyk MA, Serth J, Bokemeyer C, Jonassen J, Machtens S, Werner M, Jonas U. Alterations of the p53 tumour suppressor gene in carcinoma in situ of the testis. Cancer 1996;78(9):1958-66. http://www.ncbi.nlm.nih.gov/pubmed/8909317 Looijenga LH, Gillis AJ, Stoop H, Hersmus R, Oosterhuis JW. Relevance of microRNAs in normal and malignant development, including human testicular germ cell tumours. Int J Androl 2007;30(4):304-14; discussion 314-15. http://www.ncbi.nlm.nih.gov/pubmed/17573854 Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol 2005;18(Suppl 2):S51-S60. http://www.ncbi.nlm.nih.gov/pubmed/15761466 Osterlind A, Berthelsen JG, Abildgaard N, Hansen SO, Hjalgrim H, Johansen B, Munck-Hansen J, Rassmussen LH. Risk of bilateral testicular germ cell tumours in Denmark: 1960-1984. J Natl Cancer Inst 1991;83(19):1391-5. http://www.ncbi.nlm.nih.gov/pubmed/1656057 Moller H, Prener A, Skakkebaek NE. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark. Cancer Causes Control 1996;7(2):264-74. http://www.ncbi.nlm.nih.gov/pubmed/8740739 Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer. Cancer 1997;80(10): 1954-60. http://www.ncbi.nlm.nih.gov/pubmed/9366298 Forman D, Oliver RT, Brett AR, Marsh SG, Moses JH, Bodmer JG, Chilvers CE, Pike MC. Familial testicular cancer: a report of the UK family register, estimation of risk and a HLA class 1 sib-pair analysis. Br J Cancer 1992;65(2):255-62. http://www.ncbi.nlm.nih.gov/pubmed/1739626 Weestergaard T, Olsen JH, Frisch M, Kroman N, Nielsen JW, Melbye M. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population based study. Int J Cancer 1996;66(5):627-31. http://www.ncbi.nlm.nih.gov/pubmed/8647624 Dieckmann KP, Loy V, Buttner P. Prevalence of bilateral germ cell tumours and early detection based on contralateral testicular intra-epithelial neoplasia. Br J Urol 1993;71(3):340-5. http://www.ncbi.nlm.nih.gov/pubmed/8386582 Dieckmann KP, Pichlmeier U. Is risk of testicular cancer related to the body size? Eur Urol 2002;42(6):564-9. http://www.ncbi.nlm.nih.gov/pubmed/12477651 Wanderas EH, Tretli S, Fossa SD. Trends in incidence of testicular cancer in Norway 1955-1992. Eur J Cancer 1995;31A(12):2044-8. http://www.ncbi.nlm.nih.gov/pubmed/8562163
Limited update march 2009
29
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
30
Jones A, Fergus JN, Chapman J, Houghton L. Is surveillance for stage I germ cell tumours of the testis appropiate outside a specialist centre? BJU Int 1999;84(1):79-84. http://www.ncbi.nlm.nih.gov/pubmed/10444129 Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PH, Ney Lallemand E, Kaye SB. Impact of the treating institution on survival of patients with poor-prognosis nonseminoma. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Working Party. J Natl Cancer Inst 1999;91(10):839-46. http://www.ncbi.nlm.nih.gov/pubmed/10340903 Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A, Klepp O, Laguna MP, Pizzocaro G. Guidelines on testicular cancer. Eur Urol 2005;48(6):885-94. http://www.ncbi.nlm.nih.gov/pubmed/16126333 Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20(22):4448-52. http://www.ncbi.nlm.nih.gov/pubmed/12431967 Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: a cochrane evidencebased systematic review. Cancer Treat Rev 2002;28(5):237-53. http://www.ncbi.nlm.nih.gov/pubmed/12435371 Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Ares LP, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Uro. 2008 Mar;53(3):478-96. http://www.ncbi.nlm.nih.gov/pubmed/18191324 Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008 Mar;53(3):497-513. http://www.ncbi.nlm.nih.gov/pubmed/18191015 Deutsche Krebsgesellschaft: Leitlinie zur Diagnostik und Therapie von Hodentumouren auf Grundlage evidenzbasierter Medizin (EBM). Souchon R, Schmoll HJ, Krege S, for the German Testicular Cancer Study Group (eds). Qualitätsicherung in der Onkologie. 1st edn. München-Bern-Wien-New YorkZuckschwerdt, 2002. [German Cancer Society: Evidence-based guideline for the assessment and treatment of testicular tumours] [article in German] The Royal College of Radiologists’ Clinical Oncology Network in partnership with Scottish Intercollegiate Network 2000. Guidelines on the management of adult testicular germ cell tumours. Clin Oncol (R Coll Radiol) 2000;12(5):S173-S210. http://www.ncbi.nlm.nih.gov/pubmed/11315727 Diagnostiek en behandeling van kiemceltumouren van de testis. Richtlijnen Nederlandse Vereniging voor urologie. No 14. [Diagnosis and treatment of testicular germ cell tumours. Dutch Urological Society guidelines] [article in Dutch]
Limited update march 2009
27.
28.
29.
30.
31. 32.
33. 34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44. 45.
Segal R, Lukka H, Klotz LH, Eady A, Bestic N, Johnston M; Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group. Surveillance programs for early stage nonseminomatous testicular cancer: a practice guideline. Can J Urol 2001;8(1):1184-92. http://www.ncbi.nlm.nih.gov/pubmed/11268306 Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [accessed February 2009]. WHO histological classification of testis tumours, In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology & Genetics. Tumours of the urinary system and male genital organs. Lyons: IARC Press, 2004: 218, pp. 250-262. Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz-Ares L, Arranz JA, Guma J, Alba E, Satre J, Aparicio J, Fernandez A, Barnadas A, Terrassa J, Saenz A, Almenar D, Lopez-Brea M, Climent MA, Sanchez MA, Lasso de la Vega R, Berenguer G, Perez X; Spanish Germ-Cell Cancer Group (GG). Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002;42(6):553-62. http://www.ncbi.nlm.nih.gov/pubmed/12477650 Skakkebaek NE. Possible carcinoma-in-situ of the testis. Lancet 1972;2(7776):516-7. http://www.ncbi.nlm.nih.gov/pubmed/4115573 Richie JP, Birnholz J, Garnick MB. Ultrasonography as a diagnostic adjunct for the evaluation of masses in the scrotum. Surg Gynecol Obstet 1982;154(5):695-8. http://www.ncbi.nlm.nih.gov/pubmed/7071705 Doherty FJ. Ultrasound of the nonacute scrotum, in Raymond HW et al. (eds). Seminars in Ultrasound, CT and MRI. New York: WB Saunders, 1991, pp. 131-156. Comiter CU, Benson CJ, Capelouto CC, Kantoff P, Shulman L, Richie JP, Loughlin KR. Nonpalpable intratesticular masses detected sonographically. J Urol 1995;154(4):1367-9. http://www.ncbi.nlm.nih.gov/pubmed/7658540 Friedrich M, Claussen CD, Felix R. Immersion ultrasound of testicular pathology. Radiology 1981;141(1):235-7. http://www.ncbi.nlm.nih.gov/pubmed/7291531 Glazer HS, Lee JKT, Melson GL, McClennan BL. Sonographic detection of occult testicular neoplasm. ARJ Am J Roentgenol 1982;138(4):673-5. http://www.ncbi.nlm.nih.gov/pubmed/6978030 Bockrath JM, Schaeffer AJ, Kiess MS, Nieman HL. Ultrasound Identification of impalpable testicle tumour. J Urol 1983;130(2):355-6. http://www.ncbi.nlm.nih.gov/pubmed/6876291 Shawker TH, Javadpour N, O’Leary T, Shapiro E, Krudy AG. Ultrasonographic detection of ‘burnedout’ primary testicular germ cell tumours in clinically normal testes. J Ultrasound Med 1983;2(10): 477-9. http://www.ncbi.nlm.nih.gov/pubmed/6313958 Lenz S, Giwercman A, Skakkebaek NE, Bruun E, Frimodt-Moller C. Ultrasound in detection of early neoplasia of the testis. Int J Androl 1987;10(1):187-90. http://www.ncbi.nlm.nih.gov/pubmed/2884185 Thurnher S, Hricak H, Carroll PR, Pobiel RS, Filly RA. Imaging the testis: comparison between MR imaging and US. Radiology 1988;167(3):631-6. http://www.ncbi.nlm.nih.gov/pubmed/3283834 Mattrey RF. Magnetic resonance imaging of the scrotum. Semin Ultrasound CT MR 1991;12(2):95108. http://www.ncbi.nlm.nih.gov/pubmed/1863480 Rholl KS, Lee JKT, Ling D, Heiken JP, Glazer HS. MR imaging of the scrotum with a high resolution surface coil. Radiology 1987;163(1):99-103. http://www.ncbi.nlm.nih.gov/pubmed/3547497 Johnson JO, Mattrey RF, Phillipson J. Differentiation of seminomatous from nonseminomatous testicular tumours by MRI. AJR Am J Roentgenol 1990;154(3):539-43. http://www.ncbi.nlm.nih.gov/pubmed/2106218 Klein EA. Tumour markers in testis cancer. Urol Clin North Am 1993;20(1):67-73. http://www.ncbi.nlm.nih.gov/pubmed/7679533 Peyret C. Tumeurs du testicule. Synthèse et recommandations en onco-urologie. Prog Urol 1993;2:604. [Testicular tumours. Summary of onco-urological recommendations] [article in French]
Limited update march 2009
31
46. 47.
48.
49.
50. 51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
32
Javadpour N. The role of biologic markers in testicular cancer. Cancer 1980;45(7 Suppl):1755-61. http://www.ncbi.nlm.nih.gov/pubmed/6154517 Heidenreich A, Weissbach L, Holth W, Albers P, Kliesch S, Kohrmann KU, Dieckmann KP. German Testicular Cancer Study Group. Organ sparing surgery for malignant germ cell tumour of the testis. J Urol 2001;166(6):2161-5. http://www.ncbi.nlm.nih.gov/pubmed/11696727 Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkebaek NE, Hansen SW, von der Maase H. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-insitu in the testis. J Clin Oncol 2002;20(6):1537-43. http://www.ncbi.nlm.nih.gov/pubmed/11896102 Heidenreich A, Holtl W, Albrecht W, Pont J, Engelmann UH. Testis-preserving surgery in bilateral testicular germ cell tumours. Br J Urol 1997;79(2):253-7. http://www.ncbi.nlm.nih.gov/pubmed/9052478 Weissbach L. Organ preserving surgery of malignant germ cell tumours. J Urol 1995;153(1):90-3. http://www.ncbi.nlm.nih.gov/pubmed/7966800 Dieckmann KP, Loy V. Prevalence of contralatral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 1996;14(12):3126-32. http://www.ncbi.nlm.nih.gov/pubmed/8955658 Von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG, Skakkebaek NE. Carcinoma-in-situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 1986; 293(6559):1398-401. http://www.ncbi.nlm.nih.gov/pubmed/3026550 Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, Roberts JT, Stenning SP. Intratubular germ cell neoplasia of contralateral testis in testicular cancer: defining a high risk group. J Urol 1998;160(4):1353-7. http://www.ncbi.nlm.nih.gov/pubmed/9751353 Tabernero J, Paz-Ares L, Salazar R, Lianes P, Guerra J, Borras J, Villavicencio H, Leiva O, CortesFunes H. Incidence of contralateral germ cell testicular tumours in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol 2004;171(1):164-7. http://www.ncbi.nlm.nih.gov/pubmed/14665868 Herr HW, Sheinfeld J. Is biopsy of the contralateral testis necessary in patients with germ cell tumors? J Urol 1997;158(4):1331-4. http://www.ncbi.nlm.nih.gov/pubmed/9302113 Albers P, Goll A, Bierhoff E, Schoeneich G, Muller SC. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumours. Urology 1999;54(4):714-8. http://www.ncbi.nlm.nih.gov/pubmed/10510934 Giwercman A, Bruun E, Frimotd-Muller C, Skakkebaek NE. Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. J Urol 1989;142(4):998-1001. http://www.ncbi.nlm.nih.gov/pubmed/2571738 Heidenreich A, Moul JW. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? Sem Urol Oncol 2002;20(4):234-8. http://www.ncbi.nlm.nih.gov/pubmed/12489055 Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 2007:51(1):175-83; discussion 183-5. http://www.ncbi.nlm.nih.gov/pubmed/16814456 Kliesch S, Thomaidis T, Schütte B, Puhse G, Kater B, Roth S, Bergmann M. Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN). APMIS 2003;111(1):70-4. http://www.ncbi.nlm.nih.gov/pubmed/12752238 Classen J, Dieckmann K, Bamberg M, Souchon R, Kliesch S, Kuehn M, Loy V; German Testicular Cancer Study Group. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer 2003;88(6):828-31. http://www.ncbi.nlm.nih.gov/pubmed/12644817 Leibovitch I, Foster RS, Kopecky KK, Donohue JP. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995;154(5):1759-63. http://www.ncbi.nlm.nih.gov/pubmed/7563341
Limited update march 2009
63.
64.
65.
66.
67.
68.
69.
70.
71.
72. 73. 74.
75.
76. 77.
78.
Jing B, Wallace S, Zornoza J. Metastases to retroperitoneal and pelvic lymph nodes: computed tomography and lymphangiography. Radiol Clin North Am 1982;20(3):511-30. http://www.ncbi.nlm.nih.gov/pubmed/7051132 Husband JE, Barrett A, Peckham MJ. Evaluation of computed tomography in the management of testicular teratoma. Br J Urol 1981;53(2):179-83. http://www.ncbi.nlm.nih.gov/pubmed/7237052 Swanson DA. Role of retroperitoneal lymphadenectomy (RLDN) when patients with nonseminomatous germ cell testicular tumours are at high risk of needing lymph node surgery plus chemotherapy, in Donohue JP (ed.). Lymph Node Surgery in Urology. International Society of Urology Reports. Oxford: Isis Medical Media, 1995, pp. 133-140. Ellis JH, Blies JR, Kopecky KK, Klatte EC, Rowland RG, Donohue JP. Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma. J Comput Assist Tomogr 1984;8(4):709-9. http://www.ncbi.nlm.nih.gov/pubmed/6539790 See WA, Hoxie L. Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol 1993;150(3):874-8. http://www.ncbi.nlm.nih.gov/pubmed/8345604 Cremerius U, Wildberger JE, Borchers H, Zimny M, Jakse G, Gunther RW, Buell U. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?– Results of a study in 50 patients. Urology 1999;54(5):900-4. http://www.ncbi.nlm.nih.gov/pubmed/10565755 Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumours. Urology 1999;53(4):808-11. http://www.ncbi.nlm.nih.gov/pubmed/10197862 De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22(6):1034-9. http://www.ncbi.nlm.nih.gov/pubmed/15020605 Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int, 2002;89(6):549-56. http://www.ncbi.nlm.nih.gov/pubmed/11942962 Sobin LH, Wittekind C (eds). TNM classification of malignant tumours. 6th edn. UICC/Wiley, 2002. http://www.wiley.com/ Zagars GK. Management of stage I seminoma: radiotherapy, in Horwich A (ed.). Testicular Cancer: Investigation and Management. London: Chapman & Hall Medical, 1999, p. 99. Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, Fossa SD, Paus E. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of preand postorchidectomy serum tumour marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol 1990;1(4): 281-8. http://www.ncbi.nlm.nih.gov/pubmed/1702312 International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15(2):594-603. http://www.ncbi.nlm.nih.gov/pubmed/9053482 Bokemeyer C, Schmoll HJ. Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J Cancer Res Clin Oncol 1996;122:575-84. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M; German Testicular Cancer Study Group. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumours: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003;21(8):1505-12. http://www.ncbi.nlm.nih.gov/pubmed/12697874 Petersen PM, Giwercman A, Skakkebaek NE, Rorth M. Gonadal function in men with testicular cancer. Semin Oncol 1998;25(2):224-33. http://www.ncbi.nlm.nih.gov/pubmed/9562456
Limited update march 2009
33
79.
80.
81.
82.
83.
84.
85.
86. 87.
88.
89.
90.
91.
92.
93. 94.
95.
34
De Santis M, Albrecht W, Holtl W, Pont J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 1999;83(6):864-5. http://www.ncbi.nlm.nih.gov/pubmed/10597213 Jacobsen KD, Fossa SD, Bjoro TP, Aass N, Heilo A, Stenwig AE. Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. Eur Urol 2002;42(3):229-38. http://www.ncbi.nlm.nih.gov/pubmed/12234507 Kliesch S, Behre HM, Jurgens H, Nieschlag E. Cryopreservation of semen from adolescent patients with malignancies. Med Pediatr Oncol 1996;26(1):20-7. http://www.ncbi.nlm.nih.gov/pubmed/7494508 Giwercman A, von der Maase H, Rorth M, Skakkebaek NE. Semen quality in testicular tumour and CIS in the contralateral testis. Lancet 1993;341(8841):384-5. http://www.ncbi.nlm.nih.gov/pubmed/8094162 Kliesch S, Bergmann M, Hertle L, Nieschlag E, Behre HM. Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. Hum Reprod 1997;12(12):2830-35. http://www.ncbi.nlm.nih.gov/pubmed/9455863 Spermon JR, Kiemeney LA, Meuleman EJ, Ramos L, Wetzels AM, Witjes JA. Fertility in men with testicular germ cell tumours. Fertil Steril 2003;79(Suppl 3):1543-9. http://www.ncbi.nlm.nih.gov/pubmed/12801557 Nieschlag E, Behre HM. Pharmacology and clinical use of testosterone, in Nieschlag E, Behre HM (eds). Testosterone-Action, Deficiency, Substitution. Berlin–Heidelberg-New York: Springer, 1999, pp. 92-114. Sternberg CN. The management of stage I testis cancer. Urol Clin North Am 1998 Aug;25(3):435-49. http://www.ncbi.nlm.nih.gov/pubmed/9728213 Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007;64(3):182-97. http://www.ncbi.nlm.nih.gov/pubmed/17644403 Chung P, Parker C, panzarella T, Gospodarowicz MK, Jewett S, Milosevic MF, Catton CN, Bayley AJ, Tew-George B, Moore M, Sturgeon JF, Warde P. Surveillance in stage I testicular seminoma-risk of late relapse. Can J Urol 2002;9(5):1637-40. http://www.ncbi.nlm.nih.gov/pubmed/12431325 Warde P, Jewett MAS. Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 1998;25(3):425-33. http://www.ncbi.nlm.nih.gov/pubmed/9728212 Aparicio J, Garcia del Muro X, Maroto P, Paz-Ares L, Alba E, Saenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sanchez M, Fernandez A, Sastre J, Carles J, Dorca J, Guma J, Yuste AL, Germa JR; Spanish Germ Cell Cancer Cooperative Group (GG). Multicenter study evaluating a dual policy of postorchidectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003;14(6):867-72. http://www.ncbi.nlm.nih.gov/pubmed/12796024 Sharda N, Kinsella T, Ritter M. Adjuvant radiation versus observation: a cost analysis of alternate management schemes in earlystage testicular seminoma. J Clin Oncol 1996;14(11):2933-9. http://www.ncbi.nlm.nih.gov/pubmed/8918490 Francis R, Bower M, Brunstrom G, Holden L, Newlands ES, Rustin GJS, Seckl MJ. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 2000;36(15):1925-32. http://www.ncbi.nlm.nih.gov/pubmed/11000572 Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M, Jewett M. Issues in the management of stage I testicular seminoma. Int J Radiat Oncol Biol Phys 1997;39:S156. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP; MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005;23-29;366(9482):293-300. http://www.ncbi.nlm.nih.gov/pubmed/16039331 Aparicio J, Germà JR, García del Muro X, Maroto P, Arranz JA, Sáenz A, Barnadas A, Dorca J, Gumà J, Olmos D, Bastús R, Carles J, Almenar D, Sánchez M, Paz-Ares L, Satrústegui JJ, Mellado B, Balil A, López-Brea M, Sánchez A; The Second Spanish Germ Cell Cancer Cooperative Group. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005;23(34):8717-23. http://www.ncbi.nlm.nih.gov/pubmed/16260698
Limited update march 2009
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
Schoffski P, Höhn N, Kowalski R, Classen J, Meisner C, Fechner G, Dieckmann K, Winkler C, Bamberg M. Health-related quality of life (QoL) in patients with seminoma stage I treated with either adjuvant radiotherapy (RT) or two cycles of carboplatinum chemotherapy (CT): Results of a randomized phase III trial of the German Interdisciplinary Working Party on Testicular Cancer. ASCO Annual Meeting Proceedings. Part 1. J Clin Oncol 2007;25(Suppl 18S):5050. http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d /?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_ view&confID=47&abstractID=32158 Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reed NS, Widmer B, Stenning SP. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999;17(4):1146. http://www.ncbi.nlm.nih.gov/pubmed/10561173 Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Naylor S, Tenning SP. A randomized trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE 18). Eur J Cancer 2001;37(Suppl 6):S157, abstr 572. Melchior D, Hammer P, Fimmers R, Schuller H, Albers P. Long term results and morbidity of paraaortic compared with paraaortic and iliac adjuvant radiation in clinical stage I seminoma. Anticancer Res 2001;21(4B):2989-93. http://www.ncbi.nlm.nih.gov/pubmed/11712799 Livsey JE, Taylor B, Mobarek N, Cooper RA, Carrington B, Logue PJ. Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for followup. Clin Oncol (R Coll Radiol) 2001;13(4):296-300. http://www.ncbi.nlm.nih.gov/pubmed/11554630 Van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, Delemarre JF, Somers R. Second cancer risk following testicular cancer: a follow-up study of 1909 patients. Clin Oncol 1993;11(3):415-24. http://www.ncbi.nlm.nih.gov/pubmed/8445415 Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF Jr, Boice JD Jr. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89(19):1429-39. http://www.ncbi.nlm.nih.gov/pubmed/9326912 Horwich A, Bell J. Mortality and cancer incidence following treatment for seminoma of the testis. Radiother Oncol 1994;30(3):193-8. http://www.ncbi.nlm.nih.gov/pubmed/8209001 Bieri S, Rouzaud M, Miralbell R. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol 1999;50(3):349-53. http://www.ncbi.nlm.nih.gov/pubmed/10392822 Warszawski N, Schmucking M. Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scan J Urol Nephrol 1997;31(4):335-9. http://www.ncbi.nlm.nih.gov/pubmed/9290165 Heidenreich A, Albers P, Hartmann M, Kliesch S, Kohrmann KU, Krege S, Lossin P, Weissbach L; German Testicular Cancer Study Group. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumours of the testis: experience of the German Testicular Cancer Study Group. J Urol 2003;169(5):1710-4. http://www.ncbi.nlm.nih.gov/pubmed/12686815 Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G, Newlands ES, Williams CJ. Histopathology in the prediction of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987;2(8554):294-8. http://www.ncbi.nlm.nih.gov/pubmed/2886764 Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992;10(11):1762-8. http://www.ncbi.nlm.nih.gov/pubmed/1403057 Colls BM, Harvey VJ, Skelton L, Frampton CM, Thompson PI, Bennett M, Perez DJ, Dady PJ, Forgeson GV, Kennedy IC. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years’ experience in a national study in New Zealand. Br J Urol Int 1999;83(1):76-82. http://www.ncbi.nlm.nih.gov/pubmed/10233456
Limited update march 2009
35
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
36
Oliver RT, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sizer B, Levay J, Robinson A, Neal DE, Williams M; Anglian Germ Cell Cancer Group. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004;63(3):556-61. http://www.ncbi.nlm.nih.gov/pubmed/15028457 Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, Persson BE, Cavallin-Stahl E, Fossa SD, Wahlqvist L. Prognostic factors in clinical stage I nonseminomatous germ cell tumours of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 1990;8(3):509-18. http://www.ncbi.nlm.nih.gov/pubmed/1689773 Kakiashvili D, Anson-Cartwright L, Sturgeon JF, Warde PR, Chung P, Moore M, Wang L, Azuero J, Jewett MA. Non risk-adapted surveillance management for clinical stage I nonseminomatous testis tumors. J Urol 2007;177:278 (abstr 835). Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, Harland SJ, Williams MV, Jakes R. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumours of the testis: a Medical Research Council report. J Clin Oncol 1996;14(4):1106-13. http://www.ncbi.nlm.nih.gov/pubmed/8648364 Oliver RTD, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. J Urol 1992;148(5):1453-6. http://www.ncbi.nlm.nih.gov/pubmed/1279211 Studer UE, Fey MF, Calderoni A. Adjuvant chemotherapy after orchidectomy in high risk patients with clinical stage I nonseminomatous testicular cancer. Eur Urol 1993;23(4):444-9. http://www.ncbi.nlm.nih.gov/pubmed/7687549 Bohlen D, Borner M, Sonntag RW, Fey MF, Studer UE. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumours with high risk factors. J Urol 1999;161(4):1148-52. http://www.ncbi.nlm.nih.gov/pubmed/10081858 Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W. Adjuvant chemotherapy for high risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14(2):441-8. http://www.ncbi.nlm.nih.gov/pubmed/8636755 Chevreau C, Mazerolles C, Soulié M, Gaspard MH, Mourey L, Bujan L, Plante P, Rischmann P, Bachaud JM, Malavaud B. Long-term efficacy of two cycles of PEB regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 2004;46(2):209-14. http://www.ncbi.nlm.nih.gov/pubmed/15245815 Bohlen D, Burkhard FC, Mills R, Sonntag RW, Studer UE. Fertility and sexual function following orchidectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 2001;165(2):441-4. http://www.ncbi.nlm.nih.gov/pubmed/11176393 Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13(5):1170-6. http://www.ncbi.nlm.nih.gov/pubmed/7537800 Baniel J, Roth BJ, Foster RS, Donohue JP. Cost and risk benefit considerations in the management of clinical stage I nonseminomatous testicular tumours. Ann Surg Oncol 1996;3(1):86-93. http://www.ncbi.nlm.nih.gov/pubmed/8770308 Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA, Sokal MP, Joffe JK, Harland SJ, Kirk SJ; National Cancer Research Institute Testis Cancer Clinical Studies Group. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007;25(11):1310-5. http://www.ncbi.nlm.nih.gov/pubmed/17416851 Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J,Nilsson S, Daehlin L, Tornblom M, Smaland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Stahl E. Riskadapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 1997;33(7):1038-44. http://www.ncbi.nlm.nih.gov/pubmed/9376184 Ondrus D, Matoska J, Belan V. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumours: rationale for different risk-adapted treatment. Eur Urol 1998;33(6):562-6. http://www.ncbi.nlm.nih.gov/pubmed/9743698
Limited update march 2009
125.
126.
127.
128.
129.
130.
131.
132.
133. 134.
135.
136.
137.
138.
139.
140.
141.
Maroto P, García del Muro X, Aparicio J, Paz-Ares L, Arranz JA, Guma J, Terrassa J, Barnadas J, Dorta J, Germà-Lluch JR. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol 2005;16(12):1915-20. http://www.ncbi.nlm.nih.gov/pubmed/16126737 Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Ståhl E, Solberg A, Langberg C, Bremnes R, Lauerell A, Wijkström H, Klepp O: Risk-adapted treatment in clinical stage 1 (CS1), nonseminomatous germ cell testicular cancer (NSGCT), the SWENOTECA management program. JCO in press. Spermon JR, Roeleveld TA, van der Poel HG, Hulsbergen-van de Kaa CA, Ten Bokkel-Huinink WW, van de Vijver M, Witjes JA, Horenblas S. Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumours. Urology 2002;59(6):923-9. http://www.ncbi.nlm.nih.gov/pubmed/12031382 Hendry WF, Norman A, Nicholls J, Dearnaley DP, Peckham MJ, Horwich A. Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int 2000;86(1):89-93. http://www.ncbi.nlm.nih.gov/pubmed/10886090 Pizzocaro G, Salvioni R, Zanoni F. Unilateral lymphadenectomy in intraoperative stage I nonseminomatous testis cancer. J Urol 1985;134(3):485-9. http://www.ncbi.nlm.nih.gov/pubmed/2993672 Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965-1989): modifications of technique and impact on ejaculation. J Urol 1993;149(2):237-43. http://www.ncbi.nlm.nih.gov/pubmed/8381190 Lashley DB, Lowe BA. A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 1998;25(3):405-23. http://www.ncbi.nlm.nih.gov/pubmed/9728211 Foster RS, Roth BJ. Clinical stage I nonseminoma: surgery versus surveillance. Semin Oncol 1998;25(2):145-53. http://www.ncbi.nlm.nih.gov/pubmed/9562447 Kratzik C, Holtl W, Albrecht W et al. Risk adapted management for NSGCT stage I: long-term results of a multicenter study. J Urol 1996;155:547A. Ondrus D, Goncalves F, Kausitz J, Mat’oska J, Belan V. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumours (NSGCTT). Neoplasma 1996;43(3):195-7. http://www.ncbi.nlm.nih.gov/pubmed/8841507 Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Clinical stage B nonseminomatous germ cell testis cancer: the Indiana University experience using routine primary retroperitoneal lymph node dissection. Eur J Cancer 1995;31A(10):1599-604. http://www.ncbi.nlm.nih.gov/pubmed/7488408 Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage 1B testicular cancer? J Clin Oncol 1991;9(8):1393-8. http://www.ncbi.nlm.nih.gov/pubmed/2072143 Pizzocaro G, Monfardini S. No adjuvant chemotherapy in selected patients with pathological stage II nonseminomatous germ cell tumours of the testis. J Urol 1984;131(4):677-80. http://www.ncbi.nlm.nih.gov/pubmed/6200611 Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317(23):1433-8. http://www.ncbi.nlm.nih.gov/pubmed/2446132 Bianci G, Beltrami P, Giusti G. Unilateral laparoscopic lymph node dissection for clinical stage I nonseminomatous germ cell testicular neoplasm. Eur Urol 1998;33(2):190-4. http://www.ncbi.nlm.nih.gov/pubmed/9519363 Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 2000;37(3):251-60. http://www.ncbi.nlm.nih.gov/pubmed/10720848 Janetschek G, Hobisch A, Peschel R, Hittmair A, Bartsch G. Laparoscopic retyroperitoneal lymph node dissection for clinical stage I non-seminomatous testicular carcinoma: long-term outcome. J Urol 2000;163(6):1793-6. http://www.ncbi.nlm.nih.gov/pubmed/10799184
Limited update march 2009
37
142.
143.
144. 145.
146.
147.
148.
149.
150. 151.
152.
153.
154.
155.
156.
157.
38
LeBlanc E, Caty A, Dargent D, Querleu D, Mazeman E. Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumours of the testis with introduction of a nerve sparing technique: description and results. J Urol 2001;165(1):89-92. http://www.ncbi.nlm.nih.gov/pubmed/11125371 Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M; German Testicular Cancer Study Group. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008 Jun 20;26(18):2966-72. http://www.ncbi.nlm.nih.gov/pubmed/18458040 Pizzocaro G, Nicolai N, Salvioni R. Marker positive clinical stage I non seminomatous germ cell tumours (NSGCT) of the testis: which primary therapy? J Urol 1996;155(Suppl):328A. Davis BE, Herr HW, Fair WR, Bosl GJ. The management of patients with nonseminomatous germ cell tumours of the testis with serologic disease only after orchidectomy. J Urol 1994;152(1):111-3. http://www.ncbi.nlm.nih.gov/pubmed/7515445 International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15(2): 594-603. http://www.ncbi.nlm.nih.gov/pubmed/9053482 Garcia-del-Muro X, Maroto P, Gumà J, Sastre J, López Brea M, Arranz JA, Lainez N, Soto de Prado D, Aparicio J, Piulats JM, Pérez X, Germá-Lluch JR. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008 Nov 20;26(33):5416-21. http://www.ncbi.nlm.nih.gov/pubmed/18936476 Krege S, Boergermann C, Baschek R, Hinke A, Pottek T, Kliesch S, Dieckmann KP, Albers P, Knutzen B, Weinknecht S, Schmoll HJ, Beyer J, Ruebben H; German Testicular Cancer Study Group (GTCSG). Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 2006;17(2):276-80. http://www.ncbi.nlm.nih.gov/pubmed/16254023 Frohlich MW, Small EJ. Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol Clin North Am 1998;25(3):451-9. http://www.ncbi.nlm.nih.gov/pubmed/9728214 Baniel J, Donohue JP. Cost and risk benefit considerations in low stage (I and II) nonseminomatous testicular tumours. AUA Update Series 1997;26:50-5. Peckham MJ, Hendry WF. Clinical stage II non-seminatous germ cell testicular tumors. Results of management by primary chemotherapy. Br J Urol 1985;57(6):763-8. http://www.ncbi.nlm.nih.gov/pubmed/2417652 Logothetis CJ, Samuels ML, Selig DE, Johnson DE, Swanson DA, von Eschenbach AC. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J Urol 1985;134(6):1127–30. http://www.ncbi.nlm.nih.gov/pubmed/2414470 Horwich A, Stenning S. Initial chemotherapy for stage II testicular nonseminoma. World J Urol 1994;12(3):148–50. http://www.ncbi.nlm.nih.gov/pubmed/7951341 Weissbach L, Bussar-Maatz R, Fletchner H, Pichlmeier U, Hartmann M, Keller L. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumours. Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000;37(5):582-94. http://www.ncbi.nlm.nih.gov/pubmed/10765098 Sternberg CN. Role of primary chemotherapy in stage I and low-volume stage II nonseminomatous germ-cell testis tumours. Urol Clin North Am 1993;20(1):93-109. http://www.ncbi.nlm.nih.gov/pubmed/8382000 Horwich A, Norman A, Fisher C, Hendry WF, Nicholls J, Dearnaley DP. Primary chemotherapy for stage II nonseminomatous germ cell tumours of the testis. J Urol 1994;151(1):72-7. http://www.ncbi.nlm.nih.gov/pubmed/8254836 Donohue JP, Thornhill JA, Foster RS, Bihrle R, Rowland RG, Einhorn LH. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University Experience (1965 to 1989). J Urol 1995;153(1):85-9. http://www.ncbi.nlm.nih.gov/pubmed/7966799
Limited update march 2009
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168
169.
Motzer RJ, Sheinfeld J, Mazumdar M, Bajorin DF, Bosl GJ, Herr H, Lyn P, Vlamis V. Etoposide and cisplatin adjuvant therapy for patients with pathological stage II germ cell tumours. J Clin Oncol 1995;13(11):2700-4. http://www.ncbi.nlm.nih.gov/pubmed/7595727 Hartlapp JH, Weissbach L, Bussar-Maatz R. Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 1987;10(1):277-84. http://www.ncbi.nlm.nih.gov/pubmed/2438221 Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, von Eschenbach AC, Johnson DE, Samuels ML. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumours of the testis: a follow-up of 50 patients. J Clin Oncol 1987;5(6):906-11. http://www.ncbi.nlm.nih.gov/pubmed/2438389 Saxman S, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ-cell tumours: the Indiana University Experience. J Clin Oncol 1998;16(2):702-6. http://www.ncbi.nlm.nih.gov/pubmed/9469360 de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15(5):1837-43. http://www.ncbi.nlm.nih.gov/pubmed/9164193 Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 1997;15(5):1844-52. http://www.ncbi.nlm.nih.gov/pubmed/9164194 De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, Cook P, de Pryck L, Stenning S, Collette L. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5- day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical research Council. J Clin Oncol 2001;19(6):1629-40. http://www.ncbi.nlm.nih.gov/pubmed/11250991 Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose intensive chemotherapy. Ann Hematol 1996;72(1):1-9. http://www.ncbi.nlm.nih.gov/pubmed/8605273 Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, Ferrara J, Bosl GJ, Motzer RJ. Longterm follow-up of patients with good-risk germ cell tumours treated with etoposide and cisplatin. J Clin Oncol 1997;15(7):2553-8. http://www.ncbi.nlm.nih.gov/pubmed/9215824 Culine S, Kerbrat P, Kramar A, Théodore C, Chevreau C, Geoffrois L, Bui NB, Pény J, Caty A, Delva R, Biron P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18(5):917-24. http://www.ncbi.nlm.nih.gov/pubmed/17351252 Fossa SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, van Groeningen CJ, de Mulder PH, Stenning S, Lallemand E, de Pryck L, Collette L. Filgastrim during combination chemotherapy of patients with poor prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party. J Clin Oncol 1998;16(2):716-24. http://www.ncbi.nlm.nih.gov/pubmed/9469362 De Wit R, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Pryck L, Collette L, Sylvester R. Four cycles of PEB vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998;78(6):828-32. http://www.ncbi.nlm.nih.gov/pubmed/9743309
Limited update march 2009
39
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
40
De Witt R, Louwerens M, de Mulder PH, Verweij J, Rodenhuis S, Schornagel J. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-PEB. Int J Cancer 1999;83(6):831-3. http://www.ncbi.nlm.nih.gov/pubmed/10597204 Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumours: and Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukaemia Group B Study. J Clin Oncol 1998;16(9):1287-93. http://www.ncbi.nlm.nih.gov/pubmed/10597204 Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN Jr, Einhorn L, Mazumdar M, Bosl GJ. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007;25(3): 247-56. http://www.ncbi.nlm.nih.gov/pubmed/17235042 Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumours. J Clin Oncol 1997;15(7):2546-52. http://www.ncbi.nlm.nih.gov/pubmed/9215823 Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumours: a multivariate and matched-pair analysis. J Clin Oncol 1999;17(11):3450-6. http://www.ncbi.nlm.nih.gov/pubmed/10550141 Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004;22(19):3868-76. http://www.ncbi.nlm.nih.gov/pubmed/15302906 Gerl A, Clemm C, Lamerz R, Mann K, Wilmanns W. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer 1993;29A(7):961-5. http://www.ncbi.nlm.nih.gov/pubmed/7684597 Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ. Serum tumour markers decline is an early predictor of treatment outcome in germ cell tumour patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 1994;73(10):2520-6. http://www.ncbi.nlm.nih.gov/pubmed/7513603 Andre F, Fizazi K, Culine S, Droz J, Taupin P, Lhomme C, Terrier-Lacombe M, Theodore C. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000;36(11):1389-94. http://www.ncbi.nlm.nih.gov/pubmed/10899652 De Wit R, Collette L, Sylvester R, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Stoter G. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has and adverse prognostic significance. Br J Cancer 1998;78(10):1350-5. http://www.ncbi.nlm.nih.gov/pubmed/9823978 Zon RT, Nichols C, Einhorn LH. Management strategies and outcomes of germ cell tumour patients with very high human chorionic gonadotropin levels. J Clin Oncol 1998;16(4):1294-7. http://www.ncbi.nlm.nih.gov/pubmed/9552028 Fossa AD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 1999;80(9):1392-9. http://www.ncbi.nlm.nih.gov/pubmed/10424741 Fossa SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaalhus O. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 1987;5(7):1071-7. http://www.ncbi.nlm.nih.gov/pubmed/2439660 Herr HW, Bosl G. Residual mass after after chemotherapy for seminoma: changing concepts of management. J Urol 1987;137(6):1234-5. http://www.ncbi.nlm.nih.gov/pubmed/2438431
Limited update march 2009
184.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194. 195.
196.
197.
198.
199. 200.
Hofmockel G, Gruss A, Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int 1996;57(1):38-42. http://www.ncbi.nlm.nih.gov/pubmed/8840489 Kamat MR, Kulkarni JN, Tongoankar HB, Ravi R. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J Surg Oncol 1992;51(1):65-7. http://www.ncbi.nlm.nih.gov/pubmed/1381455 Loehrer PJ Sr, Birch R, Williams SD, Greco FA, Einhorn LH. Chemotherapy of metastatic seminoma: the SouthEastern Cancer Study Group Experience. J Clin Oncol 1987;5(8):1212-20. http://www.ncbi.nlm.nih.gov/pubmed/2442317 Motzer R, Bosl G, Heelan R, Fair W, Whitmore W, Sogani P, Herr H, Morse M. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987;5(7):1064-70. http://www.ncbi.nlm.nih.gov/pubmed/3598610 Peckham MJ, Horwich A, Hendry WF. Advanced seminoma treatment with cisplatinum based combination chemotherapy or carboplatin (JM8). Br J Cancer 1985;52(1):7-13. http://www.ncbi.nlm.nih.gov/pubmed/3893507 De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22(6):1034-9. http://www.ncbi.nlm.nih.gov/pubmed/15020605 Duchesne GM,Stenning SP, Aass N, Mead GM, Fossa SD, Oliver RT, Horwich A, Read G, Roberts IT, Rustin G, Cullen MH, Kaye SB, Harland SJ, Cook PA. Radiotherapy after chemotherapy for metastatic seminoma – a diminishing role. Eur J Cancer 1997;33(6):829-35. http://www.ncbi.nlm.nih.gov/pubmed/9291801 Bamberg M, Classen J. Stellenwert der Strahlentherapie von Residualtumouren nach Chemotherapie matastasierter Seminome. Strahlenther Onkol 1998;174(8):442-443. [Significance of radiotherapy for residual tumours following chemotherapy for metastatic seminoma] [article in German] http://www.ncbi.nlm.nih.gov/pubmed/9739390 Puc H, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V, Bajorin DF, Bosl GJ, Mencel P, Motzer RJ. Management of residual mass in advanced seminoma: results and recommendations from Memorial Sloan Kettering Cancer Center. J Clin Oncol 1996;14(2):454-60. http://www.ncbi.nlm.nih.gov/pubmed/8636757 Herr HW, Sheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencel P, Bosl GJ, Motzer RJ. Surgery for a postchemotherapy residual mass in seminoma. J Urol 1997;157(3):860-2. http://www.ncbi.nlm.nih.gov/pubmed/9072586 Mosharafa AA. Foster RS, Leibovich BC, Bihrle R, Donahue JP. Is the post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 2002;167:172, abstract 692. Kuczyk M, Machtens S, Stief C, Jonas U. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumours (GCT). Int J Cancer 1999;83(6):852-5. http://www.ncbi.nlm.nih.gov/pubmed/10597210 Fossa SD, Ous S, Lien HH, Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989;141(3):557-9. http://www.ncbi.nlm.nih.gov/pubmed/2918591 Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, Motzer RJ, Scher HI, Herr HW, Morse MJ et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumours: recommendations for patient selection. J Clin Oncol 1990;8(10):1683-94. http://www.ncbi.nlm.nih.gov/pubmed/2170590 Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG, Einhorn L, Williams S, Loehrer P. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph nodedissection after chemotherapy for testis cancer. J Urol 1987;137(6):1176-9. http://www.ncbi.nlm.nih.gov/pubmed/3035236 Richie JP. The surgical management of advanced abdominal disease. Semin Urol 1984;2(4):238-43. http://www.ncbi.nlm.nih.gov/pubmed/6505446 Stomper PC, Fung CY, Socinski MA, Jochelson MS, Garnick MB, Richie JP. Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: analysis of different CT criteria. Am J Roentgenol 1987;149(6):1187-90. http://www.ncbi.nlm.nih.gov/pubmed/2825494
Limited update march 2009
41
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.
214.
215.
216.
42
Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 2007;25(9):1033-7. http://www.ncbi.nlm.nih.gov/pubmed/17261854 Aprikian AG, Herr HW, Bajorin DF, Bosl GJ. Resection of post-chemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumours. Cancer 1994;74(4):1329-34. http://www.ncbi.nlm.nih.gov/pubmed/8055456 Herr HW. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol 1997;80(4):653-7. http://www.ncbi.nlm.nih.gov/pubmed/9352708 Hendry WF, A’Hern RP, Hetherington JW, Peckham MJ, Dearnaley DP, Horwich A. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol 1993;71(2):208-13. http://www.ncbi.nlm.nih.gov/pubmed/8384914 Wood DP, Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, Fair WR, Bosl GJ. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumours. J Urol 1992;148(6):1812-5. http://www.ncbi.nlm.nih.gov/pubmed/1331547 Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995;153(3 Pt 2):976-80. http://www.ncbi.nlm.nih.gov/pubmed/7853586 Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C. Post-chemotherapy resection of residual masses from metastatic non-seminomatous germ cell tumours. Ann Oncol 1997;8(6):531-8. http://www.ncbi.nlm.nih.gov/pubmed/9261521 Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N, Sullivan LD. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of the residual mass sufficient? Br J Urol 1998;81(2):295-300. http://www.ncbi.nlm.nih.gov/pubmed/9488075 Tekgul S, Özen HA, Celebi I, Ozgu I, Ergen A, Demircin M, Remzi D. Postchemotherapeutic surgery for metastatic testicular germ cell tumours: results of extended primary chemotherapy and limited surgery. Urology 1994;43(3):349-54. http://www.ncbi.nlm.nih.gov/pubmed/8134989 Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt Koops H, Mulders PF, Messemer JE, Ney K, Donohue JP et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumour: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13(5):1177-87. http://www.ncbi.nlm.nih.gov/pubmed/7537801 Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic nonseminomatous germ cell tumours. Eur J Cancer 1997;33(6):843-7. http://www.ncbi.nlm.nih.gov/pubmed/9291803 Stenning SP, Parkinson MC, Fisher C, Mead GN, Cook PA, Fossa SD, Horwich A, Jones WG, Newlands ES, Oliver RT, Stenwig AE, Wilkinson PM. Post-chemotherapy residual masses in germ cell tumour patients: content, clinical features and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 1998;83(7):1409-19. http://www.ncbi.nlm.nih.gov/pubmed/9762943 Weinknecht S, Hartmann M, Weissbach L. [In which marker positive germ-cell tumour patients is residual tumour resection useful?] Urologe A 1998;37(6):621-4. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/9887490 Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, Horwich A. Metastatic nonseminomatous germ cell tumours of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 2002;94(6):1668-76. http://www.ncbi.nlm.nih.gov/pubmed/11920527 Sheinfeld J. The role of adjunctive post-chemotherapy surgery for nonseminomatous germ-cell tumours: current concepts and controversies. Sem Urol Oncol 2002;20(4):262-71. http://www.ncbi.nlm.nih.gov/pubmed/12489059 Foster RS, Donohue JP. Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? Urol Clin North Am 1998;25(3):479-84. http://www.ncbi.nlm.nih.gov/pubmed/9728217
Limited update march 2009
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
227.
228.
229.
230.
Steyerberg EW, Kaiser HJ, Habbema JD. Prediction models of the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Int J Cancer 1999;83(6):856-9. http://www.ncbi.nlm.nih.gov/pubmed/10597211 Vergouwe Y, Steyerbeg EW, De Wit R, Roberts JT, Keizer HJ, Collette L, Stenning SP, Habbema JD. External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer 2003;88(6):843-7. http://www.ncbi.nlm.nih.gov/pubmed/12644820 Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahe C. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol 2001;19(10):2647-57. http://www.ncbi.nlm.nih.gov/pubmed/11352956 Besse B, Grunenwald D, Fléchon A, Caty A, Chevreau C, Culine S, Théodore C, Fizazi K. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg 2009;137(2):448-52). http://www.ncbi.nlm.nih.gov/pubmed/19185168 Fizazi K, Oldenburg J, Dunant A, Chen I, Salvioni R, Hartmann JT, De Santis M, Daugaard G, Flechon A, de Giorgi U, Tjulandin S, Schmoll HJ, Bouzy J, Fossa SD, Fromont G. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 2008;19(2):259-64. http://www.ncbi.nlm.nih.gov/pubmed/18042838 Miller KD, Loehrer PJ, Gonin R, Einhorn LH. Salvage chemotherapy with vinblastine, ifosfamide and cisplatin in recurrent seminoma. J Clin Oncol 1997;15(4):1427-31. http://www.ncbi.nlm.nih.gov/pubmed/9193335 Beyer J, Bokemeyer C, Schmoll HJ. [Salvagetherapie rezidivierter und refraktärer Hodentumouren] Onkologe 1998;4:541-546. [Salvage chemotherapy for relapsed and refractory germ cell tumours] [article in German] Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus iofosfamide plus cisplatin as initial salvagetherapy in recurrent germ cell tumour. J Clin Oncol 1998;16(7):2500-4. http://www.ncbi.nlm.nih.gov/pubmed/9667270 Beyer J, Rick O, Siegert W, Bokemeyer C. Salvage chemotherapy in relapsed germ cell tumours. World J Urol 2001;19(2):90-3. http://www.ncbi.nlm.nih.gov/pubmed/11374323 Schmoll HJ, Beyer J. Prognostic factors in metastatic germ cell tumours. Semin Oncol 1998;25(2): 174-85. http://www.ncbi.nlm.nih.gov/pubmed/9562450 Kaye SB, Mead GM, Fossa SD, Cullen M, de Wit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, de Pryck L, Lallemand E, de Mulder P. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with PEB/EP for poor prognosis metastatic germ celltumour: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16(2):692-701. http://www.ncbi.nlm.nih.gov/pubmed/9469359 Beyer J, Schmoll HJ. [Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumouren.] Onkologe 1998;4:518-523. [Prognostic factors in metastatic seminoma and nonseminoma germ-cell tumours] [article in German] Beyer J, Stenning S, Gerl A, Fossa S, Siegert W. High-dose versus conventional-dose chemotherapy as a first-salvage treatment in patients with non-seminomatous germ-cell tumours: a matched pair analysis. Ann Oncol 2002;13(4):599-605. http://www.ncbi.nlm.nih.gov/pubmed/12056711 Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols CR, Cornetta K, Einhorn LH. High-dose chemotherapy as inital salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000;18(19):3346-51. http://www.ncbi.nlm.nih.gov/pubmed/11013274
Limited update march 2009
43
231.
232.
233.
234.
235.
236.
237.
238. 239.
240.
241.
242. 243.
244.
245.
44
Rosti G, Pico JL, Wandt H et al. High-dose chemotherapy (HDC) in the salvage treatment of patients failling first-line platinum chemotherapy for advanced germ cell tumours (GCT): first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT- 94 study. Proc Ann Soc Clin Oncol 2002;21:180a, abstr 716. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, Bosl GJ, Motzer RJ. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005;23(27):6549-55. http://www.ncbi.nlm.nih.gov/pubmed/16170162 Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, Stenning SP, Mason M; MRC Testicular Tumour Working Party. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-PEB) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005;93(2):178-84. http://www.ncbi.nlm.nih.gov/pubmed/15999102 Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, Theodore C, Lelli G, Siegert W, Horwich A, Marangolo M, Linkesch W, Pizzocaro G, Schmoll HJ, Bouzy J, Droz JP, Biron P; Genito-Urinary Group of the French Federation of Cancer Centers (GETUG-FNCLCC), France; European Group for Blood and Marrow Transplantation (EBMT). A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005;16(7):1152-9. http://www.ncbi.nlm.nih.gov/pubmed/15928070 Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O; German Testicular Cancer Study Group. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007;25(19):2778-84. http://www.ncbi.nlm.nih.gov/pubmed/17602082 Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000;18(6):1173-80. http://www.ncbi.nlm.nih.gov/pubmed/10715285 Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003;21(22):4100-4. http://www.ncbi.nlm.nih.gov/pubmed/14615439 Reinhorn LH, Rajhavan D, Kindlen H. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory advanced germ cell tumours. Proc ASCO 1999;18:207A (abstr 796). Motzer JR, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl GJ. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18(12):2413-8. http://www.ncbi.nlm.nih.gov/pubmed/10856101 Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L. Gemcitabine in patients with relapse or cisplatin refractory testicular cancer. J Clin Oncol 1999;17(2):512-6. http://www.ncbi.nlm.nih.gov/pubmed/10080593 George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC, Jung SH, Shen J, Finch DE, Kelley MR, Einhorn LH. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 2003;21(1):113-22. http://www.ncbi.nlm.nih.gov/pubmed/12506179 Lipphardt ME, Albers P. Late relapse of testicular cancer. World J Urol 2004;22(1):47-54. http://www.ncbi.nlm.nih.gov/pubmed/15064970 Tiffany P, Morse MJ, Bosl G, Vaughan ED Jr, Sogani PC, Herr HW, Whitmore WF Jr. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumours. Cancer 1986;57(5):978-83. http://www.ncbi.nlm.nih.gov/pubmed/3002596 Cassidy J, Lewis CR, Kaye SB, Kirk D. The changing role of surgery in metastatic non-seminomatous germcell tumour. Br J Cancer 1992;65(1):127-9. http://www.ncbi.nlm.nih.gov/pubmed/1370759 Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER Jr, Einhorn LH, Roth BJ, Donohue JP. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumour markers after primary chemotherapy alone. Urology 1997;50(6):957-62. http://www.ncbi.nlm.nih.gov/pubmed/9426730
Limited update march 2009
246.
247.
248.
249.
250. 251.
252.
253.
254.
255.
256.
257.
258.
259.
260.
261.
262.
Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumour who fail to normalize serum tumour markers after chemotherapy. Urology 1994;43(1):74-80. http://www.ncbi.nlm.nih.gov/pubmed/7506856 Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumours after cisplatin-based chemotherapy. Ann Oncol 1997;8(1):41-7. http://www.ncbi.nlm.nih.gov/pubmed/9093706 Kisbenedek L, Bodrogi I, Szeldeli P, Baki M, Tenke P, Horti J. Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy. Int Urol Nephrol 1995;27(3):325-9. http://www.ncbi.nlm.nih.gov/pubmed/7591598 Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH. Surgical salvage of chemorefractory germ cell tumours. J Clin Oncol 1993;11(2):324-9. http://www.ncbi.nlm.nih.gov/pubmed/8381163 Nichols C. Treatment of recurrent germ cell tumours. Semin Surg Oncol 1999;17(4):268-74. http://www.ncbi.nlm.nih.gov/pubmed/10588856 Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br J Urol 1998;81(6):884-8. http://www.ncbi.nlm.nih.gov/pubmed/9666776 Albers P, Ganz A, Hanning E, Miersch WD, Muller SC. Salvage surgery of chemorefractory germ cell tumours with elevated tumour markers. J Urol, 2000;164(2):381-4. http://www.ncbi.nlm.nih.gov/pubmed/10893590 Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mead GM, Germa-Luch JR, Pont J, Schmoll HJ, Tjulandin S. Treatment outcome of patients with brain metastases from malignant germ cell tumours. Cancer 1999;85(4):988-97. http://www.ncbi.nlm.nih.gov/pubmed/10091779 Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 1997;15(4):1449-54. http://www.ncbi.nlm.nih.gov/pubmed/9193339 Hartmann JT, Bamberg M, Albers P et al. Multidiciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin. Proc Ann Soc Clin Oncol 2003;22:400, abstr 1607. Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy. J Gen Intern Med 1997;12(5):318-31. http://www.ncbi.nlm.nih.gov/pubmed/9159703 Rathmell AJ, Brand IR, Carey BM, Jones WG. Early detection of relapse after treatment for metastatic germ cell tumour of the testis: an exercise in medical audit. Clin Oncol (R Coll Radiol) 1993;5(1):34-8. http://www.ncbi.nlm.nih.gov/pubmed/7678749 Gietema JA, Meinardi MT, Sleifer DT, Hoekstra HJ, van der Graaf WT. Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol 2002;13(10): 1616-20. http://www.ncbi.nlm.nih.gov/pubmed/12377651 Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W. Adjuvant chemotherapy for high risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14(2):441-8. http://www.ncbi.nlm.nih.gov/pubmed/8636755 Bohlen D, Borner M, Sonntag RW, Fey MF, Studer UE. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumours with high risk factors. J Urol 1999;161(4):1148-52. http://www.ncbi.nlm.nih.gov/pubmed/10081858 Tjan-Heijnen VCG, Oosterhof GON, de Wit R, de Mulder PHM. Treatment of germ cell tumours: state of the art. Eur J Surg Oncol 1997;23(2):110-7. http://www.ncbi.nlm.nih.gov/pubmed/9158183 Lowe BA. Surveillance versus nerve-sparing retroperitoneal lymphadenectomy in stage I germ cell tumours. Urol Clin North Am 1993;20(1):75-83. http://www.ncbi.nlm.nih.gov/pubmed/8381999
Limited update march 2009
45
263.
264.
265.
266.
267.
268.
269.
270.
271.
272.
273.
274.
275.
276.
277.
278.
46
Gels ME, Hoekstra HJ, Sleijfer DT, Marrink J, de Bruijn HW, Molenaar WM, Freling NJ, Droste JH, Schraffordt Koops H. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumours and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995;13(5):1188-94. http://www.ncbi.nlm.nih.gov/pubmed/7537802 van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP, Horwich A, Huddart RA. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 2008:17;98(12):1894-902. http://www.ncbi.nlm.nih.gov/pubmed/18542063 McLeod DG, Weiss RB, Stablein DM, Muggia FM, Paulson DF, Ellis JH, Spaulding JT, Donohue JP. Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 1991;145(6):1178-83. http://www.ncbi.nlm.nih.gov/pubmed/1851890 Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer: review of the Indiana University Experience 1965-1989. Br J Urol 1993;71(3):326-35. http://www.ncbi.nlm.nih.gov/pubmed/8386580 Schmoll HJ, Weissbach L. [Diagnostik und Therapie von Hodentumouren.] Interdisziplinäre Konsensus-Konferenz, Halle (Saale), 1996. EBM IIa, IIb, III. [Diagnosis and therapy for germ cell tumours] [article in German] McCaffrey JA, Bajorin DF, Motzer RJ. Risk assessment for metastatic testis cancer. Urol Clin North Am 1998;25(3):389-95. http://www.ncbi.nlm.nih.gov/pubmed/9728209 Buchholz TA, Walden TL, Prestidge BR. Cost-effectiveness of post-treatment surveillance after radiation therapy for early stage seminoma. Cancer 1998;82(6):1126-33. http://www.ncbi.nlm.nih.gov/pubmed/9506359 Tana S, Cerrotta A, Gardani G, Palazzi M, Pizzocaro G. Post surgical policy in stage I testicular seminoma: cost and benefit of prophylactic irradiation in a long-term experience. Tumouri 1997;83(6):918-21. http://www.ncbi.nlm.nih.gov/pubmed/9526584 Sultanem K, Souhami L, Benk V, Bahary JP, Roman T, Shenouda G, Freeman C. Para-aortic irradiation only appears to be adequate treatment for patients with stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 1998;40(2):455-9. http://www.ncbi.nlm.nih.gov/pubmed/9457835 Kiricuta IC, Sauer J, Bohndorf W. Omission of the pelvic irradiation in stage I testicular seminoma: a study of postorchidectomy paraaortic radiotherapy. Int J Radiat Oncol Biol Phys 1996;35(2):293-8. http://www.ncbi.nlm.nih.gov/pubmed/9457835 Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF, Moore M, Goodman P, Jewett MA. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13(9):2255-62. http://www.ncbi.nlm.nih.gov/pubmed/7666083 Fossa SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989;16(2):383-8. http://www.ncbi.nlm.nih.gov/pubmed/7666083 Baniel J, Foster RS, Einhorn LH, Donohue JP. Late relapse of clinical stage I testicular cancer. J Urol 1995;154(4):1370-2. http://www.ncbi.nlm.nih.gov/pubmed/7658541 Stein ME, Leviov M, Drumea K, Moshkovitz B, Nativ O, Milstein D, Sabo E, Kuten A. Radiationinduced tumours in irradiated stage I testicular seminoma: results of a 25-year follow-up (1968-1993). J Surg Oncol 1998;67(1):38-40. http://www.ncbi.nlm.nih.gov/pubmed/9457255 Akimoto T, Takahashi I, Takahashi M, Yamakawa M, Hayakawa K, Mitsuhashi N, Niibe H. Long-term outcome of postorchidectomy radiation therapy for stage I and II testicular seminoma. Anticancer Res 1997;17(5B):3781-5. http://www.ncbi.nlm.nih.gov/pubmed/9427780 Von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M, Rorth M, Schultz H. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993;29A(14):1931-4. http://www.ncbi.nlm.nih.gov/pubmed/8280484
Limited update march 2009
279.
280.
281.
282.
283.
284.
285.
286.
287.
288.
289.
290.
291.
292.
293. 294. 295. 296.
Horwich A, Alsanjari N, A’Hern, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 1992;65(5):775-8. http://www.ncbi.nlm.nih.gov/pubmed/1586607 Germá Lluch JR, Climent MA, Villavicencio H, Gomez de Segura G, Blanco R, Mercedes A, de Andres L, Sole Balcells FJ. Treatment of stage I testicular tumours. Br J Urol 1993;71(4):473-7. http://www.ncbi.nlm.nih.gov/pubmed/8499994 Warde P, Gospodarowicz MK, Goodman PJ, Sturgeon JF, Jewett MA, Catton CN, Richmond H, Thomas GM, Duncan W, Munro AJ. Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 1993;27(1):11-5. http://www.ncbi.nlm.nih.gov/pubmed/8365931 Allhoff EP, Liedke S, de Riese W, Stief C, Schneider B. Stage I seminoma of the testis: adjuvant radiotherapy or surveillance? Br J Urol 1991;68(2):190-4. http://www.ncbi.nlm.nih.gov/pubmed/1715798 Fosså SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, Travis LB. Risk of contralateral testicular cancer: a population-based study of 29,515 US men. J Natl Cancer Inst 2005;97(14):1056- 66. http://www.ncbi.nlm.nih.gov/pubmed/1603030 Wierecky J, Kollmannsberger C, Boehlke I, Kuczyk M, Schleicher J, Schleucher N, Metzner B, Kanz L, Hartmann JT, Bokemeyer C. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol 2005;131(4):255-60. http://www.ncbi.nlm.nih.gov/pubmed/15627215 Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, van den Berg MP, Hoekstra HJ, Sluiter WJ, Gietema JA. Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur J Clin Invest 2005;35(2):99-103. http://www.ncbi.nlm.nih.gov/pubmed/15667580 Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21(8): 1513-23. http://www.ncbi.nlm.nih.gov/pubmed/12697875 van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, Schimmel EC, Aleman BM, van Leeuwen FE. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24(3):467-75. http://www.ncbi.nlm.nih.gov/pubmed/16421423 Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Svartberg J, Wilsgaard T, Bremnes RM. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007;18(2):241-8. http://www.ncbi.nlm.nih.gov/pubmed/17060482 Huddart RA, Joffe JK. Preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin Oncol (R Coll Radiol) 2006;18(9):693-5. http://www.ncbi.nlm.nih.gov/pubmed/17100155 Krege S, Kalund G, Otto T, Goepel M, Rubben H. Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 1997;31(4):405-7. http://www.ncbi.nlm.nih.gov/pubmed/9187898 Dieckmann KP, Krain J, Kuster J, Bruggeboes B. Adjuvant carboplatin treatment for seminoma clinical stage I. J Cancer Res Clin Oncol 1996;122(1):63-6. http://www.ncbi.nlm.nih.gov/pubmed/8543595 Bukowski RM. Management of advanced and extragonadal germ-cell tumours. Urol Clin North Am 1993;20(1):153-60. http://www.ncbi.nlm.nih.gov/pubmed/8381995 Fair W, Dalbagni G, Machele Donat S, Theodorescu D. Evaluation and follow-up of patients with urologic cancer. AUA Office of Education Publications 9958 PG, 1999. Pizzocaro G. Non-seminomatous germ-cell tumours (NSGCT) of the testis: diagnosis and management, stage by stage. Eur Urol Update Series 1997;6:139-45. Sheinfeld J, Bajorin DF, Solomon M. Management of postchemotherapy residual masses in advanced germ cell tumours. Urol Clin North Am 1997;3:18-23. Little JS, Foster RS, Ulbright TM, Donohue JP. Unusual neoplasms detected in testis cancer patients undergoing postchemotherapy retroperitoneal lymphadenectomy. J Urol 1994;152(4):1144-9. http://www.ncbi.nlm.nih.gov/pubmed/8072083
Limited update march 2009
47
11.2
Non-germ cell tumours
1.
Cheville JC, Sebo TJ, Lager DJ, Bostwick DG, Farrow GM. Leydig cell tumour of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumours. Am J Surg Pathol 1998;22(11):1361-7. http://www.ncbi.nlm.nih.gov/pubmed/9808128 Kim I, Young RH, Scully RE. Leydig cell tumours of the testis. A clinicopathological analysis of 40 cases and review of the literature. Am J Surg Pathol 1985;9(3):177-92. http://www.ncbi.nlm.nih.gov/pubmed/3993830 Matveev BP, Gurarii LL. [Leydig-cell tumours of the testis] Urol Nefrol (Mosk) 1997;(4):34-6. [article in Russian] http://www.ncbi.nlm.nih.gov/pubmed/9381620 Young RH, Koelliker DD, Scully RE. Sertoli cell tumours of the testis, not otherwise specified: a clinicopathologic analysis of 60 cases. Am J Surg Pathol 1998;22(6):709-21. http://www.ncbi.nlm.nih.gov/pubmed/9630178 Proppe KH, Scully RE. Large-cell calcifying Sertoli cell tumour of the testis. Am J Clin Pathol 1980;74(5):607-19. http://www.ncbi.nlm.nih.gov/pubmed/7446466 Zukerberg LR, Young RH, Scully RE. Sclerosing Sertoli cell tumour of the testis. A report of 10 cases. Am J Surg Pathol 1991;15(9):829-34. http://www.ncbi.nlm.nih.gov/pubmed/1719830 WHO histological classification of testis tumours, In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds). Pathology & Genetics. Tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004: 218, pp. 250-262. Ulbright TM, Amin MB, Young RH. Tumours of the testis, adnexia, spermatic cord and scrotum. AFIP1999. Cheville JC, Sebo TJ, Lager DJ, Bostwick DG, Farrow GM. Leydig cell tumour of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of non-metastasizing and metastasizing tumours. Am J Surg Pathol 1998;22(11):1361-7. http://www.ncbi.nlm.nih.gov/pubmed/9808128 McCluggage WG, Shanks JH, Arthur K, Banerjee SS. Cellular proliferation and nuclear ploidy assessments augment established prognostic factors in predicting malignancy in testicular Leydig cell tumours. Histopathology 1998;33(4):361-8. http://www.ncbi.nlm.nih.gov/pubmed/9822927 Mineur P, de Cooman S, Hustin J, Verhoeven G, de Hertogh E. Feminizing testicular Leydig cell tumour: hormonal profile before and after unilateral orchidectomy. J Clin Endocrinol Metab 1987;64(4):686-91. http://www.ncbi.nlm.nih.gov/pubmed/3818898 Reznik Y, Rieu M, Kuhn JM, Mandard JC, Bottet P, Lemonnier D, Bekka S, Mahoudeau J. Luteinizing hormone regulation by sex steroids in men with germinal and Leydig cell tumours. Clin Endocrinol (Oxf) 1993;38(5):487-93. http://www.ncbi.nlm.nih.gov/pubmed/8392454 Bercovici JP, Nahoul K, Tater D, Charles JF, Scholler R. Hormonal profile of Leydig cell tumours with gynecomastia. J Clin Endocrinol Metab 1984;59(4):625-30. http://www.ncbi.nlm.nih.gov/pubmed/6434575 Haas GP, Pittaluga S, Gomella L, Travis WD, Sherins RJ, Doppman JL, Linehan WL, Robertson C. Clinical occult Leydig cell tumour presenting with gynecomastia. J Urol 1989;142(5):1325-7. http://www.ncbi.nlm.nih.gov/pubmed/2810523 Ruthgers JL, Young RH, Scully RE. The testicular ‘tumour’ of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol 1988;12(7):503-13. http://www.ncbi.nlm.nih.gov/pubmed/3291624 Maizlin ZV, Belenky A, Kunichezky M, Sandbank J, Strauss S. Leydig cell tumours of the testis: gray scale and color Doppler sonographic appearance. J Ultrasound Med 2004;23(7):959-64. http://www.ncbi.nlm.nih.gov/pubmed/15292565 Ponce de Leon Roca J, Algaba Arrea F, Bassas Arnau L, Villavicencio Mavrich H. [Leydig-cell tumours of the testis] Arch Esp Urol 2000;53(6):453-8. [article in Spanish] http://www.ncbi.nlm.nih.gov/pubmed/11002512 Wegner HE, Dieckmann KP, Herbst H, Andresen R, Miller K. Leydig cell tumour–comparison of results of radical and testis sparing surgery in a single center. Urol Int 1997;59(3):170-3. http://www.ncbi.nlm.nih.gov/pubmed/9428434
2.
3.
4.
5.
6.
7.
8. 9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
48
Limited update march 2009
19.
20.
21. 22.
23. 24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34. 35.
Mosharafa AA, Foster RS, Bihrle R, Koch MO, Ulbright TM, Einhorn LH, Donohue JP. Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumours? Cancer 2003;98(4):753-7. http://www.ncbi.nlm.nih.gov/pubmed/9428434 Giglio M, Medica M, De Rose AF, Germinale F, Ravetti JL, Carmignani G. Testicular Sertoli cell tumours and relative sub-types. Analysis of clinical and prognostic features. Urol Int 2003;70(3): 205-10. http://www.ncbi.nlm.nih.gov/pubmed/12660458 Jacobsen GK. Malignant Sertoli cell tumours of the testis. J Urol Pathol 1993;1:233-55. Kratzer SS, Ulbright TM, Talerman A, Srigley JR, Roth LM, Wahle GR, Moussa M, Stephens JK, Millos A, Young RH. Large cell calcifying Sertoli cell tumour of the testis: contrasting features of six malignant and six benign tumours and a review of the literature. Am J Surg Pathol 1997;21(11): 1271-80. http://www.ncbi.nlm.nih.gov/pubmed/9351565 Henley JD, Young RH, Ulbright TM. Malignant Sertoli cell tumours of the testis: a study of 13 examples of a neoplasm frequently misinterpreted as seminoma. Am J Surg Pathol 2002;26:541-50. Plata C, Algaba F, Andujar M, Nistal M, Stocks P, Martinez JL, Nogales FF. Large cell calcifying Sertoli cell tumour of the testis. Histopathology 1995;26(3):255-9. http://www.ncbi.nlm.nih.gov/pubmed/7541015 Anderson GA. Sclerosing Sertoli cell tumour of the testis: a distinct histological subtype. J Urol 1995;154(5):1756-8. Review. http://www.ncbi.nlm.nih.gov/pubmed/7563340 Grabrilove JL, Freiberg EK, Leiter E, Nicolis GL. Feminizing and non-feminizing Sertoli cell tumour. J Urol 1980;124(6):757-67. http://www.ncbi.nlm.nih.gov/pubmed/7003168 Gierke CL, King BF, Bostwick DG, Choyke PL, Hattery RR. Large-cell calcifying Sertoli cell tumour of the testis: appearance at sonography. AJR Am J Roentgenol 1994;163(2):373-5. http://www.ncbi.nlm.nih.gov/pubmed/8037034 Chang B, Borer JG, Tan PE, Diamond DA. Large-cell calcifying Sertoli cell tumour of the testis: case report and review of the literature. Urology 1998;52(3):520-2. http://www.ncbi.nlm.nih.gov/pubmed/9730477 Washecka R, Dresner MI, Honda SA. Testicular tumours in Carney’s complex. J Urol 2002;167(3):1299-302. http://www.ncbi.nlm.nih.gov/pubmed/11832717 Young S, Gooneratne S, Straus FH, Zeller WP, Bulun SE, Rosenthal IM. Feminizing Sertoli cell tumours in boys with Peutz-Jeghers syndrome. Am J Surg Pathol 1995;19(1):50-8. http://www.ncbi.nlm.nih.gov/pubmed/7802138 Kaplan GW, Cromie WJ, Kelalis PP, Silber I, Tank ES Jr. Gonadal stromal tumours: a report of theprepuberal testicular tumours registry. J Urol 1986;136(1Pt2):300-2. http://www.ncbi.nlm.nih.gov/pubmed/3723681 Al-Bozom IA, El-Faqih SR, Hassan SH, El-Tiraifi AE, Talic RF. Granulosa cell tumour of the adult type. A case report and review of the literature of a very rare testicular tumour. Arch Pathol Lab Med 2000;124(10):1525-8. http://www.ncbi.nlm.nih.gov/pubmed/11035589 Perito PE, Ciancio G, Civantos F, Politano VA. Sertoli-Leydig cell testicular tumour. case report and review of sex cord/gonadal stromal tumour histogenesis. J Urol 1992;148(3):883-5. http://www.ncbi.nlm.nih.gov/pubmed/1512847 Scully RE. Gonadoblastoma. A review of 74 cases. Cancer 1970;25(6):1340-56. http://www.ncbi.nlm.nih.gov/pubmed/4193741 Ulbright TM, Srigley JR, Reuter VE, Wojno K, Roth LM, Young RH. Sex-cord-stromal tumours of the testis with entrapped germ cells: a lesion mimicking unclassified mixed germ cell sex cord-stromal tumours. Am J Surg Pathol 2000;24(4):535-42. http://www.ncbi.nlm.nih.gov/pubmed/10757400
Limited update march 2009
49
12. ABBREVIATIONS USED IN THE TEXT
This list is not comprehensive for the most common abbreviations.
AFP AUC hCG Cg A CI CS CT EAU EBM EP EORTC FDG-PET FSH GI G-CSF GR HPF IGCCCG LE LH LDH MRC MRI NSGCT PA PEB PEI PET PFS PS PLAP PVB RPLND SWENOTECA Tin TIP TNM UICC ULN VelP WHO VIP (VP-16)
alpha-fetoprotein area under curve human chorionic gonadotrophin chromogranine A confidence interval clinical stage computed tomography European Association of Urology evidence-based medicine etoposide, cisplatin European Organisation for Research and Treatment of Cancer fluorodeoxyglucose-positron emission tomography follicle-stimulating hormone gastrointestinal granulocyte colony-stimulating factor grade of recommendation high-power field International Germ Cell Cancer Collaborative Group level of evidence luteinising hormone lactate dehydrogenase Medical Research Council magnetic resonance imaging non-seminomatous germ cell tumour para-aortic cisplatin, etoposide, bleomycin cisplatin, etoposide, ifosfamide positron emission tomography progression-free survival pathological stage placental alkaline phosphatase cisplatin, vinblastine, bleomycin retroperitoneal lymph node dissection Swedish-Norwegian Testicular Cancer Project carcinoma in situ pathological definition: undifferentiated intratubular germ cell carcinoma paclitaxel, ifosfamide, cisplatin Tumour Node Metastasis International Union Against Cancer upper limit of normal vinblastine, ifosfamide, cisplatin World Health Organization etoposide, ifosfamide, cisplatin
Conflict of interest All members of the Testicular Cancer Guidelines writing panel have provided disclosure statements on all relationships that they have and that might be perceived to be a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
50
Limited update march 2009
Guidelines on
Benign Prostatic Hyperplasia J. de la Rosette, G. Alivizatos, S. Madersbacher, C. Rioja Sanz, J. Nordling, M. Emberton, S. Gravas, M.C. Michel, M. Oelke
© European Association of Urology 2009
TABLE OF CONTENTS 1. Background 1.1 Prevalence 1.2 Is BPH a progressive disorder? 1.2.1 Indicators of progression 1.2.2 Conclusions 1.2.3 References
page 5 5 5 6 7 7
2. RISK FACTORS 2.1 For developing the disease 2.2 For surgical treatment 2.3 References
9 9 9 10
3. ASSESSMENT 3.1 Symptom scores 3.1.1 International Prostate Symptom Score (I-PPS) 3.1.2 Quality-of-life assessment 3.1.3 Symptom score as decision tool for treatment 3.1.4 Symptom score as outcome predictor 3.1.5 Conclusions 3.1.6 Recommendations 3.1.7 References 3.2 Prostate specific antigen (PSA) measurement 3.2.1 Factors influencing the serum levels of PSA 3.2.2 PSA and prediction of prostatic volume 3.2.3 PSA and probability of having prostate cancer 3.2.4 PSA and prediction of BPH-related outcomes 3.2.5 Conclusions 3.2.6 Recommendation 3.2.7 References 3.3 Creatinine measurement 3.3.1 Conclusions 3.3.2 References 3.4 Urinalysis 3.4.1 Recommendation 3.5 Digital rectal examination (DRE) 3.5.1 DRE and cancer detection 3.5.2 DRE and prostate size evaluation 3.5.3 Conclusions and recommendations 3.5.4 References 3.6 Imaging of the urinary tract 3.6.1 Upper urinary tract 3.6.2 Lower urinary tract 3.6.3 Urethra 3.6.4 Prostate 3.6.5 References 3.7 Voiding charts (diaries) 3.7.1 Conclusions 3.7.2 References 3.8 Uroflowmetry 3.8.1 References 3.9 Post-void residual volume (PVR) 3.10 Urodynamic studies 3.10.1 Outcome 3.10.2 Conclusions 3.10.3 References 3.11 Endoscopy 3.11.1 LUTS caused by bladder outlet obstruction 3.11.2 Morbidity of urethrocystoscopy
10 11 11 11 11 11 12 12 12 12 12 12 12 12 12 13 13 14 14 14 15 15 15 15 16 16 16 17 17 18 18 18 18 20 20 20 20 21 21 21 21 22 22 23 23 23
2
UPDATE MARCH 2004
3.11.3 Relationship between trabeculation and peak flow rate 3.11.4 Relationship between trabeculation and symptoms 3.11.5 Relationship between trabeculation and prostate size 3.11.6 Relationship between trabeculation and obstruction 3.11.7 Bladder diverticula and obstruction 3.11.8 Bladder stones and obstruction 3.11.9 Intravesical pathology 3.11.10 Conclusions 3.11.11 References 3.12 Recommendations for assessment
23 23 23 23 24 24 24 24 24 25
4. TREATMENT 4.1 Watchful waiting (WW) 4.1.1 Patient selection 4.1.2 Education, reassurance and periodic monitoring 4.1.3 Lifestyle advice 4.1.4 Conclusions 4.1.5 References 4.2 Medical treatment 4.2.1 5-Alpha reductase inhibitors 4.2.1.1 Finasteride (type 2, 5-Alpha reductase inhibitor) 4.2.1.1.1 Efficacy and clinical endpoints 4.2.1.1.2 Haematuria and finasteride 4.2.1.1.3 Side-effects 4.2.1.1.4 Effect on PSA 4.2.1.2 Dutasteride 4.2.1.3 Combination therapy 4.2.1.4 Conclusions 4.2.1.5 References 4.2.2 Alpha-blockers 4.2.2.1 Uroselectivity 4.2.2.2 Mechanism of action 4.2.2.3 Pharmacokinetics 4.2.2.4 Assessment 4.2.2.5 Clinical efficacy 4.2.2.6 Durability 4.2.2.7 Adverse effects 4.2.2.8 Acute urinary retention 4.2.2.9 Conclusions 4.2.2.10 References 4.2.3 Phytotherapeutic agents 4.2.3.1 Conclusions 4.2.3.2 References 4.3 Surgical management 4.3.1 Indications for surgery 4.3.2 Choice of surgical technique 4.3.3 Perioperative antibiotics 4.3.4 Treatment outcome 4.3.5 Complications 4.3.6 Long-term outcome 4.3.7 Conclusions and recommendations 4.3.8 References 4.4 Lasers 4.4.1 Laser types 4.4.2 Right-angle fibres 4.4.3 Interstitial Laser Coagulation (ILC) 4.4.4 Holmium laser resection of the prostate (HoLRP) 4.4.5 Conclusions 4.4.6 References
26 26 26 26 27 27 27 28 28 28 28 28 28 29 29 29 29 30 32 32 32 33 33 33 33 33 33 33 34 34 34 35 35 35 35 36 36 36 36 37 37 38 38 38 39 40 41 41
UPDATE MARCH 2004
3
4.5 Transrectal high-intensity focused ultrasound (HIFU) 4.5.1 Assessment 4.5.2 Procedure 4.5.3 Morbidity/complications 4.5.4 Outcome 4.5.5 Urodynamics 4.5.6 Quality of life and sexual function 4.5.7 Durability 4.5.8 Patient selection 4.5.9 Conclusions 4.5.10 References 4.6 Transurethral needle ablation (TUNA®) 4.6.1 Assessment 4.6.2 Procedure 4.6.3 Morbidity/complications 4.6.4 Outcome 4.6.5 Randomized clinical trials 4.6.6 Impact on bladder outflow obstruction 4.6.7 Durability 4.6.8 Patient selection 4.6.9 Conclusions 4.6.10 References 4.7 Transurethral microwave therapy (TUMT) 4.7.1 Assessment 4.7.2 Procedure 4.7.3 The microwave thermotherapy principle 4.7.4 Morbidity 4.7.5 High-intensity-dose-protocol 4.7.6 Prostatic temperature feedback treatment 4.7.7 Durability 4.7.8 Patient selection 4.7.9 Conclusions 4.7.10 References 4.8 Recommendations for treatment
43 43 43 43 44 44 44 44 44 45 45 46 46 46 46 46 46 46 46 46 46 47 47 47 47 48 48 49 49 49 49 49 49 50
5.
FOLLOW-UP 5.1 Watchful waiting 5.2 Alpha-blocker therapy 5.3 5-Alpha-reductase inhibitors 5.4 Surgical management 5.5 Alternative therapies
52 52 52 52 52 52
6. ABBREVIATIONS USED IN THE TEXT
53
4
UPDATE MARCH 2004
1. BACKGROUND Benign prostatic hyperplasia (BPH) is a condition intimately related to ageing (1). Although it is not lifethreatening, its clinical manifestation as lower urinary tract symptoms (LUTS) reduces the patient’s quality of life (2). Troublesome LUTS can occur in up to 30% of men older than 65 years (3).
1.1 Prevalence Although many epidemiological clinical studies have been conducted worldwide over the last 20 years, the prevalence of clinical BPH remains difficult to determine. A standardized clinical definition of BPH is lacking, which makes it intrinsically difficult to perform adequate epidemiological studies. Among the published epidemiological studies, some include probability samples from an entire country, while others represent agestratified random samples or enroll participants from general practice, hospital populations or responders to selective screening programmes. There is also a lack of homogeneity among these studies in the way in which BPH is assessed, with different questionnaires and methods of administration. Barry et al. have provided the histological prevalence of BPH, based on a review of five studies relating age to histological findings in human male prostate glands (4). Histological BPH was not found in men under the age of 30 years but its incidence rose with age, reaching a peak in the ninth decade. At that age, BPH was found in 88% of histological samples (4). A palpable enlargement of the prostate has been found in up to 20% of males in their 60s and in 43% in their 80s (5); however, prostate enlargement is not always related to clinical symptoms (2). Clinical BPH is a highly prevalent disease. By the age of 60 years, nearly 60% of the cohort of the Baltimore Longitudinal Study of Aging had some degree of clinical BPH (6). In the USA, results of the Olmstead County survey, in a sample of unselected Caucasian men aged 40-79 years, showed that moderate-to-severe symptoms can occur among 13% of men aged 40-49 years and among 28% of those older than 70 years (1). In Canada, 23% of the cohort studied presented with moderate-to-severe symptoms (7). The findings for prevalence of LUTS in Europe are similar to those in the USA. In Scotland and in the area of Maastricht, the Netherlands, the prevalence of symptoms increased from 14% of men in their 40s to 43% in their 60s (8,9). Depending on the sample, the prevalence of moderate-to-severe symptoms varies from 14% in France to 30% in the Netherlands (10,11). The proportion of men with moderate-to-severe symptoms doubles with each decade of life (10). Preliminary results of one of the most recent European epidemiological studies on the prevalence of LUTS show that approximately 30% of German males aged 50-80 years present with moderateto-severe symptoms according to the International Prostate Symptom Score (i.e. I-PSS > 7) (12). A multicentre study performed in different countries in Asia showed that the age-specific percentages of men with moderate-to-severe symptoms were higher than those in America (13,14). The prevalence increases from 18% for men in their 40s to 56% for those in their 70s (13). Curiously, the average weight of Japanese glands seemed to be smaller than those of their American counterparts (15). Despite methodological differences, some conclusions can be drawn from the studies mentioned above: • Mild urinary symptoms are very common among men aged 50 years and older • Mild symptoms are associated with little bother, while moderate and severe symptoms are associated with increasingly higher levels of inconvenience and interference with living activities (16) • The same symptoms can cause different troublesome and daily living interference (17) • The correlation between symptoms, prostate size and urinary flow rate is relatively low (18). It must be stressed that there is still a need for an epidemiological definition of BPH and its true incidence has yet to be determined (19).
1.2
Is BPH a progressive disorder?
As it is almost impossible to obtain agreement on what it is that defines a man with LUTS/BPH, it seems logical to say that progression cannot be defined in terms of a transition from non-cases to cases. Instead, progression must be measured by documenting deterioration in any number of physiological variables that we associate with the LUTS/BPH syndrome. Traditionally these have included the following: • decrease in maximum flow rate • increase in residual volume • increase in prostate size • deterioration (increase) in symptom score. In addition, definable events, such as the occurrence of acute urinary retention or prostate surgery, have been used. Less commonly, changes in urodynamic variables and deterioration in disease-specific quality of life have been advocated. Considerable interest currently rests with PSA. It appears to be as good a predictor of progression as any of the variables mentioned above.
UPDATE MARCH 2004
5
1.2.1 Indicators of progression The strongest evidence to support progression comes from the Olmsted County (20) community-based study and the PLESS placebo group (21). The strength of evidence for individual parameters as indicators of progression is summarised in Table 1 and is categorised as strong, weak, or none. The actual rates of progression of the individual parameters as determined from the papers reviewed is shown in Table 2. These parameters could potentially be used in decisions about treatment management. Patients who show signs of more pronounced disease progression could be targeted for preventative strategies. The same strategy could be applied to patients who are at increased risk of progression based on recognised risk factors. Risk factors for progression were found to be age (Olmsted County), PSA (PLESS) and prostate volume (combined 2-year placebo analysis). Other baseline risk factors can be identified, such as symptom severity and decreased urinary flow rate, but current data are not as convincing as those for age, PSA level and prostate volume. Several other complications, such as renal impairment and bladder dysfunction, have been associated with progression of BPH. Although these are important, they are very rare and therefore could not be evaluated accurately in community-based and clinical studies. The evidence for the progression of BPH has been summarised previously (22). Table 1: Strength of evidence for specific parameters as indicators of progression of benign prostatic hyperplasia (BPH) Parameter Community- based studies Clinical trials LUTS I-PSS S N/W* BII S N/N QoL N W/S* BPE DRE N N TRUS S S MRI N S/S* BOO Qmax S W/S* BPH Histology N/A N/A Miscellaneous AUR S S/S* Surgery S W/S* Crossover/treatment S N *Conditional risk factors: age and prostate-specific antigen (PSA); S = strong; W = weak; N = no evidence; N/A = not available. AUR = acute urinary retention; BOO = bladder outlet obstruction; BPE = benign prostatic enlargement; BII = BPH Impact Index; DRE = digital rectal examination; I-PSS = International Prostate Symptom Score; LUTS = lower urinary tract symptoms; MRI = magnetic resonance imaging; Qmax = maximum flow rate; QoL = quality of life; TRUS = transrectal ultrasonography. Table 2: Rates of progression of individual parameters in BPH Study Rate of progression LUTS Flow rate Prostate Acute urinary retentiona Surgerya (points) size (Incidence/1000 (Incidence/1000 person years) person years) 40-49 > 70 40-49 > 70 years years years years Olmsted 0.18 -2% 1.9% 3.0 34.7 0.3 10.9 (20, 23-26) per year per year per year Health Pro- NR NR NR 3.3 11.3 NR NR fessional (27) PLESS (28) -1.3 in +0.2 mL/s +14% 7% over 4 years 10% over 4 years 4 yearsb in 4 yearsb in 4 years 2-year studies NR NR NR 1.6-4.2%c NR (22, 29-32) 0.5-3.9%d North Ame- NR NR NR NR 10-39%e rican (33) a Men with moderate to severe symptoms. b Flow rate and LUTS responded to placebo treatment by showing an initial improvement, which deteriorated
6
UPDATE MARCH 2004
baseline during the course of the placebo-controlled trial. According to baseline prostate volume. d According to baseline prostate-specific antigen (PSA) level. LUTS = lower urinary tract symptoms; NR = not reported. c
1.2.2 Conclusions Based on published data on consequences and complications of the disease, BPH can be considered a progressive disease. There are limited published data on longitudinal studies and the key pieces of evidence that support this notion are the Olmsted County and PLESS studies. A group of patients at increased risk of progression can be identified based on specific risk factors, i.e. age, PSA level and prostate volume. It might be appropriate to identify these patients at risk of progression and initiate early preventative treatment. 1.2.3 References 1. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM. The prevalence of prostatism: a population based survey of urinary symptoms. J Urol 1993;150(1):85-9. http://www.ncbi.nlm.nih.gov/pubmed/7685427 2. Donovan JL, Kay HE, Peters TJ, Abrama P, Coast J, Matos-Ferreira A, Rentzhog L, Bosch JL, Nordling J, Gajewski JB, Barbalias G, Schick E, Silva MM, Nissenkorn I, de la Rosette JJ. Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-‘BPH’ study. International Continence Society - Benign Prostatic Hyperplasia. Br J Urol 1997;80(5):712-21. http://www.ncbi.nlm.nih.gov/pubmed/9393291 3. Chapple CR. BPH disease management. Eur Urol 1999; 36(Suppl 3):1-6. http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&ArtikelNr=52342&Ausgab e=227835&ProduktNr=224083 4. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132(3):474-9. http://www.ncbi.nlm.nih.gov/pubmed/6206240 5. Lytton B, Emery JM, Harvard BM. The incidence of benign prostatic obstruction. J Urol 1968;99(5):639-45. http://www.ncbi.nlm.nih.gov/pubmed/4171950 6. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy, the Baltimore Longitudinal Study of Aging. Urology 1991;35(Suppl):4-8. http://www.ncbi.nlm.nih.gov/pubmed/1714657 7. Norman RW, Nickel JC, Fish D, Pickett SN. Prostate-related symptoms in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 1994;74(5):542-50. http://www.ncbi.nlm.nih.gov/pubmed/7530115 8. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338(8765):469-71. http://www.ncbi.nlm.nih.gov/pubmed/1714529 9. Wolfs GG, Knottnerus JA, Janknegt RA. Prevalence and detection of micturition problems among 2,734 elderly men. J Urol 1994;152(5 Pt 1):1467-70. http://www.ncbi.nlm.nih.gov/pubmed/7933185 10. Sagnier PP, McFarlane G, Teillac P, Botto H, Richard F, Boyle P. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol 1995;153(3 Pt 1):669-73. http://www.ncbi.nlm.nih.gov/pubmed/7532230 11. Bosch JL, Hop WC, Kirkels WJ, Schröder FH. The international prostate symptom score in a community-based sample of men between fifty-five and seventy-four years of age. Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995;75(5):622-30. http://www.ncbi.nlm.nih.gov/pubmed/7542132 12. Berges RR, Pientka L. Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 1999; 36(Suppl 3):21-7. http://www.ncbi.nlm.nih.gov/pubmed/10559627 13. Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K, Okajima E, Yoshida O, Kumazawa J, Gu FL, Lee C, Hsu TC, dela Cruz RC, Tantiwang A, Lim PH, Sheikh MA, Bapat SD, Marshall VR, Tajima K, Aso Y. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the International Prostate Symptom Score. Int Urol 1997;4(4):40-6. http://www.ncbi.nlm.nih.gov/pubmed/9179665
UPDATE MARCH 2004
7
14.
Tsukamoto T, Kumamoto Y, Masumori N, Miyakr H, Rhodes T, Girman GJ, Guess HA, Jacobsen SJ, Lieber MM. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995;154(2 Pt 1):391-5. http://www.ncbi.nlm.nih.gov/pubmed/7541852 15. Masumori N, Tsukamoto T, Kumamoto Y, Miyake H, Rhodes T, Girman CJ, Guess HA, Jacobsen SJ, Lieber MM. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol 1996;155(4):1324-7. http://www.ncbi.nlm.nih.gov/pubmed/8632564 16. Guess HA. Population-based studies of benign prostatic hyperplasia. In: Kirby R et al. eds. Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media,1996, pp. 117-124. http://www.isismedical.com/ 17. Guess HA, Chute CG, Garraway WM, Girman CJ, Panser LA, Lee RJ, Jacobsen SJ, McKelvie GB, Oesterling JE, Lieber MM. Similar levels of urological symptoms have similar impact on Scottish and American men although Scots report less symptoms. J Urol 1993;150(5 Pt 2):1701-5. http://www.ncbi.nlm.nih.gov/pubmed/7692105 18. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, Lieber MM. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow. J Urol 1995;153(5):1510-5. http://www.ncbi.nlm.nih.gov/pubmed/7536258 19. Oishi K, Boyle P, Barry JM, et al. Epidemiology and natural history of benign prostatic hyperplasia. In: Denis L, Griffiths K, Khoury S et al, eds. Fourth International Consultation on BPH, Paris, July 1997. Plymouth: Health Publications, 1998, pp. 25-59. http://www.congress-urology.org/ 20. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996;155(2):595-600. http://www.ncbi.nlm.nih.gov/pubmed/8558668 21. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl J Med 1998;338(9):557-63. http://www.ncbi.nlm.nih.gov/pubmed/9475762 22. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001; 39(4):390-9. http://www.ncbi.nlm.nih.gov/pubmed/11306876 23. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158(2):481-7. http://www.ncbi.nlm.nih.gov/pubmed/9224329 24. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County Study of urinary symptoms and health status. J Urol 1999;162(4):1301-6. http://www.ncbi.nlm.nih.gov/pubmed/10492184 25. Rhodes T, Girman CJ, Jacobsen DJ, Roberts RO, Lieber MM, Jacobsen SJ. Longitudinal prostate volume in a community-based sample: 7 year followup in the Olmsted County Study of urinary symptoms and health status among men. J Urol 2000;163(Suppl 4):249 abstr 1105. 26. Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community-based cohort. J Urol 2000;163(1):107-13. http://www.ncbi.nlm.nih.gov/pubmed/10604326 27. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the Health Professional Followup Study. J Urol 1999;162(2):376-82. http://www.ncbi.nlm.nih.gov/pubmed/10411042 28. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. New Engl J Med 1998;338(9):557-63. http://www.ncbi.nlm.nih.gov/pubmed/9475762 29. Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990;16(3):253-61. http://www.ncbi.nlm.nih.gov/pubmed/1691843
8
UPDATE MARCH 2004
30. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J. PLESS Study Group. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a fouryear, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999;54(4): 662-9. http://www.ncbi.nlm.nih.gov/pubmed/10510925 31. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J. PLESS Study Group. Serum prostate-specific antigen is a powerful predictor of acute urinary retention and the need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999;53(3):473-80. http://www.ncbi.nlm.nih.gov/pubmed/10096369 32. Roehrborn CG, McConnell JD, Bonilla J Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF, Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P, Roy J, Andriole G, Resnick M, Waldstreicher J. PROSCAR long term efficacy and safety group. Serum prostate-specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR longterm efficacy and safety study. J Urol 2000;163(1):13-20. http://www.ncbi.nlm.nih.gov/pubmed/10604304 33. Gormley GJ, Stoner E, Bruskowitz RC, Imperato-McKinley J, Walsh PC, McConnell JD, Adriole GL, Geller J, Bracken BR, Tenover JS et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl J Med 1992 Oct 22;327(17):1185-91. http://www.ncbi.nlm.nih.gov/pubmed/1383816
2. RISK FACTORS 2.1
For developing the disease
The aetiology of BPH is multifactorial. Currently, there is no strong evidence that smoking, vasectomy, obesity or high alcohol intake are risk factors in the development of clinical BPH. Results of the different epidemiolo gical studies are controversial, probably because of differences in sampling and methods of analysis. In most cases only insufficient marginal differences can be established (1). Chronic conditions, such as hypertension or diabetes, have been related to clinical BPH, but given the frequent occurrence of these conditions in ageing men a large proportion of patients can be expected to suffer from such an association (2,3). Recently, it has been stated that diabetes and clinical BPH are associated more frequently than would be expected based on chance alone. Although more severe BPH symptoms (increased I-PSS and post-void residual) seem to be found in diabetic males even after age adjustment, the fact that both conditions increase with age and can cause partially similar voiding symptoms, produces a considerable bias (3). The only true factors related to the development of the disease are age and hormonal status (4). The crucial role of the testis has been recognized for more than a century and current research has extended into the field of molecular biology (5). Both of these risk factors are currently beyond prevention.
2.2
For surgical treatment
Although the number of surgical procedures for BPH has declined in the USA and Europe over the last decade (6), they still represent the second most common major operation in aged men (7). Ultimately, three in 10 men may undergo surgery for this condition (2). Surgical risk depends on age and the presence of clinical symptoms. In the absence of clinical symptoms, the likelihood of being treated surgically is about 3% (8,9). The need for surgery increases with symptoms and is twice as high in men with a high baseline-symptom score than for those with a low score (10). For men presenting with urinary retention, the cumulative incidence for prostatectomy is 60% at 1 year and 80% at 7 years (11). Multivariate analysis carried out on a sample of 16,219 men, aged at least 40 years, with a mean follow-up of 12 years, showed a positive association with surgery for age, low body mass index, nonsmokers, urine pH greater than 5, and a history of kidney X-ray and/or tuberculosis, for each of the five clinical urinary symptoms studied (12). In the Veterans Normative Aging Study, in a cohort of 2,280 men, the main predictor for surgery was the presence of urinary symptoms. The risk of requiring subsequent surgery also varied with age, the odds ratio being 1.8 for nocturia and 4.3 for hesitancy in young men (aged < 65 years). Among older men, only nocturia (odds ratio 2.4) was predictive of surgery (13). In the Baltimore study, the three predictive symptoms for surgery were change in size and force of the urinary stream, sensation of incomplete voiding and digital rectal
UPDATE MARCH 2004
9
enlargement of the prostate. Men with one factor had a cumulative incidence of surgery of 9%, those with two factors of 16%, and those with three factors of 37%. Nevertheless, the same study showed that increasing age was the predominant risk factor for surgery (8). From the above, it can be concluded that the risk of needing surgery for BPH increases with age and with the degree of clinical symptoms at baseline. Nocturia and changes in urinary stream seem to be the most important predictive symptoms.
2.3
REFERENCES
1. Oishi K, Boyle P, Barry JM et al. Epidemiology and natural history of benign prostatic hyperplasia. In: Denis L, Griffiths K, Khoury S et al. eds. Fourth International Consultation on BPH, Paris, July 1997. Plymouth: Health Publications, 1998, pp. 25-59. http://www.congress-urology.org/ 2. Boyle P. Epidemiology of benign prostatic hyperplasia: risk factors and concomitance with hypertension. Br J Clin Pract Suppl 1994;74:18-22. http://www.ncbi.nlm.nih.gov/pubmed/7519437 3. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163(6):1725-9. http://www.ncbi.nlm.nih.gov/pubmed/10799169 4. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989;(Suppl 2):33-50. http://www.ncbi.nlm.nih.gov/pubmed/2482772 5. Voller MC, Schalken JA. Molecular genetics of benign prostatic hyperplasia. In: Kirby R et al, eds. Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media, 1996, pp. 109-113. http://www.isismedical.com/ 6. Holtgrewe HL, Ackermann R, Bay-Nielsen H et al. Report from the Committee on the Economics of BPH. In: Cockett ATK et al, eds. Third international consultation on benign prostatic hyperplasia (BPH). Jersey: Scientific Communication International, 1996, pp. 51-70. http://www.congress-urology.org/ 7. Meigs JB, Barry MJ. Natural history of benign prostatic hyperplasia. In: Kirby R et al, eds. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media, 1996, pp. 125-135. http://www.isismedical.com/ 8. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy, the Baltimore Longitudinal Study of Aging. Urology 1991;38(1 Suppl):4-8. http://www.ncbi.nlm.nih.gov/pubmed/1714657 9. Diokno AC, Brown MB, Goldstein N, Herzog AR. Epidemiology of bladder emptying symptoms in elderly men. J Urol 1992;148(6):1817-21. http://www.ncbi.nlm.nih.gov/pubmed/1279223 10. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995;332(2):75-9. http://www.ncbi.nlm.nih.gov/pubmed/7527493 11. Craigen AA, Hickling JD, Saunders CR, Carpenter RS. Natural history of prostatic obstruction: a prospective survey. J R Coll Gen Pract 1969;18(87):226-32. http://www.ncbi.nlm.nih.gov/pubmed/4186545 12. Sidney S, Quesenberry C Jr, Sadler MC, Lydick EG, Guess HA, Cattolica EV. Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology 1991;38(Suppl 1):13-9. http://www.ncbi.nlm.nih.gov/pubmed/1714653 13. Epstein RS, Lydick E, deLabry L, Vokonas PS. Age-related differences in risk factors for prostatectomy for benign prostatic hyperplasia: the VA Normative Aging Study. Urology 1991; 38(Suppl 1):9-12. http://www.ncbi.nlm.nih.gov/pubmed/1714659
3. ASSESSMENT Diagnostic investigations have been classified as: • recommended: there is evidence to support the use of this test
10
UPDATE MARCH 2004
• •
optional: this test is done at the discretion of the clinician not recommended: there is no evidence to support the use of this test.
3.1
Symptom scores
Probably the best way to assess symptom severity is with a validated symptom score. A number of instruments exist that can measure symptom severity, bother and quality of life (Table 3) (1). Most instruments in current use conform to acceptable standards of validity, reliability and responsiveness; in other words they measure what they purport to measure, are stable over time and are able to reflect clinically important changes (2). 3.1.1 International Prostate Symptom Score (I-PSS) The I-PSS has become the international standard. It is derived from the American Urological Association (AUA) 7 score described by Barry and his colleagues in the early 1990s (3). By adding the scores (with equal weighting) to its constituent questions, a summary or index score is generated which has been shown to be an accurate reflection of a man’s overall symptoms over the preceding month (4). The extent to which the self-reported scores reflect actual events has been questioned. Men report nocturia with accuracy but tend to overstate daytime frequency. Correlation of the self-reported score to intermittency or to the strength of stream was poor (5). Age and cultural factors may be important. The I-PSS appears less reliable in men over 65 years old (6) and careful linguistic validation needs to be undertaken prior to its use in non-North American cultures (7). Numerous authors have reported and commented upon the poor correlations between I-PSS and other physiological variables. For example, there are numerous reports of symptom severity (as expressed by I-PSS) correlating poorly with peak urinary flow rate, average flow rate, post-void residual volume, prostate size or pressure-flow relationships (1, 8-10). This lack of correlation has troubled many investigators and has led to some questions raised about the validity of the I-PSS. Correlations of similar magnitude have been seen in many other disease areas, e.g. peak respiratory flow correlates poorly with patient’s own reports of the severity of their asthma. The lack of correlation can be explained in two ways. Firstly, I-PSS and physiological measures measure different things. Secondly, there are statistical issues related to the clustering of values or data points, which will also result in poor correlation. A validated symptom score assesses symptom severity. It can be used to monitor change in symptoms over time or following an intervention. 3.1.2 Quality-of-life assessment The impact of urinary symptoms on the quality of life is generally evaluated by means of question 8 of the I-PSS. However, this question measures the extent to which patients tolerate their symptoms rather than evaluating their quality of life. A number of health-related, quality-of-life instruments have been used for clinical research. One of the best known is the generic measure, the Medical Outcomes Study, a 36-item short-form health survey (SF36) (14). It is a self-completed questionnaire used to measure general health status and quality of life. It has been used in a number of studies addressing men with lower urinary tract symptoms. Using this score, a postal population survey among 217 men aged 55 years and over with LUTS showed that, depending on the respondent’s activity, 9-49% of those with moderate or severe urinary symptoms reported interference with some of their daily activities. Increasing symptom severity was associated with worsening physical condition, social functioning, vitality, mental health and perception of general health. Increasing ‘bothersome ness’ was associated with a worsening of all dimensions of general health status and quality of life. The association between the outcome of this population survey and the degree of ‘bothersomeness’ was stronger than that with the I-PSS symptom score. 3.1.3 Symptom score as decision tool for treatment Can symptom severity alone be used to allocate treatment? The US Agency for Health Care Policy and Research Guidelines (1) tried to do this. Three categories of symptom severity were described: mild (0-7), moderate (8-19) and severe (20-35). The authors suggested that patients with mild symptoms were most appropriately managed by a watchful waiting approach. Patient with moderate symptoms might benefit from pharmacotherapy, while patients with severe symptoms may derive most benefit from prostatectomy. Although notions of appropriateness have not been well-studied, the proposed policy appears to hold true for patients with mild symptoms but is less reliable for men with moderate or severe symptoms (15). 3.1.4 Symptom score as outcome predictor Symptom score may be one of the more powerful predictors of symptomatic outcome (16). As men with mild symptoms have little room for improvement it is of little surprise that they do not experience high levels of symptom reduction following surgery. A man with a pre-operative I-PSS of 17, or more, has an 87% chance of experiencing a substantial symptom reduction (17). There is little evidence that physiological measures improve
UPDATE MARCH 2004
11
the chances of predicting a favourable symptomatic outcome. 3.1.5 Conclusions Evaluating symptom severity with a symptom score is an important part of the initial assessment of a man. It is helpful in allocating treatment, and in both predicting and monitoring the response to therapy. 3.1.6 Recommendations Recommended investigations: • Clinical history • Symptom assessment • Physical examination • Validated symptom score, e.g. I-PSS.
3.2 Prostate-specific antigen (PSA) measurement Before selecting the proper treatment for men with LUTS, every urologist will perform a DRE and most will measure the serum value of PSA. 3.2.1 Factors influencing the serum levels of PSA In cases where the architecture of the prostatic gland is disrupted, PSA will ‘leak’ into the circulation. This occurs when prostatic carcinoma is present but also in BPH, prostatitis and after urinary retention. This is why PSA is not considered as being cancer-specific, but organ-specific. Other known causes of PSA serum elevations are biopsy of the prostate gland and ejaculation (1). In addition, small and clinically insignificant changes occur after DRE. Two other important factors, age and race, must also be considered when evaluating PSA values in men with LUTS (2,3). African-Americans with no evidence of prostate carcinoma have higher PSA values after their fourth decade of life, and therefore age-specific reference ranges must be adapted and interpreted according to race and ethnicity (4). A recent community-based study of African-American men contradicts the beliefs of racial PSA differences, since only minor variations in PSA reference ranges were found (5). 3.2.2 PSA and prediction of prostatic volume Stamey et al. were the first to correlate PSA serum values and volume of prostatic tissue (6). In their studies in the late 1980s, they found that the serum PSA contribution from BPH was 0.30 ng/mL per gram of tissue and 3.5 ng/mL per cm3 of cancer tissue. Roehrborn et al, have shown that PSA and prostate volume have an agedependent, log-linear relationship and that PSA has a good predictive value for assessing prostatic volume (7). Vesely et al, also found that prostate volume and serum PSA are significantly correlated and increase with advanced age (8). Prediction of prostate volume can also be based on total and free PSA. Both PSA forms were found to be able to predict the TRUS prostate volume (± 20%) in more than 90% of the cases (9). 3.2.3 PSA and probability of having prostate cancer The chance of having prostate cancer is strongly related with the serum value of PSA. For many years the value of 4ng/mL was considered as the upper normal limit of PSA (10) but lately a lower threshold of PSA for recommending prostate biopsy in younger men has shown to improve the clinical value of this test (11). In order to avoid unnecessary biopsies, Potter et al, (12) have used three clinical parameters - age, PSA and DRE - and have calculated the likelihood of detecting prostate cancer on sextant TRUS-guided biopsies among 2,054 men. At the same time, predictive nomograms have been developed by various groups. These nomograms are being constructed from variables such as age, race, family history, DRE, PSA, PSA density and TRUS findings (13,14). 3.2.4 PSA and prediction of BPH-related outcomes In a series of studies, Roehrborn et al. (15,16) have shown that PSA and prostatic volume can be used to evaluate the risks of either needing surgery or developing acute urinary retention. These parameters were also related with long-term changes in symptom scores and flow rates. In a recent epidemiological study, elevated free PSA levels could predict clinical BPH, independent of total PSA levels (17). 3.2.5 • • • •
12
Conclusions various factors (cancer, BPH, infection, trauma, age, may influence serum PSA levels the level of PSA correlates with the volume of the prostate gland the higher the PSA level, the greater is the probability of having prostate cancer the PSA level might predict the natural history of BPH.
UPDATE MARCH 2004
3.2.6 Recommendation The measurement of PSA is recommended when a diagnosis of prostatic carcinoma will change the decision made about which therapeutic option to use. 3.2.7 1.
References Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate specific antigen concentrations. Urology 1997;50(2):239-43. http://www.ncbi.nlm.nih.gov/pubmed/9255295 2. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860-4. http://www.ncbi.nlm.nih.gov/pubmed/7688054 3. Laguna P, Alivizatos G. Prostate specific antigen and benign prostatic hyperplasia. Curr Opin Urol 2000;10(1):3-8. http://www.ncbi.nlm.nih.gov/pubmed/10650506 4. Eastham JA, Sartor O, Richey W, Moparty B, Sullivan J. Racial variation in prostate specific antigen in a large cohort of men without prostate cancer. J La State Med Soc 2001;153(4):184-9. http://www.ncbi.nlm.nih.gov/pubmed/11394329 5. Cooney KA, Strawderman MS, Wojno KJ, Doerr KM, Taylor A, Alcser KH, Heeringa SG, Taylor JM, Wei JT, Montie JE, Schottenfeld D. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology 2001;57(1):91-6. http://www.ncbi.nlm.nih.gov/pubmed/11164150 6. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-16. http://www.ncbi.nlm.nih.gov/pubmed/2442609 7. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53(3):581-9. http://www.ncbi.nlm.nih.gov/pubmed/10096388 8. Vesely S, Knutson T, Damber JE, Dicuio M, Dahlstrand C. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2003,37(4):322-8. http://www.ncbi.nlm.nih.gov/pubmed/12944191 9. Morote J, Encabo G, López M, de Torres IM. Prediction of prostate volume based on total and free serum prostate specific antigen: is it reliable? Eur Urol 2000;38(1):91-5. http://www.ncbi.nlm.nih.gov/pubmed/10859448 10. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001;344(18):1373-7. http://www.ncbi.nlm.nih.gov/pubmed/11333995 11. Punglia RS, D’ Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003,349(3):335-42. http://www.ncbi.nlm.nih.gov/pubmed/12878740 12. Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW. Age, prostate specific antigen and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001;157(6):1100-4. http://www.ncbi.nlm.nih.gov/pubmed/11377318 13. Kalra P, Togami J, Bansal BSG, Partin AW, Brawer MK, Babaian RJ, Ross LS, Niederberger CS. A neurocomputational model for prostate carcinoma detection. Cancer 2003;98(9):1849-54. http://www.ncbi.nlm.nih.gov/pubmed/14584066 14. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive modelling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels= 10 ng/mL. Cancer 2003;98(7):1417-22. http://www.ncbi.nlm.nih.gov/pubmed/14508828 15. Roehrborn CG, McConnell JD, Saltzman B, Bergner D, Gray T, Narayan P, Cook TJ, JohnsonLevonas AO, Quezada WA, Waldstreicher J. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002;42(1):1-6. http://www.ncbi.nlm.nih.gov/pubmed/12121721 16. Roehrborn CG, Malice MP, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001;58(2):210-6. http://www.ncbi.nlm.nih.gov/pubmed/11489703
UPDATE MARCH 2004
13
17.
Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54(9): 935-44. http://www.ncbi.nlm.nih.gov/pubmed/11520654
3.3
Creatinine measurement
It is well-accepted today that bladder outlet obstruction due to BPH might cause hydronephrosis and renal failure (1). Ten years ago, it was shown that patients with BPH and renal insufficiency had a 25% risk of developing post-operative complications compared with the 17% risk in patients with normal renal function (2). Earlier studies also showed a much higher mortality among BPH patients who underwent surgical treatment when renal insufficiency was present at the same time (3,4). Most studies have found that the incidence of azotaemia in men with BPH varies from 15-30% (5,6). However, these figures might be overestimates as these studies involved patients undergoing surgical treatment (i.e. those with severe symptoms and with urinary retention). A recent study evaluated 246 men presenting with BPH symptoms and found that approximately one in 10 (11%) had renal insufficiency (7). It was also shown that neither the symptom score nor the quality-of-life assessment was associated with serum creatinine levels in patients with BPH. When renal dysfunction was present, diabetes and hypertension were the most probable causes of the elevated creatinine level among this group of patients. This study also noted that it was rather rare to find patients with high creatinine levels due to bladder outlet obstruction only. Comiter et al. (8) reported a study in which voiding dysfunction of a non-neurogenic aetiology did not appear to be a risk factor for elevated BUN (blood urea/nitrogen) and creatinine levels. Bruskewitz et al. (9) also found that an isolated serum creatinine level could not predict the outcome after TURP, as measured by an improvement in quality of life. Despite all of the above, it is probably unwise to avoid measuring serum creatinine levels in patients undergoing BPH evaluation in an effort to minimize costs. Koch et al. (10) studied the additional value of renal ultrasonography in the assessment of patients with BPH and concluded that only those with an elevated creatinine level needed such an investigation. Although the recently released MTOP’s data suggest that creatinine measurements might not be indicated, we feel that this study does not address this issue. This study suggests that it is not necessary to control the serum creatinine if voiding is normal. 3.3.1 Conclusions As it is difficult to select those with renal insufficiency from among evaluable BPH patients, it is probably cost effective to measure serum creatinine levels in all patients. In this way, proper therapy can be offered to the right men and the costs of long-term renal damage and post-surgical complications can be avoided. This point is increasingly emphasized, as the use of certain α-blockers might cause additional problems in men with renal insufficiency. In the report from the AHCPR (11) and in the recommendations of the Fourth International Consultation on BPH (12), the measurement of creatinine is highly recommended. 3.3.2 1.
References Sacks SH, Aparicio SA, Bevan A, Oliver DO, Will EJ, Davison AM. Late renal failure due to prostatic outflow obstruction: a preventable disease. Br Med J 1989;298(6667):156-9. http://www.ncbi.nlm.nih.gov/pubmed/2466506 2. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and post operative complications. A comparative study of 13 participating institutions evaluating 3,885 patients. J Urol 2002;167(2 pt 2):999-1003; discussion 1004. http://www.ncbi.nlm.nih.gov/pubmed/11908420 3. Holtgrewe HL, Valk WL. Factors influencing the mortality and morbidity of transurethral prostatectomy: a study of 2015 cases. J Urol 1962;87:450-9. http://www.ncbi.nlm.nih.gov/pubmed/13908592 4. Melchior J, Valk WL, Foret JD, Mebust WK. Transurethral prostatectomy in the azotemic patient. J Urol 1974;112(5):643-6. http://www.ncbi.nlm.nih.gov/pubmed/4424347 5. Roehrborn CG. Initial diagnostic evaluation of men with lower urinary tract symptoms. In: Cockett AT et al., eds. Proceedings of the Third International Consultation on Benign Prostatic Hyperplasia (BPH). Channel Islands, Geneva: Scientific Communication International Jersey, 1996, pp. 167-254. http://www.congress-urology.org/ 6. Mukamel E, Nissenkorn I, Boner G, Servadio C. Occult progressive renal damage in the elderly male due to benign prostatic hypertrophy. J Am Geriatr Soc 1979;27(9):403-6. http://www.ncbi.nlm.nih.gov/pubmed/89133
14
UPDATE MARCH 2004
7. Gerber GS, Goldfisher ER, Karrison TG, Bales GT. Serum creatinine measurement in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 1997;49(5):697-702. http://www.ncbi.nlm.nih.gov/pubmed/9145973 8. Comiter CV, Sullivan MP, Schacterle RS, Cohen LH, Valla SV. Urodynamic risk factors for renal dysfunction in men with obstructive and non-obstructive voiding dysfunction. J Urol 1997;158(1): 181-5. http://www.ncbi.nlm.nih.gov/pubmed/9186351 9. Bruskewitz RC, Reda DJ, Wasson JH, Barrett L, Phelan M. Testing to predict outcome after transurethral resection of the prostate. J Urol 1997;157(4):1304-8. http://www.ncbi.nlm.nih.gov/pubmed/9120927 10. Koch WF, Ezz El Din K, de Wildt MJ, Debruyne FM, de la Rosette JJ. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol 1996;155(1):186-9. http://www.ncbi.nlm.nih.gov/pubmed/7490828 11. McConnell JD, Barry MJ, Bruskewitz RC. Benign Prostatic Hyperplasia: Diagnosis and Treatment. In: Quick Reference Guide for Clinicians. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1994. AHCPR Publication 94-0583. http://www.ahrq.gov/clinic/medtep/bphguide.htm#bphimp 12. Koyanagi T, Artibani W, Correa R et al. In: Denis L, Griffiths K, Khoury S et al., eds. Proceedings of the Fourth International Consultation on BPH, Paris, July 1997. Plymouth: Health Publications, 1998, pp.179-265. http://www.congress-urology.org/
3.4
Urinalysis
Since LUTS is not only observed in patients with BPH, but also frequently in men with urinary tract infections, whether related or not to benign enlargement of the gland, and in at least 25% of patients with carcinoma of the bladder, analytical and microscopic urine analysis was considered to be mandatory. However, microscopic urine analysis has not been accepted as a screening test for the early detection of severe urological diseases, such as malignancies. This is mainly due to the low specificity of this highly sensitive test, causing unnecessary further diagnostic measures in a large number of patients. Overall, we concluded that this inexpensive test which does not require sophisticated technical equipment should be incorporated in the primary evaluation of any patient presenting with LUTS. 3.4.1 Recommendation Urinalysis is recommended in the primary evaluation. However, it should be noted that there is little evidence in the literature to support this conclusion.
3.5
Digital rectal examination (DRE)
Digital rectal examination (DRE) is an important examination in men with LUTS for two reasons. Firstly, it can help to determine the co-existence of prostatic carcinoma. Secondly, it enhances the capacity to estimate prostate volume, and in this way may assist in choosing the right treatment, as prostate size has been shown to be a determining factor for certain treatment options. 3.5.1 DRE and cancer detection The positive predictive value (PPV) of a suspicious DRE to actually diagnose prostate cancer is 26-34% (1). These figures are based on screening studies and it is believed that DRE will have a higher PPV for cancer among men with LUTS, as these patients are usually older. Potter et al., used three clinical parameters, age, PSA and DRE, to determine the probability of having prostate cancer and constructed a nomogram to help in the decision whether or not to perform a prostate biopsy. In this study, DRE had a significant influence on the likelihood of a positive biopsy in all PSA and age ranges (2). In the “Quebec” (3), the “Innsbruck”(4) and the “Olmsted County”(5) screening trials, DRE has been used in the screening process. In the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial and in the European Randomized study of Screening for Prostate Cancer in Europe (ERSPC), DRE has been used as an ancillary screening tool. In 1997 the use of DRE in the ERSPC trial as a screening test, was abandoned (6). In the European Prostate Cancer Detection Study (EPCDS) of 1,051 men, DRE results were not a significant predictor of prostate cancer (P=0,21) (7).
UPDATE MARCH 2004
15
3.5.2 DRE and prostate size evaluation A number of options are currently available for the treatment of patients with BPH. Response to certain types of therapy, e.g. finasteride, depends on the actual prostate volume. In patients for whom invasive therapy, such as surgery, is recommended, an estimation of the prostate gland volume will help the urologist to select the most suitable form of treatment with the lowest cost and best outcome. Correct estimation of the prostatic volume by DRE is not an easy task and therefore investigators for the PLCO (Prostate, Lung, Colorectal and Ovarian Cancer) trial have described quality-control procedures for DRE examination (8). It is well-accepted that TRUS is more accurate in determining prostate volume than DRE. Roehrborn has analyzed the data from four studies in which estimations of prostate volume by DRE were compared with those performed by TRUS (9). Although different methods and criteria were used in the four studies, it was concluded that underestimation of DRE increased with increasing TRUS volume, particularly if the volume was greater than 30 mL. For this reason, Roehrborn developed a model of visual aids to help urologists predict prostate volume more accurately (10). Similar models to assist training for DRE examinations have been proposed by other groups as well (11). Finally, Frank et al. have compared the knee-elbow to the left-lateral position of the patient in examining and evaluating the prostate. They concluded that both methods were equal in completeness of examination, pain, and embarrassment (12). 3.5.3 Conclusions and recommendation 1. DRE has been used in all major screening trials but its actual impact in the early diagnosis of PCa has been questioned. 2. DRE is useful in evaluating the size of the prostate gland and also in order to exclude other pelvic pathologies, but proper training is needed. Recommendation: DRE is recommended in the evaluation of men with LUTS. 3.5.4. References 1. Resnick M, Ackerman R, Bosch J, Cidre J, Foo K, Frand I. Fifth International Consultation on BPH. In: Chatelain C, Denis L, Foo S, Khoury S, McConnell J eds. Benign prostatic hyperplasia. Plymbridge Distributions, 2000, pp. 169-188. http://www.congress-urology.org/ 2. Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001;57(6):1100-4. http://www.ncbi.nlm.nih.gov/pubmed/11377318 3. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, Lévesque J, Belanger A. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999,38(2):83-91. http://www.ncbi.nlm.nih.gov/pubmed/9973093 4. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P; Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate-specific antigen; mass screening in the Federal State of Tyrol, Austria. Urology 2001;58(3):417-24. http://www.ncbi.nlm.nih.gov/pubmed/11549491 5. Roberts RO, Bergstaralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999;161(2):529-33. http://www.ncbi.nlm.nih.gov/pubmed/9915441 6. Schröder FH.Screening for prostate cancer. Urol Clin N Am 2003;30(2):239-51. http://www.ncbi.nlm.nih.gov/pubmed/12735501 7. Djavan B, Zlotta AR, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M. Optimal predictors of prostate cancer in repeat prostate biopsy: a prospective study in 1,051 men. J Urol 2000,163(4):1144-8. http://www.ncbi.nlm.nih.gov/pubmed/10737484 8. Weissfeld JL, Fagerstrom RM, O’Brien B. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21(Suppl 6):S390-S399. http://www.ncbi.nlm.nih.gov/pubmed/111896909
16
UPDATE MARCH 2004
9. Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 1998;51(Suppl 4A):19-22. http://www.ncbi.nlm.nih.gov/pubmed/9586592 10. Roehrborn CG, Sech S, Montoya J, Rhodes T, Girman CJ. Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology 2001;57(6):1087-92. http://www.ncbi.nlm.nih.gov/pubmed/11377314 11. Burdea G, Patounakis G, Popescu V, Weiss RE. Virtual reality-based training for the diagnosis of prostate cancer. IEEE Trans Biomed Eng 1999;46(10):1253-60. http://www.ncbi.nlm.nih.gov/pubmed/10513131 12. Frank J, Thomas K, Oliver S, Andrews S, Choong S, Taylor R, Emberton M. Couch or crouch? Examining the prostate, a randomized study comparing the knee-elbow and the left-lateral position. BJU Int 2001;87(4):331-3. http://www.ncbi.nlm.nih.gov/pubmed/11251525
3.6
Imaging of the urinary tract
Imaging of the entire (including the upper) urinary tract, particularly prior to prostate surgery, has been an integral part of the diagnostic assessment of elderly men with LUTS due to BPH during past decades (1-12). In parallel with endoscopy, the role of routine imaging of the upper and lower urinary tract in all patients with LUTS has been increasingly questioned in recent years (5,6,9,13). Ideally, an imaging modality for patients with LUTS should provide both imaging of the urinary tract and demonstrate the morphological effects of prostate pathology upon the rest of the lower and/or upper urinary tract. 3.6.1 Upper urinary tract A recent survey of 24 urological centres in the UK found that 21 of 24 centres (79%) used either intravenous urography (IVU) or sonography, and that 16 of 24 centres (67%) used plain films as routine procedures prior to prostatectomy (14). Similar findings, particularly a high rate of IVU, have been reported in the USA (15). The most common argument in favour of routine imaging of the upper urinary tract was ‘not to miss anything’. Data from several large-scale studies have led to doubts concerning the role of routine upper urinary tract imaging in patients with LUTS. Wilkinson and Wild (12) reported on 175 patients with LUTS with no urinary retention and identified no abnormalities on renal ultrasound and IVU that would have altered the therapeutic approach. Similar data have been published by Koch et al., who performed renal ultrasound scans in a consecutive series of 556 elderly men with LUTS; 14 (2.5%) had hydronephrosis (13). Serum creatinine levels appeared to be correlated with dilatation of the renal pelvis. The authors concluded that renal ultrasound is only indicated in patients with an elevated serum creatinine level and/or post-void residual urine volume (13). A recent review was carried out on data from 25 published reports on the findings of IVU. A total of 6,131 men from nine ultrasound series were involved, including 778 patients with LUTS due to BPH. The mean patient age in these series was 68.4 years (16). Overall, 74.3% of all IVUs and 70% of all the ultrasound studies performed were normal. Hydronephrosis was found in 7.6% of IVU and 6.8% of ultrasonography patients; 30% had measurable degrees of renal insufficiency. Poor or no renal function was found in 12.3% and 0.8%. Renal cysts were seen in 4.5% and 15.3%, and solid renal masses were identified in 0.81% and 0.51% of IVU and of ultrasonography patients, respectively. These data need to be correlated with the incidence of renal cell cancer in the general population. Based on several autopsy and epidemiological studies, it has been estimated that the risk of elderly men developing renal cell cancer ranges from 0.18% to 0.56%. These figures are comparable with the results of large-scale studies in elderly men with LUTS and indicate that the incidence of renal carcinoma is not increased in these patients. Other malignancies found during routine examination of the urinary tract are bladder and ureteral cancer, usually seen in about 1% of cases. However, most of the cancers suspected during imaging were not identified during endoscopy. A number of tumours were identified during endoscopy that had been overlooked during imaging. IVU adverse events A review of 10 reported studies involving over 2.1 million patients revealed an incidence of adverse effects due to contrast medium in approximately 6% of patients, an incidence of serious adverse effects in 1 in 1,0002,000, and a risk of dying from an allergic reaction of 1 in 100,000-200,000 (17,18). The average radiation dose is 1.58 rem. Low-osmolar contrast material (LOCM) resulted in a six-fold improvement in safety compared with high-osmolar contrast material (18). Furthermore, in patients with pre-existing renal failure, the use of LOCM reduces the risk of nephrotoxicity (18).
UPDATE MARCH 2004
17
IVU or renal ultrasound Several arguments support the use of renal ultrasound. Among the most important are: • better characterization of renal masses • possibility of investigating the liver and retroperitoneum • simultaneous evaluation of the bladder, post-void residual urine volume and prostate • costs • avoidance of irradiation • no side-effects. 3.6.2 Lower urinary tract Urinary bladder voiding cysto-urethrogram This investigation suffers from the fact that the information on the lower urinary tract is only indirect and gives, at best, only limited urodynamic information. It is therefore not recommended in the routine diagnostic workup of elderly men with LUTS. More recently, the measurement of bladder wall thickness by transabdominal ultrasound has gained considerable interest as a non-invasive tool to assess bladder outflow obstruction (19). Manieri et al. (20) concluded that bladder wall thickness appeared to be a useful predictor of bladder outlet obstruction, with a value exceeding that of uroflowmetry. Reliable data on inter- and intra-observer variability, as well as reproducibility, are still lacking and, therefore, measurement of bladder wall thickness is currently not part of the recommended diagnostic work-up of patients with LUTS. 3.6.3 Urethra Retrograde urethrography gives only indirect information on the effect of benign prostatic enlargement (BPE) on adjacent structures. 3.6.4 Prostate Imaging of the prostate is performed to assess: • prostate size • prostate shape • occult carcinoma • tissue characterization. Choice of imaging modalities The prostate can be imaged using: • transabdominal ultrasound • TRUS • computed tomography (CT) and magnetic resonance imaging (MRI) (including transrectal MRI). In daily routine practice, however, only imaging of the prostate by TRUS, or, if this is not available, by transabdominal ultrasound, is currently used (21). Prostate size A large body of evidence documents the accuracy of TRUS in calculating the volume of the prostate (22,23). TRUS has significantly higher accuracy than that of cystoscopy, IVU, rectal examination and or urethral pressure profile (24). The prostate volume estimated by DRE and endoscopy is known to underestimate prostates over 40 mL in size (24). Prostate volume can be estimated by serial planimetry, orthogonal plane, rotational body (single plane, ellipsoid) and three-dimensional methods (23). Prostate shape Watanabe (25) introduced the concept of the presumed circle area ratio (PCAR). This is based on the usual normal triangular-shaped appearance of the prostate in the absence of benign prostatic enlargement (BPE). In BPE, the shape of the prostate is changed by the continuous growth of the transition zone. Watanabe reported that pathological residual urine is seen if the presumed circle area ratio (PCAR) is greater than 0.75 or less than 75, and that BPE is very unlikely to be the cause of the post-void residual urine volume. More likely causes include bladder cancer or prostate cancer. However, validation of these data by others is still lacking. 3.6.5 References 1. Andersen JT, Jacobsen O, Standgaard L. The diagnostic value of intravenous pyelography in infravesical obstruction in males. Scand J Urol Nephrol 1977;11(3):225-30. http://www.ncbi.nlm.nih.gov/pubmed/74088 2. Bohne AW, Urwiller RD, Pantos TG. Routine intravenous urograms prior to prostatectomy. J Urol 1961;86:171-2.
18
UPDATE MARCH 2004
3.
Bundrick TJ, Katz PG. Excretory urography in patients with prostatism. Am J Radiol 1986;147(5): 957-9. http://www.ncbi.nlm.nih.gov/pubmed/2429536 4. Butler MR, Donnelly B, Komaranchat A. Intravenous urography in evaluation of acute retention. Urology 1978;12(4):464-6. http://www.ncbi.nlm.nih.gov/pubmed/715976 5. Christofferson I, Moller I. Excretory urography: a superfluous routine examination in patients with prostatic hypertrophy? Eur Urol 1981;7:(2)65-7. http://www.ncbi.nlm.nih.gov/pubmed/6161822 6. DeLacey G, Johnson S, Mee D. Prostatism: how useful is routine imaging of the urinary tract?. Br Med J 1988;296(6627):965-7. http://www.ncbi.nlm.nih.gov/pubmed/2451969 7. Donker PJ, Kakiailatu F. Preoperative evaluation of patients with bladder outlet obstruction with particular regard to excretory urography. J Urol 1978;120(6):685-6. http://www.ncbi.nlm.nih.gov/pubmed/731806 8. Marshall V, Singh M, Blandy JP. Is urography necessary for patients with acute retention of urine before prostatectomy?. Br J Urol 1975;47(1):73-6. http://www.ncbi.nlm.nih.gov/pubmed/1131499 9. Morrison JD. Help or habit? Excretion urography before prostatectomy. Br J Clin Pract 1980;34(89):239-41. http://www.ncbi.nlm.nih.gov/pubmed/6158963 10. Pinck BD, Corrigan MJ, Jasper P. Pre-prostatectomy excretory urography: does it merit the expense?. J Urol 1980;123(3):390-1. http://www.ncbi.nlm.nih.gov/pubmed/6767041 11. Wasserman NF, Lapointe S, Eckmann DR, Rosel PR. Assessment of prostatism: role of intravenous urography. Radiology 1987;165(3):831-5. http://www.ncbi.nlm.nih.gov/pubmed/2446348 12. Wilkinson AG, Wild SR. Is pre-operative imaging of the urinary tract worthwhile in the assessment of prostatism? Br J Urol 1992;70(1):53-7. http://www.ncbi.nlm.nih.gov/pubmed/1379105 13. Koch WF, Ezz el Din K, de Wildt MJ, Debruyne FM, de la Rosette JJ. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol 1996;155(1):186-9. http://www.ncbi.nlm.nih.gov/pubmed/7490828 14. Wilkinson AG, Wild SR.Survey of urological centres and review of current practice in the pre-operative assessment of prostatism. Br J Urol 1992;70(1):43-5. http://www.ncbi.nlm.nih.gov/pubmed/1379104 15. Holtgrewe HL, Mebust WK, Dowd JB, Cockett AT, Peters PC, Proctor C. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 1989;141(2):248-53. http://www.ncbi.nlm.nih.gov/pubmed/2643720 16. Koyanagi T, Artibani W, Correa R et al. In: Denis L, Griffiths K, Khoury S, et al, eds. Proceedings of the Fourth International Consultation on BPH, Paris, July 1997. Plymouth: Health Publications, pp. 179265. http://www.congress-urology.org/ 17. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolarity iodinated contrast media. Radiology 1993;188(1):171-8. http://www.ncbi.nlm.nih.gov/pubmed/8511292 18. Thomson HS, Dorph S. High-osmolar and low-osmolar contrast media. An update on frequency of adverse drug reactions. Acta Radiol 1993;34(3):205-9. http://www.ncbi.nlm.nih.gov/pubmed/8489830 19. Kojima M, Inui E, Ochiai A, Naya Y, Ukimura O, Watanabe H. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. J Urol 1997;157(2):476-9. http://www.ncbi.nlm.nih.gov/pubmed/8996337 20. Manieri C, Carter SS, Romano G, Trucchi A, Valenti M, Tubaro A. The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. J Urol 1998;159(3):761-5. http://www.ncbi.nlm.nih.gov/pubmed/9474143 21. Scheckowitz EM, Resnick MI. Imaging of the prostate. Benign prostatic hyperplasia. Urol Clin North Am 1995;22(2):321-32. http://www.ncbi.nlm.nih.gov/pubmed/7539178
UPDATE MARCH 2004
19
22. Aarnink RG, de la Rosette JJ, Debruyne FM, Wijkstra H. Reproducibility of prostate volume measurements from transrectal ultrasonography by an automated and a manual technique. Br J Urol 1996;78(2):219-23. http://www.ncbi.nlm.nih.gov/pubmed/8813917 23. Aarnink RG, Beerlage HP, de la Rosette JJ, Debruyne FM, Wijkstra H. Transrectal ultrasound of the prostate: innovations and future applications. J Urol 1998;159(5):1568-79. http://www.ncbi.nlm.nih.gov/pubmed/9554357 24. Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 1998;51(Suppl 4A):19-22. http://www.ncbi.nlm.nih.gov/pubmed/9586592 25. Watanabe H. New concept of BPH: PCAR theory. Prostate 1998;37(2):116-25. http://www.ncbi.nlm.nih.gov/pubmed/9759706
3.7
Voiding charts (diaries)
Voiding charts (diaries) are simple to complete and can provide useful and objective clinical information (1,2). There is no standard frequency volume chart available. However, recent data indicate that a 24-hour voiding chart is sufficient and that longer time periods provide only little additional information (3). There is a close correlation between LUTS, as assessed by symptom scores, and data generated by voiding charts, such as frequency and nocturia. The ICS BPH study reported an exact correlation in 41% of the number of voids, 61% for the time of voids and 68% for episodes of nocturia (2). Voiding charts allow, for example, the identification of patients with nocturnal polyuria, one of the causes of nocturia in elderly men (4-6). 3.7.1 Conclusions Recording of a 24-hour frequency volume chart in the course of an initial consultation is considered to be a standard investigation. A frequency volume chart is non-invasive , inexpensive, and provides important insights into LUTS. 3.7.2 References 1. Abrams P, Klevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl 1996;179:47-53. http://www.ncbi.nlm.nih.gov/pubmed/8908664 2. Reynard JM, Yang Q, Donovan JL, Peters TL, Schäfer W, de la Rosette JJ, Dabhoiwala NF, Osawa D, Lim AT, Abrams P. The ICS-BPH study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998;82(5):619-23. http://www.ncbi.nlm.nih.gov/pubmed/9839573 3. Gisolf KW, van Venrooij GE, Eckhardt MD, Boon TA. Analysis and reliability of data from 24-hour frequency-volume charts in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2000;38(1):45-52. http://www.ncbi.nlm.nih.gov/pubmed/10859441 4. Van Venrooij GE, Eckhardt MD, Gisholf KW, Boon TA. Data from frequency-volume charts versus symptom scores and quality of life score in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2001;39(1):42-7. http://www.ncbi.nlm.nih.gov/pubmed/11173938 5. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Bosch JL. Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol 2000;164(4):1201-5. http://www.ncbi.nlm.nih.gov/pubmed/10992366 6. Matthiesen TB, Rittig S, Mortensen JT, Djurhuus JC. Nocturia and polyuria in men referred with lower urinary tract symptoms, assessed using a 7-day frequency-volume chart. BJU Int 1999;83(9):1017-22. http://www.ncbi.nlm.nih.gov/pubmed/10368248
3.8
Uroflowmetry
Uroflowmetry is recommended as a diagnostic assessment in the work-up of patients with LUTS and is an obligatory test prior to surgical intervention. It is a simple, non-invasive test that can reveal abnormal voiding. Flow rate machinery provides information on voided volume, maximum flow rate (Qmax), average flow (Qave) and time to Qmax, and this information should be interpreted by the physician to exclude artifacts (1-3). Serial flows (two or more) with a voided volume exceeding 150 mL are recommended to get a representative flow rate. BOO can only be diagnosed with a pressure flow study (pQs) (see section 3.10) and flow rates should interpreted with caution in particular as elderly men with LUTS have age-related urodynamic changes (4). However, men with a Qmax less than 10 mL/sec are more likely to have BOO and are therefore more likely to
20
UPDATE MARCH 2004
improve with surgery. Men with LUTS and normal Qmax are more likely to have a non-BPH-related cause of their symptoms. 3.8.1 References 1. Rowan D, James ED, Kramer AE, Sterling AM, Suhel PF. Urodynamic equipment: Technical aspects produced by the International Continence Society Working Party on Urodynamic Equipment. J Med Eng Technol 1987;11(2):57-64. http://www.ncbi.nlm.nih.gov/pubmed/2956425 2. Grino PB, Bruskewitz R, Blaivas JG, Siroky MB, Andersen JT, Cook T, Stoner E. Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation. J Urol 1993;149(2):339-41. http://www.ncbi.nlm.nih.gov/pubmed/7678870 3. Witjes WP, de la Rosette JJ, Zerbib M, Vignoli GC, Geffriaud C, Debruyne FM, Wijkstra H. Computerized artefact detection and correction of uroflow curves: Towards a more consistent quantitative assessment of maximum flow. Eur Urol 1998;33(1):54-63. http://www.ncbi.nlm.nih.gov/pubmed/9471041 4. Madersbacher S, Klingler HC, Schatzl G, Stulnig T, Schmidbauer CP, Marberger M. Age-related urodynamic changes in patients with benign prostatic hyperplasia. J Urol 1996;156(5):1662-7. http://www.ncbi.nlm.nih.gov/pubmed/8863566
3.9 Post-void residual volume (PVR) Post-void residual (PVR) urine measurement is recommended during initial assessment. It should be calculated by measurement of the bladder height, width, and length obtained by transabdominal ultrasonography. This is a simple, accurate and non-invasive method. Large PVR volumes (> 200-300 mL) may indicate bladder dysfunction and predict a less favourable response to treatment. Still, residual urine is not a contraindication to watchful waiting or medical therapy. Because of large test-retest variability and lack of outcome studies, it is not possible to establish a PVR “cut-point” for treatment decision.
3.10
Urodynamic studies
Pressure-flow studies are regarded as an additional diagnostic test and are considered optional by both the AUA guideline panel on management of benign prostatic hyperplasia (2003) (1) and the Fifth International Consultation on BPH (2). Flow rates only determine the probability of obstruction, whereas pressure-flow studies can categorize the degree of obstruction and identify patients in whom a low flow rate may be due to a low-pressure detrusor contraction. Flow rates may be particularly limited in predicting obstruction in specific situations, such as in elderly patients, individuals with low voided volumes, or men with a Qmax of more than 10mL/s, as well as in the presence of neurological disease. Although pressure-flow studies are the only means of diagnosing obstruction accurately, debate continues as to their role in predicting treatment outcomes. Recent methodological studies looking on intra-individual variation in pressure-flow results as well as intra- und and inter-individual observer accuracy in interpretation of pressure-flow curves have demonstrated a considerable methodological variation (3-6). This makes it more difficult to judge the influence of infravesical obstruction on lower urinary tract symptoms in patients with BPH. For this reason, and because pressure-flow studies are regarded as invasive, they remain optional. In specific patient subgroups, the case for pressure-flow studies is stronger. The methodology for performing pressure-flow studies is now standardized (7) and requires simultaneous recording of both intravesical and intra-abdominal pressure. Detrusor pressure at the point of maximum flow must be recorded in order to diagnose obstruction. Different nomograms exist with which to classify patients into categories of obstruction. Those developed by Schafer (8), Abrams and Griffiths (9) and Rollema and Van Mastrigt (URA – Urethral Resistance Index) (10) are most commonly used, and they all correlate closely. The ICS (International Continence Society) nomogram (11) has now been adopted as the standard nomogram to aid comparison of different data sets, and should be used in clinical practice. 3.10.1 Outcome Pressure-flow studies do not predict the response to medical therapy and have no role in this setting. However, it is known that patients with high-pressure and low-flow urodynamics have the best outcome from prostatectomy. Patients with low-pressure and low-flow urodynamics may also have a successful outcome following prostatectomy, but the probability is lower. Most work in relation to pressure-flow studies and treatment of LUTS due to BPO relates to TURP. Studies reported by Neal et al. (12,13), Abrams et al. (14), Jensen (15), Robertson et al. (16) and Langen et al. (17) all report improved outcomes in patients who are obstructed prior to surgery, based on pressure-flow studies.
UPDATE MARCH 2004
21
3.10.2 Conclusions Pressure-flow studies remain optional tests in straightforward cases presenting for the first time with LUTS. These studies are the most useful investigations available for the purpose of counselling patients regarding the outcome of surgical therapies for BPH. The ICS nomogram should be used for the diagnosis of obstruction in order to standardize data for comparative purposes. 3.10.3 References 1. AUA practice guideline committee. AUA guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170(2 Pt 1):530-47. http://www.ncbi.nlm.nih.gov/pubmed/12853821 2. Chatelain C, Denis L, Foo KT, Khoury S, McConnell J eds. Proceedings of the Fifth International Consultation on BPH, Paris, July 2000. Plymouth: Health Publications, 2001, p. 524. http://www.congress-urology.org/ 3. Hansen F, Olsen L, Atan A, Nordling J. Pressure-flow studies: Short-time repeatability. Neurourol Urodyn 1999;18(3):205-14. http://www.ncbi.nlm.nih.gov/pubmed/10338441 4. Sonke GS, Kortmann BB, Verbeek AL, Kiemeney LA, Debruyne FM, de La Rossette JJ. Variability of pressure-flow studies in men with lower urinary tract symptoms. Neurourol Urodyn 2000;19(6):637-51. http://www.ncbi.nlm.nih.gov/pubmed/11071695 5. Eri LM, Wessel N, Berge V. Test-retest variation of pressure flow parameters in men with bladder outlet obstruction. J Urol 2001;165(4):1188-92. http://www.ncbi.nlm.nih.gov/pubmed/11257668 6. Kortmann BB, Sonke GS, Wijkstra H, Nordling J, Kallestrup E, Holm NR, de La Rosette JJ. Intra- and Inter-investigator variation in the analysis of pressure-flow studies in men with lower urinary tract symptoms. Neurourol Urodyn 2000;19(3):221-32. http://www.ncbi.nlm.nih.gov/pubmed/10797579 7. Rowan D, James ED, Kramer AE, Sterling AM, Suhel PF. Urodynamic equipment: technical aspects. Produced by the International Continence Society Working Party on Urodynamic Equipment. J Med Eng Technol 1987;11(2):57-64. http://www.ncbi.nlm.nih.gov/pubmed/2956425 8. Schafer W. A new concept for simple but specific grading of bladder outflow condition independent from detrusor function. J Urol 1993;149(2):574-7. 9. Abrams PH, Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979;51(2):129-34. http://www.ncbi.nlm.nih.gov/pubmed/465971 10. Rollema HJ, van Mastrigt R. Improved indication and follow-up in transurethral resection of the prostate using the computer program CLIM: a prospective study. J Urol 1992;148(1):111-5. http://www.ncbi.nlm.nih.gov/pubmed/1377287 11. Griffiths D, Hofner K, van Mastrigt R, Rollema HJ, Spångberg A, Gleason D. Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies. Neurourol Urodyn 1997;16(1):1-18. http://www.ncbi.nlm.nih.gov/pubmed/9021786 12. Neal DE, Styles RA, Powell PH, Thong J, Ramsden PD. Relationship between voiding pressure, symptoms and urodynamic findings in 253 men undergoing prostatectomy. Br J Urol 1987;60(6): 554-9. http://www.ncbi.nlm.nih.gov/pubmed/3427341 13. Neal DE, Ramsden PD, Sharples L, Smith A, Powell PH, Styles RA, Webb RJ. Outcome of elective prostatectomy. BMJ 1989;299(6702):762-7. http://www.ncbi.nlm.nih.gov/pubmed/2508914 14. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979;121(5):640-2. http://www.ncbi.nlm.nih.gov/pubmed/86617 15. Jensen KM-E. Clinical evaluation of routine urodynamic investigations in prostatism. Neurourol Urodynam 1989;8:545-78. 16. Robertson AS, Griffiths C, Neal DE. Conventional urodynamics and ambulatory monitoring in the definition and management of bladder outflow obstruction. J Urol 1996;155(2):506-11. http://www.ncbi.nlm.nih.gov/pubmed/8558647
22
UPDATE MARCH 2004
17.
Langen PH, Schafer W, Jakse G. Urodynamic assessment in patients undergoing transurethral resection of the prostate: a prospective study. In: Jakse G, et al, eds. Benign Prostatic Hyperplasia. New York: Springer-Verlag, 1992, pp. 75-84
3.11
Endoscopy
The standard endoscopic procedure for diagnostic evaluation of the lower urinary tract (urethra, prostate, bladder neck and bladder) is a urethrocystoscopy. This investigation can confirm causes of outflow obstruction while eliminating intravesical abnormalities. 3.11.1 LUTS caused by bladder outlet obstruction Voiding complaints in elderly men are most frequently caused by BPH resulting in benign prostatic obstruction. This obstruction has a critical role in altering voiding, resulting in significant (pathological) changes in the urinary tract of some patients and symptoms alone in others. However, the role of BPH in the voiding dysfunction experienced by elderly men is often unclear (1). Hyperplasia may be associated with striking lateral lobe enlargement, but symptoms may be negligible if the degree of obstruction is not severe. Conversely, BPH may be associated with a relatively small prostate and marked obstructive symptoms if the obstructing tissue originates exclusively within the central zone of the peri-urethral gland area (2). It is generally accepted that therapies aimed at removing obstruction will relieve LUTS in most men. Patients with BPH or other forms of bladder outlet obstruction may develop certain signs seen by urethrocystoscopy, indicating the presence of such obstruction. These signs may include: • enlargement of the prostate gland with visual obstruction of the urethra and the bladder neck • obstruction of the bladder neck by a high posterior lip of the bladder neck • muscular hypertrophy of the detrusor muscle, indicated by the presence of muscular trabeculation and the formation of cellules as well as diverticula • formation of bladder stones • retention of (post-void residual) urine. Thus, urethrocystoscopy may provide information about the cause, size and severity of obstruction, patency of the bladder neck, prostatic occlusion of the urethra and estimated prostate size (3). Several studies have addressed these issues. 3.11.2 Morbidity of urethrocystoscopy Berge et al. (4) studied 85 patients and found that the risk of acquiring clinically significant urinary tract infection was 2.4% after urethral instrumentation alone. 3.11.3 Relationship between trabeculation and peak flow rate Shoukry et al. (5) evaluated 122 patients of mean age 64 years with LUTS using three post-operative uroflowmetry tests and symptom evaluation. Urethrocystoscopy was also performed in these patients. The pre-operative peak flow rate was normal in 25% of 60 patients who had no bladder trabeculation, 21% of 73 patients with mild trabeculation and 12% of 40 patients with marked trabeculation on cystoscopy. All 21 patients who presented with diverticula had an ‘obstructive’ peak flow rate prior to surgery. Anikwe (6) showed that there was no significant correlation (p > 0.5) between the degree of trabeculation, as graded from I to IV, and the peak pre-operative flow rate in 39 men aged 53-83 years with LUTS. There appeared to be a trend towards lower peak flow rates in men with higher degrees of trabeculation. 3.11.4 Relationship between trabeculation and symptoms Simonsen et al. (7) found a correlation between the presence of trabeculation and the number of obstructive symptoms. When patients were grouped by age, it was noted that trabeculation significantly increased with increasing age (p < 0.5). In another study, none of the trabeculation ratings were predictive of symptom severity, while moderate-to-severe trabeculation was predictive of larger prostate size and reduced flow rate (8). 3.11.5 Relationship between trabeculation and prostate size Anderson and Nordling (9) examined the correlation between cystoscopic findings and the presence of trabeculation. While the cystoscopically estimated weight correlated with the presence of trabeculation (p = 0.003), the bladder neck to verumontanum distance and the cystoscopic appearance of occlusion did not correlate significantly (p > 0.5). Homma et al. (10) showed that patients had a high likelihood of outlet obstruction when their prostate size was greater than 30 mL or if their posterior urethra was severely obstructed on endoscopy. 3.11.6 Relationship between trabeculation and obstruction El Din et al. (11) evaluated urethroscopic findings and the results of urodynamic studies in 492 elderly men
UPDATE MARCH 2004
23
with LUTS. They noted a clear correlation between cystoscopic appearance (grade of trabeculation and grade of urethral obstruction) and urodynamic indices, detrusor instability and low compliance. It should be noted, however, that bladder outlet obstruction is present in approximately 15% of patients with normal cystoscopic findings, while approximately 8% of patients have no obstruction at all even if severe trabeculation is present, suggesting the inadvisability of drawing the same conclusion in all patients. They believe that the value of urethrocystoscopy is limited and advise against its use in the diagnosis of bladder outlet obstruction. Instead, it should be used primarily to exclude bladder pathology and to decide between interventional approaches. 3.11.7 Bladder diverticula and obstruction The detection of large bladder diverticula might be of therapeutic importance. For example, the presence of a large bladder diverticulum might dictate the type of intervention. It is, however, evident that other diagnostic modalities, such as cystography, intravenous pyelography (IVP) or transabdominal sonography, are equally sensitive, or more sensitive, at detecting large bladder diverticula, without carrying the risks of invasive urethrocystoscopy. No data are available to document the sensitivity or specificity of cystography, IVP, cystoscopy or transabdominal sonography for evaluating large bladder diverticula. Quirinia and Hoffmann (12) reported on 104 patients with BPH of whom 51% had diverticula by cystography. Although the presence of diverticula was related to age, upper tract dilation, increasing amounts of residual urine and bladder instability, there was no relationship with bladder capacity, peak flow rate or prostate size. At present, no final decision about the value of cystoscopy in the assessment of bladder diverticula can be made. Equally poorly documented is the impact that the presence or absence of bladder diverticula might have on outcome after prostate surgery. 3.11.8 Bladder stones and obstruction There is no doubt that the presence of bladder stones can be assessed accurately by urethrocystoscopy. Bladder stones are a clear indicator of bladder outlet obstruction. While it is not always clear whether the obstruction is of an organic, anatomical or neurogenic nature, the presence of stones in the bladder indicates an abnormality in the bladder-emptying mechanism and is usually preceded by the presence of residual urine or recurrent urinary tract infections. However, there is also no doubt that bladder stones are detected equally well by IVP or by the non-invasive method of transabdominal sonography. In fact, stones composed of poorly radio-opaque or radiolucent material are seen very well by transabdominal sonography, while being missed on a renal ultrasound. The crux of the matter has to be whether or not the detection of bladder stones dictates the surgical procedure of choice. It is obvious that the presence of a large bladder stone should guide the surgeon towards an open procedure rather than a lengthy electrohydraulic lithotripsy. However, the majority of all bladder stones are rather small, and can be removed during TURP through the sheath of the resectoscope, or by destroying them with endoscopic instruments prior to washing them out. It is therefore questionable whether or not urethrocystoscopy should be performed to assess the presence or absence of bladder stones prior to surgery for BPH, particularly as most patients with bladder stones will have microscopic haematuria that will have been detected during the standard basic evaluation. 3.11.9 Intravesical pathology The detection of other pathology (urethral or intravesical) is advantageous and can be accomplished by endoscopy better than with most other modalities. In a study by Ezz El Din et al. (13), urinalysis and a cystoscopy were performed in 750 consecutive patients with BPH. Only three patients had a bladder tumour while 49 had urinary calculi. There was no correlation between any clinical parameter and the finding of microscopic haematuria. It was concluded that haematuria is a frequent finding in the assessment of BPH patients and that additional tests should only be performed if indicated (e.g. in the case of abnormal urine cytology). 3.11.10 Conclusions Diagnostic endoscopy of the lower urinary tract should be considered an optional test for the following reasons: • the outcomes of the intervention are unknown • the benefits do not outweigh the harm of the invasive study • patients’ preferences are expected to be divided. 3.11.11 References 1. Grayhack JT. Benign prostatic hyperplasia. The scope of the problem. Cancer 1992;70(Suppl 1): 275-9. http://www.ncbi.nlm.nih.gov/pubmed/1376196
24
UPDATE MARCH 2004
Bostwick DG. Pathology of benign prostatic hyperplasia. In: Textbook of Benign Prostatic Hyperplasia. Kirby R et al, eds. Oxford: Isis Medical Media, 1996, pp. 91-104. http://www.isismedical.com/ 3. Larsen EH, Bruskewitz RC. Urodynamic evaluation of male outflow obstruction. Krane RJ, Siroky B, eds. Clinical Neurourol. New York 1991, pp 427-443. 4. Berge V, Eri LM, Tveter KJ. Complications of invasive, urodynamic examinations and prostate biopsies in patients with benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1995;172:95-8. http://www.ncbi.nlm.nih.gov/pubmed/8578262 5. Shoukry I, Susset JG, Elhilali MM, Dutartre D. Role of uroflowmetry in the assessment of lower urinary tract obstruction in adult males. Br J Urol 1975;47(5):559-66. http://www.ncbi.nlm.nih.gov/pubmed/1191927 6. Anikwe RM. Correlations between clinical findings and urinary flow rate in benign prostatic hypertrophy. Int Surg 1976;61(8):392-4. http://www.ncbi.nlm.nih.gov/pubmed/61184 7. Simonsen O, Møller-Madsen B, Dørflinger T, Nørgaard JP, Jørgensen HS, Lundhus E. The significance of age on symptoms and urodynamic and cystoscopic findings in benign prostatic hypertrophy. Urol Res 1987;15(6):355-8. http://www.ncbi.nlm.nih.gov/pubmed/2448939 8. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993;150(2 Pt 1):351-8. http://www.ncbi.nlm.nih.gov/pubmed/7686980 9. Andersen JT, Nordling J. Prostatism. II. The correlation between cysto-urethroscopic, cystometric and urodynamic findings. Scand J Urol Nephrol 1980;14(1):23-7. http://www.ncbi.nlm.nih.gov/pubmed/7375838 10. Homma Y, Gotoh M, Takei M, Kawabe K, Yamaguchi T. Predictability of conventional tests for the assessment of bladder outlet obstruction in benign prostatic hyperplasia. Int J Urol 1998;5(1):61-6. http://www.ncbi.nlm.nih.gov/pubmed/9535603 11. El Din KE, de Wildt MJ, Rosier PF, Wijkstra H, Debruyne FM, de la Rosette JJ. The correlation between urodynamic and cystoscopic findings in elderly men with voiding complaints. J Urol 1996;155(3):1018-22. http://www.ncbi.nlm.nih.gov/pubmed/8583551 12. Quirinia A, Hoffmann AL. Bladder diverticula in patients with prostatism. Int Urol Nephrol 1993;25(3):243-7. http://www.ncbi.nlm.nih.gov/pubmed/7693606 13. Ezz el Din K, Koch WF, de Wildt MJ, Debruyne FM, de la Rosette JJ. The predictive value of microscopic haematuria in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Eur Urol 1996;30(4):409-13. http://www.ncbi.nlm.nih.gov/pubmed/8977059 2.
3.12 RECOMMENDATIONS FOR ASSESSMENT 1. Among all the different urinary symptom score systems currently available, the use of I-PSS is recommended because of its worldwide distribution and use. 2. In patients undergoing investigation for LUTS, the minimal requirement is to assess the upper urinary tract function with a creatinine measurement and/or an ultrasonographic examination. Urinalysis may be included in the primary evaluation. However, it should be noted that there is little evidence in the literature to support this conclusion. 3. DRE is a minimal requirement in patients undergoing investigation for LUTS. 4. There is a consensus that if imaging of the upper urinary tract is performed, ultrasonography is the method of choice. 5. Imaging of the upper urinary tract is recommended in patients with LUTS and one of the following: • History of, or a current, urinary tract infection • History of urolithiasis • History of urinary tract surgery • History of urothelial tumour (including IVU) • Haematuria (including IVU) • Urinary retention. 6. CT and MRI currently have no place in the routine imaging of the upper urinary tract in elderly men with LUTS. 7. Routine imaging of the urinary bladder cannot be recommended as a diagnostic test in the work-
UPDATE MARCH 2004
25
up of patients with LUTS. Ultrasound of the bladder, however, is a valuable diagnostic tool for the detection of bladder diverticula or bladder stones. 8. Routine imaging of the urethra is not recommended in the diagnostic work-up of patients with LUTS. 9. The method of choice for the determination of prostate volume is ultrasonography, preferably via the transrectal route. However, imaging of the prostate by transabdominal ultrasound and TRUS is optional. 10. Prostate size should be assessed when considering open prostatectomy and TUIP, and prior to finasteride therapy. 11. If the voided volume is less than 150 mL or Qmax is greater than 10 mL/s, pressure-flow studies should be considered before surgical intervention, particularly in elderly men. 12. Measurement of residual urine volume is a recommended test in the assessment of patients with LUTS suggestive of benign prostatic obstruction. 13. Uroflowmetry is recommended as a diagnostic assessment in the work-up of patients with LUTS and is an obligatory test prior to surgical intervention. 14. Post-void residual urine measurement is recommended during initial assessment. 15. Endoscopy is recommended as a guideline at the time of surgical treatment to rule out other pathology and to assess the shape and size of the prostate, which may have an impact on the treatment modality chosen. 16. Pressure-flow studies should be considered for patients prior to surgical treatment in the following subgroups: • younger men (e.g. < 50 years of age) • elderly patients (i.e. > 80 years of age) • post-void residual urine volume over 300 mL • Qmax more than 15 mL/s • suspicion of neurogenic bladder dysfunction • after radical pelvic surgery • previous unsuccessful invasive treatment. In straightforward cases presenting for the first time with LUTS, pressure-flow studies remain optional tests.
4. TREATMENT 4.1
Watchful waiting (WW)
Many men with LUTS do not complain of high levels of bother and so are suitable for non-medical non-surgical management - a policy of care that has been called watchful waiting (WW). It is customary for this type of management to include the following components: education, reassurance, periodic monitoring and lifestyle advice. In many men it is regarded as the first tier in the therapeutic cascade and therefore the majority of men will be offered watchful waiting at some point. WW is a viable option to many men as few, if left untreated, will progress to acute urinary retention and complications such as renal insufficiency and stones (1,2). Similarly some men’s symptoms may improve spontaneously whilst others remain stable for many years (3). 4.1.1 Patient selection All men with LUTS should be formally assessed prior to starting any form of management in order to identify those with complications that may benefit from intervention therapy. Men with mild to moderate uncomplicated LUTS (causing no serious health threat) who are not too bothered by their symptoms are suitable for a trial of WW. A large study comparing WW and TURP in men with moderate symptoms showed that those who had surgery had improved bladder function over the WW group (flow rates and post void residual volumes) with the best results being in those with high levels of bother. 36% crossed over to surgery in 5 years leaving 64% doing well in the WW group (4). Approximately 85% of men will be stable on WW at 1 year, deteriorating progressively to 65% at 5 years (5,6). The reason why some men deteriorate with WW and others do not is not well understood; increasing symptom bothersomeness and post-void residual volumes appeared to be strongest predictors of failure. 4.1.2 Education, reassurance and periodic monitoring Although there is little high quality evidence to support this (the studies have not been done) it seems rational to provide the following for men who are candidates for WW: • prostate, BPH and LUTS education with the help of written information
26
UPDATE MARCH 2004
• •
•
reassurance that LUTS does not progress in everyone. Reassurance that serious complications are unlikely to occur. information about prostate cancer is nearly always required. Anxiety regarding prostate cancer can be the principal reason why a man consults his doctor about his urinary symptoms. Most men over 50 will note changes in their urinary function with or without high levels of bother. If these men harbour an anxiety about prostate cancer, this may focus their attention on specific symptoms and reinforce their fear. At least three high-quality studies have shown that men with LUTS are at no greater risk of prostate cancer than asymptomatic men of the same age (7-9). It is however not possible to guarantee against early undetectable prostate cancer. WW does not imply no activity; men should be periodically seen by either a urologist, general practitioner or specialist nurse. Symptom scores, symptom bothersomeness, flow rates and postvoid residual volume measurements are useful in determining whether a patient’s condition has deteriorated.
4.1.3 Lifestyle advice Optimization of WW can be achieved with lifestyle modifications. Minor changes in lifestyle and behaviour can have a beneficial effect on symptoms and may prevent deterioration requiring medical or surgical treatment. Lifestyle advice should include: • reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient, for example at night or when going out in public. The recommended total daily fluid intake of 1500 mL should not be reduced. • avoidance or moderation of caffeine and alcohol which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia. - use of relaxed and double-voiding techniques - urethral stripping to prevent postmicturition dribble. • distraction techniques, such as penile squeeze, breathing exercises, perineal pressure and mental ‘tricks’ to take the mind off the bladder and toilet in the control of irritative symptoms. • bladder re-training, by which men are encouraged to ‘hold on’ when they have sensory urgency to increase their bladder capacity (to around 400 mL) and the time between voids. • reviewing a man’s medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects. • providing necessary assistance when there is impairment of dexterity, mobility or mental state. • treatment of constipation. Again it must be stated that there is little high-quality evidence that provides reliable information on any of these lifestyle activities. Research in this area is required so that lifestyle advice to men with LUTS can be refined. 4.1.4 Conclusions Men with mild to moderate LUTS with low levels of bother are suitable for WW. Reassurance, periodic monitoring and lifestyle modifications can be used to optimise WW. Further research in this area is required.
4.1.5 1.
References Ball AJ, Feneley RC, Abrams PH. The natural history of untreated ‘prostatism’. Br J Urol 1981;53(6):613-6. http://www.ncbi.nlm.nih.gov/pubmed/6172172 2. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade?. Urology 2000;56(5 Suppl 1):3-6. http://www.ncbi.nlm.nih.gov/pubmed/11074195 3. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl. 1990;3:1-7. http://www.ncbi.nlm.nih.gov/pubmed/1689166 4. Flanigan RC, Reda DJ, Wasson JH Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic BPH: a department of Veterans Affairs cooperative study. J Urol 1998;160(1):12-6;discussion 16-7. http://www.ncbi.nlm.nih.gov/pubmed/9628595
UPDATE MARCH 2004
27
5.
Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of Transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. New Engl J Med 1995;332(2):75-9. http://www.ncbi.nlm.nih.gov/pubmed/7527493 6. Netto NR Jr, de Lima ML, Netto MR, D’Ancona CA. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urol 1999;53(2):314-6. http://www.ncbi.nlm.nih.gov/pubmed/9933046 7. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicentre clinical trial of 6,630 men. J Urol 1994;15(5):1283-90. http://www.ncbi.nlm.nih.gov/pubmed/7512659 8. Mettlin C, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup RJ, Mostofi FK, Ray PS, Shanberg AM, Toi A. American Cancer Society National Prostate Cancer Detection Project. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1996;77(1):150-9. http://www.ncbi.nlm.nih.gov/pubmed/8630923 9. Rietbergen JB, Kranse R, Boeken Kruger AE, et al. Additional value of the AUA 7 symptoms score in prostate cancer (PC) detection. J Urol 1997;157:467.
4.2
Medical treatment
4.2.1 5-alpha reductase inhibitors 4.2.1.1 Finasteride (type 2, 5-alpha reductase inhibitor) 4.2.1.1.1 Efficacy and clinical endpoints Today, after the completion of many trials, the efficacy of 5-alpha reductase inhibitors is unquestionable and has been demonstrated over large clinical trials. It can reduce the size of the prostate gland by 20-30%; it improves symptom scores by approximately 15% and can also cause a moderate improvement in the urinary flow rate of 1.3-1.6 mL/s (1-4). A meta-analysis of six randomized clinical trials showed that baseline prostate volume was a key predictor of various treatment outcomes and that finasteride was more effective in prostates larger than 40 mL (5). Various trials have concluded that finasteride significantly reduced acute urinary retention and the need for surgical treatment in men with BPH (6-8). In a major placebo controlled trial including 3,040 men, finasteride-treated patients had significantly less bother, activity interference and worry due to urinary symptoms. Baseline PSA levels of 1.4 ng/mL, or enlarged prostate glands, could predict the best long-term response to finasteride (9). Data from three multinational, multicentre, placebo-controlled finasteride trials, in 4,222 men, showed that patients with larger prostate volumes or higher PSA levels have an increased risk of developing acute urinary retention and therefore derive the greatest benefit from finasteride therapy (10). The long-term effects of finasteride have also been examined. The North American Finasteride Study Group reported that patients treated with finasteride maintained a reduction of prostate volume and an improvement in symptom score and maximal urinary flow rate over a period of 5 years (11). In addition, the Scandinavian Finasteride Study Group has verified an earlier observation that the maximum efficacy of finasteride action is obtained after 6 months, and has shown that this improvement could be maintained for at least 6 years (12). A recent North American study has also verified that long term (10 year) treatment is well tolerated and results in durable symptom relief (13). 4.2.1.1.2 Haematuria and finasteride Another important benefit of finasteride in common clinical urological practice is that it can be used to treat haematuria associated with BPH. Various studies have confirmed this alternative for patients with haematuria due to BPH who, at the same time, had no significant obstruction or adenocarcinoma of the prostate (14-16). 4.2.1.1.3 Side-effects These are mainly related to sexual function. In the PLESS study the side effects reported were decreased libido (6,4%), impotence (8,1%), decreased ejaculate (3,7%) and in less than 1% of the patients other disorders such as rash, breast enlargement and breast tenderness (9). All these figures were higher than those observed for placebo. Such side-effects are considered ‘minimal’ since they did not increase over time and did not cause many patients to discontinue their treatment. In a recent publication from the PLESS study group it was shown that the finasteride-related sexual adverse experiences occurred mainly during the first year of therapy (17). Another conclusion from the PLESS study was that in both older and younger men with symptomatic BPH,
28
UPDATE MARCH 2004
finasteride had the same safety profile and no drug interactions of clinical importance were observed (18). Finally it has also been shown that the four year inhibition of type 2 5alpha-reductase with finasteride does not adversely affect bone mineral density (19). 4.2.1.1.4 Effect on PSA It is known that finasteride lowers serum PSA levels. Thus, the question of whether or not it masks the early detection of localized prostatic adenocarcinomas has been raised. It has been agreed that 12 months of finasteride, 5 mg/day, reduces serum PSA levels by 50%. Two major studies (20,21) verified earlier reports, and concluded that doubling the PSA level allowed appropriate interpretation of PSA values and that finasteride treatment did not mask the detection of prostatic adenocarcinomas. It was also shown, at the histopathological level, that finasteride did not cause problems in the diagnosis of cancer from needle specimens as cancer tissue remained unaltered (22). The results of papers dealing with the impact of finasteride on free PSA level are confusing. In one paper, finasteride seemed to lower total and free PSA levels equally, so that the ratio of free PSA to total PSA remained unchanged (23). In another report, the percentage of free PSA did not change significantly (24). 4.2.1.2 Dutasteride It is known that finasteride suppresses dihydrotestosterone (DHT) by about 70% in the serum and by 90% in the prostate. The remaining DHT is the result of type 1 5-alpha reductase activity. Dutasteride is a new drug that has the ability to suppress both type 1 and type 2 isoenzymes and as a consequence serum DHT decreases by about 90% (25). A phase II study including 399 patients showed that dutasteride can cause greater suppression of DHT than finasteride (26). The results of four large randomized, double-blind clinical trials have been presented (27, 28). Three of these studies were placebo controlled studies and they showed that dutasteride can reduce prostatic volume by almost 26%, improve symptoms and urinary flow rate and reduces also the incidence of acute urinary retention and BPH related surgery. The fourth compared dutasteride with finasteride for one year which showed that drug related adverse events were similar for both compounds. Pooled data from the patients enrolled in all four studies proved that dutasteride is well tolerated and adverse events included erectile dysfunction, ejaculatory disorders and gynecomastia (27). In a recently published study it was also shown that dutasteride is associated with clinically significant improvement in BPH specific health status as measured by the BPH Impact Index (BII) (29). Dutasteride shows similar efficacy and tolerability as finasteride in suppressing both type 1 and type 2 isoenzymes but further randomized studies are needed. 4.2.1.3 Combination therapy The combination of finasteride with an alpha-blocker was examined earlier in two clinical trials (30,31). No additional benefit from combining these two drugs was observed in either study. The lack of finasteride efficacy in these two trials may be due to smaller baseline prostate volumes. Recently the results of a multicentre randomized, placebo-controlled double-blinded trial (MTOPS trial), have shown that the combination of finasteride to doxazocin was beneficial (32).The combination therapy was superior to either drug alone in reducing AUA symptom scores, in increasing median maximal flow rates, and in reducing the likelihood of acute urinary retention and surgery. The follow-up period of the MTOPS trial was 4.5 years and another conclusion drawn from this study was that finasteride needs time to reveal its beneficial therapeutic capacity. In another study examining combination therapy, it was shown that patients with lower urinary tract symptoms and moderately enlarged prostates initially receiving combination therapy with finasteride and an alpha-blocker were likely to experience no significant symptom deterioration after discontinuing the alphablocker following 9 to 12 months of combination therapy (33). A multicentre, placebo-controled study, SMART Study C (Symptom Management After Reducing Therapy), on the short term combination of dutasteride and tamsulosin involving 327 patients confirmed compatible results (34). 4.2.1.4 Conclusions • It has been shown in numerous randomized, placebo-controlled clinical trials that 5-alpha reductase inhibitors are capable of reducing prostate volume and improving symptom scores and flow rates. Maximum benefits are seen at a mean period after 6 months. • Men with small prostates (< 40 mL) are less likely to benefit from finasteride. • 5-alpha reductase inhibitors can alter the natural history of symptomatic BPH by influencing prostatectomy and acute urinary retention rates. The costs of such protocols, however, should be further evaluated. • The long-term (up to 10 years) effects of 5- alpha reductase inhibitors are substantial.
UPDATE MARCH 2004
29
• • •
The combination of a 5-alpha reductase inhibitor with an alpha-blocker seems beneficial according to the data currently available. Side-effects of 5-alpha reductase inhibitors are minimal Treatment with 5-alpha reductase inhibitors does not mask the detection of prostate carcinoma. By doubling PSA serum levels, an accurate estimation can be expected.
4.2.1.5 References 1. Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo-controlled study. The Scandinavian BPH study group. Urology 1995;46(5):631-7. http://www.ncbi.nlm.nih.gov/pubmed/7495111 2. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327(17):1185-91. http://www.ncbi.nlm.nih.gov/pubmed/1383816 3. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomised controlled trial (the PROSPECT Study). CMAJ 1996;155(9):1251-9. http://www.ncbi.nlm.nih.gov/pubmed/8911291 4. Vaughan D, Imperato-McGinley J, McConnell J, Matsumoto AM, Bracken B, Roy J, Sullivan M, Pappas F, Cook T, Daurio C, Meeha A, Stoner E, Waldstreicher J. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 2002,60(6):1040-4. http://www.ncbi.nlm.nih.gov/pubmed/12475666 5. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts the outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48(3):398-405. http://www.ncbi.nlm.nih.gov/pubmed/8804493 6. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with sympomatic benign prostatic hyperplasia. Urology 1997;49(6):839-45. http://www.ncbi.nlm.nih.gov/pubmed/9187688 7. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-term Efficacy and Safety Study Group. N Engl J Med 1998;338(9):557-63. http://www.ncbi.nlm.nih.gov/pubmed/9475762 8. Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox C, Anderson R, Kandzari S, Herlihy R, Kornitzer G, Brown BT, Holtgrewe HL, Taylor A, Wang D, Waldstreicher J. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur Urol 2000;37(5):528-36. http://www.ncbi.nlm.nih.gov/pubmed/10765090 9. Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB Fusilier HA, Kozlowski D, Kantor SD, Johnson EL, Wang DZ, Waldstreicher J. Effect of finasteride on bother and other healthrelated quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999;54(4):670-8. http://www.ncbi.nlm.nih.gov/pubmed/10510926 10. Marberger MJ, Andersen JT, Nickel JC, Malice MP, Gabriel M, Pappas F, Meehan A, Stoner E, Waldstreicher J. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urology 2000;38(5):563-8. http://www.ncbi.nlm.nih.gov/pubmed/11096237 11. Hudson PB, Boake R, Trachtenberg J, Romas NA, Rosenblatt S, Narayan P, Geller J, Lieber MM, Elhilali M, Norman R, Patterson L, Perreault JP, Malek GH, Bruskewitz RC, Roy JB, Ko A, Jacobsen CA, Stoner E. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology 1999;53(4):690-5. http://www.ncbi.nlm.nih.gov/pubmed/10197842
30
UPDATE MARCH 2004
12.
Ekman P. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-extension Study. The Scandinavian Finasteride Study Group. Eur Urol 1998;33(3):312-7. http://www.ncbi.nlm.nih.gov/pubmed/9555559 13. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003;61(2):354-8. http://www.ncbi.nlm.nih.gov/pubmed/12597947 14. Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, Holmes SA. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000;163(2):496-8. http://www.ncbi.nlm.nih.gov/pubmed/10647664 15. Kearney MC, Bingham JB, Bergland R, Meade-D’Alisera P, Puchmer PJ. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 2002;167(6):2489-91. http://www.ncbi.nlm.nih.gov/pubmed/11992064 16. Perimenis P, Gyftopoulos K, Markou S, Barbalias G. Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. Urology 2002;59(3):373-7. http://www.ncbi.nlm.nih.gov/pubmed/11880073 17. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J; PLESS Study Group. Incidence and severity of sexual adverse experiences in finasterides and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61(3):579-84. http://www.ncbi.nlm.nih.gov/pubmed/12639651 18. Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P, Lund RH, Weiner S, Wells G, Cook TJ, Meehan A, Waldstreicher J. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001;57(6):1073-7. http://www.ncbi.nlm.nih.gov/pubmed/11377309 19. Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GK, Schmidt J, Taylor AM, Lee M, Waldstreicher J. PLESS Study Group. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002;167(5):2105-8. http://www.ncbi.nlm.nih.gov/pubmed/11956450 20. Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, Lagerkvist M, Gormley G, Bach M, Waldstreicher J. Biologic variability of prostate specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology 1997;50(1):13-8. http://www.ncbi.nlm.nih.gov/pubmed/9218012 21. Andriole GL, Guess HA, Epstein JL, Wise H, Kadmon D, Crawford ED, Hudson P, Jackson CL, Romas NA, Patterson L, Cook TJ, Waldstreicher J. Treatment with finasteride preserves usefulness of prostate specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998;52(2):195-201. http://www.ncbi.nlm.nih.gov/pubmed/9697781 22. Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Rouse S, Waldstreicher J, Epstein JI. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999;53(4):696-700. http://www.ncbi.nlm.nih.gov/pubmed/10197843 23. Keetch DW, Andriole GL, Ratliff TL, Catalona WJ. Comparison of percent free prostate specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin or watchful waiting. Urology 1997;50(6):901-5. http://www.ncbi.nlm.nih.gov/pubmed/9426721 24. Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E, Partin AW. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998;159(2):449-53. http://www.ncbi.nlm.nih.gov/pubmed/9649261 25. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5 alpha – reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002,19(6):413-25. http://www.ncbi.nlm.nih.gov/pubmed/12022710
UPDATE MARCH 2004
31
26. Clarke R, Hermann D, Gabriel H, Wilson T, Morril B, Hobbs S. Effective suppression of dihydrotestosterone (DHT) by GI 198745, a novel, dual 5-alpha reductase inhibitor. J Urol 1999;161:1037. 27. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001, ARIA3002 and ARIA3003 study investigators. Efficacy and safety of a dual inhibitor or 5-alphareductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434-41. http://www.ncbi.nlm.nih.gov/pubmed/12350480 28. Andriole GL, Kirby R Safety and tolerability of the Dual 5 alpha-Reductase Inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44(1):82-8. http://www.ncbi.nlm.nih.gov/pubmed/12814679 29. O’Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5 alpha-reductase inhibitor. BJU Inter 2003;92(3):262-5. http://www.ncbi.nlm.nih.gov/pubmed/12887480 30. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies, Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335(8):533-9. http://www.ncbi.nlm.nih.gov/pubmed/8684407 31. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC, McCarthy C, GeffriaudRicouard C. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998;34(3):169-75. http://www.ncbi.nlm.nih.gov/pubmed/9732187 32. Mc Connell JD. The long term effects of medical therapy on the progression of BPH: Results from the MTOPS trial. J Urol 2002;167:265, abstr 1042. 33. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001;58(2):203-9. http://www.ncbi.nlm.nih.gov/pubmed/11489700 34. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alphareductase inhibitor dutasteride. Eur Urol 2003;44(4):461-6. http://www.ncbi.nlm.nih.gov/pubmed/14499682 4.2.2 Alpha-blockers Over the past 10 years, the prescribing of alpha-blockers has steadily increased. This increase has been driven partly by patients wishing to achieve symptomatic relief without undergoing surgical treatments and partly by the marketing of these drugs by pharmaceutical companies. In view of the very real placebo effect seen in the treatment of patients with LUTS secondary to BPH, this review will focus on the results of randomized, prospective, placebo-controlled clinical studies. 4.2.2.1 Uroselectivity Alpha-blockers were first introduced into clinical practice for the treatment of LUTS secondary to BPH in 1978, following experimental work demonstrating the predominance of adrenoceptors in human prostate smooth muscle (1). Initially, the non-selective alpha-blocker, phenoxybenzamine, was investigated. However, the side-effect profile, due to its unselective nature, was unacceptable to patients (2,3). Subsequently, alpha1adrenoceptors were identified and selective, better-tolerated, alpha-blockers were developed. A large number of alpha1-selective, alpha-blockers are available (tamsulosin, alfuzosin, doxazosin, indoramin, prazosin, terazosin). Broadly speaking, they all have a similar efficacy and side-effect profile. 4.2.2.2 Mechanism of action Alpha-blockers are thought to act by reducing the dynamic element of prostatic obstruction by antagonizing the adrenergic receptors responsible for smooth muscle tone within the prostate and bladder neck. This is implied from in-vitro experiments and the predominant distribution of alpha1-receptors within the prostate and bladder neck. However, the exact contributions of alpha1-receptor subtypes and the potential central effects in vivo remain unclear. Urodynamic studies measuring voiding pressures do not reveal any significant relief of obstruction, although flow rates do improve with these agents relative to placebo.
32
UPDATE MARCH 2004
4.2.2.3 Pharmacokinetics Alpha-blockers are taken orally and the dosage depends on the half-life of the relevant drug. Tamsulosin, alfuzosin, terazosin and doxazosin have the advantage of being long-acting, once-daily preparations. 4.2.2.4 Assessment It is not unreasonable to offer a trial of alpha-blockers to all men with uncomplicated LUTS. The optimal duration of the trial of therapy has been debated. Symptoms can improve within 48 hours. An I-PSS assessment requires at least one month of therapy. There is no justification in prolonging therapy beyond one month in men who do not respond. One-third of men will not experience significant symptom reduction. Currently there is no method of predicting which men will show a response (4). 4.2.2.5 Clinical efficacy The interpretation of existing literature regarding the efficacy of alpha-blocker therapy is clouded by the wide dis crepancy in methodology and reporting of clinical studies. Because of this, secondary publications that have com pared outcomes between these studies have been useful (5-7). Djavan and Marberger’s meta-analysis estimated that overall symptoms improved by 30-40% and that flow rates improved by 16-25%, compared with placebo (6). Predicting response for any individual is more difficult and therefore a trial of therapy is required. The various types of alpha-blockers cannot be distinguished by their ability to relieve symptoms or improve flow. 4.2.2.6 Durability Good data on long-term efficacy and the effect on natural history are currently not available. Long-term studies tend to be open-label extensions or increasingly ‘real life practice’ studies which do not conform to an experimental design. Nevertheless, in this context these types of design are informative. Patients may choose to stop taking medication for a number of reasons. Studies have concentrated on two important reasons, namely, the occurrence of adverse effects and lack of efficacy (8). In general, the symptom status of men did not predict whether they were likely to stop therapy. Drop-outs occurred at the same rate, irrespective of whether symptoms were moderate or severe. The rate of drop-out in men on alphablockers appears to be between 0.01 and 1.6 per month. There is no evidence that efficacy diminishes with time. 4.2.2.7 Adverse effects The most commonly reported side-effects with alpha-blocker therapy are headaches, dizziness, postural hypotension, asthenia, drowsiness, nasal congestion and retrograde ejaculation (6). In general, the rate of sideeffects in studies looking at tamsulosin and alfuzosin were equivalent to placebo (4-10%). Tamsulosin resulted in less orthostatic hypotension than alfuzosin under test conditions. Whether this translates into a reduction in clinical side-effects remains to be seen. 4.2.2.8 Acute urinary retention Early trials comparing alpha-blockers to placebo showed an increased likelihood of a successful trial, without catheter, following an episode of acute urinary retention. As a result, a large number of urologists have adopted this practice. The effect seems to be independent of the type of alpha-blocker studied. Two trials have looked at alfuzosin (11), and one at terazosin (12). None of these trials continued therapy beyond the period of catheterization. Most men experience re-retention within the first two months (13). Studies are underway which address the question of whether men do benefit from alpha-blockade in the six months following acute urinary retention. 4.2.2.9 Conclusions • Alpha-blocker therapy can result in a rapid improvement in symptoms by a factor of 20-50% and an improvement in the flow rate of 20-30%. These changes have been shown to be significant in randomized, placebo-controlled studies. • Long-term data are limited but suggest that the benefits of treatment are sustained. If a patient does not experience an improvement in symptoms after an 8-week trial, treatment should be discontinued. • Patients should be informed about the side-effects of alpha-blocker therapy and the need for longterm use. • There is no difference between different alpha-blockers in terms of efficacy. Although the side-effect profiles for some drugs are reported to be more favourable, supportive data are weak.
UPDATE MARCH 2004
33
4.2.2.10 References 1. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975;47(2):193-202. http://www.ncbi.nlm.nih.gov/pubmed/1148621 2. Caine M, Perlberg S, Meretyk S. A placebo controlled double blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978;50(7):551-4. http://www.ncbi.nlm.nih.gov/pubmed/88984 3. Abrams PH, Shah PJ, Stone R, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982;54(5):527-30. http://www.ncbi.nlm.nih.gov/pubmed/6184106 4. Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction. A stratified analysis. Urology 1997;49(2):197-205. http://www.ncbi.nlm.nih.gov/pubmed/9037281 5. Chapple CR, Andersson KF, Bono VA et al. a-blockers clinical results. In: Denis L, Griffiths K, Khoury S, et al. eds. Proceedings of the Fourth International Consultation on BPH, Paris, July 1997. Plymouth:Health Publications, 1998, pp. 610-632. http://www.congress-urology.org/ 6. Djavan B, Marberger M. Meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36(1):1-13. http://www.ncbi.nlm.nih.gov/pubmed/10364649 7. Debruyne FM. Alpha blockers: are all created equal? Urology. 2000;56(5 Suppl 1):20-2. http://www.ncbi.nlm.nih.gov/pubmed/11074198 8. Lukacs B, McCarthy C, Grange JC. Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7093 patients treated with alpha-1 adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice. Eur Urol 1993;24 Suppl 1:34-40. http://www.ncbi.nlm.nih.gov/pubmed/7687557 9. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998;51(6):901-6. http://www.ncbi.nlm.nih.gov/pubmed/9609624 10. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC, McCarthy C, GeffriaudRicouard C. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998;34(3):169-75. http://www.ncbi.nlm.nih.gov/pubmed/9732187 11. McNeil SA, Daruwala PD, Mitchel ID, Shearer MG, Hargreave TB. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective placebo-controlled. BJU Int 1999;84(6):622-7. http://www.ncbi.nlm.nih.gov/pubmed/10510105 12. Chan PSF, Wong WS, Chan LW, Cheng CW. Can terazosin (alpha blocker) relieve acute urinary retention and obviate the need for an indwelling urethral catheter?. Br J Urol 1996;77:Suppl.1:27. 13. McNeill SA, Hargreave TB, Gallagher H, Daruwala PD, Mitchell I-DC, Rizvi S. Long term follow-up following presentation with first episode of acute urinary retention. J Urol 2000;163:307. 4.2.3 Phytotherapeutic agents The use of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia has been popular in Europe for many years and has recently spread in the USA. These agents are composed of various plant extracts and it is always difficult to identify which component has the major biological activity. A few short term randomized trials and some meta-analyses show clinical efficacy without major side effects for compounds such as Pygeum africanum and Serenoa repens (1-4). In some studies the efficacy of these compounds was found to be equivalent to finasteride and α-blockers (5,6). Many questions concerning the composition, the extraction and the mechanism of action of these compounds still remain unanswered and therefore additional randomized, placebo controlled trials are needed (7). 4.2.3.1 Conclusions The mode of action of phytotherapeutic agents is unknown. The biological effects in unclear although a few randomized clinical trials show encouraging results.
34
UPDATE MARCH 2004
4.2.3.2 References 1. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;(1):CD001044. http://www.ncbi.nlm.nih.gov/pubmed/11869585 2. Wilt T, Ishani A, Stark G, Mac Donald R, Mulrow C, Lau J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000;(2):CD001423. http://www.ncbi.nlm.nih.gov/pubmed/10796790 3. Fagelman E, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am 2002;29(1):23-9, vii. http://www.ncbi.nlm.nih.gov/pubmed/12109350 4. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 2002;12(1):15-8. http://www.ncbi.nlm.nih.gov/pubmed/11753128 5. Lowe FC. Phytotherapy in the management of benign prostatic hyperplasia. Urology 2001; 58(6 Suppl 1):71-6; discussion 79-7. http://www.ncbi.nlm.nih.gov/pubmed/11750257 6. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, VelaNavarrete R, Raynaud JP. Comparison of a phytotherapeutic agent (Permixon) with an alphablocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002;41(5):497-506. http://www.ncbi.nlm.nih.gov/pubmed/12074791 7. Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World J Urol 2002;19(6):426-35. http://www.ncbi.nlm.nih.gov/pubmed/12022711
4.3
Surgical management
Transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP) and open prostatectomy are the conventional surgical options. Transurethral vaporisation, an electrosurgical modification of the TURP-technique, is also included to this chapter. Two randomized controlled trials (RCTs) are available for open prostatectomy, while TURP, TUIP and TUVP have been subjected to a number of RCTs. 4.3.1 Indications for surgery The most frequent indication for surgical management is bothersome LUTS refractory to medical management (1,2). The following complications of BPH/BPE are considered strong indications for surgery: • refractory urinary retention • recurrent urinary retention • recurrent haematuria refractory to medical treatment with 5-alpha reductase inhibitors • renal insufficiency • bladder stones. Increased post-void residual volume may also be used as an indication for surgery. However, there is a great intra-individual variability and an upper limit requiring intervention has not been requiring intervention has not been defined. Variables that most likely predict the outcome of prostatectomy are severity of LUTS, the degree of bother and the presence of BPO (see above) (3,4). 4.3.2 Choice of surgical treatment Ten RCT comparing TUIP to TURP are available (5-7). They showed similar improvements of LUTS in patients with small prostates (< 20-30 mL) and no middle lobe (5-7). TUIP has several advantages has several advantages over TURP, such as a lower incidence of complications, minimal risk of bleeding and blood transfusion, decreased risk of retrograde ejaculation and shorter operating time and hospital stay, yet a higher long-term failure rate. TURP comprises 95% of all surgical procedures and is the treatment of choice for prostates sized 30-80mL. Intra- and postoperative complications are correlated with the size of the prostate and the length of the procedure. Open prostatectomy is the treatment of choice for large glands (> 80-100 mL), associated complications such as large bladder stones, or if resection of bladder diverticula is indicated (8-10). A recent RCT has shown that Holmium-laser enucleation leads to similar outcome as open prostatectomy for men with large glands (> 100 mL) at a significantly lower complication rate (11). TUVP is considered an alternative to TUIP and TURP, particularly for patients with bleeding disorders and small prostates. Coagulating intermittent cutting, rotoresection and bipolar electrocautery are electrosurgical modifications of the conventional technique (12-14). Encouraging data are available for all these techniques, the data of large scale RCT are awaited with interest (12-14). As RCT-data are not yet available, these methods are not described in more detail below.
UPDATE MARCH 2004
35
4.3.3 Perioperative antibiotics A known urinary tract infection should be treated before surgery (15,16). The routine use of prophylactic antibiotics remains controversial. However, antibiotics are recommended in patients on catheterisation prior to surgery. 4.3.4 Treatment outcome LUTS All four surgical procedures (TURP, TUIP, TUVP and open prostatectomy) result in an improvement of LUTS exceeding 70%, with open prostatectomy leading to slightly superior results (4-11). Mean improvement of LUTS in a meta-analysis of 29 RCT with a TURP-arm was 71% (range: 66-76%) (6). In the 10 RCTs comparing TURP to TUIP, both procedures resulted in a similar improvement in symptoms after 12 months (5-7). The RCTs comparing TURP to TUVP also revealed similar improvements of LUTS in both study arms (6). Uroflowmetry The mean increase of Qmax following TURP is 115% (range: 80-150%) (6); in absolute terms + 9.7 mL/s (range: 4-11.6 mL/s) (6). Following TUVP, the Qmax increased by 155% (range: 128-182%) (6). The highest Qmax improvement (+175%) is seen after open prostatectomy (absolute numbers: 8.2-22.6 mL/s) (6,8-10). Post-void residual volume All four surgical procedures allow a reduction of the post-void residual volume of more than 50%: -65% after open prostatectomy; -60% after TUVP; -60% after TURP; and –55% after TUIP (4-11). 4.3.5 Complications Intra-/peri-operative Mortality following prostatectomy has decreased significantly within the past two decades and is less than < 0.25% in contemporary series (6,17-19). The risk of a TUR-syndrome (fluid intoxication, serum Na+ < 130 nmol/L) is in the range of 2%. Risk factors for the development of the TUR-syndrome are excessive bleeding with opening of venous sinuses, prolonged operation time, large glands and past or present smoking (20). The estimated need for blood transfusion following TURP is in the range of 2-5%. Higher percentages have been reported following open prostatectomy (6,8-10). The risk of bleeding following TUIP and TUVP is negligible (6). Long-term complications Incontinence: Median probability for developing stress incontinence ranges is 1.8% following TUIP, 2.2% following TURP, and up to 10% following open prostatectomy (4-11). Limited information on this issue is available for TUVP; one RCT reported an incontinence rate of 5% (6,21). Bladder neck contracture and urethral stricture: The risk of developing an urethral stricture is 2.6% after open prostatectomy, 3.8% after TURP and 1.7% after TUIP (4-11). The risk of bladder neck contracture is 1.8% after open surgery, 4% after TURP and 0,4% after TUIP (4-11). The respective figures for TUVP are in the range of TURP (6). Sexual function: Retrograde ejaculation results from the destruction of the bladder neck and is reported in 80% after open prostatectomy, 65-70% after TURP and 40% after TUIP (4-11). There is a long-standing controversy on the impact of prostatectomy, particularly TURP, on erectile function. The only RCT that compared TURP to a “wait and see” policy reported identical rates of erectile dysfunction in both arms (4). In the 29 RCTs recently reviewed, the incidence of erectile dysfunction following TURP was 6.5% (95% Cl: 0.2-12.7%) (6). The frequently reported rise of erectile dysfunction after TURP is therefore most likely not a direct consequence of TURP but rather caused by confounding factors, such as age. 4.3.6 Long-term outcome Retreatment rate Favourable long-term outcome is common after open prostatectomy, TURP and TUIP. A secondary prostatic operation is reported at a constant rate of approximately 1-2% per year (4-11). Few data are available on the long-term outcome following TUVP. Long-term risk of mortality The possibility of an increased long-term risk of mortality after TURP compared to open surgery has been raised by Roos et al. (18). These findings have not been replicated by others (17,19,22).
36
UPDATE MARCH 2004
4.3.7 Conclusions Surgery should be considered for those men: • who are moderately/severely bothered by LUTS, yet who do not improve after non-surgical (including medical) treatment. • with bothersome LUTS, who not want medical treatment but who request active intervention. • with a strong indication for surgery. In addition: • Surgical prostatectomy (open, TURP, TUIP, TUVP) results in significant subjective and objective improvements superior to medical or minimally invasive treatment. All four surgical procedures have been evaluated in randomised controlled trials. • TUIP is the surgical therapy of choice for men with prostates < 30 mL and no middle lobes. 4.3.8 1.
References Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol 1999;162(4):1307-10. http://www.ncbi.nlm.nih.gov/pubmed/10492185 2. Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol 1998;81(5):712-20. http://www.ncbi.nlm.nih.gov/pubmed/9634047 3. Bruskewitz RC, Reda DJ, Wasson JH, Barrett L, Phelan M. Testing to predict outcome after transurethral resection of the prostate. J Urol 1997;157(4):1304-8. http://www.ncbi.nlm.nih.gov/pubmed/9120927 4. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. New Engl J Med 1995;332(2):75-9. http://www.ncbi.nlm.nih.gov/pubmed/7527493 5. Yang Q, Peters TJ, Donovan JL, Wilt TJ, Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomised controlled trials. J Urol 2001;165(5):1526-32. http://www.ncbi.nlm.nih.gov/pubmed/11342911 6. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? Br J Urol 1999;83(3):227-37. http://www.ncbi.nlm.nih.gov/pubmed/10233485 7. Tkocz M, Prajsner A. Comparison of long-term results of transurethral incision of the prostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy. Neurourol Urody 2002;21(2):112-6. http://www.ncbi.nlm.nih.gov/pubmed/11857663 8. Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001;166(1):172-6. http://www.ncbi.nlm.nih.gov/pubmed/11435849 9. Mearini E, Marzi M, Mearini L, Zucchi A, Porena M. Open prostatectomy in benign prostatic hyperplasia: 10-year experience in Italy. Eur Urol 1998;34(6):480-5. http://www.ncbi.nlm.nih.gov/pubmed/9831789 10. Serretta V, Morgia G, Fondacaro L, Curto G, Lo bianco A, Pirritano D, Melloni D, Orestano F, Motta M, Pavone-Macaluso M for the members of the Sicilian-Calabrian Society of Urology. Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. Urology 2002;60(4):623-7. http://www.ncbi.nlm.nih.gov/pubmed/12385922 11. Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100gm: a randomised prospective trial of 120 patients. J Urol 2002;168(4 Pt 1):1465-9. http://www.ncbi.nlm.nih.gov/pubmed/12352419 12. Hartung R, Leyh H, Liapi C, Fastenmeier K, Barba M. Coagulating intermittent cutting. Improved highfrequency surgery in transurethral prostatectomy. Eur Urol 2001;39(6):676-81. http://www.ncbi.nlm.nih.gov/pubmed/11464057 13. Michel MS, Knoll T, Trojan L, Kohrmann KU, Alken P. Rotoresect for bloodless transurethral resection of the prostate: a 4-year follow-up. BJU Int 2003;91(1):65-8. http://www.ncbi.nlm.nih.gov/pubmed/12614253
UPDATE MARCH 2004
37
14.
Eaton AC, Francis RN. The provision of transurethral prostatectomy on a day-case basis using bipolar plasma kinetic technology. BJU Int 2002;89(6):534-7. http://www.ncbi.nlm.nih.gov/pubmed/11942959 15. Elmalik EM, Ibrahim AI, Gahli AM, Saad MS, Bahar YM. Risk factors in prostatectomy bleeding: preoperative urinary tract infection is the only reversible factor. Eur Urol 2000;37(2):199-204. http://www.ncbi.nlm.nih.gov/pubmed/10705199 16. Scholz M, Luftenegger W, Harmuth H, Wolf D, Holtl W. Single-dose antibiotic prophylaxis in transurethral resection of the prostate: a prospective randomized trial. Br J Urol 1998;81(6):827-9. http://www.ncbi.nlm.nih.gov/pubmed/9666765 17. Holman CD, Wisniewski ZS, Semmens JB, Rouse IL, Bass AJ. Mortality and prostate cancer risk in 19,598 men after surgery for benign prostatic hyperplasia. BJU Int 1999;84(1):37-42. http://www.ncbi.nlm.nih.gov/pubmed/10444122 18. Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF, Cohen MM, Ramsey E. Mortality and reoperation after open and transurethral resection of the prostate for benignprostatic hyperplasia. N Engl J Med 1989;320(17):1120-4. http://www.ncbi.nlm.nih.gov/pubmed/2469015 19. Hahn RG, Farahmand BY, Hallin A, Hammar N, Persson PG. Incidence of acute myocardial infarction and cause-specific mortality after transurethral treatments of prostatic hypertrophy. Urology 2000;55(2):236-40. http://www.ncbi.nlm.nih.gov/pubmed/10688086 20. Hahn RG. Smoking increases the risk of large scale fluid absorption during transurethral prostatic resection. J Urol 2001;166(1):162-5. http://www.ncbi.nlm.nih.gov/pubmed/11435847 21. Gallucci M, Puppo P, Perachino M, Fortunato P, Muto G, Breda G, Mandressi A, Comeri G, Boccafoschi C, Francesca F, Guazzieri S, Pappagallo GL. Transurethral electrovaporization of the prostate vs. transurethral resection. Resection of a multicentric, randomised clinical study on 150 patients. Eur Urol 1998;33(4):359-64. http://www.ncbi.nlm.nih.gov/pubmed/9612677 22. Shalev M, Richter S, Kessler O, Shpitz B, Fredman B, Nissenkorn I. Long-term incidence of acute myocardial infarction after open and transurethral resection of the prostate for benign prostatic hyperplasia. J Urol 1999;161(2):491-3. http://www.ncbi.nlm.nih.gov/pubmed/9915433
4.4
Lasers
The use of lasers to treat BPH has been contemplated since 1986 but was anecdotal until the early 1990s (1,2), when Shanberg et al. (3) reported the use of the Nd:YAG laser to perform prostatectomy in 10 patients with BPH, resulting in marked improvement in their voiding symptoms. With the development of the right-angle fibre and the refinement of both equipment and technique, the results of many studies have been published. However, as far as durability is concerned, long-term follow-up results are only available from initial studies. 4.4.1 Laser types Four types of laser have been used to treat the prostate: Nd:YAG, Holmium:YAG, KTP:YAG and diode. Energy can be delivered through a bare fibre, right-angle fibre or interstitial fibre. The use of contact lasers using a bare fibre has been abandoned. In addition, energy levels can be varied to achieve coagulation or vaporization. The difference between coagulation and vaporization is that coagulation causes little vaporization and depends on temperature changes to achieve permanent tissue damage. There is also secondary tissue slough, which is associated with tissue oedema. Vaporization depends upon temperature changes of over 100oC, which cause the tissue to be dehydrated (4,5). This effect decreases forward scatter into tissue and may cause less tissue oedema. Interstitial treatments depend on inserting the fibre into the prostatic tissue and the use of coagulation techniques (6). 4.4.2 Right-angle fibres From 1991 onward, reports describing a TRUS-guided, side-firing Nd:YAG laser instrument (the TULIPTM device) for BPH therapy appeared in the urological literature (7,8). These, and other, reports documented the fact that prostatic tissue ablation could be achieved using the Nd:YAG laser. In subsequent years, the TULIPTM device was abandoned and other authors experimented with even greater prostatic tissue ablation using a much simpler side-firing Nd:YAG laser delivery system. This consisted of a gold-plated mirror affixed to the distal end of a standard, flexible, silica-glass, laser transmission fibre (UrolaseTM fibre) (9).
38
UPDATE MARCH 2004
Operative technique Side-firing laser prostatectomy is performed using Nd:YAG laser light at 1064 nm and relatively high power settings (typically between 40 and 80 W), delivered via an optical fibre equipped with a distal reflecting mechanism. This fibre fits through standard cystoscopes and all laser applications are performed transurethrally under the direct visual control of the surgeon. The operation may be performed under general or regional anaesthesia, or under local peri-prostatic block as described by Leach et al. (10). The operating time is approximately 45 minutes or less. Optimal tissue ablation is achieved using long-duration (60-90 seconds) Nd:YAG laser applications to fixed spots along the prostatic urethra. These laser applications are repeated systematically and with considerable overlap until all visible obstructing prostatic tissue has been coagulated (11). Outcome, morbidity, durability and limitations There have been many studies comparing side-fire laser to TURP. If randomized studies are considered, the results are quite similar, showing an equivalent improvement in symptom scores and increases in uroflow rates in both groups, although they are higher in the TURP arms (12-17). An improvement in voiding produced by side-firing Nd:YAG laser prostatectomy has been extensively documented in the urological literature. Kabalin et al. (18) reported that 85% of men undergoing laser prostatectomy could expect at least a 50% improvement in either prostate symptom score or peak urinary flow rate. As far as complex urodynamic evaluation is concerned, several studies have demonstrated the ability of side-firing laser prostatectomy to produce a significant improvement in bladder outflow obstruction. Results of pressure-flow studies have been reported by several authors (8,19-21). These authors reported that 78.6-95% of men undergoing laser treatment were rendered unobstructed at 3- or 6-months of post-operative follow-up. Catheter irrigation is generally not required and blood loss is statistically lower with Nd:YAG laser coagulation than with TURP because of the excellent haemostasis produced. Both the US and UK multicentre trials documented dramatic differences in serious treatment-related complications, favouring laser prostatectomy as a much safer procedure than TURP (12,13). Disadvantages are the delayed time to normal voiding and severe dysuria (8,12,22). In a single-institution, randomized, prospective evaluation, Costello et al. (14) found equivalent voiding outcomes for the two procedures, but again documented differences in morbidity between these operations. During the 3-year post-operative follow-up, serious treatment-related complications occurred in 11.8% of laser prostatectomy patients and 35.1% of TURP patients. No study has reported any occurrence of impotence or sustained incontinence. Retrograde ejaculation has been reported in up to 22% of patients. With regard to durability, the observed retreatment rates following laser prostatectomy - approximately 2% per year of followup - seem comparable to documented reoperation rates after TURP (18). Conversely, an Italian retrospective study of 36 patients submitted to side-fire Nd:YAG laser prostatectomy with a minimum follow-up of 5 years reported striking results (23). All patients had undergone pressure-flow studies at 3 months after laser treatment: 32 previously obstructed patients were unobstructed. After 5 years, 43.8% of these patients underwent TURP because of recurring obstruction. Such a retreatment rate is definitely greater than that observed after TURP and even after TUIP. These data therefore suggest caution in giving indications to laser treatment, particularly in patients who are candidates for TURP or TUIP. In fact, these techniques, TURP and TUIP, offer better long-term results and comparable (if not superior) efficacy than laser prostatectomy. Further long-term follow-up studies are needed. The major limitation of the laser technique compared with conventional TURP is the lack of immediate effect and requirement for urinary catheter drainage for several post-operative days. Some patients may require catheterization for 3-4 weeks or more (24). Even after catheter removal, an improvement in voiding occurs only gradually, and most patients do not notice significant benefits until approximately 3-4 weeks post-operatively. The best results are obtained if the weight of the gland is below 50-60 g; in larger glands significant amounts of obstructive prostatic tissue can be left behind (17). Moreover, men with chronic urinary tract infections and chronic bacterial prostatitis are not good candidates for Nd:YAG laser coagulation of the prostate (18) because of the possibility of infection of the necrotic tissue that remains in situ for several weeks after the operation; emergent TURP has been reported to solve this problem (8). 4.4.3 Interstitial Laser Coagulation (ILC) ILC as a therapy for BPH was first mentioned by Hofstetter in 1991 (25). Since then, several variations and technical and procedural developments have been introduced and tested in clinical trials (26). The objective of ILC of BPH is to achieve marked volume reduction and to decrease urethral obstruction and symptoms. Coagulation necrosis is generated within the adenoma, sparing its urethral surface. As the applicator can be inserted as deeply and as often as necessary, it is possible to coagulate any amount of tissue at any desired location. Post-procedure, the intraprostatic lesions result in secondary atrophy and regression of the prostate lobes rather than sloughing of necrotic tissue (27).
UPDATE MARCH 2004
39
Operative technique Fibres employed for ILC must emit laser radiation at a relatively low power density. The most commonly used fibres are ITT Light GuideTM, Dornier, and the Diffusor-TipTM, Indigo. Nd:YAG lasers or diode lasers are used for ILC. ILC can be carried out using the transurethral approach, with local, regional or systemic anaesthesia. The laser fibre is introduced from a cystoscope within the urethra. The total number of fibre placements is dictated by the total prostate volume and configuration. As a general guideline, one or two placements are used for each estimated 5-10 cm3 of prostate volume. In general, the sites for fibre placement are chosen according to where the bulk of hyperplastic tissue is found (26). Outcome, morbidity, durability and limitations Studies were performed to compare the results with ILC with those of other laser techniques, primarily TURP. The results of several studies indicated the effectiveness of ILC in treating BPH with regard to symptoms, obstruction and enlargement. All studies reported marked improvements in symptom score, peak flow rate, residual urine volume and prostate volume (26-31). Urodynamic parameters were also measured before and after ILC treatment (32,33). Pressure-flow studies demonstrated a sufficient decrease of the intravesical pressure, urethral opening pressure and urethral resistance. Prospective and randomized studies were also performed to compare the results achieved with ILC with those of other laser techniques (33) and TURP (30,34,35). Muschter et al. reported on a series of 97 patients with severely symptomatic BPH; 48 patients received ILC and 49 underwent TURP (34). Within 12 months, there were no statistical differences between groups for all the considered parameters. However, four ILC patients (8.3%) were considered to be treatment failures and underwent TURP. As for morbidity, there is a temporary increase of obstruction after ILC, which can result in urinary retention and temporary irritative symptoms, such as urgency (25). Post-operative irritative symptoms have been observed in 5-15% of patients (28,31,34). Post-operative catheterization was required for an average of up to 18 days, although the catheter was removed within 10 days in more than 70% of cases. No study has reported any occurrence of impotence or sustained incontinence, though retrograde ejaculation was occasionally reported, with an incidence ranging from 0-11.9%. Urethral strictures or bladder neck strictures are not common, and have been reported in approximately 5% of patients. The retreatment rate is up to 15.4% with a maximum follow-up of 12 months; although as follow-up becomes longer, the retreatment rate is expected to be higher. Currently, the results of only one long-term follow-up study are available (36). In 394 patients followed for up to 3 years, the retreatment rate was 3.1% per year in the first year, rising to 9.6% thereafter (36). ILC can be performed in small prostates and also seems to be suitable to debulk larger prostates or to treat highly obstructed patients (26). This procedure can be seen as a true alternative to TURP in selected patients with some advantages, such as almost no serious morbidity, and certain disadvantages, such as the need for longer post-operative catheterization and the lack of tissue for biopsy. However, further comparative randomized studies with longer follow-up are needed to assess the durability of this procedure. 4.4.4 Holmium laser resection of the prostate (HoLRP) The Holmium laser (2140 nm) is a pulsed, solid-state laser that has been used in urology for a variety of endourological applications in soft tissues and for the disintegration of urinary calculi (37). Prostatectomy using this energy source is a relatively new technique with the first patient reports appearing in 1995 (37, 38). The Ho:YAG wavelength is strongly absorbed by water and the zone of coagulation necrosis in tissue is limited to 3-4 mm, sufficient to obtain adequate haemostasis (38). The peak power achieved results in intense tissue vaporization and in precise and efficient cutting ability in the prostatic tissue. Operative technique Instrumentation for this technique includes a 550-µm end-firing quartz fibre and an 80-W Ho:YAG laser. A continuous flow resectoscope is required with a working element; normal saline is used as the irrigant. The basic principle of the technique consists of retrograde enucleation of the prostate and fragmentation of the enucleated tissue to allow its elimination through the operating channel of the resectoscope (38,39). Outcome, morbidity, durability and limitations As this technique is relatively new, only a few studies with a short follow-up have been published to date. Gilling et al. (40) presented the results of a prospective, randomized trial comparing TURP with HoLRP; so far, 120 patients with urodynamic obstruction have been enrolled with prostates less than 100 g in size (Schafer grade 2). Preliminary analysis has revealed a longer mean resection time (42.1 vs. 25.8 minutes; p < 0.0001) for HoLRP patients, but a shorter mean catheter time (20.0 vs. 37.2 hours; p < 0.0001) and length of hospital stay (26.4 vs. 47.4 hours; p < 0.0001). Symptomatic and urodynamic improvement were equivalent in the two groups.
40
UPDATE MARCH 2004
Comparative studies of Nd:YAG versus prostatectomy have been conducted, clearly demonstrating that HoLRP is associated with significantly shorter catheter time and a lower incidence of post-operative dysuria (41). Unfortunately, the longest available follow-up is only 12 months, which has confirmed the shortterm durability of the procedure (36). Post-operative dysuria is the most common complication, with an incidence of approximately 10% (38,40,42). No major complication has been described; however, the technique is a surgical procedure that requires significant endoscopic skill and cannot be considered easy to learn. Conversely, there are no specific limitations to the procedure; the size of the prostate that can be treated depends on the experience and patience of the urologist, although the presence of a prostate gland over 100 mL is a relative contraindication in urologists’ early experience (38). Patients on anticoagulant medication and those with urinary retention can be safely treated (43). Retrograde ejaculation occurs in 75-80% of patients; no post-operative impotence has been reported (38). 4.4.5 Conclusions Laser prostatectomy should be advised for patients who are: • receiving anticoagulant medication • unfit for TURP (side-fire or ILC) • wanting to maintain ejaculation (side-fire or ILC) • holmium laser prostatectomy is a viable alternative to TURP and irrespective of any anatomical configuration. 4.4.6 References 1. Kandel LB, Harrison LH, McCullough DL. Transurethral laser prostatectomy: Creation of a technique for using the Neodymium-Yttrium-Aluminium-Garnet (YAG) laser in the canine model. J Urol 1986;133:110A. 2. Johnson DE, Levinson AK, Greskovich FJ. Transurethral laser prostatectomy using a right-angle delivery system. SPIE Proceedings 1991;1421:36. 3. Shanberg AM, Tansey LA, Baghdassarian R. The use of the neodymium YAG laser in prostatotomy. J Urol 1985;133:331A. 4. Stein BS. Laser-tissue interaction. In: Smith JA et al. eds. Lasers in Urologic Surgery. St Louis, USA: Mosby, 1994, p. 10. 5. Johnson DE, Price RE, Cromeens DM. Pathologic changes occurring in the prostate following transurethral laser prostatectomy. Lasers Surg Med 1992;12(3):254-63. http://www.ncbi.nlm.nih.gov/pubmed/1508019 6. Muschter R, Hofstetter A, Hessel S. Interstitial laser prostatectomy - experimental and first clinical results. J Urol 1992;147:346A. 7. Assimos DG, McCullough DL, Woodruff RD, et al. Canine transurethral laser-induced prostatectomy. J Endourol 1991;5:145-9. 8. Puppo P, Perachino M, Ricciotti G, Scannapieco G. Transurethral ultrasound-guided laser-induced prostatectomy: objective and subjective assessment of its efficacy for treating benign prostatic hyperplasia. Eur Urol 1994;25(3):220-5. http://www.ncbi.nlm.nih.gov/pubmed/7515349 9. Costello AJ, Bowsher WG, Bolton DM, Braslis KG, Burt J. Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol 1992;69(6):603-8. http://www.ncbi.nlm.nih.gov/pubmed/1379101 10. Leach GE, Sirls L, Ganabathi K, Roskamp D, Dmochowski R. Outpatient visual laser-assisted prostatectomy under local anesthesia. Urology 1994;43(2):149-53. http://www.ncbi.nlm.nih.gov/pubmed/7509525 11. Muschter R, Perlmutter AP. The optimisation of laser prostatectomy. Part II. Other lasing techniques. Urology 1994;44(6):856–61. http://www.ncbi.nlm.nih.gov/pubmed/7985315 12. Cowles RS 3rd, Kabalin JN, Childs S, Lepor H, Dixon C, Stein B, Zabbo A. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology 1995;46(2):155-60. http://www.ncbi.nlm.nih.gov/pubmed/7542818 13. Anson K, Nawrocki J, Buckley J, Fowler C, Kirby R, Lawrence W, Paterson P, Watson G. A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology 1995;46(3):305-10. http://www.ncbi.nlm.nih.gov/pubmed/7544932
UPDATE MARCH 2004
41
14. Costello AJ, Crowe HR, Asopa R. Long-term results of randomized laser prostatectomy vs. TURP: modification of laser prostatectomy technique with biodegradable stent insertion. J Urol 1996;155:316A. 15. Oswald M, Schmidlin F, Jichilinski P, et al. Combination of thermocoagulation and vaporisation using a Nd:YAG/KTP laser versus TURP in BPH treatment: preliminary results of a multicenter prospective randomized study. J Urol 1997;157:42A. 16. Kabalin JN. Neodymium: YAG laser coagulation prostatectomy for patients in urinary retention. J Endourol 1997;11(3):207-9. http://www.ncbi.nlm.nih.gov/pubmed/9181452 17. Costello AJ, Kabalin JN. Side-firing neodymium:YAG laser prostatectomy. Eur Urol 1999;35(2):138-46. http://www.ncbi.nlm.nih.gov/pubmed/9933807 18. Kabalin JN, Bite G, Doll S. Neodymium:YAG laser coagulation prostatectomy: 3 years of experience with 227 patients. J Urol 1996;155(1):181-5. http://www.ncbi.nlm.nih.gov/pubmed/7490827 19. Te Slaa E, De Wildt MJ, Rosier PF, Wijkstra H, Debruyne FM, de la Rosette JJ. Urodynamic assessment in the laser treatment of benign prostatic enlargement. Br J Urol 1995;76(5):604-10. http://www.ncbi.nlm.nih.gov/pubmed/8535680 20. Cannon A, De Wildt M, Abrams PH, De la Rosette JJ. Urodynamics and laser prostatectomy. World J Urol 1995;13(2):134-6. http://www.ncbi.nlm.nih.gov/pubmed/7542968 21. Choe JM, Sirls LT. High-energy visual laser ablation of the prostate in men with urinary retention: pressure flow analysis. Urology 1996;48(4):584-8. http://www.ncbi.nlm.nih.gov/pubmed/8886064 22. Stein BS, Altwein JE, Bruschter R et al. Laser prostatectomy. In: Denis L, Griffiths K, Khoury S, et al, eds. Proceedings of the Fourth International Consultation on BPH, Paris, July 1997. Plymouth: Health Publications, 1998, pp. 529-540. http://www.congress-urology.org/ 23. Perachino M, Puppo P. [Prostatectomia laser con metodica side-fire: risultati a distanza di 5 anni.] Acta Urol Ital 1998;12(Suppl 1):44. [article in Italian] 24. Kabalin JN, Bite G. Laser prostatectomy performed with right angle firing neodymium: YAG laser fiber at 40 watt power settings. J Urol 1997;158(5):1923. http://www.ncbi.nlm.nih.gov/pubmed/9334638 25. Hofstetter A. Interstitielle Thermokoagulation (ITK) von Prostatatumoren. Lasermedizin 1991;7:179-80. [article in German][Interstitial laser coagulation treatment for benign prostatic hyperplasia] http://www.freepatentsonline.com/5312392.html 26. Muschter R, Whitfield H. Interstitial laser therapy of benign prostatic hyperplasia. Eur Urol 1999;35(2):147-54. http://www.ncbi.nlm.nih.gov/pubmed/9933808 27. Muschter R, Hofstetter A. Technique and results of interstitial laser coagulation. World J Urol 1995;13(2):109-14. http://www.ncbi.nlm.nih.gov/pubmed/7542962 28. Bhatta KM, Perlmutter A, Cho G, et al. A new technique of subsurface and interstitial laser therapy using a diode laser (wavelength = 1000 nm) and a catheter delivery device. J Urol 1996;155:310A. 29. Schettini M, Diana M, Fortunato P et al. Results of interstitial laser coagulation of the prostate. J. Endourol 1996;10 (Suppl 1):S191. 30. Whitfield HN. A randomized prospective multicenter study evaluating the efficacy of interstitial laser coagulation. J Urol 1996;155:318A. 31. Fay R, Chan SL, Kahn R, et al. Initial results of a randomized trial comparing interstitial laser coagulation therapy to transurethral resection of the prostate. J Urol 1997;157(Suppl 1):41. 32. Henkel TO, Greschner M, Luppold T, Alken P. Transurethral and transperineal interstitial laser therapy of BPH. In: Muller G, et al, eds. Laser-induced Interstitial Thermotherapy. Bellingham: SPIE Press, 1995, pp. 416-423. http://bookstore.spie.org/index.cfm?fuseaction=SearchResultsVolume&keywords=Laser-induced%20 Interstitial%20&searchtype=SearchResultsVolume&quicksearch=1&CFID=353971&CFTOKEN=68929120 33. Horninger W, Janetschek G, Watson G, Reissigl A, Strasser H, Bartsch G. Are contact laser, interstitial laser, and transurethral ultrasound-guided laser-induced prostatectomy superior to transurethral prostatectomy?. Prostate 1997;31(4):255-63. http://www.ncbi.nlm.nih.gov/pubmed/9180936
42
UPDATE MARCH 2004
34.
Muschter R, Sroka R, Perlmutter AP, et al. High power interstitial laser coagulation of benign prostatic hyperplasia. J Endourol 1996;10(Suppl 1):S197. 35. Whitfield HN. The use of an interstitial diode laser (Indigo) in laser prostatectomy. A randomized, controlled, prospective study. J Endourol 1995;9(Suppl 1):S149. 36. Muschter R, Hofstetter A. [Laser thermocoagulation of adenoma of the prostate using an interstitial approach]. Ann Urol (Paris) 1997;31(1):27-37. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/9157819 37. Le Duc A, Gilling PJ. Holmium laser resection of the prostate. Eur Urol 1999;35(2):155-60. http://www.ncbi.nlm.nih.gov/pubmed/9933809 38. Gilling PJ, Cass CB, Malcolm AR, Fraundorfer MR. Combination Holmium and Nd: YAG laser ablation of the prostate: initial clinical experience. J Endourol 1995;9(2):151-53. http://www.ncbi.nlm.nih.gov/pubmed/7633476 39. Chun SS, Razvi HA, Denstedt JD. Laser prostatectomy with the holmium:YAG laser. Tech Urol 1995;1(4):217-21. http://www.ncbi.nlm.nih.gov/pubmed/9118394 40. Gilling PJ, Fraundorfer MR, Kabalin JB. Holmium: YAG laser resection of the prostate (HoLRP) versus transurethral electrocautery resection of the prostate (TURP): a prospective randomized, urodynamicbased clinical trial. J Urol 1997;157:149A. 41. Gilling PJ, Cass CB, Malcolm A, Cresswell M, Fraundorfer MR, Kabalin JN. Holmium laser resection of the prostate versus neodymium: neodymium:yttrium-aluminum-garnet visual laser ablation of the prostate (VLAP): a randomized prospective comparison of two techniques for laser prostatectomy. Urology 1998; 51(4): 573-7. http://www.ncbi.nlm.nih.gov/pubmed/9586609 42. Le Duc A, Anidjar M, Teillac P, Desgrandchamps F. The Holmium YAG laser in the transurethral resection of prostate. Br J Urol 1997;80(Suppl 2):A773. 43. Kabalin JN, Mackey MJ, Cresswell MD, Fraundorfer MR, Gilling PJ. Holmium: YAG laser resection of the prostate (HoLRP) for patients in urinary retention. J Endourol 1997;11(4):291-3. http://www.ncbi.nlm.nih.gov/pubmed/9376851
4.5
Transrectal high-intensity focused ultrasound (HIFU)
4.5.1 Assessment No specific diagnostic work-up prior to transrectal HIFU therapy is necessary. However, the following parameters should be obtained: • I-PSS, including quality of life • Free uroflowmetry, including post-void residual urine volume • Serum PSA • TRUS • Pressure-flow study advisable. 4.5.2 Procedure A beam of ultrasound can be brought to a tight focus at a selected depth within the body, thus producing a region of high energy density within which tissue can be destroyed without damage to the overlying or intervening structures (1-3). If the site-intensity is set below the tissue cavitation threshold, the predominant therapeutic effect is the induction of heat. This technique is known as high-intensity focused ultrasound (HIFU). The source for HIFU is a piezoceramic transducer, which has the property of changing its thickness in response to an applied voltage (1-3). Theoretically the prostate can be ablated by HIFU via a transabdominal or transrectal route. In clinical use, however, only transrectal HIFU devices are applied for the indication of BPH. Clinical data are only available for one device, the Sonablate® (1-4). This system uses the same 4.0 MHz transrectal transducer for imaging and therapy. The focal length (2.5-4.0 cm) is dependent upon the crystal used. The site intensity can be varied from 1.260 to 2.200 W/cm2. Within the HIFU beam focus, an ellipsoidal tissue volume approximately 2 mm in diameter and 10 mm in length is destroyed (1-3). In order to create a clinically useful volume of necrosis, a multiplicity of laterally or axially displaced individual lesions is generated by physical movement of the sound-head. The histological effect of transrectal HIFU therapy using the Sonablate® on the canine and human prostate has been studied in detail (1-3,5,6). 4.5.3 Morbidity/complications In general, transrectal HIFU is well-tolerated but requires general anaesthesia or heavy intravenous sedation. The most prominent side-effect is prolonged urinary retention, lasting for 3-6 days. Haematospermia for 4-6 weeks is observed in up to 80% of sexually active men, and patients frequently discharge two to three drops of blood prior to micturition for several weeks. Urinary tract infection occurs in around 7% of patients. No cases
UPDATE MARCH 2004
43
of urethral strictures, incontinence or the need for blood transfusion have been reported in the literature. Two severe complications have been reported. In one patient, perforation of the descending colon approximately 50-60 cm above the treatment zone occurred. It was caused by inadvertent overfilling to 500 mL and subsequent rupture of the condom that covered the ultrasound probe. This complication led to reconstruction of the filling apparatus and the probe such that the problem can now be reliably avoided. The second severe complication was a thermolesion of the rectum requiring surgical intervention. This was most likely caused by using an inappropriately high-site intensity exceeding 2.300 W/cm2. As a consequence, the maximum site intensity was set at 2.000 W/cm2. 4.5.4 Outcome In June 1992, an international Phase II clinical trial was initiated to evaluate the safety and efficacy of transrectal HIFU therapy for patients with LUTS due to BPH. To date, several hundred patients have been treated with the Sonablate® at various sites. In the initial US series, Bihrle et al. (7) reported on experience with 15 patients and a follow-up of 90 days. The Qmax increased from 9.3 mL/s to 14.0 mL/s and the post-void residual urine volume decreased from 154 mL to 123 mL (7). Ebert et al. (8) treated 35 patients, eight of whom had urinary retention. The Qmax increased from 7.6 mL/s to 15.2 mL/s after 3 months. Within the same time period, the post-void residual urine volume decreased from 182 mL to 50 mL and the I-PSS from 17.9 to 7.1. The initial report of the study included 50 patients, 20 of whom were followed up for 12 months (5). The Qmax increased from 8.9 (± 4.1) to 12.4 (± 5.6) mL/s (6 months, n = 33) and 13.1 (± 6.5) mL/s (12 months, n = 20). In the same time period, the post-void residual urine volume decreased from 131 (± 120) mL to 48 (± 41) mL at 6 months and to 35 (± 30) mL at 12 months. The AUA symptom score reduced from 24.5 (± 4.7) to 13.4 (± 4.7) at 6 months and to 10.8 (± 2.5) at 12 months (5). Several other sites have confirmed these data (9-11). 4.5.5 Urodynamics The urodynamic effect of transrectal HIFU therapy has been studied by Madersbacher et al. (12). Thirty patients underwent urodynamic investigations (pressure-flow study) before and after a mean of 4.5 months following HIFU therapy. Pre-operatively, 80% of patients were obstructed and a further 20% were in the intermediate zone according to the Abrams-Griffith nomogram. After therapy, a statistically significant decrease in maximum detrusor pressure, detrusor pressure at Qmax and linear passive urethral resistance relation was observed. After HIFU, half of the patients were in the equivocal zone and 13% were clearly unobstructed, yet 37% were still obstructed according to the Abrams-Griffith nomogram. The authors concluded that the capability of transrectal HIFU to reduce bladder outlet obstruction was moderate (12). As a consequence, transrectal HIFU should not be considered for severely obstructed patients or those with an absolute indication for surgery. 4.5.6 Quality of life and sexual function There are no reliable data on quality of life after transrectal HIFU except from a study by Schatzl et al. (13), who studied in detail the early post-operative morbidity of several less invasive procedures. Similarly, there is little data on sexual function. Haematospermia lasting for a maximum of 4-6 weeks is seen in the majority of sexually active patients. Retrograde ejaculation and erectile dysfunction can be safely avoided, although some patients report a decreased ejaculate volume. 4.5.7 Durability The long-term outcome of 80 patients with a follow-up of up to 4 years and a minimum follow-up of 2 years has been studied (14). The mean follow-up of the study population (excluding patients who crossed over to TURP due to insufficient therapeutic response) was 41.3 months (range: 13-48 months). Thirty-five men (43.8%) underwent TURP due to an insufficient therapeutic response during the 4-year study period. The retreatment-free period was significantly longer for patients with a pre-treatment average flow rate of more than 5 mL/s (p = 0.05) and lower grades of urodynamically documented bladder outlet obstruction (p = 0.03) (14). A similar trend, which did not reach statistical significance, was noted for individuals with a higher Qmax and lower post-void residual urine volume. 4.5.8 Patient selection The fact that only a handful of clinical studies with a limited number of patients have been published, hinders a reliable statement concerning patient selection, yet a few selection criteria have been identified. Patients with one or more of the following criteria are unsuitable for transrectal HIFU therapy: • Prostates with dense calcifications (possibility of tissue cavitation) • Large prostates (> 75 mL) • Rectum to bladder neck distance over 40 mm • Large middle lobes • Higher grades of bladder outlet obstruction (BOO) - (higher treatment failure rate)
44
UPDATE MARCH 2004
•
Absolute indication for surgery.
4.5.9 Conclusions Transrectal HIFU therapy is the only technique that provides non-invasive tissue ablation; however, general anaesthesia or at least heavy intravenous sedation is required. Improvement of urinary symptoms is in the range 50-60% and Qmax increases by a mean of 40-50%. Long-term efficacy is limited, with a treatment failure rate of approximately 10% per year. No data are yet available from randomized, controlled trials. 4.5.10 References 1. Madersbacher S, Marberger M. Urological applications of high-intensity focused ultrasound. Curr Opinion Urol 1995;5:147-9. http://www.co-urology.com/pt/re/courology/toc.00042307-199505000-00000.htm;jsessionid=J8nV74 ghYvQhNTcxnsT218WhR3x7QhpQX91Xw7T13Bq0p1kvcMKL!-1854079795!181195628!8091!-1 2. Madersbacher S, Marberger M. Therapeutic applications of ultrasound in urology. In: Marberger M ed. Application of Newer Forms of Therapeutic Energy in Urology. Oxford: Isis Medical Media, 1995, pp. 115-136. http://www.isismedical.com/ 3. Madersbacher S, Marberger M. High-intensity focused ultrasound for prostatic tissue ablation. Curr Opinion Urol 1996;6:28-32. http://www.co-urology.com/pt/re/courology/toc.00042307-199601000-00000.htm;jsessionid=J8sNzh QhhhCvtwGFJPv9Pnz7LymxQJFQ73J3q51p31kTzLhQxBLh!97158217!181195629!8091!-1 4. Madersbacher S, Djavan B, Marberger M. Minimally invasive therapy in BPH. Curr Opinion Urol 1998;8:17-26. http://www.ncbi.nlm.nih.gov/pubmed/17035837 5. Madersbacher S, Kratzik C, Susani M, Marberger M. Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol 1994;152(6 Pt 1):1956-60. http://www.ncbi.nlm.nih.gov/pubmed/7525992 6. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995;55(15):3346-51. http://www.ncbi.nlm.nih.gov/pubmed/7542168 7. Bihrle R, Foster RS, Sanghvi NT, Donohue JP, Hood JP. High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience. J Urol 1994;151(5):1271-5. http://www.ncbi.nlm.nih.gov/pubmed/7512658 8. Ebert T, Graefen M, Miller S, Saddeler D, Schmitz-Dräger B, Ackermann R. High-intensity focused ultrasound (HIFU) in the treatment of benign prostatic hyperplasia (BPH). Keio J Med 1995;44(4): 146-9. http://www.ncbi.nlm.nih.gov/pubmed/8587227 9. Mulligan ED, Lynch TH, Mulvin D, Greene D, Smith JM, Fitzpatrick JM. High-intensity focused ultrasound in the treatment of benign prostatic hyperplasia. Br J Urol 1997;79(2):177-80. http://www.ncbi.nlm.nih.gov/pubmed/9052466 10. Nakamura K, Baba S, Saito S, Tachibana M, Murai M. High-intensity focused ultrasound energy for benign prostatic hyperplasia: clinical response at 6 months to treatment using Sonablate 200. J Endourol 1997;11(3):197-201. http://www.ncbi.nlm.nih.gov/pubmed/9181450 11. Sullivan LD, McLoughlin MG, Goldenberg LG, Gleave ME, Marich KW. Early experience with high-intensity focused ultrasound for the treatment of benign prostatic hypertrophy. Br J Urol 1997;79(2):172-6. http://www.ncbi.nlm.nih.gov/pubmed/9052465 12. Madersbacher S, Klingler CH, Schatzl G, Schmidbauer CP, Marberger M. The urodynamic impact of transrectal high intensity focused ultrasound on bladder outflow obstruction. Eur Urol 1996;30(4): 437-45. http://www.ncbi.nlm.nih.gov/pubmed/8977064 13. Schatzl G, Madersbacher S, Lang T, Marberger M. The early postoperative morbidity of transurethral resection of the prostate and of 4 minimally invasive treatment alternatives. J Urol 1997;158(1):105-11. http://www.ncbi.nlm.nih.gov/pubmed/9186334
UPDATE MARCH 2004
45
14.
Madersbacher S, Schatzl G, Djavan B, Stulnig T, Marberger M. Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol 2000;37(6): 687-94. http://www.ncbi.nlm.nih.gov/pubmed/10828669
4.6
Transurethral needle ablation (TUNA®)
4.6.1 Assessment No specific diagnostic work-up prior to TUNA® is necessary. 4.6.2 Procedure The TUNA® device delivers low-level, radio-frequency energy to the prostate via needles inserted transurethrally (1). 4.6.3 Morbidity/complications Is usually performed as an out-patient procedure under local anaesthesia, although intravenous sedation is required in some patients (1). Post-operative urinary retention is seen in 13.3-41.6% of patients and lasts for a mean of 1-3 days; within 1 week, 90-95% of patients are catheter-free (1). Irritative voiding symptoms lasting up to 4-6 weeks are frequently present (2). Continence status is not affected. 4.6.4 Outcome Several non-randomized clinical trials have documented the clinical efficacy of this procedure with a fairly consistent outcome (3-7). The symptomatic improvement reported ranged from 40-70%. These data are statistically significantly better than at baseline and surpass the expected placebo effect. Improvements in Qmax vary widely from 26-121% in non-retention patients. A recent report with 5 years follow up in 188 patients demonstrated a symptomatic improvement of 58% and an improvement in flow rate of 41%, 21.2% required additional treatment (8). There is no convincing evidence that prostate size is significantly reduced following TUNA® (7-9). 4.6.5 Randomized clinical trials TUNA® has been compared with TURP in one trial (8) with 12-month follow-up data. In both treatment arms, there was a significant decrease in AUA symptom score and bother score, although improvements were slightly higher in the TURP arm. Improvement in Qmax was significantly higher after TURP than after TUNA®. Adverse events, such as bleeding, dysuria, erectile dysfunction, urinary tract infection or strictures, were more frequent in the TURP arm. 4.6.6 Impact on bladder outflow obstruction The impact of TUNA® on bladder outflow obstruction as assessed by pressure-flow studies was determined in seven clinical studies (7-13). In all studies, a statistically significant decrease in maximum detrusor pressure or detrusor pressure at Qmax was demonstrable, yet a number of patients remained in the obstructed range after TUNA® therapy. 4.6.7 Durability Several authors have reported on the long-term efficacy of the TUNA® procedure. Within 1 year, positive results can be translated into percentages ranging from 5-42% (1). Schulman et al. (14) recently presented 3-year follow-up data on 49 patients after TUNA®. Improvement in Qmax exceeding 50% was seen in 53% of patients after 36 months. Ten patients (20%) underwent TURP because of an insufficient therapeutic response (1). Long-term follow-up data exceeding this time period are not yet available. 4.6.8 Patient selection Few selection criteria have been identified. TUNA® is not suitable for patients with prostate volumes exceeding 75 mL or isolated bladder neck obstruction. 4.6.9 Conclusions TUNA® is a simple and safe technique and can be performed under local anaesthesia in a significant number of patients. It results in an improvement of urinary symptoms in the range 50-60% and Qmax increases by a mean of 50-70%. Clinical efficacy has been proven in only one randomized controlled trial, and there is limited evidence of long-term efficacy.
46
UPDATE MARCH 2004
4.6.10 References 1. Chapple CR, Issa MM, Woo H. Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. Eur Urol 1999;35(2):119-28. http://www.ncbi.nlm.nih.gov/pubmed/9933805 2. Schatzl G, Madersbacher S, Lang T, Marberger M. The early postoperative morbidity of transurethral resection of the prostate and of four minimally invasive treatment alternatives. J Urol 1997;158(1):10510. http://www.ncbi.nlm.nih.gov/pubmed/9186334 3. Ramon J, Lynch TH, Eardley I, Ekman P, Frick J, Jungwirth A, Pillai M, Wiklund P, Goldwasser B, Fitzpatrick JM. Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study. Br J Urol 1997;80(1):128-34. http://www.ncbi.nlm.nih.gov/pubmed/9240192 4. Roehrborn CG, Issa MM, Bruskewitz RC, Naslund MJ, Oesterling JE, Perez-Marrero R, Shumaker BP, Narayan P. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter US study. Urology 1998;51(1):415-21. http://www.ncbi.nlm.nih.gov/pubmed/9510346 5. Schulman CC, Zlotta AR. Transurethral needle ablation (TUNA) of the prostate: clinical experience with two years’ follow-up in patients with benign prostatic hyperplasia (BPH). J Urol 1997;157:98-102. 6. Minardi D, Garafolo F, Yehia M, Cristalli AF, Giammarco L, Galosi AB, Muzzonigro G. Pressure-flow studies in men with benign prostatic hypertrophy before and after treatment with transurethral needle ablation. Urol Int 2001;66(2):89-93. http://www.ncbi.nlm.nih.gov/pubmed/11223750 7. Bruskewitz R, Issa MM, Roehrborn CG, Naslund MJ, Perez-Marrero R, Shumaker BP, Oesterling JE. A prospective randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998;159(5):1588-93. http://www.ncbi.nlm.nih.gov/pubmed/9554360 8 Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol. 2003;44(1):89-93. http://www.ncbi.nlm.nih.gov/pubmed/12814680 9. Rosario DJ, Woo H, Potts KL, Cutinha PE, Hastie KJ, Chapple CR. Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol 1997;80(4):579-86. http://www.ncbi.nlm.nih.gov/pubmed/9352697 10. Issa MM. Transurethral needle ablation of the prostate: report of initial United States experience. J Urol 1996;156(2 Pt 1):413-9. http://www.ncbi.nlm.nih.gov/pubmed/8683692 11. Millard RJ, Harewood LM, Tamaddon K. A study of the efficacy and safety of transurethral needle ablation (TUNA) treatment for benign prostatic hyperplasia. Neurourol Urodyn 1996;15(6):619-28. http://www.ncbi.nlm.nih.gov/pubmed/8916114 12. Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology 1997;49(6):847-50. http://www.ncbi.nlm.nih.gov/pubmed/9187689 13. Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year follow-up. J Urol 1997;158(5):1834-8. http://www.ncbi.nlm.nih.gov/pubmed/9334612 14. Schulman CC, Zlotta AR. Transurethral needle ablation (TUNA™) of the prostate: clinical experience with three years follow-up in patients with benign prostatic hyperplasia (BPH). Eur Urol 1998;33(Suppl 1):148.
4.7
Transurethral microwave therapy (TUMT)
4.7.1 Assessment Diagnostic endoscopy is essential because it is important to identify the presence of an isolated enlarged middle lobe or an insufficient length of the prostatic urethra. 4.7.2 Procedure TUMT is a registered trademark of Technomed Medical Systems (France), a company considered to be the pioneer of microwave thermotherapy. To date, tens of thousands of patients worldwide have been treated with the Prostatron® device. Other thermotherapy devices have also been developed: Prostcare®
UPDATE MARCH 2004
47
(Brucker, France); ProstaLund® (Lund Systems, Sweden); and Targis® (Urologix, USA). On a conceptional basis, they are all similar in delivering microwave energy to the prostate with some type of feedback system. The majority of data in the literature on thermotherapy has been based on the Prostatron® device. Initial experience focused on low-energy protocols, but subsequently higher energy levels were used to improve treatment outcomes and response rates. 4.7.3 The microwave thermotherapy principle Microwave thermotherapy devices consist of a treatment module that contains the microwave generator with a temperature measurement system and a cooling system. A treatment catheter is connected to the module and inserted into the prostatic urethra. The main difference between the devices available is the design of the urethral applicator. Apart from differences in the construction of the catheter, the characteristics of the applicators differ, significantly affecting the heating profile (1,2). The similarity in catheter construction consists of the presence of a microwave antenna positioned in the tip of the catheter just below the balloon. Fluid channels surrounding the catheter provide urethral cooling. Also incorporated in the catheter are one or more temperature sensors that differ in the way in which they measure temperature. 4.7.4 Morbidity Morbidity following TUMT is an important issue. Low-energy TUMT is well-tolerated by patients. Most patients experience perineal discomfort and urinary urgency for several days after treatment, but not usually for longer. Occasionally, haematuria is noticed. No tissue sloughing occurs and urinary retention is expected in up to 25% of patients (2-6). In these cases, a catheter may be necessary for an average of 7 days. High-energy treatment is also well-tolerated, although pain medication needs to be administered to most patients prior to or during therapy. In contrast to the low-energy protocol, urinary retention is usual in patients treated with high-energy TUMT; the average catheterization time is 2 weeks. Only two papers mention erectile dysfunction following thermotherapy (incidence 0.8-5%) (7,8). For patients treated with low-energy protocols, the retrograde ejaculation rate ranges from 0-11%, while for high-energy protocols, this figure increases up to 44%. Outcome: objective, subjective and urodynamics Low-energy protocols: The standard operating software for the Prostatron® is version 2.0, and remarkably similar clinical results have been reported worldwide from several centres (2-4,7,9-13). The clinical efficacy of TUMT has been confirmed in several randomized, SHAM-(placebo) controlled studies (4,5,14,15). Symptomatic improvement is significant, with a decrease in Madsen symptom score from around 13 to 4. Changes in objective parameters are less pronounced. The mean increase in Qmax is 3-4 mL/s, representing a mean improvement of approximately 35% over baseline. These improvements are noted from 6 weeks and persist over a period of 5 years (16,17). A randomized study comparing TUMT with TURP was performed by Dahlstrand et al. (3). This study showed significant improvement after both TUMT and TURP in symptom score, Qmax, post-void residual urine volume and grade of bladder outlet obstruction. Although the decrease in symptom score was more pronounced after TURP (92%) than after TUMT (78%). High-energy protocol: The first reports on the application of high-energy levels using Prostasoft® 2.5 were published by de la Rosette et al. (18) and Devonec et al. (19) and demonstrated clinically significant improvements. More recently, the European BPH Study Group performed a multicentre study of 116 patients using high-energy TUMT (20). In this study, the mean Madsen score improved from 13.6 at baseline to 5.5 at 26 weeks. Qmax improved from 9.6 mL/s at baseline to 14.1 mL/s at 26 weeks of follow-up. These objective and subjective improvements were sustained at 52 weeks. At 3-months of follow-up TRUS identified a prostatic cavity in almost 40% of patients. There appeared to be a good correlation between the presence of a cavity and uroflowmetry improvement (21). The best candidates for this treatment protocol appeared to be patients with moderate-to-severe bladder outlet obstruction, as measured by pressure-flow studies, and those with larger prostates (22). One-year follow-up results of a prospective randomized study comparing high-energy TUMT with TURP were reported recently (23). After TURP and thermotherapy, there was a significant improvement in all clinical para meters. At 1 year of follow-up, the symptomatic improvement was 78% in the TURP group versus 68% in the TUMT group, with improvements in free flow being 100% and 69%, respectively. Both groups had showed significant relief of bladder outlet symptoms. No serious complications occurred in either group, but one patient in each group required another treatment. It was concluded that satisfactory results were obtained after both treatments, with improvements observed following high-energy TUMT being in the same range as those seen after TURP.
48
UPDATE MARCH 2004
4.7.5 High-intensity-dose protocol Although the results following high-energy TUMT are good, changes to the Prostasoft® software have recently been reported. It was concluded from clinical experience that a shorter duration of treatment did not alter efficacy or decrease morbidity (22). On a conceptual basis, the so-called Prostasoft® 3.5 protocol differed significantly from former protocols. Firstly, the principle of stepwise energy increments was abandoned and the treatment was initiated at an 80 W energy level. Secondly, the urethral temperature feedback system was also abandoned. Energy delivery is now guided by the rectal temperature sensor via a feedback loop. Third, the cooling temperature starts at a lower value (8oC) and is also linked to rectal temperature. Finally, the total treatment duration is shortened to only 30 minutes. This Prostasoft® 3.5 protocol can therefore be considered to be high-intensity-dose TUMT. Pace et al. (24) found in 56 patients, at six months, a decrease in I-PSS from 18.1 to 5.1, an increase in maximum flow from 9.1 mL/s to 17.8 mL/s and cavities within the prostatic tissue of 54 of the 56 patients (95%). De La Rosette et al. (26) found in 167 patients, at 12 months, a decrease in I-PSS from 19.2 to 7.9 and an increase in maximum flow rate from 8.9 to 16.4. 4.7.6 Prostatic temperature feedback treatment A treatment protocol with calculated tissue necrosis based on simultaneous intraprostatic tissue temperature has been introduced with the Prostalund Micowave apparatus (PLFT, ProstaLund Feedback Treatment) (27). In a prospective, randomized, international, multicentre study against TURP, there was no statistically significant differences between the 2 treatments in decrease in symptom score (66% vs 65%), quality of life (I-PSS) (69% vs. 64%), increase in flow rate (74% vs. 94%) or decrease in detrusor pressure at max. flow rate (34% vs. 47%). Only decrease in prostate volume was higher in the TURP group (51%) than in the PLFT group (30%) (28). 4.7.7 Durability Several studies using low-energy thermotherapy report on surgical retreatment rates for up to 1 year of 11% (25) and 10% (20). On the other hand, Van Cauwelaert et al. (11) reported only low retreatment rates with significant subjective and objective improvements. Recently Tsai et al. (29) reported a 5-year retreatment rate in 45 patients of 84.4% with medication (46.7%) or endoscopic surgery ( 37.7%), while Daehlin et al. (30) found a retreatment rate after 5 years in 71 patients of 68%. When applying higher energy levels, the outcome seems improved and may eventually result in a more durable response. In a study by de la Rosette et al. (5,18) additional TURP was performed in only three out of 116 patients. De Wildt et al. (31) confirmed these findings, documenting five surgical interventions at 1-year follow-up in 85 patients treated. 4.7.8 Patient selection As the morbidity is relatively low and the treatment can be performed without anaesthesia, patients in poor health are particularly good candidates for thermotherapy. In particular, such patients with retention can benefit from this treatment. Good results with regard to catheter release have been obtained, with a success rate of 72% after 6 months in 29 patients (32). In a larger study of 200 patients, with a follow up of 2 years in 155 patients, only 7% failed to respond (33). 4.7.9 Conclusions • High-energy TUMT produces significant subjective and objective improvement, with sustained and durable long-term results. • Morbidity after TUMT consists mainly of the need for catheter drainage after treatment due to urinary retention. • High-energy TUMT is associated with improved objective results compared with low-energy TUMT, but with increased morbidity. 4.7.10 References 1. Bolmsjö M, Wagrell L, Hallin A, Eliasson T, Erlandsson BE, Mattiasson A. The heat is on – but how? A comparison of TUMT devices. Br J Urol 1996;78(4):564-72. http://www.ncbi.nlm.nih.gov/pubmed/8944513 2. Blute ML, Tomera KM, Hellerstein DK, McKiel CF Jr, Lynch JH, Regan JB, Sankey NE. Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study. J Urol 1993;150(5 Pt 2):1591-6. http://www.ncbi.nlm.nih.gov/pubmed/7692092
UPDATE MARCH 2004
49
3. Dahlstrand C, Waldén M, Deirsson G, Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br J Urol 1995;76(5):614-8. http://www.ncbi.nlm.nih.gov/pubmed/8535682 4. Ogden CW, Reddy P, Johnson H, Ramsay JW, Carter SS. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet 1993;341(8836):14-7. http://www.ncbi.nlm.nih.gov/pubmed/7678047 5. De la Rosette JJ, de Wildt MJ, Alivizatos G, Froeling FM, Debruyne FM. Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology 1994;44(1): 58-63. http://www.ncbi.nlm.nih.gov/pubmed/7518982 6. Servadio C. Ten years of clinical experience in transurethral hyperthermia to the prostate. In: Non surgical treatment of BPH. Fitzpatrick JM ed. SIU report 3. Edinburgh: Churchill-Livingstone, 1992, pp. 175-186. 7. Rodrigues Netto N, Claro Jde A, Cortado PL. Ejaculatory dysfunction after transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia. J Endourol 1994;8(3):217–9. http://www.ncbi.nlm.nih.gov/pubmed/7524916 8. Francisca EA, d’Ancona FC, Hendriks JC, Kiemeney LA, Debruyne FM, de la Rosette JJ. Quality of life assessment in patients treated with lower energy thermotherapy (Prostasoft 2.0): results of a randomized transurethral microwave thermotherapy versus sham study. J Urol 1997;158(5):1839-44. http://www.ncbi.nlm.nih.gov/pubmed/9334613 9. Marteinsson VT, Due J. Transurethral microwave thermotherapy for uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol 1994;28(1):83-9. http://www.ncbi.nlm.nih.gov/pubmed/7516577 10. Kirby RS, Williams G, Witherow R, Milroy EJ, Philip T. The Prostatron transurethral microwave device in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia. Br J Urol 1993;72(2):190-4. http://www.ncbi.nlm.nih.gov/pubmed/7691371 11. Van Cauwelaert RR, Castillo OC, Aquirre CA, Azocar GH, Medina FI. Transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia: preliminary experience. Eur Urol 1993;23(2):282-4. http://www.ncbi.nlm.nih.gov/pubmed/7683987 12. Terai A, Arai Y, Onishi H, Oishi K, Takeuchi H, Yoshida O. Transurethral microwave thermotherapy for benign prostatic hyperplasia: clinical results after a 1-year follow-up. Int J Urol 1995;2(1):24-8. http://www.ncbi.nlm.nih.gov/pubmed/7542159 13. Devonec M, Tomera K, Perrin P. Review: transurethral microwave thermotherapy in benign prostatic hyperplasia. J Endourol 1993;7(3):255-9. http://www.ncbi.nlm.nih.gov/pubmed/7689386 14. Devonec M, Houdelette P, Colombeau P, et al. A multicenter study of SHAM versus thermotherapy in benign prostatic hypertrophy. J Urol 1994;151:415A (abstr). 15. Blute ML, Patterson DE, Segura JW, Tomera KM, Hellerstein DK. Transurethral microwave thermotherapy vs. SHAM: double-blind randomized study. J Endourol. 1996;10(6):565-73. http://www.ncbi.nlm.nih.gov/pubmed/8972794 16. De Wildt MJ, d’Ancona FC, Hubregtse M, Carter SS, Debruyne FM, de la Rosette JJ. Three year follow-up of patients treated with lower energy thermotherapy. J Urol 1996;156(6):1959-63. http://www.ncbi.nlm.nih.gov/pubmed/8911365 17. Keijzers GB, Francisca EA, d’Ancona FC, Kiemeney LA, Debruyne FM, de la Rosette JJ. Long-term results of lower energy transurethral microwave thermotherapy. J Urol 1998;159(6):1966-72. http://www.ncbi.nlm.nih.gov/pubmed/9598499 18. De la Rosette JJ, de Wildt MJ, Hofner K, Carter SS, Debruyne FM, Tubaro A. High energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European Benign Prostatic Hyperplasia Study Group. J Urol 1996;156(1):97-101. http://www.ncbi.nlm.nih.gov/pubmed/8648849 19. Devonec M, Carter SS, Tubaro A et al. Microwave thermotherapy. Curr Opinion Urol 1995;5:3-9. 20. De Wildt MJ, Tubaro A, Höfner K, Carter SS. Debruyne FM, de la Rosette JJ. Responders and nonresponders to transurethral microwave thermotherapy: a multicenter retrospective analysis. J Urol 1995;154(5):1775-8. http://www.ncbi.nlm.nih.gov/pubmed/7563344
50
UPDATE MARCH 2004
21. De la Rosette JJ, de Wildt MJ, Höfner K, Carter SS, Debruyne FM, Tubaro A. Pressure/flow study analyses in patients treated with high-energy thermotherapy (Prostasoft 2.5). J Urol 1996;156(4): 1428-33. http://www.ncbi.nlm.nih.gov/pubmed/8808890 22. De la Rosette JJ, d’Ancona FC, Francisca EA et al. Clinical results of strategies to reduce morbidity in high energy transurethral microwave thermotherapy (HE-TUMT). (Congress report). AFU, 1997. 23. D’Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, de la Rosette JJ. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia (BPH): results of a prospective randomized study with 1 year follow up. J Urol 1997;158(1):120-5. http://www.ncbi.nlm.nih.gov/pubmed/9186336 24. Pace G, Selvaggio O, Palumbo F, Selvaggi FP. Initial experience with a new transurethral microwave thermotherapy treatment protocol ‘30-minute TUMT’. Eur Urol 2001;39(4):405-11. http://www.ncbi.nlm.nih.gov/pubmed/11306878 25. Carter SStC, Ogden CW, Patel A. Long term results of transurethral microwave thermotherapy for benign prostatic obstruction. In: Urology 1992. Guliani L, et al, eds. Bologna, 1992, pp. 257-261. 26. De la Rossette JJ, Laguna MP, Pace G, Kortmann BB, Selvaggio O, Debruyne FM, Selvaggi FP. Efficacy and safety of the new high-energy 30-minute transurethral microwave thermotherapy: results of 1-year follow-up in a multicenter study. Tech Urol 2000;6(4):271-5. http://www.ncbi.nlm.nih.gov/pubmed/11108564 27. Wagrell L, Schelin S, Bolmsjö M, Brudin L. Intraprostatic temperature monitoring during transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia. J Urol 1998;159(5): 1583-7. http://www.ncbi.nlm.nih.gov/pubmed/9554359 28. Wagrell L, Schelin S, Nordling J, Richthoff J, Magnusson B, Schain M, Larson T, Boyle E, Duelund J, Kroyer K, Ageheim H, Mattiasson A. Feedback microwave thermotherapy versus TURP for clinical BPH - a randomized controlled multicenter study. Urology. 2002;60(2):292-9. http://www.ncbi.nlm.nih.gov/pubmed/12137829 29. Tsai YS, Lin JS, Tong YC, Tzai TS, Yang WH, Chang CC, Cheng HL, Lin YM, Jou YC. Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: long-term durability with Prostcare. Eur Urol 2001;39(6):688-92. http://www.ncbi.nlm.nih.gov/pubmed/11464059 30. Daehlin L, Frugård J. Transurethral microwave thermotherapy in the management of lower urinary tract symptoms from benign prostatic obstruction: follow-up after five years. Scand J Urol Nephrol 2000;34(5):304-8. http://www.ncbi.nlm.nih.gov/pubmed/11186468 31. De Wildt MJ, Debruyne FM, de la Rosette JJ. High-energy transurethral microwave thermotherapy: a thermoablative treatment for benign prostatic obstruction. Urology 1996;48(3):416-23. http://www.ncbi.nlm.nih.gov/pubmed/8804495 32. Djavan B, Wammack R, Ghawidel K, Alavi S, Hasenzagel C, Dobronski P, Stoklosa A, Jakubcky T, Borkowski A, Marberger M. Microwave thermotherapy in patients with chronic urinary retention. Tech Urol 2000;6(4):278-81. http://www.ncbi.nlm.nih.gov/pubmed/11108566 33. Naqvi SA, Rizvi SA, Hasan AS. High-energy microwave thermotherapy in patients in urinary retention. J Endourol 2000;14(8):677-81. http://www.ncbi.nlm.nih.gov/pubmed/11083411
4.8
RECOMMENDATIONS FOR TREATMENT
1.
The WW policy should be recommended to patients with mild symptoms that have minimal or no impact on their quality of life. 2. 5 ARI’s are an acceptable treatment option for patients with bothersome LUTS and an enlarged prostate (> 40 mL) and can be used when there is no absolute indication for surgical treatment. 3. Alpha-blocker therapy is a treatment option for patients with bothersome LUTS who do not have an absolute indication for surgical treatment. 4. Surgical management (TURP, TUIP, open prostatectomy) is recommended as first-line treatment for patients with complications due to BPH with (an absolute indication for treatment of) LUTS. 5. Significant post-operative morbidity, disappointing long-term data and higher costs have resulted in a substantial decline in the clinical use of lasers. It is not recommended as a first-line surgical treatment for patients with LUTS, but may have a role in the treatment of high-risk patient subgroups. 6. HoLRP is a promising new technique with outcomes in the same range as those of TURP.
UPDATE MARCH 2004
51
7. 8. 9.
Transrectal HIFU therapy is currently not recommended as a therapeutic option for elderly men with LUTS and is considered an investigational therapy. TUNA® is an encouraging technology as an alternative with acceptable results. TUMT is an acceptable alternative to TURP and for those who prefer to avoid surgery or who no longer respond favourably to medication.
5. FOLLOW-UP All patients who receive treatment require follow-up, which will depend on the type of treatment modality undertaken. Patients who subsequently develop chronic retention will require evaluation of their upper tract by serum creatinine measurement and/or renal ultrasound. These patients may be candidates for urodynamic assessment and surgical treatment.
5.1
Watchful waiting
Patients who elect to pursue a WW policy should be reviewed at 6 months and then annually, provided there is no deterioration of symptoms or development of absolute indications for surgical treatment. The following are recommended: • I-PSS • Uro-flowmetry and post-void residual urine volume.
5.2
Alpha-blocker therapy
Patients should be reviewed after the first 6 weeks of therapy in order to determine their response. If patients gain symptomatic relief in the absence of troublesome side-effects, alpha-blocker therapy may be continued. Patients should be reviewed at 6 months and then annually, provided there is no deterioration of symptoms or development of absolute indications for surgical treatment. The following are recommended: • I-PSS • Uro-flowmetry and post-void residual urine volume.
5.3
5-alpha-reductase inhibitors
Patients should be reviewed after 12 weeks and at 6 months to determine their response. Subsequent review is as for alpha-blocker therapy. The following are recommended: • I-PSS • Uro-flowmetry and post-void residual urine volume.
5.4
Surgical management
Following surgical treatment, patients may be seen within 6 weeks to discuss the histological findings and to identify early post-operative morbidity. Long-term follow-up should be scheduled at 3 months to determine the final outcome. Patients who fail treatment should have urodynamic studies with pressure-flow analysis. Assessment includes: • I-PSS: recommended • Uro-flowmetry and post-void residual urine volume: recommended • Urine culture: optional • Histology: mandatory.
5.5
Alternative therapies
Long-term follow-up is recommended because of concerns about the efficacy and durability of alternative therapies. The intervals for follow-up will depend on the treatment modality employed. The following time schedule is appropriate for the majority of minimally invasive therapies: within 6 weeks, at 3 months, at 6 months, and then annually. Assessment includes: • I-PSS: recommended • Uroflowmetry and post-void residual urine volume: recommended • Urine culture: optional • Histology where available: mandatory.
52
UPDATE MARCH 2004
6. ABBREVIATIONS USED IN THE TEXT
This list is not comprehensive for the most common abbreviations.
AHCPR Agency for Health Care Policy and Research ALFIN study European multicenter double-blind study to assess the efficacy and safety of Alfuzosin (5 mg twice daily) versus finasteride (5mg once daily) and the combination of both in patients with symptomatic BPH ARI alpha reductase inhibitor AUA American Urological Association AUR Acute urinary retention BII BPH Impact Index BOO bladder outlet obstruction BPE benign prostatic enlargement BPH benign prostatic hyperplasia BUN blood urea/nitrogen CT computed tomography DAN-PSS Danish Prostate Symptom Score dL/dt 40 velocity of detrusor contraction at 40 mL volume DHT dihydrotestosterone DRE digital rectal examination EPCDS European Prostate Cancer Detection Study ERSPC European Randomized Study of Screening for Prostate Cancer HE-TUMT high-energy thermotherapy HIFU high-intensity focused ultrasound HoLRP Holmium laser resection of the prostate ICS International Continence Society I-PSS International Prostate Symptom Score ILC interstitial laser coagulation IVP intravenous pyelography IVU intravenous urography LOCM low-osmolar contrast material LinPURR Linear Passive Urethral Resistance Relation LUTS lower urinary tract symptoms MRI magnetic resonance imaging PCAR presumed circle area ratio PLESS Proscar Long-term efficacy and safety study PLCO Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial pQs pressure flow study PPV predictive positive value PQSF Prostate weight, Quality of life, Symptoms, Maximum flow rate PSA prostate-specific antigen PVR post-void residual volume Qav average flow Qmax maximum flow Qm90 mean flow for middle 90% of voided volume RCT randomized controlled trial ROC Receiver Operating Characteristics QoL Quality of Life VLAP visual laser ablation Tdesc time from Qmax until 95% of volume voided TRUS transrectal ultrasonography TUIP transurethral incision of the prostate TUMT transurethral microwave therapy TUNA® transurethral needle ablation TURP transurethral resection of the prostate TUVP transurethral electrovaporization URA Urethral Resistance Index VLAP visual laser ablation WW watchful waiting (deferred treatment)
UPDATE MARCH 2004
53
Conflict of interest All members of the Male LUTS Guidelines writing panel have provided disclosure statements of all relationships which they have and which may be perceived as a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel - and meeting expenses. No honoraria or other reimbursements have been provided.”
54
UPDATE MARCH 2004
Guidelines on
Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation E. Wespes, E. Amar, I. Eardley, F. Giuliano, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi, Y. Vardi
© European Association of Urology 2009
TABLE OF CONTENTS 1.
page
BACKGROUND 1.1 Introduction 1.2 References
4 4 4
2. ERECTILE DYSFUNCTION (ED) 2.1 Epidemiology and risk factors 2.1.1 Epidemiology 2.1.2 Risk factors 2.1.3 Post-radical prostatectomy ED 2.2 Managing ED: implications for everyday clinical practice 2.3 Conclusions 2.4 References 2.5 Diagnosis 2.5.1 Basic work-up 2.5.1.1 Sexual history 2.5.1.2 Physical examination 2.5.1.3 Laboratory testing 2.5.2 Cardiovascular system and sexual activity: the patient at risk 2.5.2.1 Low-risk category 2.5.2.2 Intermediate-risk or indeterminate-risk category 2.5.2.3 High-risk category 2.5.3 Specialized diagnostic tests 2.5.3.1 Nocturnal penile tumescence and rigidity (NPTR) 2.5.3.2 Intracavernous injection test 2.5.3.3 Duplex ultrasound of penile arteries 2.5.3.4 Arteriography and dynamic infusion cavernosometry or cavernosography 2.5.3.5 Psychiatric assessment 2.5.3.6 Penile abnormalities 2.5.4 Patient education – consultation and referrals 2.5.5 Guidelines on the diagnosis of ED 2.5.6 References
4 4 4 4 5 5 5 5 7 7 8 8 8 9 10 10 11 11 11 11 11 11
3. TREATMENT OF ED 3.1 Treatment options 3.2 Lifestyle management in ED with concomitant risk factors 3.3 ED after radical prostatectomy (RP) 3.4 ‘Curable’ causes of ED 3.4.1 Hormonal causes 3.4.2 Post-traumatic arteriogenic ED in young patients 3.4.3 Psychosexual counselling and therapy 3.5 First-line therapy 3.5.1 Oral pharmacotherapy 3.5.1.1 Sildenafil 3.5.1.2 Tadalafil 3.5.1.3 Vardenafil 3.5.1.4 Choice or preference between the different PDE5 inhibitors 3.5.1.5 On-demand or chronic use of PDE5 inhibitors 3.5.1.6 Safety issues for PDE5 inhibitors Cardiovascular safety Nitrates are totally contraindicated with PDE5 inhibitors Antihypertensive drugs Alpha-blocker interactions Dosage adjustment 3.5.1.7 Management of non-responders to PDE5 inhibitors Check that the patient has been using a licensed medication Check that the medication has been properly prescribed and correctly used
13 13 15 15 16 16 16 16 16 16 16 16 17 17 17 18 18 18 18 19 19 19 19 19
2
11 11 11 12 12
Update march 2009
Possible manoeuvres in patients correctly using a PDE5 inhibitor 3.5.1.8 Apomorphine sublingual 3.5.1.9 Other oral agents 3.6 Topical pharmacotherapy 3.7 Vacuum constriction devices 3.8 Second-line therapy 3.8.1 Intracavernous injections 3.8.1.1 Alprostadil Action to be taken with a prolonged erection 3.8.1.2 Combination therapy 3.8.1.3 Intraurethral alprostadil 3.9 Third-line therapy (penile prostheses) 3.9.1 Complications 3.9.2 Conclusion 3.10 Guideline recommendations for the treatment of ED 3.11 References
20 20 21 21 21 21 22 22 22 22 23 23 23 23 23 24
4. PREMATURE EJACULATION (PE) 4.1 Introduction 4.2 Definition of PE 4.2.1 Overview 4.2.2 Classifications 4.3 Epidemiology of PE 4.3.1 Prevalence 4.3.2 Pathophysiology and risk factors 4.4 Impact of PE on QoL 4.5 Diagnosis of PE 4.5.1 Intravaginal ejaculatory latency time (IELT) 4.5.2 PE assessment questionnaires 4.5.3 Physical examination and investigations 4.6 Guidelines on diagnosis of PE 4.7 References 4.8 Treatment 4.8.1 Psychological/behavioural strategies 4.8.2 Topical anaesthetic agents 4.8.2.1 Lidocaine-prilocaine cream 4.8.2.2 SS-cream 4.8.2.3 Guideline recommendation 4.8.3 Selective serotonin reuptake inhibitors 4.8.3.1 Dapoxetine 4.8.3.2 Guideline recommendation 4.8.4 Phosphodiesterase type 5 inhibitors 4.8.5 Other drugs 4.8.6 Guidelines on the treatment of PE 4.9 References 5. CONCLUSION
33 33 33 33 33 34 34 34 34 35 35 35 35 36 36 39 39 40 40 40 40 40 41 41 41 42 42 44
6.
48
ABBREVIATIONS USED IN THE TEXT
Update march 2009
46
3
1. BACKGROUND 1.1
Introduction
Erectile dysfunction (ED, impotence) and premature ejaculation (PE) are the two main complaints in male sexual medicine. New oral therapies have completely changed the diagnostic and therapeutic approach to ED and the Guidelines Office of The European Association of Urology (EAU) has appointed an Expert Panel to update previously published EAU guidelines for ED or impotence (1). The update is based on a review of available scientific information, current research and clinical practice in the field (1, 2). The Expert Panel has also identified critical problems and knowledge gaps, setting priorities for future clinical research. Level of evidence and grade of recommendation have been included in these guidelines when possible. The aim of this practice is to provide transparency between the underlying evidence and the recommendation made (3).
1.2
References
1.
Wespes E, Amar E, Hatzichristou DG, Montorsi F, Pryor J, Vardi Y. EAU guidelines on erectile dysfunction. Update March 2004. Eur Urol 2002;41(1):1-5. http://www.ncbi.nlm.nih.gov/pubmed/11999460 Rosenberg MT, Sadovsky R. Identification and diagnosis of premature ejaculation. Int J Clin Pract 2007;61(6):903-8. http://www.ncbi.nlm.nih.gov/pubmed/17504352 Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [access date Oct 24, 2008].
2.
3.
2. DIAGNOSIS 2.1
Epidemiology and risk factors
Erection is a neurovascular phenomenon under hormonal control. It includes arterial dilatation, trabecular smooth muscle relaxation and activation of the corporeal veno-occlusive mechanism (1). Erectile dysfunction has been defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. Although ED is a benign disorder, it affects physical and psychosocial health and has a significant impact on the quality of life (QoL) of sufferers and their partners and families (2). 2.1.1 Epidemiology Recent epidemiological data have shown a high prevalence and incidence of ED worldwide. The first largescale, community-based study of ED was the Massachusetts Male Aging Study (MMAS). The study reported an overall prevalence of 52% ED in non-institutionalized 40- to 70-year-old men in the Boston area in the USA (3); specific prevalences for minimal, moderate and complete ED were 17.2%, 25.2% and 9.6%, respectively. In the Cologne study of men aged 30-80 years old, the prevalence of ED was 19.2%, with a steep age-related increase from 2.3% to 53.4% (4). In the National Health and Social Life Survey (NHSLS), the prevalence of sexual dysfunctions (not specific ED) was 31% (5). The incidence rate of ED (new cases per 1000 men annually) was 26 in the MMAS study (6), 65.6 (mean follow-up of 2 years) in a Brazilian study (7) and 19.2 (mean followup of 4.2 years) in a Dutch study (8). Differences between these studies can be explained by differences in methodology and in the ages and socio-economic status of the populations studied. 2.1.2 Risk factors Erectile dysfunction shares common risk factors with cardiovascular disease (e.g. lack of exercise, obesity, smoking, hypercholesterolaemia, metabolic syndrome), some of which can be modified. In the MMAS, men who began exercising in midlife had a 70% reduced risk for ED compared to sedentary men and a significantly lower incidence of ED over an 8-year follow-up period of regular exercise (9). A multicentre, randomised, openlabel study in obese men with moderate ED compared 2 years of intensive exercise and weight loss with a control group given general information about healthy food choices and exercise (10). Significant improvements in body mass index (BMI) and physical activity scores, as well as in erectile function, were observed in the
4
Update march 2009
lifestyle intervention group. These changes were highly correlated with both weight loss and activity levels. However, it should be emphasized that controlled prospective studies are necessary to determine the effects of exercise or other lifestyle changes in prevention or treatment of ED. 2.1.3 Post-radical prostatectomy ED Radical prostatectomy (RP) in any form (open, laparoscopic, or robotic) is a widely performed procedure for patients with clinically localized prostate cancer (PCa) and a life expectancy of at least 10 years. This procedure may lead to treatment-specific sequelae affecting health-related QoL. This outcome has become increasingly important with the more frequent diagnosis of PCa in younger patients (11-13). Research has shown that about 25-75% of men experience post-operative ED (14). Post-RP ED is multifactorial. Cavernosal nerve injury induces pro-apoptotic (loss of smooth muscle) and pro-fibrotic (increase in collagen) factors within the corpora cavernosa. These changes may also be caused by poor oxygenation due to changes in the blood supply to the cavernosa. Because pre-operative potency is a major factor associated with the recovery of erectile function after surgery, patients being considered for a nerve-sparing radical prostatectomy (NSRP) should ideally be potent (15). It is also clear that cavernosal nerves must be preserved to ensure erectile function recovers after RP. In addition, the role of vascular insufficiency is of increasing interest in post-operative ED (16, 17).
2.2
Managing ED: implications for everyday clinical practice
Advances in basic and clinical research in ED during the past 15 years have led to the development of several new treatment options for ED, including new pharmacological agents for intracavernous, intraurethral, and, more recently, oral use (18-20). Treatment strategies have also changed following the poor outcomes seen in long-term follow-up of reconstructive vascular surgery (21, 22). An increasing number of men are seeking help for ED due to the great media interest in ED and the availability of effective and safe oral drug therapy. However, there are many physicians evaluating and treating ED without appropriate background knowledge and clinical experience. Thus, some men with ED may receive little or no evaluation before treatment and will therefore not receive treatment for any underlying disease that may be causing their ED. Other men without ED may be requesting treatment simply to enhance their sexual performance. Given this situation, these EAU guidelines for the diagnosis and treatment of ED are a necessity.
2.3
Conclusions
Conclusion LE GR • Erection is a neurovascular phenomenon under hormonal control in a 2b C psychological environment physiologenic environment • ED is common worldwide 3 B • ED shares several risk factors with cardiovascular disease 3 B • Lifestyle modification (intensive exercise and a decrease in body mass index) 1b A can improve erectile function • ED is a symptom, not a disease. Some men may not be properly evaluated or 4 C receive treatment for an underlying disease or condition that may be causing ED. • Radical prostatectomy is a common cause of ED 3 B LE = level of evidence; GR = grade of recommendation; ED = erectile dysfunction.
2.4
References
1.
Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol 1987;137(5):829-36. http://www.ncbi.nlm.nih.gov/pubmed/3553617 Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151(1):54-61. http://www.ncbi.nlm.nih.gov/pubmed/8254833 Wespes E. Ejaculation et ses troubles. Editions techniques EMC (Encyclopédie Médico-chirurgicale) (Paris) Nephrologie-Urologie, 18-710-A-10, 1992. [article in French] [Ejaculation and its disorders] Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000;12(6):305-11. http://www.ncbi.nlm.nih.gov/pubmed/11416833 Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281(6):537-44. http://www.ncbi.nlm.nih.gov/pubmed/10022110
2.
3. 4.
5.
Update march 2009
5
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
6
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study [see comments]. J Urol 2000;163(2):460-3. http://www.ncbi.nlm.nih.gov/pubmed/10647654 Moreira ED Jr, Lbo CF, Diament A, Nicolosi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 2003;61(2):431-6. http://www.ncbi.nlm.nih.gov/pubmed/12597962 Schouten BW, Bosch JL, Bernsen RM, Blanker MH, Thomas S, Bohnen AM. Incidence rates of erectile dysfunction in the Dutch general population. Effects of definition, clinical relevance and duration of follow-up in the Krimpen Study. Int J Impot Res 2005 Jan-Feb;17(1):58-62. http://www.ncbi.nlm.nih.gov/pubmed/15510192 Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000;56(2):302-6. http://www.ncbi.nlm.nih.gov/pubmed/10925098 Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F, D’Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291(24):2978-84. http://www.ncbi.nlm.nih.gov/pubmed/15213209 Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR, CaPSURE Investigators. The contemporary management of prostate cancer in the United States: lessons from the cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry. J Urol 2004;171(4):1393-401. http://www.ncbi.nlm.nih.gov/pubmed/15017184 Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 2000;283(3):354-60. http://www.ncbi.nlm.nih.gov/pubmed/10647798 Heidenreich A. Radical prostatectomy in 2007: oncologic control and preservation of functional integrity. Eur Urol 2008;53(5):877-9. http://www.ncbi.nlm.nih.gov/pubmed/18243495 Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12):1250-61. http://www.ncbi.nlm.nih.gov/pubmed/18354103 Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 2004;45:123-33. http://www.ncbi.nlm.nih.gov/pubmed/14733995 Mulhall JP, Slovick R, Hotaling J, Aviv N, Valenzuela R, Waters WB, Flanigan RC. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol 2002;167(3):1371-5. http://www.ncbi.nlm.nih.gov/pubmed/11832735 Secin FP, Touijer K, Mulhall J, Guillonneau B. Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy. Eur Urol 2007;51(5):1229-35. http://www.ncbi.nlm.nih.gov/pubmed/16989942 Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA; Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol 2002;167(2 Pt 2):1197-203. http://www.ncbi.nlm.nih.gov/pubmed/11905901 Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H; Vardenafil Study Group. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, doubleblind, 26-week placebo-controlled pivotal trial. Urology 2003;61(4 Suppl 1):8-14. http://www.ncbi.nlm.nih.gov/pubmed/12657355 Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168(4 Pt 1):1332-6. http://www.ncbi.nlm.nih.gov/pubmed/12352386 Wespes E, Schulman CC. Venous impotence: pathophysiology, diagnosis and treatment. J Urol 1993;149(5 Pt 2):1238-45. http://www.ncbi.nlm.nih.gov/pubmed/8479008
Update march 2009
22.
Rao DS, Donatucci CF. Vasculogenic impotence. Arterial and venous surgery. Urol Clin North Am 2001;28(2):309-19. http://www.ncbi.nlm.nih.gov/pubmed/11402583
2.5
Diagnosis
2.5.1 Basic work-up The first step in evaluating ED is always a detailed medical and psychological history of patients and partners (1, 2). Often it is not possible to include the partner on the patient’s first visit, but an effort should be made to include the partner at the second visit. The pathophysiology of ED may be vasculogenic, neurogenic, hormonal, anatomical, drug-induced or psychogenic (Table 1) (3) and taking a medical history may reveal one of the many common disorders associated with ED It is important to establish a relaxed atmosphere during history-taking. This will make it easier to ask questions about erectile function and other aspects of sexual history, particularly when patients do not find it easy to talk about their problem. It will also make it easier to explain the diagnosis and therapeutic approach to the patient and his partner. Table 1: Pathophysiology of ED Vasculogenic • Cardiovascular disease • Hypertension • Diabetes mellitus • Hyperlipidaemia • Smoking • Major surgery (radical prostatectomy) or radiotherapy (pelvis or retroperitoneum) Neurogenic Central causes • Multiple sclerosis • Multiple atrophy • Parkinson’s disease • Tumours • Stroke • Disk disease • Spinal cord disorders Peripheral causes • Diabetes mellitus • Alcoholism • Uraemia • Polyneuropathy • Surgery (pelvis or retroperitoneum, radical prostatectomy) Anatomical or structural • Peyronie’s disease • Penile fracture • Congenital curvature of the penis • Micropenis • Hypospadias, epispadias Hormonal • Hypogonadism • Hyperprolactinemia • Hyper- and hypo-thyroidism • Cushing’s disease Drug-induced • Antihypertensives (diuretics and beta-blockers are the most common causes) • Antidepressants • Antipsychotics • Antiandrogens • Antihistamines • Recreational drugs (heroin, cocaine, methadone) Psychogenic • Generalized type (e.g. lack of arousability and disorders of sexual intimacy)
Update march 2009
7
•
Situational type (e.g. partner-related, performance-related issues or due to distress)
2.5.1.1 Sexual history The sexual history may include information about previous and current sexual relationships, current emotional status, onset and duration of the erectile problem, and previous consultations and treatments. A detailed description should be made of the rigidity and duration of both erotic and morning erections and of problems with arousal, ejaculation and orgasm. Validated questionnaires, such as the International Index for Erectile Function (IIEF), help to assess all sexual function domains (erectile function, orgasmic function, sexual desire, ejaculation, intercourse and overall satisfaction), as well as the impact of a specific treatment modality (4). 2.5.1.2 Physical examination Every patient must be given a physical examination focused on the genitourinary, endocrine, vascular and neurological systems (1). A physical examination may reveal unsuspected diagnoses, such as Peyronie’s disease, prostatic enlargement or cancer, or signs and symptoms suggesting hypogonadism (small testes, alterations in secondary sexual characteristics, diminished sexual desire and changes in mood) (2). A rectal examination should be performed in every patient older than 50 years. Blood pressure and heart rate should be measured if they have not been assessed in the previous 3-6 months. Particular attention must be given to patients with cardiovascular disease (see Section 2.5.2). 2.5.1.3 Laboratory testing Laboratory testing must be tailored to the patient’s complaints and risk factors. All patients must undergo a fasting glucose and lipid profile if not assessed in the previous 12 months. Hormonal tests must include a morning sample of total testosterone. Tests that measure bioavailable or calculated-free testosterone are preferred to total testosterone tests because they are better at establishing hypogonadism. Additional laboratory tests must be considered only in selected patients, e.g. prostate-specific antigen (PSA) for detection of prostate cancer. Additional hormonal tests, e.g. prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), must be carried out when low testosterone levels are detected. If any abnormality is observed, referral to another specialist may be necessary (5, 6). Figure 1 gives the minimal diagnostic evaluation (basic work-up) in patients with ED.
8
Update march 2009
Figure 1: Minimal diagnostic evaluation (basic work-up) in patients with ED
Patient with erectile dysfunction (self-reported)
Medical and psychosexual history (use of validated instruments, e.g. IIEF)
Identify other than ED sexual problems
Identify common causes of ED
Identify reversible risk factors for ED
Assess psychosocial status
Focused physical examination
Penile deformities
Prostatic disease
Signs of hypogonadism
Cardiovascular and neurological status
Laboratory tests
Glucose-lipid profile (if not assessed in the last 12 months)
Total testosterone (morning sample) If available: bio-available or free testosterone (instead of total)
2.5.2 Cardiovascular system and sexual activity: the patient at risk Patients who seek treatment for sexual dysfunction have a high prevalence of cardiovascular disease. The cardiac risks associated with sexual activity are well established. Recent epidemiological studies have emphasized the association between cardiovascular and metabolic risk factors and sexual dysfunction in both men and women (7). There has been an intensive investigation of the pharmacological properties of phosphodiesterase type 5 (PDE5) inhibitors, including their effects on cardiac smooth muscle activity and overall cardiovascular safety. The EAU Guidelines recommendations given here for using PDE5 inhibitors in PE have been adapted from previously published recommendations from consensus conferences on sexual dysfunction and cardiac risk (8, 9). Patients with ED can be stratified into three cardiovascular risk categories (Table 2), which can be used as the basis for a treatment algorithm for initiating or resuming sexual activity (Figure 2). It is also possible for the clinician to estimate the risk of sexual activity in most patients from their level of exercise tolerance, determined when taking the patient’s history.
Update march 2009
9
Table 2: Cardiac risk stratification Low-risk category Intermediate-risk category High-risk category Asymptomatic, < 3 risk factors for ≥ 3 risk factors for CAD High-risk arrhythmias CAD (excluding gender) (excluding gender) Mild, stable angina Moderate, stable angina Unstable or refractory angina (evaluated and/or being treated) Uncomplicated previous MI Recent MI (> 2, < 6 weeks) Recent MI (< 2 weeks) LVD/CHF (NYHA class I) LVD/CHF (NYHA class II) LVD/CHF (NYHA class III/IV) Post-successful coronary Non-cardiac sequelae of Hypertrophic obstructive and other revascularization atherosclerotic disease (e.g. stroke, cardiomyopathies peripheral vascular disease) Controlled hypertension Uncontrolled hypertension Mild valvular disease Moderate-to-severe valvular disease CAD = coronary artery disease; CHF = congestive heart failure; LVD = left ventricular dysfunction; MI = myocardial infarction; NYHA = New York Heart Association.
Figure 2: Treatment algorithm for determining level of sexual activity according to cardiac risk in ED
Sexual inquiry
Clinical evaluation
Low risk
Intermediate risk
Initiate or resume sexual activity or Treatment for sexual dysfunction
Cardiovascular assessment and restratification
High risk
Sexual activity deferred until stabilization of cardiac condition
Risk factors and coronary heart disease evaluation, treatment and follow-up for all patients with erectile dysfunction
2.5.2.1 Low-risk category The low-risk category includes patients who do not have any significant cardiac risk associated with sexual activity. Low risk is typically implied by the ability to perform exercise of modest intensity, which is defined as six or more ‘metabolic equivalents of energy expenditure in the resting state’ (METs) without symptoms. According to current knowledge of the exercise demand or emotional stress associated with sexual activity, low-risk patients do not need cardiac testing or evaluation before the initiation or resumption of sexual activity or therapy for sexual dysfunction. 2.5.2.2 Intermediate-risk or indeterminate-risk category The intermediate- or indeterminate-risk category consists of patients with an uncertain cardiac condition or patients whose risk profile requires testing or evaluation before the resumption of sexual activity. Based upon the results of testing, these patients may be moved to either the high- or low-risk group. A cardiology
10
Update march 2009
consultation may be needed in some patients to help the primary physician determine the safety of sexual activity. 2.5.2.3 High-risk category High-risk patients have a cardiac condition that is sufficiently severe and/or unstable for sexual activity to carry a significant risk. Most high-risk patients have moderately to severely symptomatic heart disease. High-risk individuals should be referred for cardiac assessment and treatment. Sexual activity should be stopped until the patient’s cardiac condition has been stabilized by treatment or a decision made by the cardiologist and/or internist that it is safe to resume sexual activity. 2.5.3 Specialized diagnostic tests Most patients with ED can be managed within the sexual care setting, but some patients may need specific diagnostic tests (Tables 3 and 4). 2.5.3.1 Nocturnal penile tumescence and rigidity (NPTR) The nocturnal penile tumescence and rigidity (NPTR) assessment should be done on at least two nights. A functional erectile mechanism is indicated by an erectile event of at least 60% rigidity recorded on the tip of the penis that lasts for 10 min or more (10). 2.5.3.2 Intracavernous injection test The intracavernous injection test gives limited information about vascular status. A positive test is a rigid erectile response (unable to bend the penis) that appears within 10 min after the intracavernous injection and lasts for 30 min (11). This response indicates a functional, but not necessarily normal, erection, as the erection may co-exist with arterial insufficiency or veno-occlusive dysfunction (12). A positive test shows that a patient will respond to the intracavernous injection programme. The test is inconclusive as a diagnostic procedure and Duplex ultrasound of the penile arteries should be requested. 2.5.3.3 Duplex ultrasound of penile arteries A peak systolic blood flow higher than 30 cm/s and a resistance index higher than 0.8 are generally considered normal (10). Further vascular investigation is unnecessary when a Duplex examination is normal. 2.5.3.4 Arteriography and dynamic infusion cavernosometry or cavernosography Arteriography and dynamic infusion cavernosometry or cavernosography (DICC) should be performed only in patients who are being considered for vascular reconstructive surgery (13). 2.5.3.5 Psychiatric assessment Patients with psychiatric disorders must be referred to a psychiatrist who is particularly interested in ED. In younger patients (< 40 years) with long-term primary ED, psychiatric assessment may be helpful before any organic assessment is carried out. 2.5.3.6 Penile abnormalities Surgical correction may be needed for patients with ED due to penile abnormalities, e.g. hypospadias, congenital curvature, or Peyronie’s disease with preserved rigidity. Success rates are high. 2.5.4 Patient education – consultation and referrals The consultation with the patient should include a discussion of the expectations and needs of both the patient and his partner. It should also review both the patient’s and partner’s understanding of ED and results of the diagnostic tests, and provide a rational selection of treatment options. Patient and partner education are an essential part of ED management (14, 15). Table 3: Indications for specific diagnostic tests Indications for specific diagnostic tests • Primary erectile disorder (not caused by organic disease or psychogenic disorder) • Young patients with a history of pelvic or perineal trauma who could benefit from potentially curative vascular surgery • Patients with penile deformities that might require surgical correction, e.g. Peyronie’s disease, congenital curvature • Patients with complex psychiatric or psychosexual disorders • Patients with complex endocrine disorders
Update march 2009
11
• •
Specific tests may be indicated at the request of the patient or his partner Medicolegal reasons, e.g. implantation of penile prosthesis, sexual abuse
Table 4: Specific diagnostic tests Diagnostic test • Nocturnal penile tumescence and rigidity (NTPR) using Rigiscan® • Vascular studies - Intracavernous vasoactive drug injection - Duplex ultrasound of the cavernous arteries - Dynamic infusion cavernosometry or cavernosography (DICC) - Internal pudendal arteriography • Neurological studies, e.g. bulbocavernosus reflex latency, nerve conduction studies • Endocrinological studies • Specialized psychodiagnostic evaluation
2.5.5
Guidelines on the diagnosis of ED
Diagnostice guideline • Clinical use of validated questionnaire related to ED may help to assess all sexual function domains and the effect of a specific treatment modality • Physical examination is needed in the initial assessment of men with ED to identify underlying medical conditions that may be associated with ED • Routine laboratory tests, including glucid-lipid profile and total testosterone, are required to identify and treat any reversible risk factors and lifestyle factors that can be modified • Specific diagnostic tests are indicated by only a few conditions LE = level of evidence; GR = grade of recommendation.
LE GR 3 B 4
B
4
B
4
B
2.5.6
References
1.
Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 1995;45(3):498-502. http://www.ncbi.nlm.nih.gov/pubmed/7879338 Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol 2002;168(2):615-20. http://www.ncbi.nlm.nih.gov/pubmed/12131320 Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am 2001;28(2):209-16, vii. http://www.ncbi.nlm.nih.gov/pubmed/11402575 Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49(6):822-30. http://www.ncbi.nlm.nih.gov/pubmed/9187685 Morales A, Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am 2001;28(2):279-88. http://www.ncbi.nlm.nih.gov/pubmed/11402581 Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1(1):6-23. http://www.ncbi.nlm.nih.gov/pubmed/16422979 Laumann EO, Paik A, Rosen RC. The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey. Int J Impot Res 1999;11(Suppl 1):S60-S64. http://www.ncbi.nlm.nih.gov/pubmed/10554933
2.
3. 4.
5.
6.
7.
12
Update march 2009
8.
9.
10.
11.
12.
13.
14.
15.
DeBusk R, Drory Y, Goldstein I, Jackson G, Kaul S, Kimmel SE, Kostis JB, Kloner RA, Lakin M, Meston CM, Mittleman M, Muller JE, Padma-Nathan H, Rosen RC, Stein RA, Zusman R. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000;86(6):62F-68F. http://www.ncbi.nlm.nih.gov/pubmed/10554933 Kostis J, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett A, Carson C, Cheitlin M, Debusk R, Fonseca V, Ganz P, Goldstein I, Guay A, Hatzichristou D, Hollander JE, Hutter A, Katz S, Kloner RA, Mittleman M, Montorsi F, Montorsi P, Nehra A, Sadovsky R, Shabsigh R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96(B):313-21. http://www.ncbi.nlm.nih.gov/pubmed/16018863 Hatzichristou DG, Hatzimouratidis K, Ioannides E, Yannakoyorgos K, Dimitriadis G, Kalinderis A. Nocturnal penile tumescence and rigidity monitoring in young potent volunteers: reproducibility, evaluation criteria and the effect of sexual intercourse. J Urol 1998;159(6):1921-6. http://www.ncbi.nlm.nih.gov/pubmed/9598488 Meuleman EJ, Diemont WL. Investigation of erectile dysfunction. Diagnostic testing for vascular factors in erectile dysfunction. Urol Clin North Am 1995;22(4):803-19. http://www.ncbi.nlm.nih.gov/pubmed/7483130 Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Ioannidis E, Yannakoyorgos K, Kalinderis A. Hemodynamic characterization of a functional erection. Arterial and corporeal veno-occlusive function in patients with a positive intracavernosal injection test. Eur Urol 1999;36(1):60-7. http://www.ncbi.nlm.nih.gov/pubmed/10364657 Wespes E, Schulman C. Venous impotence: pathophysiology, diagnosis and treatment. J Urol 1993;149(5 Pt 2):1238-45. http://www.ncbi.nlm.nih.gov/pubmed/8479008 Rosen RC, Leiblum SR, Spector IP. Psychologically based treatment for male erectile disorder: a cognitive-interpersonal model. J Sex Marital Ther 1994;20(2):67-85. http://www.ncbi.nlm.nih.gov/pubmed/8035472 Hatzichristou D, Rosen RC, Broderick G, Clayton A, Cuzin B, Derogatis L, Litwin M, Meuleman E, O’Leary M, Quirk F, Sadovsky R, Seftel A. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004 Jul;1(1):49-57. http://www.ncbi.nlm.nih.gov/pubmed/16422983
3. TREATMENT of ed 3.1
Treatment options
The primary goal in the management strategy of a patient with ED is to determine the aetiology of the disease and treat it when possible, and not to treat the symptom alone. Erectile dysfunction may be associated with modifiable or reversible factors, including lifestyle or drug-related factors. These factors may be modified either before, or at the same time as, specific therapies are used. As a rule, ED can be treated successfully with current treatment options, but cannot be cured. The only exceptions are psychogenic ED, post-traumatic arteriogenic ED in young patients and hormonal causes (e.g. hypogonadism, hyperprolactinaemia), which can be potentially cured with specific treatment. Most men with ED will be treated with treatment options that are not cause-specific. This results in a structured treatment strategy that depends on efficacy, safety, invasiveness and cost, as well as patient preference (1). To counsel patients properly with ED, physicians must be fully informed of all treatment options. The assessment of treatment options must consider the effects on patient and partner satisfaction and other QoL factors as well as efficacy and safety. A treatment algorithm for ED is given in Figure 3.
Update march 2009
13
Figure 3: Treatment algorithm for ED Treatment of erectile dysfunction
Identify and treat ‘curable’ causes of ED
Lifestyle changes and risk factor modification
Provide education and counselling to patients and partners
Identify patient needs and expectations Shared decision-making Offer conjoint psychosocial and medical treatment
Apomorphine SL Intracavernous injections Intraurethral alprostadil Vacuum devices
PDE5 inhibitors
Assess therapeutic outcome: • Erectile response • Side-effects • Satisfaction with treatment
Inadequate treatment outcome
Assess adequate use of treatment options Provide new instructions and counselling Re-trial Consider alternative or combination therapy
Inadequate treatment outcome
Consider penile prosthesis implantation
PDE5 inhibitor = phosphodiesterase type 5 inhibitor
14
Update march 2009
3.2
Lifestyle management in ED with concomitant risk factors
The basic work-up of the patient must identify reversible risk factors for ED. Lifestyle changes and risk factor modification must precede or accompany ED treatment. The potential benefits of lifestyle changes may be particularly important in individuals with ED and specific comorbid cardiovascular or metabolic diseases, such as diabetes or hypertension (2-4). Besides improving erectile function, aggressive lifestyle changes may also benefit overall cardiovascular and metabolic health, with recent studies supporting the potential of lifestyle intervention to benefit both ED and overall health (5). Although further studies are needed to make clear the role of lifestyle changes in the management of ED and related cardiovascular disease, lifestyle changes can be recommended alone or combined with PDE5 therapy. Some studies have suggested that the therapeutic effects of PDE5 inhibitors may be enhanced when other comorbidities or risk factors are aggressively managed (6). However, these results have yet to be confirmed in well-controlled, long-term studies. Because of the success of pharmacological therapy for ED, clinicians need to provide specific evidence for the benefits of lifestyle change and hopefully future research will show this.
3.3
Erectile dysfunction after radical prostatectomy (RP)
Use of pro-erectile drugs following RP is very important in achieving erectile function following surgery. Several trials have shown higher rates of erectile function recovery after RP in patients receiving any drug (therapeutic or prophylactic) for ED. Historically, the treatment options for post-operative ED included intracavernous injections (7), urethral microsuppository (8), vacuum device therapy (9) and penile implants (10). Intracavernous injections and penile implants are still suggested as second- and third-line treatments, respectively, when oral compounds are not adequately effective or contraindicated for post-operative patients (see Sections 3.8 and 3.9). The management of post-RP ED has been revolutionized by the advent of PDE5 inhibitors, with their demonstrated efficacy, ease of use, good tolerability, excellent safety, and positive impact on QoL. At present, PDE5 inhibitors are the first-line choice of oral pharmacotherapy for post-RP ED in patients who have undergone a nerve-sparing (NS) surgical approach. The choice of PDE5 inhibitors as first-line treatment is controversial because the experience (surgical volume) of the surgeon is a key factor in preserving postoperative erectile function in addition to patient age and NS technique (11-13). In fact, PDE5 inhibitors are most effective in patients who have undergone a rigorous NS procedure, which is more commonly performed by the largest-volume surgeons (12, 13). The early use of a high dose of sildenafil after RP is associated with the preservation of smooth muscle within the human corpora cavernosa (14). Daily sildenafil also resulted in a greater return of spontaneous normal erectile function post RP compared to placebo following bilateral nerve-sparing RP (NSRP) in patients who were fully potent before surgery (15, 16). The response rate to sildenafil treatment for ED after RP in different trials ranged from 35% to 75% among those who underwent NSRP and from 0% to 15% among those who underwent non-NSRP (15-18). The effectiveness of both tadalafil and vardenafil as on-demand treatment has also been evaluated in post-RP ED: • A large multicentre trial in Europe and USA studied tadalafil in patients with ED following a bilateral NS procedure. Erectile function was improved in 71% of patients treated with tadalafil 20 mg versus 24% treated with placebo, while the rate of successful intercourse attempts was 52% with tadalafil 20 mg versus 26% with placebo (19). • Similarly, vardenafil has been tested in patients treated with ED following either an unilateral or bilateral NS procedure in a multicentre, prospective, placebo-controlled, randomised North American study (20). Following bilateral NSRP, erectile function improved by 71% and 60% with vardenafil, 20 mg and 10 mg, respectively. An extended analysis of the same patients undergoing NSRP has underlined the benefit of vardenafil compared to placebo regarding intercourse satisfaction, hardness of erection, orgasmic function and overall satisfaction with sexual experience (21). A randomized, double-blind, double-dummy, multicentre, parallel-group study in 87 centres across Europe, Canada, South Africa and the USA, compared on- demand and nightly dosing of vardenafil in men with ED following bilateral NSRP. In patients whose IIEF erectile function domain (IIEF-EF) score was ≥ 26 before surgery, vardenafil was efficacious when used on demand, supporting a paradigm shift towards on-demand dosing with PDE5 inhibitors in post-RP ED (22). Patients who do not respond to oral PDE5 inhibitors after NSRP should be treated with prophylactic intracorporeal alprostadil (23). A penile prosthesis remains a very satisfactory approach for patients who do not respond to either oral or intracavernous pharmacotherapy or to a vacuum device (24).
Update march 2009
15
3.4
‘Curable’ causes of ED
3.4.1 Hormonal causes An endocrinologist’s advice is essential for managing patients with hormonal abnormalities. Testosterone deficiency is either a result of primary testicular failure or secondary to pituitary/hypothalamic causes, including a functional pituitary tumour resulting in hyperprolactinaemia. Testosterone replacement therapy (intramuscular, oral or transdermal) is effective, but should only be used after other endocrinological causes for testicular failure have been excluded (25). Testosterone replacement is contraindicated in men with a history of prostate carcinoma or with symptoms of prostatism. Before initiating testosterone replacement, a digital rectal examination (DRE) and serum PSA test should be performed. Patients given androgen therapy should be monitored for clinical response and the development of hepatic or prostatic disease. There is no contraindication for testosterone therapy in men with coronary artery disease who have been properly diagnosed with hypogonadism and/or ED. However, the haematocrit level should be monitored and a dose adjustment of testosterone may be necessary, especially in congestive heart failure. Hormonal treatment is not always effective in the management of ED associated with hypogonadism (26). 3.4.2 Post-traumatic arteriogenic ED in young patients In young patients with pelvic or perineal trauma, surgical penile revascularization has a 60-70% long-term success rate (27). The lesion must be demonstrated by Duplex ultrasound and confirmed by penile pharmacoarteriography. Corporeal veno-occlusive dysfunction is a contraindication to revascularization and must be excluded by DICC (9, 10). Vascular surgery for veno-occlusive dysfunction is no longer recommended because of poor long-term results (28). 3.4.3 Psychosexual counselling and therapy For patients with a significant psychological problem, psychosexual therapy may be given either alone or with another therapeutic approach. Psychosexual therapy takes time and has had variable results (29).
3.5
First-line therapy
3.5.1 Oral pharmacotherapy The PDE5 enzyme hydrolyzes cyclic guanosine monophosphate (cGMP) in the cavernosum tissue of the penis. Inhibition of PDE5 results in increased arterial blood flow leading to smooth muscle relaxation, vasodilatation and penile erection (30). Three potent selective PDE5 inhibitors have been approved by the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) for treatment of ED. They are not initiators of erection and require sexual stimulation to facilitate an erection. 3.5.1.1 Sildenafil Sildenafil, launched in 1998, was the first PDE5 inhibitor available on the market. Efficacy is defined as an erection with rigidity sufficient for vaginal penetration. Sildenafil is effective from 30 to 60 min after administration. Its efficacy is reduced after a heavy fatty meal due to prolonged absorption. It is administered in 25, 50 and 100 mg doses. The recommended starting dose is 50 mg and should be adapted according to the patient’s response and side-effects. Efficacy may be maintained for up to 12 h (31). The pharmacokinetic data of sildenafil are presented in Table 5. Adverse events (Table 6) are generally mild in nature and self-limited by continuous use. The drop-out rate due to adverse events is similar to placebo (32). After 24 weeks in a dose-response study, improved erections were reported by 56%, 77% and 84% of men taking 25, 50 and 100 mg of sildenafil, respectively, compared to 25% of men taking placebo (33). Sildenafil statistically improved patient scores in IIEF, sexual encounter profile 2 (SEP2), SEP3 and general assessment question (GAQ) and treatment satisfaction. The efficacy of sildenafil in almost every subgroup of patients with ED has been successfully established. In diabetic patients, 66.6% reported improved erections (GAQ) and 63% successful intercourse attempts compared to 28.6% and 33% of men taking placebo, respectively (34). 3.5.1.2 Tadalafil Tadalafil, licenced for the treatment of ED as of February 2003, is effective from 30 min after administration, with peak efficacy after about 2 h. Efficacy is maintained for up to 36 h (35) and is not affected by food. It is administered in 10 and 20 mg doses. The recommended starting dose is 10 mg and should be adapted according to the patient’s response and side-effects. Pharmacokinetic data of tadalafil are presented in Table 5. Adverse events (Table 6) are generally mild in nature, self-limited by continuous use. The drop-out rate due to adverse events is similar to placebo (36).
16
Update march 2009
In pre-marketing studies, after 12 weeks of treatment and in a dose-response study, improved erections were reported by 67% and 81% of men taking 10 mg and 20 mg of tadalafil compared to 35% of men in the control placebo group (36). Tadalafil statistically improved patient scores in IIEF, SEP2, SEP3 and GAQ and treatment satisfaction. These results were confirmed in post-marketing studies (37). Tadalafil also improved erections in difficult-to-treat subgroups. In diabetic patients, 64% reported improved erections (i.e. improved GAQ) versus 25% of patients in the control group and the change in the final score for IIEF-EF was 7.3 compared to 0.1 for placebo (38). 3.5.1.3 Vardenafil Vardenafil, commercially available as of March 2003, is effective from 30 min after administration. Its effect is reduced by a heavy fatty meal (> 57% fat). It is administered in 5, 10 and 20 mg doses. The recommended starting dose is 10 mg and should be adapted according to the patient’s response and side-effects. In vitro, it is 10-fold more potent than sildenafil, though this does not necessarily mean greater clinical efficacy (39). Pharmacokinetic data of vardenafil are presented in Table 5. Adverse events (Table 6) are generally mild in nature and self-limited by continuous use, with a drop-out rate similar to placebo (40). After 12 weeks in a dose-response study, improved erections were reported by 66%, 76% and 80% of men taking 5 mg, 10 mg and 20 mg of vardenafil, respectively, compared with 30% of men taking placebo (41). Vardenafil statistically improved patient scores for IIEF, SEP2, SEP3 and GAQ and treatment satisfaction. Efficacy was confirmed in post-marketing studies (42). Vardenafil improved erections in difficult-to-treat subgroups. In diabetic patients, 72% reported improved erections (i.e. improved GAQ) compared to 13% of patients taking placebo and the final IIEF-EF score was 19 compared to 12.6 for placebo (43). 3.5.1.4 Choice or preference between the different PDE5 inhibitors To date, no data are available from double- or triple-blind multicentre studies comparing the efficacy and/ or patient preference for sildenafil, tadalafil and vardenafil. Choice of drug will depend on the frequency of intercourse (occasional use or regular therapy, 3-4 times weekly) and the patient’s personal experience. Patients need to know whether a drug is short- or long-acting, possible disadvantages and how to use it. 3.5.1.5 On-demand or chronic use of PDE5 inhibitors Animal studies have shown that chronic use of PDE5 inhibitors improves or prevents significantly the intracavernous structure alterations due to age, diabetes or surgical damage (44-50). In humans, a randomised study (n = 145) showed that daily tadalafil led to a significantly higher IIEFEF score and higher completion of successful intercourse attempts compared to on-demand tadalafil (51). Two major double-blind randomised studies, using daily 5 and 10 mg tadalafil for 12 weeks (n = 268) (52) and daily 2.5 and 5 mg tadalafil for 24 weeks (n = 286) (53), showed that daily dosing was well tolerated and significantly improved erectile function. However, these studies lacked an on-demand treatment arm. An openlabel extension was carried out of both studies in 234 patients for 1 year and 238 patients for 2 years. Tadalafil, 5 mg once daily, was shown to be well tolerated and effective (54). Tadafil, 5 mg once daily, therefore provides an alternative to on-demand dosing of tadalafil for couples who prefer spontaneous rather than scheduled sexual activities or who anticipate frequent sexual activity, with the advantage that dosing and sexual activity no longer need to be temporally linked. Nevertheless, in the 1-year open-label 5 mg tadalafil extension study followed by 4 weeks of wash-out, erectile function was not maintained after discontinuation of therapy in most patients (about 75%). A double-blind, placebo-controlled, multicentre, parallel-group study was conducted in 236 men with mild-to-moderate ED randomised to receive once-daily vardenafil 10 mg plus on-demand placebo for 12 or 24 weeks, or once-daily placebo plus on-demand vardenafil 10 mg for 24 weeks, followed by 4 weeks of wash-out (55). Despite preclinical evidence, the results suggested that once-daily dosing of vardenafil 10 mg does not offer any sustainable effect after cessation of treatment compared to on-demand administration in patients with mild-to-moderate ED. Other studies (open-label, randomised, cross-over studies with limited patient numbers) showed that chronic, but not on-demand, tadalafil treatment improved endothelial function with sustained effect after its discontinuation (56, 57). This was confirmed in another study of chronic sildenafil in men with type 2 diabetes (58). Recently, in the first double-blind placebo-controlled study, enrolling 298 men with diabetes and ED for 12 weeks, once-daily tadalafil 2.5 mg and 5 mg was efficacious and well tolerated. This regimen provides an alternative to on-demand treatment for some diabetic men (59). However, when patients have the choice, it seems that they prefer on-demand rather than continuous therapy (60).
Update march 2009
17
Table 5: Summary of the key pharmacokinetic data for the three PDE5 inhibitors used to treat ED* Parameter Sildenafil, 100 mg Tadalafil, 20mg Vardenafil, 20 mg Cmax 560 µg/L 378 µg/L 18.7 µg/L Tmax 0.8-1 h 2 h 0.9 h T1/2 2.6-3.7 h 17.5 3.9 h AUC 1685 µg/h/L 8066 µg.h/L 56.8 µg.h/L Protein binding 96% 94% 94% Bioavailability 41% NA 15% Cmax: maximal concentration, Tmax: time-to-maximum plasma concentration; T1/2: plasma elimination halftime; AUC: area under curve or serum concentration time curve. * Fasted state, higher recommended dose. Data adapted from EMEA statements on product characteristics. Sildenafil: http://www.emea.europa.eu/humandocs/Humans/EPAR/viagra/viagra.htm Tadalafil: http://www.emea.europa.eu/humandocs/Humans/EPAR/cialis/cialis.htm Vardenafil: http://www.emea.europa.eu/humandocs/Humans/EPAR/levitra/levitra.htm Table 6: Common adverse events of the three PDE5 inhibitors used to treat ED* Adverse event Sildenafil Tadalafil Headache 12.8% 14.5% Flushing 10.4% 4.1% Dyspepsia 4.6% 12.3% Nasal congestion 1.1% 4.3% Dizziness 1.2% 2.3% Abnormal vision 1.9% Back pain 6.5% Myalgia 5.7% * Adapted from EMEA statements on product characteristics. Sildenafil: http://www.emea.europa.eu/humandocs/Humans/EPAR/viagra/viagra.htm Tadalafil: http://www.emea.europa.eu/humandocs/Humans/EPAR/cialis/cialis.htm Vardenafil: http://www.emea.europa.eu/humandocs/Humans/EPAR/levitra/levitra.htm
Vardenafil 16% 12% 4% 10% 2% <2%
3.5.1.6 Safety issues for PDE5 inhibitors Cardiovascular safety Clinical trial results and post-marketing data of sildenafil, tadalafil and vardenafil have demonstrated no increase in myocardial infarction rates in patients receiving PDE5 inhibitors, as part of either double-blind, placebo-controlled trials or open-label studies, or compared to expected rates in age-matched male populations. None of the PDE5 inhibitors had an adverse effect on total exercise time or time-to-ischaemia during exercise testing in men with stable angina (61, 62). In fact, they may improve exercise tests. Sildenafil does not alter cardiac contractility, cardiac output or myocardial oxygen consumption according to available evidence. Chronic or on-demand use is well tolerated with a similar safety profile. Nitrates are totally contraindicated with PDE5 inhibitors Organic nitrates (e.g. nitroglycerine, isosorbide mononitrate, isosorbide dinitrate) and other nitrate preparations used to treat angina, as well as amyl nitrite or amyl nitrate (‘poppers’ used for recreation), are absolute contraindications with the use of PDE5 inhibitors. They result in cGMP accumulation and unpredictable falls in blood pressure and symptoms of hypotension. The duration of interaction between organic nitrates and PDE5 inhibitors depends upon the PDE5 inhibitor and nitrate used. If a PDE5 inhibitor is taken and the patient develops chest pain, nitroglycerine must be withheld for at least 24 h if sildenafil (and probably also vardenafil) was used (half-life, 4 h), and for at least 48 h if tadalafil was used (half-life, 17.5 h). If a patient develops angina while taking a PDE5 inhibitor, other agents may be given instead of nitroglycerine until the appropriate time has passed. If nitroglycerine must be re-introduced following administration of a PDE5 inhibitor, the patient should receive it only after an appropriate interval has elapsed, as described above, and under close medical observation. Antihypertensive drugs Co-administration of PDE5 inhibitors with antihypertensive agents (angiotensin-converting enzyme inhibitors,
18
Update march 2009
angiotensin-receptor blockers, calcium blockers, beta-blockers, diuretics) may result in small additive drops in blood pressure, which are usually minor. In general, the adverse event profile of a PDE5 inhibitor is not made worse by a background of antihypertensive medication, even when the patient is taking several antihypertensive agents. Alpha-blocker interactions All PDE5 inhibitors show some interaction with alpha-blockers, which under some conditions may result in orthostatic hypotension. • Sildenafil labelling currently advises that 50 or 100 mg of sildenafil should not be taken within 4 h following treatment with an alpha-blocker. This restriction does not apply to 25 mg dose of sildenafil. • In the USA, vardenafil is absolutely contraindicated with alpha-blockers. • Co-administration of vardenafil with tamsulosin is not associated with clinically significant hypotension (63). • Tadalafil is contraindicated in patients taking alpha-blockers, except for tamsulosin, 0.4 mg (64). These interactions are more pronounced when PDE5 inhibitors are given to healthy volunteers not previously taking alpha-blockers. Further research is needed into the interaction between other PDE5 inhibitors and other alpha-blockers (e.g. alfuzosin, once-daily), or mixed alpha-/beta-blockers (e.g. carvedilol, labetalol). Dosage adjustment Drugs that inhibit the CYP34A pathway will inhibit the metabolic breakdown of PDE5 inhibitors. They include ketoconazole, itraconazole, erythromycin, clarithromycin and HIV protease inhibitors (ritonavir, saquinavir). Such agents may increase blood levels of PDE5 inhibitors, so that lower doses of PDE5 inhibitors are necessary. However, other agents, such as rifampin, phenobarbital, phenytoin and carbamazepine, may induce CYP3A4 and enhance the breakdown of PDE5 inhibitors, so that higher doses of PDE5 inhibitors are required. Severe kidney or hepatic dysfunction may require dose adjustments or warnings. 3.5.1.7 Management of non-responders to PDE5 inhibitors The two main reasons why patients fail to respond to a PDE5 inhibitor are either incorrect drug use or inefficacy of the drug. The management of a non-responder depends upon identifying the underlying cause. Check that the patient has been using a licensed medication There is a very large ‘black market’ in PDE5 inhibitors. The amount of active drug in these medications varies enormously and it is important to check how and from which source the patient has obtained his medication. Check that the medication has been properly prescribed and correctly used The main reason why a patient fails to use his medication correctly is inadequate counselling from his physician. The main ways in which a drug may be incorrectly used are: • failure to use adequate sexual stimulation • failure to use an adequate dose • failure to wait an adequate amount of time between taking the medication and attempting sexual intercourse. Lack of adequate sexual stimulation: PDE5 inhibitors depend for their action upon the release of nitric oxide (NO) by the parasympathetic nerves of the penis. The usual stimulus for NO release is sexual stimulation, and without adequate sexual stimulation (and NO release), the drugs cannot work. Not enough time between taking the medication and intercourse attempt: Oral PDE5 inhibitors take different times to reach maximal plasma concentrations (65-67). Although pharmacological activity is achieved at plasma levels well below the maximal plasma concentration, there will be a period of time following oral ingestion of the medication during which the drug is ineffective. Even though all three drugs have an onset of action in some patients within 30 min of oral ingestion (68-70), most patients require a longer delay between taking the medication, with at least 60 min being required for men using sildenafil and vardenafil and up to 2 h being required for men using tadalafil. Food may affect drug absorption: sildenafil’s absorption can be delayed by a meal (65), while varenafil’s absorption can be delayed by a fatty meal (71). Tadalafil’s absorption is less affected provided there is enough delay between oral ingestion and an attempt at sexual intercourse (67). Too much time between taking medication and intercourse attempt: It is also possible to wait too long after
Update march 2009
19
taking medication before attempting sexual intercourse. The half-life of sildenafil and vardenafil is about 4 h, suggesting that the normal window of efficacy is about 6-8 h following ingestion of the medication, though responses following this time period are well recognized. Tadalafil had a longer half-life of about 17.5 h, so the window of efficacy is much longer at about 36 h. Insufficient dose: For financial reasons, some physicians may prescribe only the lower doses of a medication. It is important to check that the patient has had an adequate trial of the maximal dose of the drug. Data suggests an adequate trial involves at least six attempts with a particular drug (72). Benefit of education for a non-responding patient: Data from uncontrolled studies suggests patient education can help salvage an apparent non-responder to a PDE5 inhibitor. After emphasizing the importance of dose, timing and sexual stimulation to the patient, erectile function was effectively restored following re-administration of the relevant PDE5 inhibitor (73-76). One study (74) went further, and in those patients who still did not respond to the PDE5 inhibitor, a second-line adjustment was instituted. Patients taking tadalafil were advised to wait at least 2 h between oral ingestion and attempting intercourse. Patients taking vardenafil were advised to use the drug only after a fast. ln both patient groups, further apparent non-responders were ’salvaged‘. No patients using sildenafil were included in this study. Possible manoeuvres in patients correctly using a PDE5 inhibitor When the patient is using an adequate dose of the drug properly and the response is still inadequate, there are a number of changes that may improve the efficacy of the medication, though the evidence supporting these interventions is limited. Modification of associated risk factors: ED is typically a symptom of an underlying condition, such as diabetes, hypertension, dyslipidaemia, etc. Limited evidence suggests that, in a hypogonadal patient, normalization of the serum testosterone might improve the patient’s response to a PDE5 inhibitor (77). So far, modification of other risk factors, such as diabetic control, hypertension and dyslipidaemia, has not been shown to be effective in improving response to a PDE5 inhibitor. Change the PDE5 inhibitor: A randomised trial suggested vardenafil might benefit non-responders to sildenafil (78), but the results are considered to overstate the benefits of switching PDE5 inhibitors because of poor study design. However, a randomized, open-label, crossover trial comparing sildenafil and tadalafil indicated that some patients might respond better to one PDE5 inhibitor than to another (79). According to the IIEF-EF score, 17% of patients had a better response (≥ 5 points) to tadalafil than to sildenafil, while 14% had a better response to sildenafil than tadalafil. Although these differences might be explained by variation in drug pharmacokinetics, they do raise the possibility that, despite an identical mode of action, switching to a different PDE5 inhibitor might be helpful. Regular dosing of PDE5 inhibitor: Two non-randomised trials have suggested that daily dosing with a PDE5 inhibitor might salvage some non-responders to intermittent dosing. In one trial (80), some men benefited from regular dosing with either vardenafil or tadalafil, while in the other trial (75) daily dosing with tadalafil salvaged some men who had failed to respond to intermittent dosing with a PDE5 inhibitor. Currently, there are no randomized trials to support this intervention. Although tadalafil is licensed for daily dosing at a dose of 2.5 mg and 5 mg, neither sildenafil nor vardenafil are licensed for use in this way. lntroduction of an alternative therapeutic modality: If drug treatment fails, then the patient should be offered an alternative therapy, with intracavernosal injection therapy of with a vacuum erection device. Intraurethral therapy is usually ineffective in these patients. 3.5.1.8 Apomorphine sublingual Apomorphine is a centrally acting dopamine agonist that improves erectile function by enhancing the natural central erectile signals that normally occur during sexual stimulation (81, 82). It is administered sublingually on demand in 2 or 3 mg doses. Apomorphine has been approved for ED treatment in several countries but not in the USA. Efficacy rates (erections sufficient for intercourse) range from 28.5% to 55% (83-85). Due to rapid absorption, 71% of erections are achieved within 20 min. The most common adverse events are nausea (7%), headache (6.8%) and dizziness (4.4%). These events are generally mild in nature and self-limited (85). Severe events, such as syncope, are extremely rare (<0.2%) (86). Apomorphine is not contraindicated in patients taking nitrates or antihypertensive drugs (of all classes)
20
Update march 2009
and it does not affect vital signs (87, 88). There was no marked improvement in sexual desire, but a slight improvement in orgasmic function was noticed. Comparative studies clearly show that apomorphine is associated with significantly lower efficacy and satisfaction rates than sildenafil (89-91). The most significant strength of apomorphine is its safety profile (92). Even in pre-marketing studies, apomorphine significantly improves erectile function, intercourse and overall satisfaction domains of the IIEF compared to placebo. Its use is limited to patients with mild-to-moderate ED or psychogenic causes of sexual dysfunction due to reduced efficacy rates. It may also be a first-line treatment in patients with certain contraindications for the use of PDE5 inhibitors, e.g. nitrates. 3.5.1.9 Other oral agents Several other drugs have been used in the treatment of ED with various mechanisms of action (93), but today there is no place for these drugs in the treatment of ED. • Yohimbine is a centrally and peripherally active alpha-2 adrenergic antagonist used as an aphrodisiac for almost a century. • Delequamine is a more specific and selective alpha-2 adrenergic antagonist than yohimbine. • Trazodone is a serotonin reuptake inhibitor (antidepressant) associated with prolonged erections and priapism. It is also a non-selective alpha-adrenergic antagonist in the corporal smooth muscle cells. • L-arginine is a nitric oxide donor and nalmefene/naltrexone is an opioid-receptor antagonist. • Red Korea ginseng is a formulation with an unknown mechanism of action (though it may possibly act as a nitric oxide donor). • Limaprost is an alprostadil derivative for oral use. • An oral formulation of phentolamine (non-selective alpha-adrenergic antagonist) has undergone phase III clinical trials (94). Randomised trials have shown that yohimbine and trazodone have a similar efficacy to placebo in patients with organic causes of ED (95, 96). Oral phentolamine had efficacy rates (erections sufficient for intercourse) of about 50% (94), but possible carcinogenesis in animal models stopped further development. Efficacy data on Red Korea ginseng suggested it might have a role in treatment of ED (97). There are no efficacy data on the other drugs listed above.
3.6
Topical pharmacotherapy
Several vasoactive drugs (2% nitroglycerine, 15-20% papaverine gel and 2% minoxidil solution or gel) have been used for topical application to the penis. To overcome the poor drug absorption through the thick and dense tunica albuginea, several drug absorption enhancers have been developed for combination with vasoactive drugs (98). The combination (TopiglanTM) of alprostadil gel 1% with 5% SEPA® (absorption enhancer) resulted in an erection sufficient for vaginal penetration in 38.9% of patients compared to 6.9% of placebo-treated patients (99). Adverse events include skin and glans erythema, burning sensation, allergic reactions and side-effects in the partner (hypotension, headache) due to vaginal absorption. No topical therapy has been approved and currently these agents have no role in treatment of ED.
3.7
Vacuum constriction devices
Vacuum constriction devices (VCD) provide passive engorgement of the corpora cavernosa together with a constrictor ring placed at the base of the penis to retain blood within the corpora. Thus, erections with these devices are not normal since they do not use physiological erection pathways. Efficacy, in terms of erections satisfactory for intercourse, is as high as 90%, regardless of the cause of ED and satisfaction rates range between 27% and 94% (100). Men with a motivated, interested and understanding partner report the highest satisfaction rates. Long-term use of VCDs decreases to 50-64% after 2 years (101). Most men who discontinue use of VCDs do so within 3 months. The commonest adverse events include pain, inability to ejaculate, petechiae, bruising and numbness, which occur in less than 30% of patients (102). Serious adverse events (skin necrosis) can be avoided if patients remove the constriction ring within 30 min. Vacuum constriction devices are contraindicated in patients with bleeding disorders or on anticoagulant therapy. Vacuum constriction devices are generally unacceptable to younger patients. They may be the treatment of choice in well-informed older patients with infrequent sexual intercourses and comorbidities requiring a non-invasive, drug-free management of ED.
3.8
Second-line therapy
Patients not responding to oral drugs may be offered intracavernous injections. Success rate is high (85%) (100). Intracavernous administration of vasoactive drugs was the first medical treatment for ED more than 20 years ago (103).
Update march 2009
21
3.8.1 Intracavernous injections 3.8.1.1 Alprostadil Alprostadil (CaverjectTM, Edex/ViridalTM) is the first and only drug approved for intracavernous ED treatment (104). It is the more efficacious monotherapy for intracavernous treatment in 5-40 µg doses. The erection appears after 5-15 min and lasts according to the dose injected. An office-training programme (one or two visits) is required for the patient to learn the correct injection process. In cases of limited manual dexterity, the technique may be taught to their partners. The use of an automatic special pen that avoids a view of the needle can resolve fear of penile puncture and simplifies the technique. Efficacy rates for intracavernous alprostadil of more than 70% have been found in general ED populations, as well as in patient subgroups (e.g. diabetes or cardiovascular disease), with reported sexual activity after 94% of the injections and satisfaction rates of 87-93.5% in patients and 86-90.3% in partners (105-107). Complications of intracavernous alprostadil include penile pain (50% of patients, after 11% of injections), prolonged erections (5%), priapism (1%) and fibrosis (2%) (108). Pain is usually self-limited after prolonged use. It can be alleviated with the addition of sodium bicarbonate or local anaesthesia (109, 110). Fibrosis requires temporary discontinuation of the injection programme for several months. Systemic sideeffects are uncommon. The most common is mild hypotension especially when using higher doses. Contraindications include men with a history of hypersensitivity to alprostadil, men at risk of priapism and men with bleeding disorders. Despite these favourable data, intracavernous pharmacotherapy is associated with high drop-out rates and limited compliance. Drop-out rates of 41-68% have been described (111-113), with most drop outs occurring within the first 2-3 months. In a comparative study, alprostadil monotherapy had the lowest discontinuation rates (27.5%) compared to overall drug combinations (37.6%), with an attrition rate after the first few months of therapy of 10% per year. Reasons for discontinuation included desire for a permanent modality of therapy (29%), lack of a suitable partner (26%), poor response (23%) (especially among early drop out patients) fear of needles (23%), fear of complications (22%) and lack of spontaneity (21%). Careful counselling of patients during the office-training phase as well as close follow-up is important in addressing patient withdrawal from an intracavernous injection programme (114). Today, intracavernous pharmacotherapy is considered a second-line treatment. Patients not responding to oral drugs may be offered intracavernous injections with a high success rate of 85%. Most long-term injection users can switch to sildenafil despite underlying pathophysiology (115-117). However, almost one-third of long-term intracavernous injections users who subsequently responded also to sildenafil preferred to continue with an intracavernous injection programme (117, 118). Action to be taken with a prolonged erection After 4 h of erection, patients are advised to consult their physician to avoid any damage to the intracavernous muscle, which would provoke permanent impotence. A 19-gauge needle is used to aspirate blood and thereby decrease intracavernous pressure. This simple method is usually sufficient to make the penis flaccid. However, if the penis becomes rigid again after this, an intracavernous injection of phenylephrine is required, starting at a dose of 200 µg every 5 min and increasing to 500 µg if necessary. The risk of having a prolonged erection during following subsequent injections cannot be predicted. When this problem occurs, the dose is usually reduced for the next injection. 3.8.1.2 Combination therapy Combination treatment enables a patient to take advantage of the different modes of action of the drugs being used, as well as alleviating side-effects by using lower doses of each drug. • Papaverine (20-80 mg) was the first oral drug used for intracavernous injections. It is only used in combination therapy today due to its high incidence of side-effects as monotherapy. • Phentolamine has been used in combination therapy to increase efficacy. As monotherapy, it produces a poor erectile response. • Sparse data in the literature support the use of other drugs, such as vasoactive intestinal peptide (VIP), NO donors (linsidomine), forskolin, potassium channel openers, moxisylyte or calcitonin generelated peptide (CGRP), usually combined with the main drugs (119, 120). Most combinations are not standardized and some drugs have limited availability worldwide. • Papaverine (7.5-45 mg) plus phentolamine (0.25-1.5 mg), and papaverine (8-16 mg) plus phentolamine (0.2-0.4 mg) plus alprostadil (10-20 µg), have been widely used with improved efficacy rates, although they have never been licensed for ED (121-123). The triple combination regimen of papaverine, phentolamine and alprostadil had the highest efficacy rates, reaching 92%; this combination had similar side-effects as alprostadil monotherapy, but a lower incidence of penile pain due to lower doses of alprostadil. However, fibrosis was more common (5-10%) when papaverine was used
22
Update march 2009
(depending on total dose). In addition, mild hepatotoxicity has been reported with papaverine (124). Despite high efficacy rates, 5-10% of patients will not respond to combination intracavernous injections. The combination of sildenafil with intracavernous injection of the triple combination regimen may salvage as many as 31% of patients who do not respond to the triple combination alone (125). However, combination therapy was associated with an incidence of adverse effects in 33% of patients, including dizziness in 20% of patients. This strategy can be considered in carefully selected patients before proceeding to a penile implant. 3.8.1.3 Intraurethral alprostadil A specific formulation of alprostadil (125-1000 µg) in a medicated pellet (MUSETM) has been approved for use in ED (126). A vascular interaction between the urethra and the corpora cavernosa enables drug transfer between these structures (127). Erections sufficient for intercourse were achieved in 30-65.9% of patients. In clinical practice, only the higher doses (500 and 1000 µg) have been used with low consistency rates (127-129). The application of a constriction ring at the root of the penis (ACTISTM) may improve efficacy (130). The most common adverse events are local pain (29-41%) and dizziness (1.9-14%). Penile fibrosis and priapism are very rare (< 1%). Urethral bleeding (5%) and urinary tract infections (0.2%) are adverse events related to the mode of administration. Efficacy rates are significantly lower than intracavernous pharmacotherapy (131). Intraurethral pharmacotherapy is a second-line therapy and provides an alternative to intracavernous injections in patients who prefer a less invasive, though less efficacious, treatment.
3.9
Third-line therapy (penile prostheses)
The surgical implantation of a penile prosthesis may be considered in patients who do not respond to pharmacotherapy or who prefer a permanent solution to their problem. Two types of prosthesis exist: malleable (semi-rigid) and inflatable (two- or three-piece). Most patients prefer the three-piece inflatable devices due to the more ‘natural’ erections obtained. However, the two-piece inflatable prosthesis can be a reliable option with fewer mechanical complications and is easier to implant. A semi-rigid prosthesis provides a constantly rigid penis and may be suitable in older patients with infrequent sexual intercourse (132). The inflatable prosthesis is much more expensive. In several countries, patients are reimbursed for the cost of the prosthesis provided the ED has an organic cause and the patient has undergone a complete impotence assessment. Prosthesis implantation has one of the highest satisfaction rates (70-87%) among treatment options for ED based on appropriate consultation (133-137). 3.9.1 Complications The two main complications of penile prosthesis implantation are mechanical failures and infection. Several technical modifications of the most commonly used three-piece prosthesis (AMS 700CX/CXMTM and Mentor Alpha ITM) resulted in mechanical failure rates of less than 5% at 5-year follow-up (136, 137). Careful surgical technique with proper antibiotic prophylaxis against Gram-positive and Gram-negative bacteria reduced infections rates to 2-3%. The infection rate may be further reduced to 1% by implanting an antibioticimpregnated prosthesis (AMS InhibizoneTM) or hydrophilic-coated prosthesis (Mentor TitanTM) (138, 139). Although diabetes is considered to be one of the main risk factors for infection, this is not supported by current data (132). Infections, as well as erosions, are significantly higher (9%) in patients with spinal cord injuries (9%) (132). Infection requires removal of the prosthesis, antibiotic administration and re-implantation after 6-12 months. However, salvage therapy with removal and re-implantation at the same time, after copious irrigation of the corpora with multi-drug solutions, had an 82% success rate (140). 3.9.2 Conclusion Penile implants are an attractive solution for patients who do not respond to oral therapy (141).
3.10 Guideline recommendations for the treatment of ED Recommendation • Lifestyle changes and risk factor modification must precede or accompany ED treatment • Pro-erectile treatments have to be given at the earliest opportunity after radical prostatectomy • When a curable cause of ED is found, the cause must be treated first • PDE5 inhibitors are first-line therapy
Update march 2009
LE GR 1b A 1b
A
1b 1a
B A
23
• Daily administration of PDE5 inhibitors may improve results and restore 1b erectile function • Inadequate/incorrect prescription and poor patient education are the main 3 causes of a lack of response to PDE5 inhibitors • Testosterone replacement restores efficacy in hypogonadic 1b non-responders to PDE5 inhibitors • Apomorphine can be used in mild-to-moderate ED or psychogenic causes 1b or in patients with contraindications for the use of PDE5 inhibitors • A vacuum constriction device can be used in patients with stable relationship 4 • Intracavernous injection is second-line therapy 1b • Penile implant is third-line therapy 4 LE = level of evidence; GR = grade of recommendation; ED = erectile dysfunction; PDE5 inhibitor = phosphodiesterase type 5 inhibitor.
A B B B C B C
3.11
References
1.
Hatzichristou D, Rosen RC, Broderick G, Clayton A, Cuzin B, Derogatis L, Litwin M, Meuleman E, O’Leary M, Quirk F, Sadovsky R, Seftel A. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004 Jul;1(1):49-57. http://www.ncbi.nlm.nih.gov/pubmed/16422983 Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000;56(2):302-6. http://www.ncbi.nlm.nih.gov/pubmed/10925098 Moyad MA, Barada JH, Lue TF, Mulhall JP, Goldstein I, Fawzy A. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. Urol Clin North Am 2004;31(2):249-57. http://www.ncbi.nlm.nih.gov/pubmed/15123405 Moyad MA, Barada JH, Lue TF, Mulhall JP, Goldstein I, Fawzy A. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin North Am 2004;31(2):259-73. http://www.ncbi.nlm.nih.gov/pubmed/15123406 Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F, D’Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291(24):2978-84. http://www.ncbi.nlm.nih.gov/pubmed/15213209 Guay AT. Optimizing response to phosphodiesterase therapy: impact of risk-factor management. J Androl 2003;24(6 Suppl):S59-S62. http://www.ncbi.nlm.nih.gov/pubmed/14581497 Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, Rigatti P, Pizzini G, Miani A. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomised trial. J Urol 1997;158(4):1408-10. http://www.ncbi.nlm.nih.gov/pubmed/9302132 Raina R, Pahlajani G, Agarwal A, Zippe CD. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int 2007;100(6):1317-21. http://www.ncbi.nlm.nih.gov/pubmed/17850385 Raina R, Agarwal A, Ausmundson S, Lakin M, Nandipati KC, Montague DK, Mansour D, Zippe CD. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006;18(1):77-81. http://www.ncbi.nlm.nih.gov/pubmed/16107868 Lane BR, Abouassaly R, Angermeier KW, Montague DK. Three-piece inflatable penile prostheses can be safely implanted after radical prostatectomy through a transverse scrotal incision. Urology 2007;70(30):539-42. http://www.ncbi.nlm.nih.gov/pubmed/17686509 Bianco F, Kattan M, Eastham J, Scardino PT, Mulhall JP. Surgeon and surgical volume as predictors of erectile function outcomes following radical prostatectomy. J Sex Med 2004;1(Suppl 1):34. abstr O17.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
24
Update march 2009
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
Ayyathurai R, Manoharan M, Nieder AM, Kava B, Soloway MS. Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int 2008;101(7):833-6. http://www.ncbi.nlm.nih.gov/pubmed/18190627 Hollenbeck BK, Dunn RL, Wei JT, Montie JE, Sanda MG. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol 2003;169(4):1453-7. http://www.ncbi.nlm.nih.gov/pubmed/12629382 Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubis prostatectomy. J Urol 2004;171(2 Pt 4):771-4. http://www.ncbi.nlm.nih.gov/pubmed/14713808 Padma-Nathan H, McCullough AR, Levine LA, Lipschultz LI, Siegel R, Montorsi F, Giuliano F, Brock G; Study Group. Collaborators (12) Andrianne R, Bell D, Broderick G, Carrier S, Cuzin B, Deeths HJ, Hellstrom W, Herschorn S, Lewis RW, Rosen RC, Shabsigh R, Stricker P. Randomized, doubleblind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008;20(5):479-86. http://www.ncbi.nlm.nih.gov/pubmed/18650827 Bannowsky A, Schulze H, van der Horst C, Hautmann S, Jünemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 2008;101(10):1279-83. http://www.ncbi.nlm.nih.gov/pubmed/18284406 Raina R, Lakin MM, Agarwal A, Mascha E, Montagne DK, Klein E, Zippe CD. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004;63(5):960-6. http://www.ncbi.nlm.nih.gov/pubmed/15134989 McCullough AR, Levine LA, Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled trial. J Sex Med 2008;5(2):476-84. http://www.ncbi.nlm.nih.gov/pubmed/18086170 Montorsi F, Padma-Nathan H, McCullough A, Brock GB, Broderick G, Ahuja S, Whitaker S, Hoover A, Novack D, Murphy A, Varanese L. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004;172(3):1036-41. http://www.ncbi.nlm.nih.gov/pubmed/15311032 Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M, Padma-Nathan H. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003;170(4 Pt 1):1278-83. http://www.ncbi.nlm.nih.gov/pubmed/14501741 Nehra A, Grantmyre J, Nadel A, Thibonnier M, Brock G. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J UroI 2005;173(6):2067-71. http://www.ncbi.nlm.nih.gov/pubmed/15879836 Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, Stief C. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008;54(4):924-31. http://www.ncbi.nlm.nih.gov/pubmed/18640769 Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005;2(4):532-45. http://www.ncbi.nlm.nih.gov/pubmed/16422848 Montague DK. Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy. Rev Urol 2005;7(2):S51-S57. http://www.ncbi.nlm.nih.gov/pubmed/16985898 Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005;173(2):530-2. http://www.ncbi.nlm.nih.gov/pubmed/15643239 Morales A, Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am 2001;28(2):279-88. http://www.ncbi.nlm.nih.gov/pubmed/11402581
Update march 2009
25
27.
28.
29.
30. 31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
26
Rao DS, Donatucci CF. Vasculogenic impotence. Arterial and venous surgery. Urol Clin North Am 2001;28(2):309-19. http://www.ncbi.nlm.nih.gov/pubmed/11402583 Wespes E, Wildschutz T, Roumeguere T, Schulman CC.The place of surgery for vascular impotence in the third millennium. J Urol 2003;170(4 Pt 1):1284-6. http://www.ncbi.nlm.nih.gov/pubmed/14501742 Rosen RC. Psychogenic erectile dysfunction. Classification and management. Urol Clin North Am 2001;28(2):269-78. http://www.ncbi.nlm.nih.gov/pubmed/11402580 Lue TF. Erectile dysfunction. N Engl J Med 2000;342(24):1802-13. http://www.ncbi.nlm.nih.gov/pubmed/10853004 Moncada I, Jara J, Subira D, Castano I, Hernandez C. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 2004;46(3):357-60; discussion 60-1. http://www.ncbi.nlm.nih.gov/pubmed/15306108 Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999;57(6): 967-89. http://www.ncbi.nlm.nih.gov/pubmed/10400408 Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA; Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol 2002;167(2 Pt 2):1197-203. http://www.ncbi.nlm.nih.gov/pubmed/11905901 Stuckey BG, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, Manzano P, Deerochanawong C. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003;26(2):279-84. http://www.ncbi.nlm.nih.gov/pubmed/12547849 Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003;62(1):121-5; discussion 125-6. http://www.ncbi.nlm.nih.gov/pubmed/11905901 Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168(4 Pt 1):1332-6. http://www.ncbi.nlm.nih.gov/pubmed/12352386 Montorsi F, Verheyden B, Meuleman E, Junemann KP, Moncada I, Valiquette L, Casabe A, Pacheco C, Denne J, Knight J, Segal S, Watkins VS. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004;45(3):339-44; discussion 344-5. http://www.ncbi.nlm.nih.gov/pubmed/15036680 Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25(12):2159-64. http://www.ncbi.nlm.nih.gov/pubmed/12453954 Bischoff E, Schneider K. A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Int J Impot Res 2001;13(4):230-5. http://www.ncbi.nlm.nih.gov/pubmed/11494080 Keating GM, Scott LJ. Vardenafil: a review of its use in erectile dysfunction. Drugs 2003;63(23):2673703. http://www.ncbi.nlm.nih.gov/pubmed/14636086 Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13(4):192-9. http://www.ncbi.nlm.nih.gov/pubmed/11494074 Potempa AJ, Ulbrich E, Bernard I, Beneke M. Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. Eur Urol 2004;46(1):73-9. http://www.ncbi.nlm.nih.gov/pubmed/15183550 Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicentre double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26(3):777-83. http://www.ncbi.nlm.nih.gov/pubmed/12610037 Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW, Kang SK, Lee BC, Hwang WS. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl;28(5):260-6. http://www.ncbi.nlm.nih.gov/pubmed/16128985
Update march 2009
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
Kovanecz I, Rambhatia A, Ferrini MG, Vernet D, Sanchez S, Rajfer J, Gonzalez-Cadavid N. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008;101(2):203-10. http://www.ncbi.nlm.nih.gov/pubmed/17888043 Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006;68(2):429-35. http://www.ncbi.nlm.nih.gov/pubmed/16904479 Vignozzi L, Filippi S, Morelli A, Ambrosini S, Luconi M, Vannelli GB, Donati S, Crescioli C, Zhang XH, Mirone V, Forti G, Maggi M. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med 2006;3(3):419-31. http://www.ncbi.nlm.nih.gov/pubmed/16681467 Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J, Gonzalez-Cadavid NF. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod 2007;76(5):915-23. http://www.ncbi.nlm.nih.gov/pubmed/17287493 Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabe J, Burgess G, Wayman C, Alexandre L, Giuliano F. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxation in rats: lack of tachyphylaxis. Eur Urol 2005;47(1):87-91. http://www.ncbi.nlm.nih.gov/pubmed/15582254 McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on demand tadalafil. J Sex Med 2004;1(3):292-300. http://www.ncbi.nlm.nih.gov/pubmed/16422959 McMahon C. Comparison of efficacy, safety and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2(3):415-25. http://www.ncbi.nlm.nih.gov/pubmed/16422874 Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion- Mboussa A, Shen W, Whitacker JS. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50(2):351-9. http://www.ncbi.nlm.nih.gov/pubmed/16766116 Rajfer J, Aliotta PJ, Steidle CP, Fitch III WP, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2006;19(1):95-103. Porst H, Rajfer J, Casabé A, Feldman R, Ralph D, Vieiralves LF, Esler A, Wolka AM, Klise SR. Longterm safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5(9):2160-9. http://www.ncbi.nlm.nih.gov/pubmed/18557812 Zumbé J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E. Comparable efficacy of oncedaily versus on-demand vardenafil in men with mild to moderate erectile dysfunction: findings of the RESTORE study. Eur Urol 2008;54(1):204-10. http://www.ncbi.nlm.nih.gov/pubmed/18395326 Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47(2):214-20. http://www.ncbi.nlm.nih.gov/pubmed/15661417 Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007;19(2):200-7. http://www.ncbi.nlm.nih.gov/pubmed/16943794 Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, Rosano GM. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 2008;25(1):37-44. http://www.ncbi.nlm.nih.gov/pubmed/18199130 Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, Rose L, Lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008;25(2):138-46. http://www.ncbi.nlm.nih.gov/pubmed/18290855
Update march 2009
27
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
28
Mirone V, Costa P, Damber JE, Holmes S, Moncada I, Van Ahlen H, Wespes E, Cordell WH, Chan M, Lembo D, Varanese L. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 2005;47(6):846-54. http://www.ncbi.nlm.nih.gov/pubmed/15925082 Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol 2004;27(4 Suppl 1):I20-I25. http://www.ncbi.nlm.nih.gov/pubmed/15115192 Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, Stein RA, Larkin S, Mazzu A, Tota R, Pomerantz K, Sundaresan P. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002;40(11):2006-12. http://www.ncbi.nlm.nih.gov/pubmed/12475462 Vardi Y, Bulus M, Reisner S, Nassar S, Aboud L, Sprecher E, Gruenwald I. Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. Eur Urol 2003;43(5): 544-51. http://www.ncbi.nlm.nih.gov/pubmed/12706001 Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004;64(5):998-1003; discussion 1004. http://www.ncbi.nlm.nih.gov/pubmed/15533493 Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR, Pereira A. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172(5 Pt 1):1935-40. http://www.ncbi.nlm.nih.gov/pubmed/15540759 Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharm 2002;53(1);5S-12S. http://www.ncbi.nlm.nih.gov/pubmed/11879254 Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006;61(3):280-8. http://www.ncbi.nlm.nih.gov/pubmed/16487221 Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G, Wensing G, Horstmann R, Engelmann R. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001;19(1):32-9. http://www.ncbi.nlm.nih.gov/pubmed/11289568 Padma-Nathan H, Stecher VJ, Sweeney M, Orazem J, Tseng L-J, deRiesthal H. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebocontrolled trial. Urology 2003:62(3):400-3. http://www.ncbi.nlm.nih.gov/pubmed/12946731 Rosen RC, Padma-Nathan H, Shabsigh R, Saikali K, Watkins V, Pullman W. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. J Sex Med 2004:1(2);193-200. http://www.ncbi.nlm.nih.gov/pubmed/16422974 Montorsi F, Padma-Nathan H, Buvat J, Schwaibold H, Beneke M, Ulbrich E, Bandel TJ, Porst H; Vardenafil Study Group. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med 2004; 1(2):168-78. http://www.ncbi.nlm.nih.gov/pubmed/16422971 Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderatefat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003;43(3):260-7. http://www.ncbi.nlm.nih.gov/pubmed/12638394 McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou DG. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002;60(2 Suppl 2):28-38. http://www.ncbi.nlm.nih.gov/pubmed/12414331 Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K, Ioannidis E. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 nonresponders. Eur Urol 2006;47(4):518-22. http://www.ncbi.nlm.nih.gov/pubmed/15774252
Update march 2009
75.
76.
77.
78.
79.
80.
81.
82.
83. 84.
85.
86.
87.
88.
89.
90.
Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for ‘non-responders’ to tadalafil and vardenafil: a real-life study. Eur Urol 2006;50(1):126-32. http://www.ncbi.nlm.nih.gov/pubmed/16564127 Gruenwald I, Shenfeld O, Chen J, Raviv G, Richter S, Cohen A, Vardi Y. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006;50(1):134-40. http://www.ncbi.nlm.nih.gov/pubmed/16527391 Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;72(2):658-63. http://www.ncbi.nlm.nih.gov/pubmed/15247755 Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P, Auerbach S, Murdock M, Wilkins HJ, McBride TA, Colopy MW; Patient Response with Vardenafil in Slidenafil Non-Responders (PROVEN) Study Group. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004;94(9):1301-9. http://www.ncbi.nlm.nih.gov/pubmed/15610110 Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K, Vail GM, Beardsworth A. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int 2007;100(1):122-9. http://www.ncbi.nlm.nih.gov/pubmed/17552960 McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on demand tadalafil. J Sex Med 2004;1(3):292-300. http://www.ncbi.nlm.nih.gov/pubmed/16422959 Hagemann JH, Berding G, Bergh S, Sleep DJ, Knapp WH, Jonas U, Stief CG. Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction. Eur Urol 2003;43(4):412-20. http://www.ncbi.nlm.nih.gov/pubmed/12667723 Montorsi F, Perani D, Anchisi D, Salonia A, Scifo P, Rigiroli P, Deho F, De Vito ML, Heaton J, Rigatti P, Fazio F. Brain activation patterns during video sexual stimulation following the administration of apomorphine: results of a placebo-controlled study. Eur Urol 2003;43(4):405-11. http://www.ncbi.nlm.nih.gov/pubmed/12667722 Heaton JP. Apomorphine: an update of clinical trial results. Int J Impot Res 2000;12(Suppl 4):S67-S73. http://www.ncbi.nlm.nih.gov/pubmed/11035390 Dula E, Bukofzer S, Perdok R, George M. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39(5):55863; discussion 564. http://www.ncbi.nlm.nih.gov/pubmed/11464037 Martinez R, Puigvert A, Pomerol JM, Rodriguez-Villalba R. Clinical experience with apomorphine hydrochloride: the first 107 patients. J Urol 2003;170(6 Pt 1):2352-5. http://www.ncbi.nlm.nih.gov/pubmed/14634414 Buvat J, Montorsi F. Safety and tolerability of apomorphine SL in patients with erectile dysfunction. BJU Int 2001;88 (Suppl 3):30-5. http://www.ncbi.nlm.nih.gov/pubmed/11578277 Bukofzer S, Livesey N. Safety and tolerability of apomorphine SL (Uprima). Int J Impot Res 2001;13(Suppl 3):S40-S44. http://www.ncbi.nlm.nih.gov/pubmed/11477491 Fagan TC, Buttler S, Marbury T, Taylor A, Edmonds A. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am J Cardiol 2001;88(7):760-6. http://www.ncbi.nlm.nih.gov/pubmed/11589843 Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93(9):1271-5. http://www.ncbi.nlm.nih.gov/pubmed/15180621 Perimenis P, Gyftopoulos K, Giannitsas K, Markou SA, Tsota I, Chrysanthopoulou A, Athanasopoulos A, Barbalias G. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res 2004;16(1):2-7. http://www.ncbi.nlm.nih.gov/pubmed/14963464
Update march 2009
29
91.
92. 93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
30
Afif-Abdo J, Teloken C, Damião R, Koff W, Wroclawski E, Yamasaki R, Torres LO, Sabaneeff J, Faria G, Pompea AC, Cortado P, Glina S. Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. BJU Int 2008;102(7):829-34. http://www.ncbi.nlm.nih.gov/pubmed/18537952 Montorsi F. Tolerability and safety of apomorphine SL (Ixense™). Int J Impot Res 2003;15(2):S7-S9. http://www.ncbi.nlm.nih.gov/pubmed/12825097 Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, Carson C, Corbin J, Francis S, DeBusk R, Eardley I, Hedlund H, Hutter A, Jackson G, Kloner R, Lin CS, McVary K, McCullough A, Nehra A, Porst H, Schulman C, Seftel A, Sharlip I, Stief C, Teloken C. Pharmacotherapy for erectile dysfunction. J Sex Med 2004;1(2):128-40. http://www.ncbi.nlm.nih.gov/pubmed/16422967 Goldstein I. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. Int J Impot Res 2000;12(1):S75-S80. http://www.ncbi.nlm.nih.gov/pubmed/10845768 Teloken C, Rhoden EL, Sogari P, Dambros M, Souto CA. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998;159(1):122-4. http://www.ncbi.nlm.nih.gov/pubmed/9400452 Costabile RA, Spevak M. Oral trazodone is not effective therapy for erectile dysfunction: a doubleblind, placebo controlled trial. J Urol 1999;161(6):1819-22. http://www.ncbi.nlm.nih.gov/pubmed/10332444 Hong B, Ji YH, Hong JH, Nam KY, Ahn TY. A double-blind crossover study evaluating the efficacy of korean red ginseng in patients with erectile dysfunction: a preliminary report. J Urol 2002;168(5): 2070-3. http://www.ncbi.nlm.nih.gov/pubmed/12394711 Montorsi F, Salonia A, Zanoni M, Pompa P, Cestari A, Guazzoni G, Barbieri L, Rigatti P. Current status of local penile therapy. Int J Impot Res 2002;14(Suppl 1):S70-S81. http://www.ncbi.nlm.nih.gov/pubmed/11850739 Goldstein I, Payton TR, Schechter PJ. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology 2001;57(2):301-5. http://www.ncbi.nlm.nih.gov/pubmed/11182341 Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am 2001;28(2):335-41, ix-x. http://www.ncbi.nlm.nih.gov/pubmed/11402585 Cookson MS, Nadig PW. Long-term results with vacuum constriction device. J Urol 1993;149(2): 290-4. http://www.ncbi.nlm.nih.gov/pubmed/8426404 Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol 1997;15(1):78-82. http://www.ncbi.nlm.nih.gov/pubmed/9066099 Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000;55(4):477-80. http://www.ncbi.nlm.nih.gov/pubmed/10736486 Leungwattanakij S, Flynn V Jr, Hellstrom WJ. Intracavernosal injection and intraurethral therapy for erectile dysfunction. Urol Clin North Am 2001;28(2):343-54. http://www.ncbi.nlm.nih.gov/pubmed/11402586 Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996;334(14):873-7. http://www.ncbi.nlm.nih.gov/pubmed/8596569 Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996;155(3):802-15. http://www.ncbi.nlm.nih.gov/pubmed/8583582 Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, Kim JJ, Zhi-Zhou S, Israr D, Niazi D, Rajatanavin R, Suyono S, Benard F, Casey R, Brock G, Belanger A. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001;13(6):317-21. http://www.ncbi.nlm.nih.gov/pubmed/11918246 Lakin MM, Montague DK, VanderBrug Medendorp S, Tesar L, Schover LR. Intracavernous injection therapy: analysis of results and complications. J Urol 1990;143(6):1138-41. http://www.ncbi.nlm.nih.gov/pubmed/2342174
Update march 2009
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
Kattan S. Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence. Urology 1995;45:1032-6. http://www.ncbi.nlm.nih.gov/pubmed/7771004 Moriel EZ, Rajfer J. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. J Urol 1993;149(5 Pt 2):1299-300. http://www.ncbi.nlm.nih.gov/pubmed/8386779 Flynn RJ, Williams G. Long-term follow-up of patients with erectile dysfunction commenced on self injection with intracavernosal papaverine with or without phentolamine. Br J Urol 1996;78(4):628-31. http://www.ncbi.nlm.nih.gov/pubmed/8944522 Sundaram CP, Thomas W, Pryor LE, Sidi AA, Billups K, Pryor JL. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997;49(6):932-35. http://www.ncbi.nlm.nih.gov/pubmed/9187703 Gupta R, Kirschen J, Barrow RC 2nd, Eid JF. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 1997;157(5):1681-86. http://www.ncbi.nlm.nih.gov/pubmed/9112505 Vardi Y, Sprecher E, Gruenwald I. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters. J Urol 2000;163(2):467-70. http://www.ncbi.nlm.nih.gov/pubmed/10647656 Montorsi F, Althof SE, Sweeney M, Menchini-Fabris F, Sasso F, Giuliano F. Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E(1) intracavernosal injection therapy to oral sildenafil citrate. Int J Impot Res 2003;15(6):444-9. http://www.ncbi.nlm.nih.gov/pubmed/14671665 Raina R, Lakin MM, Agarwal A, Ausmundson S, Montague DK, Zippe CD. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology 2004;63(3):532-7; discussion 538. http://www.ncbi.nlm.nih.gov/pubmed/15028452 Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A. Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000;164(4):1197-200. http://www.ncbi.nlm.nih.gov/pubmed/10992365 Buvat J, Lemaire A, Ratajczyk J. Acceptance, efficacy and preference of sildenafil in patients on long term auto-intracavernosal therapy: a study with follow-up at one year. Int J Impot Res 2002;14(2): 483-6. http://www.ncbi.nlm.nih.gov/pubmed/12494282 Mulhall JP, Daller M, Traish AM, Gupta S, Park K, Salimpour P, Payton TR, Krane RJ, Goldstein I. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy [see comments]. J Urol 1997;158(5):1752-8; discussion 1758-9. http://www.ncbi.nlm.nih.gov/pubmed/9334594 Buvat J, Costa P, Morlier D, Lecocq B, Stegmann B, Albrecht D. Double-blind multicentre study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol 1998;159(1):116-9. http://www.ncbi.nlm.nih.gov/pubmed/9400450 Bechara A, Casabe A, Cheliz G, Romano S, Rey H, Fredotovich N. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol 1997;157(6):2132-4. http://www.ncbi.nlm.nih.gov/pubmed/9146599 Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991;146(6):1564-5. http://www.ncbi.nlm.nih.gov/pubmed/1719248 McMahon CG. A comparison of the response to the intracavernosal injection of papaverine and phentolamine, prostaglandin E1 and a combination of all three agents in the management of impotence. Int J Impot Res 1991;3:113-21. Levine SB, Althof SE, Turner LA, Risen CB, Bodner DR, Kursh ED, Resnick MI. Side effects of self administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989;141(1):54-7. http://www.ncbi.nlm.nih.gov/pubmed/2908954 McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 1999;162(6):1992-7; discussion 1997-8. http://www.ncbi.nlm.nih.gov/pubmed/10569554
Update march 2009
31
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140. 141.
32
Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336(1):1-7. http://www.ncbi.nlm.nih.gov/pubmed/8970933 Guay AT, Perez JB, Velasquez E, Newton RA, Jacobson JP. Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. Eur Urol 2000;38(6):671-6. http://www.ncbi.nlm.nih.gov/pubmed/11111182 Fulgham PF, Cochran JS, Denman JL, Feagins BA, Gross MB, Kadesky KT, Kadesky MC, Clark AR, Roehrborn CG. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998;160(6 Pt 1):2041-6. http://www.ncbi.nlm.nih.gov/pubmed/9817319 Mulhall JP, Jahoda AE, Ahmed A, Parker M. Analysis of the consistency of intraurethral prostaglandin E(1) (MUSE) during at-home use. Urology 2001;58(2):262-6. http://www.ncbi.nlm.nih.gov/pubmed/11489714 Lewis RW, Weldon K, Nemo K; the MUSE-ACTIS Study Group. Combined use of transurethral alprostadil and an adjustable penile constriction band in men with erectile dysfunction: results from a multicentre trial. Int J Impot Res 1998;10:S49 (365). Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicentre study. Urology 2000;55(4): 109-13. http://www.ncbi.nlm.nih.gov/pubmed/10736486 Montague DK, Angermeier KW. Penile prosthesis implantation. Urol Clin North Am 2001;28(2): 355-61, x. http://www.ncbi.nlm.nih.gov/pubmed/11402587 Holloway FB, Farah RN. Intermediate term assessment of the reliability, function and patient satisfaction with the AMS700 Ultrex penile prosthesis. J Urol 1997;157(5):1687-91. http://www.ncbi.nlm.nih.gov/pubmed/9112506 Tefilli MV, Dubocq F, Rajpurkar A, Gheiler EL, Tiguert R, Barton C, Li H, Dhabuwala CB. Assessment of psychosexual adjustment after insertion of inflatable penile prosthesis. Urology 1998;52:1106-12. http://www.ncbi.nlm.nih.gov/pubmed/9836564 Wilson SK, Cleves MA, Delk JR 2nd. Comparison of mechanical reliability of original and enhanced Mentor Alpha I penile prosthesis. J Urol 1999;162(3 Pt 1):715-8. http://www.ncbi.nlm.nih.gov/pubmed/10458350 Montorsi F, Rigatti P, Carmignani G, Corbu C, Campo B, Ordesi G, Breda G, Silvestre P, Giammusso B, Morgia G, Graziottin A. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi- institutional study in 200 consecutive patients. Eur Urol 2000;37(1):50-5. http://www.ncbi.nlm.nih.gov/pubmed/10671785 Goldstein I, Newman L, Baum N, Brooks M, Chaikin L, Goldberg K, McBride A, Krane RJ. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol 1997;157(3):833-9. http://www.ncbi.nlm.nih.gov/pubmed/9072580 Carson CC 3rd. Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol 2004;171(4):1611-4. http://www.ncbi.nlm.nih.gov/pubmed/15017233 Wolter CE, Hellstrom WJG. The hydrophilic-coated inflatable penile prosthesis: 1-year experience. J Sex Med 2004;1(2):221-4. http://www.ncbi.nlm.nih.gov/pubmed/16429621 Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol 2000;163(2):481-2. http://www.ncbi.nlm.nih.gov/pubmed/10647660 Montorsi F, Deho F, Salonia A, Briganti A, Bua L, Fantini GV, Gallina A, Sacca A, Mirone V, Rigatti P . Penile implants in the era of oral drug treatment for erectile dysfunction. BJU Int 2004;94(5):745-51. http://www.ncbi.nlm.nih.gov/pubmed/15329092
Update march 2009
4. PREMATURE EJACULATION (PE) 4.1
Introduction
Although PE is a very common male sexual dysfunction, it is poorly understood. Patients are often unwilling to discuss their symptoms and many physicians do not know about effective treatments. As a result, patients may be misdiagnosed or mistreated (1). In addition, there is currently no registered pharmacological treatment for PE. These guidelines provide an evidence-based analysis (2) of published data on definition, clinical evaluation and treatment. It provides recommendations to clinicians on the diagnosis and treatment of PE, without preempting physician judgement on individual cases.
4.2
Definition of PE
4.2.1 Overview There have previously been two official definitions of PE, neither of which were universally accepted: • In the Diagnostic and Statistical Manual of Mental Disorders IV-Text Revision (DSM-IV-TR), PE is defined as a ‘persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the person wishes it. The clinician must take into account factors that affect duration of the excitement phase, such as age, novelty of the sexual partner or situation, and recent frequency of sexual activity’ (3). • In the World Health Organization’s International Classification of Diseases-10 (ICD-10), PE is defined as ‘the inability to delay ejaculation sufficiently to enjoy lovemaking, which is manifested by either an occurrence of ejaculation before or very soon after the beginning of intercourse (if a time limit is required: before or within 15 seconds of the beginning of intercourse) or ejaculation occurs in the absence of sufficient erection to make intercourse possible. The problem is not the result of prolonged absence from sexual activity’ (4). •
•
Recently, two more definitions have been proposed: The Second International Consultation on Sexual and Erectile Dysfunction defined PE as ‘ejaculation with minimal stimulation and earlier than desired, before or soon after penetration, which causes bother or distress, and over which the sufferer has little or no voluntary control’ (5). The International Society for Sexual Medicine (ISSM) has adopted a completely new definition of PE which is the first evidence-based definition, ‘Premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy’. It must be noted that this definition is limited to men with lifelong PE who engage in vaginal intercourse since there are insufficient objective data to propose an evidence-based definition for acquired PE (6).
All four definitions have taken into account the time to ejaculation, the inability to control or delay ejaculation and negative consequences (bother/distress) from PE. However, the major point of debate is quantifying the time to ejaculation, which is usually described by intravaginal ejaculatory latency time (IELT). Several proposals for updating the definition of PE in the forthcoming DSM-V and ICD-11 have been presented (7-11). 4.2.2 Classifications Premature ejaculation is classified as ‘lifelong’ (primary) or ‘acquired’ (secondary) (12). Lifelong PE is characterized by onset from the first sexual experience, remains so during life and ejaculation occurs too fast (before vaginal penetration or <1-2 min after). Acquired PE is characterized by a gradual or sudden onset following normal ejaculation experiences before onset and time to ejaculation is short (usually not as short as in lifelong PE). Recently, two more PE syndromes have been proposed (11): • ‘Natural variable PE’ is characterized by inconsistent and irregular early ejaculations, representing a normal variation in sexual performance. • ‘Premature-like ejaculatory dysfunction’ is characterized by subjective perception of consistent or inconsistent rapid ejaculation during intercourse, while ejaculation latency time is in the normal range or can even last longer. It should not be regarded as a symptom or manifestation of true medical pathology. The addition of these new types may aid patient stratification, diagnosis and treatment, but their exact role remains to be defined (13).
Update march 2009
33
4.3
Epidemiology of PE
4.3.1 Prevalence The major problem in assessing the prevalence of PE is the lack of an accurate (validated) definition at the time the surveys were conducted (14). However, epidemiological research has consistently shown that PE, at least according to the DSM-IV definition, is the most common male sexual dysfunction, with prevalence rates of 20-30% (15-17). The highest prevalence rate of 31% (men aged 18-59 years) was found by the NHSLS study in USA (16). Prevalence rates from 18 to 29 years, 30 to 39 years, 40 to 49 years and 50 to 59 years were 30%, 32%, 28% and 55%, respectively. These high prevalence rates may be a result of the dichotomous scale (yes/ no) in a single question asking if ejaculation occurred too early, as the prevalence rates in European studies have been significantly lower. A British mailed questionnaire survey estimated that the prevalence rate of PE was between 14% (3 months) and 31% (life-time) (18). A French telephone survey of men aged 18 to 69 years estimated the life-time prevalence of early ejaculation at 15%, including 5% who often had experienced ejaculation prior to penetration and 10% who often had ejaculated too rapidly after vaginal intromission (19). A Swedish interview reported an overall prevalence rate of 9% in men aged 18 to 74 years (20), with prevalence by age being 4% for 18-24 years, 7% for 25-34 years, 8% for 35-49 years, 8% for 50-65 years and 14% for 66-74 years. A Danish study about sexual problems using a questionnaire (12 questions) and an interview (23 questions) reported the prevalence rate for PE to be 14% in men aged 51 years (21). An Italian questionnaire survey recorded a prevalence rate of 21% (22). Finally, in a self-adminstered questionnaire survey in the Netherlands, the prevalence rate was 13% in men aged 50-78 years (23). The prevalence of PE in the Premature Ejaculation Prevalence and Attitudes (PEPA) survey (a multinational, internet-based survey) was 22.7% (24.0% in the USA, 20.3% in Germany, and 20.0% in Italy) (17). The Global Study of Sexual Attitudes and Behaviors (GSSAB) survey was conducted in men between 40 and 80 years old in 29 different countries using personal and telephone interviews and self-completed mailed questionnaires; it confirmed that the worldwide prevalence of PE was almost 30%. Except for a low reported rate of PE in Middle Eastern countries (10-15%), prevalence was relatively similar throughout the rest of the world (15). Finally, the prevalence rate of PE was 18% in a five-country European Observational study using the IELT and the Premature Ejaculation Profile (PEP) (24), comparable to those obtained in a similarly designed US observational study (25). Further research is needed on the prevalence of lifelong and acquired PE. Limited data suggests that the prevalence of lifelong PE, defined as IELT <1-2 min, is about 2-5% (20, 25). These results are supported by the moderate genetic influence on PE (26) and low prevalence rates of IELT <1 min (27). 4.3.2 Pathophysiology and risk factors The aetiology of PE is unknown, with little data to support suggested biological and psychological hypotheses, including anxiety, penile hypersensitivity and 5-HT receptor dysfunction (5). In addition, the pathophysiology of PE is largely unknown. In contrast to ED, there is no impairment of the physiological events leading up to the forceful expulsion of sperm at the urethral meatus. A significant proportion of men with ED also experience PE (15). High levels of performance anxiety related to ED may worsen PE, with a risk of misdiagnosing PE instead of the underlying ED. According to the NHLS, the prevalence of PE is not affected by age (16, 17), unlike ED, which increases with age. Premature ejaculation is not affected by marital or income status (16). However, PE is more common in blacks, Hispanic men and men from Islamic backgrounds (28, 29) and may be higher in men with a lower educational level (15, 16). Other risk factors may include a genetic predisposition (30), poor overall health status and obesity (16), prostate inflammation (31, 32), thyroid hormone disorders (33), emotional problems and stress (16, 34), and traumatic sexual experiences (15, 16). In the only published study on risk modification/prevention strategies (35), successful eradication of causative organisms in patients with chronic prostatitis and PE produced marked improvements in IELT and ejaculatory control compared to untreated patients.
4.4
Impact of PE on QoL
Men with PE are more likely to report low satisfaction with their sexual relationship, low satisfaction with sexual intercourse, difficulty relaxing during intercourse and less frequent intercourse (36, 37). However, the negative impact of PE extends beyond sexual dysfunction. PE has a detrimental effect on self-confidence and the relationship with the partner, and may cause mental distress, anxiety, embarrassment and depression (36, 38). Sex drive and overall interest in sex does not appear to be affected by PE (39). However, the partner’s satisfaction with the sexual relationship decreased with increasing severity of the man’s condition (40). Despite the serious psychological and QoL consequences of PE, few men seek treatment. In the GSSAB survey, 78% of men who self-reported a sexual dysfunction sought no professional help or advice for their sexual problems (15), with men more likely to seek treatment for ED than for PE (15). In the PEPA survey,
34
Update march 2009
only 9% of men with self-reported PE consulted a doctor (17). The main reasons for not discussing PE with their physician are patient embarrassment and a belief that there is no treatment. Physicians are often uncomfortable discussing sexuality with their patients usually because of embarrassment and a lack of training or expertize in treating PE (41, 42). Physicians need to encourage patients to talk about PE.
4.5
Diagnosis of PE
Diagnosis of PE is based on the patient’s medical and sexual history (43, 44). History should classify PE as lifelong or acquired and determine whether PE is situational (under specific circumstances or with a specific partner) or consistent. Special attention should be given to the duration time of ejaculation, degree of sexual stimulus, impact on sexual activity and QoL, and drug use or abuse. It is also important to distinguish PE from ED. Many patients with ED develop secondary PE caused by the anxiety associated with difficulty in attaining and maintaining an erection (45). Furthermore, some patients are not aware that loss of erection after ejaculation is normal and may erroneously complain of ED, while the actual problem is PE (46). There are several overlapping definitions of PE, with four shared factors (Table 7), resulting in a multidimensional diagnosis (47). Table 7: Common factors in different definitions of ED • • • •
Time to ejaculation assessed by IELT Perceived control Distress Interpersonal difficulty related to the ejaculatory dysfunction
4.5.1 Intravaginal ejaculatory latency time (IELT) The use of IELT alone is not sufficient to define PE, as there is significant overlap between men with and without PE (24, 25). Moreover, IELT has a significant direct effect on perceived control over ejaculation, but not a significant direct effect on ejaculation-related personal distress or satisfaction with sexual intercourse (48). In addition, perceived control over ejaculation has a significant direct effect on both ejaculation-related personal distress and satisfaction with sexual intercourse (each showing direct effects on interpersonal difficulty related to ejaculation). In everyday clinical practice, self-estimated IELT is sufficient. Self-estimated and stopwatch-measured IELT are interchangeable and correctly assign PE status with 80% sensitivity and 80% specificity (49). Specificity can be improved further to 96% by combining IELT with a single-item patient-reported outcome (PRO) on control over ejaculation and satisfaction with sexual intercourse (scale ranging from 0 = very poor to 4 = very good) and on personal distress and interpersonal difficulty (0 = not at all to 4 = extremely). However, stopwatch-measured IELT is necessary in clinical trials. 4.5.2 PE assessment questionnaires The need to assess PE objectively has led to the development of several questionnaires based on the use of PROs (47). Only two questionnaires can discriminate between patients who have PE and those who do not: • Premature Ejaculation Diagnostic Tool (PEDT: five-item questionnaire based on focus groups and interviews from the USA, Germany and Spain. Assesses control, frequency, minimal stimulation, distress and interpersonal difficulty (50, 51). • Arabic Index of Premature Ejaculation (AIPE): seven-item questionnaire developed in Saudi Arabia assesses sexual desire, hard erections for sufficient intercourse, time to ejaculation, control, satisfaction for the patient andpartner, anxiety or depression (52). These tools are a significant step in simplifying the methodology of PE drug studies, though further cross-cultural validation is needed (53). Other questionnaires used to characterize PE and determine treatment effects include the Premature Ejaculation Profile (PEP) (25), Index of Premature Ejaculation (IPE) (54) and Male Sexual Health Questionnaire Ejaculatory Dysfunction (MSHQ-EjD) (55). Currently, their role is optional in everyday clinical practice. 4.5.3 Physical examination and investigations Physical examination is part of the initial assessment of men with PE. It includes a brief examination of the vascular, endocrine and neurological systems to identify underlying medical conditions associated with PE or other sexual dysfunctions, such as chronic illness, endocrinopathy, autonomic neuropathy, Peyronie’s disease, urethritis or prostatitis. Laboratory or physiological testing should be directed by specific findings from history or physical examination and is not routinely recommended (44).
Update march 2009
35
4.6 Guidelines on diagnosis of PE Recommendation • Diagnosis and classification of PE is based on medical and sexual history. It should be multidimensional and assess IELT, perceived control, distress and interpersonal difficulty due to the ejaculatory dysfunction • Clinical use of self-estimated IELT is adequate. Stopwatch-measured IELT is necessary in clinical trials • Patient-reported outcomes (PROs) have the potential to identify men with PE. Further research is needed before PROs can be recommended for clinical use • Physical examination may be necessary in initial assessment of PE to identify underlying medical conditions that may be associated with PE or other sexual dysfunctions, particularly ED • Routine laboratory or neurophysiological tests are not recommended. They should only be directed by specific findings from history or physical examination LE = level of evidence; GR = grade of recommendation.
LE GR 1a
A
2a
B
3
C
3
C
3
C
4.7
References
1.
Rosenberg MT, Sadovsky R. Identification and diagnosis of premature ejaculation. Int J Clin Pract 2007;61(6):903-8. http://www.ncbi.nlm.nih.gov/pubmed/17504352 Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [access date February 2009]. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Text Revision. Washington, D.C., American Psychiatric Publishing, Inc, 2000. International Classification of Diseases and Related Health Problems. 10th Ed. Geneva, World Health Organization, 1994. McMahon CG, Abdo C, Incrocci L, Perelman M, Rowland D, Waldinger M, Xin ZC. Disorders of orgasm and ejaculation in men. J Sex Med 2004;1(1):58-65. http://www.ncbi.nlm.nih.gov/pubmed/16422984 McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip ID, Adaikan PG, Becher E, Broderick GA, Buvat J, Dabees K, Giraldi A, Giuliano F, Hellstrom WJ, Incrocci L, Laan E, Meuleman E, Perelman MA, Rosen RC, Rowland DL, Segraves R. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med 2008;5(7):1590-606. http://www.ncbi.nlm.nih.gov/pubmed/18466262 Balon R, Segraves RT, Clayton A. Issues for DSM-V: sexual dysfunction, disorder, or variation along normal distribution: toward rethinking DSM criteria of sexual dysfunctions. Am J Psychiatry 2007;164(2):198-200. http://www.ncbi.nlm.nih.gov/pubmed/17267778 Waldinger MD, Schweitzer DH. The DSM-IV-TR is an inadequate diagnostic tool for premature ejaculation. J Sex Med 2007;4(3):822-3. http://www.ncbi.nlm.nih.gov/pubmed/17498112 Waldinger MD, Schweitzer DH. The use of old and recent DSM definitions of premature ejaculation in observational studies: a contribution to the present debate for a new classification of PE in the DSMV. J Sex Med 2008;5(5):1079-87. http://www.ncbi.nlm.nih.gov/pubmed/18331260 Waldinger MD, Schweitzer DH. Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part I-validity of DSM-IV-TR. J Sex Med 2006;3(4):682-92. http://www.ncbi.nlm.nih.gov/pubmed/16839325 Waldinger MD, Schweitzer DH. Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II-proposals for DSM-V and ICD11. J Sex Med 2006;3(4):693-705. http://www.ncbi.nlm.nih.gov/pubmed/16839326
2.
3. 4. 5.
6.
7.
8.
9.
10.
11.
36
Update march 2009
12.
13. 14. 15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Godpodinoff ML. Premature ejaculation: clinical subgroups and etiology. J Sex Marital Ther 1989;15(2):130-4. http://www.ncbi.nlm.nih.gov/pubmed/2769774 Waldinger MD. Premature ejaculation: state of the art. Urol Clin North Am 2007;34:591-9, vii-viii. http://www.ncbi.nlm.nih.gov/pubmed/17983899 Waldinger MD. The neurobiological approach to premature ejaculation. J Urol 2002;168(6):2359-67. http://www.ncbi.nlm.nih.gov/pubmed/12441918 Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, Wang T; GSSAB Investigators’ Group. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005;17(1):39-57. http://www.ncbi.nlm.nih.gov/pubmed/15215881 Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281(6):537-44. http://www.ncbi.nlm.nih.gov/pubmed/10022110 Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 2007;51(5):816-23; discussion 24. http://www.ncbi.nlm.nih.gov/pubmed/16934919 Dunn KM, Croft PR, Hackett GI. Sexual problems: a study of the prevalence and need for health care in the general population. Fam Pract 1998;15(6):519-24. http://www.ncbi.nlm.nih.gov/pubmed/10078790 Spira A, Bajos N, Giami A, Michaels S. Cross-national comparisons of sexual behavior surveys-methodological difficulties and lessons for prevention. Am J Public Health 1998;88(5):730-1. http://www.ncbi.nlm.nih.gov/pubmed/9585733 Fugl-Meyer AR, Sjogren Fugl-Meyer K. Sexual disabilities, problems and satisfaction in 18-74 year old Swedes. Scan J Sexol 1999;2:79-105. http://dissertations.ub.rug.nl/FILES/faculties/medicine/2008/e.a.nijland/04_c4.pdf Solstad K, Hertoft P. Frequency of sexual problems and sexual dysfunction in middle-aged Danish men. Arch Sex Behav 1993;22(1):51-8. http://www.ncbi.nlm.nih.gov/pubmed/8435039 Basile Fasolo C, Mirone V, Gentile V, Parazzini F, Ricci E; Andrology Prevention Week centers; Italian Society of Andrology (SIA).Premature ejaculation: prevalence and associated conditions in a sample of 12,558 men attending the andrology prevention week 2001–a study of the Italian Society of Andrology (SIA). J Sex Med 2005;2(3):376-82. http://www.ncbi.nlm.nih.gov/pubmed/16422869 Blanker MH, Bosch JL, Groeneveld FP, Bohnen AM, Prins A, Thomas S, Hop WC. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001;57(4):763-8. http://www.ncbi.nlm.nih.gov/pubmed/11306400 Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, Rothman M, Gagnon DD, Polverejan E; 3004 Study Group. Premature Ejaculation: Results from a five-country European observational study. Eur Urol 2008;53(5):1048-57. http://www.ncbi.nlm.nih.gov/pubmed/17950985 Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, McNulty P, Rothman M, Jamieson C. Premature ejaculation: an observational study of men and their partners. J Sex Med 2005;2(3):358-67. http://www.ncbi.nlm.nih.gov/pubmed/16422867 Jern P, Santtila P, Witting K, Alanko K, Harlaar N, Johansson A, von der Pahlen B, Varjonen M, Vikström N, Algars M, Sandnabba K. Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. J Sex Med 2007;4(6):1739-49. http://www.ncbi.nlm.nih.gov/pubmed/17888070 Waldinger MD, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M. A multinational population survey of intravaginal ejaculation latency time. J Sex Med 2005;2(4):492-7. http://www.ncbi.nlm.nih.gov/pubmed/16422843 Richardson D, Goldmeier D. Premature ejaculation–does country of origin tell us anything about etiology? J Sex Med 2005;2(4):508-12. http://www.ncbi.nlm.nih.gov/pubmed/16422845 Carson C, Gunn K. Premature ejaculation: definition and prevalence. Int J Impot Res 2006;18(1): S5-S13. http://www.ncbi.nlm.nih.gov/pubmed/16953247
Update march 2009
37
30.
31.
32.
33.
34.
35.
36.
37.
38.
39. 40.
41.
42.
43.
44. 45.
46.
47.
48.
38
Waldinger MD, Rietschel M, Nothen MM, Hengeveld MW, Olivier B. Familial occurrence of primary premature ejaculation. Psychiatr Genet 1998;8(1):37-40. http://www.ncbi.nlm.nih.gov/pubmed/9564687 Screponi E, Carosa E, Di Stasi SM, Pepe M, Carruba G, Jannini EA. Prevalence of chronic prostatitis in men with premature ejaculation. Urology 2001;58(2):198-202. http://www.ncbi.nlm.nih.gov/pubmed/11489699 Shamloul R, el-Nashaar A. Chronic prostatitis in premature ejaculation: a cohort study in 153 men. J Sex Med 2006;3(1):150-4. http://www.ncbi.nlm.nih.gov/pubmed/16409229 Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, Jannini EA. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005;90(12):6472-9. http://www.ncbi.nlm.nih.gov/pubmed/16204360 Dunn KM, Croft PR, Hackett GI. Association of sexual problems with social, psychological, and physical problems in men and women: a cross sectional population survey. J Epidemiol Community Health 1999;53(3):144-8. http://www.ncbi.nlm.nih.gov/pubmed/10396490 El-Nashaar A, Shamloul R. Antibiotic treatment can delay ejaculation in patients with premature ejaculation and chronic bacterial prostatitis. J Sex Med 2007;4(2):491-6. http://www.ncbi.nlm.nih.gov/pubmed/17367444 Rowland D, Perelman M, Althof S, Barada J, McCullough A, Bull S, Jamieson C, Ho KF. Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med 2004;1(2): 225-32. http://www.ncbi.nlm.nih.gov/pubmed/16429622 Rowland DL, Patrick DL, Rothman M, Gagnon DD. The psychological burden of premature ejaculation. J Urol 2007;177(3):1065-70. http://www.ncbi.nlm.nih.gov/pubmed/17296413 Symonds T, Roblin D, Hart K, Althof S. How does premature ejaculation impact a man’s life? J Sex Marital Ther 2003;29(5):361-70. http://www.ncbi.nlm.nih.gov/pubmed/14504007 Riley A, Segraves RT. Treatment of premature ejaculation. Int J Clin Pract 2006;60(6):694-7. http://www.ncbi.nlm.nih.gov/pubmed/16805755 Byers ES, Grenier G. Premature or rapid ejaculation: heterosexual couples’ perceptions of men’s ejaculatory behavior. Arch Sex Behav 2003;32(3):261-70. http://www.ncbi.nlm.nih.gov/pubmed/12807298 Sotomayor M. The burden of premature ejaculation: the patient’s perspective. J Sex Med 2005;2(2):110-4. http://www.ncbi.nlm.nih.gov/pubmed/16422797 Solursh DS, Ernst JL, Lewis RW, Prisant LM, Mills TM, Solursh LP, Jarvis RG, Salazar WH. The human sexuality education of physicians in North American medical schools. Int J Impot Res 2003;15(5): S41-S45. http://www.ncbi.nlm.nih.gov/pubmed/14551576 Sharlip I. Diagnosis and treatment of premature ejaculation: the physician’s perspective. J Sex Med 2005;2(2):103-9. http://www.ncbi.nlm.nih.gov/pubmed/16422796 Shabsigh R. Diagnosing premature ejaculation: a review. J Sex Med 2006;3(4):318-23. http://www.ncbi.nlm.nih.gov/pubmed/16939476 Rowland DL, Slob AK. Premature ejaculation: psychophysiological considerations in theory, research, and treatment. Annu Rev Sex Res 1997;8:224-53. http://www.ncbi.nlm.nih.gov/pubmed/10051895 Althof SE. Prevalence, characteristics and implications of premature ejaculation/rapid ejaculation. J Urol 2006;175(3 Pt 1):842-8. http://www.ncbi.nlm.nih.gov/pubmed/16469562 Althof SE, Symonds T. Patient reported outcomes used in the assessment of premature ejaculation. Urol Clin North Am 2007;34(4):581-9, vii. http://www.ncbi.nlm.nih.gov/pubmed/17983898 Patrick DL, Rowland D, Rothman M. Interrelationships among measures of premature ejaculation: the central role of perceived control. J Sex Med 2007;4(3):780-8. http://www.ncbi.nlm.nih.gov/pubmed/17419817
Update march 2009
49.
50.
51.
52.
53.
54.
55.
4.8
Rosen RC, McMahon CG, Niederberger C, Broderick GA, Jamieson C, Gagnon DD. Correlates to the clinical diagnosis of premature ejaculation: results from a large observational study of men and their partners. J Urol 2007;177(3):1059-64; discussion 64. http://www.ncbi.nlm.nih.gov/pubmed/17296411 Symonds T, Perelman M, Althof S, Giuliano F, Martin M, Abraham L, Crossland A, Morris M, May K. Further evidence of the reliability and validity of the premature ejaculation diagnostic tool. Int J Impot Res 2007;19(5):521-5. http://www.ncbi.nlm.nih.gov/pubmed/17568761 Symonds T, Perelman MA, Althof S, Giuliano F, Martin M, May K, Abraham L, Crossland A, Morris M. Development and validation of a premature ejaculation diagnostic tool. Eur Urol 2007;52(2):565-73. http://www.ncbi.nlm.nih.gov/pubmed/17275165 Arafa M, Shamloul R. Development and evaluation of the Arabic Index of Premature Ejaculation (AIPE). J Sex Med 2007;4(6):1750-6. http://www.ncbi.nlm.nih.gov/pubmed/17970977 McMahon CG. Ejaculatory latency vs. patient-reported outcomes (PROs) as study end points in premature ejaculation clinical trials. Eur Urol 2007;52(2):321-3. http://www.ncbi.nlm.nih.gov/pubmed/17445975 Althof S, Rosen R, Symonds T, Mundayat R, May K, Abraham L. Development and validation of a new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation. J Sex Med 2006;3:465-75. http://www.ncbi.nlm.nih.gov/pubmed/16681472 Rosen RC, Catania JA, Althof SE, Pollack LM, O’Leary M, Seftel AD, Coon AW. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology 2007;69(5):805-9. http://www.ncbi.nlm.nih.gov/pubmed/17482908
Treatment
In many relationships, PE causes few if any problems. In such cases, treatment should be limited to psychosexual counselling. Before beginning treatment, it is essential to discuss patient expectations thoroughly. Erectile dysfunction, in particular, or other sexual dysfunction or genitourinary infection (e.g. prostatitis), should be treated first or at the same time as PE. Various behavioural techniques have demonstrated benefit in treating PE and are indicated for patients uncomfortable with pharmacological therapy. In lifelong PE, behavioural techniques are not recommended for first-line treatment. They are time-intensive, require the support of a partner and can be difficult to do. In addition, long-term outcomes of behavioural techniques for PE are unknown. Pharmacotherapy is the basis of treatment in lifelong PE. Since no drug for PE has been approved by the EMEA or FDA, all medical treatments are off-label indications. Only chronic selective serotonin reuptake inhibitors (SSRIs) and on-demand topical anaesthetic agents have consistently shown efficacy in PE. Again, long-term outcomes for pharmacological treatments are unknown. An evidence-based analysis of all current treatment modalities was performed. Levels of evidence and grade of recommendation are provided and a treatment algorithm is presented (Figure 3). 4.8.1 Psychological/behavioural strategies Behavioural strategies mainly include the ‘stop-start’ programme developed by Semans (1) and its modification, the ‘squeeze’ technique, proposed by Masters and Johnson. • In the ‘stop-start’ programme, the partner stimulates the penis until the patient feels the urge to ejaculate. At this point, he instructs his partner to stop, waits for the sensation to pass and then stimulation is resumed. • The ‘squeeze’ technique is similar but the partner applies manual pressure to the glans just before ejaculation until the patient loses his urge. Both these procedures are typically applied in a cycle of three pauses before proceeding to orgasm. Behavioural strategies are based on the hypothesis that PE occurs because the man fails to appreciate the sensations of heightened arousal and recognize the feelings of ejaculatory inevitability. Re-training may attenuate stimulus-response connections by gradually exposing the patient to progressively more intense and more prolonged stimulation, while maintaining the intensity and duration of the stimulus just below the threshold for triggering the response. There are several modifications of these techniques making comparison difficult. Masturbation before anticipation of sexual intercourse is a technique used by many younger men. Following masturbation, the penis is desensitized resulting in greater ejaculatory delay after the refractory period is over. In a different approach, the man learns to recognize the signs of increased sexual arousal and
Update march 2009
39
how to keep his level of sexual excitement below the intensity that elicits the ejaculatory reflex. Efficacy is similar to the ‘start-stop’ programme (2). Overall, success rates of 50-60% have been reported short term (3, 4). However, there is no controlled research to support the efficacy of behavioural techniques, while a double-blind, randomised, crossover study showed that pharmacological treatment (chlomipramine, sertraline, paroxetine and sildenafil) resulted in greater IELT prolongation than behavioural therapy (5). Furthermore, clinical experience suggests that improvements achieved with these techniques are generally not maintained long term (6, 7). 4.8.1.1 Guideline recommendation Treatment of PE Psychological/behavioural therapies
Level of evidence Grade of recommendation 3 C
4.8.2 Topical anaesthetic agents The use of local anaesthetics to delay ejaculation is the oldest form of pharmacological therapy for PE (8). Several trials (9, 10) support the hypothesis that topical desensitizing agents reduce the sensitivity of the glans penis so delaying ejaculatory latency, but without adversely affecting the sensation of ejaculation. 4.8.2.1 Lidocaine-prilocaine cream In a randomised, double-blind, placebo-controlled trial, lidocaine-prilocaine cream increased the IELT from 1 min in the placebo group to 6.7 min in the treatment group (11). In another randomised, double-blind, placebocontrolled trial, lidocaine-prilocaine cream significantly increased the stopwatch-measured IELT from 1.49 to 8.45 min while no difference was recorded in the placebo group (1.67 to 1.95 min) (12). Lidocaine-prilocaine cream (5%) is applied for 20 to 30 min prior to intercourse. Prolonged application of topical anaesthetic (30 to 45 min) may result in loss of erection due to numbness of the penis in a significant percentage of men (11). A condom is required to avoid diffusion of the topical anaesthetic agent into the vaginal wall causing numbness in the partner. Alternatively, the condom may be removed prior to sexual intercourse and the penis washed clean of any residual active compound. Although no significant side-effects have been reported, topical anaesthetics are contraindicated in patients or partners with an allergy to any component of the product. An aerosol formulation of lidocaine 7.5 mg plus prilocaine 2.5 mg (Topical Eutectic Mixture for Premature Ejaculation, TEMPE (13) has been evaluated in a phase II study (14). Intravaginal ejaculatory latency time increased from a baseline of 1 min to 4.9 min in the TEMPE-treated group compared to an increase from baseline of 0.9 min to 1.6 min (p<0.01) in the placebo-treated group. It has been suggested that lidocaineprilocaine can penetrate the glans within 5–10 min, but penetrates intact keratinized skin less easily, reducing penile numbness and ED (14, 15). Finally, in a randomised, double-blind, placebo-controlled, parallel-group study, lidocaine-prilocaine cream showed similar efficacy to combination with sildenafil (50 mg before coitus) and significantly better efficacy than sildenafil alone (16). However, no specific data on estimated IELT were provided. 4.8.2.2 SS-cream SS-cream is a topical anaesthetic agent made from the extracts of nine herbs. It is applied to the glans penis 1 h before and washed off immediately prior to coitus. SS-cream increased the vibratory threshold in a dosedependent fashion, as well as the latency and amplitude of somatosensory-evoked potentials measured at the glans penis (17, 18). In a double-blind, randomised, placebo-controlled study (19), application of 0.2 g SS-cream improved IELT from 1.37 min to 10.92 min in the treatment group versus 2.45 min in the placebo group. Sexual satisfaction improved by 82% in the treatment group versus 20% in the placebo group. Mild local burning and mild pain were reported by 18.5% of patients. No adverse effects on sexual function or partner or systemic side-effects were observed. 4.8.2.3 Guideline recommendation Topical therapy for PE Lidocaine-prilocaine cream SS-cream
Level of evidence 1B 1B
Grade of recommendation A A
4.8.3 Selective serotonin reuptake inhibitors Ejaculation is mediated by a spinal ejaculation generator (20, 21) and by descending supraspinal modulation from several brain regions. The neurotransmitter 5-hydroxytryptamine (5-HT, serotonin) is also involved in ejaculatory control. The retarding effect of 5-HT on ejaculation is probably due to central activation (i.e. spinally
40
Update march 2009
and supraspinally) of 5-HT1B and 5-HT2C receptors, while stimulation of 5-HT1A receptors precipitates ejaculation. Selective serontonin reuptake inhibitors (SSRIs) are used to treat mood disorders, but can delay ejaculation and are therefore widely used ‘off-label’ for PE. As in depression, SSRIs must be given for 1 to 2 weeks to be effective in PE (22). Chronic SSRI administration causes prolonged increases in synaptic cleft serotonin, which desensitize the 5-HT1A and 5-HT1B receptors (23). Clomipramine, the most serotoninergic tricyclic antidepressant, was first reported in 1973 as an effective PE treatment (24). Selective serontonin reuptake inhibitors have revolutionized treatment of PE, but they have also changed our understanding of PE since the first publication on paroxetine in 1970 (25). Today, daily treatment with SSRIs has become the first choice of treatment in PE. Commonly used SSRIs include citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline, all of which have a similar pharmacological mechanism of action. A systematic review and meta-analysis of all drug treatment studies reported that, despite methodological problems in most studies, there still remained several, well-designed, double-blind, placebocontrolled trials supporting the therapeutic effect of daily SSRIs on PE (26). Open-design studies and studies using subjective reporting or questionnaires showed greater variation in ejaculation delay than double-blind studies in which the ejaculation delay was prospectively assessed with a stopwatch. Based on this meta-analysis, SSRIs were expected to increase the geometric mean IELT by 2.6-fold to 13.2-fold. Paroxetine was found to be superior to fluoxetine, clomipramine and sertraline. Sertraline was superior to fluoxetine, whereas the efficacy of clomipramine was not significantly different from fluoxetine and sertraline. Paroxetine was evaluated in doses of 20-40 mg, sertraline 25-200 mg, fluoxetine 10-60 mg and clomipramine 25-50 mg; there was no significant relationship between dose and response among the various drugs. There is limited evidence that citalopram may be less efficacious compared to other SSRIs, while fluvoxamine may not be effective (27, 28). Ejaculation delay may start a few days after drug intake, but it is more evident after 1 to 2 weeks since receptor desensitization requires time to occur. While efficacy may be maintained for several years, tachyphylaxis (decreasing response to a drug following chronic administration) may occur after 6 to 12 months (24). Common side-effects of SSRIs include fatigue, drowsiness, yawning, nausea, vomiting, dry mouth, diarrhoea and perspiration; they are usually mild and gradually improve after 2 to 3 weeks (24). Decreased libido, anorgasmia, anejaculation and ED have been also reported. In one controlled trial, on-demand use of clomipramine (but not paroxetine), 3 to 5 h before intercourse, was reported to be efficacious, though IELT improvement was inferior compared to daily treatment with the same drug (29). However, on-demand treatment may be combined with an initial trial of daily treatment or concomitant low-dose daily treatment reducing adverse effects (30, 31). 4.8.3.1 Dapoxetine Dapoxetine is a potent SSRI, which has been designed as an on-demand oral treatment for PE. It is quickly absorbed with a Tmax of 1.5 h and is rapidly cleared, avoiding accumulation. An integrated analysis of two, double-blind, randomised, controlled trials (1958 patients) with dapoxetine was published (32). Dapoxetine, 30 and 60 mg, was administered 1 to 3 h before intercourse. Intravaginal ejaculatory latency time improved from a baseline of 0.9 min to 1.75 min, 2.78 min and 3.32 min in the patient groups treated with placebo, 30 mg dapoxetine, and 60 mg dapoxetine, respectively. Improved ejaculation control was reported by 51% and 58% of patients in the 30 mg and 60 mg groups, respectively. Both dapoxetine doses were effective on the first dose. Common adverse events for 30 mg and 60 mg doses of dapoxetine, respectively, were nausea (8.7%, 20.1%), diarrhoea (3.9%, 6.8%), headache (5.9%, 6.8%), and dizziness (3.0%, 6.2%). This analysis was recently confirmed by a study showing that dapoxetine increased substantially IELT and satisfaction with sexual intercourse (33). This drug was the first to be submitted for FDA approval on treatment of PE, but at the time of publication was awaiting approval. 4.8.3.2 Guideline recommendation Treatment for PE Selective serotonin receptor inhibitors (SSRIs)
Level of evidence Grade of recommendation 1A A
4.8.4 Phosphodiesterase type 5 inhibitors Several recent studies have supported the therapeutic role of PDE5 inhibitors in PE. They may reduce performance anxiety due to better erections and may down-regulate the erectile threshold to a lower level of arousal so that greater arousal is required to achieve the ejaculation threshold. However, many of the mechanisms involved remain speculative (33-36).
Update march 2009
41
There is only one well-designed, randomised, double-blind, placebo-controlled study comparing sildenafil to placebo (37). Although IELT was not significantly improved, sildenafil increased confidence, the perception of ejaculatory control and overall sexual satisfaction, reduced anxiety and decreased the refractory time to achieve a second erection after ejaculation. In another randomised, double-blind, placebo-controlled study, lidocaine-prilocaine had similar efficacy to combination with sildenafil (50 mg before intercourse), while the efficacy of sildenafil was similar to placebo (no IELT data provided) (16). In contrast, in a randomised, double-blind, parallel group study, sildenafil significantly improved IELT and satisfaction and reduced overall anxiety compared to several SSRIs and the ‘pause-squeeze’ technique. From a baseline of IELT at 1 min, IELT improved to 15 min with sildenafil, 4 min with clomipramine, 3 min with sertraline, 4 min with paroxetine and 3 min with the ‘pause-squeeze’ technique (5). Finally, several open-label studies showed that sildenafil combined with an SSRI is superior to SSRI monotherapy. Sildenafil combined with paroxetine improved IELT significantly and satisfaction versus paroxetine alone (38). Sildenafil combined with sertraline improved IELT and satisfaction significantly versus sertraline alone (39). Sildenafil combined with paroxetine and psychological and behavioural counselling significantly improved IELT and satisfaction in patients in whom other treatments failed (40). Finally, sildenafil combined with behavioural therapy significantly improved IELT and satisfaction versus behavioural therapy alone (41). There is limited data on the efficacy in PE of other PDE5 inhibitors (tadalafil and vardenafil) (35, 36). Overall, the role of PDE5 inhibitors in PE patients without ED is not established, with only minimal double-blind placebo controlled data are available. 4.8.4.1 Guideline recommendation Treatment for PE PDE5 inhibitors
Level of evidence Grade of recommendation 2B C
4.8.5 Other drugs Adrenergic blockade for PE aims to decrease the sympathetic tone of the seminal tract and therefore delay ejaculation (42). Tramadol is a centrally acting analgesic agent that combines opioid receptor activation and re-uptake inhibition of serotonin and noradrenaline. Research suggests that the alpha-1 adrenergic antagonists, terazosin and alfuzosin (43,44), and tramadol (45, 46) may have some efficacy in PE. However, further research is needed to investigate their role fully. Currently they are not recommended in clinical practice (47). 4.8.6 Guidelines on treatment of PE Recommendation LE GR • ED, other sexual dysfunction or genitourinary infection (e.g. prostatitis) 2a B should be treated first • Behavioural techniques have demonstrated benefit in treating PE. However, 3 C they are time intensive, require the support of a partner and can be difficult to do • Pharmacotherapy is the basis of treatment in lifelong PE 1a A • Daily SSRIs are first-line, off-label, pharmacological treatment for PE. 1a A The pharmacokinetic profile of SSRIs is not amenable to pm dosing • Dapoxetine, a short-acting SSRI, is in the final phase of development for 1a A the on-line demand treatment of PE • Topical anaesthetic agents provide viable alternatives to SSRIs (off-line) 1b A • Recurrence is likely after treatment cessation 1b A • Behavioural therapy may augment pharmacotherapy to enhance 3 C relapse prevention LE = level of evidence; GR = grade of recommendation; ED = erectile dysfunction; PE = premature ejaculation; SSRI = selective serotonin reuptake inhibitor ; pm = on-demand adminstration
42
Update march 2009
Figure 4. Management of PE*
Clinical diagnosis of premature ejaculation based on patient/partner history • Time to ejaculation (IELT) • Perceived degree of ejaculatory control • Degree of bother/distress • Onset and duration of PE • Psychosocial/Relationship issues • Medical history
Treatment of premature ejaculation •Patient counselling •Discussion of treatment options •If PE is secondary to ED, treat ED first or concomitantly
Lifelong PE
Acquired PEPE Acquired
• Pharmacotherapy • Relationship counselling • Behavioural therapy • Combination treatment
• Behavioural therapy • Pharmacotherapy • Relationship counselling • Combination treatment
Attempt graduated withdrawal of Drug therapy after 6 – 8 weeks
• Behavioural therapy includes stop/start technique, squeeze and sensate focus • Pharmacotherapy (off label) includes SSRIs (daily use) and topical anaesthetics. It is recommended as first-line treatment option in lifelong PE * Adapted *from Lue etfrom al. 2004 Adapted Lue (47). et al. 20044 (46). IELT = intravaginal ejaculatory time; PEejaculation; = premature ED = erectile dysfunction; IELT = intravaginal ejaculatory latency time;latency PE = premature EDejaculation; = erectile dysfunction; SSRI = SSRI = selective serotonin receptor inhibitor. selective serotonin receptor inhibitor.
Update march 2009
43
4.9
References
1.
Semans JH. Premature ejaculation: a new approach. South Med J 1956;49(4):353-8. http://www.ncbi.nlm.nih.gov/pubmed/13311629 de Carufel F, Trudel G. Effects of a new functional-sexological treatment for premature ejaculation. J Sex Marital Ther 2006;32(2):97-114. http://www.ncbi.nlm.nih.gov/pubmed/16418103 Grenier G, Byers ES. Rapid ejaculation: a review of conceptual, etiological, and treatment issues. Arch Sex Behav 1995;24(4):447-72. http://www.ncbi.nlm.nih.gov/pubmed/7661658 Metz ME, Pryor JL, Nesvacil LJ, Abuzzahab F Sr, Koznar J. Premature ejaculation: a psychophysiological review. J Sex Marital Ther 1997;23(1):3-23. http://www.ncbi.nlm.nih.gov/pubmed/9094032 Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001;13(1):41-5. http://www.ncbi.nlm.nih.gov/pubmed/11313839 De Amicis LA, Goldberg DC, LoPiccolo J, Friedman J, Davies L. Clinical follow-up of couples treated for sexual dysfunction. Arch Sex Behav 1985;14(6):467-89. http://www.ncbi.nlm.nih.gov/pubmed/4084048 Hawton K, Catalan J, Martin P, Fagg J. Long-term outcome of sex therapy. Behav Res Ther 1986;24(4):665-75. http://www.ncbi.nlm.nih.gov/pubmed/3800838 Morales A, Barada J, Wyllie MG. A review of the current status of topical treatments for premature ejaculation. BJU Int 2007;100(3):493-501. http://www.ncbi.nlm.nih.gov/pubmed/17608824 Sachs BD, Liu YC. Maintenance of erection of penile glans, but not penile body, after transection of rat cavernous nerves. J Urol 1991;146(3):900-5. http://www.ncbi.nlm.nih.gov/pubmed/1875517 Wieder JA, Brackett NL, Lynne CM, Green JT, Aballa TC. Anesthetic block of the dorsal penile nerve inhibits vibratory-induced ejaculation in men with spinal cord injuries. Urology 2000;55(6):915-7. http://www.ncbi.nlm.nih.gov/pubmed/10840108 Atikeler MK, Gecit I, Senol FA. Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andrologia. 2002;34(6):356-9. http://www.ncbi.nlm.nih.gov/pubmed/12472618 Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int 2004;93(7):1018-21. http://www.ncbi.nlm.nih.gov/pubmed/15142155 Henry R, Morales A, Wyllie MG. TEMPE: Topical Eutectic-Like Mixture for Premature Ejaculation. Expert Opin Drug Deliv 2008;5(2):251-61. http://www.ncbi.nlm.nih.gov/pubmed/18248322 Dinsmore WW, Hackett G, Goldmeier D, Waldinger M, Dean J, Wright P, Callander M, Wylie K, Novak C, Keywood C, Heath P, Wyllie M. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 2007;99(2):369-75. http://www.ncbi.nlm.nih.gov/pubmed/17129234 Henry R, Morales A. Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study. Int J Impot Res 2003;15(4):277-81. http://www.ncbi.nlm.nih.gov/pubmed/12934056 Atan A, Basar MM, Tuncel A, Ferhat M, Agras K, Tekdogan U. Comparison of efficacy of sildenafilonly, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urology 2006;67(2):388-91. http://www.ncbi.nlm.nih.gov/pubmed/16461091 Xin ZC, Choi YD, Seong DH, Choi HK. Sensory evoked potential and effect of SS-cream in premature ejaculation. Yonsei Med J 1995;36(5):397-401. http://www.ncbi.nlm.nih.gov/pubmed/8545998 Xin ZC, Choi YD, Lee WH, Choi YJ, Yang WJ, Choi HK, Kim DK. Penile vibratory threshold changes with various doses of SS-cream in patients with primary premature ejaculation. Yonsei Med J 2000;41(1):29-33. http://www.ncbi.nlm.nih.gov/pubmed/10731916
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
44
Update march 2009
19.
20.
21.
22.
23.
24. 25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
Choi HK, Jung GW, Moon KH, Xin ZC, Choi YD, Lee WH, Rha KH, Choi YJ, Kim DK. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology 2000;55(2):257-61. http://www.ncbi.nlm.nih.gov/pubmed/10688090 Truitt WA, Coolen LM. Identification of a potential ejaculation generator in the spinal cord. Science 2002;297(5586):1566-9. http://www.ncbi.nlm.nih.gov/pubmed/12202834 Borgdorff AJ, Bernabe J, Denys P, Alexandre L, Giuliano F. Ejaculation elicited by microstimulation of lumbar spinothalamic neurons. Eur Urol 2008;54:449-56. http://www.ncbi.nlm.nih.gov/pubmed/18394782 Giuliano F. 5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci 2007;30(2):79-84. http://www.ncbi.nlm.nih.gov/pubmed/17169440 Olivier B, van Oorschot R, Waldinger MD. Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol 1998;13(6):S9-S14. http://www.ncbi.nlm.nih.gov/pubmed/9728669 Waldinger MD. Premature ejaculation: definition and drug treatment. Drugs 2007;67(4):547-68. http://www.ncbi.nlm.nih.gov/pubmed/17352514 Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994;151(1):1377-9. http://www.ncbi.nlm.nih.gov/pubmed/8067497 Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and metaanalysis. Int J Impot Res 2004;16(4):369-81. http://www.ncbi.nlm.nih.gov/pubmed/14961051 Waldinger MD, Zwinderman AH, Olivier B. SSRIs and ejaculation: a double-blind, randomized, fixeddose study with paroxetine and citalopram. J Clin Psychopharmacol 2001;21(6):556-60. http://www.ncbi.nlm.nih.gov/pubmed/11763001 Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998;18(4):274-81. http://www.ncbi.nlm.nih.gov/pubmed/9690692 Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol 2004;46(4):510-5; discussion 6. http://www.ncbi.nlm.nih.gov/pubmed/15363569 McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol 1999;161(6):1826-30. http://www.ncbi.nlm.nih.gov/pubmed/10332446 Kim SW, Paick JS. Short-term analysis of the effects of as needed use of sertraline at 5 PM for the treatment of premature ejaculation. Urology 1999;54(3):544-7. http://www.ncbi.nlm.nih.gov/pubmed/10475369 Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Shabsigh R, Miloslavsky M, Kell S; Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006;368(9539):929-37. http://www.ncbi.nlm.nih.gov/pubmed/16962882 Shabsigh R, Patrick DL, Rowland DL, Bull SA, Tesfaye F, Rothman M. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine. BJU Int 2008;102(7):824-8. http://www.ncbi.nlm.nih.gov/pubmed/18647300 Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur Urol 2007;52(5):1331-9. http://www.ncbi.nlm.nih.gov/pubmed/17728050 McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int 2006;98(2): 259-72. http://www.ncbi.nlm.nih.gov/pubmed/16879663
Update march 2009
45
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
Wang WF, Minhas S, Ralph DJ. Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation. Int J Androl 2006;29(5):503-09. http://www.ncbi.nlm.nih.gov/pubmed/16573707 McMahon CG, Stuckey BG, Andersen M, Purvis K, Koppiker N, Haughie S, Boolell M. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2005;2(3):368-75. http://www.ncbi.nlm.nih.gov/pubmed/16422868 Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, Cestari A, Guazzoni G, Rigatti P, Montorsi F. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002;168(6):2486-9. http://www.ncbi.nlm.nih.gov/pubmed/12441946 Zhang XS, Wang YX, Huang XY, Leng J, Li Z, Han YF. [Comparison between sildenafil plus sertraline and sertraline alone in the treatment of premature ejaculation]. Zhonghua Nan Ke Xue. 2005;11(7):5202, 5. [Chinese] http://www.ncbi.nlm.nih.gov/pubmed/16078671 Chen J, Mabjeesh NJ, Matzkin H, Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology 2003;61(1):197-200. http://www.ncbi.nlm.nih.gov/pubmed/12559295 Tang W, Ma L, Zhao L, Liu Y, Chen Z. [Clinical efficacy of Viagra with behavior therapy against premature ejaculation]. Zhonghua Nan Ke Xue. 2004;10(5):366-7, 370. [article in Chinese] http://www.ncbi.nlm.nih.gov/pubmed/15190831 Hsieh JT, Chang HC, Law HS, Hsieh CH, Cheng JT. In vivo evaluation of serotonergic agents and alpha-adrenergic blockers on premature ejaculation by inhibiting the seminal vesicle pressure response to electrical nerve stimulation. Br J Urol 1998;82(2):237-40. http://www.ncbi.nlm.nih.gov/pubmed/9722759 Basar MM, Yilmaz E, Ferhat M, Basar H, Batislam E. Terazosin in the treatment of premature ejaculation: a short-term follow-up. Int Urol Nephrol 2005;37(4):773-7. http://www.ncbi.nlm.nih.gov/pubmed/16362597 Cavallini G. Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Eur Urol 1995;28(2):126-30. http://www.ncbi.nlm.nih.gov/pubmed/8529737 Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2006;26(1):27-31. http://www.ncbi.nlm.nih.gov/pubmed/16415702 Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med 2008;5(1):188-93. http://www.ncbi.nlm.nih.gov/pubmed/17362279 Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6-23. http://www.ncbi.nlm.nih.gov/pubmed/16422979
5. conclusion Modern treatment of ED has been revolutionized by the worldwide availability of three PDE5 inhibitors for oral use – sildenafil, tadalafil and vardenafil. These drugs have high efficacy and safety rates, even in difficult-to-treat populations, such as patients with diabetes mellitus or who have undergone RP. Patients should be encouraged to try all three PDE5 inhibitors. Patients should make up their own minds about which compound has the best efficacy, while also considering other factors, such as time of onset, duration of action, window of opportunity and how side-effects affect them individually. Treatment options for patients who do not respond to oral drugs, or for whom drugs are contraindicated, include intracavernous injections, intraurethral alprostadil, vacuum constriction devices or implantation of a penile prosthesis. It is very important that the physician warns the patient that sexual intercourse is a vigorous physical activity, which increases heart rate as well as cardiac work. Physicians should assess the cardiac fitness of patients prior to treating ED.
46
Update march 2009
Any successful pharmacological treatment for erectile failure demands a degree of integrity of the penile mechanisms of erection. Further studies of individual agents and synergistic activity of available substances are underway. The search for the ideal pharmacological therapy for erectile failure aims to fulfil the following characteristics: good efficacy, easy administration, freedom from toxicity and side-effects, with a rapid onset and a possible long-acting effect. Premature ejaculation (PE) is another very common male sexual dysfunction, with prevalence rates of 20% to 30%. Four major definitions of PE are currently used and the most widely accepted classification of PE includes “lifelong” (primary) and “acquired” (secondary) forms (syndromes). Diagnosis of PE in everyday clinical practice is based on medical and sexual history assessing IELT, perceived control, distress, and interpersonal difficulty related to the ejaculatory dysfunction. Physical examination and laboratory testing may be needed in selected patients only. Pharmacotherapy is the basis of treatment in lifelong PE including daily dosing of SSRI’s and topical anesthetics. Behavioral techniques may be efficacious as a monotherapy or in combination with pharmacotherapy, but they can be difficult to perform. In every case, recurrence is likely to occur after treatment withdrawal
Update march 2009
47
6. ABBREVIATIONS USED IN THE TEXT This list is not comprehensive for the most common abbreviations
AIPE AUC BMI CAD cGMP CGRP CHF Cmax DICC DRE DSM-IV-TR EAU ED EMEA FDA FSH GAQ GSSAB ICD-10 IELT IIEF IPE ISSM LH MET MI MMAS NHSLS MSHQ-EjD NS NO NPTR NSRP NYHA PDE5 PE PEDT PEP PEPA PRO PSA PCa QoL RP SEP SSRI TEMPE Tmax VCD VIP
48
Arabic Index of Premature Ejaculation area under curve - serum concentration time curve body mass index coronary artery disease cyclic guanosine monophosphate calcitonin gene-related peptide congestive heart failure maximal concentration dynamic infusion cavernosometry or cavernosography digital rectal examination Diagnostic and Statistical Manual of Mental Disorders IV-Text Revision European Association of Urology erectile dysfunction European Medicines Agency (US) Food and Drug Administration follicle-stimulating hormone General Assessment Question Global Study of Sexual Attitudes and Behaviors International Classification of Diseases-10 intravaginal ejaculatory latency time International Index for Erectile Function Index of Premature Ejaculation International Society for Sexual Medicine luteinizing hormone metabolic equivalent of energy expenditure in the resting state myocardial infarction Massachusetts Male Aging Study National Health and Social Life Survey Male Sexual Health Questionnaire Ejaculatory Dysfunction nerve sparing nitric oxide nocturnal penile tumescence and rigidity nerve-sparing radical prostatectomy New York Heart Association phosphodiesterase type 5 [inhibitors] premature ejaculation Premature Ejaculation Diagnostic Tool Premature Ejaculation Profile Premature Ejaculation Prevalence and Attitudes Patient reported outcome prostate-specific antigen prostate cancer quality of life radical prostatectomy sexual encounter profile selective serotonin reuptake inhibitor topical eutectic mixture for premature ejaculation time to maximum plasma concentration vacuum constriction devices vasointestinal peptide
Update march 2009
Conflict of interest All members of the Male Sexual Dysfunction guidelines writing panel have provided disclosure statements of all relationships which they have and which may be perceived as a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel - and meeting expenses. No honoraria or other reimbursements have been provided.
Update march 2009
49
50
Update march 2009
Guidelines on
Male Infertility G.R. Dohle, A. Jungwirth, Z. Kopa, A. Giwercman, T. Diemer, T.B. Hargreave
© European Association of Urology 2009
TABLE OF CONTENTS 1.
PAGE
Introduction 1.1 Definition 1.2 Epidemiology and aetiology 1.3 Prognostic factors 1.4 Recommendations 1.5 References
6 6 6 6 7 7
2. INVESTIGATIONS 2.1 Semen analysis 2.1.1 Frequency of semen analysis 2.2 Recommendations 2.3 References
7 7 7 8 8
3. PRIMARY SPERMATOGENIC FAILURE 3.1 Definition 3.2 Aetiology 3.3 History and physical examination 3.4 Investigations 3.4.1 Semen analysis 3.4.2 Hormonal determinations 3.4.3 Testicular biopsy 3.5 Conclusions 3.6 Recommendations 3.7 References
8 8 8 9 9 9 9 9 10 10 10
4. GENETIC DISORDERS IN INFERTILITY 13 4.1 Introduction 13 4.2 Chromosomal abnormalities 13 4.2.1 Sperm chromosomal abnormalities 13 4.2.2 Sex chromosome abnormalities (Klinefelter’s syndrome and variants [mosaicism]) 13 4.2.3 Autosomal abnormalities 13 4.2.4 Translocations 13 4.3 Genetic defects 14 4.3.1 X-linked genetic disorders and male fertility 14 4.3.2 Kallmann’s syndrome 14 4.3.3 Androgen insensitivity: Reifenstein’s syndrome 14 4.3.4 Other X-disorders 14 4.4. Y genes and male infertility 14 4.4.1 Introduction 14 4.4.2 Clinical implications of Y microdeletions 14 4.4.2.1 Testing for Y microdeletions 15 4.4.2.2 Recommendations 15 4.4.3 Autosomal defects with severe phenotypic abnormalities as well as infertility 15 4.5 Cystic fibrosis mutations and male infertility 15 4.6 Unilateral or bilateral absence/abnormality of the vas and renal anomalies 16 4.7 Other single gene disorders 16 4.8 Unknown genetic disorders 16 4.9 Genetic and DNA abnormalities in sperm 17 4.10 Genetic counselling and ICSI 17 4.11 Conclusions 17 4.12 Recommendations 17 4.13 References 17
2
UPDATE MARCH 2007
5. OBSTRUCTIVE AZOOSPERMIA 5.1 Definition 5.2 Classification 5.2.1 Intratesticular obstruction 5.2.2 Epididymal obstruction 5.2.3 Vas deferens obstruction 5.2.4 Ejaculatory duct obstruction 5.2.5 Functional obstruction of the distal seminal ducts 5.3 Diagnostic management 5.3.1 Clinical history 5.3.2 Clinical examination 5.3.3 Semen analysis 5.3.4 Hormone levels 5.3.5 Ultrasonography 5.3.6 Testicular biopsy 5.4 Treatment 5.4.1 Intratesticular obstruction 5.4.2 Epididymal obstruction 5.4.3 Proximal vas obstruction 5.4.4 Distal vas deferens obstruction 5.4.5 Ejaculatory duct obstruction 5.5 Conclusions 5.6 Recommendations 5.7 References
22 22 22 22 22 23 23 23 23 23 23 24 24 24 24 25 25 25 25 25 25 25 26 26
6.
VARICOCELE 6.1 Introduction 6.2 Classification 6.3 Diagnosis 6.4 Basic considerations 6.5 Treatment 6.6 Conclusions 6.7 Recommendations 6.8 References
28 28 28 28 28 29 29 30 30
7.
HYPOGONADISM 7.1 Introduction 7.2 Hypogonadotrophic hypogonadism: aetiology, diagnosis and therapeutic management 7.3 Hypergonadotrophic hypogonadism: aetiology, diagnosis and therapeutic management 7.4 Conclusions 7.5 Recommendations 7.6 References
32 32 33 33 33 33 34
8. CRYPTORCHIDISM 8.1 Introduction 8.2 Incidence of cryptorchidism 8.3 Testicular descent and maldescent 8.4 Hormonal control of testicular descent 8.5 Pathophysiological effects in maldescended testes 8.5.1 Degeneration of germ cells 8.5.2 Relationship with fertility 8.5.3 Germ cell tumours 8.6 Treatment of undescended testes 8.6.1 Hormonal treatment 8.6.2 Surgical treatment 8.7 Conclusions 8.8 Recommendations 8.9 References
UPDATE MARCH 2007
34 34 34 35 35 35 35 35 35 35 35 36 36 36 36
3
9.
IDIOPATHIC MALE INFERTILITY 9.1 Introduction 9.2 Empirical treatments 9.3 Recommendations 9.4 References
37 37 37 38 38
10. MALE CONTRACEPTION 10.1 Introduction 10.2 Vasectomy 10.2.1 Surgical techniques 10.2.2 Complications 10.2.3 Vasectomy failure 10.2.4 Counselling 10.3 Vasectomy reversal 10.3.1 Length of time since vasectomy 10.3.2 Epididymo-vasostomy 10.3.3 Microsurgical vasectomy reversal versus epididymal or testicular sperm retrieval and ICSI 10.4 Conclusions 10.5 Recommendations 10.6 References
38 38 39 39 39 39 39 39 39 40
11. MALE ACCESSORY GLAND INFECTIONS (MAGIs) 11.1 Introduction 11.2 Urethritis 11.2.1 Diagnosis and treatment 11.3 Prostatitis 11.3.1 Microbiology 11.3.2 Diagnosis 11.3.3 Ejaculate analysis 11.3.4 Microbiological findings 11.3.5 White blood cells 11.3.6 Sperm quality 11.3.7 Seminal plasma alterations 11.3.8 Glandular secretory dysfunction 11.3.9 Sperm antibodies 11.3.10 Reactive oxygen species 11.3.11 Therapy 11.4 Orchitis and epididymo-orchitis 11.4.1 Introduction 11.4.2 Diagnosis 11.4.3. Ejaculate analysis 11.4.4 Therapy 11.5 Epididymitis 11.5.1 Introduction 11.5.2 Diagnosis 11.5.3 Ejaculate analysis 11.5.4 Treatment 11.6 Conclusions 11.7 Recommendations 11.8 References
41 41 42 42 42 42 43 43 43 43 43 43 44 44 44 44 44 44 44 44 44 45 45 45 45 45 46 46 46
12.
49 49 50 50 50 50
4
GERM CELL MALIGNANCIES AND TESTICULAR MICROCALCIFICATIONS 12.1 Germ cell malignancies and male infertility 12.2 Testicular germ cell cancer and reproductive function 12.3 Testicular microlithiasis 12.4 Recommendations 12.5 References
40 40 40 40
UPDATE MARCH 2007
13. DISORDERS OF EJACULATION 13.1 Definition 13.2 Classification and aetiology 13.2.1 Anejaculation 13.2.2 Anorgasmia 13.2.3 Delayed ejaculation 13.2.4 Retrograde ejaculation 13.2.5 Asthenic ejaculation 13.2.6 Premature ejaculation 13.2.7 Painful ejaculation 13.3 Diagnosis 13.3.1 Clinical history 13.3.2 Physical examination 13.3.3 Post-ejaculatory urinalysis 13.3.4 Microbiological examinations 13.3.5 Optional diagnostic work up 13.4 Treatment 13.5 Aetiological treatments 13.6 Symptomatic treatments 13.6.1 Premature ejaculation 13.6.2 Retrograde ejaculation 13.6.3 Anejaculation 13.7 Conclusions 13.8 Recommendations 13.9 References
52 52 52 52 52 52 52 53 53 53 53 53 53 53 53 53 54 54 54 54 54 54 55 55 55
14. SEMEN CRYOPRESERVATION 14.1 Definition 14.2 Introduction 14.3 Indications for storage 14.4 Precautions and techniques 14.4.1 Freezing and thawing 14.4.2 Cryopreservation of very small numbers of sperm 14.4.3 Testing for infections and preventing cross examination 14.4.4 Fail-safe precautions to prevent loss of stored materials 14.4.5 Orphan samples 14.5 Biological aspects 14.6 Conclusions 14.7 Recommendations 14.8 References
56 56 56 57 57 57 57 57 58 58 58 58 59 59
15.
levels of evidence and grades of guidelines recommendations 15.1 References
60 60
16.
ABBREVIATIONS USED IN THE TEXT
61
UPDATE MARCH 2007
5
1. INTRODUCTION 1.1
Definition
‘Infertility is the inability of a sexually active, non-contracepting couple to achieve pregnancy in one year’ (WHO) (1).
1.2
Epidemiology and aetiology
About 15% of couples do not achieve pregnancy within 1 year and seek medical treatment for infertility. Eventually 5% remain unwillingly childless. Infertility affects both men and women. In 50% of involuntarily childless couples a male infertility associated factor is found together with abnormal semen parameters. A fertile partner may compensate for the fertility problem of the men and thus infertility usually becomes manifest if both partners have reduced fertility (1). Male fertility can be reduced as a result of: • congenital or acquired urogenital abnormalities (including obstructions and testicular dysgenesis • urogenital tract infections • increased scrotal temperature (e.g as a consequence of varicocele) • endocrine disturbances • genetic abnormalities • immunological factors (1). In at least 44% of cases, no male infertility associated factor is found (idiopathic male infertility). These men present with no previous history of fertility problems and have normal findings on physical examination and endocrine laboratory testing. Semen analysis, however, reveals a decreased number of spermatozoa (oligozoospermia), decreased sperm motility (asthenozoospermia) and many abnormal forms of sperm (teratozoospermia); these sperm abnormalities usually occur together and are called oligo-asthenoteratozoospermia (OAT) syndrome. Table 1 summarises the main male infertility associated factors. Idiopathic male infertility may be explained by several factors, including endocrine disruption as a result of environmental pollution, reactive oxygen species or genetic abnormalities. Table 1: Aetiology and distribution of male infertility among 7,057 men Aetiology • Sexual factors • Urogenital infection • Congenital abnormalities • Acquired factors • Varicocele • Endocrine disturbances • Immunological factors • Other abnormalities • Idiopathic abnormal semen (OAT syndrome) or no demonstrable cause * From WHO (2000) (1). * OAT = Oligo-astheno-teratozoospermia.
1.3
Distribution (%) 1.7 6.6 2.1 2.6 12.3 0.6 3.1 3.0 75.1
Prognostic factors
The prognostic factors for male infertility are: • duration of infertility • primary or secondary infertility • results of semen analysis • age and fertility status of female partner. If the duration of infertility is > 4 years of unprotected sexual intercourse, the conception rate per month is only 1.5%. In many Western countries, women postpone their first pregnancy until they have finished their education and have started a career. Female age is the most important single variable influencing outcome in assisted reproduction (2). Compared to a woman at 25 years old, the fertility potential is reduced to 50% at age 35, to 25% by 38 years and < 5% at over 40 years.
6
UPDATE MARCH 2007
1.4 RECOMMENDATIONS (3) Recommendations • To categorise infertility, both partners should be investigated simultaneously. • In the diagnosis and management of male infertility, the fertility status of the female partner must be considered, as this might determine the final outcome (2). • The urologist/andrologist should examine any male with fertility problems for urogenital abnormalities. This applies to all males diagnosed with reduced sperm quality. A diagnosis is mandatory to initiate appropriate therapy (drugs, surgery, assisted reproduction) (1). GR = grade of reccomendation
1.5
GR C B C
REFERENCES
1.
World Health Organization. WHO Manual for the Standardised Investigation and Diagnosis of the Infertile Couple. Cambridge: Cambridge University Press, 2000. 2. Rowe T. Fertility and a woman’s age. J Reprod Med 2006:51(3);157-63. http://www.ncbi.nlm.nih.gov/pubmed/16674009 3. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [access date January 2009].
2. INVESTIGATIONS 2.1
Semen analysis
Andrological examination is indicated if semen analysis shows abnormalities compared with standard values (Table 2). Important treatment decisions are based on the results of semen analysis and standardisation of the complete laboratory work-up is essential. Ejaculate analysis has been standardised by the WHO and disseminated by continuing work and publications in the WHO Laboratory Manual for Human Semen and Sperm-Cervical Mucus Interaction (4th edition) (1). It is the consensus that modern spermatology must follow these guidelines, without exception. Table 2: Overview of standard values for semen analysis according to the 1999 WHO criteria* • Volume > 2.0 mL • pH 7.0-8.0 • Sperm concentration > 20 million/mL • Total no. of spermatozoa > 40 million/ejaculate • Motility > 50% with progressive motility or 25% with rapid motility within 60 min after ejaculation • Morphology > 14% of normal shape and form** • Viability > 50% of spermatozoa • Leukocytes < 1 million/mL • Immunobead test (IBT) < 50% spermatozoa with adherent particles • MAR test** < 50% spermatozoa with adherent particles * From WHO (2000) (1). ** Assessment according to Kruger and Menkfeld criteria. † IBT = Immunobead test ‡ MAR = Mixed antiglobulin reaction 2.1.1 Frequency of semen analysis If the results of semen analysis are normal according to WHO criteria, one test should be sufficient. If the results are abnormal in at least two tests, further andrological investigation is indicated. It is important to distinguish between the following: • oligozoospermia: < 20 million spermatozoa/mL • asthenozoospermia: < 50% motile spermatozoa
UPDATE MARCH 2007
7
• teratozoospermia: < 14% normal forms. Quite often, all three pathologies occur simultaneously as OAT syndrome. In extreme cases of OAT syndrome (< 1 million spermatozoa/mL), as in azoospermia, there is an increased incidence of obstruction of the male genital tract and genetic abnormalities.
2.2
RECOMMENDATIONS
Recommendations • Andrological investigations are indicated if semen analysis is abnormal, according to WHO criteria, in at least two tests. • Assessment of andrological status must consider the suggestions made by the WHO for the standardised investigation, diagnosis and management of infertile men; this will result in implementation of evidence-based medicine in this interdisciplinary field of reproductive medicine (2). • Semen analysis must follow the guidelines of the WHO Laboratory Manual for Human Semen and Sperm-Cervical Mucus Interaction (4th edition) (1). GR = grade of recommendation; WHO = World Health Organization
2.3
REFERENCES
1.
World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 4th edn. Cambridge: Cambridge University Press, 1999. World Health Organization. WHO Manual for the Standardised Investigation, Diagnosis and Management of the Infertile Male. Cambridge: Cambridge University Press, 2000.
2.
GR C C
C
3. PRIMARY SPERMATOGENIC FAILURE 3.1
Definition
Primary spermatogenic (testicular) failure is any spermatogenic alteration caused by conditions other than hypothalamic-pituitary disease. Severe forms of primary spermatogenic failure have different aetiologies but present clinically as non-obstructive azoospermia (NOA). The prevalence of azoospermia in the general population is approximately 2%; the incidence at a male infertility clinic 10-20% (1).
3.2
Aetiology
The causes of spermatogenic failure are summarized in Table 3. Table 3: Causes of spermatogenic failure • Anorchia • Congenital factors (testicular dysgenesis) • Acquired factors (trauma, testicular torsion, tumour, surgery) • Maldescended testes • Klinefelter’s syndrome* • Other chromosomal alterations* • Germ cell aplasia • Complete and focal germ cell aplasia (Sertoli cell-only syndrome), either congenital or acquired: maldescended testes, irradiation, cytostatic drugs • Spermatogenic arrest • Post-inflammatory (orchitis) • Exogenous factors (medications, toxins, irradiation, heat) • Systemic diseases (liver cirrhosis, renal failure) • Testicular tumour • Varicocele • Surgeries that can damage vascularization of the testes • Idiopathic * See section 4 Genetic disorders in infertility.
8
UPDATE MARCH 2007
3.3
History and physical examination
Typical findings from the history and physical examination of a patient with spermatogenic failure are: • • • • • • • • • • • • • •
cryptorchidism testicular torsion genito-urinary infection testicular trauma exposure to environmental toxin(s) gonadotoxic medication exposure to radiation or chemical(s) testicular cancer absence of testes abnormal secondary sexual characteristics gynaecomastia cryptorchidism abnormal testicular volume and/or consistency varicocele.
3.4
Investigations
Routine investigations include semen analysis and hormonal determinations. Other investigations may be required depending on the individual situation. 3.4.1 Semen analysis In NOA, semen analysis shows normal ejaculate volume and azoospermia after several centrifugations. A recommended method is semen centrifugation at 600 g for 10 min and thorough microscopic examination of the pellet (x 600). The upper fluid is then re-centrifuged (8000 g) for an additional 10 minutes and then examined. All samples can be stained and re-examined microscopically (2). 3.4.2 Hormonal determinations Generally, the levels of follicle-stimulating hormone (FSH) correlate with the number of spermatogonia: • When spermatogonia are absent or markedly diminished, FSH values are usually elevated. • When the number of spermatogonia is normal, but spermatocyte or spermatid blockage is complete, FSH values are within normal range. However, for an individual patient, FSH levels do not accurately predict the spermatogenesis status (3-5). Preliminary data indicate a stronger correlation between low inhibin B level and spermatogenic damage (6). 3.4.3 Testicular biopsy Testicular biopsy is usually part of an ICSI treatment in patients with clinical evidence of NOA: part of the specimen is used for pathological examination and part is cryopreserved for future ICSI cycles if spermatozoa are present (7, 8). Spermatogenesis may be focal: in about 50-60% of men with NOA, only some seminiferous tubules have spermatozoa that can be used for ICSI. Most authors therefore recommend taking several testicular samples (9, 10). A good correlation is seen between diagnostic biopsy histology and the likelihood of finding mature sperm cells during testicular sperm retrieval and ICSI (11, 12). No clear relationship has been found between successful sperm harvesting and FSH, Inhibin B or testicular volume. In case of AZFa and AZFb microdeletions, no spermatozoa can be retrieved (18, 19). Testicular sperm extraction and Microsurgical testicular sperm extraction (MicroTESE) are the techniques of choice and show excellent repeatability (20); TESE results in sperm retrievals in 50-60% of cases (21, 22). Microsurgical testicular sperm extraction may increase retrieval rates (21, 23, 24). After opening the testis, fluid from large calibre tubules is aspirated with the aid of the operating microscope: complications appear to be lower with MicroTESE than with classical TESE (25). Positive retrievals are reported even in conditions such as Sertoli cell only syndrome (21). Testicular fine-needle aspiration (TEFNA) results in lower retrieval rates and does not allow histological examination to detect carcinoma in situ (CIS) and testicular malignancies (26, 27). TEFNA may also result in more tubular and vascular damage than TESE (28). The results of ICSI are worse when sperm retrieved from men with NOA are used compared to sperm from men with obstructive azoospermia (OA) (29-31):
UPDATE MARCH 2007
9
• fertilisation, implantation and birth rates are lower in NOA vs OA (19% vs 28%) (32,33) • miscarriage rates are higher in NOA vs OA (11.5% vs 2.5%) (34). In OA, no significant difference in ICSI results was found between testicular or epididymal sperm (35). Also, no significant differences have been reported in ICSI results between the use of fresh and frozen-thawed sperm (32, 35-39).
3.5
CONCLUSIONS
• •
Impaired spermatogenesis is often associated with elevated FSH concentration. Testicular biopsy is the best procedure to define the histological diagnosis and the possibility of finding sperm. Spermatozoa should be cryopreserved for future ICSI. Spermatozoa are found in about 60% of patients with NOA. Men who are candidates for sperm retrieval must receive appropriate genetic advice. For patients with NOA who have spermatozoa in their testicular biopsy, ICSI with fresh or cryopreserved spermatozoa is the only therapeutic option. Pregnancies and life births are achieved in 30-50% of couples with NOA, when spermatozoa are found in the testicular biopsy.
• • • •
3.6
RECOMMENDATIONS
Recommendations • Men with non-obstructive azoospermia (NOA) can be offered a testicular sperm extraction with cryopreservation of the spermatozoa to be used for intracytoplasmic sperm injection (40-42). Part of the specimen can be used for pathological examination. • To increase the chances of positive sperm retrievals in men with NOA, testicular sperm extraction (single, multiple or microsurgical) should be used rather than testicular fine-needle extraction. GR = grade of recommendation; NOA = non-obstructive azoospermia
3.7
GR B
B
REFERENCES
World Health Organization. WHO Manual for the Standardised Investigation, Diagnosis and Management of the Infertile Male. Cambridge: Cambridge University Press, 2000. 2. World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and Spermcervical Mucus Interaction. 4th edn. Cambridge: Cambridge University Press, 1999. 3. Hauser R, Temple-Smith PD, Southwick GJ, de Kretser DM. Fertility in cases of hypergonadotropic azoospermia. Fertil Steril 1995;63(3):631-6. http://www.ncbi.nlm.nih.gov/pubmed/7851598 4. Martin-du Pan RC, Bischof P. Increased follicle stimulating hormone in infertile men. Is increased plasma FSH always due to damaged germinal epithelium? Hum Reprod 1995;10(8):1940-5. http://www.ncbi.nlm.nih.gov/pubmed/8567817 5. De Kretser DM, Burger HG, Hudson B. The relationship between germinal cells and serum FSH in males with infertility. J Clin Endocrinol Metab 1974;38(5):787-93. http://www.ncbi.nlm.nih.gov/pubmed/4823921 6. Pierik FH, Vreeburg JT, Stijnen T, De Jong FH, Weber RF. Serum inhibin B as a marker of spermatogenesis. J Clin Endocrinol Metab 1998;83(9):3110-4. http://www.ncbi.nlm.nih.gov/pubmed/9745412 7. Turek PJ, Kim M, Gilbaugh JH 3rd, Lipshultz LI. The clinical characteristics of 82 patients with Sertoli cell-only testis histology. Fertil Steril 1995;64(6):1197-200. http://www.ncbi.nlm.nih.gov/pubmed/7589676 8. Silber SJ, Nagy Z, Devroey P, Tournaye H, Van Steirteghem AC. Distribution of spermatogenesis in the testicles of azoospermic men: the presence or absence of spermatids in the testes of men with germinal failure. Hum Reprod 1997;12(11):2422-8. Erratum in Hum Reprod 1998;13(3):780. http://www.ncbi.nlm.nih.gov/pubmed/9436677 9. Gottschalk-Sabag S, Weiss DB, Folb-Zacharow N, Zukerman Z. Is one testicular specimen sufficient for quantitative evaluation of spermatogenesis? Fertil Steril 1995;64(2):399-402. http://www.ncbi.nlm.nih.gov/pubmed/7615120 10. Turek PJ, Cha I, Ljung BM. Systematic fine-needle aspiration of the testis: correlation to biopsy and results of organ ‘mapping’ for mature sperm in azoospermic men. Urology 1997;49(5):743-8. http://www.ncbi.nlm.nih.gov/pubmed/9145981 1.
10
UPDATE MARCH 2007
11.
Schulze W, Rehder U. Organization and morphogenesis of the human seminiferous epithelium. Cell Tissue Res 1984;237(3):395-407. http://www.ncbi.nlm.nih.gov/pubmed/6488283 12. Kim ED, Gilbaugh JH 3rd, Patel VR, Turek PJ, Lipshultz LI. Testis biopsies frequently demonstrate sperm in men with azoospermia and significantly elevated follicle-stimulating hormone levels. J Urol 1997;157(1):144-6. http://www.ncbi.nlm.nih.gov/pubmed/8976237 13. Schoysman R, Vanderzwalmen P, Nijs M, Segal L, Segal-Bertin G, Geerts L, van Roosendaal E, Schoysman D. Pregnancy after fertilization with human testicular spermatozoa. Lancet 1993;342(8881):1237. http://www.ncbi.nlm.nih.gov/pubmed/7901551 14. Devroey P, Liu J, Nagy Z, Tournaye H, Silber SJ, Van Steirteghem AC. Normal fertilization of human oocytes after testicular sperm extraction and intracytoplasmic sperm injection. Fertil Steril 1994;62(2):639-41. http://www.ncbi.nlm.nih.gov/pubmed/8062963 15. Silber SJ, Van Steirteghem AC, Liu J, Nagy Z, Tournaye H, Devroey P. High fertilization and pregnancy rate after intracytoplasmic sperm injection with spermatozoa obtained from testicle biopsy. Hum Reprod 1995;10(1):148-52. http://www.ncbi.nlm.nih.gov/pubmed/7745045 16. Devroey P, Nagy P, Tournaye H, Liu J, Silber S, Van Steirteghem A. Outcome of intracytoplasmic sperm injection with testicular spermatozoa in obstructive and non-obstructive azoospermia. Hum Reprod 1996;11(5):1015-8. http://www.ncbi.nlm.nih.gov/pubmed/8671382 17. Zheng J, Huang X, Li C. Predictive factors for successful sperm recovery in azoospermia patients. Zhonghua Wai Ke Za Zhi 2000;38(5):366-8. [article in Chinese] http://www.ncbi.nlm.nih.gov/pubmed/11832060 18. Foresta C, Ferlin A, Rossi A, Salata E, Tessari A. [Alteration of spermatogenesis and Y chromosome microdeletions. Analysis of the DAZ gene family. ] Minerva Endocrinol. 2002;27(3): 193-207. [article in Italian] http://www.ncbi.nlm.nih.gov/pubmed/12091794 19. Hopps CV, Mielnik A, Goldstein M, Palermo GD, Rosenwaks Z, Schlegel PN. Detection of sperm in men with Y chromosome microdeletions of the AZFa, AZFb, and AZFc regions. Hum Reprod 2003;18(8):1660-5. http://www.ncbi.nlm.nih.gov/pubmed/12871878 20. Amer M, Haggar SE, Moustafa T, Abd El-Naser, Zohdy W. Testicular sperm extraction: impact to testicular histology on outcome, number of biopsies to be performed and optional time for repetition. Hum Reprod 1999;14(12):3030-4. http://www.ncbi.nlm.nih.gov/pubmed/10601092 21. Colpi GM, Piediferro G, Nerva F, Giacchetta D, Colpi EM, Piatti E. Sperm retrieval for intra-cytoplasmic sperm injection in non-obstructive azoospermia. Minerva Urol Nefrol 2005(2); 57:99-107. http://www.ncbi.nlm.nih.gov/pubmed/15951734 22. Vernaeve V, Verheyen G, Goossens A, Van Steirteghem A, Devroey P, Tournaye H. How successful is repeat testicular sperm extraction in patients with azoospermia? Hum Reprod 2006; 21(6):1551-4. http://www.ncbi.nlm.nih.gov/pubmed/16473930 23. Schlegel PN. Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision. Hum Reprod 1999:14(1):131-5. http://www.ncbi.nlm.nih.gov/pubmed/10374109 24. Okada H, Dobashi M, Yamazaki T, Hara I, Fujisawa M, Arakawa S, Kamidono S. Conventional versus microdissection testicular sperm extraction for non obstructive azoospermia. J Urol 2002;168(3): 1063-7. http://www.ncbi.nlm.nih.gov/pubmed/12187223 25. Dardashti K, Williams RH, Goldstein M. Microsurgical testis biopsy: a novel technique for retrieval of testicular tissue. J Urol 2000;163(4):1206-7. http://www.ncbi.nlm.nih.gov/pubmed/10737497 26. Shulze W, Thoms F, Knuth UA. Testicular sperm extraction: comprehensive analysis with simultaneously performed histology in 1418 biopsies from 766 subfertile men. Hum Reprod 1999;14(1):82-96. http://www.ncbi.nlm.nih.gov/pubmed/10573026
UPDATE MARCH 2007
11
27. 28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
12
Piediferro G, Contalbi GF, Nerva F, Colpi GM. Carcinoma in situ in azoospermia non-ostruttiva sfuggito alla TEFNA e diagnosticato con TESE: Case report. Arch Ital Urol Androl 2004;11:123. Shufaro Y, Prus D, Laufer N, Simon A. Impact of repeated fine needle aspiration (TEFNA) and testicular sperm extraction (TESE) on the microscopic morphology of the testis: an animal model. Hum Reprod 2002;17(7):1795-9. http://www.ncbi.nlm.nih.gov/pubmed/12093842 Monzo A, Kondylis F, Lynch D, Mayer J, Jones E, Nehchiri F, Morshedi M, Schuffner , Muasher S, Gibbons W, Oehninger S. Outcome of intracytoplasmic sperm injection in azoospermic patients: stressing the liaison between the urologist and reproductive medicine specialist. Urology 2001;58(1):69-75. http://www.ncbi.nlm.nih.gov/pubmed/11445482 Vernaeve V, Tournaye H, Osmanagaoglu K, Verheyen G, Van Steirteghem A, Devroey P. Intracytoplasmic sperm injection with testicular spermatozoa is less successful in men with nonobstructive azoospermia than in men with obstructive azoospermia. Fertil Steril 2003;79(3):529-33. http://www.ncbi.nlm.nih.gov/pubmed/12620435 Silber S, Munné S. Chromosomal abnormalities in embryos derived from testicular sperm extraction (tese) in men with non-obstructive azoospermia. Proceedings EAA International Symposium ‘Genetics of Male Infertility: from Research to Clinic’. Florence, Italy, October 2-4, 2003. Schwarzer J, Fiedler K, Hertwig I, Krusmann G, Wurfel W, Schleyer M, Muhlen B, Pickl U, LochnerErnst D. Sperm retrieval procedures and intracytoplasmatic spermatozoa injection with epididymal and testicular sperms. Urol Int 2003;70(2):119-23. http://www.ncbi.nlm.nih.gov/pubmed/12592040 Ghanem M, Bakr NI, Elgayaar MA, El Mongy S, Fathy H, Ibrahim AH. Comparison of the outcome of intracytoplasmic sperm injection in obstructive and non-obstructive azoospermia in the first cycle: a report of case series and meta-analysis. Int J Androl 2005;28(1):16-21. http://www.ncbi.nlm.nih.gov/pubmed/15679616 Borges E Jr, Rossi-Ferragut LM, Pasqualotto FF, dos Santos DR, Rocha CC, Iaconelli A Jr. Testicular sperm results in elevated miscarriage rates compared to epididymal sperm in azoospermic patients. Sao Paulo Med J 2002;120(4):122-6. http://www.ncbi.nlm.nih.gov/pubmed/12436160 Gil Salom M. [Spermatic recovery techniques for intracytoplasmic spermatozoid injection (ICSI) in male infertility. ]Arch Esp Urol 2004;57(9):1035-46. [article in Spanish] http://www.ncbi.nlm.nih.gov/pubmed/15624403 Ben-Yosef D, Yogev L, Hauser R, Yavetz H, Azem F, Yovel I, Lessing JB, Amit A. Testicular sperm retrieval and cryopreservation prior to initiating ovarian stimulation as the first line approach in patients with non-obstructive azoospermia. Hum Reprod 1999;14(7):1794-801. http://www.ncbi.nlm.nih.gov/pubmed/10402392 Gil-Salom M, Romero J, Rubio C, Ruiz A, Remohi J, Pellicer A. Intracytoplasmic sperm injection with cryopreserved testicular spermatozoa. Mol Cell Endocrinol 2000;169(1-2):15-9. http://www.ncbi.nlm.nih.gov/pubmed/11155947 Sousa M, Cremades N, Silva J, Oliveira C, Ferraz L, Teixeira da Silva J, Viana P, Barros A. Predictive value of testicular histology in secretory azoospermic subgroups and clinical outcomes after microinjection of fresh and frozen-thawed sperm and spermatids. Hum Reprod 2002;17(7):1800-10. http://www.ncbi.nlm.nih.gov/pubmed/12093843 Hauser R, Yogev L, Amit A, Yavetz H, Botchan A, Azem F, Lessing JB, Ben-Yosef D. Severe hypospermatogenesis in cases of nonobstructive azoospermia: should we use fresh or frozen testicular spermatozoa? J Androl 2005;26(6):772-8. http://www.ncbi.nlm.nih.gov/pubmed/16291973 Friedler S, Raziel A, Soffer Y, Strassburger D, Komarovsky D, Ron-El R. Intracytoplasmic injection of fresh and cryopreserved testicular spermatozoa in patients with nonobstructive azoospermia-a comparative study. Fertil Steril 1997;68(5):892-7. http://www.ncbi.nlm.nih.gov/pubmed/9389822 Ghazzawi IM, Sarraf MG, Taher MR, Khalifa FA. Comparison of the fertilizing capability of spermatozoa from ejaculates, epididymal aspirates and testicular biopsies using intracytoplasmic sperm injection. Hum Reprod 1998;13(2):348-52. http://www.ncbi.nlm.nih.gov/pubmed/9557836 Palermo GD, Schlegel PN, Hariprashad JJ, Ergun B, Mielnik A, Zaninovic N, Veeck LL, Rosenwaks Z. Fertilization and pregnancy outcome with intracytoplasmic sperm injection for azoospermic men. Hum Reprod 1999;14(3):741-8. http://www.ncbi.nlm.nih.gov/pubmed/10221707
UPDATE MARCH 2007
4. GENETIC DISORDERS IN INFERTILITY 4.1
Introduction
All urologists working in andrology must have a knowledge of genetic abnormalities in infertility so that they can provide correct advice to couples seeking fertility treatment. Men with very low sperm counts can be given a reasonable chance of paternity using in vitro fertilisation (IVF), ICSI and TESE. However, the sperm of infertile men show an increase in aneuploidy, other genetic abnormalities and DNA damage and therefore the possibility of passing genetic abnormalities to the next generation. Although there are prospects for screening of sperm (1), current routine clinical practice is based on screening peripheral blood samples.
4.2
Chromosomal abnormalities
Chromosome abnormalities can be numerical (e.g. trisomy) or structural (e.g. inversions or translocations) (2, 3). In a survey of pooled data from 11 publications including 9,766 infertile men, the incidence of chromosomal abnormalities was 5.8% (2). Of these, sex chromosome abnormalities accounted for 4.2% and autosomal abnormalities for 1.5%. For comparison, the incidence of abnormalities in pooled data from three series totalling 94,465 newborn male infants was 0.38%, of which 131 (0.14%) were sex chromosome abnormalities and 232 (0.25%) autosomal abnormalities (3). Standard karyotype analysis should be offered to all men with damaged spermatogenesis who are seeking fertility treatment by IVF/ICSI. 4.2.1 Sperm chromosomal abnormalities Using multicolour fluorescent in situ hybridisation (FISH) analysis sperm can be examined for chromosomal normality. Aneuploidy in sperm, in particular sex chromosome aneuploidy, is associated with severe damage to spermatogenesis (2, 4, 5, 7-11) and is also seen in men with translocations (6). FISH analysis of spermatozoa is a research investigation but should be used, particularly to assess spermatozoa from men with defined andrological conditions. Techniques are needed to separate populations of genetically abnormal sperm from normal sperm or to safely safe screen individual spermatozoa before IVF and ICSI. 4.2.2 Sex chromosome abnormalities (Klinefelter’s syndrome and variants [47,XXY; 46,XY; 47,XXY mosaicism]) Klinefelter’s syndrome is the most frequent sex chromosome abnormality (3). Adult men with Klinefelter’s syndrome have small firm testicles. The phenotype can vary from a normally virilised man to one with stigmata of androgen deficiency, including female hair distribution, scanty body hair and long arms and legs because of late epiphyseal closure. Leydig cell function is commonly impaired in men with Klinefelter’s syndrome (12). Testosterone levels may be normal or low, oestradiol levels normal or elevated and FSH levels increased. Libido is often normal despite low testosterone levels, but androgen replacement may be needed as the patient ages. Germ cell presence and sperm production are variable in men with Klinefelter’s mosaicism, 46,XY, 47,XXY. Preimplantation genetic diagnosis using FISH analysis of cells from embryos can be used to confirm normality (13). The production of 24,XY sperm has been reported in 0.9% and 7.0% of men with Klinefelter’s mosaicism (14-16) and in 1.36-25% of men with somatic karyotype 47,XXY (17-21). There is one case report of declining spermatogenesis in a man with Klinefelter’s syndrome, with the recommendation that early sperm retrieval sperm should be considered (22). Haploid sperm in men with Klinefelter’s syndrome may be the result of a clone of normal cells in a mosaic population, and in certain circumstances some 47,XXY male germ cells may be viable and capable of producing haploid sperm (23). Klinefelter’s syndrome patients have an increased chance of producing 47,XXY spermatozoa. When IVF/ICSI carried out, pre-implantation diagnosis or amniocentesis and karyotype analysis should undertaken. Embryos with known Klinefelter’s karyotype should probably not be implanted. Men with Klinefelter’s syndrome might require androgen replacement therapy as they get older. All men with Klinefelter’s syndrome who undergo testicular biopsy procedures for sperm retrieval need long-term endocrine follow-up. 4.2.3 Autosomal abnormalities Genetic counselling should be offered to all couples seeking fertility treatment (including IVF/ICSI) where the male partner is known, or found to have, autosomal karyotype abnormality. 4.2.4 Translocations Reciprocal balanced translocations occur in 1 in 500 people. An individual with a balanced translocation has a complete set of genetic information and a normal phenotype. However, when this individual has children,
UPDATE MARCH 2007
13
the child receives unbalanced genetic information (either too much or too little genetic material). A parental balanced translocation involving chromosome 21 is one cause of Down’s syndrome. When IVF/ICSI is carried out for men with translocations, pre-implantation genetic diagnosis or, amniocentesis and karyotype analysis should be used. Embryos with known unbalanced translocation should probably not be implanted.
4.3
Genetic defects
4.3.1 X-linked genetic disorders and male fertility Each man has only one X-chromosome. An X-linked recessive disorder manifests in males, and the defect will be transmitted to daughters but not to sons. 4.3.2 Kallmann’s syndrome The most common X-linked disorder in infertility practice is Kallmann’s syndrome. The predominant form is an X-linked recessive disorder caused by a mutation in the KALIG-1 gene on Xp22.3 (24). Rarer forms of Kallmann’s syndrome include an autosomal-dominant form (25). Patients with Kallmann’s syndrome have hypogonadotropic hypogonadism and might have other clinical features, including anosmia, facial asymmetry, cleft palate, colour blindness, deafness, maldescended testes and renal abnormalities. Some men with Kallmann’s syndrome have an isolated gonadotrophin deficiency without any other phenotypic abnormalities and might present de novo with infertility. It is often possible to stimulate spermatogenesis with replacement therapy (26). 4.3.3 Androgen insensitivity: Reifenstein’s syndrome Androgen insensitivity is a rare disorder and might first present with infertility. The condition has X-linked recessive inheritance as a result of a defect in the androgen receptor gene located on Xq 11-12. The phenotype varies widely, from complete testicular feminisation to an apparently normal man with infertility, although the latter is rare. Disorders of the androgen receptor causing infertility in the absence of any genital abnormality are rare (27), although some cases have been identified (28). 4.3.4 Other X-disorders A case has been reported of an azoospermic man with biopsy-proven spermatogenetic arrest, who was found to have a submicroscopic interstitial deletion on the Xp pseudo-autosomal region in peripheral blood and skin fibroblast samples. Other genetic and chromosome examinations were entirely normal, including probing of the Yq region (29). There is also a report about two men with azoospermia and X pseudo-autosomal deletions (30).
4.4
Y genes and male infertility
4.4.1 Introduction The first cases of Y microdeletions and male infertility were reported in 1992 (31) and many case series have subsequently been published. Microdeletions may occur in fertile men, but they are more prevalent in infertile men (32). Microdeletions have been found in three non-overlapping regions of the Y chromosome, AZF a-b-c (33). A fourth region AZFd overlaps with AZFc and is considered by some to be a separate area (34, 35). The most common microdeletion is in the AZFc region, encompassing the DAZ gene. However, there is a poor correlation between AZFc microdeletions or DAZ gene deletion and spermatogenesis; men with apparently similar microdeletions can have different degrees of damage to their spermatogenesis (32, 36). TESE can be used for men with AZFc Y microdeletions (37). AZFa and AZFb microdeletions are much rarer. If the AZFa microdeletion is large enough to remove both the USP9Y (DFFRY) and the DDX3Y (DBY) genes, azoospermia occurs (38-40). There is no recorded case of sperm recovery by micro-TESE (37). Azoospermia also occurs in men with larger AZFb Y microdeletions (37). Microdeletions are a subset of rearrangments of the long arm of the Y chromosome, others include duplications and inversions. The biological significance of these haplotypes has yet to be determined (41), but some of them might be associated with reduced fertility (42). 4.4.2 Clinical implications of Y microdeletions Men with Y microdeletions are unlikely to have phenotypic abnormalities other than abnormalities of the male reproductive system. Y microdeletions are associated with varying degrees of derangement of spermatogenesis (33, 35, 36, 39, 43). The AZFc microdeletion 51gr/51gr, which is associated with male infertility, (44) is a rare low penetrance allele that confers susceptibility to testicular germ cell tumour (TGCT) (45). This finding has implications when ICSI is used for a man with a gr/gr microdeletion. More information is needed about Y genes and Y microdeletions and diseases of the male reproductive system. There is also one report of a higher frequency of AZFc microdeletions in the husbands of women with recurrent pregnancy loss (46). Y microdeletions can be transmitted to male offspring, although this is rare in the normal population
14
UPDATE MARCH 2007
because, without ICSI treatment, men with very low sperm counts are unlikely to father children (32, 33, 47-53). In most cases, the microdeletion in the son is the same as in the father, but there have been reports that the size of the microdeletion is greater in the son (49, 53). When ICSI is used in the presence of a Y microdeletion, long-term follow up of any male children is needed with respect to their fertility status and, in the case of gr/gr microdeletions, their risk of developing germ cell tumours. 4.4.2.1 Testing for Y microdeletions Testing for microdeletions is now widespread, and methodology is being standardised (33, 54, 55). The following genes are located in the AZF regions and specifically expressed in the testis, RBMY1A1, DAZ, VCY, XKRY, CDY1, DY2, HSFY, PRY, and BPY2. Other genes, including RPS4Y2, USP9Y, DDX3Y, UTY, JARIDID, and EIF1AY, are expressed in more than one tissue. Studies are needed to correlate testis histopathology with different combinations of loss of one or more of these genes. (For complete listings of Y genes, see the NCBI web site http://www.ncbi.nlm.nih. gov). The best test is to use selected sequence tagged sites (STS) probes chosen to define the most likely microdeletions. In future, gene array analysis may replace testing for Y microdeletions. Direct testing for genes is a research procedure. 4.4.2.2 Conclusions • For men with severely damaged spermatogenesis, testing for microdeletions before intracytoplasmic sperm injection (ICSI) is desirable. However, it is reasonable to consider the cost and availability of testing and to discuss this with the couple. • If AZFa or AZFb Y microdeletions are detected, testicular sperm extraction is not worthwhile because the chance of finding sperm is extremely low. • Microdeletions will be passed to sons, but not to daughters. • A son who inherits a microdeletion will probably have a fertility problem. 4.4.3 Autosomal defects with severe phenotypic abnormalities as well as infertility Several inherited disorders are associated with severe or considerable generalised abnormalities and infertility (Table 4). Patients with these defects will be well known to doctors, often from childhood, and any fertility problem must be managed in the context of the care of the man as a whole and with consideration of the couple’s ability to care for a child. Table 4: Less common inherited disorders associated with infertility and other alterations to phenotype Disorder Phenotype Genetic basis Prader–Willi Obesity, mental retardation Deletion of 15q12 on paternally inherited chromosome Bardet–Biedle Obesity, mental retardation, Autosomal recessive retinitis pigmentosa, polydactyly 16q21 Cerebellar ataxia and Eunuchoidism, disturbances of Autosomal recessive hypogonadotropic hypogonadism gait and speech Noonan’s syndrome Short stature, webbed neck, Autosomal dominant cardiac and pulmonary abnormalities, cryptorchidism Myotonic dystrophy Muscle wasting, cataract testicular Autosomal dominant atrophy 19q13.3 Dominant polycystic Renal cysts, obstruction from Autosomal dominant kidney disease epididymal cysts 16p13.3 and 4q 5-alpha reductase deficiency Perineal or scrotal hypospadias, Autosomal recessive vaginal pouch, immature female phenotype
4.5
Cystic fibrosis mutations and male infertility
Cystic fibrosis (CF), a fatal autosomal-recessive disorder, is the most common genetic disease of Caucasians; 4% are carriers of gene mutations involving the CF transmembrane conductance regulator (CFTR) gene. This gene is located on the short arm of chromosome 7. It encodes a membrane protein that functions as an ion channel and also influences the formation of the ejaculatory duct, seminal vesicle, vas deferens and distal twothirds of the epididymis. Congenital bilateral absence of the vas deferens (CBAVD) is associated with CFTR mutations and was found in approximately 2% of men with OA attending a clinic in Edinburgh (56). The incidence in men with OA
UPDATE MARCH 2007
15
varies between different countries. The clinical diagnosis of absent vasa is easy to miss and all men with azoospermia should be very carefully examined to exclude CBAVD, particularly those with a semen volume of < 1.5 mL and pH less than 7.0. Approximately 1500 mutations are listed on the CFTR database (http://www.genet.sickkids.on.ca/ cftr/). Many series of men with CBAVD, who were tested for varying numbers of mutations, have been published. In general, the more mutations tested for, the higher the percentage of men found to have them. In a review of published series of 449 men with CBAVD, the Delta F508 mutation was detected in 244 men, the R117H mutation in 54 men and the W1282X mutation in 37; 63 other mutations were found in 1-9 men, but not all mutations were tested for in all case series (57). As more mutations are defined and tested for, almost all men with CBAVD will probably be found to have mutations. It is not practical to test for all known mutations, as many have a very low prevalence in a particular population. Testing is usually restricted to mutations that occur most commonly in a particular community. Mutations may be found in both copies of the CFTR gene; however, in most men with CBAVD, mutation is found in only one copy. In some of these supposedly heterozygous cases, there may be an unknown second mutation, but there is also another mechanism. In two-thirds of men with CBAVD a DNA variant (the 5th allele) can be detected in a non-coding region of CFTR (58). Men with CBAVD often have mild clinical stigmata of CF (e.g. history of chest infections). Children born after ICSI, where the father has CBAVD and is either hetero- or homozygous, must be followed up. When a man has CBAVD, it is important to test him and his partner for CF mutations. If the female partner is found to be a carrier of CFTR, the couple must consider very carefully whether to proceed with ICSI using the husband’s sperm, as the chance of a having a baby with CF will be 25% if the man is heterozygous and 50% if the man is homozygous. If the female partner is negative for known mutations, her chance of being a carrier of unknown mutations is about 0.4%. In these circumstances, the possibility of her heterozygous partner fathering a child with CF is approximately 1:410.
4.6
Unilateral or bilateral absence/abnormality of the vas and renal anomalies
Unilateral absence of the vas deferens is usually associated with ipsilateral absence of the kidney (59) and probably has a different genetic causation. Men with unilateral absence of the vas deferens are usually fertile, and the condition is most commonly encountered as an incidental finding in the vasectomy clinic. Nevertheless, men with unilateral absence of the vas deferens and CF mutations may have the same underlying genetic diseases as men with true CBAVD. Men with bilateral absence of vas deferens and renal abnormalities do not have CFTR abnormalities (60). Men who have unilateral absence of the vas and normal kidneys or bilateral absence or bilateral abnormality, should be tested for CF mutations. If the results are negative and renal anatomy has not been defined, an abdominal ultrasound should be undertaken. Findings may range from unilateral absence of the vas with ipsilateral absence of the kidney to bilateral vessel abnormalities and renal abnormalities, such as pelvic kidney.
4.7
Other single gene disorders
There is intense research into genes that control spermatogenesis, and in particular unique Y genes as their products may be targets for non-hormonal contraception. Many research publications discuss candidate genes for spermatogenesis, for example: • ubiquitin protease 26 gene (61, 62) • polymorphisms in the oestrogen receptor gene (63, 64) • polymorphisms of the gonadotrophin-regulated testicular helicase gene (65) • UTP14c (66) • SPAG16L (67) • BGR-like gene (68) • SPO11, EIF5A2, ACT (69) • N372H variant of the BRCA2 gene (70) • heat shock transcription factor in AZFb (71). Clinical application of these findings is limited; single gene mutations of these various genes probably account for only a small proportion of male infertility. The practicality of testing is limited by expense and availability of testing techniques; however, the advent of cheap gene array testing techniques, with the capacity to screen all or most of the known single gene defects with one test, might change the approach to testing.
4.8
Unknown genetic disorders
ICSI is used to enable men with severely damaged spermatogenesis to father children in situations formerly considered hopeless and where very few spermatozoa can be obtained. This has led to worries that children
16
UPDATE MARCH 2007
may be born with a fetal abnormality, because ICSI may enable defective sperm to bypass the selective processes of the female genital tract and egg covering. Alternatively, eggs may be fertilised that would otherwise not be fertilised. Fetal abnormality statistics from ICSI centres do not, however, indicate any increase in congenital malformations compared with the general population. Indications for ICSI are constantly being extended to include fertilisation with immature sperm forms, and it is therefore particularly important to continue to monitor fetal abnormality rates, using detailed subgroup analysis according to the clinical and molecular diagnosis of the father.
4.9
Genetic and DNA abnormalities in sperm
The DNA damage in spermatozoa from men with oligozoospermia is increased. This increase is associated with reduced chances of natural conception and, to a lesser extent, conception after IVF/ICSI (72) and with an increase in early pregnancy loss (73). DNA damage may improve after varicocele ligation (74).
4.10
Genetic counselling and ICSI
The best management is to agree treatment with the couple and provide them with complete details of the genetic risk. Initially, the couple should be given full information about the risks to the child to help them decide whether to proceed with ICSI. Where there is conflict between the wishes of the couple and the interests of the future child, it may be ethically correct to withhold therapy. When both partners are known to carry defects (e.g. CF mutations), the chance of the child developing a clinical condition and dying early after a number of years of morbidity can be up to 50%. Many clinicians and infertility clinic personnel may consider it is unethical to proceed on the basis that the duty of care to the future child and the interests of society outweigh the wishes of the individual couple. If there is a conflict that cannot be resolved by agreement, the interests of a future child probably take precedence over the interests of a couple. The couple also need to give consideration to pre-implantation diagnosis and replacement only of normal embryos.
4.11 CONCLUSIONS • •
4.12
ew insights into the genetic basis of infertility and the advent of ICSI require a good understanding N of genetics by clinicians and the general public. Diagnostic advances will allow us to identify the genetic basis of more disorders and diagnose known disorders at a lower cost. For some of these disorders, gene therapy might be practical.
RECOMMENDATIONS
Recommendations • Standard karyotype analysis should be offered to all men with damaged spermatogenesis who are seeking fertility treatment by in vitro fertilisation/intracytoplasmic sperm injection (ICSI) (2). • For men with severely damaged spermatogenesis, testing for Yq microdeletions before ICSI is desirable. • When a man has structural abnormalities of the vas deferens (congenital bilateral absence of the vas deferens [CBAVD]), it is important to test him and his partner for cystic fibrosis gene mutations (57). • Genetic counselling is mandatory in couples with a genetic abnormality found in clinical or genetic investigation and in patients who carry a (potential) inheritable disease (1). GR = grade of recommendation
4.13
GR A
B
A
REFERENCES
1.
Griffin DK, Finch KA. The genetic and cytogenetic basis of male infertility. Human Fertil 2005;8(1); 19-26. http://www.ncbi.nlm.nih.gov/pubmed/15823847 2. Johnson MD. Genetic risks of intracytoplasmic sperm injection in the treatment of male infertility: recommendations for genetic counseling and screening. Fertil Steril 1998;70(3):397-411. http://www.ncbi.nlm.nih.gov/pubmed/9757865 3. van Assche EV, Bonduelle M, Tournaye H, Joris H, Verheyen G, Devroey P, Van Steirteghem A, Liebaers I. Cytogenetics of infertile men. Hum Reprod 1996;11(Suppl 4):1-24. http://www.ncbi.nlm.nih.gov/pubmed/9147109 4. Chandley AC. Chromosomes. In: Hargreave TB (ed). Male Infertility. Berlin: Springer-Verlag, 1994, pp. 149-164.
UPDATE MARCH 2007
17
5. Clementini E, Palka C, Iezzi I, Stuppia L, Guanciali-Franchi P, Tiboni GM. Prevalence of chromosomal abnormalities in 2078 inferitle couples referred for assisted reproduction technologies. Hum Reprod 2005;20(2):437-42. http://www.ncbi.nlm.nih.gov/pubmed/15567875 6. Baccetti B, Collodel G, Marzella R, Moretti E, Piomboni P, Scapigliati G, Serafini F. Ultrastructural studies of spermatozoa from infertile males with Robertsonian translocations and 18, X, Y aneuploidies. Hum Reprod 2005;20(8):2295-300. http://www.ncbi.nlm.nih.gov/pubmed/15878922 7. Martin RH. The risk of chromosomal abnormalities following ICSI. Hum Reprod 1996;11(5):924-5. http://www.ncbi.nlm.nih.gov/pubmed/8671360 8. Gianaroli L, Magli MC, Cavallini G, Grippa A, Nadalini M, Bernardini L, Menchini Fabris GF, Voliani S, Ferraretti AP. Frequency of aneuploidy in sperm from patients with extremely severe male factor infertility. Hum Reprod 2005;20(8):2140-52. http://www.ncbi.nlm.nih.gov/pubmed/15845594 9. Pang MG, Kim YJ, Lee SH, Kim CK. The high incidence of meiotic errors increases with decreased sperm count in severe male factor infertilities. Hum Reprod 2005;20(6):1688-94. http://www.ncbi.nlm.nih.gov/pubmed/15734753 10. Machev N, Gosset P, Viville S. Chromosome abnormalities in sperm from infertile men with normal somatic karyotypes: teratozoospermia. Cytogenet Genome Res 2005;111(3-4):352-7. http://www.ncbi.nlm.nih.gov/pubmed/16192715 11. Miharu N. Chromosome abnormalities in sperm from infertile men with normal somatic karyotypes: oligozoospermia. Cytogenet Genome Res 2005;111(3-4):347-51. http://www.ncbi.nlm.nih.gov/pubmed/16192714 12. Wang C, Baker HW, Burger HG, De Kretser DM, Hudson B. Hormonal studies in men with Klinefelter’s syndrome. Clin Endocrinol (Oxf) 1975;4(4):399-411. http://www.ncbi.nlm.nih.gov/pubmed/1157343 13. Tournaye H, Staessen C, Liebaers I, Van Assche E, Devroey P, Bonduelle M, Van Steirteghem A. Testicular sperm recovery in nine 47,XXY Klinefelter patients. Hum Reprod 1996;11(8):1644-9. http://www.ncbi.nlm.nih.gov/pubmed/8921109 14. Chevret E, Rousseaux S, Monteil M, Usson Y, Cozzi J, Pelletier R, Sele B. Increased incidence of hyperhaploid 24 XY spermatozoa detected by three-colour FISH in a 46,XY/47,XXY male. Hum Genet 1996;97(2):171-5. http://www.ncbi.nlm.nih.gov/pubmed/8566948 15. Martini E, Geraedts JPM, Liebaers I, Land JA, Capitanio GL, Ramaekers FC, Hopman AH. Constitution of semen samples from XYY and XXY males as analysed by in-situ hybridization. Hum Reprod 1996;11(8):1638-43. http://www.ncbi.nlm.nih.gov/pubmed/8921108 16. Lenz P, Luetjens CM, Kamischke A, Kuhnert B, Kennerknecht I, Nieschlag E. Mosaic status in lymphocytes of infertile men with or without Klinefelter syndrome. Hum Reprod 2005;20(5):1248-55. http://www.ncbi.nlm.nih.gov/pubmed/15665007 17. Cozzi J, Chevret E, Rousseaux S, Pelletier R, Benitz V, Jalbert H, Sele B. Achievement of meiosis in XXY germ cells: study of 543 sperm karyotypes from an XY/XXY mosaic patient. Hum Genet 1994;93(1):32-4. http://www.ncbi.nlm.nih.gov/pubmed/8270252 18. Guttenbach M, Michelmann HW, Hinney B, Engel W, Schmid M. Segregation of sex chromosomes into sperm nuclei in a man with 47,XXY Klinefelter’s karyotype: a FISH analysis. Hum Genet 1997;99(4):474-7. http://www.ncbi.nlm.nih.gov/pubmed/9099836 19. Estop AM, Munne S, Cieply KM, Vandermark KK, Lamb AN, Fisch H. Meiotic products of a Klinefelter 47,XXY male as determined by sperm fluorescence in-situ hybridization analysis. Hum Reprod 1998;13(1):124-7. http://www.ncbi.nlm.nih.gov/pubmed/9512242 20. Foresta C, Galeazzi C, Bettella A, Stella M, Scandellari C. High incidence of sperm sex chromosomes aneuploidies in two patients with Klinefelter’s syndrome. J Clin Endocrinol Metab 1998;83(1):203-5. http://www.ncbi.nlm.nih.gov/pubmed/9435442 21. Hennebicq S, Pelletier R, Rousseaux S, Sèle B. Segregation of sex chromosomes in a Klinefelter patient (47,XXY). Hum Reprod (Abstract Book 1) 1999;14:66. 22. Ichioka K, Utsunomiya N, Kohei N, Ueda N, Inoue K, Terai A. Adult onset of declining spermatogenesis in a man with nonmosaic Klinefelter’s syndrome. Fertil Steril 2006;85(5):1511.e1-e2. http://www.ncbi.nlm.nih.gov/pubmed/16616747
18
UPDATE MARCH 2007
23.
Gonsalves J, Turek PJ, Schlegel PN, Hopps CV, Weier JF, Pera RA. Recombination in men with Klinefelter syndrome. Reproduction 2005;130(2):223-9. http://www.ncbi.nlm.nih.gov/pubmed/16049160 24. Franco B, Guioli S, Pragliola A, Incerti B, Bardoni B, Tonlorenzi R, Carrozzo R, Maestrini E, Pieretti M, Taillon-Miller P, et al. A gene deleted in Kallmann’s syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991;353(6344):529-36. http://www.ncbi.nlm.nih.gov/pubmed/1922361 25. Santen RJ, Paulsen CA. Hypogonadotropic eunuchoidism. I. Clinical study of the mode of inheritance. J Clin Endocrinol Metab 1973;36(1):47-54. http://www.ncbi.nlm.nih.gov/pubmed/4404632 26. Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A, Koga M, Takeyama M, Fujioka H, Takada S, Koide T, Okuyama A. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. J Urol 2005;173(6):2072-5. http://www.ncbi.nlm.nih.gov/pubmed/15879837 27. Tincello DG, Saunders PT, Hargreave TB. Preliminary investigations on androgen receptor gene mutations in infertile men. Mol Hum Reprod 1997;3(11):941-3. http://www.ncbi.nlm.nih.gov/pubmed/9433918 28. Gottlieb B, Lombroso R, Beitel LK, Trifiro MA. Molecular pathology of the androgen receptor in male (in)fertility. Reprod Biomed Online 2005;10(1):42-8. http://www.ncbi.nlm.nih.gov/pubmed/15705293 29. Gonialves J, McElreavey K, Carreiro H, et al. An azoospermic man with a submicroscopic interstitial deletion on the Xp pseudoautosomal region. Hum Reprod (Abstract Book 1)1996;11:pp. 158-159. 30. Gabriel-Robez O, Rumpler Y, Ratomponirina C, Petit C, Levilliers J, Croquette MF, Couturier J. Deletion of the pseudoautosomal region and lack of sex-chromosome pairing at pachytene in two infertile men carrying an X,Y translocation. Cytogenet Cell Genet 1990;54(1-2):38-42. http://www.ncbi.nlm.nih.gov/pubmed/2249473 31. Ma K, Sharkey, A, Kirsch S, Vogt P, Keil R, Hargreave TB, McBeath S, Chandley AC. Towards the molecular localisation of the AZF locus: mapping of microdeletions in azoospermic men within 14 subintervals of interval 6 of the human Y chromosome. Hum Mol Genet 1992;1(1):29-33. http://www.ncbi.nlm.nih.gov/pubmed/1301132 32. Pryor JL, Kent-First M, Muallem A, van Bergen AH, Nolten WE, Meisner L, Roberts KP. Microdeletions in the Y chromosome of infertile men. New Engl J Med 1997;336(8):534-9. http://www.ncbi.nlm.nih.gov/pubmed/9023089 33. Vogt P, Edelmann A, Kirsch S, Henegariu O, Hirschmann P, Kiesewetter F, Kohn FM, Schill WB, Farah S, Ramos C, Hartmann M, Hartschuh W, Meschede D, Behre HM, Castel A, Nieschlag E, Weidner W, Grone HJ, Jung A, Engel W, Haidl G. Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. Hum Mol Genet 1996;5(7):933-43. http://www.ncbi.nlm.nih.gov/pubmed/8817327 34. Muslumanoglu MH, Turgut M, Cilingir O, Can C, Ozyurek Y, Artan S. Role of the AZFd locus in spermatogenesis. Fertil Steril 2005;84(2):519-22. http://www.ncbi.nlm.nih.gov/pubmed/16084901 35. Kent-First M, Muallem A, Shultz J, Pryor J, Roberts K, Nolten W, Meisner L, Chandley A, Gouchy G, Jorgensen L, Havighurst T, Grosch J. Defining regions of the Y-chromosome responsible for male infertility and identification of a fourth AZF region (AZFd) by Y-chromosome microdeletion detection. Mol Reprod Dev 1999;53(1):27-41. http://www.ncbi.nlm.nih.gov/pubmed/10230814 36. Hsu CC, Kuo PL, Chuang L, Lin YH, Teng YN, Lin YM. Uniform deletion junctions of complete azoospermia factor region c deletion in infertile men in Taiwan. Asian J Androl 2006;8(2):205-11. http://www.ncbi.nlm.nih.gov/pubmed/16491273 37. Hopps CV, Mielnik A, Goldstein M, Palermo GD, Rosenwaks Z, Schlegel PN. Detection of sperm in men with Y chromosome microdeletions of the AZFa, AZFb and AZFc regions. Hum Reprod 2003;18(8):1660-5. http://www.ncbi.nlm.nih.gov/pubmed/12871878 38. Sargent CA, Boucher CA, Kirsch S, Brown G, Weiss B, Trundley A, Burgoyne P, Saut N, Durand C, Levy N, Terriou P, Hargreave T, Cooke H, Mitchell M, Rappold GA, Affara NA. The critical region of overlap defining the AZFa male infertility interval of proximal Yq contains three transcribed sequences. J Med Genet 1999;36(9):670-7. http://www.ncbi.nlm.nih.gov/pubmed/10507722
UPDATE MARCH 2007
19
39.
Foresta C, Moro E, Rossi A, Rossato M, Garolla A, Ferlin A. Role of the AZFa candidate genes in male infertility. J Endocrinol Invest 2000;23(10):646-51. http://www.ncbi.nlm.nih.gov/pubmed/11097428 40. Kamp C, Huellen K, Fernandes S, Sousa M, Schlegel PN, Mielnik A, Kleiman S, Yavetz H, Krause W, Kupker W, Johannisson R, Schulze W, Weidner W, Barros A, Vogt PH. High deletion frequency of the complete AZFa sequence in men with Sertoli-cell-only syndrome. Mol Hum Reprod 2001;7(10): 987-94. http://www.ncbi.nlm.nih.gov/pubmed/11574668 41. Vogt PH. AZF deletions and Y chromosomal haplogroups: history and update based on sequence. Hum Reprod Update 2005;11(4):319-36. http://www.ncbi.nlm.nih.gov/pubmed/15890785 42. Teng YN, Lin YM, Sun HF, Hsu PY, Chung CL, Kuo PL. Association of DAZL haplotypes with spermatogenic failure in infertile men. Fertil Steril 2006;86(1):129-35. http://www.ncbi.nlm.nih.gov/pubmed/16730721 43. Reijo R, Lee TY, Salo P, Alagappan R, Brown LG, Rosenberg M, Rozen S, Jaffe T, Straus D, Hovatta O et al. Diverse spermatogenic defects in humans caused by Y chromosome deletions encompassing a novel RNA-binding protein gene. Nat Genet 1995;10(4):383-93. http://www.ncbi.nlm.nih.gov/pubmed/7670487 44. Lynch M, Cram DS, Reilly A, O’Bryan MK, Baker HW, de Kretser DM, McLachlan RI. The Y chromosome gr/gr subdeletion is associated with male infertility. Mol Hum Reprod 2005;11(7):507-12. http://www.ncbi.nlm.nih.gov/pubmed/16123079 45. Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Bonaiti-Pellie C, Heidenreich A, Olah E, Geczi L, Bodrogi I, Ormiston WJ, Daly PA, Oosterhuis JW, Gillis AJ, Looijenga LH, Guilford P, Fossa SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W. Rudd M, Huddart R, Crockford GP, Forman D, Oliver DT, Einhorn L, Weber BL, Kramer J, McMaster M, Greene MH, Pike M, Cortessis V, Chen C, Schwartz SM, Bishop DT, Easton DF, Stratton MR, Rapley EA. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet 2005;77(6):1034-43. http://www.ncbi.nlm.nih.gov/pubmed/16380914 46. Dewan S, Puscheck EE, Coulam CB, Wilcox AJ, Jeyendran RS. Y-chromosome microdeletions and recurrent pregnancy loss. Fertil Steril 2006;85(2):441-5. http://www.ncbi.nlm.nih.gov/pubmed/16595224 47. Kobayashi K, Mizuno K, Hida A, Komaki R, Tomita K, Matsushita I, Namiki M, Iwamoto T, Tamura S, Minowada S, et al. PCR analysis of the Y chromosome long arm in azoospermic patients: evidence for a second locus required for spermatogenesis. Hum Mol Genet 1994;3(11):1965-7. http://www.ncbi.nlm.nih.gov/pubmed/7661932 48. Kent-First MG, Kol S, Muallem A, Blazer S, Itskovitz-Eldor J. Infertility in intracytoplasmic sperm injection-derived sons. Lancet 1996;348(9023):332. http://www.ncbi.nlm.nih.gov/pubmed/8709700 49. Stuppia L, Gatta V, Calabrese G, Guanciali Franchi P, Morizio E, Bombieri C, Mingarelli R, Sforza V, Frajese G, Tenaglia R, Palka G. A quarter of men with idiopathic oligo-azospermia display chromosomal abnormalities and microdeletions of different types in interval 6 of Yq11. Hum Genet 1998;102(5):566-70. http://www.ncbi.nlm.nih.gov/pubmed/9654206 50. Mulhall JP, Reijo R, Alagappan R, Brown L, Page D, Carson R, Oates RD. Azoospermic men with deletion of the DAZ gene cluster are capable of completing spermatogenesis: fertilization, normal embryonic development and pregnancy occur when retrieved testicular spermatozoa are used for intracytoplasmic sperm injection. Hum Reprod 1997;12(3):503-8. http://www.ncbi.nlm.nih.gov/pubmed/9130751 51. Silber SJ, Alagappan R, Brown LG, Page DC. Y chromosome deletions in azoospermic and severely oligozoospermic men undergoing intracytoplasmic sperm injection after testicular sperm extraction. Hum Reprod 1998;13(12):3332-7. http://www.ncbi.nlm.nih.gov/pubmed/9886509 52. Kamischke A, Gromoll J, Simoni M, Behre HM, Nieschlag E. Transmisson of a Y chromosomal deletion involving the deleted in azoospermia (DAZ) and chromodomain (CDYI) genes from father to son through intracytoplasmic sperm injection: case report. Hum Reprod 1999;14(9):2320-2. http://www.ncbi.nlm.nih.gov/pubmed/10469702
20
UPDATE MARCH 2007
53.
Lee SH, Ahn SY, Lee KW, Kwack K, Jun HS, Cha KY. Intracytoplasmic sperm injection may lead to vertical transmission, expansion, and de novo occurrence of Y-chromosome microdeletions in male fetuses. Fertil Steril 2006;85(5):1512-5. http://www.ncbi.nlm.nih.gov/pubmed/16566932 54. Kent-First M, Muallem A. Development of a large highly diagnostic panel of multiplexed sequence tagged sites (STSs) which cover key regions on human Yq: its application in fertile and infertile zoospermic and oligozoospermic) populations. Proceedings of the Second International Workshop on the Y Chromosome. Organized by the National Institutes of Health USA and Human genome organization, Medical Research Council, UK. Asilomar Conference Centre, Pacific Grove, California, Sept 17-20, 1995, pp. 24-25. 55. Simoni M, Nieschlag E. Molecular diagnostics of Y chromosomal microdeletions: the international quality control programme of the European Academy of Andrology. Hum Reprod (Abstract Book 1) 1999;14:92-3. 56. Donat R, McNeill AS, Fitzpatrick DR, Hargreave TB. The incidence of cystic fibrosis gene mutations in patients with congenital bilateral absence of the vas deferens in Scotland. Br J Urol 1997;79(1):74-7. http://www.ncbi.nlm.nih.gov/pubmed/9043501 57. De Braekeleer M, Ferec C. Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens. Mol Hum Reprod 1996;2(9):669-77. http://www.ncbi.nlm.nih.gov/pubmed/9239681 58. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, Romey MC, Ruiz-Romero J, Verlingue C, Claustres M et al. Mutations in cystic fibrosis gene in patients with congenital absence of the vas deferens. New Engl J Med 1995;332(22):1475-80. http://www.ncbi.nlm.nih.gov/pubmed/7739684 59. Drake MJ, Quinn FM. Absent vas deferens and ipsilateral multicystic dysplastic kidney in a child. Br J Urol 1996;77(5):756-7. http://www.ncbi.nlm.nih.gov/pubmed/8689131 60. Augarten A, Yahav Y, Kerem BS, Halle D, Laufer J, Szeinberg A, Dor J, Mashiach S, Gazit E, Madgar I. Congenital bilateral absence of the vas deferens in the absence of cystic fibrosis. Lancet 1994;344(8935):1473-4. http://www.ncbi.nlm.nih.gov/pubmed/7968122 61. Paduch DA, Mielnik A, Schlegel PN. Novel mutations in testis-specific ubiquitin protease 26 gene may cause male infertility and hypogonadism. Reprod Biomed Online (2005 Jun);10(6):747-54. http://www.ncbi.nlm.nih.gov/pubmed/15970005 62. Stouffs K, Lissens W, Tournaye H, Van Steirteghem A, Liebaers I. Possible role of USP26 in patients with severely impaired spermatogenesis. Eur J Hum Genet 2005;13(3):336-40. http://www.ncbi.nlm.nih.gov/pubmed/15562280 63. Aschim EL, Giwercman A, Stahl O, Eberhard J, Cwikiel M, Nordenskjold A, Haugen TB, Grotmol T, Giwercman YL. The RsaI polymorphism in the estrogen receptor-beta gene is associated with male infertility. J Clin Endocrinol Metab 2005;90(9):5343-8. http://www.ncbi.nlm.nih.gov/pubmed/15998774 64. Guarducci E, Nuti F, Becherini L, Rotondi M, Balercia G, Forti G, Krausz C. Estrogen receptor alpha promoter polymorphism: stronger estrogen action is coupled with lower sperm count. Hum Reprod 2006;21(4):994-1001. http://www.ncbi.nlm.nih.gov/pubmed/16396937 65. A Z, Zhang S, Yang Y, Ma Y, Lin L, Zhang W. Single nucleotide polymorphisms of the gonadotrophinregulated testicular helicase (GRTH) gene may be associated with the human spermatogenesis impairment. Hum Reprod 2006; 21(3):755-9. http://www.ncbi.nlm.nih.gov/pubmed/16293649 66. Rohozinski J, Lamb DJ, Bishop CE. UTP14c is a recently acquired retrogene associated with spermatogenesis and fertility in man. Biol Reprod 2006;74(4):644-51. http://www.ncbi.nlm.nih.gov/pubmed/16354793 67. Zhang Z, Kostetskii I, Tang W, Haig-Ladewig L, Sapiro R, Wei Z, Patel AM, Bennett J, Gerton GL, Moss SB, Radice GL, Strauss JF 3rd. Deficiency of SPAG16L causes male infertility associated with impaired sperm motility. Biol Reprod 2006;74(4):751-9. http://www.ncbi.nlm.nih.gov/pubmed/16382026 68. Zheng Y, Zhou ZM, Min X, Li JM, Sha JH. Identification and characterization of the BGR-like gene with a potential role in human testicular development/spermatogenesis. Asian J Androl 2005;7(1):21-32. http://www.ncbi.nlm.nih.gov/pubmed/15685348
UPDATE MARCH 2007
21
69. Carrell DT, De Jonge C, Lamb DJ. The genetics of male infertility: a field of study whose time is now. Arch Androl 2006;52(4):269-74. http://www.ncbi.nlm.nih.gov/pubmed/16728342 70. Zhoucun A, Zhang S, Yang Y, Ma Y, Zhang W, Lin L. The common variant N372H in BRCA2 gene may be associated with idiopathic male infertility with azoospermia or severe oligozoospermia. Eur J Obstet Gynecol Reprod Biol 2006;124(1):61-4. http://www.ncbi.nlm.nih.gov/pubmed/16257105 71. Tessari A, Salata E, Ferlin A, Bartoloni L, Slongo ML, Foresta C. Characterization of HSFY, a novel AZFb gene on the Y chromosome with a possible role in human spermatogenesis. Mol Hum Reprod 2004;10(4):253-8. http://www.ncbi.nlm.nih.gov/pubmed/14985478 72. Greco E, Romano S, Iacobelli M, Ferrero S, Baroni E, Minasi MG, Ubaldi F, Rienzi L, Tesarik J. ICSI in cases of sperm DNA damage: beneficial effect or oral antioxidant treatment. Hum Reprod 2005;20(9):2590-4. http://www.ncbi.nlm.nih.gov/pubmed/15932912 73. Zini A, Meriano J, Kader K, Jarvi K, Laskin CA, Cadesky K. Potential adverse effect of sperm DNA damage on embryo quality after ICSI. Hum Reprod 2005;20(12);3476-80. http://www.ncbi.nlm.nih.gov/pubmed/16123087 74. Zini A, Blumenfeld A, Libman J, Willlis J. Beneficial effect of microsurgical varicocelectomy on human sperm DNA integrity. Hum Reprod 2005;20(4):1018-21. http://www.ncbi.nlm.nih.gov/pubmed/15608026
5. OBSTRUCTIVE AZOOSPERMIA 5.1
Definition
OA is the absence of both spermatozoa and spermatogenetic cells in semen and post-ejaculate urine due to bilateral obstruction of the seminal ducts. OA is less common than NOA and occurs in 15-20% of men with azoospermia. Common causes of OA are summarised in Table 5. Table 5: Classification of OA on the basis of ductal obstruction due to congenital and acquired causes. Conditions Congenital • Epididymal Idiopathic epididymal obstruction obstruction Post-surgical (epididymal cysts) • Vas deferens Congenital absence of vas deferens obstruction Post-surgical (hernia, scrotal surgery) • Ejaculatory duct Prostatic cysts (Müllerian cysts) obstruction
Acquired Post-infective (epididymitis) Post-vasectomy Post-surgical (bladder neck surgery) Post-infective
Men with OA present with normal size testes and normal FSH. On examination, enlargement of the epididymis can be found. Sometimes, the vas deferens is absent due to congenital factors or previous inguinal or scrotal surgery. Obstructions in primary infertile men are often present at the epididymal level; other sites of obstruction are the ejaculatory ducts and the vas deferens. In 25% of men with a suspected obstruction, no spermatozoa are found in the epididymis during scrotal exploration, indicating an intratesticular obstruction.
5.2
Classification
5.2.1 Intratesticular obstruction Intratesticular obstruction occurs in 15% of OA (1). Congenital forms (dysjunction between rete testis and efferent ductules) are less common than acquired forms, (i.e. post-inflammatory or post-traumatic obstructions). Acquired forms are often associated with an obstruction of epididymis and vas deferens. 5.2.2 Epididymal obstruction Epididymal obstruction is the most common cause of OB, affecting 30-67% of azoospermic men with a serum FSH less than twice the upper limit of normal (1-4). Congenital epididymal obstruction usually manifests as CBAVD, which is associated with at least one mutation of the CF gene in 82% of cases (5). This form is often accompanied by absence of the distal part of
22
UPDATE MARCH 2007
the epididymis and seminal vesicle agenesis (see Section 4 Genetic disorders in infertility). Other congenital forms of obstruction (e.g. dysjunction between efferent ductules and corpus epididymis, agenesis/atresia of a short part of the epididymis) are rare. Congenital forms of epididymal obstruction include chronic sino-pulmonary infections (Young’s syndrome) (6), in which obstruction results from a mechanical blockage due to debris within the proximal epididymal lumen. Acquired forms secondary to acute (e.g. gonococcal) and subclinical (e.g. chlamydial) epididymitis are most frequent (7, 8) (see Section 11 Male accessory gland infections)Acute or chronic traumas can result in epididymal damage (9). Azoospermia caused by surgery might occur after epididymal cyst removal. Epididymal obstruction secondary to long-lasting distal obstruction must be considered when repairing seminal ducts (10). 5.2.3 Vas deferens obstruction Vas deferens obstruction is the most common cause of acquired obstruction following vasectomy for sterilisation, with possible subsequent germ cell impairment and fibrosis (11, 12). Approximately 2-6% of these men request vasectomy reversal. Of those undergoing vaso-vasostomy, 5-10% have epididymal blockage as a result of tubule rupture, making epididymo-vasostomy mandatory (see Section 10 Male contraception). Vasal obstruction may also occur after herniotomy (13). Polypropylene mesh herniorrhaphy seems to induce a fibroblastic response able to entrap, or obliterate, the vas deferens (14). The most common congenital vasal obstruction is CBAVD, often accompanied by CF. Unilateral agenesis or a partial defect is associated with contralateral seminal duct anomalies or renal agenesis in 80% and 26% of cases, respectively (15) (see Section 4 Genetic disorders in infertility). Distal vas deferens obstruction includes CBAVD and accidental injury to the vas deferens during hernia surgery (16). 5.2.4 Ejaculatory duct obstruction Ejaculatory duct obstruction is found in about 1-3% of OA (1). These obstructions can be classified as cystic or post-inflammatory. Cystic obstructions are usually congenital (i.e. Müllerian duct cyst or urogenital sinus/ejaculatory duct cysts) and are medially located in the prostate between the ejaculatory ducts. In urogenital sinus abnormalitiesone or both ejaculatory ducts empty into the cyst (17), while in Müllerian duct anomalies, ejaculatory ducts are laterally displaced and compressed by the cyst (18). Paramedian or lateral intraprostatic cysts are Wolffian in origin and seldom found in clinical practice (19). Post-inflammatory obstructions of the ejaculatory duct are usually secondary to acute, non-acute or chronic urethro-prostatitis (20). Congenital or acquired complete obstructions of the ejaculatory ducts are commonly associated with low semen volume, decreased or absent seminal fructose and acid pH. The seminal vesicles are usually dilated (anterior-posterior diameter > 15 mm) (20, 21). 5.2.5 Functional obstruction of the distal seminal ducts Functional obstruction of the distal seminal ducts might be attributed to local neuropathy (22). This abnormality is often associated with urodynamic dysfunctions because of the vasographic patterns of ampullo-vesicular atony or of ejaculatory duct hypertony. Functional obstruction of the distal seminal ducts has been seen in juvenile diabetes and polycystic kidney disease (23); however, no relevant pathology has been found in most cases. Results of semen analysis vary between azoospermia, cryptozoospermia and severe OAT syndrome.
5.3
Diagnosis
5.3.1 Clinical history Clinical history taking should follow the suggestions for investigation of infertile men (see section 2 Investigations), ask about: • haematospermia • post-ejaculatory pain • previous or present urethritis or prostatitis • obstructive or irritative urinary symptoms • previous scrotal enlargement or pain or surgery • previous inguinal herniorrhaphy or traumas • chronic sino-pulmonary infections. 5.3.2 Clinical examination Clinical examination should follow suggestions for investigation of the infertile man. The following findings indicate OA:
UPDATE MARCH 2007
23
• • • • • •
t least one testis > 15 mL volume (although a smaller testicular volume may be found in some a patients with OA and concomitant partial testicular failure) enlarged and hardened epididymis nodules in the epididymis or vas deferens absence or partial atresia of the vas signs of urethritis prostatic abnormalities.
5.3.3 Semen analysis At least two examinations must be carried out at an interval of 2-3 months, according to the WHO (see section 2 Investigations). Azoospermia means absence of spermatozoa after centrifugation at x400 magnification. Careful repeat observation of several smears after semen liquefaction is needed. If no spermatozoa are found in wet preparation, aliquots or the whole semen sample should be centrifuged (600 rpm for 15 min). The pellet must be examined for spermatozoa. A semen volume <1.5 mL and with an acid pH and low fructose level suggests ejaculatory duct obstruction or CBAVD. When semen volume is low, a search must be made for spermatozoa in urine after ejaculation, as their presence confirms an ejaculatory disorder. Absence of spermatozoa and immature germ cells in semen smears suggest complete proximal or distal seminal duct obstruction. 5.3.4 Hormone levels Serum FSH levels may be normal but do not exclude a testicular cause of azoospermia (e.g. spermatogenic arrest). FSH is normal in 40% of men with primary spermatogenic failure. Inhibin B appears has a higher predictive value for normal spermatogenesis (4). 5.3.5 Ultrasonography Scrotal ultrasound can help to find signs of obstruction (e.g dilatation of rete testis, enlarged epididymis with cystic lesions and absence of vas deferens) and to exclude signs of testicular dysgenesis (e.g. nonhomogenous testicular architecture and microcalcifications). For patients with a low seminal volume and in whom distal obstruction is suspected, transurethral ultrasound (TRUS) is essential. If possible, TRUS should be performed at high resolution and with high frequency (7 MHz) biplane transducers. Seminal vesicle enlargement (anterior-posterior diameter 15 mm) (21) and roundish, anechoic areas in the seminal vesicle (24) are TRUS anomalies more often associated with ejaculatory duct obstruction, especially when semen volume is <1.5 mL. Other known anomalies in cases of obstructive azoospermia are Müllerian duct cysts or urogenital sinus/ejaculatory duct cysts (20) and ejaculatory duct calcifications (25). Transrectal ultrasound may also be used to aspirate seminal vesicle fluid (26). Invasive diagnosis, including testicular biopsy, scrotal exploration and distal seminal duct evaluation, are indicated in patients with OA in whom an acquired obstruction of the seminal ducts is suspected. Explorative and recanalisation surgery should be carried out at the same time. 5.3.6 Testicular biopsy In selected cases, testicular biopsy may be indicated to exclude spermatogenic failure. Testicular biopsy can also be used to extract testicular spermatozoa (i.e. TESE) for cryopreservation and subsequent ICSI, when surgical recanalisation cannot be carried out or has failed. A scoring system for testicular biopsies is given in Table 6 (27). Table 6: Scoring system for testicular biopsies (Johnsen score)* Score Histological criteria 10 Full spermatogenesis 9 Slightly impaired spermatogenesis, many late spermatids, disorganized epithelium 8 Less than five spermatozoa per tubule, few late spermatids 7 No spermatozoa, no late spermatids, many early spermatids 6 No spermatozoa, no late spermatids, few early spermatids 5 No spermatozoa or spermatids, many spermatocytes 4 No spermatozoa or spermatids, few spermatocytes 3 Spermatogonia only 2 No germinal cells, Sertoli cells only 1 No seminiferous epithelium * From Johnsen, 1970 (27)
24
UPDATE MARCH 2007
5.4
Treatment
5.4.1 Intratesticular obstruction At this level seminal duct recanalisation is impossible; TESE or fine-needle aspiration is therefore recommended. The spermatozoa retrieved may be used immediately for ICSI or may be cryopreserved. Both TESE and fine-needle aspiration allow sperm retrieval in nearly all OA patients. 5.4.2 Epididymal obstruction Microsurgical epididymal sperm aspiration (28) is indicated in men with CBAVD. Retrieved spermatozoa are usually used for ICSI. Usually, one MESA procedure provides sufficient material for several ICSI cycles (29). There is limited evidence that a micropuncture with nerve stimulation may be better for sperm recovery than a simple MESA technique, as it produces higher pregnancy and fertilisation rates (30). In patients with azoospermia due to acquired epididymal obstruction, end-to-end or end-to-side microsurgical epididymovasostomy is recommended, with microsurgical intussusception epididymo-vasostomy being the preferred technique (31). Reconstruction may be carried out unilaterally or bilaterally; patency and pregnancy rates are usually higher with bilateral reconstruction. Before microsurgery, it is important to check for full patency downstream of the epididymis. Anatomical recanalisation following surgery may require 3-18 months. Before microsurgery (and in all cases where recanalisation is impossible), epididymal spermatozoa should be aspirated and cryopreserved for use in ICSI in case of surgical failure (29). Patency rates range between 60% and 87% (32-34) and cumulative pregnancy rates between 10% and 43%. Recanalisation success rates may be adversely affected by pre-operative and operative findings (e.g. concomitant abnormal testicular histology, absence of sperm in the spermatic fluid on sectioning the small epididymal tubules, wide fibrosis of the epididymis). 5.4.3 Proximal vas obstruction Proximal vas obstruction after vasectomy requires microsurgical vasectomy reversal (see section 10 Male contraception). Vaso-vasostomy is also required in the rare cases of proximal vasal obstructions (iatrogenic, post-traumatic, post-inflammatory). When spermatozoa are absent in the intraoperative vas fluid, a secondary epididymal obstruction may be present, especially if the seminal fluid of the proximal vas has a thick ‘toothpaste’ appearance. Microsurgical vaso-epididymostomy is indicated. 5.4.4 Distal vas deferens obstruction It is usually impossible to correct, large bilateral vas defects resulting from involuntary vas excision during hernia surgery in early childhood or previous orchidopexy (16). In these cases, proximal vas deferens sperm aspiration (35) or TESE/MESA can be used for cryopreservation for future ICSI. In large mono-lateral vas defects associated with contralateral testicular atrophy, the vas of the atrophic testis can be used for a crossover vaso-vasostomy or vaso-epididymostomy. 5.4.5 Ejaculatory duct obstruction Treatment of ejaculatory duct obstruction depends on the aetiology. In large post-inflammatory obstruction and when one or both ejaculatory ducts empty into an intraprostatic midline cyst, transurethral resection of the ejaculatory ducts (TURED) (20, 36) can be used. Resection may remove part of the verumontanum. In cases of obstruction due to a midline intraprostatic cyst, incision or unroofing of the cyst is required (20). Intraoperative TRUS makes this procedure safer. If distal seminal tract evaluation is carried out at the time of the procedure, installation of methylene blue dye into the vas can help to document opening of the ducts. Complications following TURED include retrograde ejaculation due to bladder neck injury, and reflux of urine into ducts, seminal vesicles and vasa (causing poor sperm motility, acid semen pH and epididymitis). Alternatives to TURED are MESA, TESE, proximal vas deferens sperm aspiration, seminal vesicle ultrasonically guided aspiration and direct cyst aspiration. In cases of functional obstruction of the distal seminal ducts, TURED often fails to improve sperm output. Spermatozoa can then be retrieved by antegrade seminal tract washout (36). Spermatozoa retrieved by any of the aforementioned surgical techniques should always be cryopreserved for assisted reproductive procedures.
5.5
CONCLUSIONS
•
Obstructive lesions of the seminal tract should be suspected in azoospermic or severely oligozoospermic patients with normal-sized testes and normal endocrine parameters. Results of reconstructive microsurgery depend on the cause and location of the obstruction and the expertise of the surgeon. Standardised procedures include vaso-vasostomy and epididymovasostomy. Sperm retrieval techniques such as MESA, TESE and testicular fine-needle aspiration can be used
•
•
UPDATE MARCH 2007
25
additionally. These methods should be used only when cryostorage of the material obtained is available.
5.6
RECOMMENDATIONS
Recommendation • In azoospermia caused by epididymal obstruction, a scrotal exploration with microsurgical epididymal sperm aspiration and cryopreservation of the spermatozoa should be carried out together with a microsurgical reconstruction (37) GR=grade of recommendation
5.7
GR B
REFERENCES
Hendry WF. Azoospermia and surgery for testicular obstruction. In: Hargreave TB (ed). Male Infertility. Berlin: Springer-Verlag, 1997, pp. 319-336. 2. Hendry WF, Parslow JM, Stedronska J. Exploratory scrototomy in 168 azoospermic males. Br J Urol 1983;55(6):785-91. http://www.ncbi.nlm.nih.gov/pubmed/6652453 3. Jequier AM. Obstructive azoospermia: a study of 102 patients. Clin Reprod Fertil 1985;3(1):21-36. http://www.ncbi.nlm.nih.gov/pubmed/3978535 4. Pierik FH, Vreeburg JT, Stijnen T, De Jong FH, Weber RF. Serum inhibin B as a marker of spermatogenesis. J Clin Endocrinol Metab 1998;83(9):3110-4. http://www.ncbi.nlm.nih.gov/pubmed/9745412 5. Oates RD, Amos JA. The genetic basis of congenital bilateral absence of the vas deferens and cystic fibrosis. J Androl 1994;15(1):1-8. http://www.ncbi.nlm.nih.gov/pubmed/8188533 6. Handelsman DJ, Conway AJ, Boylan LM, Turtle JR. Young’s syndrome: obstructive azoospermia and chronic sinopulmonary infections. New Engl J Med 1984;310(1):3-9. http://www.ncbi.nlm.nih.gov/pubmed/6689737 7. Silber SJ, Grotjan HE. Microscopic vasectomy reversal 30 years later: a summary of 4010 cases by the same surgeon. J Androl 2004;25(6):845-59. http://www.ncbi.nlm.nih.gov/pubmed/15477352 8. Schoysman R. Vaso-epididymostomy - a survey of techniques and results with considerations of delay of appearance of spermatozoa after surgery. Acta Eur Fertil 1990;21(5):239-45. http://www.ncbi.nlm.nih.gov/pubmed/2132475 9. Matthews GJ, Schlegel PN, Goldstein M. Patency following microsurgical vasoepididymostomy and vasovasostomy: temporal considerations. J Urol 1995;154(6):2070-3. http://www.ncbi.nlm.nih.gov/pubmed/7500460 10. Jarvi K, Zini A, Buckspan MB, Asch M, Ginzburg B, Margolis M. Adverse effects on vasoepididymostomy outcomes for men with concomitant abnormalities in the prostate and seminal vesicle. J Urol 1998;160(4):1410-2. http://www.ncbi.nlm.nih.gov/pubmed/9751365 11. Raleigh D, O’Donnell L, Southwick GJ, de Kretser DM, McLachlan RI. Stereological analysis of the human testis after vasectomy indicates impairment of spermatogenic efficiency with increasing obstructive interval. Fertil Steril 2004;81(6):1595-603. http://www.ncbi.nlm.nih.gov/pubmed/15193483 12. McVicar CM, O’Neill DA, McClure N, Clements B, McCullough S, Lewis SEM. Effects of vasectomy on spermatogenesis and fertility outcome after testicular sperm extraction combined with ICSI. Hum Reprod 2005;20(10): 2795-800. http://www.ncbi.nlm.nih.gov/pubmed/15958397 13. Sheynkin YR, Hendin BN, Schlegel PN, Goldstein M. Microsurgical repair of iatrogenic injury to the vas deferens. J Urol 1998;159(1):139-41. http://www.ncbi.nlm.nih.gov/pubmed/9400456 14. Shin D, Lipshultz LI, Goldstein M, Barme GA, Fuchs EF, Nagler HM, McCallum SW, Niederberger CS, Schoor RA, Brugh VM 3rd, Honig SC. Herniorrhaphy with polypropylene mesh causing inguinal vassal obstruction: a preventable cause of obstructive azoospermia. Ann Surg 2005;241(4):553-8. http://www.ncbi.nlm.nih.gov/pubmed/15798455 1.
26
UPDATE MARCH 2007
15.
Schlegel PN, Shin D, Goldstein M. Urogenital anomalies in men with congenital absence of the vas deferens. J Urol 1996;155(5):1644-8. http://www.ncbi.nlm.nih.gov/pubmed/8627844 16. Borovikov A. Treatment of large vasal defects. In: Goldstein M (ed). Surgery of Male Infertility. Philadelphia: WB Saunders, 1995, pp. 77-95. 17. Elder JS, Mostwin JL. Cyst of the ejaculatory duct/urogenital sinus. J Urol 1984;132(4):768-71. http://www.ncbi.nlm.nih.gov/pubmed/6471229 18. Schuhrke TD, Kaplan GW. Prostatic utricle cysts (Mullerian duct cysts). J Urol 1978;119(6):765-7. http://www.ncbi.nlm.nih.gov/pubmed/26814 19. Surya BV, Washecka R, Glasser J, Johanson KE. Cysts of the seminal vesicles: diagnosis and management. Br J Urol 1988;62(5):491-3. http://www.ncbi.nlm.nih.gov/pubmed/3208033 20. Schroeder-Printzen I, Ludwig M, Kohn F, Weidner W. Surgical therapy in infertile men with ejaculatory duct obstruction: technique and outcome of a standardized surgical approach. Hum Reprod 2000;15(6):1364-8. http://www.ncbi.nlm.nih.gov/pubmed/10831570 21. Kuligowska E, Baker CE, Oates RD. Male infertility: role of transrectal US in diagnosis and management. Radiology 1992;185(2):353-60. http://www.ncbi.nlm.nih.gov/pubmed/1410338 22. Colpi GM, Casella F, Zanollo A, Ballerini G, Balerna M, Campana A, Lange A. Functional voiding disturbances of the ampullo-vesicular seminal tract: a cause of male infertility. Acta Eur Fertil 1987;18(3):165-79. http://www.ncbi.nlm.nih.gov/pubmed/3125711 23. Hendry WF, Rickards D, Pryor JP, Baker LR. Seminal megavesicles with adult polycystic kidney disease. Hum Reprod 1998;13(6):1567-9. http://www.ncbi.nlm.nih.gov/pubmed/9688393 24. Colpi GM, Negri L, Nappi RE, Chinea B. Is transrectal ultrasonography a reliable diagnostic approach in ejaculatory duct sub-obstruction? Hum Reprod 1997;12(10):2186-91. http://www.ncbi.nlm.nih.gov/pubmed/9402280 25. Meacham RB, Hellerstein DK, Lipshultz LI. Evaluation and treatment of ejaculatory duct obstruction in the infertile male. Fertil Steril 1993;59(2):393-7. http://www.ncbi.nlm.nih.gov/pubmed/8425637 26. Jarow JP. Seminal vesicle aspiration of fertile men. J Urol 1996;156(3):1005-7. http://www.ncbi.nlm.nih.gov/pubmed/8709296 27. Johnsen SG. Testicular biopsy score count–a method for registration of spermatogenesis in human testes: normal values and results in 335 hypogonadal males. Hormones 1970;1(1):2-25. http://www.ncbi.nlm.nih.gov/pubmed/5527187 28. Silber SJ, Balmaceda J, Borrero C, Ord T, Asch R. Pregnancy with sperm aspiration from the proximal head of the epididymis: a new treatment for congenital absence of the vas deferens. Fertil Steril 1988;50(3):525-8. http://www.ncbi.nlm.nih.gov/pubmed/3410105 29. Schroeder-Printzen I, Zumbe G, Bispink L, Palm S, Schneider U, Engelmann U, Weidner W. Microsurgical epididymal sperm aspiration: aspirate analysis and straws available after cryopreservation in patients with non-reconstructable obstructive azoospermia. MESA/TESE Group Giessen. Hum Reprod 2000;15(12):2531-5. http://www.ncbi.nlm.nih.gov/pubmed/11098022 30. Van Peperstraten A, Proctor ML, Johnson NP, Philipson G. Techniques for surgical retrieval of sperm prior to ICSI for azoospermia. Cochrane Database Syst Rev 2006 Jul 19;3:CD002807. DOI: 10.1002/14651858.CD002807.pub2. Date of Most Recent Substantive Amendment: 16 May 2006. http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002807/frame.html 31. Chan PT, Brandell RA, Goldstein M. Prospective analysis of outcomes after microsurgical intussusception vasoepididymostomy. BJU Int 2005;96(4):598-601. http://www.ncbi.nlm.nih.gov/pubmed/16104917 32. Matthews GJ, Schlegel PN, Goldstein M. Patency following microsurgical vasoepididymostomy and vasovasostomy: temporal consideration. J Urol 1995;154(6):2070-3. http://www.ncbi.nlm.nih.gov/pubmed/7500460 33. Jarow JP, Oates RD, Buch JP, Shaban SF, Sigman M. Effect of level of anastomosis and quality of intraepididymal sperm on the outcome of end-to-sid epididymovasostomy. Urology 1997;49(4):590-5. http://www.ncbi.nlm.nih.gov/pubmed/9111630
UPDATE MARCH 2007
27
34.
Kim ED, Winkel E, Orejuela F, Lipshultz LI. Pathological epididymal obstruction unrelated to vasectomy: results with microsurgical reconstruction. J Urol 1998;160(6 Pt 1):2078-80. http://www.ncbi.nlm.nih.gov/pubmed/9817328 35. Ruiz-Romero J, Sarquella J, Pomerol JM. A new device for microsurgical sperm aspiration. Andrologia 1994;26(2):119-20. http://www.ncbi.nlm.nih.gov/pubmed/8042769 36. Colpi GM, Negri L, Patrizio P, Pardi G. Fertility restoration by seminal tract washout in ejaculatory duct obstruction. J Urol 1995;153(6):1948-50. http://www.ncbi.nlm.nih.gov/pubmed/7752365 37. Kolettis PN, Thomas AJ Jr. Vasoepididymostomy for vasectomy reversal: a critical assessment in the era of intracytoplasmic sperm injection. J Urol 1997;158(2):467-70. http://www.ncbi.nlm.nih.gov/pubmed/9224325
6. VARICOCELE 6.1
Introduction
Varicocele is a common abnormality (see section 2 Investigations) with the following andrological implications: • Failure of ipsilateral testicular growth and development • Symptoms of pain and discomfort • Infertility.
6.2
Classification
The following classification of varicocele (1, 2) is useful in clinical practice. • Subclinical: Not palpable or visible at rest or during Valsalva manoeuvre, but demonstrable by special tests (reflux found upon Doppler examination) (3) • Grade 1: Palpable during Valsalva manoeuvre but not otherwise • Grade 2: Palpable at rest, but not visible • Grade 3: Visible and palpable at rest.
6.3
Diagnosis
The diagnosis of varicocele has been defined by the WHO (2). Diagnostic procedure and classification of a varicocele, including analysis, must follow these accepted criteria (2). The diagnosis of varicocele is made by clinical examination and can be confirmed by colour Doppler analysis. In centres where treatment is carried out by antegrade or retrograde sclerotherapy or embolisation, diagnosis is additionally confirmed by X-ray.
6.4
Basic considerations
Various studies have been conducted on the epidemiology of varicocele, its association with male infertility and whether treatment is beneficial. • Varicocele is a physical abnormality present in 11% of adult males (4, 5) and in 25% of those with abnormal semen analysis (6). • The incidence of pain and discomfort associated with varicocele is 2-10% (7). • The exact association between reduced male fertility and varicocele is not known, but WHO data (8) clearly indicates that varicocele is related to semen abnormalities, decreased testicular volume and decline in Leydig cell function. • Two prospective randomised studies showed increased ipsi- and contra-lateral testis growth in adolescents who had received varicocele treatment compared with those who did not (9, 10). A cohort follow-up study, which took serial measurements of testicular size in children, showed that varicocele halted testicular development. However, following treatment for varicocele, catch-up growth occurred and reached the expected growth percentile (11). • A series of studies suggested that altered endocrine profiles in men with varicocele might predict who would benefit from treatment (12, 13). • Five prospective randomised studies of varicocele treatment in adults gave conflicting results (6, 14-18); the largest study indicated that treatment was beneficial (16, 18). The externally randomised study involved 10 centres and included men of infertile couples who had moderate oligozoospermia (5-20 x 106/mL) and grade II or III varicocele. Immediate therapy was significantly more effective than delaying treatment for 1 year with regard to achieving pregnancy and the pregnancy rate per
28
UPDATE MARCH 2007
menstrual cycle (fecundability). However, a meta-analysis of the five trials indicated no benefit (common odds ratio 0.85%; 95% confidence interval: 0.49-1.45) (19). The studies mentioned above were summarised in a recent review (20), criticising the Cochrane meta-analysis of randomised controlled trials on varicocele treatment and pregnancies (21). The authors concluded that the Cochrane meta-analysis conclusions should not support guidelines recommendation against varicocele treatment in subfertile patients. In a randomised controlled study varicocele repair in men with a subclinical varicocele was found to be ineffective (22). A recent meta-analysis excluding men with subclinical varicoceles and studies that included embolisation for treatment showed a benefit in favour of surgical treatment with an odds ratio of 2.87 (95 % CI, 1.33-6.2) for inducing pregnancy (23).
6.5
Treatment
Several treatments are available for varicocele (Table 7). The type of intervention chosen depends mainly on the therapist’s experience. Although laparoscopic varicocelectomy is feasible, it must be justified in terms of cost effectiveness. Table 7: Recurrence and complication rates of different treatment methods for varicocele Treatment Recurrence/persistence rates • Antegrade 9% sclerotherapy • Retrograde Recurrence and persistence sclerotherapy rate 9.8% (25) • Retrograde 3.8-10% (27,28) embolisation Open operation • Scrotal – operation • Inguinal 13.3% (30) approach • High ligation 29% (30) • Microsurgical 0.8-4% (32,33) • Laparoscopy 3-7% (34-36)
Complications Complication rate 0.3-2.2%; testicular atrophy; scrotal haematoma; epididymitis; left-flank erythema Adverse reaction to the contrast medium; flank pain; persistent thrombophlebitis; vascular perforation (26) Pain due to thrombophlebitis (28); bleeding haematoma; infection; venous perforation; hydrocele; radiological complication, e.g. reaction to contrast media; misplacement or migration of coils (29); retroperitoneal haemorrhage; fibrosis; ureteric obstruction (5) Testicular atrophy (5); arterial damage with risk of devascularization and gangrene of testicle Possibility of missing out a branch of testicular vein 5-10% incidence of hydrocele (31) Post-operative hydrocele arterial injury; scrotal haematoma Injury to testicular artery and lymph vessels; intestinal, vascular and nerve damage; pulmonary embolism; peritonitis (36); bleeding; post-operative pain in right shoulder (due to diaphragmatic stretching during pneumo-peritoneum) (35); pneumoscrotum; wound infection (36)
6.6
CONCLUSIONS
•
Current information supports the hypothesis that in some men, the presence of varicocele is associated with progressive testicular damage from adolescence onwards and consequent reduction in fertility. However, in infertile couples this impaired fertility potential will only manifest if female fertility is also reduced. Although treatment of varicocele in adolescents may be effective, there is a significant risk of overtreatment Varicocele repair may be effective in men with subnormal semen analysis, a clinical varicocele and a partner without obvious fertility problems. Further studies are needed to confirm that this subgroup of infertile couples will benefit from treatment.
• •
UPDATE MARCH 2007
29
6.7
RECOMMENDATIONS
Recommendations GR • Varicocele treatment is recommended for adolescents who have progressive failure B of testicular development documented by serial clinical examination (9, 10). • No evidence indicates benefit from varicocele treatment in adolescents who have B normal semen analysis or in men with subclinical varicocele. In this situation, varicocele treatment cannot be recommended. (14,20) • Although varicocele treatment may be effective in selected couples, reviews of randomised clinical trials have raised doubts about the benefit of varicocele treatment in infertile men. B Varicocele treatment for infertility should not be undertaken, unless there has been full discussion with the infertile couple regarding the uncertainties of treatment benefit (19, 22, 23) GR = grade of recommendation
6.8
REFERENCES
1.
Hudson RW, Perez Marrero RA, Crawford VA, McKay DE. Hormonal parameters in incidental varicoceles and those causing infertility. Fertil Steril 1986;45(5):692-700. http://www.ncbi.nlm.nih.gov/pubmed/3084304 2. World Health Organization. WHO Manual for the Standardized Investigation, Diagnosis and Management of the Infertile Male. Cambridge: Cambridge University Press, 2000. 3. Dhabuwala CB, Hamid S, Moghissi KS. Clinical versus subclinical varicocele: improvement in fertility after varicocelectomy. Fertil Steril 1992;57(4):854-7. http://www.ncbi.nlm.nih.gov/pubmed/1555699 4. Pfeiffer D, Berger J, Schoop C, Tauber R. A Doppler-based study on the prevalence of varicocele in German children and adolescents. Andrologia 2006;38(1):13-9. http://www.ncbi.nlm.nih.gov/pubmed/16420237 5. Hargreave TB. Varicocele. In: Hargreave, TB (ed). Male Infertility. Berlin: Springer-Verlag, 1994. 6. Nieschlag E, Hertle L, Fischedick A, Behre HM. Treatment of varicocele: counselling as effective as occlusion of the vena spermatica. Hum Reprod 1995;10(2):347-53. http://www.ncbi.nlm.nih.gov/pubmed/7769060 7. Peterson AC, Lance RS, Ruiz HE. Outcomes of varicocele ligation done for pain. J Urol 1998;159(5):1565-7. http://www.ncbi.nlm.nih.gov/pubmed/9554356 8. [No authors listed.] The influence of varicocele on parameters of fertility in a large group of men presenting to infertility clinics. World Health Organization. Fertil Steril 1992;57(6):1289-93. http://www.ncbi.nlm.nih.gov/pubmed/1601152 9. Laven JS, Haans LC, Mali WP, te Velde ER, Wensing CJ, Eimers JM. Effects of varicocele treatment in adolescents: a randomized study. Fertil Steril 1992;58(4):756-62. http://www.ncbi.nlm.nih.gov/pubmed/1426322 10. Paduch DA, Niedzielski J. Repair versus observation in adolescent varicocele: a prospective study. J Urol 1997;158(3 Pt 2):1128-32. http://www.ncbi.nlm.nih.gov/pubmed/9258155 11. Butler GE, Ratcliffe SG. Serono symposia reviews. Serono Symposia Reviews 1984 (Suppl 1):244. 12. Hudson RW. Free sex steroid and sex hormone-binding globulin levels in oligozoospermic men with varicoceles. Fertil Steril 1996;66(2):299-304. http://www.ncbi.nlm.nih.gov/pubmed/8690120 13. Kass EJ. Pediatric varicocele. In: O’Donnell B, Koff SA (eds). Pediatric Urology. Oxford: Butterworth Heinemann, 1996, pp. 608-617. 14. Nilsson S, Edvinsson A, Nilsson B. Improvement of semen and pregnancy rate after ligation and division of the internal spermatic vein: fact or fiction? Br J Urol 1979;51(6):591-6. http://www.ncbi.nlm.nih.gov/pubmed/534846 15. Breznik R, Vlaisavljevic V, Borko E. Treatment of varicocele and male fertility. Arch Androl 1993;30(3):157-60. http://www.ncbi.nlm.nih.gov/pubmed/8498867 16. Madgar I, Weissenberg R, Lunenfeld B, Karasik A, Goldwasser B. Controlled trial of high spermatic vein ligation for varicocele in infertile men. Fertil Steril 1995;63(1):120-4. http://www.ncbi.nlm.nih.gov/pubmed/7805900
30
UPDATE MARCH 2007
17. Nieschlag E, Hertle L, Fischedick A, Abshagen K, Behre HM. Update on treatment of varicocele: counselling as effective as occlusion of the vena spermatica. Hum Reprod 1998;13(8):2147-50. http://www.ncbi.nlm.nih.gov/pubmed/9756286 18. Hargreave TB. Varicocele: overview and commentary on the results of the WHO varicocele trial. Waites GM, Frick J, Baker GW (eds). Current Advances in Andrology. Proceedings of the VIth International Congress of Andrology, Salzburg, Austria. Bologna: Monduzzi Editore, 1997, pp. 31-44. 19. Evers JL, Collins JA. Assessment of efficacy of varicocele repair for male subfertility: a systematic review. Lancet 2003;361(9372):1849-52. http://www.ncbi.nlm.nih.gov/pubmed/12788571 20. Ficarra V, Cerruto MA, Liguori G, Mazzoni G, Minucci S, Tracia A, Gentile V. Treatment of varicocele in subfertile men: The Cochrane review - a contrary opinion. Eur Urol 2006;49(2):258-63. http://www.ncbi.nlm.nih.gov/pubmed/16426727 21. Evers JL, Collins JA. Surgery or embolisation for varicocele in subfertile men. Cochrane Database Syst Rev 2004;(3):CD000479. http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000479/frame.html 22. Yamamoto M, Hibi H, Hirata Y, Miyake K, Ishigaki T. Effect of varicocelectomy on sperm parameters and pregnancy rates in patients with subclinical varicocele: a randomized prospective controlled study. J Urol 1996;155(5):1636-8. http://www.ncbi.nlm.nih.gov/pubmed/8627841 23. Marmar JL, Agarwal A, Prabakaran S, Argawal R, Short RA, Benoff S, Thomas AJ Jr. Reassessing the value of varicocelectomy as a treatment for male subfertility with a new meta-analysis. Fertil Steril 2007:88(3):639-48. http://www.ncbi.nlm.nih.gov/pubmed/17434508 24. World Health Organization. Towards more objectivity in diagnosis and management of male fertility. Results of a World Health Organization multicentre study. Int J Androl 1987;(Suppl 7). 25. Sigmund G, Bahren W, Gall H, Lenz M, Thon W. Idiopathic varicoceles: feasibility of percutaneous sclerotherapy. Radiology 1987;164(1):161-8. http://www.ncbi.nlm.nih.gov/pubmed/3588899 26. Seyferth W, Jecht E, Zeitler E. Percutaneous sclerotherapy of varicocele. Radiology 1981;139(2):33540. http://www.ncbi.nlm.nih.gov/pubmed/7220877 27. Lenk S, Fahlenkamp D, Gliech V, Lindeke A. Comparison of different methods of treating varicocele. J Androl 1994;15(Suppl):34S-37S. http://www.ncbi.nlm.nih.gov/pubmed/7721674 28. Feneley MR, Pal MK, Nockler IB, Hendry WF. Retrograde embolisation and causes of failure in the primary treatment of varicocele. Br J Urol 1997;80(4):642-6. http://www.ncbi.nlm.nih.gov/pubmed/9352706 29. Lenz M, Hof N, Kersting-Sommerhoff B, Bautz W. Anatomic variants of the spermatic vein: importance for percutaneous sclerotherapy of idiopathic varicocele. Radiology 1996;198(2):425-31. http://www.ncbi.nlm.nih.gov/pubmed/8596844 30. Bassi R, Radice F, Bergami G, De Grazia F, Papa B. [Surgical treatment of varicocele. Our experience in the last 10 years.] Minerva Chir 1996;51(7-8):533-6. [article in Italian] http://www.ncbi.nlm.nih.gov/pubmed/8975158 31. Wallijn E, Desmet R. Hydrocele: a frequently overlooked complication after high ligation of the spermatic vein for varicocele. Int J Androl 1978;1:411-5. 32. Goldstein M, Kim FY, Mathews GJ. Mini-incision microsurgical subinguinal varicocelectomy with delivery of the testis. J Urol 1996;155 (Suppl) abstr videotape:305A. 33. Goldstein M. Varicocelectomy: general considerations. In: Goldstein M (ed). Surgery of Male Infertility. Philadelphia, USA, WB Saunders, 1995, pp. 169-172. 34. McDougall E. Minimally invasive therapy. J Urol 1995;153(3 Pt 1):712-3. http://www.ncbi.nlm.nih.gov/pubmed/7861516 35. Miersch WD, Schoeneich G, Winter P, Buszello H. Laparoscopic varicocelectomy: indication, technique and surgical results. Br J Urol 1995;76(5):636-8. http://www.ncbi.nlm.nih.gov/pubmed/8535687 36. Tan SM, Ng FC, Ravintharan T, Lim PH, Chng HC. Laparoscopic varicocelectomy: technique and results. Br J Urol 1995;75(4):523-8. http://www.ncbi.nlm.nih.gov/pubmed/7788264
UPDATE MARCH 2007
31
7. HYPOGONADISM 7.1
Introduction
Hypogonadism is deficient androgen secretion. The symptoms of hypogonadism depend on the degree of androgen deficiency and whether the condition develops before or after pubertal development of the secondary sex characteristics. The symptoms and signs of hypogonadism debuting before and after completion of puberty are given in Table 8. Table 8: The symptoms and signs of hypogonadism debuting before and after completion of puberty Affected organ/function Before completed puberty • Larynx No voice mutation • Hair Horizontal pubic hairline Straight frontal hairline Diminished beard growth • Skin Absent sebum production Lack of acne Pallor Skin wrinkling • Bones Eunuchoid tall stature Osteoporosis • Bone marrow Low-level anaemia • Muscles Underdeveloped • Prostate Underdeveloped • Penis Infantile • Testes Possibly maldescended testes Small volume • Spermatogenesis Not initiated • Libido and potency Not developed
After completed puberty No voice mutation Diminished secondary body hair
Decreased sebum production Lack of acne Pallor Skin wrinkling Osteoporosis Low-level anaemia Atrophy Atrophy No change of size Decrease of testicular volume Involuted Loss
The aetiological and pathogenetic mechanisms of male hypogonadism can be divided into three main categories: 1. Primary (hypergonadotropic) hypogonadism due to testicular failure 2. Secondary (hypogonadotropic) hypogonadism caused by insufficient gonadotrophin-releasing hormone (GnRH) and/or gonadotrophin secretion 3. Androgen insensitivity (end-organ resistance). The most common conditions within these three categories are given in Table 9. Table 9: Disorders with male hypogonadism* Primary (hypergonadotropic) hypogonadism (= testicular insufficiency) • Anorchia • Congenital factors (testicular dysgenesis) • Acquired factors (trauma, testicular torsion, tumour, surgery) • Maldescended testes • Klinefelter’s syndrome** • Other chromosomic abnormalities • Germ cell aplasia • Complete and focal germ cell aplasia (Sertoli cell-only syndrome), either congenital or acquired: maldescended testes, irradiation, cytostatic drugs • Spermatogenic arrest • Post-inflammatory (orchitis) • Exogenous factors (medications, toxins, irradiation, heat) • Systemic diseases (liver cirrhosis, renal failure) • Testicular tumour • Varicocele • Surgeries that can damage vascularisation of the testes • Idiopathic
32
UPDATE MARCH 2007
Secondary (hypothalamic or pituitary origin) (hypogonadotropic state with secondary hypogonadism) • Idiopathic hypogonadotropic hypogonadism (including Kallmann’s syndrome) • Delay of puberty • Hyperprolactinaemia • Drugs/anabolic steroids Target organ resistance to androgens • Testicular feminization • Reifenstein’s syndrome * Modified from Nieschlag et al. (1998) (1). ** See Section 4 Genetic disorders in infertility.
7.2
Hypogonadotropic hypogonadism: aetiology, diagnosis and therapeutic management
Primary hypogonadotropic hypogonadism is caused by either hypothalamic or pituitary diseases. The failure of hormonal regulation can easily be determined (2). Endocrine deficiency leads to a lack of spermatogenesis and testosterone secretion as a result of decreased secretion of luteinising hormone (LH) and FSH. The therapy of choice depends on whether the goal is to achieve normal androgen levels or to achieve fertility. Normal androgen levels and subsequent development of secondary sex characteristics (in cases of onset of hypogonadism before puberty) and eugonadal state can be achieved by androgen replacement alone. However, stimulation of sperm production requires treatment with human chorionic gonadotrophin (hCG) combined with recombinant FSH. In the rare cases of ‘fertile eunuchs’ having sufficient production of FSH but not LH, treatment with hCG alone may be sufficient to stimulate sperm production and to achieve normal testosterone levels (3). If hypogonadotropic hypogonadism is hypothalamic in origin, an alternative to hCG treatment is therapy with pulsatile GnRH (4). In patients who have developed hypogonadism before puberty and have not been treated with gonadotropins or GnRH, 1-2 years of therapy may be needed to achieve sperm production. Once pregnancy has been established patients can return to testosterone substitution. Secondary hypogonadotropic hypogonadism can be caused by some drugs, hormones and anabolic steroids.
7.3
Hypergonadotropic hypogonadism: aetiology, diagnosis and therapeutic management
Common conditions associated in men with hypergonadotropic hypogonadisminclude injury to, and loss of, the testicles (e.g. after bilateral testicular cancer) (Table 9). Men with Klinefelter’s syndrome are at risk of hypogonadism (5) with ageing. Men with infertility problems are at higher risk for developing hypogonadism (6). Men undergoing extensive testicular biopsy in the context of IVF/ICSI will almost certainly have an increased risk of developing hypogonadism (7). Hypergonadotropic hypogonadism may occur spontaneously in the ageing men, in patients with erectile dysfunction (8), and after luteinising hormone-releasing hormone (LHRH) treatment or surgical castration for prostatic cancer (9). Hypogonadism may result in osteoporosis (10). Laboratory diagnosis of hypergonadotropic hypogonadism is based on decreased serum testosterone and increased LH levels (2). Testosterone levels should be evaluated in view of the concentration of the serum concentration of sex hormone binding globulin (SHBG). Based on levels of total testosterone and SHBG, free and bioavailable testosterone can be calculated (http://www.issam.ch/freetesto.htm). Due to diurnal variation, blood samples for testosterone assessment should be taken before 10.00 am. The existing guidelines for androgen replacement are based on mainly total testosterone levels, and testosterone supplementation is indicated only in men with levels consistently lower than normal (< 12 nmol/L [300 ng/dL]). Injectable, oral and transdermal testosterone preparations are available for clinical use (2). The best preparation to use is one that maintains serum testosterone levels as close as possible to physiological concentrations (11).
7.4
CONCLUSIONS
It is generally agreed that patients with primary or secondary hypogonadism should receive testosterone substitution therapy.
7.5
RECOMMENDATIONS
Recommendations • Effective drug therapy is available to achieve fertility in men with hypogonadotropic hypogonadism (4). GR = grade of recommendation
UPDATE MARCH 2007
GR A
33
7.6
REFERENCES
1. Nieschlag E, Behre HM. Testosterone: Action, Deficiency, Substitution. 2nd edn. Berlin: Springer Verlag, 1998. 2. World Health Organization. WHO manual for the Standardized Investigation, Diagnosis and Management of the Infertile Male. Cambridge: Cambridge University Press, 2000. 3. Burris AS, Rodbard HW, Winters SJ, Sherins RJ. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J Clin Endocrinol Metab 1988;66(6):1144-51. http://www.ncbi.nlm.nih.gov/pubmed/3372679 4. Schopohl J, Mehltretter G, von Zumbusch R, Eversmann T, von Werder K. Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism. Fertil Steril 1991;56(6):1143-50. http://www.ncbi.nlm.nih.gov/pubmed/1743335 5. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter’s syndrome. Lancet 2004;364(9430):273-83. http://www.ncbi.nlm.nih.gov/pubmed/15262106 6. Andersson AM, Jorgensen N, Frydelund-Larsen L, Rajpert-De Meyts E, Skakkebaek NE. Impaired Leydig cell function in infertile men: a study of 357 idiopathic infertile men and 318 proven fertile controls. J Clin Endocrinol Metab 2004;89(7):3161-7. http://www.ncbi.nlm.nih.gov/pubmed/15240588 7. Manning M, Junemann KP, Alken P. Decrease in testosterone blood concentrations after testicular sperm extraction for intracytoplasmic sperm injection in azoospermic men. Lancet 1998;352(9121):37. http://www.ncbi.nlm.nih.gov/pubmed/9800753 8. Gray A, Jackson DN, McKinlay JB. The relation between dominance, anger, and hormones in normally aging men: results from the Massachusetts Male Aging Study. Psychosom Med 1991;53(4):375-85. http://www.ncbi.nlm.nih.gov/pubmed/1924650 9. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157(2):439-44. http://www.ncbi.nlm.nih.gov/pubmed/8996327 10. Finkelstein JS. Androgens and bone metabolism. In: Nieschlag E, Behre HM (eds). Testosterone: Action, Deficiency, Substitution. 2nd edn. Berlin: Springer-Verlag, 1998, pp. 187-207. 11. Nieschlag E, Wang C, Handelsman DJ, Swerdloff RS, Wu F, Einer-Jensen N, Waites G. Guidelines for the Use of Androgens in Men. Geneva: WHO, 1992.
8. CRYPTORCHIDISM 8.1
Introduction
Cryptorchidism is the most common congenital abnormality of the male genitalia and is found in 2-5% of newborn boys, depending on gestational age (frequency of cryptorchidism is higher in premature boys), and age after birth. At the age of 3 months, the incidence of cryptorchidism falls spontaneously to 1-2%. Approximately 20% of undescended testes are non-palpable and can be located within the abdominal cavity. The aetiology of cryptorchidism is multi-factorial; both disrupted endocrine regulation and several gene defects may be involved. For a normal descent of the testes, a normal hypothalamo-pituitary-gonadal axis is needed. Endocrine disruption in early pregnancy can potentially affect gonadal development and normal descent of the testes; however, most boys with maldescended testes show no endocrine abnormalities after birth. It has been postulated that cryptorchidism may be the consequence of testicular dysgenesis, a developmental disorder of the gonads resulting from environmental and/or genetic influences early in pregnancy. Testicular dysgenesis syndrome can result in maldescence, hypospadias, reduced fertility and an increased risk of malignancy (1).
8.2
Incidence of cryptorchidism
The Caucasian population has a three-fold higher incidence of cryptorchidism compared to African-Americans. Even between Caucasians, there are significant differences in the risk of this malformation; cryptorchidism is significantly more common among Danish than among Finish newborns (2). Premature babies have a much higher incidence of cryptorchidism than full-term babies. In a UK study, the incidence of cryptorchidism in more than 3000 boys weighing > 2500 g was 2.7%; in premature boys weighing < 2500 g the corresponding number was 21%. At the age of 3 months, spontaneous descence occurred in most boys, and the incidence of cryptorchidism fell to 0.9 and 1.7%, in the > 2500 g and < 2500 g group, respectively (3).
34
UPDATE MARCH 2007
8.3
Testicular descent and maldescent
The process of testicular descent has two distinct phases: a) transabdominal and b) inguinal. During ‘transabdominal descence’, development of the gubernaculum and genito-inguinal ligament plays an important role. The antiMüllerian hormone regulates the transabdominal descence of the testis. Induction of the gubernaculum depends on functional Insl3 gene in mice (4). This gene is expressed in Leydig cells, and its targeted deletion causes bilateral cryptorchidism with free-moving testes and genital ducts (5). Other gene families (e.g. the homeobox (HOX) genes, GREAT gene), are important for the development of genital organs and may be associated with testicular maldescence (6, 7).
8.4
Hormonal control of testicular descent
Maldescence can be caused by two hormonal factors: hypogonadism and androgen insensitivity. The increasing incidence of reproductive abnormalities in human males might be explained by an increased oestrogen exposure during gestation (8). Some pesticides and synthetic chemicals act as hormonal modulators, often possessing oestrogenic activity (xeno-oestrogens) (9). The oestrogenic and anti-androgenic properties of these chemicals might cause hypospadia, cryptorchidism, reduction of sperm density, and an increase in the incidence of testicular tumours in animal models by receptor-mediated mechanisms or direct toxic effects (10).
8.5
Pathophysiological effects in maldescended testes
8.5.1 Degeneration of germ cells Degeneration of germ cells in maldescended testes is apparent after the first year. The degenerative changes vary, depending on the position of the testis (11). During the second year of life, the number of germ cells declines. In 10-45% of affected patients, complete loss of germ cells can be detected. Early treatment is therefore recommended to conserve spermatogenesis, especially in bilateral cases. Surgical treatment is the most effective and reliable method of bringing testes into the scrotum, but hormone treatment with either hCG or GnRH analogues can be considered, particularly in cases where testes are located in the high scrotal position (12). 8.5.2 Relationship with fertility Semen parameters are often impaired in men with a history of cryptorchidism (13). Surgical treatment during the first or second year of life might have a positive effect on subsequent fertility (14). However, there is no definitive proof of the protective effect of early orchidopexy. In men with a history of unilateral cryptorchidism, paternity is almost equal (89.7%) to paternity in men without cryptorchidism (93.7%). In men with unilateral cryptorchidism, paternity is independent of the age at orchidopexy, preoperative testicular location and testicular size (15) However, a history of unilateral cryptorchidism may result in reduced fertility potential (i.e. causing a prolonged time to achieve pregnancy). In men with bilateral cryptorchidism, oligozoospermia can be found in 31% and azoospermia in 42%. In cases of bilateral cryptorchidism, the rate of paternity is only 35-53%. 8.5.3 Germ cell tumours Cryptorchidism is a risk factor for testicular cancer and is associated with testicular microcalcification and CIS of the testis. In about 5-10% of testicular cancers, there is a history of cryptorchidism (16). The risk of a germ cell tumour is 3.6-7.4 times higher than in the general population, and 2-6% of men with a history of cryptorchidism will develop a testicular tumour (16). There is no evidence for a protective effect of early orchidopexy (17).
8.6
Treatment of undescended testes
8.6.1 Hormonal treatment In randomised, controlled trials investigating the efficacy and safety of hCG and GnRH treatment, a large variation in success rates has been reported. The corresponding figures in a multicenter randomised trial were 21%, 19% and 4% for GnRH, hCG and placebo, respectively (12) A meta-analysis of 33 studies showed that the success rate was highest in pre-scrotal and high scrotal testes (18). Non-palpable testes rarely descend as a result of hormonal treatment. The current hormonal protocol used for high scrotal testes is three hCG injections given once per week. The dosage is 1500 IU per injection for children aged 1-3 years, 3000 IU at age 4-6 years, and 5000 IU at age 6-15 years. The recommended age for treatment using hCG is 12-18 months. In a patient with bilateral impalpable testes, an hCG stimulation test can be carried out; a rise in testosterone level confirms the presence of testes. Inhibin B is produced by the Sertoli cells of the testis and can be a good indicator of testicular function in children (19). Hormonal treatment is generally considered safe, with few side-effects. However, some studies have
UPDATE MARCH 2007
35
indicated an increased risk of interstitial fibrosis and germ cell apoptosis following hCG treatment (20). Early adverse effects include penile growth, pain in the genital region, pain at the site of injection and psychological changes as a result of androgen effects. 8.6.2 Surgical treatment The success rate of surgical treatment for undescended testes is 70-90% (21). When the spermatic cord or vessels are too short to allow proper mobilisation of the testis into the scrotum, a staged orchidopexy (FowlerStephenson procedure) can be used. The applied techniques are open surgery, laparoscopy, or microsurgery. A biopsy at the time of orchidopexy (see page 51, sections 12.1-12.2) can reveal a CIS, which can be removed, thus preventing development of a malignant tumour. If not corrected by adulthood, an undescended testis should not be removed. Following orchidopexy, vascular damage is the most severe complication and can cause testicular atrophy in 1-2% of cases. In non-palpable testes, the post-operative atrophy rate was 12% in cases where the vascular pedicles were long enough to allow scrotal positioning. Up to 40% post-operative atrophy was reported in cases of staged orchidopexy.
8.7
CONCLUSIONS
•
Cryptorchidism is multi-factorial in origin and may be caused by genetic factors and endocrine disruption early in pregnancy. Cryptorchidism can be associated with testicular dysgenesis and is a risk factor for infertility and germ cell tumours. Paternity in men with unilateral cryptorchidism in almost equal to paternity in men without cryptorchidism. Bilateral cryptorchidism, significantly reduces the likelihood of paternity.
• • •
8.8
RECOMMENDATIONS
Recommendations • Early surgical treatment of undescended testis may prevent germ cell loss. • If undescended testes are corrected in adulthood, a testicular biopsy for detection of carcinoma in situ is recommended at the time of the orchidopexy (16). GR = grade of recommendation
8.9
GR C B
REFERENCES
1.
Skakkebaek NS, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001;16(5):972-8. http://www.ncbi.nlm.nih.gov/pubmed/11331648 2. Boisen KA, Kaleva M, Main KM, Virtanen HE, Haavisto AM, Schmidt IM, Chellakooty M, Damgaard IN, Mau C, Reunanen M, Skakkebaek NE, Toppari J. Difference in prevalence of congenital cryptorchidism in infants between two Nordic countries. Lancet 2004;363(9417):1264-9. http://www.ncbi.nlm.nih.gov/pubmed/15094270 3. Heyns CF, Hutson JM. Historical review of theories on testicular descent. J Urol 1995;153(3 Pt 1): 754-67. http://www.ncbi.nlm.nih.gov/pubmed/7861531 4. Scorer CG. The descent of the testis. Arch Dis Child 1964;39:605-9. http://www.ncbi.nlm.nih.gov/pubmed/14230757 5. Nguyen MT, Showalter PR, Timmons CF, Nef S, Parada LF, Baker LA. Effects of orchiopexy on congenitally cryptorchid insulin-3 knockout mice. J Urol 2002;168(4 Pt 2):1779-83; discussion 1783. http://www.ncbi.nlm.nih.gov/pubmed/12352358 6. Lewis AG, Pecha BR, Smith EP, Gardner BJ, Hsieh-Li HM, Potter SS, Sheldon CA. Early orchidopexy restores fertility in Hoxa 11 gene knockout mouse. J Urol 2003;170:302-5. http://www.ncbi.nlm.nih.gov/pubmed/12796710 7. Gorlov IP, Kamat A, Bogatcheva NV, Jones E, Lamb DJ, Truong A, Bishop CE, McElreavey K, Agoulnik AI. Mutations of the GREAT gene cause cryptorchidism. Hum Mol Genet 2002;11(19): 2309-18. http://www.ncbi.nlm.nih.gov/pubmed/12217959
36
UPDATE MARCH 2007
8.
Hadziselimovic F, Geneto R, Emmons LR. Elevated placental estradiol: a possible etiological factor of human cryptorchidism. J Urol 2000;164(5):1694-5. http://www.ncbi.nlm.nih.gov/pubmed/11025750 9. Hosi S, Loff S, Witt K, Niessen K, Waag KL. Is there a correlation between organochlorine compounds and undescended testes? Eur J Pediatr Surg 2000;10(5):304-9. http://www.ncbi.nlm.nih.gov/pubmed/11194541 10. Toppari J, Larsen JC, Christiansen P, Giwercman A, Grandjean P, Guillette LJ Jr, Jegou B, Jensen TK, Jouannet P, Keiding N, Leffers H, McLachlan JA, Meyer O, Muller J, Rajpert-De Meyts E, Scheike T, Sharpe R, Sumpter J, Skakkebaek NE. Male reproductive health and environmental xenoestrogens. Environ Health Perspect 1996;104(Suppl 4):741-803. http://www.ncbi.nlm.nih.gov/pubmed/8880001 11. Garcia J, González N, Gómez ME, Plaza L, Sanchez J, Alba J. Clinical and anatomopathological study of 2000 cryptorchid testes. Br J Urol 1995(6);75:697-701. http://www.ncbi.nlm.nih.gov/pubmed/7613821 12. Christiansen P, Muller J, Buhl S, Hansen OR, Hobolth N, Jacobsen BB, Jorgensen PH, Kastrup KW, Nielsen K, Nielsen LB. Hormonal treatment of cryptorchidism - hCG or GnRH - a multicentre study. Acta Paediatr 1992;81(8):605-8. http://www.ncbi.nlm.nih.gov/pubmed/1356527 13. Yavetz H, Harash B, Paz G, Yogev L, Jaffa AJ, Lessing JB, Homonnai ZT. Cryptorchidism: incidence and sperm quality in infertile men. Andrologia 1992;24(5):293-97. http://www.ncbi.nlm.nih.gov/pubmed/1356318 14. Wilkerson ML, Bartone FF, Fox L, Hadziselimovic F. Fertility potential: a comparison of intraabdominal and intracanalicular testes by age groups in children. Horm Res 2001;55(1):18-20. http://www.ncbi.nlm.nih.gov/pubmed/11423737 15. Miller KD, Coughlin MT, Lee PA. Fertility after unilateral cryptorchidism: paternity, time to conception, pretreatment testicular location and size, hormone and sperm parameters. Horm Res 2001; 55(5): 249-53. http://www.ncbi.nlm.nih.gov/pubmed/11740148 16. Giwercman A, Bruun E, Frimodt-Moller C, Skakkebaek NE. Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. J Urol 1989;142(4):998-1001. http://www.ncbi.nlm.nih.gov/pubmed/2571738 17. Pike MC, Chilvers C, Peckham MJ. Effect of age at orchidopexy on risk of testicular cancer. Lancet 1986;1(8492):1246-8. http://www.ncbi.nlm.nih.gov/pubmed/2872394 18. Pyorala S, Huttunen NP, Uhari M. A review and meta-analysis of hormonal treatment of cryptorchidism. J Clin Endocrinol Metab 1995;80(9):2795-9. http://www.ncbi.nlm.nih.gov/pubmed/7673426 19. Andersson AM. Inhibin B in the assessment of seminiferous tubular function. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14(3):389-97. http://www.ncbi.nlm.nih.gov/pubmed/11517906 20. Kaleva M, Arsalo A, Louhimo I, Rapola J, Perheentupa J, Henriksen K, Toppari J. Treatment with human chorionic gonadotrophin for cryptorchidism: clinical and histological effects. Int J Androl 1996;19(5):293-8. http://www.ncbi.nlm.nih.gov/pubmed/8985778 21. Jones PF. Approaches to orchidopexy. Br J Urol 1995;75(6):693-6. http://www.ncbi.nlm.nih.gov/pubmed/7613820
9. IDIOPATHIC MALE INFERTILITY 9.1
Introduction
No demonstrable cause of male infertility, other than idiopathic OAT syndrome, is found in at least 44% of infertile men (1).
9.2
Empirical treatments
A wide variety of empirical drug approaches for the treatment of idiopathic male infertility have been used; however, there is little scientific evidence for an empirical approach (2).
UPDATE MARCH 2007
37
Androgens, hCG/hMG, bromocriptine, alpha-blockers, systemic corticosteroids and magnesium supplementation are not effective in the treatment of OAT syndrome. FSH (3) and anti-oestrogens in combination with testosterone (4) might be beneficial in a selection of patients; however, further evaluation in multicenter studies of these agents is required (3, 4).
9.3
RECOMMENDATIONS
Recommendation • Medical treatment of male infertility is recommended only for cases of hypogonadotropic hypogonadism (1). GR = grade of recommendation
GR A
9.4
REFERENCES
1.
Pierik FH, Van Ginneken AM, Dohle GR, Vreeburg JT, Weber RF. The advantages of standardized evaluation of male infertility. Int J Androl 2000 23(6):340-6. http://www.ncbi.nlm.nih.gov/pubmed/11114979 Foresta C, Bettella A, Spolaore D, Merico M, Rossato M, Ferlin A. Suppression of the high endogenous levels of plasma FSH in infertile men are associated with improved Sertoli cell function as reflected by elevated levels of plasma inhibin B. Hum Reprod 2004;19(6):1431-7. http://www.ncbi.nlm.nih.gov/pubmed/15117900 Paradisi R, Busacchi P, Seracchioli R, Porcu E, Venturoli S. Effects of high doses of recombinant human follicle-stimulating hormone in the treatment of male factor infertility: results of a pilot study. Fertil Steril 2006;86(3):728-31. http://www.ncbi.nlm.nih.gov/pubmed/16782097 Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril 2003;80(4):914-20. http://www.ncbi.nlm.nih.gov/pubmed/14556812
2.
3.
4.
10. MALE CONTRACEPTION 10.1
Introduction
‘Male contribution to contraception’ is a more accurate phrase than ‘male contraception’, as men do not conceive. Development of male contraceptive methods is important because up to 40% of women have an unmet need for family planning; approximately 80 million women every year having unintended or unwanted pregnancies. (1). Three of the four methods of male contraception have been in use for hundreds of years (i.e. condoms, periodic abstinence and withdrawal). The typical first-year failure rates of traditional male methods are high (withdrawal 19%, periodic abstinence 20%, and condoms between 3-14%) compared to the failure rates of 0.1-3% for modern reversible female methods (2). For men to take more responsibility for family planning, male contraceptive methods must be acceptable, cheap, reversible, and effective. Research is attempting to (3): • prevent sperm production, by using androgens, progestogen and GnRH in various combinations) • interfere with the ability of sperm to mature and fertilise by using an epididymal approach to create a hostile environment for sperm • produce better barrier methods; polyurethane condoms can be used by those with latex allergy, although they have higher breakage rates (4) • produce an antisperm contraceptive vaccine (5) • inhibit sperm-egg interactions. These approaches remain experimental. The method nearest to being generally available clinically is hormonal male contraception, which is based on suppression of gonadotrophins and the use of testosterone substitution to maintain male sexual function and bone mineralisation and to prevent muscle wasting (6). Various contraceptive regimens have been developed and tested, including testosterone monotherapy, androgen/progestin combinations, testosterone with GnRH analogues, and selective androgen- and progestinreceptor modulators. There are racial differences in the response to androgens alone. However, a combination
38
UPDATE MARCH 2007
of testosterone with progestin has resulted in complete suppression of spermatogenesis in all races and provided contraceptive efficacy equivalent to female hormonal methods (7). Phase III clinical trials of depot preparations of androgen/progestin combinations are in progress.
10.2
Vasectomy
Vasectomy is an effective method of permanent male surgical sterilisation (8). Before the vasectomy, the couple should be given accurate information about the benefits and risks. An Australian telephone survey found that 9.2% of respondents said they regretted having a vasectomy (9). 10.2.1 Surgical techniques Various techniques are available for vasectomy. The least invasive approach is the no-scalpel vasectomy (10); this is associated with a low rate of complications (11). The most effective occlusion technique is cauterisation of the lumen of the vas and fascial interposition (12-14). Most techniques can be carried out safely under local anaesthesia in the out-patient clinic. 10.2.2 Complications Vasectomy does not significantly alter spermatogenesis and Leydig cell function. The volume of ejaculate remains unchanged. Potential systemic effects of vasectomy, including atherosclerosis, have not been proven, and there is no evidence of a significant increase of any systemic disease after vasectomy. An increased rate of prostate cancer in men who underwent vasectomy has not been detected (17). Acute local complications associated with vasectomy include haematoma, wound infection and epididymitis in up to 5% of cases (15). The potential long-term complications (e.g. chronic testicular pain) (16), must be discussed with the patient before the procedure. Epididymal tubal damage is common, and is associated with consequent development of sperm granuloma and time-dependent secondary epididymal obstruction, which limits vasectomy reversal. 10.2.3 Vasectomy failure If an effective occlusion technique is used, the risk of recanalisation after vasectomy should be <1% (12). However, patients should be informed pre-operatively that, although rare, long-term re-canalisation may occur (19). No motile spermatozoa should be detected 3 months after vasectomy. Persistent motility is a sign of vasectomy failure, and the procedure will need to be repeated. A ‘special clearance’ can be given to men who continue to produce non-motile spermatozoa up to 1 year after vasectomy (18) . 10.2.4 Counselling Counselling with regard to vasectomy must address the following aspects: • Vasectomy should be considered irreversible • Vasectomy is associated with a low complication rate; however, because it is an elective operation, even small risks must be explained, as men (and their partners) might wish to consider these before giving consent • Vasectomy can fail, although the failure rate is low • Couples should be advised to continue with other effective contraception until clearance is confirmed. • All available data indicate that vasectomy is not associated with any serious, long-term side-effects (15) • Vascetomy involving fascial interposition and cauterisation appears to be the most effective technique (12-14).
10.3
Vasectomy reversal
A wide range of surgical success rates has been published for vasectomy reversal (up to 90%), depending on the time since vasectomy, type of vasectomy (e.g. open-ended or sealed), type of reversal (vaso-vasostomy or vaso-epididymostomy) and whether reversal was unilateral or bilateral. Although there have been no randomised, controlled trials that compare macro-surgery (loops) and microsurgery, microsurgical techniques with the help of magnification and smaller suture materials should be used (20). 10.3.1 Length of time since vasectomy Vaso-vasostomy results have shown patency rates up to 90%. The longer the interval from vasectomy to reversal, the lower the pregnancy rate. In a study of 1,469 men who had undergone microsurgical vasectomy reversal, patency and pregnancy rates, were 97% and 76%, respectively, for an interval up to 3 years after vasectomy, 88% and 53% for 3-8 years, 79% and 44% for 9-14 years and 71% and 30% for ≥15 years (21).
UPDATE MARCH 2007
39
10.3.2 Epididymovasostomy The chance of secondary epididymal obstruction after vasectomy increases with time. If secondary epididymal obstruction occurs, epididymo-vasostomy is needed to reverse the vasectomy (see Section 5 Obstructive azoospermia). 10.3.3 Microsurgical vasectomy reversal versus epididymal or testicular sperm retrieval and ICSI Calculations of cost per delivery for vasectomy reversal versus sperm retrieval-ICSI under a wide variety of initial assumptions clearly indicate that vasectomy reversal is associated with a considerably lower cost per delivery and higher delivery rates (live births) (22, 23). Sperm retrieval and ICSI must yield a 81% pregnancy rate per cycle to achieve equal costs to vasectomy reversal.
10.4 CONCLUSIONS • • • • •
10.5
All available data indicate vasectomy is not associated with any serious, long-term side-effects (15). The most cost-effective approach to treatment of post-vasectomy infertility is microsurgical reversal. This procedure is also associated with the highest chance of pregnancy. Pregnancy is still achievable after successful vasectomy reversal. MESA/TESE and ICSI should be reserved for failed vasectomy reversal surgery.
RECOMMENDATIONS
Recommendations • Fascial interposition and cauterisation appears to be the most effective technique (12-14). • Patients seeking consultation regarding vasectomy must be given information about the surgical method, risk of failure, irreversibility, need for postprocedure contraception until clearance, and risk of complications. • Methods of male contraception other than vasectomy are associated with high failure rates or are still experimental (e.g. hormonal approach). • Microsurgical vasectomy reversal is a low-risk and (cost-) effective method of restoring fertility. • For couples wanting to achieve pregnancy, sperm aspiration together with intracyctoplasmic spermic injection is a second-line option for selected cases and in cases of failed vaso-vasostomy. GR = grade of recommendation
10.6
GR B C
B B B
REFERENCES
Reproductive Health Strategy. Reproductive Health Research World Health Organisation, Geneva. Adopted at the 57th World Health Assembly, 2004. http://www.who.int/reproductive-health/publications/strategy.pdf 2. Handelsman D, Waites G. Tradional methods. In: Schill W, Comhaire F, Hargreave T (eds). Andrology for the Clinician. Berlin: Springer Verlag, 2006, pp. 122-124. 3. Griffin D, Ringheim K. Male hormonal contraception. What prospects exist and how acceptable are they? Plan Parent Chall 1996;2:20-4. http://www.ncbi.nlm.nih.gov/pubmed/12291936 4. Gallo MF, Grimes DA, Lopez LM, Schulz KF. Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev (2006)(1):CD003550. http://www.ncbi.nlm.nih.gov/pubmed/16437459 5. Naz RK. Antisperm immunity for contraception. J Androl 2006;27(2):153-9. http://www.ncbi.nlm.nih.gov/pubmed/16474022 6. Matthiesson KL, McLachlan RI. Male hormonal contraception: concept proven, product in sight? Hum Reprod Update 2006;12(4):463-82. http://www.ncbi.nlm.nih.gov/pubmed/16597629 7. Handelsman DJ, Waites GMH. Hormonal male contraception. In: Schill W, Comhaire F, Hargreave T (eds). Andrology for the Clinician. Berlin: Springer Verlag, 2006, pp. 520-524. 8. Schwingl PJ, Guess HA. Safety and effectiveness of vasectomy. Fertil Steril 2000;73)5):923-36. http://www.ncbi.nlm.nih.gov/pubmed/10785217 1.
40
UPDATE MARCH 2007
9.
Holden CA, McLachlan RI, Cumming R, Wittert G, Handelsman DJ, de Kretser DM, Pitts M. Sexual activity, fertility and contraceptive use in middle-aged and older men: Men in Australia, Telephone Survey (MATeS). Hum Reprod 2005: 20(12):3429-34. http://www.ncbi.nlm.nih.gov/pubmed/16172145 10. Li SQ, Goldstein M, Zhu J, Huber D. The no-scalpel vasectomy. J Urol 1991;145(2):341-4. http://www.ncbi.nlm.nih.gov/pubmed/1988727 11. Nirapathpongporn A, Huber D, Krieger N. No-scalpel vasectomy at the King’s birthday vasectomy festival. Lancet 1990;335(8694);894. http://www.ncbi.nlm.nih.gov/pubmed/1969992 12. Sokal, D, Irsula, B, Hays M, Chen-Mok M, Barone MA: Investigator Study Group. Vasectomy by ligation and excision, with or without fascial interposition: a randomized controlled trial. BMC Med 2004 31;2:6. http://www.ncbi.nlm.nih.gov/pubmed/15056388 13. Barone MA, Irsula B, Chen-Mok M, Sokal DC: Investigator Study Group. Effectiveness of vasectomy using cautery. BMC Urol 2004;4:10. http://www.ncbi.nlm.nih.gov/pubmed/15260885 14. Sokal DC, Irsula B, Chen-Mok M, Labrecque M, Barone MA. A comparison of vas occlusion techniques: cautery more effective than ligation and excision with fascial interposition. BMC Urol 2004;27;4(1):12. http://www.ncbi.nlm.nih.gov/pubmed/15509302 15. Schwingl PJ, Guess HA. Safety and effectiveness of vasectomy. Fertil Steril 2000;73(5):923-36. http://www.ncbi.nlm.nih.gov/pubmed/10785217 16. Christiansen CG, Sandlow JI. Testicular pain following vasectomy: a review of postvasectomy pain syndrome. J Androl 2003;24(3):293-8. http://www.ncbi.nlm.nih.gov/pubmed/12721203 17. Bernal-Delgado E, Latour-Perez J, Pradas-Arnal F, Gomez-Lopez LI. The association between vasectomy and prostate cancer: a systematic review of the literature. Fertil Steril 1998;70(2):191-200. http://www.ncbi.nlm.nih.gov/pubmed/9696205 18. Davies AH, Sharp RJ, Cranston D, Mitchell RG. The long-term outcome following ‘special clearance’ after vasectomy. Br J Urol 1990;66(2):211-2. http://www.ncbi.nlm.nih.gov/pubmed/2390708 19. Verhulst APM, Hoekstra JW. Paternity after bilateral vasectomy. BJU Int 1999;83:280-2. http://www.ncbi.nlm.nih.gov/pubmed/10233494 20. Schroeder-Printzen I, Diemer T, Weidner W. Vasovasostomy. Urol Int 2003;70(2):101-7. http://www.ncbi.nlm.nih.gov/pubmed/12592037 21. Belker AM, Thomas AJ Jr, Fuchs EF, Konnak JW, Sharlip ID. Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. J Urol 1991;145(3):505-11. http://www.ncbi.nlm.nih.gov/pubmed/1997700 22. Pavlovich CP, Schlegel PN. Fertility options after vasectomy: a cost-effectiveness analysis. Fertil Steril 1997;67(1):133-41. http://www.ncbi.nlm.nih.gov/pubmed/8986698 23. Heidenreich A, Altmann P, Engelmann UH. Microsurgical vasovasostomy versus microsurgical epididymal sperm aspiration/testicular extraction of sperm combined with intracytoplasmic sperm injection. A cost-benefit analysis. Eur Urol 2000;37(5):609-14. http://www.ncbi.nlm.nih.gov/pubmed/10765102
11. MALE ACCESSORY GLAND INFECTIONS (MAGIs) 11.1
Introduction
Infections of the male urogenital tract are potentially curable causes of male infertility (1-3). The WHO considers urethritis, prostatitis, orchitis, and epididymitis to be male accessory gland infections (MAGIs) (2). However, specific data are not available to confirm that these diseases have a negative influence on sperm quality and male fertility in general.
UPDATE MARCH 2007
41
11.2
Urethritis
Infectious, sexually-acquired urethritis can be caused by various of pathogens, most commonly Chlamydia trachomatis, Ureaplasma urealyticum, and Neisseria gonorrhoea (4). Non-infectious causes of urethritis include irritations as a result of allergic reactions, trauma and manipulations. Urethral discharge and bladder voiding problems are the predominant symptoms of acute urethritis. 11.2.1 Diagnosis and treatment Diagnosis is based on analysis of urethral smear and first-voided urine (VB1). Evidence of ≥ 4 granulocytes per microscopic high-power field (x1000) in an urethral smear, or of 15 granulocytes per microscopic field (x400) in the smear of the sediment of 3 mL VB1, is pathognomonic (4). In urethritis, defined by inflammatory discharge, semen analysis for disorders of male fertility is not possible as the anterior urethra is full of infectious and inflammatory material that hampers any useful analysis (5). The impact of urethritis on semen quality and fertility has not been proven as the ejaculate is contaminated with inflammatory material from the urethra. The negative influence of sexually transmitted micro-organisms on sperm function is still debatable (1, 6, 7). Male fertility can be impaired by urethral strictures, ejaculatory disturbances (2), or by the development of obstruction (8). Obstruction can develop as either a normal urethral stricture or lesion in the posterior urethra in the area of the verumontanum, both of which may lead to ejaculatory disturbances and central obstruction of the seminal pathway (2). The Centers of Disease Control and Prevention in Atlanta (GA, USA) have published guidelines standardising the treatment of sexually transmitted diseases (9). As the aetiology of acute urethritis is usually unknown at the time of diagnosis, empirical therapy directed against potential pathogens is suggested. A single dose of a fluoroquinolone is given, followed by a 2-week regimen of doxycycline. Treatment is effective both for gonococcal and (co-existing) chlamydial/ureaplasmal infections.
11.3
Prostatitis
Prostatitis represents the most common urological diagnosis in men < 50 years of age (10). Traditionally, prostatitis has been classified into four clinical entities: • acute bacterial prostatitis (ABP) and prostatic abscess as a sequela/complication of ABP • chronic bacterial prostatitis (CBP) • non- or abacterial prostatitis (NBP) • prostatodynia. To improve the definition and understanding of the prostatitis, a classification system has been proposed by the National Institute of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Washington DC, USA (10) (Table 10). Table 11: New NIH/NIDDK classification of the prostatitis syndrome (10). New NIH category Clinical entity Description I ABP Acute infection of the prostate gland II CBP Recurrent infection of the prostate III Chronic abacterial prostatitis/CPPS No demonstrable infection IIIA Inflammatory CPPS White cells in semen, expressed prostatic secretions or post-prostatic massage urine IIIB Non-inflammatory CPPS No white cells in semen, expressed prostatic secretions or post-prostatic massage urine IV Asymptomatic inflammatory prostatitis No subjective symptoms. Inflammation detected either by prostate biopsy or by the presence of white cells in expressed prostatic secretions or semen during evaluation for other disorders * Adapted from Wgenlehner et al (10). ABP = acute bacterial prostatitis; CBP = chronic bacterial prostatitis; CPPS = chronic pelvic pain syndrome. 11.3.1 Microbiology Acute bacterial prostatits (NIH I), CBP (NIH II) and more significantly, prostatic abscesses are clinically relevant, but uncommon, diseases. The most common causes of bacterial prostatitis are Gram-negative bacteria,
42
UPDATE MARCH 2007
predominantly strains of Escherichia coli (11). The role of Gram-positive bacteria in bacterial prostatitis is controversial. Although enterococci may cause bacterial prostatitis and associated recurrent urinary tract infection (UTI), the importance of other Gram-positive bacteria in chronic prostatitis is doubtful (11), as is that of C. trachomatis and Mycoplasma, particularly U. urealyticum, (11-15). Hidden bacteria may be aetiologically involved in patients with chronic idiopathic prostatitis after exclusion of typical bacterial infection (16). Detection of bacteria by molecular techniques has not been evaluated definitively. 11.3.2 Diagnosis Symptoms must be evaluated using standardised scores, especially the NIH symptom score (17). Other investigative procedures include laboratory diagnosis of CBP using the four-specimen test for bacterial localisation (10, 11), which measures sequential quantitative bacteriological cultures of the urethra, bladder urine and prostatic secretions, both in expressed prostatic excretion (EPS) and urine after prostatic massage (12). Simplified techniques compare bacterial and leukocyte counts in the urine before and after prostatic massage (18). Screening of bladder voiding and imaging analysis of the prostate gland must be integrated. Key for diagnosis is demonstration of leukocytes in EPSs, urine after prostatic massage and/or ejaculate to differentiate between inflammatory and non-inflammatory CPPS. 11.3.3 Ejaculate analysis An ejaculate analysis (see section 2 Investigations) helps to clarify whether the prostate is part of a generalised infection of the accessory sex glands (MAGI) and provides information about sperm quality. In addition, leukocyte analysis allows differentiation between inflammatory and non-inflammatory CPPS (NIH IIa vs. NIH IIIb). 11.3.4 Microbiological findings After exclusion of urethritis and bladder infection, ≥ 106 peroxidase-positive white blood cells per mL ejaculate are indicative of an inflammatory process. In these cases, a culture should be made for common urinary tract pathogens, particularly Gram-negative bacteria. A concentration of ≥ 103 cfu/mL urinary tract pathogens in the ejaculate is a significant bacteriospermia. Various micro-organisms are found in genital tract of men seen in infertility clinics, with more than one strain of bacteria in most cases (1). The time of sampling can influence the positive rate of microorganisms in semen and the frequency of isolation of different strains (19). The ideal diagnostic test for C. trachomatis in semen has not yet been established (14). In contrast to serological findings in women, antibody tests for C. trachomatis in seminal plasma are not indicative if no type-specific methods are used (14). Ureaplasma urealyticum is pathogenic only in high concentrations (≥ 103 cfu/mL ejaculate). No more than about 10% of samples analysed for ureaplasma exceed this concentration (20). Normal colonisation of the urethra hampers the clarification of ‘mycoplasmal-associated’ urogenital infections using samples such as the ejaculate (15). 11.3.5 White blood cells The clinical significance of an increased concentration of white blood cells (WBC) or leukocytes in the ejaculate is controversial (21). Infection is indicated only by an increased level of leukocytes (particularly polymorphonuclear leukocytes) and their products (e.g. leukocyte elastase) secreted into the seminal fluid. Most leukocytes are neutrophilic granulocytes, as suggested by the specific staining of the peroxidase reaction (2). Although leukocytospermia is a sign of inflammation, it is not necessarily associated with bacterial or viral infections (7). Earlier findings showed that elevated leukocyte numbers are not a natural cause of male infertility (22). According to WHO classification, > 1 x 106 WBC/mL have been defined as leukospermia. Only two studies have analysed alterations of WBC in the ejaculate of patients with proven prostatitis (23, 24); both studies found more leukocytes in men with prostatitis compared to men without inflammation (CPPS, type NIH IIIb). 11.3.6 Sperm quality The deleterious effects of chronic prostatitis on sperm density, motility and morphology are under debate (1). All investigations have given contradictory results, and have not confirmed that chronic prostatitis has a decisive role in altering conventional semen parameters (25-27). 11.3.7 Seminal plasma alterations Seminal plasma elastase is a biochemical indicator of polymorphonuclear lymphocyte activity in the ejaculate (1, 28, 29), with a suggested cut-off level of approximately 600 ng/mL (1). Various cytokines are involved in inflammation and may influence sperm function. Several studies have investigated the association between
UPDATE MARCH 2007
43
interleukin concentration, leukocytes and sperm function (30-32): no correlations were found. The prostate is the main site of origin of interleukin-6 (IL-6) in the seminal plasma. Cytokines, especially IL-6, must play an important role in the male accessory gland inflammatory process (33). However, elevated cytokine levels do not depend on the number of leukocytes in EPS (34). 11.3.8 Glandular secretory dysfunction Infections of the sex glands can impair their excretory function. Decreased quantities of citric acid, phosphatase, fructose, zinc and alpha-glutamyl-transferase activity are indicators of disturbed prostatic secretory parameters (1). Reduced fructose concentration indicates impaired vesicular function (20, 35). 11.3.9 Sperm antibodies Serum antibodies to sperm antigens are not useful in the diagnosis of immune infertility. Early reports stated an association between increased levels of sperm antibodies in serum and NBP (36, 37). However, except suspected chlamydial infections (38), only a history of vasectomy is predictive of sperm antibody formation (39). 11.3.10 Reactive oxygen species Reactive oxygen species might be increased in chronic urogenital infections associated with increased leukocyte numbers (40). However, the biological significance in prostatitis remains unclear (1). 11.3.11 Therapy Treatment of chronic prostatitis is usually targeted at relieving symptoms (10, 41). Andrologically, therapy for altered semen composition in male adnexitis (acute and chronic infections of the male urogenital tract) is aimed at: • reduction or eradication of micro-organisms in prostatic secretions and semen • normalisation of inflammatory (e.g. leukocytes) and secretory parameters • improvement of sperm parameters to counteract fertility impairment (42). Treatment includes antibiotics, anti-inflammatory drugs, surgical procedures, normalisation of urine flow, physical therapy and alterations in general and sexual behaviour. Only antibiotic therapy of CBP (NIH II) has provided symptomatic relief, eradication of microorganisms and a decrease in cellular and humoral inflammatory parameters in urogenital secretions. The use of alpha-blockers for symptom relief is controversial. Although antibiotics might improve sperm quality (42), there is no evidence that treatment of chronic prostatitis increases the probability of conception (1, 43).
11.4
Orchitis and epididymo-orchitis
11.4.1 Introduction Orchitis is an inflammatory lesion of the testis associated with a predominantly WBC exudate inside and outside the seminiferous tubules, potentially resulting in tubular sclerosis. The inflammation causes pain and swelling. Chronic inflammatory alterations in the seminiferous tubules disrupt the normal process of spermatogenesis and alter sperm number and quality (44). Orchitis might also be an important cause of spermatogenetic arrest (45), which might be reversible in most cases. Testicular atrophy can develop as a result of tubular sclerosis (45). 11.4.2 Diagnosis Epididymo-orchitis usually presents with unilateral scrotal pain (46). Diagnosis is based on past medical history and palpation. Ultrasonography usually indicates a swollen, enlarged testis. The sonographic feature of the tissue does not allow any differential diagnosis (47). 11.4.3 Ejaculate analysis Ejaculate analysis, including leukocyte analysis, indicates persistent inflammatory activity. In many cases, especially in acute epididymo-orchitis, transiently decreased sperm counts and reduced forward motility occur (44, 46). Obstructive azoospermia due to complete obstruction is a rare complication. Mumps orchitis may result in bilateral testicular atrophy (45) and testicular azoospermia. When granulomatous orchitis is suspected, sperm-bound auto-antibodies occur. 11.4.4 Therapy Only therapy of acute bacterial epididymo-orchitis and of specific granulomatous orchitis is standardised (45) (Table 11). Several regimens improve the inflammatory lesion. Unfortunately, therapies using corticosteroids and non-steroidal antiphlogistic substances (e.g. diclofenac, indomethacin, and acetylsalicylic acid) have not
44
UPDATE MARCH 2007
been evaluated for their andrological outcome (47). In mumps orchitis, systemic interferon alpha-2b therapy prevents testicular atrophy and azoospermia (48). In idiopathic granulomatous orchitis, surgical removal of the testis is the therapy of choice. Table 12: Treatment of epididymo-orchitis Condition and pathogen Treatment • Acute bacterial epididymo-orchitis N. gonorrhoeae Tetracyclines C. trachomatis Tetracyclines E. coli, Enterobacteriaceae Fluoroquinolones • Mumps orchitis Interferon alpha-2b • Non-specific chronic epididymo-orchitis Steroidal and non-steroidal antiphlogistic agents • Granulomatous (idiopathic) orchitis Semi-castration • Specific orchitis According to therapy of underlying diseases
11.5
Epididymitis
11.5.1 Introduction Inflammation of the epididymis causes unilateral pain and swelling, usually with acute onset. Among sexually active men < 35 years of age, epididymitis is most often caused by C. trachomatis or N. gonorrhoea (Table 11) (49, 50). Sexually transmitted epididymitis is usually accompanied by urethritis. Non-sexually transmitted epididymitis is associated with UTI and occurs more often in men aged > 35 years, those who have recently undergone urinary tract instrumentation or surgery, and those who have anatomical abnormalities (50). 11.5.2 Diagnosis In acute epididymitis, inflammation and swelling usually begin in the tail of the epididymis, and can spread to involve the rest of the epididymis and testicular tissue (46). Although men with epididymitis caused by sexually transmitted micro-organisms always have a history of sexual activity, exposure may have occurred several months before onset. The microbial aetiology of epididymitis is usually easy to determine by Gramstained examination of both a urethral smear for urethritis and of a mid-stream urine specimen for Gramnegative bacteriuria (49, 50). Intracellular Gram-negative diplococci on the smear indicate presence of N. gonorrhoea. Only WBCs on urethral smear indicate non-gonorrhoeal urethritis; C. trachomatis will be isolated in approximately two-thirds of these patients (51). 11.5.3 Ejaculate analysis Ejaculate analysis according to WHO criteria, including leukocyte analysis, might indicate persistent inflammatory activity. In many cases, transiently decreased sperm counts and forward motility are observed (46, 49, 52). Ipsilateral low-grade orchitis (53, 54) might be the cause of this slight impairment in sperm quality (Table 12) (55). Development of stenosis in the epididymal duct, reduction of sperm count and azoospermia are more important in the follow-up of bilateral epididymitis (see Section 5 Obstructive azoospermia). The extent of azoospermia after epididymitis is unclear. Table 13: Acute epididymitis and impact on sperm parameters Author
Density
Negative influence on: Motility Morphology
Comment
Ludwig & Haselberger (56) + + + Pyospermia in 19 of 22 cases Berger et al. (49) + Weidner et al. (47) + + + Azoospermia in 3 of 70 men Haidl (57) + Chronic infections; macrophages elevated Cooper et al. (58) Decrease in epididymal markers: alpha-glucosidase, L-carnitine 11.5.4 Treatment Antibiotic therapy is indicated before culture results are available (Table 11). Treatment of epididymitis will result in:
UPDATE MARCH 2007
45
• • • • •
microbiological cure of infection improvement of clinical signs and symptoms prevention of potential testicular damage prevention of transmission decrease of potential complications (e.g. infertility or chronic pain).
Patients with epididymitis that is known or suspected to be caused by N. gonorrhoea or C. trachomatis must be told to refer their sexual partners for evaluation and treatment (59).
11.6 CONCLUSIONS • •
11.7
Urethritis and prostatitis are not clearly associated with male infertility. Antibiotic treatment often only eradicates micro-organisms; it has no positive effect on inflammatory alterations and/or cannot reverse functional deficits and anatomical dysfunctions.
RECOMMENDATIONS
Recommendations • In most cases, the aetiology of acute urethritis is unknown at the time of diagnosis; empirical therapy is therefore suggested using a single dose of a fluoroquinolone, followed by a 2-week regimen of doxycycline. Treatment is effective both for gonococcal and (co-existing) chlamydial/ureaplasmal infections (9) • Patients with epididymitis that is known or suspected to be caused by N. gonorrhoea or C. trachomatis must be instructed to refer their sexual partners for evaluation and treatment (59). GR = grade of recommendation
11.8
GR B
B
REFERENCES
1.
Weidner W, Krause W, Ludwig M. Relevance of male accessory gland infection for subsequent fertility with special focus on prostatitis. Hum Reprod Update 1999;5(5):421-32. http://www.ncbi.nlm.nih.gov/pubmed/10582781 2. World Health Organization. WHO Manual for the Standardized Investigation, Diagnosis and Management of the Infertile Male. Cambridge: Cambridge University Press, 2000. 3. Purvis K, Christiansen E. Infection in the male reproductive tract. Impact, diagnosis and treatment in relation to male infertility. Int J Androl 1993;16(1):1-13. http://www.ncbi.nlm.nih.gov/pubmed/8468091 4. Schiefer HG. Microbiology of male urethroadnexitis: diagnostic procedures and criteria for aetiologic classification. Andrologia 1998;30(Suppl 1):7-13. http://www.ncbi.nlm.nih.gov/pubmed/9629437 5. Chambers RM. The mechanism of infection in the urethra, prostate and epididymis. In: Keith LG, Berger GS, Edelmann DA, (eds). Infections in Reproductive Health: Common Infections. Lancaster: MTP Press, pp. 283-296. 6. Ness RB, Markovic N, Carlson CL, Coughlin MT. Do men become infertile after having sexually transmitted urethritis? An epidemiologic examination. Fertil Steril 1997;68(2):205-13. http://www.ncbi.nlm.nih.gov/pubmed/9240243 7. Trum JW, Mol BW, Pannekoek Y, Spanjaard L, Wertheim P, Bleker OP, van der Veen F. Value of detecting leukocytospermia in the diagnosis of genital tract infection in subfertile men. Fertil Steril 1998;70(2):315-9. http://www.ncbi.nlm.nih.gov/pubmed/9696227 8. Purvis K, Christiansen E. The impact of infection on sperm quality. J Br Fertil Soc 1995;1:31-41. 9. Krieger JN. New sexually transmitted diseases treatment guidelines. J Urol 1995;154(1):209-13. http://www.ncbi.nlm.nih.gov/pubmed/7776428 10. Wagenlehner FM, Diemer T, Naber KG, Weidner W. Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status. Andrologia 2008:;40(2):100-4. http://www.ncbi.nlm.nih.gov/pubmed/18336459 11. Naber KG, Weidner W. Chronic prostatitis–an infectious disease? J Antimicrob Chemother 2000;46(2):157-61. http://www.ncbi.nlm.nih.gov/pubmed/10933636
46
UPDATE MARCH 2007
12.
Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection 1991;19(3): S119-S125. http://www.ncbi.nlm.nih.gov/pubmed/2055646 13. Bruce AW, Reid G. Prostatitis associated with Chlamydia trachomatis in 6 patients. J Urol 1989;142(4):1006-7. http://www.ncbi.nlm.nih.gov/pubmed/2677408 14. Taylor-Robinson D. Evaluation and comparison of tests to diagnose Chlamydia trachomatis genital infections. Hum Reprod 1997;12(11 Suppl):113-20. http://www.ncbi.nlm.nih.gov/pubmed/9433967 15. Taylor-Robinson D. Infections due to species of Mycoplasma and Ureaplasma: an update. Clin Infect Dis 1996;23(4):671-84; quiz 683-4. http://www.ncbi.nlm.nih.gov/pubmed/8909826 16. Krieger JN, Riley DE, Roberts MC, Berger RE. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol 1996;34(12):3120-8. http://www.ncbi.nlm.nih.gov/pubmed/8940458 17. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhourn EA, Pontari MA, Alexander RB, Farrar JT, O’Leary MP. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaboration Research Network. J Urol 1999;162(2):369-75. http://www.ncbi.nlm.nih.gov/pubmed/10411041 18. Ludwig M, Schroeder-Printzen I, Ludecke G, Weidner W. Comparison of expressed prostatic secretions with urine after prostatic massage–a means to diagnose chronic prostatitis/inflammatory chronic pelvic pain syndrome. Urology 2000;55(2):175-7. http://www.ncbi.nlm.nih.gov/pubmed/10688073 19. Liversedge NH, Jenkins JM, Keay SD, LcLaughlin EA, Al-Sufyan H, Maile LA, Joels LA, Hull MG. Antibiotic treatment based on seminal cultures from asymptomatic male partners in in-vitro fertilization is unnecessary and may be detrimental. Hum Reprod 1996;11(6):1227-31. http://www.ncbi.nlm.nih.gov/pubmed/8671429 20. Weidner W, Krause W, Schiefer HG, Brunner H, Friedrich HJ. Ureaplasmal infections of the male urogenital tract, in particular prostatitis, and semen quality. Urol Int 1985;40(1):5-9. http://www.ncbi.nlm.nih.gov/pubmed/3883615 21. Aitken RJ, Baker HW. Seminal leukocytes: passengers, terrorists or good samaritans? Hum Reprod1995;10(7):1736-9. http://www.ncbi.nlm.nih.gov/pubmed/8582971 22. Tomlinson MJ, Barratt CLR, Cooke ID. Prospective study of leukocytes and leukocyte subpopulations in semen suggests they are not a cause of male infertility. Fertil Steril 1993;60(6):1069-75. http://www.ncbi.nlm.nih.gov/pubmed/8243688 23. Krieger JN, Berger RE, Ross SO, Rothman I, Muller CH. Seminal fluid findings in men with nonbacterial prostatitis and prostatodynia. J Androl 1996;17(3):310-8. http://www.ncbi.nlm.nih.gov/pubmed/8243688 24. Weidner W, Jantos C, Schiefer HG, Haidl G, Friedrich HJ. Semen parameters in men with and without proven chronic prostatitis. Arch Androl 1991;26(3):173-83. http://www.ncbi.nlm.nih.gov/pubmed/1872650 25. Giamarellou H, Tympanidis K, Bitos NA, Leonidas E, Daikos GK. Infertility and chronic prostatitis. Andrologia 1984;16(5):417-22. http://www.ncbi.nlm.nih.gov/pubmed/6496959 26. Christiansen E, Tollefsrud A, Purvis K. Sperm quality in men with chronic abacterial prostatovesiculitis verified by rectal ultrasonography. Urology 1991;38(6):545-9. http://www.ncbi.nlm.nih.gov/pubmed/1746084 27. Leib Z, Bartoov B, Eltes F, Servadio C. Reduced semen quality caused by chronic abacterial prostatitis: an enigma or reality? Fertil Steril 1994;61(6):1109-16. http://www.ncbi.nlm.nih.gov/pubmed/8194626 28. Wolff H, Bezold G, Zebhauser M, Meurer M. Impact of clinically silent inflammation on male genital tract organs as reflected by biochemical markers in semen. J Androl 1991;12(5):331-4. http://www.ncbi.nlm.nih.gov/pubmed/1765569 29. Wolff H. The biologic significance of white blood cells in semen. Fertil Steril 1995;63(6):1143-57. http://www.ncbi.nlm.nih.gov/pubmed/7750580
UPDATE MARCH 2007
47
30. Dousset B, Hussenet F, Daudin M, Bujan L, Foliguet B, Nabet P. Seminal cytokine concentrations (IL-1beta, IL-2, IL-6, sR IL-2, sR IL-6), semen parameters and blood hormonal status in male infertility. Hum Reprod 1997;12(7):1476-9. http://www.ncbi.nlm.nih.gov/pubmed/9262280 31. Huleihel M, Lunenfeld E, Levy A, Potashnik G, Glezerman M. Distinct expression levels of cytokines and soluble cytokine receptors in seminal plasma of fertile and infertile men. Fertil Steril 1996;66(1):135-9. http://www.ncbi.nlm.nih.gov/pubmed/8752625 32. Shimonovitz S, Barak V, Zacut D, Ever-Hadani P, Ben Chetrit A, Ron M. High concentration of soluble interleukin-2 receptors in ejaculate with low sperm motility. Hum Reprod 1994;9(4):653-5. http://www.ncbi.nlm.nih.gov/pubmed/8046017 33. Zalata A, Hafez T, van Hoecke MJ, Comhaire F. Evaluation of beta-endorphin and interleukin-6 in seminal plasma of patients with certain andrological diseases. Hum Reprod 1995;10(12):3161-5. http://www.ncbi.nlm.nih.gov/pubmed/8822435 34. Alexander RB, Ponniah S, Hasday J, Hebel JR. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 1998;52(5):744-9. http://www.ncbi.nlm.nih.gov/pubmed/9801092 35. Comhaire F, Verschraegen G, Vermeulen L. Diagnosis of accessory gland infection and its possible role in male infertility. Int J Androl 1980;3(1):32-45. http://www.ncbi.nlm.nih.gov/pubmed/7409893 36. Jarow JP, Kirkland JA Jr, Assimos DG. Association of antisperm antibodies with chronic nonbacterial prostatitis. Urology 1990;36(2):154-6. http://www.ncbi.nlm.nih.gov/pubmed/2385884 37. Witkin SS, Zelikovsky G. Immunosuppression and sperm antibody formation in men with prostatitis. J Clin Lab Immunol 1986;21(1):7-10. http://www.ncbi.nlm.nih.gov/pubmed/3543373 38. Munoz MG, Witkin SS. Autoimmunity to spermatozoa, asymptomatic Chlamydia trachomatis genital tract infection and gamma delta T lymphocytes in seminal fluid from the male partners of couples with unexplained infertility. Hum Reprod 1995;10(5):1070-4. http://www.ncbi.nlm.nih.gov/pubmed/7657743 39. Jarow JP, Sanzone JJ. Risk factors for male partner antisperm antibodies. J Urol 1992;148(6):1805-7. http://www.ncbi.nlm.nih.gov/pubmed/1433613 40. Depuydt CE, Bosmans E, Zalata A, Schoonjans F, Comhaire FH. The relation between reactive oxygen species and cytokines in andrological patients with or without male accessory gland infection. J Androl 1996;17(6):699-707. http://www.ncbi.nlm.nih.gov/pubmed/9016401 41. Schaeffer AJ. Clinical practice. Chronic prostatitis and chronic pelvic pain syndrome. N Engl J Med 2006;355(16):1690-8. http://www.ncbi.nlm.nih.gov/pubmed/17050893 42. Weidner W, Ludwig M, Miller J. Therapy in male accessory gland infection–what is fact, what is fiction? Andrologia 1998;30(Suppl 1):87-90. http://www.ncbi.nlm.nih.gov/pubmed/9629448 43. Comhaire FH, Rowe PJ, Farley TM. The effect of doxycycline in infertile couples with male accessory gland infection: a double blind prospective study. Int J Androl 1986;9(2):91-8. http://www.ncbi.nlm.nih.gov/pubmed/3539821 44. Purvis K, Christiansen E. Infection in the male reproductive tract. Impact, diagnosis and treatment in relation to male infertility. Int J Androl 1993;16(1):1-13. http://www.ncbi.nlm.nih.gov/pubmed/8468091 45. Diemer T, Desjardins C. Disorders of Spermatogenesis. In: Knobil E, Neill JD, eds. Encyclopedia of Reproduction. Vol 4. San Diego: Academic Press, 1999, pp. 546-556. 46. [No authors listed.] Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases: National guideline for the management of epididymo-orchitis. Sex Transm Infect 1999;75(Suppl 1): S51-S53. http://www.ncbi.nlm.nih.gov/pubmed/10616385 47. Weidner W, Garbe C, Weissbach L, Harbrecht J, Kleinschmidt K, Schiefer HG, Friedrich HJ. [Initial therapy of acute unilateral epididymitis using ofloxacin. II. Andrological findings.] Urologe A 1990;29(5):277-80. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/2120839
48
UPDATE MARCH 2007
48. Ruther U, Stilz S, Rohl E, Nunnensiek C, Rassweiler J, Dorr U, Jipp P. Successful interferon-alpha 2, a therapy for a patient with acute mumps orchitis. Eur Urol 1995;27(2):174-6. http://www.ncbi.nlm.nih.gov/pubmed/7744163 49. Berger RE, Alexander RE, Harnisch JP, Paulsen CA, Monda GD, Ansell J, Holmes KK. Etiology, manifestations and therapy of acute epididymitis: prospective study of 50 cases. J Urol 1979;121(6):750-4. http://www.ncbi.nlm.nih.gov/pubmed/7744163 50. Berger RE. Epididymitis. In: Holmes KK, Mardh PA, Sparling PF et al. (eds). Sexually Transmitted Diseases. New York: McGraw-Hill, 1984, pp. 650-662. 51. Weidner W, Schiefer HG, Garbe C. Acute nongonococcal epididymitis. Aetiological and therapeutic aspects. Drugs 1987;34(Suppl 1):111-17. http://www.ncbi.nlm.nih.gov/pubmed/3481311 52. Weidner W, Krause W. Orchitis. In: Knobil E, Neill JD, eds. Encyclopedia of Reproduction. Vol. 3. San Diego: Academic Press, 1999, pp. 92-95. 53. Nilsson S, Obrant KO, Persson PS. Changes in the testis parenchyma caused by acute non-specific epididymitis. Fertil Steril 1968;19:748-57. http://www.ncbi.nlm.nih.gov/pubmed/5676481 54. Osegbe DN. Testicular function after unilateral bacterial epididymo-orchitis. Eur Urol 1991;19(3):204-8. http://www.ncbi.nlm.nih.gov/pubmed/1855525 55. Weidner W, Krause W, Ludwig M. Relevance of male accessory gland infection for subsequent fertility with special focus on prostatitis. Hum Reprod Update 1999;5(5):421-32. http://www.ncbi.nlm.nih.gov/pubmed/10582781 56. Ludwig G, Haselberger J. [Epididymitis and fertility. Treatment results in acute unspecific epididymitis.] Fortschr Med 1977;95(7):397-9. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/849851 57. Haidl G. Macrophages in semen are indicative of chronic epididymal infection. Arch Androl 1990;25(1):5-11. http://www.ncbi.nlm.nih.gov/pubmed/2389992 58. Cooper TG, Weidner W, Nieschlag E. The influence of inflammation of the human genital tract on secretion of the seminal markers alpha-glucosidase, glycerophosphocholine, carnitine, fructose and citric acid. Int J Androl 1990;13(5):329-36. http://www.ncbi.nlm.nih.gov/pubmed/2283178 59. Robinson AJ, Grant JB, Spencer RC, Potter C, Kinghorn GR. Acute epididymitis: why patient and consort must be investigated. Br J Urol 1990;66(6):642-5. http://www.ncbi.nlm.nih.gov/pubmed/2265337
12. GERM CELL MALIGNANCIES AND TESTICULAR MICROCALCIFICATIONS 12.1
Germ cell malignancies and male infertility
Testicular germ cell tumour is the most common malignancy in Caucasian males aged 15-40 years and affects approximately 1% of subfertile men. The lifetime risk of TGCT varies between ethnic groups and from country to country. The highest annual incidence of TGCT occurs in Caucasians, and varies from 10/100,000 (e.g. in Denmark and Norway) to 2/100,000 (e.g. in Finland and the Baltic countries). Generally seminomas and nonseminomas are always preceded by CIS, and untreated CIS will eventually progress to an invasive cancer (1, 2). The most convincing evidence for a general decline in male reproductive health is the increase in testicular cancer seen in Western countries (3). In almost all countries that have reliable cancer registers, the incidence of testicular cancer has increased (4). Both cryptorchidism and hypospadias are associated with an increased risk of testicular cancer; men with cryptorchidism and/or hypospadias are over-represented among patients with testicular cancer. Males with dysgenic testes have an increased risk of developing testicular cancer in adulthood. These cancers arise from pre-malignant gonocytes or CIS cells (5). Testicular microlithiasis can be associated with both germ cell tumours and CIS of the testis.
UPDATE MARCH 2007
49
12.2
Testicular germ cell cancer and reproductive function.
Men with TGCT have decreased semen quality, even before cancer is diagnosed (6). Orchidectomy implies a risk of azoospermia in these men, with sperm found in the ejaculate before the tumour-bearing testis has been removed. Semen cryopreservation before orchidectomy should therefore be considered (see Section 14 Semen cryopreservation) Treatment of TGCT can result in additional impairment of semen quality (7). In addition to spermatogenic failure, patients with TGCT have Leydig cell dysfunction, even in the contralateral testis (8). The risk of hypogonadism may therefore be increased in men treated for TGCT. Obtaining pre-treatment levels of testosterone, SHBG, LH and oestradiol, might help to anticipate posttreatment hypogonadism. Men who have had TGCT and have low normal androgen levels should be followed up long term because they are at risk of developing hypogonadism as a result of age-related decrease in testosterone production (9).
12.3
Testicular microlithiasis
Microcalcifications inside the testicular parenchyma can be found in 0.6-9% of men referred for testicular ultrasound (10-13). Although the true incidence of microcalcifications in the general population is unknown, it is probably rare. However, ultrasound findings of testicular microlithiasis are common in men with TGCT, cryptorchidism, testicular dysgenesis, male infertility, testicular torsion and atrophy, Klinefelter’s syndrome, hypogonadism, male pseudo-hermaphroditism, varicocele, epididymal cysts, pulmonary microlithiasis and non-Hodgkin’s lymphoma. The incidence reported seems to be higher with high-frequency ultrasound machines (14). The relationship between testicular microlithiasis (TM) and infertility is unclear, but probably relates to dysgenesis of the testis, with degenerate cells being sloughed inside an obstructed seminiferous tubule and failure of the Sertoli cells to phagocytose the debris. Subsequently, calcification occurs. Testicular microcalcification is a condition found in testes at risk of malignant development. The reported incidence of TM in men with TGCT is 6-46% (15-17); TM should therefore be considered premalignant. However, it has not been established whether TM is present before development of invasive TGCT, or whether TM might be an indicator for the preinvasive stage of TGCTs (i.e. CIS). Testicular biopsies from men with TM have found a higher prevalence of CIS, especially in men with bilateral microlithiasis (18). However, TM is found most often in men with a benign testicular condition and the microcalcifications themselves are not malignant. Further investigation of the association between TM and CIS will require testicular biopsies in large series of men without signs of a TGCT. Available data indicate high-risk patients (e.g. patients referred for infertility and/or cryptorchidism) in whom TM is found, should be followed-up by repeated ultrasound and/or testicular biopsy for detection of CIS.
12.4
RECOMMENDATIONS
Recommendations • In men with testicular microlithiasis (TM) and a history of male infertility, cryptorchidism or testicular cancer and in men with atrophic testis, a testicular biopsy or a follow-up scrotal ultrasound is recommended to rule out carcinoma in situ of the testis (17, 18). • It is important to encourage and educate these patients about self-examination, as this may result in early detection of testicular germ cell tumour (TGCT). • If there are suspicious findings on physical examination or ultrasound in patients with TM and associated lesions, a surgical exploration with testicular biopsy or orchidectomy should be considered. • Testicular biopsy, follow-up scrotal ultrasound or routine use of biochemical tumour markers, abdominal and pelvic computed tomography scanning is not justified for men with isolated TM without associated risk factors (e.g. male infertility, cryptorchidism, testicular cancer, atrophic testis) (11). • Men with TGCT are at increased risk of developing hypogonadism and should therefore be followed up (9). GR = grade of recommendation
GR B
B
B
B
12.5
REFERENCES
1.
Skakkebaek NE. Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. Histopathology 1978;2(3):157-70. http://www.ncbi.nlm.nih.gov/pubmed/27442
50
UPDATE MARCH 2007
2.
von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG, Skakkebaek NE. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J 1986;293(6559):1398-401. http://www.ncbi.nlm.nih.gov/pubmed/3026550 3. Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen JH, Skakkebaek NE, Moller H. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ 2000;321(7264):789-92. http://www.ncbi.nlm.nih.gov/pubmed/11009515 4. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170(1):5-11. http://www.ncbi.nlm.nih.gov/pubmed/12796635 5. Giwercman A, Muller J, Skakkebaek NE. Carcinoma in situ of the undescended testis. Semin Urol 1988;6(2):110-9. http://www.ncbi.nlm.nih.gov/pubmed/2903524 6. Petersen PM, Skakkebaek NE, Vistisen K, Rorth M, Giwercman A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999;17(3):941-7. http://www.ncbi.nlm.nih.gov/pubmed/10071288 7. Eberhard J, Stahl O, Giwercman Y, Cwikiel M, Cavallin-Stahl E, Lundin KB, Flodgren P, Giwercman A. Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study. Hum Reprod 2004;19(6):1418-25. http://www.ncbi.nlm.nih.gov/pubmed/15105386 8. Willemse PH, Sleijfer DT, Sluiter WJ, Schraffordt Koops H, Doorenbos H. Altered Leydig cell function in patients with testicular cancer: evidence for bilateral testicular defect. Acta Endocrinol (Copenh) 1983;102(4):616-24. http://www.ncbi.nlm.nih.gov/pubmed/6133401 9. Nord C, Bjoro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, Bremnes RM, Wist E, Fossa SD. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003;44(3):322-8. http://www.ncbi.nlm.nih.gov/pubmed/12932930 10. Parra BL, Venable DD, Gonzalez E, Eastham JA. Testicular microlithiasis as a predictor of intratubular germ cell neoplasia. Urology 1996;48(5):797-9. http://www.ncbi.nlm.nih.gov/pubmed/8911532 11. Peterson AC, Bauman JM, Light DE, McMann LP, Costabile RA. The prevalence of testicular microlithiasis in an asymptomatic population of men 18 to 35 years old. J Urol 2001;166(6):2061-4. http://www.ncbi.nlm.nih.gov/pubmed/11696707 12. von Eckardstein S, Tsakmakidis G, Kamischke A, Rolf C, Nieschlag E. Sonographic testicular microlithiasis as an indicator of premalignant conditions in normal and infertile men. J Androl 2001;22(5):818-24. http://www.ncbi.nlm.nih.gov/pubmed/11545295 13. Thomas K, Wood SJ, Thompson AJ, Pilling D, Lewis-Jones DI. The incidence and significance of testicular microlithiasis in a subfertile population. Br J Radiol 2000;73(869):494-7. http://www.ncbi.nlm.nih.gov/pubmed/10884745 14. Pierik FH, Dohle GR, van Muiswinkel JM, Vreeburg JT, Weber RF. Is routine scrotal ultrasound advantageous in infertile men? J Urol 1999;162(5):1618-20. http://www.ncbi.nlm.nih.gov/pubmed/10524881 15. Derogee M, Bevers RF, Prins HJ, Jonges TG, Elbers FH, Boon TA. Testicular microlithiasis, a premalignant condition: prevalence, histopathologic findings, and relation to testicular tumor. Urology 2001;57(6):1133-7. http://www.ncbi.nlm.nih.gov/pubmed/11377326 16. Miller FN, Sidhu PS. Does testicular microlithiasis matter? A review. Clin Radiol 2002;57(10):883-90. http://www.ncbi.nlm.nih.gov/pubmed/12413911 17. Giwercman A, Muller J, Skakkebaek NE. Prevalence of carcinoma in situ and other histopathological abnormalities in testes from 399 men who died suddenly and unexpectedly. J Urol 1991;145(1):77-80. http://www.ncbi.nlm.nih.gov/pubmed/1984105 18. de Gouveia Brazao CA, Pierik FH, Oosterhuis JW, Dohle GR, Looijenga LH, Weber RF. Bilateral testicular microlithiasis predicts the presence of the precursor of testicular germ cell tumors in subfertile men. J Urol 2004;171(1):158-60. http://www.ncbi.nlm.nih.gov/pubmed/14665866
UPDATE MARCH 2007
51
13. DISORDERS OF EJACULATION 13.1
Definition
Disorders of ejaculation are uncommon, but important, causes of male infertility. This group includes several heterogeneous dysfunctions, which can be either organic or functional.
13.2
Classification and aetiology
13.2.1 Anejaculation Anejaculation involves complete absence of an antegrade or retrograde ejaculation and is caused by a failure of emission of semen from the seminal vesicles, the prostate and the ejaculatory ducts into the urethra (1). True anejaculation is usually associated with a normal orgasmic sensation. Occasionally (e.g. in incomplete spinal cord injuries), this sensation may be altered or decreased. True anejaculation is always associated with central or peripheral nervous system dysfunctions or with drugs (2) (Table 13). Table 14: Aetiologies of anejaculation Neurogenic causes • Spinal cord injury • Cauda equina lesion • Retroperitoneal lymphadenectomy • Aortoiliac or horseshoe-kidney surgery • Colorectal surgery • Multiple sclerosis • Parkinson’s disease • Autonomic neuropathy (diabetes mellitus)
Drug-related causes • Antihypertensives • Antipsychotics • Antidepressants • Alcohol
13.2.2 Anorgasmia Anorgasmia is the inability to reach orgasm and may give rise to anejaculation. Anorgasmia is often a primary condition and its cause is usually psychological. Some patients report sporadic events of nocturnal emission or of ejaculation occurring during great emotional excitement unrelated to sexual activity (3). 13.2.3 Delayed ejaculation In delayed ejaculation, abnormal stimulation of the erect penis is needed to achieve orgasm with ejaculation (1). Delayed ejaculation can be considered a mild form of anorgasmia; both conditions can be found alternately in the same patient. The causes of delayed ejaculation may be psychological or organic, e.g. incomplete spinal cord lesion (3), iatrogenic penile nerve damage (4) or pharmacological (antidepressants, antihypertensives, antipsychotics) (5). 13.2.4 Retrograde ejaculation Retrograde ejaculation is the total, or sometimes partial, absence of an antegrade ejaculation as a result of semen passing backwards through the bladder neck into the bladder. Patients experience a normal or decreased orgasmic sensation, except in paraplegia Partial antegrade ejaculation must not be confused with the secretion of bulbo-urethral glands. The causes of retrograde ejaculation can be divided into neurogenic, pharmacological urethral, or bladder neck incompetence (Table 14). Table 15: Aetiology of retrograde ejaculation Neurogenic causes • Spinal cord injury • Cauda equina lesions • Multiple sclerosis • Autonomic neuropathy (juvenile diabetes) • Retroperitoneal lymphadenectomy • Sympathectomy • Colorectal and anal surgery Urethral causes • Ectopic ureterocele • Urethral stricture • Urethral valves or verumontaneum
52
Pharmacological causes • Antihypertensives • Alpha1-adrenoceptor antagonists • Antipsychotics • Antidepressants Bladder neck incompetence • Congenital defects/dysfunction of hemitrigone • Bladder extrophy • Bladder neck resection
UPDATE MARCH 2007
•
hyperplasia Congenital dopamine beta-hydroxylase deficiency
•
Prostatectomy
13.2.5 Asthenic ejaculation Asthenic ejaculation, also defined as partial ejaculatory incompetence or ‘ejaculation baveuse’ (6), is characterised by an altered propulsive phase with a normal emission phase. The orgasmic sensation is reduced and the typically rhythmical contractions associated with ejaculation are missing, while in asthenic ejaculation due to urethral obstruction, these contractions are present. Asthenic ejaculation is generally due to the neurogenic or urethral pathologies already listed in Table 14. Asthenic ejaculation does not usually alter semen quality. 13.2.6 Premature ejaculation Premature ejaculation is the inability to control ejaculation for a ‘sufficient’ length of time during vaginal penetration. Although a universally accepted definition of ‘sufficient’ length of time does not exist, some patients are unable to delay ejaculation beyond a few coital thrusts, or even after vaginal penetration. Premature ejaculation may be strictly organic (e.g. prostatitis-related) or ‘psychogenic’ (i.e. neurobiologically based), primary or acquired, partner-related or non-selective, and can be associated with erectile dysfunction. Premature ejaculation does not impair fertility, provided intravaginal ejaculation occurs. For more extensive discussion on this topic, the EAU Male Sexual Dysfunction guidelines may be consulted (http://www.uroweb. org/nc/professional-resources/guidelines/online/). 13.2.7 Painful ejaculation Painful ejaculation is usually an acquired condition, often related to lower urinary tract symptoms (7). It sometimes causes moderate sexual dysfunction. The painful sensation may be felt in the perineum, or urethra and urethral meatus (8). It can be caused by ejaculatory duct obstruction, all types of chronic prostatitis/ chronic pelvic pain syndrome, urethritis, urethrocele, antidepressant drugs and psychological problems.
13.3
Diagnosis
Diagnostic management includes the following recommended procedures. 13.3.1 Clinical history The patient must be carefully checked for diabetes, neuropathies, traumas, urogenital infections, previous surgery and medications. Particular attention must be paid to the characteristics of micturition and ejaculation (presence of nocturnal emission, ejaculatory ability in given circumstances, primary or acquired disorder), as well as to psychosexual aspects (education, features of affective relationship, pre-existent psychological traumas, previous psychological therapies). 13.3.2 Physical examination Genital and rectal examinations are conducted, including evaluation of the prostate, bulbo-cavernosus reflex and anal sphincter tone. Minimal neurological tests include: • sensitivity of scrotum, testes and perineum • cremasteric and abdominal cutaneous reflex • leg osteotendinous and plantar reflexes. 13.3.3 Post-ejaculatory urinalysis Post-ejaculatory urinalysis will determine if there is total or partial retrograde ejaculation. 13.3.4 Microbiological examinations Initial, mid-stream urine, EPS and/or urine after prostatic massage are cultured for evidence of prostatic infection. In cases of increased leukocytes in semen, semen culture is also suggested (9). 13.3.5 Optional diagnostic work up This diagnostic workup can include: • neurophysiological tests (bulbocavernosus evoked response and dorsal nerve somatosensory evoked potentials) • tests for autonomic neuropathies (i.e. appreciation of temperature regulation in the feet) • psychosexual evaluation • video-cystometry
UPDATE MARCH 2007
53
• • • •
cystoscopy transrectal ultrasonography uroflowmetry vibratory stimulation of the penis
13.4
Treatment
Infertility caused by disorders of ejaculation is seldom treated on the basis of aetiology. Treatment usually involves retrieving spermatozoa for use in assisted reproduction techniques (ART). The following aspects must be considered when selecting treatment: • age of patient and his partner • psychological problems of the patient and his partner • couple’s willingness and acceptance of different fertility procedures • associated pathologies • psychosexual counselling.
13.5
Aetiological treatments
If possible, stop any pharmacological treatments that are interfering with ejaculation. Tamsulosin can be administered during antidepressant treatment (10). Treatment should be given for urogenital infections (i.e. in cases of painful ejaculation) (9). Selective serotonin re-uptake inhibitors (SSRIs) should be given for premature ejaculation, which appears to be related to serotonin levels (11). If possible, any underlying urethral pathology or metabolic disorder (e.g. diabetes) should be corrected. Psychotherapy is not usually very effective.
13.6
Symptomatic treatments
13.6.1 Premature ejaculation This can be treated with topical anaesthetic agents to increase intravaginal ejaculation latency time or the offlabel use of SSRIs (e.g. paroxetine, fluoxetine), behavioural therapy and/or psychotherapy. 13.6.2 Retrograde ejaculation In the absence of spinal cord injury, anatomical anomalies of the urethra, or pharmacological agents, drug treatment must be used to induce antegrade ejaculation (Table 15). Alternatively, the patient can be encouraged to ejaculate when his bladder is full to increase bladder neck closure (12). Table 16: Drug therapy for retrograde ejaculation • • • • •
Ephedrine sulphate, 10-15 mg four times daily (13) Midodrin, 5 mg three times daily (14) Brompheniramine maleate, 8 mg twice daily(15) Imipramine, 25-75 mg three times daily (16) Desipramine, 50 mg every second day (17)
Sperm collection from post-orgasmic urine for use in ART is recommended if: • drug treatment is ineffective or intolerable as a result of side-effects • the patient has a spinal cord injury • drug therapy inducing retrograde ejaculation cannot be interrupted. Sperm retrieval is timed to coincide with the partner’s ovulation. Urine must be alkalinised (pH 7.2-7.8) and osmolarity must be 200-300 mOsmol/kg. The patient is asked to have intercourse or to masturbate. Within 10 minutes after ejaculation, urine must be voided and centrifuged, and the pellet resuspended in 0.5 mL Tyrode’s or Ham’s F-10 medium and immediately inseminated (18). Alternatively, a catheter may be applied to the bladder and 10-50 mL Tyrode’s or Ham’s F-10 medium instilled into the bladder. The patient must ejaculate, and a second catheterisation is carried out immediately to retrieve spermatozoa. The latter treatment minimises contact between spermatozoa and urine (19). If the biological sperm preparation is not of sufficient quality for intrauterine insemination, the couple must undergo in vitro reproductive procedures (i.e. ICSI) with fresh or cryopreserved spermatozoa. 13.6.3 Anejaculation Drug treatment for anejaculation caused by lymphadenectomy and neuropathy or psychosexual therapy in anorgasmic men is not very effective. In all these cases and in men who have a spinal cord injury, vibrostimulation (i.e. the application of a vibrator to the penis) is first-line therapy. In anejaculation, vibro-stimulation evokes the ejaculation reflex (20), which requires an intact
54
UPDATE MARCH 2007
lumbosacral spinal cord segment. Complete spinal injuries and injuries above T10 show a better response to vibro-stimulation. Once the safety and efficacy of this procedure has been assessed, patients can manage the process in their own home. Intravaginal insemination using a 10 mL syringe during ovulation can be carried out. If the quality of semen is poor, or ejaculation is retrograde, the couple may enter an IVF programme. If vibro-stimulation has failed, electro-ejaculation is the therapy of choice (21). Electro-ejaculation involves electric stimulation of the periprostatic nerves via a probe inserted into the rectum, which seems unaffected by reflex arc integrity. Anaesthesia is required except in cases of complete spinal cord injury. In 90% of patients, electro-stimulation induces ejaculation, which is retrograde in one-third of cases. Semen quality is often poor and most couples will need to enter an IVF programme (22). When electro-ejaculation fails or cannot be carried out, sperm can be retrieved from the seminal ducts by aspiration from the vas deferens (23) (see Section 5 Obstructive azoospermia) or seminal tract washout (24). When sperm cannot be retrieved, epididymal obstruction or testicular failure must be suspected. TESE can then be used (9, 25). Anejaculation following either surgery for testicular cancer or total mesorectal excision can be prevented using monolateral lymphadenectomy or autosomic nerve preservation (25), respectively.
13.7 CONCLUSIONS •
13.8
Ejaculation disorders can be treated using a wide range of drugs and physical stimulation trials with a high level of efficacy.
RECOMMENDATIONS
Recommendations GR • Aetiological treatments for ejaculatory disorders should be offered before sperm collection and ART is performed. • Premature ejaculation can be treated successfully with either topical anaesthetic creams or SSRIs (23). • In men with spinal cord injury, vibro-stimulation and electro-ejaculation are effective methods of sperm retrieval. GR = grade of recommendation
13.9
REFERENCES
Buvat J. Glossaire. [Ejaculation and its Disruptions] In: Buvat J, Jouannet P (eds). [L’éjaculation et ses Perturbations.] Lyon-Villeurbanne: SIMEP, 1984, p. 9. [Book in French] 2. Wang R, Monga M, Hellstrom WJG. Ejaculatory dysfunction. In: Comhaire FH (ed). Male Infertility: Clinical Investigation. Cause, Evaluation and Treatment. London: Chapman Hall, 1996, pp. 205-221. 3. Pryor JP. Erectile and ejaculatory problems in infertility. In: Hargreave TB (ed). Male Infertility. Berlin: Springer-Verlag, 1997, pp. 319-336. 4. Yachia D. Our experience with penile deformations: incidence, operative techniques, and results. J Androl 1994;15(Suppl):63S-68S. http://www.ncbi.nlm.nih.gov/pubmed/7721682 5. Rudkin L, Taylor MJ, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2004 18;(4):CD003382. http://www.ncbi.nlm.nih.gov/pubmed/15495050 6. Chapelle PA. [[Séquelles génito-sexuelles du paraplégique ] 2-Neuro-physiologie. Tempo Medical 1982;103:67-70. [article in French] 7. Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003;169(6):2257-61. http://www.ncbi.nlm.nih.gov/pubmed/12771764 8. Hermabessiere J, Bouquet de la Joliniere J, Buvat J. [Painful ejaculation. Researching organic causes.] In: Buvat J, Jouannet P (eds). [Ejaculation and its Disruptions.] Lyon-Villeurbanne: SIMEP, 1984, pp. 129-134. [book in French] 9. Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001;13(1):41-5. http://www.ncbi.nlm.nih.gov/pubmed/11313839 10. Perimenis P, Gyftopoulos K, Ravazoula P, Athanassopoulos A, Barbalias G. Excessive verumontanum hyperplasia causing infertility. Urol Int 2001;67(2):184-5. http://www.ncbi.nlm.nih.gov/pubmed/11490221 1.
UPDATE MARCH 2007
55
11. Demyttenaere K, Huygens R. Painful ejaculation and urinary hesitancy in association with antidepressant therapy: relief with tamsulosin. Eur Neuropsychopharmacol 2002;12(4):337-41. http://www.ncbi.nlm.nih.gov/pubmed/12126873 12. Crich JP, Jequier AM. Infertility in men with retrograde ejaculation: the action of urine on sperm motility, and a simple method for achieving antegrade ejaculation. Fertil Steril 1978;30(5):572-6. http://www.ncbi.nlm.nih.gov/pubmed/720646 13. Gilja I, Parazajder J, Radej M, Cvitkovic P, Kovacic M. Retrograde ejaculation and loss of emission: possibilities of conservative treatment. Eur Urol 1994;25(3):226-8. http://www.ncbi.nlm.nih.gov/pubmed/8200405 14. Jonas D, Linzbach P, Weber W. The use of midodrin in the treatment of ejaculation disorders following retroperitoneal lymphadenectomy. Eur Urol 1979;5(3):184-7. http://www.ncbi.nlm.nih.gov/pubmed/87324 15. Schill WB. Pregnancy after brompheniramine treatment of a diabetic with incomplete emission failure. Arch Androl 1990;25(1):101-4. http://www.ncbi.nlm.nih.gov/pubmed/2389987 16. Brooks ME, Berezin M, Braf Z. Treatment of retrograde ejaculation with imipramine. Urology 1980;15(4):353-5. http://www.ncbi.nlm.nih.gov/pubmed/7190335 17. Hendry WF. Disorders of ejaculation: congenital, acquired and functional. Br J Urol 1998;82(3):331-41. http://www.ncbi.nlm.nih.gov/pubmed/9772867 18. Schill WB. Diagnosis and treatment of ejaculatory sterility. In: Paulson JD, Nigro-Vilar A, Lucena E, Martini L (eds). Andrology. Male Fertility and Sterility. Orlando: Academic Press, 1986, pp. 599-617. 19. Hotchkiss RS, Pinto AB, Kleegman S. Artificial insemination with semen recovered from the bladder. Fertil Steril 1954;6(1):37-42. http://www.ncbi.nlm.nih.gov/pubmed/13220644 20. Brindley GS. Reflex ejaculation under vibratory stimulation in paraplegic men. Paraplegia 1981;19(5):299-302. http://www.ncbi.nlm.nih.gov/pubmed/7279433 21. Elliott S, Rainsbury PA. Treatment of anejaculation. In: Colpi GM, Balerna M (eds). Treating Male Infertility: New Possibilities. Basel: Karger AG, 1994, pp. 240-254. 22. Denil J, Kuczyk MA, Schultheiss D, Jibril S, Kupker W, Fischer R, Jonas U, Schlosser HW, Diedrich K. Use of assisted reproductive techniques for treatment of ejaculatory disorders. Andrologia 1996;28(Suppl 1):43-51. http://www.ncbi.nlm.nih.gov/pubmed/9082877 23. Waldinger MD. The neurobiological approach to premature ejaculation. J Urol 2002;168(6):2359-67. http://www.ncbi.nlm.nih.gov/pubmed/12441918 24. Jankowicz E, Drozdowski W, Pogumirski J. [Idiopathic autonomic neuropathy (pandysautonomia)]. Neurol Neurochir Pol 2001;35(3):439-52. [article in Polish] http://www.ncbi.nlm.nih.gov/pubmed/11732267 25. Maurer CA, Z’Graggen K, Renzulli P, Schilling MK, Netzer P, Buchler MW. Total mesorectal excision preserves male genital function c0ompared with conventional rectal cancer surgery. Br J Surg 2001;88(11):1501-5. http://www.ncbi.nlm.nih.gov/pubmed/11683749
14. SEMEN CRYOPRESERVATION 14.1
Definition
Cryopreservation is the storage of biological material at subzero temperatures (e.g. -80°C or -196°C [the boiling point of liquid nitrogen]), at which biochemical processes of cell metabolism are slowed or interrupted. At -196°C, the biochemical reactions that lead to cell death are effectively stopped.
14.2
Introduction
Cryopreservation was first developed in the 1940s by veterinarians and adapted for human sperm in the 1950s. The first pregnancy that involved the use of cryopreservation techniques was in 1954 (1). In fertility practice, clinical indications for cyropreservation include storage of sperm, testicular and ovarian tissue and early embryos.
56
UPDATE MARCH 2007
14.3
Indications for storage
Storage of sperm is available in many clinics for the following indications: • before potentially sterilising chemotherapy or radiotherapy for cancer (2) or for non-malignant disease (e.g. Behçet’s disease) • before surgery that might interfere with fertility (e.g. bladder neck surgery in a younger man or removal of the second testicle in a man with bilateral testicular malignancy) • for men with progressive decrease in semen quality as a result of diseases carrying an associated risk of subsequent azoospermia (i.e. pituitary macro-adenomas, cranio-pharyngiomas, empty sella syndrome, chronic nephropathies, uncontrolled diabetes mellitus, multiple sclerosis). • for men with paraplegia when sperm have been obtained by electro-ejaculation • for men with psychogenic anejaculation, after sperm have been obtained either by electro-ejaculation or a sperm retrieving procedure • after gonadotrophin treatment has induced spermatogenesis in men with hypogonadotropic hypogonadism • for men with NOA, the chance of finding sperm using micro-TESE is approximately 60-70%; cryopreservation can be used to separate sperm collection from ICSI, thus avoiding unnecessary hyper-stimulation of the female partner. It may also be used to avoid repeated sperm retrieval procedures. • in any situation where sperm have been obtained by a sperm retrieving procedure (e.g. after failed vasectomy reversal, or in some cases of epididymal obstruction not amenable to surgery) • for storage of sperm before vasectomy; this service is offered by a few clinics as an insurance policy against change of mind or circumstances • for storage of donor sperm; cryopreservation and a 3-6 months quarantine period reduce the risk of transmission of infection from sperm donors; in most countries, fresh sperm are no longer used.
14.4
Precautions and techniques
14.4.1 Freezing and thawing process The cryopreservation techniques currently in use are not yet optimal as damage occurs to cells during cyropreservation and during prolonged storage. Most damage occurs during freezing and thawing. Major causes of damage during freezing are ice crystal formation and cell dehydration causing disruption of the cell wall and intracellular organelle .Sperm morphology, motility and vitality decrease significantly after thawing, and cryopreservation increases the damage done to sperm DNA (3-5, 6). Further damage may be caused by contamination of samples with micro-organisms and high levels of superoxide radicals (7, 8). To reduce ice crystal formation, a cryopreservation solution is added before freezing. Various cryopreservation solutions are available commercially, most of which contain varying proportions of glycerol and albumen. After freezing, the tissues are immersed in liquid nitrogen. Several techniques have been developed to try to reduce damage caused by freezing and thawing. • Rapid method (9, 10): sample is held in the vapour phase for 10 min before being plunged into liquid nitrogen. • Slow method (11): sample is gradually cooled in the vapour phase for approximately 40 min. • A programmable automatic freezing machine, which is pre-set to cool at a rate of 1-10°C/min, is used. The method available depends on the laboratory’s resources. Whichever freezing technique is employed, it should be tested using donor sperm and post-thaw examination, and should regularly undergo a qualitycontrol programme. The likelihood of sperm survival decreases with increased storage time and repeated freezing and thawing. The maximum viable storage time for human sperm is not known. Many laboratory or regulatory authorities apply a storage time limit of up to 10 years (12); however, longer storage times are sometimes needed (e.g. for a 17-year-old male who has had sperm stored before undergoing chemotherapy for testicular cancer). 14.4.2 Cryopreservation of very small numbers of sperm Standard cryopreservation in straws is an efficient way of storing large number of sperm (e.g. for a donor insemination programme). However, in micro-TESE, very few sperm might be obtained, and the choice is either to freeze testicular tissue and find sperm after thawing the tissue, or to freeze very small numbers of sperm. If sperm are frozen in straws, it can be very difficult to find any sperm after thawing. Instead, the sperm should be frozen in the form of a pellet (13) or in a container (14). 14.4.3 Testing for infections and preventing cross-contamination Sperm storage in straws is used extensively. Large numbers of straws are stored in canisters, and the straws are bathed in a pool of liquid nitrogen. Micro-organism contamination of the pool of liquid nitrogen results
UPDATE MARCH 2007
57
in contamination of the outside of all the straws. The most widely used safeguard is to accept samples for storage only from patients whose semen samples have been tested for infection and confirmed as safe. Donor samples should be tested for viral (hepatitis B and C, HIV) and sexually transmitted infections (C. trachomatis, gonorrhoea, syphilis). Until the test results are known, samples must be stored in an individual quarantine vessel (15) (http://www.hfea.gov.uk/cps/rde/xchg/SID-3F57D79B-1F88B22E/hfea/hs.xsl/576.html). Some laboratories use the additional safeguard of double-wrapping the straws before freezing, although this is more costly and can interfere with the freezing process, reducing sample quality upon thawing. Some centres carry out cytomegalovirus (CMV) testing and store CMV-negative and CMV-positive samples separately. Considerable ethical issues surround the storage of samples before cancer chemotherapy for a man who is hepatitis- or HIV-positive. Very few clinics have separate storage facilities for HIV-positive samples. However, the success of antiretroviral treatment is increasing the number of HIV-positive men who may wish to store sperm. There is also concern about HIV transmission to children conceived using HIV-positive sperm, as sperm-washing techniques fail in about 5%. 14.4.4 Fail-safe precautions to prevent loss of stored materials Any laboratory undertaking long-term storage of human biological materials should have procedures that guard against accidental loss of material caused by storage vessel failure. This is particularly important for sperm stored before potentially sterilising cancer chemotherapy because these patients may not be able to obtain further sperm. The level of precaution will depend on the cost and resources available to the laboratory, but if possible the following safeguards should be in place. • All in-use storage vessels should be fitted with an alarm system activated by a rising temperature or liquid nitrogen leakage • The alarm system should alert a laboratory staff member, according to a 24-hour 365-day rota • Ideally, there should be a spare storage container into which samples can be transferred following a vessel failure. 14.4.5 ‘Orphan’ samples In malignancy and some other situations, years may pass before stored samples are required. Inevitably, during this time, the owners of some samples might disappear or die, leaving behind ‘orphan’ samples for which the owner is no longer contactable. The duty of the laboratory and the legal ownership of these samples can create considerable problems. It is best to obtain instructions from the owner of the sample at the time of, or very shortly after, storage, about what to do with the sample in the event of death or untraceability. In some countries, owners are legally required to provide instructions/consent. Choices available for the owner of the sample, depend on the laws of the country, might or might not be appropriate in all situations, and include: • a request that the sample should be destroyed • use of the sample by their wife or partner • use of the sample in research • donation of the sample to help another infertile couple.
14.5
Biological aspects
Cryopreservation induces deterioration of the seminal quality. After the sample has been thawed, motility (16) and morphology (17, 18) are worsened, including mitochondrial acrosomal and sperm tail damage (19). Sperm freezing decreases motility by 31%, morphology by 37%, and mitochondrial activity by 36% (9). Motility is correlated best with IVF capacity of the thawed sample. Further improvement can be achieved by selecting the subpopulation of sperm with the best motility and DNA integrity and freezing these sperm in seminal plasma (13).
14.6 CONCLUSIONS • •
The purpose of sperm cryopreservation is to secure future pregnancies using ART. Cryopreservation techniques are not optima, and future efforts are needed to improve the outcome of sperm banking.
58
UPDATE MARCH 2007
14.7
RECOMMENDATIONS
Recommendations • Cryopreservation of semen should be offered to all men who are candidates for chemotherapy, radiation or surgical interventions that might interfere with spermatogenesis or cause ejaculatory disorders. • If cryopreservation is not available locally, patients should be advised about the possibility of visiting, or transferring to, the nearest cryopreservation unit before therapy starts. • Precautions should be taken to prevent transmission of viral, sexually transmitted or any other infection by cryostored materials from donor to recipient and also to prevent contamination of stored samples.
14.8
REFERENCES
1.
Bunge RG, Keettel WC, Sherman JK. Clinical use of frozen semen; report of four cases. Fertil Steril. 1954;5(6):520-9. http://www.ncbi.nlm.nih.gov/pubmed/13210484 2. Saito K, Suzuki K, Iwasaki A, Yumura Y, Kubota Y. Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer. Cancer 2005;104(3):521-4. http://www.ncbi.nlm.nih.gov/pubmed/15968690 3. Desrosiers P, Legare C, Leclerc P, Sullivan R. Membranous and structural damage that occur during cryopreservation of human sperm may be time-related events. Fertil Steril 2006;85(6):1744-52. http://www.ncbi.nlm.nih.gov/pubmed/16643911 4. Donnelly ET, McClure N, Lewis SE. Cryopreservation of human semen and prepared sperm: effects on motility parameters and DNA integrity. Fertil Steril 2001;76(5):892-900. http://www.ncbi.nlm.nih.gov/pubmed/11704107 5. Chohan KR, Griffin JT, Carrell DT. Evaluation of chromatin integrity in human sperm using acridine orange staining with different fixatives and after cryopreservation. Andrologia 2004;36(5):321-6. http://www.ncbi.nlm.nih.gov/pubmed/15458552 6. Askari HA, Check JH, Peymer N, Bollendorf A. Effect of natural antioxidants tocopherol and ascorbic acids in maintenance of sperm activity during freeze-thaw process. Arch Androl 1994;33(1):11-5. http://www.ncbi.nlm.nih.gov/pubmed/7979804 7. Smith KD, Steinberger E. Survival of spermatozoa in a human sperm bank. Effects of long-term storage in liquid nitrogen. J Am Med Assoc 1973;223(7):774-7. http://www.ncbi.nlm.nih.gov/pubmed/4739258 8. Agarwal A, Said TM. Oxidative stress, DNA damage and apoptosis in male infertility: a clinical approach. BJU Int 2005;95(4):503-7. http://www.ncbi.nlm.nih.gov/pubmed/15705068 9. Grischenko VI, Dunaevskaya AV, Babenko VI. Cryopreservation of human sperm using rapid cooling rates. Cryo Letters 2003;24(2):67-76. http://www.ncbi.nlm.nih.gov/pubmed/12819827 10. Sherman JK, Bunge RG. Observations on preservation of human spermatozoa at low temperatures. Proc Soc Exp Biol Med 1953;82(4):686-8. http://www.ncbi.nlm.nih.gov/pubmed/13055973 11. Sawada Y, Ackerman D, Behrman SJ. Motility and respiration of human spermatozoa after cooling to various low temperatures. Fertil Steril 1967;18(6):775-81. http://www.ncbi.nlm.nih.gov/pubmed/13055973 12. Henry MA, Noiles EE, Gao D, Mazur P, Critser JK. Cryopreservation of human spermatozoa. IV. The effects of cooling rate and warming rate on the maintenance of motility, plasma membrane integrity, and mitochondrial function. Fertil Steril 1993;60(5):911-8. http://www.ncbi.nlm.nih.gov/pubmed/8224279 13. Bahadur G, Ling KL, Hart R, Ralph D, Wafa R, Ashraf A, Jaman N, Mahmud S, Oyede AW. Semen quality and cryopreservation in adolescent cancer patients. Hum Reprod 2002;17(12):3157-61. http://www.ncbi.nlm.nih.gov/pubmed/12456617 14. Hallak J, Hendin BN, Thomas AJ Jr, Agarwal A. Investigation of fertilizing capacity of cryopreserved spermatozoa from patients with cancer. J Urol 1998;159(4):1217-20. http://www.ncbi.nlm.nih.gov/pubmed/9507838 15. Clarke GN. Sperm cryopreservation: is there a significant risk of cross-contamination? Hum Reprod 1999;14(12):2941-3. http://www.ncbi.nlm.nih.gov/pubmed/10601075
UPDATE MARCH 2007
59
16. O’Connell M, McClure N, Lewis SE. The effects of cryopreservation on sperm morphology, motility and mitochondrial function. Hum Reprod 2002;17(3):704-9. http://www.ncbi.nlm.nih.gov/pubmed/11870124 17. Woolley DM, Richardson DW. Ultrastructural injury to human spermatozoa after freezing and thawing. J Reprod Fertil 1978;53(2):389-94. http://www.ncbi.nlm.nih.gov/pubmed/567693 18. Watson PF. Recent developments and concepts in the cryopreservation of spermatozoa and the assessment of their post-thawing function. Reprod Fertil Dev 1995;7(4):871-91. http://www.ncbi.nlm.nih.gov/pubmed/8711221 19. Donnelly ET, McClure N, Lewis SE. Cryopreservation of human semen and prepared sperm: effects on motility parameters and DNA integrity. Fertil Steril 2001;76(5):892-900. http://www.ncbi.nlm.nih.gov/pubmed/11704107
15. LEVELS OF EVIDENCE AND GRADES OF GUIDELINE RECOMMENDATIONS Table 17: Levels of evidence.* Level Type of evidence 1a Evidence obtained from meta-analysis of randomised trials 1b Evidence obtained from at least one randomised trial 2a Evidence obtained from one well-designed controlled study without randomisation 2b Evidence obtained from at least one other type of well-designed quasi-experimental study 3 Evidence obtained from well-designed non-experimental studies (e.g. comparative studies, correlation studies and case reports) 4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities * Modified from Sacket et al. (1). Table 18: Grades of guideline recommendations.* Grade Nature of recommendations A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial B Based on well-conducted clinical studies, but without randomised clinical trials C Made despite the absence of directly applicable clinical studies of good quality * Modified from Sacket et al. (1).
15.1
REFERENCES
1.
Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [access date Oct 24, 2008].
60
UPDATE MARCH 2007
16. ABBREVIATIONS USED IN THE TEXT This list is not comprehensive for the most common abbreviations
ABP acute bacterial prostatitis ART assisted reproduction techniques CBAVD congenital bilateral absence of the vas deferens CBP chronic bacterial prostatitis CF cystic fibrosis CFTR cystic fibrosis transmembrane conductance regulator gene CIS carcinoma in situ CMV cytomegalovirus CPPS chronic pelvic pain syndrome CFTR cystic fibrosis transmembrane conductance regulator EPS espressed prostatic excretion FISH (multicolour) fluorescent in situ hybridisation HIV human immunodeficiency virus FSH follicle-stimulating hormone GnRH gonadotrophin-releasing hormone hCG human chorionic gonadotrophin hMG human menopausal gonadotrophin IBT immunobead test ICSI intracytoplasmic sperm injection IL-6 interleukin-6 IVF in vitro fertilisation LH luteinising hormone MAGI male accessory gland infection MAR mixed antiglobulin reaction MESA microsurgical epididymal sperm aspiration NBP non- or abacterial prostatitis NIDDK National Institute of Diabetes and Digestive and Kidney Diseases NIH National Institute of Health NOA non-obstructive azoospermia OA obstructive azoospermia OAT oligo-astheno-teratozoospermia [syndrome] SHBG sex hormone binding globulin SSRIs selective serotonin reuptake inhibitors STS sequence tagged sites TESE testicular sperm extraction TEFNA testicular fine-needle aspiration TGCT testicular germ cell tumour TM testicular microlithiasis TRUS transurethral ultrasound TURED transurethral resection of the ejaculatory ducts WBC white blood cells VB1 first-voided urine
Conflict of interest All members of the Male Infertility guidelines writing panel have provided disclosure statements of all relationships which they have and which may be perceived as a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
UPDATE MARCH 2007
61
62
UPDATE MARCH 2007
Guidelines on
Urinary Incontinence A. Schröder, P. Abrams (Co-Chairman), K-E. Andersson, W. Artibani, C.R. Chapple, M.J. Drake, C. Hampel, A. Neisius, A. Tubaro, J.W. Thüroff (Chairman)
© European Association of Urology 2009
TABLE OF CONTENTS 1.
page
Introduction 1.1 References
4 5
2. Epidemiology 2.1 Introduction 2.2 Risk factors in women 2.2.1. Risk factors in pelvic organ prolapse (POP) 2.3 Risk factors in men 2.4 Overactive bladder (OAB) 2.5 Disease progression 2.5.1 Longitudinal studies 2.5.2 Genetic epidemiology 2.5.3 Twin studies 2.5.4 Worldwide estimates of current and future LUTS including urinary incontinence (UI) and OAB in individuals > 20 yrs 2.5.5 Conclusions 2.6 References
5 5 5 5 5 6 6 6 6 6 6 6 6
3. Pharmacotherapy 3.1 Introduction 3.2 Drugs used in the treatment of OAB/detrusor overactivity (DO) 3.3 Drugs used in the treatment of stress urinary incontinence (SIU) 3.4 Drugs used for the treatment of ‘overflow incontinence’ 3.5 Hormonal treatment of UI 3.5.1 Oestrogen 3.5.2 Other steroid hormones/receptor ligands 3.5.3 Desmopressin 3.6 References
7 7 7 8 9 9 9 9 9 10
4. Incontinence in men 4.1 Initial assessment 4.2 Initial treatment 4.2.1 General management 4.2.2 Post-radical prostatectomy (RP) incontinence 4.2.3 Conclusions 4.3 Specialised management 4.3.1 Assessment 4.3.2 Interventions 4.3.3 Sphincter incompetence 4.3.3.1 Detrusor overactivity (DO) 4.3.3.2 Poor bladder emptying 4.3.3.3 Bladder outlet obstruction (BOO) 4.4 Surgical treatment 4.4.1 Incontinence after surgery for benign prostatic obstruction (BPO) or prostate cancer (CaP) 4.4.1.1 Incontinence after surgery for BPO or prostate cancer (CaP) 4.4.1.2 Incontinence after surgery for prostate cancer (CaP 4.4.1.3 Definitions of post-RP continence 4.4.1.4 Incontinence risk factors 4.4.1.5 Interventional treatment for post-RP incontinence 4.4.1.6 Age 4.4.1.7 Post-RP incontinence with bladder neck stricture 4.4.2 Incontinence after external beam radiotherapy for CaP 4.4.2.1 Artificial urinary sphincter (AUS) after radiotherapy 4.4.2.2 Conclusion 4.4.2.3 Other treatments for SIU after radiotherapy 4.4.3 Incontinence after other treatment for CaP 4.4.3.1 Brachytherapy
11 11 11 11 12 12 13 13 13 13 13 13 14 14
2
15 15 15 15 15 15 16 16 16 16 16 16 16 16
Update march 2009
4.4.3.2 Cryotherapy 4.4.3.3 High-intensity focused ultrasound (HIFU) 4.4.3.4 Recommendation 4.4.4 Treatment of incontinence after neobladder 4.4.5 Urethral and pelvic floor injuries 4.4.5.1 Recommendation 4.4.6 Incontinence in adult epispadias-exstrophy complex 4.4.7. Refractory UUI and idiopathic DO 4.4.8 Incontinence and reduced capacity bladder 4.4.9 Urethro-cuteneous fistula and recto-urethral fistula 4.4.10 Management of AUS complications 4.5 References
16 16 16 16 16 17 17 17 17 17 17 17
5. INCONTINENCE IN WOMEN 5.1 Initial Assessment 5.2 Initial treatment of UI in women 5.2.1 Pelvic floor muscle training (PFMT) under special circumstances 5.3 Specialised management of UI in women 5.3.1 Assessment 5.3.2 Treatment 5.4 Surgery for UI in women 5.4.1 Outcome measures 5.5 Outcome measures 5.6 References
28 28 28 30 31 31 31 32 34 34 34
6. URINARY INCONTINENCE IN FRAIL / OLDER MEN AND WOMEN 6.1 History and symptom assessment 6.1.1 General principles 6.1.2 Nocturia 6.1.3 Post-void residual (PVR) volume 6.2 Clinical diagnosis 6.3 Initial management 6.3.1 Drug therapy 6.4 Ongoing management and reassessment 6.5 Specialised management 6.5.1 Surgical approaches to UI in the frail / older men and women 6.6 References
44 44 44 44 45 45 45 45 45 46 46 47
7.
52
Abbreviations used in the text
Update march 2009
3
1. Introduction In the first International Consultation on Incontinence in 1998, a structure of ‘Clinical Guidelines for Management of Incontinence’ was developed (1). This included a summary and overview, which were presented in flow sheets (‘algorithms’), with recommendations for ‘Initial Management’ and ‘Specialised Management’ of urinary incontinence (UI) in children, men, women, patients with neuropathic bladder and elderly patients. These algorithms have already been presented in the previous EAU Guidelines on Incontinence and continue to be the skeleton of the guidelines. The algorithms are uniformly constructed to follow from top to bottom a chronological pathway from patient’s history and symptoms assessment, clinical assessment using appropriate studies and tests so that the condition of the underlying pathophysiology can be defined as a basis for rational treatment decisions. To limit the number of diagnostic pathways in the algorithms, clinical presentations that require a similar complexity of diagnostic evaluation have been grouped together by history and symptoms. Again, for simplification, treatment options have been grouped under a few diagnoses (‘conditions’) and their underlying pathophysiology, for which the terminology as standardised by the International Continence Society (ICS) is used. As a rule, the least invasive treatment option is recommended first, proceeding in a stepwise escalation to a more invasive treatment option, when the former fails. Depth and intensity of diagnostic evaluation and therapeutic interventions are grouped into two levels, ‘Initial Management’ and ‘Specialised Management’. The level of ‘Initial Management’ comprises measures generally needed at the first patient contact with a health professional. Depending on the healthcare system and local or general service restrictions, this first contact maybe with an incontinence nurse, a primary care physician or a specialist. The primary information about the patient’s condition is established by medical history, physical examination and applying basic diagnostic tests, which are readily available. If treatment is at all installed at this level of care, it will be mostly of an empirical nature. The level of ‘Specialised Management’ appeals to patients in whom a diagnosis could not be established at the ‘Initial Management’, in whom primary treatment failed, or in whom history and symptoms suggest a more complex or serious condition requiring more elaborate diagnostic evaluation and/or specific treatment options. For instance, at this level urodynamic studies are usually required for establishing a diagnosis on the grounds of pathophysiology, and treatment options at this level include invasive interventions and surgery. The principles of ‘evidence-based medicine’ (EBM) apply for analysis and rating of the relevant papers published in the literature, for which a modified Oxford system has been developed (2, 3). This approach applies ‘levels of evidence’ (LE) to the body of analysed literature and, from there, derives ‘grades of recommendation’ (GR) (Tables 1 and 2). This document presents a synthesis of the findings of the 4th International Consultation on Incontinence held in July 2008 (4). References have been included in the text, with a focus on new publications covering the time span 2005 to the present. An exhaustive reference list is available for consultation on line at the society website (http://www.uroweb.org/professional-resources/guidelines/) and on the CD-rom version. Additionally, an ultra short document is available. Table 1: Level of evidence* Level Type of evidence 1a Evidence obtained from meta-analysis of randomised trials 1b Evidence obtained from at least one randomised trial 2a Evidence obtained from one well-designed controlled study without randomisation 2b Evidence obtained from at least one other type of well-designed quasi-experimental study 3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports 4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities Modified from Sackett et al. (2, 3).
4
Update march 2009
Table 2: Grade of recommendation* Grade Nature of recommendations A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial B Based on well-conducted clinical studies, but without randomised clinical trials C Made despite the absence of directly applicable clinical studies of good quality Modified from Sackett et al. (2, 3).
1.1 REFERENCES 1. Thüroff JW, Abrams P, Artibani W, Haab F, Khoury S, Madersbacher H, Nijman R, Norton P. Clinical guidelines for the management of incontinence. In: Abrams P, Khoury S, Wein A, (eds). Incontinence. Plymouth: Health Publications Ltd, 1999, pp. 933-943. 2. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [accessed February 2009]. 3. Abrams P, Khoury S, Grant A. Evidence-based medicine overview of the main steps for developing and grading guideline recommendations. In: Abrams P, Cardozo L, Khoury S, Wein A, (eds). Incontinence. Paris: Health Publications Ltd, 2005, pp. 10-11. 4. Abrams P, Cardozo L, Wein A, Khoury S. 4th International Consultation on Incontinence. Paris, July 5-8, 2008. Publication due in the course of 2009.
2. EPIDEMIOLOGY* 2.1
Introduction
There is a large variation in the estimated prevalence of urinary incontinence (UI), even after taking into account differences in definitions, epidemiological methodology and demographic characteristics. However, recent prospective studies have provided much data on the incidence of UI and the natural history (progression, regression and resolution) of UI (1-4). Urinary incontinence, or urine loss occurring at least once during the last 12 months, has been estimated as occurring in 5-69% of women and 1-39% of men. In general, UI is twice as common in women as in men. Limited data from twin studies suggest there is a substantial genetic component to UI, especially stress urinary incontinence (SUI) (5, 6).
2.2 Risk factors in women Pregnancy and vaginal delivery are significant risk factors, but become less important with age. Contrary to previous popular belief, menopause per se does not appear to be a risk factor for UI and there is conflicting evidence regarding hysterectomy. Diabetes mellitus is a risk factor in most studies. Research also suggests that oral oestrogen substitution and body mass index are important modifiable risk factors for UI. Although mild loss of cognitive function is not a risk factor for UI, it increases the impact of UI. Smoking, diet, depression, urinary tract infections (UTIs) and exercise are not risk factors. 2.2.1 Risk factors in pelvic organ prolapse (POP) Pelvic organ prolapse (POP) has a prevalence of 5-10% based on the finding of a mass bulging in the vagina. Childbirth carries an increased risk for POP later in life, with the risk increasing with the number of children. It is unclear whether Caesarean section (CS) prevents the development of POP though most studies indicate CS carries less risk than vaginal delivery for subsequent pelvic floor morbidity. Several studies suggest hysterectomy and other pelvic surgery increase the risk of POP. Further research is needed.
2.3 Risk factors in men Risk factors for UI in men include increasing age, lower urinary tract symptoms (LUTS), infections, functional and cognitive impairment, neurological disorders and prostatectomy. *This section of the guidelines is based on the recommendations of the ICI committee chaired by Ian Milsom (Committee 1: Epidemiology).
Update march 2009
5
2.4
Overactive bladder (OAB)
The prevalence of OAB in adult males varies from 10% to 26% and in adult females from 8% to 42%. It increases with age and often occurs with other LUTS. Several common chronic conditions, such as depression, constipation, neurological conditions and erectile dysfunction, have been significantly associated with OAB, even after adjusting for important covariates, such as age, gender and country (7).
2.5 Disease progression 2.5.1 Longitudinal studies The literature on incidence and remission of UI is still scarce, particularly among men. However, the annual incidence rates of UI in women ranges from 2% to 11%, with the highest incidence occurring during pregnancy. Rates of complete remission of UI range from 0% to 13%, with the highest remission rate after pregnancy. The annual incidence rates of OAB range from 4% to 6%, while annual remission rates of OAB range from 2% to 3%. The annual incidence of prolapse surgery ranges from 0.16% to 0.2%. The estimated life-time cumulative risk for prolapse surgery is estimated to be 7-11%. 2.5.2 Genetic epidemiology The familial transmission of UI is well documented. However, it is often difficult to differentiate between heritability and non-inherited transmission (environmental factors) in the family environment. Ethnic and racial differences for UI and POP are also well documented. 2.5.3 Twin studies It is possible to estimate the relative proportions of phenotypic variance caused by genetic and environmental factors by comparing monozygotic female twins (who have an identical genotype) with dizygotic female twins (who share an average of 50% of their segregating genes). A genetic influence is suggested when monozygotic twins are more concordant for the disease than dizygotic twins. Suggested candidate genes include, for example, a polymorphism of the gene for collagen type I. In contrast, an environmental effect is suggested when monozygotic twins are discordant for the disease 2.5.4 Worldwide estimates of current and future LUTS including UI and OAB in individuals > 20 years old The EPIC study is a population-based study estimating the prevalence of UI, OAB and other LUTS among men and women from five countries using the 2002 ICS definitions. The age- and gender-specific prevalence rates from the EPIC study were used to estimate the current and future worldwide number of individuals with LUTS, OAB and UI (8). This was done by extrapolating prevalence rates to the worldwide population aged 20 years and older (4.2 billion). Males and females from the age of 20 to 80+ years were stratified into five-year age groups (e.g. 20-24 years) to estimate the current and future worldwide number of individuals with LUTS, OAB and UI, and the age- and gender-specific prevalence rates. Projected population estimates for all worldwide regions are based on information from the United States (US) Census Bureau International Database (IDB) (9). 2.5.5 Conclusions As the population ages, the prevalence of LUTS is also expected to increase. LUTS are burdensome to individuals. The projected increase in the number of individuals experiencing LUTS has implications for healthcare resources and overall health burden. The estimated number of individuals with LUTS has been based on a conservative prevalence rate. Thus, the future number of those with LUTS may be much higher.
2.6 REFERENCES* 1. Offermans MP, Du Moulin MF, Hamers JP, Dassen T, Halfens RJ. Prevalence of urinary incontinence and associated risk factors in nursing home residents: A systematic review. Neurourol Urodyn 2009 Feb 3. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19191259 2. Botlero R, Davis SR, Urquhart DM, Shortreed S, Bell RJ. Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire. Maturitas 2009 Jan 30. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19181467 3. Wennberg AL, Molander U, Fall M, Edlund C, Peeker R, Milsom I. A Longitudinal Population-based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in
6
Update march 2009
Women. Eur Urol 2009 Jan 13. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19157689 4. Long RM, Giri SK, Flood HD. Current concepts in female stress urinary incontinence. Surgeon 2008;6(6):366-72. http://www.ncbi.nlm.nih.gov/pubmed/19110826 5. Altman D, Forsman M, Falconer C, Lichtenstein P. Genetic influence on stress urinary incontinence and pelvic organ prolapse. Eur Urol 2008;54(4):918-22. Epub 2007 Dec 17. http://www.ncbi.nlm.nih.gov/pubmed/18155350 6. Rohr G, Kragstrup J, Gaist D, Christensen K. Genetic and environmental influences on urinary incontinence: a Danish population-based twin study of middle-aged and elderly women. Acta Obstet Gynecol Scand 2004;83(10):978-82. http://www.ncbi.nlm.nih.gov/pubmed/15453898 7. Irwin DE, Milsom I, Reilly K, Hunskaar S, Kopp Z, Herschorn S, Coyne KS, Kelleher CJ, Artibani W, Abrams P. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med 2008;5(12):2904-10. http://www.ncbi.nlm.nih.gov/pubmed/19090944 8. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50(6):1306-14; discussion 1314-5. Epub 2006 Oct 2. http://www.ncbi.nlm.nih.gov/pubmed/17049716 9. US Census Bureau, International Data Base http://www.census.gov/ipc/www/idb/index.html [accessed February 2009] *An exhaustive reference list is available for consultation on line at the society website (http://www.uroweb.org/ professional-resources/guidelines/) and on the guidelines CD-rom version.
3. PHARMACOTHERAPY* 3.1
Introduction
More than 50 million people in the developed world are affected by UI and many drugs have been used for treatment (Table 3). Although drugs may be efficacious in some patients, side-effects mean they are often discontinued after short periods of time and they are best used as an adjuvant to conservative and surgical therapy (1).
3.2 Drugs used in the treatment of overactive bladder (OAB)/detrusor overactivity (DO) The clinical relevance of efficacy of antimuscarinic drugs relative to placebo has been widely discussed (2). However, recent large meta-analyses of the most widely used antimuscarinic drugs have clearly shown these drugs provide a significant clinical benefit (3, 4). More research is needed to decide the best drugs for first-, second-, or third-line treatment (4). None of the commonly used antimuscarinic drugs (darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine and trospium) is an ideal first-line treatment for all OAB/DO patients. Optimal treatment should be individualised, considering the patient’s co-morbidities, concomitant medications and the pharmacological profiles of the different drugs (5).
Table 3: Drugs used in the treatment of OAB/DO* Drugs Antimuscarinic drugs • Tolterodine • Trospium • Solifenacin • Darifenacin • Propantheline • Atropine, hyoscyamine
LE
GR
1 1 1 1 2 3
A A A A B C
*This section of the guidelines is based on the recommendations of the ICI committee chaired by Karl-Erik Andersson (Committee 8: Drug Treatment).
Update march 2009
7
Drugs acting on membrane channels • Calcium antagonists • K+-channel openers Drugs with mixed actions • Oxybutynin • Propiverine • Dicyclomine • Flavoxate Antidepressants • Imipramine • Duloxetine Alpha-adrenoreceptor antagonists • Alfuzosin • Doxazosin • Prazosin • Terazosin • Tamsulosin Beta-adrenoreceptor antagonists • Terbutaline (beta-2) • Salbutamol (beta-2) • YM-178 (beta-3) PDE-5 inhibitors (for male LUTS/OAB) • Sildenafil, taladafil, vardenafil • COX inhibitors • Indomethacin • Flurbiprofen Toxins • Botulinum toxin (neurogenic), injected into bladder wall • Botulinum toxin (idiopathic), injected into bladder wall • Capsaicin (neurogenic), intravesical • Resiniferatoxin (neurogenic), intravesical Other drugs • Baclofen, intrathecal Hormones • Oestrogen • Desmopressin, for nocturia (nocturnal polyuria), but care should be taken because of the risk of hyponatraemia, especially in the elderly
2 2 1 1 3 2
A A C
3 2
C C
3 3 3 3 3
C C C C C
3 3 2
C C B
2
B
2 2
C C
2 3 2 2
A B C C
3
C
2 1
C A
Assessments have been done according to the Oxford modified system, see Tables 1 and 2 LE = level of evidence; GR = grade or recommendation; PDE-5 inhibitor = phosphodiesterase-type 5 inhibitor; COX inhibitor = cyclo-oxygenase inhibitor.
3.3 Drugs used in the treatment of stress urinary incontinence (SUI) Factors that may contribute to urethral closure include: • the tone of urethral smooth and striated muscle • the passive properties of the urethral lamina propria, particularly its vasculature. The relative contribution of these factors to intraurethral pressure is still debated. However, evidence shows that a substantial part of urethral tone is mediated through stimulation of alpha-adrenoreceptors in the urethral smooth muscle by released noradrenaline (6, 7). A contributory factor to SUI, mainly in elderly women with a lack of oestrogen, may be a deterioration in the mucosal co-adaptation function. Pharmacological treatment of SUI aims to increase the force of intraurethral closure by increasing tone in the urethral smooth and striated muscles. Several drugs may contribute to such an increase (8, 9). Their clinical use is limited by low efficacy and/or side-effects (Table 4).
8
Update march 2009
Table 4: Drugs used in the treatment of stress urinary incontinence Drug LE GR • Duloxetine 1 B • Imipramine 3 NR • Clenbuterol 3 C • Methoxamine 2 NR • Midodrine 2 C • Ephedrine 3 NR • Norephedrine (phenylpropanolamine) 3 NR • Oestrogen 2 NR GR = grade of recommendation; NR = no recommendation possible.
3.4 Drugs used for the treatment of ‘overflow incontinence’ Incontinence may occur when there are large quantities of residual urine with a markedly distended bladder (chronic urinary retention). The ICS no longer approves of the term, ‘overflow incontinence’ (10). Various medical approaches to overflow incontinence have been suggested (11, 12) based upon theoretical reasoning, animal studies (13, 14) and reports of drugs associated with poor bladder emptying (15). These include direct or indirect muscarinic receptor agonists and alpha-1-adrenoreceptor antagonists. However, a recent review of controlled clinical studies on direct and indirect parasympathetic agonists in patients with an underactive detrusor found these drugs were not consistently beneficial and may even be harmful (16). In contrast, alpha-1-adrenoreceptor antagonists have been consistently beneficial in patients with acute urinary retention (17). A recent Medline search using the keyword ‘overflow incontinence’ did not find any randomised controlled trials (RCT) for treatment using parasympathomimetic drugs or alpha-1-adrenoreceptor antagonists nor even a case series with a meaningful number of patients. This indicates that medical treatments currently used to treat overflow incontinence are being used on the basis of empirical evidence. Any previous recommendations for the medical treatment of overflow incontinence can be considered as ‘expert opinion’ at best. In addition, it is important to make sure any medical treatment for overflow incontinence is likely to reduce or eliminate residual urine better than the alternatives of catheterisation or surgery.
3.5
Hormonal treatment of UI
3.5.1 Oestrogen Oestrogen deficiency is an aetiological factor in the pathogenesis of several conditions. However, oestrogen treatment, either alone or combined with progestogen, has achieved only poor results in UI. The current evidence (level of evidence: 1) against the treatment of UI with oestrogen is based on studies originally designed to assess oestrogen for preventing cardiovascular events. In fact, the evidence is derived from secondary analyses of these studies using subjective, self-reported symptoms of urinary leakage. Nevertheless, these large RCTs showed a worsening of pre-existing UI (stress and urgency) and an increased new incidence of UI, with either oestrogen monotherapy or oestrogen combined with progestogen. It should be noted, however, that most patients were taking combined equine oestrogen, which may not be representative of all oestrogens taken by all routes of administration. A systematic review of the effects of oestrogen on symptoms suggestive of OAB concluded that oestrogen therapy may be effective in alleviating OAB symptoms and local administration may be the most beneficial route of administration (18). It is possible that urinary urgency, frequency and urgency incontinence are symptoms of urogenital atrophy in older post-menopausal women (19). There is good evidence that low-dose (local) vaginal oestrogen therapy may reverse the symptoms and cytological changes of urogenital atrophy. However, oestrogens (with or without progestogens) should not be used to treat UI, as there is no evidence to show they have a direct effect on the lower urinary tract. 3.5.2 Other steroid hormones/receptor ligands There are no reported clinical trials evaluating the effect of androgens, particularly testosterone, on UI in women. 3.5.3 Desmopressin Desmopressin (DDVAP) was found to be well tolerated and resulted in a significant improvement in UI
Update march 2009
9
compared to placebo in reducing nocturnal voids and increasing the hours of undisturbed sleep. Quality of life (QOL) also improved. However, hyponatraemia is one of the main, clinically important, side-effects of DDVAP administration. Hyponatraemia can lead to a range of adverse events from mild headache, anorexia, nausea, and vomiting to loss of consciousness, seizures and death. The risk of hyponatraemia has been reported in a meta-analysis as about 7.6% (20) and seems to increase with age, cardiac disease and a high 24-hour urine volume (21).
3.6 REFERENCES* 1.
Andersson K-E, Appell R, Cardozo L et al. Pharmacological treatment of urinary incontinence, in Abrams P, Khoury S, Wein A (Eds), Incontinence, 3rd International Consultation on Incontinence. Plymouth, Plymbridge Distributors Ltd, UK, Plymouth, 2005, p 811. 2. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 2003;326(7394):841-4. http://www.ncbi.nlm.nih.gov/pubmed/12702614 3. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J; for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48(3):464-70. http://www.ncbi.nlm.nih.gov/pubmed/15990220 4. Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, Ficarra V, Artibani W.. Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder. Eur Urol 2008;54(4):740-63. http://www.ncbi.nlm.nih.gov/pubmed/18632201 5. Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008;102(9):1128-32. http://www.ncbi.nlm.nih.gov/pubmed/18647298 6. Andersson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993;45(3):253-308. http://www.ncbi.nlm.nih.gov/pubmed/8248281 7. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract–basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004;56(4):581-631. http://www.ncbi.nlm.nih.gov/pubmed/15602011 8. Andersson KE. Current concepts in the treatment of disorders of micturition. Drugs 1988;35(4):477-94. http://www.ncbi.nlm.nih.gov/pubmed/3292211 9. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S;Trospium Study Group.Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171(6 Pt 1):2311-5. http://www.ncbi.nlm.nih.gov/pubmed/15126811 10. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-78. http://www.ncbi.nlm.nih.gov/pubmed/11857671 11. Chutka DS, Takahashi PY. Urinary incontinence in the elderly. Drug treatment options. Drugs 1998;56(4):587-95. http://www.ncbi.nlm.nih.gov/pubmed/9806105 12. Hampel C, Gillitzer R, Pahernik S, Melchior SW, Thüroff JW. [Drug therapy of female urinary incontinence] Urologe A 2005;44(3):244-55. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/15711814 13. Kamo I, Chancellor MB, De Groat WC, Yoshimura A. Differential effects of activation of peripheral and spinal tachykinin neurokinin3 receptors on the micturition reflex in rats. J Urol 2005;174(2):776-81. http://www.ncbi.nlm.nih.gov/pubmed/16006975 14. Gu B, Fraser MO, Thor KB, Dolber PC. Induction of bladder sphincter dyssynergia by kappa-2 opioid receptor agonists in the female rat. J Urol 2004 Jan;171(1):472-7. http://www.ncbi.nlm.nih.gov/pubmed/14665958 15. Anders RJ, Wang E, Radhakrishnan J, Sharifi R, Lee M. Overflow urinary incontinence due to carbamazepine. J Urol 1985 Oct;134(4):758-9. http://www.ncbi.nlm.nih.gov/pubmed/4032590
10
Update march 2009
16.
Barendrecht MM, Oelke M, Laguna MP, Michel C. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 2007;99(4):749-52. http://www.ncbi.nlm.nih.gov/pubmed/17233798 17. McNeill SA, Hargreave TB; Members of the Alfaur Study Group. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 2004;171(6 Pt 1):2316-20. http://www.ncbi.nlm.nih.gov/pubmed/15126812 18. Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE, Huang M, Ridder AM. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5 Pt 1):1919-24. http://www.ncbi.nlm.nih.gov/pubmed/15540755 19. Robinson D, Cardozo L, Terpstra G, Bolodeoku J; Tamsulosin Study Group. A randomized doubleblind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 2007;100(4):840-5. http://www.ncbi.nlm.nih.gov/pubmed/17822465 21. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn 2004;23(4):302-5. http://www.ncbi.nlm.nih.gov/pubmed/15227644 21. Rembratt A, Norgaard JP, Andersson KE. Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns. BJU Int 2003;91(7):642-6. http://www.ncbi.nlm.nih.gov/pubmed/12699476 *An exhaustive reference list is available for consultation on line at the society website (http://www.uroweb.org/ professional-resources/guidelines/) and on the guidelines CD-rom version.
4. INCONTINENCE IN MEN* 4.1
Initial assessment
Initial assessment in men should triage patients with a ‘complicated’ incontinence, who need to be referred for specialist management, from the remainder who are suitable for general assessment. The ‘complicated’ incontinence group comprises patients with: • pain • haematuria • recurrent infection • previous failed incontinence surgery • total incontinence • voiding dysfunction (e.g. due to bladder outlet obstruction). Poor bladder emptying may be suspected from symptoms, physical examination or if imaging has been performed by ultrasound or X-ray after voiding • previous pelvic radiotherapy. The group of remaining patients, with a history of UI identified by initial assessment, can be stratified into four main symptomatic groups of men suitable for initial management: • post-micturition dribble alone • OAB symptoms: urgency (with or without urge incontinence), frequency, and nocturia • stress incontinence, most often after prostatectomy • mixed urgency and stress incontinence, most often after prostatectomy.
4.2
Initial treatment
4.2.1 General management Conservative management is the main approach to UI in men at the primary care level (Figure 1), and is often considered to be simple and low cost. The term ‘conservative management’ describes any treatment that does not involve pharmacological or surgical intervention. However, for conditions, such as OAB, conservative strategies are often combined with drug treatment. *
This section of the guidelines is based on the recommendations of the ICI committees chaired by Jean Hay-Smith and Sender Herschorn. 4.1 (Initial assessment of UI) and 4.2 (Initial treatment of UI) provide the management algorithms and the explanatory notes; 4.4 (Surgical treatment of UI) provides additional evidence from the chapters.
Update march 2009
11
Many conservative management interventions require a change of behaviour, which is neither easy to initiate nor to maintain. Most patients with minor-to-moderate symptoms wish to try less invasive treatments first. However, patients with complicated or severe symptoms may need to be referred directly for specialised management. For men with post-micturition dribble, no further assessment is generally required. However, the patient should be told how to exert a strong pelvic floor muscle contraction after voiding or to manually compress the bulbous urethra directly after micturition (grade of recommendation: B). For men with stress incontinence, urgency or mixed stress/urgency incontinence, initial treatment should include appropriate lifestyle advice, physical therapies, scheduled voiding regimes, behavioural therapies and medication. In summary, these initial treatments carry lower grades of recommendation. Recommendations for initial treatments for UI in men Recommendations
GR
• Lifestyle intervention
NR
• Supervised pelvic floor muscle training for post prostatectomy SUI
B
• Scheduled voiding regimes for OAB
C
• When there is no evidence of significant post-void residual urine, antimuscarinic drugs for OAB symptoms, with or without urgency incontinence • Alpha-adrenergic antagonists (alpha-blockers) can be added if there is also bladder outlet obstruction GR = grade of recommendation; NR = no recommendation possible.
C C
4.2.2 Post-radical prostatectomy RP incontinence Despite the prevalence of UI and LUTS in older men, the only group to have been researched properly is men who have had RP. Overall, the effect of conservative treatment (lifestyle interventions, physical therapies, scheduled voiding regimes, complementary therapies) has been much less researched in men compared to women. There is generally insufficient level 1 or 2 evidence and most recommendations are essentially hypotheses requiring further research. Recommendations for conservative treatment of UI in men Recommendations Lifestyle interventions • It seems reasonable for health professionals to offer men advice on healthy lifestyle choices that may reduce or delay the onset of continence problems Pelvic floor muscle training (PFMT) • Some pre-operative or immediate post-operative instructions in PFMT for men undergoing radical prostatectomy may be helpful • It is not clear whether PFMT taught by digital rectal examination (DRE) has more benefit than verbal or written instruction in PFMT • The use of biofeedback to assist PFMT is currently a therapist/patient decision based on economics and preference Electrical stimulation • For men with post-prostatectomy incontinence, adding electrical stimulation to a PFMT programme does not appear to be of benefit
GR NR
B B B
B
GR = grade of recommendation; NR = no recommendation possible 4.2.3 Conclusions • There is generally insufficient level 1 or 2 evidence for these initial treatments. Most ‘recommendations’ are hypotheses needing further testing in high-quality research studies. • If initial treatment is unsuccessful after a reasonable period of time (e.g. 8-12 weeks), specialist’s advice is highly recommended.
12
Update march 2009
Figure 1: Algorithm for initial management of UI in men.
s
s s
4.3
Specialised management of UI in men
The specialist may first decide to re-institute initial management if previous therapy might have been inadequate. Specialised management of UI in men is summarised in Figure 2. 4.3.1 Assessment Patients with ‘complicated’ incontinence referred directly to specialised management will probably need additional testing to exclude any other underlying pathology, i.e. cytology, cystourethroscopy and urinary tract imaging. If these tests are normal, patients can be treated for incontinence by initial or specialised management options as appropriate. If symptoms suggestive of detrusor overactivity or of sphincter incompetence persist, urodynamic studies are recommended to establish a diagnosis based on pathophysiological findings (urodynamic diagnosis). 4.3.2 Interventions If initial management has failed and the patient’s incontinence is affecting quality of life, invasive therapies may be considered. 4.3.3 Sphincter incompetence For sphincter incompetence, the recommended option is surgical implantation of an artificial urinary sphincter (AUS) (grade of recommendation: B). An alternative option is a male sling. 4.3.3.1 Detrusor overactivity (DO) For idiopathic DO (with intractable OAB symptoms), the recommended therapies are: • surgical bladder augmentation with intestinal segments (grade of recommendation: C) • implantation of a neuromodulator (grade of recommendation: B). Detrusor injections with botulinum toxin continue to show promise in the treatment of symptomatic detrusor overactivity unresponsive to other therapies. 4.3.3.2 Poor bladder emptying If incontinence is associated with poor bladder emptying due to detrusor underactivity, effective means should be used to ensure bladder emptying, e.g. CIC (grade of recommendation: B-C).
Update march 2009
13
4.3.3.3 Bladder outlet obstruction (BOO) If incontinence is due to bladder outlet obstruction, then the obstruction should be relieved (grade of recommendation: B-C). Pharmacological treatment options for UI and proven outlet obstruction are alphablockers or 5-alpha-reductase inhibitors (grade of recommendation: C-D). There is increasing evidence for the safety of antimuscarinic agents for OAB symptoms in men with outlet obstruction, when combined with an alpha-blocker (grade of recommendation: B). Currently, botulinum toxin injections into the detrusor muscle are being used ‘off-label’ for this indication. Figure 2: Algorithm for specialised management of UI in men
4.4
Surgical treatment
Urinary incontinence in men suitable for surgical correction can be classified by cause into sphincter-related incontinence (post-operative, post-traumatic, and congenital), bladder-related incontinence and fistulae (Table 5). Initial routine assessment and further evaluations are described in Table 6. Table 5: Aetiological classification of surgically correctable UI in men Sphincter-related • Postoperative - Post-prostatectomy for benign disease - Post-prostatectomy for prostate cancer - Post radiotherapy, brachytherapy, cryosurgery, HIFU for prostate cancer - Post cystectomy and neobladder for bladder cancer • Post-traumatic - After prostato-membranous disruption and urethral reconstruction - Pelvic floor trauma • Unresolved paediatric UI - Exstrophy and incontinent epispadias Bladder-related • Refractory UUI (overactive bladder) • Reduced capacity bladder Fistulae • Urethro-cutaneous • Recto-urethral HIFU = high-intensity focused ultrasound; UI = urinary incontinence; UUI = urge urinary incontinence.
14
Update march 2009
Table 6: Initial assessment prior to surgical therapy Routine assessment • Medical history and physical examination, urinalysis, post void residual urine, frequency/volume chart, pad test, and serum creatinine if renal disease is suspected Further evaluation as required (level of evidence: 2-4, grade of recommendation: A-C) • Cysto-urethroscopy to assess urethral integrity, sphincter appearance, stricture, bladder pathology and imaging of the upper and lower urinary tract (ultrasound, cysto-urethrography, intravenous pyelogram) • Urodynamic studies to assess sphincter and/or detrusor function • Valsalva leak point pressure to measure sphincter weakness • Urethral pressure profile (UPP) or retrograde perfusion sphincterometry may be performed if AUS or slings are to be implanted • Sphincter electromyography to investigate suspected neuropathy • Multichannel pressure/flow video-urodynamic evaluation to assess detrusor function and characterise the underlying pathophysiology 4.4.1 Incontinence after surgery for BPO or prostate cancer (CaP) 4.4.1.1 Incontinence after surgery for benign prostatic obstruction (BPO) Incidence of UI is similar after open surgery, transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP) and Holium laser enucleation. 4.4.1.2 Incontinence after surgery for prostate cancer (CaP) Generally, the incidence of UI after RP has decreased, but it is still a significant problem. Overall, the reported incidences range between 5% and 48%. Generally, patients report higher degrees of UI than do their physicians. The degree of UI varies and is often estimated by the numbers of pads and their wetness, social impairment and bothersomeness, which are usually assessed by non-standardised instruments. 4.4.1.3 Definitions of post-RP continence The definitions of post-RP continence are: • total control without any pad or leakage • no pad but loss of few drops of urine (‘underwear staining’) • none or 1 pad (‘safety pad’) per day. 4.4.1.4 Incontinence risk factors Reported risk factors for incontinence after RP include age at surgery, prostate size, co-morbidities, nervesparing surgery, bladder neck stenosis, tumour stage (possibly related to surgical technique), and preoperative bladder and sphincter dysfunction. The risk is unrelated to the technique of prostatectomy (radical vs non-radical vs robotic: these reports are entirely from centres of excellence). 4.4.1.5 Interventional treatment for post-RP incontinence After a period of conservative management of at least 6-12 months, the artificial urinary sphincter (AUS) is the treatment of choice for patients with moderate-to-severe UI. In studies that report treatment results of UI after surgery of BPO and CaP together, the success rates for AUS range between 59% and 90% (0-1 pad/ day). Long-term success rates and high patient satisfaction seem to outweigh the need for periodic revisions in some patients. Until similar experience is seen with newer, less invasive treatments, the AUS remains the reference standard to which all other treatments must be compared (level of evidence: 2) (grade of recommendation: B). Male slings are an alternative for men with mild-to-moderate UI (radiotherapy is an adverse risk factor). The overall minimum success is 58%, with best results achieved in patients with low-to-moderate leakage of urine, who had not undergone radiotherapy (level of evidence: 3) (grade of recommendation: C). Bulking agents are a less effective option for some men with mild-to-moderate UI. The early failure rate is about 50% and any beneficial effects decrease with time (level of evidence: 3) (grade of recommendation: C). The implantation of compressive adjustable balloons is a new treatment option. Early high complication rates appear to have been resolved. However, more evidence is required before specific recommendations can be made (level of evidence: 3) (grade of recommendation: D).
Update march 2009
15
4.4.1.6 Age Age is not a restriction for surgical treatment of post-prostatectomy incontinence. However, cognitive impairment and a lack of normal dexterity may restrict use of an AUS and must be assessed pre-operatively (level of evidence: 3-4) (grade of recommendation: C). 4.4.1.7 Post-RP incontinence with bladder neck stricture Treatment options for incontinence following RP with concomitant bladder neck stricture and other types of surgical stricture are visual internal urethrotomy, followed by implantation of an AUS once the urethra has been stabilised. 4.4.2 Incontinence after external beam radiotherapy for CaP The risk of incontinence after external beam radiotherapy ranges between 0 and 18.9%, but it may increase over time. There is a higher earlier risk in patients, who have had either a pre- or post-treatment TURP of 5-11%. Adjuvant radiotherapy may increase the risk of incontinence after RP. Also salvage RP after radiotherapy has an increased risk of incontinence. 4.4.2.1 AUS after radiotherapy There is a variably higher revision rate after radiotherapy than without radiotherapy, due to a higher incidence of erosion and infection, possibly caused by urethral atrophy from radiation-induced vasculitis. Detrusor overactivity and bladder neck contractures may also occur. Prolonged and/or intermittent de-activation of the sphincter is recommended; the cuff of the sphincter must be placed outside the radiotherapy field. 4.4.2.2 Conclusion An artificial sphincter is the most widely used treatment. Radiotherapy is a risk factor for an increase in complications (level of evidence: 3, grade of recommendation: C) 4.4.2.3 Other treatments for SUI after radiotherapy Limited evidence suggests that perineal compression slings can be an alternative therapy. However, injectable agents have not been successful (level of evidence 3; grade of recommendation: C). 4.4.3 Incontinence after other treatment for CaP 4.4.3.1 Brachytherapy After brachytherapy, incontinence occurs in 0-45% of the cases. TURP after brachytherapy carries a high risk of incontinence. 4.4.3.2 Cryotherapy Radiotherapy prior to cryotherapy is a risk factor for incontinence, fistulae occur in 0-5%. 4.4.3.3 High-intensity focused ultrasound (HIFU) The rate of incontinence decreases with surgical experience. 4.4.3.4 Recommendation The artificial sphincter is most widely used (grade of recommendation: C). Injectable agents have not been successful (grade of recommendation: C). 4.4.4 Treatment of incontinence after neobladder Continence rates achieved 2 years after orthotopic urinary diversion are 85-100% during the day and 55-100% at night. Treatment includes conservative management, intermittent catheterisation and artificial sphincter implantation (grade of recommendation: C). 4.4.5 Urethral and pelvic floor injuries Incontinence following injuries of the posterior urethra occurs in 0-20% of patients. The most commonly published surgical therapy is the AUS (level of evidence: 2) (grade of recommendation: B). Depending on the individual case, additional procedures are needed, i.e. urethral or bladder neck reconstruction. If reconstruction is impossible, one treatment option is bladder neck closure and construction of a Mitrofanoff catheterisable abdominal stoma (level of evidence: 3) (grade of recommendation: C). For patients with severe bladder neck stricture and incontinence, an intra-urethral stent may be used together with an AUS (level of evidence: 3) (grade of recommendation: C).
16
Update march 2009
4.4.5.1 Recommendation Recommendation • Although other treatments are possible, the AUS provides a reasonable outcome in appropriate cases. 4.4.6 Incontinence in adult epispadias-exstrophy complex Patients should be treated in centres of excellence using a patient-directed approach. Treatment choices include: • bladder neck reconstructive surgery • bladder neck closure • bladder reconstruction • urinary diversion. There is not enough data to provide a specific recommendation. The patient’s transition is important between the paediatric and adult urologist. Life-long follow-up is mandatory, particularly for continence, voiding efficiency, upper tract status and other urological complications (level of evidence: 3) (grade of recommendation: C). 4.4.7 Refractory UUI and idiopathic DO Botulinum toxin A detrusor injection is a minimally invasive treatment with some efficacy that is currently used as an ‘off-label detrusor injection for this indication. Other treatment options include neuromodulation or detrusor myectomy, which have both been successful in a few male patients. Augmentation cystoplasty with intestinal segments is potentially successful in controlling symptoms but may have side-effects. Urinary diversion is a final option (level of evidence: 3) (grade of recommendation: C). 4.4.8 Incontinence and reduced capacity bladder Augmentation cystoplasty has been successful in helping with reduced capacity bladder due to most aetiologies except radiotherapy cystitis (level of evidence: 3) (grade of recommendation: C). 4.4.9 Urethro-cutaneous fistula and recto-urethral fistula The aetiology of acquired fistulae can be iatrogenic, trauma, inflammation, and tumour. Fistulae in men are most often iatrogenic (surgery, radiotherapy, cryotherapy, HIFU) or inflammatory (diverticulitis). The localisation and size of acquired urethro-cutaneous fistulae are demonstrated by clinical, endoscopic and imaging studies. Surgical reconstruction is performed as required. Similar diagnostic manoeuvres are applied to recto-urethral fistulas. Surgical reconstruction may be carried out in fistulae that do not close, with or without temporary urinary and faecal diversion. Most repairs are carried out after prior faecal diversion. Various techniques are available for closure and can be done in collaboration with colorectal surgeons (level of evidence: 3) (grade of recommendation: C). 4.4.10 Management of AUS complications Recurrent incontinence after AUS implantation may result from alteration in bladder function, urethral atrophy, or mechanical malfunction. All or part of the prosthesis must be surgically removed if there is infection and/ or erosion of components. Risk factors are surgery, radiotherapy, catheterisation and endoscopy (level of evidence: 3) (grade of recommendation: C).
4.5 REFERENCES* •
•
•
•
Herschorn S, Thuroff J, Bruschini H, et al. Surgical treatment of urinary incontinence in men. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: Third International Consultation. Paris: Health Publications Ltd, 2005, pp.1241-1296. Blatt AH, Titus J, Chan L. Ultrasound measurement of bladder wall thickness in the assessment of voiding dysfunction. J Urol 2008;179(6):2275-8; discussion 2278-9. http://www.ncbi.nlm.nih.gov/pubmed/17382743 Fischer MC, Huckabay C, Nitti VW. The male perineal sling: assessment and prediction of outcome. J Urol 2007;177(4):1414-18. http://www.ncbi.nlm.nih.gov/pubmed/17382743 Migliari R, Pistolesi D, Leone P, Viola D, Trovarelli S. Male bulbourethral sling after radical prostatectomy: intermediate outcomes at 2 to 4-year followup. J Urol 2006;176(5):2114-18; discussion 2118. http://www.ncbi.nlm.nih.gov/pubmed/17070273
Update march 2009
17
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
18
Hübner WA, Schlarp OM. Adjustable continence therapy (ProACT): evolution of the surgical technique and comparison of the original 50 patients with the most recent 50 patients at a single centre. Eur Urol 2007;52(3):680-6. http://www.ncbi.nlm.nih.gov/pubmed/17097218 Rehder P, Gozzi C. Transobturator sling suspension for male urinary incontinence including postradical prostatectomy. Eur Urol 2007;52(3):860-6. http://www.ncbi.nlm.nih.gov/pubmed/17316969 Fassi-Fehri H, Badet L, Cherass A, Murat FJ, Colombel M, Martin X, Gelet A. Efficacy of the InVance male sling in men with stress urinary incontinence. Eur Urol 2007;51(2):498-503. http://www.ncbi.nlm.nih.gov/pubmed/16996679 Lebret T, Cour F, Benchetrit J, Grise P, Bernstein J, Delaporte V, Chartier-Kastler E, Botto H, Costa P. Treatment of postprostatectomy stress urinary incontinence using a minimally invasive adjustable continence balloon device, ProACT: results of a preliminary, multicenter, pilot study. Urology 2008;71(2):256-60. http://www.ncbi.nlm.nih.gov/pubmed/18308096 Imamoglu MA, Tuygun C, Bakirtas H, Yiğitbasi O, Kiper A. The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. Eur Urol 2005;47(2):209-13. http://www.ncbi.nlm.nih.gov/pubmed/15661416 Trigo Rocha F, Gomes CM, Mitre AI, Arap S, Srougi M. A prospective study evaluating the efficacy of the artificial sphincter AMS 800 for the treatment of postradical prostatectomy urinary incontinence and the correlation between preoperative urodynamic and surgical outcomes. Urology 2008;71(1): 85-9. http://www.ncbi.nlm.nih.gov/pubmed/18242371 Rodriguez E Jr, Skarecky DW, Ahlering TE. Post-robotic prostatectomy urinary continence: characterization of perfect continence versus occasional dribbling in pad-free men. Urology 2006;67(4):785-8. http://www.ncbi.nlm.nih.gov/pubmed/16566988 Rodriguez E Jr, Skarecky DW, Ahlering TE. Post-robotic prostatectomy urinary continence: characterization of perfect continence versus occasional dribbling in pad-free men. Urology 2006;67(4):785-8. http://www.ncbi.nlm.nih.gov/pubmed/16566988 Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005;173(5):1701-5. http://www.ncbi.nlm.nih.gov/pubmed/15821561 Jacobsen NE, Moore KN, Estey E, Voaklander D. Open versus laparoscopic radical prostatectomy: a prospective comparison of postoperative urinary incontinence rates. J Urol 2007;177(2):615-19. http://www.ncbi.nlm.nih.gov/pubmed/17222646 Sacco E, Prayer-Galetti T, Pinto F, Fracalanza S, Betto G, Pagano F, Artibani W. Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int 2006;97(6):1234-41. http://www.ncbi.nlm.nih.gov/pubmed/16686718 Moore KN, Truong V, Estey E, Voaklander DC. Urinary incontinence after radical prostatectomy: can men at risk be identified preoperatively? J Wound Ostomy Continence Nurs 2007;34(3):270-9; quiz 280-1. http://www.ncbi.nlm.nih.gov/pubmed/17505246 Majoros A, Bach D, Keszthelyi A, Hamvas A, Romics I. Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study). Neurourol Urodyn 2006;25(1):2-7. http://www.ncbi.nlm.nih.gov/pubmed/16224797 Mohamad BA, Marszalek M, Brossner C, Ponholzer A, Wehrberger C, Willinger M, Madersbacher S. Radical prostatectomy in Austria: a nationwide analysis of 16,524 cases. Eur Urol 2007;51(3):684-8; discussion 689. http://www.ncbi.nlm.nih.gov/pubmed/16835007 Rogers CG, Su LM, Link RE, Sullivan W, Wagner A, Pavlovich CP. Age stratified functional outcomes after laparoscopic radical prostatectomy. J Urol 2006;176(6Pt1):2448-52. http://www.ncbi.nlm.nih.gov/pubmed/17085126
Update march 2009
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Pierorazio PM, Spencer BA, McCann TR, McKiernan JM, Benson MC. Preoperative risk stratification predicts likelihood of concurrent PSA-free survival, continence, and potency (the trifecta analysis) after radical retropubic prostatectomy. Urology 2007;70(4):717-22. http://www.ncbi.nlm.nih.gov/pubmed/17991543 Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007;69(6):1170-5. http://www.ncbi.nlm.nih.gov/pubmed/17572209 Nandipati KC, Raina R, Agarwal A, Zippe CD. Nerve-sparing surgery significantly affects long-term continence after radical prostatectomy. Urology 2007;70(6):1127-30. http://www.ncbi.nlm.nih.gov/pubmed/18158032 Burkhard FC, Kessler TM, Fleischmann A, Thalmann GN, Schumacher M, Studer UE. Nerve sparing open radical retropubic prostatectomy – does it have an impact on urinary continence? J Urol 2006;176(1):189-95. http://www.ncbi.nlm.nih.gov/pubmed/16753399 Onur R, Singla A. Comparison of bone-anchored male sling and collagen implant for the treatment of male incontinence. Int J Urol 2006;13(9):1207-11. http://www.ncbi.nlm.nih.gov/pubmed/16984554 Hurtado EA, McCrery RJ, Appell RA. Complications of ethylene vinyl alcohol copolymer as an intraurethral bulking agent in men with stress urinary incontinence. Urology 2008;71(4):662-5. http://www.ncbi.nlm.nih.gov/pubmed/18279931 Mitterberger M, Marksteiner R, Margreiter E, Pinggera GM, Frauscher F, Ulmer H, Fussenegger M, Bartsch G, Strasser H. Myoblast and fibroblast therapy for post-prostatectomy urinary incontinence: 1-year followup of 63 patients. J Urol 2008;179(1):226-31. http://www.ncbi.nlm.nih.gov/pubmed/18001790 Strasser H, Marksteiner R, Margreiter E, Mitterberger M, Pinggera GM, Frauscher F, Fussenegger M, Kofler K, Bartsch G. Transurethral ultrasonography-guided injection of adult autologous stem cells versus transurethral endoscopic injection of collagen in treatment of urinary incontinence. World J Urol 2007;25(4):385-92. http://www.ncbi.nlm.nih.gov/pubmed/17701044 Kleinert S, Horton R. Retraction – autologous myoblasts and fibroblasts versus collagen [corrected] for treatment of stress urinary incontinence in women: a [corrected] randomised controlled trial. Lancet 2008;372(9641):789-90. http://www.ncbi.nlm.nih.gov/pubmed/18774408 Strasser H, Marksteiner R, Margreiter E, Pinggera GM, Mitterberger M, Frauscher F, Ulmer H, Fussenegger M, Kofler K, Bartsch G. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. Lancet 2007;369(9580):2179-86. http://www.ncbi.nlm.nih.gov/pubmed/17604800 Kielb SJ, Clemens JQ. Comprehensive urodynamics evaluation of 146 men with incontinence after radical prostatectomy. Urology 2005;66(2):392-6. http://www.ncbi.nlm.nih.gov/pubmed/16040102 Klingler HC, Marberger M. Incontinence after radical prostatectomy: surgical treatment options. Curr Opin Urol 2006;16(2):60-4. http://www.ncbi.nlm.nih.gov/pubmed/16479205 Stern JA, Clemens JQ, Tiplitsky SI, Matschke HM, Jain PM, Schaeffer AJ. Long-term results of the bulbourethral sling procedure. J Urol 2005;173(5):1654-6. http://www.ncbi.nlm.nih.gov/pubmed/15821529 Xu YM, Zhang XR, Sa YL, Chen R, Fei XF. Bulbourethral composite suspension for treatment of maleacquired urinary incontinence. Eur Urol 2007;51(6):1709-14; discussion 17156. http://www.ncbi.nlm.nih.gov/pubmed/17011113 Rajpurkar AD, Onur R, Singla A. Patient satisfaction and clinical efficacy of the new perineal boneanchored male sling. Eur Urol 2005;47(2):237-42; discussion 242. http://www.ncbi.nlm.nih.gov/pubmed/15661420 Comiter CV, Rhee EY. The ‘ventral urethral elevation plus’ sling: a novel approach to treating stress urinary incontinence in men. BJU Int 2008;101(2):187-91. http://www.ncbi.nlm.nih.gov/pubmed/17970788
Update march 2009
19
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
20
Rapp DE, Reynolds WS, Lucioni A, Bales GT. Surgical technique using AdVance sling placement in the treatment of post-prostatectomy urinary incontinence. Int Braz J Urol 2007;33(2):231-5; discussion 236-7. http://www.ncbi.nlm.nih.gov/pubmed/17488544 Moreno Sierra J, Victor Romano S, Galante Romo I, Barrera Ortega J, Salinas Casado J, Silmi Moyano A. [New male sling ‘Argus’ for the treatment of stress urinary incontinence]. Arch Esp Urol 2006;59(6):607-13. [article in Spanish.] http://www.ncbi.nlm.nih.gov/pubmed/16933489 Romano SV, Metrebian SE, Vaz F, Muller V, D’Ancona CA, Costa De Souza EA, Nakamura F. An adjustable male sling for treating urinary incontinence after prostatectomy: a phase III multicentre trial. BJU Int 2006;97(3):533-9. http://www.ncbi.nlm.nih.gov/pubmed/16469021 Castle EP, Andrews PE, Itano N, Novicki DE, Swanson SK, Ferrigni RG. The male sling for postprostatectomy incontinence: mean followup of 18 months. J Urol 2005;173(5):1657-60. http://www.ncbi.nlm.nih.gov/pubmed/15821530 Gallagher BL, Dwyer NT, Gaynor-Krupnick DM, Latini JM, Kreder KJ. Objective and quality-of-life outcomes with bone-anchored male bulbourethral sling. Urology 2007;69(6):1090-4. http://www.ncbi.nlm.nih.gov/pubmed/17572193 Giberti C, Gallo F, Schenone M, Cortese P. The bone-anchor sub-urethral sling for the treatment of iatrogenic male incontinence: subjective and objective assessment after 41 months of mean follow-up. World J Urol 2008;26(2):173-8. http://www.ncbi.nlm.nih.gov/pubmed/17982750 Comiter CV. Surgery Insight: surgical management of postprostatectomy incontinence – the artificial urinary sphincter and male sling. Nat Clin Pract Urol 2007;4(11):615-24. http://www.ncbi.nlm.nih.gov/pubmed/17982438 Suburethral synthetic sling insertion for stress urinary incontinence in men. National Institute for Health and Clinical Excellence. Issued March 2008. [accessed on 21 September 2008]. http://www.nice.org.uk/nicemedia/pdf/IPG256Guidance.pdf Gregori A, Simonato A, Lissiani A, Scieri F, Rossi R, Gaboardi F. Transrectal ultrasound guided implantation of the ProACT adjustable continence therapy system in patients with post-radical prostatectomy stress urinary incontinence: a pilot study. J Urol 2006;176(5):2109-13; discussion 2113. http://www.ncbi.nlm.nih.gov/pubmed/17070270 Hübner WA, Schlarp OM. Treatment of incontinence after prostatectomy using a new minimally invasive device: adjustable continence therapy. BJU Int 2005;96(4):587-94. http://www.ncbi.nlm.nih.gov/pubmed/16104915 Trigo-Rocha F, Gomes CM, Pompeo AC, Lucon AM, Arap S. Prospective study evaluating efficacy and safety of Adjustable Continence Therapy (ProACT) for post radical prostatectomy urinary incontinence. Urology 2006;67(5):965-9. http://www.ncbi.nlm.nih.gov/pubmed/16698356 Cansino Alcaide JR, Alvarez Maestro M, Martín Hernández M, Cabrera Castillo PM, Pérez-Utrilla Pérez M, Rodríguez de Bethencourt F, Hidalgo Togores L, De la Peña Barthel JJ. [Paraurethral balloon implantation in the treatment of male urinary incontinence. La Paz University Hospital experience]. Arch Esp Urol 2007;60(6):647-55. [article in Spanish] http://www.ncbi.nlm.nih.gov/pubmed/17847738 Kocjancic E, Crivellaro S, Ranzoni S, Bonvini D, Gontero P, Frea B. Adjustable Continence Therapy for the treatment of male stress urinary incontinence: a single-centre study. Scand J Urol Nephrol 2007;41(4):324-8. http://www.ncbi.nlm.nih.gov/pubmed/17763225 Kim SP, Sarmast Z, Daignault S, Faerber GJ, McGuire EJ, Latini JM. Long-term durability and functional outcomes among patients with artificial urinary sphincters: a 10-year retrospective review from the University of Michigan. J Urol 2008;179(5):1912-16. http://www.ncbi.nlm.nih.gov/pubmed/18353376 Lai HH, Hsu EI, Teh BS, Butler EB, Boone TB. 13 years of experience with artificial urinary sphincter implantation at Baylor College of Medicine. J Urol 2007;177(3):1021-5. http://www.ncbi.nlm.nih.gov/pubmed/17296403 O’Connor RC, Lyon MB, Guralnick ML, Bales GT. Long-term follow-up of single versus double cuff artificial urinary sphincter insertion for the treatment of severe postprostatectomy stress urinary incontinence. Urology 2008;71(1):90-3. http://www.ncbi.nlm.nih.gov/pubmed/18242372
Update march 2009
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Galli S, Simonato A, Bozzola A, Gregori A, Lissiani A, Scaburri A, Gaboardi F. Oncologic outcome and continence recovery after laparoscopic radical prostatectomy: 3 years’ follow-up in a ‘second generation center’. Eur Urol 2006;49(5):859-65. http://www.ncbi.nlm.nih.gov/pubmed/16519991 Colombo R, Naspro R, Salonia A, Montorsi F, Raber M, Suardi N, Saccà A, Rigatti P. Radical prostatectomy after previous prostate surgery: clinical and functional outcomes. J Urol 2006;176(6Pt1):2459-63; discussion 2463. http://www.ncbi.nlm.nih.gov/pubmed/17085129 Schneider T, Sperling H, Rossi R, Schmidt S, Rübben H. Do early injections of bulking agents following radical prostatectomy improve early continence? World J Urol 2005;23(5):338-42. http://www.ncbi.nlm.nih.gov/pubmed/16261366 Jones JS, Vasavada SP, Abdelmalak JB, Liou L, Ahmed ES, Zippe CD, Rackley RR. Sling may hasten return of continence after radical prostatectomy. Urology 2005;65(6):1163-7. http://www.ncbi.nlm.nih.gov/pubmed/15922423 Wendt-Nordahl G, Bucher B, Häcker A, Knoll T, Alken P, Michel MS. Improvement in mortality and morbidity in transurethral resection of the prostate over 17 years in a single center. J Endourol 2007;21(9):1081-7. http://www.ncbi.nlm.nih.gov/pubmed/17941791 Roehrborn CG, McConnell JD, Barry MJ, Benaim E, Bruskewitz R, Blute M,HL Holtgrewe, Kaplan S, Lange J, Lowe F, Roberts R, Stein B. Guideline on the Management of Benign Prostatic Hyerplasia (BPH), 2006. American Urological Association. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg 2007;94(10):1201-8. http://www.ncbi.nlm.nih.gov/pubmed/17729384 Gupta N, Sivaramakrishna, Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int 2006;97(1):85-9. http://www.ncbi.nlm.nih.gov/pubmed/16336334 Westney OL, Bevan-Thomas R, Palmer JL, Cespedes RD, McGuire EJ. Transurethral collagen injections for male intrinsic sphincter deficiency: the University of Texas-Houston experience. J Urol 2005;174(3):994-7. http://www.ncbi.nlm.nih.gov/pubmed/16094021 Dylewski DA, Jamison MG, Borawski KM, Sherman ND, Amundsen CL, Webster GD. A statistical comparison of pad numbers versus pad weights in the quantification of urinary incontinence. Neurourol Urodyn 2007;26(1):3-7. http://www.ncbi.nlm.nih.gov/pubmed/17080415 O’Connor RC, Nanigian DK, Patel BN, Guralnick ML, Ellision LM, Stone AR. Artificial urinary sphincter placement in elderly men. Urology 2007;69(1):126-8. http://www.ncbi.nlm.nih.gov/pubmed/17270633 Ponholzer A, Brössner C, Struhal G, Marszalek M, Madersbacher S. Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. World J Urol 2006;24(3):325-30. http://www.ncbi.nlm.nih.gov/pubmed/16688458 Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin WP, Wei JT. Longterm outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005;23(12):2772-80. http://www.ncbi.nlm.nih.gov/pubmed/15837992 Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110(7):1417-28. http://www.ncbi.nlm.nih.gov/pubmed/17694553 Raj GV, Peterson AC, Webster GD. Outcomes following erosions of the artificial urinary sphincter. J Urol 2006;175(6):2186-90; discussion 2190. http://www.ncbi.nlm.nih.gov/pubmed/16697836 Bottomley D, Ash D, Al-Qaisieh B, Carey B, Joseph J, St Clair S, Gould K. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol 2007;82(1):46-9. http://www.ncbi.nlm.nih.gov/pubmed/17161481
Update march 2009
21
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
22
Petit JH, Gluck C, Kiger WS 3rd, Laury Henry D, Karasiewicz C, Talcott JA, Berg S, Holupka EJ, Kaplan ID. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume. Brachytherapy 2007;6(4):267-71. http://www.ncbi.nlm.nih.gov/pubmed/17959423 Robinson JW, Donnelly BJ, Coupland K, Siever JE, Saliken JC, Scott C, Brasher PM, Ernst DS. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urol Oncol 2006;24(6):472-86. http://www.ncbi.nlm.nih.gov/pubmed/17138127 Rebillard X, Soulié M, Chartier-Kastler E, Davin JL, Mignard JP, Moreau JL, Coulange C; Association Francaise d’Urologie. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 2008;101(10):1205-13. http://www.ncbi.nlm.nih.gov/pubmed/18325057 Nieuwenhuijzen JA, de Vries RR, Bex A, van der Poel HG, Meinhardt W, Antonini N, Horenblas S. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol 2008;53(4):834-42; discussion 842-34. http://www.ncbi.nlm.nih.gov/pubmed/17904276 Cerqueira M, Xambre L, Silva V, Santos R, Lages R, Prisco R, Carreira F. [Bulbourethral sling. The experience of our service]. Actas Urol Esp 2005;29(4):401-7. http://www.ncbi.nlm.nih.gov/pubmed/15981429 Raj GV, Peterson AC, Toh KL, Webster GD. Outcomes following revisions and secondary implantation of the artificial urinary sphincter. J Urol 2005;173(4):1242-5. http://www.ncbi.nlm.nih.gov/pubmed/16697836 Simonato A, Gregori A, Lissiani A, Carmignani G. Two-stage transperineal management of posterior urethral strictures or bladder neck contractures associated with urinary incontinence after prostate surgery and endoscopic treatment failures. Eur Urol 2007;52(5):1499-504. http://www.ncbi.nlm.nih.gov/pubmed/17418481 Woodhouse CR, North AC, Gearhart JP. Standing the test of time: long-term outcome of reconstruction of the exstrophy bladder. World J Urol 2006;24(3):244-9. http://www.ncbi.nlm.nih.gov/pubmed/16518662 Lee C, Reutter HM, Grasser MF, Fisch M, Noeker M. Gender-associated differences in the psychosocial and developmental outcome in patients affected with the bladder exstrophy-epispadias complex. BJU Int 2006;97(2):349-53. http://www.ncbi.nlm.nih.gov/pubmed/16430645 Burki T, Hamid R, Duffy P, Ransley P, Wilcox D, Mushtaq I. Long-term followup of patients after redo bladder neck reconstruction for bladder exstrophy complex. J Urol 2006;176(3):1138-41; discussion 1141-2. http://www.ncbi.nlm.nih.gov/pubmed/16890709 Baird AD, Frimberger D, Gearhart JP. Reconstructive lower urinary tract surgery in incontinent adolescents with exstrophy/epispadias complex. Urology 2005;66(3):636-40. http://www.ncbi.nlm.nih.gov/pubmed/16140093 Burki T, Hamid R, Ransley PG, Mushtaq I, Duffy PG. Injectable polydimethylsiloxane for treating incontinence in children with the exstrophy-epispadias complex: long-term results. BJU Int 2006;98(4):849-53. http://www.ncbi.nlm.nih.gov/pubmed/16978283 Lottmann HB, Margaryan M, Lortat-Jacob S, Bernuy M, Lackgren G. Long-term effects of dextranomer endoscopic injections for the treatment of urinary incontinence: an update of a prospective study of 61 patients. J Urol 2006;176(4Pt2):1762-6. http://www.ncbi.nlm.nih.gov/pubmed/16945642 Quek P. A critical review on magnetic stimulation: what is its role in the management of pelvic floor disorders? Curr Opin Urol 2005;15(4):231-5. http://www.ncbi.nlm.nih.gov/pubmed/15928511 Kuo HC. Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. BJU Int 2005;95(7):1023-7. http://www.ncbi.nlm.nih.gov/pubmed/15839924 Kuo HC, Liu HT, Yang WC. Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. J Urol 2006;176(2):641-5. http://www.ncbi.nlm.nih.gov/pubmed/16813911
Update march 2009
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Rios LA, Panhoca R, Mattos D Jr, Srugi M, Bruschini H. Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: a single dose, 4 weeks, double-blind, randomized, placebo controlled trial. Neurourol Urodyn 2007;26(6):773-8. http://www.ncbi.nlm.nih.gov/pubmed/17638305 Cruz F, Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourol Urodyn 2007;26(6Suppl.):920-7. http://www.ncbi.nlm.nih.gov/pubmed/17705161 Liu HT, Kuo HC. Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity. BJU Int 2007;100(5):1086-90. http://www.ncbi.nlm.nih.gov/pubmed/17711510 Silva C, Silva J, Castro H, Reis F, Dinis P, Avelino A, Cruz F. Bladder sensory desensitization decreases urinary urgency. BMC Urol 2007;7:9. http://www.ncbi.nlm.nih.gov/pubmed/17561998 Apostolidis A, Gonzales GE, Fowler CJ. Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur Urol 2006;50(6):1299-1305. http://www.ncbi.nlm.nih.gov/pubmed/16697519 Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007;100(6):1302-6. http://www.ncbi.nlm.nih.gov/pubmed/17979928 Kuschel S, Werner M, Schmid DM, Faust E, Schuessler B. Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2008;19(7):905-9. http://www.ncbi.nlm.nih.gov/pubmed/18204796 Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006;176(1):177-85. http://www.ncbi.nlm.nih.gov/pubmed/16753396 Lee JC, Yokoyama T, Hwang HJ, Arimitsu H, Yamamoto Y, Kawasaki M, Takigawa T, Takeshi K, Nishikawa A, Kumon H, Oguma K. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity. FEMS Immunol Med Microbiol 2007;51(1):201-11. http://www.ncbi.nlm.nih.gov/pubmed/17692094 Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174(3):984-9. http://www.ncbi.nlm.nih.gov/pubmed/16094019 Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005;96(6):848-52. http://www.ncbi.nlm.nih.gov/pubmed/16153215 Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 2007;178(4Pt1):1359-63. http://www.ncbi.nlm.nih.gov/pubmed/17706718 Ghalayini IF, Al-Ghazo MA. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 2007;26(4):531-6. http://www.ncbi.nlm.nih.gov/pubmed/17330289 Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177(6):2231-6. http://www.ncbi.nlm.nih.gov/pubmed/17509328 Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005;24(3):231-6. http://www.ncbi.nlm.nih.gov/pubmed/15747344
Update march 2009
23
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
24
Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174(3):977-82; discussion 982-3. http://www.ncbi.nlm.nih.gov/pubmed/16094018 Sinha D, Karri K, Arunkalaivanan AS. Applications of Botulinum toxin in urogynaecology. Eur J Obstet Gynecol Reprod Biol 2007;133(1):4-11. http://www.ncbi.nlm.nih.gov/pubmed/17275980 De Laet K, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 2005;43(7):397-9. http://www.ncbi.nlm.nih.gov/pubmed/15741978 Early communication about an ongoing safety review Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B). [accessed 8 February 2008]. http://www.fda.gov/cder/drug/early_comm/botulinium_toxins.htm Schurch B, Corcos J. Botulinum toxin injections for paediatric incontinence. Curr Opin Urol 2005;15(4):264-7. http://www.ncbi.nlm.nih.gov/pubmed/15928517 Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006;49(3):528-35. http://www.ncbi.nlm.nih.gov/pubmed/16426735 Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, Warner J, Elneil S, Fowler CJ, Dasgupta P. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49(3):519-27. http://www.ncbi.nlm.nih.gov/pubmed/16413656 Hirst GR, Watkins AJ, Guerrero K, Wareham K, Emery SJ, Jones DR, Lucas MG. Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 2007;69(1):69-73. http://www.ncbi.nlm.nih.gov/pubmed/17270619 Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007;177(3):1011-14. http://www.ncbi.nlm.nih.gov/pubmed/17296399 Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49(4):644-50. http://www.ncbi.nlm.nih.gov/pubmed/16426734 Sahai A, Dowson C, Khan MS, Dasgupta P. Re: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2008;101(4):515-16; author reply 516-17. http://www.ncbi.nlm.nih.gov/pubmed/18234066 Smaldone MC, Chancellor MB. Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neurotoxin. Nat Clin Pract Urol 2008;5(3):120-1. http://www.ncbi.nlm.nih.gov/pubmed/18195722 Sahai A. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2006;97(2):413. http://www.ncbi.nlm.nih.gov/pubmed/16430657 Nitti VW. Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Rev Urol 2006;8(4):198-208. http://www.ncbi.nlm.nih.gov/pubmed/17192799 Patel AK, Patterson JM, Chapple CR. The emerging role of intravesical botulinum toxin therapy in idiopathic detrusor overactivity. Int J Clin Pract Suppl 2006;(151):27-32. http://www.ncbi.nlm.nih.gov/pubmed/17169008 Casanova N, McGuire E, Fenner DE. Botulinum toxin: a potential alternative to current treatment of neurogenic and idiopathic urinary incontinence due to detrusor overactivity. Int J Gynaecol Obstet 2006;95(3):305-11. http://www.ncbi.nlm.nih.gov/pubmed/17070528
Update march 2009
•
• •
•
•
•
•
• •
•
•
•
•
•
•
•
•
•
•
Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol 2006;50(4):684-709; discussion 709-10. http://www.ncbi.nlm.nih.gov/pubmed/16934391 Patterson JM, Chapple CR. Botulinum toxin in urinary incontinence. Curr Opin Urol 2006;16(4):255-60. http://www.ncbi.nlm.nih.gov/pubmed/16770124 Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int 2007;99(2):247-62. http://www.ncbi.nlm.nih.gov/pubmed/17313422 Apostolidis A, Fowler CJ. The use of botulinum neurotoxin type A (BoNTA) in urology. J Neural Transm 2008;115(4):593-605. http://www.ncbi.nlm.nih.gov/pubmed/18322639 Ho MH, Lin LL, Haessler AL, Bhatia NN. Intravesical injection of botulinum toxin for the treatment of overactive bladder. Curr Opin Obstet Gynecol 2005;17(5):512-18. http://www.ncbi.nlm.nih.gov/pubmed/18322639 Kim DK, Thomas CA, Smith C, Chancellor MB. The case for bladder botulinum toxin application. Urol Clin North Am 2006;33(4):503-10, ix. http://www.ncbi.nlm.nih.gov/pubmed/17011386 MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ. Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects. Spinal Cord 2007;45(8):535-41. http://www.ncbi.nlm.nih.gov/pubmed/17453012 Schmidt RA. Treatment of unstable bladder. Urology 1991;37(1):28-32. http://www.ncbi.nlm.nih.gov/pubmed/1986470 van der Pal F, Heesakkers JP, Bemelmans BL. Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction. Curr Opin Urol 2006;16(4):261-7. http://www.ncbi.nlm.nih.gov/pubmed/16770125 Daneshgari F, Moy ML. Current indications for neuromodulation. Urol Clin North Am 2005;32(1):37-40, vi. http://www.ncbi.nlm.nih.gov/pubmed/15698874 Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am 2005;32(1):11-18. http://www.ncbi.nlm.nih.gov/pubmed/15698871 Keppene V, Mozer P, Chartier-Kastler E, Ruffion A. [Neuromodulation in the management of neurogenic lower urinary tract dysfunction]. Prog Urol 2007;17(3):609-15. http://www.ncbi.nlm.nih.gov/pubmed/17622098 Nakib N, Siegel S. Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neuromodulation. Nat Clin Pract Urol 2008;5(3):118-19. http://www.ncbi.nlm.nih.gov/pubmed/18195723 van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178(5):2029-34. http://www.ncbi.nlm.nih.gov/pubmed/17869298 Groen J, Ruud Bosch JL, van Mastrigt R. Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding. J Urol 2006;175(3 Pt 1):1005-9; discussion 1009. http://www.ncbi.nlm.nih.gov/pubmed/16469603 Groenendijk PM, Lycklama a Nyeholt AA, Heesakkers JP, et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int 2008;101(3):325-9. http://www.ncbi.nlm.nih.gov/pubmed/18070199 South MM, Romero AA, Jamison MG, Webster GD, Amundsen CL. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct 2007;18(12):1395-8. http://www.ncbi.nlm.nih.gov/pubmed/17364132 Groenendijk PM, Heesakkers JP, Lycklama ANAA. Urethral instability and sacral nerve stimulation-a better parameter to predict efficacy? J Urol 2007;178(2):568-2; discussion 572. http://www.ncbi.nlm.nih.gov/pubmed/17570438 Humphreys MR, Vandersteen DR, Slezak JM, et al. Preliminary results of sacral neuromodulation in 23 children. J Urol 2006;176(5):2227-31. http://www.ncbi.nlm.nih.gov/pubmed/17070300?
Update march 2009
25
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
26
McAchran SE, Daneshgari F. Sacral neuromodulation in the older woman. Clin Obstet Gynecol 2007;50(3):735-44. http://www.ncbi.nlm.nih.gov/pubmed/17762421 Hussain Z, Harrison SC. Neuromodulation for lower urinary tract dysfunction--an update. ScientificWorldJournal 2007;7:1036-45. http://www.ncbi.nlm.nih.gov/pubmed/17619785 Oerlemans DJ, van Kerrebroeck PE. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn 2008;27(1):28-33. http://www.ncbi.nlm.nih.gov/pubmed/17563110 Spinelli M, Malaguti S, Giardiello G, Lazzeri M, Tarantola J, Van Den Hombergh U. A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data. Neurourol Urodyn 2005;24(4):305-309. http://www.ncbi.nlm.nih.gov/pubmed/15977260 Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006;175(3 Pt 1):835-41. http://www.ncbi.nlm.nih.gov/pubmed/16469561 Kumar SP, Abrams PH. Detrusor myectomy: long-term results with a minimum follow-up of 2 years. BJU Int 2005;96(3):341-4. http://www.ncbi.nlm.nih.gov/pubmed/16042727 Blaivas JG, Weiss JP, Desai P, Flisser AJ, Stember DS, Stahl PJ. Long-term followup of augmentation enterocystoplasty and continent diversion in patients with benign disease. J Urol 2005;173(5):1631-4. http://www.ncbi.nlm.nih.gov/pubmed/15821519 de Figueiredo AA, Lucon AM, Srougi M. Bladder augmentation for the treatment of chronic tuberculous cystitis. Clinical and urodynamic evaluation of 25 patients after long term follow-up. Neurourol Urodyn 2006;25(5):433-40. http://www.ncbi.nlm.nih.gov/pubmed/16791845 Lima SV, Araujo LA, Vilar Fde O, Lima RS, Lima RF. Nonsecretory intestinocystoplasty: a 15-year prospective study of 183 patients. J Urol 2008;179(3):1113-6; discussion 1116-7. http://www.ncbi.nlm.nih.gov/pubmed/18206934 Shakespeare D, Mitchell DM, Carey BM, et al. Recto-urethral fistula following brachytherapy for localized prostate cancer. Colorectal Dis 2007;9(4):328-31. http://www.ncbi.nlm.nih.gov/pubmed/17432984 Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007;100(4):760-4. http://www.ncbi.nlm.nih.gov/pubmed/17662081 Larson DW, Chrouser K, Young-Fadok T, Nelson H. Rectal complications after modern radiation for prostate cancer: a colorectal surgical challenge. J Gastrointest Surg 2005;9(4):461-6. http://www.ncbi.nlm.nih.gov/pubmed/15797224 Lane BR, Stein DE, Remzi FH, Strong SA, Fazio VW, Angermeier KW. Management of radiotherapy induced rectourethral fistula. J Urol 2006;175(4):1382-1387; discussion 1387-8. http://www.ncbi.nlm.nih.gov/pubmed/16516003 Chrouser KL, Leibovich BC, Sweat SD, et al. Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol 2005;173(6):1953-7. http://www.ncbi.nlm.nih.gov/pubmed/15879789 Marguet C, Raj GV, Brashears JH, Ludwig K, Mouraviev V, Robertson CN, Polascik TJ. Rectourethral fistula after combination radiotherapy for prostate cancer. Urology 2007;69(5):898-901. http://www.ncbi.nlm.nih.gov/pubmed/17482930 Rivera R, Barboglio PG, Hellinger M, Gousse AE. Staging rectourinary fistulas to guide surgical treatment. J Urol 2007;177(2):586-8. http://www.ncbi.nlm.nih.gov/pubmed/17222638 Elliott SP, McAninch JW, Chi T, Doyle SM, Master VA. Management of severe urethral complications of prostate cancer therapy. J Urol 2006;176(6 Pt 1):2508-13. http://www.ncbi.nlm.nih.gov/pubmed/17085144 Singh I, Mittal G, Kumar P, Gangas R. Delayed post-traumatic prostatic-urethrorectal fistula: transperineal rectal sparing repair - point of technique. Int J Urol 2006;13(1):92-4. http://www.ncbi.nlm.nih.gov/pubmed/16448443 Pratap A, Agrawal CS, Pandit RK, Sapkota G, Anchal N. Factors contributing to a successful outcome of combined abdominal transpubic perineal urethroplasty for complex posterior urethral disruptions. J Urol 2006;176(6 Pt 1):2514-7; discussion 2517. http://www.ncbi.nlm.nih.gov/pubmed/17085145
Update march 2009
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Dal Moro F, Mancini M, Pinto F, Zanovello N, Bassi PF, Pagano F. Successful repair of iatrogenic rectourinary fistulas using the posterior sagittal transrectal approach (York-Mason): 15-year experience. World J Surg 2006;30(1):107-13. http://www.ncbi.nlm.nih.gov/pubmed/16369708 Erickson BA, Dumanian GA, Sisco M, Jang TL, Halverson AL, Gonzalez CM. Rectourethral fistula associated with two short segment urethral strictures in the anterior and posterior urethra: singlestage reconstruction using buccal mucosa and a radial forearm fasciocutaneous free flap. Urology 2006;67(1):195-8. http://www.ncbi.nlm.nih.gov/pubmed/16413364 Castillo OA, Bodden E, Vitagliano G. Management of rectal injury during laparoscopic radical prostatectomy. Int Braz J Urol 2006;32(4):428-33. http://www.ncbi.nlm.nih.gov/pubmed/16953909 Quinlan M, Cahill R, Keane F, Grainger R, Butler M. Transanal endoscopic microsurgical repair of iatrogenic recto-urethral fistula. Surgeon 2005;3(6):416-7. http://www.ncbi.nlm.nih.gov/pubmed/16353863 Bochove-Overgaauw DM, Beerlage HP, Bosscha K, Gelderman WA. Transanal endoscopic microsurgery for correction of rectourethral fistulae. J Endourol 2006;20(12):1087-90. http://www.ncbi.nlm.nih.gov/pubmed/17206908 Varma MG, Wang JY, Garcia-Aguilar J, Shelton AA, McAninch JW, Goldberg SM. Dartos muscle interposition flap for the treatment of rectourethral fistulas. Dis Colon Rectum 2007;50(11):1849-55. http://www.ncbi.nlm.nih.gov/pubmed/17828402 Chirica M, Parc Y, Tiret E, Dehni N, McNamara D, Parc R. Coloanal sleeve anastomosis (Soave procedure): the ultimate treatment option for complex rectourinary fistulas. Dis Colon Rectum 2006;49(9):1379-83. http://www.ncbi.nlm.nih.gov/pubmed/16819570 Reynolds WS, Patel R, Msezane L, Lucioni A, Rapp DE, Bales GT. Current use of artificial urinary sphincters in the United States. J Urol 2007;178(2):578-83. http://www.ncbi.nlm.nih.gov/pubmed/17570407 Catto JW, Natarajan V, Tophill PR. Simultaneous augmentation cystoplasty is associated with earlier rather than increased artificial urinary sphincter infection. J Urol 2005;173(4):1237-41. http://www.ncbi.nlm.nih.gov/pubmed/15758760 Henry GD, Graham SM, Cleves MA, Simmons CJ, Flynn B. Perineal approach for artificial urinary sphincter implantation appears to control male stress incontinence better than the transscrotal approach. J Urol 2008;179(4):1475-9; discussion 1479. http://www.ncbi.nlm.nih.gov/pubmed/18295275 Kendirci M, Gupta S, Shaw K, et al. Synchronous prosthetic implantation through a transscrotal incision: an outcome analysis. J Urol 2006;175(6):2218-22. http://www.ncbi.nlm.nih.gov/pubmed/16697843 Sellers CL, Morey AF, Jones LA. Cost and time benefits of dual implantation of inflatable penile and artificial urinary sphincter prosthetics by single incision. Urology 2005;65(5):852-3. http://www.ncbi.nlm.nih.gov/pubmed/15882709 van der Horst C, Naumann CM, Wilson SK, Wefer B, Braun PM, Junemann KP. [Dysfunctions of artificial urinary sphincters (AMS 800) and their management via a transscrotal access. Optimum procedure illustrated by reference to clinical examples]. Urologe A 2007;46(12):1704-9. http://www.ncbi.nlm.nih.gov/pubmed/17932644 Hussain M, Greenwell TJ, Venn SN, Mundy AR. The current role of the artificial urinary sphincter for the treatment of urinary incontinence. J Urol 2005;174(2):418-24. http://www.ncbi.nlm.nih.gov/pubmed/16006857 Petrou SP, Thiel DD, Elliot DS, Broderick GA, Wehle MJ, Young PR. Does indigo carmine prevent early artificial urinary sphincter cuff erosion? Can J Urol 2006;13(4):3195-8. http://www.ncbi.nlm.nih.gov/pubmed/16952328 Webster GD, Sherman ND. Management of male incontinence following artificial urinary sphincter failure. Curr Opin Urol 2005;15(6):386-90. http://www.ncbi.nlm.nih.gov/pubmed/16205488 Lopez Pereira P, Somoza Ariba I, Martinez Urrutia MJ, Lobato Romero R, Jaureguizar Monroe E. Artificial urinary sphincter: 11-year experience in adolescents with congenital neuropathic bladder. Eur Urol 2006;50(5):1096-101; discussion 101. http://www.ncbi.nlm.nih.gov/pubmed/16530321
Update march 2009
27
•
•
•
•
•
Ruiz E, Puigdevall J, Moldes J, et al. 14 years of experience with the artificial urinary sphincter in children and adolescents without spina bifida. J Urol 2006;176(4 Pt 2):1821-5. http://www.ncbi.nlm.nih.gov/pubmed/16945659 Patki P, Hamid R, Shah PJ, Craggs M. Long-term efficacy of AMS 800 artificial urinary sphincter in male patients with urodynamic stress incontinence due to spinal cord lesion. Spinal Cord 2006;44(5):297-300. http://www.ncbi.nlm.nih.gov/pubmed/16249789 Magera JS, Jr., Elliott DS. Tandem transcorporal artificial urinary sphincter cuff salvage technique: surgical description and results. J Urol 2007;177(3):1015-19; discussion 1019-20. http://www.ncbi.nlm.nih.gov/pubmed/17296400 Rahman NU, Minor TX, Deng D, Lue TF. Combined external urethral bulking and artificial urinary sphincter for urethral atrophy and stress urinary incontinence. BJU Int 2005;95(6):824-6. http://www.ncbi.nlm.nih.gov/pubmed/15794791 Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005;192(5):1735-40. http://www.ncbi.nlm.nih.gov/pubmed/15902187
An exhaustive reference list is available for consultation on line at the society website (http://www.uroweb.org/ professional-resources/guidelines/) and on the guidelines CD-rom version.
5. INCONTINENCE IN WOMEN* 5.1
Initial assessment
Initial assessment should triage patients into those with a ‘complicated’ incontinence, who require referral for specialised management and those suitable for general assessment. The ‘complicated’ incontinence group comprises patients with: • Pain • Haematuria • Recurrent infections • Voiding dysfunction • Significant pelvic organ prolapse • Failed previous incontinence surgery • Previous pelvic radiotherapy • Previous pelvic surgery • Suspected fistula. The remaining patients, with a history of UI identified by initial assessment, can be stratified into three main symptomatic groups of women suitable for initial primary care management: • Stress incontinence • Overactive bladder (OAB) symptoms: urgency with or without urgency incontinence, frequency and nocturia • Mixed urgency and stress incontinence. Routine physical examination includes abdominal, pelvic and perineal examinations. Women should perform a ‘stress test’ (cough and strain) to detect leakage secondary to sphincter incompetence. Any POP or urogenital atrophy must be assessed. It is also important to assess voluntary pelvic floor muscle function by vaginal or rectal examination before teaching pelvic floor muscle training (PFMT).
5.2
Initial treatment of UI in women
For women with stress, urgency or mixed urinary incontinence, initial treatment includes appropriate lifestyle advice, physical therapy, a scheduled voiding regime, behavioural therapy and medication (Table 7, Figure 3). Some recommendations are based on good and consistent evidence of effect. However, many other recommendations are based on insufficient level 1 or 2 evidence and are essentially hypotheses requiring better evidence of their benefit. * This section of the guidelines is based on the recommendations of the ICI committees chaired by Jean Hay-Smith (Committee 12: Adult Conservative Management), Tony Smith (Committee 14: Surgery for Urinary Incontinence in Women) and Linda Brubaker (Committee 15: Surgery for Pelvic Organ Prolapse).
28
Update march 2009
Table 7: Initial treatment for UI in women Treatment Lifestyle interventions • For morbidly and moderately obese women, weight loss helps to reduce UI prevalence • Caffeine intake reduction may benefit UI symptoms •A decrease in fluid intake should only be tried in patients with abnormally high fluid intakes, as a decrease in fluids may lead to UTIs, constipation, or dehydration •C rossing the legs and bending forward can help to reduce leakage during coughing or other provocations Pelvic floor muscle training: general considerations •P FMT should be offered as first-line conservative therapy to women with stress, urgency, or mixed UI •P rovide the most intensive PFMT programme possible (i.e. amount of exercise and of health professional supervision) within service constraints, as health-professional or supervised programmes are more effective than self-directed programmes. In addition, greater health professional contact is better than less •T he addition of biofeedback to the PFMT programme does not appear to be of benefit: - clinic biofeedback - home-based biofeedback Vaginal cones • VC may be offered to women with SUI or MUI •V C can be offered as first-line conservative therapy to those who can, and are prepared to use them • VC may not be helpful because of side-effects and discomfort •V C and EStim seem equally effective in SUI and MUI, but the usefulness of VC and EStim is limited because of side-effects and discomfort Electrical stimulation • EStim may be offered to women with SUI, UUI or MUI •F or treating SUI, 6 months of EStim, 50 Hz twice daily at home, may be better than no treatment •L ow-intensity home-based EStim daily for 6 months may be better than 16 sessions of maximal clinic-based EStim •F or treating UUI secondary to DO, 9 weeks of EStim, 4-10 Hz twice daily at home, might be better than no treatment •A ddition of EStim to a biofeedback-assisted PFMT programme does not appear to add benefit •E Stim may have limited usefulness, because some women cannot use it (due to contraindications), have difficulty using it, or dislike it Magnetic stimulation (MStim) • MStim should only be used as part of a clinical trial as its benefit has not been established Bladder training • BT is an appropriate first-line treatment for UUI in women • Either BT or antimuscarinic drugs may be effective for treating UUI •S ome patients may prefer BT because it does not produce the adverse events associated with drug therapy • Addition of a brief written instruction for BT, in addition to drug therapy, has no benefit •F or women with symptoms of SUI or MUI, a combination of PFMT/BT may be better than PFMT alone in the short-term •C linicians and researchers should refer to the operant conditioning and educational literature to explain their choice of training parameters or approach •C linicians should provide the most intensive BT supervision possible within service constraints Timed voiding •T imed voiding with a 2-hour voiding interval may be beneficial as a sole intervention for women with mild UI and infrequent voiding patterns
Update march 2009
GR A B C C
A A
A B
B
B
C C C C
NR A B
B B NR B
C
29
GR = grade of recommendation; UI = urinary incontinence; UTI = urinary tract infection; PFMT = pelvic floor muscle training; VC = vaginal cone; SUI = stress urinary incontinence; MUI = mixed urinary incontinence; EStim = electrical stimulation; MStim = magnetic stimulation; UUI = urge urinary incontinence; DO = detrusor overactivity; NR = no recommendation possible; BT = bladder training. 5.2.1 Pelvic floor muscle training (PFMT) under special circumstances The following recommendations may help with decision-making for specific groups. However, most of these are essentially hypotheses that need further testing. Since empirical evidence is lacking the recommendations presented below are supported by expert opinion. Recommendations for PFMT in special circumstances Recommendations Pregnant women expecting their first baby • Offer an intensive strengthening ante-partum PFMT • Provide regular health professional contact to supervise PFMT training to prevent postpartum UI: - women continent at 18 weeks -p opulation approaches, i.e. intervention offered whether or not women are continent at 20 weeks’ gestation Post-partum women, immediately after delivery • After vaginal delivery of a large baby (> 4000 g) or a forceps delivery an individually-taught PFMT programme, which includes advice on how to keep to the programme, will be beneficial Post-partum women with persistent symptoms of UI at 3 months after delivery • PFMT is offered as first-line conservative therapy • ‘Intensive’ programmes, i.e. highly supervised and high amount of exercise Women with SUI • PFMT is more effective than EStim as first-line conservative therapy, particularly if PFMT is intensively supervised • PFMT is more effective than BT as first-line conservative therapy • PFMT and duloxetine are both effective. Clinicians and women may choose to try PFMT first because of the side-effects associated with drug therapy • PFMT and surgery are both effective, but many clinicians and women may prefer PFMT as a first-line therapy because it is less invasive • PFMT and VC are both effective. PFMT is the preferred first choice because there is less leakage and some women cannot or do not like to use VCs • PFMT is better than clenbuterol or phenylpropanolamine hydrochloride as first-line therapy because of the side-effects experienced with the medications • A combination of PFMT + BT may be better than PFMT alone in short-term Women with UUI or MUI • PFMT and BT are both effective as first-line conservative therapies • PFMT is better than oxybutynin as first-line therapy
GR
A B
C
A B B B C C B B C B B
GR = grade of recommendation; PFMT = pelvic floor muscle training; UI = urinary incontinence; SUI = stress urinary incontinence; EStim = electrical stimulation; BT = bladder training; VC = vaginal cone; UUI = urgency urinary incontinence; MUI = mixed urinary incontinence.
30
Update march 2009
Figure 3: Algorithm for initial management of UI in women
s
5.3
Specialised management of UI in women
5.3.1 Assessment Women with ‘complicated’ incontinence requiring specialist management will probably need additional testing to rule out any underlying pathology, i.e. cytology, cysto-urethroscopy or urinary tract imaging. If these tests reveal no further pathology, the patient should be treated for UI by initial or specialised management options, as appropriate (Figure 4). Women who have failed initial management and with an impaired QoL are likely to request further treatment. If initial management has been given an adequate trial, then interventional therapy may be helpful. Urodynamic testing to diagnose the type of UI is highly recommended prior to intervention if the results are likely to influence the choice of management. It may also be helpful to test urethral function by urethral pressure profile or leak point pressure during urodynamic testing. A systematic assessment for POP is highly recommended. The Pelvic Organ Prolapes Quantification (POPQ) method should be used in research studies. Co-existing POP should be treated. 5.3.2 Treatment If urodynamic SUI is confirmed, the following treatment options may be recommended for patients with some bladder-neck and urethral mobility: • full range of non-surgical treatments • retropubic suspension procedures • bladder neck/sub-urethral sling operations. It may be helpful to correct symptomatic POP at the same time. For patients with limited bladder-neck mobility, consider using bladder neck sling procedures, injectable bulking agents and the artificial urinary sphincter. Urgency incontinence (overactive bladder) secondary to idiopathic DO may be treated by neuromodulation or bladder augmentation. Botulinum toxin injection can be used to treat symptomatic DO unresponsive to other therapies (grade of recommendation: C). Botulinum toxin is currently being used for detrusor injection ‘off-label’ for this indication. Patients with voiding dysfunction leading to significant post-void residual urine may have bladder outlet obstruction or detrusor underactivity. Pelvic organ prolapse is a common cause of voiding dysfunction.
Update march 2009
31
Figure 4: Algorithm for specialised management of UI in women
5.4
Surgery for UI in women
Surgical approaches to UI in women are listed in Table 8. There are various confounding variables for successful surgery (Table 9). The true incidence of complications associated with surgery for UI is not known, due to a lack of standard methods of reporting and definitions. In addition, there is a discrepancy between academic and community practice. However, there appears to be a low incidence of most complications, which makes it difficult to perform power calculations for RCTs. National registries provide some information about the level of complications. Complications are less likely with proper surgical training (level of evidence: 2-3) and skills can be maintained by performing at least 20 cases annually for each primary procedure (National Institute of Clinical Excellence, NICE). Table 8: Surgery for UI in women Surgical approach Anterior colporrhaphy • Outcome of anterior colporrhaphy is comparable to needle suspension, but less effective than open colposuspension. The effectiveness deteriorates substantially with time • Anterior colporrhaphy is not recommended as treatment of SUI alone Open colposuspension • Similar success compared to mid-urethral retropubic slings • Similar success compared to bladder neck slings • Similar success compared to transobturator slings • Risk of voiding dysfunction is higher than with TVT • Risk of voiding dysfunction is less than with slings • Prolapse after colposuspension is more likely than after TVT • The risk of de-novo DO is the same as after TVT • Mitrofanoff urethroplasty, BNS suspension, and paravaginal repair are not recommended for treatment of SUI alone • Open colposuspension is an effective, long-lasting treatment for primary SUI Laparoscopic colposuspension • Laparoscopic colposuspension is comparable to open colposuspension when performed by experienced laparoscopic surgeons • Equal or higher cure rates compared to TVT • Shorter operating time and faster recovery compared to TVT
32
LE
GR
2 A 1 1-2 2 1 1 1 1 B A 1-2 1-2 1-2
Update march 2009
• Laparoscopic colposuspension is an option for treating SUI B •L aparoscopic colposuspension should only be performed by experienced laparoscopic NR surgeons Traditional sling procedures • Autologous fascial sling is effective 1 • Autologous fascial sling may be more effective than biological and synthetic slings 2 • Adverse events may be more common than with non-autologous materials 3 •A utologous fascial sling is recommended as an effective, long-lasting treatment for SUI A Urethral bulking agents • Urethral bulking agents show similar symptomatic improvement with both placebo and 1 autologous fat • Less effective than conventional surgery 2 • No evidence to show that any bulking agent is more effective than another 2 • No data to compare urethral bulking agents with non-surgical treatments or with other 2 minimal-access surgical techniques B • Women should be aware that efficacy of ureteral bulking agents decreases with time, repeat injections may be necessary, and efficacy is less than that of other surgical techniques Mid-urethral tapes • TVT® is more effective than SPARC® tape 2 2 • IVS® has similar efficacy as TVT®, but a higher complication rate Mid-urethral tapes vs other procedures 1-2 • TVT® is equally effective as colposuspension and traditional sling operations ® 1-2 •O peration time, hospital stay and return to normal activity is shorter with TVT than with colposuspension • Post-operative voiding problems and need for prolapse surgery are more common with 1-2 colposuspension Retropubic tapes vs transobturator tapes • Similar efficacy up to 12 months • Similar complication rates in Finnish study 1 • Relative risk of bladder injury increased by 6-fold for retropubic sling • Relative risk of urethral injury increased by 4-fold for transobturator sling Contraindications for mid-urethral slings • Absolute contraindications are urethrovaginal fistula, urethral diverticulum, intra-operative 4 urethral injury and untreated urinary malignancy • Increased risk of complications including failure with radiotherapy, UTI, steroids, COPD, anticoagulant therapy, vaginal atrophy, congenital anomalies (exstrophy, ureteral ectopy, etc) and planned pregnancy ‘Mini-slings’ • Data immature, no recommendation possible NR Surgery for detrusor overactivity • Sacral neuromodulation appears to have benefit for patients with urgency incontinence, as 1-3 A well as urgency and frequency • Posterior tibial nerve stimulation is effective, but durability is a concern 3-4 Urethral diverticulae • No grade A recommendations regarding optimal diagnostic algorithm or adjuvant therapy of concomitant SUI • One long-term study showing recurrence of diverticulum in 17%, de-novo SUI in 38%, and 3 dyspareunia in 22% Non-obstetric urinary fistulae 2-4 • No grade A recommendation for fistula evaluation, timing of corrective intervention, methods and adjuncts of correction, and associated management strategies. All evidence is based on clinical series and/or case studies and lacks randomised and/or controlled studies LE = level of evidence; GR = grade of recommendation; SUI = stress urinary incontinence; TVT = tension-free vaginal tape; NR = no recommendation possible; MMK = Marshall-Marchetti-Krantz; BNS = bladder-neck suspension; DO = detrusor overactivity; IVS = intravaginal slingplasty; UTI = urinary tract infection; COPD = chronic obstructive pulmonary disease.
Update march 2009
33
Table 9: Confounding variables for use of surgery for UI in women Confounding variables for use of surgery • Age • Physical activity • Medical illness • Psychiatric illness • Obesity • Parity • Previous incontinence surgery • Hysterectomy during anti-incontinence procedure • Race • Severity and duration of symptoms • Overactive bladder • Urethral occlusive forces • Surgical factors 5.4.1 Outcome measures Until a universal outcome tool has been established, multiple outcome measures must be used. They include: • symptoms and separate bother questionnaire • clinically important outcomes (pad use, re-operation rates, anticholinergics, clean intermittent selfcatherisation (CIC) and recurrent UTIs) • complications • QoL tool with ‘minimal clinically important difference’ (MCID) Global Impression Index • health-economic outcome. Recommendations for surgical treatment of SUI Surgical procedure GR • Anterior colporrhaphy NR • Transvaginal BNS (needle) NR • Burch procedure: open A • Burch procedure: laparoscopic (by experienced laparoscopic surgeon only) B • Paravaginal NR • MMK urethroplasy NR • BN sling: autologous fascia A • Sub-urethral slings (TVT) A • Urethral bulking agents B NR = no recommendation possible; BNS = bladder-neck suspension; GR = grade of recommendation; MMK = Marshall-Marchetti-Krantz; BN = bladder neck; TVT = tension-free vaginal tape.
5.6 REFERENCES* •
•
•
•
34
Hilton P. Long-term follow-up studies in pelvic floor dysfunction: the Holy Grail or a realistic aim? BJOG 2008;115(2):135-43. Epub 2007. http://www.ncbi.nlm.nih.gov/pubmed/17999691 Atkins D, et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 2005;5(1):25. http://www.ncbi.nlm.nih.gov/pubmed/15788089 Guyatt GH, et al. What is “quality of evidence” and why is it important to clinicians? BMJ 2007;336(7651):995-8. http://www.ncbi.nlm.nih.gov/pubmed/18456631 Guyatt GH, et al. Going from evidence to recommendations. BMJ 2008;336(7652):1049-51. http://www.ncbi.nlm.nih.gov/pubmed/18467413
Update march 2009
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. http://www.ncbi.nlm.nih.gov/pubmed/18436948 Bezerra CA, Bruschini H, Cody DJ. Traditional suburethral sling operations for urinary incontinence in women. Cochrane Database of Syst Rev 2005;(3):CD001754 http://www.ncbi.nlm.nih.gov/pubmed/16034866 Lapitan MC, Cody DJ, Grant AM. Open retropubic colposuspension for urinary incontinence in women. Cochrane Database of Syst Rev 2005;(3):CD002912. http://www.ncbi.nlm.nih.gov/pubmed/16034879 Dean NM, Ellis G, Wilson PD, Herbison GP. Laparoscopic colposuspension for urinary incontinence in women. Cochrane Database of Syst Rev 2006;(3):CD002239. http://www.ncbi.nlm.nih.gov/pubmed/16855989 Keegan PE, Atiemo K, Cody J, McClinton S, Pickard R. Periurethral injection therapy for urinary incontinence in women. Cochrane Database of Syst Rev 2007;(3):CD003881. http://www.ncbi.nlm.nih.gov/pubmed/17636740 Smith A, Daneshgari F, Dmochowski R, Milani R, Miller K, Paraiso MF, Rovner E. Surgery for urinary incontinence in women. In: Incontinence, 3rd ed. Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: Plymouth, UK: Health Publications Ltd, 2005;1:pp 1297-1230. Klarskov P, Belving D, Bischoff N, Dorph S, Gerstenberg T, Okholm B, Pedersen PH, Tikjob G, Wormslev M, Hald T. Pelvic floor exercise versus surgery for female urinary stress incontinence. Urol Int 1986;41(2):129-32. http://www.ncbi.nlm.nih.gov/pubmed/3727190 Colombo M, Vitobello D, Proietti F, Milani R. Randomised comparison of Burch colposuspension versus anterior colporrhaphy in women with stress urinary incontinence and anterior vaginal wall prolapse. BJOG 2007;107(4):544-51. http://www.ncbi.nlm.nih.gov/pubmed/10759276 Carey MP, Goh JT, Rosamilia A, Cornish A, Gordon I, Hawthorne G, Maher CF, Dwyer PL, Moran P, Gilmour DT. Laparoscopic versus open Burch colposuspension: a randomised controlled trial. BJOG 2006;113(9):999-1006. http://www.ncbi.nlm.nih.gov/pubmed/16956331 Dumville JC, Manca A, Kitchener HC, Smith AR, Nelson L, Torgerson DJ; COLPO Study Group. Costeffectiveness analysis of open colposuspension versus laparoscopic colposuspension in the treatment of urodynamic stress incontinence. BJOG 2006;113(9):1014-22. Ward KL, Hilton P; UK and Ireland TVT Trial Group. Tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence: 5-year follow up. BJOG 2008;115(2):226-33. http://www.ncbi.nlm.nih.gov/pubmed/17970791 Albo ME, et al; Urinary Incontinence Treatment Network. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med 2007;356(21):2143-55. http://www.ncbi.nlm.nih.gov/pubmed/17517855 Sivaslioglu AA, Caliskan E, Dolen I, Haberal A. A randomized comparison of transobturator tape and Burch colposuspension in the treatment of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2007;18(9):1015-9. http://www.ncbi.nlm.nih.gov/pubmed/17180553 McCrery RJ, Rebecca J, Thompson PK. Outcomes of urethropexy added to paravaginal defect repair: a randomized trial of Burch versus Marshall-Marchetti-Krantz. Journal of Pelvic Medicine and Surgery 2005;11(3):137-43. http://www.jpelvicsurgery.com/pt/re/spv/abstract.00146866-200505000-00003.htm Bai SW, Sohn WH, Chung DJ, Park JH, Kim SK. Comparison of the efficacy of Burch colposuspension, pubovaginal sling, and tension-free vaginal tape for stress urinary incontinence. Int J Gynaecol Obstet 2005;91(3):246-51. http://www.ncbi.nlm.nih.gov/pubmed/16242695 Tennstedt S; Urinary Incontinence Treatment Network. Design of the Stress Incontinence Surgical Treatment Efficacy Trial (SISTEr). Urology 2005;66(6):1213-7. http://www.ncbi.nlm.nih.gov/pubmed/16360445 Mallett VT, Brubaker L, Stoddard AM, Borello-France D, Tennstedt S, Hall L, Hammontree L; Urinary Incontinence Treatment Network. The expectations of patients who undergo surgery for stress incontinence. Am J Obstet Gynecol 2008;198(3):308.e1-e6. http://www.ncbi.nlm.nih.gov/pubmed/18313452
Update march 2009
35
•
•
•
•
•
•
•
•
•
•
•
•
•
• •
•
•
36
Richter HE, Diokno A, Kenton K, Norton P, Albo M, Kraus S, Moalli P, Chai TC, Zimmern P, Litman H, Tennstedt S; Urinary Incontinence Treatment Network. Predictors of treatment failure 24 months after surgery for stress urinary incontinence. J Urol 2008;179(3):1024-30. http://www.ncbi.nlm.nih.gov/pubmed/18206917 El-Barky E, El-Shazly A, El-Wahab OA, Kehinde EO, Al-Hunayan A, Al-Awadi, KA. Tension free vaginal tape versus Burch colposuspension for treatment of female stress urinary incontinence. Int Urol Nephrol 2005;37(2):277-81. http://www.ncbi.nlm.nih.gov/pubmed/16142556 Ankardal M, Milsom I, Stjerndahl JH, Engh ME. A three-armed randomized trial comparing open Burch colposuspension using sutures with laparoscopic colposuspension using sutures and laparoscopic colposuspension using mesh and staples in women with stress urinary incontinence. Acta Obstet Gynecol Scand 2005;84(8):773-9. http://www.ncbi.nlm.nih.gov/pubmed/16026404 Ustün Y, Engin-Ustün Y, Güngör M, Tezcan S. Randomized comparison of Burch urethropexy procedures concomitant with gynecologic operations. Gynecol Obstet Invest 2005;59(1):19-23. http://www.ncbi.nlm.nih.gov/pubmed/15627777 Kitchener HC, Dunn G, Lawton V, Reid F, Nelson L, Smith AR. & Group, O. B. O. T. C. S. Laparoscopic versus open colposuspension—results of a prospective randomised controlled trial. BJOG 2006;113(9):1007-13. http://www.ncbi.nlm.nih.gov/pubmed/16956332 Dietz HP, Wilson PD. Laparoscopic colposuspension versus urethropexy: a case-control series. Int Urogynecol J Pelvic Floor Dysfunct 2005;16(1):15-8. http://www.ncbi.nlm.nih.gov/pubmed/15647961 McCracken GR, Henderson NA, Ashe RG. Five year follow-up comparing tension-free vaginal tape and colposuspension. Ulster Med J 2007;76(3):146-9. http://www.ncbi.nlm.nih.gov/pubmed/17853641 Sun MJ, Ng SC, Tsui KP, Chang NE, Lin KC, Chen GD. Are there any predictors for failed Burch colposuspension? Taiwan J Obstet Gynecol 2006;45(1):33-8. http://www.ncbi.nlm.nih.gov/pubmed/17272205 Ng S, Tee YT, Tsui KP, Chen GD. Is the role of Burch colposuspension fading away in this epoch for treating female urinary incontinence? Int Urogynecol J Pelvic Floor Dysfunct 2007;18(8):937-42. http://www.ncbi.nlm.nih.gov/pubmed/17139462 Rardin CR, Sung VW, Hampton BS, Clemons JL, Aguilar V, Sokol ER. Long-term follow-up of a transvaginal Burch urethropexy for stress urinary incontinence. Am J Obstet Gynecol 2007;197(6):656. e1-e5. http://www.ncbi.nlm.nih.gov/pubmed/18060969 Reid SV, Parys BT. Long-term 5-year followup of the results of the vesica procedure. J Urol 2005;173(4):1234-6. http://www.ncbi.nlm.nih.gov/pubmed/15758759 Gregorakis A, Bouropoulos C, Dimitriou D, Rallis G, Vernadakis S, Papadopoulos IN, Kastriotis I. Delayed reaction to the Dacron buttress used in Stamey bladder neck suspension. Int Urol Nephrol 2006;38(2):269-72. http://www.ncbi.nlm.nih.gov/pubmed/16868695 Smith A, Rovner E. Long-term chronic complications from Stamey endoscopic bladder neck suspension: a case series. Int Urogynecol J Pelvic Floor Dysfunct 2006;17(3):290-4. http://www.ncbi.nlm.nih.gov/pubmed/15965575 Mirosh M, Epp A. TVT vs laparoscopic Burch colposuspension for the treatment of stress urinary incontinence. International Continence Society. 35th annual meeting. Montreal, Canada, 2005. Dean NM, Herbison P, Ellis G, Wison D. Laparoscopic colposuspension and tension-free vaginal tape: a systematic review. BJOG 2006;113(12):1345-53. http://www.ingentaconnect.com/content/bsc/bjo/2006/00000113/00000012/art00002;jsessionid=194 6gsz6wq8wg.alexandra Tan E, Tekkis PP, Cornish J, Teoh TG, Darzi AW, Khullar V. Laparoscopic versus open colposuspension for urodynamic stress incontinence. Neurourol Urodyn 2007;26(2):158-69. http://www.ncbi.nlm.nih.gov/pubmed/17252603 Jelovsek JE, Barber MD, Karram MM, Walters MD, Paraiso MF. Randomised trial of laparoscopic Burch colposuspension versus tension-free vaginal tape: long-term follow up. BJOG 2008;115(2):21925; discussion 225. http://www.ncbi.nlm.nih.gov/pubmed/18081602
Update march 2009
•
•
•
• •
•
•
•
•
•
•
•
•
•
•
Valpas A, Rissanen P, Kujansuu E, Nilsson CG. A cost-effectiveness analysis of tension-free vaginal tape versus laparoscopic mesh colposuspension for primary female stress incontinence. Acta Obstet Gynecol Scand 2006;85(12):1485-90. http://www.ncbi.nlm.nih.gov/pubmed/17260226 Corcos J, Collet JP, Shapiro S, Herschorn S, Radomski SB, Schick E, Gajewski JB, Benedetti A, MacRamallah E, Hyams B. Multicenter randomized clinical trial comparing surgery and collagen injections for treatment of female stress urinary incontinence. Urology 2005;65(5):898-904. http://www.ncbi.nlm.nih.gov/pubmed/15882720 Maher CF, O’Reilly BA, Dwyer PL, Carey MP, Cornish A, Schulter P. Pubovaginal sling versus transurethral Macroplastique for stress urinary incontinence and intrinsic sphincter deficiency: a prospective randomised controlled trial. BJOG 2005;112(6):797-801. http://www.ncbi.nlm.nih.gov/pubmed/15924540 Appell R, Roger D, Robert M, Ira K, Hubbard W. Clinical experience with coaptite® urological bulking agent. International Continence Society, 33rd annual meeting, 2005. Florence, Italy. Bano F, Barrington JW, Dyer R. Comparison between porcine dermal implant (Permacol) and silicone injection (Macroplastique) for urodynamic stress incontinence. International Urogynecology Journal & Pelvic Floor Dysfunction 2005;16(2):147-50. http://www.ncbi.nlm.nih.gov/pubmed/15378234 Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K, Graham CW, Snyder JA, Nitti VW, Winters JC. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology 2007;69(5): 876-80. http://www.ncbi.nlm.nih.gov/pubmed/17482925 Ghoniem G, Bernhard P, Corcos J, Comiter C, Tomera K, Westney O, Herschorn S, Lucente V, Smith J, Wahle G, Mulcahy J. Multicenter randomised controlled trial to evaluate Macroplastique® urethral bulking agent for the Treatment of female stress urinary incontinence. International Continence Society, 35th annual meeting, 2005. Montreal, Canada. Abdelwahab HA, Ghoniem GM. Obstructive suburethral mass after transurethral injection of dextranomer/hyaluronic acid copolymer. Int Urogynecol J 2007;18(11);1379-80. http://www.ncbi.nlm.nih.gov/pubmed/17437054 Petrou SP, Pak RW, Lightner DJ. Simple aspiration technique to address voiding dysfunction associated with transurethral injection of dextranomer/hyaluronic acid copolymer. Urology 2006;68(1):186-8. http://www.ncbi.nlm.nih.gov/pubmed/16777199 Hagemeier T, Blau U, Gauruder-Burmester A, Tunn R. [Paraurethral abscess developing after midurethral Zuidex-injection in women with stress urinary incontinence -- management of complications and retrospective comparison with bladder neck located injection technique]. Zentralbl Gynakol 2006;128(2):68-70. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/16673247 Madjar S, Sharma AK, Waltzer WC, Frischer Z, Secrest CL. Periurethral mass formations following bulking agent injection for the treatment of urinary incontinence. J Urol 2006;175(4):1408-10. http://www.ncbi.nlm.nih.gov/pubmed/16516009 Wadie BS, Edwan A, Nabeeh AM. Autologous fascial sling vs polypropylene tape at short-term followup: a prospective randomized study. J Urol 2005;174(3):990-3. http://www.ncbi.nlm.nih.gov/pubmed/16094020 Guerrero K, Watkins A, Emery S, Wareham K, Stephenson T, Logan V, Lucas M. A randomised controlled trial comparing two autologous fascial sling techniques for the treatment of stress urinary incontinence in women: short, medium and long-term follow-up. International Urogynecology Journal & Pelvic Floor Dysfunction 2007;18(11):1263-70. http://www.biomedexperts.com/Abstract.bme/17347792 McBride AW, Ellerkmann RM, Bent AE, Melick CF. Comparison of long-term outcomes of autologous fascia lata slings with Suspend Tutoplast fascia lata allograft slings for stress incontinence. Am J Obstet Gynecol 2005;192(5):1677-81. http://www.ncbi.nlm.nih.gov/pubmed/15902176 Simsiman AJ, Powell CR, Stratford RR, Menefee SA. Suburethral sling materials: best outcome with autologous tissue. Am J Obstet Gynecol 2005;193(6):2112-6. http://www.ncbi.nlm.nih.gov/pubmed/16325625
Update march 2009
37
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
38
Campeau L, Tu LM, Lemieux MC, Naud A, Karsenty G, Schick E, Corcos J. A multicenter, prospective, randomized clinical trial comparing tension-free vaginal tape surgery and no treatment for the management of stress urinary incontinence in elderly women. Neurourol Urodyn 2007;26(7):990-4. http://www.ncbi.nlm.nih.gov/pubmed/17638307 Foote AJ, Maughan V, Carne C. Laparoscopic colposuspension versus vaginal suburethral slingplasty: a randomised prospective trial. Aust N Z J Obstet Gynaecol 2006;46(6):517-20. http://www.ncbi.nlm.nih.gov/pubmed/17116057 Andonian S, Chen T, St-Denis B, Corcos J. Randomized clinical trial comparing suprapubic arch sling (SPARC) and tension-free vaginal tape (TVT): one-year results. Eur Urol 2005;47(4):537-41. http://www.ncbi.nlm.nih.gov/pubmed/15774255 Lord HE, Taylor JD, Finn JC, Tsokos N, Jeffery JT, Atherton MJ, Evans SF, Bremner AP, Elder GO, Holman CD. A randomized controlled equivalence trial of short-term complications and efficacy of tension-free vaginal tape and suprapubic urethral support sling for treating stress incontinence. BJU Int 2006;98(2):367-76. http://www.ncbi.nlm.nih.gov/pubmed/16879679 Lim YN, Muller R, Corstiaans A, Dietz HP, Barry C, Rane A. Suburethral slingplasty evaluation study in North Queensland, Australia: the SUSPEND trial. Aust N Z J Obstet Gynaecol 2005;45(1):52-9. http://www.ncbi.nlm.nih.gov/pubmed/15730366 Meschia M, Pifarotti P, Bernasconi F, Magatti F, Viganò R, Bertozzi R, Barbacini P. Tension-free vaginal tape (TVT) and intravaginal slingplasty (IVS) for stress urinary incontinence: a multicenter randomized trial. Am J Obstet Gynecol 2006;195(5):1338-42. http://www.ncbi.nlm.nih.gov/pubmed/16769016 Zullo MA, Plotti F, Calcagno M, Marullo E, Palaia I, Bellati F, Basile S, Muzii L, Angioli R, Panici PB. One-year follow-up of tension-free vaginal tape (TVT) and trans-obturator suburethral tape from inside to outside (TVT-O) for surgical treatment of female stress urinary incontinence: a prospective randomised trial. Eur Urol 2007;51(5):1376-82; discussion 1383-4. http://www.ncbi.nlm.nih.gov/pubmed/17110021 Liapis A, Bakas P, Giner M, Creatsas G.Tension-free vaginal tape versus tension-free vaginal tape obturator in women with stress urinary incontinence. Int J Gynaecol Obstet 2006;92(1):48-51. http://www.ncbi.nlm.nih.gov/pubmed/16253254 Laurikainen E, Valpas A, Kivelä A, Kalliola T, Rinne K, Takala T, Nilsson CG. Retropubic compared with transobturator tape placement in treatment of urinary incontinence: a randomized controlled trial. Obstet Gynecol 2007;109(1):4-11. http://www.ncbi.nlm.nih.gov/pubmed/17197581 Araco F, Gravante G, Sorge R, Overton J, De Vita D, Sesti F, Piccione E. TVT-O vs TVT: a randomized trial in patients with different degrees of urinary stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008;19(7):917-26. http://www.ncbi.nlm.nih.gov/pubmed/18217177 Rinne K, Laurikainen E, Kivelä A, Aukee P, Takala T, Valpas A, Nilsson CG. A randomized trial comparing TVT with TVT-O: 12 months results. Int Urogynecol J Pelvic Floor Dysfunct 2008;19(8):1049-54. http://www.ncbi.nlm.nih.gov/pubmed/18373046 Andonian S, St-Denis B, Lemieux MC, Corcos J. Prospective clinical trial comparing Obtape and DUPS to TVT: one-year safety and efficacy results.[see comment]. Eur Urol 2007;52(1):245-51. http://www.ncbi.nlm.nih.gov/pubmed/17234331 Porena M, Costantini E, Frea B, Giannantoni A, Ranzoni S, Mearini L, Bini V, Kocjancic E. Tensionfree vaginal tape versus transobturator tape as surgery for stress urinary incontinence: results of a multicentre randomised trial. Eur Urol 2007;52(5):1481-90. http://www.ncbi.nlm.nih.gov/pubmed/17482343 Gillon G, Stanton SL. Long-term follow-up of surgery for urinary incontinence in elderly women. Br J Urol 1984;56(5):478-81. http://www.ncbi.nlm.nih.gov/pubmed/6534447 Gordon D, Gold R, Pauzner D, Lessing JB, Groutz A. Tension-free vaginal tape in the elderly: is it a safe procedure? Urology 2005;65(3):479-82. http://www.ncbi.nlm.nih.gov/pubmed/15780359 Lowenstein L, Kenton K, Dooley Y, R Mueller E, Brubaker L. Women who experience detrusor overactive at lower bladder volumes report greater bother. Neurourol Urodyn 2008;27(1):45-7. http://www.ncbi.nlm.nih.gov/pubmed/17600369
Update march 2009
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Anger JT, Saigal CS, Madison R, Joyce G, Litwin MS; Urologic Diseases of America Project. Increasing Costs of Urinary Incontinence Among Female Medicare Beneficiaries. J Urol 2006;176(1):247-51; discussion 251. http://www.ncbi.nlm.nih.gov/pubmed/16753411 Anger JT, Rodríguez LV, Wang Q, Chen E, Pashos CL, Litwin MS. Racial disparities in the surgical management of stress incontinence among female Medicare beneficiaries. J Urol 2007;177(5): 1846-50. http://www.ncbi.nlm.nih.gov/pubmed/17437833 Kraus SR, Markland A, Chai TC, Stoddard A, FitzGerald MP, Leng W, Mallett V, Tennstedt SL; Urinary Incontinence Treatment Network. Race and ethnicity do not contribute to differences in preoperative urinary incontinence severity or symptom bother in women who undergo stress incontinence surgery. Am J Obstet Gynecol 2007;197(1):92.e1-e6. http://www.ncbi.nlm.nih.gov/pubmed/17618773 Daneshgari F, Moore C. Advancing the understanding of pathophysiological rationale for the treatment of stress urinary incontinence in women: the ‘trampoline theory’. BJU Int 2006;98 Suppl 1:8-14; discussion 15-6. http://www.ncbi.nlm.nih.gov/pubmed/16911594 Kjølhede P, Wahlström J, Wingren G. Pelvic floor dysfunction after Burch colposuspension--a comprehensive study. Part I. Acta Obstet Gynecol Scand 2005;84(9):894-901. http://www.ncbi.nlm.nih.gov/pubmed/16097983 Anger JT, Rodríguez LV, Wang Q, Chen E, Pashos CL, Litwin MS. Racial disparities in the surgical management of stress incontinence among female Medicare beneficiaries. J Urol 2007;177(5): 1846-50. http://www.ncbi.nlm.nih.gov/pubmed/17437833 Skriapas K, Poulakis V, Dillenburg W, de Vries R, Witzsch U, Melekos M, Becht E. Tension-free vaginal tape (TVT) in morbidly obese patients with severe urodynamic stress incontinence as last option treatment. Eur Urol 2006;49(3):544-50. http://www.ncbi.nlm.nih.gov/pubmed/16387416 Rogers RG, Lebküchner U, Kammerer-Doak DN, Thompson PK, Walters MD, Nygaard IE. Obesity and retropubic surgery for stress incontinence: is there really an increased risk of intraoperative complications? Am J Obstet Gynecol 2006;195(6):1794-8. http://www.ncbi.nlm.nih.gov/pubmed/17014816 Nam SB, Bae JH, Lee JG. Surgical considerations for recurrent stress urinary incontinence after the midurethral sling procedure: Redo midurethral sling and shortening of the tape. [Korean]. Korean J Urol 2007;48:527-35. http://www.urology.or.kr/journal/viewJournal.html?year=2007&vol=48&page=527 Moore RD, Gamble K, Miklos JR. Tension-free vaginal tape sling for recurrent stress incontinence after transobturator tape sling failure. International Urogynecology Journal & Pelvic Floor Dysfunction 2007;18:309-13. http://www.ncbi.nlm.nih.gov/pubmed/16868658 Argirovic R, Likic I, Kadija S, Milenkovic V, Ilic-Mostic T, Arsenijevic Lj. [Outcome of Burch retropubic urethropexy and the effect of concomitant abdominal hysterectomy]. Acta Chir Iugosl 2006;53(1): 77-81. http://www.ncbi.nlm.nih.gov/pubmed/16989152 Botros SM, Abramov Y, Goldberg RP, Beaumont JL, Gandhi S, Miller JJ, Sand PK. Detrusor overactivity and urge urinary incontinence [corrected] following midurethral versus bladder sling procedures. Am J Obstet Gynecol 2005;193(6):2144-8. Erratum in: Am J Obstet Gynecol 2006;194(2):595. http://www.ncbi.nlm.nih.gov/pubmed/16325631 Duckett JR & Tamilselvi A. Effect of tension-free vaginal tape in women with a urodynamic diagnosis of idiopathic detrusor overactivity and stress incontinence. BJOG: Int J Obstet Gynaecol 2006;113(1):30-3. http://www.ncbi.nlm.nih.gov/pubmed/16398768 Choe JH, Choo MS, Lee KS. The impact of tension-free vaginal tape on overactive bladder symptoms in women with stress urinary incontinence: significance of detrusor overactivity. J Urol 2008;179(1): 214-9. http://www.ncbi.nlm.nih.gov/pubmed/18001792 McLennan MT, Melick CF. Bladder perforation during tension-free vaginal tape procedures: analysis of learning curve and risk factors. Obstet Gynecol 2005;106(5 Pt 1):1000-4. http://www.ncbi.nlm.nih.gov/pubmed/16260518
Update march 2009
39
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
40
Digesu GA, Salvatore S, Chaliha C, Athanasiou S, Milani R, Khullar V. Do overactive bladder symptoms improve after repair of anterior vaginal wall prolapse? Int Urogynecol J Pelvic Floor Dysfunct 2007;18(12):1439-43. http://www.ncbi.nlm.nih.gov/pubmed/17429557 Foster RT Sr, Barber MD, Parasio MF, Walters MD, Weidner AC, Amundsen CL. A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse. Am J Obstet Gynecol 2007;197(1):82.e1-e4. http://www.ncbi.nlm.nih.gov/pubmed/17618768 Boyles SH, Edwards R, Gregory W, Clark A. Complications associated with transobturator sling procedures. Int Urogynecol J Pelvic Floor Dysfunct 2007;18(1):19-22. http://www.ncbi.nlm.nih.gov/pubmed/16568214 Deng DY, Rutman M, Raz S, Rodriguez LV. Presentation and management of major complications of midurethral slings: Are complications under-reported? Neurourol Urodyn 2007;26(1):46-52. http://www.ncbi.nlm.nih.gov/pubmed/17149713 TAUB Taub DA, Hollenbeck BK, Wei JT, Dunn RL, McGuire EJ, Latini JM. Complications following surgical intervention for stress urinary incontinence: a national perspective. Neurourol Urodyn 2005;24(7):659-65. http://www.ncbi.nlm.nih.gov/pubmed/16173038 Adams E, Bardsley A, Crumlin L, Currie I, Evans L, Haslam J, Hilton P, Jones M, Lucas M, Spinks J, Townsend J, Wagg A, Dougherty M, Wyn Evans B, Jacklin P, Kwan I, Pledge D, Vahidi S. Urinary Incontinence: The management of urinary incontinence in women. In: National Collaborating Centre for Women’s and Children’s Health, Hace NIF (Ed.). London, UK. RCOG Press. ISBN 1-904752-32-2, 2006. http://www.nice.org.uk/nicemedia/pdf/CG40fullguideline.pdf Schraffordt Koops SE, Bisseling TM, Heintz AP, Vervest HA. Prospective analysis of complications of tension-free vaginal tape from The Netherlands Tension-free Vaginal Tape study. Am J Obstet Gynecol 2005;193(1):45-52. http://www.ncbi.nlm.nih.gov/pubmed/16021057 Zhu L, Lang J, Hai N, Wong F. Comparing vaginal tape and transobturator tape for the treatment of mild and moderate stress incontinence. Int J Gynaecol Obstet. 2007;99(1):14-7. http://www.ncbi.nlm.nih.gov/pubmed/17707822 Lee KS, Han DH, Choi YS, Yum SH, Song SH, Doo CK, Choo MS. A prospective trial comparing tension-free vaginal tape and transobturator vaginal tape inside-out for the surgical treatment of female stress urinary incontinence: 1-year followup. J Urol 2007;177(1):214-8. http://www.ncbi.nlm.nih.gov/pubmed/17162048 David-Montefiore E, Frobert JL, Grisard-Anaf M, Lienhart J, Bonnet K, Poncelet C, Daraï E. Perioperative complications and pain after the suburethral sling procedure for urinary stress incontinence: a French prospective randomised multicentre study comparing the retropubic and transobturator routes. Eur Urol 2006;49(1):133-8. http://www.ncbi.nlm.nih.gov/pubmed/16310932 Debodinance P. [Trans-obturator urethral sling for surgical correction of female stress urinary incontinence: Outside-in (Monarc) versus inside-out (TVT-O). Are both ways safe?]. J Gynecol Obstet Biol Reprod (Paris). 2006;35(6):571-7. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/17003744 Lee KS, Choo MS, Lee YS, Han JY, Kim JY, Jung BJ, Han DH. Prospective comparison of the ‘inside-out’ and ‘outside-in’ transobturator-tape procedures for the treatment of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(4):577-82. http://www.ncbi.nlm.nih.gov/pubmed/17940717 Anger JT, Litwin MS, Wang Q, Pashos CL.The effect of age on outcomes of sling surgery for urinary incontinence. J Am Geriatr Soc 2007;55(12):1927-31. http://www.ncbi.nlm.nih.gov/pubmed/18081671 Rogers RG, Lebküchner U, Kammerer-Doak DN, Thompson PK, Walters MD, Nygaard I.E. Obesity and retropubic surgery for stress incontinence: is there really an increased risk of intraoperative complications? Am J Obstet Gynecol 2006;195(6):1794-8. http://www.ncbi.nlm.nih.gov/pubmed/17014816 LaSala CA, Schimpf MO, Udoh E, O’Sullivan DM, Tulikangas P. Outcome of tension-free vaginal tape procedure when complicated by intraoperative cystotomy. Am J Obstet Gynecol 2006;195(6):1857-61. http://www.ncbi.nlm.nih.gov/pubmed/17132487
Update march 2009
•
•
•
• •
•
•
•
•
•
•
•
•
•
•
•
•
Hodroff MA, Sutherland SE, Kesha JB, Siegel SW. Treatment of stress incontinence with the SPARC sling: intraoperative and early complications of 445 patients. Urology 2005;66(4):760-2. http://www.ncbi.nlm.nih.gov/pubmed/16230134 Davila GW, Johnson JD, Serels S. Multicenter experience with the Monarc transobturator sling system to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2006;17(5):460-5. http://www.ncbi.nlm.nih.gov/pubmed/16314996 Barber MD, Gustilo-Ashby AM, Chen CC, Kaplan P, Paraiso MF, Walters MD. Perioperative complications and adverse events of the MONARC transobturator tape, compared with the tensionfree vaginal tape. Am J Obstet Gynecol 2006;195(6):1820-5. http://www.ncbi.nlm.nih.gov/pubmed/17027591 MAUDE database. 2007. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/TextSearch.cfm Gandhi S, Abramov Y, Kwon C, Beaumont JL, Botros S, Sand PK, Goldberg RP. TVT versus SPARC: comparison of outcomes for two midurethral tape procedures. Int Urogynecol J Pelvic Floor Dysfunct 2006;17(2):125-30. http://www.ncbi.nlm.nih.gov/pubmed/16079957 Rajan S, Kohli N. Retropubic hematoma after transobturator sling procedure. Obstet Gynecol 2005;106(5 Pt 2):1199-202. http://www.ncbi.nlm.nih.gov/pubmed/16260571 Kölle D, Tamussino K, Hanzal E, Tammaa A, Preyer O, Bader A, Enzelsberger H, Ralph G, Riss P; Austrian Urogynecology Working Group. Bleeding complications with the tension-free vaginal tape operation. Am J Obstet Gynecol 2005;193(6):2045-9. http://www.ncbi.nlm.nih.gov/pubmed/16325613 Roumeguère T, Quackels T, Bollens R, de Groote A, Zlotta A, Bossche MV, Schulman C. Transobturator vaginal tape (TOT) for female stress incontinence: one year follow-up in 120 patients. Eur Urol 2005;48(5):805-9. http://www.ncbi.nlm.nih.gov/pubmed/16182440 Dietz HP, Barry C, Lim Y, Rane A. TVT vs Monarc: a comparative study. Int Urogynecol J Pelvic Floor Dysfunct 2006;17(6):566-9. http://www.ncbi.nlm.nih.gov/pubmed/16525760 Morey AF, Medendorp AR, Noller MW, Mora RV, Shandera KC, Foley JP, Rivera LR, Reyna JA, Terry PJ. Transobturator versus transabdominal mid urethral slings: a multi-institutional comparison of obstructive voiding complications. J Urol 2006;175(3 Pt 1):1014-7. http://www.ncbi.nlm.nih.gov/pubmed/16469607 Mishra VC, Mishra N, Karim OM, Motiwala HG. Voiding dysfunction after tension-free vaginal tape: a conservative approach is often successful. Int Urogynecol J Pelvic Floor Dysfunct 2005;16(3):210-4; discussion 214. http://www.ncbi.nlm.nih.gov/pubmed/15372143 Starkman JS, Duffy JW 3rd, Wolter CE, Kaufman MR, Scarpero HM, Dmochowski RR. The evolution of obstruction-induced overactive bladder (OAB) symptoms following urethrolysis for female bladder outlet obstruction. J Urol 2008;179(3):1018-23. http://www.ncbi.nlm.nih.gov/pubmed/18206925 Starkman JS, Wolter C, Gomelsky A, Scarpero HM, Dmochowski RR. Voiding dysfunction following removal of eroded synthetic midurethral slings. J Urol 2006;176(3):1040-4.. http://www.ncbi.nlm.nih.gov/pubmed/16890687 Abdel-Fattah M, Sivanesan K, Ramsay I, Pringle S, Bjornsson S. How common are tape erosions? A comparison of two versions of the transobturator tension-free vaginal tape procedure. BJU Int 2006;98(3):594-8. http://www.ncbi.nlm.nih.gov/pubmed/16925759 Feifer A, Corcos J. The use of synthetic sub-urethral slings in the treatment of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2007;18(9):1087-95 http://www.ncbi.nlm.nih.gov/pubmed/17464439 de Boer F. Multifilament polypropylene mesh for urinary incontinence: 10 cases of infections requiring removal of the sling. BJOG 2005;112(10):1456. http://www.ncbi.nlm.nih.gov/pubmed/16167961 Siegel AL, Kim M, Goldstein M, Levey S, Ilbeigi P. High incidence of vaginal mesh extrusion using the intravaginal slingplasty sling. Urol 2005;174(4 Pt 1):1308-11. http://www.ncbi.nlm.nih.gov/pubmed/16145409
Update march 2009
41
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
42
Siegel AL. Vaginal mesh extrusion associated with use of Mentor transobturator sling. Urology 2005;66(5):995-9. http://www.ncbi.nlm.nih.gov/pubmed/16286110 Yamada BS, Govier FE, Stefanovic KB, Kobashi KC. High rate of vaginal erosions associated with the mentor ObTape. J Urol 2006;176(2):651-4; discussion 654. http://www.ncbi.nlm.nih.gov/pubmed/16813914 Robert M, Murphy M, Birch C, Swaby C, Ross S. Five cases of tape erosion after transobturator surgery for urinary incontinence. Obstet Gynecol 2006;107(2 Pt 2):472-4. http://www.ncbi.nlm.nih.gov/pubmed/16449154 Hammad FT, Kennedy-Smith A, Robinson RG. Erosions and urinary retention following polypropylene synthetic sling: Australasian survey. Eur Urol 2005;47(5):641-6; discussion 646-7. http://www.ncbi.nlm.nih.gov/pubmed/15826756 Giri SK, Drumm J, Flood HD. Endoscopic holmium laser excision of intravesical tension-free vaginal tape and polypropylene suture after anti-incontinence procedures. J Urol 2005;174(4 Pt 1):1306-7. http://www.ncbi.nlm.nih.gov/pubmed/16145408 Vervest HA, Bongers MY, van der Wurff AA. Nerve injury: an exceptional cause of pain after TVT. Int Urogynecol J Pelvic Floor Dysfunct 2006;17(6):665-7. http://www.ncbi.nlm.nih.gov/pubmed/16633884 Shah SM, Bukkapatnam R, Rodríguez LV. Impact of vaginal surgery for stress urinary incontinence on female sexual function: is the use of polypropylene mesh detrimental? Urology 2005;65(2):270-4. http://www.ncbi.nlm.nih.gov/pubmed/15708036 Babalola EO, Famuyide AO, McGuire LJ, Gebhart JB, Klingele CJ. Vaginal erosion, sinus formation, and ischiorectal abscess following transobturator tape: ObTape implantation. Int Urogynecol J Pelvic Floor Dysfunct 2006;17(4):418-21. http://www.ncbi.nlm.nih.gov/pubmed/16186998 Benassi G, Marconi L, Accorsi F, Angeloni M, Benassi L. Abscess formation at the ischiorectal fossa 7 months after the application of a synthetic transobturator sling for stress urinary incontinence in a type II diabetic woman. Int Urogynecol J Pelvic Floor Dysfunct 2007;18(6):697-9. http://www.ncbi.nlm.nih.gov/pubmed/17333445 Busby G, Broome J. Necrotising fasciitis following unrecognised bladder injury during transobturator sling procedure. BJOG 2007;114(1):111-2. http://www.ncbi.nlm.nih.gov/pubmed/17233867 Deffieux X, Donnadieu AC, Mordefroid M, Levante S, Frydman R, Fernandez H. Prepubic and thigh abscess after successive placement of two suburethral slings. Int Urogynecol J Pelvic Floor Dysfunct 2007;18(5):571-4. http://www.ncbi.nlm.nih.gov/pubmed/16832590 Goldman HB. Large thigh abscess after placement of synthetic transobturator sling. Int Urogynecol J Pelvic Floor Dysfunct 2006;17(3):295-6. http://www.ncbi.nlm.nih.gov/pubmed/15986099 Hurtado EA, McCrery RJ, Appell RA. Complications of ethylene vinyl alcohol copolymer as an off-label intra-urethral bulking agent in men with atress urinary incontinence. SUFU 2007. http://www.urotoday.com/48/browse_categories/stress_urinary_incontinence_sui/sufu_2007__ complications_of_ethylene_vinyl_alcohol_copolymer_as_an_offlabel_intraurethral_bulking_agent_in_ men_with_stress_urinary_incontinence.html Hurtado EA, McCrery RJ, Appell RA. Complications of ethylene vinyl alcohol copolymer s an intraurethral bulking agent in men with stress urinary incontinence. Urology 2008;71(4):662-5. http://www.ncbi.nlm.nih.gov/pubmed/18279931 Juang CM, Yu KJ, Chou P, Yen MS, Twu NF, Horng HC, Hsu WL. Efficacy analysis of trans-obturator tension-free vaginal tape (TVT-O) plus modified Ingelman-Sundberg procedure versus TVT-O alone in the treatment of mixed urinary incontinence: a randomized study. Eur Urol 2007;51(6):1671-8; discussion 1679. http://www.ncbi.nlm.nih.gov/pubmed/17254697 Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 2006;367(9518):1241-6. http://www.ncbi.nlm.nih.gov/pubmed/16631879 Hijaz A, Vasavada SP, Daneshgari F, Frinjari H, Goldman H, Rackley R. Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience. Urology 2006;68(3):533-7. http://www.ncbi.nlm.nih.gov/pubmed/16979724
Update march 2009
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama á Nijholt AA, Siegel S, Jonas U, Fowler CJ, Fall M, Gajewski JB, Hassouna MM, Cappellano F, Elhilali MM, Milam DF, Das AK, Dijkema HE, van den Hombergh U. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178(5):2029-34. http://www.ncbi.nlm.nih.gov/pubmed/17869298 Van Voskuilen AC, Oerlemans DJ, Weil EH, de Bie RA, van Kerrebroeck PE. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol 2006;49(2):366-72. http://www.ncbi.nlm.nih.gov/pubmed/16413105 Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006;175(3 Pt 1):835-41. http://www.ncbi.nlm.nih.gov/pubmed/16469561 Han DH, Jeong YS, Choo MS, Lee KS. Outcomes of surgery of female urethral diverticula classified using magnetic resonance imaging. Eur Urol 2007;51(6):1664-70. http://www.ncbi.nlm.nih.gov/pubmed/17335961 Ljungqvist L, Peeker R, Fall M. Female urethral diverticulum: 26-year followup of a large series. J Urol 2007;177(1):219-24; discussion 224. http://www.ncbi.nlm.nih.gov/pubmed/17162049 Karantanis E, Allen W, Stevermuer TL, Simons AM, O’Sullivan R, Moore KH. The repeatability of the 24-hour pad test. Int Urogynecol J Pelvic Floor Dysfunct 2005;16(1):63-8; discussion 68. http://www.ncbi.nlm.nih.gov/pubmed/15647965 Dylewski DA, Jamison MG, Borawski KM, Sherman ND, Amundsen CL, Webster GD. A statistical comparison of pad numbers versus pad weights in the quantification of urinary incontinence. Neurourol Urodyn 2007;26(1):3-7. http://www.ncbi.nlm.nih.gov/pubmed/17080415 Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T; The Clinical Significance Consensus Meeting Group. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005;14(2):285-95. http://www.ncbi.nlm.nih.gov/pubmed/15892420 Yalcin I, Patrick DL, Summers K, Kinchen K, Bump RC. Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence. Urology 2006;67(6):1304-8. http://www.ncbi.nlm.nih.gov/pubmed/16750246 Hendriks MR, Evers SM, Bleijlevens MH, van Haastregt JC, Crebolder HF, van Eijk JT. Costeffectiveness of a multidisciplinary fall prevention program in community-dwelling elderly people: a randomized controlled trial (ISRCTN 64716113). Int J Technol Assess Health Care 2008;24(2):193-202. http://www.ncbi.nlm.nih.gov/pubmed/18400123 Brazier, J. Measuring and valuing mental health for use in economic evaluation. J Health Serv Res Policy 2008;13 Suppl 3:70-5. http://www.ncbi.nlm.nih.gov/pubmed/18806195 Ghoniem G, Stanford E, Kenton K, Achtari C, Goldberg R, Mascarenhas T, Parekh M, Tamussino K, Tosson S, Lose G, Petri E. Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice. Int Urogynecol J Pelvic Floor Dysfunct 2008;19(1):5-33. http://www.ncbi.nlm.nih.gov/pubmed/18026681 Ngninkeu BN, van Heugen G, di Gregorio M, Debie B, Evans A. Laparoscopic artificial urinary sphincter in women for type III incontinence: preliminary results. Eur Urol 2005;47(6):793-7; discussion 797. http://www.ncbi.nlm.nih.gov/pubmed/15925075 Shaikh S, Ong EK, Glavind K, Cook J, N’Dow JM. Mechanical devices for urinary incontinence in women. Cochrane Database Syst Rev 200619;(2):CD001756. http://www.ncbi.nlm.nih.gov/pubmed/16625547
An exhaustive reference list is available for consultation on line at the society website (http://www.uroweb.org/ professional-resources/guidelines/) and on the guidelines CD-rom version.
Update march 2009
43
6. URINARY INCONTINENCE IN FRAIL / OLDER MEN AND WOMEN* Healthy older persons should be offered a similar range of treatment options as younger persons. Frail / older persons, however, require a different approach. Their evaluation must address the potential role of co-morbidity, current medications (prescribed, over-the-counter, and/or naturopathic), and functional and/or cognitive impairment for the management of UI. Studies and intervention in frail / older people should consider the degree of bother to the patient and/or carer, their goals for care, level of co-operation, and the overall prognosis and life expectancy. Effective management to meet the goals of care should be possible for most frail elderly persons.
6.1
History and symptom assessment
6.1.1 General principles Because frail / older men and women have a very high prevalence of UI, active case finding and screening for UI should be done in all frail / older persons (grade of recommendation: A). The history should identify co-morbid conditions and medications likely to cause or worsen UI. Recommendations for evaluation Recommendations GR Rectal examination for faecal loading or impaction C Functional assessment (mobility, transfers, manual dexterity, ability to successfully toilet A Screening test for depression B Cognitive assessment to assist in planning management C GR = grade of recommendation The mnemonic DIAPPERS (Delirium, Infection, Atrophic vaginitis, Pharmaceuticals, Psychological condition, Excess urine output, Reduced mobility, Stool impaction) includes some co-morbid conditions and factors to be considered. Two alterations from the original mnemonic should be noted; they are: • atrophic vaginitis does not by itself cause UI and should not be treated solely for the purpose of decreasing UI alone (grade of recommendation: B). • current consensus criteria for diagnosis of UTIs are both poorly sensitive and non-specific in nursinghome residents (level of evidence: 2). The patient and/or their carer should be asked directly about: • the degree of bother of UI (grade of recommendation: B). • goals for UI care (dryness, specific decrease in symptom severity, quality of life, reduction of co-morbidity, decreased care burden) (grade of recommendation: B). • the likely level of co-operation with management (grade of recommendation: C). It is also important to consider the patient’s overall prognosis and remaining life expectancy (grade of recommendation: C). All patients must be screened for haematuria (grade of recommendation: C), as it is not known if treatment of otherwise asymptomatic bacteriuria and pyuria is beneficial (no recommendation possible). Such treatment may cause harm by increasing the risk of antibody resistance and causing severe adverse effects, such as Clostridium difficile colitis (grade of recommendation: C). There is insufficient evidence to recommend a clinical stress test in frail / older persons. 6.1.2 Nocturia For frail / older people with bothersome nocturia, assessment should focus on identifying the potential underlying cause(s), including (grade of recommendation: C): • nocturnal polyuria • primary sleep problem (including sleep apnoea) • conditions resulting in a low voided volumes (e.g. elevated post-voiding residual) co-morbidity. A bladder diary (frequency-volume chart) or wet checks may be useful in the evaluation of patients with nocturia (grade of recommendation: C). Wet checks can be used to assess UI frequency in long-term care residents (grade of recommendation: C). * This section of the guidelines focuses on frail / older men and women. It has been based on the recommendations of the ICI committee chaired by Catherine Dubeau.
44
Update march 2009
6.1.3 Post-void residual (PVR) volume A post-void residual volume (PVR) is impractical to obtain in many care settings. However, there is compelling clinical experience for measuring PVR in selected frail / older persons with: • diabetes mellitus (especially if longstanding) • prior episodes of urinary retention or history of high PVR • recurrent UTIs • medications that impair bladder emptying (e.g. anticholinergics) • chronic constipation • persistent or worsening UI despite treatment with antimuscarinics • prior urodynamic study demonstrating detrusor underactivity and/or bladder outlet obstruction (grade of recommendation: C). Treatment of co-existing conditions (e.g. constipation) and stopping anticholinergic drugs may reduce PVR. There is no consensus regarding what constitutes ‘high’ PVR in any population. A trial of catheter decompression may be considered in patients with PVR > 200–500 mL, in whom high PVR may be a major contributor to UI or bothersome frequency (grade of recommendation: C).
6.2
Clinical diagnosis
The most common types of UI in frail / older persons are urgency UI, stress UI, and mixed UI (in frail / older women). Frail / older persons with urgency UI often have concomitant detrusor underactivity with an elevated PVR in the absence of outlet obstruction, a condition called detrusor hyperactivity with impaired contractility during voiding (DHIC). There is no published evidence that antimuscarinics are less effective or cause retention in persons with DHIC (no recommendation possible).
6.3
Initial management
Initial treatment should be individualised and influenced by goals of care, treatment preferences, and estimated remaining life expectancy, as well as the most likely clinical diagnosis (grade of recommendation: C). In some patients, it is important to recognise that contained UI (e.g. managed with pads) may be the only possible outcome for UI that persists after treatment of contributing co-morbidity and other factors. This is especially true for frail persons with no or minimal mobility (i.e. require the help of at least two persons to transfer), advanced dementia (i.e. unable to state their own name), and/or nocturnal UI. Conservative and behavioural therapies for UI include: • lifestyle changes (grade of recommendation: C) • bladder training in fit or alert patients (grade of recommendation: B) • prompted voiding for frail and cognitively impaired patients (grade of recommendation: A). For selected, cognitively intact, frail persons, pelvic muscle exercises may be considered, but they have not been well studied in this population (grade of recommendation: C). 6.3.1 Drug therapy Any drug treatment should be started with a low dose and titrated with regular review, until the desired improvement has been achieved or there are adverse effects. Recommendations for drug therapy in frail / older men and women with UI Recommendations GR • A trial of antimuscarinic drugs may be considered as an adjunct to conservative therapy of UUI A-C, depending on agent •S imilarly, alpha-blockers may be cautiously considered in frail men with suspected outlet C obstruction from prostate disease •B ecause DDAVP (vasopressin) carries a high risk of clinically significant hyponatraemia, it A should not be used in frail / older persons to treat nocturia or nocturnal polyuria GR = grade of recommendation
6.4
Ongoing management and reassessment
Urinary incontinence can usually be managed successfully using a combination of the above approaches. However, if initial management does not provide sufficient improvement in UI, then the next step should be to reassess the patient for contributing co-morbidity and/or functional impairment and to treat it.
Update march 2009
45
6.5
Specialised management
Specialist referral should be considered if the initial assessment finds that a frail / older person with UI has: • Other significant factors (e.g. pain, haematuria) • UI symptoms that cannot be classified as urgency, stress, or mixed incontinence, or other complicated co-morbidity, which the primary clinician is unable to address (e.g. dementia, functional impairment) • An insufficient response to initial management. The type of specialist will depend on local resources and the reason for referral. Surgical specialists could include urologists or gynaecologists. Patients with functional impairment could be referred to a geriatrician or physical therapist. Continence nurse specialists may be helpful for homebound patients. The decision to refer a patient should take into account the goals of care, patient/carer’s desire for invasive therapy, and estimated life expectancy. 6.5.1 Surgical approaches to UI in frail / older men and women Age itself is not a contraindication to incontinence surgery (grade of recommendation: C). Before surgery is considered, all patients should undergo the following. Recommendations for patient care prior to surgery Recommendations GR • Evaluation and treatment for any co-morbidity, medications and cognitive and/or functional C impairment that may be contributing to UI and/or could compromise the outcome of the planned surgery. For example, artificial sphincter should not be placed in men with dementia, who cannot manage the device on their own • An adequate trial of conservative therapy followed by reassessment of the need for surgery C • A discussion with the patient and/or carer to make sure that the anticipated surgical outcome is C consistent with the preferred goals of care in the context of the patient’s remaining life expectancy • Urodynamic testing because the clinical diagnosis may be inaccurate B • Pre-operative assessment and peri-operative care to establish risks for, and to minimise, common post-operative complications in the elderly, such as: - delirium and infection A - dehydration and falls C GR = grade of recommendation Figure 5: Management of UI in the frail / older men and women
s
46
Update march 2009
6.6 REFERENCES* •
• •
•
•
•
• •
• •
•
•
•
•
•
•
•
• •
•
Baztan JJ, Arias E, Gonzalez N, de Prada MIR. New-onset urinary incontinence and rehabilitation outcomes in frail older patients. Age Ageing 2005;34(2):172-5. http://www.ncbi.nlm.nih.gov/pubmed/15713862 Morrison A, Levy R. Fraction of Nursing Home Admissions Attributable to Urinary Incontinence: Value in Health. Blackwell Publishing Ltd, 2006, vol. 9, pp. 272-274. Boyington J, Howard D, Carter-Edwards L, Gooden K, Erdem N, Jallah Y, Busby-Whitehead J. Differences in resident characteristics and prevalence of urinary incontinence in nursing homes in the southeastern United States. Nurs Res 2007;56(2):97-107. http://www.ncbi.nlm.nih.gov/pubmed/17356440 Anger JT, Saigal CS, Pace J, Rodríguez LV, Litwin MS. True prevalence of urinary incontinence among female nursing home residents. Urology 2006;67(2):281-7. http://www.ncbi.nlm.nih.gov/pubmed/16461078 Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 2007;55(5):780-91. http://www.ncbi.nlm.nih.gov/pubmed/17493201 Dubeau CE. Beyond the bladder: management of urinary incontinence in older women. Clin Obstet Gynecol 2007;50(3):720-34. http://www.ncbi.nlm.nih.gov/pubmed/17762420 Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol 2005;174:1862-7. Tadic SD, Griffiths D, Schaefer W, Resnick NM. Abnormal connections in the supraspinal bladder control network in women with urge urinary incontinence. Neuroimage 2008;39(4):1647-53. http://www.ncbi.nlm.nih.gov/pubmed/18089297 Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: Evidence from functional brain imaging. Neurourol Urodyn 2007. Andrews-Hanna JR, Snyder AZ, Vincent JL, Lustig C, Head D, Raichle ME, Buckner RL. Disruption of large-scale brain systems in advanced aging. Neuron 2007;56(5):924-35. http://www.ncbi.nlm.nih.gov/pubmed/18054866 Pfisterer MH, Griffiths DJ, Schaefer W, Resnick NM. The effect of age on lower urinary tract function: a study in women. J Am Geriatr Soc 2006;54(3):405-12. http://www.ncbi.nlm.nih.gov/pubmed/16551306 Taylor JA, III, Kuchel GA. Detrusor underactivity: Clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 2006;54(12):1920-32. http://www.ncbi.nlm.nih.gov/pubmed/17198500 Taylor J, III. Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer 2007;7:135. http://www.ncbi.nlm.nih.gov/pubmed/17650334 Pfisterer MH, Griffiths DJ, Rosenberg L, Schaefer W, Resnick NM. The impact of detrusor overactivity on bladder function in younger and older women. J Urol 2006;175(5):1777-83. http://www.ncbi.nlm.nih.gov/pubmed/16600758 Yang J, Yang SH. Huang WC. Functional correlates of Doppler flow study of the female urethral vasculature. Ultrasound in Obstet Gynecol 2006;28(1):96-102. http://www.ncbi.nlm.nih.gov/pubmed/16758440 Siracusano S: Bertolotto M. Cucchi A. Lampropoulou N. Tiberio A. Gasparini C. Ciciliato S. Belgrano E. Application of ultrasound contrast agents for the characterization of female urethral vascularization in healthy pre- and postmenopausal volunteers: preliminary report. Eur Urol 2006;50(6):1316-22. http://www.ncbi.nlm.nih.gov/pubmed/16831513 Liang C: Chang SD. Chang YL. Wei TY. Wu HM. Chao AS. Three-dimensional power Doppler measurement of perfusion of the periurethral tissue in incontinent women -- a preliminary report. Acta Obstet Gynecol Scand 2006;85(5):608-13. http://www.ncbi.nlm.nih.gov/pubmed/16752242 Clobes A: DeLancey JO. Morgan DM. Urethral circular smooth muscle in young and old women. Am J Obstet Gynecol 2008;198(5):587.e1-e5. Trowbridge ER: Wei JT. Fenner DE. Ashton-Miller JA. Delancey JO. Effects of aging on lower urinary tract and pelvic floor function in nulliparous women. Obstet Gynecol 2007;109(3):715-20. http://www.ncbi.nlm.nih.gov/pubmed/17329525 Kenton K: Lowenstein L. Simmons J. Brubaker L. Aging and overactive bladder may be associated with loss of urethral sensation in women. Neurourol Urodyn 2007;26(7):981-4.
Update march 2009
47
•
• •
•
• •
•
• •
•
•
•
•
•
•
•
•
48
Kenton K: Simmons J. FitzGerald MP. Lowenstein L. Brubaker L. Urethral and bladder current perception thresholds: normative data in women. J Urol 2007;178(1):189-92;discussion192. http://www.ncbi.nlm.nih.gov/pubmed/17499783 Lawrence J: Lukacz ES. Nager CW. Hsu JW. Luber KM. Prevalence and co-occurrence of pelvic floor disorders in community-dwelling women. Obstet Gynecol 2008;111(3):678-85. Talasz H, Himmer-Perschak G. Marth E. Fischer-Colbrie J. Hoefner E. Lechleitner M. Evaluation of pelvic floor muscle function in a random group of adult women in Austria. Int Urogynecol J 2008;19(1):131-5. http://www.ncbi.nlm.nih.gov/pubmed/17876492 Jundt K, Kiening M, Fischer P, Bergauer F, Rauch E, Janni W, Peschers U, Dimpfl T. Is the histomorphological concept of female pelvic floor and its changes due to age and vaginal delivery correct? Neurourol Urodyn 2005;24(1):44-50. http://www.ncbi.nlm.nih.gov/pubmed/15573382 Fox J: Fletcher JG. Zinsmeister AR. Seide B. Riederer SJ. Bharucha AE. Effect of aging on anorectal and pelvic floor functions in females. Dis Colon Rectum 2006;49(11):1726-35. Pal L, Hailpern SM. Santoro NF. Freeman R. Barad D. Kipersztok S. Barnabei VM. WassertheilSmoller S. Association of pelvic organ prolapse and fractures in postmenopausal women: analysis of baseline data from the Women’s Health Initiative Estrogen Plus Progestin trial. Menopause 2008;15(1):59-66. http://www.ncbi.nlm.nih.gov/pubmed/18257143 Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2008;288;49-57. http://www.ncbi.nlm.nih.gov/pubmed/12090862 Tan J: Lukacz ES. Menefee SA. Luber KM. Albo ME. Nager CW. Determinants of vaginal length. Am J Obstet Gynecol 2006;195(6):1846-50. Mishra V, Allen DJ. Nicolaou C. Sharif H. Hudd C. Karim OM. Motiwala HG. Laniado ME. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007;100(2):327-31. http://www.ncbi.nlm.nih.gov/pubmed/17617139 Juthani-Mehta M, Tinetti M, Perrelli E, Towle V, Van Ness P, Quagliarello V. Diagnostic accuracy of criteria for urinary tract infection in a cohort of nursing home residents. J Am Geriatr Soc 2007;55(7):1072-7. http://www.ncbi.nlm.nih.gov/pubmed/17608881 Cigolle CT, Langa KM, Kabeto MU, Zhiyi T and Blaum CS: Geriatric Conditions and Disability: The Health and Retirement Study. Ann Intern Med 2007;147(3):156-64. http://www.ncbi.nlm.nih.gov/pubmed/17679703 Rait G, Fletcher A, Smeeth L, Brayne C, Stirling S, Nunes M, Breeze E, Ng ES, Bulpitt CJ, Jones D, Tulloch AJ. Prevalence of cognitive impairment: results from the MRC trial of assessment and management of older people in the community. Age Ageing 2005;34(3):242-8. http://www.ncbi.nlm.nih.gov/pubmed/15863409 Mecocci P, von Strauss E, Cherubini A, Ercolani S, Mariani E, Senin U, Winblad B, Fratiglioni L. Cognitive impairment is the major risk factor for development of geriatric syndromes during hospitalization: results from the GIFA study. Dement Geriatr Cogn Disord 2005;20(4):262-9. http://www.ncbi.nlm.nih.gov/pubmed/16103670 Huang A, Brown J, Thom D, Fink H, Yaffe K. Study of Osteoporotic Fractures Research Group. Urinary incontinence in older community-dwelling women: the role of cognitive and physical function decline. Obstet Gynecol 2007;109(4):909-16. http://www.ncbi.nlm.nih.gov/pubmed/17400853 Pantoni L: Leukoaraiosis: from an ancient term to an actual marker of poor prognosis. Stroke 2008;39:1401-3. http://www.ncbi.nlm.nih.gov/pubmed/18340098 Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger’s report. A review. Stroke 2005;26(7):1293-301. http://www.ncbi.nlm.nih.gov/pubmed/7604429 Wullner U, T. Schmitz-Hubsch GA, R. Fimmers, A. Spottke, W. H.Oertel, G. Deuschl TK, K. Eggert on behalf of the KNP e.V. Autonomic dysfunction in 3414 Parkinson’s disease patients enrolled in the German Network on Parkinson’s disease (KNP e.V.): the effect of ageing. Eur J Neurol 2007;14: 1405–8.
Update march 2009
•
•
•
•
•
•
•
•
•
•
• •
•
• •
•
•
•
•
Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff J, Giladi N. Falls in outpatients with Parkinson’s disease. J Neurol 2005;252:1310-5. http://www.ncbi.nlm.nih.gov/pubmed/15895303 Fultz NH, Rahrig Jenkins K, Østbye T, Taylor JDH, Kabeto MU and Langa KM: The impact of own and spouse’s urinary incontinence on depressive symptoms. Soc Sci Med 2005;60:2537-48. http://www.ncbi.nlm.nih.gov/pubmed/15814179 Yoshida Y, Kim H, Iwasa H, Kwon J, Sugiura M, Furuna T, Yoshida H and Suzuki T: Prevalence and characteristics of urinary incontinence in community-dwelling-elderly as determined by comprehensive health examination and interview for the prevention of geriatric syndrome and bedridden state. Nippon Ronen Igakkai Zasshi 2007;44:83-9. http://www.ncbi.nlm.nih.gov/pubmed/17337859 Song H and Bae J: Prevalence of urinary incontinence and lower urinary tract symptoms for community-dwelling elderly 85 years of age and older. J Wound Ostomy Continence Nurs 2007;34: 535-41. http://www.ncbi.nlm.nih.gov/pubmed/17876216 Ko Y, Lin S, Salmon J and Bron M: The impact of urinary incontinence on quality of life of the elderly. Am J Managed Care 2005;11(4 Suppl):S103-S111. http://www.ncbi.nlm.nih.gov/pubmed/16161383 Nelson RL and Furner SE: Risk factors for the development of fecal and urinary incontinence in Wisconsin nursing home residents. Maturitas 2005;52:26-31. http://www.ncbi.nlm.nih.gov/pubmed/16143223 Landi F, Onder G, Cesari M, Zamboni V, Russo A, Barillaro C and Bernabei R: The Silvernet-HC study group. Functional decline in frail community-dwelling stroke patients. J Neurol 2006;13:17-23. http://www.ncbi.nlm.nih.gov/pubmed/16420389 Takazawa K and Arisawa K: Relationship between the type of urinary incontinence and falls among frail elderly women in Japan. J Med Invest 2005;52:165-71. http://www.ncbi.nlm.nih.gov/pubmed/16167534 Chen JS, March LM, Schwarz J, Zochling J, Makaroff J, Sitoh YY, Lau TC, Lord SR, Cameron ID, Cumming RG, Sambrook PN. A multivariate regression model predicted falls in residents living in intermediate hostel care. J Clinical Epidemiol 2005;58: 503-8. http://www.ncbi.nlm.nih.gov/pubmed/15845337 Becker C, Loy S, Sander S, Nikolaus T, Rissmann U and Kron M: An algorithm to screen long-term care residents at risk for accidental falls. Aging Clin Exp Res 2005;17:186-92. http://www.ncbi.nlm.nih.gov/pubmed/16110730 Woodford H and George J: NICE guidelines on urinary incontinence in women. Age Ageing 2007;36:349-50. DuBeau CE, Ouslander JG and Palmer MH: Knowledge and attitudes of nursing home staff and surveyors about the revised federal guidance for incontinence care. Gerontologist 2007;47:468-79. http://www.ncbi.nlm.nih.gov/pubmed/17766668 Fung C, Spencer B, Eslami M and Crandall C: Quality indicators for the screening and care of urinary incontinence in vulnerable elders. J Am Geriatr Soc 2007;55 Suppl 2:S443-S449. http://www.ncbi.nlm.nih.gov/pubmed/17910569 Wagg A, Potter J, Irwin P, Lowe D, Pearson M. National audit of continence care for older people: management of urinary incontinence. Age Ageing 2008;37:39–44. Wagg A, Mian S, Lowe D, Potter J, Pearson M. National audit of continence care for older people: results of a pilot study. J Eval Clin Pract 2005;11:525-32. http://www.ncbi.nlm.nih.gov/pubmed/16364105 van Gerwen M and Lagro-Janssen A. Diagnostic value of patient history and physical examination in elderly patients with urinary incontinence; a literature review [De diagnostische waarde van anamnese en lichamelijk onderzoek bij ouderen met urine-incontinentie; een overzicht van de literatuur]. Ned Tijdschr Geneeskd 2006;150:1771-5. [article in Dutch] Jansen L and Forbes D: The psychometric testing of a urinary incontinence nursing assessment instrument. J Wound Ostomy Continence Nurs 2006;33(1):69-76. http://www.ncbi.nlm.nih.gov/pubmed/16444108 Ouslander JG, Griffiths PC, McConnell E, Riolo L, Kutner M and Schnelle J: Functional incidental training: a randomized, controlled, crossover trial in Veterans Affairs nursing homes. J Am Geriatr Soc 2005 Jul;53(7):1091-100. http://www.ncbi.nlm.nih.gov/pubmed/16108924 DuBeau C, Simon S, Morris JN. The Impact of urinary incontinence on quality of life in nursing home residents, 2006.
Update march 2009
49
•
•
•
•
•
•
•
•
•
•
•
•
•
•
• •
•
•
•
50
Fonda D, Abrams P. Cure sometimes, help always--a “continence paradigm” for all ages and conditions. Neurourol Urodyn 2006;25(3):290-2. http://www.ncbi.nlm.nih.gov/pubmed/16496393 Cai L, Lubitz J. Was there compression of disability for older Americans from 1992 to 2003? Demography 2007;44(3):479-95. http://www.ncbi.nlm.nih.gov/pubmed/17913007 Kincade JE, Dougherty MC, Carlson JR, Hunter GS and Busby-Whitehead J: Randomized clinical trial of efficacy of self-monitoring techniques to treat urinary incontinence in women. Neurourol Urodyn 2007;26(4):507-11. http://www.ncbi.nlm.nih.gov/pubmed/17366526 Townsend MK, Curhan GC, Resnick NM, Grodstein F. BMI, Waist Circumference, and Incident Urinary Incontinence in Older Women. Obesity (Silver Spring) 2008;16(4):881-6. http://www.ncbi.nlm.nih.gov/pubmed/18379564 Perrin L, Dauphinee SW, Corcos J, Hanley JA and Kuchel GA: Pelvic floor muscle training with biofeedback and bladder training in elderly women: a feasibility study. J Wound Ostomy Continence Nurs 2005;32(3):186-99. http://www.ncbi.nlm.nih.gov/pubmed/15931150 Palmer MH: Effectiveness of prompted voiding for incontinent nursing home residents. In: Melnyk BM, Fineout-Overholt E, eds. Evidence-based practice in nursing & healthcare: a guide to the best practice. Lippincott Williams & Williams, 2005, pp CD20-CD30. Ostaszkiewicz J. A clinical nursing leadership model for enhancing continence care for older adults in a subacute inpatient care setting. J Wound Ostomy Continence Nurs 2006;33(6):624-9. http://www.ncbi.nlm.nih.gov/pubmed/17108772 Ostaszkiewicz J, Roe B and Johnston L. Effects of timed voiding for the management of urinary incontinence in adults: systematic review. J Adv Nurs 2005;52(4):420-31. http://www.ncbi.nlm.nih.gov/pubmed/16268846 van Houten P, Achterberg W, Ribbe M. Urinary incontinence in disabled elderly women: a randomized clinical trial on the effect of training mobility and toileting skills to achieve independent toileting. Gerontology 2007;53(4):205-10. http://www.ncbi.nlm.nih.gov/pubmed/17347567 Campeau L, Tu L, Lemieux M, Naud A, Karsenty G, Schick E, Corcos J. A multicenter, prospective, randomized clinical trial comparing tension-free vaginal tape surgery and no treatment for the management of stress urinary incontinence in elderly women. Neurourol Urodyn 2007;26(7):990-4. http://www.ncbi.nlm.nih.gov/pubmed/17638307 Dalpiaz O, Primus G, Schips L. SPARC sling system for treatment of female stress urinary incontinence in the elderly. Eur Urol 2006;50(4):826-30; discussion 830-1. http://www.ncbi.nlm.nih.gov/pubmed/16687203 Britton A, Russell R. Multidisciplinary team interventions for delirium in patients with chronic cognitive impairment. Cochrane Database Syst Rev 2007;(2):CD000395. http://www.ncbi.nlm.nih.gov/pubmed/17636635 Cathcart P, van der Meulen J, Armitage J, Emberton M. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol 2006;176(1):200-4; discussion 204. http://www.ncbi.nlm.nih.gov/pubmed/16753401 Gehrich A: Stany MP. Fischer JR. Buller J. Zahn CM. Establishing a mean postvoid residual volume in asymptomatic perimenopausal and postmenopausal women. Obstet Gynecol 2007;110(4):827-32. http://www.ncbi.nlm.nih.gov/pubmed/17906016 Tang MWS, Kwok TCY, Hui E, Woo J. Intermittent versus indwelling urinary catheterization in older female patients. Maturitas 2006;53:274-281. Wu J, Baguley IJ. Urinary Retention in a General Rehabilitation Unit: Prevalence, Clinical Outcome, and the Role of Screening. Arch Phys Med Rehabil 2005 Sep;86(9):1772-7. http://www.ncbi.nlm.nih.gov/pubmed/16181941 Haylen B, Krishnan S, Schulz S, Verity L, Law M, Zhou J, Sutherst J. Has the true prevalence of voiding difficulty in urogynecology patients been underestimated? Int Urogynecol J Pelvic Floor Dysfunct 2007;18(1):53-6. Epub 2006. http://www.ncbi.nlm.nih.gov/pubmed/16596458 Lukacz E: DuHamel E. Menefee SA. Luber KM. Elevated postvoid residual in women with pelvic floor disorders: prevalence and associated risk factors. Int Urogynecol J Pelvic Floor Dysfunct 2007;18(4):397-400. Epub 2006. http://www.ncbi.nlm.nih.gov/pubmed/16804634 Pilloni S, Krhut J, Mair D, Madersbacher H, Kessler TM. Intermittent catheterisation in older people: a
Update march 2009
•
•
•
•
valuable alternative to an indwelling catheter? Age Ageing 2005;34(1):57-60. http://www.ncbi.nlm.nih.gov/pubmed/15537679 Omli R: Skotnes LH. Mykletun A. Bakke AM. Kuhry E. Residual urine as a risk factor for lower urinary tract infection: a 1-year follow-up study in nursing homes. J Am Geriatr Soc 2008;56(5):871-4. http://www.ncbi.nlm.nih.gov/pubmed/18331294 Cohen R, Wilkins KM, Ostroff R, Tampi RR. Olanzapine and acute urinary retention in two geriatric patients. Am J Geriatr Pharmacother 2007;5(3):241-6. http://www.ncbi.nlm.nih.gov/pubmed/17996664 Semaan W, Doyon J, Jolicoeur F, Duchesneau J. Dose-dependent urinary retention following olanzapine administration. Ann Pharmacother 2006;40(9):1693. http://www.ncbi.nlm.nih.gov/pubmed/16896022 Matsumoto M, Inoue K. Predictors of institutionalization in elderly people living at home: the impact of incontinence and commode use in rural Japan. J Cross Cult Gerontol 2007;22(4):421-32. http://www.ncbi.nlm.nih.gov/pubmed/17763930
An exhaustive reference list is available for consultation on line at the society website (http://www.uroweb.org/ professional-resources/guidelines/) and on the guidelines CD-rom version.
Update march 2009
51
7. ABBREVIATIONS USED IN THE TEXT This list is not comprehensive for the most common abbreviations.
AUS artificial urinary sphincter CaP cancer of the prostate CS Caesarean section BF biofeedback BOO bladder outlet obstruction BPO benign prostatic obstruction BT bladder training COX inhibitor cyclo-oxygenase inhibitor DHIC detrusor hyperactivity with impaired contractility during voiding DIAPPERS Delirium, Infection, Atrophic vaginitis, Pharmaceuticals, Psychological condition, Excess urine output, Reduced mobility, Stool impaction DO detrusor overactivity EStim electrical stimulation GR grade of recommendation (modified Oxford system) HIFU high-intensity focused ultrasound LE level of evidence (modified Oxford system) MStim magnetic stimulation MUI mixed urinary incontinence OAB overactive bladder PFMT pelvic floor muscle training PDE-5 inhibitor phosphodiesterase-type 5 inhibitor POP pelvic organ prolapse PVR post-void residual (urine) QoL Quality of Life RCT randomised controlled trial RP radical prostatectomy SUI stress urinary incontinence TURP transurethral resection of prostate TUIP transurethral incision of the prostate (TUIP) UPP urethral pressure profile UUI urgency urinary incontinence UTI urinary tract infection VC vaginal cones
Conflict of interest All members of the Incontinence Guidelines writing panel have provided disclosure statements on all relationships that they have and that might be perceived to be a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
52
Update march 2009
Guidelines on
Urological Infections M. Grabe (Chairman), M.C. Bishop, T.E. Bjerklund-Johansen, H. Botto, M. Çek, B. Lobel, K.G. Naber, J. Palou, P. Tenke, F. Wagenlehner
© European Association of Urology 2009
TABLE OF CONTENTS
page
1. INTRODUCTION 1.1 Pathogenesis of urinary tract infections 1.2 Microbiological and other laboratory findings 1.3 Classification of urological infections 1.4 Aim of guidelines 1.5 Methods 1.6 Level of evidence and grade of guideline recommendation 1.7 References 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 2.1 Summary and Recommendations 2.1.1 Definition 2.1.2 Aetiological spectrum 2.1.3 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 2.1.4 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 2.1.5 Recurrent (uncomplicated) UTIs in women 2.1.6 UTIs in pregnancy 2.1.7 UTIs in post-menopausal women 2.1.8 Acute uncomplicated UTIs in young men 2.1.9 Asymptomatic bacteriuria 2.2 Background 2.3 Definition 2.4 Aetiological spectrum 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 2.5.1 Incidence, risk factors, morbidity 2.5.2 Diagnosis 2.5.3 Treatment 2.5.4 Post-treatment follow-up 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 2.6.1 Diagnosis 2.6.2 Treatment 2.6.3 Post-treatment follow-up 2.7 Recurrent (uncomplicated) UTIs in women 2.7.1 Background 2.7.2 Prophylactic antimicrobial regimens 2.7.3 Alternative prophylactic methods 2.8 UTIs in pregnancy 2.8.1 Epidemiology 2.8.2 Asymptomatic bacteriuria 2.8.3 Acute cystitis during pregnancy 2.8.4 Acute pyelonephritis in pregnancy 2.9 UTIs in postmenopausal women 2.10 Acute uncomplicated UTIs in young men 2.10.1 Pathogenesis and risk factors 2.10.2 Diagnosis 2.10.3 Treatment 2.11 Asymptomatic bacteriuria 2.12 References
11 11 11 11 11 11 12 12 12 12 12 13 13 13 14 14 14 14 19 19 19 20 22 22 22 23 25 26 26 26 27 27 27 28 28 28 28 29 29
3. URINARY TRACT INFECTIONS IN CHILDREN 3.1 Summary and recommendations 3.2 Background 3.3 Aetiology 3.4 Pathogenesis and risk factors 3.5 Signs and symptoms 3.6 Classification 3.6.1 Severe UTI 3.6.2 Simple UTI
38 38 38 38 38 39 39 39 39
2
7 7 7 8 8 9 9 9
UPDATE MARCH 2009
3.7 Diagnosis 3.7.1 Physical examination 3.7.2 Laboratory tests 3.7.2.1 Collection of urine 3.7.2.1.1 Suprapubic bladder aspiration 3.7.2.1.2 Bladder catheterization 3.7.2.1.3 Plastic bag attached to the genitalia 3.7.2.2 Quantification of bacteriuria 3.7.2.3 Other biochemical markers 3.7.2.3.1 Nitrite 3.7.2.3.2 Leucocyte esterase 3.7.2.3.3 C-reactive protein 3.7.2.3.4 Urinary N-acetyl-ß-glucosaminidase 3.7.2.3.5 Interleukin-6 3.7.3 Imaging of the urinary tract 3.7.3.1 Ultrasonography 3.7.3.2 Radionuclide studies 3.7.3.3 Cystourethrography 3.7.3.3.1 Conventional voiding cystourethrography 3.7.3.3.2 Radionuclide cystography (indirect) 3.7.3.3.3 Cystosonography 3.7.3.4 Additional imaging 3.7.3.5 Urodynamic evaluation 3.8 Schedule of investigation 3.9 Treatment 3.9.1 Severe UTIs 3.9.2 Simple UTIs 3.9.3 Prophylaxis 3.10 Acknowledgement 3.11 References
39 39 40 40 40 40 40 40 40 40 41 41 41 41 41 41 42 42 42 42 42 42 42 42 43 43 44 44 45 45
4. UTIs IN RENAL INSUFFICIENCY, TRANSPLANT RECIPIENTS, DIABETES MELLITUS AND IMMUNOSUPRESSION 4.1 Summary 4.1.1 Acute effects of UTI on the kidney 4.1.2 Chronic renal disease and UTI 4.1.2.1 Adult polycystic kidney disease (APCKD) 4.1.2.2 Calculi and UTI 4.1.2.3 Obstruction and UTI 4.1.3 UTI in renal transplantation and immunosuppression 4.1.4 Antibiotic treatment for UTI in renal insufficiency and after renal transplantation 4.2 Background 4.3 Acute effects of a UTI on the kidney 4.3.1 Vesicoureteric and intrarenal reflux 4.3.2 Obstructive neuropathy 4.3.3 Renal effects of severe UTI 4.3.4 Acute effects of UTI on the normal kidney 4.3.5 Renal scarring 4.3.6 Specific conditions in which an acute UTI causes renal damage 4.3.6.1 Diabetes mellitus 4.3.6.2 Tuberculosis 4.4 Chronic renal disease and UTI 4.4.1 Adult dominant polycystic kidney disease (ADPK) 4.4.2 Renal calculi 4.5 UTI in renal transplantation 4.5.1 Donor organ infection 4.5.2 Graft failure 4.5.3 Kidney and whole-organ pancreas transplantation 4.6 Antibiotic therapy in renal failure/transplantation 4.6.1 Treatment of UTI in renal transplant recipients
49
UPDATE MARCH 2009
49 49 49 49 50 50 50 50 50 50 50 51 51 51 51 52 52 53 53 53 53 54 54 54 54 54 55
3
4.7 4.8
4.6.2 Fungal infections 4.6.3 Schistosomiasis Immunosuppression 4.7.1 HIV infection 4.7.2 Viral and fungal infections References 4.8.1 Further reading
56 56 56 56 56 56 60
5. COMPLICATED UTIs DUE TO UROLOGICAL DISORDERS 5.1 Summary and recommendations 5.2 Definitions and classification 5.2.1 Clinical presentation 5.2.2 Urine cultures 5.3 Microbiology 5.3.1 Spectrum and antibiotic resistance 5.3.2 Complicated UTIs associated with urinary stones 5.3.3 Complicated UTIs associated with urinary catheters 5.4 Treatment 5.4.1 General principles 5.4.2 Choice of antibiotics 5.4.3 Duration of antibiotic therapy 5.4.4 Complicated UTIs associated with urinary stones 5.4.5 Complicated UTIs associated with indwelling catheters 5.4.6 Complicated UTIs in spinal-cord injured patients 5.4.7 Follow-up after treatment 5.5 Conclusions 5.6 References 6. CATHETER-ASSOCIATED UTIs 6.1 Abstract 6.2 Summary of recommendations 6.3 References 7. SEPSIS IN UROLOGY (UROSEPSIS) 7.1 Summary and recommendations 7.2 Background 7.3 Definition and clinical manifestation of sepsis in urology 7.4 Physiology and biochemical markers 7.4.1 Cytokines as markers of the septic response 7.4.2 Procalcitonin is a potential marker of sepsis 7.5 Prevention 7.5.1 Preventive measures of proven or probable efficacy 7.5.2 Appropriate peri-operative antimicrobial prophylaxis 7.5.3 Preventive measures of debatable efficacy 7.5.4 Ineffective or counterproductive measures 7.6 Treatment 7.6.1 Relief of obstruction 7.6.2 Antimicrobial therapy 7.6.3 Adjunctive measures 7.7 Conclusion 7.8 Acknowledgement 7.9 References
67 67 68 68 69 69 69 69 69 70 70 70 70 70 70 70 70 71 71
8.
72 72 72 72 72 72 72
4
URETHRITIS 8.1 Definition 8.2 Epidemiology 8.3 Pathogens 8.4 Route of infection and pathogenesis 8.5 Clinical course 8.6 Diagnosis
60 60 60 61 61 61 61 61 62 62 62 62 63 63 63 63 64 64 64 65 66 66 67
UPDATE MARCH 2009
8.7 8.8 8.9
Therapy Prevention References
73 73 73
9. PROSTATITIS AND CHRONIC PELVIC PAIN SYNDROME 9.1 Summary and recommendations 9.2 Introduction and definition 9.3 Diagnosis 9.3.1 History and symptoms 9.3.1.1 Symptom questionnaires 9.3.2 Clinical findings 9.3.3 Urine cultures and expressed prostatic secretion 9.3.4 Perineal biopsy 9.3.5 Other tests 9.3.6 Classification systems 9.3.7 Diagnostic evaluation 9.3.8 Additional investigations 9.4 Treatment 9.4.1 Antibiotics 9.4.2 Antibiotics and α-blockers in combination therapy 9.4.3 Other oral medication 9.4.4 Intraprostatic injection of antibiotics 9.4.5 Surgery 9.4.6 Other treatment forms 9.5 References
74 74 74 75 75 75 75 75 76 76 76 77 77 78 78 78 79 79 79 79 79
10. EPIDIDYMITIS AND ORCHITIS 10.1 Definition and classification 10.2 Incidence and prevalence 10.3 Morbidity 10.4 Pathogenesis and pathology 10.5 Diagnosis 10.5.1 Differential diagnosis 10.6 Treatment 10.7 References 11. PERI-OPERATIVE ANTIBACTERIAL PROPHYLAXIS IN UROLOGY 11.1 Summary 11.2 Introduction 11.3 Goals of peri-operative antibacterial prophylaxis 11.4 Risk factors 11.5 Principles of antibiotic prophylaxis 11.5.1 Timing 11.5.2 Route of administration 11.5.3 Duration of the regimen 11.5.4 Choice of antibiotics 11.6 Prophylactic regimens in defined procedures 11.6.1 Diagnostic procedures 11.6.2 Endo-urological treatment procedures 11.6.3 Laparoscopic surgery 11.6.4 Open urological operations without bowel segment with or without opening of the urinary tract 11.6.5 Open urological operations with bowel segment 11.6.6 Post-operative drainage of the urinary tract 11.6.7 Implant of prosthetic devices 11.7 References
82 82 82 83 83 83 83 83 84
89 89 89 90
12. SPECIFIC INFECTIONS 12.1 Urogenital Tuberculosis 12.1.1 Reference
92 92 92
UPDATE MARCH 2009
84 84 85 85 86 86 86 87 87 87 87 88 88 89 89
5
12.2
Urogenital Schistosomiasis 12.2.1 Reference
92 93
13.
SEXUALLY TRANSMITTED INFECTIONS 13.1 Reference
93 93
14. APPENDICES 14.1 Criteria for the diagnosis of a UTI 14.1.1 References 14.2 Recommendations for antimicrobial therapy in urology 14.3 Recommendations for antibiotic prescribing in renal failure 14.4 Recommendations for peri-operative antibacterial prophylaxis in urology 14.5 Chronic Prostatitis Symptom Index (CPSI) 14.6 Meares & Stamey localization technique 14.7 Antibacterial agents 14.7.1 Penicillins 14.7.1.1 Aminopenicillins 14.7.1.2 Acylaminopenicillins 14.7.1.3 Isoxazolylpenicillins 14.7.2 Parental cephalosporins 14.7.2.1 Group 1 cephalosporins 14.7.2.2 Group 2 cephalosporins 14.7.2.3 Group 3a cephalosporins 14.7.2.4 Group 3b cephalosporins 14.7.2.5 Group 4 cephalosporins 14.7.2.6 Group 5 cephalosporins 14.7.3 Oral cephalosporins 14.7.3.1 Group 1 oral cephalosporins 14.7.3.2 Group 2 oral cephalosporins 14.7.3.3 Group 3 oral cephalosporins 14.7.4 Monobactrams 14.7.5 Carpabenens 14.7.6 Fluoroquinolones 14.7.6.1 Group 1 fluoroquinolones 14.7.6.2 Group 2 fluoroquinolones 14.7.6.3 Group 3 fluoroquinolones 14.7.7 Co-trimoxazole 14.7.8 Fosfomycin 14.7.9 Nitrofurantoin 14.7.10 Macrolides 14.7.11 Tetracyclines 14.7.12 Aminoglycosides 14.7.13 Glycopeptides 14.7.14 Oxazolidinones 14.7.15 References 14.8 Relevant bacteria for urological infections 15. ABBREVIATIONS USED IN THE TEXT
6
93 93 94 94 95 97 99 100 101 102 102 102 102 102 102 102 102 102 103 103 103 104 104 104 104 104 104 105 105 105 106 106 106 106 106 106 106 107 107 108 109
UPDATE MARCH 2009
1. INTRODUCTION Urinary tract infections (UTIs) are among the most prevalent infectious diseases with a substantial financial burden on society. Unfortunately, in Europe, there are no good data concerning the prevalence of various types of UTIs and their impact on the quality of life of the affected population. Nor is there good data regarding the impact of UTIs on economics in general and that of the health care system especially. For a well-functioning public health system, such data are urgently needed. Data obtained from other countries and societies, e.g. the USA, can only be applied with caution to the European situation. In the USA, UTIs are responsible for over 7 million physician visits annually, including more than 2 million visits for cystitis (1). Approximately 15% of all community-prescribed antibiotics in the USA are dispensed for UTI, at an estimated annual cost of over US $1 billion (2). Furthermore, the direct and indirect costs associated with community-acquired UTIs in the USA alone exceed an estimated US $1.6 billion (1). Urinary tract infections account for more than 100,000 hospital admissions annually, most often for pyelonephritis (1). They also account for at least 40% of all hospital-acquired infections and are in the majority of cases catheter-associated (2-4). Nosocomial bacteriuria develops in up to 25% of patients requiring a urinary catheter for > 7 days, with a daily risk of 5% (5). It has been estimated that an episode of nosocomial bacteriuria adds US $500-1,000 to the direct cost of acute-care hospitalization (6). In addition, the pathogens are fully exposed to the nosocomial environment, including selective pressure by antibiotic or antiseptic substances. Nosocomial UTIs therefore comprise perhaps the largest institutional reservoir of nosocomial antibiotic-resistant pathogens (5).
1.1 Pathogenesis of urinary tract infections Micro-organisms can reach the urinary tract by haematogenous or lymphatic spread, but there is abundant clinical and experimental evidence to show that the ascent of micro-organisms from the urethra is the most common pathway leading to a UTI, especially organisms of enteric origin (i.e. Escherichia coli and other Enterobacteriaceae). This provides a logical explanation for the greater frequency of UTIs in women than in men and for the increased risk of infection following bladder catheterization or instrumentation. A single insertion of a catheter into the urinary bladder in ambulatory patients results in urinary infection in 1-2% of cases. Indwelling catheters with open-drainage systems result in bacteriuria in almost 100% of cases within 3-4 days. The use of a closed-drainage system, including a valve preventing retrograde flow, delays the onset of infection, but ultimately does not prevent it. It is thought that bacteria migrate within the mucopurulent space between the urethra and catheter, and that this leads to the development of bacteriuria in almost all patients within about 4 weeks. Haematogenous infection of the urinary tract is restricted to a few relatively uncommon microbes, such as Staphylococcus aureus, Candida spp., Salmonella spp. and Mycobacterium tuberculosis, which cause primary infections elsewhere in the body. Candida albicans readily causes a clinical UTI via the haematogenous route, but is also an infrequent cause of an ascending infection if an indwelling catheter is present or following antibiotic therapy. The concept of bacterial virulence or pathogenicity in the urinary tract infers that not all bacterial species are equally capable of inducing infection. The more compromised the natural defence mechanisms (e.g. obstruction, bladder catheterization), the fewer the virulence requirements of any bacterial strain to induce infection. This is supported by the well-documented in-vitro observation that bacteria isolated from patients with a complicated UTI frequently fail to express virulence factors. The virulence concept also suggests that certain bacterial strains within a species are uniquely equipped with specialized virulence factors, e.g. different types of pili, which facilitate the ascent of bacteria from the faecal flora, introitus vaginae or periurethral area up the urethra into the bladder, or, less frequently, allow the organisms to reach the kidneys to induce systemic inflammation.
1.2
Microbiological and other laboratory findings
The number of bacteria is considered relevant for the diagnosis of a UTI. In 1960, Kass developed the concept of ’significant‘ bacteriuria (> 105 cfu) in the context of pyelonephritis in pregnancy (7). Although this concept introduced quantitative microbiology into the diagnostics of infectious diseases and is therefore still of general importance, it has recently become clear that there is no fixed number of significant bacteriuria, which can be applied to all kinds of UTIs and in all circumstances. As described in Appendix 12.1, the following bacterial counts are clinically relevant: • > 103 colony-forming units (cfu) of uropathogen/mL of a mid-stream sample of urine (MSU) in acute uncomplicated cystitis in a woman • > 104 cfu uropathogen/mL of MSU in acute uncomplicated pyelonephritis in a woman
UPDATE MARCH 2009
7
• > 105 cfu uropathogen/mL of MSU in a woman, or > 104 cfu uropathogen/mL of MSU in a man or in straight catheter urine in women in a complicated UTI. In a suprapubic bladder puncture specimen, any count of bacteria is relevant. The problem of counting low numbers, however, has to be considered. If an inoculum of 0.1 mL of urine is used and 10 identical colonies are necessary for statistical reasons of confidence, then in this setting, the lowest number that can be counted is 102 cfu uropathogen/mL. Asymptomatic bacteriuria is diagnosed if two cultures of the same bacterial strain (in most cases the species only is available) taken > 24 hours apart show bacteriuria of > 105 cfu uropathogen/mL. It is obvious that methods of urine collection and culture, as well as the quality of laboratory investigations, may vary. Two levels of standard must therefore be used for the management of patients. A basic standard level is necessary for routine assessment, while a higher standard level is required for scientific assessment and in special clinical circumstances, e.g. fever of unknown origin in immunocompromised patients. In research, the need for a precise definition of sampling methods, the time that urine is kept in the bladder, etc., must be recognized and these parameters carefully recorded. In clinical routine assessment, a number of basic criteria must be looked at before a diagnosis can be established, including: • clinical symptoms • results of selected laboratory tests (blood, urine or expressed prostatic secretion [EPS]) • evidence of the presence of microbes by culturing or other specific tests. Most of these investigations can today be performed in any laboratory. It has to be considered, however, that microbiological methods and definitions applied must follow accepted standards concerning specimen transport, pathogen identification and antimicrobial susceptibility testing. Since these methods, and also microbiological definitions, may vary from country to country and institution to institution, e.g. the breakpoints for classification of a pathogen as susceptible or resistant, it is important to report not only the results but also which methods and standards were applied, e.g. the European Committee for Antimicrobial Susceptibility Testing (EUCAST) (8-10), the National Committee for Clinical Laboratory Standards (NCCLS) (11). Mixing results obtained by different methods, e.g. rates of bacterial resistance, can be problematic and requires careful interpretation. Histological investigation sometimes shows the presence of non-specific inflammation. Only in some cases, such findings (e.g. prostatitis in patients who have elevated levels of prostate-specific antigen [PSA]) may help determine the appropriate treatment, whereas in more specific inflammations, such as tuberculosis, actinomycosis, etc., histology may be diagnostic. In general, however, histological findings usually contribute very little to the treatment decision.
1.3
Classification of urological infections
For practical reasons, this section of the guidelines is called Guidelines on Urological Infections. It includes the management of urinary tract infections in both male and females and the infections of the male genital tract, leaving out the female genital tract infections, clinically bound to the field of gynaecology. The guidelines focus on urology and therefore also look into the prevention of urogenital infections associated, or not, with urological interventions. For clinical reasons, however, UTIs and infections of the male genital tract are classified according to the predominant clinical symptoms: • uncomplicated lower UTI (cystitis) • uncomplicated pyelonephritis • complicated UTI with or without pyelonephritis • urosepsis • urethritis • special forms: prostatitis, epididymitis and orchitis. The clinical presentation and management of different UTI categories may vary during life and may depend on the patient’s condition. Therefore, special patient groups (the elderly, those with underlying diseases and the immunocompromised) have also to be considered. Criteria for the diagnosis of a UTI, modified according to the guidelines of the Infectious Diseases Society of America (IDSA) (12) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (13), are summarized in Appendix 14.1. There is still an ongoing discussion about how guidelines on UTI could be improved (14).
1.4
Aim of guidelines
These EAU guidelines cover the UTI categories as listed above in section 1.3 on classification and provide some general advice on the diagnosis and management of male and female urinary UTIs. It is hoped that the guidelines may assist not only the urologist, but also physicians from other medical specialities in their daily practice.
8
UPDATE MARCH 2009
1.5
Methods
The members of the UTI Working Group (K.G. Naber (chairman), B. Bergman, M.C. Bishop, T.E. Bjerklund-Johansen, H. Botto, B. Lobel, F. Jiminez Cruz, F.P. Selvaggi) of the EAU Guidelines Office established the first version of these guidelines in several consensus conferences. The first edition was published in 2001 in Geneva by the EAU (15) and in a more condensed version was published for the first time in 2001 (16). The members of the current UTI Working Group (M. Grabe [chairman], M.C. Bishop, T.E. Bjerklund-Johansen, H. Botto, M. Çek, B. Lobel, K.G. Naber, J. Palou, P. Tenke) updated the guidelines in several consensus conferences thereafter and subsequently added several chapters, one of which comprises a chapter on catheter-associated UTI. EAU guidelines on special forms of urogenital infections, such as sexual transmitted infections (17), urogenital tuberculosis (18) and urogenital schistosomiasis (19), have been published elsewhere. Chapters 12 and 13 of the present guidelines present separate short summaries including a reference link. For literature review, PubMed was searched for published meta-analyses, which were used as far as available. Otherwise there was a non-structured literature review process by the group members. Each member was responsible for one chapter (reporter). The first draft of each chapter was sent to the committee members asking for comments, which were then considered, discussed and incorporated accordingly. The formal agreement to each updated chapter was achieved by the EAU working group in a series of meetings.
1.6
Level of evidence and grade of guideline recommendations
In the updated guidelines, the studies cited from the literature were rated according to the level of evidence and the recommendations were graded accordingly (Tables 1.1 and 1.2). Table 1.1: Levels of evidence, modified from Sackett et al (20). Level Ia Ib IIa IIb III IV
Type of evidence Evidence obtained from meta-analysis of randomized trials Evidence obtained from at least one randomized trial Evidence obtained from at least one well-designed controlled study without randomization Evidence obtained from at least one other type of well-designed quasi-experimental study Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities
Table 1.2: Grades of recommendations, modified from Sackett et al (20). Grade A B C
Nature of recommendations Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomized trial Based on well-conducted clinical studies, but without randomized clinical studies Made despite the absence of directly applicable clinical studies of good quality
1.7
References
1.
Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113 Suppl 1A:5S-13S. http://www.ncbi.nlm.nih.gov/pubmed/12113866 Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J Urol 2002;168(4 Pt 2):1720-22. http://www.ncbi.nlm.nih.gov/pubmed/12352343 Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, Pfaller MA, Doern GV. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J Antimicrob Chemother 2000;45(3):295-303. http://www.ncbi.nlm.nih.gov/pubmed/10702547 Rüden H, Gastmeier P, Daschner FD, Schumacher M. Nosocomial and community-acquired infections in Germany. Summary of the results of the First National Prevalence Study (NIDEP). Infection 1997;25(4):199-202. http://www.ncbi.nlm.nih.gov/pubmed/9266256
2.
3.
4.
UPDATE MARCH 2009
9
5.
6.
7. 8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
10
Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 2001;7(2):342-7. http://www.ncbi.nlm.nih.gov/pubmed/11294737 Patton JP, Nash DB, Abrutyn E. Urinary tract infection: economic considerations. Med Clin North Am 1991;75(2):495-513. http://www.ncbi.nlm.nih.gov/pubmed/1996046 Kass EH. Bacteriuria and pyelonephritis of pregnancy. Arch Intern Med 1960;105:194-8. http://www.ncbi.nlm.nih.gov/pubmed/14404662 European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Dieases (ESCMID). EUCAST Definitive Document E.DEF 3.1, June 2000: Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin Microbiol Infect 2000;6(9):503-8. http://www.ncbi.nlm.nih.gov/pubmed/11168186 European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Dieases (ESCMID). EUCAST Definitive Document E. Def 1.2, May 2000: Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000;6(9):503-8. http://www.ncbi.nlm.nih.gov/pubmed/11168186 European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). EUCAST Definitive Document E.DEF 2.1, August 2000: Determination of antimicrobial susceptibility test breakpoints. Clin Microbiol Infect 2000;6(10):570-2. http://www.ncbi.nlm.nih.gov/pubmed/11168058 National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard 4th Edition M7-A5 (2002) and M100-S12, 2004. Wayne, PA. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15 Suppl 1:S216-S227. http://www.ncbi.nlm.nih.gov/pubmed/1477233 Rubin RH, Shapiro ED, Andriole VT, Davies RJ, Stamm WE, with modifications by a European Working Party (Norrby SR). General guidelines for the evaluation of new anti-infective drugs for the treatment of UTI. Taufkirchen, Germany: The European Society of Clinical Microbiology and Infectious Diseases, 1993;294-310. Naber KG. Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. Int J Antimicrob Agents 1999;11(3-4):189-96; discussion 213-6. http://www.ncbi.nlm.nih.gov/pubmed/10394969 Naber KG, Bergman B, Bjerklund-Johansen TE, Botto H, Lobel B, Jiminez Cruz F, Selvaggi FP. Guidelines on urinary and male genital tract infections. In: EAU Guidelines. Edition presented at the 16th EAU Congress, Geneva, Switzerland, 2001. ISBN 90-806179-3-9. Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, Jininez Cruz F, Selvaggi FP; Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Eur Urol 2001;40(5):576-88. http://www.ncbi.nlm.nih.gov/pubmed/11752870 Schneede P, Tenke P, Hofstetter AG; Urinary Tract Infection Working Group of the Health Care Office of the European Association of Urology. Sexually transmitted diseases (STDs) – a synoptic overview for urologists. Eur Urol 2003;44(1):1-7. http://www.ncbi.nlm.nih.gov/pubmed/12814668 Cek M, Lenk S, Naber KG, Bishop MC, Johansen TE, Botto H, Grabe M, Lobel B, Redorta JP, Tenke P; Members of the Urinary Tract Infection (UTI) Working Group of the European Association of Urology (EAU) Guidelines Office. EAU guidelines for the management of genitourinary tuberculosis. Eur Urol 2005;48(3):353-62. http://www.ncbi.nlm.nih.gov/pubmed/15982799 Bichler KH, Savatovsky I; the Members of the Urinary Tract Infection (UTI) Working Group of the Guidelines Office of the European Association of Urology (EAU):, Naber KG, Bischop MC, BjerklundJohansen TE, Botto H, Cek M, Grabe M, Lobel B, Redorta JP, Tenke P. EAU guidelines for the management of urogenital schistosomiasis. Eur Urol 2006;49(6):998-1003. http://www.ncbi.nlm.nih.gov/pubmed/16519990
UPDATE MARCH 2009
20.
Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [access date December 2008].
2. Uncomplicated urinary tract infections in adult 2.1
Summary and recommendations
2.1.1 Definition Acute, uncomplicated UTIs in adults include episodes of acute cystitis and acute pyelonephritis in otherwise healthy individuals. These UTIs are seen mostly in women who have none of the factors known to increase the risk of complications or of treatment failure. 2.1.2 Aetiological spectrum The spectrum of aetiological agents is similar in uncomplicated upper and lower UTIs, with E. coli the causative pathogen in approximately 70-95% of cases and Staphylococcus saprophyticus in about 5-10% of cases. Occasionally, other Enterobacteriaceae, such as Proteus mirabilis and Klebsiella spp., are isolated (IIb). 2.1.3 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women Besides physical examination, urinalysis (e.g. using a dipstick method), including the assessment of white and red blood cells and nitrites, is recommended for routine diagnosis (B). Colony counts > 103 cfu uropathogen/ mL are considered to be a clinically relevant bacteriuria (IIb). Short courses of antimicrobials are highly effective and are desirable because of the improved compliance that they promote, their lower cost and lower frequency of adverse reactions. Single-dose therapy (with some exceptions) is generally less effective than the same antibiotic used for a longer duration. However, with most suitable antimicrobials, there is little to be gained from treatment given beyond 3 days and the risk of adverse events is higher (IaA). Trimethoprim (TMP) or TMP-sulphamethoxazole (SMX) can only be recommended as first-line drugs for empirical therapy in communities with rates of uropathogen resistance to TMP of less than 20% (IbA). Otherwise, fluoroquinolones, fosfomycin trometamol, pivmecillinam and nitrofurantoin are recommended as alternative oral drugs for empirical therapy. However, in some areas, the rate of fluoroquinolone-resistant E. coli is also increasing. Urinalysis, including a dipstick method, is sufficient for routine follow-up. Post-treatment cultures in asymptomatic patients may not be indicated. In women whose symptoms do not resolve, or which resolve and then recur within 2 weeks, urine culture and antimicrobial susceptibility testing should be performed (IVC). 2.1.4 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women Acute pyelonephritis is suggested by flank pain, nausea and vomiting, fever (> 38°C), or costovertebral angle tenderness. It may occur in the absence of cystitis symptoms, e.g. dysuria, frequency. Besides physical examination, urinalysis (e.g. using a dipstick method), including the assessment of white and red blood cells and nitrites, is recommended for routine diagnosis (C). Colony counts > 104 cfu uropathogen/mL can be considered to be a clinically relevant bacteriuria (IIb). An evaluation of the upper urinary tract with ultrasound should be performed to rule out urinary obstruction or renal stone disease (C). Additional investigations, such as an unenhanced helical computed tomography (CT), an excretory urogram, or dimercaptosuccinic acid (DMSA) scan, should be considered if the patients remain febrile after 72 hours of treatment to rule out further complicating factors, e.g. urolithiasis, renal or perinephric abscesses (C). As first-line therapy in mild cases, an oral fluoroquinolone for 7 days is recommended in areas where the rate of fluoroquinolone-resistant E. coli is still low (<10%) (IbA). If a Gram-positive organism is seen on the initial Gram stain, an aminopenicillin plus a ß-lactamase inhibitor (BLI) could be recommended (IIbB). More severe cases of acute uncomplicated pyelonephritis should be admitted to hospital and treated according to the patient’s condition parenterally with a fluoroquinolone (ciprofloxacin or levofloxacin), a third-generation cephalosporin or an amino/acylaminopenicillin plus a BLI according to the local susceptibility pattern (IIbB). With improvement, the patient can be switched to an oral regimen using a fluoroquinolone or TMP-SMX (if active against the infecting organism) to complete the 1- or 2-week course, respectively (IIbB). In areas
UPDATE MARCH 2009
11
with increased resistance rate of E. coli against fluoroquinolones and in situations in which fluoroquinolones are contraindicated (e.g. pregnancy, lactating women, adolescence), a second- or third-generation oral cephalosporin is recommended (IIbB). Routine post-treatment cultures in an asymptomatic patient may not be indicated; routine urinalysis using a dipstick method is sufficient (IIbB). In women whose symptoms of pyelonephritis resolve but then recur within 2 weeks, it is important to carry out a repeat urine culture, antimicrobial susceptibility testing, and an appropriate investigation to rule out urinary tract abnormalities (C). 2.1.5 Recurrent (uncomplicated) UTIs in women Recurrent UTIs (RUTIs) are common among young, healthy women, even though they generally have anatomically and physiologically normal urinary tracts. The following prophylactic antimicrobial regimens are recommended: • long-term, low-dose prophylactic antimicrobials taken at bedtime (IaA) • post-intercourse prophylaxis for women in whom episodes of infection are associated with sexual intercourse (IbA) • a patient-initiated treatment may also be suitable for management of RUTIs in well-informed, young women (IIaB). Prophylactic alternative methods include immunotherapy (IaB) and probiotic therapy (IIaC), acidification (IIaC), and cranberry juice (IIaC). These regimens are not yet as effective as antimicrobial prophylaxis, though directly comparative studies have not been performed. 2.1.6 UTIs in pregnancy Urinary tract infections are common during pregnancy. Most women acquire bacteriuria before pregnancy, while 20-40% of women with asymptomatic bacteriuria will develop pyelonephritis during pregnancy. Treatment of asymptomatic bacteriuria lowers this risk (IIa). Most symptomatic UTIs in pregnant women present as acute cystitis. Short-term therapy is not as established as in non-pregnant women. For a recurrent UTI, low-dose cephalexin (125-250 mg) or nitrofurantoin (50 mg) at night is recommended for prophylaxis against re-infection (IbA). Post-intercourse prophylaxis may be an alternative approach (IbA). For acute pyelonephritis, second- or third-generation cephalosporins, an aminoglycoside, or an aminopenicillin plus a BLI may be recommended antibiotics (IIbB). During pregnancy, quinolones, tetracyclines and TMP are contraindicated in the first trimester, while sulphonamides should not be used in the last trimester (IIbB). In cases of delayed defervescence and upper tract dilatation, a ureteral stent may be indicated and antimicrobial prophylaxis should be considered until delivery (IIbB). 2.1.7 UTIs in post-menopausal women In acute cystitis, the antimicrobial treatment policy in post-menopausal women is similar to that in premenopausal women. However, short-term therapy in post-menopausal women is not as well documented as that in younger women. In the case of a recurrent UTI, urological or gynaecological evaluation should be performed in order to eliminate a tumour, obstructive problems, detrusor failure or a genital infection (IIIB). In post-menopausal women with a recurrent UTI, therapy with intravaginal oestriol is able to reduce significantly the rate of recurrences (IbA). For the remainder of patients, an antimicrobial prophylactic regimen should be recommended in addition to hormonal treatment (IIIB). For acute pyelonephritis, the same treatment modalities are recommended as for pre-menopausal, non-pregnant women (see section 2.1.3). 2.1.8 Acute uncomplicated UTIs in young men Only a small number of 15 to 50-year-old men suffer from acute uncomplicated UTI. Such men should receive, as minimum therapy, a 7-day antibiotic regimen (IIaB). Most men with febrile UTI have a concomitant infection of the prostate, as measured by transient increases in serum PSA and prostate volume (IIa). Urological evaluation should be carried out routinely in adolescents and men with febrile UTI, pyelonephritis, recurrent infections, or whenever a complicating factor is suspected (IIIB). A minimum treatment duration of 2 weeks is recommended (IIIB), preferably with a fluoroquinolone since prostatic involvement is frequent. 2.1.9 Asymptomatic bacteriuria Asymptomatic bacteriuria is common. Populations with structural or functional abnormalities of the genitourinary tract may have an exceedingly high prevalence of bacteriuria, but even healthy individuals frequently have positive urine cultures. Asymptomatic bacteriuria is seldom associated with adverse outcomes. Screening for, or treatment of, asymptomatic bacteriuria is not recommended for the following persons: • pre-menopausal, non-pregnant women (IbA)
12
UPDATE MARCH 2009
• diabetic women (IbA) • older persons living in community (IIB) • elderly institutionalized subjects (IIaB) • persons with spinal cord injury (IIaB) • catheterized patients while the catheter remains in situ (IbA). Screening for asymptomatic bacteriuria and treatment is recommended only for selected groups where benefit has been shown: pregnant women (IbA); before transurethral resection of the prostate (TURP) (IbA) and other traumatic urological interventions (IIIB). Antimicrobial therapy should be initiated shortly before the procedure (IIIB).
2.2
Background
Acute, uncomplicated UTIs in adults include episodes of acute cystitis and acute pyelonephritis occurring in otherwise healthy individuals. These UTIs are seen mostly in women who have no risk factors, i.e. no structural or functional abnormalities within the urinary tract and the kidneys and no underlying disease known to increase the risks of acquiring infection or of failing therapy (1). Uncomplicated UTIs are extremely common infections. Approximately 25-35% of women between the ages of 20 and 40 years have experienced an episode described by their physician as an uncomplicated UTI (2).
2.3
Definition
The distinction between an uncomplicated and a complicated UTI is important because of implications with regard to pre- and post-treatment evaluation, the type and duration of antimicrobial regimens, and the extent of the evaluation of the urinary tract. In contrast to an uncomplicated UTI (see above), a complicated UTI is an infection associated with a condition that increases the risks of acquiring an infection or of failing therapy. At the time of presentation with an acute onset of urinary tract symptoms, it is usually not possible to classify definitively patients as having a complicated or an uncomplicated UTI. Several factors have been identified, however, that are markers for a potential complicated UTI (Table 2.1). Table 2.1: Factors that suggest a potential complicated UTI • Male sex • Elderly • Hospital-acquired infection • Pregnancy • Indwelling urinary catheter • Recent urinary tract intervention • Functional or anatomical abnormality of the urinary tract • Recent antimicrobial use • Symptoms for > 7 days at presentation • Diabetes mellitus • Immunosuppression. These factors only provide guidance to the clinician who must decide, based on limited clinical information, whether to embark on a more extensive evaluation and treatment course. It is generally safe to assume that a pre-menopausal, non-pregnant woman with acute onset of dysuria, frequency or urgency, who has not recently been instrumented or treated with antimicrobials and who has no history of a genitourinary tract abnormality, has an uncomplicated lower (cystitis) or upper (pyelonephritis) UTI (1). Recurrent UTIs are common among pre-menopausal, sexually active, healthy women, even though they generally have anatomically and physiologically normal urinary tracts. Whether a UTI in pregnancy by itself is to be classified as an uncomplicated or a complicated UTI remains debatable. Although data on UTIs in healthy post-menopausal women without genitourinary abnormalities are limited, it is likely that most UTIs in such women are also uncomplicated. Data on UTIs in healthy adult men are sparse and much less is known about the optimal diagnostic and therapeutic approaches to UTIs in men.
2.4
Aetiological spectrum
The spectrum of aetiological agents is similar in uncomplicated upper and lower UTIs, with E. coli being the causative pathogen in approximately 70-95% of cases and S. saprophyticus in about 5-19% of cases, whereas S. saprophyticus is less frequently found in pyelonephritis than in cystitis. Occasionally, other Enterobacteriaceae, such as P. mirabilis and Klebsiella spp., or enterococci (mostly in mixed cultures indicating contamination), are isolated from such patients. In as many as 10-15% of symptomatic patients, bacteriuria cannot be detected using routine methods (1, 3).
UPDATE MARCH 2009
13
2.5
Acute uncomplicated cystitis in pre-menopausal, non-pregnant women
At this stage in life, the incidence of acute uncomplicated cystitis is high and this infection is associated with considerable morbidity. Therefore, even small improvements in diagnostics, therapy or prophylaxis have a high impact on public health. 2.5.1 Incidence, risk factors, morbidity A prospective study at a university health centre or a health maintenance organization (HMO) revealed an incidence of 0.7 per person-year in the university cohort and 0.5 per person-year in the HMO cohort (4). Cohort and case control studies in young women showed that the risk is strongly and independently associated with recent sexual intercourse, recent use of diaphragm with spermicide, preceding asymptomatic bacteriuria, a history of recurrent UTI, the age of first UTI and history of UTI in the mother (4-6). On average, each episode of this type of UTI in pre-menopausal women was shown to be associated with 6.1 days of symptoms, 2.4 days of restricted activity, 1.2 days in which they were not able to attend classes or work and 0.4 days in bed (7). 2.5.2 Diagnosis A non-pregnant pre-menopausal woman presenting with acute dysuria usually has one of three types of infection (1): • acute cystitis • acute urethritis, caused by Chlamydia trachomatis, Neisseria gonorrhoeae, or herpes simplex virus • vaginitis caused by Candida spp. or Trichomonas vaginalis. A distinction between these three entities can usually be made with a high degree of certainty from the history and physical examination (1). Acute cystitis is more likely if the woman complains of urgency and suprapubic pain; has suprapubic tenderness; is a diaphragm-spermicide user; has symptoms that mimic those of previously confirmed cystitis; or has recently undergone urethral instrumentation. Although approximately 40% of women with cystitis have haematuria, this is not a predictor of a complicated infection. Urethritis caused by N. gonorrhoeae or C. trachomatis is relatively more likely if a women has had a new sexual partner in the past few weeks or if her sexual partner has urethral symptoms; there is a past history of a sexually transmitted disease (STD); symptoms were of gradual onset over several weeks and there are accompanying vaginal symptoms such as vaginal discharge or odour. Vaginitis is suggested by the presence of vaginal discharge or odour, pruritus, dyspareunia, external dysuria and no increased frequency or urgency. Urinalysis (e.g. using a dipstick method) to look for pyuria, haematuria and nitrites is indicated if a UTI is suspected. Pyuria is present in almost all women with an acutely symptomatic UTI and in most women with urethritis caused by N. gonorrhoeae or C. trachomatis; its absence strongly suggests an alternative diagnosis. The definitive diagnosis of a UTI is made in the presence of significant bacteriuria, the definition of which remains somewhat controversial. The traditional standard for significant bacteriuria is > 105 cfu uropathogen/ mL in voided MSU, based on studies of women with acute pyelonephritis and asymptomatic bacteriuria that were carried out four decades ago (8). Several more recent studies have shown that this is an insensitive standard when applied to acutely symptomatic women and that approximately one-third to one-half of cases of acute cystitis have bacteriuria < 105 cfu/mL (9) (II). For practical purposes, colony counts > 103 cfu/mL should be used for the diagnosis of acute uncomplicated cystitis (10, 11). The determination of a urine culture is generally not necessary in women with uncomplicated cystitis because the causative organisms and their antimicrobial susceptibility profiles are predictable. Also, culture results become available only after the patient’s symptoms have resolved or are considerably improved. Voided MSU or straight catheter (by trained urological personnel) urine cultures should probably be performed if the patient’s symptoms are not characteristic of a UTI. The laboratory must be instructed to look for ‘low count’ bacteriuria if such UTIs are to be detected. A pelvic examination is indicated if any of the factors suggesting urethritis or vaginitis listed above are present or if there is doubt as to the diagnosis. A pelvic examination should include a careful evaluation for evidence of vaginitis, urethral discharge, or herpetic ulcerations; a cervical examination for evidence of cervicitis and cervical and urethral cultures for N. gonorrhoeae and C. trachomatis (or other sensitive and specific tests in first-voided urine in the morning, such as polymerase chain reaction tests). 2.5.3 Treatment There seems to be no long-term adverse effects with respect to renal function or increased mortality associated with acute uncomplicated cystitis, even in women who experience frequent recurrences, and in the non-pregnant population. Untreated cystitis rarely progresses to symptomatic upper tract infection. Thus, the significance of lower tract infection in non-pregnant women seems to be limited to the morbidity of symptoms caused by the infection, which can lead to substantial disruption of the lives of affected individuals.
14
UPDATE MARCH 2009
In fact, most lower UTIs (50-70%) clear spontaneously if untreated, although symptoms may persist for several months. In a prospective, placebo-controlled study (12) (Ib), 288 patients were treated with placebo for 7 days, of whom 39% dropped out after the first follow-up visit (8-10 days). The spontaneous cure rate of symptoms was 28% after the first week, while 37% had neither symptoms nor bacteriuria after 5-7 weeks. In another study (13) (Ib), symptomatic improvement and cure occurred in 52% of 33 placebo-treated patients with bacteriologically proven urinary tract infection after 1 week, but only 20% of these patients showed bacteriological eradication as well. Both parameters were significantly lower than in the group of patients treated with nitrofurantoin (100 mg four times daily for 3 days). Knowledge of the antimicrobial susceptibility profile of uropathogens causing uncomplicated UTIs in the community should guide therapeutic decisions, although the trend away from routinely culturing patients with uncomplicated cystitis may unfortunately lead to the lack of such data. The resistance pattern of E. coli strains causing an uncomplicated UTI, however, may vary considerably between European regions and countries, so that no general recommendations are suitable throughout Europe. In an international survey of the antimicrobial susceptibility of uropathogens from uncomplicated UTI, the overall resistance rate was lowest in the Nordic countries and Austria and highest in Portugal and Spain (3, 14) (IIb). Short courses of antimicrobials are highly effective in the treatment of acute uncomplicated cystitis in pre-menopausal women (15, 16) (Ia). Short-course regimens are desirable because of the improved compliance that they promote, their lower cost, and lower frequency of adverse reactions. However, in assessing the potential cost advantages of short-course regimens, it is necessary to consider the potential added expense associated with treatment failures or recurrences arising from short-course therapy. It is also important to consider the potential psychological aspects of single-dose therapy; as symptoms may not subside for 2 or 3 days, the patient may have misgivings during this time about the ‘insufficient’ treatment provided to her. Such a scenario may result in unnecessary visits or calls to the physician. A wide variety of antimicrobial regimens comprising different drugs, doses, schedules and durations have been used to treat these common bacterial infections. Only a few of these regimens have been compared directly in adequately designed studies. To develop evidence-based guidelines for the antimicrobial therapy of uncomplicated acute bacterial cystitis and pyelonephritis in women, a committee of the IDSA systematically reviewed the English medical literature up to 1997 and developed guidelines for the antimicrobial treatment of acute uncomplicated bacterial cystitis and pyelonephritis in women (16). The UTI Working Group of the EAU Guidelines Office has used this database and more recent publications to develop the following, updated, guidelines on antimicrobial therapy. The following antimicrobials were considered by the UTI Working Group: trimethoprim (TMP), trimethoprim-sulfamethoxazole (TMP-SMX), fluoroquinolones (ciprofloxacin, enoxacin, fleroxacin, gatifloxacin, levofloxacin, lomefloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin), ß-lactams (amoxycillin, ampicillin-like compounds, cefadroxil, cefuroxime axetil, cefpodoxime proxetil, ceftibuten, pivmecillinam, ritipenem axetil), fosfomycin trometamol, and nitrofurantoin. The following conclusions about antimicrobial therapy can be made: i) Treatment duration In otherwise healthy, adult, non-pregnant women with acute uncomplicated cystitis, single-dose therapy (with some exceptions) is significantly less effective in eradicating initial bacteriuria than are longer durations of treatment with antimicrobials tested in this manner, such as TMP-SMX, TMP, norfloxacin, ciprofloxacin, fleroxacin, and as a group ß-lactams. However, TMP-SMX, TMP, norfloxacin, ciprofloxacin, and fleroxacin given for 3 days are as effective as the same antimicrobials used over longer durations. Longer treatment usually shows a higher rate of adverse events (Ib). Although not examined in controlled trials, cystitis caused by S. saprophyticus may respond better to longer treatment durations, e.g. 7 days (16) (IIIB). ii) Trimethoprim, co-trimoxazole TMP-SMX was the most studied drug (30 studies). A 3-day regimen with TMP-SMX can therefore be considered to be the standard therapy (IaA). TMP alone was equivalent to TMP-SMX with regard to eradication and adverse effects. However, a recent study on more than 10,000 Dutch women revealed that better results were obtained for trimethoprim prescribed for 5-7 days than for 3 days (17) (IIaB). Considering possible rare, but serious, adverse effects caused by sulphonamides, TMP alone may be considered the preferred drug over TMP-SMX (IIIC). TMP or TMP-SMX can be recommended as first-line drugs for empirical therapy, but only in communities with rates of uropathogen resistance to TMP < 10-20% because there is a close correlation between susceptibility and the eradication of E. coli on the one hand and resistance and persistence of the uropathogen on the other (18, 19) (Ib). The risk of emerging resistant uropathogens in the case of recurrence was also much higher when using TMP as a first-line drug than when using pivmecillinam or ciprofloxacin (20) (III), which had the lowest risk of the drugs investigated.
UPDATE MARCH 2009
15
iii) Fluoroquinolones The fluoroquinolones (ciprofloxacin, fleroxacin, norfloxacin and ofloxacin) are equivalent to TMP-SMX when given as a 3-day regimen (IbA). Pefloxacin and rufloxacin, each as single-day therapies, are interesting options and may be equivalent to TMP-SMX in the eradication of bacteriuria and its recurrence. Questions remain as to the possibility of a higher incidence of adverse effects with these agents than with other recommended therapies (21-24) (IbB). Two more recent studies investigated short-term therapy with levofloxacin and with the extended-release formulation of ciprofloxacin (CiproXR). A 3-day regimen with levofloxacin, 250 mg once daily, was similarly effective to a 3-day regimen of ofloxacin 200 mg twice daily, but with levofloxacin there was a trend to lesser adverse events (25) (IbA). A 3-day course with CiproXR (500 mg) once daily was equivalent in regard to efficacy and safety as a course of conventional ciprofloxacin (250 mg twice daily) (26) (IbA). Fluoroquinolones are more expensive than TMP and TMP-SMX, and are thus not recommended as first-line drugs for empirical therapy except in communities with rates of uropathogen resistance to TMP > 10-20%. Concern about fluoroquinolone resistance led practitioners to be appropriately hesitant about the widespread use of fluoroquinolones for the routine treatment of uncomplicated UTIs, although there are no published studies demonstrating that short-course fluoroquinolone therapy for acute cystitis in women results in the selection of fluoroquinolone-resistant flora (27-29) (III). In some countries, however, the resistance of E. coli to fluoroquinolones has already increased to more than 10%. In this situation, alternative oral drugs should be considered for empirical therapy (see Table 2.3). Treatment with any of these agents should result in more than 90% eradication of the bacteriuria. iv) ß-lactam antibiotics In general, ß-lactams as a group are less effective than the aforementioned drugs (III). No sufficiently large comparative studies between one of the above recommended regimens (3-day TMP, TMP-SMX, or one of the above-mentioned fluoroquinolones) and second- and third-generation oral cephalosporins or an aminopenicillin plus a BLI were available for the IDSA analysis (16). Only one study of adequate size compared a 3-day course of ß-lactam antimicrobial (pivmecillinam) with treatment for a longer duration (30) (Ib). The study found that 3 days of therapy were equivalent to 7 days of therapy with regard to the eradication of the initial bacteriuria, although the shorter treatment was associated with an increased incidence of recurrence. Pooled bacteriological outcomes from more recent studies showed that 7 days of pivmecillinam, 200 mg twice daily, and 3 days of norfloxacin, 400 mg twice daily, have similar results (31, 32) (IbA). With pivmecillinam, however, the rate of vaginal candidiasis was significantly lower than with norfloxacin (33) (Ib). Pivmecillinam also shows low resistance rates for E. coli and other Enterobacteriaceae, without cross-resistance to other antimicrobials used for the treatment of UTI (14, 34) (IIb). In general, first- and second-generation oral cephalosporines are not recommended as first-line antimicrobials for a 3-day treatment of uncomplicated UTI (16, 35, 36) (IbA). However, among third-generation oral cephalosporins, a 3-day course with cefpodoxime-proxetil (200 mg twice daily) was as safe and effective as that of TMP-SMX in 133 evaluable patients (37) (IbA). In contrast, a more recent study of 370 women (38) showed that a 3-day regimen of amoxycillin-clavulanate (500 mg/125 mg twice daily) was not as effective as a 3-day regimen of ciprofloxacin (250 mg twice daily) even in women infected with susceptible strains (Ib). This difference may be due to the inferior ability of amoxycillin-clavulanate to eradicate vaginal E. coli, facilitating early re-infection. v) Fosfomycin Fosfomycin trometamol was evaluated as single-dose (3 g) therapy by a meta-analysis comprising 15 comparative trials on 2048 patients (39) (IaA), in whom short-term bacteriological eradication was identified in 1540 patients with confirmed UTI, and obtained with fosfomycin trometamol in 85.6% of cases and with other treatments (single dose and 3-7 day regimens) in 86.7% of cases. In patients who completed long-term follow-up, the overall eradication rate with fosfomycin trometamol (84.6%) was significantly (p<0.05) higher than with other treatments (79.6%). In a more recent large trial (18) (IbA) on 547 female patients, singledose fosfomycin trometamol and a 5-day course of trimethoprim (200 mg twice daily) showed equivalent microbiological cure rates (83% by either drug). As regards safety, in the meta-analysis, the single-dose and the 3-7 day regimens were found to be equivalent concerning the number of adverse events. Considering that fosfomycin trometamol has been extensively used in several European countries for single-dose therapy of uncomplicated UTI since 1988, the resistance rate for E. coli remained very low without cross-resistance to other antimicrobials used for the treatment of UTI (14, 34, 40) (IIb). vi) Nitrofurantoin Nitrofurantoin (50-100 mg four times daily, or sustained release formulation 100 mg twice daily) cannot be considered a suitable drug for short-term therapy (up to 3 days) of acute uncomplicated cystitis. A course of 5-7 days is recommended if nitrofurantoin is used for this indication (17) (IIaB). Despite the clinical use of
16
UPDATE MARCH 2009
nitrofurantoin for many years, the resistance rate for E. coli and S. saprophyticus is still low throughout Europe (3) (IIb), although in some areas a two-fold increase in nitrofurantoin resistance has already been observed for E. coli within the last 10 years (40). Nitrofurantoin is, however, not active against P. mirabilis and Klebsiella spp., the second and third most frequently isolated Gram-negative uropathogens (3) (IIb). There is also some concern about the safety of nitrofurantoin, especially the acute and chronic pulmonary syndromes, which are common in the elderly (41, 42). These severe adverse events, however, were not observed when nitrofurantoin was used for long-term and low-dose prophylaxis for recurrent UTIs in girls and women (43, 44) (III). In Table 2.2, the pivotal clinical studies with various oral antimicrobial treatment options of acute uncomplicated bacterial cystitis in adult pre-menopausal non-pregnant women are summarized according to the level of evidence and grade of recommendations as defined in the Introduction (Section 1.1 and 1.2). See also the recommendations in Appendix 12.2.
UPDATE MARCH 2009
17
18
UPDATE MARCH 2009
Substance Dosage Duration LE GR Reference Ref Remarks Cefpodoxime 100 mg bid 3 days Ib A Kavatha 2003 37 Cefpodoxime proxetil for 3 days was as safe and effective as TMP-SMX for 3 days proxetil Ciprofloxacin 250 mg bid 3 days Ib A Iravani 1995 45 Also for treatment of post-menopausal non-institutionalized women Vogel 2004 46 Cipro XR 500 mg od 3 days Ib A Henry 2002 26 Efficacy and tolerance of extended release ciprofloxacin (ciproXR) 500 mg od was equivalent to 3-day conventional ciprofloxacin 250 mg bid Enoxacin 200 mg bid 3 days Ib B Backhouse 1987 47 3-day therapy (85% cure rate) better than single dose (77%); insufficient statistical power; abstract only Fleroxacin 400 mg SD Ib B Iravani 1993 48 Single dose showed a comparable clinical response, but inferior bacteriological eradication when compared to a 7-day course (200 mg od) Fleroxacin 200 mg od 3 days Ib B Iravani 1995 49 3-day fleroxacin 200 mg od was equivalent to 7-day course of fleroxacin 200 mg od or ciprofloxacin 250 mg bid (abstract) Fosfomycin 3000 mg SD Ia A Lecomte 1997 39 Meta-analysis of 15 comparative trials: overall results indicated that single-dose fosfomycin trometamol had Ib Minassian 1998 18 equivalent efficacy with comparators (single dose and 3-7 day treatment regimens) at short-term follow-up, but significantly better results were obtained at long-term follow-up with fosfomycin trometamol Gatifloxacin 200 mg od 3 days Ib A* Richard 2002 50 Efficacy and tolerance were equivalent with single-dose gatifloxacin 400 mg vs 3-day therapy with gatifloxacin 200 mg Naber 2004 51 od or ciprofloxacin 250/100 mg bid; not available in Europe Gatifloxacin 400 mg SD Ib A* Richard 2002 50 Efficacy and tolerance were equivalent with single-dose gatifloxacin 400 mg vs 3-day therapy with gatifloxacin 200 mg Naber 2004 51 od or ciprofloxacin 250/100 mg bid; not available in Europe Levofloxacin 250 mg od 3 days Ib A Richard 1998 25 Levofloxacin (250 mg od) showed equivalent efficacy compared with ofloxacin (200 mg bid), with levofloxacin showing a trend to less AE than with ofloxacin Lomefloxacin 400 mg od 3 days Ib B Neringer 1992 52 With lomefloxacin, there were significantly more AE than with norfloxacin Nicolle 1993 53 Nitrofurantoin 50-100 mg qid; 5-7 days IIa B Spencer 1994 54 Sustained release (SR) formulation; eradication rates for all three comparative drugs (nitrofurantoin, TMP, TMP-SMX) 100 mg SR bid Goettsch 2004 17 were low (77-83%) in Spencer (1994), while 5- and 7-day therapy were more effective than 3-day therapy (Goettsch 2004) Norfloxacin 400 mg bid 3 days Ib A Inter-Nordic 1988 55 Recurrence rates with 3-day were significantly higher than with 7-day therapy Piipo 1990 56 Ofloxacin 200 mg bid 3 days Ib A Block 1987 57 Equivalent to 3-day regimen with TMP-SMX Hooton 1989, 1991 58 59 Pefloxacin 800 mg SD Ia B Naber 1994 60 With pefloxacin, there was significantly more AE than with norfloxacin 5-day therapy. Pefloxacin should be given with food to lower the gastrointestinal AE Pivmecillinam 200 mg bid 7 days Ib A Nicolle 2000 31 Pooling bacteriological outcomes showed similar results with 7-day pivmecillinam 200 mg bid or 3-day norfloxacin Nicolle 2002 32 400 mg bid, but significantly lower incidence of candidal vaginitis with pivmecillinam than with norfloxacin Menday 2002 33 Pivmecilinam 400 mg bid 3 days Ib B Nicolle 2000 31 Lower rate of bacterial eradication occurred with 3-day pivmecillinam 400 mg od than with 7-day therapy (200 mg bid) Nicolle 2002 32 Menday 2002 33 Rufloxacin 400 mg SD Ib B Jardin 1995 23 With rufloxacin significantly more AE than with pefloxacin and norfloxacin TMP 200 mg bid 5-7 days Ib A Warren 1999 16 Can be considered as one standard empirical therapy, but only if the prevalence of TMP-resistant E. coli is less than IIa Goettsch 2004 17 (10%-)20%; 5- and 7-day courses were more effective than 3-day courses TMP 200 mg bid 3 days Ib B Gossius 1985 61 With 3-day therapy, significantly less AE occurred than with 10-day therapy TMP-SMX 160/800 mg 3 days Ia A Warren 1999 16 For empirical therapy only, if prevalence of resistant E. coli < (10%-)20% TMP; with 3-day therapy, there was a trend to bid increased recurrence rate, which was counterbalanced by a trend towards more AE with therapy of longer duration LE = level of evidence; GR = grade of recommendation; TMP = trimethoprim; SMX = sulphamethoxazole; qid = four times daily; tid = three times daily; bid = twice daily; od = once daily; SD = single dose; SR = sustained release; AE = adverse events; *not available in Europe.
Table 2.2: Oral treatment options of acute uncomplicated bacterial cystitis in adult pre-menopausal non-pregnant women according to level of evidence and grade of recommendation
Considering only those studies of antimicrobials, which have no apparent disadvantages (see remarks in Table 2.2), the regimens in Table 2.3 can probably be recommended equally (see also the recommendations in Appendix 12.2). The recommendation to use nitrofurantoin has been rated as B, because of the rare, but serious, adverse events associated with its use. However, its efficacy is established when used according to the recommended regimens. Table 2.3: Recommended antimicrobial regimens for the treatment of acute uncomplicated bacterial cystitis in adult premenopausal, non-pregnant women Substance Dosage Duration Cefpodoxime 100 mg bid 3 days Ciprofloxacin* 250 mg bid 3 days CiproXR* 500 mg od 3 days Fosfomycin trometamol 3000 mg SD 1 day Levofloxacin* 250 mg od 3 days Nitrofurantoin 50-100 mg tid, 5-7 days 100 mg SR bid Norfloxacin* 400 mg bid 3 days Ofloxacin* 200 mg bid 3 days Pivmecillinam 200 mg bid 7 days Trimethoprim (TMP)* 200 mg bid 5-7 days TMP-SMX* 160/800 mg bid 3 days *Resistance rates of E.coli vary considerably within Europe. These substances are only recommended for empirical therapy when the resistance rate of E. coli is < (10%-)20%. CiproXR = ciprofloxacin sustained release; SMX = sulphamethoxazole; od = once daily; bid = twice daily; qid = four times daily; SD = single dose; SR = sustained release. vii) Other treatment modalities Urinary analgesics, such as phenazopyridine, 200 mg three times daily, can be administered to patients who have experienced severe dysuria for 1 or 2 days. Women with cystitis, including those with severe dysuria and urgency, usually show resolution or marked improvement of symptoms within 2-3 days of initiating therapy. This should be explained to the patient. Thus, the need for, and duration of, analgesic therapy in women with UTIs must be individualized. Although it is generally recommended that patients with UTIs increase their fluid intake to promote micturition and the elimination of uropathogens, it remains unclear as to whether this is beneficial or detrimental to patients with UTI (2). 2.5.4 Post-treatment follow-up Urinalysis (e.g using a dipstick method) is sufficient for routine follow-up. Routine post-treatment cultures in asymptomatic patients may not be indicated because the benefit of detecting and treating asymptomatic bacteriuria in healthy women has been demonstrated only in pregnancy and prior to urological instrumentation or surgery. In women whose symptoms do not resolve by the end of treatment and in those whose symptoms resolve but recur within 2 weeks, urine culture and antimicrobial susceptibility testing should be performed. For therapy in this situation, one should assume that the infecting organism is not susceptible to the agent originally used and retreatment with a 7-day regimen using another agent should be considered (IVC).
2.6
Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women
2.6.1 Diagnosis Acute pyelonephritis is suggested by flank pain, nausea and vomiting, fever (> 38°C), or costovertebral angle tenderness, and may occur with or without cystitis symptoms. The presentation of an acute uncomplicated pyelonephritis usually varies from a mild to a moderate illness. A life-threatening condition with multi-organ system dysfunction, including sepsis syndrome with or without shock and renal failure, must be considered a complicated case. Urinalysis is indicated to look for pyuria and haematuria. In contrast to cystitis, 80-95% of episodes of pyelonephritis are associated with > 105 cfu uropathogen/mL (62). For routine diagnosis, a breakpoint 4 of 10 cfu/mL can be recommended (10, 11). An evaluation of the upper urinary tract with ultrasound (63) should be performed to rule out urinary obstruction. Additional investigations, such as an unenhanced helical computed tomography (64) (to rule out urolithiasis), an excretory urogram or DMSA scan, according to the clinical situation should be considered if the patient remains febrile after 72 hours of treatment to rule out further complicating factors, e.g. urolithiasis, renal or perinephric abscesses. Routine performance of an
UPDATE MARCH 2009
19
excretory urogram in patients with acute uncomplicated pyelonephritis has little value because most adults with uncomplicated acute pyelonephritis have a normal upper urinary tract. 2.6.2 Treatment Of several hundred articles screened by the IDSA group (16), only five were prospective, randomized, controlled trials (8, 64-68) and the following conclusions can be drawn for initial therapy from their analysis and the five studies (69-72) published thereafter. 1. TMP-SMX is preferred over ampicillin (IbA) (no controlled study used TMP alone). 2. Two weeks of therapy with TMP-SMX for acute uncomplicated pyelonephritis appears to be adequate for the majority of women (IbA). In some studies with various antibiotics, e.g. aminoglycosides (but none that were sufficiently powered), an even shorter duration of therapy of 5-7 days was recommended (IIIB). 3. In communities in which the resistance rate of E. coli to TMP is > 10%, a fluoroquinolone should be recommended as the drug of choice for empirical therapy. It was demonstrated that a 7-day regimen of ciprofloxacin, 500 mg twice daily, showed a significantly higher rate of bacterial eradication and a lower rate of adverse effects when compared with a 14-day therapy using TMP-SMX, 960 mg twice daily (69) (IbA). The higher efficacy seen with ciprofloxacin was mainly due to TMP-resistant E. coli strains. In clinical trials, the following fluoroquinolones were comparable to conventional ciprofloxacin 500 mg twice daily, ciprofloxacin extended release formulation (1000 mg once daily), gatifloxacin (400 mg once daily), levofloxacin (250 mg twice daily), and lomefloxacin (400 mg once daily) (70-72) (IbA). 4. For an aminopenicillin plus a BLI, as well as for most group two and group three oral cephalosporins, there are no sufficiently powered comparative studies versus a fluoroquinolone or TMP-SMX. In a prospectively randomized study, a 10-day therapy with cefpodoxime proxetil 200 mg twice daily showed equivalent clinical efficacy as that with ciprofloxacin 500 mg twice daily (73) (IbA). 5. In areas with a rate of E. coli resistance to fluoroquinolones > 10% and in situations in which fluoroquinolones are contraindicated (e.g. pregnancy, lactating women, adolescence), an aminopenicillin plus a BLI, or a group three oral cephalosporin is recommended, either for initial use, or if a patient has to be switched to an oral regimen (IIIB). Based on this analysis, the UTI Working Group of the EAU Guidelines Office recommends in mild and moderate cases an oral fluoroquinolone for 7 days as first-line therapy. In situations where a fluoroquinolone is not indicated (see above), a group three oral cephalosporin, e.g. cefpodoxime proxetil, may be an alternative for empirical therapy (B). If a Gram-positive organism is seen on the initial Gram stain, an aminopenicillin plus a BLI is recommended (B). More severe cases of acute uncomplicated pyelonephritis should be admitted to hospital and, if the patient cannot take oral medication, treated parenterally with a fluoroquinolone, an aminopenicillin plus a BLI, a group three cephalosporin, or an aminoglycoside (B). With improvement, the patient can be switched to an oral regimen using one of the above-mentioned antibacterials (if active against the infecting organism) to complete the 1-2 weeks’ course of therapy (B). In Table 2.4, the oral antimicrobial treatment options of acute uncomplicated pyelonephritis in adult pre-menopausal non-pregnant women according to level of evidence and grade of recommendations as defined in the Introduction (Section 1) are summarized (see also the recommendations in Appendix 12.2). Although approximately 12% of patients hospitalized with acute uncomplicated pyelonephritis have bacteraemia (74), it is common practice to obtain blood cultures only if the patient appears ill enough to warrant hospitalization. There is no evidence that bacteraemia has prognostic significance or warrants longer therapy in an otherwise healthy individual with pyelonephritis.
20
UPDATE MARCH 2009
UPDATE MARCH 2009
21
Substance Dosage Duration LE GR Author, year Ref Remarks Ciprofloxacin 500 mg bid 7 days Ib A Talan 2000 69 a) Ciprofloxacin significantly more effective than cetriaxone/TMP-SMX and with trend b) towards less AE CiproXR 1000 mg od 7-10 days Ib A Talan 2004 70 b) Efficacy and tolerance of extended release ciprofloxacin (ciproXR) 1000 mg od b) equivalent with 10-day conventional ciprofloxacin Cefpodoxime* 200 mg bid 10 days Ib B Naber 2001 73 c) Clinically equivalent with ciprofloxacin 500 mg bid Gatifloxacin 400 mg od 10 days Ib A Naber 2004 71 d) Equivalent with ciprofloxacin 500 mg bid, not available in Europe Levofloxacin 250 mg od 10 days Ib A Richard 1998 72 e) Equivalent with ciprofloxacin 500 mg bid Lomefloxacin 400 mg od 10 days Ib B Richard 1998 72 f ) Study statistically underpowered TMP-SMX 160/800 mg bid 14 days Ib B Stamm 1987 68 g) Only if uropathogen is known to be susceptible to TMP Talan 2004 70 *Cefpodoxime proxetil. LE = level of evidence; GR = grade of recommendation; TMP = trimethoprim; SMX = sulphamethoxazole; tid = three times daily; bid = twice daily; od = once daily; AE = adverse events.
Table 2.4: Oral treatment options of acute uncomplicated pyelonephritis in adult pre-menopausal non-pregnant women according to level of evidence and grade of recommendation. (For parenteral therapy, see text.)
2.6.3 Post-treatment follow-up Routine post-treatment cultures in an asymptomatic patient may not be indicated; routine urinalysis using a dipstick method is sufficient. In women whose pyelonephritis symptoms do not improve within 3 days, or that resolve and then recur within 2 weeks, a repeat urine culture, antimicrobial susceptibility testing and an appropriate investigation, such as renal ultrasound or scan, should be performed. In the patient with no urological abnormality, it should be assumed that the infecting organism is not susceptible to the agent originally used and retreatment with a 2-week regimen using another agent should be considered. For those patients who relapse with the same pathogen as the initially infecting strain, a 6-week regimen is usually curative. An overview of the clinical management of acute pyelonephritis is shown in Figure 2.1. Figure 2.1. Clinical management of acute pyelonephritis Symptoms and signs of pyelonephritis (fever, flank pain, pyuria, leucocytosis)
No
Nausea, vomiting or sepsis syndrome
Urinalysis and urine culture Ultrasonography Outpatient treatment Oral therapy: 7-14 days • Fluoroquinolone • Aminopenicillin plus a BLI • Cephalosporin (3rd gen) • TMP-SMX, only if susceptibility of pathogen is confirmed
Improvement within 72 hours
• Oral therapy • Urine culture 4 days on and 10 days off therapy • Urological evaluation if indicated
Yes
Urinalysis, urine and blood cultures Ultrasonography Inpatient treatment Start parenteral therapy: 1-3 days • Fluoroquinolone • Aminopenicillin plus a BLI • Cephalosporin (3rd gen) • Aminoglycoside Total therapy duration: 14-21 days
No improvement or deterioration • Hospitalize outpatient • Review cultures and sensitivities • Urological evaluation for complicating factors • Drain obstruction or abscess
BLI = ß-lactamase inhibitor; TMP = trimethoprim; SMX = sulphamethoxazole.
2.7
Recurrent (uncomplicated) UTIs in women
2.7.1 Background Recurrent urinary tract infection (RUTI) is defined in the literature by three episodes of UTI in the last 12 months or two episodes in the last 6 months. Risk factors for RUTI are genetic and behavioural (75) (IIa). Some studies estimate that 20-30% of women who have a UTI will have a RUTI (76). Women who are non-secretors of blood group substances have an increased occurrence of RUTI (77) (IIa). A secretor is defined as a person who secretes their blood type antigens into body fluids and secretions, such as saliva, etc. A non-secretor on the other hand puts little to none of their blood type antigens into these fluids. In the USA about 20% of the population are non-secretors. Women with RUTI have an increased frequency of urinary infection in firstdegree female relatives (78) (IIa). In addition, E. coli, the most common uropathogen, adheres more readily to epithelial cells in women who experience RUTI (79, 80) (IIb). Behavioural factors associated with RUTI include sexual activity, with a particularly high risk in those who use spermicides as a birth control method (81,82) (IIa). According to cohort and case control studies (4-6) (IIa), risk factors associated with RUTI in sexually active premenopausal women are frequency of sexual intercourse, spermicide use, age of first UTI (less than 15 years of age indicates a greater risk of RUTI) and history of UTI in the mother, suggesting that genetic factors and/or long-term environmental exposures might predispose to this condition. Following the menopause, risk factors strongly associated with RUTI are vesical prolapse, incontinence and post-voiding residual urine. Other risk factors such as blood group substance non-secretor status and a history of UTI before the menopause need to be confirmed by further research (83). Recurrent UTIs result in significant discomfort for women and have a high impact on ambulatory health care costs as a result of outpatient visits, diagnostic tests and prescriptions. Different approaches have been proposed for the prevention of RUTI, including non-pharmacological therapies, such as voiding after
22
UPDATE MARCH 2009
sexual intercourse or the ingestion of cranberry juice (84), and the use of antibiotics as preventive therapy given regularly or postcoital prophylaxis in sexually active women. With respect to antibiotic prophylaxis, it is not known which antibiotic schedule is best or the optimal duration of prophylaxis, the incidence of adverse events, or the recurrence of infections after stopped prophylaxis or treatment compliance. 2.7.2 Prophylactic antimicrobial regimens One effective approach for the management of recurrent uncomplicated UTI is the prevention of infection through the use of long-term, prophylactic antimicrobials taken on a regular basis at bedtime (85-87) (Ib) or postcoital (88) (Ib). In a Cochrane review (89) (Ia) every published randomized controlled trial from 1966 to April 2004 was analyzed in which antibiotics were used as a preventive strategy for recurrent UTIs and administered for at least 6 months. Nineteen out of 108 studies involving 1120 women were eligible for inclusion. In nine of these studies one antibiotic regimen was compared with placebo. In another seven studies different antibiotic regimens were compared concerning microbiological outcome, while in another three studies antibiotic regimens with non-antibiotic regimes were compared concerning microbiological outcome (Table 2.5) (90-107). During active prophylaxis the rate of microbiological recurrence per patient-year was 0 to 0.9 per patient-year in the antibiotic group, which was significantly lower than 0.8 to 3.6 per patient-year in the placebo group. The relative risk of having one microbiological recurrence was 0.21 (95% CI 0.13-0.34), significantly favouring antibiotic prophylaxis. For clinical recurrences the relative risk was 0.15 (95% CI 0.08-0.28), significantly favouring antibiotic prophylaxis. The relative risk of having one microbiological recurrence after prophylaxis was 0.82 (95% CI 0.44-1.53). The relative risk for severe side effects was 1.58 (95% CI 0.47-5.28) and for other side effects the relative risk was 1.78 (95% CI 1.06-3.00), significantly favouring placebo. Side effects included vaginal and oral candidiasis and gastrointestinal symptoms. Generally, the number of patients with microbiological recurrent UTIs decreased by eightfold as compared to the period of time before prophylaxis and compared to placebo by fivefold. The UTI episodes per patient-year was reduced in general by 95% during antimicrobial prophylaxis as compared to the period of time before prophylaxis. The initial duration of prophylactic therapy was usually 6 months or 1 year. However, for co-trimoxazole (TMP-SMX), continuous prophylaxis for as long as 2 (86) or 5 years (85) has remained efficacious. Prophylaxis does not appear to modify the natural history of a recurrent UTI. When discontinued, even after extended periods, approximately 60% of women will become re-infected within 3-4 months. Thus, prophylaxis did not appear to exert a long-term effect on the baseline infection rate (108) (III).
UPDATE MARCH 2009
23
24
UPDATE MARCH 2009
8/49 Nitrofurantoin 50 mg24h 2/26 Nitrofurantoin 100 mg/24h 16/38 Nitrofurantoin 100 mg/24h 1/13 Nitrofurantoin 100 mg/24h 1/12 Cinoxacin 500 mg/24h 17/185 Pefloxacin 400 mg/mon 2/70 Ciprofloxacin 125 mg/24h 47/393 (12.0%)
8/48 20.0 0/26 7.2 4/34 19.2 1/13 8.5 2/14 10.3 52/176 22.6 2/65 12.2 69/376 (18.4%)
(0.40-2.40) (0.25-99.4) (1.33-9.66) (0.07-14,3) (0.06-5.66) (0.19-0.52) (0.13-6.40)
Brumfitt 1995 Nunez 1990 Brumfitt 1985 Stamm 1980 Seppanen 1988 Guibert 1995 Melekos 1997
Martens 1995 Martorana 1984 Schaeffer 1982 Scheckler 1982 Nicolle 1989 Rugendorff 1987 Stamm 1980 Bailey 1971 Gower 1975 Stamm 1980 Stapleton 1990
0.06 (0.01-0.39) 0.43 (0.24-0.75) 0.43 (0.09-1.99) 0.13 (0.02-0.96) 0.06 (0.00-0.85) 0.29 (0.12-0.72) 0.09 (0.01-0.63) 0.20 (0.07-0.61) 0.09 (0.01-0.62) 0.11 (0.02-0.75) 0.15 (0.04-0.58) 0.21 (0.13-0.34)
0.98 5.00 3.58 1.00 0.58 0.31 0.93
Author, Year
Relative Risk (95% CI)
100 101 102 97 103 104 105
91 92 93 94 95 96 97 98 99 97 90
Ref
Antibiotics vs Non-antibiotics Nitrofurantoin 50 mg/12h 4/43 Meth. hippurate 1 g/12h 19/56 0.27 (0.10-0.75) Brumfitt 1981 106 Trimethoprim 100 mg/24h 8/20 Povidone iodine Topical 10/19 0.76 (0.38-1.51) Brumfitt 1983 107 Trimethoprim 100 mg/24h 8/20 Meth. hippurate 1 g/12h 10/25 1.00 (0.49-2.05) Brumfitt 1983 107 TMP-SMX = trimethoprim-sulphamethoxazole; Meth. hippurate = methanamine hippurate.
Antibiotic vs Antibiotic Cefaclor 250 mg/24 Norfloxacin 400 mg/24 Trimethoprim 100 mg/24h TMP-SMX 40/200 mg/24h Trimethoprim 100 mg/24h Pefloxacin 400 mg/weekly Ciprofloxacin 125 mg postcoital Total
Substance Dosage n/N Comparator Dosage n/N Weight (%) Antibiotic vs Placebo Cinoxacin 250 mg/24h 1/23 Placebo 17/22 5.4 Cinoxacin 500 mg/24h 8/21 Placebo 17/19 24.2 Cinoxacin 500 mg/24h 2/15 Placebo 4/13 7.9 Cinoxacin 500 mg/24h 1/20 Placebo 8/21 5.1 Norfloxacin 200 mg/24h 0/11 Placebo 10/13 2.9 Norfloxacin 200 mg/24h 4/18 Placebo 13/17 16.0 Nitrofurantoin 100 mg/24h 1/13 Placebo 5/6 5.5 Nitrofurantoin 50 mg/24h 3/25 Placebo 15/25 12.5 Cephalexin 125 mg/24h 1/20 Placebo 13/23 5.3 TMP-SMX 40/200 mg/24h 1/13 Placebo 5/7 5.3 TMP-SMX 40/200 mg postcoital 2/16 Placebo 9/11 9.8 Total 24/195 (12.3%) 116/177 (65.5%)
Table 2.5: Efficacy (reduction of microbiological recurrences) of antibiotics for preventing recurrent urinary tract infection in non-pregnant women (modified according 85) with a study period of at least 6 months
The recommendations for antimicrobial regimens for the prevention (prophylaxis) of recurrent uncomplicated UTI in pre-menopausal women are listed in Table 2.6. Trimethoprim, co-trimoxazole or nitrofurantoin can still be considered as the standard regimen. Fosfomycin trometamol (FT), 3g every 10 days for 6 months can be considered as an alternative as shown by a recent placebo (PL) controlled study in 302 evaluable non-pregnant females suffering from recurrent lower UTI (109) (Ib). The UTI episodes per patientyear (0.14 vs 2.97), the time to first infection recurrence (38 days vs 6 days), the percentage of patients with at least one episode of recurrent UTI (7.0% vs 75.0%), and the number of UTI episodes per patient during 6 months treatment (0.07 vs 1.44) and during the 6 months, follow-up, period (0.55 vs 1.54) were all statistically in favour of the FT-treated group. In cases of ‘breakthrough’ infection due to resistant pathogens, low doses of fluoroquinolones may also be used. No increased emergence of resistance was observed (101, 105). During pregnancy, an oral first-generation cephalosporin is recommended. An alternative prophylactic approach is post-intercourse prophylaxis for women in whom episodes of infection are associated with sexual intercourse (88, 89, 105) (IbA). Generally, for this approach, the same antimicrobials can be used in the same doses as though recommended for continuous prophylaxis. A patientinitiated treatment may also be suitable for management in well-informed, young women, in whom the rate of recurrent episodes is not too common (112). This is, however, strictly speaking, not prophylaxis but early treatment. Table 2.6: Recommendations for antimicrobial prophylaxis of recurrent uncomplicated UTI in women (IA) Agent1 Standard regimen: • Nitrofurantoin • Nitrofurantoin macrocrystals • Trimethoprim-sulphamethoxazole • Trimethoprim • Fosfomycin trometamil
Dose 50 mg/day (98) 100 mg/day (101, 106) 40/200 mg/day (97) or three times weekly (110) 100 mg/day (103) 3 g/10 day (109)
‘Breakthrough’ infections: • Ciprofloxacin • Norfloxacin • Pefloxacin
125 mg/day (105) 200-400 mg/day (101, 111) 800 mg/week (104)
During pregnancy: • Cephalexin Cefaclor
125 mg/day (99) 250 mg/day (100)
1
Taken at bedtime.
2.7.3 Alternative prophylactic methods Alternative methods, such as the acidification of urine (113), cranberry juice (84), extract from uvae ursi and the vaginal application of lactobacilli (114, 115), show variable effects. A meta-analysis of five, placebocontrolled, double-blind studies using oral immuno-active E. coli fractions (UroVaxom) resulted in a significant reduction of recurrent infections as compared with placebo (116) (Ia). In a recently published study (117) (Ib), a total of 453 patients were included in a placebo-controlled, double-blind study. Patients received either the immunotherapeutic OM-89 (UroVaxom) or a matching placebo. After receiving one capsule per day for 90 days, patients had 3 months without treatment, before being given one capsule on the first 10 days in the following 3 months. Patients were followed up for 12 months from the beginning of treatment. The mean rate of post-baseline UTI episodes was significantly lower in the active group than in the placebo group (0.84 vs 1.28; p<0.003), corresponding to a 34% reduction in patients treated with OM-89 as compared to placebo. In the OM-89 treated group, 93 patients (40.3%) had 185 post-baseline UTI episodes, compared to 276 UTI episodes in 122 patients (55.0%) in the placebo group (p=0.001). The safety profile of OM-89 was good and consistent with earlier reports. The most frequent adverse event was headache, followed by gastrointestinal events, amounting to respectively 17% and 15% in both groups (Ib). Another method of immunoactive prophylaxis is intramuscular and intravaginal immunization with heat-killed uropathogenic bacteria. In one small study, 27 adult women with recurrent cystitis (subgroup analysis) were immunized by three intramuscular injections (Solco-Urovac) at biweekly intervals compared to a control group of 26 patients without immunization. Within 6 months, 16/27 (59%) of the immunized were statistically significantly free of recurrent cystitis compared with only 1/26 (4%) of the control patients (118) (Ib).
UPDATE MARCH 2009
25
In a phase 2, double-blind, placebo-controlled trial using a vaginal vaccine, 54 women received either three doses of primary vaccination alone or, in addition, three booster immunizations or placebo. Women receiving six immunizations remained free of infections for a significantly longer period than those receiving placebo or primary immunization (119) (Ib). Unfortunately, there are no studies comparing directly antimicrobial prophylaxis with immuno-active prophylaxis. However, from the reported results, it seems that the efficacy of antimicrobial prophylaxis is superior to immunization regimens presently available. Water diuresis may be effective in some women with an uncomplicated UTI, but it often delays more effective management. The evidence is also too weak to recommend that women change their usual habits and menstrual practices or void after intercourse.
2.8
UTIs in pregnancy
Urinary tract infections are common during pregnancy. There is some debate about whether these infections can be classified as uncomplicated, even in cases where no further risk factors besides pregnancy can be found. Bearing this in mind, the three entities, asymptomatic bacteriuria, acute cystitis and acute pyelonephritis, will be discussed in this section with regard only to pregnancy and not to other risk factors. The factors that predispose a woman to UTI in pregnancy appear to be related to the anatomical and physiological changes in the kidney and urinary tract that occur during pregnancy. The ureters become dilated above the pelvic brim and the bladder is displaced anteriorly and superiorly by the enlarging uterus. Renal blood flow and the glomerular filtration rate increase by about 30-40% during pregnancy and the kidneys become slightly enlarged and hyperaemic. Urine flow may be sluggish and the bladder may not empty completely. 2.8.1 Epidemiology The prevalence of asymptomatic bacteriuria in American, European and Australian studies varies between 4% and 7% (120). Incidence relates to sexual activity and increases with increasing age and gravidity. It is also higher among patients from lower socio-economic groups. Symptomatic infection occurs in about 1-2% of pregnant women. Most women acquire bacteriuria before pregnancy. At the first examination, the rates of bacteriuria in pregnant women are similar to those in non-pregnant women with similar risk factors. About 37-57% of bacteriuric schoolgirls develop UTIs during pregnancy. An additional 1% of infections occur during pregnancy (121) (III). In a study conducted in Sweden, the risk of acquiring bacteriuria increased with the duration of pregnancy, reaching a maximum between gestational weeks 9 and 17 (122) (III). Bacteriuria during pregnancy is associated with a significant increase in the number of low-birth-weight infants (< 2500 g), low gestational age (< 37 weeks), and neonatal mortality. Women with persistent infection despite treatment or with evidence of ‘tissue invasion’ are at a higher risk of delivering premature infants. It should, however, be mentioned that bacterial vaginosis is also an important independent risk factor for premature birth; hence, treatment is recommended. 2.8.2 Asymptomatic bacteriuria Early studies by Kass (121) and others demonstrated that 20-40% of women with asymptomatic bacteriuria develop pyelonephritis during pregnancy. Treatment of the bacteriuria lowers this risk (123) (IIa). It is therefore generally recommended that pregnant women should be screened for bacteriuria by urine culture at least once in early pregnancy, and they should be treated if results are positive (124) (IaA). Wadland and Plante (125) found screening to be cost effective when the prevalence of bacteriuria was > 2%. In socially stable populations with a low prevalence of asymptomatic bacteriuria, screening programmes may be not necessary (125) (IIIB). On the other hand, a sharp reduction in the annual incidence of pyelonephritis could be achieved following the introduction of a programme to screen and treat asymptomatic bacteriuria among pregnant women (123) (IIaB). To avoid unnecessary treatment, asymptomatic bacteriuria is defined as two consecutive positive cultures of the same species. The false-positive rate of a single MSU may be as high as 40% (IIb). Therefore, women with a positive urine culture should be asked to return within 1-2 weeks, at which time, after stressing the importance of a careful cleansing of the vulva before micturition, a second MSU or straight catheter urine specimen is obtained for culture (IIaB). Treatment should be based on antibiotic sensitivity testing and usually involves a 5- to 7-day course of antibiotics (124) (IIIB); however, some authors recommend short-term therapy, as for acute cystitis (126) (IIaB). Follow-up cultures should be obtained 1-4 weeks after treatment and at least once more before delivery (IIIB). A Cochrane analysis of eight studies involving 400 patients was performed concerning the duration of treatment for asymptomatic bacteriuria during pregnancy (127). All the studies were comparisons of singledose treatment with 4-7 days of treatment, though it should be noted that the trials were generally of poor quality. The analysis found no difference in ‘no-cure’ rates between single dose and short course (4-7 day)
26
UPDATE MARCH 2009
treatment for asymptomatic bacteriuria in pregnant women (relative risk 1.13, 95% CI 0.82-1.54), as well as in recurrent asymptomatic bacteriuria (relative risk 1.08, 95% CI 0.70-1.66). However, these results showed significant heterogeneity. No differences were detected for preterm births and pyelonephritis, but the trials involved had a small sample size. Treatment of longer duration was associated with increased adverse events (relative risk 0.53, 95% CI 0.31-0.91). Overall, there was therefore not enough evidence to evaluate whether single dose or longer-duration doses were more effective in treating asymptomatic bacteriuria in pregnant women (C). Since a single dose costs less and is likely to increase patient compliance, this comparison should be explored in an adequately powered randomized controlled trial. 2.8.3 Acute cystitis during pregnancy Most symptomatic UTIs in pregnant women present as acute cystitis, as occurs in non-pregnant women. Usually a 7-day treatment course is recommended, e.g. with pivmecillinam (128) (IbA). Short-term therapy is not as established in pregnant women as it is in non-pregnant women, but it is recommended by smaller studies and expert opinion (126) (IIaB). Fosfomycin trometamol (3 g single dose) or second- and thirdgeneration oral cephalosporins (e.g. ceftibuten 400 mg once daily) could be considered candidates for effective short-term therapy (129) (IIaB). Otherwise conventional therapy with amoxycillin, cephalexin or nitrofurantoin is recommended (IVC). Follow-up urine cultures should be obtained after therapy to demonstrate eradication of the bacteriuria. As in non-pregnant women, there is no advantage to be gained by using long-term prophylaxis except for recurrent infections. Low-dose cephalexin (125-250 mg) or nitrofurantoin (50 mg) at night are recommended for prophylaxis against re-infection if indicated, lasting up to and including the puerperium. Postcoital prophylaxis may be an alternative approach (130, 131) (IIaB). 2.8.4 Acute pyelonephritis in pregnancy Acute pyelonephritis tends to occur during the later stages of pregnancy, usually in the last trimester. A review by Gilstrap et al. (132) found acute pyelonephritis in 2% of 24,000 obstetric patients. The incidence is increased in the puerperium. Characteristically, the patient is acutely ill with high fever, leucocytosis and costovertebral angle pain. Bacteraemia is common, but mortality and complications are low when the patient is treated with effective therapy. The major causes of concern are the presence of underlying urological abnormalities and associated risks to the mother and fetus, such as toxaemia, hypertension, prematurity and perinatal mortality. Currently, antimicrobial therapy is so effective that, even with bacteraemia, almost all patients with uncomplicated pyelonephritis do well and become afebrile within a few days. Recommended antibiotics include second- or third-generation cephalosporins, an aminopenicillin plus a BLI, or an aminoglycoside. During pregnancy, quinolones, tetracyclines and TMP should not be used during the first trimester, while sulphonamides should not be used in the last trimester (133, 134). In cases of delayed defeverescence and upper tract dilatation, a ureteral stent may be indicated and antimicrobial prophylaxis until delivery and including the puerperium should be considered (C). In a Cochrane analysis on treatments for symptomatic UTIs during pregnancy, eight studies were included recruiting a total of 905 pregnant women. In most of the comparisons, there were no significant differences between treatments with regard to cure rates, recurrent infection, incidence of preterm delivery and premature rupture of membranes, admission to the neonatal intensive care unit, need for change of antibiotic and incidence of prolonged pyrexia. Although antibiotic treatment is effective for the cure of UTIs (A), there are insufficient data to recommend any specific treatment regimen for symptomatic UTIs during pregnancy. Complications were very rare. Future studies should evaluate the most promising antibiotics, in terms of class, timing, dose, acceptibility, maternal and neonatal outcomes and costs (135).
2.9
UTIs in post-menopausal women
The normal vagina contains only low numbers of Gram-negative enteric bacteria because of competition from the resident microbial flora. Lactobacilli account for the low vaginal pH. They tend to be less abundant in post-menopausal women and after antimicrobial therapy. Oestrogens are presumed to exert a protective force against recurrent UTIs in post-menopausal women because they enhance the growth of lactobacilli and decrease vaginal pH (136) (IIb). Gram-negative enteric bacteria do not ordinarily colonize the vagina in post-menopausal women unless these women are prone to recurrent UTIs (137) (IIb). In post-menopausal women with recurrent UTIs, therapy with oral (138, 139) or intravaginal oestriol (136) reduced significantly the rate of recurrence (IbA). For other patients, an antimicrobial prophylactic regimen (see previously) should be recommended in addition to hormonal treatment. In the case of an acute UTI, the antimicrobial treatment policy is similar to that in pre-menopausal women. Short-term therapy in post-menopausal women is not, however, as well documented as in younger women. Raz et al. (140) (Ib) published a study in post-menopausal women (mean age 65 years) with an uncomplicated UTI in which ofloxacin, 200 mg once daily for 3 days, was significantly more effective in both
UPDATE MARCH 2009
27
short- and long-term follow-up than a 7-day course of cephalexin, 500 mg four times daily, even though all the uropathogens were susceptible to the two agents. In another double-blind study (46) (Ib), including a total of 183 post-menopausal women of at least 65 years of age with acute uncomplicated UTI, similar results were obtained with either a 3-day or a 7-day oral course of ciprofloxacin 250 mg two times daily (bacterial eradication 2 days after treatment 98% vs 93%, p=0.16), but the shorter course was better tolerated. The rate of bacterial eradication in this study was generally high and the rate of bacterial resistance to ciprofloxacin low. However, these results should not be extended to the frail elderly population with significant comorbidities, who frequently present with UTI caused by Gram-negative or resistant organisms. In the case of RUTI, a urological or gynaecological evaluation should be performed in order to eliminate a tumour, obstructive problems, detrusor failure or a genital infection (IVC).
2.10
Acute uncomplicated UTIs in young men
2.10.1 Pathogenesis and risk factors It has been conventional to consider all UTIs in men as complicated because most UTIs occurring in the newborn, infant or elderly male are associated with urological abnormalities, bladder outlet obstruction or instrumentation. A UTI in an otherwise healthy adult man between the ages of 15 and 50 years is very uncommon. In Norway, a rate of 6-8 UTIs per year per 10,000 men aged 21-50 years has been reported (141). The large difference in the prevalence of UTIs between men and women is thought to be caused by a variety of factors, including the greater distance between the usual source of uropathogens (the anus and the urethral meatus); the drier environment surrounding the male urethra; the greater length of the male urethra; and the antibacterial activity of the prostatic fluid. It has become clear, however, that a small number of men aged 15-50 years suffer acute uncomplicated UTIs. The exact reasons for such infections are not clear, but risk factors associated with such infections include intercourse with an infected partner, anal intercourse and lack of circumcision (142); however, these factors are not always present. More than 90% of men with febrile UTI (fever > 38.0°C), with or without clinical symptoms of pyelonephritis, have a concomitant infection of the prostate, as measured by transient increases in serum PSA and prostate volume (143), irrespective of prostatic tenderness. 2.10.2 Diagnosis The symptoms of uncomplicated UTIs in men are similar to those in women. Urethritis must be ruled out in sexually active men using a urethral Gram stain or a first-voided urine specimen wet mount to look for urethral leucocytosis. A urethral Gram stain demonstrating leucocytes and predominant Gram-negative rods suggests E. coli urethritis, which may precede or accompany a UTI. Dysuria is common to both UTI and urethritis. The aetiological agents that cause uncomplicated UTIs in men are also similar to those in women. Krieger et al. (144) noted that 93% of 40 uncomplicated UTIs in men were caused by E. coli. 2.10.3 Treatment Due to the infrequency with which UTIs occur in this group of men, data from controlled treatment studies are non-existent. Empirical use of the agents discussed previously for uncomplicated cystitis or pyelonephritis in women are recommended (IIIB). Nitrofurantoin should not be used in men with a UTI, since it does not achieve reliable tissue concentrations (IVC). For acute uncomplicated pyelonephritis, the use of a fluoroquinolone as initial empirical treatment is recommended in areas where the rate of E. coli resistance to fluoroquinolones is low (< 10%) (IIaB). Otherwise, alternative drugs have to be considered (see Table 2.4). Since in most men with febrile UTI or pyelonephritis, prostatic involvement also has to be considered, the goal of treatment is not only to sterilize the urine, but also to eradicate the prostatic infection. Thus, antimicrobials with good prostatic tissue and fluid penetration are preferable, e.g. fluoroquinolones (143) (IIbB). Although it is possible that short-course treatment is effective in men with uncomplicated cystitis, there are no studies to support this practice. It is therefore recommended that such men receive a minimum of 7 days of therapy because of the relatively greater likelihood of an occult complicating factor in men compared with women (IIIB). Also, longer treatment may reduce the likelihood of persistent prostatic infection. There was, however, no statistically significant difference in outcome when men with febrile UTI were treated orally for 2 or 4 weeks with ciprofloxacin 500 mg twice daily, but the study did not have sufficient statistical power to show equivalence (145) (IIaB). Serum PSA should not be analyzed in conjunction with, or earlier than 6 months after, an episode of febrile UTI, unless prostate cancer is otherwise suspected (143) (IIbB). The value of a urological evaluation in a man who has had a single uncomplicated UTI has not been determined. Urological evaluation should be carried out routinely in adolescents and in men with febrile UTI, pyelonephritis and recurrent infections, or whenever a complicating factor is present (IIIB).
28
UPDATE MARCH 2009
2.11
Asymptomatic bacteriuria
Asymptomatic bacteriuria is common (146-150). Populations with structural or functional abnormalities of the genitourinary tract may have an exceedingly high prevalence of bacteriuria, but even healthy individuals frequently have positive urine cultures. Asymptomatic bacteriuria is seldom associated with adverse outcomes. Pregnant women (see section 2.8.2) and individuals undergoing traumatic genitourinary interventions are at risk for complications of bacteriuria and show benefit from screening and treatment programmes (124) (IbA). Although some experts (151) recommend screening for renal transplant recipients, the benefits for these patients are less clear; no recommendation can therefore be made (124). For other populations, including most bacteriuric individuals, negative outcomes attributable to asymptomatic bacteriuria have not been described. Screening for or treatment of asymptomatic bacteriuria is not recommended for the following persons (124): • pre-menopausal, non-pregnant women (IbA) • diabetic women (IbA) • older persons living in community (IIaB) • elderly institutionalized subjects (IbA) • persons with spinal cord injury (IIaB) • catheterized patients while the catheter remains in situ (IaA). In fact, treatment of bacteriuria may be associated with harmful outcomes, such as increased shortterm frequency of symptomatic infection, adverse drug effects, and re-infection with organisms of increased antimicrobial resistance. Screening for asymptomatic bacteriuria and treatment is recommended only for selected groups where benefit has been shown (124): • pregnant women (IbA) • before transurethral resection of the prostate (IbA) and other traumatic urological interventions (IIaB). Antimicrobial therapy should be initiated before the procedure (124) (IIaB). Short-term antimicrobial treatment of asymptomatic women with catheter-acquired bacteriuria that persists 48 hours after removal of the indwelling catheter may be considered (124, 152) (IIaB).
2.12
References
1.
Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997;11:(3)551-81. http://www.ncbi.nlm.nih.gov/pubmed/9378923 Kunin CM. Detection, prevention and management of UTIs. 5th edition. Philadelphia: Lea & Febiger, 1997. Kahlmeter G; ECO.SENS. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003;51(1): 69-76. http://www.ncbi.nlm.nih.gov/pubmed/12493789 Hooton TM, Scholes D, Hughes JP, Winter C, Roberts PL, Stapleton AE, Stergachis A, Stamm WE. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 2000 Oct 5;343(14):992-7. http://www.ncbi.nlm.nih.gov/pubmed/11018165 Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000;182(4):1177-82. Epub 2000 Aug 31. http://www.ncbi.nlm.nih.gov/pubmed/10979915 Hooton TM, Scholes D, Stapleton AE, Roberts PL, Winter C, Gupta K, Samadpour M, Stamm WE. A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med 2000;343(14):992-7. http://www.ncbi.nlm.nih.gov/pubmed/11018165 Foxman B, Frerichs RR. Epidemiology of urinary tract infection: I. Diaphragm use and sexual intercourse. Am J Public Health 1985;75(11):1308-13. http://www.ncbi.nlm.nih.gov/pubmed/4051066 Kass EH. Asymptomatic infections of the urinary tract. J Urol 2002 Feb;167(2 Pt 2):1016-9; discussion 1019-21. http://www.ncbi.nlm.nih.gov/pubmed/11905871 Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med. 1982;307(8):463-8. http://www.ncbi.nlm.nih.gov/pubmed/7099208
2. 3.
4.
5.
6.
7.
8.
9.
UPDATE MARCH 2009
29
10.
11.
12.
13.
14.
15. 16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
30
Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992 Nov;15 Suppl 1:S216-S217. http://www.ncbi.nlm.nih.gov/pubmed/1477233 Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE, with modifications by a European Working Party. General guidelines for the evaluation of new anti-infective drugs for the treatment of UTI. Taufkirchen, Germany: The European Society of Clinical Microbiology and Infectious Diseases, 1993;240-310. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004;36(4):296-301. http://www.ncbi.nlm.nih.gov/pubmed/15198188 Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002;52(482):729-34. http://www.ncbi.nlm.nih.gov/pubmed/12236276 Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents 2003;22 Suppl 2:49-52. http://www.ncbi.nlm.nih.gov/pubmed/14527771 Naber KG. Short-term therapy of acute uncomplicated cystitis. Curr Opin Urol 1999;9(1):57-64. http://www.ncbi.nlm.nih.gov/pubmed/10726073 Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29(4):745-58. http://www.ncbi.nlm.nih.gov/pubmed/10589881 Goettsch WG, Janknegt R, Herings RM. Increased treatment failure after 3-days’ courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database. Br J Clin Pharmacol 2004;58(2):184-9. http://www.ncbi.nlm.nih.gov/pubmed/15255801 Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998;10(1):39-47. http://www.ncbi.nlm.nih.gov/pubmed/12634070 Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, Lavi I, Stamm W; Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34(9):1165-9. http://www.ncbi.nlm.nih.gov/pubmed/11941541 Henning C, Bengtsson L. [Treatment of acute urinary disorders. Simple tests and questions make the diagnosis and therapeutic choices easier.] Lakartidningen 1997;94(25):2387-90. [article in Swedish] http://www.ncbi.nlm.nih.gov/pubmed/9229660 Petersen EE, Wingen F, Fairchild KL, Halfhide A, Hendrischk A, Links M, Schad M, Scholz HR, Schurmann N, Siegmann S, et al. Single dose pefloxacin compared with multiple dose co-trimoxazole in cystitis. J Antimicrob Chemother 1990;26 Suppl B:147-52. http://www.ncbi.nlm.nih.gov/pubmed/2258341 Dubois J, St-Pierre C, Auger P, Phillips R, Perrier A. Single-dose pefloxacin vs. seven days of trimethoprim-sulfamethoxazole in uncomplicated infection of the lower urinary tract in women. Rev Infect Dis 1989;11(Suppl 5):S1343-S1344. Jardin A, Cesana M. Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract InfectionRufloxacin Group. Antimicrob Agents Chemother 1995;39(1):215-20. http://www.ncbi.nlm.nih.gov/pubmed/7695309 Del Rio G, Dalet F, Aguilar L, Caffaratti J, Dal-Ré R. Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations. Antimicrob Agents Chemother 1996;40(2):408-12. http://www.ncbi.nlm.nih.gov/pubmed/8834888 Richard G, deAbate C, Ruoff G, Corrado M, Fowler C. Short-course levofloxacin (250 mg qid) vs ofloxacin (200 mg bid) in uncomplicated UTI: a double-blind, randomized trial. Abstract. 6th Int Symp New Quinolones, Denver, Colorado, USA, Nov 15-17, 1998.
UPDATE MARCH 2009
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39. 40.
41.
42. 43.
Henry DC Jr, Bettis RB, Riffer E, Haverstock DC, Kowalsky SF, Manning K, Hamed KA, Church DA. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002;24(12):2088-104. http://www.ncbi.nlm.nih.gov/pubmed/12581547 Schaeffer AJ, Sisney GA. Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora. J Urol. 1985;133(4):628-30. http://www.ncbi.nlm.nih.gov/pubmed/3157008 Hooton TM, Latham RH, Wong ES, Johnson C, Roberts PL, Stamm WE. Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis. Antimicrob Agents Chemother 1989;33(8):1308-12. http://www.ncbi.nlm.nih.gov/pubmed/2802557 Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents 2003;22 Suppl 2:65-72. http://www.ncbi.nlm.nih.gov/pubmed/14527774 Pitkäjärvi T, Pyykönen ML, Kannisto K, Piippo T, Viita P. Pivmecillinam treatment in acute cystitis. Three versus seven days study. Arzneimittelforschung 1990;40(10):1156-8. http://www.ncbi.nlm.nih.gov/pubmed/2291755 Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 2000 Sep;46 Suppl 1:35-9; discussion 63-5. http://www.ncbi.nlm.nih.gov/pubmed/11051622 Nicolle LE, Madsen KS, Debeeck GO, Blochlinger E, Borrild N, Bru JP, McKinnon C, O’Doherty B, Spiegel W, Van Balen FA, Menday P. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis 2002;34(7):487-92. http://www.ncbi.nlm.nih.gov/pubmed/12195873 Menday AP. Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection. Int J Antimicrob Agents 2002;20(4):297-300. http://www.ncbi.nlm.nih.gov/pubmed/12385688 Kahlmeter G, Menday P. Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO.SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J Antimicrob Chemother 2003;52(1):128-31. http://www.ncbi.nlm.nih.gov/pubmed/12805266 Naber KG, Koch EM. Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women. Infection 1993;21(1):34-9. http://www.ncbi.nlm.nih.gov/pubmed/8449579 Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995;273(1):41-5. http://www.ncbi.nlm.nih.gov/pubmed/7654268 Kavatha D, Giamarellou H, Alexiou Z, Vlachogiannis N, Pentea S, Gozadinos T, Poulakou G, Hatzipapas A, Koratzanis G. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for shortterm therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother 2003; 47(3):897-900. http://www.ncbi.nlm.nih.gov/pubmed/12604518 Hooton TM, Scholes D, Gupta K, Stapelton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005;293(8):949-55. http://www.ncbi.nlm.nih.gov/pubmed/15728165 Lecomte F, Allaert FA. Single-dose treatment of cystitis with fosfomycin trometamol (Monuril): analysis of 15 comparative trials on 2.048 patients. Giorn It Ost Gin 1997;19:399-404. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI?. Int J Antimicrob Agents 2003;22 Suppl 2:79-83. http://www.ncbi.nlm.nih.gov/pubmed/14527776 Guay DR. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 2001;61(3):353-64. http://www.ncbi.nlm.nih.gov/pubmed/11293646 Cunha BA. Antibiotic side effects. Med Clin North Am 2001;85(1):149-85. http://www.ncbi.nlm.nih.gov/pubmed/11190350 Brumfitt W, Hamilton-Miller JM. Efficacy and safety profile of long-term nitrofurantoin in urinary tract infections: 18 years’ experience. J Antimicrob Chemother 1998;42(3):363-71. http://www.ncbi.nlm.nih.gov/pubmed/9786476
UPDATE MARCH 2009
31
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56. 57.
58.
59.
32
Karpman E, Kurzrock EA. Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol 2004;172(2):448-53. http://www.ncbi.nlm.nih.gov/pubmed/15247700 Iravani A, Tice AD, McCarty J, Sikes DH, Nolen T, Gallis HA, Whalen EP, Tosiello RL, Heyd A, Kowalsky SF, et al. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected]. Arch Intern Med 1995;155(5):485-94. http://www.ncbi.nlm.nih.gov/pubmed/7864704 Vogel T, Verreault R, Gourdeau M, Morin M, Grenier-Gosselin L, Rochette L. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized trial. CMAJ 2004;170(4):469-73. http://www.ncbi.nlm.nih.gov/pubmed/14970093 Backhouse CI, Matthews JA. Single-dose enoxacin compared with 3-day treatment of urinary tract infection. Antimicrob Agents Chemother 1989;33(6):877-80. http://www.ncbi.nlm.nih.gov/pubmed/2764538 Iravani A. Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. Am J Med 1993;94(3A):89S-96S. http://www.ncbi.nlm.nih.gov/pubmed/8452189 Iravani A, Clair PS, Maladorno D. Fleroxacin in the treatment of uncomplicated urinary tract infections in women. 7th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria, March 26-30, 1995. Abstr 727. Richard GA, Mathew CP, Kirstein JM, Orchard D, Yang JY. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology 2002;59(3):334-9. http://www.ncbi.nlm.nih.gov/pubmed/11880065 Naber KG, Allin DM, Clarysse L, Haworth DA, James IG, Raini C, Schneider H, Wall A, Weitz P, Hopkins G, Ankel-Fuchs D. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents. 2004;23(6):596-605. http://www.ncbi.nlm.nih.gov/pubmed/15194131 Neringer R, Forsgren A, Hansson C, Ode B. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group. Scand J Infect Dis 1992;24(6):773-80. http://www.ncbi.nlm.nih.gov/pubmed/1337623 Nicolle LE, DuBois J, Martel AY, Harding GK, Shafran SD, Conly JM. Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. Antimicrob Agents Chemother 1993;37(3):574-9. http://www.ncbi.nlm.nih.gov/pubmed/8384818 Spencer RC, Moseley DJ, Greensmith MJ. Nitrofurantoin modified release versus trimethoprim or cotrimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J Antimicrob Chemother 1994;33 Suppl A:121-9. http://www.ncbi.nlm.nih.gov/pubmed/7928829 Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections. The Inter-Nordic Urinary Tract Infection Study Group. Scand J Infect Dis 1988;20(6):619-24. http://www.ncbi.nlm.nih.gov/pubmed/2906171 Piipo T, Pitkäjärvi T, Salo SA. Three-day versus seven-day treatment with norfloxacin in acute cystitis. Curr Ther Res 1990;47:644-53. Block JM, Walstad RA, Bjertnaes A, Hafstad PE, Holte M, Ottemo I, Svarva PL, Rolstad T, Peterson LE. Ofloxacin versus trimethoprim-sulphamethoxazole in acute cystitis. Drugs 1987;34 Suppl 1:100-6. http://www.ncbi.nlm.nih.gov/pubmed/3501750 Hooton TM, Latham RH, Wong ES, Johnson C, Roberts PL, Stamm WE. Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis. Antimicrob Agents Chemother 1989;33(8):1308-12. http://www.ncbi.nlm.nih.gov/pubmed/2802557 Hooton TM, Johnson C, Winter C, Kuwamura L, Rogers ME, Roberts PL, Stamm WE. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrob Agents Chemother 1991;35(7):1479-83. http://www.ncbi.nlm.nih.gov/pubmed/1929311
UPDATE MARCH 2009
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
Naber KG, Baurecht W, Fischer M, Kresken M. Pefloxacin single-dose in the treatment of acute uncomplicated lower urinary tract infections in women: a meta-analysis of seven clinical trials. Int J Antimicrob Agents 1994;4(3):197-202. http://www.ncbi.nlm.nih.gov/pubmed/18611611 Gossius G, Vorland L. The treatment of acute dysuria-frequency syndrome in adult women: doubleblind, randomized comparison of three-day vs ten-day trimethoprim therapy. Curr Ther Res 1985;37:34-42. Roberts FJ. Quantitative urine culture in patients with urinary tract infection and bacteremia. Am J Clin Pathol 1986;85(5):616-8. http://www.ncbi.nlm.nih.gov/pubmed/3706200 Weidner W, Ludwig M, Weimar B, Rau W. Rational diagnostic steps in acute pyelonephritis with special reference to ultrasonography and computed tomography scan. Int J Antimicrob Agents 1999;11(3-4):257-9. http://www.ncbi.nlm.nih.gov/pubmed/10394980 Hamm M, Wawroschek F, Weckermann D, Knopfle E, Hackel T, Hauser H, Krawczak G, Harzmann R. Unenhanced helical computed tomography in the evaluation of acute flank pain. Eur Urol 2001;39(4):460-5. http://www.ncbi.nlm.nih.gov/pubmed/11306887 Gleckman R, Bradley P, Roth R, Hibert D, Pelletier C. Therapy of symptomatic pyelonephritis in women. J Urol 1985;133(2):176-8. http://www.ncbi.nlm.nih.gov/pubmed/3881598 Jernelius H, Zbornik J, Bauer CA. One or three weeks’ treatment of acute pyelonephritis? A doubleblind comparison, using a fixed combination of pivampicillin plus pivmecillinam. Acta Med Scand 1988;223(5):469-77. http://www.ncbi.nlm.nih.gov/pubmed/3287839 Ode B, Bröms M, Walder M, Cronberg S. Failure of excessive doses of ampicillin to prevent bacterial relapse in the treatment of acute pyelonephritis. Acta Med Scand 1980;207(4):305-7. http://www.ncbi.nlm.nih.gov/pubmed/7386225 Stamm WE, McKevitt M, Counts GW. Acute renal infection in women: treatment with trimethoprimsulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med 1987;106(3):341-5. http://www.ncbi.nlm.nih.gov/pubmed/3492950 Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000;283(12):1583-90. http://www.ncbi.nlm.nih.gov/pubmed/10735395 Talan DA, Klimberg IW, Nicolle LE, Song J, Kowalsky SF, Church DA. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol 2004;171(2 Pt 1):734-9. http://www.ncbi.nlm.nih.gov/pubmed/14713799 Naber KG, Bartnicki A, Bischoff W, Hanus M, Milutinovic S, van Belle F, Schonwald S, Weitz P, AnkelFuchs D. Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents 2004;23(Suppl 1):S41-S53. http://www.ncbi.nlm.nih.gov/pubmed/15037328 Richard GA, Klimberg IN, Fowler CL, Callery-D’Amico S, Kim SS. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998;52(1):51-5. http://www.ncbi.nlm.nih.gov/pubmed/9671870 Naber KG, Schoenwald S, Hauke W. [Cefpodoxime proxetil in patients with acute uncomplicated pyelonephritis. International, prospective, randomized comparative study versus ciprofloxacin in general practice.] Chemotherapie Journal 2001;10:29-34. [article in German] Finkelstein R, Kassis E, Reinhertz G, Gorenstein S, Herman P. Community-acquired urinary tract infection in adults: a hospital viewpoint. J Hosp Infect 1998;38(3):193-202. http://www.ncbi.nlm.nih.gov/pubmed/9561470 Engel JD, Schaeffer AJ. Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. Urol Clin North Am 1998;25(4):685-701. http://www.ncbi.nlm.nih.gov/pubmed/10026775 Sanford JP. Urinary tract symptoms and infection. Annu Rev Med 1975;26:485-98. http://www.ncbi.nlm.nih.gov/pubmed/1096777
UPDATE MARCH 2009
33
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
34
Kinane DF, Blackwell CC, Brettle RP, Weir DM, Winstanley FP, Elton RA. ABO blood group, secretor state and susceptibility to recurrent urinary tract infection in women. Br Med J (Clin Res Ed) 1982;285(6334):7-9. http://www.ncbi.nlm.nih.gov/pubmed/6805820 Fennell RS, Wilson SG, Garin EH, Pryor ND, Sorgen CD, Walker RD, Richard GA. Bacteriuria in families of girls with recurrent bacteriuria. A survey of 112 family members showed similar infections in 14% of the female siblings. Clin Pediatr (Phila) 1977;16(12):1132-5. http://www.ncbi.nlm.nih.gov/pubmed/589889 Schaeffer AJ, Jones JM, Dunn JK. Association of vitro Escherichia coli adherence to vaginal and buccal epithelial cells with susceptibility of women to recurrent urinary-tract infections. N Engl J Med 1981;304(18):1062-6. http://www.ncbi.nlm.nih.gov/pubmed/7010174 Kozody NL, Harding GKM, Nicolle LE, Kelly K, Ronald AR. Adherence of Escherichia coli to epithelial cells in the pathogenesis of urinary tract infection. Clin Invest Med 1985;8(2):121-5. http://www.ncbi.nlm.nih.gov/pubmed/3914382 Nicolle LE, Harding GK, Preiksaitis J, Ronald AR. The association of urinary tract infection with sexual intercourse. J Infect Dis 1982;146(5):579-83. http://www.ncbi.nlm.nih.gov/pubmed/7130747 Fihn SD, Latham RH, Roberts P, Running K, Stamm WE. Association between diaphragm use and urinary tract infection. JAMA 1985;254(2):240-5. http://www.ncbi.nlm.nih.gov/pubmed/3999367 Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S, Rottensterich E, Stamm WE. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis. 2000;30(1):152-6. http://www.ncbi.nlm.nih.gov/pubmed/10619744 Jepson RG, Mihaljevic L, Craig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2004;(2):CD001321. http://www.ncbi.nlm.nih.gov/pubmed/15106157 Nicolle LE, Ronald AR. Recurrent urinary tract infection in adult women: diagnosis and treatment. Infect Dis Clin North Am 1987;1(4):793-806. http://www.ncbi.nlm.nih.gov/pubmed/3333659 Harding GK, Ronald AR, Nicolle LE, Thomson MJ, Gray GJ. Long-term antimicrobial prophylaxis for recurrent urinary tract infection in women. Rev Infect Dis 1982;4(2):438-43. http://www.ncbi.nlm.nih.gov/pubmed/6981161 Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis 1988;157(6):1239-42. http://www.ncbi.nlm.nih.gov/pubmed/3259613 Vosti KL. Recurrent urinary tract infections. Prevention by prophylactic antibiotics after sexual intercourse. JAMA 1975;231(9):934-40. http://www.ncbi.nlm.nih.gov/pubmed/1173099 Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;(3):CD001209. http://www.ncbi.nlm.nih.gov/pubmed/15266443 Stapleton A, Latham RH, Johnson C, Stamm WE. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial. JAMA 1990;264(6):703-6. http://www.ncbi.nlm.nih.gov/pubmed/2197450 Martens MG, Richards GA. Cinoxacin prophylaxis for urinary tract infections in young women: a prospective, randomized, double-blind, placebo-controlled trial. Advances in Therapy 1995;12(5): 255-60. Martorana G, Giberti C, Damonte P. [Preventive treatment of recurrent cystitis in women. Double-blind randomized study using cinoxacin and placebo.] Minerva Urol Nefrol 1984;36(1):43-9. [article in Italian] http://www.ncbi.nlm.nih.gov/pubmed/6398519 Schaeffer AJ, Jones JM, Flynn SS. Prophylactic efficacy of cinoxacin in recurrent urinary tract infection: biologic effects on the vaginal and fecal flora. J Urol 1982;127(6):1128-31. http://www.ncbi.nlm.nih.gov/pubmed/7087019 Scheckler WE, Burt RA, Paulson DF. Comparison of low-dose cinoxacin therapy and placebo in the prevention of recurrent urinary tract infections. J Fam Pract 1982;15(5):901-4. http://www.ncbi.nlm.nih.gov/pubmed/6752331
UPDATE MARCH 2009
95.
96.
97.
98.
99.
100.
101. 102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Prospective, randomized, placebo-controlled trial of norfloxacin for the prophylaxis of recurrent urinary tract infection in women. Antimicrob Agents Chemother 1989;33(7):1032-5. http://www.ncbi.nlm.nih.gov/pubmed/2675752 Rugendorff E, Haralambie E. Low-dose norfloxacin versus placebo for long-term prophylaxis of recurrent uncomplicated urinary tract infection. Chemioterapia 1987;6(2 Suppl):533-5. http://www.ncbi.nlm.nih.gov/pubmed/3334616 Stamm WE, Wagner KF, Amsel R, Alexander ER, Turck M, Counts GW, Holmes KK. Causes of the acute urethral syndrome in women. N Engl J Med 1980;303(8):409-15. http://www.ncbi.nlm.nih.gov/pubmed/6993946 Bailey RR, Roberts AP, Gower PE, De Wardener HE. Prevention of urinary-tract infection with lowdose nitrofurantoin. Lancet 1971;2(7734):1112-4. http://www.ncbi.nlm.nih.gov/pubmed/4107395 Gower PE. The use of small doses of cephalexin (125 mg) in the management of recurrent urinary tract infection in women. J Antimicrob Chemother 1975;1(3 Suppl):93-8. http://www.ncbi.nlm.nih.gov/pubmed/1104559 Brumfitt W, Hamilton-Miller JM. A comparative trial of low dose cefaclor and macrocrystalline nitrofurantoin in the prevention of recurrent urinary tract infection. Infection 1995;23(2):98-102. http://www.ncbi.nlm.nih.gov/pubmed/7622272 Nunez U, Solis Z. Macrocrystalline nitrofurantoin versus norfloxacin as treatment and prophylaxis in uncomplicated recurrent urinary tract infection. Curr Therap Res Clin Exp 1990;48:234-45. Brumfitt W, Smith GW, Hamilton-Miller JM, Gargan RA. A clinical comparison between Macrodantin and trimethoprim for prophylaxis in women with recurrent urinary infections. J Antimicrob Chemother 1985;16(1):111-20. http://www.ncbi.nlm.nih.gov/pubmed/4044461 Seppänen J. Cinoxacin vs trimethoprim-safety and efficacy in the prophylaxis of uncomplicated urinary tract infections. Drugs Exp Clin Res 1988;14(10):669-71. http://www.ncbi.nlm.nih.gov/pubmed/3246212 Guibert J, Humbert G, Meyrier A, Jardin A, Vallancien G, Piccoli S, Delavault P. [Antibioprevention of recurrent cystitis.] A randomized double-blind comparative trial of 2 dosages of pefloxacin.] Presse Med 1995;24(4):213-6. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/7899366 Melekos MD, Asbach HW, Gerharz E, Zarakovitis IE, Weingaertner K, Naber KG. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol 1997;157(3):935-9. http://www.ncbi.nlm.nih.gov/pubmed/9072603 Brumfitt W, Cooper J, Hamilton-Miller JM. Prevention of recurrent urinary infections in women: a comparative trial between nitrofurantoin and methenamine hippurate. J Urol 1981;126(1):71-4. http://www.ncbi.nlm.nih.gov/pubmed/7019458 Brumfitt W, Hamilton-Miller JM, Gargan RA, Cooper J, Smith GW. Long-term prophylaxis of urinary infections in women: comparative trial of trimethoprim, methenamine hippurate and topical povidoneiodine. J Urol 1983;130(6):1110-4. http://www.ncbi.nlm.nih.gov/pubmed/6227756 Harding GK, Ronald AR, Nicolle LE, Thomson MJ, Gray GJ. Long-term antimicrobial prophylaxis for recurrent urinary tract infection in women. Rev Infect Dis 1982;4(2):438-43. http://www.ncbi.nlm.nih.gov/pubmed/6981161 Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung 2005;55(7):420-7. http://www.ncbi.nlm.nih.gov/pubmed/16080282 Brumfitt W, Hamilton-Miller JM, Smith GW, al-Wali W. Comparative trial of norfloxacin and macrocrystalline nitrofurantoin (Macrodantin) in the prophylaxis of recurrent urinary tract infection in women. Q J Med 1991;81(294):811-20. http://www.ncbi.nlm.nih.gov/pubmed/1801054 Stamm WE, Counts GW, McKevitt M, Turck M, Holmes KK. Urinary prophylaxis with trimethoprim and trimethoprim-sulfamethoxazole: efficacy, influence on the natural history of recurrent bacteriuria, and cost control. Rev Infect Dis 1982;4(2):450-5. http://www.ncbi.nlm.nih.gov/pubmed/6981163
UPDATE MARCH 2009
35
112.
113.
114.
115.
116.
117.
118. 119.
120. 121. 122.
123.
124.
125.
126.
127.
128.
129.
130.
36
Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 2001;135(1):9-16. http://www.ncbi.nlm.nih.gov/pubmed/6981163 Fünfstück R, Straube E, Schildbach O, Tietz U. [Prevention of reinfection by L-methionine in patients with recurrent urinary tract infection] Med Klinik (Munich) 1997;92(10):574-81. http://www.ncbi.nlm.nih.gov/pubmed/9446004 Reid G. Probiotic therapy and functional food for prevention of urinary tract infections: State of the Art and Science. Curr Infect Dis Rep 2000;2(6):518-22. http://www.ncbi.nlm.nih.gov/pubmed/11095902 Baerheim A, Larsen E, Digranes A. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand J Prim Health Care 1994;12(4):239-43. http://www.ncbi.nlm.nih.gov/pubmed/7863140 Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents 2002;19(6):451-6. http://www.ncbi.nlm.nih.gov/pubmed/12135831 Bauer HW, Alloussi S, Egger G, Blümlein HM, Cozma G, Schulman CC; Multicenter UTI Study Group. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol 2005;47(4):542-8. http://www.ncbi.nlm.nih.gov/pubmed/15774256 Riedasch G, Möhring K. [Immunotherapy in women with recurrent urinary tract infections.] Therapiewoche 1986;6:896-900. [German] Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol 2003;170(3):867-69. http://www.ncbi.nlm.nih.gov/pubmed/12913718 MacLean AB. Urinary tract infection in pregnancy. Br J Urol 1997;80 Suppl 1:10-3. http://www.ncbi.nlm.nih.gov/pubmed/9240218 Kass EH. Bacteriuria and pyelonephritis of pregnancy. Arch Intern Med 1960;105:194-8. http://www.ncbi.nlm.nih.gov/pubmed/14404662 Stenqvist K, Dahlén-Nilsson I, Lidin-Janson G, Lincoln K, Odén A, Rignell S, Svanborg-Edén C. Bacteriuria in pregnancy. Frequency and risk of acquisition. Am J Epidemiol 1989;129(2):372-9. http://www.ncbi.nlm.nih.gov/pubmed/2912046 Gratacós E, Torres PJ, Vila J, Alonso PL, Cararach V. Screening and treatment of asymptomatic bacteriuria in pregnancy prevent pyelonephritis. J Infect Dis 1994;169(6):1390-2. http://www.ncbi.nlm.nih.gov/pubmed/8195624 Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM; Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40(5):643-54. http://www.ncbi.nlm.nih.gov/pubmed/15714408 Wadland WC, Plante DA. Screening for asymptomatic bacteriuria in pregnancy. A decision and cost analysis. J Fam Pract 1989;29(4):372-6. http://www.ncbi.nlm.nih.gov/pubmed/2794885 Bailey RR. Single-dose/short-term therapy in children and in pregnant women. Infection 1994; 22 Suppl 1:S47-S48. http://www.ncbi.nlm.nih.gov/pubmed/8050794 Villar J, Lydon-Rochelle MT, Gülmezoglu AM, Roganti A. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev 2000;(2):CD000491. http://www.ncbi.nlm.nih.gov/pubmed/10796207 Nicolle LE. Pivmecillinam for the treatment of acute uncomplicated urinary infection. Int J Clin Pract 1999;53(8):612-7. http://www.ncbi.nlm.nih.gov/pubmed/10692756 Krcmery S, Hromec J, Demesova D. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents 2001;17(4):279-82. http://www.ncbi.nlm.nih.gov/pubmed/11295408 Pfau A, Sacks TG. Effective prophylaxis for recurrent urinary tract infections during pregnancy. Clin Infect Dis 1992;14(4):810-4. http://www.ncbi.nlm.nih.gov/pubmed/1576275
UPDATE MARCH 2009
131. 132.
133.
134. 135.
136.
137.
138.
139.
140.
141.
142.
143. 144.
145.
146.
147.
148.
149.
150.
Pfau A. Recurrent UTI in pregnancy. Infection 1994;22 Suppl 1:S49. http://www.ncbi.nlm.nih.gov/pubmed/8050795 Gilstrap LC 3rd, Cunningham FG, Whalley PJ. Acute pyelonephritis in pregnancy: a anterospective study. Obstet Gynecol 1981;57(4):409-13. http://www.ncbi.nlm.nih.gov/pubmed/7243084 Kämmerer W, Mutschler E. [Drugs in pregnancy – an overview.] In: Freise K, Melchert F (eds): Arzneimitteltherapie in der Frauenheilkunde. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2002. [article in German] Anonymous. Antimicrobials in pregnancy. FDA pregnancy categories. http://users.lmi.net/wilworks/ehnlinx/a.htm [access date December 2008] Vazquez JC, Villar J. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev 2003;(4):CD002256. http://www.ncbi.nlm.nih.gov/pubmed/14583949 Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329(11):753-6. http://www.ncbi.nlm.nih.gov/pubmed/8350884 Pfau A, Sacks T. The bacterial flora of the vaginal vestibule, urethra and vagina in the normal premenopausal woman. J Urol 1977;118(2):292-5. http://www.ncbi.nlm.nih.gov/pubmed/561197 Privette M, Cade R, Peterson J, Mars D. Prevention of recurrent urinary tract infections in postmenopausal women. Nephron 1988;50(1):24-7. http://www.ncbi.nlm.nih.gov/pubmed/3173598 Kirkengen AL, Andersen P, Gjersøe E, Johannessen GR, Johnsen N, Bodd E. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scand J Prim Health Care 1992;10(2):139-42. http://www.ncbi.nlm.nih.gov/pubmed/1641524 Raz R, Rozenfeld S. 3-day course of ofloxacin versus cefalexin in the treatment of urinary tract infections in postmenopausal women. Antimicrob Agents Chemother 1996;40(9):2200-1. http://www.ncbi.nlm.nih.gov/pubmed/8878607 Vorland LH, Carlson K, Aalen O. An epidemiological survey of urinary tract infections among outpatients in Northern Norway. Scand J Infect Dis 1985;17(3):277-83. http://www.ncbi.nlm.nih.gov/pubmed/4059868 Stamm WE. Urinary tract infections in young men. In: Bergan T (ed). Urinary tract infections. Basel, Switzerland: Karger, 1997;pp.46-47. http://content.karger.com/ProdukteDB/produkte.asp?Doi=61396 Ulleryd P. Febrile urinary tract infection in men. Int J Antimicrob Agents 2003;22 Suppl 2:89-93. http://www.ncbi.nlm.nih.gov/pubmed/14527778 Krieger JN, Ross SO, Simonsen JM. Urinary tract infections in healthy university men. J Urol 1993;149(5):1046-8. http://www.ncbi.nlm.nih.gov/pubmed/8483206 Ulleryd P, Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis 2003;35(1):34-9. http://www.ncbi.nlm.nih.gov/pubmed/12685882 Raz R, Gronich D, Ben-Israel Y, Nicolle LE. Asymptomatic bacteriuria in institutionalized elders in Israel. J Am Med Dir Assoc 2001;2(6):275-8. http://www.ncbi.nlm.nih.gov/pubmed/12812530 de Oliveira LC, Lucon AM, Nahas WC, Ianhez LE, Arap S. Catheter-associated urinary infection in kidney post-transplant patients. Sao Paulo Med J 2001;119(5):165-8. http://www.ncbi.nlm.nih.gov/pubmed/11723526 Harding GK, Zhanel GG, Nicolle LE, Cheang M; Manitoba Diabetes Urinary Tract Infection Study Group. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med 2002;347(20):1576-83. http://www.ncbi.nlm.nih.gov/pubmed/12432044 Raz R. Asymptomatic bacteriuria. Clinical significance and management. Int J Antimicrob Agents 2003;22 Suppl 2:45-7. http://www.ncbi.nlm.nih.gov/pubmed/14527770 Nicolle LE. Asymptomatic bacteriuria: when to screen and when to treat. Infect Dis Clin North Am 2003;17(2):367-94. http://www.ncbi.nlm.nih.gov/pubmed/12848475
UPDATE MARCH 2009
37
151. 152.
Snydman DR. Posttransplant microbiological surveillance. Clin Infect Dis 2001;33 Suppl 1:S22-S25. http://www.ncbi.nlm.nih.gov/pubmed/11389518 Harding GK, Nicolle LE, Ronald AR, Preiksaitis JK, Forward KR, Low DE, Cheang M. How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study. Ann Intern Med 1991;114(9):713-9. http://www.ncbi.nlm.nih.gov/pubmed/2012351
3. URINARY TRACT INFECTIONS IN CHILDREN 3.1
Summary and recommendations
Urinary tract infection (UTI) in children is a frequent health problem, with the incidence of UTIs only a little lower than the incidences for upper respiratory and digestive infections. The incidence of UTI varies depending on age and sex. In the first year of life, mostly the first 3 months, UTI is more common in boys (3.7%) than in girls (2%), after which the incidence changes, being 3% in girls and 1.1% in boys. Paediatric UTI is the most common cause of fever of unknown origin in boys less than 3 years. The clinical presentation of a UTI in infants and young children can vary from fever to gastrointestinal, lower or upper urinary tract symptoms. Investigation should be undertaken after two episodes of a UTI in girls and one in boys (B). The objective is to rule out the unusual occurrence of obstruction, vesicoureteric reflux (VUR) and dysfunctional voiding, e.g. as caused by a neuropathic disorder. Chronic pyelonephritic renal scarring develops very early in life due to the combination of a UTI, intrarenal reflux and VUR. It sometimes arises in utero due to dysplasia. Although rare, renal scarring may lead to severe long-term complications such as hypertension and chronic renal failure. Vesicoureteric reflux is treated with long-term prophylactic antibiotics (B). Surgical re-implantation or endoscopic treatment is reserved for the small number of children with breakthrough infection (B). In the treatment of a UTI in children, short courses are not advised and therefore treatment is continued for 5-7 days and longer (A). If the child is severely ill with vomiting and dehydration, hospital admission is required and parenteral antibiotics are given initially (A).
3.2
Background
The urinary tract is a common source of infection in children and infants. It represents the most common bacterial infection in children less than 2 years of age (1) (IIa). The outcome of a UTI is usually benign, but in early infancy it can progress to renal scarring, especially when associated with congenital anomalies of the urinary tract. Delayed sequelae related to renal scarring include hypertension, proteinuria, renal damage and even chronic renal failure, requiring dialysis treatment in a significant number of adults (2) (IIa). The risk of a UTI during the first decade of life is 1% in males and 3% in females (3). It has been suggested that 5% of schoolgirls and up to 0.5% of schoolboys undergo at least one episode of UTI during their school life. The incidence is different for children under 3 months of age, when it is more common in males. The incidence of asymptomatic bacteriuria is 0.7-3.4% in neonates, 0.7-1.3% in infants under 3 months of age and between 0.2% and 0.8% in preschool boys and girls, respectively (3). The incidence of symptomatic bacteriuria is 0.14% in neonates, with a further increase to 0.7% in boys and 2.8% in girls aged less than 6 months. The overall recurrence rate for the neonatal period has been reported to be 25% (3, 4).
3.3
Aetiology
The common pathogenic sources are Gram-negative, mainly enteric, organisms. Of these, Escherichia coli is responsible for 90% of episodes of UTIs (5). Gram-positive organisms (particularly enterococci and staphylocci) represent 5-7% of cases. Hospital-acquired infections show a wider pattern of aggressive organisms, such as Klebsiella, Serratia and Pseudomonas spp. Groups A and B streptococci are relatively common in the newborn (6). There is an increasing trend towards the isolation of Staphylococcus saprophyticus in UTIs in children, although the role of this organism is still debatable (7).
3.4 Pathogenesis and risk factors The urinary tract is a sterile space with an impermeable lining. Retrograde ascent is the most common mechanism of infection. Nosocomial infection and involvement as part of a systemic infection are less common (8).
38
UPDATE MARCH 2009
Obstruction and dysfunction are among the most common causes of urinary infection. Phimosis predisposes to UTI (9,10) (IIa). Enterobacteria derived from intestinal flora colonize the preputial sac, glandular surface and the distal urethra. Among these organisms are strains of E. coli expressing P fimbriae which adhere to the inner layer of the preputial skin and to uroepithelial cells (11). A wide variety of congenital urinary tract abnormalities can cause UTIs through obstruction, e.g. urethral valves, pelvi-ureteric junction obstruction or non-obstructive urinary stasis (e.g. prune belly syndrome, VUR). More mundane but significant causes of UTIs include labial adhesion and chronic constipation (7). Dysfunctional voiding in an otherwise normal child may result in infrequent bladder emptying aided by delaying manoeuvres, e.g. crossing legs, sitting on heels (12). Neuropathic bladder dysfunction (spina bifida, sphincter dyssynergia, etc) may lead to postvoid residual urine and secondary VUR (4). The link between renal damage and UTIs is controversial. The mechanism in obstructive nephropathy is self-evident, but more subtle changes occur where there is VUR. Almost certainly the necessary components include VUR, intrarenal reflux and a UTI. These must all work together in early childhood when the growing kidney is likely to be susceptible to parenchymal infection. Later on in childhood, the presence of bacteriuria seems irrelevant to the progression of existing scars or the very unusual formation of new scars. Another confounding factor is that many so-called scars are dysplastic renal tissue which developed in utero (13).
3.5
Signs and symptoms
Symptoms are non-specific, and vary with the age of the child and the severity of the disease. Epididymoorchitis is extremely unusual. With scrotal pain and inflammation in a boy, testicular torsion has to be considered. A UTI in neonates may be non-specific and with no localization. In small children, a UTI may present with gastrointestinal signs, such as vomiting and diarrhoea. In the first weeks of life, 13.6% of patients with fever have a UTI (14). Rarely, septic shock will be the presentation. Signs of a UTI may be vague in small children, but later on, when they are older than 2 years, frequent voiding, dysuria and suprapubic, abdominal or lumbar pain may appear with or without fever.
3.6
Classification
Urinary tract infections may be classified either as a first episode or recurrent, or according to severity (simple or severe). Recurrent UTI may be subclassified into three groups (8): • Unresolved infection: subtherapeutic level of antimicrobial, non-compliance with treatment, malabsorption, resistant pathogens. • Bacterial persistence: may be due to a nidus for persistent infection in the urinary tract. surgical correction or medical treatment for urinary dysfunction may be needed. • Reinfection: each episode is a new infection acquired from periurethral, perineal or rectal flora. From the clinical point of view, severe and simple forms of UTIs should be differentiated because to some extent the severity of symptoms dictates the degree of urgency with which investigation and treatment are to be undertaken (Table 3.1). Table 3.1: Clinical classification of urinary tract infections (UTIs) in children Severe UT • Fever > 39°C • Persistent vomiting • Serious dehydration • Poor treatment compliance
Simple UTI • Mild pyrexia • Good fluid intake • Slight dehydration • Good treatment compliance
3.6.1 Severe UTI Severe UTI is related to the presence of fever of > 39ºC, the feeling of being ill, persistent vomiting, and moderate or severe dehydration. 3.6.2 Simple UTI A child with a simple UTI may have only mild pyrexia, but is able to take fluids and oral medication. The child is only slightly or not dehydrated and has a good expected level of compliance. When a low level of compliance is expected, such a child should be managed as one with a severe UTI.
3.7
Diagnosis
3.7.1 Physical examination It is mandatory to look for phimosis, labial adhesion, signs of pyelonephritis, epididymo-orchitis, and stigmata
UPDATE MARCH 2009
39
of spina bifida, e.g. hairy patch on the sacral skin. The absence of fever does not exclude the presence of an infective process. 3.7.2 Laboratory tests The definitive diagnosis of infection in children requires a positive urine culture (8, 15). Urine must be obtained under bacteriologically reliable conditions when undertaking a urine specimen culture (16). A positive urine culture is defined as the presence of more than 100,000 cfu/mL of one pathogen. The urine specimen may be difficult to obtain in a child less than 4 years old and different methods are advised since there is a high risk of contamination (17, 18). 3.7.2.1 Collection of the urine 3.7.2.1.1 Suprapubic bladder aspiration Suprapubic bladder aspiration is the most sensitive method, even though urine may be obtained in 23-99% of cases (8, 18). 3.7.2.1.2 Bladder catheterization Bladder catheterization is also a most sensitive method, even though there is the risk of introduction of nosocomial pathogens (8, 19). 3.7.2.1.3 Plastic bag attached to the genitalia Prospective studies showed a high incidence of false-positive results, ranging from 85-99% (8, 18). It is helpful when the culture is negative (8, 18) and has a positive predictive value of 15% (16). In order to obtain a urine sample in the best condition in children under 2 years of age (girls and uncircumcised boys without sphincteric control), it is better to use suprapubic bladder aspiration or bladder catheterization. In older children with sphincteric control, midstream urine (MSU) collection is possible and reliable (18). 3.7.2.2 Quantification of bacteriuria The final concentration of bacteria in urine is directly related to the method of collection, diuresis, method of storage and transport of the specimen (15). The classical definition of significant bacteriuria of more than 105 cfu/mL is still used and depends on the clinical environment (15, 17). The presence of pyuria (more than 5 leucocytes per field) and bacteriuria in a fresh urine sample will reinforce the clinical diagnosis of UTI (17). In boys, when the urine is obtained by bladder catheterization, the urine culture is considered positive with more than 104 cfu/mL. Even though Hoberman (20) identified a micro-organism in 65% of cases with colony counts between 10,000 and 50,000 cfu/mL, there was a mixed growth pattern suggesting contamination. In these cases, it is better to repeat the culture or to evaluate the presence of other signs, such as pyuria, nitrites or other biochemical markers (15). The collection of MSU or in a collecting bag of more than 105 cfu/mL is considered positive (16) (Table 3.2). Table 3.2: Criteria of UTI in children Urine specimen from suprapubic Urine specimen from bladder bladder puncture catheterization > 1,000-50,000 cfu/mL Any number of cfu/mL (at least 10 identical colonies)
Urine specimen from midstream void > 104 cfu/mL with symptoms > 105 cfu/mL without symptoms
3.7.2.3 Other biochemical markers The presence of other biochemical markers in a urine sample are useful to establish the diagnosis of UTI (8). The most frequent markers are nitrite and leucocyte esterase usually combined in a dipstick test. 3.7.2.3.1 Nitrite This is the degradation product of the nitrates of bacterial metabolism, particularly of Gram-negative bacteria. When an infection is caused by Gram-positive bacteria, the test may be negative (8, 16). Limitations of the nitrite test include: • not all uropathogens reduce nitrate to nitrite, e.g. Pseudomonas aeruginosa, enterococci • even nitrite-producing pathogens may show a negative test result, due to the short transit time in the bladder in cases of high diuresis and urine dilution, e.g. neonates. The nitrite test has a sensitivity of only 45-60%, but a very good specificity of 85-98% (8, 17, 21).
40
UPDATE MARCH 2009
3.7.2.3.2 Leucocyte esterase Leucocyte esterase is produced by the activity of leucocytes. The test for leucocyte esterase has a sensitivity of 48-86% and a specificity of 17-93% (8, 17, 20, 21). A combination of nitrite and leucocyte esterase testing improves sensitivity and specificity, but carries the risk of false-positive results (21). The dipstick test has become useful to exclude rapidly and reliably the presence of a UTI, provided both nitrite and leucocyte esterase tests are negative. If the tests are positive, it is better to confirm the results in combination with the clinical symptoms and other tests (17, 21). Bacteriuria without pyuria may be found: • in bacterial contamination • in colonization (asymptomatic bacteriuria) • when collecting a specimen before the onset of an inflammatory reaction. In such cases, it is advisable to repeat the urinalysis after 24 hours to clarify the situation. Even in febrile children with a positive urine culture, the absence of pyuria may cast doubt on the diagnosis of UTI. Instead, asymptomatic bacteriuria with a concomitant septic focus responsible for the febrile syndrome has to be considered. Bacteriuria without pyuria is found in 0.5% of specimens. This figure corresponds well with the estimated rate of asymptomatic bacteriuria in childhood (20, 22) (IIa). Pyuria without bacteriuria may be due to: • incomplete antimicrobial treatment of UTI • urolithiasis and foreign bodies • infections caused by Mycobacterium tuberculosis and other fastidious bacteria, e.g. Chlamydia trachomatis. Thus, either bacteriuria or pyuria may not be considered reliable parameters to diagnose or exclude UTI. Their assessment can be influenced by other factors, such as the degree of hydration, method of specimen collection, mode of centrifugation, volume in which sediment is resuspended and subjective interpretation of results (23). However, according to Landau et al. (24), pyuria in febrile children is indicative of acute pyelonephritis. For all of these reasons, in neonates and children under 6 months of age, either pyuria, bacteriuria or the nitrite test, separately, have minimal predictive value for UTI (25, 26) (III). In contrast, the positive predictive value of significant Gram staining with pyuria is 85% (20) (IIb). In older children, pyuria with a positive nitrite test is more reliable for the diagnosis of UTI, with a positive predictive value of 98%. Combining bacteriuria and pyuria in febrile children, the findings of > 10 WBC/mm3 and > 50,000 cfu/ mL in a specimen collected by catheterization are significant for a UTI and discriminate between infection and contamination (20, 25). 3.7.2.3.3 C-reactive protein Although non-specific in febrile children with bacteriuria, C-reactive protein seems to be useful in distinguishing between acute pyelonephritis and other causes of bacteriuria. It is considered significant at a concentration above 20 µg/mL. 3.7.2.3.4 Urinary N-acetyl-ß-glucosaminidase This is a marker of tubular damage. It is increased in a febrile UTI and may become a reliable diagnostic test for UTIs, although it is also elevated in VUR (27). 3.7.2.3.5 Interleukin-6 The clinical use of urinary concentrations of interleukin-6 in UTIs (28) is still at the research stage. 3.7.3 Imaging of the urinary tract A ‘gold standard’ imaging technique has to be cost-effective, painless, safe, with minimal or nil radiation, and an ability to detect any significant structural anomaly. Current techniques do not fulfil all such requirements. 3.7.3.1 Ultrasonography Ultrasonography (US) has become very useful in children because of its safety, speed and high accuracy in identifying the anatomy and size of the renal parenchyma and collecting system (29). It is subjective and therefore operator-dependent, and gives no information on renal function. However, scars can be identified, although not as well as with technetium-99m dimercaptosuccinic acid (Tc-99m DMSA) scanning (29, 30) (IIa). This technique has been shown to be very sensitive and excretory urography must be reserved only for when images need to be morphologically clarified (31) (IIa).
UPDATE MARCH 2009
41
3.7.3.2 Radionuclide studies Tc-99m DMSA is a radiopharmaceutical that is bound to the basement membrane of proximal renal tubular cells; half of the dose remains in the renal cortex after 6 hours. This technique is helpful in determining functional renal mass and ensures an accurate diagnosis of cortical scarring by showing areas of hypoactivity indicating lack of function. A UTI interferes with the uptake of this radiotracer by the proximal renal tubular cells, and may show areas of focal defect in the renal parenchyma. A star-shaped defect in the renal parenchyma may indicate an acute episode of pyelonephritis. A focal defect in the renal cortex usually indicates a chronic lesion or a ‘renal scar’ (32-34) (IIa). A focal scarring or a smooth uniform loss of renal substance as demonstrated by Tc-99m DMSA has generally been regarded as being associated with VUR (reflux nephropathy) (35, 36). However, Rushton et al. (37) stated that significant renal scarring may develop, regardless of the existence or absence of VUR. Ransley and Risdon (38) reported that Tc-99m DMSA showed a specificity of 100% and sensitivity of 80% for renal scarring. The use of Tc-99m DMSA scans can be helpful in the early diagnosis of acute pyelonephritis. About 50-85% of children will show positive findings in the first week. Minimal parenchymal defects, when characterized by a slight area of hypoactivity, can resolve with antimicrobial therapy (39, 40). However, defects lasting longer than 5 months are considered to be renal scarring (41) (IIa). Tc-99m DMSA scans are considered more sensitive than excretory urography and ultrasonography in the detection of renal scars (42-45). It remains questionable whether radionuclide scans could substitute for echography as a first-line diagnostic approach in children with a UTI (46, 47). 3.7.3.3 Cystourethrography 3.7.3.3.1 Conventional voiding cystourethrography Voiding cystourethrography (VCU) is the most widely used radiological exploration for the study of the lower urinary tract and especially of VUR. It is considered mandatory in the evaluation of UTIs in children less than 1 year of age. Its main drawbacks are the risk of infection, the need for retrogrades filling of the bladder and the possible deleterious effect of radiation on children (48). In recent years, tailored low-dose fluoroscopic VCU has been used for the evaluation of VUR in girls in order to minimize radiological exposure (49). Voiding cystourethrography is mandatory in the assessment of febrile childhood UTI, even in the presence of normal ultrasonography. Up to 23% of these patients may reveal VUR (50). 3.7.3.3.2 Radionuclide cystography (indirect) This investigation is performed by prolonging the period of scanning after the injection of Tc-99m diethylene triamine pentaacetate (DTPA) or mercaptoacetyltriglycine (MAG-3) as part of a dynamic renography. It represents an attractive alternative to conventional cystography, especially when following patients with reflux, because of its lower dose of radiation. Disadvantages are a poor image resolution and difficulty in detecting lower urinary tract abnormalities (51, 52). 3.7.3.3.3 Cystosonography Contrast material-enhanced voiding ultrasonography has been introduced for the diagnoses of VUR without irradiation (47,52). Further studies are necessary to determine the role of this new imaging modality in UTI. 3.7.3.4 Additional imaging Excretory urography remains a valuable tool in the evaluation of the urinary tract in children, but its use in UTIs is debatable unless preliminary imaging has demonstrated abnormalities requiring further investigation. The major disadvantages in infants are the risks of side effects from exposure to contrast media and radiation (53). However, the role of excretory urography is declining with the increasing technical superiority of CT (54) and MRI. However, the indications for their use is still limited in UTI. 3.7.3.5 Urodynamic evaluation When voiding dysfunction is suspected, e.g. incontinence, residual urine, increased bladder wall thickness, urodynamic evaluation with uroflowmetry, (video) cystometry, including pressure flow studies, and electromyography should be considered.
3.8
Schedule of investigation
Screening of infants for asymptomatic bacteriuria is unlikely to prevent pyelonephritic scar formation, as these usually develop very early in infancy. Only a minority of children with a UTI have an underlying urological disorder, but when present such a disorder can cause considerable morbidity. Thus, after a maximum of two UTI episodes in a girl and one episode in a boy, investigations should be undertaken (Figure 3.1), but not in the
42
UPDATE MARCH 2009
case of asymptomatic bacteriuria (51-58). The need for DTPA/MAG-3 scanning is determined by the ultrasound findings, particularly if there is suspicion of an obstructive lesion. Figure 3.1. Schedule of investigation of a UTI in a child
Physical examination + Urinalysis/urine culture
> 2 UTI episodes in girls
Echography + VCU
Optional : Intravenous urography DMSA scan
> 1 UTI episode in boys
DMSA = dimercaptosuccinic acid; UTI = urinary tract infection; VCU = voiding cystourethrography.
3.9
Treatment
Treatment has four main goals: 1. elimination of symptoms and eradication of bacteriuria in the acute episode 2. prevention of renal scarring 3. prevention of a recurrent UTI 4. correction of associated urological lesions. 3.9.1 Severe UTIs A severe UTI requires adequate parenteral fluid replacement and appropriate antimicrobial treatment, preferably with cephalosporins (third generation). If a Gram-positive UTI is suspected by Gram stain, it is useful to administer aminoglycosides in combination with ampicillin or amoxycillin/clavulanate (59) (IIa). Antimicrobial treatment has to be initiated on an empirical basis, but should be adjusted according to culture results as soon as possible. In patients with an allergy to cephalosporins, aztreonam or gentamicin may be used. When aminoglycosides are necessary, serum levels should be monitored for dose adjustment. Chloramphenicol, sulphonamides, tetracyclines, rifampicin, amphotericin B and quinolones should be avoided. The use of ceftriaxone must also be avoided due to its undesired side effect of jaundice. A wide variety of antimicrobials can be used in older children, with the exception of tetracyclines (because of teeth staining). Fluorinated quinolones may produce cartilage toxicity (58), but if necessary may be used as second-line therapy in the treatment of serious infections, since musculoskeletal adverse events are of moderate intensity and transient (60, 61). For a safety period of 24-36 hours, parenteral therapy should be administered. When the child becomes afebrile and is able to take fluids, he/she may be given an oral agent to complete the 10-14 days of treatment, which may be continued on an outpatient basis. This provides some advantages, such as less psychological impact on the child and more comfort for the whole family. It is also less expensive, well tolerated and eventually prevents opportunistic infections (20). The preferred oral antimicrobials are: trimethoprim (TMP), co-trimoxazole (TMP plus sulphamethoxazole), an oral cephalosporin, or amoxycillin/clavulanate. However, the indication for TMP is declining in areas with increasing resistance. In children less than 3 years of age, who have difficulty taking oral medications, parenteral treatment for 7-10 days seems advisable, with similar results to those with oral treatment (62). If there are significant abnormalities in the urinary tract (e.g. VUR, obstruction), appropriate urological intervention should be considered. If renal scarring is detected, the patient will need careful follow-up by a paediatrician in anticipation of sequelae such as hypertension, renal function impairment and recurrent UTI. An overview of the treatment of febrile UTIs in children is given in Figure 3.2 and the dosing of antimicrobial agents is outlined in Table 3.3 (63).
UPDATE MARCH 2009
43
Figure 3.2. Treatment of febrile UTIs in children
Severe UTI
Simple UTI
parental therapy until afebrile • adequate hydration • cephalosporins (third generation) • amoxycillin/clavulanate if cocci are present
oral therapy parenteral single-dose therapy (only in case) of doubtful compliance) • cephalosporins (third generation) • gentamicin
oral therapy to complete 10-14 days of treatment
oral therapy to complete 5-7 days of treatment
• amoxycillin • cephalosporins • trimethoprim
• • • •
daily oral prophylaxis nirofurantoin cefalexin trimethoprim
3.9.2 Simple UTIs A simple UTI is considered to be a low-risk infection in children. Oral empirical treatment with TMP, an oral cephalosporin or amoxycillin/clavulanate is recommended, according to the local resistance pattern. The duration of treatment in uncomplicated UTIs treated orally should be 5-7 days (64, 65) (Ib). A single parenteral dose may be used in cases of doubtful compliance and with a normal urinary tract (66) (IIa). If the response is poor or complications develop, the child must be admitted to hospital for parenteral treatment (67). 3.9.3 Prophylaxis If there is an increased risk of pyelonephritis, e.g. VUR, and recurrent UTI, low-dose antibiotic prophylaxis is recommended (68,69) (IIa). It may also be used after an acute episode of UTI until the diagnostic work-up is completed. The most effective antimicrobial agents are: nitrofurantoin, TMP, cephalexin and cefaclor (68).
44
UPDATE MARCH 2009
3.10
Acknowledgement
With our grateful thanks, the chapter on UTIs in children was updated also by Jorge Caffaratti Sfulcini, Paediatric Urology, Fundació Puigvert, Barcelona, Spain, as co-author. Table 3.3: Dosing of antimicrobial agents in children aged 3 months to 12 years* Antimicrobial agent Ampicillin Ampicillin
Application Intravenous Intravenous
Age 3-12 months 1-12 years
Total dosage per day 100-300 mg/kg BW 60-150 (-300) mg/kg BW
Doses per day 3 3
Amoxycillin Oral
3 months to 12 years
50-100 mg/kg BW
2-3
Amoxycillin/clavulanate Intravenous Amoxycillin/clavulanate Oral Cephalexin Treatment Oral Prophylaxis Oral
3 months to 12 years 3 months to 12 years
60-100 mg/kg BW
3
37.5-75 mg/kg BW
2-3
50-100 mg/kg BW
3
10 mg/kg BW
1-2
3 months to 12 years 1-12 years
Cefaclor • Treatment Oral 3 months to 50-100 mg/kg BW 3 12 years • Prophylaxis Oral 1-12 years 10 mg/kg BW 1-2 Cefixime Oral 3 months to 8-12 mg/kg BW 1-2 12 years Cetriaxone Intravenous 3 months to 50-100 mg/kg BW 1 12 years Aztreonam Intravenous 3 months to (50)-100 mg/kg BW 3 12 years Gentamicin Intravenous 3-12 months 5-7.5 mg/kg BW 1-3 Gentamicin Intravenous 1-2 years 5 mg/kg BW 1-3 Trimethoprim • Treatment Oral 1-12 years 6 mg/kg BW 2 • Prophylaxis Oral 1-12 years 1-2 mg/kg BW 1 Nitrofurantoin • Treatment Oral 1-12 years 3-5 mg/kg BW 2 • Prophylaxis Oral 1-12 years 1mg/kg BW 1-2 BW = body weight. * Adapted from ref. 63.
3.11
REFERENCES
1.
Jodal U. The natural history of bacteriuria in childhood. Infect Dis Clin North Am 1987;1(4):713-29. http://www.ncbi.nlm.nih.gov/pubmed/3333655 Jacobson SH, Eklöf O, Eriksson CG, Lins LE, Tidgren B, Winberg J. Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. BMJ 1989;299(6701):703-6. http://www.ncbi.nlm.nih.gov/pubmed/2508881 Foxman B. Epidemiology of urinary infections: incidence, morbidity, and economic costs. Am J Med 2002;113 Suppl1A:5S-135S. http://www.ncbi.nlm.nih.gov/pubmed/12113866
2.
3.
UPDATE MARCH 2009
45
4. 5. 6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16. 17. 18.
19. 20.
21.
22.
23. 24.
46
Schulman SL. Voiding dysfunction in children. Urol Clin North Am 2004;31(3):481-90, ix. http://www.ncbi.nlm.nih.gov/pubmed/15313057 Shapiro ED. Infections of the urinary tract. Pediatr Infect Dis J 1992;11(2):165-8. http://www.ncbi.nlm.nih.gov/pubmed/1741197 Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1999; 103(4):e39. http://www.ncbi.nlm.nih.gov/pubmed/10103331 Abrahamsson K, Hansson S, Jodal U, Lincoln K. Staphylococcus saprophyticus urinary tract infections in children. Eur J Pediatr 1993;152(1):69-71. http://www.ncbi.nlm.nih.gov/pubmed/8444210 Ma JF, Shortliffe LM. Urinary tract infection in children: etiology and epidemiology. Urol Clin North Am 2004;31(3):517-26, ix-x. http://www.ncbi.nlm.nih.gov/pubmed/15313061 Craig JC, Knight JF, Sureshkuman P, Mantz E, Roy LP. Effect of circumcision on incidence of urinary tract infection in preschool boys. J Pediatr 1996;128(1):23-7. http://www.ncbi.nlm.nih.gov/pubmed/8551417 To T, Agha M, Dick PT, Feldman W. Cohort study on circumcision of newborn boys and subsequent risk of urinary-tract infection. Lancet 1998;352(9143):1813-6. http://www.ncbi.nlm.nih.gov/pubmed/9851381 Fussell EN, Kaack MB, Cherry R, Roberts JA. Adherence of bacteria to human foreskins. J Urol 1988;140(5):997-1001. http://www.ncbi.nlm.nih.gov/pubmed/2902235 Wan J, Kaplinsky R, Greenfield S. Toilet habits of children evaluated for urinary tract infection. J Urol 1995;154(2 Pt 2):797-9. http://www.ncbi.nlm.nih.gov/pubmed/7609183 Yeung CK, Godley ML, Dhillon HK, Gordon I, Duffy PG, Ransley PG. The characteristics of primary vesico-ureteric reflux in male and female infants with pre-natal hydronephrosis. Br J Urol 1997;80(2):319-27. http://www.ncbi.nlm.nih.gov/pubmed/9284209 Lin DS, Huang SH, Lin CC, Tung YC, Huang TT, Chiu NC, Koa HA, Hung HY, Hsu CH, Hsieh WS, Yang DI, Huang FY. Urinary tract infection in febrile infants younger than eight weeks of Age. Pediatrics 2000;105(2):E20. http://www.ncbi.nlm.nih.gov/pubmed/10654980 Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005:18(2):417-22. http://www.ncbi.nlm.nih.gov/pubmed/15831830 Cavagnaro F. [Urinary tract infection in childhood.] Rev Chilena Infectol 2005:22(2):161-8. http://www.ncbi.nlm.nih.gov/pubmed/15891797 Watson AR. Pediatric urinary tract infection. EAU Update Series 2, 2004, pp. 94-100. Koch VH, Zuccolotto SM. [Urinary tract infection: a search for evidence.] J Pediatr (Rio J) 2003;79 Suppl 1: S97-S106. [article in Portuguese] http://www.ncbi.nlm.nih.gov/pubmed/14506522 Hellerstein, S. Urinary tract infection in children: pathophysiology, risk factors and management. Infect Med 2002;19:554-60. Hoberman A, Wald ER. Urinary tract infections in young febrile children. Pediatr Infect Dis J 1997;16(1):11-7. http://www.ncbi.nlm.nih.gov/pubmed/9002094 Devillé WL, Yzermans JC, van Duijn NP, Bezemer PD, van der Windt DA, Bouter LM. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol 2004;4:4. http://www.ncbi.nlm.nih.gov/pubmed/15175113 Wettergren B, Jodal U. Spontaneous clearance of asymptomatic bacteriuria in infants. Acta Paediatr Scand 1990;79(3):300-4. http://www.ncbi.nlm.nih.gov/pubmed/2333743 Stamm WE. Measurement of pyuria and its relation to bacteriuria. Am J Med 1983;75(1B):53-8. http://www.ncbi.nlm.nih.gov/pubmed/6349345 Landau D, Turner ME, Brennan J, Majd M. The value of urinalysis in differentiating acute pyelonephritis from lower urinary tract infection in febrile infants. Pediatr Infect Dis J 1994;13(9):777-81. http://www.ncbi.nlm.nih.gov/pubmed/7808845
UPDATE MARCH 2009
25.
26. 27.
28.
29.
30.
31.
32. 33.
34. 35.
36.
37.
38.
39.
40.
41.
42.
43.
Hoberman A, Chao HP, Keller DM, Hickey R, Davis HW, Ellis D. Prevalence of urinary tract infection in febrile infants. J Pediatr 1993;123(1):17-23. http://www.ncbi.nlm.nih.gov/pubmed/8320616 Piercey KR, Khoury AE, McLorie GA, Churchill BM. Diagnosis and management of urinary tract infections. Curr Opin Urol 1993;3:25-9. antausch BA, Rifai N, Getson P, Akram S, Majd M, Wiedermann BL. Urinary N-acetylbetaglucosaminidase and beta-2-microglobulin in the diagnosis of urinary tract infection in febrile infants. Pediatr Infect Dis J 1994;13(4):294-9. http://www.ncbi.nlm.nih.gov/pubmed/8036046 Benson M, Jodal U, Andreasson A, Karlsson A, Rydberg J, Svanborg C. Interleukin 6 response to urinary tract infection in childhood. Pediatr Infect Dis J 1994;13(7):612-6. http://www.ncbi.nlm.nih.gov/pubmed/7970949 Kass EJ, Fink-Bennett D, Cacciarelli AA, Balon H, Pavlock S. The sensitivity of renal scintigraphy and sonography in detecting nonobstructive acute pyelonephritis. J Urol 1992;148(2 Pt 2):606-8. http://www.ncbi.nlm.nih.gov/pubmed/1640534 Pickworth FE, Carlin JB, Ditchfield MR, de Campo MP, de Campo JF, Cook DJ, Nolan T, Powell HR, Sloane R, Grimwood K. Sonographic measurement of renal enlargement in children with acute pyelonephritis and time needed for resolution: implications for renal growth assessment. AJR Am J Roentgenol 1995;165(2):405-8. http://www.ncbi.nlm.nih.gov/pubmed/7618567 Kangarloo H, Gold RH, Fine RN, Diament MJ, Boechat MI. Urinary tract infection in infants and children evaluated by ultrasound. Radiology 1985;154(2):367-73. http://www.ncbi.nlm.nih.gov/pubmed/3880909 Kass EJ. Imaging in acute pyelonephritis. Curr Opin Urol 1994;4:39-44. Stutley JE, Gordon I. Vesico-ureteric reflux in the damaged non-scarred kidney. Pediatr Nephrol 1992;6(1):25-9. http://www.ncbi.nlm.nih.gov/pubmed/1311185 Britton KE. Renal radionuclide studies. In: Whitfield HN, Hendry WF, Kirby RS, Duckett JW, eds. Textbook of genitourinary surgery. Oxford: Blackwell Science, 1998; pp. 76-103. Rosenberg AR, Rossleigh MA, Brydon MP, Bass SJ, Leighton DM, Farnsworth RH. Evaluation of acute urinary tract infection in children by dimercaptosuccinic acid scintigraphy: a prospective study. J Urol 1992;148(5 Pt 2):1746-9. http://www.ncbi.nlm.nih.gov/pubmed/1331546 Jakobsson B, Söderlundh S, Berg U. Diagnostic significance of 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy in urinary tract infection. Arch Dis Child 1992;67(11):1338-42. http://www.ncbi.nlm.nih.gov/pubmed/1335226 Rushton HG, Majd M, Jantausch B, Wiedermann BL, Belman AB. Renal scarring following reflux and nonreflux pyelonephritis in children: evaluation with 99mtechnetium-dimercaptosuccinic acid scintigraphy. J Urol 1992;147(5):1327-32. http://www.ncbi.nlm.nih.gov/pubmed/1314912 Ransley PG, Risdon RA. Renal papillary morphology in infants and young children. Urol Res 1975;3(3):111-3. http://www.ncbi.nlm.nih.gov/pubmed/1189138 Risdon RA. The small scarred kidney of childhood. A congenital or an acquired lesion. Pediatr Nephrol 1987;1(4):632-7. http://www.ncbi.nlm.nih.gov/pubmed/3153344 Risdon RA, Godley ML, Parkhouse HF, Gordon I, Ransley PG. Renal pathology and the 99mTcDMSA image during the evolution of the early pyelonephritic scar: an experimental study. J Urol 1994;151(3):767-73. http://www.ncbi.nlm.nih.gov/pubmed/8309003 Jakobsson B, Svensson L. Transient pyelonephritic changes on 99mTechnetium-dimercaptosuccinic acid scan for at least five months after infection. Acta Paediatr 1997;86(8):803-7. http://www.ncbi.nlm.nih.gov/pubmed/9307157 Rushton HG, Majd M, Chandra R, Yim D. Evaluation of 99mtechnetium-dimercaptosuccinic acid renal scans in experimental acute pyelonephritis in piglets. J Urol 1988;140(5 Pt 2):1169-74. http://www.ncbi.nlm.nih.gov/pubmed/2846898 Bircan ZE, Buyan N, Hasano ˘ glu E, Oztürk E, Bayhan H, I ,sik S. Radiologic evaluation of urinary tract infection. Int Urol Nephrol 1995;27(1):27-32. http://www.ncbi.nlm.nih.gov/pubmed/7615367
UPDATE MARCH 2009
47
44.
45.
46.
47.
48.
49.
50.
51.
52.
53. 54.
55.
56.
57.
58.
59. 60.
61.
62.
48
Elison BS, Taylor D, Van der Wall H, Pereira JK, Cahill S, Rosenberg AR, Farnworth RH, Murray IP. Comparison of DMSA scintigraphy with intravenous urography for the detection of renal scarring and its correlation with vesicoureteric reflux. Br J Urol 1992;69(3):294-302. http://www.ncbi.nlm.nih.gov/pubmed/1314684 MacKenzie JR, Fowler K, Hollman AS, Tappin D, Murphy AV, Beattie TJ, Azmy AF. The value of ultrasound in the child with an acute urinary tract infection. Br J Urol 1994;74(2):240-4. http://www.ncbi.nlm.nih.gov/pubmed/7921944 Mucci B, Maguire B. Does routine ultrasound have a role in the investigation of children with urinary tract infection? Clin Radiol 1994;49(5):324-5. http://www.ncbi.nlm.nih.gov/pubmed/8013196 Westwood ME, Whiting PF, Cooper J, Watt IS, Kleijnen J. Further investigation of confirmed urinary tract infection (UTI) in children under five years: a systematic review. BMC Pediatr 2005;5(1):2. http://www.ncbi.nlm.nih.gov/pubmed/15769296 Haycock GB. A practical approach to evaluating urinary tract infection in children. Pediatr Nephrol 1991;5(4):401-2. http://www.ncbi.nlm.nih.gov/pubmed/1654977 Kleinman PK, Diamond BA, Karellas A, Spevak MR, Nimkin K, Belanger P. Tailored low-dose fluoroscopic voiding cystourethrography for the reevaluation of vesicoureteral reflux in girls. AJR Am J Roentgenol 1994;162(5):1151-6. http://www.ncbi.nlm.nih.gov/pubmed/8166001 Kass EJ, Kernen KM, Carey JM. Paediatric urinary tract infection and the necessity of complete urological imaging. BJU Int 2000;86(1):94-6. http://www.ncbi.nlm.nih.gov/pubmed/10886091 De Sadeleer C, De Boe V, Keuppens F, Desprechins B, Verboven M, Piepsz A. How good is technetium-99m mercaptoacetyltriglycine indirect cystography? Eur J Nucl Med 1994;21(3):223-7. http://www.ncbi.nlm.nih.gov/pubmed/8200390 Piaggio G, Degl’ Innocenti ML, Tomà P, Calevo MG, Perfumo F. Cystosonography and voiding cystourethrography in the diagnosis of vesicoureteral reflux. Pediatr Nephrol 2003;18(1):18-22. http://www.ncbi.nlm.nih.gov/pubmed/12488985 Vela Navarrete R. [Urinary tract infections in children.] In: Tratado de urología tomo I. Jiménez Cruz JF, Rioja LA, eds. Barcelona: Ed Prous, 1993; pp. 499-507. [article in Spanish] Huang JJ, Sung JM, Chen KW, Ruaan MK, Shu GH, Chuang YC. Acute bacterial nephritis: a clinicoradiologic correlation based on computer tomography. Am J Med 1992;93(3):289-98. http://www.ncbi.nlm.nih.gov/pubmed/1524081 Majd M, Rushton HG, Jantausch B, Wiedermann BL. Relationship among vesicoureteral reflux, Pfimbriated Escherichia coli, and acute pyelonephritis in children with febrile urinary tract infection. J Pediatr 1991;119(4):578-85. http://www.ncbi.nlm.nih.gov/pubmed/1681043 Melis K, Vandevivere J, Hoskens C, Vervaet A, Sand A, Van Acker KJ. Involvement of the renal parenchyma in acute urinary tract infection: the contribution of 99mTc dimercaptosuccinic acid scan. Eur J Pediatr 1992;151(7):536-9. http://www.ncbi.nlm.nih.gov/pubmed/1327798 Smellie JM, Rigden SP. Pitfalls in the investigation of children with urinary tract infection. Arch Dis Child 1995;72(3):251-8. http://www.ncbi.nlm.nih.gov/pubmed/7741579 Smellie JM, Rigden SP, Prescod NP. Urinary tract infection: a comparison of four methods of investigation. Arch Dis Child 1995;72(3):247-50. http://www.ncbi.nlm.nih.gov/pubmed/7741578 Broseta E, Jimenez-Cruz JF. [Urinary tract infection in children.] In: Broseta E, Jimenez-Cruz JF, eds. Infeccion urinaria. Madrid: Ed Aula Medica, 1999; pp. 185-194. [article in Spanish] Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 2003;22(12):1128-32. http://www.ncbi.nlm.nih.gov/pubmed/7741578 [No authors listed.] Fluoroquinoles in children: poorly defined risk of joint damage. Prescrire Int 2004;13(73):184-6. http://www.ncbi.nlm.nih.gov/pubmed/15499700 Bloomfield P, Hodson EM, Craig JC. Antibiotics for acute pyelonephritis in children. Cohrane Database Syst Rev 2005;(1):CD003772. http://www.ncbi.nlm.nih.gov/pubmed/15674914
UPDATE MARCH 2009
63. 64.
65.
66.
67.
68.
69.
Deutsche Gesellschaft für pädiatrische Infektiologie e.V. (DGPI) (ed). [Textbook for infections in children and adolescents.] 4th edn. Futuramed: Munich, 2003, pp. 148-157. [article in German] Michael M, Hodson EM, Craig JC, Martin S, Moyer VA. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database Syst Rev 2003;(1):CD003966. http://www.ncbi.nlm.nih.gov/pubmed/12535494 Tran D, Muchant DG, Aronoff SC. Short-course versus conventional length antimicrobial therapy for uncomplicated lower urinary tract infections in children: a meta-analysis of 1279 patients. J Pediatr 2001;139(1):93-9. http://www.ncbi.nlm.nih.gov/pubmed/11445800 Khan AJ. Efficacy of single-dose therapy of urinary tract infection in infants and children: a review. J Nalt Med Assoc 1994;86(9):690-6. http://www.ncbi.nlm.nih.gov/pubmed/7966433 Hellerstein S. Urinary tract infections. Old and new concepts. Pediatr Clin North Am 1995;42(6): 1433-57. http://www.ncbi.nlm.nih.gov/pubmed/8614594 Smellie JM, Gruneberg RN, Bantock HM, Prescod N. Prophylactic co-trimoxazole and trimethoprim in the management of urinary tract infection in children. Pediatr Nephrol 1988;2(1):12-7. http://www.ncbi.nlm.nih.gov/pubmed/3152984 Arant BS Jr. Vesicoureteral reflux and evidence-based management. J Pediatr 2001;139(5):620-1. http://www.ncbi.nlm.nih.gov/pubmed/11713435
4. UTIs IN RENAL INSUFFICIENCY, TRANSPLANT RECIPIENTS, DIABETES MELLITUS AND IMMUNOSUPPRESSION 4.1
Summary
4.1.1 Acute effects of UTI on the kidney In acute pyelonephritis very dramatic changes can occur with focal reduction in perfusion on imaging and corresponding renal tubular dysfunction. However, if in the adult, the kidney is normal beforehand, chronic renal damage is most unlikely. There is no evidence that more prolonged or intensive antibiotic treatment of acute pyelonephritis will shorten the episode or prevent complications. In diabetes mellitus, overwhelming infection can predispose to pyogenic infection with intrarenal perinephric abscess formation, emphysematous pyelonephritis, and, very rarely, a specific form of infective interstitial nephropathy. Papillary necrosis is a common consequence of pyelonephritis in diabetics. Females are more prone to asymptomatic bacteriuria than diabetic men but in both sexes progression to clinical pyelonephritis is more likely than in normal individuals. The risk factors for developing asymptomatic bacteriuria differ between type I and type II diabetes. It is arguable that diabetic patients are susceptible to rapid progression of parenchymal infection. However, the clearance of asymptomatic bacteriuria should not be attempted if the intention is to prevent complications, notably acute pyelonephritis (A). 4.1.2 Chronic renal disease and UTI There are several factors of general potential importance predisposing to infection in uraemia, including the loss of several urinary defence mechanisms and a degree of immunosuppression. Typically, adult polycystic kidney disease (APCKD), gross vesicoureteric reflux (VUR) and endstage obstructive uropathy will harbour infective foci or promote ascending infection, but not invariably so. Clearly, severe urinary tract infection (UTI) with accompanying bacteraemia can hasten progression of renal failure, but there is little evidence that vigorous treatment of lesser degrees of infection or prophylaxis will slow renal functional impairment once it is established (C). In patients with VUR and UTI in endstage chronic renal failure bilateral nephroureterectomy should only be undertaken as a last resort (B). 4.1.2.1 Adult polycystic kidney disease (APCKD) In patients with acute pyelonephritis and infected cysts (presenting as recurrent bacteraemia or ‘local sepsis’) treatment requires a long course of high-dose systemic fluoroquinolones, followed by prophylaxis. Bilateral
UPDATE MARCH 2009
49
nephrectomy should be utilized as a last resort (B). 4.1.2.2 Calculi and UTI Management is similar to that for patients without renal impairment, i.e. to clear the stones if possible and to minimize antibiotic treatment if the calculus cannot be removed. Nephrectomy should be performed as a last resort, but even residual renal function may be of vital importance (B). 4.1.2.3 Obstruction and UTI As in all other situations, the combination of obstruction and infection is dangerous and should be treated vigorously. Obstruction may be covert and require specific diagnostic tests, e.g. video-urodynamics, upper tract pressure flow studies. 4.1.3 UTI in renal transplantation and immunosuppression The need to correct uropathy or to remove a potential focus of infection in a diseased endstage kidney is more pressing in a patient enlisted for renal transplantation. Even so, the results of nephrectomy for a scarred or hydronephrotic kidney may be disappointing. Immunosuppression is of secondary importance, although if this is extreme, immunosuppression will promote, at least, persistent bacteriuria, which may become symptomatic. In the context of renal transplantation, UTI is very common, but immunosuppression is only one of many factors which are mainly classified as ‘surgical’. HIV infection is associated with acute and chronic renal disease, possibly through the mechanisms of thrombotic microangiopathy and immune mediated glomerulonephritis. Steroids, angiotensin-converting enzyme (ACE) inhibitors and highly active retroviral therapy appear to have reduced progression to endstage renal disease. 4.1.4 Antibiotic treatment for UTI in renal insufficiency and after renal transplantation The principles of antibiotic treatment for UTI in the presence of renal impairment, during dialysis treatment and after renal transplantation, is discussed in the text and summarized in Tables 3.1-3.4.
4.2
Background
Whenever UTI is present in patients with renal insufficiency, problems arise in both the treatment of infection and the management of the renal disease. There are also important scientific issues to be considered concerning the cause, special susceptibilities, effects and complications of renal parenchymal infection, particularly in the immunosuppressed patient. This part of the guidelines can be subdivided into four sections. 1. What are the acute effects of UTI on the kidney and do the lesions become chronic? 2. Does chronic renal disease progress more quickly as a result of infection and do particular renal diseases predispose to UTI? 3. Are immunosuppressed patients prone to UTI particularly in the context of renal transplantation? Is UTI a significant cause of graft failure? 4. Which problems arise in antibiotic therapy in patients with renal insufficiency and after renal transplantation?
4.3
Acute effects of UTI on the kidney
Some authors regard acute pyelonephritis as ‘complicated’ because in their view it may cause renal scarring in a previously normal kidney (1,2) (IIa). Pathologically, a similar process may occur in such fundamentally different situations as obstructive and reflux nephropathies, although the distribution and extent of the lesions may be different (3-5) (IIa). 4.3.1 Vesicoureteric and intrarenal reflux The effects of VUR and intrarenal reflux on the renal parenchyma and the contribution of ascending infection are still unresolved. Renal scarring can certainly be acquired as a result of these three factors, although, in almost all cases, this usually occurs very early in life. In this narrow age range, developmental renal dysplasia must be a major consideration in the pathogenesis of chronic pyelonephritis. Although acute infection is important in the early stages of this disease, the status of either recurrent acute urinary infection or asymptomatic bacteriuria specifically in the progression of scar formation is tenuous. Prophylactic antibiotics will therefore offer little benefit in preserving renal tissue in reflux nephropathy in the older child and adult, even if the reflux has not already been successfully treated (6) (A). However, further discussion of reflux nephropathy is beyond the scope of these guidelines.
50
UPDATE MARCH 2009
4.3.2 Obstructive neuropathy Obstruction occurring through a voiding disorder or supravesically causes renal tubular dysfunction and ultimately renal damage, mainly through the process of apoptosis. Infection enhances the process of parenchymal loss. In extreme cases, pyonephrosis, perinephric abscess and widespread systemic sepsis will develop. Obstruction has to be cleared if infection is to be eradicated (7) (A). A detailed discussion of obstructive nephropathy is not appropriate here, but the kidney which is permanently damaged from any cause will have less reserve to withstand the effects of reflux, obstruction and infection. In any circumstances, the combination of obstruction and infection is a surgical emergency and both must be relieved without delay. It is sometimes difficult to exclude an element of obstruction when discussing the pathogenesis of putative infective renal damage in the alleged normal kidney. Urinary calculi and pregnancy can cause urinary stasis and an intermittent increase in pressure in the upper tracts, which can cause subtle and persistent damage. 4.3.3 Renal effects of severe UTI Severe infection can lead to renal functional impairment through sepsis, endotoxaemia, hypotension and poor renal perfusion, as part of the process of multiorgan failure. The presence of renal calculi and diabetes mellitus will further reduce host defences (8). 4.3.4 Acute effects of UTI on the normal kidney The acute effects of UTI on the normal kidney are complex. They are worth reviewing as they may provide a lead in deciding how chronic changes can occur and therefore a basis for the development of guidelines on the prevention of renal damage. Escherichia coli is the commonest of the Gram-negative organisms isolated in the majority of patients with acute pyelonephritis. The proportion of infections caused by E. coli is lower in adults than children (69% vs 80%) (9) (IIb). Virulent organisms cause direct cellular injury, usually after colonizing the renal pelvis. Damage can also occur indirectly from the effects of inflammatory mediators. Metastatic infection will rarely cause renal infection, presenting as cortical abscesses and usually only in susceptible individuals (see the sections below on Diabetes mellitus and Immunosuppression) (10). Bacterial infection in the urinary tract can induce fever and elevate acute phase reactants, such as C-reactive protein and erythrocyte sedimentation rate (ESR). Bacterial infection also elicits immunoglobulin A and cytokine responses (11) (IIb). In particular, serum levels of interleukin-6 (IL-6) and interleukin-8 (IL-8) are elevated (12, 13) (IIb). Tissue damage is reflected by urinary secretion of tubular proteins and enzymes, such as α2-macroglobulin, ß2-microglobulin and N-acetyl-ß-D-glucosaminadase enzyme (NDMA). In functional terms, there may be a loss of concentrating power which can persist long term (14, 15) (IIb). The fact that there is a serological immune response and bacteria become coated with antibodies to various antigenic components of the micro-organism is regarded as evidence of an immune response and therefore of exposure to microorganisms which are potentially damaging to the renal parenchyma (16) (IIb). There are many identifiable factors relating to virulence of the bacterial cell and to its ability to adhere to the mucosa as a preliminary to invasion (17). For example, type 1 pili or fimbriae will combine with mannose receptors on the uromucoid, which is part of the protective mucopolysaccharide layer found on uroepithelial cells lining the urinary tract. Type 2 or P fimbriae bind to glycolipids of the blood group substances which are secreted by the host urothelium. In practical terms, E. coli micro-organisms which are pathological to the kidney appear to express P (or pyelonephritis-associated) or type 2 fimbriae, at least in children where 90% of individuals with acute pyelonephritis express these micro-organisms compared with a much smaller proportion of those who have had cystitis or asymptomatic bacteriuria (18) (IIb). Bacterial adhesion may be of variable benefit to the micro-organism, as its attachment may mean that it is easier for host defence mechanisms to localize and abolish it (19). The cellular and humeral inflammatory host response is also a critical part of host defence. Various cytokines (e.g. IL-6, IL-8) are responsible for inducing leucocyte migration and may be intrinsically deficient in converting asymptomatic bacterial colonization to clinical infection. Paradoxically, reduced adhesiveness can facilitate silent penetration into the renal parenchyma. In a Swedish study, a group of 160 patients who had recently suffered an acute UTI all developed reduced concentrating power, even though a significant proportion (40%) did not develop a febrile illness. In the majority of these patients, the infiltrating bacteria had reduced adhesive characteristics, perhaps facilitating their penetration into the renal parenchyma and promoting more permanent structural and functional damage (15) (IIb). 4.3.5 Renal scarring The possible development of scarring, as a result of UTI in the absence of reflux, obstruction or calculi, is
UPDATE MARCH 2009
51
controversial (20) (IIa). It is agreed that dramatic reduction in renal perfusion and excretion can occur acutely and so-called ‘lobar nephronia’ has been demonstrated with the newer methods of imaging, such as CT or dimercaptosuccinic acid (DMSA) scanning, but not with standard intravenous urography (IVU). A study has shown that 55% of patients with no pre-existing lesions developed acute parenchymal lesions during an episode of acute pyelonephritis (2) (IIa). These lesions were found to have persisted 3-6 months later at follow-up in 77% of patients (9) (III). An earlier study by Alwall (21) described 29 women followed for 20-30 years with evidence of increasing renal damage and chronic pyelonephritis upon biopsy (III). As this study would have used cruder diagnostic techniques, which might not have identified pre-existing disease, patients may have had renal damage initially. Over such a long period, it was impossible to exclude other causes of renal impairment and interstitial nephropathy, e.g. analgesic abuse. This important issue is clarified by a recent more critical study of DMSA scanning during the acute phase of acute pyelonephritis. In the study, 37 of 81 patients had one or more perfusion defects, of which the majority resolved within 3 months. In lesions that persisted, further imaging invariably showed evidence of reflux or obstructive nephropathy that must have predated the acute infective episode (22) (IIa). In summary, small parenchymal scars demonstrated by modern imaging may develop as a result of acute non-obstructive pyelonephritis. However, such patients do not develop chronic renal failure and the scar is a very different lesion from the typical scar of reflux nephropathy. This is reflected in clinical experience. Thus, in acute pyelonephritis, IVU or DMSA scanning during an acute urinary infection can have very alarming and dramatic results, but in practical terms the observed changes will mostly resolve. The poor correlation between the severity of the symptoms in an episode of acute pyelonephritis and the risk of permanent damage, which is very small, should discourage the clinician from prescribing excessive antibiotic treatment beyond that needed to suppress the acute inflammatory reaction (A). In the future, the rare occurrence of renal damage apparently arising from acute or recurrent uncomplicated UTI may be prevented by targeting long-term treatment at selected patients. These patients will have been identified as having an intrinsic genetic defect in the host response of cytokine release to infection. Such a genetic defect would be even more important if a patient also had structural abnormalities causing complicated UTI. 4.3.6 Specific conditions in which an acute UTI causes renal damage There are several specific conditions in which acute UTI can cause renal damage: 4.3.6.1 Diabetes mellitus Asymptomatic bacteriuria is common in diabetic women. In a prospective study of non-pregnant women with diabetes mellitus, 26% had significant bacteriuria (> 105 cfu/mL) compared with 6% of controls. Women with type I diabetes were particularly at risk if they had had diabetes for a long time or complications had developed, particularly peripheral neuropathy and proteinuria. Risk factors in patients with type II diabetes were old age, proteinuria, a low body mass index and a past history of recurrent UTIs (23) (IIa). Diabetes mellitus increases the risk of acute pyelonephritis from infection by Enterobacteriaceae originating in the lower urogenital tract. Klebsiella infection is particularly common (25% compared with 12% in non-diabetics). Asymptomatic bacteriuria is common in female diabetics (though not in males). If left untreated, it may lead to renal functional impairment (24). The mechanism is ill-understood and, as in uncomplicated acute pyelonephritis, a direct causal link is dubious. Other subtle factors may be present, such as an underlying diabetic nephropathy (25) and autonomic neuropathy causing voiding dysfunction. Impaired host resistance is thought to predispose to the persistence of nephropathogenic organisms, but specific evidence is lacking for the development of renal complications. Glycosuria inhibits phagocytosis and perhaps cellular immunity and encourages bacterial adherence. However, diabetic women with asymptomatic bacteriuria can have good glycaemic control, but still show reduced urinary cytokine and leucocyte concentration (although polymorph function is normal). Interestingly, poor glycaemic control has not been shown to increase the risk of bacteriuria (26). It has always been recognized that diabetic patients are particularly susceptible to rapid progression of renal parenchymal infection and ensuing complications. Until recently, there was no consensus on the questions of pre-emptive screening, treatment and prophylaxis of asymptomatic bacteriuria. However, these issues have been addressed in a placebo-controlled double-blind randomized trial (27) (Ib), which concluded that treatment did not reduce complications and diabetes should not therefore be regarded as an indication for screening or treatment of asymptomatic bacteriuria. The findings from this trial were subsequently recognized in the guidelines published by the Infectious Diseases Society of America (IDSA) on the diagnosis and treatment of asymptomatic bacteriuria in general (28).
52
UPDATE MARCH 2009
Diabetic patients are also prone to an under-reported and probably unusual form of infective interstitial nephritis, which is sometimes infected by gas-forming organisms, with a high mortality (emphysematous pyelonephritis) (29). This is characterized histologically by acute pyogenic infiltrate with microabscesses and the development of acute renal failure. The origin of the organisms may be haematogenous. Even in the absence of obstruction, acute parenchymal infection may progress insidiously to form an intrarenal abscess which ruptures leading to a perinephric collection and a psoas abscess. The presentation can occasionally be quite indolent. Papillary necrosis is common in diabetics, particularly in association with acute pyelonephritis. It is certainly associated with permanent renal parenchymal scarring, although it is difficult to exclude obstruction by the sloughed papillae as the cause of the nephropathy. Antibiotic prophylaxis in the treatment of asymptomatic bacteriuria is probably required (C). 4.3.6.2 Tuberculosis Tuberculosis can cause both acute and chronic renal damage through bilateral renal infiltration. Rarely, this can lead to endstage renal failure. However, a more subtle form of interstitial granulomatous disease can occur, which is sufficient to cause renal failure in the absence of fibrosis, calcification or obstruction (30,31) (III) Tuberculosis and leprosy can cause renal damage through the development of amyloid and also of a form of proliferative glomerulonephritis (32, 33). (IIb). For more details see EAU guidelines on genitourinary tuberculosis (34).
4.4
Chronic renal disease and UTI
There are good reasons why all uraemic patients should be prone to UTI and why UTI should increase the rate of deterioration of function. The antibacterial properties of normal urine, due to urea or low pH and high osmolality, may be lost (35). Uraemic patients are also mildly immunosuppressed and the formation of protective uroepithelial mucus may be inhibited (36-38) (IIb). However, apart from a few exceptions, there is little evidence for a causal relationship between preexisting chronic renal disease and persisting UTI (7). The results of removing a scarred or hydronephrotic kidney in the hope of curing infection are often disappointing. The few exceptions include the following. 4.4.1 Adult dominant polycystic kidney disease (ADPK) Urinary tract infection is a prominent complication of ADPK, with symptomatic UTI being the presenting feature in 23-42% of patients, who are usually female (39). It may be difficult to obtain a positive culture on standard laboratory media, but pyuria is common, particularly in the later stages of disease progression. Acute pyelonephritis is common and may originate from pyogenic infection in the cysts (40) (III). The efficacy of antibiotic treatment may depend on whether cysts are derived from proximal (active secretion) or distal tubules (passive diffusion) and on the liposolubility of the agent used. Cephalosporins, gentamicin and ampicillin, which are standard treatments of acute pyelonephritis and require active transport, are often ineffective (41) (IIb). Fluoroquinolones are generally the most effective (A). After transplantation, overall graft and patient survival rates do not differ between ADPK and control groups (42) (IIa). However, despite close monitoring of patients, UTI and septicaemic episodes are still a significant cause of morbidity, so that bilateral nephrectomy may be the only option. Polycystic disease is not to be confused with acquired renal cystic disease of the endstage kidney which has no predisposition to UTI. The issue of whether urological complications including UTI affect the progression of renal failure in polycystic disease or in any other renal pathology is controversial. Severe symptomatic UTI may indicate an adverse prognosis, particularly in males with ADPK. 4.4.2 Renal calculi Nephrolithiasis, particularly from infective struvite stones, obstructive uropathy and gross reflux, clearly do promote infection, although not always so. However, it is doubtful whether vigorous treatment of asymptomatic bacteriuria or even mild clinical UTI will make any difference to the progression of renal disease (43) (III). It is disappointing that, as yet, there are few studies providing long-term serial data identifying renal damage and its causal relationship with infection. In this respect, it is of some interest that a study of 100 patients undergoing reflux prevention surgery at least 20 years before has recently been published (44). It was concluded that even patients whose reflux prevention surgery had been successful were prone to recurrent UTI, hypertension and complications, which even occasionally included progressive renal scarring. Such consequences should at least inform the patient’s decision in deciding between surgical and medical treatment of VUR.
UPDATE MARCH 2009
53
4.5
UTI in renal transplantation
Urinary tract infection is common after renal transplantation. Bacteriuria is present in 35-80% of patients, although the risk has been reduced by improvements in donation surgery, which have lowered the dose of immunosuppressive therapy and of prophylactic antibiotics (45). 4.5.1 Donor organ infection Early factors predisposing to UTI include infection in the transplanted kidney. Clearly, the organ donor should be screened for a variety of viral and bacterial infections. Detailed discussion of this process is beyond the limits of these guidelines. However, it must be acknowledged that the urinary tract of the cadaver donor is rarely investigated, even if the mid-stream urine (MSU) culture is positive. Antibiotics are given empirically, but usually the first suspicion of occurrence of a renal tract abnormality is raised during the organ donation operation. Under these circumstances, only the most obvious renal or ureteric abnormality will be detected. Very occasionally, organ donation will be abandoned at this late stage. After the kidney is removed from its storage box, the effluent from the renal vein and surrounding fluid in the sterile plastic bags containing the excised kidney should ideally be cultured as micro-organisms are likely to have been introduced during the donation process. Bladder catheters and ureteric stents promote the loss of the glycosoaminoglycan layer from the uroepithelium, as well as providing a source of micro-organism within the mucous biofilm covering the foreign body. Infection in the native kidneys may worsen considerably as a result of maximum immunosuppression. In patients with a renal transplant the following problems are most troublesome: papillary necrosis, particularly in diabetes mellitus (46), massive infective VUR, polycystic disease and infective calculi. There is also concern about the increasing number of children with congenital uropathies, often associated with neuropathic bladder dysfunction and the sinister combination of intravesical obstruction, poor bladder compliance, residual urine and VUR. A full urodynamic assessment, establishing a routine of intermittent self-catheterization and any necessary bladder surgery must be completed well in advance of renal transplantation. Urinary diversions and bladder augmentation and substitution have also been successfully completed in patients on dialysis treatment and after transplantation, though bacteriuria is common and may require antibiotic treatment (47). In the first 3 months, UTI is more likely to be symptomatic with a high rate of relapse. Later on, there is a lower rate of pyelonephritis and bacteraemia and a better response to antibiotics unless there are urological complications (e.g. fistula, obstruction). Infarction, either of the whole kidney or of a segment due to arterial damage, can promote UTI through bacterial colonization of dead tissue. This often occurs by commensal or fastidious pathogens. The infection may be impossible to eradicate until the kidney or at least the dead segment is removed. 4.5.2 Graft failure There are several potential mechanisms by which severe UTI can cause graft failure. There was an early suggestion that reflux into the graft could lead to pyelonephritis and parenchymal scarring. However, these findings have not been confirmed and most surgeons do not make a special effort to perform an antireflux anastomosis. Infection can theoretically induce graft failure by three other mechanisms, such as by the direct effect of cytokines, growth factors (e.g. tumour necrosis factor) and free radicals as part of the inflammation cascade (45). Urinary tract infections can also reactivate cytomegalovirus infection, which can lead to acute transplant rejection. Sometimes it can be very difficult to distinguish rejection from infection (48) (IIb). For many years, the polyomavirus type BK has been listed as a possible candidate for causing transplant ureteric stenosis. Improved detection of so-called ‘decoy cells’ in urine and of virus DNA by polymerase chain reaction has confirmed the causal relationship between infection and obstruction, but also with interstitial nephropathy progressing to graft loss in possibly 5% of recipients. The virus is susceptible to treatment with an antiviral agent (cidofovir) (49) (IIa). 4.5.3 Kidney and whole-organ pancreas transplantation Simultaneous kidney and whole-organ pancreas transplantation can present specific urological complications when the bladder is chosen for drainage of exocrine secretions. These may include recurrent UTI, chemical urethritis and bladder calculi of sufficient severity to warrant cystoenteric conversion. The risk of such complications is minimized if urodynamic abnormalities, e.g. obstruction, are identified and corrected well in advance of the transplant procedure (50) (III).
4.6
Antibiotic therapy in renal failure/transplantation
Much of the detailed information on antibiotic prescribing in renal failure is summarized in Tables 4.1-4.5 and appendix 14.3. It is important to note that peritoneal dialysis and haemodialysis will clear certain antibiotics,
54
UPDATE MARCH 2009
which should either be avoided or given in much higher dosage. Secondly, there are important interactions to consider between immunosuppressive agents and antibiotics. Table 4.1: Use of antibiotics for UTI with renal impairment • Most antibiotics have a wide therapeutic index. No adjustment of dose is necessary until GFR < 20 mL/min, except antibiotics with nephrotoxic potential, e.g. aminoglycoside • Drugs removed by dialysis should be administered after a dialysis treatment • Combination of loop diuretics, e.g. furosemide and a cephalosporin, is nephrotoxic • Nitrofurantoin and tetracyclines are contraindicated, but not doxycyclin GFR = glomerular filtration rate. Table 4.2: Clearance of antibiotics at haemodialysis Dialyzed Slightly dialyzed Not dialyzed Amoxycillin/ampicillin Fluoroquinolones* Amphotericin Carbenicillin Co-trimoxazole Methicillin Cephalosporins* Erythromycin Teicoplanin Aminoglycosides* Vancomycin Trimethoprim Metronidazole Aztreonam* Fluconazole* * Drugs cleared by peritoneal dialysis. Table 4.3: Treatment of tuberculosis in renal failure Rifampicin and INAH not cleared by dialysis. Give pyridoxine. Ethambutol not dialyzed. Reduce dose if GFR < 30 mL/min Avoid rifampicin with cyclosporine
Table 4.4: Recommendations for prevention and treatment of UTI in renal transplanation • Treat infection in recipient before transplantation • Culture donor tissue sample and perfusate • Perioperative antibiotic prophylaxis. • 6-month low-dose TMP-SMX (co-trimoxazole) (IbA) • Empirical treatment of overt infection (quinolone, TMP-SMX for 10-14 days) TMX = trimethoprim-sulphamethoxazole. Table 4.5: Drug interactions with cyclosporin and tacrolimus Rifampicin Erythromycin Aminoglycosides TMP-SMX Amphotericin B TMP-SMX = trimethoprim-sulphamethoxazole. 4.6.1 Treatment of UTI in renal transplant recipients The treatment of a symptomatic UTI is similar to treatment given to non-transplant patients. However, a short course of treatment has yet to be established and in most cases a 10-14 day course of treatment will be given. The choice of antibiotic is dictated by the special need for penetration into the renal parenchyma rather than for merely a ‘mucosal’ antibiotic. Fluoroquinolones seem to be particularly effective. There is good evidence for the beneficial effects of treating asymptomatic bacteriuria in the first 6 months after renal transplantation (51) (IIa). Patients must be investigated for a surgical complication. In most units, the combination of trimethoprim and sulphamethoxazole (TMP-SMX, co-trimoxazole) is effective in preventing UTI (52) (Ib). It will also prevent Pneumocystis carinii pneumonia (PCP) and infection with
UPDATE MARCH 2009
55
other rare fastidious organisms. Low-dose antibiotic prophylaxis with co-trimoxazole has been recommended for 6 months after transplantation. This will cover the high-risk period when infection is more likely to be symptomatic and associated with acute graft impairment. At a low dose, adverse interactions with cyclosporin do not occur, although the higher dose advocated by some units will result in synergistic nephrotoxicity with trimethoprim. A number of other drug interactions need to be considered, e.g. gentamicin, TMP-SMX and amphotericin B promote cyclosporin and tacrolimus toxicity. Rifampicin and eythromycin also interact with calcineurin inhibitors by increasing cytochrome p450 synthetase and inhibiting hepatic cyclosporin A metabolism. In any patients with relapsing or recurrent infection, an anatomical cause, such as a urological complication in the transplant kidney or recipient bladder dysfunction, must be considered and treated vigorously. 4.6.2 Fungal infections Candidal infections can occur in any immunosuppressed patient, but are more common in diabetic patients and those with chronic residual urine and where there is an indwelling catheter or stent. It is wise to treat all patients even when they are asymptomatic with antifungal agents (fluconazole, amphotericin B plus flucytosine). Removal of the catheter or stents is usually necessary (B). 4.6.3 Schistosomiasis Schistosomiasis is a familiar problem for patients treated for endstage renal failure from locations where the disease is endemic. Renal transplantation is possible, even when live donors and recipients have active lesions provided they are treated. Combined medication (praziquantil and oxaminoquine) are recommended for 1 month. In a trial comparing infected patients with those free of schistosomiasis, there is no difference between the incidences of acute and chronic rejection. However, UTI and urological complications occurred in the infected group and a higher cyclosporin dosage was required. Despite this, however, it was concluded that active schistosomiasis did not preclude transplantation (53) (III). For further details on schistosomiasis in genitourinary tract infections see Bichler et al. (54).
4.7
Immunosuppression
It is well known that viral and fungal infections are common in immunosuppressed patients. 4.7.1 HIV infection HIV infection can lead to acute renal failure through non-specific severe systemic illness, and to chronic renal failure through a variety of nephropathies. These include HIV-induced thrombotic microangiopathy, immunemediated glomerulonephritis and nephropathy due to virus-induced cellular damage, primarily to the glomerular epithelial cell. Combination therapy using corticosteroids, ACE inhibitors and highly active antiretroviral therapy seems to delay and prevent progression of nephropathy, although evidence from randomized trials is not available (55). HIV infection is therefore no longer a contraindication to renal replacement therapy. The place of immunosuppression per se in the development of UTI remains unresolved (56). Patients with endstage renal failure are generally not particularly susceptible to the usual Gram-negative urinary pathogens, although they may acquire unusual and granulomatous infections. Patients have evidence of reduced cellular and humoral immunity. However, the situation is a little clearer in male patients with HIV and AIDS where there is a close relationship between CD4 counts and the risk of bacteriuria, particularly in patients whose counts are less than 200 cells/mL (57). About 40% of patients with bacteriuria will be asymptomatic. In these patients, PCP prophylaxis of the type used in transplant patients may not reduce the rate of bacteriuria, perhaps due to the previous development of resistant organisms. 4.7.2 Viral and fungal infections Viral and fungal infections are relatively common in immunosuppressed patients.
4.8
References
1.
2.
Kincaid-Smith P, Fairley KF. Complicated urinary tract infection in adults. In: Cattell WR, ed. Infections of the kidney and urinary tract. Oxford: Oxford Medical Publications (Oxford University Press), 1996, pp. 186-205. Meyrier A, Condamin MC, Fernet M, Labigne-Roussel A, Simon P, Callard P, Rianfray M, Soilleux M, Groc A. Frequency of development of early cortical scarring in acute primary pyelonephritis. Kidney Int 1989;35(2):696-703. http://www.ncbi.nlm.nih.gov/pubmed/2651759
56
UPDATE MARCH 2009
3.
4.
5. 6. 7.
8.
9.
10. 11.
12.
13.
14.
15.
16.
17. 18.
19.
20.
Matz LR, Hodson CJ, Craven JD. Experimental obstructive nephropathy in the pig. 3. Renal artery changes in experimental hydronephrosis, with special reference to renal artery stenosis due to fibromuscular hyperplasia. Br J Urol 1969;41 Suppl:36-41. http://www.ncbi.nlm.nih.gov/pubmed/5359479 Hodson CJ, Maling TM, McManamon PJ, Lewis MG. The pathogenesis of reflux nephropathy (chronic atrophic pyelonephritis). Br J Radiol 1975;Suppl 13:1-26. http://www.ncbi.nlm.nih.gov/pubmed/766885 Bishop MC. Obstructive uropathy. In: Mundy AR, ed. Scientific basis of urology. Edinburgh: Churchill Livingstone 1987, pp. 115-151. Bailey RR. Vesico-ureteric reflux and reflux nephropathy. In: Cameron S et al., eds. Oxford textbook of clinical nephrology. Oxford: Oxford University Press,1992, pp. 1983–2002. Bishop MC. Urosurgical management of urinary tract infection. J Antimicrob Chemother 1994;33 Suppl A:74-91. http://www.ncbi.nlm.nih.gov/pubmed/7928839 Roberts JA. Management of pyelonephritis and upper urinary tract infections. Urol Clin North Am 1999;26(4):753-63. http://www.ncbi.nlm.nih.gov/pubmed/10584616 Fraser IR, Birch D, Fairley KF, John S, Lichtenstein M, Tress B, Kincaid-Smith PS. A prospective study of cortical scarring in acute febrile pyelonephritis in adults: clinical and bacteriological characteristics. Clin Nephrol 1995;43(3):159-64. http://www.ncbi.nlm.nih.gov/pubmed/7774071 George NJ. Urinary tract infection. In: Mundy AR, George NJ, Fitzpatrick JM, Neill DE, eds. Scientific basis of urology. 2nd edition. ISIS Medical Media, 1998, pp. 143-173. Svanborg C, de Man P, Sandberg T. Renal involvement in urinary tract infection. Kidney Int 1991;39(3):541-9. http://www.ncbi.nlm.nih.gov/pubmed/2062037 Hedges S, Stenqvist K, Lidin-Janson G, Martinell J, Sandberg T, Svanborg C. Comparison of urine and serum concentrations of interleukin-6 in women with acute pyelonephritis or asymptomatic bacteriuria. J Infect Dis 1992;166(3):653-6. http://www.ncbi.nlm.nih.gov/pubmed/1500753 Jacobson SH, Hylander B, Wretlind B, Brauner A. Interleukin-6 and interleukin-8 in serum and urine in patients with acute pyelonephritis in relation to bacterial- virulence-associated traits and renal function. Nephron 1994;67(2):172-9. http://www.ncbi.nlm.nih.gov/pubmed/7915403 Ronald AR, Cutler RE, Turck M. Effect of bacteriuria on renal concentrating mechanisms. Ann Intern Med 1996;70(4):723-33. http://www.ncbi.nlm.nih.gov/pubmed/5771530 de Man P, Cläeson I, Johnson IM, Jodal U, Svanborg Edén C. Bacterial attachment as a predictor of renal abnormalities in boys with urinary tract infection. J Pediatr 1989;115(6):915–22. http://www.ncbi.nlm.nih.gov/pubmed/2685219 Percival A, Birumfitt W, Delouvois J. Serum antibody levels as an indication of clinically inapparent pyelonephritis. Lancet 1964;2:1027-33. http://www.ncbi.nlm.nih.gov/pubmed/14206013 Wullt B, Bergsten G, Fischer H. Application of laboratory research in UTI. European Urology EAU Update Series 2, 2004, pp. 116-124. Kallenius G, Mollby R, Svenson SB, Helin I, Hultberg H, Cedergren B, Winberg J. Occurrence of Pfimbriated Escherichia coli in urinary tract infections. Lancet 1981;2(8260-8261):1369-72. http://www.ncbi.nlm.nih.gov/pubmed/6171697 Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc Natl Acad Sci USA 2000:97(16):8829-35. http://www.ncbi.nlm.nih.gov/pubmed/10922042 Gordon I, Barkovics M, Pindoria S, Cole TJ, Woolf AS. Primary vesicoureteric reflux as a predictor of renal damage in children hospitalized with urinary tract infection: a systematic review and metaanalysis. J Am Soc Nephrol 2003;14(3):739-44. http://www.ncbi.nlm.nih.gov/pubmed/12595511
UPDATE MARCH 2009
57
21.
22.
23.
24.
25. 26.
27.
28.
29. 30.
31.
32.
33. 34.
35.
36.
37.
58
Alwall N. On controversial and open questions about the course and complications of non-obstructive urinary tract infection in adult women. Follow-up for up to 80 months of 707 participants in a population study and evaluation of a clinical series of 36 selected women with a history of urinary tract infection for up to 40 years. Acta Med Scand 1978;203(5):369-77. http://www.ncbi.nlm.nih.gov/pubmed/665302 Bailey RR, Lynn KL, Robson RA, Smith AH, Maling TM, Turner JG. DMSA renal scans in adults with acute pyelonephritis. Clin Nephrol 1996;46(2):99-104. http://www.ncbi.nlm.nih.gov/pubmed/8869786 Geerlings SE, Stolk RP, Camps MJ, Netten PM, Hoekstra JB, Bouter KP, Bravenboer B, Collet JT, Jansz AR, Hoepelman AI. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabetes Care 2000;23(6):744-9. http://www.ncbi.nlm.nih.gov/pubmed/10840989 Ooi BS, Chen BT, Yu M. Prevalence and site of bacteriuria in diabetes mellitus. Postgrad Med J 1974;50(586):497-9. http://www.ncbi.nlm.nih.gov/pubmed/4464512 Korzeniowski OM. Urinary tract infection in the impaired host. Med Clin North Am 1991;75(2):391-404. http://www.ncbi.nlm.nih.gov/pubmed/1996041 Mackie AD, Drury PL. Urinary tract infection in diabetes mellitus. In: Cattell WR, ed. Infections of the kidney and urinary tract. Oxford: Oxford, Medical Publications (Oxford University Press), 1996, pp. 218-233. Harding GK, Zhanel GG, Nicolle LE, Cheang M; Manitoba Diabetes Urinary Tract Infection Study Group. Antimicrobial treatment of diabetic women with asymptomatic bacteriuria. N Eng J Med 2002;347(20):1576-83. http://www.ncbi.nlm.nih.gov/pubmed/12432044 Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM; Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40(5):643-54. http://www.ncbi.nlm.nih.gov/pubmed/15714408 Cattell WR. Urinary tract infection and acute renal failure. In: Raine AE, ed. Advanced renal medicine. Oxford: Oxford University Press, 1992, pp. 302-313. Mallinson WJ, Fuller RW, Levison DA, Baker LR, Cattell WR. Diffuse interstitial renal tuberculosis – an unusual cause of renal failure. Q J Med 1981;50(198):137-48. http://www.ncbi.nlm.nih.gov/pubmed/7302115 Morgan SH, Eastwood JB, Baker LR. Tuberculous interstitial nephritis - the tip of an iceberg? Tubercle 1990;71(1):5-6. http://www.ncbi.nlm.nih.gov/pubmed/2371760 McAdam KP, Anders RF, Smith SR, Russell DA, Price MA. Association of amyloidosis with erythema nodosum leprosum reactions and recurrent neutrophil leucocytosis in leprosy. Lancet 1975;2(7935): 572-3. http://www.ncbi.nlm.nih.gov/pubmed/51405 Ng WL, Scollard DM, Hua A. Glomerulonephritis in leprosy. Am J Clin Pathol 1981;76(3):321-9. http://www.ncbi.nlm.nih.gov/pubmed/6456662 Cek M, Lenk S, Naber KG, Bishop MC, Johansen TE, Botto H, Grabe M, Lobel B, Redorta JP, Tenke P; Members of the Urinary Tract Infection (UTI) Working Group of the European Association of Urology (EAU) Guidelines Office. EAU guidelines for the management of genitourinary tuberculosis. Eur Urol 2005;48(3):353-62. http://www.ncbi.nlm.nih.gov/pubmed/15982799 Neal DE Jr. Host defense mechanisms in urinary tract infections. Urol Clin North Am 1999;26(4): 677-86, vii. http://www.ncbi.nlm.nih.gov/pubmed/10584610 Khan I H, Catto GR. Long-term complications of dialysis: infection. Kidney Int Suppl 1993;41:S143–S148. http://www.ncbi.nlm.nih.gov/pubmed/8320909 Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993;64(1):95-100. http://www.ncbi.nlm.nih.gov/pubmed/8502343
UPDATE MARCH 2009
38.
39.
40.
41.
42.
43.
44.
45. 46.
47.
48.
49.
50.
51. 52.
53.
54.
55.
Saitoh H, Nakamura K, Hida M, Satoh T. Urinary tract infection in oliguric patients with chronic renal failure. J Urol 1985;133(6):990-3. http://www.ncbi.nlm.nih.gov/pubmed/3999225 Elzinga LW, Bennett WM. Miscellaneous renal and systemic complications of autosomal dominant polycystic kidney disease including infection. In: Watson ML and Torres VE, eds. Polycystic kidney disease. Oxford: Oxford Clinical Nephrology series (Oxford University Press), 1996, pp. 483-499. Sklar AH, Caruana RJ, Lammers JE, Strauser GD. Renal infections in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1987;10(2):81-8. http://www.ncbi.nlm.nih.gov/pubmed/3300296 Schwab SJ, Bander SJ, Klahr S. Renal infection in autosomal dominant polycystic kidney disease. Am J Med 1987;82(4):714-8. http://www.ncbi.nlm.nih.gov/pubmed/3565428 Stiasny B, Ziebell D, Graf S, Hauser LA, Schulze BD. Clinical aspects of renal transplantation in polycystic kidney disease. Clin Nephrol 2002;58(1):16-24. http://www.ncbi.nlm.nih.gov/pubmed/12141402 Gower PE. A prospective study of patients with radiological pyelonephritis, papillary necrosis and obstructive atrophy. Q J Med 1976;45(187):315-49. http://www.ncbi.nlm.nih.gov/pubmed/940921 Mor Y, Leibovitch I, Zalts R, Lotan D, Jonas P, Ramon J. Analysis of the long term outcome of surgically corrected vesico-ureteric reflux. BJU Int 2003;92(1):97-100. http://www.ncbi.nlm.nih.gov/pubmed/12823390 Tolkoff-Rubin NE, Rubin RH. Urinary tract infection in the renal transplant recipient. In: Bergan T, ed. Urinary tract infections. Basel: Karger 1997, pp. 27-33. Tolkoff-Rubin NE, Rubin RH. The infectious disease problems of the diabetic renal transplant recipient. Infect Dis Clin North Am 1995;9(1):117-30. http://www.ncbi.nlm.nih.gov/pubmed/7769213 Müller T, Arbeiter K, Aufricht C. Renal function in meningomyelocele: risk factors, chronic renal failure, renal replacement therapy and transplantation. Curr Opin Urol 2002;12(6):479-84. http://www.ncbi.nlm.nih.gov/pubmed/12409876 Steinhoff J, Einecke G, Niederstadt C, de Groot K, Fricke L, Machnik H, Sack K. Renal graft rejection or urinary tract infection? The value of myeloperoxidase, C-reactive protein, and alpha2-macroglobulin in the urine. Transplantation 1997;64(3):443-7. http://www.ncbi.nlm.nih.gov/pubmed/9275111 Keller LS, Peh CA, Nolan J, Bannister KM, Clarkson AR, Faull RJ. BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant 2003;18(5):1013-4. http://www.ncbi.nlm.nih.gov/pubmed/12686681 Blanchet P, Droupy S, Eschwege P, Hammoudi Y, Durrbach A, Charpentier B, Benoit G. Urodynamic testing predicts long term urological complications following simultaneous pancreas-kidney transplantation. Clin Transplant 2003;17(1):26-31. http://www.ncbi.nlm.nih.gov/pubmed/12588318 Snydman DR. Posttransplant microbiological surveillance. Clin Infect Dis 2001;33 Suppl 1:S22-S25. http://www.ncbi.nlm.nih.gov/pubmed/11389518 Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomised double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulphamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 1990;89(3):255-74. http://www.ncbi.nlm.nih.gov/pubmed/2118307 Mahmoud KM, Sobh MA, El-Agroudy AE, Mostafa FE, Baz ME, Shokeir AA, Ghoneim MA. Impact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years’ follow-up. Nephrol Dial Transplant 2001;16(11):2214-21. http://www.ncbi.nlm.nih.gov/pubmed/11682670 Bichler KH, Savatovsky I; the Members of the Urinary Tract Infection (UTI) Working Group of the Guidelines Office of the European Association of Urology (EAU):, Naber KG, Bischop MC, BjerklundJohansen TE, Botto H, Cek M, Grabe M, Lobel B, Redorta JP, Tenke P. Eur Urol 2006;49(6):998-1003. http://www.ncbi.nlm.nih.gov/pubmed/16519990 Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med 2003;139(3):214-26. http://www.ncbi.nlm.nih.gov/pubmed/12899589
UPDATE MARCH 2009
59
56.
57.
Tolkoff-Rubin NE, Rubin RH. Urinary tract infection in the immunocompromised host. Lessons from kidney transplantation and the AIDS epidemic. Infect Dis Clin North Am 1997;11(3):707-17. http://www.ncbi.nlm.nih.gov/pubmed/9378931 Van Dooyeweert DA, Schneider MM, Borleffs JC, Hoepelman AI. Bacteriuria in male patients infected with human immunodeficiency virus type 1. In: Bergan T, ed. Urinary tract infections. Basel: Karger, 1997, pp 37-45.
4.8.1 Further reading Antibiotic prescribing in renal failure: evidence base of guidelines. Information has been derived from the following standard reference sources: 1. BMA and RPSGB. British national formulary. Summary of product characteristics from electronic medicines compendium for individual drugs. Datapharm Communications Ltd. Available from http://emc.medicines.org.uk 2. Ashley C, Currie A. The renal drug handbook. 2nd edn. Oxford: Radcliffe Medical Press, 2004.
5. COMPLICATED UTIs DUE TO UROLOGICAL DISORDERS 5.1
Summary and recommendations
A complicated urinary tract infection (UTI) is an infection associated with a condition, such as a structural or functional abnormality of the genitourinary tract, or the presence of an underlying disease that interferes with host defence mechanisms, which increase the risks of acquiring infection or of failing therapy. A broad range of bacteria can cause a complicated UTI. The spectrum is much larger than in uncomplicated UTIs and bacteria are more likely to be resistant to antimicrobials, especially in a treatmentrelated complicated UTI. Enterobacteriaceae are the predominant pathogens, with Escherichia coli being the most common pathogen. However, non-fermenters (e.g. Pseudomonas aeruginosa) and Gram-positive cocci (e.g. staphylococci and enterococci) may also play an important role, depending on the underlying conditions. Treatment strategy depends on the severity of the illness. Treatment encompasses three goals: management of the urological abnormality, antimicrobial therapy, and supportive care when needed. Hospitalization is often required. To avoid the emergence of resistant strains, therapy should be guided by urine culture whenever possible. If empirical therapy is necessary, the antibacterial spectrum of the antibiotic agent should include the most relevant pathogens (A). A fluoroquinolone with mainly renal excretion, an aminopenicillin plus a ß-lactam inhibitor (BLI), a Group 2 or 3a cephalosporin or, in the case of parenteral therapy, an aminoglycoside, are recommended alternatives (1bB). In case of failure of initial therapy, or in case of clinically severe infection, a broader-spectrum antibiotic should be chosen that is also active against Pseudomonas (1bB), e.g. a fluoroquinolone (if not used for initial therapy), an acylaminopenicillin (piperacillin) plus a BLI, a Group 3b cephalosporin, or a carbapenem, with or without combination with an aminoglycoside (1bB). The duration of therapy is usually 7-14 days (1bA), but has sometimes to be prolonged for up to 21 days (1bA). Until predisposing factors are completely removed, true cure without recurrent infection is usually not possible. Therefore, a urine culture should be carried out 5-9 days after the completion of therapy and also 4-6 weeks later (B).
5.2
Definitions and classification
A complicated UTI is an infection associated with a condition, such as structural or functional abnormalities of the genitourinary tract or the presence of an underlying disease, which increases the risks of acquiring an infection or of failing therapy (1-3). Two criteria are mandatory to define a complicated UTI: a positive urine culture and one or more of the factors listed in Table 5.1.
60
UPDATE MARCH 2009
Table 5.1 Factors that suggest a potential complicated UTI • • • • • • • •
The presence of an indwelling catheter, stent or splint (urethral, ureteral, renal) or the use of intermittent bladder catheterization A post-void residual urine of > 100 mL An obstructive uropathy of any aetiology, e.g. bladder outlet obstruction (including neurogenic urinary bladder), stones and tumour Vesicoureteric reflux or other functional abnormalities Urinary tract modifications, such as an ileal loop or pouch Chemical or radiation injuries of the uroepithelium Peri- and post-operative UTI Renal insufficiency and transplantation, diabetes mellitus and immunodeficiency
Complicated UTI can arise in a heterogeneous group of patients. But neither patient age nor gender per se are part of the definition of a complicated UTI. With regard to prognosis and clinical studies, it is advisable to stratify complicated UTIs due to urological disorders into at least two groups (4): 1. Patients in whom the complicating factors could be eliminated by therapy, e.g. stone extraction, removal of an indwelling catheter. 2. Patients in whom the complicating factor could not be or is not removed satisfactorily during therapy, e.g. permanent indwelling catheter, stone residuals after treatment or neurogenic bladder. 5.2.1 Clinical presentation A complicated UTI may or may not be associated with clinical symptoms (e.g. dysuria, urgency, frequency, flank pain, costovertebral angle tenderness, suprapubic pain and fever). Clinical presentation may vary from severe obstructive acute pyelonephritis with imminent urosepsis to a catheter-associated post-operative UTI, which might disappear spontaneously as soon as the catheter is removed. It also has to be recognized that symptoms, especially lower urinary tract sympoms (LUTS), are not only caused by UTIs but also by other urological disorders, such as benign prostatic hyperplasia (BPH), TURP, etc. Apart from urological abnormalities, concomitant medical conditions, such as diabetes mellitus (10%) and renal failure, which can be related to urological abnormalities (5), are often present in a complicated UTI. These are discussed in more details in Sections 4.1.3 and 4.1.4 on UTIs in renal insufficiency, transplant recipients, diabetes mellitus and immunosuppression. 5.2.2 Urine cultures Significant bacteriuria in a complicated UTI is defined by counts of > 105 cfu/mL and > 104 cfu/mL, in the MSU of women and men, respectively (1, 2). If a straight catheter urine sample is taken, > 104 cfu/mL can be considered relevant. For an asymptomatic patient, two consecutive urine cultures (at least 24 hours apart) yielding > 105 cfu/mL of the same micro-organism are required. The requirement for pyuria is > 10 WBC per high-power field (x 400) in the resuspended sediment of a centrifuged aliquot of urine or per mm3 in unspun urine. A dipstick method can also be used for routine assessment, including a leucocyte esterase test, haemoglobin and probably a nitrite reaction.
5.3
Microbiology
5.3.1 Spectrum and antibiotic resistance Patients with a complicated UTI, both community and hospital-acquired, tend to show a diversity of microorganisms with a higher prevalence of resistance against antimicrobials, and higher rates of treatment failure if the underlying abnormality cannot be corrected. However, the presence of a resistant strain on its own is not enough to define a complicated UTI. Urinary abnormality (anatomical or functional) or the presence of an underlying disease predisposing to a UTI is also necessary. A broad range of bacteria can cause a complicated UTI. The spectrum is much larger than with an uncomplicated UTI and the bacteria are more likely to be antibiotic-resistant (especially in a treatmentrelated complicated UTI) than those isolated in an uncomplicated UTI. Escherichia coli, Proteus, Klebsiella, Pseudomonas, Serratia spp. and enterococci are the usual strains found in cultures. Enterobacteriaceae predominate (60-75%) (6-8), with E. coli as the most common pathogen, particularly if the UTI is a first infection. Otherwise, the bacterial spectrum may vary from time to time and from one hospital to another. 5.3.2 Complicated UTIs associated with urinary stones In the subset of complicated UTIs related to urinary stones, the frequency of E. coli and enterococci infection seems less important pathogens. In contrast, a greater portion of Proteus spp. and Pseudomonas (9) is found.
UPDATE MARCH 2009
61
Of the urease-producing organisms, Proteus, Providencia, Morganella spp., and Corynebacterium urealyticum are predominant, but Klebsiella, Pseudomonas, Serratia and staphylococci are also urease producers to a certain extent. Among patients with staghorn calculus disease, 88% were found to have a UTI at the time of diagnosis, with 82% of patients infected with urease-producing organisms (10). The enzyme, urease, splits urea into carbon dioxide and ammonia. The resulting increase in ammonia in the urine injures the glycosaminoglycan (GAG) layer, which in turn increases bacterial adherence (11) and enhances the formation of struvite crystals. These aggregate to form renal stones and incrustations on urinary catheters (12). The pathogenic potential of coagulase-negative staphylococci and non-group D streptococci is controversial (13, 14). Under certain circumstances, such as the presence of a stone or foreign bodies, staphylococci can be relevant pathogens. Otherwise, staphylococci are not so common in complicated UTIs (0-11%), according to published reports (6, 15). 5.3.3 Complicated UTIs associated with urinary catheters In catheter-associated UTIs, the distribution of micro-organisms is similar (16), and biofilm has to be considered. Antimicrobial therapy may only be effective in the early stages of the infection (15). For more details see chapter 6 on catheter associated UTI.
5.4
Treatment
5.4.1 General principles Treatment strategy depends on the severity of the illness. Appropriate antimicrobial therapy and the management of the urological abnormality are mandatory. If needed, supportive care is given. Hospitalization is often necessary depending on the severity of the illness. 5.4.2 Choice of antibiotics Empirical treatment of a symptomatic complicated UTI requires a knowledge of the spectrum of possible pathogens and local antibiotic resistance patterns, as well as assessment of the severity of the underlying urological abnormality (including the evaluation of renal function). Bacteraemia is usually reported too late to influence the choice of antibiotics. However, suspicion of bacteraemia must influence the empirical treatment. Most important for the prognosis is still the severity of the associated illness and of the underlying urological condition. Many therapeutic trials have been published on the use of specific antimicrobial therapies in complicated UTIs. Unfortunately, most reports are of limited use for the practical management of the patient in a day-to-day situation because of limitations such as: • poor characterization of the patient populations • unclear evaluation of the severity of the illness • nosocomial and community-acquired infections are not accurately distinguished • urological outcome is seldom taken into consideration. Intense use of any antimicrobial, especially when used on an empirical basis in this group of patients with a high likelihood of recurrent infection, will lead to the emergence of resistant micro-organisms in subsequent infections. Whenever possible, empirical therapy should be replaced by a therapy adjusted for the specific infective organism(s) identified in the urine culture. Therefore, a urine specimen for culture must be obtained prior to initiating therapy and the selection of an antimicrobial agent should be re-evaluated once culture results are available (7). So far, it has not been shown that any agent or class of agents is superior in a case where the infective organism is susceptible to the drug administered. In patients with renal failure, whether related to a urological abnormality or not, appropriate dose adjustments have to be made. If empirical treatment is necessary, fluoroquinolones with mainly renal excretion are recommended because they have a large spectrum of antimicrobial activity covering most of the expected pathogens and they reach high concentration levels both in urine and the urogenital tissues. Fluoroquinolones can be used orally as well as parenterally. An aminopenicillin plus a BLI, a Group 2 or 3a cephalosporin, or, in the case of parenteral therapy, an aminoglycoside, are alternatives. A new Group 1 oral carbapenem, ertapenem, in a prospective randomized trial, has been shown to be as effective as ceftriaxone (17). In most countries, E. coli shows a high rate of resistance against TMP-SMX (18% in the last US evaluation) (16) and should therefore be avoided as a first-line treatment. Fosfomycin trometamol is licensed only for a single-dose therapy of uncomplicated cystitis (18). The aminopenicillins, ampicillin or amoxicillin, are no longer sufficiently active against E. coli. In the case of failure of initial therapy, or if microbiological results are not yet available, or as initial therapy in the case of clinically severe infection, treatment should be switched to an antibiotic with a broader spectrum that is also active against Pseudomonas, such as a fluoroquinolone (if not used for initial therapy),
62
UPDATE MARCH 2009
an acylaminopenicillin (piperacillin) plus a BLI, a Group 3b cephalosporin, or a carbapenem, eventually in combination with an aminoglycoside. Similarly, many experts concur that empirical therapy for the institutionalized or hospitalized patients with a serious UTI should include an intravenous antipseudomonal agent because of an increased risk of urosepsis (19). Patients can generally be treated as outpatients. In more severe cases (e.g. hospitalized patients), antibiotics have to be given parenterally. A combination of an aminoglycoside with a BLI or a fluoroquinolone is widely used for empirical therapy. After a few days of parenteral therapy and clinical improvement, patients can be switched to oral treatment. Therapy has to be reconsidered when the infective strains have been identified and their susceptibilities are known. The successful treatment of a complicated UTI always combines effective antimicrobial therapy, optimal management of the underlying urological abnormalities or other diseases, and sufficient lifesupporting measures. The antibacterial treatment options are summarized in Table 5.2 and Appendix 12.2 (Recommendations for antimicrobial therapy in urology). 5.4.3 Duration of antibiotic therapy Treatment for 7-14 days is generally recommended, but the duration should be closely related to the treatment of the underlying abnormality (1). Sometimes, a prolongation for up to 21 days, according to the clinical situation, is necessary (2). 5.4.4 Complicated UTIs associated with urinary stones If a nidus of either a stone or an infection remains, stone growth will occur. Complete removal of the stones and adequate antimicrobial therapy are both needed. Eradication of the infection will probably eliminate the growth of struvite calculi (20). Long-term antimicrobial therapy should be considered if complete removal of the stone can not be achieved (21). 5.4.5 Complicated UTIs associated with indwelling catheters Current data do not support the treatment of asymptomatic bacteriuria, either during short-term catheterization (< 30 days) or during long-term catheterization, because it will promote the emergence of resistant strains (22,23). In short-term catheterization, antibiotics may delay the onset of bacteriuria, but do not reduce complications (24). A symptomatic complicated UTI associated with an indwelling catheter is treated with an agent with as narrow a spectrum as possible, based on culture and sensitivity results. The optimal duration is not well established. Treatment durations that are both too short as well as too long may cause the emergence of resistant strains. A 7-day course may be a reasonable compromise. 5.4.6 Complicated UTIs in spinal-cord injured patients It is generally accepted that asymptomatic bacteriuria in these patients should not be treated (25), even in cases of intermittent catheterization. For symptomatic episodes of infection in the spinal-cord injured patient, only a few studies have investigated the most appropriate agent and the most appropriate duration of therapy. Currently, 7-10 days of therapy is most commonly used. There is no superiority of one agent or class of antimicrobials in this group of patients. Antimicrobial treatment options are summarized in Table 5.2. Table 5.2
Antimicrobial treatment options for empiric therapy
Antibiotics recommended for initial empirical treatment • Fluoroquinolones • Aminopenicillin plus a BLI • Cephalosporin (Groups 2 or 3a) • Aminoglycoside Antibiotics recommended for empirical treatment in case of initial failure or for severe cases • Fluoroquinolone (if not used for initial therapy) • Ureidopenicillin (piperacillin) plus BLI • Cephalosporin (Group 3b) • Carbapenem • Combination therapy: - Aminoglycoside + BLI - Aminoglycoside + fluoroquinolone Antibiotics not recommended for empirical treatment • Aminopenicillins, e.g. amoxicillin, ampicillin
UPDATE MARCH 2009
63
• Trimethoprim-sulphamethoxazole (only if susceptibility of pathogen is known) • Fosfomycin trometamol BLI = ß-lactam inhibitor 5.4.7 Follow-up after treatment The greater likelihood of the involvement of resistant micro-organisms in complicated UTIs is another feature of these infectious diseases. This is not a priori related to the urinary abnormality, but is related more to the fact that patients with a complicated UTI tend to have recurrent infection (7). For these reasons, prior to and after the completion of the antimicrobial treatment, urine cultures must be obtained for the identification of the micro-organisms and the evaluation of susceptibility testing.
5.5
Conclusions
Until predisposing factors are completely removed, true cure (i.e. without recurrent infection) is usually not possible. Correction of these abnormalities must be performed, whenever possible, as an essential part of treatment. Recurrent infection is the rule when the underlying urological abnormality cannot be removed: either relapse (e.g. with the same micro-organism) or a re-infection (e.g. with a new micro-organism). For this reason, a urine culture has to be carried out between 5 and 9 days after the completion of therapy and repeated between 4 and 6 weeks later.
5.6
References
1.
Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15 Suppl 1:S216-S227. http://www.ncbi.nlm.nih.gov/pubmed/1477233 Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE, with modifications by a European Working Party. General guidelines for the evaluation of new anti-infective drugs for the treatment of UTI. Taufkirchen, Germany: The European Society of Clinical Microbiology and Infectious Diseases, 1993, pp. 240-310. Kumazawa J, Matsumoto T. Complicated UTIs. In: Bergan T, ed. UTIs. Infectiology. Vol 1. Basel: Karger, 1997, pp. 19-26. Naber KG. Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. Int J Antimicrob Agents 1999;11(3-4):189-96. http://www.ncbi.nlm.nih.gov/pubmed/10394969 Sharifi R, Geckler R, Childs S. Treatment of urinary tract infections: selecting an appropriate broadspectrum antibiotic for nosocomial infections. Am J Med 1996;100(6A):76S-82S. http://www.ncbi.nlm.nih.gov/pubmed/8678101 Frankenschmidt A, Naber KG, Bischoff W, Kullmann K. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections. J Urol 1997;158(4):1494-9. http://www.ncbi.nlm.nih.gov/pubmed/9302150 Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs 1997;53(4):583-92. http://www.ncbi.nlm.nih.gov/pubmed/9098661 Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/ cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995;21(1):86-92. http://www.ncbi.nlm.nih.gov/pubmed/7578765 Dobardzic AM, Dobardzic R. Epidemiological features of complicated UTI in a district hospital of Kuwait. Eur J Epidemiol 1997;13(4):465-70. http://www.ncbi.nlm.nih.gov/pubmed/9258554 Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6(4):428-42. http://www.ncbi.nlm.nih.gov/pubmed/8269394 Parsons CL, Stauffer C, Mulholland SG, Griffith DP. Effect of ammonium on bacterial adherence to bladder transitional epithelium. J Urol 1984;132(2):365-6. http://www.ncbi.nlm.nih.gov/pubmed/6376829 Dumanski AJ, Hedelin H, Edin-Liljergen A, Beauchemin D, McLean RJ. Unique ability of the Proteus mirabilis capsule to enhance mineral growth in infectious urinary calculi. Infect Immun 1994;62(7):2998-3003. http://www.ncbi.nlm.nih.gov/pubmed/8005688
2.
3. 4.
5.
6.
7.
8.
9.
10.
11.
12.
64
UPDATE MARCH 2009
13.
14.
15.
16.
17.
18.
19.
20. 21.
22.
23.
24.
25.
Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329(18):1328-34. http://www.ncbi.nlm.nih.gov/pubmed/8413414 US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Complicated urinary tract infections and pyelonephritis-developing antimicrobial drugs for treatment. Clin-Anti. Rockville, MD: Drug Information Branch. Division of Communications Management, 1998. http://www.fda.gov/cder/guidance/2559dft.htm Reid G. Biofilms in infectious disease and on medical devices. Int J Antimicrob Agents 1999;11(34):223-6. http://www.ncbi.nlm.nih.gov/pubmed/10394974 Sahm DF, Vaughan D, Thornsberry C. Antimicrobial resistance profiles among Escherichia (EC) urinary tract isolates in the United States: a current view. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, USA, 1999: Abstract 611. http://www.thebody.com/confs/icaac99/icaac99.html Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by an appropriate oral therapy. J Antimicrob Chemother 2004;53 Suppl 2:ii67-74. http://www.ncbi.nlm.nih.gov/pubmed/15150185 Lerner SA, Price S, Kulkarni S. Microbiological studies of fosfomycin trometamol against urinary isolates in vitro. In: New trends in urinary tract infections. Williams N, ed. Basel: Karger, 1988, pp. 121129. Carson C, Naber KG. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. Drugs 2004;64(12):1359-73. http://www.ncbi.nlm.nih.gov/pubmed/15200349 Griffith DP, Osborne CA. Infection (urease) stones. Miner Electrolyte Metab 1987;13(4):278-85. http://www.ncbi.nlm.nih.gov/pubmed/3306321 Beck EM, Riehle RA Jr. The fate of residual fragments after extracorporeal shock wave lithotripsy monotherapy of infection stones. J Urol 1991;145(1):6-9. http://www.ncbi.nlm.nih.gov/pubmed/1984100 Alling B, Brandberg A, Seeberg S, Svanborg A. Effect of consecutive antibacterial therapy on bacteriuria in hospitalized geriatric patients. Scand J Infect Dis 1975;7(3):201-7. http://www.ncbi.nlm.nih.gov/pubmed/809837 Warren JW, Anthony WC, Hoopes JM, Muncie HL Jr. Cephalexin for susceptible bacteriuria in afebrile, long term catheterized patients. JAMA 1982;248(4):454-8. http://www.ncbi.nlm.nih.gov/pubmed/7045440 Yoshikawa TT, Nicolle LE, Norman DC. Management of complicated urinary tract infection in older patients. J Am Geriatr Soc 1996;44(10):1235-41. http://www.ncbi.nlm.nih.gov/pubmed/8856005 National Institute on Disability and Rehabilitation Research. The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27-29, 1992. J Am Paraplegia Soc 1992;15(3):194-204. http://www.ncbi.nlm.nih.gov/pubmed/1500945
6. CATHETER-ASSOCIATED UTIs Based on the EAU guidelines published in 2007 (ISBN-13:978-90-70244-59-0) the following text presents the findings of a comprehensive update produced as a collaborative effort by the European Society for Infection in Urology (the ESIU is a full EAU section office), the Urological Association of Asia, the Asian Association of UTI/ STD, the Western Pacific Society for Chemotherapy, the Federation of European Societies for Chemotherapy and Infection, and the International Society of Chemotherapy for Infection and Cancer. This text was recently published as “The European and Asian guidelines on management and prevention of catheter-associated urinary tract infections” (1). Since the complete document is available online, only the abstract and a summary of the recommendations are presented here.
UPDATE MARCH 2009
65
6.1
Abstract
We surveyed the extensive literature regarding the development, therapy and prevention of catheterassociated urinary tract infections (UTIs). We systematically searched for meta-analyses of randomised controlled trials available in Medline giving preference to the Cochrane Central Register of Controlled Trials and also considered other relevant publications, rating them on the basis of their quality. The studies’ recommendations, rated according to a modification of the US Department of Health and Human Services (1992), give a close-to-evidence based guideline for all medical disciplines, with special emphasis on urology where catheter-care is an important issue. The survey found that the urinary tract is the commonest source of nosocomial infection, particularly when the bladder is catheterised (Level of evidence: 2a). Most catheter-associated UTIs are derived from the patient’s own colonic flora (Level of evidence: 2b) and the catheter predisposes to UTI in several ways. The most important risk factor for the development of catheter-associated bacteriuria is the duration of catheterisation (Level of evidence: 2a). Most episodes of short-term catheter-associated bacteriuria are asymptomatic and are caused by a single organism (Level of evidence: 2a). Further organisms tend to be acquired by patients catheterised for more than 30 days. The clinician should be aware of two priorities: the catheter system should remain closed and the duration of catheterisation should be minimal (Grade of recommendation: A). While the catheter is in place, systemic antimicrobial treatment of asymptomatic catheter-associated bacteriuria is not recommended (Grade of recommendation: A), except for some special cases. Routine urine culture in an asymptomatic catheterised patient is also not recommended (Grade of recommendation: C) because treatment is in general not necessary. Antibiotic treatment is recommended only for symptomatic infection (Grade of recommendation: B). Long-term antibiotic suppressive therapy is not effective (Grade of recommendation: A). Antibiotic irrigation of the catheter and bladder is of no advantage (Grade of recommendation: A). Routine urine cultures are not recommended if the catheter is draining properly (Grade of recommendation: C). A minority of patients can be managed with the use of the non-return (flip) valve catheter, avoiding the closed drainage bag. Such patients may exchange the convenience of on-demand drainage with an increased risk of infection. Patients with urethral catheters in place for 10 years or more should be screened annually for bladder cancer (Grade of recommendation: C). Clinicians should always consider alternatives to indwelling urethral catheters that are less prone to causing symptomatic infection. In appropriate patients, suprapubic catheters, condom drainage systems and intermittent catheterisation are each preferable to indwelling urethral catheterisation (Grade of recommendation: B).
6.2
Summary of Recommendations
Recommendation GR* General aspects 1. Written catheter care protocols are necessary. B 2. Health care workers should observe protocols on hand hygiene and the need to use A disposable gloves between catheterised patients. Catheter insertion and choice of catheter 3. An indwelling catheter should be introduced under antiseptic conditions. B 4. Urethral trauma should be minimised by the use of adequate lubricant and the smallest B possible catheter calibre. 5. Antibiotic-impregnated catheters may decrease the frequency of asymptomatic bacteriuria B within 1 week. There is, however, no evidence they decrease symptomatic infection. Therefore, they cannot be recommended routinely. 6. Silver alloy catheters significantly reduce the incidence of asymptomatic bacteriuria, but B only for less than 1 week. There was some evidence of reduced risk for symptomatic UTI. Therefore they may be useful in some settings. Prevention 7. The catheter system should remain closed. A 8. The duration of catheterisation should be minimal. A 9. Topical antiseptics or antibiotics applied to the catheter, urethra or meatus are not A recommended. 10. Benefits from prophylactic antibiotics and antiseptic substances have never been A established, therefore they are not recommended. 11. Removal of the indwelling catheter after non-urological operation before midnight may B be beneficial.
66
UPDATE MARCH 2009
12. Long-term indwelling catheters should be changed in intervals adapted to the individual patient, but must be changed before blockage is likely to occur, however there is no evidence for the exact intervals of changing catheters. 13. Chronic antibiotic suppressive therapy is generally not recommended. Diagnostics 14. Routine urine culture in asymptomatic catheterised patients is not recommended. 15. Urine, and in septic patients also blood for culture must be taken before any antimicrobial therapy is started. 16. Febrile episodes are only found in less than 10% of catheterised patients living in a long-term facility. It is therefore extremely important to rule out other sources of fever. Treatment 17. Whilst the catheter is in place, systemic antimicrobial treatment of asymptomatic catheter-associated bacteriuria is not recommended, except in certain circumstances: especially prior to traumatic urinary tract interventions. 18. In case of asymptomatic candiduria, neither systemic nor local antifungal therapy is indicated, but removal of the catheter or stent should be considered. 19. Antimicrobial treatment is recommended only for symptomatic infection. 20. In case of symptomatic catheter associated UTI it may be reasonable to replace or remove the catheter before starting antimicrobial therapy if the indwelling catheter has been in place for more than 7 days. 21. For empiric therapy broad-spectrum antibiotics should be given based on local susceptibility patterns. 22. After culture results are available antibiotic therapy has to be adjusted according to sensitivities of the pathogens. 23. In case of candiduria associated with urinary symptoms or if candiduria is the sign of a systemic infection, systemic therapy with antifungals are indicated. 24. Elderly female patients may need treatment if bacteriuria does not resolve spontaneously after catheter removal. Alternative drainage systems 25. There is limited evidence that post-operative intermittent catheterisation reduces the risk of bacteriuria compared with indwelling catheter. No recommendation can be made. 26. In appropriate patients suprapubic, condom drainage system or intermittent catheter are preferable to indwelling urethral catheter. 27. There is little evidence suggesting that antibiotic prophylaxis decreases bacteriuria in patients using intermittent catheterisation, therefore it is not recommended. Long-term follow up 28. Patients with urethral catheters in place for 10 years or more should be screened for bladder cancer *GR = grade of recommendation
B
A B C A
A
A/C B B
C B B C
C B B
C
6.3
Reference
1.
Tenke P, Kovacs B, Bjerklund Johansen TE, Matsumoto T, Tambyah PA, Naber KG. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents 2008;31S: S68-S78. http://www.ischemo.org/abstracts/TenkeIJAA2008.pdf
7. SEPSIS syndrome IN UROLOGY (UROSEPSIS) 7.1
Summary and recommendations
Patients with urosepsis should be diagnosed at an early stage, especially in the case of a complicated UTI. The systemic inflammatory response syndrome, known as SIRS (fever or hypothermia, hyperleucocytosis or leucopenia, tachycardia, tachypnoea), is recognized as the first event in a cascade to multi-organ failure. Mortality is considerably increased when severe sepsis or septic shock are present, though the prognosis of urosepsis is globally better than sepsis due to other infectious sites. The treatment of urosepsis calls for the combination of adequate life-supporting care, appropriate and prompt antibiotic therapy, adjunctive measures (e.g. sympathomimetic amines, hydrocortisone, blood glucose control, recombinant activated protein C) and the optimal management of urinary tract disorders
UPDATE MARCH 2009
67
(IaA). The drainage of any obstruction in the urinary tract is essential as first-line treatment (IbA). Urologists are recommended to treat patients in collaboration with intensive care and infectious diseases specialists (IIaB). Urosepsis can due to both community- or nosocomial-acquired infections. Most nosocomial urosepsis can be avoided by measures used to prevent nosocomial infection, e.g. reduction of hospital stay, early removal of indwelling urethral catheters, avoidance of unnecessary urethral catheterizations, correct use of closed catheter systems and attention to simple daily asepsis techniques in order to avoid crossinfection (IIaB).
7.2
Background
Urinary tract infections can manifest as bacteriuria with limited clinical symptoms, sepsis or severe sepsis, depending on localized or systemic extension. Sepsis is diagnosed when clinical evidence of infection is accompanied by signs of systemic inflammation (fever or hypothermia, tachycardia, tachypnoea, leucocyturia or leucopenia). Severe sepsis is defined by the presence of symptoms of organ dysfunction, and septic shock by the presence of a persistent hypotension associated with tissue anoxia. Severe sepsis is a severe situation with a reported mortality rate ranging from 20% to 42% (1). Most severe sepsis reported in the literature is related to pulmonary (50%) or abdominal infections (24%), with UTIs accounting for only 5% (2). Sepsis is commoner in men than in women (3). In recent years, the incidence of sepsis has increased by 8.7% per year (1), but the associated mortality has decreased suggesting improved management of patients (the total in-hospital mortality rate fell from 27.8% to 17.9% during the period 19952000) (4). Globally (this is not true for urosepsis), the rate of sepsis due to fungal organisms increased while Gram-positive bacteria became the predominant pathogen in sepsis even if in urosepsis Gram-negative bacteria remain predominant. In urosepsis, as in other types of sepsis, the severity of sepsis depends mostly upon the host response. Patients who are more likely to develop urosepsis include: elderly patients; diabetics; immunosuppressed patients, such as transplant recipients; patients receiving cancer chemotherapy or corticosteroids; and patients with acquired immunodeficiency syndrome. Urosepsis also depends on local factors, such as urinary tract calculi, obstruction at any level in the urinary tract, congenital uropathies, neurogenic bladder disorders or endoscopic manoeuvres. However, all patients can be affected by bacterial species capable of inducing inflammation within the urinary tract. Moreover, it is now recognized that SIRS may be present without infection (pancreatitis, burns, non-septic shock, etc) (5). For therapeutic purposes, the diagnostic criteria of sepsis should identify patients at an early stage of the syndrome, prompting urologists and intensive care specialists to search for and treat infection, apply appropriate therapy, and monitor for organ failure and other complications.
7.3
Definition and clinical manifestation of sepsis in urology
The clinical evidence of UTI is based on symptoms, physical examination, sonographic and radiological features, and laboratory data, such as bacteriuria and leucocyturia. The following definitions apply (Table 7.1): • Sepsis is a systemic response to infection. The symptoms of SIRS which were initially considered to be ‘mandatory’ for the diagnosis of sepsis (5), are now considered to be alerting symptoms (6). Many other clinical or biological symptoms must be considered. • Severe sepsis is sepsis associated with organ dysfunction. • Septic shock is persistence of hypoperfusion or hypotension despite fluid resuscitation. • Refractory septic shock is defined by an absence of response to therapy. Table 7.1: Clinical diagnostic criteria of sepsis and septic shock (5, 6) Disorder Infection Bacteraemia Systemic inflammatory response syndrome (SIRS)
68
Definition Presence of organisms in a normally sterile site that is usually, but not necessarily, accompanied by an inflammatory host response Bacteria present in blood as confirmed by culture. May be transient Response to a wide variety of clinical insults, which can be infectious, as in sepsis but may be non-infectious in aetiology (e.g. burns, pancreatitis). This systemic response is manifested by two or more of the following conditions: Temperature > 38°C or < 36°C Heart rate > 90 beats min Respiratory rate > 20 breaths/min or PaCO2 < 32mmHg (< 4.3kPa) 3 WBC > 12,000 cells/mm3 or < 4,000 cells/mm or > 10% immature (band) forms
UPDATE MARCH 2009
Sepsis Hypotension Severe sepsis Septic shock Refractory septic shock
Activation of the inflammatory process due to infection A systolic blood pressure of < 90mmHg or a reduction of > 40mmHg from baseline in the absence of other causes of hypotension Sepsis associated with organ dysfunction, hypoperfusion or hypotension. Hypoperfusion and perfusion abnormalities may include but are not limited to lactic acidosis, oliguria or an acute alteration of mental status Sepsis with hypotension despite adequate fluid resuscitation along with the presence of perfusion abnormalities that may include, but are not limited to lactic acidosis, oliguria, or an acute alteration in mental status. Patients who are on inotropic or vasopressor agents may not be hypotensive at the time that perfusion abnormalities are measured Septic shock that last for more than 1 hour and does not respond to fluid administration or pharmacological intervention
7.4 Physiology and biochemical markers Micro-organisms reach the urinary tract by way of the ascending, haematogenous, or lymphatic routes. For urosepsis to be established, the pathogens have to reach the bloodstream. The risk of bacteriaemia is increased in severe UTIs, such as pyelonephritis and acute bacterial prostatitis (ABP), and is facilitated by obstruction. Escherichia coli remains the most prevalent micro-organism. Particularly in several countries, some bacterial strains can be resistant to quinolones or third-generation cephalosporins. Some micro-organisms are multi-resistant, such as methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and Serratia spp. and therefore difficult to treat. Most commonly, the condition develops in compromised patients (e.g. those with diabetes or the immunosuppressed) with typical signs of generalized sepsis associated with local signs of infection. A fatal outcome is described in 20-40% of all patients. 7.4.1 Cytokines as markers of the septic response Cytokines are involved in the pathogenesis of sepsis syndrome. They are peptides that regulate the amplitude and duration of the host inflammatory response. They are released from various cells including monocytes, macrophages and endothelial cells, in response to various infectious stimuli. When they become bound to specific receptors on other cells, cytokines change their behaviour in the inflammatory response. The complex balance between pro- and anti-inflammatory responses is modified in severe sepsis. An immunodepressive phasis follows the initial pro-inflammatory mechanism. Other cytokines are involved such as interleukins. Tumour necrosis factor-α (TNF-9 pt), interleukin-1 (IL-1), IL-6, and IL-8 are cytokines that are associated with sepsis. Sepsis may indicate an immune system that is severely compromised and unable to eradicate pathogens or a non-regulated and excessive activation of inflammation or both. A genetic predisposition is more than likely to explain sepsis in several patients. Mechanisms of organ failure and death in patients with sepsis remain only partially understood (2). 7.4.2 Procalcitonin is a potential marker of sepsis Procalcitonin is the propeptide of calcitonin, but is devoid of hormonal activity. Normally in healthy humans, levels are undetectable. During severe generalized infections (bacterial, parasitic and fungal) with systemic manifestations, procalcitonin levels may rise to > 100 ng/mL. In contrast, during severe viral infections or inflammatory reactions of non-infectious origin, procalcitonin levels show only a moderate or no increase. The exact site of procalcitonin production during sepsis is not known. Procalcitonin monitoring may be useful in patients likely to develop a SIRS of infectious origin. High procalcitonin levels, or an abrupt increase in levels in these patients, should prompt a search for the source of infection. Procalcitonin may be useful in differentiating between infectious and non-infectious causes of severe inflammatory status (7, 8).
7.5 Prevention Septic shock is the most frequent cause of death for patients hospitalized for both community and nosocomial acquired infection (20-40%). Sepsis initiates the cascade that progresses to severe sepsis and then septic shock in a clinical continuum. Urosepsis treatment calls for the combination of treatment of the cause (obstruction), adequate life-supporting care and appropriate antibiotic therapy (2). In such a situation it is recommended that urologists collaborate with intensive care and infectious disease specialists for the best management of the patient. 7.5.1 Preventive measures of proven or probable efficacy (9, 10) The most effective methods to prevent nosocomial urosepsis are the same as those used to prevent other nosocomial infections:
UPDATE MARCH 2009
69
• •
• •
• • •
Isolation of all patients infected with multi-resistant organisms to avoid cross-infection. Prudent use of antimicrobial agents, both in prophylaxis and in treatment of established infections, to avoid selection of resistant strains. Antibiotic agents should be chosen according to the predominant pathogens at a given site of infection in the hospital environment. Reduction in hospital stay. It is well known that long in-patient periods prior to surgery lead to a greater incidence of nosocomial infections. Early removal of indwelling urethral catheters, as soon as allowed by the patient’s condition. Nosocomial UTIs are promoted by bladder catheterization as well as by ureteral stenting (11). Antibiotic prophylaxis does not prevent stent colonization, which appears in 100% of patients with a permanent ureteral stent and in 70% of those temporarily stented. Use of closed catheter drainage and minimization of breaks in the integrity of the system, e.g. for urine sampling or bladder wash-out. Use of least invasive method to release urinary tract obstruction until the patient is stabilized. Attention to simple everyday techniques to assure asepsis, including the routine use of protective, disposable gloves, frequent hand disinfection, and using infectious disease control measures to prevent cross-infections.
7.5.2 Appropriate peri-operative antimicrobial prophylaxis For appropriate peri-operative antimicrobial prophylaxis, see Section 11. The potential side effects of antibiotics must be considered prior to their administration in a prophylactic regimen. 7.5.3 • •
Preventive measures of debatable efficacy Instillation of antibiotic or antiseptic drugs into catheters and drainage bags. Use of urinary catheters coated with antibiotics or silver.
7.5.4 •
Ineffective or counterproductive measures Continuous or intermittent bladder irrigations with antibiotics or urinary antiseptics that increase the risk of infection with resistant bacteria (9, 12). Routine administration of antimicrobial drugs to catheterized patients, which reduces the incidence of bacteriuria only for a few days and increases the risk of infection with multi-resistant bacteria (9,12). Its use may be reserved for immunosuppressed patients.
•
7.6
Treatment
7.6.1 Relief of obstruction Drainage of any obstruction in the urinary tract and removal of foreign bodies, such as urinary catheters or stones, may themselves cause resolution of symptoms and lead to recovery. These are key components of the strategy. This condition is an absolute emergency. 7.6.2 Antimicrobial therapy Empirical initial treatment should provide broad antimicrobial coverage and should later be adapted on the basis of culture results. The antibacterial treatment options are summarized in Appendix 12. 7.6.3 Adjunctive measures (12, 13) The management of fluid and electrolyte balance is a crucial aspect of patient care in sepsis syndrome, particularly when the clinical course is complicated by shock. The use of human albumin is debatable. An early goal-directed therapy has been shown to reduce mortality (14). Volaemic expansion and vasopressor therapy have considerable impact on the outcome. Early intervention with appropriate measures to maintain adequate tissue perfusion and oxygen delivery by prompt institution of fluid therapy, stabilization of arterial pressure and providing sufficient oxygen transport capacity are highly effective. Hydrocortisone (with a debate on dosage) is useful in patients with relative insufficiency in the pituitary gland-adrenal cortex axis (ACTH test) (15). Tight blood glucose control by administration of insulin doses up to 50 units/hour is associated with a reduction in mortality (16). Recombinant activated protein C (dotrecogin alpha) is a new drug that has been approved for therapy of severe sepsis since November 2002. This expensive treatment has been proven to be more effective in patients with more severe disease, as assessed by Acute Physiology and Chronic Health Evaluation (APACHE) II scores > 25 or the presence of > two organ dysfunctions (17). The best strategy has been summarized and graded according to a careful evidence-based methodology in the recently published ‘Surviving Sepsis Guidelines’ (18).
70
UPDATE MARCH 2009
7.7
Conclusion
Sepsis syndrome in urology remains a severe situation with a mortality rate as high as 20-40%. A recent campaign, ‘Surviving Sepsis Guidelines’, aimed at reducing mortality by 25% in the next few years has been published recently (18). Early recognition of the symptoms may decrease the mortality by timely treatment of urinary tract disorders, e.g. obstruction, urolithiasis. Adequate life-support measures and appropriate antibiotic treatment provide the best conditions for improving patients’ survival. The prevention of sepsis syndrome is dependent on good practice to avoid nosocomial infections and using antibiotic prophylaxis and therapy in a prudent and well-accepted manner.
7.8
Acknowledgement
The authors are thankful to Jean M. Carlet, Head of Intensive Care, Hôpital Saint Joseph, Paris, France, for reviewing this manuscript on urosepsis.
7.9
References
1.
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348(16):1546-54. http://www.ncbi.nlm.nih.gov/pubmed/12700374 Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348(2):13850. http://www.ncbi.nlm.nih.gov/pubmed/12519925 Rosser CJ, Bare RL, Meredith JW. Urinary tract infections in the critically ill patient with a urinary catheter. Am J Surg 1999;177(4):287-90. http://www.ncbi.nlm.nih.gov/pubmed/10326844 Brun-Buisson C, Meshaka P, Pinton P, Vallet B; EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30(4):580-8. http://www.ncbi.nlm.nih.gov/pubmed/14997295 Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644-55. http://www.ncbi.nlm.nih.gov/pubmed/1303622 Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31(4):1250-6. http://www.ncbi.nlm.nih.gov/pubmed/12682500 Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med. 2000;26(Suppl.2):S148-S152 . http://www.ncbi.nlm.nih.gov/pubmed/18470710 Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J; Geneva Sepsis Network. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164(3):396-402. http://www.ncbi.nlm.nih.gov/pubmed/11500339 Carlet J, Dumay MF, Gottot S, Gouin F, Pappo M. (Guideliness for prevention of nosocomial infections in intensive care unit.) Arnette Ed Paris 1994:41-53. [article in French] Riedl CR, Plas E, Hübner WA, Zimmer H, Ulrich W, Pflüger H. Bacterial colonization of ureteral stents. Eur Urol 1999;36(1):53-9. http://www.ncbi.nlm.nih.gov/pubmed/10364656 DeGroot-Kosolcharoen J, Guse R, Jones JM. Evaluation of a urinary catheter with a preconnected closed drainage bag. Infect Control Hosp Epidemiol 1988;9(2):72-6. http://www.ncbi.nlm.nih.gov/pubmed/3343502 Persky L, Liesen D, Yangco B. Reduced urosepsis in a veterans’ hospital. Urology 1992;39(5):443-5. http://www.ncbi.nlm.nih.gov/pubmed/1580035 Glück T, Opal SM. Advances in sepsis therapy. Drugs 2004;64(8):837-59. http://www.ncbi.nlm.nih.gov/pubmed/15059039 Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345(19):1368-77. http://www.ncbi.nlm.nih.gov/pubmed/11794169
2.
3.
4.
5.
6.
7.
8.
9. 10.
11.
12. 13. 14.
UPDATE MARCH 2009
71
15.
16.
17.
18.
Annane D, Sebille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azouley E, Troch´ G, Chaumet-Riffaut P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):86271. http://www.ncbi.nlm.nih.gov/pubmed/12186604 van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345(19):1359-67. http://www.ncbi.nlm.nih.gov/pubmed/11794168 Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriquez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699-709. http://www.ncbi.nlm.nih.gov/pubmed/11236773 Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73. http://www.ncbi.nlm.nih.gov/pubmed/15090974
8. URETHRITIS 8.1
Definition
Primary urethritis has to be differentiated from secondary urethritis, which may be found in patients with indwelling catheters or urethral strictures and can be caused by uropathogens or by staphylococci. Besides infective causes of urethritis, chemical, mechanical and non-infective inflammatory causes also have to be considered, such as Reiter’s, Behçet’s and Wegener’s diseases (1). Only selected aspects of primary urethritis will be discussed in this chapter (2). For further details see also the EAU guidelines on sexually transmitted diseases (3).
8.2
Epidemiology
From a therapeutic and clinical point of view, gonorrhoeal urethritis has to be differentiated from non-specific urethritis. Non-specific urethritis is much more frequent in Central Europe than gonorrhoeal urethritis. There is a correlation between promiscuity and low socio-economic status and the frequency of infections due to N. gonorrhoeae and C. trachomatis. Infection is spread by sexual contact.
8.3 Pathogens Pathogens include N. gonorrhoeae, C. trachomatis, Mycoplasma genitalium and T. vaginalis. The frequency of the different species varies between patient populations (4-8). Mycoplasma hominis probably does not cause urethritis, while Ureaplasma urealyticum is an infrequent cause. In most cases, clinical evidence of Mycoplasma or Ureaplasma is due to an asymptomatic colonization of the urogenital tract.
8.4
Route of infection and pathogenesis
Causative agents either remain extracellularly on the epithelial layer or penetrate into the epithelium (N. gonorrhoeae, C. trachomatis) causing a pyogenic infection. Although arising from urethritis, chlamydiae and gonococci can spread further through the genito-urinary tract to cause epididymitis in the male or cervicitis, endometritis and salpingitis in the female.
8.5
Clinical course
Purulent discharge and alguria are symptoms of urethritis. However, many infections of the urethra are asymptomatic.
8.6
Diagnosis
A Gram stain of a urethral discharge or a urethral smear showing more than five leucocytes per high power field (x 1,000) and, eventually, gonococci located intracellularly as Gram-negative diplococci, indicate pyogenic urethritis. A positive leucocyte esterase test or > 10 leucocytes per high power field (x 400) in the first voiding
72
UPDATE MARCH 2009
urine specimen are diagnostic. In all patients with urethritis, and when sexual transmission is suspected, the aim should be to identify the pathogenic organisms. If an amplification system is used for identifying the pathogens, the first voiding urine specimen can be taken instead of a urethral smear. Trichomonas can usually be identified microscopically.
8.7
Therapy
The following guidelines for therapy comply with the recommendations of the Center for Disease Control and Prevention (9-11). The following antimicrobials can be recommended for the treatment of gonorrhoea: • Cefixime, 400 mg orally as a single dose • Ceftriaxone, 125 mg intramuscularly (with local anaesthetic) as a single dose • Ciprofloxacin, 500 mg orally as single dose • Ofloxacin, 400 mg orally as single dose • Levofloxacin, 250 mg orally as as single dose. Please note that fluoroquinolones, such as ciprofloxacin, levofloxacin, and ofloxacin, are contraindicated in adolescents (<18 years) and pregnant women. As gonorrhoeae is frequently accompanied by chlamydial infection, an antichlamydial active therapy should be added. The following treatments have been successfully applied in C. trachomatis infections. As first choice of treatment: • Azithromycin, 1 g orally as single dose • Doxycycline, 100 mg orally twice daily for 7 days. • • • •
As second choice of treatment: Erythromycin base, 500 mg orally four times daily for 7 days Erythromycin ethylsuccinate, 800 mg orally four times daily for 7 days Ofloxacin, 300 mg orally twice daily for 7 days Levofloxacin, 500 mg orally once daily for 7 days.
Doxycycline and azithromycin are considered to be equally effective in the treatment of chlamydial infections. Erythromycin is less effective and causes more side effects. Since in pregnant women fluoroquinolones and doxycycline are contraindicated, besides erythromycin and azithromycin a regimen with amoxicillin 500 mg three times daily for seven days is also recommended. If therapy fails, one should consider treating infections by T. vaginalis and/or Mycoplasma with a combination of metronidazole (2 g orally as single dose) and erythromycin (500 mg orally four times daily for 7 days). As in other sexually transmitted diseases, the treatment of sexual partners is necessary.
8.8 Prevention Patients with sexually transmitted urethritis should avoid unprotected sexual contact for the duration of the treatment and until symptoms have disappeared.
8.9
References
1.
Ebo DG, Mertens AV, De Clerck LS, Gentens P, Daelemans R. Relapse of Wegener’s granulomatosis presenting as a destructive urethritis and penile ulceration. Clin Rheumatol 1998;17(3):239-41. http://www.ncbi.nlm.nih.gov/pubmed/9694061 Friese K, Naber KG, Bredt W, Kuhn J. Urethritis. In: Marre R, Mertens T, Trautmann M, Vanek E, eds. Klinische infektiologie. Munich: Urban & Fischer, 2000, pp. 472-477. Schneede P, Tenke P, Hofstetter AG; Urinary Tract Infection Working Group of the Health Care Office of the European Association of Urology. Sexually transmitted Diseases (STDs) - a synoptic overview for urologists. Eur Urol 2003;44(1):1-7. http://www.ncbi.nlm.nih.gov/pubmed/12814668 Borchardt KA, al-Haraci S, Maida N. Prevalence of Trichomonas vaginalis in a male sexually transmitted disease clinic population by interview, wet mount microscopy, and the InPouch TV test. Genitourin Med 1995;71(6):405-6. http://www.ncbi.nlm.nih.gov/pubmed/8566985 Busolo F, Camposampiero D, Bordignon G, Bertollo G. Detection of Mycoplasma genitalium and Chlamydia trachomatis DNAs in male patients with urethritis using the polymerase chain reaction. New Microbiol 1997;20(4):325-32. http://www.ncbi.nlm.nih.gov/pubmed/9385602
2. 3.
4.
5.
UPDATE MARCH 2009
73
6.
7.
8. 9.
10.
11.
Evans BA, Bond RA, MacRae KD. Racial origin, sexual behaviour, and genital infection among heterosexual men attending a genitourinary medicine clinic in London (1993-4). Sex Transm Infect 1998;74(1):40-4. http://www.ncbi.nlm.nih.gov/pubmed/9634302 Evans BA, Kell PD, Bond RA, MacRae KD. Racial origin, sexual lifestyle, and genital infection among women attending a genitourinary medicine clinic in London (1992). Sex Transm Infect 1998;74(1):45-9. http://www.ncbi.nlm.nih.gov/pubmed/9634303 Krieger JN. Trichomoniasis in men: old issues and new data. Sex Transm Dis 1995;22(2):83-96. http://www.ncbi.nlm.nih.gov/pubmed/7624817 Workowski KA, Berman SM. CDC sexually transmitted diseases treatment guidelines. Clin Infect Dis 2002;35(Suppl 2):S135-S137. http://www.ncbi.nlm.nih.gov/pubmed/12353199 Burstein GR, Workowski KA. Sexually transmitted diseases treatment guidelines. Curr Opin Pediatr 2003;15(4):391-7. http://www.ncbi.nlm.nih.gov/pubmed/12891051 Scharbo-Dehaan M, Anderson DG. The CDC 2002 guidelines for the treatment of sexually transmitted diseases: implications for women’s health care. J Midwifery Womens Health 2003;48(2):96-104. http://www.ncbi.nlm.nih.gov/pubmed/12686941
9. PROSTATITIS AND CHRONIC PELVIC PAIN SYNDROME 9.1
Summary and recommendations
Bacterial prostatitis is a disease entity diagnosed clinically and by evidence of inflammation and infection localized to the prostate. According to the duration of symptoms, bacterial prostatitis is described as either acute or chronic, when symptoms persist for at least 3 months. It is recommended that European urologists use the classification suggested by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), in which bacterial prostatitis with confirmed or suspected infection is distinguished from chronic pelvic pain syndrome (CPPS). Acute bacterial prostatitis can be a serious infection. Parenteral administration of high doses of a bactericidal antibiotic is usually required, which may include a broad-spectrum penicillin, a third-generation cephalosporin, or a fluoroquinolone. All of these agents can be combined with an aminoglycoside for initial therapy. Treatment is required until there is defeverescence and normalization of infection parameters (IIIB). In less severe cases, a fluoroquinolone may be given orally for 10 days (IIIB). In chronic bacterial prostatitis, and if infection is strongly suspected in CPPS, a fluoroquinolone or trimethoprim should be given orally for 2 weeks after the initial diagnosis. The patient should then be reassessed and antibiotics only continued if pre-treatment cultures are positive and/or the patient has reported positive effects from the treatment. A total treatment period of 4-6 weeks is recommended (IIIB). Patients with CPPS are treated empirically with numerous medical and physical modalities. Despite the existence of some scientifically valid studies, no specific recommendations have been made until now. This has been because patients with CPPS probably represent a heterogeneous group of diseases and therapeutic outcome is always uncertain.
9.2
Introduction and definition
Traditionally, the term ‘prostatitis’ has included both acute and chronic bacterial prostatitis, in which an infective origin is accepted, and the term ‘prostatitis syndrome’ or more recently CPPS, in which no infective agent can be found and whose origin is multifactorial and in most cases obscure. Prostatitis and CPPS are diagnosed by symptoms and evidence of inflammation and infection localized to the prostate (1). A causative pathogen, however, is detected by routine methods in only 5-10% of cases (2), and for whom antimicrobial therapy therefore has a rational basis. The remainder of patients are treated empirically with numerous medical and physical modalities. However, recent improvement in classification and application of modern methods, including molecular biology, should allow proper systematization of treatment (3-5). This chapter will review documented or suspected bacterial infections of the prostate.
74
UPDATE MARCH 2009
9.3
Diagnosis
9.3.1 History and symptoms According to the duration of symptoms, bacterial prostatitis is described as either acute or chronic, the latter being defined by symptoms persisting for at least 3 months (3-5). The predominant symptoms are pain at various locations and lower urinary tract symptoms (LUTS) (Tables 9.1 and 9.2) (6-8). Chronic bacterial prostatitis is the most frequent cause of recurrent urinary tract infections in the male (9). Table 9.1: Localization of pain in prostatitis and CPPS* Site of pain Percentage of patients (%) • Prostate/perineum 46% • Scrotum and/or testes 39% • Penis 6% • Urinary bladder 6% • Lower back 2% *Adapted from Zermann et al. (6). Table 9.2: Lower urinary tract symptoms in prostatitis and CPPS* • Frequent need to urinate • Difficulty urinating, e.g. weak stream and straining • Pain on urination, or that increases with urination *Adapted from Alexander et al. (8). 9.3.1.1 Symptom questionnaires Symptoms appear to have the strongest basis for use as a classification parameter in bacterial prostatitis as well as in CPPS (10). Prostatitis symptom questionnaires have therefore been developed for the quantification of symptoms (10, 11). They include the Chronic Prostatitis Symptom Index (CPSI), which was recently developed by the International Prostatitis Collaborative Network (IPCN), initiated by the NIH (USA) (12). Although the CPSI has been validated, so far its benefit in clinical studies is still uncertain. The questionnaire contains four questions regarding pain or discomfort, two questions regarding urination and three questions related to quality of life (see Appendix 11.4). 9.3.2 Clinical findings In acute prostatitis, the prostate may be swollen and tender on digital rectal examination (DRE). Prostatic massage is contraindicated. Otherwise, the prostate is usually normal on palpation. An essential consideration in the clinical evaluation is to exclude differential diagnoses, such as other diseases in the urogenital organs and anorectal disorders. Clinical examination should include evaluation of the pelvic floor musculature. 9.3.3 Urine cultures and expressed prostatic secretion The most important investigations in the evaluation of the patient with prostatitis are quantitative bacteriological localization cultures and microscopy of the segmented urine and of expressed prostatic secretion (EPS), as described by Meares and Stamey (1) (see Appendix 12.6). According to the classification developed by the NIDDK/NIH (Table 9.3), the presence of leucocytes in post-massage urine and ejaculate are also included in the definition of inflammatory chronic prostatitis or CPPS (group IIIA) (3). The inclusion of leucocytes in the ejaculate as part of the new consensus CPPS concept allows almost twice as many patients to be reclassified into group IIIA as were formerly included in the category ‘abacterial prostatitis‘ using the earlier Drach’s classification (13). Table 9.3: Classification of prostatitis and CPPS according to NIDDK/NIH (3-5) Type Name and description I Acute bacterial prostatitis II Chronic bacterial prostatitis III Chronic abacterial prostatitis - chronic pelvic pain syndrome (CPPS) A. Inflammatory CPPS (white cells in semen/EPS/VB3) B. Non-inflammatory CPPS (no white cells in semen/EPS/VB3) IV Asymptomatic inflammatory prostatitis (histological prostatitis) CPPS = chronic pelvic pain syndrome; EPS = expressed prostatic secretion; VB3 = voided bladder urine 3 (urine following prostatic massage).
UPDATE MARCH 2009
75
The Enterobacteriaceae, especially E. coli, are the predominant pathogens in bacterial prostatitis (Table 9.4) (14). The significance of intracellular bacteria, such as Chlamydia trachomatis, is uncertain (15). In patients with immune deficiency or HIV infection, prostatitis may be caused by fastidious pathogens, such as Mycobacterium tuberculosis, Candida spp. and rare pathogens, such as Coccidioides immitis, Blastomyces dermatitidis and Histoplasma capsulatum (16). Table 9.4: The most common pathogens in prostatitis Aetiologically recognized pathogens* Escherichia coli Klebsiella spp. Proteus mirabilis Enterococcus faecalis Pseudomonas aeruginosa Organisms of debatable significance Staphylococci Streptococci Corynebacterium spp. Chlamydia trachomatis Ureaplasma urealyticum Mycoplasma hominis *Adapted from Weidner et al. (2) and Schneider et al. (14). There is no correlation between leucocyte and bacterial counts and the severity of symptoms in men with chronic prostatitis/CPPS (17). It has also been shown that culture, leucocyte and antibody status does not predict antibiotic response in this group of prostatitis (18). In both studies, however, patients with clearly defined chronic bacterial prostatitis were excluded. 9.3.4 Perineal biopsy Perineal biopsies may be taken to help in the detection of difficult-to-culture micro-organisms, but perineal biopsy should be reserved for research purposes and cannot be recommended as part of the routine work-up. Bacteria have been cultured from perineal prostate biopsies in 36% of men with CPPS, but these results do not differ from the findings in asymptomatic controls (19). 9.3.5 Other tests The main parameter for diagnosis of inflammation in the male urogenital tract is increased leucocyte counts in the prostatic fluid, post-prostate massage urine, and seminal fluid. Prostatic biopsy is not indicated in the routine management of prostatitis/CPPS. However, histological prostatitis is frequently diagnosed in biopsies taken for suspected prostate cancer. If such patients are asymptomatic, they are classified in the new category of ‘asymptomatic prostatitis’ (type IV) (Table 9.3). Other inflammatory markers include elevated pH, lactate dehydrogenase (LDH) and immunoglobulins (20). The cytokines, interleukin (IL)-1ß and tumour necrosis factor (TNF)-α, may be identified in EPS (20) and complement C3, coeruloplasmin or polymorphonuclear (PMN) elastase in the ejaculate. These tests, however, cannot be considered to be part of routine diagnostic work-up (21). Transrectal ultrasound (TRUS) may reveal intraprostatic abscesses, calcification in the prostate and dilatation in the seminal vesicles. However, TRUS is not an important classification parameter in prostatitis (22), as it is unreliable in the diagnosis of prostatitis. 9.3.6 Classification systems The purpose of the culture technique described by Meares and Stamey in 1968 was to decide whether bacteriuria originated from the urethra, the prostate or the bladder. Ten years, later Drach et al. (23) suggested a classification of prostatitis based on the work of Meares and Stamey, in which various types of prostatitis were differentiated according to the number of leucocytes and positive cultures in EPS and in segmented urine samples, i.e. first voided bladder urine-1 (VB1), mid-stream urine (second voided bladder urine-2, VB2) and urine following prostatic massage (third voided bladder urine-3, VB3). This has been the most widely used classification of prostatitis for almost three decades (Table 9.5) and is still included in the latest WHO classification of diseases (ICD 10) (24).
76
UPDATE MARCH 2009
Table 9.5: Classification of prostatitis according to Drach et al. (23) Classification Acute bacterial prostatitis Chronic bacterial prostatitis Chronic abacterial prostatitis Prostatodynia
Clinical and laboratory findings Clinically significant infection of the prostate Significant inflammation of the prostate Isolation of an aetiologically recognized organism from the prostatic fluid/urine Significant prostatic inflammation Failure to isolate an organism from the prostatíc fluid/urine, or isolation of an organism whose aetiological significance is debatable No significant prostatic inflammation Failure to isolate an organism from the prostatic fluid/urine
In 1995, the NIDDK of the NIH (USA) convened a workshop to ‘develop a plan which would enable clinicians and research investigators to effectively diagnose, treat, and eventually prevent the prostatitis syndrome‘ (4). The NIDDK recommended a new classification of the prostatitis syndrome, which has been accepted by the IPCN. The terms ‘abacterial prostatitis‘ and ‘prostatodynia’ were exchanged for ‘chronic pelvic pain syndrome (CPPS)’, with or without inflammation, respectively. Seminal secretion was added to segmented urine and EPS as an additional parameter. A new category (type IV) of asymptomatic prostatitis (histological prostatitis) was added (Table 9.3). This classification is now used as a logical basis for choice of treatment. 9.3.7 Diagnostic evaluation The content and order of procedures in the diagnostic evaluation of a patient with suspected prostatitis will depend on previous examinations undertaken by the GP, the established routines in different hospitals and countries and the distance from the patient’s home to the urologist. A suggested algorithm for diagnostic evaluation is presented in Table 9.6. Table 9.6: Algorithm for diagnostic urological work-up in prostatitis • • • • • • • •
Clinical evaluation Urinalysis and urine culture Exclude sexually transmitted diseases Micturition chart, uroflowmetry and residual urine Four-glass test according to Meares and Stamey Microscopy Culture Try antibiotics if signs of inflammation
9.3.8 Additional investigations The EAU working group believes that guidelines on prostatitis should not contain a set of minimum differential diagnostic examinations. An experienced urologist should decide which investigations are relevant for each individual patient. Bladder outflow and urethral obstruction should always be considered and ruled out by uroflowmetry, retrograde urethrography or endoscopy. If suspected, bladder cancer must be excluded with urine cytology and cystoscopy. A ureteric calculus is ruled out by unenhanced spiral computerized tomography or intravenous pyelography. Interstitial cystitis is diagnosed by means of a micturition chart, cystoscopy and biopsy. Anorectal examination is carried out whenever indicated. Microscopic examination of ejaculate is inferior to microscopy of EPS. It is difficult to differentiate between spermatocytes and leucocytes, unless specific methods are applied, e.g. peroxidase staining (25), and the detection rate for positive cultures is significantly reduced (26). Video-urodynamics and advanced urodynamic examination with measurement of urethral closing pressure are not justified in the routine evaluation of a prostatitis patient, although intriguing results have been obtained in some studies (27). The measurement of cytokines, biofilms, etc. in EPS has research interest only (6,28). Prostatespecific antigen (PSA) values may be elevated in both symptomatic and asymptomatic prostatitis (29). If a patient has elevated PSA and evidence of prostatic inflammation, serum PSA will normalize after antimicrobial treatment for 4 weeks in about 50% of patients (30). A delay of at least 3 months should be allowed before it can be assumed a stable level of PSA has been reached. Measurement of free and total PSA adds no practical diagnostic information in prostatitis (31).
UPDATE MARCH 2009
77
9.4
Treatment
9.4.1 Antibiotics Antibiotics are life-saving in acute bacterial prostatitis, recommended in chronic bacterial prostatitis and may be tried in inflammatory CPPS. Acute bacterial prostatitis can be a serious infection with fever, intense local pain and general symptoms. Parenteral administration of high doses of bactericidal antibiotics, such as a broad-spectrum penicillin, a third-generation cephalosporin or a fluoroquinolone, may be administered. For initial therapy, these regimens may be combined with an aminoglycoside. After defeverescence and normalization of infection parameters, oral therapy can be substituted and continued for a total of about 2-4 weeks (32). In less severe cases, a fluoroquinolone may be given orally for 10 days (5) (IVC). The recommended antibiotics in chronic bacterial prostatitis and inflammatory CPPS (NIH type IIIA), together with their advantages and disadvantages, are listed in Table 9.7 (33). Fluoroquinolones, such as ciprofloxacin and levofloxacin, are considered drugs of choice because of their favourable pharmacokinetic properties (33) (IIbB), their generally good safety profile, and antibacterial activity against Gram-negative pathogens, including Pseudomonas aeruginosa. In addition, levofloxacin is active against Gram-positive and ‘atypical’ pathogens, such as C. trachomatis and genital mycoplasmas (IIbB). The duration of antibiotic treatment is based on experience and expert opinion and is supported by many clinical studies (34). In chronic bacterial prostatitis and in inflammatory CPPS, antibiotics should be given for 2 weeks after the initial diagnosis. The patient should then be reassessed and antibiotics continued only if cultures are positive or the patient reports positive effects from the treatment. A total treatment period of 4-6 weeks is recommended. Relatively high doses are needed and oral therapy is preferred (33, 34) (IIIB). The reason for administration of antibiotics in inflammatory CPPS is that there may be a bacterial infection, even though bacteria have not been detected by routine methods (35, 36). Furthermore, many clinical studies report a beneficial effect of antibiotics in inflammatory CPPS (37, 38) (IIaB). If intracellular bacteria have been detected or are suspected, tetracyclines or erythromycin should be given (33, 38) (IIbB). 9.4.2 Antibiotics and α-blockers in combination therapy Urodynamic studies have shown increased urethral closing pressure in patients with chronic prostatitis (5). A combination treatment of α-blockers and antibiotics is reported to have a higher cure rate than antibiotics alone in inflammatory CPPS (Type IIIA+B) (39) (IbB). This is a treatment option favoured by many urologists. However, in a recent, randomized, double-blind placebo-controlled multicentre study, it was shown that neither ciprofloxacin, tamsulozin, nor the combination of both ciprofloxacin and tamsulozin were superior to placebo in reducing symptoms in men with moderate to severe symptoms (40) (IbB). However, in this latter study, many patients were included who had already been heavily pretreated with different drug regimens.
Table 9.7: Antibiotics in chronic bacterial prostatitis* Antibiotic Advantages Fluoroquinolones • Favourable pharmacokinetics • Excellent penetration into the prostate • Good bioavailability • Equivalent oral and parenteral pharmacokinetics (depending on the substance) • Good activity against ‘typical’ and atypical pathogens and Pseudomonas aeruginosa • In general, good safety profile
Disadvantages
Depending on the substance: Recommend • Drug interactions • Phototoxicity • Central nervous system adverse events
Trimethoprim • Good penetration into prostate • • Oral and parenteral forms available • Relatively cheap • Monitoring unnecessary
78
Recommendation
No activity against Pseudomonas, some enterococci and some Enterobacteriaceae
Consider
UPDATE MARCH 2009
• Active against most relevant pathogens Tetracyclines • Cheap • • Oral and parenteral forms available • • Good activity against Chlamydia and Mycoplasma • • Macrolides • Reasonably active against • Gram-positive bacteria • Active against Chlamydia • • Good penetration into prostate • Relatively non-toxic *Adapted from Bjerklund Johansen et al. (33).
No activity against Reserve for Ps. aeruginosa special indications Unreliable activity against coagulase-negative staphylococci, E.coli, other Enterobacteriaceae, and enterococci Contraindicated in renal and liver failure Risk of skin sensitization
Minimal supporting data from clinical trials Unreliable activity against Gram-negative bacteria
Reserve for special indications
9.4.3 Other oral medication The α-blocker, terazosin, was found to be superior to placebo in reducing symptoms for patients with CPPS (41) (IbB). Pentosan polysulphate sodium may reduce symptoms and improve quality of life in patients with CPPS (42) (IIaB). Finasteride will provide some improvement for patients with category IIIA prostatitis (43) (IbB). 9.4.4 Intraprostatic injection of antibiotics This treatment has not been evaluated in controlled trials and should be considered only if oral treatment fails to eradicate the infection (44, 45). 9.4.5 Surgery In acute prostatitis, some patients need bladder drainage, preferably with a suprapubic catheter. A positive effect of transurethral resection of the prostate (TURP) and transurethral needle ablation has been observed in patients with severe discomfort (46, 47) (IIaB). Even radical prostatovesiculectomies have been carried out to relieve the pain of chronic prostatitis, the results of which are dubious (48). In general, surgery should be avoided in the treatment of prostatitis patients, except for drainage of prostatic abscesses. 9.4.6 Other treatment forms Microwave energy delivered from Prostatron 2.0 has an in-vitro bactericidal effect on laboratory-cultured E. coli and E. cloacae (49), and transurethral microwave thermotherapy (TUMT) in inflammatory CPPS was proven superior to sham-treated controls (50) (IbB). However, TUMT is still considered an experimental treatment option in patients with a suspected infection. A number of other medical and physical treatment modalities have been suggested in noninflammatory CPPS. Since in this condition there is no evidence of an infection, a full coverage of this topic lies beyond the scope of this review and the reader is referred to other publications. It should be recalled, however, that symptoms will resolve within 1 year in about 30% of men with CPPS (51) (2).
9.5
References
1.
Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968;5(5):492-518. http://www.ncbi.nlm.nih.gov/pubmed/4870505 Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection 1991;19 Suppl 3:S119-S125. http://www.ncbi.nlm.nih.gov/pubmed/2055646 Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282(3):236-7. http://www.ncbi.nlm.nih.gov/pubmed/10422990
2.
3.
UPDATE MARCH 2009
79
4. 5. 6.
7.
8. 9. 10.
11. 12.
13.
14.
15.
16. 17.
18.
19.
20.
21.
22.
80
Workshop Committee of the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK). Chronic prostatitis workshop. Bethesda, Maryland, 1995, Dec 7-8. Schaeffer AJ. Prostatitis: US perspective. Int J Antimicrob Agents 1999;11(3-4):205-11. http://www.ncbi.nlm.nih.gov/pubmed/10394972 Zermann DH, Ishigooka M, Doggweiler R, Schmidt RA. Neurourological insights into the etiology of genitourinary pain in men. J Urol 1999;161(3):903-8. http://www.ncbi.nlm.nih.gov/pubmed/10022711 Alexander RB, Ponniah S, Hasday J, Hebel JR. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 1998;52(5):744-9. http://www.ncbi.nlm.nih.gov/pubmed/9801092 Alexander RB, Trissel D. Chronic prostatitis: results of an Internet survey. Urology 1996;48(4):568-74. http://www.ncbi.nlm.nih.gov/pubmed/8886062 Krieger JN. Recurrent lower urinary tract infections in men. J New Rem Clin 1998;47:4-15. Krieger JN, Egan KJ, Ross SO, Jacobs R, Berger RE. Chronic pelvic pains represent the most prominent urogenital symptoms of ‘chronic prostatitis‘. Urology 1996;48(5):715-21. http://www.ncbi.nlm.nih.gov/pubmed/8911515 Nickel JC. Effective office management of chronic prostatitis. Urol Clin North Am 1998;25(4):677-84. http://www.ncbi.nlm.nih.gov/pubmed/10026774 Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, Alexander RB, Farrar JT, O’Leary MP. The National Institute of Health chronic prostatitis symptom index: development and validation of new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;162(2):369-75. http://www.ncbi.nlm.nih.gov/pubmed/10411041 Krieger JN, Jacobs RR, Ross SO. Does the chronic prostatitis/pelvic pain syndrome differ from nonbacterial prostatitis and prostatodynia? J Urol 2000;164(5):1554-8. http://www.ncbi.nlm.nih.gov/pubmed/11025703 Schneider H, Ludwig M, Hossain HM, Diemer T, Weidner W. The 2001 Giessen Cohort Study on patients with prostatitis syndrome - an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia 2003;35(5):258-62. http://www.ncbi.nlm.nih.gov/pubmed/14535851 Badalyan RR, Fanarjyan SV, Aghajanyan IG. Chlamydial and ureaplasmal infections in patients with nonbacterial chronic prostatitis. Andrologia 2003;35(5):263-5. http://www.ncbi.nlm.nih.gov/pubmed/14535852 Naber KG, Weidner W. Prostatitits, epididymitis and orchitis. In: Armstrong D, Cohen J, eds. Infectious diseases. London: Mosby, 1999; Chapter 58. Schaeffer AJ, Knauss JS, Landis, JR, Propert KJ, Alexander RB, Litwin MS, Nickel JC, O’Leary MP, Nadler RB, Pontari MA, Shoskes DA, Zeitlin SI, Fowler JE Jr, Mazurick CA, Kusek JW, Nyberg LM; Chronic Prostatitis Collaborative Research Network Study Group. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 2002;168(3):1048-53. http://www.ncbi.nlm.nih.gov/pubmed/12187220 Nickel JC, Downey J, Johnston B, Clark J; Canadian Prostatitis Research Group. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol 2001;165(5):1539-44. http://www.ncbi.nlm.nih.gov/pubmed/11342913 Lee JC, Muller CH, Rothman I, Agnew KJ, Eschenbach D, Ciol MA, Turner JA, Berger, RE. Prostate biopsy culture findings of men with chronic pelvis pain syndrome do not differ from those of healthy controls. J Urol 2003;169(2):584-8. http://www.ncbi.nlm.nih.gov/pubmed/12544312 Nadler RB, Koch AE, Calhoun EA, Campbell PL, Pruden DL, Bennett CL, Yarnold PR, Schaeffer AJ. IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol 2000;164(1):214-8. http://www.ncbi.nlm.nih.gov/pubmed/10840462 Blenk H, Hofstetter A. Complement C3, coeruloplasmin and PMN-elastase in the ejaculate in chronic prostato-adnexitis and their diagnostic value. Infection 1991;19 Suppl 3:S138-S140. http://www.ncbi.nlm.nih.gov/pubmed/2055649 Doble A, Carter SS. Ultrasonographic findings in prostatitis. Urol Clin North Am 1989;16(4):763-72. http://www.ncbi.nlm.nih.gov/pubmed/2683305
UPDATE MARCH 2009
23.
24. 25.
26.
27.
28.
29.
30.
31.
32.
33.
34. 35.
36.
37.
38.
39.
40.
Drach GW, Fair WR, Meares EM, Stamey TA. Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia? J Urol 1978;120(2):266. http://www.ncbi.nlm.nih.gov/pubmed/671653 International Classification of Diseases (ICD). 10th version. Geneva: WHO, 1989. Krieger JN, Berger RE, Ross SO, Rothman I, Muller CH. Seminal fluid findings in men with nonbacterial prostatitis and prostatodynia. J Androl 1996;17(3):310-8. http://www.ncbi.nlm.nih.gov/pubmed/8792222 Weidner W, Jantos C, Schiefer HG, Haidl G, Friedrich HJ. Semen parameters in men with and without proven chronic prostatitis. Arch Androl 1991;26(3):173-83. http://www.ncbi.nlm.nih.gov/pubmed/1872650 Kaplan SA, Santarosa RP, D’Alisera PM, Fay BJ, Ikeguchi EF, Hendricks J, Klein L, Te AE. Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option. J Urol 1997;157(6): 2234-7. http://www.ncbi.nlm.nih.gov/pubmed/9146624 Goto T, Nakame Y, Nishida M, Ohi Y. Bacterial biofilms and catheters in experimental urinary tract infection. Int J Antimicrob Agents 1999;11(3-4):227-31. http://www.ncbi.nlm.nih.gov/pubmed/10394975 Carver BS, Bozeman CB, Williams BJ, Venable DD. The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J Urol 2003;169(2):589-91. http://www.ncbi.nlm.nih.gov/pubmed/12544313 Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 2002;167(4):1723-6. http://www.ncbi.nlm.nih.gov/pubmed/11912396 Polascik TJ, Oesterling JE, Partin AW: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999;162(2):293-306. http://www.ncbi.nlm.nih.gov/pubmed/10411025 Schaeffer AJ, Weidner W, Barbalias GA, Botto H, Bjerklund Johansen TE, Hochreiter WW, Krieger JN, Lobel B, Naber KG, Nickel JC, Potts JM, Tenke P, Hart C. Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2003;43(Suppl 2):1-4. Bjerklund Johansen TE, Grüneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, Palou Redorta J, van Cangh PJ. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1998;34(6):457-66. http://www.ncbi.nlm.nih.gov/pubmed/9831786 Naber KG. Antimicrobial treatment of bacterial prostatitis. Eur Urol 2003;43(Suppl 2):23-6. Krieger JN, Riley DE, Roberts MC, Berger RE. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol 1996;34(12):3120-8. http://www.ncbi.nlm.nih.gov/pubmed/8940458 Krieger JN, Riley DE, Vesella RL, Miner DC, Ross SO, Lange PH. Bacterial dna sequences in prostate tissue from patients with prostate cancer and chronic prostatitis. J Urol 2000;164(4):1221-8. http://www.ncbi.nlm.nih.gov/pubmed/10992370 de la Rosette JJ, Hubregtse MR, Meuleman EJ, Stolk-Engelaar MV, Debruyne FM. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993;41(4):301-7. http://www.ncbi.nlm.nih.gov/pubmed/8470312 Ohkawa M, Yamaguchi K, Tokunaga S, Nakashima T, Shoda R. Antimicrobial treatment for chronic prostatitis as a means of defining the role of Ureaplasma urealyticum. Urol Int 1993;51(3):129-32. http://www.ncbi.nlm.nih.gov/pubmed/8249222 Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998;159(3):883-7. http://www.ncbi.nlm.nih.gov/pubmed/9474175 Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O’Leary MP, Pontari MA, McNaughtonCollins M, Shoskes DA, Comiter CV, Datta NS, Fowler JE Jr, Nadler RB, Zeitlin SI, Knauss JS, Wang Y, Kusek JW, Nyberg LM Jr, Litwin MS; Chronic Prostatitis Collaborative Research Network. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004;141(8):581-9. http://www.ncbi.nlm.nih.gov/pubmed/15492337
UPDATE MARCH 2009
81
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, Yap HW, Krieger JN. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 2003;169(2):592-6. http://www.ncbi.nlm.nih.gov/pubmed/12544314 Nickel JC, Johnston B, Downey J, Barkin J, Pommerville P, Gregoire M, Ramsey E. Pentosan polysulfate therapy for chronic nonbacterial prostatitis (chronic pelvic pain syndrome category IIIA): a prospective multicenter clinical trial. Urology 2000;56(3):413-7. http://www.ncbi.nlm.nih.gov/pubmed/10962305 Nickel JC, Downey J, Pontari MA, Shoskes DA, Zeitlin SI. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int 2004;93(7):991-5. http://www.ncbi.nlm.nih.gov/pubmed/15142149 Mayersak JS. Transrectal ultrasonography directed intraprostatic injection of gentamycin-xylocaine in the management of the benign painful prostate syndrome. A report of a 5 year clinical study of 75 patients. Int Surg 1998;83(4):347-9. http://www.ncbi.nlm.nih.gov/pubmed/10096759 Jiménez-Cruz JF, Tormo FB, Gómez JG. Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. J Urol 1988;139(5):967-70. http://www.ncbi.nlm.nih.gov/pubmed/3283385 Darenkov AF, Simonov VIa, Kuz’min GE, Koshkarov II. [Transurethral electroresection in chronic prostatitis and its complications.] Urol Nefrol (Mosk) 1989;(1):18-23. [article in Russian] http://www.ncbi.nlm.nih.gov/pubmed/2470185 Lee KC, Jung PB, Park HS, Whang JH, Lee JG. Transurethral needle ablation for chronic nonbacterial prostatitis. BJU Int 2002;89(3):226-9. http://www.ncbi.nlm.nih.gov/pubmed/11856102 Frazier HA, Spalding TH, Paulson DF. Total prostatoseminal vesiculectomy in the treatment of debilitating perineal pain. J Urol 1992;148(2 Pt 1):409-11. http://www.ncbi.nlm.nih.gov/pubmed/1635150 Sahin A, Eiley D, Goldfischer ER, Stravodimos KG, Zeren S, Isenberg HD, Smith AD. The in vitro bactericidal effect of microwave energy on bacteria that cause prostatitis. Urology 1998;52(3):411-5. http://www.ncbi.nlm.nih.gov/pubmed/9730452 Nickel JC, Sorensen R. Transurethral microwave thermotherapy for nonbacterial prostatitis: a randomized double-blind sham controlled study using new prostatitis specific assessment questionnaires. J Urol 1996;155(6):1950-5. http://www.ncbi.nlm.nih.gov/pubmed/8618295 Nickel JC, Downey JA, Nickel KR, Clark JM. Prostatitis-like symptoms: one year later. BJU Int 2002;90(7):678-81. http://www.ncbi.nlm.nih.gov/pubmed/12410746
10. EPIDIDYMITIS AND ORCHITIS 10.1
Definition and classification
Epididymitis, inflammation of the epididymis, causes pain and swelling which is almost always unilateral and relatively acute in onset. In some cases, the testis is involved in the inflammatory process (epididymo-orchitis). On the other hand, inflammatory processes of the testicle, especially virally induced orchitis, often involve the epididymis. Orchitis and epididymitis are classified as acute or chronic processes according to the onset and clinical course. Chronic disease with induration develops in 15% of acute epididymitis cases. In the case of testicular involvement, chronic inflammation may result in testicular atrophy and the destruction of spermatogenesis (1, 2).
10.2
Incidence and prevalence
There are no new data available concerning the incidence and prevalence of epididymitis. According to older data, acute epididymitis was a major cause for admission to hospitals of military personnel (2) (III). Acute epididymitis in young males is associated with sexual activity and infection of the consort (3) (III). The most common type of orchitis, mumps-orchitis, develops in 20-30% of post-pubertal patients undergoing mumps infection. The incidence depends upon the vaccination status of the population (4). A
82
UPDATE MARCH 2009
primary chronic orchitis is the granulomatous disease, a rare condition with uncertain aetiology reported in about 100 cases in the literature (5).
10.3
Morbidity
Complications in epididymo-orchitis include abscess formation, testicular infarction, testicular atrophy, development of chronic epididymal induration and infertility (2). Epididymitis caused by sexually transmitted organisms occurs mainly in sexually active males aged < 35 years (2, 6) (III). The majority of cases of epididymitis are due to common urinary pathogens, which are also the most common cause of bacteriuria (2, 6) (III). Bladder outlet obstruction and urogenital malformations are risk factors for this type of infection.
10.4 Pathogenesis and pathology Typically, in epididymitis due to common bacteria and sexually transmitted organisms, the infection is spread from the urethra or bladder. In non-specific granulomatous orchitis, auto-immune phenomena are assumed to trigger chronic inflammation (5, 7). Orchitis of the child and mumps-orchitis are of haematogenous origin (7). Epididymo-orchitis is also seen in systemic infections such as tuberculosis, lues, brucellosis and cryptococcus disease.
10.5
Diagnosis
In acute epididymitis, the inflammation and swelling usually begin in the tail of the epididymis, and may spread to involve the rest of the epididymis and testicular tissue. The spermatic cord is usually tender and swollen. All men with epididymitis that results from sexually transmitted organisms have a history of sexual exposure, which can lie dormant for months before the onset of symptoms. If the patient is examined immediately after obtaining a urinalysis, urethritis and urethral discharge may be missed because WBC and bacteria have been washed out of the urethra during urination. The microbial aetiology of epididymitis can usually be determined by examination of a Gram stain of a urethral smear and/or an MSU for the detection of Gram-negative bacteriuria. The presence of intracellular Gram-negative diplococci on the smear correlates with an infection of N. gonorrhoeae. The presence of only WBC on a urethral smear indicates the presence of non-gonorrhoic urethritis. C. trachomatis will be isolated in approximately two-thirds of these patients (2, 6) (III). Ejaculate analysis according to WHO criteria including leucocyte analysis may indicate persistent inflammatory activity. In many cases, transient decreased sperm counts and forward motility can be found. Azoospermia due to a complete obstruction of both epididymis is a rare complication (8). If mumps-orchitis is suspected, a history of parotitis and evidence of IgM antibodies in the serum supports the diagnosis. In about 20% of mumps-orchitis cases, the disease occurs bilaterally in post-pubertal men with a risk of testicular atrophy and azoospermia (3) (III). 10.5.1 Differential diagnosis It is imperative for the physician to differentiate between epididymitis and spermatic cord torsion as soon as possible using all available information, including the age of the patient, history of urethritis, clinical evaluation and Doppler (duplex) scanning of testicular blood flow.
10.6
Treatment
Only a few studies have been performed measuring the penetration of antimicrobial agents into epididymis and testis in human. Of these, the fluoroquinolones have shown favourable properties (9) (IIa). Antimicrobials should be selected on the empirical basis that in young, sexually active men C. trachomatis is usually causative, and that in older men with BPH or other micturition disturbances, the most common uropathogens are involved. Studies comparing microbiological results from puncture of the epididymis and from urethral swabs as well as urine have shown very good correlation. Therefore, prior to antimicrobial therapy, a urethral swab and MSU should be obtained for microbiological investigation (C). Again, fluoroquinolones, preferably those with activity against C. trachomatis (e.g. ofloxacin and levofloxacin), should be the drugs of first choice, because of their broad antibacterial spectra and their favourable penetration into the tissues of the urogenital tract. If C. trachomatis has been detected as an aetiological agent, treatment could also be continued with doxycycline, 200 mg/day, for a total treatment period of at least 2 weeks. Macrolides may be used as alternative agents (C). Supportive therapy includes bed rest, uppositioning of the testes and antiphlogistic therapy. Since, for young men, epididymitis can lead to permanent occlusion of the epididymal ducts and thus to infertility, one should consider antiphlogistic therapy with methylprednisolone, 40 mg/day, and reduce the dose by half every second day (C). In case of C. trachomatis epididymitis, the sexual partner should also be treated (C). If uropathogens
UPDATE MARCH 2009
83
are found as causative agents, a thorough search for micturition disturbances should be carried out to prevent relapse (C). Abscess-forming epididymitis or orchitis also needs surgical treatment. Chronic epididymitis can sometimes be the first clinical manifestation of urogenital tuberculosis.
10.7
References
1.
Naber KG, Weidner W. Prostatitis, epididymitis, orchitis. In: Armstrong D, Cohen J, eds. Infectious diseases. London: Mosby, Harcourt Publishers Ltd, 1999, pp. 1-58. Berger RE. Epididymitis. In: Sexually transmitted diseases. Holmes KK, Mardh P-A, Sparling PF, Wiesner PJ (eds). New York: McGraw-Hill, 1984; pp. 650-662. Robinson AJ, Grant JB, Spencer RC, Potter C, Kinghorn GR. Acute epididymitis: why patient and consort must be investigated. Br J Urol 1990;66(6):642-5. http://www.ncbi.nlm.nih.gov/pubmed/2265337 Rüther U, Stilz S, Röhl E, Nunnensiek C, Rassweiler J, Dörr U, Jipp P. Successful interferon-alpha 2, a therapy for a patient with acute mumps orchitis. Eur Urol 1995;27(2):174-6. http://www.ncbi.nlm.nih.gov/pubmed/7744163 Aitchison M, Mufti GR, Farrell J, Paterson PJ, Scott R. Granulomatous orchitis. Review of 15 cases. Br J Urol 1990;66(3):312-4. http://www.ncbi.nlm.nih.gov/pubmed/2207549 Weidner W, Schiefer HG, Garbe C. Acute nongonococcal epididymitis. Aetiological and therapeutic aspects. Drugs 1987;34 Suppl 1:111-7. http://www.ncbi.nlm.nih.gov/pubmed/3481311 Nistal M, Paniagua R. Testicular and Epididymal Pathology. Stuttgart: Thieme, 1984. Weidner W, Garbe C, Weissbach L, Harbrecht J, Kleinschmidt K, Schiefer HG, Friedrich HJ. [Initial therapy of acute unilateral epididymitis using ofloxacin. II. Andrological findings.] Urologe A 1990;29(5):277-80. http://www.ncbi.nlm.nih.gov/pubmed/2120839 Ludwig M, Jantos CA, Wolf S, Bergmann M, Failing K, Schiefer HG, Weidner W. Tissue penetration of sparfloxacin in a rat model of experimental Escherichia coli epididymitis. Infection 1997;25(3):178-84. http://www.ncbi.nlm.nih.gov/pubmed/9181388
2. 3.
4.
5.
6.
7. 8.
9.
11. PERI-OPERATIVE ANTIBACTERIAL PROPHYLAXIS IN UROLOGY 11.1
Summary
The aim of antimicrobial prophylaxis in urological surgery is to prevent infective complications resulting from diagnostic and therapeutic procedures. However, the evidence on the best choice of antibiotics and prophylactic regimens is limited. There is no evidence for any benefits of antibiotic prophylaxis in standard non-complicated endoscopic procedures and extracorporeal shockwave lithotripsy (ESWL), though it is recommended in complicated procedures and patients with identified risk factors. For open surgery, the same rules as in abdominal surgery can be applied. No antibiotic prophylaxis is required for clean operations, while a single or 1-day dosage is recommended in clean-contaminated operations. Opening of the urinary tract should be considered as clean-contaminated surgery. It is essential to categorize patients according to risk factors for infection. These include: • history of genitourinary infection • previous instrumentation • assumed bacterial colonization • prolonged hospital or institutional stay • risk factors related to general health, e.g. diabetes mellitus, impaired immune system, malnutrition. A single dose or a short course of antimicrobials can be given, either parenterally or orally. The administration route will depend on the type of intervention and patient characteristics. Oral administration requires drugs having good bioavailability. In a case of continuous urinary drainage, prolongation of perioperative antibiotic prophylaxis is not recommended. Many antibiotics are suitable for peri-operative antibacterial prophylaxis, e.g. second-generation cephalosporins, co-trimoxazole-sulphamethoxazole (TMP-SMZ), fluoroquinolones, aminopenicillins plus a beta-lactam inhibitor (BLI), and aminoglycosides. Broader-spectrum antibiotics should be used sparingly and
84
UPDATE MARCH 2009
reserved for treatment. This applies also to the use of vancomycin. The use of antimicrobials should be based on knowledge of the local pathogen profile and antibiotic susceptibility pattern. Best practice includes surveillance and an audit of infectious complications.
11.2
Introduction
Antibiotic prophylaxis in urology has been controversial for many years. Most studies in the past have been poorly designed and have lacked statistical power. There has been inconsistency concerning definitions and assessment of risk factors. Urological practice has changed particularly in the last decade and older studies are no longer relevant. Several surveys among urologists in Europe have revealed wide differences in regimens and choice of antibiotics for prophylaxis. Clearly, there is a need for evidence-based guidelines (1-5). The present section aims to clarify the current state of knowledge and to propose practical recommendations based on clinical studies, expert opinions and professional consensus. The section also considers the recommendations of societies, such as the Paul Ehrlich Society for Chemotherapy, the corresponding working groups of the German Society of Urology (6), the French Association of Urology (7) and the Swedish-Norwegian Consensus Group (8). A recent Pan-European survey was carried out by the European Society for Infection in Urology, which is associated to the EAU in a large number of European countries including more than 200 urological services or units. The survey found that 9.7% of patients had a healthcare-(nosocomial-) associated urinary tract infection (NAUTI) (9). The result illustrates the need for a stringent antibiotic policy throughout Europe and that recommendations for antibiotic prophylaxis should be included in the general antibiotic policy of each hospital.
11.3 Goals of peri-operative antibacterial prophylaxis Antibiotic prophylaxis and antibiotic therapy are two different issues. Antibiotic prophylaxis aims at preventing healthcare-associated infections resulting from diagnostic and therapeutic procedures. Antibiotic prophylaxis is only one of several measures to prevent infections and can never compensate for poor hygiene and operative technique. On the other hand, antibiotic therapy is the treatment of a clinically suspected or microbiologically proven infection. There are some clinical situations, however, that are not easily classified as either ‘prophylaxis’ or ‘therapy’, e.g. patients with long-term indwelling catheters and bacteriuria. These patients must receive antibiotics at the time of surgery, regardless of how they are classified. There is also a dilemma regarding the definition of infections. The US Centers for Disease Control and Prevention (CDC) have presented definitions that are currently the most comprehensive and are recommended for the evaluation of infectious complications (10). These definitions were also used in the recent Pan-European study on NAUTI (see above) (9). Revision of definitions and recommendations are on-going in some countries (11). Table 11.1 illustrates the different types of infectious complications encountered in urological surgery. Table 11.1: Main types of healthcare associated infections encountered in urological practice Site of infection Minor Surgical wound Superficial wound infection Urinary tract Asymptomatic bacteriuria (bacterial colonization) Other urogenital sites Epididymitis Other sites Bacteraemia
Major Deep wound infection Wound rupture (abdominal dehiscence) Deep abdominal or surgical site abscess Febrile genitourinary infection Pyelonephritis Renal abscess Acute bacterial prostatitis Sepsis Pneumonia Septic embolism
Surgical site infections are seen after open surgery and to some extent after laparoscopic surgery. Febrile and complicated urinary tract infections (UTIs) are mainly complications of endoscopic surgery and the use of indwelling catheters and stents. They may also occur following open surgery of the urinary tract. Sepsis can be seen in all forms of procedures. The endpoints of peri-operative prophylaxis in urology are debatable. It is generally agreed that its main aim is to prevent symptomatic, febrile genitourinary infections such as acute pyelonephritis, prostatitis, epididymitis and urosepsis, as well as serious wound infections (Table 11.1). This might be extended to asymptomatic bacteriuria and even minor wound infections, which could easily be treated on an outpatient basis. In some circumstances, even minor wound infections can have serious consequences, as in implant surgery. On the other hand, asymptomatic bacteriuria after transurethral resection of the prostate (TURP)
UPDATE MARCH 2009
85
or other endourological procedures may disappear spontaneously and is usually of no clinical significance. Another question is whether peri-operative prophylaxis should also be concerned with the prevention of nonurological infections, e.g. endocarditis and post-operative pneumonia. Obviously, peri-operative antibacterial prophylaxis in urology has to go beyond the traditional aim of prophylaxis in surgery, which is the prevention of wound infections.
11.4
Risk factors
Risk factors (Table 11.2) are underestimated in most trials. However, they are important in pre-operative assessment of the patient. They are related to: (a) general condition of the patient, (b) special risk factors, which are either endogenous (e.g. urinary tract stone, bacteriuria, impaired renal function), or exogenous (e.g. catheters, ureteral stents or prosthetic devices) procedures. The traditional classification of surgical procedures according to Cruse and Foord (12) into clean, clean-contaminated, contaminated, and dirty operations applies to open surgery but not to endourological interventions. It is still controversial whether opening of the urinary tract (i.e. bladder surgery, radical prostatectomy and surgery of the renal pelvis and ureter) should be classified as clean or clean-contaminated surgery. The classification of transurethral surgery is also controversial, but considered by the members of the EAU Expert Group as clean-contaminated because the lower genitourinary tract is colonized by a microflora, even in the presence of sterile urine (5, 13, 14). Table 11.2: Generally accepted risk factors for infectious complications General risk factors Special risk factors associated with an increased bacterial load High age Long pre-operative hospital stay or recent hospitalization Deficient nutritional status History of recurrent genitourinary infections Impaired immune response Surgery involving bowel segment Diabetes mellitus Colonization with micro-organisms Smoking Long-term drainage Extreme weight Urinary obstruction Co-existing infection at a remote site Urinary stone Lack of control of risk factors
The Pan-European study on NAUTI (9) identified the three most important risk factors for infectious complications as: (a) an indwelling catheter (b) previous urogenital infection (c) long pre-operative hospital stay The risk of infection varies with the type of intervention. The wide spectrum of interventions further complicates the provision of clearcut recommendations. Furthermore, the bacterial load, the duration and difficulty of the operation, the surgeon’s skill and peri-operative bleeding may also influence the risk of infection (5).
11.5 Principles of antibiotic prophylaxis Antibiotic prophylaxis aims at protecting the patient but not at the expense of promoting resistance. However, there is good evidence that intelligent use of prophylaxis can lower the overall consumption of antibiotics (14, 15). It is essential to individualize the choice of antibiotic prophylaxis according to each patient’s cumulative risk factors (16). Urine culture prior to surgery is strongly recommended. Antibiotics cannot replace other basic measures to reduce infection (17-19). Unfortunately, the benefit of antibiotic prophylaxis for most modern urological procedures has not yet been established by well-designed interventional studies. 11.5.1 Timing There is a given time-frame during which antibiotic prophylaxis should be administered. Although the following guidelines are based on research into skin wounds and clean-contaminated bowel surgery, there is good reason to believe that the same findings apply to urological surgery. The optimal time for antibiotic prophylaxis is from 2 hours before but not later than 3 hours after the start of an intervention (20-22). For practical purposes, oral antibiotic prophylaxis should be given approximately 1 hour before the intervention. Intravenous antibiotic prophylaxis should be given at the induction of anaesthesia. These timings allow antibiotic prophylaxis to reach a peak concentration at the time of highest risk during the procedure and an effective
86
UPDATE MARCH 2009
concentration shortly afterwards (23). It is worth noting that a bloodstream infection can develop in less than an hour (20). 11.5.2 Route of administration Oral administration is as effective as the intravenous route for antibiotics with sufficient bioavailability. This is recommended for most interventions when the patient can easily take the drug between 1 and 2 hours before intervention. Giving the drug several hours before surgery is probably less effective. In other cases, intravenous administration is recommended. Local irrigation of the operating field with antibiotics is not recommended. 11.5.3 Duration of the regimen For most procedures, this issue has not yet been adequately addressed and cannot be answered. In principle, the duration of peri-operative prophylaxis should be minimized, ideally to a single pre-operative antibiotic dose. Peri-operative prophylaxis should be prolonged only where there are significant risk factors (see Section 11.4) (C). 11.5.4 Choice of antibiotics No clearcut recommendations can be given, as there are considerable variations in Europe regarding both bacterial spectra and susceptibility to different antibiotics. Antimicrobial resistance is usually higher in the Mediterranean countries compared with the Northern European countries; resistance is correlated with an up to four-fold difference in sales of antibiotics (24). Thus, knowledge of the local pathogen profile, susceptibility and virulence is mandatory in establishing local antibiotic guidelines. It is also essential to define the predominant pathogens for each type of procedure. When choosing an antimicrobial agent, it is necessary to consider the procedure-specific risk factors, the contamination load, the target organ, and the role of local inflammation. In general, many antibiotics are suitable for peri-operative antibacterial prophylaxis, e.g. second generation cephalosporins, TMP-SMZ, fluoroquinolones, aminopenicillins plus a BLI and aminoglycosides. Broader-spectrum antibiotics should be used sparingly and reserved for treatment. This applies also to the use of vancomycin.
11.6 Prophylactic regimens in defined procedures The list of major urological diagnostic and therapeutic procedures is given in Table 11.3 and the empirical relationship between the level of invasiveness and risk for infective complications is illustrated in Figure 11.1. Table 11.3: List of urological interventions Diagnostic procedures Fine-needle biopsy of the prostate Core-needle biopsy of the prostate Cystoscopy Urodynamic examination Radiological diagnostic intervention of the urinary tract Ureteroscopy Deviation procedures Insertion of indwelling catheter Insertion of suprapubic catheter Insertion of nephrostomy tube Insertion of ureteric stent Endourological operations Resection of bladder tumour Resection of prostate Minimal invasive prostatic operation, i.e. microwave thermotherapy Ureteroscopy for stone or tumour fulguration Percutaneous stone or tumour surgery Extracorporeal shockwave lithotripsy Laparoscopic surgery Radical prostatectomy Pyeloplasty Nephrectomy and nephrone-sparing surgery of the kidney Other major laparoscopic surgery including bowel surgery Open surgery Open surgery of the prostate, i.e. enucleation of prostatic adenoma Open stone surgery
UPDATE MARCH 2009
87
Pyeloplasty Nephrectomy and nephrone-sparing surgery of the kidney Nephro-ureterectomy including bladder resection Bladder resection Urethroplasty Implantation of prosthetic devices Urinary diversion procedures using intestinal segments
Figure 11.1 Level of invasiveness and risk of infection in urological procedures (empirical scheme) (5)
Open: clean contaminated
Risk of infection
Endourological: complex TRUS biopsy prostate
TURP Endourological: simple
Open: open UT Laparoscopic surg
Cystoscopy+ Cystoscopy
ESWL
Open: clean Laparoscopic surg Invasiveness
The recommendations for antibiotic prophylaxis in standard urological surgery is summarized in Table 11.4 and Appendix 12.4. 11.6.1. Diagnostic procedures Antimicrobial prophylaxis in core biopsy of the prostate is generally recommended (25, 26) (A). However, the choice of regimens remains debatable. Most regimens used are effective and recent studies suggest that oneday doses and even single doses are sufficient (27, 28) (IbA). No benefit of antibiotic prophylaxis has been reported for cystoscopy, urodynamic examinations and diagnostic simple ureteroscopy. However, bacteriuria, indwelling catheter and a history of genitourinary infection are risk factors that must be considered (29, 30) (IbA). 11.6.2. Endo-urological treatment procedures There is little evidence for benefit of antibiotic prophylaxis in transurethral resection of a bladder tumour (TURB). However, antibiotic prophylaxis should be considered in large tumours with a prolonged resection time, in large necrotic tumours and in patients with risk factors (IIIC). Transurethral resection of the prostate is the best-studied urological intervention. A meta-analysis of 32 prospective, randomized and controlled studies, including more than 4,000 patients, showed a benefit of antibiotic prophylaxis with a relative risk reduction of 65% and 77% for bacteriuria and septicaemia, respectively (31) (IaA). There is a difference between smaller resections in healthy patients and large resections in at-risk patients (Figure 11.1). There are few studies defining the risk of infection following ureteroscopy. No clearcut evidence exists. It is reasonable, however, to distinguish between low-risk procedures, such as simple diagnostic and distal stone treatment, from higher-risk procedures, such as treatment of proximal, impacted stones and intrarenal interventions (Figure 11.1) (5). Other risk factors (i.e. size, length, bleeding, and the surgeon’s experience) also need to be considered in the choice of regimen (5, 32-34) (IIbB). ESWL is one of the most commonly performed procedures in urology. No standard prophylaxis is recommended. However, prophylaxis must be considered in cases of internal stent and treatment due to the increased bacterial burden (e.g. indwelling catheter, nephrostomy tube, infectious stones) (35) (IbA). Most antibiotic groups have been evaluated, such as fluoroquinolones, BLIs, including cephalosporins, as well as TMP-SMZ, but comparative studies are limited.
88
UPDATE MARCH 2009
11.6.3. Laparoscopic surgery There is a lack of sufficiently powered studies in laparoscopic surgery. However, it seems reasonable to manage laparoscopic surgical procedures in the same manner as the corresponding open procedures (IVC). 11.6.4. Open urological operations without bowel segment, with or without opening of the urinary tract No standard antibiotic prophylaxis is recommended in clean operations. In a case of opening of the urinary tract, a single peri-operative parenteral dose is recommended. This is particularly true for open enucleation of prostatic adenoma for which there is a very high risk of post-operative infection (36) (IIbB). 11.6.5. Open urological operations with bowel segment Antibiotic prophylaxis is recommended as for clean-contaminated operations in general surgery. Single-dose or one-day dosage is recommended, although prolonged operation and other morbidity risk factors may support the use of a prolonged regimen, which should be less than 72 hours. The choice of antibiotic should focus on both aerobic and anaerobic pathogens. Evidence is based on colorectal surgery (IaA), but the experience is limited as for specific urological interventions (IIIB). 11.6.6. Post-operative drainage of the urinary tract When continuous urinary drainage is left in place after surgery, the prolongation of peri-operative antibacterial prophylaxis is not recommended unless a complicated infection requiring treatment is suspected. Asymptomatic bacteriuria (bacterial colonization) is only to be treated prior to surgery or after removal of the drainage tube (IIIB). 11.6.7. Implant of prosthetic devices When infectious complications occur in implant surgery, they are usually problematic and often result in removal of the prosthetic device. Diabetes mellitus is considered a specific risk factor for infection. Skin-related staphylococci are responsible for most infections. The antibiotics used must be chosen to target these strains (37-39) (IIaB). Table 11.4: recommendations for antibiotic prophylaxis in standard urological surgery Procedure Pathogens Prophylaxis (expected) Diagnostic procedures Transrectal biopsy Enterobacteriaceae All patients of the prostate Anaerobes? Cystoscopy Enterobacteriaceae No Urodynamic Enterococci examination Staphylococci Ureteroscopy Enterobacteriaceae No Enterococci Staphylococci Endourological surgery and ESWL ESWL Enterobacteriaceae No Enterococci Ureteroscopy for Enterobacteriaceae No uncomplicated distal Enterococci stone Staphylococci Ureteroscopy of Enterobacteriaceae All patients proximal or impacted Enterococci stone and Staphylococci percutaneous stone extraction TUR of the prostate Enterobacteriaceae All patients Enterococci UPDATE MARCH 2009
Antibiotics
Remarks
Fluoroquinolones Short course (<72h) TMP ± SMX Metronidazole? Cephalosporin 2nd Consider only in generation risk patients TMP ± SMX Cephalosporin 2nd Consider in risk generation patients TMP ± SMX Cephalosporin 2nd or 3rd generation TMP ± SMX Aminopenicillin/BLIa Cephalosporin 2nd or 3rd generation TMP ± SMX Aminopenicillin/BLI Fluoroquinolones Cephalosporin 2nd or 3rd generation TMP ± SMX Aminopenicillin/BLI Fluoroquinolones Cephalosporin 2nd or 3rd generation TMP ± SMX Aminopenicillin/BLI
In patients with stent or nephrostomy tube Consider in risk patients In patients with stent or nephrostomy tube Consider in risk patients Short course Length to be determined Intravenous suggested Low-risk patients and small-size prostate require no prophylaxis 89
TUR of bladder tumour Enterobacteriaceae No Cephalosporin 2nd Consider in risk Enterococci or 3rd generation patients and TMP ± SMX large necrotic Aminopenicillin/BLI tumours Open urological surgery Clean operations Skin-related No Consider in high-risk pathogens, patients e.g. staphylococci Short post-operative Catheter- associated catheter treatment uropathogens Clean-contaminated Enterobacteriaceae Recommended Cephalosporin 2nd Single peri-operative (opening of Enterococci or 3rd generation course urinary tract) Staphylococci TMP + SMX Aminopenicillin/BLI Clean-contaminated Enterobacteriaceae All patients Cephalosporin 2nd As for colonic (use of bowel Enterococci or 3rd generation surgery segments) Anaerobes Metronidazole Skin-related bacteria Implant of prosthetic Skin-related All patients Cephalosporin 2nd devices bacteria, or 3rd generation e.g. staphylococci Penicillin (penicillinase stable) Laparoscopic procedures As for open surgery BLI = beta-lactamase inhibitor; TMP ± SMX = trimethoprim with or without sulphametoxazole (co-trimoxazole); TUR = transurethral resection.
11.7
References
1.
Hedelin H, Bergman B, Frimodt-Møller C, Grabe M, Nurmi M, Vaage S, Walter S. [Antibiotic prophlaxis in diagnostic and therapeutic urological interventions.] Nord Med 1995;110(1):9-11,25. [article in Swedish] http://www.ncbi.nlm.nih.gov/pubmed/7831109 Wilson NI, Lewis HJ. Survey of antibiotic prophylaxis in British urological practice. Br J Urol 1985;57(4):478-82. http://www.ncbi.nlm.nih.gov/pubmed/4040787 Taylor HM, Bingham JB. Antibiotic prophylaxis for transrectal prostate biopsy. J Antimicrob Chemother 1997;39(2):115-7. http://www.ncbi.nlm.nih.gov/pubmed/9069529 Grabe M. Perioperative antibiotic prophylaxis in urology. Curr Opin Urol 2001;11(1):81-5. http://www.ncbi.nlm.nih.gov/pubmed/11148751 Grabe M. Controversies in antibiotic prophylaxis in urology. Int J Antimicrob Agents 2004;23 Suppl 1:S17-S23. http://www.ncbi.nlm.nih.gov/pubmed/15037324 Naber KG, Hofstetter AG, Brühl P, Bichler KH, Lebert C. [Guidelines for perioperative prophylaxis in interventions of the urinary and the male genital tract.] Chemotherapie J 2000;9:165-70. [article in German] Societé Francaise d’Anesthésie et de Réanimation (SFAR). (Recommendations for antibacterial prophylaxis in surgery. Actualisation 1999). Pyrexie 1999;3:21-30. [article in French] Antibiotic prophylaxis in surgery: summary of a Swedish-Norwegian Consensus Conference. Scand J Infect Dis 1998;30(6):547-57. http://www.ncbi.nlm.nih.gov/pubmed/10225381 Bjerklund-Johansen TE, Naber K, Tenke P. The Paneuropean prevalence study on nosocomial urinary tract infections. European Association of Urology, Vienna, Austria, 24-27 March, 2004. www.uroweb.org/peap Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayhall CG (ed). Hospital epidemiology and infection control. 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 2004: pp. 1659-1702. Association Française d’Urologie et Société de Pathologie Infectieuse de Langue Française. [Nosocomial urinary tract infections in adults.] www.urofrance.org [article in French]
2.
3.
4. 5.
6.
7. 8.
9.
10.
11.
90
UPDATE MARCH 2009
12.
13. 14.
15.
16. 17. 18. 19. 20.
21.
22.
23.
24.
25.
26. 27.
28.
29.
30.
31.
Cruse PJ, Foord R. The epidemiology of wound infection. A 10-year prospective of 62,939 wounds. Surg Clin North Am 1980;60(1):27-40. http://www.ncbi.nlm.nih.gov/pubmed/7361226 Love TA. Antibiotic prophylaxis and urologic surgery. Urology 1985; 26(5 Suppl):2-5. http://www.ncbi.nlm.nih.gov/pubmed/3904137 Wagenlehner FM, Wagenlehner C, Schinzel S, Naber KG; Working Group ‘Urological Infections’ of German Society of Urology. Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/ sulfamethoxazole versus a control group in patients undergoing TUR of the prostate. Eur Urol 2005;47(4):549-56. http://www.ncbi.nlm.nih.gov/pubmed/15774257 Grabe M, Forsgren A, Björk T, Hellsten S. Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery. Eur J Clin Microbiol 1987;6(1): 11-7. http://www.ncbi.nlm.nih.gov/pubmed/3569248 Grabe M, Shortliffe L, Lobel B et al. Risk factors. In: Naber KG, Pechère JC, Kumazawa J et al., eds. Nosocomial and health care associated infections in urology. Health Publications Ltd, 2001, pp. 35-57. Adam D, Daschner F. [Prevention of infection in surgery: hygienic measurements and antibiotic prophylaxis.] Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1993. [article in German] Blumenberg EA, Abrutyn E. Methods for reduction of UTI. Curr Opin Urol 1997;7:47-51. Mignard JP for the Comité de Formation Continue, Association Francaise d’Urologie. [Sterilisation and disinfection of instruments.] Progrès en Urologie 2004;14 (Suppl 1):1049-92. [article in French] Burke JF. The effective period of preventive antibiotic action in experimental incision and dermal lesion. Surgery 1961;50:161-8. http://www.ncbi.nlm.nih.gov/pubmed/16722001 Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992;326(5):281-6. http://www.ncbi.nlm.nih.gov/pubmed/1728731 Bates T, Siller G, Crathern BC, Bradley SP, Zlotnik RD, Couch C, James RD, Kaye CM. Timing of prophylactic antibiotics in abdominal surgery: trial of a pre-operative versus an intra-operative first dose. Br J Surg 1989;76(1):52-6. http://www.ncbi.nlm.nih.gov/pubmed/2645013 Bergamini TM, Polk HC Jr. The importance of tissue antibiotic activity in the prevention of operative wound infection. J Antimicrob Chemother 1989;23(3):301-13. http://www.ncbi.nlm.nih.gov/pubmed/2659564 Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Chemother 2003;22 Suppl 2:49-52. http://www.ncbi.nlm.nih.gov/pubmed/14527771 Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000;85(6):682-5. http://www.ncbi.nlm.nih.gov/pubmed/10759665 Webb NR, Woo HH. Antibiotic prophylaxis for prostate biopsy. BJU Int 2002;89(8):824-8. http://www.ncbi.nlm.nih.gov/pubmed/11972504 Sabbagh R, McCormack M, Péloquin F, Faucher R, Perreault JP, Perrotte P, Karakiewicz PI, Saad F. A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. Can J Urol 2004;11(2):2216-9. http://www.ncbi.nlm.nih.gov/pubmed/15182413 Lindstedt S, Lindström U, Ljunggren E, Wullt B, Grabe M. Single dose antibiotic prophylaxis in core prostate biopsy: Impact of Timing and identification of risk factors. Eur Urol 2006;50(4):832-7. http://www.ncbi.nlm.nih.gov/pubmed/16750292 Kraklau DM, Wolf JS Jr. Review of antibiotic prophylaxis recommendations for office based urologic procedures. Tech Urol 1999;5(3):123-8. http://www.ncbi.nlm.nih.gov/pubmed/10527253 Wilson L, Ryan J, Thelning C, Masters J, Tuckey J. Is antibiotic prophylaxis required for flexible cystoscopy? A truncated randomized double-blind controlled trial. J Endourol 2005;19(8):1006-8. http://www.ncbi.nlm.nih.gov/pubmed/16253070 Berry A, Barratt A. Prophylactic antibiotic use in transurethral prostatic resection: a meta-analysis. J Urol 2002;167(2 Pt 1):571-7. http://www.ncbi.nlm.nih.gov/pubmed/11792921
UPDATE MARCH 2009
91
32.
33. 34.
35.
36.
37.
38.
39.
Hendrikx AJ, Strijbos WE, de Knijff DW, Kums JJ, Doesburg WH, Lemmens WA. Treatment for extended-mid and distal ureteral stones: SWL or ureteroscopy? Results of a multicenter study. J Endourol 1999;13(10):727-33. http://www.ncbi.nlm.nih.gov/pubmed/10646679 Lindkvist K. [ESWL or ureteroscopy as primary treatment for ureteric stones. Doctoral dissertation.] University of Göteborg, 2004. [article in German] Rao PN, Dube DA, Weightman NC, Oppenheim BA, Morris J. Prediction of septicaemia following endourological manipulation for stones in the upper urinary tract. J Urol 1991;146:955-60. http://www.ncbi.nlm.nih.gov/pubmed/1895450 Pearle MS, Roehrborn CG. Antimicrobial prophylaxis prior to shock wave lithotripsy in patients with sterile urine before treatment: a meta-analysis and cost-effectivness analysis. Urology 1997;49(5): 679-86. http://www.ncbi.nlm.nih.gov/pubmed/9145970 Richter S, Lang R, Zur F, Nissenkorn I. Infected urine as a risk factor for postprostatectomy wound infection. Infect Control Hosp Epidemiol 1991;12(3):147-9. http://www.ncbi.nlm.nih.gov/pubmed/2022859 Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guidelines for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999;27(2):97-132. http://www.ncbi.nlm.nih.gov/pubmed/10196487 Kabalin JN, Kessler R. Infectious complications of penile prosthesis surgery. J Urol 1988;139(5): 953-5. http://www.ncbi.nlm.nih.gov/pubmed/3361672 Radomski SB, Herschorn S. Risk factors associated with penile prosthesis infection. J Urol 1992;147(2):383-5. http://www.ncbi.nlm.nih.gov/pubmed/1732599
12. SPECIFIC INFECTIONS Urogenital tuberculosis and bilharziasis are two infections that may affect the urogenital tracts. Although not endemic in Europe, cases of urogenital tuberculosis are occasionally diagnosed in all communities. In a world of globalisation, travellers are regularly confronted with situations in which they may be infected. Guidelines on the diagnosis and management of these two infectious have been published elsewhere. Following the abstract printed hereby, there is a direct link to these published Guidelines, free for consultation.
12.1.
Urogenital Tuberculosis
Nearly one third of the world’s population is estimated to be infected with Mycobacterium tuberculosis. Moreover, tuberculosis is the most common opportunistic infection in AIDS patients. Genitourinary tuberculosis is not very common but it is considered as a severe form of extra-pulmonary tuberculosis. The diagnosis of genitourinary tuberculosis is made based on culture studies by isolation of the causative organism; however, biopsy material on conventional solid media may occasionally be required. Drug treatment is the first line therapy in genitourinary tuberculosis. Treatment regiments of 6 months are effective in most of the patients. Although chemotherapy is the mainstay of treatment, surgery in the form of ablation or reconstruction may be unavoidable. Both radical and reconstructive surgery should be carried out in the first 2 months of intensive chemotherapy.
12.1.1 Reference 1.
Mete Cek M, Lenk S, Naber KG, Bishop MC, Bjerklund Johansen TE, Botto H, Grabe M, Lobel B, Palou Redorta J, Tenke P; the Members of the Urinary Tract Infection (UTI). EAU Guidelines for the Management of Genitourinary Tuberculosis. Eur Urol 2005;48(3):353-62. http://www.ncbi.nlm.nih.gov/pubmed/15982799
12.2.
Urogenital Schistosomiasis
More than 100 million people worldwide are affected by bilharziasis, caused by Schistosoma heamatobium. For travellers precaution is most important. For the population in endemic areas, an integrated approach including health education is necessary. Effective pharmacologic treatment is available.
92
UPDATE MARCH 2009
12.2.1 Reference 1.
Bichler KH, Savatovsky I; the Members of the Urinary Tract Infection (UTI) Working Group of the Guidelines Office of the European Association of Urology (EAU):, Naber KG, Bischop MC, BjerklundJohansen TE, Botto H, Cek M, Grabe M, Lobel B, Redorta JP, Tenke P. EAU guidelines for the management of urogenital schistosomiasis. Eur Urol 2006;49(6):998-1003. http://www.ncbi.nlm.nih.gov/pubmed/16519990
13. SEXUALLY TRANSMITTED INFECTIONS The classical bacteria that cause venereal diseases, e.g. gonorrhea, syphilis, chancroid and inguinal granuloma only account for a small proportion of all known STDs today. Other bacteria and viruses as well as yeasts, protozoa and epizoa must also be regarded as causative organisms of STD. Taken together, all sexually transmitted infections (STI) comprise more than 30 relevant STD pathogens. However, not all pathogens that can be sexually transmitted manifest diseases in the genitals and not all infections of the genitals are exclusively sexually transmitted. Concise information and tables summarising the diagnostic and therapeutic management of STDs in the field of Urology allow a synoptic overview and are in agreement with recent international guidelines of other specialities. Special considerations (i.e. HIV infection, pregnancy, infants, allergy) and recommended regimens may be looked up here.
13.1 Reference 1.
Schneede P, Tenke P, Hofstetter AG; Urinary Tract Infection Working Group of the Health Care Office of the European Association of Urology. Sexually transmitted diseases (STDs)--a synoptic overview for urologists. Eur Urol 2003;44(1):1-7. http://www.ncbi.nlm.nih.gov/pubmed/12814668
14. APPENDICES 14.1
Criteria for the diagnosis of a UTI, as modified according to IDSA/ESCMID guidelines (1-3)
Category Description Clinical features 1 Acute uncomplicated UTI Dysuria, urgency, frequency, in women; acute uncomplicated suprapubic pain, no urinary cystitis in women symptoms in 4 weeks before this episode 2 Acute uncomplicated Fever, chills, flank pain; other pyelonephritis diagnoses excluded; no history or clinical evidence of urological abnormalities (ultrasonography, radiography) 3 Complicated UTI Any combination of symptoms from categories 1 and 2 above; one or more factors associated with a complicated UTI (see text) 4 Asymptomatic bacteriuria No urinary symptoms
UPDATE MARCH 2009
Laboratory investigations > 10 WBC/mm3 > 103 cfu/mL*
> 10 WBC/mm3 > 104 cfu/mL*
> 10 WBC/mm3 > 105 cfu/mL* in women > 104 cfu/mL* in men, or in straight catheter urine in women > 10 WBC/mm3 > 105 cfu/mL* in two consecutive MSU cultures > 24 hours apart
93
5 Recurrent UTI At least three episodes of < 103 cfu/mL* (antimicrobial prophylaxis) uncomplicated infection documented by culture in last 12 months: women only; no structural/functional abnormalities MSU = mid-stream sample of urine; UTI = urinary tract infection; WBC = white blood cells. All pyuria counts refer to unspun urine. *Uropathogen in MSU culture.
14.1.1 References 1.
2.
3.
Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15 Suppl 1:S216-S227. http://www.ncbi.nlm.nih.gov/pubmed/1477233 Rubin RH, Shapiro ED, Andriole VT, Davies RJ, Stamm WE, with modifications by a European Working Party (Norrby SR). General guidelines for the evaluation of new anti-infective drugs for the treatment of UTI. Taufkirchen, Germany: The European Society of Clinical Microbiology and Infectious Diseases, 1993; pp. 294-310. Naber KG. Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. Int J Antimicrob Agents 1999;11(3-4):189-96. http://www.ncbi.nlm.nih.gov/pubmed/10394969
14.2 Recommendations for antimicrobial therapy in urology Diagnosis Most frequent Initial, empirical Therapy duration pathogen/species antimicrobial therapy Cystitis • E. coli • Trimethoprim-sulphamethoxazole° 3 days acute, • Klebsiella • Fluoroquinolone* (1-)3 days uncomplicated • Proteus • Fosfomycin trometamol 1 day • Staphylococci • Pivmecillinam (3-)7 days • Nitrofurantoin (5-)7 days Pyelonephritis • E. coli • Fluoroquinolone* 7-10 days acute, • Proteus • Cephalosporin (group 3a) uncomplicated • Klebsiella Alternatives: • Other enterobacteria • Aminopenicillin/BLI • Staphylococci • Aminoglycoside UTI with • E. coli • Fluoroquinolone* 3-5 days after complicating • Enterococci • Aminopenicillin/BLI defeverescence or factors • Pseudomonas • Cephalosporin (group 2) control/elimination • Staphylococci • Cephalosporin (group 3a) of complicating Nosocomial UTI • Klebsiella • Aminoglycoside factor • Proteus In case of failure of initial therapy Pyelonephritis • Enterobacter within 1-3 days or in clinically severe acute, • Other enterobacteria cases: complicated • (Candida) Anti-Pseudomonas active: • Fluoroquinolone, if not used initially • Acylaminopenicillin/BLI • Cephalosporin (group 3b) • Carbapenem • ± Aminoglycoside In case of Candida: • Fluconazole • Amphotericin B Prostatitis acute, chronic
94
• E. coli • Other enterobacteria • Pseudomonas
• Fluoroquinolone* Acute: Alternative in acute bacterial prostatitis: 2-4 weeks • Cephalosporin (group 3a/b)
UPDATE MARCH 2009
Epididymitis acute
• Enterococci • Staphylococci • Chlamydia • Ureaplasma
In case of Chlamydia or Ureaplasma: • Doxycycline • Macrolide
Chronic: 4-6 weeks or longer
Urosepsis • E. coli • Cephalosporin (group 3a/b) 3-5 days after • Other enterobacteria • Fluoroquinolone* defeverescence or After urological • Anti-Pseudomonas active control/elimination interventions – multi- acylaminopenicillin/BLI of complicating resistant pathogens: • Carbapenem factor • Pseudomonas • ± Aminoglycoside • Proteus • Serratia • Enterobacter BLI = ß-lactamase inhibitor; UTI = urinary tract infection. *Fluoroquinolone with mainly renal excretion (see text). °Only in areas with resistance rate < 20% (for E. coli).
14.3 Recommendations for antibiotic prescribing in renal failure Antibiotic GFR (ml/min Mild Moderate Severe 50-20 20-10 <10 *Aciclovir normal dose every normal dose every 50% of normal 12h 24h dose every 24h Aciclovir po normal Simplex: normal Simplex: 200mg Zoster: 800mg tds bd Zoster: 800mg bd Amikacin 5-6mg/kg 12h 3-4mg/kg 24h 2mg/kg 24-48h HD: 5mg/kg post HD and monitor levels Amoxicillin po normal normal 250mg 8h (normal) Amphotericin
normal
normal
Give post HD Give post HD
Give post HD Monitor pre and 1hr post-dose levels after 3rd dose &adjust dose as required Give post HD
normal
(Liposonal + Lipid Amphotericin is highly NEPHROTOXIC. complex) Consider using liposomal/lipid complex amphotericin. Daily monitoring of renal function (GFR) essential. Ampicillin IV normal 250-500mg 6h 250mg 6h (500mg 6h) Benzylpenicillin normal 75% 20-50% Max. 3.6g/day (1.2g.qds) Caspofungin normal normal normal Cefotaxime normal normal 1g stat then 50% Cefradine normal Normal 250mg 6h Ceftazidime 1g 12h 1g 24h 500mg 24h (1g 24h) Ceftriaxone normal normal normal Max 2g/day Cefuroxime IV normal 750mg-1.5g 12h 750mg 24h (750mg 12h) Ciproflazin normal 50% 50% IV + po
UPDATE MARCH 2009
Comments
Give post HD Give post HD Refer to microbiology for dosing in SBE Give post HD Give post HD Give post HD
Give post HD
95
Clarithromycin normal normal 50% Give post HD IV + po Clindamycin normal normal normal IV + po Co-Amoxiclav IV normal 1.2 stat then 50% 1.2 stat then 50% Give post HD (Augmentin) 12h 24h (1.2g 12h) (1.2g stat then 600mg 12h) Co-Amoxiclav po normal 375mg-625mg 12h 375mg 12h Give post HD (Augmentin) (375mg 8h) (375mg 8h) *Co-trimoxazole IV normal Normal for 3/7 then 50% Give post HD 50% Doxycycline normal normal normal All other tetracyclines contraindicated in renal impairment Erythromycin normal normal normal IV + po Max. 1.5g/day (500mg qds) *Ethambutol normal 24-36h 48h Give post HD Monitor levels if GFR < 30ml/min (contact Mirco) Flucloxacillin normal normal normal IV + po Max 4g/day Fluconazole normal normal 50% Give post HD. No adjustments in single dose therapy required *Flucytosine 50mg/kg 12h 50mg/kg 24h 50mg/kg stat then Give post HD. dose according to Levels should be levels monitored pre dialysis. Fusidic acid normal normal Normal 1) Gentamicin GFR 10-40ml/min GFR < 10ml/min BOTH METHODS 3mg/kg stat (max 300mg) 2mg/kg (max Give post HD ONCE DAILY Check pre-dose levels 18-24 hours after 200mg) redose first dose. according to levels Monitor blood Redose only when level < 1mg/L. levels: 2) Gentamicin 80mg 48h Once daily: pre 80mg 12h 80mg 24h HD: 1-2 mg/kg only CONVENTIONAL Post HD: redoes Conventional: pre According to levels and 1hr post level required. Imipenem 500mg 8-12h 250-500mg bd Risk of Give post HD convulsions – use Meropenem: see below Isoniazid normal normal 200mg-300mg 24h Give post HD Itraconazole normal normal normal Levoflaxacin 500mg stat 500mg stat then 500mg stat then **applies if full Then 250mg bd** 125mg bd** 125mg od dose is 500mg bd. If full dose 500mg od five reduced dose daily Linezolid normal normal normal Give post HD Meropenem 12h 50% 12h 50% 24h Give post HD Metronidazole normal normal 12h (normal) Give post HD Nitrofurantoin Do NOT use in renal impairment Penicillin V normal normal normal Give post HD
96
UPDATE MARCH 2009
Piperacillin/ 4.5g 8h 4.5g 12h 4.5g 12h Give post HD Tazobactam (Tazocin) Pyrazinamide normal normal normal Rifampicin normal normal 50-100% *Teicoplanin 100% 48h 100% 72h 100% 72h Dose reduction after day 3 of therapy Tetracycline See Doxycycline Trimethoprim normal Normal for 3/7 then 50% 24h Give post HD 50% 18h Vancomycin 1g od 1g 48h 1g stat (or 15mg.kg, Monitor pre-dose Check pre-dose Check pre-dose up to max 2 g). levels & adjust level before 3rd level before 2nd Recheck level dose as required. dose dose after 4-5 days. ONLY give subsequent dose when level < 12mg/L. Vorinconazole normal normal normal Give post HD bid = twice daily; GFR; glomerular filtration rate; HD = haemodialysis; IV = intravenous; od = once daily; po = by mouth; qid = four times daily; SBE = subacute bacterial endocarditis
14.4 Recommendations for peri-operative antibacterial prophylaxis in urology Procedure Pathogens Prophylaxis (expected) Diagnostic procedures Transrectal biopsy Enterobacteriaceae All patients of the prostate Anaerobes? Cystoscopy Enterobacteriaceae No Urodynamic Enterococci examination Staphylococci Ureteroscopy Enterobacteriaceae No Enterococci Staphylococci Endourological surgery and ESWL ESWL Enterobacteriaceae No Enterococci Ureteroscopy for Enterobacteriaceae No uncomplicated distal Enterococci stone Staphylococci Ureteroscopy of Enterobacteriaceae All patients proximal or impacted Enterococci stone and Staphylococci percutaneous stone extraction TUR of the prostate Enterobacteriaceae All patients Enterococci (see Section 9.6.2)
UPDATE MARCH 2009
Antibiotics
Remarks
Fluoroquinolones Short course (<72h) TMP ± SMX Metronidazole? Cephalosporin 2nd Consider only in generation risk patients TMP ± SMX Cephalosporin 2nd Consider in risk generation patients TMP ± SMX Cephalosporin 2nd or 3rd generation TMP ± SMX Aminopenicillin/BLIa Cephalosporin 2nd or 3rd generation TMP ± SMX Aminopenicillin/BLI Fluoroquinolones Cephalosporin 2nd or 3rd generation TMP ± SMX Aminopenicillin/BLI Fluoroquinolones Cephalosporin 2nd or 3rd generation TMP ± SMX Aminopenicillin/BLI
In patients with stent or nephrostomy tube Consider in risk patients In patients with stent or nephrostomy tube Consider in risk patients Short course Length to be determined Intravenous suggested Low-risk patients and small-size prostate require no prophylaxis
97
TUR of bladder tumour Enterobacteriaceae No Cephalosporin 2nd Consider in risk Enterococci or 3rd generation patients and TMP ± SMX large necrotic Aminopenicillin/BLI tumours Open urological surgery Clean operations Skin-related No Consider in high-risk pathogens, patients e.g. staphylococci Short post-operative Catheter- associated catheter treatment uropathogens Clean-contaminated Enterobacteriaceae Recommended Cephalosporin 2nd Single peri-operative (opening of Enterococci or 3rd generation course urinary tract) Staphylococci TMP + SMX Aminopenicillin/BLI Clean-contaminated Enterobacteriaceae All patients Cephalosporin 2nd As for colonic (use of bowel Enterococci or 3rd generation surgery segments) Anaerobes Metronidazole Skin-related bacteria Implant of prosthetic Skin-related All patients Cephalosporin 2nd devices bacteria, or 3rd generation e.g. staphylococci Penicillin (penicillinase stable) Laparoscopic procedures As for open surgery BLI = beta-lactamase inhibitor; TMP ± SMX = trimethoprim with or without sulphametoxazole (co-trimoxazole); TUR = transurethral resection.
98
UPDATE MARCH 2009
14.5
Chronic Prostatitis Symptom Index (CPSI)
from: . Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun MA, Pontari MA, Alexander RB, Farrar JT, O’Leary MP. The National Institute of Health chronic prostatitis symptom index: development and validation of new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999:162;369-375. NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) Pain or Discomfort 1. In the last week, have you experienced any pain or discomfort in the following areas? Yes No a. Area between rectum and 1 0 testicles (perineum) b. Testicles
1
0
c. Tip of penis (not related to urination)
1
0
d. Below your waist, in your pubic or bladder area
1
0
2. In the last week, have you experienced: Yes a. Pain or burning during 1 urination?
No 0
b. Pain or discomfort during or after sexual climax (ejaculation)?
1
0 1 2 3 4 5
3
4
5
6
7
8 9 10 PAIN AS BAD AS YOU CAN IMAGINE
Urination 5. How often have you had a sensation of not emptying your bladder completely after you finished urinating over the last week? 0 Not at all 1 Less than 1 time in 5 2 Less than half the time 3 About half the time 4 More than half the time 5 Almost always
UPDATE MARCH 2009
Not at all Less than 1 time in 5 Less than half the time About half the time More than half the time Almost always
Impact of Symptoms 7. How much have your symptoms kept you from doing the kinds of things you would usually do over the last week?
0 1 2 3
None Only a little Some A lot
0 1 2 3
None Only a little Some A lot
Quality of life 9. If you were to spend the rest of your life with your symptoms, just the way they have been during the last week, how would you feel about that?
4. Which number best describes your AVERAGE pain or discomfort on the days that you had it, over the last week? 2
0 1 2 3 4 5
8. How much did you think about your symptoms, over the last week?
Never Rarely Sometimes Often Usually Always
0 1 NO PAIN
0
3. How often have you had pain or discomfort in any of these areas over the last week?
6. How often have you had to urinate again less than two hours after you finished urinating, over the last week?
0 1 2 3 4 5 6
Delighted Pleased Mostly satisfied Mixed (about equally satisfied and dissatisfied) Mostly dissatisfied Unhappy Terrible
Scoring the NIH-CPSI Prostatitis Symptom Index Domain Pain: Total of items 1a,1b,1c,1d,2a,2b,3 and 4 = __________ Urinary Symptoms: Total of items 5 and 6 Quality of Life Impact: Total of items 7,8, and 9
= __________
= __________
99
14.6
Meares & Stamey Localization technique*
© Elsevier 2004 Infections Disease 2e - www.idreference.com
* Naber KG, Weidner W. Prostatitis, epididymitis, orchitis. In: Armstrong D, Cohen J, eds. Infectious Diseases. London: Mosby, Harcourt Publishers Ltd, 1999, pp. 1-58.
100
UPDATE MARCH 2009
14.7
Antibacterial agents
Table 14.7.1 Antibacterial agents according to groups and agents used in urology Groups Trimethoprim-sulphonamide combinations
Agents Trimethoprim, co-trimoxazole (TMP-SMX), co-tetroxoprime (TXP-SDX), trimethoprim plus sulfametrol
Fluoroquinolones1,2 • Group 1 • Group 2 • Group 3 • Group 4
Norfloxacin, pefloxacin Enoxacin, fleroxacin, lomefloxacin, ofloxacin, ciprofloxacin Levofloxacin Gatifloxacin, moxifloxacin
Macrolides
Erythromycin, roxithromycin, clarithromycin, azithromycin
Tetracyclines
Doxycycline, minocycline, tetracycline
Fosfomycin
Fosfomycin-sodium, fosfomycin trometamol3
Nitrofuran4
Nitrofurantoin
Penicillins Benzylpenicillin Phenoxypenicillins Isoxazolylpenicillins Aminobenzylpenicillins5 Aminopenicillins/BLI6 Acylaminopenicillins ±BLI6
Penicillin G Penicillin V, propicillin, azidocillin Oxacillin, cloxacillin, dicloxacillin, flucloxacillin Ampicillin, amoxycillin, bacampicillin Ampicillin/sulbactam, amoxycillin/clavulanic acid7 Mezlocillin, piperacillin Piperacillin/tazobactam, sulbactam6
Cephalosporins1 • Group 1 (oral) • Group 2 (oral) • Group 3 (oral) • Group 1 (parenteral) • Group 2 (parenteral) • Group 3a (parenteral) • Group 3b (parenteral) • Group 4 (parenteral) • Group 5 (parenteral)
Cefalexin, cefadroxil, cefaclor Loracarbef, cefuroxime axetile Cefpodoxime proxetile, cefetamet pivoxile, ceftibuten, cefixime Cefazolin Cefamandole, cefuroxime, cefotiame Cefodizime, cefotaxime, ceftriaxone Cefoperazone, ceftazidime Cefepime, cefpirome Cefoxitin
Monobactams
Aztreonam
Carbapenems
Imipenem, meropenem, ertapenem
Aminoglycosides
Gentamicin, netilmicin, tobramycin, amikacin
Glycopeptides
Vancomycin, teicoplanin
Oxazolidones Linezolid BLI = ß-lactamase inhibitors; INH = isoniazid. 1 Classification according to the Paul Ehrlich Society for Chemotherapy (1, 2, 3). 2 Only in adults, except pregnant and lactating women. 3 Only in acute, uncomplicated cystitis as a single dose. 4 Contraindicated in renal failure and in the newborn. 5 In cases of resistance, the pathogen is most likely to be a ß-lactamase producer. 6 BLIs can only be used in combination with ß-lactam antibiotics. 7 In solution, storage instability.
UPDATE MARCH 2009
101
14.7.1 Penicillins Penicillin G and the oral penicillins, penicillin V, propicillin and azidocillin, have a high intrinsic activity against streptococci and pneumococci. However, the resistance rate of pneumococci may vary considerably from country to country. In Germany, penicillin resistance in pneumococci is still < 1%. Because of their narrow spectrum of activity, these penicillins do not have any role in the treatment of urogenital infections. 14.7.1.1 Aminopenicillins Aminopenicillins, e.g. ampicillin and amoxycillin, have a broader spectrum of activity. Apart from streptococci and pneumococci, they cover enterococci, Haemophilus influenzae, H. parainfluenzae, Listeria, E. coli, P. mirabilis, Salmonella and Shigella spp. However, resistance may occur. Aminopenicillins are sensitive to ß-lactamases. They are therefore not sufficiently active against certain species, such as staphylococci, Moraxella catarrhalis, Bacteroides fragilis and many enterobacteria. This gap in the spectrum of activity can be closed by the use of a BLI (clavulanic acid, sulbactam). Amoxycillin/ clavulanic acid and ampicillin/sulbactam are available on the market as fixed combinations. Indications for aminopenicillins and their combinations with a BLI are mild respiratory tract infections, UTIs, as well as infections of the skin and soft tissues. 14.7.1.2 Acylaminopenicillins The acylaminopenicillins include apalcillin, azlocillin, mezlocillin and piperacillin. They are characterized by their high activity against enterococci, enterobacteria and Pseudomonas (weaker activity of mezlocillin). Acylaminopenicillins are hydrolyzed by ß-lactamases and are therefore active only against ß-lactamaseproducing strains of staphylococci, B. fragilis, and if used in combination with a BLI, some of the enterobacteria. The acylaminopenicillin/BLI combination provides a broad spectrum of activity and may be used for a large number of indications, including complicated UTIs and urosepsis. A selection of free combinations with sulbactam is available, or there is the fixed combination of tazobactam and piperacillin, which has the advantages of being easy to use and a well-documented database drawn from qualified clinical studies. 14.7.1.3 Isoxazolylpenicillins Isoxazolylpenicillins, available as parenteral drugs with oxacillin and flucloxacillin, have a narrow spectrum of activity. Their indications are limited to infections caused by Staph. aureus. Due to their suboptimal pharmacokinetic parameters, isoxazolylpenicillins are preferably used in milder infections of the skin and soft tissues, and of the ear, nose and throat area. They play no role in the treatment of UTIs, but may be used for staphylococcal abscesses in the genital area. 14.7.2 Parenteral cephalosporins According to the Paul Ehrlich Society for Chemotherapy (1), the parenteral cephalosporins have been classified into five groups, according to their spectrum of activity (Table 14.7.2). 14.7.2.1 Group 1 cephalosporins Group 1 cephalosporins (cefazolin, cefazedone) are very active against streptococci and staphylococci (including penicillin-G-resistant strains). They have only weak activity against Gram-negative micro-organisms. Like all cephalosporins, cefazolin is not active against enterococci and methicillin-resistant staphylococci (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRSE). 14.7.2.2 Group 2 cephalosporins Compared with Group 1 cephalosporins, Group 2 cephalosporins, e.g. cefuroxime, cefotiame and cefamandole, exhibit a markedly improved activity against Gram-negative pathogens and maintain high activity against staphylococci. 14.7.2.3 Group 3a cephalosporins Group 3a cephalosporins have high activity against Gram-negative bacteria and less activity against staphylococci. They differ mainly in their pharmacokinetic characteristics. 14.7.2.4 Group 3b cephalosporins Group 3b cephalosporins, e.g. ceftazidime, cefoperazone, have added high anti-pseudomonal activity. However, the activity of cefoperazone against Ps. aeruginosa is markedly inferior to that of the other substances of this group.
102
UPDATE MARCH 2009
14.7.2.5 Group 4 cephalosporins Group 4 cephalosporins, e.g. cefepime, cefpirome, have a comparable activity against Gram-negatives, but are more stable against extended-spectrum betalactamases, and a better activity against Gram-positive bacteria. 14.7.2.6 Group 5 cephalosporins The Group 5 cephalosporins are characterized by their anti-anaerobic activity. These cephalosporins have superior activity against Gram-negative bacteria compared with Group 1 and 2 cephalosporins, but most of them are weaker than Group 3 drugs. At present, cefoxitin is the only drug of that group available on the market in some countries. Table 14.7.2: Classification of parenteral cephalosporins (2) Group Generic Features of the group names Group 1 Cefazolin • Active against Gram-positive and partly also against (1st generation) Cefazedone Gram-negative bacteria • Stable against staphylococcal penicillinases • Unstable against ß-lactamases of Gram-negative bacteria Group 2 Cefuroxime • Activity against Gram-positive bacteria good, but weaker than Group 1 (2nd generation) Cefotiame • Activity against Gram-negative bacteria superior to that of Group 1 Cefamandole • Stable against staphylococcal penicillinases • Limited stability against ß-lactamases of Gram-negative bacteria Group 3a Cefotaxime • Activity against Gram-negative bacteria clearly superior to (3rd generation) Ceftriaxone that of Groups 1 and 2 Ceftizoxime • Stable against numerous ß-lactamases of Gram-negative bacteria Cefmenoxime • Microbiologically less active against staphylococci Cefodizime Group 3b Ceftazidime (3rd generation) Cefoperazone
• Spectrum of antibacterial activity similar to that of Group 3a • Additional activity against Ps. aeruginosa
Group 4 Group 5
• Spectrum of antibacterial activity similar to that of Group 3a • Additional activity against Ps. aeruginosa • Higher stability against beta-lactamases than group 3b • With anti-anaerobic activity • Superior activity against Gram-negative bacteria than Group 1 and 2 • Weaker than Group 3
Cefepime Cefpirome Cefoxitin
14.7.3 Oral cephalosporins Oral cephalosporins are classified into three groups, based on their spectrum of activity, according to the recommendations of the Paul Ehrlich Society for Chemotherapy (1) (Table 14.7.3). Table 14.7.3: Classification of oral cephalosporins (1) Oral cephalosporins Group 1 Group 2 Group 3
UPDATE MARCH 2009
Drug names Cefalexin Cefadroxil Cefaclor Cefprozil Loracarbef Cefuroxime axetile Cefpodoxime proxetile Cefetamet pivoxile Ceftibuten Cefixime
103
14.7.3.1 Group 1 oral cephalosporins Group 1 oral cephalosporins include cefalexin, cefadroxil and cefaclor. They are mainly active against Grampositive cocci with limited activity against H. influenzae (cefaclor). Their main indications are skin and softtissue infections and, with limitations, respiratory tract infections. Since their activity against enterobacteria is limited, they can only be recommended for the treatment or prophylaxis of uncomplicated UTIs in children or pregnant women, for whom the use of other antibiotics is limited. 14.7.3.2 Group 2 oral cephalosporins The activity of cefprozil against Staph. aureus, S. pyogenes, S. pneumoniae, H. influenzae and M. catarrhalis is somewhat higher than that of cefaclor. However, cefprozil is less active than cefaclor against E. coli, Klebsiella pneumoniae and P. mirabilis. Loracarbef is structurally close to cefaclor. In contrast to cefaclor, it is stable in solution, has better pharmacokinetics and a broader antibacterial spectrum. However, its activity against staphylococci is lower than that of cefaclor. The main indications are respiratory tract, skin and soft-tissue infections and uncomplicated UTIs. Cefuroxime axetile has a higher ß-lactamase stability and thus a broader spectrum than others in this group. It can be used mainly for bacterial infections of the upper (including otitis media) and lower respiratory tract, for skin and soft-tissue infections, and UTIs. 14.7.3.3 Group 3 oral cephalosporins Group 3 oral cephalosporins have a higher activity and a broader spectrum against enterobacteria than group 2 cephalosporins. In contrast, their activity against Gram-positive bacteria is lower. Against staphylococci, the activity of cefpodoxime proxetile is intermediate, whereas cefetamet pivoxile, ceftibuten and cefixime are inactive. The main indications for the oral cephalosporins of group 3 are complicated infections of the respiratory tract (provided that staphylococci can be excluded) and infections due to enterobacteria, e.g. UTIs or infections in immunocompromised patients. Group 3 oral cephalosporins are also suitable for oral switch therapy, i.e. when initial parenteral therapy (using a parenteral group 3a cephalosporin) needs to be continued orally. In addition, cefixime is licensed also for the treatment of gonorrhoea. 14.7.4 Monobactams Of this group, only aztreonam is available. It is active only against Gram-negative aerobes. In this respect, its spectrum and activity is similar to that of the parenteral group 3b cephalosporins. 14.7.5 Carbapenems Carbapenems are broad-spectrum antibiotics with good activity against Gram-positive and Gram-negative bacteria, including anaerobes. They are preferably used in the treatment of mixed infections and in the initial therapy of life-threatening diseases, including urosepsis. Imipenem/cilastatin and meropenem are also active against Ps. aeruginosa. However, ertapenem is not active against Ps. aeruginosa. Ertapenem has a longer halflife than the imipenem/cilastatin and meropenem and is therefore suitable for once-daily dosing. 14.7.6 Fluoroquinolones Non-fluorinated quinolones are no longer recommended because of their poor antibacterial activity. According to the Paul Ehrlich Society for Chemotherapy, the fluoroquinolones are classified into four groups, based on their spectrum of activity, their pharmacokinetics and indications (Table 14.7.4).
104
UPDATE MARCH 2009
Table 14.7.4: Classification of fluoroquinolones, as modified according to the Paul Ehrlich Society for Chemotherapy (33) Generic name Trade name* / Features of the group Group 1 Indications essentially limited to UTIs in some countries, e.g. Germany Norfloxacin Pefloxacin** Group 2 Broad indications for systemic use Enoxacin Fleroxacin*** Lomefloxacin Ofloxacin Ciprofloxaci Group 3 Improved activity against Gram-positive and ‘atypical’ pathogens Levofloxacin Group 4 Improved activity against Gram-positive and ‘atypical’ pathogens and anaerobes Gatifloxacin Moxifloxacin UTI = urinary tract infections. * Listed according to increasing in-vitro activity (minimum inhibitory concentration) against indicative pathogens. ** In France and other countries, pefloxacin is also available for systemic use *** Investigated in acute exacerbations of chronic bronchitis, UTIs, gonorrhoea and gastrointestinal infections. 14.7.6.1 Group 1 fluoroquinolones The indications for group 1 fluoroquinolones is limited to UTIs in some countries, e.g. Germany. In France and some other countries, pefloxacin is also used for systemic oral and parenteral use. Norfloxacin is not available as parenteral antibiotic. 14.7.6.2 Group 2 fluoroquinolones Group 2 fluoroquinolones includes fluoroquinolones for systemic use with a broad spectrum of indications. These include infections of the urinary tract, respiratory tract, skin and soft tissues, bones and joints, as well as systemic infections and even sepsis. Group 2 fluoroquinolones exhibit good activity against enterobacteria and H. influenzae with less activity against staphylococci, pneumococci and enterococci and ‘atypical’ pathogens, e.g. Chlamydia, Legionella and Mycoplasma. Their activity against Ps. aeruginosa varies, with ciprofloxacin being most active in vitro. In addition, ciprofloxacin, ofloxacin and fleroxacin are also available for parenteral use. 14.7.6.3 Group 3 fluoroquinolones The main difference in the spectrums of activity of group 3 fluoroquinolones (levofloxacin) and of group 4 fluoroquinolones (gatifloxacin, moxifloxacin) is that group 3 fluoroquinolones have a higher intrinsic activity against Gram-positive pathogens, such as staphylococci, streptococci, pneumococci and enterococci. However, group 3 and group 4 fluoroquinolones have comparable activity against Gram-negative pathogens. In addition, they have improved activity against the so-called ‘atypical’ pathogens, such as Chlamydia, Mycoplasma and Legionella spp. In addition, group 4 fluoroquinolones have improved anti-anaerobic activity. The only group 3 fluoroquinolone available for parenteral use is levofloxacin, the left enantiomer of the ofloxacin racemate. The main indications for levofloxacin are respiratory tract infections, and, due to its high renal elimination rate, UTIs, as well as skin and soft-tissue infections. Among group 4 fluoroquinolones, gatifloxacin (not on the market in Europe), moxifloxacin and trovafloxacin have been licensed. However, in June 1999, trovafloxacin was taken off the market because of severe side effects. Thus, so far, no parenteral fluoroquinolone of this group has been made available. Apart from respiratory tract infections, these broad-spectrum fluoroquinolones are appropriate for the treatment of skin and soft-tissue infections, of intra-abdominal infections, and of the oral treatment of gynaecological infections. However, final judgement of their position in the treatment of these diseases is not yet possible. Gatifloxacin has the highest renal excretion (about 84%) after oral administration. It is therefore also the most suitable for the treatment of uncomplicated and complicated UTI. The urinary excretion of moxifloxacin after oral administration is only in the range of about 20%.
UPDATE MARCH 2009
105
14.7.7 Co-trimoxazole (trimethoprim-sulphamethoxazole, TMP-SMX) The treatment of UTIs is the main indication for trimethoprim (TMP) alone or in combination with a sulphonamide, e.g. sulphamethoxazole (SMX). TMP with or without SMX can also be used for the prophylaxis of recurrent cystitis. The resistance rate against E. coli can vary from country to country. It is therefore not recommended for empirical therapy of acute uncomplicated cystitis or pyelonephritis, when the resistance rate in the area is > 10-20% (4). In complicated UTIs, TMP-SMX should only be used in accordance with sensitivity testing. TMP, especially in combination with SMX, can lead to severe although rare adverse events, such as Lyell syndrome, Stevens-Johnson syndrome and pancytopenia. 14.7.8 Fosfomycin Fosfomycin is active against Gram-negative and Gram-positive bacteria. The natrium salt is only for parenteral use. Fosfomycin trometamol is licensed for single-dose (3 g) treatment of uncomplicated cystitis in women. 14.7.9 Nitrofurantoin The antibacterial activity of nitrofurantoin is limited to the urinary tract because of its low serum concentrations. It is active against E. coli, Citrobacter and most strains of Klebsiella and Enterobacter, whereas Providencia and Serratia are mostly resistant. Proteus, Ps. aeruginosa and Acinetobacter are almost always resistant. It is active against Gram-positive cocci, e.g. enterococci and staphylococci. It is suitable only for the treatment or prophylaxis of uncomplicated UTIs. Short-term therapy for this indication has not been proven in sufficiently large studies. Little development of resistance has been observed over many years. Treatment can lead to severe, though rare adverse events, such as chronic desquamative interstitial pneumonia with fibrosis. 14.7.10 Macrolides Erythromycin is the only macrolide available for both oral and parenteral use. The newer macrolides, roxithromycin, clarithromycin, azithromycin, are better tolerated than erythromycin, but can only be administered orally. The macrolides have good activity against streptococci, pneumococci, Bordetella pertussis, Chlamydia, Mycoplasma and Legionella spp. Because the macrolides are not active against Gramnegative rods, their use in the treatment of UTIs is limited to special indications, such as non-gonococcal urethritis due to C. trachomatis. 14.7.11 Tetracyclines The resistance against doxycycline and tetracycline of pneumococci, streptococci, H. influenzae and E. coli shows marked regional differences. Tetracyclines are therefore only suited for empirical initial therapy if the local resistance situation is sufficiently well known and justifies their use. Because of their high activity against the so-called ‘atypical’ pathogens (Legionella, Chlamydia, Mycoplasma spp.), they may be used as alternative antibiotics in infections caused by these micro-organisms, e.g. in non-gonococcal urethritis due to C. trachomatis. 14.7.12 Aminoglycosides Aminoglycosides are for parenteral use only. These drugs have a narrow therapeutic window. Their effective levels of activity are close to toxic borderline concentrations, making a strict therapeutic indication mandatory. With few exceptions (e.g. the treatment of UTIs), aminoglycosides should only be used in combination with another appropriate antibiotic. Ideal partners are ß-lactam antibiotics, as this combination has a marked synergistic effect against certain bacterial species. Streptomycin is one of the older aminoglycosides and is used only for the treatment of tuberculosis. Newer aminoglycosides include netilmicin, gentamicin, tobramycin and amikacin. They have good activity against enterobacteria and Pseudomonas (especially tobramycin). Their activity against streptococci, anaerobes and H. influenzae is not satisfactory. Resistance data for tobramycin, gentamicin and netilmicin are almost identical, whereas the resistance situation is more favourable for amikacin against many enterobacteria. 14.7.13 Glycopeptides The glycopeptides vancomycin and teicoplanin are active against Gram-positive pathogens, i.e. staphylococci (including oxacillin-resistant strains), streptococci, enterococci, Clostridium difficile, diphtheria bacteria and Gram-positive aerobes. They are inactive against Gram-negative pathogens. Their use is indicated: • In infections caused by the above-mentioned pathogens in case of allergy against all other suitable antibiotics. • In infections caused by ampicillin-resistant enterococci or oxacillin-resistant staphylococci, or multiresistant corynebacteria. • As an alternative, in oral form, to metronidazole for the treatment of pseudomembranous colitis.
106
UPDATE MARCH 2009
Due to the risk of selection of glycopeptide-resistant enterococci and staphylococci, the use of glycopeptides should be highly restricted. Similar to the aminoglycosides, glycopeptides have a narrow therapeutic window. 14.7.14 Oxazolidinones The only substance of this group is linezolid, which can be administered parenterally and orally. It has a good activity against Gram-positive cocci, like staphylococci, including methicillin (oxacillin)-resistant strains, enterococci, including vancomycin-resistant strains, and streptococci. 14.7.15 References 1. Scholz H, Naber KG, and an expert group of the Paul Ehrlich Society for Chemotherapy. [Classification of oral cephalosporins.] Chemotherapie Journal 1999;8:227-9. [article in German] http://www.wissenschaftliche-verlagsgesellschaft.de/CTJ/CTJ2000/scholz.pdf 2. Vogel F, Bodmann K-F and the expert group of the Paul Ehrlich Society for Chemotherapy. [Recommendations for empiric parenteral initial therapy of bacterial infections in adults.] Chemotherapie Journal 2004;13:46-105. [article in German] http://www.wissenschaftliche-verlagsgesellschaft.de/CTJ/CTJ2004/CTJ2-2004/Consensus-par.pdf 3. Naber KG, Adam D, and an expert group of the Paul Ehrlich Society for Chemotherapy. [Classification of fluoroquinolones.] Chemotherapie Journal 1998;7:66-8. [article in German] http://www.wissenschaftliche-verlagsgesellschaft.de/CTJ/CTJEMPF.HTM 4. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29(4):745-58. http://www.ncbi.nlm.nih.gov/pubmed/10589881
UPDATE MARCH 2009
107
108
UPDATE MARCH 2009
(Bacilli)
(Listeria)
No cell wall
Mykoplasma - M. hominus - M. genitalium Ureaplasma - U. urealyticum
- Escherichia - Klebsiella - Citrobacter - Proteus - Serratia - Providencia - Enterobacter - Pantoea - Hafnia (- Salmonella) (- Shigella)
Enterobacteriacaeae
Gram-negative aerobic
Rods*
Corynebacteria - C. urealyticum
*Anaerobic bacteria not considered.
Mycobacteria - M. tuberculosis
Gram-positive Aerobic
Chlamydia - C. trachomatis
Obligate intracellular bacteria
Relevant bacteria for urological infections
Ziehl-Neelsen Postivie
14.8
- Pseudomonas - Acinetobacter - Xanthomonas - Burgholderia
Non-Fermenter
Haemophilus - Gardnerella vaginalis
Parvobacteria
Cocci*
ß-hemolytic - S. pyogenes group A - S. agalactiae group B
α-haemolytic - S. viridans
Enterococcus - E. faecalis - E. faecium - others
non-hemolytic
Streptococcus
Gram-positive aerobic
Treponema - T. pallidum
Spirochetes
Neisseria - N. gonorrhoeae
Gram-negative aerobic
- S. aureus - S. epidermidis group - S. saprophyticus group
Staphylococcus
15. ABBREVIATIONS USED IN THE TEXT
This list is not comprehensive for the most common abbreviations.
ABP ACE ACTH ADPK APACHE APCKD AUA BLI BPH CBP CDC cfu CPPS CPSI CRP CT DMSA DRE DTPA EMG EPS ESCMID ESR ESWL EUCAST GAG G-CSF GFR GM-CSF HCO HIV HMO IC IDSA IL IPCN IVU LDH LUTS MAG-3 MRI MRSA MRSE MSU NAUTI NCCLS NDMA NIDDK NIH PaCO2 PCP PL PMN PSA RUTIs SIRS SMX
acute bacterial prostatitis angiotensin-converting enzyme adrenocorticotropic hormone test adult dominant polycystic disease acute physiology and chronic health evaluation adult polycystic kidney disease American Urological Association ß-lactamase inhibitor benign prostatic hyperplasia chronic bacterial prostatitis centres for disease control and prevention colony-forming unit chronic pelvic pain syndrome Chronic Prostatitis Symptom Index C-reactive protein computed tomography dimercaptosuccinic acid digital rectal examination diethylenetriaminepentaacetate electromyography expressed prostatic secretion European Society of Clinical Microbiology and Infectious Diseases erythrocyte sedimentation rate extracorporeal shockwave lithotripsy European Committee for Antimicrobial Susceptibility Testing glucosaminoglycan granulocyte-colony stimulating factor glomerular filtration rate. granulocyte-macrophage-colony stimulating factor Health Care Office of the EAU human immunodeficiency virus health maintenance organization intermittent catheterization Infectious Diseases Society of America interleukin International Prostatitis Collaborative Network intravenous urogram lactate dehydrogenase lower urinary tract symptoms mercaptoacethylglycine magnetic resonance imaging methicillin-resistant Staphylococcus aureus methicillin-resistant coagulase-negative staphylococci mid-stream sample of urine nosocomial urinary tract infection National Committee for Clinical Laboratory Standards N-acetyl-ß-D-glucoseaminadase enzyme National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health partial pressure of carbon dioxide in alveolar gas Pneumocystis carinii pneumonia placebo polymorphonuclear prostate-specific antigen recurrent UTIs systemic inflammatory response syndrome sulphamethoxazole
UPDATE MARCH 2009
109
SR STD Tc TMP TNF TRUS TURP UTI VB1 VB2 VB3 VCU VUR WBC WHO
sustained release sexually transmitted disease technetium trimethoprim tumour necrosis factor transrectual ultrasound transurethral resection of the prostate urinary tract infection first-voided urine mid-stream urine voided bladder urine-3 voiding cysto-urethography vesicoureteric reflux white blood cells World Health Organisation
Bacterial names B. fragilis C. trachomatis E. coli H. influenzae M. catarrhalis M. tuberculosis N. gonorrhoeae Ps. aeruginosa P. mirabilis S. aureus S. saprophyticus S. pyogenes T. vaginalis
Bacteriodes fragilis Chlamydia trachomatis Escherichia coli Haemophilus influenzae Moraxella catarrhalis Mycobacterium tuberculosis Neisseria gonorrhoeae Pseudomonas aeruginosa Proteus mirabilis Staphylococcus aureus Staphylococcus saprophyticus Streptococcus pyogenes Trichomonas vaginalis
Conflict of interest All members of the Urological Infections guidelines writing panel have provided disclosure statements of all relationships which they have and which may be perceived as a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
110
UPDATE MARCH 2009
Guidelines on
Neurogenic Lower Urinary Tract Dysfunction M. Stöhrer, D. Castro-Diaz, E. Chartier-Kastler, G. Del Popolo, G. Kramer, J. Pannek, P. Radziszewski, J-J. Wyndaele
© European Association of Urology 2009
Table of Contents 1.
AIM AND STATUS OF THESE GUIDELINES 1.1 Purpose 1.2 Standardization 1.3 References
Page 4 4 4 4
2. BACKGROUND 2.1 Risk factors and epidemiology 2.1.1 Brain tumours 2.1.2 Dementia 2.1.3 Mental retardation 2.1.4 Cerebral palsy 2.1.5 Normal pressure hydrocephalus 2.1.6 Basal ganglia pathology (Parkinson’s disease, Huntington’s disease, Shy-Drager syndrome, etc) 2.1.7 Cerebrovascular (CVA) pathology 2.1.8 Demyelinization 2.1.9 Spinal cord lesions 2.1.10 Disc disease 2.1.11 Spinal stenosis and spine surgery 2.1.12 Peripheral neuropathy 2.1.13 Other conditions (SLE) 2.1.14 HIV 2.1.15 Regional spinal anaesthesia 2.1.16 Iatrogenic 2.2 Standardization of terminology 2.2.1 Introduction 2.2.2 Definitions 2.3 Classification 2.3.1 Recommendation for clinical practice 2.4 Timing of diagnosis and treatment 2.5 References
5 5 5 5 5 6 6 6 6 6 6 6 7 9 10 10 10
3. DIAGNOSIS 3.1 Introduction 3.2 History 3.2.1 General history 3.2.2 Specific history 3.2.3 Guidelines for history taking 3.3 Physical examination 3.3.1 General physical examination 3.3.2 Neuro-urological examination 3.3.3 Essential investigations 3.3.4 Guidelines for physical examination 3.4 Urodynamics 3.4.1 Introduction 3.4.2 Urodynamic tests 3.4.3 Specific uro-neurophysiological tests 3.4.4 Guidelines for urodynamics and uro-neurophysiology 3.5 Typical manifestations of NLUTD 3.6 References
17 17 17 17 18 18 18 18 19 21 21 21 21 21 22 23 23 23
4. TREATMENT 4.1 Introduction 4.2 Non-invasive conservative treatment 4.2.1 Assisted bladder emptying 4.2.2 Lower urinary tract rehabilitation 4.2.3 Drug treatment
25 25 26 26 26 26
2
4 4 4 4 4 5 5 5
UPDATE MARCH 2008
4.3 4.4 4.5 4.6
4.2.4 Electrical neuromodulation 4.2.5 External appliances 4.2.6 Guidelines for non-invasive conservative treatment Minimal invasive treatment 4.3.1 Catheterization 4.3.2 Guidelines for catheterization 4.3.3 Intravesical drug treatment 4.3.4 Intravesical electrostimulation 4.3.5 Botulinum toxin injections in the bladder 4.3.6 Bladder neck and urethral procedures 4.3.7 Guidelines for minimal invasive treatment Surgical treatment 4.4.1 Urethral and bladder neck procedures 4.4.2 Detrusor myectomy (auto-augmentation) 4.4.3 Denervation, deafferentation, neurostimulation, neuromodulation 4.4.4 Bladder covering by striated muscle 4.4.5 Bladder augmentation or substitution 4.4.6 Urinary diversion Guidelines for surgical treatment References
27 27 27 28 28 28 28 28 28 29 29 29 29 30 30 30 30 31 31 32
5.
TREATMENT OF VESICO-URETERAL REFLUX 5.1 Treatment options 5.2 References
46 46 46
6.
QUALITY OF LIFE 6.1 Introduction 6.2 Conclusions and recommendations 6.3 References
47 47 48 48
7.
FOLLOW UP 7.1 Introduction 7.2 Guidelines for follow-up 7.3 References
48 48 48 49
8.
CONCLUSIONS
50
9.
ABBREVIATIONS USED IN THE TEXT
51
UPDATE March 2008
3
1. AIM AND STATUS OF THESE GUIDELINES 1.1
Purpose
The purpose of these clinical guidelines is to provide useful information for clinical practitioners on the incidence, definitions, diagnosis, therapy, and follow-up observation of the condition of neurogenic lower urinary tract dysfunction (NLUTD). These guidelines reflect the current opinion of the experts in this specific pathology and thus represent a state-of-the-art reference for all clinicians, as of the date of its presentation to the European Association of Urology.
1.2 Standardization The terminology used and the diagnostic procedures advised throughout these guidelines follow the recommendations for investigations on the lower urinary tract (LUT) as published by the International Continence Society (ICS) (1-3).
1.3
REFERENCES
1.
Stohrer M, Goepel M, Kondo A, Kramer G, Madersbacher H, Millard R, Rossier A, Wyndaele JJ. The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures. Neurourol Urodyn 1999;18(2):139-58. http://www.ncbi.nlm.nih.gov/pubmed/10081953 Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-78. http://www.ncbi.nlm.nih.gov/pubmed/11857671 Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, van Kerrebroeck P. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow Studies. Neurourol Urodyn 2002;21(3):261-74. http://www.ncbi.nlm.nih.gov/pubmed/11948720
2.
3.
2. BACKGROUND 2.1
Risk factors and epidemiology
NLUTD may be caused by various diseases and events affecting the nervous systems controlling the LUT. The resulting lower urinary tract dysfunction (LUTD) depends grossly on the location and the extent of the neurological lesion (see also Section 2.3). There are no figures on the overall prevalence of NLUTD in the general population, but data are available on the prevalence of the underlying conditions and the relative risk of those for the development of NLUTD. It is important to realize that most of these data show a very wide range of prevalence figures because of the low level of evidence in most published data and smaller sample sizes. 2.1.1 Brain tumours Brain tumours can cause LUTD in 24% of patients (1). More recently, mostly case reports to small series have been published (2-3). In a series of patients with brain tumours, voiding difficulty was reported in 46/152 (30%) of patients with tumours in the posterior fossa, while urinary incontinence occurred in only three (1.9%) patients (4). Urinary retention was found in 12/17 (71%) children with pontine glioma (5). 2.1.2 Dementia It is not easy to distinguish dementia-associated LUTD from LUTD caused by age-related changes of the bladder and other concomitant diseases and therefore the true incidence of incontinence caused by dementia is not known. However, it has been shown that incontinence is much more frequent in geriatric patients with dementia than in patients without dementia (6, 7). Alzheimer, Lewy body dementia, Binswanger, Nasu-Hakola and Pick diseases frequently cause nonspecific NLUTD (8-13). The occurrence of incontinence is reported to be between 23% and 48% (14, 15) in patients with Alzheimer’s disease. The onset of incontinence usually correlates with disease progression (16). A male-to-female ratio of dementia-related incontinence was found to be 1:15. 2.1.3 Mental retardation In mental retardation, depending on the grade of the disorder, 12-65% of LUTD was described (17, 18).
4
UPDATE MARCH 2008
2.1.4 Cerebral palsy LUTD has been described in about 30-40% (19, 20). 2.1.5 Normal pressure hydrocephalus There have only been case reports of LUTD (21-23). 2.1.6 Basal ganglia pathology (Parkinson’s disease, Huntington’s disease, Shy-Drager syndrome, etc) Parkinson’s disease is accompanied by NLUTD in 37.9-70% (24-25). In the rare Shy-Drager syndrome, almost all patients have NLUTD (26), with incontinence found in 73% (27). Hattori et al. (28) reported that 60% of Parkinson patients had urinary symptoms. However, Gray et al. (29) reported that functional disturbances of the LUT in Parkinson’s disease were not disease-specific and were correlated only with age. Recent, control-based studies have given the prevalence of LUT symptoms as 27-63.9% using validated questionnaires (30-32), or 53% in men and 63% in women using a non-validated questionnaire, which included a urinary incontinence category (32), with all these values being significantly higher than in healthy controls. In most patients, the onset of the bladder dysfunction occurred after the motor disorder had appeared. 2.1.7 Cerebrovascular (CVA) pathology Cerebrovascular pathology causes hemiplegia with remnant incontinence NLUTD in 20-50% of patients (3334), with decreasing prevalence in the post-insult period (35). In 1996, 53% of patients with CVA pathology had significant urinary complaints at 3 months (36). Without proper treatment, at 6 months after the CVA, 20-30% of patients still suffered from urinary incontinence (37). The commonest cystometric finding was detrusor overactivity (38-43). In 39 patients who had brainstem strokes, urinary symptoms were present in almost 50%, nocturia and voiding difficulty in 28%, urinary retention in 21%, and urinary incontinence in 8%. Several case histories have been published presenting difficulties with micturition in the presence of various brainstem pathologies (45-46). 2.1.8 Demyelinization Multiple sclerosis causes NLUTD in 50-90% of the patients (47-49). The reported incidence of voiding dysfunction in multiple sclerosis is 33-52% in patients sampled consecutively, regardless of urinary symptoms. This incidence is related to the disability status of the patient (50). There is almost a 100% chance of having LUT dysfunction once these patients experience difficulties with walking. NLUTD is the presenting symptom in 2-12% of patients, with this finding being as high as 34% in some studies (51). LUT dysfunction appears mostly during the 10 years following the diagnosis (52). 2.1.9 Spinal cord lesions Spinal cord lesions can be traumatic, vascular, medical or congenital. An incidence of 30-40 new cases per million population is the accepted average for the USA. Most of these patients will develop NLUTD (53). The prevalence of spina bifida and other congenital nerve tube defects in the UK is 8-9 per 10,000 aged 10-69 years, with the greatest prevalence in the age group 25-29 years (54), and in the USA 1 per 1,000 births (55). The incidence of urethrovesical dysfunction in myelomeningocele is not completely known, but most studies suggest it is very high at 90-97% (56). About 50% of these children will have detrusor sphincter dyssynergia (DSD) (57, 58). 2.1.10 Disc disease This is reported to cause NLUTD in 28-87% of the patients (<20%) (59-60). The incidence of cauda equina syndrome due to central lumbar disc prolapse is relatively rare and is about 1-5% of all prolapsed lumbar discs (60-63, 64-67). There have been case reports of NLUT without cauda equine syndrome (69). 2.1.11 Spinal stenosis and spine surgery About 50% of patients seeking help for intractable leg pain due to spinal stenosis report symptoms of LUTD, such as a sense of incomplete bladder emptying, urinary hesitancy, incontinence, nocturia or urinary tract infections (UTIs) (70). These symptoms may be overlooked or attributed to primary urological disorders, with 61-62% affected by LUTD (71, 72). The prevalence of neurological bladder is more significantly associated with the anteroposterior diameter of the dural sac than with its cross-sectional area. Spinal surgery is related to LUTD in 38-60% of patients (73, 74).
UPDATE March 2008
5
2.1.12 Peripheral neuropathy Diabetes: This common metabolic disorder has a prevalence of about 2.5% in the American population, but the disease may be subclinical for many years. No specific criteria exist for secondary neuropathy in this condition, but it is generally accepted that 50% of patients will develop somatic neuropathy, with 75-100% of these patients developing NLUTD (75, 76). Diabetic patients suffer from various polyneuropathies, with ‘diabetic cystopathy’ reported in 43-87% of insulin-dependent diabetics without gender or age differences. It is also described in about 25% of type 2 diabetic patients on oral hypoglycaemic treatment (77). Alcohol abuse will eventually cause peripheral neuropathy. This has a reported prevalence that varies widely from 5-15% (78) to 64% (79). NLUTD is probably more likely to be present in patients with liver cirrhosis. The parasympathetic nervous system is attacked more than the sympathetic nervous system (79). Less prevalent peripheral neuropathies include the following: • Porphyria: bladder dilatation occurs in up to 12% of patients (80). • Sarcoidosis: NLUTD is rare (81). • Lumbosacral zone and genital herpes: incidence of LUT dysfunction is as high as 28% when only lumbosacral dermatome-involved patients are considered. The overall incidence is 4% (82, 83). NLUTD is transient in most patients. • Guillain Barré syndrome: the prevalence of micturition disorders varies from 25% to more than 80% (84,85), but is regressive in most cases (86). The true incidence is uncertain because, during the acute phase, patients are usually managed by indwelling catheter. 2.1.13 Other conditions (SLE) Nervous system involvement occurs in about half of patients with systemic lupus erythematosus (SLE). Symptoms of LUT dysfunction can occur, but data on prevalence are rare and give an incidence of 1% (87, 88). 2.1.14 HIV Voiding problems have been described in 12% of HIV-infected patients, mostly in advanced stages of the disease (89, 90). 2.1.15 Regional spinal anaesthesia This may cause NLUTD but no prevalence figures have been found (91, 92). 2.1.16 Iatrogenic Abdominoperineal resection of rectum has been described as causing NLUTD in up to 50% of patients (93, 94). One study has reported that NLUTD remains a long-term problem in only 10% (95); however, the study was not clear whether this was because the neurological lesion was cured or bladder rehabilitation was successful. Surgical prevention with nerve preservation was shown to be important (96, 97). NLUTD has been reported following simple hysterectomy (98) and in 8-57% of patients following radical hysterectomy or pelvic irradiation for cervical cancer (99-102). Surgical prevention can be used to prevent it (103). Neurological dysfunction of the pelvic floor has been demonstrated following radical prostatectomy (104).
2.2 Standardization of terminology 2.2.1 Introduction Several national or international guidelines have already been published for the care of patients with NLUTD (105-108). The guidelines will evolve as time goes by. The guidelines include definitions of important terms and procedures. The ICS NLUTD standardization report (106) deals specifically with the standardization of terminology and urodynamic investigation in patients with NLUTD. Other relevant definitions are found in the general ICS standardization report (109). Section 2.2.2 lists the definitions from these references, partly adapted, and other definitions considered useful for clinical practice in NLUTD (Tables 1 and 2). For specific definitions relating to urodynamic investigation, the reader is referred to the appropriate ICS report (106).
6
UPDATE MARCH 2008
2.2.2
Definitions
Table 1: Definitions useful in clinical practice Acontractility, detrusor Acontractility, urethral sphincter Autonomic dysreflexia Capacity Catheterization, indwelling Catheterization, intermittent (IC) • Aseptic IC • Clean IC • Sterile IC • Intermittent self-catheterization (ISC) Compliance, detrusor Condition Diary, urinary • Frequency volume chart (FVC) • Micturition time chart (MTC) Filling rate, physiological Hesitancy Intermittency Leak point pressure (LPP) Lower motor neuron lesion (LMNL) Neurogenic lower urinary tract dysfunction (NLUTD) Observation, specific Overactivity, bladder Overactivity, detrusor Rehabilitation, LUT Sign Sphincter, urethral, non-relaxing Symptom Upper motor neuron lesion (UMNL) Voiding, balanced: In patients with NLUTD (<80 mL or <20% of bladder volume) Voiding, triggered Volume, overactivity
UPDATE March 2008
See below under voiding phase See below under storage phase Increase of sympathetic reflex due to noxious stimuli with symptoms or signs of headache, hypertension, flushing face and perspiration See below under storage phase Emptying of the bladder by a catheter that is introduced (semi-) permanently Emptying of the bladder by a catheter that is removed after the procedure, mostly at regular intervals The catheters remain sterile, the genitals are disinfected, and disinfecting lubricant is used Disposable or cleansed re-usable catheters, genitals washed Complete sterile setting, including sterile gloves, forceps, gown and mask IC performed by the patient See below under storage phase Evidence of relevant pathological processes Record of times of micturitions and voided volumes, incontinence episodes, pad usage, and other relevant information Times of micturitions and voided volumes only Times of micturitions only Below the predicted maximum: body weight (kg)/ 4 in mL/s (109, 110) Difficulty in initiating micturition; delay in the onset of micturition after the individual is ready to pass urine Urine flow stops and starts on one or more occasions during voiding See below under storage phase Lesion at or below the S1-S2 spinal cord level Lower urinary tract dysfunction secondary to confirmed pathology of the nervous supply Observation made during specific diagnostic procedure See below under symptom syndrome See below under storage phase Non-surgical non-pharmacological treatment for LUT dysfunction To verify symptoms and classify them See below under voiding phase Subjective indicator of a disease or change in condition, as perceived by the patient, carer, or partner that may lead the patient to seek help from healthcare professionals Lesion above the S1-S2 spinal cord level Voiding with physiological detrusor pressure and low residual Voiding initiated by manoeuvres to elicit reflex detrusor contraction by exteroceptive stimuli See below under storage phase
7
Table 2: Further definitions useful in clinical practice Storage phase Maximum anaesthetic bladder capacity Increased daytime frequency Nocturia Urgency Urinary incontinence • Stress urinary incontinence • Urge urinary incontinence • Mixed urinary incontinence • Continuous urinary incontinence Bladder sensation Normal • Symptom and history • Urodynamics Increased • Symptom and history • Urodynamics Reduced • Symptom and history • Urodynamics Absent No sensation of bladder filling or desire to void Non-specific Definitions valid after urodynamic confirmation only Cystometric capacity • Maximum cystometric capacity • High-capacity bladder Normal detrusor function Detrusor overactivity • Phasic detrusor overactivity • Terminal detrusor overactivity • High pressure detrusor overactivity • Overactivity volume • Detrusor overactivity incontinence Leak point pressure • Detrusor leak point pressure (DLPP)
8
Maximum bladder filling volume under deep general or spinal anaesthesia Self-explanatory; the normal frequency can be estimated at about 8 times per day (111) Waking at night one or more times to void The symptom of a sudden compelling desire to pass urine that is difficult to defer Any involuntary leakage of urine On effort or exertion, or on sneezing or coughing Accompanied by or immediately preceded by urgency Associated with urgency and also exertion, effort, sneezing, or coughing
Awareness of bladder filling and increasing sensation up to a strong desire to void First sensation of bladder filling, first desire to void, and strong desire to void at realistic bladder volumes An early and persistent desire to void Any of the three urodynamic parameters mentioned under ‘normal’ persistently at low bladder volume Awareness of bladder filling but no definite desire to void Diminished sensation throughout bladder filling Perception of bladder filling as abdominal fullness, vegetative symptoms, or spasticity Bladder volume at the end of the filling cystometry Bladder volume at strong desire to void Bladder volume at cystometric capacity far over the mean voided volume, estimated from the bladder diary, with no significant increase in detrusor pressure under non-anaesthetized condition Little or no pressure increase during filling: no involuntary phasic contractions despite provocation Involuntary detrusor contractions during filling; spontaneous or provoked Characteristic phasic contraction A single contraction at cystometric capacity Maximal detrusor pressure > 40 cm H2O (106, 112) Bladder volume at first occurrence of detrusor overactivity Self-explanatory Lowest value of detrusor pressure at which leakage is observed in the absence of abdominal strain or detrusor contraction
UPDATE MARCH 2008
• Abdominal leak point pressure Lowest value of intentionally increased intravesical pressure that provokes leakage in the absence of a detrusor contraction Detrusor compliance Relationship between change in bladder volume (∆V) and change in detrusor pressure (∆pdet): C=∆V/∆pdet (ml/cm H2O) • Low detrusor compliance C=∆V/∆pdet <20 mL/cm H2O (106) Break volume Bladder volume after which a sudden significant decrease in detrusor compliance is observed Urethral sphincter acontractility No evidence of sphincter contraction during filling, particularly at higher bladder volumes, or during abdominal pressure increase Voiding phase • Slow stream Reduced urine flow rate • Intermittent stream (intermittency) Stopping and starting of urine flow during micturition • Hesitancy Difficulty in initiating micturition • Straining Muscular effort to initiate, maintain, or improve urinary stream • Terminal dribble Prolonged final part of micturition when the flow has slowed to a trickle/dribble Definitions valid after urodynamic confirmation only Normal detrusor function Voluntarily initiated detrusor contraction that causes complete bladder emptying within a normal time span Detrusor underactivity Contraction of reduced strength and/or duration Acontractile detrusor Absent contraction Non-relaxing urethral sphincter Self-explanatory Detrusor sphincter dyssynergia (DSD) Detrusor contraction concurrent with an involuntary contraction of the urethra and/or periurethral striated musculature Post-micturition phase Feeling of incomplete emptying (symptom only) Post-micturition dribble: involuntary leakage of urine shortly after finishing the micturition Pain, discomfort or pressure sensation in the lower urinary tract and genitalia that may be related to bladder filling or voiding, may be felt after micturition, or be continuous Symptom syndrome: combination of symptoms • Overactive bladder syndrome: urgency with or without urge incontinence, usually with frequency and nocturia • Synonyms: Urge syndrome, urgency-frequency syndrome • This syndrome is suggestive for LUTD
2.3
Classification
The classification of NLUTD helps to facilitate the understanding and management of NLUTD and to provide a standardized terminology of the disease processes. The normal LUT function depends on neural integration at, and between, the peripheral, spinal cord, and central nervous systems. The gross type of NLUTD is dependent on the location and the extent of the lesion: suprapontine or pontine, suprasacral spinal cord, or subsacral and peripheral (53, 107). The classification systems for NLUTD are based on either the neurological substrate (type and location of the neurological lesion) (113), the neuro-urological substrate (neurological lesion and LUTD) (114-116), the type of LUTD (117, 118), or are strictly functional (107, 109, 119-122). Many descriptive terms were derived from these classification systems. However, they are standardized only within any specific system, have little meaning outside the system, and can sometimes be confusing. A perfect classification system does not exist. Neurological classification systems, by nature, cannot describe the LUTD completely and vice versa. Individual variations exist in the NLUTD caused by a specific neurological lesion, so that the description of the NLUTD should be individualized for any particular patient. Madersbacher (107, 122) presented a very simple classification, which basically focused on the therapeutic consequences (Figure 2.1). It is based on the clinical concept that the important differentiation in the diagnosis exists between the situations of high and low detrusor pressure during the filling phase and
UPDATE March 2008
9
urethral sphincter relaxation and non- relaxation or DSD during the voiding phase. A non-relaxed sphincter or DSD will cause high detrusor pressure during the voiding phase. This classification is the easiest one for general use in the clinical diagnosis of NLUTD.
Detrusor
Over- active
Over- active
Overactive
Underactive
Over- active
Underactive
Normo-active
Overactive
Urethral sphincter
Lesion: Spinal
Lumbosacral
Suprapontine
Lumbosacral
Detrusor
Under- active
Under- active
Normo- active
Normoactive
Underactive
Normo-active
Overactive
Underactive
Urethral sphincter Lesion: Subsacral
Lumbosacral
Sphincter only
Sphincter only
Figure 2.1. Madersbacher classification system (107, 122) with typical neurogenic lesions 2.3.1 Recommendation for clinical practice The Madersbacher classification system (107, 122) (Figure 2.1) is recommended for clinical practice (Grade of recommendation: B).
2.4
Timing of diagnosis and treatment
Both in congenital and in acquired NLUTD, early diagnosis and treatment is essential as irreversible changes may occur, especially in children with myelomeningocele (123-128), but also in patients with traumatic spinal cord injury (129-131), even if the related neuropathological signs may be normal (132). It must also be remembered that LUTD by itself may be the presenting symptom for neurological pathology (50, 133).
2.5
References
1.
Andrew J, Nathan PW. Lesions of the anterior frontal lobes and disturbances of micturition and defecation. Brain 1964;87:233-62. http://www.ncbi.nlm.nih.gov/pubmed/14188274 Maurice-Williams RS. Micturition symptoms in frontal tumours. J Neurol Neurosurg Psychiatry. 1974;37(4):431-6. http://www.ncbi.nlm.nih.gov/pubmed/4365244 Lang EW, Chesnut RM, Hennerici M. Urinary retention and space-occupying lesions of the frontal cortex. Eur Neurol 1996;36(1):43-7. http://www.ncbi.nlm.nih.gov/pubmed/8719650 Ueki K. Disturbances of micturition observed in some patients with brain tumor. Neurol Med Chir 1960;2:25-33. Renier WO, Gabreels FJ. Evaluation of diagnosis and non-surgical therapy in 24 children with a pontine tumour. Neuropediatrics 1980;11(3):262-73. http://www.ncbi.nlm.nih.gov/pubmed/6252517 Toba K, Ouchi Y, Orimo H, Iimura O, Sasaki H, Nakamura Y, Takasaki M, Kuzuya F, Sekimoto H, Yoshioka H, Ogiwara T, Kimura I, Ozawa T, Fujishima M. Urinary incontinence in elderly inpatients in Japan: a comparison between general and geriatric hospitals. Aging (Milano) 1996;8(1):47-54. http://www.ncbi.nlm.nih.gov/pubmed/8695676
2.
3.
4. 5.
6.
10
UPDATE MARCH 2008
7.
8.
9.
10.
11.
12.
13. 14.
15.
16.
17.
18.
19.
20.
21. 22.
23.
24. 25.
26.
Campbell AJ, Reinken J, McCosh L. Incontinence in the elderly: prevalence and prognosis. Age Ageing 198514(2):65-70. http://www.ncbi.nlm.nih.gov/pubmed/4003185 Horimoto Y, Matsumoto M, Akatsu H, Ikari H, Kojima K, Yamamoto T, Otsuka Y, Ojika K, Ueda R, Kosaka K. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol 2003;250(5):530-3. http://www.ncbi.nlm.nih.gov/pubmed/12736730 Sugiyama T, Hashimoto K, Kiwamoto H, Ohnishi N, Esa A, Park YC, Kurita T. Urinary incontinence in senile dementia of the Alzheimer type (SDAT). Int J Urol 1994;1(4):337-40. http://www.ncbi.nlm.nih.gov/pubmed/7614397 McGrother C, Resnick M, Yalla SV, Kirschner-Hermanns R, Broseta E, Muller C, Welz-Barth A, Fischer GC, Mattelaer J, McGuire EJ. Epidemiology and etiology of urinary incontinence in the elderly. World J Urol 1998;16(Suppl 1):S3-S9. http://www.ncbi.nlm.nih.gov/pubmed/9775412 Madersbacher H, Awad S, Fall M, Janknegt RA, Stohrer M, Weisner B. Urge incontinence in the elderly-supraspinal reflex incontinence. World J Urol 1998;16 (Suppl 1):S35-S43. http://www.ncbi.nlm.nih.gov/pubmed/9775414 Olsen CG, Clasen ME. Senile dementia of the Binswanger’s type. Am Fam Physician 1998;58(9): 2068-74. http://www.ncbi.nlm.nih.gov/pubmed/9861880 Honig LS, Mayeux R. Natural history of Alzheimer’s disease. Aging (Milano) 2001;13:171-82. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. IV: Disorders of behaviour. Br J Psychiatry 1990;157:86-94. http://www.ncbi.nlm.nih.gov/pubmed/2397368 Cacabelos R, Rodríguez B, Carrera C, Caamaño J, Beyer K, Lao JI, Sellers MA . APOE-related frequency of cognitive and noncognitive symptoms in dementia. Methods Find Exp Clin Pharmacol 1996;18(10):693-706. http://www.ncbi.nlm.nih.gov/pubmed/9121226 Leung KS, Ng MF, Pang FC, Au SY. Urinary incontinence: an ignored problem in elderly patients. Hong Kong Med J 1997;3(1):27-33. http://www.ncbi.nlm.nih.gov/pubmed/11847353 Mitchell SJ, Woodthorpe J. Young mentally handicapped adults in three London boroughs: prevalence and degree of disability. J Epidemiol Community Health 1981;35(1):59-64. http://www.ncbi.nlm.nih.gov/pubmed/7264535 Reid AH, Ballinger BR, Heather BB. Behavioural syndromes identified by cluster analysis in a sample of 100 severely and profoundly retarded adults. Psychol Med 1978;8(3):399-412. http://www.ncbi.nlm.nih.gov/pubmed/704707 McNeal DM, Hawtrey CE, Wolraich ML, Mapel JR. Symptomatic neurologic bladder in a cerebralpalsied population. Dev Med Child Neurol 1983;25(5):612-6. http://www.ncbi.nlm.nih.gov/pubmed/6354799 Decter RM, Bauer SB, Khoshbin S, Dyro FM, Krarup C, Colodny AH, Retik AB. Urodynamic assessment of children with cerebral palsy. J Urol 1987;138(4 Pt 2):1110-2. http://www.ncbi.nlm.nih.gov/pubmed/3656569 Jonas S, Brown J. Neurologic bladder in normal pressure hydrocephalus. Urology 1975;5(1):44-50. http://www.ncbi.nlm.nih.gov/pubmed/1114545 Black PM. Idiopathic normal-pressure hydrocephalus. Results of shunting in 62 patients. J Neurosurg 1980;52(3):371-7. http://www.ncbi.nlm.nih.gov/pubmed/7359191 Mulrow CD, Feussner JR, Williams BC, Vokaty KA. The value of clinical findings in the detection of normal pressure hydrocephalus. J Gerontol 1987;42(3):277-9. http://www.ncbi.nlm.nih.gov/pubmed/3571862 Murnaghan GF. Neurogenic disorders of the bladder in Parkinsonism. Br J Urol 1961;33:403-9. http://www.ncbi.nlm.nih.gov/pubmed/14477379 Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho RM Jr, Ribeiro SC, de Carvalho DF. Urinary symptoms in Parkinson’s disease: prevalence and associated factors. Arq Neuropsiquiatr 2003;61:359-63. http://www.ncbi.nlm.nih.gov/pubmed/12894267 Salinas JM, Berger Y, De La Rocha RE, Blaivas JG. Urological evaluation in the Shy Drager syndrome. J Urol 1986;135(4):741-3. http://www.ncbi.nlm.nih.gov/pubmed/3959195
UPDATE March 2008
11
27.
28.
29.
30.
31.
32.
33. 34.
35. 36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
12
Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 1997;80(1):100-4. http://www.ncbi.nlm.nih.gov/pubmed/9240187 Hattori T, Yasuda K, Kita K, Hirayama K. Voiding dysfunction in Parkinson’s disease. Jpn J Psychiatry Neurol 1992;46(1):181-6. http://www.ncbi.nlm.nih.gov/pubmed/1635308 Gray R, Stern G, Malone-Lee J. Lower urinary tract dysfunction in Parkinson’s disease: changes relate to age and not disease. Age Ageing 1995;24(6):499-504. http://www.ncbi.nlm.nih.gov/pubmed/8588540 Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 2000;68(4):429-33. http://www.ncbi.nlm.nih.gov/pubmed/10727477 Lemack GE, Dewey RB, Roehrborn CG, O’Suilleabhain PE, Zimmern PE. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson’s disease. Urology 2000; 56(2):250-4. http://www.ncbi.nlm.nih.gov/pubmed/10925088 Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, Hattori T. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci 2001;92(1-2):76-85. http://www.ncbi.nlm.nih.gov/pubmed/11570707 Currie CT. Urinary incontinence after stroke. BMJ (Clin Res Ed) 1986;293(6558):1322-3. http://www.ncbi.nlm.nih.gov/pubmed/3790967 Codine PH, Pellissier J, Manderscheidt JC, Costa P, Enjalbert M, Perrigot M. Les troubles urinaires au cours des hémiplegies vasculaires. In: Hémiplegie vasculaire et médicine de rééducation. Pellisier J, ed. Paris, Masson, 1988, pp. 261-269. Barer DH. Continence after stroke: useful predictor or goal of therapy? Age Ageing 1989;18(3):183-91. http://www.ncbi.nlm.nih.gov/pubmed/2782216 Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci 1996;137(1):47-56. http://www.ncbi.nlm.nih.gov/pubmed/9120487 Nakayama H, Jørgensen HS, Pedersen PM, Raaschou HO, Olsen TS. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. 1997;28(1):58-62. http://www.ncbi.nlm.nih.gov/pubmed/8996489 Khan Z, Hertanu J, Yang WC, Melman A, Leiter E. Predictive correlation of urodynamic dysfunction and brain injury after cerebrovascular accident. J Urol 1981;126(1):86-8. http://www.ncbi.nlm.nih.gov/pubmed/7253085 Tsuchida S, Noto H, Yamaguchi O, Itoh M. Urodynamic studies on hemiplegic patients after cerebrovascular accident. Urology 1983;21(3):315-8. http://www.ncbi.nlm.nih.gov/pubmed/6836813 Kuroiwa Y, Tohgi H, Ono S, Itoh M. Frequency and urgency of micturition in hemiplegic patients; relationship to hemisphere laterality of lesions. J Neurol 1987;234(2):100-2. http://www.ncbi.nlm.nih.gov/pubmed/3559632 Khan Z, Starer P, Yang WC, Bhola A. Analysis of voiding disorders in patients with cerebrovascular accidents. Urology 1990;35(3):265-70. http://www.ncbi.nlm.nih.gov/pubmed/3559632 Taub NA, Wolfe CD, Richardson E, Burney PG. Predicting the disability of first-time stroke sufferers at 1 year. 12-month follow-up of a population-based cohort in southeast England. Stroke 1994;25(2):352-7. http://www.ncbi.nlm.nih.gov/pubmed/8303744 Borrie MJ, Campbell AJ, Caradoc-Davies TH, Spears GF. Urinary incontinence after stroke: a prospective study. Age Ageing 1986;15(3):177-81. http://www.ncbi.nlm.nih.gov/pubmed/3739856 Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance and the pontine tegmental lesion: urodynamic and MRI analyses of vascular cases. J Neurol Sci 1996;141(1-2):105-10. http://www.ncbi.nlm.nih.gov/pubmed/8880701 Betts CD, Kapoor R, Fowler CJ. Pontine pathology and voiding dysfunction. Br J Urol 1992;70(1): 100-2. http://www.ncbi.nlm.nih.gov/pubmed/1638364
UPDATE MARCH 2008
46.
47.
48.
49. 50.
51.
52.
53.
54.
55.
56. 57.
58.
59.
60.
61.
62.
63.
64.
65.
Manente G, Melchionda D, Uncini A. Urinary retention in bilateral pontine tumour: evidence for a pontine micturition centre in humans. J Neurol Neurosurg Psychiatry 1996;61(5):528-9. http://www.ncbi.nlm.nih.gov/pubmed/8937354 Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol;1999;161(3): 743-57. http://www.ncbi.nlm.nih.gov/pubmed/10022678 Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Finazzi Agrò E, Collura G, Vespasiani G. LUT dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil 1999;80(4):437-41. http://www.ncbi.nlm.nih.gov/pubmed/10206607 Hinson JL, Boone TB. Urodynamics and multiple sclerosis. Urol Clin North Am 1996;23(3):475-81. http://www.ncbi.nlm.nih.gov/pubmed/8701560 Bemelmans BL, Hommes OR, Van Kerrebroeck PE, Lemmens WA, Doesburg WH, Debruyne FM. Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. J Urol 1991;145(6):1219-24. http://www.ncbi.nlm.nih.gov/pubmed/2033697 DasGupta R, Fowler CJ. Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol 2002;15(3):271-8. http://www.ncbi.nlm.nih.gov/pubmed/12045724 Perrigot M, Richard F, Veaux-Renault V, Chatelain C, Kuss R. [Bladder sphincter disorders in multiple sclerosis: symptomatology and evolution. 100 cases.] Sem Hop 1982;58(45):2543-6. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/6297048 Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine 2001;26(24):S129-S136. http://www.ncbi.nlm.nih.gov/pubmed/11805620 Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. A UK general practice database study of prevalence and mortality of people with neural tube defects. Clin Rehabil 2000;14(6):627-30. http://www.ncbi.nlm.nih.gov/pubmed/11128738 Selzman AA, Elder JS, Mapstone TB. Urologic consequences of myelodysplasia and other congenital abnormalities of the spinal cord. Urol Clin North Am 1993;20(3):485-504. http://www.ncbi.nlm.nih.gov/pubmed/8351774 Smith E. Spina bifida and the total care of spinal myelomeningocoele. Springfield, IL: CC Thomas, ed, 1965; pp. 92-123. van Gool JD, Dik P, de Jong TP. Bladder-sphincter dysfunction in myelomeningocele. Eur J Pediatr 2001;160(7):414-20. http://www.ncbi.nlm.nih.gov/pubmed/11475578 Wyndaele JJ, De Sy W. Correlation between the findings of a clinical neurological examination and the urodynamic dysfunction in children with myelodysplasia. J Urol 1985;133(4):638-40. http://www.ncbi.nlm.nih.gov/pubmed/3981715 Bartolin Z, Gilja I, Bedalov G, Savic I. Bladder function in patients with lumbar intervertebral disc protrusion. J Urol 1998;159(3):969-71. http://www.ncbi.nlm.nih.gov/pubmed/9474195 O’Flynn KJ, Murphy R, Thomas DG. Neurologic bladder dysfunction in lumbar intervertebral disc prolapse. Br J Urol 1992;69(1):38-40. http://www.ncbi.nlm.nih.gov/pubmed/1737251 Jennett WB. A study of 25 cases of compression of the cauda equina by prolapsed intervertebral discs. J Neurol Neurosurg Psychiatry 1956;19(2):109-16. http://www.ncbi.nlm.nih.gov/pubmed/13346384 Tay ECK, Chacha PB. Midline prolapse of a lumbar intervertebral disc with compression of the cauda equina. J Bone Joint Surg Br 1979;61(1):43-6. http://www.ncbi.nlm.nih.gov/pubmed/154521 Nielsen B, de Nully M, Schmidt K, Hansen RI. A urodynamic study of cauda equina syndrome due to lumbar disc herniation.Urol Int 1980;35(3):167-70. http://www.ncbi.nlm.nih.gov/pubmed/7385464 Bartels RH, de Vries J. Hemi-cauda equina syndrome from herniated lumbar disc: a neurosurgical emergency? Can J Neurol Sci 1996;23(4):296-9. http://www.ncbi.nlm.nih.gov/pubmed/8951209 Goldman HB, Appell RA. Voiding dysfunction in women with lumbar disc prolapse. Int Urogynecol J Pelvic Floor Dysfunct 1999;10(2):134-8. http://www.ncbi.nlm.nih.gov/pubmed/10384977
UPDATE March 2008
13
66.
67.
68. 69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79. 80. 81.
82.
83.
84.
14
Ahn UM, Ahn NU, Buchowski JM, Garrett ES, Sieber AN, Kostuik JP. Cauda equina syndrome secondary to lumbar disc herniation: a meta-analysis of surgical outcomes. Spine 2000;25(12): 1515-22. http://www.ncbi.nlm.nih.gov/pubmed/10851100 Shapiro S. Medical realities of cauda equina syndrome secondary to lumbar disc herniation. Spine 2000;25(3):348-51. http://www.ncbi.nlm.nih.gov/pubmed/10703108 Emmett JL, Love JG. Urinary retention in women caused by asymptomatic protruded lumbar disc: report of 5 cases. J Urol 1968;99:597-606. Rosomoff HL, Johnston JD, Gallo AE, Ludmer M, Givens FT, Carney FT, Kuehn CA. Cystometry in the evaluation of nerve root compression in the lumbar spine. Surg Gynecol Obstet 1963;117:263-70. http://www.ncbi.nlm.nih.gov/pubmed/14080336 Kawaguchi Y, Kanamori M, Ishihara H, Ohmori K, Fujiuchi Y, Matsui H, Kimura T. Clinical symptoms and surgical outcome in lumbar spinal stenosis patients with neurologic bladder. J Spinal Disord 2001;14:404-10. http://www.ncbi.nlm.nih.gov/pubmed/11586140 Tammela TL, Heiskari MJ, Lukkarinen OA. Voiding dysfunction and urodynamic findings in patients with cervical spondylotic spinal stenosis compared with severity of the disease. Br J Urol. 1992;70(2):144-8. http://www.ncbi.nlm.nih.gov/pubmed/1393436 Inui Y, Doita M, Ouchi K, Tsukuda M, Fujita N, Kurosaka M. Clinical and radiological features of lumbar spinal stenosis and disc herniation with neurologic bladder. Spine 2004;29(8):869-73. http://www.ncbi.nlm.nih.gov/pubmed/15082986 Boulis NM, Mian FS, Rodriguez D, Cho E, Hoff JT. Urinary retention following routine neurosurgical spine procedures. Surg Neurol 2001;55(1):23-7. http://www.ncbi.nlm.nih.gov/pubmed/11248301 Brooks ME, Moreno M, Sidi A, Braf ZF. Urologic complications after surgery on lumbosacral spine. Urology 1985;26:202-4. http://www.ncbi.nlm.nih.gov/pubmed/4024418 Ellenberg M. Development of urinary bladder dysfunction in diabetes mellitus. Ann Intern Med 1980;92(2 Pt 2):321-3. http://www.ncbi.nlm.nih.gov/pubmed/7356222 Frimodt-Moller C. Diabetic cystopathy: epidemiology and related disorders. Ann Intern Med 1980; 92:318-21. http://www.ncbi.nlm.nih.gov/pubmed/7356221 Bradley WE. Diagnosis of urinary bladder dysfunction in diabetes mellitus. Ann Intern Med 1980;92(2 Pt 2):323-6. http://www.ncbi.nlm.nih.gov/pubmed/7188844 Barter F, Tanner AR. Autonomic neuropathy in an alcoholic population. Postgrad Med J. 1987;63(746): 1033-6. http://www.ncbi.nlm.nih.gov/pubmed/3451229 Anonymous. Autonomic neuropathy in liver disease. Lancet 1989;2(8665):721-2. http://www.ncbi.nlm.nih.gov/pubmed/2570966 Bloomer JR, Bonkovsky HL. The porphyrias. Dis Mon 1989;35(1):1-54. http://www.ncbi.nlm.nih.gov/pubmed/2645098 Chapelon C, Ziza JM, Piette JC, Levy Y, Raguin G, Wechsler B, Bitker MO, Bletry O, Laplane D, Bousser MG, et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore); 1990;69(5):261-76. http://www.ncbi.nlm.nih.gov/pubmed/2205782 Chen PH, Hsueh HF, Hong CZ. Herpes zoster-associated voiding dysfunction: a retrospective study and literature review. Arch Phys Med Rehabil 2002;83(11):1624-8. http://www.ncbi.nlm.nih.gov/pubmed/12422336 Greenstein A, Matzkin H, Kaver I, Braf Z. Acute urinary retention in herpes genitalis infection. Urodynamic evaluation. Urology 1988;31(5):453-6. http://www.ncbi.nlm.nih.gov/pubmed/3363783 Grbavac Z, Gilja I, Gubarev N, Bozicevic D. [Neurologic and urodynamic characteristics of patients with Guillain-Barré syndrome]. Lijec Vjesn 1989;111(1-2):17-20. [article in Croatian] http://www.ncbi.nlm.nih.gov/pubmed/2739495
UPDATE MARCH 2008
85.
86. 87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997;63(5):649-53. http://www.ncbi.nlm.nih.gov/pubmed/9408108 Lichtenfeld P. Autonomic dysfunction in the Guillain-Barré syndrome. Am J Med 1971;50(6):772-80. http://www.ncbi.nlm.nih.gov/pubmed/5089852 Sakakibara R, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T. Urinary dysfunction in patients with systemic lupus erythematosis. Neurourol Urodyn 2003;22(6):593-6. http://www.ncbi.nlm.nih.gov/pubmed/12951670 Min JK, Byun JY, Lee SH, Hong YS, Park SH, Cho CS, Kim HY. Urinary bladder involvement in patients with systemic lupus erythematosus: with review of the literature. Korean J Intern Med 2000;15(1):42-50. http://www.ncbi.nlm.nih.gov/pubmed/10714091 Gyrtrup HJ, Kristiansen VB, Zachariae CO, Krogsgaard K, Colstrup H, Jensen KM. Voiding problems in patients with HIV infection and AIDS. Scand J Urol Nephrol 1995;29(3):295-8. http://www.ncbi.nlm.nih.gov/pubmed/8578272 Khan Z, Singh VK, Yang WC. Neurologic bladder in acquired immune deficiency syndrome (AIDS). Urology 1992;40(3):289-91. http://www.ncbi.nlm.nih.gov/pubmed/1523760 Mardirosoff C, Dumont L. Bowel and bladder dysfunction after spinal bupivacaine. Anesthesiology 2001; 95(5):1306. http://www.ncbi.nlm.nih.gov/pubmed/11685017 Auroy Y, Benhamou D, Bargues L, Ecoffey C, Falissard B, Mercier FJ, Bouaziz H, Samii K. Major complications of regional anesthesia in France: The SOS Regional Anesthesia Hotline Service. Anesthesiology 2002;97(5):1274-80. http://www.ncbi.nlm.nih.gov/pubmed/12411815 Hollabaugh RS Jr, Steiner MS, Sellers KD, Samm BJ, Dmochowski RR. Neuroanatomy of the pelvis: implications for colonic and rectal resection. Dis Colon Rectum 2000;43(10):1390-7. http://www.ncbi.nlm.nih.gov/pubmed/11052516 Baumgarner GT, Miller HC. Genitourinary complications of abdominoperineal resection. South Med J 1976;69(7):875-7. http://www.ncbi.nlm.nih.gov/pubmed/941055 Eickenberg HU, Amin M, Klompus W, Lich R Jr. Urologic complications following abdominoperineal resection. J Urol 1976;1152(2):180-2. http://www.ncbi.nlm.nih.gov/pubmed/1249871 Pocard M, Zinzindohoue F, Haab F, Caplin S, Parc R, Tiret E. A prospective study of sexual and urinary function before and after total mesorectal excision with autonomic nerve preservation for rectal cancer. Surgery 2002;131:368-72. http://www.ncbi.nlm.nih.gov/pubmed/11935125 Kim NK, Aahn TW, Park JK, Lee KY, Lee WH, Sohn SK, Min JS. Assessment of sexual and voiding function after total mesorectal excision with pelvic autonomic nerve preservation in males with rectal cancer. Dis Colon Rectum 2002;45(9):1178-85. http://www.ncbi.nlm.nih.gov/pubmed/12352233 Parys BT, Woolfenden KA, Parsons KF. Bladder dysfunction after simple hysterectomy: urodynamic and neurological evaluation. Eur Urol 1990;17(2):129-33. http://www.ncbi.nlm.nih.gov/pubmed/2311638 Sekido N, Kawai K, Akaza H. Lower urinary tract dysfunction as persistent complication of radical hysterectomy. Int J Urol 1997;4(3):259-64. http://www.ncbi.nlm.nih.gov/pubmed/9255663 Zanolla R, Monzeglio C, Campo B, Ordesi G, Balzarini A, Martino G. Bladder and urethral dysfunction after radical abdominal hysterectomy: rehabilitative treatment. J Surg Oncol 1985;28(3):190-4. http://www.ncbi.nlm.nih.gov/pubmed/3974245 Seski JC, Diokno AC. Bladder dysfunction after radical abdominal hysterectomy. Am J Obstet Gynecol 1977;128(6):643-51. http://www.ncbi.nlm.nih.gov/pubmed/18009 Lin HH, Sheu BC, Lo MC, Huand SC. Abnormal urodynamic findings after radical hysterectomy or pelvic irradiation for cervical cancer. Int J Gynaecol Obstet 1998;63(2):169-74. http://www.ncbi.nlm.nih.gov/pubmed/9856324 Kuwabara Y, Suzuki M, Hashimoto M, Furugen Y, Yoshida K, Mitsuhashi N. New method to prevent bladder dysfunction after radical hysterectomy for uterine cervical cancer. J Obstet Gynaecol Res 2000;26(1):1-8. http://www.ncbi.nlm.nih.gov/pubmed/10761323
UPDATE March 2008
15
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114. 115. 116. 117. 118. 119.
120. 121.
122.
123.
124.
16
Zermann DH, Ishigooka M, Wunderlich H, Reichelt O, Schubert J. A study of pelvic floor function pre and postradical prostatectomy using clinical neurourological investigations, urodynamics and electromyography. Eur Urol 2000;37(1):72-8. http://www.ncbi.nlm.nih.gov/pubmed/10671789 Burgdörfer H, Heidler H, Madersbacher H, Melchior H, Palmtag H, Richter R, Richter-Reichhelm M, Rist M, Rübben H, Sauerwein D, Schalkhäuser K, Stöhrer M. Leitlinien zur urologischen Betreuung Querschnittgelähmter. Urologe A 1998;37:222-8. [article in German] [Guidelines for the urological management of paraplegic patients]. Stöhrer M, Goepel M, Kondo A, Kramer G, Madersbacher H, Millard R, Rossier A, Wyndaele JJ. The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures, Neurourol Urodyn 1999;18(2):139-58. http://www.ncbi.nlm.nih.gov/pubmed/10081953 Wyndaele JJ, Castro D, Madersbacher H, Chartier-Kastler E, Igawa Y, Kovindha A, Radziszewski P, Stone A, Wiesel P. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Plymouth: Health Publications, 2005:1061-2. Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med 2006;29(5):527-3. http://www.ncbi.nlm.nih.gov/pubmed/17274492 Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-78. http://www.ncbi.nlm.nih.gov/pubmed/11857671 Klevmark B. Natural pressure-volume curves and conventional cystometry. Scand J Urol Nephrol Suppl 1999;201:1-4. http://www.ncbi.nlm.nih.gov/pubmed/10573769 Homma Y, Ando T, Yoshida M, Kageyama S, Takei M, Kimoto K, Ishizuka O, Gotoh M, Hashimoto T. Voiding and incontinence frequencies: variability of diary data and required diary length. Neurourol Urodyn 2002;21(3):204-9. http://www.ncbi.nlm.nih.gov/pubmed/10573769 McGuire EJ, Cespedes RD, O’Connell HE. Leak-point pressures. Urol Clin North Am 1996;23(2): 253-62. http://www.ncbi.nlm.nih.gov/pubmed/8659025 Bradley WE, Timm GW, Scott FB. Innervation of the detrusor muscle and urethra. Urol Clin North Am 1974;1(1):3-27. http://www.ncbi.nlm.nih.gov/pubmed/4372763 Bors E, Comarr AE. Neurological urology. Basel, Karger, 1971:75;144-5. Hald T, Bradley WE. The neurogenic bladder. Baltimore, Williams and Wilkins, 1982. Stöhrer M, Kramer G, Löchner-Ernst D, Goepel M, Noll F, Rübben H. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. Eur Urol Update Series 1994;3:170-5. Lapides J. Neuromuscular vesical and urethral dysfunction. In: Campbell MF, Harrison JH, eds. Urology. 3rd edn. Philadelphia, WB Saunders, 1970, pp. 1343-1379. Krane RJ, Siroky MB. Classification of neuro-urologic disorders. In: Krane RJ, Siroky MB, eds. Clinical neuro-urology. Boston: Little Brown, 1979: 143-58. Quesada EM, Scott FB, Cardus D. Functional classification of neurogenic bladder dysfunction. Arch Phys Med Rehabil 1968;49(12):692-7. http://www.ncbi.nlm.nih.gov/pubmed/5703244 Wein AJ. Pathophysiology and categorization of voiding dysfunction. In: Walsh PC, Retik AB, Vaughan Jr ED, Wein AJ, eds. Campbell’s urology. 7th edn. Philadelphia: WB Saunders, 1998, pp. 917-926. Fall M, Ohlsson BL, Carlsson CA. The neurogenic overactive bladder. Classification based on urodynamics. Br J Urol 1989;64(4):368-73. http://www.ncbi.nlm.nih.gov/pubmed/2819387 Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia 1990;28(4):217-29. http://www.ncbi.nlm.nih.gov/pubmed/2235029 Cass AS, Luxenberg M, Johnson CF, Gleich P. Incidence of urinary tract complications with myelomeningocele. Urology 1985;25(4):374-8. http://www.ncbi.nlm.nih.gov/pubmed/3984125 Fernandes ET, Reinberg Y, Vernier R, Gonzalez R. Neurogenic bladder dysfunction in children: review of pathophysiology and current management. J Pediat 1994;124(1):1-7. http://www.ncbi.nlm.nih.gov/pubmed/8283355
UPDATE MARCH 2008
125.
126.
127.
128.
129.
130.
131.
132.
133.
Stone AR. Neurourologic evaluation and urologic management of spinal dysraphism. Neurosurg Clin N Am 1995;6(2):269-77. http://www.ncbi.nlm.nih.gov/pubmed/7620353 Satar N, Bauer SB, Shefner J, Kelly MD, Darbey MM. The effects of delayed diagnosis and treatment in patients with an occult spinal dysraphism. J Urol 1995;154(2 Pt 2):754-8. http://www.ncbi.nlm.nih.gov/pubmed/7609171 Pontari MA, Keating M, Kelly M, Dyro F, Bauer SB. Retained sacral function in children with high level myelodysplasia. J Urol 1995;154(2 Pt 2):775-7. http://www.ncbi.nlm.nih.gov/pubmed/7609177 Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomeningocele. J Urol 1999;162(3 Pt 2):1068-71. http://www.ncbi.nlm.nih.gov/pubmed/10458433 Wyndaele JJ. Development and evaluation of the management of the neuropathic bladder. Paraplegia 1995,33(6):305-7. http://www.ncbi.nlm.nih.gov/pubmed/7644254 Cardenas DD, Mayo ME, Turner LR. Lower urinary changes over time in suprasacral spinal cord injury. Paraplegia 1995;33(6):326-9. http://www.ncbi.nlm.nih.gov/pubmed/7644258 Amarenco G. [Vesico-sphincter disorders of nervous origin.] Rev Prat 1995;45(3):331-5. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/7725038 Watanabe T, Vaccaro AR, Kumon H, Welch WC, Rivas DA, Chancellor MB. High incidence of occult neurogenic bladder dysfunction in neurologically intact patients with thoracolumbar spinal injuries. J Urol 1998;159(3):965-8. http://www.ncbi.nlm.nih.gov/pubmed/9474194 Ahlberg J, Edlund C, Wikkelso C, Rosengren L, Fall M. Neurological signs are common in patients with urodynamically verified ‘idiopathic’ bladder overactivity. Neurourol Urodyn 2002;21(1):65-70. http://www.ncbi.nlm.nih.gov/pubmed/11835426
3. DIAGNOSIS 3.1
Introduction
Before any functional investigation is planned, an extensive general and specific diagnosis should be performed. Part of this diagnosis is specific for neurogenic pathology and its possible sequelae. The clinical assessment of patients with NLUTD includes and extends that for other LUTD. The latter should consist of a detailed history, bladder diary and a physical examination. In urinary incontinence, leakage should be demonstrated objectively. These data are indispensable for reliable interpretation of the findings in diagnostic investigations performed subsequently in NLUTD.
3.2
History
3.2.1 General history The general history should include relevant questions about neurological and congenital abnormalities, social factors and the patient’s motivation, any previous occurrences and frequency of urinary infections, and relevant surgery. Information must be obtained on medication with known or possible effects on the lower urinary tract (1-3). The general history should also include the assessment of menstrual, sexual and bowel function, and obstetric history (3). Hereditary or familial risk factors should be recorded. Symptoms of any metabolic disorder or neurological disease that may induce NLUTD must be checked particularly. Specific signs, such as pain, infection, haematuria, fever, etc, may justify further particular diagnosis. Items of particular importance include: • Congenital anomalies with possible neurological impact • Metabolic disorders with possible neurological impact • Preceding therapy, including surgical interventions • Present medication • Lifestyle factors, such as smoking, alcohol, or addictive drug use
UPDATE March 2008
17
• • •
Infections of the urinary tract Quality of life Life expectancy.
3.2.2 Specific history Urinary history: This consists of symptoms related to both the storage and the evacuation functions of the lower urinary tract. The onset and the nature of the NLUTD (acute or insidious) should be determined. Specific symptoms and signs must be assessed in NLUTD and if appropriate should be compared with the patient’s condition before the NLUTD developed. The separate diagnostic field items should be diagnosed in as much detail as possible (3): • LUTS • Voiding pattern • Urinary incontinence • Bladder sensation • Mode and type of voiding (catheterization). The urinary (bladder) diary gives (semi-)objective information about the number of voidings, daytime and night-time voiding frequency, volumes voided, and incontinence and urge episodes. Bowel history: Patients with NLUTD may suffer from a related neurogenic condition of the lower gastrointestinal tract. The bowel history must also address symptoms related to the storage and evacuation functions. Specific symptoms and signs must be compared with the patient’s condition before the neurogenic dysfunction developed. Again, the diagnostic items should be detailed (3): • Ano-rectal symptoms • Defecation pattern • Fecal incontinence • Rectal sensation • Mode and type of defecation. Sexual history: Sexual function may also be impaired because of the neurogenic condition. The details of the history will differ of course between men and women (3): • Genital or sexual dysfunction symptoms • Sexual function • Sensation in genital area and for sexual functions • Erection or arousal • Orgasm • Ejaculation. Neurological history: This should concentrate on the following information: • Acquired or congenital neurological condition • Neurological symptoms (somatic and sensory), with onset, evolution, and performed therapy • Spasticity or autonomic dysreflexia (lesion level above Th6). Individuals with spinal cord injury (SCI) are often not accurate at knowing whether they have had a urinary tract infection based on their symptoms (4).
3.2.3 GUIDELINES FOR HISTORY TAKING 1.
2. 3.
3.3
An extensive general history is mandatory, concentrating on past and present symptoms and conditions for urinary, bowel, sexual, and neurological functions, and on general conditions that might impair any of these. Special attention should be paid to the possible existence of alarm signs, such as pain, infection, haematuria, fever, etc, that warrant further specific diagnosis. A specific history should be taken for each of the four mentioned functions.
Physical examination
3.3.1 General physical examination Attention should be paid to the patient’s physical and possible mental handicaps. Problems may be caused by impaired mobility, particularly in the hips, or extreme spasticity. Patients with very high neurological lesions may suffer from a significant drop in blood pressure when moved in a sitting or standing position. Subjective indications of bladder filling sensations may be impossible in
18
UPDATE MARCH 2008
mentally impaired patients. Inspection of the abdominal wall, prostate palpation or observation of pelvic organ prolapse is mandatory. 3.3.2 Neuro-urological examination General neurological examination: This investigates the motor and sensory functions of the body, the limbs and hand functions (Figure 3.1). A suprapubic globe should be looked for and the skin condition in the genital and perineal regions should be assessed. Figure 3.1. Dermatomes of spinal cord levels L2-S4
Figure 3.2. Urogenital and other reflexes in lower spinal cord
UPDATE March 2008
19
Figure 3.3. Innervation overview of bladder and bowel. Afferent and efferent nerves in the different peripheral nerves and central nervous system are shown
Figure 3.4. Overview of peripheral nerves innervating the lower urinary tract
Specific neuro-urological examination: This investigation is necessary in patients with NLUTD. It includes several tests for sacral reflex activity and an evaluation of the sensation in the perineal area. Figure 3.1 shows the different dermatomes and Figure 3.2 the associated reflexes in this area. Specified information should become available on: • Sensation S2-S5 on both sides of the body • Reflexes • Anal sphincter tone • Volitional contraction of anal sphincter and pelvic floor. A high correlation exists between the clinical neurological findings and NLUTD in some types of neuropathy, but less so in other types (5-10). The correspondence is low, for instance, in myelomeningocele patients (7)
20
UPDATE MARCH 2008
and in combined traumatic spinal cord lesions, but high in single-level traumatic spinal cord lesions (10). In SCI patients with thoracolumbar fractures, neurogenic voiding dysfunction cannot be predicted by the sensory evaluation (11). In SCI patients with thoracolumbar fractures, the presence of a voluntary contraction of the plantar flexors of the toes correlates with active contraction of the external anal/urethral sphincter, but does not enable differentiation of the types of neuropathic voiding disorders (12). A congenital association of lower urinary tract and bowel dysfunction with an abnormal facial expression is named the urofacial (Ochoa) syndrome. (13). Individuals with SCI were frequently not accurate at predicting whether they had a UTI based on their symptoms (4). 3.3.3 Essential investigations Essential investigations include (3): • Urinalysis • Blood chemistry • Voiding diary • Assessment of residual urine, if possible with free flowmetry. Because of natural variations, several assessments (at least 2-3) are necessary (3, 10, 11). • Quantification of urine loss by pad testing if appropriate • Urinary tract imaging studies.
3.3.4 GUIDELINES FOR PHYSICAL EXAMINATION 1. 2. 3. 4.
3.4
Individual patient handicaps should be acknowledged in planning further investigations. The neurological status should be described as completely as possible. Sensations and reflexes in the urogenital area must all be tested. The anal sphincter and pelvic floor functions must be tested extensively. Urinalysis, blood chemistry, voiding diary, residual and free flowmetry, incontinence quantification and urinary tract imaging should be performed.
Urodynamics
3.4.1 Introduction Urodynamic investigation is the only method that can objectively assess the (dys-)function of the LUT. It is essential to describe the LUT status in patients with NLUTD. In these patients, particularly when detrusor overactivity might be present, the invasive urodynamic investigation is even more provocative than in other patients. Any technical source of artefacts must be critically considered. The quality of the urodynamic recording and its interpretation must be ensured (12). In patients at risk for autonomic dysreflexia, it is advisable to measure blood pressure during the urodynamic study. In many patients with NLUTD, it may be helpful to assess the maximum anaesthetic bladder capacity. The rectal ampulla should be empty of stool before the start of the investigation. Drugs that influence the lower urinary tract function should be stopped at least 48 hours before the investigation (if feasible) or otherwise be considered when interpreting the data obtained. All urodynamic findings must be reported in detail and performed according to the ICS technical recommendations and standards (3, 12, 13). 3.4.2 Urodynamic tests A bladder diary is a semi-objective qualification of the LUT. It is a highly advisable diagnostic tool. For reliable interpretation, it should be recorded over at least 2-3 days (3, 14). Possible pathological findings: high voiding frequency, very low or very high voided volumes, nocturnal voidings, urgency, incontinence. Free uroflowmetry and assessment of residual urine gives a first impression of the voiding function. It is mandatory before planning any invasive urodynamics. For reliable information, it should be repeated at least 2-3 times (3, 10, 11). Possible pathological findings: low flow rate, low voided volume, intermittent flow, hesitancy, residual urine. Care must be taken when assessing the results in patients who are not able to void in a normal position. Both the flow pattern and the flow rate may be modified by inappropriate positions and by any constructions to divert the flow. Filling cystometry: The only method to quantify the filling function has limited significance as a solitary procedure. It is much more powerful if combined with bladder pressure measurement during micturition and
UPDATE March 2008
21
even more in video-urodynamics. This investigation is necessary to document the status of the LUT function during the filling phase. The bladder should be empty at the start of filling. A physiological filling rate should be used with body-warm saline, as fast filling and room-temperature saline are provocative (3). Possible pathological findings include detrusor overactivity, low detrusor compliance, abnormal bladder and other sensations, incontinence, incompetent or relaxing urethra. Detrusor leak point pressure (DLPP): This specific investigation may estimate the risk for the upper urinary tract or for secondary bladder damage (3, 15). The DLPP is a screening test only, because it gives no impression of the duration of the high pressure during the filling phase, which can be expected to have even more impact on the upper urinary tract (16). A high DLPP thus warrants further testing by video-urodynamics. Pressure flow study: This measurement reflects the co-ordination between detrusor and urethra or pelvic floor during the voiding phase. It is even more powerful in combination with filling cystometry and with video urodynamics. It is necessary to document the function of the lower urinary tract function during the voiding phase. Possible pathological findings: Detrusor underactivity/acontractility, DSD, non-relaxing urethra, residual urine. Most types of obstruction caused by NLUTD are due to DSD (17, 18), non-relaxing urethra, or nonrelaxing bladder neck (3, 19, 20). Pressure-flow analysis mostly assesses the amount of mechanical obstruction caused by the urethra’s inherent mechanical and anatomical properties and has limited value in patients with NLUTD. Electromyography (EMG): Registration of the activity of the external urethral sphincter, the peri-urethral striated musculature, the anal sphincter, or the striated pelvic floor muscles. The correct interpretation may be difficult due to artefacts introduced by other equipment used. In the urodynamic setting an EMG is useful as a gross indication of the patient’s ability to control the pelvic floor. Possible pathological findings: Inadequate recruitment on specific stimuli (bladder filling, hyperreflexive contractions, onset of voiding, coughing, Valsalva, etc.). More detailed analysis (motor unit potentials, single-fibre EMG) is only possible as part of a neurophysiological investigation. Urethral pressure measurement: This investigation has only a very limited place in NLUTD. There exists no basic consensus on parameters indicating pathological findings (21). Video-urodynamics: This combination of filling cystometry and pressure flow study with imaging is the gold standard for urodynamic investigation in NLUTD (3, 22, 23). Possible pathological findings: All as described under cystometry and pressure flow study, plus morphological pathology of the LUT and the upper urinary tract. Ambulatory urodynamics: Functional investigation of the urinary tract utilizing predominantly natural filling of the urinary tract and reproducing normal subject activity (24). This type of study should be considered when office urodynamics do not reproduce the patient’s symptoms and complaints. Possible pathological findings include those found under filling cystometry and pressure flow study, provided the flow is measured also. It should be kept in mind that during this study the actual bladder volume is unknown. Provocative tests during urodynamics: The LUT function can be provoked by coughing, triggered voiding, oranal stretch. Fast-filling cystometry with cooled saline (the ‘ice water test’) is considered a discriminative test between upper motor neuron lesion (UMNL) and lower motor neuron lesion (LMNL) (25-30). Patients with UMNL will develop a detrusor contraction if the detrusor muscle is intact, while patients with lower lesions will not. The test gives false-positive results in young children (27) and does not seem to be fully discriminative in other patients (28, 29). It was thought that a positive bethanechol test (31) (detrusor contraction > 25 cm H2O) provided proof of a detrusor denervation hypersensitivity and the muscular integrity of an acontractile detrusor; however, in practice, the test has given equivocal results. Recently, a variation of this method was reported using intravesical electromotive administration of the bethanechol (32); this test turned out to be both selective and predictive for successful oral bethanechol treatment. 3.4.3 Specific uro-neurophysiological tests These tests are advised as part of the neurological work-up of the patient. They comprise: • EMG (in a neurophysiological setting) of pelvic floor muscles, urethral sphincter and/or anal sphincter • Nerve conduction studies of pudendal nerve
22
UPDATE MARCH 2008
• Reflex latency measurements of bulbocavernosus and anal reflex arcs • Evoked responses from clitoris or glans penis • Sensory testing on bladder and urethra. Other elective tests may be asked for specific conditions that became obvious during patient work-up and urodynamic investigations. Possible pathological findings are dependent on the type of the test.
3.4.4 GUIDELINES FOR URODYNAMICS AND URO-NEUROPHYSIOLOGY 1. 2. 3. 4.
5. 6.
3.5
Urodynamic investigation is necessary to document the (dys-)function of the LUT (Grade of recommendation: A). The recording of a bladder diary is advisable (Grade of recommendation: B). Non-invasive testing is mandatory before invasive urodynamics is planned (Grade of recommendation: A). Video-urodynamics is the gold standard for invasive urodynamics in patients with NLUTD. If this is available, then a filling cystometry continuing into a pressure flow study should be performed (Grade of recommendation: A). A physiological filling rate and body-warm saline must be used (Grade of recommendation: A). Specific uro-neurophysiological tests are elective procedures (Grade of recommendation: C).
Typical manifestations of NLUTD
Typical findings in NLUTD are listed below: Filling phase • Hyposensitivity or hypersensitivity • Vegetative sensations • Low compliance • High capacity bladder • Detrusor overactivity, spontaneous or provoked • Sphincter acontractility. Voiding phase • Detrusor acontractility • DSD • Non-relaxing urethra • Non-relaxing bladder neck. These signs warrant further neurological evaluation, as LUTD may be the presenting symptom of NLUTD (3337).
3.6
References
1.
Bors E, Turner RD. History and physical examination in neurological urology. J Urol 1960;83:759-67. http://www.ncbi.nlm.nih.gov/pubmed/13802958 Thüroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U, Palmtag H, Tanagho EA. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998;16(Suppl 1):S48-S61. http://www.ncbi.nlm.nih.gov/pubmed/13802958 Stöhrer M, Goepel M, Kondo A, Kramer G, Madersbacher H, Millard R, Rossier A, Wyndaele JJ. The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures. International Continence Society Standardization Committee. Neurourol Urodyn 1999;18(2):139-58. http://www.ncbi.nlm.nih.gov/pubmed/10081953 Linsenmeyer TA, Oakley A. Accuracy of individuals with spinal cord injury at predicting urinary tract infections based on their symptoms. J Spinal Cord Med 2003;26(4):352-7. http://www.ncbi.nlm.nih.gov/pubmed/14992336 Wyndaele JJ, De Sy WA. Correlation between the findings of a clinical neurological examination and the urodynamic dysfunction in children with myelodysplasia. J Urol 1985;133(4):638-40. http://www.ncbi.nlm.nih.gov/pubmed/3981715 Wyndaele JJ. Correlation between clinical neurological data and urodynamic function in spinal cord injured patients. Spinal Cord 1997;35(4):213-6. http://www.ncbi.nlm.nih.gov/pubmed/9143082
2.
3.
4.
5.
6.
UPDATE March 2008
23
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
24
Keshtgar AS, Rickwood AM. Urological consequences of incomplete cord lesions in patients with myelomeningocele. Br J Urol 1998;82(2):258-60. http://www.ncbi.nlm.nih.gov/pubmed/9722763 Wyndaele JJ. Is impaired perception of bladder filling during cystometry a sign of neuropathy? Br J Urol 1993;71(3):270-3. http://www.ncbi.nlm.nih.gov/pubmed/8477312 Kirchhof K, Fowler CJ. The value of the Kurtzke Functional Systems Scales in predicting incomplete bladder emptying. Spinal Cord 2000;38(7):409-13. http://www.ncbi.nlm.nih.gov/pubmed/10962600 Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with posttraumatic spinal cord injury. Urology 2000;55(4):490-4. http://www.ncbi.nlm.nih.gov/pubmed/10736489 Schurch B, Schmid DM, Kaegi K. Value of sensory examination in predicting bladder function in patients with T12-L1 fractures and spinal cord injury. Arch Phys Med Rehabil 2003;84(1):83-9. http://www.ncbi.nlm.nih.gov/pubmed/12589626 Schurch B. The predictive value of plantar flexion of the toes in the assessment of neuropathic voiding disorders in patients with spine lesions at the thoracolumbar level. Arch Phys Med Rehabil 1999;80(6):681-6. http://www.ncbi.nlm.nih.gov/pubmed/10378495 Ochoa B. Can a congenital dysfunctional bladder be diagnosed from a smile?. The Ochoa syndrome updated. Pediatr Nephrol 2004;19(1):6-12. http://www.ncbi.nlm.nih.gov/pubmed/14648341 Reynard JM, Peters TJ, Lim C, Abrams P. The value of multiple free-flow studies in men with lower urinary tract symptoms. Br J Urol 1996;77(6):813-8. http://www.ncbi.nlm.nih.gov/pubmed/8705213 Sonke GS, Kiemeney LA, Verbeek AL, Kortmann BB, Debruyne FM, de la Rosette JJ. Low reproducibility of maximum urinary flow rate determined by portable flowmetry. Neurourol Urodyn 1999;18(3):183-91. http://www.ncbi.nlm.nih.gov/pubmed/10338438 Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, van Kerrebroeck P; International Continence Society. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21(3):261-74. http://www.ncbi.nlm.nih.gov/pubmed/11948720 Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-78. http://www.ncbi.nlm.nih.gov/pubmed/11857671 Homma Y, Ando T, Yoshida M, Kageyama S, Takei M, Kimoto K, Ishizuka O, Gotoh M, Hashimoto T. Voiding and incontinence frequencies: variability of diary data and required diary length. Neurourol Urodyn 2002;21(3):204-9. http://www.ncbi.nlm.nih.gov/pubmed/11948713 McGuire EJ, Cespedes RD, O’Connell HE. Leak-point pressures. Urol Clin North Am 1996;23(2): 253-62. http://www.ncbi.nlm.nih.gov/pubmed/8659025 Linsenmeyer TA, Bagaria SP, Gendron B. The impact of urodynamic parameters on the upper tracts of spinal cord injured men who void reflexly. J Spinal Cord Med 1998;21(1):15-20. http://www.ncbi.nlm.nih.gov/pubmed/9541882 Krongrad A, Sotolongo JR Jr. Bladder neck dysynergia in spinal cord injury. Am J Phys Med Rehabil 1996;75(3):204-7. http://www.ncbi.nlm.nih.gov/pubmed/8663928 Weld KJ, Graney MJ, Dmochowski RR. Clinical significance of detrusor sphincter dyssynergia type in patients with post-traumatic spinal cord injury. Urology 2000;56(4):565-8. http://www.ncbi.nlm.nih.gov/pubmed/11018603 Rossier AB, Fam BA. 5-microtransducer catheter in evaluation of neurogenic bladder function. Urology 1986;27(4):371-8. http://www.ncbi.nlm.nih.gov/pubmed/3962062 Al-Ali M, Haddad L. A 10 year review of the endoscopic treatment of 125 spinal cord injured patients with vesical outlet obstruction: does bladder neck dyssynergia exist? Paraplegia 1996;34(1):34-8. http://www.ncbi.nlm.nih.gov/pubmed/8848321
UPDATE MARCH 2008
25.
26. 27. 28.
29.
30.
31.
32.
33.
34.
35. 36.
37.
Lose G, Griffiths D, Hosker G, Kulseng-Hanssen S, Perucchini D, Schafer W, Thind P, Versi E. Standardisation Sub-Committee, International Continence Society. Standardisation of urethral pressure measurement: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 2002;21(3):258-60. http://www.ncbi.nlm.nih.gov/pubmed/11948719 Rivas DA, Chancellor MB. Neurogenic vesical dysfunction. Urol Clin North Am 1995;22(3):579-91. http://www.ncbi.nlm.nih.gov/pubmed/7645158 Madersbacher HG. Neurogenic bladder dysfunction. Curr Opin Urol 1999;9(4):303-7. http://www.ncbi.nlm.nih.gov/pubmed/10459465 van Waalwijk van Doorn E, Anders K, Khullar V, Kulseng-Hanssen S, Pesce F, Robertson A, Rosario D, Schafer W. Standardisation of ambulatory urodynamic monitoring: report of the Standardisation SubCommittee of the International Continence Society for Ambulatory Urodynamic Studies. Neurourol Urodyn 2000;19(2):113-25. http://www.ncbi.nlm.nih.gov/pubmed/10679828 Geirsson G, Fall M, Lindstrom S. The ice-water test–a simple and valuable supplement to routine cystometry. Br J Urol 1993;71(6):681-5. http://www.ncbi.nlm.nih.gov/pubmed/8343894 Geirsson G, Lindstrom S, Fall M. Pressure, volume and infusion speed criteria for the ice-water test. Br J Urol 1994;73(5):498-503. http://www.ncbi.nlm.nih.gov/pubmed/8012770 Geirsson G, Lindstrom S, Fall M, Gladh G, Hermansson G, Hjalmas K. Positive bladder cooling test in neurologically normal young children. J Urol 1994;151(2):446-8. http://www.ncbi.nlm.nih.gov/pubmed/8283555 Petersen T, Chandiramani V, Fowler CJ. The ice-water test in detrusor hyper-reflexia and bladder instability. Br J Urol 1997;79(2):163-7. http://www.ncbi.nlm.nih.gov/pubmed/9052463 Chancellor MB, Lavelle J, Ozawa H, Jung SY, Watanabe T, Kumon H. Ice-water test in the urodynamic evaluation of spinal cord injured patients. Tech Urol 1998;4(2):87-91. http://www.ncbi.nlm.nih.gov/pubmed/9623622 Ronzoni G, Menchinelli P, Manca A, De Giovanni L. The ice-water test in the diagnosis and treatment of the neurogenic bladder. Br J Urol 1997;79(5):698-701. http://www.ncbi.nlm.nih.gov/pubmed/9158504 Lapides J. Neurogenic bladder. Principles of treatment. Urol Clin North Am 1974;1(1):81-97. http://www.ncbi.nlm.nih.gov/pubmed/4428540 Riedl CR, Stephen RL, Daha LK, Knoll M, Plas E, Pfluger H. Electromotive administration of intravesical bethanechol and the clinical impact on acontractile detrusor management: introduction of a new test. J Urol 2000;164(6):2108-11. http://www.ncbi.nlm.nih.gov/pubmed/11061937 Bemelmans BL, Hommes OR, Van Kerrebroeck PE, Lemmens WA, Doesburg WH, Debruyne FM. Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. J Urol 1991;145(6):1219-24. http://www.ncbi.nlm.nih.gov/pubmed/2033697
4. TREATMENT 4.1
Introduction
The primary aims for treatment of NLUTD and their priorities are (1-4): 1. Protection of the upper urinary tract 2. Improvement of urinary continence 3. Restoration of (parts of) the LUT function 4. Improvement of the patient’s quality of life. Further considerations are the patient’s disability, cost-effectiveness, technical complexity and possible complications (4). Preservation of the upper tract function is of paramount importance (1-7). Renal failure was the main factor for mortality in the spinal cord-injured patient surviving the trauma (5-7). This has led to the golden rule in treatment of NLUTD: ensure that the detrusor pressure remains within safe limits during both the filling phase and the voiding phase (1-4). This approach has indeed significantly reduced the mortality from urological
UPDATE March 2008
25
causes in this patient group (8). The therapy of urinary incontinence is important for social rehabilitation of the patient and thus contributes substantially to the quality of life. It is also pivotal in preventing urinary tract infection (6, 7). If complete continence cannot be achieved, methods to attain a socially acceptable control of incontinence can be used. The patient’s quality of life is an essential part of any treatment decision. In patients with high detrusor pressure during the filling phase (detrusor overactivity, low detrusor compliance) or during the voiding phase (DSD, other causes of bladder outlet obstruction), treatment is aimed primarily at ‘conversion of an active, aggressive high-pressure bladder into a passive low-pressure reservoir‘ despite the resulting residual urine (1).
4.2 Non-invasive conservative treatment 4.2.1 Assisted bladder emptying Incomplete bladder emptying is a serious risk factor for UTI, developing a high intravesical pressure during the filling phase, and incontinence. Methods to improve the voiding process are practised in patients with NLUTD. Third party bladder expression (Credé): Regretfully, this method is still applied, foremost in infants and young children with myelomeningocele and sometimes in tetraplegics. Because of the high pressures that may be created during this procedure, it is potentially hazardous for the urinary tract (9). Voiding by abdominal straining (Valsalva): The considerations mentioned under Credé above also apply to the Valsalva manoeuvre (1, 9-11). For both methods of emptying, long-term complications are hardly avoidable (9, 10) and the already weak pelvic floor function may be further impaired, thus exacerbating the existing incontinence (11). Triggered reflex voiding: Stimulation of the sacral or lumbar dermatomes in patients with UMNL can elicit reflex contraction of the detrusor (1, 11). Morbidity occurs more often during the first decades of treatment (12-16). Strict urodynamic control is therefore required (1, 11). 4.2.2 Lower urinary tract rehabilitation Behavioural modification techniques: These are used to improve continence and include prompted voiding, timed voiding (bladder training), and lifestyle modification (17-20). Pelvic floor muscle exercises: These aim to improve continence. They may be helpful in selected patients with NLUTD (21). Pelvic floor electrostimulation: This technique may help to improve the effect of pelvic floor muscle exercises, or to teach the patient how to contract the pelvic floor, or to improve the patient’s compliance with the exercises (11, 22, 23). Biofeedback: This method can be used for supporting the voiding pattern modification (24, 25). 4.2.3 Drug treatment A single optimal medical therapy for NLUTD is not yet available. A combination of therapies is currently the best way to maximize outcomes (26-32) (Level of evidence: 1a, Grade of recommendation: A). Anticholinergic agents are the most useful medications available for neurogenic detrusor overactivity (NDO) (32-36) (Level of evidence: 1a, Grade of recommendation: A). As these drugs bind to muscarinic receptors, they are also termed muscarinic receptor antagonists. Anticholinergic agents are used to reduce detrusor overactivity and to improve bladder compliance (32) (Level of evidence: 1a, Grade of recommendation: A). Neurogenic patients may need a higher dose of anticholinergics than patients with idiopathic detrusor overactivity (32, 33, 37-39) (Level of evidence: 1b, Grade of recommendation: A). However, this may lead to early discontinuation of therapy because of adverse events (19, 21, 38, 40, 41) (Level of evidence: 1b, Grade of recommendation: A). Oxybutynin (32) (Level of evidence: 1a, Grade of recommendation: A) (33-36, 39, 40, 42), trospium chloride (32, 37, 38), tolterodine (43) (Level of evidence: 1a, Grade of recommendation: A) and propiverine (32, 40, 44) are established effective medical treatments. These drugs are well tolerated and safe, even during longterm treatment. They have diverse tolerance profiles so that a different anticholinergic agent may be prescribed if a patient experiences adverse effects or if the therapeutic effect is not sufficient. Recently, darifenacin and solifenacin have been introduced, but as yet no clinical experience with
26
UPDATE MARCH 2008
these drugs in neurogenic bladder overactivity has been published. Phosphodiesterase inhibitors demonstrated significant effects upon detrusor overactivity in pilot studies and may become a future alternative or adjunct to anticholinergic treatment (45). Additional treatment with desmopressin might improve the efficacy of the treatment (46, 47). Detrusor underactivity: Cholinergic drugs, such as bethanechol chloride and distigmine bromide, have been considered to enhance detrusor contractility and promote bladder emptying, but are not routinely used in clinical practice. The available studies do not support the use of parasympathomimetics, specifically when frequent and/or serious possible side effects are taken into account (48) (Level of evidence: 1a, Grade of recommendation: A). Combination therapy with a cholinergic drug and an alpha-blocker appears to be more useful than monotherapy (49). In conclusion, there is no drug with evidence of efficacy for underactive detrusor (11, 50-53) (Level of evidence: 2a, Grade of recommendation: B). Decreasing bladder outlet resistance: Alpha-blockers (non-selective and selective) have been partially successful for decreasing bladder outlet resistance, residual urine and autonomic dysreflexia (11, 54-58) (Level of evidence: 2a, Grade of recommendation: B). Increasing bladder outlet resistance: several drugs have shown efficacy in the treatment of selected cases of mild stress urinary incontinence, but there are hardly any publications in patients with NLUTD (11, 59). Conclusions: • Long-term efficacy and safety of anticholinergic therapy for NDO is well documented (Level of evidence: 1a, Grade of recommendation: A). • A combination of therapies is often considered to maximize outcomes for NDO (Level of evidence: 1a, Grade of recommendation: A). • There is no drug with evidence of efficacy for underactive detrusor (Level of evidence: 2a, Grade of recommendation: B). • Alpha-blockers have been partly successful for decreasing bladder outlet resistance and autonomic dysrreflexia prophylaxis in SCI patients (Level of evidence: 2a, Grade of recommendation: B). • There is a lack of prospective randomized controlled studies in the medical management of NLUTD. 4.2.4 Electrical neuromodulation A strong contraction of the urethral sphincter and/or pelvic floor, but also anal dilatation, manipulation of the genital region, and physical activity reflexly inhibit the micturition (11, 60). Whereas the first mechanism is affected by activation of efferent fibres, the latter ones are produced by activation of afferents (14). Electrical stimulation of the pudendal nerve afferents produces a strong inhibition of the micturition reflex and of the detrusor contraction (61). This stimulation might then support the restoration of the balance between excitatory and inhibitory inputs at the spinal or supraspinal level (11, 62, 63). It might also imply that patients with incomplete lesions will benefit (11, 63, 64), but patients with complete lesions will not (65). Although electrical stimulation of the posterior tibial nerve afferents has been used for neurogenic patients (66), there is no current evidence suggesting this therapy has any benefit in NLUTD patients. 4.2.5 External appliances As an ultimate remedy, social continence may be achieved by collecting urine during incontinence (1, 11). Condom catheters with urine collection devices are a practical method for men. Otherwise, incontinence pads may offer a reliable solution. In both cases, the infection risk must be closely observed (11). Because of the risk of developing high intravesical pressure, the penile clamp is absolutely contraindicated.
4.2.6 GUIDELINES FOR NON-INVASIVE CONSERVATIVE TREATMENT 1. 2. 3. 4. 5.
The first aim of any therapy is the protection of the upper urinary tract. The mainstay of treatment for overactive detrusor is anticholinergic drug therapy (Level of evidence: 1, Grade of recommendation: A). Lower urinary tract rehabilitation may be effective in selected cases. A condom catheter or pads may reduce urinary incontinence to a socially acceptable situation. Any method of assisted bladder emptying should be used with the greatest caution (Grade of recommendation: A).
UPDATE March 2008
27
4.3
Minimal invasive treatment
4.3.1 Catheterization Intermittent self- or third-party catheterization (67, 68) is the gold standard for the management of NLUTD (1, 11). It is effective in patients with: • Detrusor underactivity or acontractility (1) • With detrusor overactivity, provided the overactivity can be controlled (1, 11, 26-31). Sterile IC, as originally proposed by Guttmann and Frankel (67), significantly reduces the risk of UTI and/or bacteriuria (1, 11, 69, 70), compared with clean IC introduced by Lapides et al. (68). However, it cannot be considered a routine procedure (11, 70). Aseptic IC is an alternative (1, 71), which provides a significant benefit in reducing the potential for external contamination of an intermittent urinary catheter (72). Insufficient patient education and the inherent greater risk of UTI in patients with NLUTD are contributing factors (11, 7377). The average frequency of catheterizations per day is 4-6 times and the catheter size should be 12-14 Fr. Less frequent catheterization results in higher catheterization volumes and a higher risk of UTI (1, 73-76). More frequent catheterization increases the risk of cross-infections and other complications (1, 73-76). Bladder volume at catheterization should be lower than 400 mL. The prevalence of complications can be limited by adequate patient education, use of nontraumatizing techniques and adequate precautions to prevent infections (11, 77). Indwelling transurethral catheterization and, to a lesser extent, suprapubic cystostomy are significant and early risk factors for UTI and other complications (11, 16, 78-87). Silicone catheters are preferred because they are less susceptible to encrustation and because of the high incidence of latex allergy in the NLUTD population.
4.3.2 GUIDELINES FOR CATHETERIZATION 1. 2. 3. 4. 5. 6. 7.
Intermittent catheterization is the standard treatment for patients who are unable to empty their bladder (Level of evidence: 2, Grade of recommendation: A). Patients should be well instructed in the technique and risks of IC. Aseptic IC is the method of choice (Level of evidence: 2, Grade of recommendation: B). The catheter size should be 12-14 Fr (Grade of recommendation: B). The frequency of IC is 4-6 times per day (Grade of recommendation: B). The bladder volume should remain below 400 mL (Grade of recommendation: B). Indwelling transurethral and suprapubic catheterization should be used only exceptionally, under close control, and the catheter should be changed frequently. Silicone catheters are preferred and should be changed every 2-4 weeks, while (coated) latex catheters need to be changed every 1-2 weeks. (Grade of recommendation: A).
4.3.3 Intravesical drug treatment To reduce detrusor overactivity, anticholinergics can also be applied intravesically (88-94). This approach may reduce adverse effects because the anticholinergic drug is metabolized differently (92) and a greater amount is sequestered in the bladder, even more than with electromotive administration (93, 94). The vanilloids, capsaicin and resiniferatoxin, desensitize the C-fibres and thereby decrease detrusor overactivity for a period of a few months until the sensation of these fibres has been restored (95-100). The dosage is 1-2 mMol capsaicin in 100 mL 30% alcohol, or 10-100 nMol resiniferatoxin in 100 mL 10% alcohol for 30 minutes. Resiniferatoxin has about a 1,000-fold potency compared to capsaicin, with less pain during the instillation, and is effective in patients refractory to capsaicin. Clinical studies have shown that resiniferatoxin has limited clinical efficacy compared to botulinum toxin A injections in the detrusor (100). 4.3.4 Intravesical electrostimulation Intravesical electrostimulation (101) enhances the sensation for bladder filling and urge to void and may restore the volitional control of the detrusor (11, 102, 103). Daily stimulation sessions of 90 minutes with 10 mA pulses of 2 ms duration at a frequency of 20 Hz (103, 104) are used for at least 1 week (104). It appears that patients with peripheral lesions are the best candidates, that the detrusor muscle must be intact, and that at least some afferent connection between the detrusor and the brain must still be present (11, 103, 104). Also, the positioning of the stimulating electrodes and bladder filling are important parameters (105). With these precautions, the results in the literature are still not unequivocal: both positive (102, 104, 106, 107) and negative (Level of evidence: 3, Grade of recommendation: C) (108, 109) results have been reported. 4.3.5 Botulinum toxin injections in the bladder Botulinum toxin causes a long-lasting but reversible chemical denervation that lasts for about 9 months (110116). The toxin injections are mapped over the detrusor in a dosage that depends on the preparation used. Botulinum toxin A has been proven effective in a randomized placebo-controlled trial in NLUT (117). Repeated injections seem to be possible without loss of efficacy (116, 118, 119). Generalized 28
UPDATE MARCH 2008
muscular weakness is an occasional adverse effect (114, 116, 119). Histological studies have not found ultrastructural changes after injection (120). 4.3.6 Bladder neck and urethral procedures Reduction of the bladder outlet resistance may be necessary to protect the upper urinary tract. This can be achieved by surgical interventions (bladder neck or sphincter incision or urethral stent) or by chemical denervation of the sphincter. Incontinence may result and can be managed by external devices (see Section 4.2.5). Botulinum toxin sphincter injection can be used to treat detrusor sphincter dyssynergia effectively by injection in a dosage that depends on the preparation used. The dyssynergia is abolished for a few months, necessitating repeat injections. The efficacy of this treatment is high and there are few adverse effects (121123). Balloon dilatation: although favourable immediate results were reported (124), no further reports since 1994 have been found. Consequently, this method is no longer recommended. Sphincterotomy: by staged incision, bladder outlet resistance can be reduced without completely losing the closure function of the urethra (1, 11, 117). The laser technique appears to be advantageous (1, 126). Sphincterotomy also needs to be repeated at regular intervals in a substantial proportion of patients (127), but is efficient and without severe adverse effects (1, 9, 124-128). Secondary narrowing of the bladder neck may occur, for which combined bladder neck incision might be considered (1, 129). Bladder neck incision: This is indicated only for secondary changes at the bladder neck (fibrosis) (1, 9, 125, 129). When the detrusor is hypertrophied and causes thickening of the bladder neck, this procedure makes no sense (1). Stents: Implantation of urethral stents causes the continence to be dependent on the adequate closure of the bladder neck only (1, 4). Although the results are comparable with sphincterotomy and the stenting procedure has a shorter surgery time and reduced hospital stay (130, 131), the costs (1) and possible complications or re-interventions (130, 132, 133) are limiting factors in its use. Increasing bladder outlet resistance: This can improve the continence condition. Despite early positive results with urethral bulking agents, a relative early loss of continence is reported in patients with NLUTD (4, 16, 134138). Urethral inserts: Urethral plugs or valves for management of (female) stress incontinence have not been applied in patients with NLUTD. The experience with active pumping urethral prosthesis for treatment of the underactive or acontractile detrusor was disappointing (139).
4.3.6 GUIDELINES FOR MINIMAL INVASIVE TREATMENT 1. 2. 3. 4.
Guidelines for catheterization are listed separately under Section 4.3.2. Botulinum toxin injection in the detrusor is the most effective minimally invasive treatment to reduce neurogenic detrusor overactivity (Level of evidence: 1, Grade of recommendation: A). Sphincterotomy is the standard treatment for DSD (Level of evidence: 2, Grade of recommendation: A). Bladder neck incision is effective in a fibrotic bladder neck (Level of evidence: 3, Grade of recommendation: B).
4.4 Surgical treatment 4.4.1 Urethral and bladder neck procedures Increasing the bladder outlet resistance has the inherent risk of causing high intravesical pressure during the filling, which may become even higher during the voiding phase. Procedures to treat sphincteric incontinence are suitable only when the detrusor activity is, or can be, controlled, when no significant reflux is present. Moreover, these procedures require the urethra and bladder neck to be in good condition and mostly result in intermittent catheterization being performed after the procedure (4). Urethral sling: Various materials have been used for this procedure with enduring positive results (4, 140-153). The procedure is established in women; for men, the artificial sphincter is obviously the first choice (4). Artificial urinary sphincter: This device has stood the test of time in patients with NLUTD (4). It was introduced UPDATE March 2008
29
by Light and Scott (154) for this patient group and the need for revisions (154) has decreased significantly with new generations of devices (146, 156-159). Functional sphincter augmentation: By transposing the gracilis muscle to the bladder neck (160) or to the proximal urethra (161), the possibility exists for creating a functional autologous sphincter by electrical stimulation (160,161). This would open the possibility of restoring control over the urethral closure. Bladder neck and urethra reconstruction: The classical Young-Dees-Leadbetter (162) procedure for bladder neck reconstruction in children with bladder exstrophy and the Kropp urethral lengthening (163) improved by Salle (164) are established methods to restore continence provided that intermittent catheterization is practised and/or bladder augmentation is performed (146, 155, 163-174). 4.4.2 Detrusor myectomy (auto-augmentation) The idea of enlarging a shrunken bladder by removing lateral detrusor tissue to free the entrapped ureter in a non-functional fibrotic detrusor was put forward by Couvelaire (175). Since its clinical introduction by Cartwright and Snow (176) in children and by Stöhrer (177) in adults, this procedure for reducing detrusor overactivity or improving low detrusor compliance has gained popularity because of its acceptable long-term results, its low surgical burden, its low rate of long-term adverse effects, its positive effect on the patient’s quality of life, and because it does not preclude further interventions (1, 4, 176-195). The procedure is performed extraperitoneally under general anaesthesia and consists of the dissection of about 20% of the detrusor tissue around the umbilicus, leaving the mucosa intact (1, 176, 177). A diverticulum will develop, but this may take 1-2 years in adults (1, 165, 166). A laparoscopic procedure (26, 179, 183, 187), covering of the mucosa at the detrusor defect (transperitoneal) (24, 186, 188, 192), supporting the bladder (176, 192), or simple incision of the detrusor muscle (detrusor myotomy) (194, 195) are proposed variations of the procedure but offer no essential advantages. 4.4.3 Denervation, deafferentation, neurostimulation, neuromodulation Various procedures estimated to destroy the peripheral detrusor innervation have been abandoned because of poor long-term results and severe complications (4). These procedures include bladder distension, cystolysis, transvaginal denervation (Ingelman-Sundberg procedure) and subtrigonal phenol injections. Sacral rhizotomy, also known as sacral deafferentation (SDAF), has achieved some success in reducing detrusor overactivity (16, 196-200), but it is used nowadays mostly as an adjuvant to sacral anterior root stimulation (201-212). Alternatives for rhizotomy are sought in this treatment combination (213-215). Sacral anterior root stimulation (SARS) is aimed at producing a detrusor contraction. The technique was developed by Brindley (216) and is applicable only in complete lesions above the implant location because of its stimulation amplitude over the pain threshold. The urethral sphincter efferents are also stimulated, but as the striated muscle relaxes faster than the smooth muscle of the detrusor, a so-called ‘post-stimulus voiding’ will occur. This approach has been successful in highly selected patients (201-212). By changing the stimulation parameters, this method can also induce defecation or erection. The sacral nerve stimulation or sacral neuromodulation is based on the research by Schmidt and Tanagho (217). This technique stimulates the afferents and thereby probably restores the correct balance between excitatory and inhibitory impulses from and to the pelvic organs at a sacral and supra-sacral level, thus reducing the detrusor overactivity (62, 218). It is used either as a temporary procedure using foramen electrodes with an external stimulator, with the expectation that the changes will persevere after treatment, or as a chronic procedure with an implanted stimulator. In the latter case, a test procedure, the percutaneous nerve evaluation (PNE), with an external stimulator is performed before the implant to judge the patient’s response. This procedure also has considerable success in selected patients (184, 219-223). On the basis of the successful application of these systems, future developments towards a device that may be more integrated in the body are under research (224). 4.4.4 Bladder covering by striated muscle When the bladder is covered by a (part of) striated muscle that can be stimulated electrically, or ideally could be contracted volitionally, an acontractile bladder could be restored to perform a voiding function. The rectus abdominis (225) and the latissimus dorsi (226) have been used successfully in patients with NLUTD. 4.4.5 Bladder augmentation or substitution Replacing or expanding the bladder by intestine or other passive expandable coverage will reduce detrusor compliance and at least reduce the pressure effect of detrusor overactivity. The inherent complications associated with these procedures include recurrent infection, stone building, perforation or diverticula, possible malignant changes, and for intestine metabolic abnormality, mucus production and impaired bowel function
30
UPDATE MARCH 2008
(4, 227-229). Since the age of the NLUTD patient population, when the surgery is performed, is generally much lower than that of patients with bladder malignancy, who are elected for this surgery, it is important that any possible, very long-term, complications in particular must be appraised. Thus, the procedures should be used with caution in NLUTD patients, but may become necessary if all less-invasive treatment methods have failed. Bladder augmentation, by procedures such as clam cystoplasty, is a valid option to decrease detrusor pressure and increase bladder capacity, whenever more conservative approaches have failed. A number of different techniques have been published. The results of the various procedures are very good and comparable (182, 184-186, 189-191, 228-231). Bladder substitution to create a low pressure reservoir may be indicated in patients with severely thick and fibrotic bladder wall. Scaffolds, probably of tissue-engineered material for bladder augmentation or substitution or alternative techniques, are promising future options (190, 232-237). 4.4.6 Urinary diversion When no other therapy has been successful urinary diversion must be considered for the protection of the upper tract and for the patient’s quality of life (4, 238). Continent diversion: This should be the first choice for diversion. In patients for whom indwelling catheterization or suprapubic catheterization is the only feasible treatment option, change to a continent stoma may be a better prospect (4). Some patients with limited dexterity prefer a stoma to using the urethra for catheterization (4). The continent stoma is created following various techniques. All of them, however, do show frequent complications, including leakage or stenosis (4, 239). The short-term continence rates are over 80% and good protection of the upper urinary tract is achieved (4, 13, 237-251). For cosmetic reasons, the umbilicus is often used for the stoma site, but this may have a higher risk of stenosis (242, 244, 249). Incontinent diversion: If catheterization is impossible, incontinent diversion with a urine collecting device is indicated. Fortunately, nowadays, this indication is seldom because many appropriate alternatives can be offered (4). Ultimately, it could be considered in patients who are wheelchair bound or bed-ridden with intractable and untreatable incontinence, in devastated lower urinary tracts, when the upper urinary tract is severely compromised, and in patients who refuse other therapy (4). An ileal segment is used for the deviation in most cases (4, 252-256). The rather poor long-term results and the expected complications warrant a permanent follow-up (4). Undiversion: Long-standing diversions may be successfully undiverted or an incontinent diversion changed to a continent one with the emergence of new and better techniques for control of the detrusor pressure and the incontinence (4). Also, in young patients, body image may play a role (246). The patient must be carefully counselled and must comply meticulously with the instructions (4). Successful undiversion can then be performed (257).
4.5 GUIDELINES FOR SURGICAL TREATMENT 1. Detrusor • Overactive - Detrusor myectomy is an acceptable option for the treatment of overactive bladder when more conservative approaches have failed. It is limited invasive and has minimal morbidity (Level of evidence: 2, Grade of recommendation: B). - Sacral rhizotomy with SARS in complete lesions and sacral neuromodulation in incomplete lesions are effective treatments in selected patients (Level of evidence: 2, Grade of recommendation: B). - Bladder augmentation is an acceptable option for decreasing detrusor pressure whenever less invasive procedures have failed. For the treatment of a severely thick or fibrotic bladder wall, a bladder substitution might be considered (Level of evidence: 2, Grade of recommendation: B). • Underactive - SARS with rhizotomy and sacral neuromodulation are effective in selected patients (Level of evidence: 2, Grade of recommendation: B). - Restoration of a functional bladder by covering with striated muscle is still experimental (Level of evidence: 4). 2. Urethra • Overactive (DSD): refer to guidelines for minimal invasive treatment (see Section 4.3.6) • Underactive - The placement of a urethral sling is an established procedure (Level of evidence: 2, Grade of recommendation: B).
UPDATE March 2008
31
- -
The artificial urinary sphincter is very effective (Level of evidence: 2, Grade of recommendation: B). Transposition of the gracilis muscle is still experimental (Level of evidence: 4).
4.6
References
1.
Stöhrer M, Kramer G, Löchner-Ernst D, Goepel M, Noll F, Rübben H. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. Eur Urol Update Series 1994;3:170-5. Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine 2001;26 (24 Suppl):S129-S136. http://www.ncbi.nlm.nih.gov/pubmed/11805620 Rickwood AM. Assessment and conservative management of the neuropathic bladder. Semin Pediatr Surg 2002 May;11(2):108-19. http://www.ncbi.nlm.nih.gov/pubmed/11973763 Castro-Diaz D, Barrett D, Grise P, Perkash I, Stohrer M, Stone A, Vale P. Surgery for the neuropathic patient. In: Incontinence, 2nd edn. Abrams P, Khoury S, Wein A, eds. Plymouth: Health Publication, 2002; pp. 865-891. Donnelly J, Hackler RH, Bunts RC. Present urologic status of the World War II paraplegic: 25-year follow-up. Comparison with status of the 20-year Korean War paraplegic and 5-year Vietnam paraplegic. J Urol 1972;108(4):558-62. http://www.ncbi.nlm.nih.gov/pubmed/4651345 Hackler RH. A 25-year prospective mortality study in the spinal cord injured patient: comparison with the long-term living paraplegic. J Urol 1977;117(4):486-8. http://www.ncbi.nlm.nih.gov/pubmed/850323 Game X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudie I, De Boissezon X, Malavaud B, Marque P, Rischmann P. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2007;53(3): 613-9. http://www.ncbi.nlm.nih.gov/pubmed/17804150 Frankel HL, Coll JR, Charlifue SW, Whiteneck GG, Gardner BP, Jamous MA, Krishnan KR, Nuseibeh I, Savic G, Sett P. Long-term survival in spinal cord injury: a fifty year investigation. Spinal Cord 1998;36(4):266-74. http://www.ncbi.nlm.nih.gov/pubmed/9589527 Stöhrer M. Alterations in the urinary tract after spinal cord injury–diagnosis, prevention and therapy of late equelae. World J Urol 1990;7:205-11. Barbalias GA, Klauber GT, Blaivas JG. Critical evaluation of the Crede manoeuvre: a urodynamic study of 207 patients. J Urol 1983;130(4):720-3. http://www.ncbi.nlm.nih.gov/pubmed/6887405 Madersbacher H, Wyndaele JJ, Igawa Y, Chancellor M, Chartier-Kastler E, Kovindha A. Conservative management in neuropatic urinary incontinence. In: Incontinence, 2nd edn. Abrams P, Khoury S, Wein A, eds. Plymouth: Health Publication, 2002; pp. 697-754. Van Kerrebroeck PE, Koldewijn EL, Scherpenhuizen S, Debruyne FM. The morbidity due to lower urinary tract function in spinal cord injury patients. Paraplegia 1993;31(5):320-9. http://www.ncbi.nlm.nih.gov/pubmed/8332378 Sekar P, Wallace DD, Waites KB, DeVivo MJ, Lloyd LK, Stover SL, Dubovsky EV. Comparison of longterm renal function after spinal cord injury using different urinary management methods. Arch Phys Med Rehabil 1997;78(9):992-7. http://www.ncbi.nlm.nih.gov/pubmed/9305274 Linsenmeyer TA, Bagaria SP, Gendron B. The impact of urodynamic parameters on the upper tracts of spinal cord injured men who void reflexly. J Spinal Cord Med 1998;21(1):15-20. http://www.ncbi.nlm.nih.gov/pubmed/9541882 McKinley WO, Jackson AB, Cardenas DD, DeVivo MJ. Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. Arch Phys Med Rehabil 1999;80(11):1402-10. http://www.ncbi.nlm.nih.gov/pubmed/10569434 Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol 2000;163(3):768-72. http://www.ncbi.nlm.nih.gov/pubmed/10687973 Menon EB, Tan ES. Bladder training in patients with spinal cord injury. Urology 1992;40(5):425-9. http://www.ncbi.nlm.nih.gov/pubmed/1441039
2.
3.
4.
5.
6.
7.
8.
9. 10.
11.
12.
13.
14.
15.
16.
17.
32
UPDATE MARCH 2008
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32. 33.
34.
35.
Nijman RJ. Classification and treatment of functional incontinence in children. BJU Int 2000;85(3):3742. http://www.ncbi.nlm.nih.gov/pubmed/11954196 Aslan AR, Kogan BA. Conservative management in neurogenic bladder dysfunction. Curr Opin Urol 2002;12(6):473-7. http://www.ncbi.nlm.nih.gov/pubmed/12409875 Christ KF, Kornhuber HH. Treatment of neurogenic bladder dysfunction in multiple sclerosis by ultrasound-controlled bladder training. Arch Psychiatr Nervenkr 1980;228(3):191-5. http://www.ncbi.nlm.nih.gov/pubmed/7416934 De Ridder D, Vermeulen C, Ketelaer P, Van Poppel H, Baert L. Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg 1999;99(1):61-4. http://www.ncbi.nlm.nih.gov/pubmed/10218095 Ishigooka M, Hashimoto T, Hayami S, Suzuki Y, Nakada T, Handa Y. Electrical pelvic floor stimulation: a possible alternative treatment for reflex urinary incontinence in patients with spinal cord injury. Spinal Cord 1996;34(7):411-5. http://www.ncbi.nlm.nih.gov/pubmed/8963996 Balcom AH, Wiatrak M, Biefeld T, Rauen K, Langenstroer P. Initial experience with home therapeutic electrical stimulation for continence in the myelomeningocele population. J Urol 1997;158(3 Pt 2): 1272-6. http://www.ncbi.nlm.nih.gov/pubmed/9258193 Chin-Peuckert L, Salle JL. A modified biofeedback program for children with detrusor-sphincter dyssynergia: 5-year experience. J Urol 2001;166(4):1470-5. http://www.ncbi.nlm.nih.gov/pubmed/11547115 McClurg D, Ashe RG, Marshall K, Lowe-Strong AS. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006;25(4):337-48. http://www.ncbi.nlm.nih.gov/pubmed/16637070 Baskin LS, Kogan BA, Benard F. Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation. Br J Urol 1990;66(5):532-4. http://www.ncbi.nlm.nih.gov/pubmed/2249125 Tanaka H, Kakizaki H, Kobayashi S, Shibata T, Ameda K, Koyanagi T. The relevance of urethral resistance in children with myelodysplasia: its impact on upper urinary tract deterioration and the outcome of conservative management. J Urol 1999;161(3):929-32. http://www.ncbi.nlm.nih.gov/pubmed/10022727 Stone AR. Neurourologic evaluation and urologic management of spinal dysraphism. Neurosurg Clin N Am 1995;6(2):269-77. http://www.ncbi.nlm.nih.gov/pubmed/7620353 Edelstein RA, Bauer SB, Kelly MD, Darbey MM, Peters CA, Atala A, Mandell J, Colodny AH, Retik AB. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol 1995;154(4):1500-4. http://www.ncbi.nlm.nih.gov/pubmed/7658577 DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003;63(2):153-66. http://www.ncbi.nlm.nih.gov/pubmed/12515563 Buyse G, Verpoorten C, Vereecken R, Casaer P. Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy. Eur J Pediatr Surg 1995;5(1):31-4. http://www.ncbi.nlm.nih.gov/pubmed/8770576 Appell RA. Overactive bladder in special patient populations. Rev Urol 2003;5(8): S37-S41. http://www.ncbi.nlm.nih.gov/pubmed/16985989 Bennett N, O’Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004;171(2 Pt 1):749-51. http://www.ncbi.nlm.nih.gov/pubmed/14713802 Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006;85(6):536-45. http://www.ncbi.nlm.nih.gov/pubmed/16715024 Diokno A, Ingber M. Oxybutynin in detrusor overactivity. Urol Clin N Am 2006;33(4):439-45. http://www.ncbi.nlm.nih.gov/pubmed/17011379
UPDATE March 2008
33
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
34
Franco I, Horowitz M, Grady R, Adams RC, de Jong TP, Lindert K, Albrecht D. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol 2005;173(1):221-5. http://www.ncbi.nlm.nih.gov/pubmed/15592080 Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006;25(5):441-5. http://www.ncbi.nlm.nih.gov/pubmed/16847942 Menarini M, Del Popolo G, Di Benedetto P, Haselmann J, Bödeker RH, Schwantes U, Madersbacher H; TcP128-Study Group. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 2006;44(12):623-32. http://www.ncbi.nlm.nih.gov/pubmed/17190372 O’Leary M, Erickson JR, Smith CP, McDermott C, Horton J, Chancellor MB. Effect of controlledrelease oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 2003;26(2):159-62. http://www.ncbi.nlm.nih.gov/pubmed/12828295 Stöhrer M, Mürtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ; Propiverine Investigator Group. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007;51(1):235-42. http://www.ncbi.nlm.nih.gov/pubmed/16698176 Schwantes U, Topfmeier P. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexiachances for improvement of therapy. Int J Clin Pharmacol Ther 1999;37(5):209-18. http://www.ncbi.nlm.nih.gov/pubmed/10363619 Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol 2004;11(8):592-6. http://www.ncbi.nlm.nih.gov/pubmed/15285747 Ethans KD, Nance PW, Bard RJ, Casey AR, Schryvers OI. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. Spinal Cord Med 2004;27(3):214-8. http://www.ncbi.nlm.nih.gov/pubmed/15478523 Grigoleit U, Mürtz G, Laschke S, Schuldt M, Goepel M, Kramer G, Stohrer M. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity: a retrospective study. Eur Urol 2006;49(6):1114-21. http://www.ncbi.nlm.nih.gov/pubmed/16542772 Gacci M, Del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, Serni S, Sandner P, Maggi M, Carini M. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007;178(5):2040-3; discussion 2044. http://www.ncbi.nlm.nih.gov/pubmed/17869296 Chancellor MB, Rivas DA, Staas WE Jr. DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: preliminary report. J Am Paraplegia Soc 1994;17(4):165-7. http://www.ncbi.nlm.nih.gov/pubmed/7869058 Valiquette G, Herbert J, Maede-D’Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996;53(12):1270-5. http://www.ncbi.nlm.nih.gov/pubmed/8970454 Barendrecht MM, Oelke M, Laguna MP, Michel MC. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 2007;99(4):749-52. http://www.ncbi.nlm.nih.gov/pubmed/17233798 Yamanishi T, Yasuda K, Kamai T, Tsujii T, Sakakibara R, Uchiyama T, Yoshida K. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol 2004;11(2):88-96. http://www.ncbi.nlm.nih.gov/pubmed/14706012 Wheeler JS Jr, Robinson CJ, Culkin DJ, Nemchausky BA. Naloxone efficacy in bladder rehabilitation of spinal cord injury patients. J Urol 1987;137(6):1202-5. http://www.ncbi.nlm.nih.gov/pubmed/14706012 Komersova K, Rogerson JW, Conway EL, Lim TC, Brown DJ, Krum H, Jackman GP, Murdoch R, Louis WJ. The effect of levcromakalim (BRL 38227) on bladder function in patients with high spinal cord lesions. Br J Clin Pharmacol 1995;39(2):207-9. http://www.ncbi.nlm.nih.gov/pubmed/7742166
UPDATE MARCH 2008
52.
53.
54.
55.
56.
57.
58.
59.
60.
61. 62.
63.
64. 65.
66.
67.
68.
69.
Wyndaele JJ, van Kerrebroeck P. The effects of 4 weeks treatment with cisapride on cystometric parameters in spinal cord injury patients. A double-blind, placebo controlled study. Paraplegia 1995;33(11):625-7. http://www.ncbi.nlm.nih.gov/pubmed/8584295 Costa P, Bressolle F, Sarrazin B, Mosser J, Sabatier R. Dose-related effect of moxisylyte on maximal urethral closing pressure in patients with spinal cord injuries. Clin Pharmacol Ther 1993;53(4);443-9. http://www.ncbi.nlm.nih.gov/pubmed/8477560 Cain MP, Wu SD, Austin PF, Herndon CD, Rink RC. Alpha blocker therapy for children with dysfunctional voiding and urinary retention. J Urol 2003;170(4 Pt 2):1514-5. http://www.ncbi.nlm.nih.gov/pubmed/14501648 Schulte-Baukloh H, Michael T, Miller K, Knispel HH. Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. BJU Int 2002;90(7):716-20. http://www.ncbi.nlm.nih.gov/pubmed/12410754 Abrams P, Amarenco G, Bakke A, Buczynski A, Castro-Diaz D, Harrison S, Kramer G, Marsik R, Prajsner A, Stöhrer M, Van Kerrebroeck P, Wyndaele JJ; European Tamsulosin Neurogenic Lower Urinary Tract Dysfunction Study Group. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003;170(4 Pt 1):1242-51. http://www.ncbi.nlm.nih.gov/pubmed/14501734 Yasuda K, Yamanishi T, Kawabe K, Ohshima H, Morita T. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. J Urol 1996;156(3):1125-30. http://www.ncbi.nlm.nih.gov/pubmed/8709324 Al-Ali M, Salman G, Rasheed A, Al-Ani G, Al-Rubaiy S, Alwan A, Al-Shaikli A. Phenoxybenzamine in the management of neuropathic bladder following spinal cord injury. Aust N Z J Surg 1999;69(9): 660-3. http://www.ncbi.nlm.nih.gov/pubmed/10515340 Te AE. A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions. Clin Ther 2002;24(6):851-61; discussion 837. http://www.ncbi.nlm.nih.gov/pubmed/12117078 Fall M, Lindstrom S. Electrical stimulation. A physiologic approach to the treatment of urinary incontinence. Urol Clin North Am 1991;18(2):393-407. http://www.ncbi.nlm.nih.gov/pubmed/2017820 Vodusek DB, Light KJ, Libby JM. Detrusor inhibition induced by stimulation of pudendal nerve afferents. Neurourol Urodyn 1986;5:381-9. Bemelmans BL, Mundy AR, Craggs MD. Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction. Eur Urol 1999;36(2):81-91. http://www.ncbi.nlm.nih.gov/pubmed/10420026 Primus G, Kramer G. Maximal external electrical stimulation for treatment of neurogenic or nonneurogenic urgency and/or urge incontinence. Neurourol Urodyn 1996;15(3):187-94. http://www.ncbi.nlm.nih.gov/pubmed/8732985 Madersbacher H, Kiss G, Mair D. Transcutaneous electrostimulation of the pudendal nerve for treatment of detrusor overactivity. Neurourol Urodyn 1995;14:501-2. Previnaire JG, Soler JM, Perrigot M. Is there a place for pudendal nerve maximal electrical stimulation for the treatment of detrusor hyperreflexia in spinal cord injury patients?. Spinal Cord 1998;36(2): 100-3. http://www.ncbi.nlm.nih.gov/pubmed/9494999 Amarenco G, Ismael SS, Even-Schneider A, Raibaut P, Demaille-Wlodyka S, Parratte B, Kerdraon J. Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol 2003;169(6):2210-5. http://www.ncbi.nlm.nih.gov/pubmed/12771752 Guttmann L, Frankel H. The value of intermittent catheterisation in the early management of traumatic paraplegia and tetraplegia. Paraplegia 1966;4(2):63-84. http://www.ncbi.nlm.nih.gov/pubmed/5969402 Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol 1972;107(3):458-61. http://www.ncbi.nlm.nih.gov/pubmed/5010715 Wyndaele JJ. Intermittent catheterization: which is the optimal technique?. Spinal Cord 2002;440(9):432-7. http://www.ncbi.nlm.nih.gov/pubmed/12185603
UPDATE March 2008
35
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
36
Prieto-Fingerhut T, Banovac K, Lynne CM. A study comparing sterile and nonsterile urethral catheterization in patients with spinal cord injury. Rehabil Nurs 1997;22(6):299-302. http://www.ncbi.nlm.nih.gov/pubmed/9416190 Matsumoto T, Takahashi K, Manabe N, Iwatsubo E, Kawakami Y. Urinary tract infection in neurogenic bladder. Int J Antimicrob Agents 2001;17(4):293-7. http://www.ncbi.nlm.nih.gov/pubmed/11295411 Hudson E, Murahata RI. The ‘no-touch’ method of intermittent urinary catheter insertion: can it reduce the risk of bacteria entering the bladder?. Spinal Cord 2005;43(10):611-4. http://www.ncbi.nlm.nih.gov/pubmed/15852058 Waller L, Jonsson O, Norlen L, Sullivan L. Clean intermittent catheterization in spinal cord injury patients: long-term follow-up of a hydrophilic low friction technique. J Urol 1995;153(2):345-8. http://www.ncbi.nlm.nih.gov/pubmed/7815579 Bakke A, Digranes A, Hoisaeter PA. Physical predictors of infection in patients treated with clean intermittent catheterization: a prospective 7-year study. Br J Urol 1997;79(1):85-90. http://www.ncbi.nlm.nih.gov/pubmed/9043503 Gunther M, Lochner-Ernst D, Kramer G, Stohrer M. Auswirkungen des intermittierende aseptischen intermittierenden Katheterismus auf die männliche Harnröhre. Urologe B 2001;41:359-361. [article in German] [Effects of aseptic intermittent catheterisation on the male urethra] Wyndaele JJ. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord 2002;40(10):536-41. http://www.ncbi.nlm.nih.gov/pubmed/12235537 Sauerwein D. Urinary tract infection in patients with neurogenic bladder dysfunction. Int J Antimicrob Agents 2002;19(6):592-7. http://www.ncbi.nlm.nih.gov/pubmed/12135853 Sullivan LP, Davidson PG, Kloss DA, D’Anna JA Jr. Small-bowel obstruction caused by a long-term indwelling urinary catheter. Surgery 1990;107(2):228-30. http://www.ncbi.nlm.nih.gov/pubmed/2300902 Chao R, Clowers D, Mayo ME. Fate of upper urinary tracts in patients with indwelling catheters after spinal cord injury. Urology 1993;42(3):259-62. http://www.ncbi.nlm.nih.gov/pubmed/8379025 Chancellor MB, Erhard MJ, Kiilholma PJ, Karasick S, Rivas DA. Functional urethral closure with pubovaginal sling for destroyed female urethra after long-term urethral catheterization. Urology 1994;43(4):499-505. http://www.ncbi.nlm.nih.gov/pubmed/8154071 Bennett CJ, Young MN, Adkins RH, Diaz F. Comparison of bladder management complication outcomes in female spinal cord injury patients. J Urol 1995;153(5):1458-60. http://www.ncbi.nlm.nih.gov/pubmed/7714965 Larsen LD, Chamberlin DA, Khonsari F, Ahlering TE. Retrospective analysis of urologic complications in male patients with spinal cord injury managed with and without indwelling urinary catheters. Urology 1997;50(3):418-22. http://www.ncbi.nlm.nih.gov/pubmed/9301708 West DA, Cummings JM, Longo WE, Virgo KS, Johnson FE, Parra RO. Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. Urology 1999;53(2):292-7. http://www.ncbi.nlm.nih.gov/pubmed/9933042 Mitsui T, Minami K, Furuno T, Morita H, Koyanagi T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics? A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol 2000;38(4):434-8. http://www.ncbi.nlm.nih.gov/pubmed/11025382 Weld KJ, Wall BM, Mangold TA, Steere EL, Dmochowski RR. Influences on renal function in chronic spinal cord injured patients. J Urol 2000;164(5):1490-3. http://www.ncbi.nlm.nih.gov/pubmed/11025689 Zermann D, Wunderlich H, Derry F, Schroder S, Schubert J. Audit of early bladder management complications after spinal cord injury in first-treating hospitals. Eur Urol 2000;37(2):156-60. http://www.ncbi.nlm.nih.gov/pubmed/10705193 Park YI, Linsenmeyer TA. A method to minimize indwelling catheter calcification and bladder stones in individuals with spinal cord injury. J Spinal Cord Med 2001;24(2):105-8. http://www.ncbi.nlm.nih.gov/pubmed/11587416 Glickman S, Tsokkos N, Shah PJ. Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study. Paraplegia 1995;33(1):36-9. http://www.ncbi.nlm.nih.gov/pubmed/7715952
UPDATE MARCH 2008
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102. 103.
104.
105.
Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 1998;34(2):148-53. http://www.ncbi.nlm.nih.gov/pubmed/9693251 Haferkamp A, Staehler G, Gerner HJ, Dorsam J. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal Cord 2000;38(4):250-4. http://www.ncbi.nlm.nih.gov/pubmed/10822396 Pannek J, Sommerfeld HJ, Botel U, Senge T. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology 2000;55(3):358-62. http://www.ncbi.nlm.nih.gov/pubmed/10699610 Buyse G, Waldeck K, Verpoorten C, Bjork H, Casaer P, Andersson KE. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998;160(3 Pt 1):892-6. http://www.ncbi.nlm.nih.gov/pubmed/9720583 Riedl CR, Knoll M, Plas E, Pfluger H. Intravesical electromotive drug administration technique: preliminary results and side effects. J Urol 1998;159(6):1851-6. http://www.ncbi.nlm.nih.gov/pubmed/9598474 Di Stasi SM, Giannantoni A, Navarra P, Capelli G, Storti L, Porena M, Stephen RL. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. J Urol 2001;166(6):2232-6. http://www.ncbi.nlm.nih.gov/pubmed/11696741 Geirsson G, Fall M, Sullivan L. Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia. J Urol 1995;154(5):1825-9. http://www.ncbi.nlm.nih.gov/pubmed/7563356 Cruz F, Guimaraes M, Silva C, Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997;350(9078):640-1. http://www.ncbi.nlm.nih.gov/pubmed/9288055 De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler CJ. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. J Urol 1997;158(6):2087-92. http://www.ncbi.nlm.nih.gov/pubmed/9366318 Wiart L, Joseph PA, Petit H, Dosque JP, de Seze M, Brochet B, Deminiere C, Ferriere JM, Mazaux JM, N’Guyen P, Barat M. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord 1998;36(2):95-9. http://www.ncbi.nlm.nih.gov/pubmed/9366318 Kim JH, Rivas DA, Shenot PJ, Green B, Kennelly M, Erickson JR, O’Leary M, Yoshimura N, Chancellor MB. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003;26(4):358-63. http://www.ncbi.nlm.nih.gov/pubmed/14992337 Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004;172(1):240-3. http://www.ncbi.nlm.nih.gov/pubmed/15201783 Katona F, Benyo L, Lang J. [Intraluminary electrotherapy of various paralytic conditions of the gastrointestinal tract with the quadrangular current.] Zentralbl Chir 1958; 84(24):929-33. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/13676705 Kaplan WE. Intravesical electrical stimulation of the bladder: pro. Urology 2000;56(1):2-4. http://www.ncbi.nlm.nih.gov/pubmed/10869607 Ebner A, Jiang C, Lindstrom S. Intravesical electrical stimulation–an experimental analysis of the mechanism of action. J Urol 1992;148(3):920-4. http://www.ncbi.nlm.nih.gov/pubmed/1512860 Primus G, Kramer G, Pummer K. Restoration of micturition in patients with acontractile and hypocontractile detrusor by transurethral electrical bladder stimulation. Neurourol Urodyn 1996;15(5):489-97. http://www.ncbi.nlm.nih.gov/pubmed/8857617 De Wachter S, Wyndaele JJ. Quest for standardisation of electrical sensory testing in the lower urinary tract: the influence of technique related factors on bladder electrical thresholds. Neurourol Urodyn 2003;22(2):118-22. http://www.ncbi.nlm.nih.gov/pubmed/12579628
UPDATE March 2008
37
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
38
Katona F, Berenyi M. Intravesical transurethral electrotherapy in meningomyelocele patients. Acta Paediatr Acad Sci Hung 1975;16(3-4):363-74. http://www.ncbi.nlm.nih.gov/pubmed/773096 Hagerty JA, Richards I, Kaplan WE. Intravesical electrotherapy for neurogenic bladder dysfunction: a 22-year experience. J Urol. 2007;178(4 Pt 2):1680-3;discussion 1683. http://www.ncbi.nlm.nih.gov/pubmed/17707024 Nicholas JL, Eckstein HB. Endovesical electrotherapy in treatment of urinary incontinence in spinabifida patients. Lancet 1975;2(7948):1276-7. http://www.ncbi.nlm.nih.gov/pubmed/54798 Pugach JL, Salvin L, Steinhardt GF. Intravesical electrostimulation in pediatric patients with spinal cord defects. J Urol 2000;164(3 Pt 2):965-8. http://www.ncbi.nlm.nih.gov/pubmed/10958718 Stohrer M, Schurch B, Kramer G, Schmid D, Gaul G, Hauri D. Botulinum-A toxin in the treatment of detrusor hyperreflexia in spinal cord injury: a new alternative to medical and surgical procedures?. Neurourol Urodyn 1999;18:401-2. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A (letter). N Engl J Med 2000;342(9):665. http://www.ncbi.nlm.nih.gov/pubmed/10702067 Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164(3 Pt 1):692-7. http://www.ncbi.nlm.nih.gov/pubmed/10953127 Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002;59(3):325-7. http://www.ncbi.nlm.nih.gov/pubmed/11880062 Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40(11):599-600. http://www.ncbi.nlm.nih.gov/pubmed/12411968 Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45(4):510-15. http://www.ncbi.nlm.nih.gov/pubmed/15041117 Del Popolo G, Filocamo MT, Li Marzi V, Macchiarella A, Cecconi F, Lombardi G, Nicita G. Neurogenic detrusor overactivity treated with English Botulinum Toxin A: 8-year experience of one single centre. Eur Urol 2007 53(5):1013-9 . http://www.ncbi.nlm.nih.gov/pubmed/17950989 Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF; Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174(1):196-200. http://www.ncbi.nlm.nih.gov/pubmed/15947626 Akbar M, Abel R, Seyler TM, Bedke J, Haferkamp A, Gerner HJ, Möhring K. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 2007;100(3):639-45. http://www.ncbi.nlm.nih.gov/pubmed/17532858 Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47(5):653-9. http://www.ncbi.nlm.nih.gov/pubmed/15826758 Haferkamp A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G, Schumacher S, Bastian PJ, Büttner R, Müller SC, Stöhrer M. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004;46(6):784-91. http://www.ncbi.nlm.nih.gov/pubmed/15548448 Dykstra DD, Sidi AA. Related treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990;71(1):24-6. http://www.ncbi.nlm.nih.gov/pubmed/2297305
UPDATE MARCH 2008
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996;155(3):1023-9. http://www.ncbi.nlm.nih.gov/pubmed/8583552 Petit H, Wiart L, Gaujard E, Le Breton F, Ferriere JM, Lagueny A, Joseph PA, Barat M. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 1998;36(2): 91-4. http://www.ncbi.nlm.nih.gov/pubmed/9494997 Chancellor MB, Rivas DA, Abdill CK, Karasick S, Ehrlich SM, Staas WE. Prospective comparison of external sphincter balloon dilatation and prosthesis placement with external sphincterotomy in spinal cord injured men. Arch Phys Med Rehabil 1994;75(3):297-305. http://www.ncbi.nlm.nih.gov/pubmed/8129583 Whitmore WF 3rd, Fam BA, Yalla SV. Experience with anteromedian (12 o’clock) external urethral sphincterotomy in 100 male subjects with neuropathic bladders. Br J Urol 1978;50(2):99-101. http://www.ncbi.nlm.nih.gov/pubmed/754859 Perkash I. Use of contact laser crystal tip firing Nd:YAG to relieve urinary outflow obstruction in male neurogenic bladder patients. J Clin Laser Med Surg 1998;16(1):33-8. http://www.ncbi.nlm.nih.gov/pubmed/9728128 Noll F, Sauerwein D, Stohrer M. Transurethral sphincterotomy in quadriplegic patients: long-term follow-up. Neurourol Urodyn 1995;14(4):351-8. http://www.ncbi.nlm.nih.gov/pubmed/7581471 Reynard JM, Vass J, Sullivan ME, Mamas M. Sphincterotomy and the treatment of detrusor-sphincter dyssynergia: current status, future prospects. Spinal Cord 2003;41(1):1-11. http://www.ncbi.nlm.nih.gov/pubmed/12494314 Derry F, al-Rubeyi S. Audit of bladder neck resection in spinal cord injured patients. Spinal Cord 1998;36(5):345-8. http://www.ncbi.nlm.nih.gov/pubmed/9601115 Chancellor MB, Gajewski J, Ackman CF, Appell RA, Bennett J, Binard J, Boone TB, Chetner MP, Crewalk JA, Defalco A, Foote J, Green B, Juma S, Jung SY, Linsenmeyer TA, MacMillan R, Mayo M, Ozawa H, Roehrborn CG, Shenot PJ, Stone A, Vazquez A, Killorin W, Rivas DA. Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia. J Urol 1999;161(5):1545-50. http://www.ncbi.nlm.nih.gov/pubmed/10210393 Seoane-Rodríguez S, Sánchez R-Losada J, Montoto-Marqués A, Salvador-de la Barrera S, FerreiroVelasco ME, Alvarez-Castelo L, Balsa-Mosquera B, Rodríguez-Sotillo A. Long-term follow-up study of intraurethral stents in spinal cord injured patients with detrusor-sphincter dyssynergia. Spinal Cord 2007;45(9):621-6. http://www.ncbi.nlm.nih.gov/pubmed/17211463 Gajewski JB, Chancellor MB, Ackman CF, Appell RA, Bennett J, Binard J, Boone TB, Chetner MP, Crewalk JA, Defalco A, Foote J, Green B, Juma S, Jung SY, Linsenmeyer TA, Macaluso JN Jr, Macmillan R, Mayo M, Ozawa H, Roehrborn CG, Schmidt J, Shenot PJ, Stone A, Vazquez A, Killorin W, Rivas DA. Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application. J Urol 2000;163(3):773-6. http://www.ncbi.nlm.nih.gov/pubmed/10687974 Wilson TS, Lemack GE, Dmochowski RR. UroLume stents: lessons learned. J Urol 2002;167(6): 2477-80. http://www.ncbi.nlm.nih.gov/pubmed/11992061 Bennett JK, Green BG, Foote JE, Gray M. Collagen injections for intrinsic sphincter deficiency in the neuropathic urethra. Paraplegia 1995;33(12):697-700. http://www.ncbi.nlm.nih.gov/pubmed/8927407 Guys JM, Simeoni-Alias J, Fakhro A, Delarue A. Use of polydimethylsiloxane for endoscopic treatment of neurogenic urinary incontinence in children. J Urol 1999;162(6):2133-5. http://www.ncbi.nlm.nih.gov/pubmed/10569603 Kassouf W, Capolicchio G, Berardinucci G, Corcos J. Collagen injection for treatment of urinary incontinence in children. J Urol 2001;165(5):1666-8. http://www.ncbi.nlm.nih.gov/pubmed/11342951 Caione P, Capozza N. Endoscopic treatment of urinary incontinence in pediatric patients: 2-year experience with dextranomer/hyaluronic acid copolymer. J Urol 2002;168(4 Pt 2):1868-71. http://www.ncbi.nlm.nih.gov/pubmed/12352378
UPDATE March 2008
39
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
40
Block CA, Cooper CS, Hawtrey CE. Long-term efficacy of periurethral collagen injection for the treatment of urinary incontinence secondary to myelomeningocele. J Urol 2003;169(1):327-9. http://www.ncbi.nlm.nih.gov/pubmed/12478183 Schurch B, Suter S, Dubs M. Intraurethral sphincter prosthesis to treat hyporeflexic bladders in women: does it work? BJU Int 1999;84(7):789-94. http://www.ncbi.nlm.nih.gov/pubmed/10532973 Herschorn S, Radomski SB. Fascial slings and bladder neck tapering in the treatment of male neurogenic incontinence. J Urol 1992;147(4):1073-5. http://www.ncbi.nlm.nih.gov/pubmed/1552586 Gormley EA, Bloom DA, McGuire EJ, Ritchey ML. Pubovaginal slings for the management of urinary incontinence in female adolescents. J Urol 1994;152(2 Pt 2):822-5. http://www.ncbi.nlm.nih.gov/pubmed/8022024 Kakizaki H, Shibata T, Shinno Y, Kobayashi S, Matsumura K, Koyanagi T. Fascial sling for the management of urinary incontinence due to sphincter incompetence. J Urol 1995;153(3 Pt 1):644-7. http://www.ncbi.nlm.nih.gov/pubmed/7861504 Gosalbez R, Castellan M. Defining the role of the bladder-neck sling in the surgical treatment of urinary incontinence in children with neurogenic incontinence. World J Urol 1998;16(4):285-91. http://www.ncbi.nlm.nih.gov/pubmed/9775429 Barthold JS, Rodriguez E, Freedman AL, Fleming PA, Gonzalez R. Results of the rectus fascial sling and wrap procedures for the treatment of neurogenic sphincteric incontinence. J Urol 1999;161(1):272-4. http://www.ncbi.nlm.nih.gov/pubmed/10037423 Dik P, Van Gool JD, De Jong TP. Urinary continence and erectile function after bladder neck sling suspension in male patients with spinal dysraphism. BJU Int 1999;83(9):971-5. http://www.ncbi.nlm.nih.gov/pubmed/10368238 Kryger JV, Gonzalez R, Barthold JS. Surgical management of urinary incontinence in children with neurogenic sphincteric incompetence. J Urol 2000;163(1):256-63. http://www.ncbi.nlm.nih.gov/pubmed/10604371 Walker RD, Erhard M, Starling J. Long-term evaluation of rectus fascial wrap in patients with spina bifida. J Urol 2000;164(2):485-6. http://www.ncbi.nlm.nih.gov/pubmed/10893629 Kapoor R, Dubey D, Kumar A, Zaman W. Modified bulbar urethral sling procedure for the treatment of male sphincteric incontinence. J Endourol 2001;15(5):545-9. http://www.ncbi.nlm.nih.gov/pubmed/11465337 Nguyen HT, Bauer SB, Diamond DA, Retik AB. Rectus fascial sling for the treatment of neurogenic sphincteric incontinence in boys: is it safe and effective?. J Urol 2001;166(2):658-61. http://www.ncbi.nlm.nih.gov/pubmed/11458113 Austin PF, Westney OL, Leng WW, McGuire EJ, Ritchey ML. Advantages of rectus fascial slings for urinary incontinence in children with neuropathic bladders. J Urol 2001;165(6 Pt 2):2369-71. http://www.ncbi.nlm.nih.gov/pubmed/11398778 Mingin GC, Youngren K, Stock JA, Hanna MK. The rectus myofascial wrap in the management of urethral sphincter incompetence. BJU Int 2002;90(6):550-3. http://www.ncbi.nlm.nih.gov/pubmed/12230615 Colvert JR 3rd, Kropp BP, Cheng EY, Pope JC 4th, Brock JW 3rd, Adams MC, Austin P, Furness PD 3rd, Koyle MA. The use of small intestinal submucosa as an off-the-shelf urethral sling material for pediatric urinary incontinence. J Urol 2002;168(4 Pt 2):1872-5. http://www.ncbi.nlm.nih.gov/pubmed/12352379 Daneshmand S, Ginsberg DA, Bennet JK, Foote J, Killorin W, Rozas KP, Green BG. Puboprostatic sling repair for treatment of urethral incompetence in adult neurogenic incontinence. J Urol 2003;169(1):199-202. http://www.ncbi.nlm.nih.gov/pubmed/12478135 Light JK, Scott FB. Use of the artificial urinary sphincter in spinal cord injury patients. J Urol 1983;130(6):1127-9. http://www.ncbi.nlm.nih.gov/pubmed/6644893 Sidi AA, Reinberg Y, Gonzalez R. Comparison of artificial sphincter implantation and bladder neck reconstruction in patients with neurogenic urinary incontinence. J Urol 1987;138(4 Pt 2):1120-2. http://www.ncbi.nlm.nih.gov/pubmed/3656572 Fulford SC, Sutton C, Bales G, Hickling M, Stephenson TP. The fate of the ‘modern’ artificial urinary sphincter with a follow-up of more than 10 years. Br J Urol 1997;79(5):713-6. http://www.ncbi.nlm.nih.gov/pubmed/9158507
UPDATE MARCH 2008
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175. 176.
Elliott DS, Barrett DM. Mayo Clinic long-term analysis of the functional durability of the AMS 800 artificial urinary sphincter: a review of 323 cases. J Urol 1998;159(4):1206-8. http://www.ncbi.nlm.nih.gov/pubmed/9507835 Castera R, Podesta ML, Ruarte A, Herrera M, Medel R. 10-Year experience with artificial urinary sphincter in children and adolescents. J Urol 2001;165(6 Pt 2):2373-6. http://www.ncbi.nlm.nih.gov/pubmed/11371980 Kryger JV, Leverson G, Gonzalez R. Long-term results of artificial urinary sphincters in children are independent of age at implantation. J Urol 2001;165(6 Pt 2):2377-9. http://www.ncbi.nlm.nih.gov/pubmed/11371981 Janknegt RA, Baeten CG, Weil EH, Spaans F. Electrically stimulated gracilis sphincter for treatment of bladder sphincter incontinence. Lancet 1992;340(8828):1129-30. http://www.ncbi.nlm.nih.gov/pubmed/1359213 Chancellor MB, Heesakkers JP, Janknegt RA. Gracilis muscle transposition with electrical stimulation for sphincteric incontinence: a new approach. World J Urol 1997;15(5):320-8. http://www.ncbi.nlm.nih.gov/pubmed/9372585 Donnahoo KK, Rink RC, Cain MP, Casale AJ. The Young-Dees-Leadbetter bladder neck repair for neurogenic incontinence. J Urol 1999;161(6):1946-9. http://www.ncbi.nlm.nih.gov/pubmed/10332478 Kropp KA, Angwafo FF. Urethral lengthening and reimplantation for neurogenic incontinence in children. J Urol 1986;135(3):533-6. http://www.ncbi.nlm.nih.gov/pubmed/3944902 Salle JL, McLorie GA, Bagli DJ, Khoury AE. Urethral lengthening with anterior bladder wall flap (Pippi Salle procedure): modifications and extended indications of the technique. J Urol 1997;158(2):585-90. http://www.ncbi.nlm.nih.gov/pubmed/9224369 Mollard P, Mouriquand P, Joubert P. Urethral lengthening for neurogenic urinary incontinence (Kropp’s procedure): results of 16 cases. J Urol 1990;143(1):95-7. http://www.ncbi.nlm.nih.gov/pubmed/2294274 Nill TG, Peller PA, Kropp KA. Management of urinary incontinence by bladder tube urethral lengthening and submucosal reimplantation. J Urol 1990;144(2 Pt 2):559-61. http://www.ncbi.nlm.nih.gov/pubmed/2374240 Rink RC, Adams MC, Keating MA. The flip-flap technique to lengthen the urethra (Salle procedure) for treatment of neurogenic urinary incontinence. J Urol 1994;152(2 Pt 2):799-802. http://www.ncbi.nlm.nih.gov/pubmed/8022018 Waters PR, Chehade NC, Kropp KA. Urethral lengthening and reimplantation: incidence and management of catheterization problems. J Urol 1997;158(3 Pt 2):1053-6. http://www.ncbi.nlm.nih.gov/pubmed/9258141 Diamond DA, Bauer SB, Dinlenc C, Hendren WH, Peters CA, Atala A, Kelly M, Retik AB. Normal urodynamics in patients with bladder exstrophy: are they achievable?. J Urol 1999;162(3 Pt 1):841-4. http://www.ncbi.nlm.nih.gov/pubmed/10458392 Hayes MC, Bulusu A, Terry T, Mouriquand PD, Malone PS. The Pippi Salle urethral lengthening procedure; experience and outcome from three United Kingdom centres. BJU Int 1999;84(6):701-5. http://www.ncbi.nlm.nih.gov/pubmed/10510119 Yerkes EB, Adams MC, Rink RC, Pope JC IV, Brock JW 3rd. How well do patients with exstrophy actually void? J Urol 2000;164(3 Pt 2):1044-7. http://www.ncbi.nlm.nih.gov/pubmed/10958737 Surer I, Baker LA, Jeffs RD, Gearhart JP. Modified Young-Dees-Leadbetter bladder neck reconstruction in patients with successful primary bladder closure elsewhere: a single institution experience. J Urol 2001;165(6 Pt 2):2438-40. http://www.ncbi.nlm.nih.gov/pubmed/11371993 Chan DY, Jeffs RD, Gearhart JP. Determinants of continence in the bladder exstrophy population: predictors of success? Urology 2001;57(4):774-7. http://www.ncbi.nlm.nih.gov/pubmed/11306402 Ferrer FA, Tadros YE, Gearhart J. Modified Young-Dees-Leadbetter bladder neck reconstruction: new concepts about old ideas. Urology 2001;58(5):791-6. http://www.ncbi.nlm.nih.gov/pubmed/11711366 Couvelaire R. [Bladder surgery]. Paris: Masson, 1955. [article in French] Cartwright PC, Snow BW. Bladder autoaugmentation: early clinical experience. J Urol 1989;142(2 Pt 2):505-8. http://www.ncbi.nlm.nih.gov/pubmed/2746767
UPDATE March 2008
41
177.
178. 179.
180. 181.
182.
183.
184. 185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
42
Stohrer M, Kramer A, Goepel M, Lochner-Ernst D, Kruse D, Rubben H. Bladder auto-augmentation an alternative for enterocystoplasty: preliminary results. Neurourol Urodyn 1995;14(1):11-23. http://www.ncbi.nlm.nih.gov/pubmed/7742844 Elder JS. Autoaugmentation gastrocystoplasty: early clinical results. J Urol 1995;154(1):322-3. http://www.ncbi.nlm.nih.gov/pubmed/7776450 Poppas DP, Uzzo RG, Britanisky RG, Mininberg DT. Laparoscopic laser assisted auto-augmentation of the pediatric neurogenic bladder: early experience with urodynamic follow-up. J Urol 1996;155(5):1057-60. http://www.ncbi.nlm.nih.gov/pubmed/8583564 Snow BW, Cartwright PC. Bladder autoaugmentation. Urol Clin North Am 1996;23(2):323-31. http://www.ncbi.nlm.nih.gov/pubmed/8659030 Stohrer M, Kramer G, Goepel M, Lochner-Ernst D, Kruse D, Rubben H. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. Spinal Cord 1997;35(7):456-62. http://www.ncbi.nlm.nih.gov/pubmed/9232751 Duel BP, Gonzalez R, Barthold JS. Alternative techniques for augmentation cystoplasty. J Urol 1998;159(3):998-1005. http://www.ncbi.nlm.nih.gov/pubmed/9474216 Braren V, Bishop MR. Laparoscopic bladder autoaugmentation in children. Urol Clin North Am 1998;25(3):533-40. http://www.ncbi.nlm.nih.gov/pubmed/9728222 Chapple CR, Bryan NP. Surgery for detrusor overactivity. World J Urol 1998;16(4):268-73. http://www.ncbi.nlm.nih.gov/pubmed/9775426 Leng WW, Blalock HJ, Fredriksson WH, English SF, McGuire EJ. Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation. J Urol 1999;161(3):758-63. http://www.ncbi.nlm.nih.gov/pubmed/10022679 Comer MT, Thomas DF, Trejdosiewicz LK, Southgate J. Reconstruction of the urinary bladder by autoaugmentation, enterocystoplasty, and composite enterocystoplasty. Adv Exp Med Biol 1999; 462:43-7. http://www.ncbi.nlm.nih.gov/pubmed/10599412 Siracusano S, Trombetta C, Liguori G, De Giorgi G, d’Aloia G, Di Benedetto P, Belgrano E. Laparoscopic bladder auto-augmentation in an incomplete traumatic spinal cord injury. Spinal Cord 2000;38(1):59-61. http://www.ncbi.nlm.nih.gov/pubmed/10762200 Oge O, Tekgul S, Ergen A, Kendi S. Urothelium-preserving augmentation cystoplasty covered with a peritoneal flap. BJU Int 2000;85(7):802-5. http://www.ncbi.nlm.nih.gov/pubmed/10792156 Cranidis A, Nestoridis G. Bladder augmentation. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11(1):33-40. http://www.ncbi.nlm.nih.gov/pubmed/10738932 Niknejad KG, Atala A. Bladder augmentation techniques in women. Int Urogynecol J Pelvic Floor Dysfunct 2000;11(3):156-69. http://www.ncbi.nlm.nih.gov/pubmed/11484743 Westney OL, McGuire EJ. Surgical procedures for the treatment of urge incontinence. Tech Urol 2001;7(2):126-32. http://www.ncbi.nlm.nih.gov/pubmed/11383990 Perovic SV, Djordjevic ML, Kekic ZK, Vukadinovic VM. Bladder autoaugmentation with rectus muscle backing. J Urol 2002;168(4 Pt 2):1877-80. http://www.ncbi.nlm.nih.gov/pubmed/12352380 Marte A, Di Meglio D, Cotrufo AM, Di Iorio G, De Pasquale M, Vessella A. A long-term follow-up of autoaugmentation in myelodysplastic children. BJU Int 2002;89(9):928-31. http://www.ncbi.nlm.nih.gov/pubmed/12010242 Ter Meulen PH, Heesakkers JP, Janknegt RA. A study on the feasibility of vesicomyotomy in patients with motor urge incontinence. Eur Urol 1997;32(2):166-9. http://www.ncbi.nlm.nih.gov/pubmed/9286647 Potter JM, Duffy PG, Gordon EM, Malone PR. Detrusor myotomy: a 5-year review in unstable and non-compliant bladders. BJU Int 2002;89(9):932-5. http://www.ncbi.nlm.nih.gov/pubmed/12010243
UPDATE MARCH 2008
196.
197.
198
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
212.
Nagib A, Leal J, Voris HC. Successful control of selective anterior sacral rhizotomy for treatment of spastic bladder and ureteric reflux in paraplegics. Med Serv J Can 1966;22(7):576-81. http://www.ncbi.nlm.nih.gov/pubmed/5966992 Young B, Mulcahy JJ. Percutaneous sacral rhizotomy for neurogenic detrusor hyperreflexia. J Neurosurg 1980;53(1):85-7. http://www.ncbi.nlm.nih.gov/pubmed/7411212 Franco I, Storrs B, Firlit CF, Zebold K, Richards I, Kaplan WE. Selective sacral rhizotomy in children with high pressure neurogenic bladders: preliminary results. J Urol 1992;148(2 Pt 2):648-50. http://www.ncbi.nlm.nih.gov/pubmed/1640538 Schneidau T, Franco I, Zebold K, Kaplan W. Selective sacral rhizotomy for the management of neurogenic bladders in spina bifida patients: long-term follow-up. J Urol 1995;154(2 Pt 2):766-8. http://www.ncbi.nlm.nih.gov/pubmed/7609174 Hohenfellner M, Pannek J, Botel U, Dahms S, Pfitzenmaier J, Fichtner J, Hutschenreiter G, Thuroff JW. Sacral bladder denervation for treatment of detrusor hyperreflexia and autonomic dysreflexia. Urology 2001;58(1):28-32. http://www.ncbi.nlm.nih.gov/pubmed/11445474 MacDonagh RP, Forster DM, Thomas DG. Urinary continence in spinal injury patients following complete sacral posterior rhizotomy. Br J Urol 1990;66(6):618-22. http://www.ncbi.nlm.nih.gov/pubmed/2265335 Sauerwein D, Ingunza W, Fischer J, Madersbacher H, Polkey CE, Brindley GS, Colombel P, Teddy P. Extradural implantation of sacral anterior root stimulators. J Neurol Neurosurg Psychiatry 1990; 53(8):681-4. http://www.ncbi.nlm.nih.gov/pubmed/2213045 Koldewijn EL, Van Kerrebroeck PE, Rosier PF, Wijkstra H, Debruyne FM. Bladder compliance after posterior sacral root rhizotomies and anterior sacral root stimulation. J Urol 1994;151(4):955-60. http://www.ncbi.nlm.nih.gov/pubmed/8126835 Singh G, Thomas DG. Intravesical oxybutinin in patients with posterior rhizotomies and sacral anterior root stimulators. Neurourol Urodyn 1995;14(1):65-71. http://www.ncbi.nlm.nih.gov/pubmed/7742851 Van Kerrebroeck PE, Koldewijn EL, Rosier PF, Wijkstra H, Debruyne FM. Results of the treatment of neurogenic bladder dysfunction in spinal cord injury by sacral posterior root rhizotomy and anterior sacral root stimulation. J Urol 1996;155(4):1378-81. http://www.ncbi.nlm.nih.gov/pubmed/8632580 Schurch B, Rodic B, Jeanmonod D. Posterior sacral rhizotomy and intradural anterior sacral root stimulation for treatment of the spastic bladder in spinal cord injured patients. J Urol 1997;157(2): 610-4. http://www.ncbi.nlm.nih.gov/pubmed/8996369 Van Kerrebroeck EV, van der Aa HE, Bosch JL, Koldewijn EL, Vorsteveld JH, Debruyne FM. Sacral rhizotomies and electrical bladder stimulation in spinal cord injury. Part I: Clinical and urodynamic analysis. Dutch Study Group on Sacral Anterior Root Stimulation. Eur Urol 1997;31(3):263-71. http://www.ncbi.nlm.nih.gov/pubmed/9129914 Schumacher S, Bross S, Scheepe JR, Alken P, Junemann KP. Restoration of bladder function in spastic neuropathic bladder using sacral deafferentation and different techniques of neurostimulation. Adv Exp Med Biol 1999;462:303-9. http://www.ncbi.nlm.nih.gov/pubmed/10599434 Van der Aa HE, Alleman E, Nene A, Snoek G. Sacral anterior root stimulation for bladder control: clinical results. Arch Physiol Biochem 1999;107(3):248-56. http://www.ncbi.nlm.nih.gov/pubmed/10650355 Everaert K, Derie A, Van Laere M, Vandekerckhove T. Bilateral S3 nerve stimulation, a minimally invasive alternative treatment for postoperative stress incontinence after implantation of an anterior root stimulator with posterior rhizotomy: a preliminary observation. Spinal Cord 2000;38(4):262-4. http://www.ncbi.nlm.nih.gov/pubmed/10822398 Creasey GH, Grill JH, Korsten M, U HS, Betz R, Anderson R, Walter J; Implanted Neuroprosthesis Research Group. An implantable neuroprosthesis for restoring bladder and bowel control to patients with spinal cord injuries: a multicenter trial. Arch Phys Med Rehabil 2001;82(11):1512-9. http://www.ncbi.nlm.nih.gov/pubmed/11689969 Vignes JR, Liguoro D, Sesay M, Barat M, Guerin J. Dorsal rhizotomy with anterior sacral root stimulation for neurogenic bladder. Stereotact Funct Neurosurg 2001;76(3-4):243-5. http://www.ncbi.nlm.nih.gov/pubmed/12378103
UPDATE March 2008
43
213.
214.
215.
216.
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
227.
228. 229. 230.
231.
44
Schumacher S, Bross S, Scheepe JR, Seif C, Junemann KP, Alken P. Extradural cold block for selective neurostimulation of the bladder: development of a new technique. J Urol 1999;161(3): 950-4. http://www.ncbi.nlm.nih.gov/pubmed/10022732 Kirkham AP, Knight SL, Craggs MD, Casey AT, Shah PJ. Neuromodulation through sacral nerve roots 2 to 4 with a Finetech-Brindley sacral posterior and anterior root stimulator. Spinal Cord 2002;40(6): 272-81. http://www.ncbi.nlm.nih.gov/pubmed/12037708 Bhadra N, Grunewald V, Creasey G, Mortimer JT. Selective suppression of sphincter activation during sacral anterior nerve root stimulation. Neurourol Urodyn 2002;21(1):55-64. http://www.ncbi.nlm.nih.gov/pubmed/11835425 Brindley GS. An implant to empty the bladder or close the urethra. J Neurol Neurosurg Psychiatry 1977;40(4):358-69. http://www.ncbi.nlm.nih.gov/pubmed/406364 Schmidt RA, Tanagho EA. Feasibility of controlled micturition through electric stimulation. Urol Int 1979;34(3):199-230. http://www.ncbi.nlm.nih.gov/pubmed/382559 Braun PM, Baezner H, Seif C, Boehler G, Bross S, Eschenfelder CC, Alken P, Hennerici M, Juenemann P. Alterations of cortical electrical activity in patients with sacral neuromodulator. Eur Urol 2002;41(5):562-6. http://www.ncbi.nlm.nih.gov/pubmed/12074800 Ruud Bosch JL, Groen J. Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. Lancet 1996;348(9029):717-9. http://www.ncbi.nlm.nih.gov/pubmed/8806291 Bosch JL, Groen J. Neuromodulation: urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperreflexia. Behav Brain Res 1998;92(2):141-50. http://www.ncbi.nlm.nih.gov/pubmed/9638956 Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, Chancellor MB, Richard F, Denys P. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000;164(5):1476-80. http://www.ncbi.nlm.nih.gov/pubmed/11025686 Groen J, van Mastrigt R, Bosch JL. Computerized assessment of detrusor instability in patients treated with sacral neuromodulation. J Urol 2001;165(1):169-73. http://www.ncbi.nlm.nih.gov/pubmed/11125389 Hohenfellner M, Humke J, Hampel C, Dahms S, Matzel K, Roth S, Thuroff JW, Schultz-Lampel D. Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants. Urology 2001;58(6):887-92. http://www.ncbi.nlm.nih.gov/pubmed/11744452 Haugland M, Sinkjaer T. Interfacing the body’s own sensing receptors into neural prosthesis devices. Technol Health Care 1999;7(6):393-9. http://www.ncbi.nlm.nih.gov/pubmed/10665672 Zhang YH, Shao QA, Wang JM. Enveloping the bladder with displacement of flap of the rectus abdominis muscle for the treatment of neurogenic bladder. J Urol 1990;144(5):1194-5. http://www.ncbi.nlm.nih.gov/pubmed/2146404 Stenzl A, Ninkovic M, Kolle D, Knapp R, Anderl H, Bartsch G. Restoration of voluntary emptying of the bladder by transplantation of innervated free skeletal muscle. Lancet 1998;351(9114):1483-5. http://www.ncbi.nlm.nih.gov/pubmed/9605805 Vajda P, Kaiser L, Magyarlaki T, Farkas A, Vastyan AM, Pinter AB. Histological findings after colocystoplasty and gastrocystoplasty. J Urol 2002;168(2):698-701. http://www.ncbi.nlm.nih.gov/pubmed/12131353 Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int 2001;88(6):511-25. http://www.ncbi.nlm.nih.gov/pubmed/11678743 Gough DC. Enterocystoplasty. BJU Int 2001;88(7):739-43. http://www.ncbi.nlm.nih.gov/pubmed/11890246 Quek ML, Ginsberg DA. Long-term urodynamics followup of bladder augmentation for neurogenic bladder. J Urol 2003;169(1):195-8. http://www.ncbi.nlm.nih.gov/pubmed/12478134 Chartier-Kastler EJ, Mongiat-Artus P, Bitker MO, Chancellor MB, Richard F, Denys P. Long-term results of augmentation cystoplasty in spinal cord injury patients. Spinal Cord 2000;38(8):490-4. http://www.ncbi.nlm.nih.gov/pubmed/10962609
UPDATE MARCH 2008
232.
233.
234.
235.
236.
237. 238.
239.
240. 241.
242.
243.
244.
245.
246.
247.
248.
249.
Piechota HJ, Dahms SE, Probst M, Gleason CA, Nunes LS, Dahiya R, Lue TF, Tanagho EA. Functional rat bladder regeneration through xenotransplantation of the bladder acellular matrix graft. Br J Urol 1998;81(4):548-59. http://www.ncbi.nlm.nih.gov/pubmed/9598626 Sievert KD, Tanagho EA. Organ-specific acellular matrix for reconstruction of the urinary tract. World J Urol 2000;18(1):19-25. http://www.ncbi.nlm.nih.gov/pubmed/10766039 Kropp BP, Cheng EY. Bioengineering organs using small intestinal submucosa scaffolds: in vivo tissue-engineering technology. J Endourol 2000;14(1):59-62. http://www.ncbi.nlm.nih.gov/pubmed/10735574 Liatsikos EN, Dinlenc CZ, Kapoor R, Bernardo NO, Smith AD. Tissue expansion: a promising trend for reconstruction in urology. J Endourol 2000;14(1):93-6. http://www.ncbi.nlm.nih.gov/pubmed/10735578 Reddy PP, Barrieras DJ, Wilson G, Bagli DJ, McLorie GA, Khoury AE, Merguerian PA. Regeneration of functional bladder substitutes using large segment acellular matrix allografts in a porcine model. J Urol 2000;164(3 Pt 2):936-41. http://www.ncbi.nlm.nih.gov/pubmed/10958712 Kawai K, Hattori K, Akaza H. Tissue-engineered artificial urothelium. World J Surg 2000;24(10):1160-2. http://www.ncbi.nlm.nih.gov/pubmed/11071451 O’Donnell WF. Urological management in the patient with acute spinal cord injury. Crit Care Clin 1987;3(3):599-617. http://www.ncbi.nlm.nih.gov/pubmed/3332216 Bennett JK, Gray M, Green BG, Foote JE. Continent diversion and bladder augmentation in spinal cord-injured patients. Semin Urol 1992;10(2):121-32. http://www.ncbi.nlm.nih.gov/pubmed/1636071 Robertson CN, King LR. Bladder substitution in children. Urol Clin North Am 1986;13(2):333-44. http://www.ncbi.nlm.nih.gov/pubmed/3515729 Duckett JW, Lotfi AH. Appendicovesicostomy (and variations) in bladder reconstruction. J Urol 1993;149(3):567-9. http://www.ncbi.nlm.nih.gov/pubmed/8437267 Moreno JG, Chancellor MB, Karasick S, King S, Abdill CK, Rivas DA. Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. Arch Phys Med Rehabil 1995;76(8):758-62. http://www.ncbi.nlm.nih.gov/pubmed/7632132 Mollard P, Gauriau L, Bonnet JP, Mure PY. Continent cystostomy (Mitrofanoff’s procedure) for neurogenic bladder in children and adolescent (56 cases: long-term results). Eur J Pediatr Surg 1997;7(1):34-7. http://www.ncbi.nlm.nih.gov/pubmed/9085806 Sylora JA, Gonzalez R, Vaughn M, Reinberg Y. Intermittent self-catheterization by quadriplegic patients via a catheterizable Mitrofanoff channel. J Urol 1997;157(1):48-50. http://www.ncbi.nlm.nih.gov/pubmed/8976213 Cain MP, Casale AJ, King SJ, Rink RC. Appendicovesicostomy and newer alternatives for the Mitrofanoff procedure: results in the last 100 patients at Riley Children’s Hospital. J Urol 1999;162(5):1749-52. http://www.ncbi.nlm.nih.gov/pubmed/10524929 Stein R, Fisch M, Ermert A, Schwarz M, Black P, Filipas D, Hohenfellner R. Urinary diversion and orthotopic bladder substitution in children and young adults with neurogenic bladder: a safe option for treatment?. J Urol 2000;163(2):568-73. http://www.ncbi.nlm.nih.gov/pubmed/10647686 Liard A, Seguier-Lipszyc E, Mathiot A, Mitrofanoff P. The Mitrofanoff procedure: 20 years later. J Urol 2001;165(6 Pt 2):2394-8. http://www.ncbi.nlm.nih.gov/pubmed/11371985 Kajbafzadeh AM, Chubak N. Simultaneous Malone antegrade continent enema and Mitrofanoff principle using the divided appendix: report of a new technique for prevention of stoma complications. J Urol 2001;165(6 Pt 2):2404-9. http://www.ncbi.nlm.nih.gov/pubmed/11371987 Van Savage JG, Yepuri JN. Transverse retubularized sigmoidovesicostomy continent urinary diversion to the umbilicus. J Urol 2001;166(2):644-7. http://www.ncbi.nlm.nih.gov/pubmed/11458110
UPDATE March 2008
45
250.
251.
252.
253.
254.
255.
256.
257.
Clark T, Pope JC 4th, Adams C, Wells N, Brock JW 3rd. Factors that influence outcomes of the Mitrofanoff and Malone antegrade continence enema reconstructive procedures in children. J Urol 2002;168(4 Pt 1):1537-40. http://www.ncbi.nlm.nih.gov/pubmed/12352454 Richter F, Stock JA, Hanna MK. Continent vesicostomy in the absence of the appendix: three methods in 16 children. Urology 2002;60(2):329-34. http://www.ncbi.nlm.nih.gov/pubmed/12137836 Shapiro SR, Lebowitz R, Colodny AH. Fate of 90 children with ileal conduit urinary diversion a decade later: analysis of complications, pyelography, renal function and bacteriology. J Urol 1975;114(2): 289-95. http://www.ncbi.nlm.nih.gov/pubmed/1159925 Hald T, Hebjoorn S. Vesicostomy - an alternative urine diversion operation. Long term results. Scand J Urol Nephrol 1978;12(3):227-31. http://www.ncbi.nlm.nih.gov/pubmed/725543 Cass AS, Luxenberg M, Gleich P, Johnson CF. A 22-year follow-up of ileal conduits in children with a neurogenic bladder. J Urol 1984;132(2):529-31. http://www.ncbi.nlm.nih.gov/pubmed/6471190 Schwartz SL, Kennelly MJ, McGuire EJ, Faerber GJ. Incontinent ileo-vesicostomy urinary diversion in the treatment of lower urinary tract dysfunction. J Urol 1994;152(1):99-102. http://www.ncbi.nlm.nih.gov/pubmed/8201699 Atan A, Konety BR, Nangia A, Chancellor MB. Advantages and risks of ileovesicostomy for the management of neuropathic bladder. Urology 1999;54(4):636-40. http://www.ncbi.nlm.nih.gov/pubmed/10510920 Herschorn S, Rangaswamy S, Radomski SB. Urinary undiversion in adults with myelodysplasia: longterm followup. J Urol 1994;152(2 Pt 1):329-33. http://www.ncbi.nlm.nih.gov/pubmed/8015064
5. TREATMENT OF VESICO-URETERAL REFLUX 5.1
Treatment options
The treatment options for vesico-ureteral reflux in patients with NLUTD do not differ essentially from those in other reflux patients. They become necessary when the high intravesical pressure during the filling phase or during the voiding phase have been treated successfully, but where the reflux did not resolve (1-4). Subtrigonal injections with bulking agents or ureteral re-implantation are the standard procedures. Subtrigonal injections of bulking agents: This minimal invasive procedure has a relatively good effect with complete success in about 65% of patients (5-12). It can also be easily repeated if not effective and thereby the success rate can be increased to about 75% after the second or third session. Ureteral re-implantation: This technique has an immediate and long-lasting result in over 90% of the patients (11-13). In deciding which procedure will be offered to the patient, the relative risks of more invasive surgery and of less successful therapy should be considered.
5.2
References
1.
Kass EJ, Koff SA, Diokno AC. Fate of vesicoureteral reflux in children with neuropathic bladders managed by intermittent catheterization. J Urol 1981;125(1):63-4. http://www.ncbi.nlm.nih.gov/pubmed/7463586 Sidi AA, Peng W, Gonzalez R. Vesicoureteral reflux in children with myelodysplasia: natural history and results of treatment. J Urol 1986;136(1 Pt 2):329-31. http://www.ncbi.nlm.nih.gov/pubmed/3723683 Lopez Pereira P, Martinez Urrutia MJ, Lobato Romera R, Jaureguizar E. Should we treat vesicoureteral reflux in patients who simultaneously undergo bladder augmentation for neuropathic bladder?. J Urol 2001;165(6 Pt 2):2259-61. http://www.ncbi.nlm.nih.gov/pubmed/11371958
2.
3.
46
UPDATE MARCH 2008
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Simforoosh N, Tabibi A, Basiri A, Noorbala MH, Danesh AD, Ijadi A. Is ureteral reimplantation necessary during augmentation cystoplasty in patients with neurogenic bladder and vesicoureteral reflux?. J Urol 2002;168(4 Pt 1):1439-41. http://www.ncbi.nlm.nih.gov/pubmed/12352413 Diamond T, Boston VE. The natural history of vesicoureteric reflux in children with neuropathic bladder and open neural tube defects. Z Kinderchir 1987;42 (Suppl 1):15-6. http://www.ncbi.nlm.nih.gov/pubmed/3433968 Chancellor MB, Rivas DA, Liberman SN, Moore J Jr, Staas WE Jr. Cystoscopic autogenous fat injection treatment of vesicoureteral reflux in spinal cord injury. J Am Paraplegia Soc 1994;17(2):50-4. http://www.ncbi.nlm.nih.gov/pubmed/8064286 Sugiyama T, Hashimoto K, Kiwamoto H, Ohnishi N, Esa A, Park YC, Kurita T, Kohri K. Endoscopic correction of vesicoureteral reflux in patients with neurogenic bladder dysfunction. Int Urol Nephrol 1995;27(5):527-31. http://www.ncbi.nlm.nih.gov/pubmed/8775034 Misra D, Potts SR, Brown S, Boston VE. Endoscopic treatment of vesico-ureteric reflux in neurogenic bladder–8 years’ experience. J Pediatr Surg 1996;31(9):1262-4. http://www.ncbi.nlm.nih.gov/pubmed/8887097 Haferkamp A, Mohring K, Staehler G, Gerner HJ, Dorsam J. Long-term efficacy of subureteral collagen injection for endoscopic treatment of vesicoureteral reflux in neurogenic bladder cases. J Urol 2000;163(1):274-7. http://www.ncbi.nlm.nih.gov/pubmed/10604375 Shah N, Kabir MJ, Lane T, Avenell S, Shah PJ. Vesico-ureteric reflux in adults with neuropathic bladders treated with Polydimethylsiloxane (Macroplastique). Spinal Cord 2001;39(2):92-6. http://www.ncbi.nlm.nih.gov/pubmed/11402365 Engel JD, Palmer LS, Cheng EY, Kaplan WE. Surgical versus endoscopic correction of vesicoureteral reflux in children with neurogenic bladder dysfunction. J Urol 1997;157(6):2291-4. http://www.ncbi.nlm.nih.gov/pubmed/9146655 Granata C, Buffa P, Di Rovasenda E, Mattioli G, Scarsi PL, Podesta E, Dodero P, Jasonni V. Treatment of vesico-ureteric reflux in children with neuropathic bladder: a comparison of surgical and endoscopic correction. J Pediatr Surg 1999;34(12):1836-8. http://www.ncbi.nlm.nih.gov/pubmed/10626867 Kaplan WE, Firlit CF. Management of reflux in the myelodysplastic child. J Urol 1983;129(6):1195-7. http://www.ncbi.nlm.nih.gov/pubmed/6854797
6. QUALITY OF LIFE 6.1
Introduction
Quality of life (QoL) represents a very important aspect in the global management of neurogenic patients. Restoring QoL as much as possible is one of the aims of therapy. QoL is a reflection of the individual’s ability to cope with the new life situation (1). Besides the limitations directly related to the neurological pathology, adequate treatment is possible in most patients and should not interfere with social independence. QoL can be influenced by several factors including family support, adjustment and coping, productivity, selfesteem, financial stability, education, physical and social environment (2) (Level of evidence: 3, Grade of recommendation: B). Age, sex, ethnicity and patient’s acceptance of the condition should be taken into consideration (3) (Level of evidence: 3, Grade of recommendation: B). There are no specific QoL questionnaires for neurogenic bladder dysfunction. The only validated tools are a generic Visual Analogue Scale (VAS) for bother and Qualiveen®, which is a specific tool for QoL in spinal cord lesion and multiple sclerosis patients. Qualiveen appears to be a discriminative evaluation instrument (4, 5) (Level of evidence: 3, Grade of recommendation: B). The appropriate therapy should manage symptoms, functional abilities, QoL, and avoid secondary complications (5). Changes in NLUTD appear to be the major determinants of a patient’s QoL (6, 7) (Level of evidence: 2a, Grade of recommendation: B).
UPDATE March 2008
47
6.2
Conclusions and recommendations
1.
Assess QoL to evaluate LUTS in neurogenic patients and during any type of treatment for neurogenic bowel dysfunction (Level of evidence 2a, Grade of recommendation: B). Available tools are: Qualiveen, a specific tool for spinal cord lesion and multiple sclerosis patients, VAS for bother. However, generic (SF-36) or specific tools for incontinence (I-QOL) questionnaires could be used too. (Level of evidence: 2a, Grade of recommendation: B). There is a lack of disease-specific outcome measures assesing health-related Qol in patients with NLUTD.
2.
3.
6.3
REFERENCES
1.
Ku JH, The management of neurogenic bladder and quality of life in spinal cord injury. BJU Int 2006;98(4):739-45. http://www.ncbi.nlm.nih.gov/pubmed/16978269 Whiteneck G, Meade MA, Dijkers M, Tate DG, Bushnik T, Forchheimer MB. Environmental factors and their role in participation and life satisfaction after spinal cord injury. Arch Phys Med Rehabil 2004;85(11):1793-803. http://www.ncbi.nlm.nih.gov/pubmed/15520974 Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 2006:68(2 Suppl):29-37. http://www.ncbi.nlm.nih.gov/pubmed/16908338 Bonniaud V, Jackowski D, Parratte B, Paulseth R, Grad S, Margetts P, Guyatt G. Quality of life in multiple sclerosis patients with urinary disorders: discriminative validation of the English version of Qualiveen. Qual Life Res 2005;14(2):425-31. http://www.ncbi.nlm.nih.gov/pubmed/15892431 Pappalardo A, Patti F, Reggio A. Management of neuropathic bladder in multiple sclerosis. Clin Ter 2004;155(5):183-6. http://www.ncbi.nlm.nih.gov/pubmed/15344566 Henze T. Managing specific symptoms in people with multiple sclerosis. Int MS J 2005;12(2):60-8. http://www.ncbi.nlm.nih.gov/pubmed/16417816 Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006r;49(3):528-35. http://www.ncbi.nlm.nih.gov/pubmed/16426735
2.
3.
4.
5.
6. 7.
7 FOLLOW-UP 7.1
Introduction
NLUTD is an unstable condition and can vary considerably, even within a relatively short period. Meticulous follow-up and regular checks are necessary (1-20). Depending on the type of the underlying neurological pathology and on the current stability of the NLUTD, the interval between the detailed investigations should not exceed 1-2 years. In patients with multiple sclerosis and in acute spinal cord injury, this interval is of course much smaller. Urine dip sticks should be available for the patient and urinalysis should be performed at least every second month. The upper urinary tract, the bladder shape, and residual urine should be checked every 6 months. Physical examination and blood and urine laboratory should take place every year. Any sign indicating a risk factor warrants specialized investigation.
7.2 GUIDELINES FOR FOLLOW-UP 1. 2. 3. 4. 5.
48
Possible UTI checked by the patient (dip stick) Urinalysis every second month Upper urinary tract, bladder morphology, and residual urine every 6 months (ultrasound) Physical examination, blood chemistry, and urine laboratory every year Detailed specialistic investigation every 1-2 years and on demand when risk factors emerge. The investigation is specified according to the patient’s actual risk profile, but should in any case include a video-urodynamic investigation and should be performed in a leading neuro-urological centre.
UPDATE MARCH 2008
6.
All of the above should be more frequent if the neurological pathology or the NLUTD status demand this.
7.3
References
1.
Stohrer M. Alterations in the urinary tract after spinal cord injury–diagnosis, prevention and therapy of late sequelae. World J Urol 1990;7:205-11. Perkash I. Long-term urologic management of the patient with spinal cord injury. Urol Clin North Am 1993;20(3):423-34. http://www.ncbi.nlm.nih.gov/pubmed/8351768 Selzman AA, Elder JS, Mapstone TB. Urologic consequences of myelodysplasia and other congenital abnormalities of the spinal cord. Urol Clin North Am 1993;20(3):485-504. http://www.ncbi.nlm.nih.gov/pubmed/8351774 Stohrer M, Kramer G, Lochner-Ernst D, Goepel M, Noll F, Rubben H. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. Eur Urol Update Series 1994;3:170-5. Thon WF, Denil J, Stief CG, Jonas U. Urologische Langzeitbetreuung von Patienten mit Meningomyelozele. II. Therapie. Aktuel Urol 25:63-76. [article in German] [Long-term care of patients with meningomyelocele. II. Theraphy]. Waites KB, Canupp KC, DeVivo MJ, Lloyd LK, Dubovsky EV. Compliance with annual urologic evaluations and preservation of renal function in persons with spinal cord injury. J Spinal Cord Med 1995;18(4):251-4. http://www.ncbi.nlm.nih.gov/pubmed/8591072 Cardenas DD, Mayo ME, Turner LR. Lower urinary changes over time in suprasacral spinal cord injury. Paraplegia 1995;33(6):326-9. http://www.ncbi.nlm.nih.gov/pubmed/7644258 Capitanucci ML, Iacobelli BD, Silveri M, Mosiello G, De Gennaro M. Long-term urological follow-up of occult spinal dysraphism in children. Eur J Pediatr Surg 1996;6(Suppl 1):25-6. http://www.ncbi.nlm.nih.gov/pubmed/9008815 Chua HC, Tow A, Tan ES. The neurogenic bladder in spinal cord injury-pattern and management. Ann Acad Med Singapore 1996;25(4):553-7. http://www.ncbi.nlm.nih.gov/pubmed/8893929 Agarwal SK, Bagli DJ. Neurogenic bladder. Indian J Pediatr 1997;64(3):313-26. http://www.ncbi.nlm.nih.gov/pubmed/10771853 Rashid TM, Hollander JB. Multiple sclerosis and the neurogenic bladder. Phys Med Rehabil Clin N Am 1998;9(3):615-29. http://www.ncbi.nlm.nih.gov/pubmed/9894113 Burgdorfer H, Heidler H, Madersbacher H, Melchior H, Palmtag H, Richter R, Richter-Reichhelm M, Rist M, Rubben H, Sauerwein D, Schalkhauser K, Stohrer M. Leitlinien zur urologischen Betreuung Querschnittsgelahmter. Urologe A 1998;37:222-8. [article in German] [Guidelines for the urological care of paraplegics] McKinley WO, Jackson AB, Cardenas DD, DeVivo MJ. Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. Arch Phys Med Rehabil 1999; 80(11):1402-10. http://www.ncbi.nlm.nih.gov/pubmed/10569434 Atan A, Konety BR, Nangia A, Chancellor MB. Advantages and risks of ileovesicostomy for the management of neuropathic bladder. Urology 1999;54(4):636-40. http://www.ncbi.nlm.nih.gov/pubmed/10510920 Cranidis A, Nestoridis G. Bladder augmentation. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11(1):33-40. http://www.ncbi.nlm.nih.gov/pubmed/10738932 Elliott DS, Boone TB. Recent advances in the management of the neurogenic bladder. Urology 2000;56 (6 Suppl 1):76-81. http://www.ncbi.nlm.nih.gov/pubmed/11114567 Chen Y, DeVivo MJ, Roseman JM. Current trend and risk factors for kidney stones in persons with spinal cord injury: a longitudinal study. Spinal Cord 2000;38(6):346-53. http://www.ncbi.nlm.nih.gov/pubmed/10889563 Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 2001;20(2):138-43. http://www.ncbi.nlm.nih.gov/pubmed/11359083
2.
3.
4. 5.
6.
7.
8.
9.
10. 11.
12.
13.
14.
15.
16.
17.
18.
UPDATE March 2008
49
19.
20.
Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. Urology 2001;57(2):239-45. http://www.ncbi.nlm.nih.gov/pubmed/11182328 Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine 2001;26 (24 Suppl):S129-S136. http://www.ncbi.nlm.nih.gov/pubmed/11805620
8. CONCLUSIONs NLUTD is a multi-faceted pathology. It requires an extensive and specific diagnosis before we can embark on an individualized therapy, which takes into account the medical and physical condition of the patient and the patient’s expectations about his future social and physical situation with respect to the NLUTD. The urologist or paediatric urologist can select from a wealth of therapeutical options, each with its own pros and cons. Notwithstanding the success of any therapy embarked upon, a close surveillance is necessary for all the patient’s life. With these guidelines, we offer you expert advice on how to define the patient’s NLUTD condition as precisely as possible and how to select, together with the patient, the appropriate therapy. This last choice, as always, is governed by the golden rule: as effective as needed, as less invasive as possible.
50
UPDATE MARCH 2008
9. ABBREVIATIONS USED IN THE TEXT This list is not comprehensive for the most common abbreviations
CVA DLPP DSD EMG FVC IC ISC ICS LPP LMNL LUT LUTD LUTS MTC NDO NLUTD PNE QoL SARS SCI SDAF SLE UMNL UTI VAS
cerebrovascular detrusor leak point pressure detrusor sphincter dyssynergia electromyography, electromyogram frequency volume chart intermittent catheterization intermittent self-catheterization international Continence Society leak point pressure lower motor neuron lesion lower urinary tract lower urinary tract dysfunction lower urinary tract symptoms micturition time chart neurogenic detrusor overactivity neurogenic lower urinary tract dysfunction percutaneous nerve evaluation test quality of life sacral anterior root stimulation spinal cord injury sacral deafferentation systemic lupus erythematosus upper motor neuron lesion urinary tract infection visual Analogue Scale
Conflict of interest All members of the Neurogenic LUTS guidelines writing panel have provided disclosure statements of all relationships which they have and which may be perceived as a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.
UPDATE March 2008
51
52
UPDATE MARCH 2008
Guidelines on
Urological Trauma N. Djakovic, E. Plas, Martínez-Piñeiro, Th. Lynch, Y. Mor, R.A. Santucci, E. Serafetinidis, L.N. Turkeri, M. Hohenfellner
© European Association of Urology 2009
Table of Contents 1.
INTRODUCTION 1.1 Reference
Page 6 6
2. RENAL TRAUMA 2.1 Background 2.2 Mode of injury 2.2.1 Injury classification 2.3 Diagnosis: initial emergency assessment 2.3.1 History and physical examination 2.3.2 Recommendations 2.3.3 Laboratory evaluation 2.3.4 Recommendations 2.3.5 Imaging: criteria for radiographic assessment in adults 2.3.5.1 Ultrasonography 2.3.5.2 Standard IVP 2.3.5.3 One-shot intraoperative IVP 2.3.5.4 Computed tomography (CT) 2.3.5.5 Magnetic resonance imaging (MRI) 2.3.5.6 Angiography 2.3.5.7 Radionuclide scans 2.3.6 Recommendations 2.4 Treatment 2.4.1 Indications for renal exploration 2.4.2 Operative findings and reconstruction 2.4.3 Non-operative management of renal injuries 2.4.4 Recommendations 2.4.5 Post-operative care and follow-up 2.4.6 Recommendations 2.4.7 Complications 2.4.8 Recommendations 2.4.9 Paediatric renal trauma 2.4.10 Recommendations 2.4.11 Renal injury in the polytrauma patient 2.4.12 Recommendations 2.5 Iatrogenic renal injuries 2.5.1 Iatrogenic vascular injuries 2.5.2 Renal transplantation 2.5.3 Percutaneous renal procedures 2.5.4 Recommendations 2.6 Suggestions for future research studies 2.7 Algorithms 2.8 References
6 6 7 7 7 8 8 8 9 9 9 10 10 10 11 11 11 12 12 12 12 13 14 14 14 15 15 15 17 17 17 17 17 18 18 20 20 20 23
3. URETERAL TRAUMA 3.1 Introduction 3.2 Aetiology 3.3 Diagnosis 3.3.1 Clinical diagnosis 3.3.2 Radiological diagnosis 3.4 Classification 3.5 Management 3.5.1 Partial injuries 3.5.2 Complete injuries 3.5.3 Sterile surgery 3.5.3.1 Uretero-ureterostomy 3.5.3.2 Ureterocalycostomy 3.5.3.3 Transuretero-ureterostomy
31 31 32 32 32 32 32 32 32 33 33 33 34 34
2
Update march 2009
3.5.3.4 Ureteroneocystostomy with Boari flap 3.5.3.5 Ureterocystostomy and psoas hitch 3.5.3.6 Ileal interposition graft 3.5.3.7 Autotransplantation 3.5.3.8 Nephrectomy 3.6 References
34 34 34 35 35 35
4. BLADDER TRAUMA 4.1 Background 4.1.1 Iatrogenic trauma 4.2 Classification 4.3 Risk factors 4.4 Diagnosis 4.4.1 Macroscopic (gross) haematuria 4.4.2 Microscopic haematuria 4.4.3 Cystography 4.4.4 Excretory urography (intravenous pyelogram [IVP]) 4.4.5 Ultrasound (US) 4.4.6 Computed tomography (CT) 4.4.7 Angiography 4.4.8 Magnetic resonance imaging (MRI) 4.4.9 Cystoscopy 4.5 Treatment 4.5.1 Blunt trauma: extraperitoneal rupture 4.5.2 Blunt trauma: intraperitoneal rupture 4.5.3 Penetrating injuries 4.5.4 Iatrogenic injuries 4.6 Recommendations 4.6.1 General 4.6.2 Diagnosis 4.6.3 Treatment 4.7 References
35 35 36 37 37 37 37 38 38 38 38 38 39 39 39 39 39 39 39 39 40 40 40 40 40
5. URETHRAL TRAUMA 5.1 Anatomical and aetiological considerations 5.1.1 Posterior urethral injuries 5.1.1.1 Urethral injuries in children 5.1.1.2 Urethral injuries in women 5.1.1.3 Penetrating injuries to the perineum 5.1.2 Anterior urethral injuries 5.1.2.1 Blunt trauma 5.1.2.2 Intercourse-related trauma 5.1.2.3 Penetrating trauma 5.1.2.4 Constriction band-related trauma 5.1.2.5 Iatrogenic trauma 5.2. Diagnosis: initial emergency assessment 5.2.1 Clinical assessment 5.2.1.1 Blood at the meatus 5.2.1.2 Blood at the vaginal introitus 5.2.1.3 Haematuria 5.2.1.4 Pain on urination or inability to void 5.2.1.5 Haematoma or swelling 5.2.1.6 High-riding prostate 5.2.2 Radiographic examination 5.2.3 Endoscopic examination 5.3. Management 5.3.1 Anterior urethral injuries 5.3.1.1 Blunt injuries 5.3.1.2 Open injuries 5.3.1.2.1 Male urethral injuries
44 44 44 46 46 46 46 46 47 47 47 47 47 47 47 47 47 48 48 48 48 49 49 49 49 49 49
Update march 2009
3
5.3.1.2.2 Female urethral injuries 5.3.2 Posterior urethral injuries 5.3.2.1 Partial urethral rupture 5.3.2.2 Complete urethral rupture 5.3.2.3 Primary realignment 5.3.2.4 Immediate open urethroplasty 5.3.2.5 Delayed primary urethroplasty 5.3.2.6 Delayed urethroplasty 5.3.2.7 Reconstruction of failed repair of posterior urethral rupture 5.3.2.8 Delayed endoscopic optical incision 5.4 Recommendations for treatment: algorithms 5.5 Iatrogenic urethral trauma 5.5.1 Introduction 5.5.2 Iatrogenic urethral trauma caused by catheterisation 5.5.3 Iatrogenic urethral trauma caused by transurethral surgery 5.5.4 Iatrogenic urethral trauma related to surgical prostate cancer treatment 5.5.5 Iatrogenic urethral trauma related to radiotherapy for prostate cancer treatment 5.5.6 Iatrogenic urethral trauma related to major abdominal surgery 5.5.7 Symptoms of iatrogenic urethral injury 5.5.8 Diagnosis 5.5.9 Treatment 5.5.10 Recommendations for treatment: algorithms 5.5.11 Recommendations 5.6 References
50 50 50 50 51 53 53 53 54 55 56 58 58 58 59 59 59 59 59 60 60 60 61 61
6. GENITAL TRAUMA 6.1 Background 6.2 Pathophysiology 6.2.1 Blunt trauma 6.2.2 Penetrating trauma 6.3 Risk factors 6.4 Diagnosis 6.4.1 Blunt renal trauma 6.4.1.1 Penile fracture 6.4.2 Blunt testicular trauma 6.4.3 Blunt female trauma 6.4.4 Penetrating trauma 6.5 Treatment 6.5.1 Penile trauma 6.5.1.1 Blunt trauma 6.5.1.2 Penetrating trauma 6.5.2 Testicular trauma 6.5.2.1 Blunt trauma 6.5.2.2 Penetrating trauma 6.5.3 Vulvar injuries 6.6. References
69 69 69 69 70 71 71 71 71 71 72 72 72 72 72 72 72 72 73 73 73
7. MASS CASUALTY EVENTS, TRIAGE AND DAMAGE CONTROL 7.1 Definition 7.2 Causes of mass casualty events 7.3 Mechanisms of explosive injury 7.4 Triage 7.4.1 Primary triage 7.4.2 Secondary triage 7.4.3 Re-triage 7.5 Principles of ‘damage control’ 7.6 Urological aspects of ‘damage control’ 7.6.1 The urological consultation in the emergency room during mass casualty events 7.6.1.1 Responsibility and primary overall assessment 7.6.1.2 Imaging
76 76 76 77 77 77 77 77 78 78 78 78 78
4
Update march 2009
7.6.1.3 Primary management 7.6.2 The urological consultation in the operating room during mass casualty events 7.6.2.1 Renal trauma 7.6.2.2 Ureteral injuries 7.6.2.3 Bladder injury 7.6.2.3.1 Auxiliary damage control measures 7.6.2.4 Urethral injury 7.6.2.5 Injury of the external genitalia 7.6.2.5.1 Temporary damage control measures 7.7 Summary 7.8 References
78 79 79 80 81 81 81 81 81 81 81
6.
84
ABBREVIATIONS USED IN THE TEXT
Update march 2009
5
1. introduction 1.1 Background The European Association of Urology (EAU) Guidelines Group for Urological Trauma prepared this guidelines document to assist medical professionals in the management of urological trauma. The Urological Trauma guidelines are based on a review of the literature, using on-line searches of MEDLINE and other source documents published between 2005 and 2008. A critical assessment of the findings was made, not involving a formal appraisal of the data. There is a paucity of high-powered randomized controlled trials in this area and considerable available data are based on retrospective studies. The panel recognise this limitation. A level of evidence (LE) and/or grade of recommendation (GR) have been assigned where possible (1). The aim of grading recommendations is to provide transparency between the underlying evidence and the recommendation given. Publication history information: The Urological Trauma Guidelines were first published in 2003, with a partial update in 2006 followed by this full text update in 2009. Additionally, a quick reference guide is available. All texts can be viewed and downloaded for personal use at the society website: http://www.uroweb.org/ professional-resources/guidelines/. Levels of evidence and grade of guideline recommendations* Table 1: Level of evidence Level Type of evidence 1a Evidence obtained from meta-analysis of randomised trials 1b Evidence obtained from at least one randomised trial 2a Evidence obtained from one well-designed controlled study without randomisation 2b Evidence obtained from at least one other type of well-designed quasi-experimental study 3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports 4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities Table 2: Grade of recommendation Grade Nature of recommendations A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial B Based on well-conducted clinical studies, but without randomised clinical trials C Made despite the absence of directly applicable clinical studies of good quality *modified from Sackett et al. (1)
1.1 REFERENCE 1.
Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. http://www.cebm.net/index.aspx?o=1025 [accessed February 2009].
2. RENAL TRAUMA 2.1 Background Renal trauma occurs in approximately 1-5% of all trauma cases (1, 2). The kidney is the most commonly injured genitourinary and abdominal organ. There is a 3:1 male to female ratio in kidney trauma patients (3-5). Renal trauma can be acutely life-threatening, but the majority of renal injuries can be managed conservatively. Advances in imaging and treatment strategies during the past 20 years have decreased the need for surgical intervention and increased renal preservation (6-8).
6
Update march 2009
2.2
Mode of injury
Renal injuries are classified by their mechanism: blunt or penetrating. In rural settings, blunt trauma can account for the largest percentage (90-95%) (9), while in urban settings, the percentage of penetrating injuries can increase to 20% (6) or higher. Blunt trauma is usually caused by motor vehicle accidents, falls, vehicle-associated pedestrian accidents, contact sports and assault. Traffic accidents are the major cause of almost half the blunt renal injuries (10). Renal injury in frontal and side-impact collisions appears to occur after direct impact from objects in the vehicle compartment. For frontal crashes, occupant acceleration into the seat belt or steering wheel seems to result in renal injuries. Side impact injuries occur when the vehicle side panel intrudes into the compartment, striking the occupant (11). A 20-year review of renal injuries following free falls found a rate of 16% (12). Renal lacerations and renal vascular injuries make up only 10-15% of all blunt renal injuries. Isolated renal artery injury following blunt abdominal trauma is extremely rare, and accounts for less than 0.1% of all trauma patients (13). Renal artery occlusion is associated with rapid deceleration injuries. In theory, the kidney is displaced causing renal artery traction; the resulting tear in the inelastic intima and subsequent haemorrhage into the vessel wall leads to thrombosis. Compression of the renal artery between the anterior abdominal wall and the vertebral bodies may result in thrombosis of the renal artery. Gunshot and stab wounds represent the most common causes of penetrating injuries. Renal injuries from penetrating trauma tend to be more severe and less predictable than those from blunt trauma. Bullets, because of their higher kinetic energy, have the potential for greater parenchymal destruction and are most often associated with multiple-organ injuries (14). In wartime, the kidney is the most commonly injured urogenital organ. Most are found to be associated with major abdominal injuries, and the rate of wartime nephrectomies is relatively high (25-33%) (15-17). 2.2.1 Injury classification Classifying renal injuries helps to standardise different groups of patients, select appropriate therapy and predict results. A total of 26 classifications for renal injuries have been presented in the literature in the past 50 years (18), but the committee on organ injury scaling of the American Association for the Surgery of Trauma (AAST) has developed a renal-injury scaling system that is now widely used (19). Renal injuries are classified as grade 1 to 5 (Table 3). Abdominal computed tomography (CT) or direct renal exploration is used to classify injuries. Most recent publications in the field of renal trauma have adopted this classification. In a retrospective review, the AAST scaling system was determined as the most important variable predicting the need for kidney repair or removal (20, 21). It also predicts for morbidity after blunt or penetrating injury, and for mortality after blunt injury (22). Table 3: AAST renal injury grading scale (17) Grade* Description of injury 1 • Contusion or non-expanding subcapsular haematoma • No laceration 2 • Non-expanding peri-renal haematoma • Cortical laceration < 1 cm deep without extravasation 3 • Cortical laceration > 1 cm without urinary extravasation 4 • Laceration: through corticomedullary junction into collecting system or • Vascular: segmental renal artery or vein injury with contained haematoma, or partial vessel laceration, or vessel thrombosis 5 • Laceration: shattered kidney or • Vascular: renal pedicle or avulsion *Advance one grade for bilateral injuries up to grade III.
2.3 Diagnosis: initial emergency assessment Initial assessment of the trauma patient should include securing the airway, controlling external bleeding and resuscitation of shock, as required. In many cases, physical examination is carried out during the stabilisation
Update march 2009
7
of the patient. When renal injury is suspected, further evaluation (CT scan, laparotomy) is required for a prompt diagnosis. 2.3.1 History and physical examination A direct history is obtained from conscious patients. Witnesses and emergency personnel can provide valuable information about unconscious or seriously injured patients. Possible indicators of major renal injury include a rapid deceleration event (fall, high-speed motor vehicle accidents) or a direct blow to the flank. In assessing trauma patients after motor vehicle accidents, the history should include the vehicle’s speed and whether the patient was a passenger or pedestrian. In penetrating injuries, important information includes the size of the weapon in stabbings, and the type and calibre of weapon used in gunshot wounds, as high-velocity projectiles have the potential to cause more extensive damage. The medical history should be as detailed as possible, as pre-existing organ dysfunction can have a negative effect on trauma patient outcome (23). In the early resuscitation phase, special consideration should be given to pre-existing renal disease (24). Another point of interest is the functioning renal mass of the trauma patient, as there are numerous case reports in the literature about complicated renal trauma in solitary kidneys (25). Pre-existing renal abnormality makes renal injury more likely following trauma. Pre-existing renal pathology should be noted. Hydronephrosis due to ureteropelvic junction abnormality, renal calculi, cysts and tumours are the most commonly reported entities that may complicate a minor renal injury (26). The overall percentage of these cases varies from 4% to 22% (27, 28). Haemodynamic stability is the primary criterion for the management of all renal injuries. Shock is defined as a systolic blood pressure of less than 90 mmHg found at any time during an adult patient’s evaluation. Vital signs should be recorded throughout diagnostic evaluation. Physical examination may reveal an obvious penetrating trauma from a stab wound to the lower thoracic back, flanks and upper abdomen, or bullet entry or exit wounds in this area. In stab wounds, the extent of the entrance wound may not accurately reflect the depth of penetration. Blunt trauma to the back, flank, lower thorax or upper abdomen may result in renal injury. The following findings on physical examination could indicate possible renal involvement: • haematuria • flank pain • flank ecchymoses • flank abrasions • fractured ribs • abdominal distension • abdominal mass • abdominal tenderness. 2.3.2 Recommendations Recommendations GR • Haemodynamic stability should be decided upon admission B • History should be taken from conscious patients, witnesses and rescue team personnel with C regard to the time and setting of the incident • Past renal surgery, and known pre-existing renal abnormalities (ureteropelvic junction B obstruction, large cysts, lithiasis) should be recorded • A thorough examination should be made of the thorax, abdomen, flanks and back for B penetrating wounds • Findings on physical examination such as haematuria, flank pain, flank abrasions and B ecchymoses, fractured ribs, abdominal tenderness, distension or mass, could indicate possible renal involvement GR = grade of recommendation 2.3.3 Laboratory evaluation The trauma patient is evaluated by a series of laboratory tests. Urinalysis, haematocrit and baseline creatinine are the most important tests for evaluating renal trauma.
8
Update march 2009
Urinalysis is considered the basic test in the evaluation of patients with suspected renal trauma. Haematuria is the presence of an abnormal quantity of red blood cells in the urine and is usually the first indicator of renal injury. Microscopic haematuria in the trauma setting may be defined as greater than 5 red blood cells per highpower field (rbc/hpf), while gross haematuria is demonstrated by urine in which blood is readily visible. Haematuria is a hallmark sign of renal injury, but is neither sensitive nor specific enough for differentiating minor and major injuries. It does not necessarily correlate with the degree of injury (29). Major renal injury, such as disruption of the ureteropelvic junction, renal pedicle injuries or segmental arterial thrombosis may occur without haematuria (30). In a study by Eastham et al., 9% of patients with stab wounds and resultant proven renal injury did not manifest haematuria (31). Haematuria that is out of proportion to the history of trauma may suggest pre-existing renal pathology (32). A urine dipstick is an acceptably reliable and rapid test to evaluate haematuria. However, some studies have shown false-negative result rates ranging from 3-10% using the dipstick test for haematuria (33). Serial haematocrit determination is a method of continuous evaluation of the trauma patient. Initial haematocrit in association with vital signs implies the need for emergency resuscitation. The decrease in haematocrit and the requirement for blood transfusions is an indirect sign of the rate of blood loss and, along with the patient’s response to resuscitation, is valuable in the decision-making process. As most trauma patients are evaluated within 1 hour of injury, creatinine measurement reflects renal function prior to the injury. An increased creatinine usually reflects pre-existing renal pathology.
2.3.4 Recommendations Recommendations GR • Urine from a patient with suspected renal injury should be inspected grossly and then by B dipstick analysis • Serial haematocrit measurement indicates blood loss. However, until evaluation is complete, B it will not be clear whether it is due to renal trauma and/or associated injuries • Creatinine measurement could highlight patients who had impaired renal function prior to injury C GR = grade of recommendation 2.3.5 Imaging: criteria for radiographic assessment in adults Decisions about radiographic imaging in cases of suspected renal trauma are based on the clinical findings and the mechanism of injury. Since the majority of renal injuries are not significant and resolve without any intervention, many attempts have been made to identify which patients could be spared the discomfort, radiation exposure, possible allergic reaction, time and expense of a radiographic evaluation (34). Some patients do not require radiographic evaluation following blunt renal trauma. Patients with microscopic haematuria and no shock after blunt trauma have a low likelihood of concealing significant renal injury (35). The indications for radiographic evaluation are gross haematuria, microscopic haematuria and shock, or the presence of major associated injuries (36). However, patients with a history of rapid deceleration injury with clinical indicators of renal trauma or associated injuries also need immediate imaging to rule out ureteral avulsion or renal pedicle injury (12). Patients with penetrating trauma to the torso have a high incidence of significant renal injuries. If renal injury is clinically suspected on the basis of an entry or exit wound, renal imaging should be performed, regardless of the degree of haematuria (37). 2.3.5.1 Ultrasonography Ultrasonography is a popular imaging modality in the initial evaluation of abdominal trauma. It provides a quick, non-invasive, low-cost means of detecting peritoneal fluid collections without exposure to radiation (38). However, the usefulness of conventional ultrasound in the radiographic evaluation of renal trauma has been widely questioned. Its limitations stem from the difficulty in obtaining good acoustic windows on trauma patients who have sustained numerous associated injuries. The results are also highly dependent on the operator. Ultrasound scans can detect renal lacerations but cannot definitely assess their depth and extent and do not provide functional information about renal excretion or urine leakage. Despite the drawbacks of the method, ultrasound scans can be conveniently used during the primary assessment of renal injuries. During
Update march 2009
9
the evaluation of blunt trauma patients, ultrasound scans were more sensitive and specific than standard intravenous pyelography (IVP) in minor renal trauma (39). In another study comparing the results of ultrasound scans and IVP, the sensitivity of ultrasound decreased as the severity of the trauma increased, while that of IVP remained high for all degrees of severity (40). Another possible role for ultrasound may be for serially evaluating stable renal injuries for the resolution of urinomas and retroperitoneal haematomas (41). Ultrasound might be considered suitable for the routine followup of renal parenchymal lesions or haematomas in the intensive care unit. Contrast-enhanced sonography is more sensitive than conventional ultrasound in the detection of renal injuries. In haemodynamically stable patients, it is a useful tool in the assessment of blunt injuries (42). In conclusion, since ultrasound scans are used in the triage of patients with blunt abdominal trauma in many centres, they can be helpful in identifying which patients require a more aggressive radiological exploration to obtain a certain diagnosis (43, 44). Ultrasound findings do not provide sufficient evidence for a definite answer on the severity of renal injuries. 2.3.5.2 Standard IVP Standard IVP is no longer the study of choice for the evaluation of renal trauma. In some centres it may be the only study available, in which case IVP should establish the presence or absence of one or both of the kidneys, clearly define the renal parenchyma, and outline the collecting system. In order to stage renal trauma, the IVP should include nephrotomograms, delineate the renal contour, and visualise the excretion of contrast material from both kidneys into the renal pelvis and ureter. Non-visualisation, contour deformity, or extravasation of contrast implies a major renal injury and should prompt further radiological evaluation with CT or, less commonly, angiography if available. The most significant findings on IVP are non-function and extravasation. Non-function is usually a sign of extensive trauma to the kidney, pedicle injury (vascular avulsion or thrombosis), or a severely shattered kidney. Extravasation of the contrast medium also implies a severe degree of trauma, involving the capsule, parenchyma and collecting system. Other less reliable signs are delayed excretion, incomplete filling, calyceal distortion and obscuring of the renal shadow. The sensitivity of IVP is high (> 92%) for all degrees of trauma severity (45). 2.3.5.3 One-shot intraoperative IVP Unstable patients selected for immediate operative intervention (and thus unable to have a CT scan) should undergo one-shot IVP in the operating theatre. The technique consists of a bolus intravenous injection of 2 mL/ kg of radiographic contrast followed by a single plain film taken after 10 minutes. The study is safe, efficient, and of high quality in the majority of cases. It provides important information for decision-making in the critical time of urgent laparotomy concerning the injured kidney, as well as the presence of a normal functioning kidney on the contralateral side (46). While the majority of experts advocate its use, not all studies have shown one-shot IVP to be necessary. In cases of penetrating abdominal trauma, the positive predictive value of one-shot IVP was only 20% (80% of patients with normal one-shot IVP findings had renal injuries not detected by the IVP) (47). One-shot IVP is of no significant value in assessing penetrating abdominal trauma patients who undergo exploratory laparotomy for associated intra-abdominal injuries, and should be reserved only for patients with a flank wound or gross haematuria following penetrating trauma (48). 2.3.5.4 Computed tomography (CT) CT is the gold standard method for the radiographic assessment of stable patients with renal trauma. CT is more sensitive and specific than IVP, ultrasonography or angiography. In a retrospective study, the positive rate during evaluation of 298 patients was 96% by CT, 91% by double-dose intravenous IVP and 79% by ultrasound (45). CT more accurately defines the location of injuries, easily detects contusions and devitalised segments, visualises the entire retroperitoneum and any associated haematomas, and simultaneously provides a view of both the abdomen and pelvis. It demonstrates superior anatomical detail, including the depth and location of renal laceration and presence of associated abdominal injuries, and establishes the presence and location of the contralateral kidney (49). CT is particularly useful in evaluating traumatic injuries to kidneys with pre-existing abnormalities (50). Intravenous contrast should be administered for renal evaluation. A lack of contrast enhancement of the injured 10
Update march 2009
kidney is a hallmark of renal pedicle injury. In cases where this typical finding is not demonstrated, central parahilar haematoma increases the possibility of renal pedicle injury. This sign should be considered even if the renal parenchyma is well enhanced (51). Renal vein injury remains difficult to diagnose with any type of radiographic study. However, the presence on CT of a large haematoma, medial to the kidney and displacing the renal vasculature, should raise the suspicion of venous injury. Newer ‘spiral’ CT provides shorter scanning time and thus fewer artefacts in the examinations of patients who cannot co-operate adequately (52). Three-dimensional post-processing modalities allow assessment of the renal vascular pedicle by CT angiography and improve the demonstration of complex lacerations of the renal parenchyma. However, injury to the renal collecting system may be missed during routine spiral CT. In all cases of suspected renal trauma evaluated with spiral CT, repeat scans of the kidneys should be performed 10-15 minutes after contrast injection (53). Most blunt ureteral and ureteropelvic junction injuries can be identified if delayed excretory CT scans are performed (54). CT scanning is also safe as part of the diagnostic procedure for patients with gunshot wounds who are being considered for non-operative management (55). 2.3.5.5 Magnetic resonance imaging (MRI) Although MRI is not used in the majority of renal trauma patients, Leppäniemi et al. investigated the use of high-field strength MRI (1.0 T) in the evaluation of blunt renal trauma (56). MRI scans were accurate in finding peri-renal haematomas, assessing the viability of renal fragments, and detecting pre-existing renal abnormalities, but failed to visualise urinary extravasation on initial examination. The authors concluded that MRI could replace CT in patients with iodine allergy and could be used for initial staging if CT were not available (56). In a recent study comparing CT and MRI findings, the latter clearly revealed renal fracture with non-viable fragment, and was able to detect focal renal laceration not detected on CT due to peri-renal haematoma (57). However, MRI is not the first choice in managing patients with trauma because it requires a longer imaging time, increases the cost, and limits access to patients when they are in the magnet during the examination. MRI is therefore useful in renal trauma only if CT is not available, in patients with iodine allergy, or in the very few cases where the findings on CT are equivocal. 2.3.5.6 Angiography CT has largely replaced the use of angiography for staging renal injuries, as angiography is less specific, more time-consuming and more invasive. Angiography is, however, more specific for defining the exact location and degree of vascular injuries and may be preferable when planning selective embolisation for the management of persistent or delayed haemorrhage from branching renal vessels (50). Angiography can define renal lacerations, extravasation and pedicle injury. Additionally, it is the test of choice for evaluating renal venous injuries. The most common indication for arteriography is non-visualisation of a kidney on IVP after major blunt renal trauma when a CT is not available. Common causes for non-visualisation are: • total avulsion of the renal vessels (usually presents with life-threatening bleeding) • renal artery thrombosis • severe contusion causing major vascular spasm. Angiography is also indicated in stable patients to assess pedicle injury if the findings on CT are unclear, and for those who are candidates for radiological control of haemorrhage (31). 2.3.5.7 Radionuclide scans Radionuclide scans might be helpful for documenting renal blood flow in trauma patients with severe allergy to iodinated contrast material (50), but are not generally used or required.
Update march 2009
11
2.3.6 Recommendations Recommendations GR • Blunt trauma patients with macroscopic or microscopic haematuria (at least 5 rbc/hpf) with B hypotension (systolic blood pressure < 90 mmHg) should undergo radiographic evaluation • Radiographic evaluation is also recommended for all patients with a history of rapid B deceleration injury and/or significant associated injuries • All patients with any degree of haematuria after penetrating abdominal or thoracic injury B require urgent renal imaging • Ultrasonography can be informative during the primary evaluation of polytrauma patients C and for the follow-up of recuperating patients, although more data is required to suggest this modality universally • A CT scan with enhancement of intravenous contrast material is the best imaging study for B the diagnosis and staging of renal injuries in haemodynamically stable patients • Unstable patients who require emergency surgical exploration should undergo a one-shot C IVP with bolus intravenous injection of 2 mL/kg contrast • Formal IVP, MRI and radiographic scintigraphy are acceptable second-line alternatives for C imaging renal trauma when CT is not available • Angiography can be used for diagnosis and simultaneous selective embolisation of bleeding B vessels GR = grade of recommendation
2.4
Treatment
2.4.1 Indications for renal exploration The goal in managing patients with renal injuries is to minimise morbidity and to preserve renal function. The need for renal exploration can be predicted with accuracy with a nomogram, which uses the type of injury, transfusion requirements, blood urea nitrogen (BUN), creatinine and injury grade (58). However, the management of renal injury is usually influenced by the decision to explore or observe associated abdominal injuries (59). A life-threatening haemodynamic instability due to renal haemorrhage is an absolute indication for renal exploration, irrespective of the mode of injury (60, 61). Other indications include an expanding or pulsatile perirenal haematoma identified at exploratory laparotomy performed for associated injuries (this finding heralds a grade 5 vascular injury and is quite rare). A one-shot intraoperative IVP can provide valuable information. Poor visualisation or any other abnormality of the injured kidney is an indication for exploration. Grade 5 vascular renal injuries are, by definition, regarded as an absolute indication for exploration, although a single report has suggested that patients who are haemodynamically stable at presentation but with a grade 5 parenchymal injury (shattered kidney) after blunt trauma might be safely treated conservatively (62). The management of major renal injuries with urinary extravasation and devitalised fragments is controversial. Since these injuries are very uncommon, published series report on small numbers of patients. In recent years, it seems to have been recognised that most major injuries heal with non-operative treatment (63). Moudouni et al. suggest that an initially conservative approach is feasible in stable patients with devitalised fragments (64). These injuries are, however, associated with an increased rate of complications and late surgery (65). Persistent extravasation or urinoma are usually managed successfully with endourological techniques. Inconclusive renal imaging and a pre-existing renal abnormality or an incidentally diagnosed tumour could require surgery even after relatively minor renal injury (32). 2.4.2 Operative findings and reconstruction The overall exploration rate for blunt trauma is less than 10% (60), and may be even lower as more centres adopt a very conservative approach to the management of these patients (66). The goal of renal exploration following renal trauma is control of haemorrhage and renal salvage. Most experienced authors suggest the transperitoneal approach for surgery (67, 68). Access to the renal vascular pedicle is then obtained through the posterior parietal peritoneum, which is incised over the aorta, just medial to the inferior mesenteric vein. Temporary vascular occlusion before opening Gerota’s fascia is a safe and effective method during exploration and renal reconstruction (69). It tends to lower blood loss and the nephrectomy rate, and appears not to increase post-operative azotaemia or mortality (70). Renal reconstruction is feasible in most cases. The overall
12
Update march 2009
rate of patients who have a nephrectomy during exploration is around 13%, usually in patients with penetrating injury, and higher rates of transfusion requirements, haemodynamic instability, injury severity scores and mortality (71). Other intra-abdominal injuries also slightly increase the need for nephrectomy (72). Mortality is associated with the overall severity of the injury and is not often a consequence of the renal injury itself (73). In gunshot injuries caused by a high-velocity bullet, reconstruction can be difficult and nephrectomy is often required (14). Renorrhaphy is the most common reconstructive technique. Partial nephrectomy is required when non-viable tissue is detected. Watertight closure of the collecting system, if open, might be desirable, although some experts merely close the parenchyma over the injured collecting system with good results. If the renal capsule is not preserved, an omental pedicle flap or peri-renal fat bolster may be used for coverage (74). In a review by Shekarriz and Stoller, the use of fibrin sealant in traumatic renal reconstruction proved to be helpful (75). Newly developed haemostatic agents such as FLOSEAL (Baxter International Inc.) that have proven useful in open and laparoscopic partial nephrectomy, might also be helpful, but are largely unproven in the trauma setting. In all cases, drainage of the ipsilateral retroperitoneum is recommended to provide an outlet for any temporary leakage of urine. Renovascular injuries are uncommon. They are associated with extensive associated trauma and increased peri- and post-operative mortality and morbidity. Blunt renal artery injury is rare. Non-operative management should be considered as an acceptable therapeutic option (76). Following blunt trauma, repair of grade 5 vascular injury is seldom if ever effective (77). Repair could be attempted in those very rare cases in which there is a solitary kidney or the patient has sustained bilateral injuries (78). In all other cases, nephrectomy appears to be the treatment of choice (79). In a recent review, it appears that nephrectomy for main renal artery injury has outcomes similar to those of vascular repair, and it does not worsen post-treatment renal function in the short term. Non-operative management for segmental renal artery injury results in excellent outcomes (80). Angiography with selective renal embolisation for haemorrhage control is a reasonable alternative to laparotomy provided that no other indication for immediate surgery exists (81). Cure of haematuria after superselective transarterial embolisation is reported as high as 98% (82). Successful haemostasis by embolisation is reported to be identical in blunt and penetrating injuries (83, 84). The complication rate is minimal, and it has been proven effective for grade 4 injuries where conservative therapy failed (85). In our series, embolisation failed when applied to grade 5 injuries (85). 2.4.3 Non-operative management of renal injuries As the indications for renal exploration become clearer, non-operative management has become the treatment of choice for the majority of renal injuries. In stable patients, supportive care with bed-rest, hydration and antibiotics is the preferred initial approach (7). Primary conservative management is associated with a lower rate of nephrectomy without any increase in the immediate or long-term morbidity (86). The failure of conservative therapy is low (1.1%) (6). All grade 1 and 2 renal injuries can be managed non-operatively, whether due to blunt or penetrating trauma. Therapy of grade 3 injuries has been controversial, but recent studies support expectant treatment (87-89). Patients diagnosed with urinary extravasation in solitary injuries can be managed without major intervention and a resolution rate of > 90% (90). Persistent bleeding is the main indication for a reconstruction attempt (91). The majority of patients with grade 4 and 5 renal injuries present with major associated injuries, and consequently experience high exploration and nephrectomy rates (92), although emerging data indicate that many of these patients can be managed safely with an expectant approach. Although almost all grade 4 patients with penetrating injury require renal exploration, only 20% of those with blunt trauma do (93). Isolated grade 4 renal injuries represent a unique situation to treat the patient based solely on the extent of the renal injury, thus non-operative management is used more frequently. Persistent bleeding represents the main indication for renal exploration and reconstruction. In all cases of severe renal injury, non-operative management should occur only after complete renal staging in haemodynamically stable patients (91). Penetrating wounds have traditionally been approached surgically. However, stable patients should undergo complete staging to define the full extent of the injury. Renal gunshot injuries should be explored only if they involve the hilum or are accompanied by signs of continued bleeding, ureteral injuries, or renal pelvis lacerations (94).
Update march 2009
13
Low-velocity gunshot and stab wounds of minor degree may be managed conservatively with an acceptably good outcome (95). Tissue damage from high-velocity gunshot injuries, on the other hand, might be more extensive and nephrectomy could be required. Non-operative management of renal gunshot wounds in selected stable patients is associated with a high rate of success (96-98). If the site of penetration by stab wound is posterior to the anterior axillary line, 88% of such renal injuries can be managed non-operatively (99). Injuries to the flank are more likely to be grade 3, while injuries to the abdomen are more likely to be grade 1. A systematic approach based on clinical, laboratory and radiological evaluation might minimise negative exploration without increasing morbidity from missed injury (61). Renal stab wounds producing major renal injuries (grade 3 or higher) are more unpredictable and are associated with a higher rate of delayed complications if treated expectantly (100).
2.4.4 Recommendations Recommendations GR • Following grade 1-4 blunt renal trauma, stable patients should be managed conservatively B with bed-rest, prophylactic antibiotics and continuous monitoring of vital signs until haematuria resolves • Following grade 1-3 stab and low-velocity gunshot wounds, stable patients, after B complete staging, should be selected for expectant management • Indications for surgical management include: • haemodynamic instability • exploration for associated injuries • expanding or pulsatile peri-renal haematoma identified during laparotomy • grade 5 injury • incidental finding of pre-existing renal pathology requiring surgical therapy B • Renal reconstruction should be attempted in cases where the primary goal of controlling B haemorrhage is achieved and a sufficient amount of renal parenchyma is viable GR = grade of recommendation 2.4.5 Post-operative care and follow-up Patients who are successfully treated conservatively carry some risk of complications. This risk correlates with increasing grade. Repeat imaging 2-4 days after trauma minimises the risk of missed complications, especially in grade 3-5 blunt renal injuries (101). However, the utility of frequent CT scanning after injury has never been satisfactorily proven. CT scans should always be performed on patients with fever, unexplained decreasing haematocrit, or significant flank pain. Nuclear renal scans are useful for documenting and tracking functional recovery in patients following renal reconstruction before discharge from hospital (97). To detect many of the delayed complications, an excretory urogram is recommended within 3 months of major renal injury, although benefit to the patient has not yet been proven in the literature. Follow-up should involve physical examination, urinalysis, individualised radiological investigation, serial blood pressure measurement and serum determination of renal function (60, 64). Follow-up examinations should continue until healing is documented and laboratory findings have stabilised, although checking for latent renovascular hypertension may need to continue for years (102). The literature is generally inadequate on the subject of the long-term consequences of trauma on renal tissue. It appears that on histopathological evaluation, renal tissue may appear dystrophic following some cases of conservative management of minor renal injuries (103).
2.4.6 Recommendations Recommendations GR • Repeat imaging is recommended for all hospitalised patients within 2-4 days of significant B renal trauma (although no specific data exists). Repeat imaging is always recommended in cases of fever, flank pain, or falling haematocrit • Nuclear scintigraphy before discharge from the hospital is useful for documenting functional C recovery • Within 3 months of major renal injury, patients’ follow-up should involve: C 1. physical examination
14
Update march 2009
•
2. urinalysis 3. individualised radiological investigation 4. serial blood pressure measurement 5. serum determination of renal function Long-term follow-up should be decided on a case-by-case basis but should at the very least involve monitoring for renovascular hypertension GR = grade of recommendation
C
2.4.7 Complications Early complications occur within the first month after injury and can be bleeding, infection, peri-nephric abscess, sepsis, urinary fistula, hypertension, urinary extravasation and urinoma. Delayed complications include bleeding, hydronephrosis, calculus formation, chronic pyelonephritis, hypertension, arteriovenous fistula, hydronephrosis and pseudoaneurysms. Delayed retroperitoneal bleeding usually occurs within several weeks of an injury or procedure and may be life-threatening. Selective angiographic embolisation is the preferred treatment (104). Peri-nephric abscess formation is usually best managed by percutaneous drainage, although open drainage may sometimes be required (60). Percutaneous management of complications may pose less risk of renal loss than re-operation, which may lead to nephrectomy when infected tissues make reconstruction difficult. Renal trauma is a rare cause of hypertension, mostly in young men. The frequency of post-traumatic hypertension is estimated to be less than 5% in all published series (105, 106). Hypertension may occur acutely as a result of external compression from peri-renal haematoma (Page kidney), or chronically because of compressive scar formation (Goldblatt kidney). Hypertension is usually renin-dependent and associated with parenchymal injury. Renin-mediated hypertension may occur as a long-term complication; aetiologies include renal artery thrombosis, segmental arterial thrombosis, renal artery stenosis (Goldblatt kidney), devitalised fragments and arteriovenous fistulae. Arteriography is informative in cases of post-traumatic hypertension (107). Treatment is required if the hypertension persists, and could include medical management, excision of the ischaemic parenchymal segment, vascular reconstruction, or total nephrectomy (108). Urinary extravasation after renal reconstruction often subsides without intervention as long as ureteral obstruction and infection are not present. Ureteral retrograde stenting may improve drainage and allow healing (109). Persistent urinary extravasation from an otherwise viable kidney after blunt trauma often responds to stent placement and/or percutaneous drainage as necessary (63). Arteriovenous fistulae usually present with delayed onset of significant haematuria, most often after penetrating trauma. Percutaneous embolisation is often effective for symptomatic arteriovenous fistulae, but larger ones may require surgery (110). The development of pseudoaneurysm is a rare complication following blunt renal trauma. In numerous case reports, transcatheter embolisation appears to be a reliable minimally invasive solution (111, 112). Acute renal colic from a retained missile has been reported, and can be managed endoscopically if possible (113). Other unusual late complications, such as duodenal obstruction, may result from retroperitoneal haematoma following blunt renal trauma (114).
2.4.8 Recommendations Recommendations GR • Complications following renal trauma require a thorough radiographic evaluation B • Medical management and minimally invasive techniques should be the first choice for the C management of complications • Renal salvage should be the surgeon’s aim for patients in whom surgical intervention is C necessary GR = grade of recommendation 2.4.9 Paediatric renal trauma Blunt renal trauma is the most common injury seen in children and accounts for more than 90% of renal injuries in the paediatric population (115, 116). Children are more susceptible to renal trauma than adults. Differences in anatomy and physiology, as well as the higher incidence of pre-existing renal disease, make children
Update march 2009
15
more likely to sustain injury. The kidneys are lower in the abdomen, less well-protected by the lower ribs and muscles of the flank and abdomen, more mobile, have less protective peri-renal fat and are proportionately larger in the abdomen than in adults (117-119). History and physical examination are very important factors in the evaluation of the paediatric patient with suspected renal trauma. Unlike adults, hypotension is an unreliable sign in children, as an outpouring of catecholamines can maintain blood pressure despite a significant volume of blood loss. Hypotension is less common in children, and significant injury can be present despite stable blood pressures (120). Another important difference from adults is that children with microscopic haematuria or normal urinalyses and stable vital signs may have sustained significant renal injury (121). Haematuria is an important clinical sign of paediatric renal injury and is directly related to the severity of that renal injury and the presence of associated injuries (122). The radiographic evaluation of children with suspected renal trauma is still controversial. Stein et al. proposed that all paediatric patients with any degree of haematuria should be evaluated for renal trauma (123). In contrast, Morey et al. concluded that significant injuries are unlikely in the absence of gross or significant microscopic haematuria (> 50 rbc/hpf) (124). Nguyen and Das proposed a low threshold for renal imaging following renal trauma. The instances of its use should include patients with blunt abdominal trauma with any level of haematuria, patients with associated abdominal injury regardless of the findings of urinalysis, and patients with normal urinalyses but in whom the mechanism of injury has a high index of suspicion for renal trauma (i.e. rapid deceleration event, direct flank trauma, falls from a height) (125). After studying 720 paediatric trauma cases, Santucci et al. concluded that the decision for imaging based on the adult criteria of gross haematuria, shock and significant deceleration injury is appropriate (126). Ultrasound is considered a reliable method of screening and following the course of renal injury in paediatric patients with blunt renal trauma in Europe, although it is used much less frequently in the USA (127, 128). Ultrasound is used in some centres, mostly in stable cases with abnormal urinalyses and/or findings suggestive of a major injury (129). The diagnostic accuracy of IVP is superior to that of ultrasound, and should be performed as an emergency procedure if CT scan is not available (130). CT is the best imaging modality, however, and those with multiple injuries or suspected renal trauma should be evaluated by contrast-enhanced CT if possible (131, 132). The use of MRI in paediatric patients with vesicoureteral reflux found that MRI at 1.5 T was better than dimercaptosuccinic acid (DMSA) scans in detecting small renal parenchymal lesions (133), although MRI has little proven use in the acute management of the trauma patient. Conservative treatment for grade 1-2 renal injuries is clearly defined, and these injuries should be managed expectantly (134). Non-operative management results in an excellent long-term outcome in the majority of cases (135). Non-operative management of high grade renal injuries is effective and is recommended for stable children, but requires close clinical observation, serial CT, and frequent reassessment of the patient’s overall condition (136). The length of hospital stay does not increase with worsening severity of renal injury, but is determined by the severity of non-renal injuries (137). Haemodynamic instability and a diagnosed grade 5 injury are the strongest indications for operative management (59, 120, 136). Stable patients with urinary extravasation can also be managed expectantly since most urinomas resolve spontaneously. In cases where there is persistent leakage, the placement of a ureteral stent or percutaneous drainage is feasible and curative in most cases. Early placement of a ureteral stent can be considered for paediatric patients with blunt renal trauma who demonstrate an absence of contrast material in the ipsilateral ureter, as clinical indications for stent placement will likely develop (138). Major kidney trauma has significant consequences on the opposite side. Post-traumatic functional evaluation by DMSA scintigraphy 8 days after major injury is a valid prognostic indicator of later function, but its clinical utility has never been established. Children with renal injuries that fail with non-surgical therapy appear to do so in a median time of 4 hours, but the majority of patients fail within the first 24 hours (139). The failure rate of non-surgical management for renal injuries is 3% (140). Buckley and McAninch presented an algorithm for the management of paediatric renal injuries based on the 25 year experience of the San Francisco General Hospital, which is highly recommended (135) (Figure 1).
16
Update march 2009
Mild renal injuries do not require follow-up imaging. Follow-up is only recommended for patients with major injuries as there is an increased risk of delayed complications and loss of renal function (139). The majority of patients with severe renal injuries develop parenchymal scars. Radionuclide scans such as DMSA can be useful in the early diagnosis of scars and consequent hypertension (141).
2.4.10 Recommendations Recommendations GR • Indications for radiographic evaluation of children suspected of renal trauma include: 1. blunt and penetrating trauma patients with any level of haematuria 2. patients with associated abdominal injury regardless of the findings of urinalysis 3. patients with normal urinalyses who sustained a rapid deceleration event, direct flank trauma, B or a fall from a height • Ultrasonography is considered a reliable method of screening and monitoring blunt B renal injuries by some researchers, but is not universally accepted • CT scanning is the imaging study of choice for staging renal injuries B • Haemodynamic instability and a diagnosed grade 5 injury are absolute indications for B surgical exploration GR = grade of recommendation 2.4.11 Renal injury in the polytrauma patient Approximately 8-10% of blunt and penetrating abdominal injuries involve the kidneys. The incidence of associated injury in penetrating renal trauma ranges from 77-100%. Gunshot wounds are associated with organ injury more often than are stab wounds. The majority of patients with penetrating renal trauma have associated adjacent organ injuries that may complicate treatment. In the absence of an expanding haematoma with haemodynamic instability, associated multiorgan injuries do not increase the risk of nephrectomy (142). Blunt and penetrating trauma equally contributed to combined renal and pancreatic injury, as reported by Rosen and McAninch (143). Renal preservation was achieved in most patients, and the complication rate of the series was 15% (143). A similar rate of complications (16%) was reported in patients with simultaneous colon and renal injury. In a report reviewing this combination of injuries over a period of 17 years, 58% of patients underwent an exploration, with nephrectomies performed in 16% of explorations (144). Renal injuries seem to be rather rare in patients with blunt chest trauma. In a recent study of polytrauma patients, conservative management was safely attempted without increasing morbidity (145). In polytrauma patients undergoing partial or total nephrectomy, there is no increased mortality or renal failure rate (146).
2.4.12 Recommendations Recommendations GR • Polytrauma patients with associated renal injuries should be evaluated on the basis of the C most threatening injury • In cases where surgical intervention is chosen, all associated injuries should be evaluated C simultaneously • The decision for conservative management should consider all injuries independently C GR = grade of recommendation
2.5 Iatrogenic renal injuries 2.5.1 Iatrogenic vascular injuries Iatrogenic main renal artery injuries with perforation or rupture are rare. They are usually reported after renal artery angioplasty or stenting, and have an incidence of 1.6% (147). One case of an iatrogenic renal artery perforation as a complication of cardiac catheterisation has also been reported (148). Since most iatrogenic renal artery lesions occur during endovascular procedures, there are no reports on the clinical symptoms, but only on the angiographic findings. Arteriovenous fistulae, pseudoaneurysms, arterial dissection or contrast extravasation are the possible radiological findings in these traumatic vascular lesions. Traditional therapy for renal perforation has been renal artery ligation followed by bypass grafting or nephrectomy, but nowadays the treatment for acute iatrogenic rupture of the main renal artery is balloon tamponade. However, in case of failure, the immediate availability of a stent graft is vital.
Update march 2009
17
Patients with iatrogenic operative injuries are strikingly different from those with penetrating, blunt or catheterrelated vascular trauma. Renal vessels are vulnerable during oncological procedures. Factors that increase technical difficulty are previous operation, tumour recurrence, radiation exposure and chronic inflammatory changes. Renal vein injuries during elective abdominal operations represent a serious complication with significant morbidity. Most patients with operative venous injuries have partial lacerations that can be managed with relatively simple techniques, such as venorrhaphy. Patch angioplasty with autologous vein or polytetrafluoroethylene (ePTFE) graft may be required if venorrhaphy is not possible (149). Some renal vascular injuries, such as pseudoaneurysms following nephron-sparing surgery, can be managed by transcatheter embolisation (150).
2.5.2 Renal transplantation The orthotopic kidney is protected from external force by muscles, Gerota’s fascia and peri-nephric fat. A renal graft is located in the lower pelvis in the iliac fossa and is therefore more susceptible to injury, especially from direct blows to the abdomen. The transplanted kidney, unlike the native kidney, is fixed in position by a thick fibrotic capsule that develops post-transplant. Also, the transplant kidney is not suspended by the renal vessels, so deceleration events that cause pedicle injury to a native kidney are less likely to affect a transplanted kidney (151). As transplant recipients return to more active lifestyles, including a significant risk of becoming a trauma victim, a renal graft is liable to be severely affected by trauma that might not cause any injury to a native kidney. In transplant recipients it is very important to know patients’ baseline renal function (152). The knowledge of an abnormal renal baseline may prevent unnecessary extensive diagnostic evaluation. Radiographic evaluation should proceed as for the native kidney. The increased risk for contrast nephrotoxicity can be minimised with adequate hydration. A CT scan is the test of choice for a stable injured transplant recipient, as it will identify renal and associated intra-abdominal injuries and will also indirectly assess renal blood flow and function. A renal duplex examination can be also very helpful for identifying isolated trauma to the transplanted kidney and for identifying renal blood flow. Radionuclide scans might reveal urine leaks and are good for assessing overall blood flow and renal function, while angiography can assess blood flow and identify specific arterial injuries. The surgical management of an injured transplanted kidney is complex. A very short vascular pedicle and ureter, dense scarring, and a fibrous capsule may prevent any attempt at the direct repair of the parenchymal, collecting system and vascular pedicle injuries. Grade 1-3 injuries can be managed non-operatively. Grade 4-5 injuries might require exploration with debridement and drainage. Major injuries could require a subcapsular nephrectomy. Renovascular injuries have a poor prognosis. Renal arteriography may be helpful with embolisation of the main artery to stop bleeding, or with more selective embolisation to salvage part of the kidney. When renal graft injury occurs, saving the patient’s life is the first priority, but saving the graft is also very important to maintain renal function. Iatrogenic vascular injuries of renal transplants can be managed by embolisation. Angiographic embolisation often fails, and is associated with a high complication rate and high eventual nephrectomy rate (153). On the other hand, transcatheter embolisation is highly effective for biopsy-related vascular injury in the transplanted kidney.
2.5.3 Percutaneous renal procedures Percutaneous nephrostomy is achieved in nearly all patients without major complications. Haematuria is common for a few days, but massive retroperitoneal haemorrhage is rare. Small subcapsular renal haematomas resolve spontaneously, while arteriovenous-calyceal fistulae are best managed by angiographic embolisation. If a nephrostomy catheter is seen to transfix the renal pelvis, the possibility of injury to a large renal artery must be considered. The misplaced nephrostomy catheter should be withdrawn over a guidewire, and renal artery embolisation might enable rapid arrest of a life-threatening haemorrhage (154). In more complex cases, CT could be used to detect possible catheter malposition and successfully guide catheter repositioning into the renal collecting system (155). Renal pelvis injuries can occur during percutaneous nephrostomy placement. Haemorrhage can be prevented 18
Update march 2009
by avoiding puncture in anticoagulated or coagulopathic patients, careful puncture on to target calyceals, and avoidance of medial punctures. A pelvic injury is less likely to happen if the dilator is not advanced further than the calyx, the peelaway sheaths are handled with care, especially when advanced around the pelviureteric junction, and kinking of the guidewires is avoided (156). Percutaneous renal biopsy is a relatively safe procedure. Haemorrhage, arteriovenous fistula and renal capsular artery pseudoaneurysm might occur. Arteriovenous fistula might present with severe hypertension and is managed by embolisation (157). A pseudoaneurysm should be suspected if the patient presents with flank pain and decreasing haematocrit without haematuria. Arteriography and transarterial embolisation is the appropriate therapy (158). Percutaneous nephrolithotomy (PCNL) is a popular procedure in which stones in the renal pelvis are removed via a nephroscope, often after ultrasonic or electrohydraulic disruption. The complications include haemorrhage, extravasation and absorption of large volumes of irrigation fluid, fever, infection, colonic perforation, arteriovenous fistulae, and pneumothorax. Extravasation of fluid is often due to a tear in the pelvicalyceal system. A close watch on irrigation fluid input and output is required for early recognition of the complication. Termination of the procedure if the renal pelvis is torn or ruptured is a safe choice. Apart from intraoperative evaluation of serum electrolytes, acid-base status and oxygenation, the monitoring of airway pressure is a good indicator of this complication. Metabolic acidosis, hyponatraemia, hypokalaemia, peritonism and ileus are due to absorption of large volumes of irrigation fluids. Management of this complication requires close monitoring, placement of an abdominal or retroperitoneal drain, correction of acidosis and supportive measures (159). The diagnosis of a colon injury during or after percutaneous renal surgery can be elusive because symptoms are often variable. An unrecognised or untreated colon injury can result in abscess formation, septicaemia, and/or nephrocolic or colocutaneous fistula. Surgical exploration is inevitable when the patient experiences haemorrhage, pneumoperitoneum and peritonitis. The majority of these cases can be successfully managed conservatively. The consistent application of proper techniques, avoidance of puncturing the kidney lateral to the posterior axillary line, and puncture of the upper pole calyx when feasible, will help prevent the injuries. Vascular injuries with renal bleeding are quite frequent and can occur at any stage of the percutaneous procedure, requiring transfusion in 1-11% of cases. A high number of punctures and incorrect choice of puncture site (access that is too medial or direct puncture of the renal pelvis) have been suggested as the cause of vascular lesions after percutaneous procedures. Renal bleeding can arise from both venous and arterial lesions. Bleeding from venous vessels could be profuse at the end of a procedure, but is generally controlled by simple measures, such as placing the patient supine to reduce abdominal compression, positioning a nephrostomy catheter, and forcing diuresis through hydration and parenteral administration of mannitol after clamping of the nephrostomy catheter. In the case of major venous trauma with massive haemorrhage, patients with concomitant renal insufficiency can be treated without open exploration or angiographic embolisation using a Council balloon catheter (160). Arterial lesions may induce acute or late post-operative bleeding. Severe acute bleeding usually arises from injury to the anterior or posterior segmental arteries. Delayed bleeding is usually caused by interlobar and lower pole artery lesions, often arteriovenous fistulae and post-traumatic aneurysms. Duplex ultrasound and CT angiography can diagnose vascular injuries. Hyperselective renal embolisation is considered the most appropriate technique for the treatment of iatrogenic vascular lesions. It is essential to identify the precise site of the lesion so as to be as selective as possible and reduce the risk of renal dysfunction. Hyperselective catheterisation of the renal artery branches is achieved by means of either hydrophilic 5 French catheters or coaxial systems with low profile microcatheters (2.6 French). The use of an embolic agent helps in performing a distal and irreversible occlusion with complete haemostasis. A variety of embolic materials have been used; microcoils, homologous clots, detachable balloons, polyvinyl alcohol particles, gelfoam, silicone rubber, cotton pellets and silk filaments. The choice of the embolic agent is dependent mainly on the blood flow entity at the level of the lesion, the vessel size and the operator’s experience. Finally, complications of endopyelotomy can be classified as major (vascular injury), and minor (infection,
Update march 2009
19
urinoma) (161). Preventive steps, along with proper patient selection, minimise the risk for these complications.
2.5.4 RECOMMENDATIONS Recommendations GR • Iatrogenic rupture of the main renal artery should be treated with balloon tamponade, and, C in case of failure, with a stent graft • Surgical venous injuries should be managed with venorrhaphy or patch angioplasty C • The transplanted kidney should be evaluated on the basis of renal function, type of injury and C the patients’ condition • Hyperselective embolisation may control arterial bleeding during percutaneous procedures C GR = grade of recommendation
2.6 Suggestions for future research studies Among the topics that would be useful subjects for future research studies are: • blunt trauma grade 5 patients, as it appears that some of them may benefit from non-surgical management • the necessity and nature of follow-up imaging • the value of the administration of antibiotics in low-grade renal injuries selected for conservative management.
2.7 Algorithms Figure 1 is an algorithm for the management of renal trauma in children. Figures 2 and 3 show the suggested treatment of blunt and penetrating renal injuries in adults. Figure 1: Algorithm for the management of paediatric renal trauma (119)
Paediatric renal trauma Blunt
Penetrating
ua
ua
>50 rbc/hpf or deceleration injury
ua
<50 rbc/hpf or haemodynamically stable
Stable
Unstable
CT scan
Abdominal exploration
>5 rbc/hpf Stable
Unstable
CT scan
Abdominal exploration
Observe Observe
Observe
Renal exploration
Observe
20
nl
IVP nl
Renal exploration
abnl Renal exploration
Observe
IVP abnl Renal exploration
Update march 2009
Abnormal IVP
Pulsatile or expanding
Retroperitoneal haematoma
Grade 5
Observation, bed rest, serial Ht, antibiotics
Associated injuries requiring laparotomy
Renal exploration‡
Stable
Grade 1-2 Grade 3-4
Renal imaging†
Gross haematueria
Stable
Rapid deceleraton Injury or Major associated injuries
Observation
Microscopic haematueria
Determine haemodynamic stability
Suspected adult blunt Renal trauma*
Unstable
Normal IVP
Emergency laparotomy One-shot IVP
Figure 2: Evaluation of blunt renal trauma in adults
*Suspected renal trauma results from reported mechanism of injury and physical examination. † Renal imaging: CT scans are the gold standard for evaluating blunt and penetrating renal injuries in stable patients. In settings where the method is not available, the urologist should rely on other imaging modalities (IVP, angiography, radiographic scintigraphy, MRI). ‡ Renal exploration: Although renal salvage is a primary goal for the urologist, decisions concerning the viability of the organ and the type of reconstruction are made during the operation.
Update march 2009
21
Renal exploration‡ Associated injuries requiring laparotomy
Stable
Observation Grade 1-2 Grade 4-5
Observation, bed rest, serial Ht, antibiotics
Grade 3
Renal imaging†
Stable
Pulsatile or expanding
Retroperitoneal haematoma
Normal IVP
Determine haemodynamic stability
Suspected adult penetrating Renal trauma*
Unstable
Emergency laparotomy One-shot IVP
Abnormal IVP
Figure 3: Evaluation of penetrating renal trauma in adults
*Suspected renal trauma results from reported mechanism of injury and physical examination. † Renal imaging: CT scans are the gold standard for evaluating blunt and penetrating renal injuries in stable patients. In settings where the method is not available, the urologist should rely on other imaging modalities (IVP, angiography, radiographic scintigraphy, MRI). ‡ Renal exploration: Although renal salvage is a primary goal for the urologist, decisions concerning the viability of the organ and the type of reconstruction are made during the operation.
22
Update march 2009
2.8 REFERENCES 1.
2.
3.
4. 5.
6.
7.
8.
9.
10.
11.
12.
13.
14. 15.
16.
17.
18. 19.
Baverstock, R, Simons, R, McLoughlin, M. Severe blunt renal trauma: a 7-year retrospective review from a provincial trauma centre. Can J Urol 2001;8(5):1372-6. http://www.ncbi.nlm.nih.gov/pubmed/11718633 Meng MV, Brandes SB, McAninch JW. Renal trauma: indications and techniques for surgical exploration. World J Urol 1999;17(2):71-7. http://www.ncbi.nlm.nih.gov/pubmed/10367364 Paparel P, N’Diaye A, Laumon B, Caillot JL, Perrin P, Ruffion A. The epidemiology of trauma of the genitourinary system after traffic accidents: analysis of a register of over 43,000 victims. BJU Int 2006;97(2):338-41. http://www.ncbi.nlm.nih.gov/pubmed/16430642 Kristjánsson A, Pedersen J. Management of blunt renal trauma. Br J Urol 1993;72(5Pt2):692-6. http://www.ncbi.nlm.nih.gov/pubmed/8281396 Danuser H, Wille S, Zoscher G, Studer U. How to treat blunt kidney ruptures: primary open surgery or conservative treatment with deferred surgery when necessary? Eur Urol 2001;39(1):9-14. http://www.ncbi.nlm.nih.gov/pubmed/11173932 Hurtuk M, Reed RL 2nd, Esposito TJ, Davis KA, Luchette FA. Trauma surgeons practice what they preach. The NTDB story on solid organ injury management. J Trauma 2006;61(2):243-54; discussion 254-5. http://www.ncbi.nlm.nih.gov/pubmed/16917435 Santucci RA, Fisher MB. The literature increasingly supports expectant (conservative) management of renal trauma – a systematic review. J Trauma 2005;59(2):493-503. http://www.ncbi.nlm.nih.gov/pubmed/16294101 Santucci RA, McAninch JW. Diagnosis and management of renal trauma: past, present, and future. J Am Coll Surg 2000;191(4):443-51. http://www.ncbi.nlm.nih.gov/pubmed/11030250 Krieger JN, Algood CB, Mason JT, Copass MK, Ansell JS. Urological trauma in the Pacific Northwest: etiology, distribution, management and outcome. J Urol 1984;132(1):70-3. http://www.ncbi.nlm.nih.gov/pubmed/6726964 Brophy RH, Gamradt SC, Barnes RP, Powell JW, DelPizzo JJ, Rodeo SA, Warren RF. Kidney injuries in professional American football: implications for management of an athlete with 1 functioning kidney. Am J Sports Med 2008;36(1):85-90. http://www.ncbi.nlm.nih.gov/pubmed/17986635 Kuan JK, Kaufman R, Wright JL, Mock C, Nathens AB, Wessells H, Bulger E. Renal injury mechanisms of motor vehicle collisions: analysis of the crash injury research and engineering network data set. J Urol 2007;178(3Pt1):935-40; discussion 940. http://www.ncbi.nlm.nih.gov/pubmed/17632156 Brandes SB, McAninch JW. Urban free falls and patterns of renal injury: a 20-year experience with 396 cases. J Trauma 1999;47(4):643-9; discussion 649-50. http://www.ncbi.nlm.nih.gov/pubmed/10528597 Bruce LM, Croce MA, Santaniello JM, Miller PR, Lyden SP, Fabian TC. Blunt renal artery injury: incidence, diagnosis, and management. Am Surg 2001;67(6):550-4; discussion 555-6. http://www.ncbi.nlm.nih.gov/pubmed/11409803 Ersay A, Akgun Y: Experience with renal gunshot injuries in a rural setting. Urology 1999;54(6):972-5. http://www.ncbi.nlm.nih.gov/pubmed/10604692 Abu-Zidan FM, Al-Tawheed A, Ali YM. Urologic injuries in the Gulf War. Int Urol Nephrol 1999;31(5):577-83. http://www.ncbi.nlm.nih.gov/pubmed/10755347 Tucak A, Lukacevic T, Kuvezdic H, Petek Z, Novak R. Urogenital wounds during the war in Croatia in 1991/1992. J Urol 1995;153(1):121-2. http://www.ncbi.nlm.nih.gov/pubmed/7966742 Paquette E L. Genitourinary trauma at a combat support hospital during Operation Iraqi Freedom: the impact of body armor. J Urol 2007;177(6):2196-9; discussion 2199. http://www.ncbi.nlm.nih.gov/pubmed/17509316 Lent V. What classification is appropriate in renal trauma?. Eur Urol 1996;30(3):327-34. http://www.ncbi.nlm.nih.gov/pubmed/8931965 Moore EE, Shackford SR, Pachter HL, McAninch JW, Browner BD, Champion HR, Flint LM, Gennarelli TA, Malangoni MA, Ramenofsky ML. Organ injury scaling: spleen, liver, and kidney. J Trauma 1989;29(12):1664-6. http://www.ncbi.nlm.nih.gov/pubmed/2593197
Update march 2009
23
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
24
Shariat SF, Roehrborn CG, Karakiewicz PI, Dhami G, Stage KH. Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale. J Trauma 2007;62(4):933-9. http://www.ncbi.nlm.nih.gov/pubmed/17426551 Santucci RA, McAninch JW, Safir M, Mario LA, Service S, Segal MR. Validation of the American Association for the Surgery of Trauma organ injury severity scale for the kidney. J Trauma 2201;50(2):195-200. http://www.ncbi.nlm.nih.gov/pubmed/11242281 Kuan JK, Wright JL, Nathens AB, Rivara FP, Wessells H; American Association for the Surgery of Trauma. American Association for the Surgery of Trauma Organ Injury Scale for kidney injuries predicts nephrectomy, dialysis, and death in patients with blunt injury and nephrectomy for penetrating injuries. J Trauma 2006;60(2):351-6. http://www.ncbi.nlm.nih.gov/pubmed/16508495 Sacco WJ, Copes WS, Bain LW Jr, MacKenzie EJ, Frey CF, Hoyt DB, Weigelt JA, Champion HR. Effect of preinjury illness on trauma patient survival outcome. J Trauma 1993;35(4):538-42; discussion 542-3. http://www.ncbi.nlm.nih.gov/pubmed/8411276 Cachecho R, Millham FH, Wedel SK. Management of the trauma patient with pre-existing renal disease. Crit Care Clin 1994;10(3):523-36. http://www.ncbi.nlm.nih.gov/pubmed/7922736 Cózar JM, Cárcamo P, Hidalgo L, Navarro J, García-Matres MJ, Ortín M, Martínez-Piñeiro JA. [Management of injury of the solitary kidney]. Arch Esp Urol 1990;43(1):15-18. [article in Spanish] http://www.ncbi.nlm.nih.gov/pubmed/2331159 Sebastià MC, Rodriguez-Dobao M, Quiroga S, Pallisa E, Martinez-Rodriguez M, Alvarez-Castells A. Renal trauma in occult ureteropelvic junction obstruction: CT findings. Eur Radiol 1999;9(4):611-15. http://www.ncbi.nlm.nih.gov/pubmed/10354870 Bahloul A, Krid M, Trifa M, Mosbah AT, Mhiri MN. [Contusions to the pathologic kidney. A retrospective study, apropos of 34 cases]. Ann Urol (Paris) 1997;31(5):253-8. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/9480628 Giannopoulos A, Serafetinides E, Alamanis C, Constantinides C, Anastasiou I, Dimopoulos C. [Urogenital lesions diagnosed incidentally during evaluation for blunt renal injuries]. Prog Urol 1999;9(3):464-9. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/10434318 Buchberger W, Penz T, Wicke K, Eberle J. [Diagnosis and staging of blunt kidney trauma. A comparison of urinalysis, i.v. urography, sonography and computed tomography]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1993;158(6):507-12. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/8507839 Carroll PR, McAninch JW, Klosterman P, Greenblatt M. Renovascular trauma: risk assessment, surgical management, and outcome. J Trauma 1990;30(5):547-52; discussion 553-4. http://www.ncbi.nlm.nih.gov/pubmed/2342137 Eastham JA, Wilson TG, Larsen DW, Ahlering TE. Angiographic embolization of renal stab wounds. J Urol 1992;148(2Pt1):268-70. http://www.ncbi.nlm.nih.gov/pubmed/1635114 Schmidlin FR, Iselin CE, Naimi A, Rohner S, Borst F, Farshad M, Niederer P, Graber P. The higher injury risk of abnormal kidneys in blunt renal trauma. Scand J Urol Nephrol 1998;32(6):388-92. http://www.ncbi.nlm.nih.gov/pubmed/9925001 Chandhoke PS, McAninch JW. Detection and significance of microscopic hematuria in patients with blunt renal trauma. J Urol 1988;140(1):16-18. http://www.ncbi.nlm.nih.gov/pubmed/3379684 Miller KS, McAninch JW. Radiographic assessment of renal trauma: our 15-year experience. J Urol 1995;154(2Pt1):352-5. http://www.ncbi.nlm.nih.gov/pubmed/7609096 Hardeman SW, Husmann DA, Chinn HK, Peters PC. Blunt urinary tract trauma: identifying those patients who require radiological diagnostic studies. J Urol 1987;138(1):99-101. http://www.ncbi.nlm.nih.gov/pubmed/3599230 McAndrew JD, Corriere JN Jr. Radiographic evaluation of renal trauma: evaluation of 1103 consecutive patients. Br J Urol 1994;73(4):352-4. http://www.ncbi.nlm.nih.gov/pubmed/8199819
Update march 2009
37.
38. 39.
40.
41. 42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
Mee SL, McAninch JW. Indications for radiographic assessment in suspected renal trauma. Urol Clin North Am 1989;16(2):187-92. http://www.ncbi.nlm.nih.gov/pubmed/2652848 Brown DF, Rosen CL, Wolfe RE. Renal ultrasonography. Emerg Med Clin North Am 1997;15(4):877-93. http://www.ncbi.nlm.nih.gov/pubmed/9391497 Arena F, Peracchia G, di Stefano C, Sebastio N, Cortellini P. [The role of echotomography in minor renal traumatology]. Acta Biomed Ateneo Parmense 1997;68(3-4):53-7. [article in Italian] http://www.ncbi.nlm.nih.gov/pubmed/10068351 Qin R, Shao G, Yu M. [The diagnosis and treatment of blunt renal trauma]. Zhonghua Wai Ke Za Zhi 1996;34(8):505-7. [article in Chinese] http://www.ncbi.nlm.nih.gov/pubmed/9594202 Pollack HM, Wein AJ. Imaging of renal trauma. Radiology 1989;172(2):297-308. http://www.ncbi.nlm.nih.gov/pubmed/2664858 Valentino M, Serra C, Zironi G, De Luca C, Pavlica P, Barozzi L. Blunt abdominal trauma: emergency contrast-enhanced sonography for detection of solid organ injuries. AJR Am J Roentgenol 2006;186(5):1361-7. http://www.ncbi.nlm.nih.gov/pubmed/16632732 McGahan JP, Richards JR, Jones CD, Gerscovich EO. Use of ultrasonography in the patient with acute renal trauma. J Ultrasound Med 1999;18(3):207-13; quiz 215-6. http://www.ncbi.nlm.nih.gov/pubmed/10082355 Rosales A, Arango O, Coronado J, Vesa J, Maristany J, Gelabert A. The use of ultrasonography as the initial diagnostic exploration in blunt renal trauma. Urol Int 1992;48(2):134-7. http://www.ncbi.nlm.nih.gov/pubmed/1585506 Qin R, Wang P, Qin W, Wang H, Chen B. Diagnosis and treatment of renal trauma in 298 patients. Chin J Traumatol 2002;5(1):21-3. http://www.ncbi.nlm.nih.gov/pubmed/11835751 Morey AF, McAninch JW, Tiller BK, Duckett CP, Carroll PR. Single shot intraoperative excretory urography for the immediate evaluation of renal trauma. J Urol 1999;161(4):1088-92. http://www.ncbi.nlm.nih.gov/pubmed/10081844 Patel VG, Walker ML. The role of ‘one-shot’ intravenous pyelogram in evaluation of penetrating abdominal trauma. Am Surg 1997;63(4):350-3. http://www.ncbi.nlm.nih.gov/pubmed/9124757 Nagy KK, Brenneman FD, Krosner SM, Fildes JJ, Roberts RR, Joseph KT, Smith RF, Barrett J. Routine preoperative ‘one-shot’ intravenous pyelography is not indicated in all patients with penetrating abdominal trauma. J Am Coll Surg 1997;185(6):530-3. http://www.ncbi.nlm.nih.gov/pubmed/9404875 Steinberg DL, Jeffrey RB, Federle MP, McAninch JW. The computerized tomography appearance of renal pedicle injury. J Urol 1984;132(6):1163-4. http://www.ncbi.nlm.nih.gov/pubmed/6502811 Kawashima A, Sandler CM, Corl FM, West OC, Tamm EP, Fishman EK, Goldman SM. Imaging of renal trauma: a comprehensive review. Radiographics 2001;21(3):557-74. http://www.ncbi.nlm.nih.gov/pubmed/11353106 Shima H, Nosaka S, Hayakawa M, Kawaguchi H, Wakabayashi M, Saeki M, Yamaguchi T, Nakajima Y, Ishikawa T. [Diagnostic imaging of renal pedicle injury]. Nippon Igaku Hoshasen Gakkai Zasshi 1997;57(1):5-11. [article in Japanese] http://www.ncbi.nlm.nih.gov/pubmed/9038056 Vasile M, Bellin MF, Hélénon O, Mourey I, Cluzel P. Imaging evaluation of renal trauma. Abdom Imaging 2000;25(4):424-30. http://www.ncbi.nlm.nih.gov/pubmed/10926198 Brown SL, Hoffman DM, Spirnak JP. Limitations of routine spiral computerized tomography in the evaluation of blunt renal trauma. J Urol 1998;160(6Pt1):1979-81. http://www.ncbi.nlm.nih.gov/pubmed/9817304 Ortega SJ, Netto FS, Hamilton P, Chu P, Tien HC. CT scanning for diagnosing blunt ureteral and ureteropelvic junction injuries. BMC Urol 2008;8:3. http://www.ncbi.nlm.nih.gov/pubmed/18257927 Velmahos GC, Constantinou C, Tillou A, Brown CV, Salim A, Demetriades D. Abdominal computed tomographic scan for patients with gunshot wounds to the abdomen selected for nonoperative management. J Trauma 2005;59(5):1155-60; discussion 1160-1. http://www.ncbi.nlm.nih.gov/pubmed/16385294
Update march 2009
25
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
26
Leppäniemi A, Lamminen A, Tervahartiala P, Salo J, Haapiainen R, Lehtonen T. MRI and CT in blunt renal trauma: an update. Semin Ultrasound CT MR 1997;18(2):129-35. http://www.ncbi.nlm.nih.gov/pubmed/9163832 Ku JH, Jeon YS, Kim ME, Lee NK, Park YH. Is there a role for magnetic resonance imaging in renal trauma? Int J Urol 2001;8(6):261-7. http://www.ncbi.nlm.nih.gov/pubmed/11389740 Shariat SF, Trinh QD, Morey AF, Stage KH, Roehrborn CG, Valiquette L, Karakiewicz PI. Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma. J Trauma 2008;64(6):1451-8. http://www.ncbi.nlm.nih.gov/pubmed/18545108 Husmann DA, Gilling PJ, Perry MO, Morris JS, Boone TB. Major renal lacerations with a devitalized fragment following blunt abdominal trauma: a comparison between nonoperative (expectant) versus surgical management. J Urol 1993;150(6):1774-7. http://www.ncbi.nlm.nih.gov/pubmed/8230501 McAninch JW, Carroll PR, Klosterman PW, Dixon CM, Greenblatt MN. Renal reconstruction after injury. J Urol 1991;145(5):932-7. http://www.ncbi.nlm.nih.gov/pubmed/2016804 Armenakas NA, Duckett CP, McAninch JW. Indications for nonoperative management of renal stab wounds. J Urol 1999;161(3):768-71. http://www.ncbi.nlm.nih.gov/pubmed/10022681 Altman AL, Haas C, Dinchman KH, Spirnak JP. Selective nonoperative management of blunt grade 5 renal injury. J Urol 2000;164(1):27-30;discussion 30-1. http://www.ncbi.nlm.nih.gov/pubmed/10840417 Matthews LA, Smith EM, Spirnak JP. Nonoperative treatment of major blunt renal lacerations with urinary extravasation. J Urol 1997;157(6):2056-8. http://www.ncbi.nlm.nih.gov/pubmed/9146579 Moudouni SM, Hadj Slimen M, Manunta A, Patard JJ, Guiraud PH, Guillé F, Bouchot O, Lobel B. Management of major blunt renal lacerations: is a nonoperative approach indicated? Eur Urol 2001;40(4):409-14. http://www.ncbi.nlm.nih.gov/pubmed/11713395 Husmann DA, Morris JS. Attempted nonoperative management of blunt renal lacerations extending through the corticomedullary junction: the short-term and long-term sequelae. J Urol 1990;143(4): 682-4. http://www.ncbi.nlm.nih.gov/pubmed/2313792 Hammer CC, Santucci RA. Effect of an institutional policy of nonoperative treatment of grades I to IV renal injuries. J Urol 2003;169(5):1751-3. http://www.ncbi.nlm.nih.gov/pubmed/12686825 Robert M, Drianno N, Muir G, Delbos O, Guiter J. Management of major blunt renal lacerations: surgical or nonoperative approach? Eur Urol 1996;30(3):335-9. http://www.ncbi.nlm.nih.gov/pubmed/8931966 Nash PA, Bruce JE, McAninch JW. Nephrectomy for traumatic renal injuries. J Urol 1995;153(3 Pt 1):609-11. http://www.ncbi.nlm.nih.gov/pubmed/7861494 Gonzalez RP, Falimirski M, Holevar MR, Evankovich C. Surgical management of renal trauma: is vascular control necessary? J Trauma 1999;47(6):1039-42; discussion 1042-4. http://www.ncbi.nlm.nih.gov/pubmed/10608530 Atala A, Miller FB, Richardson JD, Bauer B, Harty J, Amin M. Preliminary vascular control for renal trauma. Surg Gynecol Obstet 1991;172(5):386-90. http://www.ncbi.nlm.nih.gov/pubmed/2028374 Davis KA, Reed RL 2nd, Santaniello J, Abodeely A, Esposito TJ, Poulakidas SJ, Luchette FA. Predictors of the need for nephrectomy after renal trauma. J Trauma 2006;60(1):164-9; discussion 169-70. http://www.ncbi.nlm.nih.gov/pubmed/16456451 Wright JL, Nathens AB, Rivara FP, Wessells H. Renal and extrarenal predictors of nephrectomy from the national trauma data bank. J Urol 2006;175(3Pt1):970-5; discussion 975. http://www.ncbi.nlm.nih.gov/pubmed/16469594 DiGiacomo JC, Rotondo MF, Kauder DR, Schwab CW. The role of nephrectomy in the acutely injured. Arch Surg 2001;136(9):1045-9. http://www.ncbi.nlm.nih.gov/pubmed/11529828
Update march 2009
74.
75. 76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
McAninch JW, Dixon CM, Carroll PR. [The surgical treatment of renal trauma]. Vestn Khir Im I I Grek 1990;145(11):64-72. [article in Russian] http://www.ncbi.nlm.nih.gov/pubmed/1966179 Shekarriz B, Stoller ML. The use of fibrin sealant in urology. J Urol 2002;167(3):1218-25. http://www.ncbi.nlm.nih.gov/pubmed/11832701 Sangthong B, Demetriades D, Martin M, Salim A, Brown C, Inaba K, Rhee P, Chan L. Management and hospital outcomes of blunt renal artery injuries: analysis of 517 patients from the National Trauma Data Bank. J Am Coll Surg 2006;203(5):612-17. http://www.ncbi.nlm.nih.gov/pubmed/17084321 Knudson MM, Harrison PB, Hoyt DB, Shatz DV, Zietlow SP, Bergstein JM, Mario LA, McAninch JW. Outcome after major renovascular injuries: a Western trauma association multicenter report. J Trauma 2000;49(6):1116-22. http://www.ncbi.nlm.nih.gov/pubmed/11130498 Tillou A, Romero J, Asensio JA, Best CD, Petrone P, Roldan G, Rojo E. Renal vascular injuries. Surg Clin North Am 2001;81(6):1417-30. http://www.ncbi.nlm.nih.gov/pubmed/11766183 el Khader K, Bouchot O, Mhidia A, Guillé F, Lobel B, Buzelin JM. [Injuries of the renal pedicle: is renal revascularization justified?]. Prog Urol 1998;8(6):995-1000. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/9894257 Elliott SP, Olweny EO, McAninch JW. Renal arterial injuries: a single center analysis of management strategies and outcomes. J Urol 2007;178(6):2451-5. http://www.ncbi.nlm.nih.gov/pubmed/17937955 Hagiwara A, Sakaki S, Goto H, Takenega K, Fukushima H, Matuda H, Shimazaki S. The role of interventional radiology in the management of blunt renal injury: a practical protocol. J Trauma 2001;51(3):526-31. http://www.ncbi.nlm.nih.gov/pubmed/11535904 Mohsen T, El-Assmy A, El-Diasty T. Long-term functional and morphological effects of transcatheter arterial embolization of traumatic renal vascular injury. BJU Int 2008;101(4):473-7. http://www.ncbi.nlm.nih.gov/pubmed/17941919 Velmahos GC, Chahwan S, Falabella A, Hanks SE, Demetriades D. Angiographic embolization for intraperitoneal and retroperitoneal injuries. World J Surg 2000;24(5):539-45. http://www.ncbi.nlm.nih.gov/pubmed/10787073 Sofocleous CT, Hinrichs C, Hubbi B, Brountzos E, Kaul S, Kannarkat G, Bahramipour P, Barone A, Contractor DG, Shah T. Angiographic findings and embolotherapy in renal arterial trauma. Cardiovasc Intervent Radiol 2005;28(1):39-47. http://www.ncbi.nlm.nih.gov/pubmed/15602636 Breyer BN, McAninch JW, Elliott SP, Master VA. Minimally invasive endovascular techniques to treat acute renal hemorrhage. J Urol 2008; 179(6):2248-52; discussion 2253. http://www.ncbi.nlm.nih.gov/pubmed/18423679 Schmidlin FR, Rohner S, Hadaya K, Iselin CE, Vermeulen B, Khan H, Farshad M, Niederer P, Graber P. [The conservative treatment of major kidney injuries]. Ann Urol (Paris) 1997;31(5):246-52. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/9480627 el Khader K, Mhidia A, Ziade J, Patard JJ, Guillé F, Lobel B. [Conservative treatment of stage III kidney injuries]. Acta Urol Belg 1998;66(4):25-8. [article in French] http://www.ncbi.nlm.nih.gov/pubmed/10083630 Thall EH, Stone NN, Cheng DL, Cohen EL, Fine EM, Leventhal I, Aldoroty RA. Conservative management of penetrating and blunt Type III renal injuries. Br J Urol 1996;77(4):512-7. http://www.ncbi.nlm.nih.gov/pubmed/8777609 Cheng DL, Lazan D, Stone N. Conservative treatment of type III renal trauma. J Trauma 1994;36(4):491-4. http://www.ncbi.nlm.nih.gov/pubmed/8158708 Alsikafi NF, McAninch JW, Elliott SP, Garcia M. Nonoperative management outcomes of isolated urinary extravasation following renal lacerations due to external trauma. J Urol 2006;176(6Pt1):2494-7. http://www.ncbi.nlm.nih.gov/pubmed/17085140 Buckley JC, McAninch JW. Selective management of isolated and nonisolated grade IV renal injuries. J Urol 2006;176(6Pt1):2498-502; discussion 2502. http://www.ncbi.nlm.nih.gov/pubmed/17085141
Update march 2009
27
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
28
Santucci RA, McAninch JM. Grade IV renal injuries: evaluation, treatment, and outcome. World J Surg 2001;25(12):1565-72. http://www.ncbi.nlm.nih.gov/pubmed/11775193 Shariat SF, Jenkins A, Roehrborn CG, Karam JA, Stage KH, Karakiewicz PI. Features and outcomes of patients with grade IV renal injury. BJU Int 2008;102(6):728-33; discussion 733. http://www.ncbi.nlm.nih.gov/pubmed/18435808 Velmahos GC, Demetriades D, Cornwell EE 3rd, Belzberg H, Murray J, Asensio J, Berne TV. Selective management of renal gunshot wounds. Br J Surg 1998;85(8):1121-4. http://www.ncbi.nlm.nih.gov/pubmed/9718011 Baniel J, Schein M. The management of penetrating trauma to the urinary tract. J Am Coll Surg 1994;178(4):417-25. http://www.ncbi.nlm.nih.gov/pubmed/8149045 DuBose J, Inaba K, Teixeira PG, Pepe A, Dunham MB, McKenney M. Selective non-operative management of solid organ injury following abdominal gunshot wounds. Injury 2007;38(9):1084-90. http://www.ncbi.nlm.nih.gov/pubmed/17544428 Wessells H, Deirmenjian J, McAninch JW. Preservation of renal function after reconstruction for trauma: quantitative assessment with radionuclide scintigraphy. J Urol 1997;157(5):1583-6. http://www.ncbi.nlm.nih.gov/pubmed/9112481 Shefler A, Gremitzky A, Vainrib M, Tykochinsky G, Shalev M, Richter S, Erlich N, Schiwartz I, Leibovitch I. [The role of nonoperative management of penetrating renal trauma]. Harefuah 2007;146(5):345-8, 406-7. [article in Hebrew.] http://www.ncbi.nlm.nih.gov/pubmed/17674549 Bernath AS, Schutte H, Fernandez RR, Addonizio JC. Stab wounds of the kidney: conservative management in flank penetration. J Urol 1983;129(3):468-70. http://www.ncbi.nlm.nih.gov/pubmed/6834529 Wessells H, McAninch JW, Meyer A, Bruce J. Criteria for nonoperative treatment of significant penetrating renal lacerations. J Urol 1997;157(1):24-7. http://www.ncbi.nlm.nih.gov/pubmed/8976207 Blankenship JC, Gavant ML, Cox CE, Chauhan RD, Gingrich JR. Importance of delayed imaging for blunt renal trauma. World J Surg 2001;25(12):1561-4. http://www.ncbi.nlm.nih.gov/pubmed/11775192 Dunfee BL, Lucey BC, Soto JA. Development of renal scars on CT after abdominal trauma: does grade of injury matter? AJR Am J Roentgenol 2008;190(5):1174-9. http://www.ncbi.nlm.nih.gov/pubmed/18430828 Pruthi RS, Issa MM, Kabalin JN, Terris MK. Renal masses presenting 25 and 50 years following blunt renal trauma. Urol Int 1998;61(1):43-6. http://www.ncbi.nlm.nih.gov/pubmed/9792983 Heyns CF, van Vollenhoven P. Increasing role of angiography and segmental artery embolization in the management of renal stab wounds. J Urol 1992;147(5):1231-4. http://www.ncbi.nlm.nih.gov/pubmed/1569655 Monstrey SJ, Beerthuizen GI, vander Werken C, Debruyne FM, Goris RJ. Renal trauma and hypertension. J Trauma 1989;29(1):65-70. http://www.ncbi.nlm.nih.gov/pubmed/2911106 Lebech A, Strange-Vognsen HH. [Hypertension following blunt kidney injury]. Ugeskr Laeger 1990;152(14):994-7. [article in Danish] http://www.ncbi.nlm.nih.gov/pubmed/2183457 Montgomery RC, Richardson JD, Harty JI. Posttraumatic renovascular hypertension after occult renal injury. J Trauma 1998;45(1):106-10. http://www.ncbi.nlm.nih.gov/pubmed/9680021 Chedid A, Le Coz S, Rossignol P, Bobrie G, Herpin D, Plouin PF. Blunt renal trauma-induced hypertension: prevalence, presentation, and outcome. Am J Hypertens 2006;19(5):500-4. http://www.ncbi.nlm.nih.gov/pubmed/16647623 Haas CA, Reigle MD, Selzman AA, Elder JS, Spirnak JP. Use of ureteral stents in the management of major renal trauma with urinary extravasation: is there a role?. J Endourol 1998;12(6):545-9. http://www.ncbi.nlm.nih.gov/pubmed/9895260 Wang KT, Hou CJ, Hsieh JJ, Chou YS, Tsai CH. Late development of renal arteriovenous fistula following gunshot trauma – a case report. Angiology 1998;49(5):415-18. http://www.ncbi.nlm.nih.gov/pubmed/9591535
Update march 2009
111.
112.
113.
114.
115.
116. 117. 118.
119.
120.
121.
122.
123.
124.
125. 126.
127.
128.
129.
Franco de Castro A, Gibanel Garanto R, Real MI, Rodríguez Casado A, Cetina Herrando A, Gutiérrez del Pozo R, Montanyà X, Vázquez F, Alcover García JB. [Selective embolization of post-traumatic renal pseudoaneurysm in monorenal patient]. Actas Urol Esp 2001;25(1):64-6. [article in Spanish] http://www.ncbi.nlm.nih.gov/pubmed/11284371 Miller DC, Forauer A, Faerber GJ. Successful angioembolization of renal artery pseudoaneurysms after blunt abdominal trauma. Urology 2002;59(3):444. http://www.ncbi.nlm.nih.gov/pubmed/11880095 Harrington TG, Kandel LB. Renal colic following a gunshot wound to the abdomen: the birdshot calculus. J Urol 1997;157(4):1351-2. http://www.ncbi.nlm.nih.gov/pubmed/9120940 Park JK, Yang SO, Park SC. Duodenal obstruction by retroperitoneal hematoma induced by severe blunt renal trauma. J Urol 2001;165(6Pt1):1993-4. http://www.ncbi.nlm.nih.gov/pubmed/11371904 McAleer IM, Kaplan GW, Scherz HC, Packer MG, Lynch FP. Genitourinary trauma in the pediatric patient. Urology 1993;42(5):563-7; discussion 567-8. http://www.ncbi.nlm.nih.gov/pubmed/8236601 Morse TS: Renal injuries. Pediatr Clin North Am 1975;22(2):379-91. http://www.ncbi.nlm.nih.gov/pubmed/1124221 Elshihabi I, Elshihabi S, Arar M. An overview of renal trauma. Curr Opin Pediatr 1998;10(2):162-6. http://www.ncbi.nlm.nih.gov/pubmed/9608894 Brown SL, Elder JS, Spirnak JP. Are pediatric patients more susceptible to major renal injury from blunt trauma? A comparative study. J Urol 1998;160(1):138-40. http://www.ncbi.nlm.nih.gov/pubmed/9628634 Chopra P, St-Vil D, Yazbeck S. Blunt renal trauma-blessing in disguise?. J Pediatr Surg 2002;37(5):779-82. http://www.ncbi.nlm.nih.gov/pubmed/11987100 Quinlan DM, Gearhart JP. Blunt renal trauma in childhood. Features indicating severe injury. Br J Urol 1990;66(5):526-31. http://www.ncbi.nlm.nih.gov/pubmed/2249124 Angus LD, Tachmes L, Kahn S, Gulmi F, Gintautas J, Shaftan GW. Surgical management of pediatric renal trauma: an urban experience. Am Surg 1993;59(6):388-94. http://www.ncbi.nlm.nih.gov/pubmed/8507066 Stalker HP, Kaufman RA, Stedje K. The significance of hematuria in children after blunt abdominal trauma. AJR Am J Roentgenol 1990;154(3):569-71. http://www.ncbi.nlm.nih.gov/pubmed/2106223 Stein JP, Kaji DM, Eastham J, Freeman JA, Esrig D, Hardy BE. Blunt renal trauma in the pediatric population: indications for radiographic evaluation. Urology 1994;44(3):406-10. http://www.ncbi.nlm.nih.gov/pubmed/8073555 Morey AF, Bruce JE, McAninch JW. Efficacy of radiographic imaging in pediatric blunt renal trauma. J Urol 1996;156(6):2014-18. http://www.ncbi.nlm.nih.gov/pubmed/8911380 Nguyen MM, Das S. Pediatric renal trauma. Urology 2002;59(5):762-6; discussion 766-7. http://www.ncbi.nlm.nih.gov/pubmed/11992916 Santucci RA, Langenburg SE, Zachareas MJ. Traumatic hematuria in children can be evaluated as in adults. J Urol 2004;171(2Pt1):822-5. http://www.ncbi.nlm.nih.gov/pubmed/14713834 Luks FI, Lemire A, St-Vil D, Di Lorenzo M, Filiatrault D, Ouimet A. Blunt abdominal trauma in children: the practical value of ultrasonography. J Trauma 1993;34(5):607-10; discussion 610-1. http://www.ncbi.nlm.nih.gov/pubmed/8496996 Wessel LM, Jester I, Scholz S, Arnold R, Lorenz C, Wirth H, Waag KL. [Diagnostic and therapeutic consequences of kidney injuries in pediatric blunt abdominal trauma]. Urologe A 2000;39(5):425-31. [article in German] http://www.ncbi.nlm.nih.gov/pubmed/11045043 Perez-Brayfield MR, Gatti JM, Smith EA, Broecker B, Massad C, Scherz H, Kirsch AJ. Blunt traumatic hematuria in children. Is a simplified algorithm justified?. J Urol 2002;167(6):2543-6; discussion 2546-7. http://www.ncbi.nlm.nih.gov/pubmed/11992085
Update march 2009
29
130.
131.
132. 133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
30
Mayor B, Gudinchet F, Wicky S, Reinberg O, Schnyder P. Imaging evaluation of blunt renal trauma in children: diagnostic accuracy of intravenous pyelography and ultrasonography. Pediatr Radiol 1995;25(3):214-8. http://www.ncbi.nlm.nih.gov/pubmed/7644308 Turnock RR, Sprigg A, Lloyd DA. Computed tomography in the management of blunt abdominal trauma in children. Br J Surg 1993;80(8):982-4. http://www.ncbi.nlm.nih.gov/pubmed/8402096 Carpio F, Morey AF. Radiographic staging of renal injuries. World J Urol 1999;17(2):66-70. http://www.ncbi.nlm.nih.gov/pubmed/10367363 Takeda M, Katayama Y, Tsutsui T, Takahashi H, Komeyama T, Mizusawa T, Sato S. Value of dimercaptosuccinic acid single photon emission computed tomography and magnetic resonance imaging in detecting renal injury in pediatric patients with vesicoureteral reflux. Comparison with dimercaptosuccinic acid planar scintigraphy and intravenous pyelography. Eur Urol 1994;25(4):320-5. http://www.ncbi.nlm.nih.gov/pubmed/8056025 Levy JB, Baskin LS, Ewalt DH, Zderic SA, Bellah R, Snyder HM 3rd, Templeton J, Duckett JW. Nonoperative management of blunt pediatric major renal trauma. Urology 1993;42(4):418-24. http://www.ncbi.nlm.nih.gov/pubmed/8212441 Buckley JC, McAninch JW. Pediatric renal injuries: management guidelines from a 25-year experience. J Urol 2004;172(2):687-90; discussion 690. http://www.ncbi.nlm.nih.gov/pubmed/15247762 Henderson CG, Sedberry-Ross S, Pickard R, Bulas DI, Duffy BJ, Tsung D, Eichelberger MR, Belman AB, Rushton HG. Management of high grade renal trauma: 20-year experience at a pediatric level I trauma center. J Urol 2007;178(1):246-50; discussion 250. http://www.ncbi.nlm.nih.gov/pubmed/17499798 Broghammer JA, Langenburg SE, Smith SJ, Santucci RA. Pediatric blunt renal trauma: its conservative management and patterns of associated injuries. Urology 2006;67(4):823-7. http://www.ncbi.nlm.nih.gov/pubmed/16566992 Cannon GM Jr, Polsky EG, Smaldone MC, Gaines BA, Schneck FX, Bellinger MF, Docimo SG, Wu HY. Computerized tomography findings in pediatric renal trauma – indications for early intervention? J Urol 2008;179(4):1529-32; discussion 1532-3. http://www.ncbi.nlm.nih.gov/pubmed/18295268 Nance ML, Holmes JH 4th, Wiebe DJ. Timeline to operative intervention for solid organ injuries in children. J Trauma 2006;61(6):1389-92. http://www.ncbi.nlm.nih.gov/pubmed/17159681 Holmes JH 4th, Wiebe DJ, Tataria M, Mattix KD, Mooney DP, Scaife ER, Brown RL, Groner JI, Brundage SI, Tres Scherer LR 3rd, Nance ML. The failure of nonoperative management in pediatric solid organ injury: a multi-institutional experience. J Trauma 2005;59(6):1309-13. http://www.ncbi.nlm.nih.gov/pubmed/16394902 Surana R, Khan A, Fitzgerald RJ. Scarring following renal trauma in children. Br J Urol 1995;75(5): 663-5. http://www.ncbi.nlm.nih.gov/pubmed/7613804 Kansas BT, Eddy MJ, Mydlo JH, Uzzo RG. Incidence and management of penetrating renal trauma in patients with multiorgan injury: extended experience at an inner city trauma center. J Urol 2004;172(4Pt1):1355-60. http://www.ncbi.nlm.nih.gov/pubmed/15371841 Rosen MA, McAninch JW. Management of combined renal and pancreatic trauma. J Urol 1994;152(1):22-5. http://www.ncbi.nlm.nih.gov/pubmed/8201670 Wessells H, McAninch JW. Effect of colon injury on the management of simultaneous renal trauma. J Urol 1996;155(6):1852-6. http://www.ncbi.nlm.nih.gov/pubmed/8618272 Sartorelli KH, Frumiento C, Rogers FB, Osler TM. Nonoperative management of hepatic, splenic, and renal injuries in adults with multiple injuries. J Trauma. 2000;49(1):56-61; discussion 61-2. http://www.ncbi.nlm.nih.gov/pubmed/10912858 Cass AS, Luxenberg M, Gleich P, Smith C. Deaths from urologic injury due to external trauma. J Trauma 1987;27(3):319-21. http://www.ncbi.nlm.nih.gov/pubmed/3560276 Morris CS, Bonnevie GJ, Najarian KE. Nonsurgical treatment of acute iatrogenic renal artery injuries occurring after renal artery angioplasty and stenting. AJR Am J Roentgenol 2001;177(6):1353-7. http://www.ncbi.nlm.nih.gov/pubmed/11717082
Update march 2009
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
Bates MC, Shamsham FM, Faulknier B, Crotty B. Successful treatment of iatrogenic renal artery perforation with an autologous vein-covered stent. Catheter Cardiovasc Interv 2002;57(1):39-43. http://www.ncbi.nlm.nih.gov/pubmed/12203925 Oderich GS, Panneton JM, Hofer J, Bower TC, Cherry KJ Jr, Sullivan T, Noel AA, Kalra M, Gloviczki P. Iatrogenic operative injuries of abdominal and pelvic veins: a potentially lethal complication. J Vasc Surg 2004;39(5):931-6. http://www.ncbi.nlm.nih.gov/pubmed/15111840 Taneja M, Tan KT. Renal vascular injuries following nephron-sparing surgery and their endovascular management. Singapore Med J 2008;49(1):63-6. http://www.ncbi.nlm.nih.gov/pubmed/18204772 Barone GW, Sailors DM, Hudec WA, Ketel BL. Trauma management in solid organ transplant recipients. J Emerg Med 1997;15(2):169-76. http://www.ncbi.nlm.nih.gov/pubmed/9144057 Del Pizzo JJ, Jacobs SC, Sklar GN. Ureteroscopic evaluation in renal transplant recipients. J Endourol 1998;12(2):135-8. http://www.ncbi.nlm.nih.gov/pubmed/9607439 Dorffner R, Thurnher S, Prokesch R, Bankier A, Turetschek K, Schmidt A, Lammer J. Embolization of iatrogenic vascular injuries of renal transplants: immediate and follow-up results. Cardiovasc Intervent Radiol 1998;21(2):129-34. http://www.ncbi.nlm.nih.gov/pubmed/9502679 Cowan NC, Traill ZC, Phillips AJ, Gleeson FV. Direct percutaneous transrenal embolization for renal artery injury following percutaneous nephrostomy. Br J Radiol 1998;71(851):1199-201. http://www.ncbi.nlm.nih.gov/pubmed/10434916 Jones CD, McGahan JP. Computed tomographic evaluation and guided correction of malpositioned nephrostomy catheters. Abdom Imaging 1999;24(4):422-5. http://www.ncbi.nlm.nih.gov/pubmed/10390572 Lewis S, Patel U. Major complications after percutaneous nephrostomy – lessons from a department audit. Clin Radiol 2004;59(2):171-9. http://www.ncbi.nlm.nih.gov/pubmed/14746788 Ozdemir S, Cekirge S, Kara A, Bakkaloğlu A. A rare complication of renal biopsy in a child with membranoproliferative glomerulonephritis. Int Urol Nephrol 1998;30(6):689-92. http://www.ncbi.nlm.nih.gov/pubmed/10195861 Silberzweig JE, Tey S, Winston JA, Mitty HA. Percutaneous renal biopsy complicated by renal capsular artery pseudoaneurysm. Am J Kidney Dis 1998;31(3):533-5. http://www.ncbi.nlm.nih.gov/pubmed/9506693 Ghai B, Dureja GP, Arvind P. Massive intraabdominal extravasation of fluid: a life threatening complication following percutaneous nephrolithotomy. Int Urol Nephrol 2003;35(3):315-18. http://www.ncbi.nlm.nih.gov/pubmed/15160530 Gupta M, Bellman GC, Smith AD. Massive hemorrhage from renal vein injury during percutaneous renal surgery: endourological management. J Urol 1997;157(3):795-7. http://www.ncbi.nlm.nih.gov/pubmed/9072568 Bellman GC. Complications of endopyelotomy. J Endourol 1996;10(2):177-81. http://www.ncbi.nlm.nih.gov/pubmed/8728685
3. URETERAL TRAUMA 3.1 Introduction The ureter is the sole conduit for urinary transport between the kidney and the bladder. Thus, any ureteral injury can threaten the function of the ipsilateral kidney. This small, mobile, worm-like, peristalsing, urotheliallined tube runs inferiorly from the renal pelvis in the retroperitoneal space. It lies anterior to the muscles of the posterior abdominal wall and lateral to the vertebral column, before descending into the bony ring of the pelvis to enter the bladder. Any external injury to the flank or back and any calamity within the bony pelvis therefore places the ureter at risk. Perhaps because of its protected location, its small size and its mobility, trauma to the ureter is relatively rare and accounts for only 1% of all urinary tract trauma. Thus, there is a relatively small volume of published clinical experience upon which to base recommendations of management.
Update march 2009
31
3.2 Aetiology The largest and most contemporary review of ureteral trauma in the European literature is from Dobrowolski et al. in Poland (1). These authors retrospectively analyzed the records of patients with upper urinary tract injuries presenting to 61 urology departments between 1995 and 1999. They identified 452 ureteral injuries. Of these, 340 (75%) were iatrogenic, 81 (18%) were from blunt trauma, and 31 (7%) were from penetrating trauma. Of the 340 iatrogenic injuries, 247 (73%) were gynaecological in origin, 46 (14%) were general surgical and 47 (14%) were urological. It is therefore important to note that ureteral injury is much more likely to occur from activity within a hospital rather than from injuries sustained outside. Dobrowolski et al. estimate the frequency of ureteral injury during gynaecological pelvic surgical procedures to be 1.6 per 1000 (1). Of the total ureteral injuries identified, the injury was in the upper third in 60 cases (13%), in the middle third in 61 cases (13%), and in the lower third in 331 (74%). The median time to diagnosis was 3.3 h. The most common diagnostic investigation was intravenous urography (IVU), which was used in 244 patients; retrograde ureteropyelography was used in 98 patients; and ureteral catheterization was used in 125. The diagnosis was also established at open surgery in 104 patients. This snapshot of ureteral trauma in a modern European setting is similar to that seen in the USA (2).
3.3 Diagnosis 3.3.1 Clinical diagnosis There are no classic clinical symptoms and signs associated with acute ureteral trauma caused by external injury (3). In view of this, the diagnosis must be one of suspicion. Ureteral trauma should be suspected in all cases of penetrating abdominal injury, especially gunshot wounds, and also in cases of blunt deceleration trauma, in which the kidney and renal pelvis can be torn away from the ureter. This deceleration injury is more likely to occur in children because of their hyperextensible vertebral column (4). Haematuria is also a poor indicator of injury, as it is present in only half of those with ureteral trauma (5). It is possible for isolated ureteral injuries to be missed. Such patients tend to present with subsequent evidence of upper tract obstruction, urinary fistula formation and sepsis (6). After gynaecological pelvic surgery, any woman who complains of flank pain, develops vaginal leakage of urine or becomes septic should also be suspected of having injury to the ureter or bladder and should be investigated appropriately. At surgery, when the ureter is explored to exclude injury, the use of intravenous indigo carmine or methylene blue is to be recommended. This will help reveal the site of injury by leakage of blue-stained urine. This is especially important in partial tears. 3.3.2 Radiological diagnosis Ureteral injury may cause radiological signs of upper urinary tract obstruction but the sine qua non of ureteral injury is extravasation of radiological contrast material (3). This sign can be produced by the use of intravenous pyelography (IVP), giving 2 mg of contrast material per kilogram of body weight. However, because of the increasing use of computed tomography (CT) scanning in polytraumatized patients, the diagnosis is increasingly made with this modality. If a high suspicion of ureteral injury exists and the CT scan is non-diagnostic, then a ‘poor man’s IVP’can be obtained by taking a plain kidney-ureter-bladder (KUB) film 30 minutes after intravenous injection of CT contrast medium. If this is also non-diagnostic and a suspicion of injury still exists, then retrograde pyelography should be undertaken as the gold standard investigation.
3.4
Classification
The American Association for the Surgery of Trauma has classified ureteral injuries as shown in Table 4 (7). Table 4: Classification of ureteral injury Grade I II III IV V
3.5
Description of injury Haematoma only Laceration < 50% of circumference Laceration > 50% of circumference Complete tear < 2 cm of devascularization Complete tear > 2 cm of devascularization
Management
3.5.1 Partial injuries These can be defined as grade I to II lesions. Once recognized, they can be managed with ureteral stenting or by placement of a nephrostomy tube to divert urine (3). There is no prospective clinical trial comparing outcomes between these techniques. We believe that ureteral stenting is probably superior because a stent
32
Update march 2009
across the injury will allow secure drainage of the kidney, as well as providing canalization and stabilization of the injury. We believe that this will reduce the subsequent risk of stricture. The stent may be placed in an antegrade or retrograde fashion. In all cases, fluoroscopy and ureteropyelography with radio-opaque contrast should be used to guide stent placement. The procedure should commence with the passage of a hydrophilic atraumatic guidewire across the damaged segment of ureter. Once across the site of the injury, an access catheter can be backloaded over the wire and passed across the injury. The hydrophilic wire can then be exchanged for a 0.038-inch wire, and the stent deployed. If this technique is utilized, a bladder catheter should be left in place for 2 days to limit stent reflux during voiding until mucosal healing has begun. The stent should be left in place for at least 3 weeks. The patient should have a follow-up dynamic renogram and IVP between 3 and 6 months, or sooner if lateralizing flank pain develops. If there is evidence of stricture, then this should be managed by endo-urological or open surgical techniques, as appropriate. If a grade II or III injury is encountered during immediate surgical exploration of an iatrogenic injury, then primary closure of the ureteral ends over a stent may be recommended, with placement of an external, non suction drain adjacent to the injury. 3.5.2 Complete injuries These are grade III to V injuries. Successful repair should utilize the principles outlined in Table 5. Table 5: Principles of repair of complete injury • • • • • •
Debridement of ureteral ends to fresh tissue Spatulation of ureteral ends Placement of internal stent Watertight closure of reconstructed ureter with absorbable suture Placement of external, non-suction drain Isolation of injury with peritoneum or omentum
The type of reconstructive repair procedure chosen by the surgeon depends on the nature and site of the injury (3). The options are depicted in Figure 4. Figure 4: Diagram of the options for repair of complete injuries, based on the site of the injury
Upper third:
Uretero-ureterostomy Transuretero-ureterostomy Ureterocalycostomy
Middle third:
Uretero-ureterostomy Transuretero-ureterostomy Boari flap and reimplantation
Lower third:
Direct reimplantation Psoas hitch Blandy cystoplasty
Complete:
Ileal interposition Autotransplantation
3.5.3 Sterile surgery 3.5.3.1 Uretero-ureterostomy Using the principles outlined above, the ureteral ends are debrided and freshened. The ends are spatulated.
Update march 2009
33
An internal JJ stent is inserted and the ends are closed over the stent using an interrupted 4/0 vicryl suture. An external, non-suction drain is placed at the site of the injury, and a catheter is left in the bladder. The bladder catheter can be removed after 2 days. The wound drain can be removed 2 days later if drainage is low. The stent should be removed after 6 weeks, and a follow-up renogram and IVP should be obtained after 3 months to assess the patency of the repair. 3.5.3.2 Ureterocalycostomy In cases were the pelvi-ureteral junction has been destroyed, the lower pole of the affected kidney can be amputated to expose the lower pole infundibulum and calyces. The distal ureteral end can then be debrided and spatulated, and anastomosed to the lower pole calyx, over an internal stent, using an interrupted 4/0 vicryl suture. An external, non-suction drain is placed at the site of the injury and a catheter is left in the bladder. The bladder catheter can be removed after 2 days. The wound drain can be removed 2 days later if drainage is low. The stent should be removed after 6 weeks and a follow-up renogram and IVP should be obtained after 3 months to assess the patency of the repair. 3.5.3.3 Transuretero-ureterostomy The distal end of the injured ureter is ligated with an absorbable suture. The proximal end is debrided and spatulated. This end is then transposed across the midline through a retroperitoneal window above the level of the inferior mesenteric artery. A 1.5 cm ureterotomy is made on the medial aspect of the contralateral ureter. A stent is placed from the ipsilateral kidney, through the anastomosis, and down the distal contralateral ureter into the bladder. A watertight anastomosis is fashioned using an interrupted 4/0 vicryl suture. An external, nonsuction drain is placed at the site of the injury, and a catheter is left in the bladder. The bladder catheter can be removed after 2 days. The wound drain can be removed 2 days later if drainage is low. The stent should be removed after 6 weeks, and a follow-up renogram and IVP should be obtained after 3 months to assess the patency of the repair. 3.5.3.4 Ureteroneocystostomy with Boari flap The proximal ureteral end is debrided and spatulated. A traction suture is placed. The distal ureteral end is ligated with an absorbable suture. The bladder is filled with 200-300 ml of normal saline via a urethral catheter, and controlling stay sutures are placed on the bladder. The L-shaped flap is raised, its base being approximately four times wider than the width of the ureter to be implanted. The ureter is pulled through a submucosal tunnel in the flap and secured to the bladder mucosa using an interrupted 4/0 vicryl suture. Anchoring sutures can be placed at the serosal aspect of the ureter to secure it to the bladder. A stent is placed across the neo-ureterocystostomy, and a suprapubic catheter is placed in the bladder. The bladder is then closed in two layers with 2/0 vicryl sutures. An external, non-suction drain should be placed at the site of the reimplant; it can be removed after 2 days. The urethral catheter can be removed at the same time. The suprapubic catheter can be removed after a cystogram at 2 weeks, and the stent can be removed after 6 weeks. An IVP and renogram should be obtained 3 months thereafter to confirm the patency of the neocystostomy. 3.5.3.5 Ureterocystostomy and psoas hitch The proximal ureteral end is debrided and spatulated. A traction suture is placed. The distal ureteral end is ligated with an absorbable suture. The fundus of the bladder is mobilized, and the contralateral superior vesical pedicle may be divided to improve fundal mobility. The bladder is filled with 200-300 ml of normal saline via a urethral catheter, and controlling stay sutures are placed. A cystotomy (Blandy) is performed perpendicular to the line of the ureter. Two fingers are placed inside the bladder to stretch it gently towards the ipsilateral psoas tendon. Three non-absorbable 2/0 sutures are placed between the bladder wall and the tendon, with care being taken to avoid the genitofemoral nerve. Ureteroneocystostomy is then undertaken using either the Leadbetter-Politano or Lich-Gregoire techniques. A JJ stent is placed across the reimplant, and a suprapubic catheter is placed in the bladder. The bladder is then closed in two layers with 2/0 vicryl in the line of the ureter, thus providing extra length to the hitch. The anastomosis is thus under no tension. An external, non-suction drain should be placed at the site of the reimplant, and can be removed after 2 days. The urethral catheter can be removed at the same time. The suprapubic catheter can be removed after a cystogram at 2 weeks, and the stent can be removed after 6 weeks. An IVP and renogram should be obtained 3 months thereafter to confirm the patency of the neocystostomy. 3.5.3.6 Ileal interposition graft In cases of long segment ureteral destruction, the ureter can be totally replaced using the distal ileum. This should be avoided in patients with coincidental gastrointestinal disease, such as Crohn’s disease, and in
34
Update march 2009
patients with impaired renal function. A 25-cm length of ileum is taken out of bowel continuity about 20 cm proximal to the ileocaecal valve. Gastrointestinal continuity is restored with an ileo-ileal anastomosis using interrupted 3/0 seromuscular vicryl. The mesenteric is repaired using 2/0 vicryl. The ileal segment is placed in the isoperistaltic orientation between the renal pelvis and the bladder. Ileo-pelvic and cysto-ileal end-to-end anastomoses are fashioned using 2/0 vicryl. A nephrostomy tube should be inserted into the ipsilateral kidney to decompress the affected upper tract. A catheter should be placed in the bladder. External, non-suction drains should cover the proximal and distal anastomoses. Lastly, the reconstruction should be wrapped in omentum. The wound drains can be removed after 2 days. A nephrostogram should be performed after 3 weeks; if no leakage is demonstrated, the nephrostomy can be clamped and then removed. Finally, the urinary catheter can be removed. Follow-up should include IVP and renography at 3 months, together with testing for the levels of serum creatinine, chloride, bicarbonate and base excess, looking for evidence of hyperchloraemic metabolic acidosis. 3.5.3.7 Autotransplantation If complete ureteral disruption should occur in the presence of coincidental gastrointestinal disease or impaired renal function, then autotransplantation of the affected renal unit can be undertaken. The renal artery and vein are divided long at the aorta and cava. The kidney is moved to the pelvis, and vascular continuity is restored using 5/0 prolene for the artery and 4/0 prolene for the vein. A Lich-Gregoire extravesical neoureterocystostomy can then be fashioned to re-establish urinary drainage. This need not be stented. A covering external, non-suction drain should be placed, and a catheter inserted in the bladder. The drain can be removed after 2 days, if dry, and the catheter removed after a cystogram at 2 weeks. Again, follow-up at 3 months with IVP and renogram is recommended. 3.5.3.8 Nephrectomy There is one circumstance in which immediate nephrectomy should be undertaken. This is when ureteral injury complicates the repair of an abdominal aortic aneurysm or other vascular procedure in which a vascular prosthesis is to be implanted. We feel that immediate excision of the corrupted renal unit and its damaged ureter leads to less chance of urinary leak, urinoma, sepsis and graft infection.
3.6 REFERENCES 1.
2.
3. 4.
5.
6.
7.
Dobrowolski Z, Kusionowicz J, Drewniak T, Habrat W, Lipczynski W, Jakubik P and Weglarz W. Renal and ureteric trauma: diagnosis and management in Poland. BJU Int 2002;89(7):748-51. http://www.ncbi.nlm.nih.gov/pubmed/11966637 Palmer LS, Rosenbaum RR, Gershbaum MD, Kreutzer ER. Penetrating ureteral trauma at an urban trauma center: 10-year experience. Urology 1999;54(1):34-6. http://www.ncbi.nlm.nih.gov/pubmed/10414723 Armenakas NA. Ureteral trauma: surgical repair. Atlas Urol Clin North Am 1998;6:71-84. Morey AF, Bruce JE, McAninch JW. Efficacy of radiographic imaging in pediatric blunt renal trauma. J Urol 1996;156(6):2014-8. http://www.ncbi.nlm.nih.gov/pubmed/8911380 Medina D, Lavery R, Ross SE, Livingston DH. Ureteral trauma: preoperative studies neither predict injury nor prevent missed injuries. J Am Coll Surg 1998;186(6):641-4. http://www.ncbi.nlm.nih.gov/pubmed/9632150 McGinty DM, Mendez R. Traumatic ureteral injuries with delayed recognition. Urology 1997;10(2): 115-7. http://www.ncbi.nlm.nih.gov/pubmed/898448 Moore EE, Cogbill TH, Jurkovitch GJ, McAninch JW, Champion HR, Gennarelli TA, Malangoni MA, Shackford SR, Trafton PG. Organ injury scaling. III: Chest wall, abdominal vascular, ureter, bladder, and urethra. J Trauma 1992;33(3):337-9. http://www.ncbi.nlm.nih.gov/pubmed/1404499
4. BLADDER TRAUMA 4.1 Background Among abdominal injuries that require surgical repair, 2% involve the bladder (1). Blunt or penetrating trauma account for 67-86% and 14-33% of bladder ruptures, respectively (2-4). Motor vehicle accidents are the
Update march 2009
35
most common cause (90%) of bladder ruptureby blunt trauma is (5-7). In the setting of blunt trauma, bladder rupture may be classified as either extraperitoneal with leakage of urine limited to the perivesical space, or intraperitoneal, in which the peritoneal surface has been disrupted, with concomitant urinary extravasation. Bladder trauma: facts and figures • 70-97% of patients with bladder injuries caused by blunt trauma have associated pelvic fractures (3, 8, 9). • Pubic symphysis diastasis, sacroiliac diastasis, and sacral, iliac, and pubic rami fractures are significantly associated with bladder rupture, whereas isolated acetabular fractures are not (10, 11). • > 50% of the associated pelvic fractures are of the pubic ramus (12). • Up to 30% of patients with pelvic fractures will have some degree of bladder injury (13). • Major bladder injury occurs in only 5-10% of patients who have pelvic fracture(s) (7, 14). • > 85% of patients with pelvic fractures have associated injuries in other organ systems (8), with a mortality rate of 22-44% (12, 13, 15). • Approximately 25% of intraperitoneal bladder ruptures occur in patients who do not have pelvic fracture(s) (7). During a motor vehicle accident, traumatic forces can be transferred to the bladder by the seatbelt; injuries usually occur in patients with a full bladder. The degree of distension of the bladder with urine determines its shape and, to some degree, the injury it sustains. A fully distended bladder can be ruptured by a light blow; however, an empty bladder is seldom injured, except by crushing or penetrating wounds. Pelvic scars or preexisting pelvic pathology can influence susceptibility to injury (16). Combined intra- and extraperitoneal rupture may occur in 2-20% of cases (7, 17-19). Simultaneous bladder and prostate-membranous urethra ruptures occur in 10-29% of male patients (10). Several studies investigating pelvic fractures and associated injuries in paediatric patients reported a lower incidence of urogenital injury (7-14%) (20-23), than in comparative adult series (7, 13, 14). In seven paediatric series (20-26), the average rate of bladder injury in patients with pelvic fractures was 4%. Motor vehicle accidents were the cause of the trauma in 97% of cases (26). 4.1.1 Iatrogenic trauma During lower abdominal operations, the bladder is the most frequently injured genitourinary organ (27). Most iatrogenic injuries occur during: • open abdominal or pelvic surgery (85%) • anterior vaginal surgery (9%) • laparoscopy (6%). The majority (92%) of these injuries are graded as III-IV, using the American Association for the Surgery of Trauma (AAST) scale (27). Most injuries occur during obstetric and gynaecological procedures (52-61%), followed by urological (12-39%) and general surgical (9-26%) interventions (27, 28). Of the general surgical operations that result in iatrogenic injury to the bladder, most involve resection of bowel as a result of malignancy, diverticulitis or inflammatory diseases (27, 28). Bladder injury occurs during gynaecological operations in 0.3-8.3% of cases (29-34). Concurrent antiincontinence surgery significantly increases the risk of injury to the bladder (13% vs 3%; P= 0.049) (34). Most cases of urological iatrogenic trauma occur during vaginal operations and laparoscopy (27, 28). The incidence of bladder wall perforation is generally low (1%) during transurethral resection of bladder tumours, and most (88%) can be managed by catheter drainage (35, 36). Transurethral resection of the prostate is also associated with low injury rates (37). Routine cystoscopy is an important adjunct to the major gynaecological procedures, and its omission may result in underestimation of iatrogenic bladder injury. An extensive review of the literature indicated that in studies not involving routine cystoscopy, the frequency of bladder injury varied from 0.2/1000 to 19.5/1000, with an overall frequency of 2.6/1000. Only 52% of bladder injuries were identified and managed intraoperatively (31). In studies involving routine cystoscopy, the frequency of bladder injury varied from 0.0/1000 to 29.2/1000, with an overall frequency of 10.4/1000. Up to 85% of unsuspected bladder injuries were identified with the use of cystoscopy and were managed successfully intraoperatively (31). Routine cystoscopy is recommended after any type of incontinence surgery as it enables identification of unsuspected bladder injury in 85% of patients (31, 32, 34, 38). Surgical procedures for the correction of stress urinary incontinence can also result in bladder trauma. The
36
Update march 2009
rate of bladder injury is below 3% in Burch colposuspension (39-41). Bladder injury is the most common complication of the tension-free vaginal tape (TVT) procedure, with an incidence of 2.0-11.5% (42-47) and up to 19% in patients with prior failed incontinence surgery (48). The transobturator tape (TOT) procedure minimizes the retropubic needle passage, and the incidence of bladder injury is expected to be low. Although during early experience with this technique rates of injury were similar to those associated with the TVT procedure (39), a recent meta-analysis indicated a lower incidence of bladder injuries (odds ratio: 0.12; 95% confidence interval: 0.05-0.33) with TOT procedures (49).
4.2
Classification
Table 6: Bladder injury scale1 Grade* Description I Hematoma Contusion, intramural hematoma Laceration Partial thickness II Laceration Extraperitoneal bladder wall laceration <2 cm III Laceration Extraperitoneal (>2 cm) or intraperitoneal (<2 cm) bladder wall laceration IV Laceration Intraperitoneal bladder wall laceration >2 cm V Laceration Intraperitoneal or extraperitoneal bladder wall laceration extending into the bladder neck or ureteral orifice (trigone) *Advance one grade for multiple injuries up to grade III 1 Adapted from the AAST.
4.3 Risk factors Individuals who driving under the influence of alcohol are likely to have a distended bladder and a motor vehicle accident. Driving after drinking alcohol is therefore a risk factor for bladder injury (19) (level of evidence: 3). Concurrent anti-incontinence surgery during gynaecological procedures results in a fourfold increased risk of bladder injury, and is therefore a risk factor for iatrogenic bladder trauma (34) (level of evidence: 3).
4.4 Diagnosis The most common signs and symptoms in patients with major bladder injuries are gross haematuria (82%) and abdominal tenderness (62%) (3). Other findings may include inability to void, bruises over the suprapubic region and abdominal distension (6). Extravasation of urine may result in swelling in the perineum, scrotum and thighs, as well as along the anterior abdominal wall within the potential space between the transversalis fascia and the parietal peritoneum. 4.4.1 Macroscopic (gross) haematuria Gross haematuria indicates urological trauma (level of evidence: 3). Traumatic bladder rupture is strongly correlated with the combination of pelvic fracture and gross haematuria; Morey et al. reported gross haematuria in all their patients with bladder rupture, and 85% had pelvic fractures (50). Thus, the classic combination of pelvic fracture and gross haematuria constitutes an absolute indication for immediate cystography in patients who have blunt trauma (3, 7, 13, 50) (level of evidence: 3). The presence of gross blood at the urethral meatus is diagnostic of a urethral injury (level of evidence: 3). A Foley catheter should not be inserted before a retrograde urethrogram has been carried out to ensure urethral integrity (51). Although grossly clear urine in a trauma patient without a pelvic fracture virtually eliminates the possibility of bladder rupture, 2-10% of patients with bladder rupture may have only microhaematuria or no haematuria at all (5, 51). In a retrospective review of more than 8000 paediatric trauma patients, of those cases with pelvic fractures, only one patient (0.5%) had an extraperitoneal bladder rupture (26). Lower urogenital injury occurred in six patients (2.8%). The absence of gross haematuria ruled out serious injury in this cohort. Based on this data, no further work-up was recommended in paediatric patients with pelvic fractures without gross haematuria. It is recommended that patients with gross haematuria, multiple associated injuries or significant abnormalities found on physical examination should be further evaluated with retrograde urethrography and cystography (level of evidence: 3).
Update march 2009
37
4.4.2 Microscopic haematuria In the trauma patient with a pelvic ring fracture, microscopic haematuria might indicate bladder laceration, and further investigation is warranted (level of evidence: 3). However, the exact quantity of blood in the urine that should trigger investigation is controversial. • Morgan et al. reported that no ruptures were seen in patients with <25 red blood cells/high-power field (rbc/hpf) (10). • Werkman et al. (52) concluded that if cystography had been restricted to patients with > 35-50 rbc/ hpf, no perforation would have been missed in their series. • Fuhrman et al. (53) believe that cystography in blunt trauma should be restricted to patients with gross haematuria, which they defined as > 200 rbc/hpf. They also thought that a retrograde urethrogram should be carried out first. Existing data do not support lower urinary tract imaging in all patients with pelvic fracture or microscopic haematuria alone. Hochberg and Stone (54) concluded that cystography might be safely reserved for those patients with pelvic fracture considered to be high risk for bladder injury (significant pubic arch involvement, gross haematuria and/or haemodynamic instability), as 90% of patients in their series with pelvic fracture did not have a bladder rupture. These observations do not appear to be valid for paediatric trauma patients. Abou-Jaoude et al. (55) reported a threshold for radiological evaluation of ≥ 20 rbc/hpf would miss 25% of cases with bladder injury. In contrast with other reported series (26), they suggested that lower urogenital tract evaluation in paediatric trauma patients, especially in the presence of pelvic fractures, should be based as much on clinical judgment as on the presence of haematuria (55) (level of evidence: 3). 4.4.3 Cystography Retrograde cystography is the standard diagnostic procedure in the evaluation of bladder trauma (7, 13, 56-58) (level of evidence: 3). This is the most accurate radiological study to identify bladder rupture. When adequate bladder filling and post-void images are obtained, cystography has an accuracy rate of 85-100% (5, 7, 59, 60). Bladder rupture is usually diagnosed when the contrast is identified outside the bladder. Adequate distension of the urinary bladder is crucial to demonstrating perforation, especially in cases of penetrating trauma, as most instances of a false-negative retrograde cystography were found in this situation (56). Cystography requires plain film, filled film, and post-drainage films (as a minimum) (level of evidence: 3); halffilled film and obliques are optional. For the highest diagnostic accuracy, the bladder must be distended using instillation of at least 350 mL of contrast medium by gravity. Bladder injury may be identified only on the postdrainage film in approximately 10% of cases (7). False-negative findings may result from incorrectly performed studies with less than 250 mL of contrast instillation or omission of a post-drainage film (61) (level of evidence: 3). Only a correctly performed cystography should be used to exclude bladder injury (7). 4.4.4 Excretory urography (intravenous pyelogram) An intravenous pyelogram (IVP) is inadequate for evaluation of the bladder and urethra after trauma, not only because of dilution of the contrast material within the bladder, but also because resting intravesical pressure is simply too low to demonstrate a small tear (16, 62). An IVP has a low accuracy (15-25%) (15) , and clinical studies have indicated that IVP has an unacceptably high false-negative rate (64-84%), which precludes its use as a diagnostic tool in bladder injuries (52, 59, 63) (level of evidence: 3). 4.4.5 Ultrasound (US) Although, the use of US in bladder rupture has been described (64), it is not routine for evaluation of bladder injury. Free peritoneal fluid in the presence of normal viscera, or failure to visualize the bladder after transurethral saline instillation, are highly suggestive of bladder rupture (66) (level of evidence: 3). Practically, however, US is not definitive in bladder or urethral trauma and is almost never used. 4.4.6 Computed tomography (CT) CT is clearly the method of choice for the evaluation of patients with blunt or penetrating abdominal and/or pelvic trauma (level of evidence: 3). However, routine CT is not reliable in the diagnosis of bladder rupture, even if an inserted urethral catheter is clamped. CT demonstrates intraperitoneal and extraperitoneal fluid, but cannot differentiate urine from ascites. As with IVP, the bladder is usually inadequately distended to reveal extravasation through a bladder laceration or perforation during routine abdominal and pelvic studies. Thus, a negative study cannot be entirely trusted,
38
Update march 2009
and routine CT cannot exclude bladder injury (12, 16, 65). In a review of the cystograms and CT scans (CT cystography) of 25 patients who underwent both investigations during the initial evaluation of blunt abdominal trauma, five patients were found to have bladder rupture, three of which were extraperitoneal and two intraperitoneal (66); all of the injuries were detected by both studies. It was concluded that delayed imaging or contrast instillation could provide the adequate bladder distention needed to demonstrate contrast extravasation from the injury site. Similarly, in a series of 316 patients, 44 cases were diagnosed with bladder ruptures (60). In patients who underwent a formal surgical repair, 82% had operative findings that exactly matched the CT cystography interpretation. Either retrograde cystography or CT cystography are diagnostic procedures of choice for suspected bladder injury (51). CT cystography can be used in place of conventional cystography (overall sensitivity 95% and specificity 100%) (level of evidence: 3), especially in patients undergoing CT scanning for other associated injuries (60). However, this procedure should be performed using retrograde filling of the bladder with a minimum of 350 mL of dilute contrast material (7, 66, 67). In conclusion, CT cystographic features may lead to accurate classification of bladder injury and allow prompt, effective treatment without further radiation exposure and the additional cost of conventional cystography (70) (level of evidence: 3). 4.4.7 Angiography Angiography is seldom, if ever, indicated. It can be useful in identifying an occult source of bleeding and can guide its subsequent therapeutic embolization (16). 4.4.8 Magnetic resonance imaging (MRI) It is extremely difficult to monitor a seriously injured patient in a strong magnetic field; MRI therefore has little place in the evaluation of acute bladder (16). The use of MRI has been described for later evaluation of urethral injury (69-71). 4.4.9 Cystoscopy Mainly useful in iatrogenic trauma, routine cystoscopy identifies 85% of the unsuspected injuries to the bladder that would otherwise go unnoticed (31, 34, 39). Thus, it must be use as an adjunct to major gynaecological operations as well as surgical interventions for incontinence (level of evidence: 3).
4.5
Treatment
The first priority in the treatment of bladder injuries is stabilization of the patient and treatment of associated life-threatening injuries (level of evidence: 3). 4.5.1 Blunt trauma: extraperitoneal rupture Most patients with extraperitoneal rupture can be managed safely by catheter drainage alone, even in the presence of extensive retroperitoneal or scrotal extravasation (61) (level of evidence: 3). Obstruction of the catheter by clots or tissue debris must be prevented for healing to occur. A success rate of ˃90% was reported with this approach in extraperitoneal rupture (5): 87% of the ruptures were healed in 10 days, and virtually all were healed in 3 weeks (57). However, bladder neck involvement (2), the presence of bone fragments in the bladder wall, or entrapment of the bladder wall will necessitate surgical intervention (19) (level of evidence: 3). 4.5.2 Blunt trauma: intraperitoneal rupture Intraperitoneal ruptures occurring after blunt trauma should always be managed by surgical exploration (level of evidence: 3). This type of injury involves a high degree of force and, because of the severity of associated injuries, carries a high mortality (20-40%) ((72). Lacerations are usually large in these cases, with the potential risk of peritonitis due to urine leakage if left untreated (61). Abdominal organs should be inspected for possible associated injuries, and urinoma must be drained, if present. 4.5.3 Penetrating injuries All bladder perforations resulting from penetrating trauma should undergo emergency exploration and repair (61) (level of evidence: 3). 4.5.4. Iatrogenic injuries Iatrogenic bladder perforations can occur during any pelvic, abdominal, or vaginal procedure (27). Prompt intraoperative recognition is extremely important to ensure a successful repair. Generally, suture repair is
Update march 2009
39
satisfactory, limiting unnecessary extravesical dissection (level of evidence: 3). Most (> 95%) of urinary bladder injuries sustained during gynaecological operations are detected and can be managed during surgery (73). Repair can be performed either transvaginally or abdominally. Simple catheter drainage is sufficient in most cases of bladder perforation during transurethral resection of prostate or bladder tumours (36-38) (level of evidence: 3).
4.6 Recommendations 4.6.1 General Recommendation GR Stabilization of the patient is always the priority in cases with associated injuries B GR = grade of recommendation 4.6.2 Diagnosis Recommendation GR • Immediate cystography is required in the presence of haematuria and pelvic fracture B • Diagnosis should be made with retrograde cystography with a minimum of 350 mL of B gravity-filled contrast medium • For cystography, the minimum requirement includes a plain film, filled film, and post-drainage B film. Half-filled film and obliques are optional • CT cystography can be used with equal efficacy if the patient is undergoing CT scanning for B associated injuries • Routine cystoscopy is recommended after major gynaecological operations and/or incontinence B surgery GR= grade of recommendation 4.6.3 Treatment Recommendation GR • In the absence of bladder neck involvement and/or associated injuries that require surgical B intervention, extraperitoneal bladder ruptures caused by blunt trauma are managed by catheter drainage alone • Intraperitoneal bladder ruptures by blunt trauma, and any type of bladder injury by penetrating B trauma, must be managed by emergency surgical exploration and repair • The technique of surgical repair used depends on the surgeon’s preference, but a two-layer B closure with absorbable sutures achieves a safe repair of the bladder wall GR = grade of recommendation
4.7 REFERENCES 1.
2.
3.
4. 5. 6. 7. 8.
9.
40
Carlin BI, Resnick MI. Indications and techniques for urologic evaluation of the trauma patient with suspected urologic injury. Semin Urol 1995;13(1):9-24. http://www.ncbi.nlm.nih.gov/pubmed/7597359 Corriere JN Jr, Sandler CM. Management of the ruptured bladder: seven years of experience with 111 cases. J Trauma 1986;26(9):830-3. http://www.ncbi.nlm.nih.gov/pubmed/3746959 Carroll PR, McAninch JW. Major bladder trauma: mechanisms of injury and a unified method of diagnosis and repair. J Urol 1984;132(2):254-7. http://www.ncbi.nlm.nih.gov/pubmed/6737572 McConnell JD, Wilkerson MD, Peters PC. Rupture of the bladder. Urol Clin North Am 1982;9(2):293-6. http://www.ncbi.nlm.nih.gov/pubmed/7101594 Cass AS and Luxenberg M. Features of 164 bladder ruptures. J Urol 1987;138(4):743-5. http://www.ncbi.nlm.nih.gov/pubmed/3656524 Sagalowsky AI, Peters PC. Genitourinary trauma. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ (eds). Campbell’s Urology, 7th ed. 1998, WB Saunders: Philadelphia, pp. 3085-3120. Sandler CM, Goldman SM, Kawashima A. Lower urinary tract trauma. World J Urol 1998;16(1):69-75. http://www.ncbi.nlm.nih.gov/pubmed/9542018 Flancbaum L, Morgan AS, Fleisher M, Cox EF. Blunt bladder trauma: manifestation of severe injury. Urology 1988;31(3):220-2. http://www.ncbi.nlm.nih.gov/pubmed/3347970 Castle WN, Richardson JR Jr, Walton BJ. Unsuspected intraperitoneal rupture of bladder presenting with abdominal free air. Urology 1986;28(6):521-3. http://www.ncbi.nlm.nih.gov/pubmed/3787926
Update march 2009
10.
11.
12.
13.
14.
15.
16.
17. 18.
19. 20. 21. 22.
23.
24.
25.
26.
27.
28.
29.
Morgan DE, Nallamala LK, Kenney PJ, Mayo MS and Rue LW 3rd. CT cystography: radiographic and clinical predictors of bladder rupture. Am J Roentgenol 2000;174(1):89-95. http://www.ncbi.nlm.nih.gov/pubmed/10628460 Aihara R, Blansfield JS, Millham FH, LaMorte WW, Hirsch EF. Fracture locations influence the likelihood of rectal and lower urinary tract injuries in patients sustaining pelvic fractures. J Trauma 2002;52(2):205-8;discussion 208-9. http://www.ncbi.nlm.nih.gov/pubmed/11834976 Cass AS. Diagnostic studies in bladder rupture. Indications and techniques. Urol Clin North Am 1989;16(2):267-73. http://www.ncbi.nlm.nih.gov/pubmed/2652855 Rehm CG, Mure AJ, O’Malley KF, Ross SE. Blunt traumatic bladder rupture: the role of retrograde cystogram. Ann Emerg Med 1991;20(8):845-7. http://www.ncbi.nlm.nih.gov/pubmed/1854066 Coppola PT, Coppola M. Emergency department evaluation and treatment of pelvic fractures. Emerg Med Clin North Am 2000;18(1):1-27, v. http://www.ncbi.nlm.nih.gov/pubmed/10678158 Festini G, Gregorutti S, Reina G, Bellis GB. Isolated intraperitoneal bladder rupture in patients with alcohol intoxication and minor abdominal trauma. Ann Emerg Med 1991;20(12):1371-2. http://www.ncbi.nlm.nih.gov/pubmed/1746742 Ben-Menachem Y, Coldwell DM, Young JW, Burgess AR. Hemorrhage associated with pelvic fractures: causes, diagnosis, and emergent management. Am J Roentgenol 1991;157(5):1005-14. http://www.ncbi.nlm.nih.gov/pubmed/1927786 Cass AS. The multiple injured patient with bladder trauma. J Trauma 1984;24(8):731-4. http://www.ncbi.nlm.nih.gov/pubmed/6471137 Taffet R. Management of pelvic fractures with concomitant urologic injuries. Orthop Clin North Am 1997;28(3):389-96. http://www.ncbi.nlm.nih.gov/pubmed/9208831 Dreitlein DA, Suner S, Basler J. Genitourinary trauma. Emerg Med Clin North Am 2001;19(3):569-90. http://www.ncbi.nlm.nih.gov/pubmed/11554276 Reed MH. Pelvic fractures in children. J Can Assoc Radiol 1976;27(4):255-61. http://www.ncbi.nlm.nih.gov/pubmed/993239 Torode I, Zieg D. Pelvic fractures in children. J Pediatr Orthop 1985;5(1):76-84. http://www.ncbi.nlm.nih.gov/pubmed/993239 Musemeche CA, Fischer RP, Cotler HB, Andrassy RJ. Selective management of paediatric pelvic fractures: a conservative approach. J Pediatr Surg 1987;22(6):538-40. http://www.ncbi.nlm.nih.gov/pubmed/3612446 Bond SJ, Gotschall CS, Eichelberger MR. Predictors of abdominal injury in children with pelvic fracture. J Trauma 1991;31(8):1169-73. http://www.ncbi.nlm.nih.gov/pubmed/1875444 Reichard SA, Helikson MA, Shorter N, White RI Jr, Shemeta DW, Haller JA Jr. Pelvic fractures in children – review of 120 patients with a new look at general management. J Pediatr Surg 1980;15(6):727-34. http://www.ncbi.nlm.nih.gov/pubmed/7463272 Koraitim MM, Marzouk ME, Atta MA, Orabi SS. Risk factors and mechanism of urethral injury in pelvic fractures. Br J Urol 1996;77(6):876-80. http://www.ncbi.nlm.nih.gov/pubmed/8705225 Tarman GJ, Kaplan GW, Lerman SL, McAleer IM, Losasso BE. Lower genitourinary injury and pelvic fractures in paediatric patients. Urology 2002;59(1):123-6. http://www.ncbi.nlm.nih.gov/pubmed/11796295 Armenakas NA, Pareek G, Fracchia JA. Iatrogenic bladder perforations: longterm followup of 65 patients. J Am Coll Surg 2004;198(1):78-82. http://www.ncbi.nlm.nih.gov/pubmed/14698314 Dobrowolski ZF, Lipczynski W, Drewniak T, Jakubik P, Kusionowicz J. External and iatrogenic trauma of the urinary bladder: a survey in Poland. BJU Int 2002;89(7):755-6. http://www.ncbi.nlm.nih.gov/pubmed/11966639 Ostrzenski A, Ostrzenska KM. Bladder injury during laparoscopic surgery. Obstet Gynecol Surv 1998;53(3):175-80. http://www.ncbi.nlm.nih.gov/pubmed/9513988
Update march 2009
41
30.
31.
32. 33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
42
Harkki-Siren P, Sjoberg J, Tiitinen A. Urinary tract injuries after hysterectomy. Obstet Gynecol 1998;92(1):113-8. http://www.ncbi.nlm.nih.gov/pubmed/9649105 Gilmour DT, Dwyer PL, Carey MP. Lower urinary tract injury during gynecologic surgery and its detection by intraoperative cystoscopy. Obstet Gynecol 1999;94(5Pt2):883-9. http://www.ncbi.nlm.nih.gov/pubmed/10546778 Mendez LE. Iatrogenic injuries in gynecologic cancer surgery. Surg Clin North Am 2001;81(4):897-923. http://www.ncbi.nlm.nih.gov/pubmed/11551133 Makinen J, Johansson J, Tomas C, Tomas E, Heinonen PK, Laatikainen T, Kauko M, Heikkinen AM, Sjoberg J. Morbidity of 10 110 hysterectomies by type of approach. Hum Reprod 2001;16(7):1473-8. http://www.ncbi.nlm.nih.gov/pubmed/11425832 Vakili B, Chesson RR, Kyle BL, Shobeiri SA, Echols KT, Gist R, Zheng YT, Nolan TE. The incidence of urinary tract injury during hysterectomy: a prospective analysis based on universal cystoscopy. Am J Obstet Gynecol 2005;192(5):1599-604. http://www.ncbi.nlm.nih.gov/pubmed/15902164 Skolarikos A, Chrisofos M, Ferakis N, Papatsoris A, Dellis A, Deliveliotis C. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence? J Urol 2005;173(6):1908-11. http://www.ncbi.nlm.nih.gov/pubmed/15879773 Murshidi MS. Intraperitoneal rupture of the urinary bladder during transurethral resection of transitional cell carcinoma. Acta Urol Belg 1988;56(1):68-73. http://www.ncbi.nlm.nih.gov/pubmed/3364323 Donovan JL, Peters TJ, Neal DE, Brookes ST, Gujral S, Chacko KN, Wright M, Kennedy LG, Abrams P. A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. J Urol 2000;164(1):65-70. http://www.ncbi.nlm.nih.gov/pubmed/10840426 Minaglia S, Ozel B, Klutke C, Ballard C, Klutke J. Bladder injury during transobturator sling. Urology 2004;64(2):376-7. http://www.ncbi.nlm.nih.gov/pubmed/15302505 Dwyer PL, Carey MP, Rosamilia A. Suture injury to the urinary tract in urethral suspension procedures for stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1999;10(1):15-21. http://www.ncbi.nlm.nih.gov/pubmed/10207762 Gill EJ, Elser DM, Bonidie MJ, Roberts KM, Hurt WG. The routine use of cystoscopy with the Burch procedure. Am J Obstet Gynecol 2001;185(2):345-8. http://www.ncbi.nlm.nih.gov/pubmed/11518889 Kenton K, Oldham L, Brubaker L. Open Burch urethropexy has a low rate of perioperative complications. Am J Obstet Gynecol 2002;187(1):107-10. http://www.ncbi.nlm.nih.gov/pubmed/12114897 Olsson I, Kroon U. A three-year postoperative evaluation of tension-free vaginal tape. Gynecol Obstet Invest 1999;48(4):267-9. http://www.ncbi.nlm.nih.gov/pubmed/10592431 Soulie M, Cuvillier X, Benaissa A, Mouly P, Larroque JM, Bernstein J, Soulie R, Tollon C, Brucher P, Vazzoler N, Seguin P, Pontonnier F, Plante P. The tension-free transvaginal tape procedure in the treatment of female urinary stress incontinence: a French prospective multicentre study. Eur Urol 2001;39(6):709-14; discussion 715. http://www.ncbi.nlm.nih.gov/pubmed/11464062 Tamussino KF, Hanzal E, Kolle D, Ralph G, Riss PA. Tension-free vaginal tape operation: results of the Austrian registry. Obstet Gynecol 2001;98(5Pt1):732-6. http://www.ncbi.nlm.nih.gov/pubmed/11704161 Meschia M, Pifarotti P, Bernasconi F, Guercio E, Maffiolini M, Magatti F, Spreafico L. Tension-Free vaginal tape: analysis of outcomes and complications in 404 stress incontinent women. Int Urogynecol J Pelvic Floor Dysfunct 2001;12 Suppl 2:S24-S27. http://www.ncbi.nlm.nih.gov/pubmed/11450976 Agostini A, Bretelle F, Franchi F, Roger V, Cravello L, Blanc B. Immediate complications of tension-free vaginal tape (TVT): Results of a French Survey. Eur J Obstet Gynecol Reprod Biol 2006;124(2):237-9. Epub 2005. http://www.ncbi.nlm.nih.gov/pubmed/16095800
Update march 2009
47.
48.
49.
50.
51. 52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
Kuuva N, Nilsson CG. A nationwide analysis of complications associated with the tension-free vaginal tape (TVT) procedure. Acta Obstet Gynecol Scand 2002;81(1):72-7. http://www.ncbi.nlm.nih.gov/pubmed/11942891 Azam U, Frazer MI, Kozman EL, Ward K, Hilton P, Rane A. The tension-free vaginal tape procedure in women with previous failed stress incontinence surgery. J Urol 2001;166(2):554-6. http://www.ncbi.nlm.nih.gov/pubmed/11458067 Latthe PM. Review of transobturator and retropubic tape procedures for stress urinary incontinence. Curr Opin Obstet Gynecol 2008;20(4):331-6. http://www.ncbi.nlm.nih.gov/pubmed/18660683 Morey AF, Iverson AJ, Swan A, Harmon WJ, Spore SS, Bhayani S, Brandes SB. Bladder rupture after blunt trauma: guidelines for diagnostic imaging. J Trauma 2001;51(4):683-6. http://www.ncbi.nlm.nih.gov/pubmed/11586159 Schneider RE. Genitourinary trauma. Emerg Med Clin North Am 1993;11(1):137-45. http://www.ncbi.nlm.nih.gov/pubmed/8432245 Werkman HA, Jansen C, Klein JP, Ten Duis HJ. Urinary tract injuries in multiply-injured patients: a rational guideline for the initial assessment. Injury 1991;22(6):471-4. http://www.ncbi.nlm.nih.gov/pubmed/1757139 Fuhrman GM, Simmons GT, Davidson BS, Buerk CA. The single indication for cystography in blunt trauma. Am Surg 1993;59(6):335-7. http://www.ncbi.nlm.nih.gov/pubmed/8507053 Hochberg E, Stone NN. Bladder rupture associated with pelvic fracture due to blunt trauma. Urology 1993;41(6):531-3. http://www.ncbi.nlm.nih.gov/pubmed/8516988 Abou-Jaoude WA, Sugarman JM, Fallat ME, Casale AJ. Indicators of genitourinary tract injury or anomaly in cases of paediatric blunt trauma. J Pediatr Surg 1996;31(1):86-9;discussion 90. http://www.ncbi.nlm.nih.gov/pubmed/8632293 Baniel J, Schein M. The management of penetrating trauma to the urinary tract. J Am Coll Surg 1994;178(4):417-25. http://www.ncbi.nlm.nih.gov/pubmed/8149045 Corriere JN, Sandler CM. Management of extraperitoneal bladder rupture. Urol Clin North Am 1989;16(2):275-7. http://www.ncbi.nlm.nih.gov/pubmed/2711545 Stine RJ, Avila JA, Lemons MF, Sickorez GJ. Diagnostic and therapeutic urologic procedures. Emerg Med Clin North Am 1988;6(3):547-78. http://www.ncbi.nlm.nih.gov/pubmed/3292227 Carroll PR, McAninch JW. Major bladder trauma: the accuracy of cystography. J Urol 983;130(5): 887-8. http://www.ncbi.nlm.nih.gov/pubmed/6632094 Deck AJ, Shaves S, Talner L, Porter JR. Computerized tomography cystography for the diagnosis of traumatic bladder rupture. J Urol 2000;164(1):43-6. http://www.ncbi.nlm.nih.gov/pubmed/10840421 Morey AF, Hernandez J, McAninch JW. Reconstructive surgery for trauma of the lower urinary tract. Urol Clin North Am 1999;26(1):49-60, viii. http://www.ncbi.nlm.nih.gov/pubmed/10086050 Bonavita JA, Pollack HM. Trauma of the adult bladder and urethra. Semin Roentgenol 1983;18(4): 299-306. http://www.ncbi.nlm.nih.gov/pubmed/6359436 MacMahon R, Hosking D, Ramsey EW. Management of blunt injury to the lower urinary tract. Can J Surg 1983;26(5):415-8. http://www.ncbi.nlm.nih.gov/pubmed/6616359 Bigongiari LR, Zarnow H. Traumatic, inflammatory, neoplastic and miscellaneous lesions of the bladder. In: Land EK (ed.). Medical Radiology of the Lower Urinary Tract, 1994, Springer Verlag: Berlin, pp. 70-147. Mee SL, McAninch JW, Federle MP. Computerized tomography in bladder rupture: di